PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kang, HT; Park, JT; Choi, K; Kim, Y; Choi, HJC; Jung, CW; Lee, YS; Park, SC				Kang, Hyun Tae; Park, Joon Tae; Choi, Kobong; Kim, Yongsub; Choi, Hyo Jei Claudia; Jung, Chul Won; Lee, Young-Sam; Park, Sang Chul			Chemical screening identifies ATM as a target for alleviating senescence	NATURE CHEMICAL BIOLOGY			English	Article							YEAST VACUOLAR-ATPASE; EPITHELIAL-CELLS; LYSOSOMAL PH; LIFE-SPAN; AUTOPHAGY; DISEASE; ACIDIFICATION; ACTIVATION; KINASE; MITOCHONDRIA	Senescence, defined as irreversible cell-cycle arrest, is the main driving force of aging and age-related diseases. Here, we performed high-throughput screening to identify compounds that alleviate senescence and identified the ataxia telangiectasia mutated (ATM) inhibitor KU-60019 as an effective agent. To elucidate the mechanism underlying ATM's role in senescence, we performed a yeast two-hybrid screen and found that ATM interacted with the vacuolar ATPase V-1 subunits ATP6V1E1 and ATP6V1G1. Specifically, ATM decreased E-G dimerization through direct phosphorylation of ATP6V1G1. Attenuation of ATM activity restored the dimerization, thus consequently facilitating assembly of the V-1 and V-0 domains with concomitant reacidification of the lysosome. In turn, this reacidification induced the functional recovery of the lysosome/autophagy system and was coupled with mitochondrial functional recovery and metabolic reprogramming. Together, our data reveal a new mechanism through which senescence is controlled by the lysosomal-mitochondrial axis, whose function is modulated by the fine-tuning of ATM activity.	[Kang, Hyun Tae; Park, Joon Tae; Choi, Kobong; Choi, Hyo Jei Claudia; Jung, Chul Won] Samsung Elect, Samsung Adv Inst Technol, Well Aging Res Ctr, Suwon, South Korea; [Kim, Yongsub] Univ Ulsan, Dept Biomed Sci, Asan Med Ctr, Coll Med, Seoul, South Korea; [Lee, Young-Sam; Park, Sang Chul] DGIST, Well Aging Res Ctr, Daegu, South Korea; [Lee, Young-Sam; Park, Sang Chul] DGIST, Dept New Biol, Daegu, South Korea	Samsung; Samsung Electronics; University of Ulsan; Asan Medical Center; Daegu Gyeongbuk Institute of Science & Technology (DGIST); Daegu Gyeongbuk Institute of Science & Technology (DGIST)	Park, JT (corresponding author), Samsung Elect, Samsung Adv Inst Technol, Well Aging Res Ctr, Suwon, South Korea.; Lee, YS; Park, SC (corresponding author), DGIST, Well Aging Res Ctr, Daegu, South Korea.; Lee, YS; Park, SC (corresponding author), DGIST, Dept New Biol, Daegu, South Korea.	joontae.park@samsung.com; lee.youngsam@dgist.ac.kr; blueocean2016@dgist.ac.kr		Kim, Yongsub/0000-0002-9334-4333	Samsung Advanced Institute of Technology; DGIST R&D Program of the Ministry of Science, ICT and Technology of Korea [20160165, 20160172]	Samsung Advanced Institute of Technology(Samsung); DGIST R&D Program of the Ministry of Science, ICT and Technology of Korea	This research was supported by the Samsung Advanced Institute of Technology and the DGIST R&D Program of the Ministry of Science, ICT and Technology of Korea (20160165 to Y.-S.L. and 20160172 to S.C.P.).	Ashcroft GS, 2002, BIOGERONTOLOGY, V3, P337, DOI 10.1023/A:1021399228395; Awasthi P, 2015, J CELL SCI, V128, P4255, DOI 10.1242/jcs.169730; Bassaneze Vinicius, 2013, Methods Mol Biol, V965, P157, DOI 10.1007/978-1-62703-239-1_9; Benlekbir S, 2012, NAT STRUCT MOL BIOL, V19, P1356, DOI 10.1038/nsmb.2422; Blackburn EH, 2015, SCIENCE, V350, P1193, DOI 10.1126/science.aab3389; Brand Martin D, 2014, Longev Healthspan, V3, P7, DOI 10.1186/2046-2395-3-7; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Breitenbach M, 2014, FEMS YEAST RES, V14, P198, DOI 10.1111/1567-1364.12134; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cao K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002346; Cimolai MC, 2015, INT J MOL SCI, V16, P17763, DOI 10.3390/ijms160817763; Chen CS, 2000, J BIOCHEM BIOPH METH, V42, P137, DOI 10.1016/S0165-022X(00)00048-8; Cho H, 2009, MOL CELL, V33, P75, DOI 10.1016/j.molcel.2008.11.022; DiCiccio JE, 2011, J GEN PHYSIOL, V137, P385, DOI 10.1085/jgp.201110596; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Goncalves S, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-20; Guo SJ, 2015, AUTOPHAGY, V11, P560, DOI 10.1080/15548627.2015.1017181; Haggie PM, 2009, J BIOL CHEM, V284, P7681, DOI 10.1074/jbc.M809161200; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Houtkooper RH, 2011, SCI REP-UK, V1, DOI 10.1038/srep00134; Hughes AL, 2012, NATURE, V492, P261, DOI 10.1038/nature11654; Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018-009-0034-2; Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023367; Kang HT, 2009, AGING CELL, V8, P426, DOI 10.1111/j.1474-9726.2009.00487.x; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009; Landis GN, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r8; Lee SS, 2015, CELL REP, V13, DOI 10.1016/j.celrep.2015.10.035; Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin JW, 2004, DEV BIOL, V270, P474, DOI 10.1016/j.ydbio.2004.02.023; Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; Nassour J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10399; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Oot RA, 2012, J BIOL CHEM, V287, P13396, DOI 10.1074/jbc.M112.343962; Pekovic V, 2011, AGING CELL, V10, P1067, DOI 10.1111/j.1474-9726.2011.00750.x; Santos RX, 2010, J ALZHEIMERS DIS, V20, pS401, DOI 10.3233/JAD-2010-100666; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Shiloh Y, 2017, AGEING RES REV, V33, P76, DOI 10.1016/j.arr.2016.05.002; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Silva LP, 2013, ANAL CHEM, V85, P9536, DOI 10.1021/ac401559v; Stehling O, 2014, BIOCHIMIE, V100, P61, DOI 10.1016/j.biochi.2014.01.010; Tong AS, 2015, CELL REP, V13, P1633, DOI 10.1016/j.celrep.2015.10.041; Tudor CO, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav020; Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9; Weber AM, 2015, PHARMACOL THERAPEUT, V149, P124, DOI 10.1016/j.pharmthera.2014.12.001; Wei JD, 2013, J BIOL CHEM, V288, P26753, DOI 10.1074/jbc.M113.470260; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11	57	85	86	4	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2017	13	6					616	+		10.1038/nchembio.2342	http://dx.doi.org/10.1038/nchembio.2342			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV0HN	28346404				2023-01-03	WOS:000401419300014
J	Vladimer, GI; Snijder, B; Krall, N; Bigenzahn, JW; Huber, KVM; Lardeau, CH; Sanjiv, K; Ringler, A; Berglund, UW; Sabler, M; de la Fuente, OL; Knobl, P; Kubicek, S; Helleday, T; Jager, U; Superti-Furga, G				Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio			Global survey of the immunomodulatory potential of common drugs	NATURE CHEMICAL BIOLOGY			English	Article							CLASS-II MOLECULES; ADAPTIVE IMMUNITY; B-CELLS; RECEPTOR; KINASE; EXPRESSION; INFECTION; MECHANISM; CANCER; ROLES	Small-molecule drugs may complement antibody-based therapies in an immune-oncology setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking. We surveyed the immumomodulatory potential of 1,402 small chemical molecules, as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image analysis. Unexpectedly, similar to 10% of the agents tested affected these cell-cell interactions differentially. The results accurately recapitulated known immunomodulatory drug classes and revealed several clinically approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiological mechanism of action. For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex molecules. The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.	[Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Ringler, Anna; Sabler, Monika; de la Fuente, Oscar Lopez; Kubicek, Stefan; Superti-Furga, Giulio] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Huber, Kilian V. M.] Univ Oxford, Struct Genom Consortium, Oxford, England; [Huber, Kilian V. M.] Univ Oxford, Target Discovery Inst, Oxford, England; [Lardeau, Charles-Hugues; Ringler, Anna; Kubicek, Stefan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Christian Doppler Lab Chem Epigenet & Antiinfect, Vienna, Austria; [Sanjiv, Kumar; Berglund, Ulrika Warpman; Helleday, Thomas] Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, Stockholm, Sweden; [Knoebl, Paul; Jaeger, Ulrich] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; [Superti-Furga, Giulio] Med Univ Vienna, Ctr Physiol & Pharmacol, Vienna, Austria; [Snijder, Berend] Inst Mol Syst Biol, Dept Biol, Zurich, Switzerland	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Oxford; University of Oxford; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Karolinska Institutet; Medical University of Vienna; Medical University of Vienna	Superti-Furga, G (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.; Superti-Furga, G (corresponding author), Med Univ Vienna, Ctr Physiol & Pharmacol, Vienna, Austria.	gsuperti-furga@cemm.oeaw.ac.at	Snijder, Berend/O-9206-2019; Superti-Furga, Giulio/AAE-5681-2019; Snijder, Berend/M-2998-2017; Knoebl, Paul/G-2787-2010; Vladimer, Gregory/X-4547-2018; Huber, Kilian V. M./L-6921-2015; Kubicek, Stefan/C-2089-2017	Snijder, Berend/0000-0003-3386-6583; Knoebl, Paul/0000-0002-7909-7225; Vladimer, Gregory/0000-0003-4205-7585; Huber, Kilian V. M./0000-0002-1103-5300; Kubicek, Stefan/0000-0003-0855-8343; Helleday, Thomas/0000-0002-7384-092X; Warpman Berglund, Ulrika/0000-0002-6372-1396; Bigenzahn, Johannes/0000-0002-5214-4570	Austrian Academy of Sciences; ERC; Austrian Science Fund [F4711-B20]; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; Torsten and Ragnar Soderberg Foundation; Swiss National Science Foundation [P300P3_147897, PP00P3_163961, P2EZP3_159114]; EMBO [1543-2012]; Marie-Sklodowska Curie Action Fellowship (SLIM)	Austrian Academy of Sciences; ERC(European Research Council (ERC)European Commission); Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development; Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Torsten and Ragnar Soderberg Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EMBO(European Molecular Biology Organization (EMBO)); Marie-Sklodowska Curie Action Fellowship (SLIM)	We are grateful to the donors and patients for their part in this study. Our screening compound libraries are from the US National Institutes of Health clinical collection or as gifts from F. Bracher, T. Nielsen, S. Nijman, J. Bradner, the Broad Institute and Haplogen GmbH. JQ1 was provided by S. Knapp (University of Oxford), and H3122 cells and SW480 cells were kind gifts from E. Haura (Moffitt Cancer Center) and W. Berger (Medical University of Vienna), respectively. We thank M. Rebsamen, A. Fauster, G. Jurisic, A. Cesar-Razquin, C.C. West, E. Girardi and G. Winter for assistance and critical reading of the manuscript and members of G.S.-F.'s laboratory for scientific discussions. CeMM is supported by the Austrian Academy of Sciences. We acknowledge funding from an ERC i-FIVE Advanced Investigator Grant (G.S.-F.), Austrian Science Fund grant F4711-B20 (G.S.-F.), the Austrian Federal Ministry of Science, Research and Economy (S.K.), the National Foundation for Research, Technology and Development (S.K.), the Swedish Cancer Society (T.H.), the Knut and Alice Wallenberg Foundation (T.H.), the Torsten and Ragnar Soderberg Foundation (T.H.), Swiss National Science Foundation Fellowships (P300P3_147897 (B.S.), PP00P3_163961 (B.S.) and P2EZP3_159114 (N.K.)), an EMBO long-term Fellowship (1543-2012; G.I.V.) and a Marie-Sklodowska Curie Action Fellowship (SLIM; N.K.).	Alam S, 2006, MOL IMMUNOL, V43, P1432, DOI 10.1016/j.molimm.2005.07.025; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x; Bhat R, 2010, P NATL ACAD SCI USA, V107, P2580, DOI 10.1073/pnas.0915139107; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Cui JJ, 2011, J MED CHEM, V54, P6342, DOI 10.1021/jm2007613; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Dennis EA, 2015, NAT REV IMMUNOL, V15, P511, DOI 10.1038/nri3859; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Flaishon L, 2004, BLOOD, V104, P933, DOI 10.1182/blood-2003-11-4013; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Germain RN, 2012, SCIENCE, V336, P1676, DOI 10.1126/science.1221063; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Harizi H, 2008, TRENDS MOL MED, V14, P461, DOI 10.1016/j.molmed.2008.08.005; Heine A, 2011, LEUKEMIA, V25, P899, DOI 10.1038/leu.2011.24; Honke N, 2012, NAT IMMUNOL, V13, P51, DOI 10.1038/ni.2169; Hoos A, 2016, NAT REV DRUG DISCOV, V15, P235, DOI 10.1038/nrd.2015.35; Hou WQ, 2012, BLOOD, V119, P3128, DOI 10.1182/blood-2011-09-379479; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Khajanchi BK, 2011, INFECT IMMUN, V79, P2646, DOI 10.1128/IAI.00096-11; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kobayashi KS, 2012, NAT REV IMMUNOL, V12, P813, DOI 10.1038/nri3339; Komaniwa S, 2009, EUR J IMMUNOL, V39, P96, DOI 10.1002/eji.200838796; Loffler A, 2003, LEUKEMIA, V17, P900, DOI 10.1038/sj.leu.2402890; LOLEKHA S, 1970, Journal of Immunology, V104, P296; Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Mallakin A, 2006, AM J RESP CELL MOL, V34, P15, DOI 10.1165/rcmb.2005-0093OC; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Ramo P, 2009, BIOINFORMATICS, V25, P3028, DOI 10.1093/bioinformatics/btp524; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; Ritchie AJ, 2005, INFECT IMMUN, V73, P1648, DOI 10.1128/IAI.73.3.1648-1655.2005; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Sanders VM, 2012, BRAIN BEHAV IMMUN, V26, P195, DOI 10.1016/j.bbi.2011.08.001; Santoni M, 2014, INT J CANCER, V134, P2772, DOI 10.1002/ijc.28503; SCHINDLER R, 1995, CYTOKINE, V7, P526, DOI 10.1006/cyto.1995.0071; Schroeder GM, 2009, J MED CHEM, V52, P1251, DOI 10.1021/jm801586s; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Snijder B, 2009, NATURE, V461, P520, DOI 10.1038/nature08282; Tian JD, 2011, AUTOIMMUNITY, V44, P465, DOI 10.3109/08916934.2011.571223; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wilson CB, 2008, J IMMUNOL, V181, P2303, DOI 10.4049/jimmunol.181.4.2303; Winter GE, 2012, NAT CHEM BIOL, V8, P905, DOI [10.1038/NCHEMBIO.1085, 10.1038/nchembio.1085]; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	56	34	37	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2017	13	6					681	+		10.1038/nchembio.2360	http://dx.doi.org/10.1038/nchembio.2360			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV0HN	28437395	Green Accepted, Green Submitted			2023-01-03	WOS:000401419300023
J	Sadler, E; Porat, T; Marshall, I; Hoang, U; Curcin, V; Wolfe, CDA; McKevitt, C				Sadler, Euan; Porat, Talya; Marshall, Iain; Hoang, Uy; Curcin, Vasa; Wolfe, Charles D. A.; McKevitt, Christopher			Shaping innovations in long-term care for stroke survivors with multimorbidity through stakeholder engagement	PLOS ONE			English	Article							SELF-MANAGEMENT PROGRAMS; RISK-FACTORS; PREVALENCE; RECOVERY; EFFICACY; PATIENT; TRENDS	Background Stroke, like many long-term conditions, tends to be managed in isolation of its associated risk factors and multimorbidity. With increasing access to clinical and research data there is the potential to combine data from a variety of sources to inform interventions to improve healthcare. A 'Learning Health System' (LHS) is an innovative model of care which transforms integrated data into knowledge to improve healthcare. The objective of this study is to develop a process of engaging stakeholders in the use of clinical and research data to co-produce potential solutions, informed by a LHS, to improve long-term care for stroke survivors with multimorbidity. Methods We used a stakeholder engagement study design informed by co-production principles to engage stakeholders, including service users, carers, general practitioners and other health and social care professionals, service managers, commissioners of services, policy makers, third sector representatives and researchers. Over a 10 month period we used a range of methods including stakeholder group meetings, focus groups, nominal group techniques (priority setting and consensus building) and interviews. Qualitative data were recorded, transcribed and analysed thematically. Results 37 participants took part in the study. The concept of how data might drive intervention development was difficult to convey and understand. The engagement process led to four priority areas for needs for data and information being identified by stakeholders: 1) improving continuity of care; 2) improving management of mental health consequences; 3) better access to health and social care; and 4) targeting multiple risk factors. These priorities informed preliminary design interventions. The final choice of intervention was agreed by consensus, informed by consideration of the gap in evidence and local service provision, and availability of robust data. This shaped a co-produced decision support tool to improve secondary prevention after stroke for further development. Conclusions Stakeholder engagement to identify data-driven solutions is feasible but requires resources. While a number of potential interventions were identified, the final choice rested not just on stakeholder priorities but also on data availability. Further work is required to evaluate the impact and implementation of data-driven interventions for long-term stroke survivors.	[Sadler, Euan; Porat, Talya; Marshall, Iain; Hoang, Uy; Curcin, Vasa; Wolfe, Charles D. A.] Kings Coll London, Fac Life Sci & Med, Div Hlth & Social Care Res, London, England; [Sadler, Euan] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Implementat Sci, Kings Improvement Sci,Hlth Serv & Populat Res Dep, London, England; [Wolfe, Charles D. A.; McKevitt, Christopher] Kings Coll Hosp NHS Fdn Trust, Natl Inst Hlth Res Collaborat Leadership Appl Hlt, London, England; [Wolfe, Charles D. A.; McKevitt, Christopher] Kings Coll London, London, England; [Wolfe, Charles D. A.; McKevitt, Christopher] Guys & St Thomas NHS Fdn Trust & Kings Coll Londo, Biomed Res Ctr, Natl Inst Hlth Res, London, England	University of London; King's College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Sadler, E (corresponding author), Kings Coll London, Fac Life Sci & Med, Div Hlth & Social Care Res, London, England.; Sadler, E (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Implementat Sci, Kings Improvement Sci,Hlth Serv & Populat Res Dep, London, England.	euan.sadler@kcl.ac.uk	mckevitt, christopher/AAN-7271-2021; Hoang, Uy/AAD-9445-2022	Hoang, Uy/0000-0002-8428-5140; Marshall, Iain/0000-0003-2594-2654; Sadler, Euan/0000-0003-3827-224X; MCKEVITT, CHRISTOPHER/0000-0002-5290-4613; Curcin, Vasa/0000-0002-8308-2886	National Institute for Health Research (NIHR); Care South London at King's College Hospital NHS Foundation Trust [NIHR CLAHRC-2013-10022]; MRC [MR/N015185/1] Funding Source: UKRI	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Care South London at King's College Hospital NHS Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	There search was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust (award number NIHR CLAHRC-2013-10022), Prof Charles DA Wolfe (stroke themelead), http://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/infrastructure/ collaborations-for-leadership-in-applied-health-research-and-care.htm. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, S LONDON STROK UNPUB; Bamford David, 2013, J Health Organ Manag, V27, P548; Batalden M, 2016, BMJ QUAL SAF, V25, P509, DOI 10.1136/bmjqs-2015-004315; Bovaird T, 2007, PUBLIC ADMIN REV, V67, P846, DOI 10.1111/j.1540-6210.2007.00773.x; Boyle D, 2006, ASPECTS COPRODUCTION; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chen RL, 2014, J NEUROL NEUROSUR PS, V85, P1294, DOI 10.1136/jnnp-2013-306413; Crandall W, 2011, INFLAMM BOWEL DIS, V17, P450, DOI 10.1002/ibd.21394; Curcin V, 2016, EMBEDDING DATA PROVE; Dawes M, 2010, FAM PRACT, V27, P1, DOI 10.1093/fampra/cmp106; Delaney BC, 2012, ANN FAM MED, V10, P54, DOI 10.1370/afm.1313; Ellis G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005066.pub2; Forster A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001919.pub3; Fortin M, 2006, QUAL LIFE RES, V15, P83, DOI 10.1007/s11136-005-8661-z; Fraccaro P, 2015, JMIR MED INF, V3, DOI 10.2196/medinform.3503; Glynn LG, 2011, FAM PRACT, V28, P516, DOI 10.1093/fampra/cmr013; Governance International, 2013, ACH CIT OUTC; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3; Heaton J, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0383-9; Heuschmann PU, 2008, STROKE, V39, P2204, DOI 10.1161/STROKEAHA.107.507285; Intercollegiate Stroke Working Party, 2016, NAT CLIN GUID STROK; Jones F, 2011, DISABIL REHABIL, V33, P797, DOI 10.3109/09638288.2010.511415; Kendall E, 2007, SOC SCI MED, V64, P735, DOI 10.1016/j.socscimed.2006.09.012; Kenning C, 2013, SAGE OPEN MED, V1, DOI 10.1177/2050312113510001; Kirkevold M, 2012, INT J NURS STUD, V49, P386, DOI 10.1016/j.ijnurstu.2011.10.006; Korpershoek C, 2011, J ADV NURS, V67, P1876, DOI 10.1111/j.1365-2648.2011.05659.x; Lager KE, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009103.pub2; Lawrence M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120902; Lennon S, 2013, CLIN REHABIL, V27, P867, DOI 10.1177/0269215513481045; MacKay-Lyons M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008656.pub2; Marshall IJ, 2013, STROKE, V44, P1809, DOI 10.1161/STROKEAHA.111.000655; Mason B, 2016, BMJ SUPPORT PALLIAT, V6, P60, DOI 10.1136/bmjspcare-2013-000639; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; McKevitt C, 2010, HEALTH EXPECT, V13, P86, DOI 10.1111/j.1369-7625.2009.00573.x; Morris RL, 2011, CHRONIC ILLN, V7, P147, DOI 10.1177/1742395310393365; National Audit Office, 2010, DEP HLTH PROGR IMPR; NIHR, 2015, GOING EXTR MIL IMPR; Olsen LA., 2007, LEARNING HEALTHCARE, DOI DOI 10.17226/; Ottmann G, 2011, SYST PRACT ACT RES, V24, P413, DOI 10.1007/s11213-011-9192-x; Pawson R., 1997, REALIST EVALUATION; Pollock A, 2014, INT J STROKE, V9, P313, DOI 10.1111/j.1747-4949.2012.00942.x; Reeve J, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-112; Roshanov PS, 2011, IMPLEMENT SCI, V6, DOI [10.1186/1748-5908-6-92, 10.1186/1748-5908-6-88]; Smith SM, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006560.pub4, 10.1002/14651858.CD006560.pub3]; Smith SM, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X514756; Social Care Institute of Excellence, 2015, SCIE GUID, V51; Starks H, 2015, QUAL LIFE RES, V24, P1097, DOI 10.1007/s11136-014-0810-9; Su P, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0352-9; Wallace E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h176; Warner G, 2015, DISABIL REHABIL, V37, P2141, DOI 10.3109/09638288.2014.996674; Wherton J, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0271-8; Wolfe CDA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001033; Wolfe CDA, 2010, STROKE, V41, P2470, DOI 10.1161/STROKEAHA.110.588046; Young J, 2003, REV CLIN GERONTOL, V13, P55	54	12	12	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2017	12	5							e0177102	10.1371/journal.pone.0177102	http://dx.doi.org/10.1371/journal.pone.0177102			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ET9SX	28475606	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000400649500047
J	Willkomm, L; Gehlert, S; Jacko, D; Schiffer, T; Bloch, W				Willkomm, Lena; Gehlert, Sebastian; Jacko, Daniel; Schiffer, Thorsten; Bloch, Wilhelm			p38 MAPK activation and H3K4 trimethylation is decreased by lactate in vitro and high intensity resistance training in human skeletal muscle	PLOS ONE			English	Article							LENGTHENING CONTRACTIONS; HISTONE MODIFICATIONS; SIGNALING PATHWAYS; GENE-EXPRESSION; EXERCISE; RECRUITMENT; RESPONSES; COMPLEXES; CELLS; PHOSPHORYLATION	Exercise induces adaptation of skeletal muscle by acutely modulating intracellular signaling, gene expression, protein turnover and myogenic activation of skeletal muscle stem cells (Satellite cells, SCs). Lactate (La)-induced metabolic stimulation alone has been shown to modify SC proliferation and differentiation. Although the mechanistic basis remains elusive, it was demonstrated that La affects signaling via p38 mitogen activated protein kinase (p38 MAPK) which might contribute to trimethylation of histone 3 lysine 4 (H3K4me3) known to regulate satellite cell proliferation and differentiation. We investigated the effects of La on p38 MAPK and H3K4me3 in a model of activated SCs. Differentiating C2C12 myoblasts were treated with La (20 mM) and samples analysed using qRT-PCR, immunofluorescence, and western blotting. We determined a reduction of p38 MAPK phosphorylation, decreased H3K4me3 and reduced expression of Myf5, myogenin, and myosin heavy chain (MHC) leading to decreased differentiation of La-treated C2C12 cells after 5 days of repeated La treatment. We further investigated whether this regulatory pathway would be affected in human skeletal muscle by the application of two different resistance exercise regimes (RE) associated with distinct metabolic demands and blood La accumulation. Muscle biopsies were obtained 15, 30 min, 1, 4, and 24 h post exercise after moderate intensity RE (STD) vs. high intensity RE (HIT). Consistent with in vitro results, reduced p38 phosphorylation and blunted H3K4me3 were also observed upon metabolically demanding HIT RE in human skeletal muscle. Our data provide evidence that La-accumulation acutely affects p38 MAPK signaling, gene expression and thereby cell differentiation and adaptation in vitro, and likely in vivo.	[Willkomm, Lena; Gehlert, Sebastian; Jacko, Daniel; Bloch, Wilhelm] German Sport Univ Cologne, Dept Mol & Cellular Sports Med, Inst Cardiovasc Res & Sports Med, Cologne, Germany; [Schiffer, Thorsten] German Sport Univ Cologne, Outpatient Clin Sports Traumatol, Cologne, Germany; [Willkomm, Lena] Bayer Pharma AG, Cross Indicat Platform, Dis Genom, Wuppertal, Germany	German Sport University Cologne; German Sport University Cologne; Bayer AG; Bayer Healthcare Pharmaceuticals	Gehlert, S (corresponding author), German Sport Univ Cologne, Dept Mol & Cellular Sports Med, Inst Cardiovasc Res & Sports Med, Cologne, Germany.	gehlert@dshs-koeln.de	Gehlert, Sebastian/AAU-7086-2021; Gehlert, Sebastian/P-7687-2016	Gehlert, Sebastian/0000-0001-6940-3084	Federal Institute of Sport Science (BISp) [IIA1-507070103-09-10]	Federal Institute of Sport Science (BISp)	The human study was funded by the Federal Institute of Sport Science (BISp), Project # IIA1-507070103-09-10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altenburg TM, 2007, J APPL PHYSIOL, V103, P1752, DOI 10.1152/japplphysiol.00496.2007; Aziz A, 2010, EPIGENETICS-US, V5, P691, DOI 10.4161/epi.5.8.13045; Baker JS, 2010, J NUTR METAB, V2010, DOI 10.1155/2010/905612; Barres R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001; Beltman JGM, 2004, EUR J APPL PHYSIOL, V92, P485, DOI 10.1007/s00421-004-1105-6; Bergman BC, 1999, J APPL PHYSIOL, P87; BIGLANDRITCHIE B, 1976, J PHYSIOL-LONDON, V260, P267, DOI 10.1113/jphysiol.1976.sp011515; Buitrago S, 2013, J STRENGTH COND RES, V27, P1091, DOI 10.1519/JSC.0b013e318260ec77; Coffey VG, 2007, SPORTS MED, V37, P737, DOI 10.2165/00007256-200737090-00001; Cole F, 2004, DEV CELL, V7, P843, DOI 10.1016/j.devcel.2004.10.009; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; Gehlert S, 2014, PFLUGERS ARCH; Gibala M, 2009, APPL PHYSIOL NUTR ME, V34, P428, DOI 10.1139/H09-046; Godin R, 2010, J PHYSIOL-LONDON, V588, P4073, DOI 10.1113/jphysiol.2010.195925; Hashimoto T, 2008, MED SCI SPORT EXER, V40, P486, DOI [10.1249/MSS.0b013e31815fcb04, 10.1249/mss.0b013e31815fcb04]; Hashimoto T, 2007, FASEB J, V21, P2602, DOI 10.1096/fj.07-8174com; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hunter GR, 2003, J STRENGTH COND RES, V17, P76, DOI 10.1519/00124278-200302000-00013; JACOBS I, 1981, ACTA PHYSIOL SCAND, V111, P465, DOI 10.1111/j.1748-1716.1981.tb06764.x; JACOBS I, 1982, MED SCI SPORT EXER, V14, P457, DOI 10.1249/00005768-198206000-00009; JACOBS I, 1983, J APPL PHYSIOL, V55, P365, DOI 10.1152/jappl.1983.55.2.365; Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012; KARLSSON J, 1971, ACTA PHYSIOL SCAND, P1; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; Krustrup P, 2004, PFLUG ARCH EUR J PHY, V449, P56, DOI 10.1007/s00424-004-1304-3; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lagally KM, 2002, MED SCI SPORT EXER, V34, P552, DOI 10.1097/00005768-200203000-00025; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; Mcgee SL, 2011, J APPL PHYSIOL, V110, P258, DOI 10.1152/japplphysiol.00979.2010; McGee SL, 2009, J PHYSIOL-LONDON, V587, P5951, DOI 10.1113/jphysiol.2009.181065; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Mendler AN, 2012, INT J CANCER, V131, P633, DOI 10.1002/ijc.26410; Milovanova TN, 2008, MOL CELL BIOL, V28, P6248, DOI 10.1128/MCB.00795-08; Moller AB, 2013, PFLUG ARCH EUR J PHY, V465, P1785, DOI 10.1007/s00424-013-1318-9; NARDONE A, 1988, J PHYSIOL-LONDON, V395, P363, DOI 10.1113/jphysiol.1988.sp016924; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rampalli S, 2007, NAT STRUCT MOL BIOL, V14, P1150, DOI 10.1038/nsmb1316; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Szivak TK, 2013, J STRENGTH COND RES, V27, P748, DOI 10.1519/JSC.0b013e318259e009; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Tannerstedt J, 2009, J APPL PHYSIOL, V106, P1412, DOI 10.1152/japplphysiol.91243.2008; Tesch P, 1980, Acta Physiol Scand Suppl, V480, P1; Thornton MK, 2002, MED SCI SPORT EXER, V34, P715, DOI 10.1249/00005768-200204000-00024; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Willkomm L, 2014, STEM CELL RES, V12, P742, DOI 10.1016/j.scr.2014.03.004	50	9	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2017	12	5							e0176609	10.1371/journal.pone.0176609	http://dx.doi.org/10.1371/journal.pone.0176609			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9SB	28467493	gold, Green Published, Green Submitted			2023-01-03	WOS:000400647000061
J	Poliakov, E; Samuel, W; Duncan, T; Gutierrez, DB; Mata, NL; Redmond, TM				Poliakov, Eugenia; Samuel, William; Duncan, Todd; Gutierrez, Danielle B.; Mata, Nathan L.; Redmond, T. Michael			Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta 4-desaturase 1	PLOS ONE			English	Article							RETINOL-BINDING-PROTEIN; N-(4-HYDROXYPHENYL)RETINAMIDE INDUCES APOPTOSIS; PIGMENT EPITHELIAL-CELLS; BREAST-CANCER PATIENTS; PLASMA RETINOL; TISSUE TRANSGLUTAMINASE; INSULIN-RESISTANCE; GROWTH-INHIBITION; MAMMARY-GLAND; VITAMIN-A	The therapeutic capacity of fenretinide (N-[4-hydroxyphenyl] retinamide; 4-HPR) has been demonstrated for several conditions, including cancer, obesity, diabetes, and ocular disease. Yet, the mechanisms of action for its pleiotropic effects are still undefined. We hypothesized that investigation of two of the major physiological metabolites of fenretinide, N-[4methoxyphenyl] retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl) retinamide (3-keto-HPR), might begin to resolve the multifaceted effects of this synthetic retinoid. We analyzed the effects of fenretinide, MPR, 3-keto-HPR, and the non-retinoid RBP4 ligand A1120, on the activity of known targets of fenretinide, stearoyl-CoA desaturase 1 (SCD1) and dihydroceramide Delta 4-desaturase 1 (DES1) in ARPE-19 cells, and purified recombinant mouse betacarotene oxygenase 1 (BCO1) in vitro. Lipids and retinoids were extracted and quantified by liquid chromatography-mass spectrometry and reversed phase HPLC, respectively. The data demonstrate that while fenretinide is an inhibitor of the activities of these three enzymes, that 3-keto-HPR is a more potent inhibitor of all three enzymes, potentially mediating most of the in vivo beneficial effects of fenretinide. However, while MPR does not affect SCD1 and DES1 activity, it is a potent specific inhibitor of BCO1. We conclude that a deeper understanding of the mechanisms of action of fenretinide and its metabolites provides new avenues for therapeutic specificity. For example, administration of 3-keto-HPR instead of fenretinide may be preferential if inhibition of SCD1 or DES1 activity is the goal (cancer), while MPR may be better for BCO1 modulation (carotenoid metabolism). Continued investigation of fenretinide metabolites in the context of fenretinide's various therapeutic uses will begin to resolve the pleotropic nature of this compound.	[Poliakov, Eugenia; Samuel, William; Duncan, Todd; Gutierrez, Danielle B.; Redmond, T. Michael] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA; [Mata, Nathan L.] Acucela Inc, Seattle, WA USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Poliakov, E; Redmond, TM (corresponding author), NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.	poliakove@nei.nih.gov; redmondd@helix.nih.gov		Redmond, T. Michael/0000-0002-1813-5291	Intramural Research Program of the National Eye Institute, National Institutes of Health; Acucela Inc.; NATIONAL EYE INSTITUTE [ZIAEY000260] Funding Source: NIH RePORTER	Intramural Research Program of the National Eye Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Acucela Inc.; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the Intramural Research Program of the National Eye Institute, National Institutes of Health. Acucela Inc. provided support in the form of salaries for author NM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.	BERNI R, 1993, FASEB J, V7, P1179, DOI 10.1096/fasebj.7.12.8375617; Bhatti RA, 2003, INVEST OPHTH VIS SCI, V44, P44, DOI 10.1167/iovs.02-0167; Bikman BT, 2012, J BIOL CHEM, V287, P17426, DOI 10.1074/jbc.M112.359950; Bu PL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-236; Cazzaniga M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/172897; Chichili GR, 2005, INVEST OPHTH VIS SCI, V46, P3562, DOI 10.1167/iovs.05-0089; Cooper JP, 2011, BRIT J PHARMACOL, V163, P1263, DOI 10.1111/j.1476-5381.2011.01310.x; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; DELIA D, 1993, CANCER RES, V53, P6036; Dillon R, 2008, ANAL CHIM ACTA, V627, P99, DOI 10.1016/j.aca.2008.05.012; Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Fabbi M, 1999, CELL DEATH DIFFER, V6, P992, DOI 10.1038/sj.cdd.4400573; FORMELLI F, 1989, CANCER RES, V49, P6149; Giandomenico V, 1999, CARCINOGENESIS, V20, P1133, DOI 10.1093/carcin/20.6.1133; Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200; Gutierrez DB, 2010, PHOTOCH PHOTOBIO SCI, V9, P1513, DOI 10.1039/c0pp00230e; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; HULTIN TA, 1986, DRUG METAB DISPOS, V14, P714; Kraveka JM, 2007, J BIOL CHEM, V282, P16718, DOI 10.1074/jbc.M700647200; Lovat PE, 2000, EXP CELL RES, V260, P50, DOI 10.1006/excr.2000.4988; Masood MA, 2012, LIPIDS, V47, P209, DOI 10.1007/s11745-011-3633-2; Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d; Matyash V, 2008, J LIPID RES, V49, P1137, DOI 10.1194/jlr.D700041-JLR200; Mcilroy GD, 2013, DIABETES, V62, P825, DOI 10.2337/db12-0458; MEHTA RG, 1991, EUR J CANCER, V27, P138, DOI 10.1016/0277-5379(91)90471-O; MEHTA RG, 1988, BIOCHEM J, V256, P579, DOI 10.1042/bj2560579; Mehta RR, 1998, EUR J CANCER, V34, P902, DOI 10.1016/S0959-8049(98)00032-X; Mershon SM, 2007, BIOORG MED CHEM LETT, V17, P836, DOI 10.1016/j.bmcl.2006.10.050; MOON RC, 1979, CANCER RES, V39, P1339; Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200; Oridate N, 1996, CLIN CANCER RES, V2, P855; Pavan B, 2008, BIOSCIENCE REP, V28, P327, DOI 10.1042/BSR20080103; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Poliakov E, 2012, ADV EXP MED BIOL, V723, P167, DOI 10.1007/978-1-4614-0631-0_23; Preitner F, 2009, AM J PHYSIOL-ENDOC M, V297, pE1420, DOI 10.1152/ajpendo.00362.2009; Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820; Rahmaniyan M, 2011, J BIOL CHEM, V286, P24754, DOI 10.1074/jbc.M111.250779; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Samuel W, 2013, J CELL PHYSL; Samuel W, 2006, J CELL PHYSIOL, V209, P854, DOI 10.1002/jcp.20774; Samuel WK R, 2005, INVEST OPHTH VIS SCI, P5140; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Tiberio P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013362; Tosetti F, 2003, MOL PHARMACOL, V63, P565, DOI 10.1124/mol.63.3.565; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Veterans Medical Research Foundation UoC San Diego, 2008, RAND DOUBL BLIND STU; Villani MG, 2006, CANCER RES, V66, P3238, DOI 10.1158/0008-5472.CAN-05-3362; Villani MG, 2004, CLIN CANCER RES, V10, P6265, DOI 10.1158/1078-0432.CCR-04-0655; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Zanotti G, 2004, VITAM HORM, V69, P271, DOI 10.1016/S0083-6729(04)69010-8	51	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2017	12	4							e0176487	10.1371/journal.pone.0176487	http://dx.doi.org/10.1371/journal.pone.0176487			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EL	28448568	Green Submitted, gold, Green Published			2023-01-03	WOS:000400383600088
J	Williams, M; Bozhilov, K; Ghai, S; Talbot, P				Williams, Monique; Bozhilov, Krassimir; Ghai, Sanjay; Talbot, Prue			Elements including metals in the atomizer and aerosol of disposable electronic cigarettes and electronic hookahs	PLOS ONE			English	Article							TRACE-ELEMENTS; IN-VITRO; MAINSTREAM; TOBACCO; COPPER	Objective Our purpose was to quantify 36 inorganic chemical elements in aerosols from disposable electronic cigarettes (ECs) and electronic hookahs (EHs), examine the effect of puffing topography on elements in aerosols, and identify the source of the elements. Methods Thirty-six inorganic chemical elements and their concentrations in EC/EH aerosols were determined using inductively coupled plasma optical emission spectroscopy, and their source was identified by analyzing disassembled atomizers using scanning electron microscopy and energy dispersive X-ray spectroscopy. Results Of 36 elements screened, 35 were detected in EC/EH aerosols, while only 15 were detected in conventional tobacco smoke. Some elements/metals were present in significantly higher concentrations in EC/EH aerosol than in cigarette smoke. Concentrations of particular elements/metals within EC/EH brands were sometimes variable. Aerosols generated at low and high air-flow rates produced the same pattern of elements, although the total element concentration decreased at the higher air flow rate. The relative amount of elements in the first and last 60 puffs was generally different. Silicon was the dominant element in aerosols from all EC/EH brands and in cigarette smoke. The elements appeared to come from the filament (nickel, chromium), thick wire (copper coated with silver), brass clamp (copper, zinc), solder joints (tin, lead), and wick and sheath (silicon, oxygen, calcium, magnesium, aluminum). Lead was identified in the solder and aerosol of two brands of EHs (up to 0.165 mu g/10 puffs). Conclusion These data show that EC/EH aerosols contain a mixture of elements, including heavy metals, with concentrations often significantly higher than in conventional cigarette smoke. While the health effects of inhaling mixtures of heated metals is currently not known, these data will be valuable in future risk assessments involving EC/EH elements/metals.	[Williams, Monique; Ghai, Sanjay; Talbot, Prue] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; [Bozhilov, Krassimir] Univ Calif Riverside, Cent Facil Adv Microscopy & Microanal, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Talbot, P (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.	talbot@ucr.edu	Talbot, Prue/AAY-3896-2021		Tobacco-Related Disease Research Program of California [22RT-0127]; Graduate Research Mentorship Program Award; Predoctoral Fellowship from the Tobacco-Related Disease Research Program of California [23DT-0101]; NIH [R01 DA036493]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036493] Funding Source: NIH RePORTER	Tobacco-Related Disease Research Program of California(University of California System); Graduate Research Mentorship Program Award; Predoctoral Fellowship from the Tobacco-Related Disease Research Program of California; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Support was provided by the Tobacco-Related Disease Research Program of California Grant #22RT-0127 (PT) (trdrp.org), a Graduate Research Mentorship Program Award (MW), a Predoctoral Fellowship from the Tobacco-Related Disease Research Program of California #23DT-0101 (MW), and a NIH grant #R01 DA036493 (PT) (NIH.gov). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASTDR, 2004, TOX PROF COPP, P121; ATSDR Division of Toxicology HHS, 2015, SUMM DAT 2015 PRIOR, P1; ATSDR U., 2007, TOXICOLOGICAL PROFIL, V1, P582; Behar RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117222; Bernhard D, 2005, IUBMB LIFE, V57, P805, DOI 10.1080/15216540500459667; Bourgeois MM, 2015, HAMILTON HARDYS IND, P109; Buhler Wayne, 2006, FQPA FOOD QUALITY PR, V1996; Chen Z, 2006, TOXICOL LETT, V163, P109, DOI 10.1016/j.toxlet.2005.10.003; Cheng TR, 2014, TOB CONTROL, V23, P11, DOI 10.1136/tobaccocontrol-2013-051482; CHIBA M, 1992, B WORLD HEALTH ORGAN, V70, P269; Coyle JC., 2015, HAMILTON HARDYS IND, P127; Cross FB, 2001, HUM EXP TOXICOL, V20, P122, DOI 10.1191/096032701678126525; Das S., 2011, INT J PHARM SCI REV, V11, P13; Food US and Drug Administration, 2012, FED REGISTER, V77, P20034; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Harbison Raymond D A, 2015, HAMILTON HARDYS IND, P247; Harper C., 2005, TOXICOLOGICAL PROFIL, P302; Hua My, 2016, Prev Med Rep, V4, P169, DOI 10.1016/j.pmedr.2016.06.002; Hua M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2324; Hua M, 2013, TOB CONTROL, V22, P103, DOI 10.1136/tobaccocontrol-2011-050226; Jenkins S, 2011, ELECT CIGARETTES MAY; Johnson G., 2015, HAMILTON HARDYS IND, P33; Knoll M, 1998, REPROD TOXICOL, V12, P57, DOI 10.1016/S0890-6238(97)00100-7; KNOLL M, 1995, BIOL REPROD, V53, P29, DOI 10.1095/biolreprod53.1.29; Laugesen M., 2008, SAFETY REPORT RUYAN; Lee N-C, 2009, MAT ADV PACKAGING, P181, DOI DOI 10.1007/978-0-387-78219-5_5; Lerner CA, 2015, ENVIRON POLLUT, V198, P100, DOI 10.1016/j.envpol.2014.12.033; LeTran D., 2017, THE IDEAL GAS LAW; Prueitt R. L., 2015, HAMILTON HARDYS IND, P173, DOI [10.1002/9781118834015.ch25, DOI 10.1002/9781118834015.CH25]; Roney N., 2005, TOXICOLOGICAL PROFIL, P352; Ryan J, 2010, J ANAL CHEM+, V1, P34; Samczytiski Z, 2012, SCI WORLD J, V216380, P1; Smith CJ, 1997, FOOD CHEM TOXICOL, V35, P1107, DOI 10.1016/S0278-6915(97)00063-X; Stephen FD, 2015, HAMILTON HARDYS IND, P131; Steve Morris, 2015, HAMILTON HARDYS IND, P25; Stohs SJ, 1997, INHAL TOXICOL, V9, P867; Talih S, 2015, NICOTINE TOB RES, V17, P150, DOI 10.1093/ntr/ntu174; Trtchounian A, 2010, NICOTINE TOB RES, V12, P905, DOI 10.1093/ntr/ntq114; Truncale T, 2015, HAMILTON HARDYS IND, P289; WHO, 2012, SOP01 WHO TOBLABNET; Williams M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138933; Williams M, 2015, NICOTINE TOB RES, V17, P201, DOI 10.1093/ntr/ntu118; Williams M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057987; Yogesh P., 2015, SPECTROSCOPY-US, V31, P8	44	83	88	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2017	12	4							e0175430	10.1371/journal.pone.0175430	http://dx.doi.org/10.1371/journal.pone.0175430			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KD	28414730	Green Published, gold			2023-01-03	WOS:000399874800025
J	Jena, AB; Mann, C; Wedlund, LN; Olenski, A				Jena, Anupam B.; Mann, Clay; Wedlund, Leia N.; Olenski, Andrew			Delays in Emergency Care and Mortality during Major US Marathons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; ACUTE MYOCARDIAL-INFARCTION; ADVANCED LIFE-SUPPORT; TO-BALLOON TIME; WORLD-CUP; RESUSCITATION EFFORTS; PRIMARY ANGIOPLASTY; FOOTBALL; DURATION; OUTCOMES	BACKGROUND Large marathons frequently involve widespread road closures and infrastructure disruptions, which may create delays in emergency care for nonparticipants with acute medical conditions who live in proximity to marathon routes. METHODS We analyzed Medicare data on hospitalizations for acute myocardial infarction or cardiac arrest among Medicare beneficiaries (>= 65 years of age) in 11 U.S. cities that were hosting major marathons during the period from 2002 through 2012 and compared 30-day mortality among the beneficiaries who were hospitalized on the date of a marathon, those who were hospitalized on the same day of the week as the day of the marathon in the 5 weeks before or the 5 weeks after the marathon, and those who were hospitalized on the same day as the marathon but in surrounding ZIP Code areas unaffected by the marathon. We also analyzed data from a national registry of ambulance transports and investigated whether ambulance transports occurring before noon in marathon-affected areas (when road closures are likely) had longer scene-to-hospital transport times than on nonmarathon dates. We also compared transport times on marathon dates with those on nonmarathon dates in these same areas during evenings (when roads were reopened) and in areas unaffected by the marathon. RESULTS The daily frequency of hospitalizations was similar on marathon and nonmarathon dates (mean number of hospitalizations per city, 10.6 and 10.5, respectively; P=0.71); the characteristics of the beneficiaries hospitalized on marathon and nonmarathon dates were also similar. Unadjusted 30-day mortality in marathon-affected areas on marathon dates was 28.2% (323 deaths in 1145 hospitalizations) as compared with 24.9% (2757 deaths in 11,074 hospitalizations) on nonmarathon dates (absolute risk difference, 3.3 percentage points; 95% confidence interval, 0.7 to 6.0;P = 0.01; relative risk difference, 13.3%). This pattern persisted after adjustment for covariates and in an analysis that included beneficiaries who had five or more chronic medical conditions (a group that is unlikely to be hospitalized because of marathon participation). No significant differences were found with respect to where patients were hospitalized or the treatments they received in the hospital. Ambulance scene-to-hospital transport times for pickups before noon were 4.4 minutes longer on marathon dates than on nonmarathon dates (relative difference, 32.1%; P = 0.005). No delays were found in evenings or in marathon-unaffected areas. CONCLUSIONS Medicare beneficiaries who were admitted to marathon-affected hospitals with acute myocardial infarction or cardiac arrest on marathon dates had longer ambulance transport times before noon (4.4 minutes longer) and higher 30-day mortality than beneficiaries who were hospitalized on nonmarathon dates.	[Jena, Anupam B.; Olenski, Andrew] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Wedlund, Leia N.] Harvard Univ, Cambridge, MA 02138 USA; [Mann, Clay] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA; [Mann, Clay] Natl EMS Informat Syst Tech Assistance Ctr, Salt Lake City, UT USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Bureau of Economic Research; Harvard University; Utah System of Higher Education; University of Utah	Jena, AB (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	jena@hcp.med.harvard.edu		Olenski, Andrew/0000-0002-7461-0536	National Institutes of Health; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD017897] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funded by the National Institutes of Health.	Berthier F, 2003, HEART, V89, P555, DOI 10.1136/heart.89.5.555; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Carroll D, 2002, BRIT MED J, V325, P1439, DOI 10.1136/bmj.325.7378.1439; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; De Luca G, 2003, J AM COLL CARDIOL, V42, P991, DOI 10.1016/S0735-1097(03)00919-7; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Goldberger ZD, 2012, LANCET, V380, P1473, DOI 10.1016/S0140-6736(12)60862-9; Goto Y, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002819; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Mann NC, 2015, PREHOSP EMERG CARE, V19, P232, DOI 10.3109/10903127.2014.959219; Mathews SC, 2012, AM J SPORT MED, V40, P1495, DOI 10.1177/0363546512444555; Redelmeier DA, 2007, BRIT MED J, V335, P1275, DOI 10.1136/bmj.39384.551539.25; Reynolds JC, 2013, CIRCULATION, V128, P2488, DOI 10.1161/CIRCULATIONAHA.113.002408; Sanghavi P, 2015, ANN INTERN MED, V163, P681, DOI 10.7326/M15-0557; Sanghavi P, 2015, JAMA INTERN MED, V175, P196, DOI 10.1001/jamainternmed.2014.5420; Wilbert-Lampen U, 2008, NEW ENGL J MED, V358, P475, DOI 10.1056/NEJMoa0707427; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209; Witte DR, 2000, BMJ-BRIT MED J, V321, P1552, DOI 10.1136/bmj.321.7276.1552; Zhang YT, 2012, NEW ENGL J MED, V367, P1724, DOI 10.1056/NEJMsa1203980	21	39	39	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2017	376	15					1441	1450		10.1056/NEJMsa1614073	http://dx.doi.org/10.1056/NEJMsa1614073			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER6EX	28402772	Green Accepted			2023-01-03	WOS:000398899200011
J	Ladhani, L; Pardon, G; Meeuws, H; van Wesenbeeck, L; Schmidt, K; Stuyver, L; van der Wijngaart, W				Ladhani, Laila; Pardon, Gaspard; Meeuws, Hanne; van Wesenbeeck, Liesbeth; Schmidt, Kristiane; Stuyver, Lieven; van der Wijngaart, Wouter			Sampling and detection of airborne influenza virus towards point-of-care applications	PLOS ONE			English	Article							ELECTROSTATIC PRECIPITATOR; EXHALED PARTICLES; COLLECTION; AEROSOLS	Airborne transmission of the influenza virus contributes significantly to the spread of this infectious pathogen, particularly over large distances when carried by aerosol droplets with long survival times. Efficient sampling of virus-loaded aerosol in combination with a low limit of detection of the collected virus could enable rapid and early detection of airborne influenza virus at the point-of-care setting. Here, we demonstrate a successful sampling and detection of airborne influenza virus using a system specifically developed for such applications. Our system consists of a custom-made electrostatic precipitation (ESP)-based bioaerosol sampler that is coupled with downstream quantitative polymerase chain reaction (qPCR) analysis. Aerosolized viruses are sampled directly into a miniaturized collector with liquid volume of 150 mu L, which constitutes a simple and direct interface with subsequent biological assays. This approach reduces sample dilution by at least one order of magnitude when compared to other liquid-based aerosol bio-samplers. Performance of our ESP-based sampler was evaluated using influenza virus-loaded sub-micron aerosols generated from both cultured and clinical samples. Despite the miniaturized collection volume, we demonstrate a collection efficiency of at least 10% and sensitive detection of a minimum of 3721 RNA copies. Furthermore, we show that an improved extraction protocol can allow viral recovery of down to 303 RNA copies and a maximum sampler collection efficiency of 47%. A device with such a performance would reduce sampling times dramatically, from a few hours with current sampling methods down to a couple of minutes with our ESP-based bioaerosol sampler.	[Ladhani, Laila; Pardon, Gaspard; van der Wijngaart, Wouter] KTH Royal Inst Technol, Dept Micro & Nanosyst, Stockholm, Sweden; [Meeuws, Hanne; van Wesenbeeck, Liesbeth; Schmidt, Kristiane; Stuyver, Lieven] Janssen Diagnost, Beerse, Belgium	Royal Institute of Technology	van der Wijngaart, W (corresponding author), KTH Royal Inst Technol, Dept Micro & Nanosyst, Stockholm, Sweden.	wouter@kth.se	Pardon, Gaspard/G-8304-2011; van der Wijngaart, Wouter/O-2378-2019	Pardon, Gaspard/0000-0001-9177-1174; van der Wijngaart, Wouter/0000-0001-8248-6670	European Union [115153]; European Federation of Pharmaceutical Industries and Associations (RAPP-ID project) [115153]	European Union(European Commission); European Federation of Pharmaceutical Industries and Associations (RAPP-ID project)	The funder (jointly between Innovative Medicines Initiative (IMI), http//www.imi.europa.eu/content/rapp-id, a public-private partnership between the European Union, and the European Federation of Pharmaceutical Industries and Associations (RAPP-ID project, grant agreement, no. 115153) provided support in the form of salaries for authors: L.L., G.P., H.M., L.vW., KS., L.S. and W.vW; and materials. The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agranovski IE, 2005, J AEROSOL SCI, V36, P609, DOI 10.1016/j.jaerosci.2004.11.014; Almstrand AC, 2010, J APPL PHYSIOL, V108, P584, DOI 10.1152/japplphysiol.00873.2009; Almstrand AC, 2009, ANAL CHEM, V81, P662, DOI 10.1021/ac802055k; Blachere FM, 2007, INFLUENZA OTHER RESP, V1, P113, DOI 10.1111/j.1750-2659.2007.00020.x; Brooke CB, 2014, FUTURE VIROL, V9, P41, DOI 10.2217/FVL.13.118; Brown JR, 2015, J HOSP INFECT, V91, P278, DOI 10.1016/j.jhin.2015.08.004; Edwards DA, 2004, P NATL ACAD SCI USA, V101, P17383, DOI 10.1073/pnas.0408159101; Fabian P, 2009, INDOOR AIR, V19, P433, DOI 10.1111/j.1600-0668.2009.00609.x; Han T, 2010, AEROSOL SCI TECH, V44, P339, DOI 10.1080/02786821003649352; Holmgren H, 2010, J AEROSOL SCI, V41, P439, DOI 10.1016/j.jaerosci.2010.02.011; Kettleson EM, 2009, ENVIRON SCI TECHNOL, V43, P5940, DOI 10.1021/es803289w; Lemon SM, 2005, THREAT PANDEMIC INFL; Mainelis G, 2002, J AEROSOL SCI, V33, P1417, DOI 10.1016/S0021-8502(02)00091-5; Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205; Nauwelaers D, 2009, J CLIN VIROL, V46, P238, DOI 10.1016/j.jcv.2009.08.013; Nikitin N, 2014, ADV VIROL, V2014, P1, DOI DOI 10.1155/2014/859090); Pardon G, 2015, SENSOR ACTUAT B-CHEM, V212, P344, DOI 10.1016/j.snb.2015.02.008; Richard M, 2016, FEMS MICROBIOL REV, V40, P68, DOI 10.1093/femsre/fuv039; Tan MM, 2011, AEROSOL SCI TECH, V45, P1154, DOI 10.1080/02786826.2011.582193; Tellier R., 2009, J R SOC INTERFACE; Van Wesenbeeck L, 2014, VIROL J, V11, P105; Van Wesenbeeck L, 2013, J CLIN MICROBIOL, V51, P2977, DOI 10.1128/JCM.00911-13; Yang W, 2011, J R SOC INTERFACE, V8, P1176, DOI 10.1098/rsif.2010.0686; Zhao Y, 2014, ANN AGR ENV MED, V21, P464, DOI 10.5604/12321966.1120585	24	30	31	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2017	12	3							e0174314	10.1371/journal.pone.0174314	http://dx.doi.org/10.1371/journal.pone.0174314			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VE	28350811	gold, Green Submitted, Green Published			2023-01-03	WOS:000399174400024
J	Rauner, N; Meuris, M; Zoric, M; Tiller, JC				Rauner, Nicolas; Meuris, Monika; Zoric, Mirjana; Tiller, Joerg C.			Enzymatic mineralization generates ultrastiff and tough hydrogels with tunable mechanics	NATURE			English	Article							POLYMER HYDROGELS; NANOCOMPOSITE HYDROGELS; FRACTURE-TOUGHNESS; BONE REGENERATION; HYBRID HYDROGELS; CARTILAGE; COMPOSITES; STIFFNESS; DESIGN; CELLS	The cartilage and skin of animals, which are made up of more than fifty per cent water, are rather stiff (having elastic moduli of up to 100 megapascals)(1,2) as well as tough and hard to break (with fracture energies of up to 9,000 joules per square metre)(3,4). Such features make these biological materials mechanically superior to existing synthetic hydrogels. Lately, progress has been made in synthesizing tough hydrogels, with double-network hydrogels achieving the toughness of skin(5) and inorganic-organic composites showing even better performance(6). However, these materials owe their toughness to high stretchability; in terms of stiffness, synthetic hydrogels cannot compete with their natural counterparts, with the best examples having elastic moduli of just 10 megapascals or less(7-11). Previously, we described the enzyme-induced precipitation and crystallization of hydrogels containing calcium carbonate, but the resulting materials were brittle(12). Here we report the enzymeinduced formation of amorphous calcium phosphate nanostructures that are homogenously distributed within polymer hydrogels. Our best materials have fracture energies of 1,300 joules per square metre even in their fully water-swollen state-a value superior to that of most known water-swollen synthetic materials. We are also able to modulate their stiffness up to 440 megapascals, well beyond that of cartilage and skin. Furthermore, the highly filled composite materials can be designed to be optically transparent and to retain most of their stretchability even when notched. We show that percolation drives the mechanical properties, particularly the high stiffness, of our uniformly mineralized hydrogels.	[Rauner, Nicolas; Meuris, Monika; Zoric, Mirjana; Tiller, Joerg C.] Tech Univ Dortmund, Emil Figge Str 66, D-44227 Dortmund, Germany	Dortmund University of Technology	Tiller, JC (corresponding author), Tech Univ Dortmund, Emil Figge Str 66, D-44227 Dortmund, Germany.	joerg.tiller@udo.edu						Arimoto H, 2015, SKIN RES TECHNOL, V21, P94, DOI 10.1111/srt.12163; BETTINI R, 1995, J CONTROL RELEASE, V37, P105, DOI 10.1016/0168-3659(95)00069-K; Buckwalter JA, 1998, AAOS INSTR COURS LEC, V47, P477; Calvert P, 2009, ADV MATER, V21, P743, DOI 10.1002/adma.200800534; Chevallet M, 2006, NAT PROTOC, V1, P1852, DOI 10.1038/nprot.2006.288; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Douglas TEL, 2014, J TISSUE ENG REGEN M, V8, P906, DOI 10.1002/term.1616; Filmon R, 2000, J BIOMAT SCI-POLYM E, V11, P849, DOI 10.1163/156856200744057; Gao GR, 2015, ACS APPL MATER INTER, V7, P5029, DOI 10.1021/acsami.5b00704; Geise GM, 2011, J MEMBRANE SCI, V369, P130, DOI 10.1016/j.memsci.2010.11.054; Gkioni K, 2010, TISSUE ENG PART B-RE, V16, P577, DOI 10.1089/ten.TEB.2010.0462; Hoffmann C, 2008, J MATER SCI-MATER M, V19, P907, DOI 10.1007/s10856-007-0165-7; Killion JA, 2013, MAT SCI ENG C-MATER, V33, P4203, DOI 10.1016/j.msec.2013.06.013; KOUTROUPI KS, 1990, J BIOMECH, V23, P281, DOI 10.1016/0021-9290(90)90018-X; Langer R, 1998, NATURE, V392, P5; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Li JY, 2014, ACS MACRO LETT, V3, P520, DOI 10.1021/mz5002355; Lin ST, 2014, SOFT MATTER, V10, P7519, DOI 10.1039/c4sm01039f; Lin WC, 2010, MACROMOLECULES, V43, P2554, DOI 10.1021/ma901937r; Little CJ, 2011, TISSUE ENG PART B-RE, V17, P213, DOI [10.1089/ten.teb.2010.0572, 10.1089/ten.TEB.2010.0572]; Long R, 2016, SOFT MATTER, V12, P8069, DOI 10.1039/c6sm01694d; Luo YX, 2015, RSC ADV, V5, P43480, DOI 10.1039/c5ra04308e; Mayumi K, 2016, EXTREME MECH LETT, V6, P52, DOI 10.1016/j.eml.2015.12.002; Moutos FT, 2007, NAT MATER, V6, P162, DOI 10.1038/nmat1822; Rauner N, 2015, MACROMOL RAPID COMM, V36, P224, DOI 10.1002/marc.201400426; Rauner N, 2014, ACTA BIOMATER, V10, P3942, DOI 10.1016/j.actbio.2014.05.021; Razmjou A, 2013, CHEM ENG J, V215, P913, DOI 10.1016/j.cej.2012.11.088; RIVLIN RS, 1953, J POLYM SCI, V10, P291, DOI 10.1002/pol.1953.120100303; Sato K, 2015, ADV MATER, V27, P6990, DOI 10.1002/adma.201502967; Schweizer S, 2007, MACROMOL BIOSCI, V7, P1085, DOI 10.1002/mabi.200600283; Simha NK, 2004, J MATER SCI-MATER M, V15, P631, DOI 10.1023/B:JMSM.0000026104.30607.c7; Song RQ, 2011, CRYSTENGCOMM, V13, P1249, DOI 10.1039/c0ce00419g; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Tanriseven A, 2008, BIOCHEM ENG J, V39, P430, DOI 10.1016/j.bej.2007.10.011; Wegst UGK, 2004, PHILOS MAG, V84, P2167, DOI 10.1080/14786430410001680935; Yuan SS, 2014, J MATER SCI, V49, P5481, DOI 10.1007/s10853-014-8261-9; Zhao LZ, 2015, SOFT MATTER, V11, P9229, DOI 10.1039/c5sm01277e	37	156	157	27	520	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2017	543	7645					407	+		10.1038/nature21392	http://dx.doi.org/10.1038/nature21392			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9RN	28241140				2023-01-03	WOS:000396337400047
J	Sun, EC; Dixit, A; Humphreys, K; Darnall, BD; Baker, LC; Mackey, S				Sun, Eric C.; Dixit, Anjali; Humphreys, Keith; Darnall, Beth D.; Baker, Laurence C.; Mackey, Sean			Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DRUG-MONITORING PROGRAMS; UNITED-STATES; ATTRIBUTABLE FRACTION; PRESCRIBING PATTERNS; GEOGRAPHIC-VARIATION; SUBSTANCE USE; CHRONIC PAIN; VETERANS; COHORT; RATES	OBJECTIVES To identify trends in concurrent use of a benzodiazepine and an opioid and to identify the impact of these trends on admissions to hospital and emergency room visits for opioid overdose. DESIGN Retrospective analysis of claims data, 2001-13. SETTING Administrative health claims database. PARTICIPANTS 315 428 privately insured people aged 18-64 who were continuously enrolled in a health plan with medical and pharmacy benefits during the study period and who also filled at least one prescription for an opioid. INTERVENTIONS Concurrent benzodiazepine/opioid use, defined as an overlap of at least one day in the time periods covered by prescriptions for each drug. MAIN OUTCOME MEASURES Annual percentage of opioid users with concurrent benzodiazepine use; annual incidence of visits to emergency room and inpatient admissions for opioid overdose. RESULTS 9% of opioid users also used a benzodiazepine in 2001, increasing to 17% in 2013 (80% relative increase). This increase was driven mainly by increases among intermittent, as opposed to chronic, opioid users. Compared with opioid users who did not use benzodiazepines, concurrent use of both drugs was associated with an increased risk of an emergency room visit or inpatient admission for opioid overdose (adjusted odds ratio 2.14, 95% confidence interval 2.05 to 2.24; P< 0.001) among all opioid users. The adjusted odds ratio for an emergency room visit or inpatient admission for opioid overdose was 1.42 (1.33 to 1.51; P< 0.001) for intermittent opioid users and 1.81 (1.67 to 1.96; P< 0.001) chronic opioid users. If this association is causal, elimination of concurrent benzodiazepine/opioid use could reduce the risk of emergency room visits related to opioid use and inpatient admissions for opioid overdose by an estimated 15% (95% confidence interval 14 to 16). CONCLUSIONS From 2001 to 2013, concurrent benzodiazepine/opioid use sharply increased in a large sample of privately insured patients in the US and significantly contributed to the overall population risk of opioid overdose.	[Sun, Eric C.; Darnall, Beth D.; Mackey, Sean] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Sch Med, 300 Pasteur Dr,H3580, Stanford, CA 94305 USA; [Dixit, Anjali] Univ Calif San Francisco, Dept Anesthesiol & Perioperat Care, 521 Parnassus Ave, San Francisco, CA 94131 USA; [Humphreys, Keith] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 401 N Quarry Rd,MC 5717, Stanford, CA 94305 USA; [Humphreys, Keith] Stanford Univ, Dept Psychiat, Sch Med, 401 N Quarry Rd,MC 5717, Stanford, CA 94305 USA; [Baker, Laurence C.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, 150 Governors Lane,HRP Redwood Bldg, Stanford, CA 94305 USA; [Baker, Laurence C.] Natl Bur Econ Res, 150 Governors Lane,HRP Redwood Bldg, Stanford, CA 94305 USA	Stanford University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; National Bureau of Economic Research	Sun, EC (corresponding author), Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Sch Med, 300 Pasteur Dr,H3580, Stanford, CA 94305 USA.	esun1@stanford.edu	Sun, Eric/K-3900-2019; Mackey, Sean/AAF-3314-2019	Dixit, Anjali/0000-0002-4327-4832; Mackey, Sean/0000-0001-7744-5348; Darnall, Beth D./0000-0003-3590-511X	Foundation for Anesthesia Education and Research; Anesthesia Quality Institute; Veterans Affairs health services research and development service	Foundation for Anesthesia Education and Research; Anesthesia Quality Institute; Veterans Affairs health services research and development service(US Department of Veterans Affairs)	ECS was supported by a mentored research training grant from the Foundation for Anesthesia Education and Research and the Anesthesia Quality Institute. KNH was supported by funding from the Veterans Affairs health services research and development service. The research conducted was independent of any involvement from the sponsors of the study. Study sponsors were not involved in study design, data interpretation, writing, or the decision to submit the article for publication.	Aizcorbe Ana, 2012, Stat J IAOS, V28, P43, DOI 10.3233/SJI-2012-0743; Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; Baker L, 2013, HEALTH AFFAIR, V32, P1583, DOI 10.1377/hlthaff.2013.0309; Bertrand M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Brady AR, 1998, STATA TECHNICAL B, P8; Carroll I, 2012, ANESTH ANALG, V115, P694, DOI 10.1213/ANE.0b013e31825c049f; Chen JH, 2016, JAMA INTERN MED, V176, P259, DOI 10.1001/jamainternmed.2015.6662; Chernew ME, 2010, AM J MANAG CARE, V16, P131; Clarke Hance, 2014, BMJ, V348, pg1251, DOI 10.1136/bmj.g1251; DARKE S, 1992, DRUG ALCOHOL DEPEN, V31, P31, DOI 10.1016/0376-8716(92)90005-W; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Dor A, 2012, CANCER-AM CANCER SOC, V118, P5741, DOI 10.1002/cncr.27573; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Dunn A, 2013, HEALTH SERV RES, V48, P1173, DOI 10.1111/1475-6773.12008; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Sobrino AMF, 2009, ADICCIONES, V21, P143, DOI 10.20882/adicciones.241; Friedly J, 2008, ARCH PHYS MED REHAB, V89, P1011, DOI 10.1016/j.apmr.2007.10.037; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Gugelmann HM, 2011, JAMA-J AM MED ASSOC, V306, P2258, DOI 10.1001/jama.2011.1712; Hermos JA, 2004, ARCH INTERN MED, V164, P2361, DOI 10.1001/archinte.164.21.2361; Jones JD, 2012, DRUG ALCOHOL DEPEN, V125, P8, DOI 10.1016/j.drugalcdep.2012.07.004; Karaca-Mandic P, 2012, JAMA-J AM MED ASSOC, V307, P1284, DOI 10.1001/jama.2012.340; Lan CW, 2016, AM J ADDICTION, V25, P7, DOI 10.1111/ajad.12319; Leider HL, 2011, AM J MANAG CARE, V17, P32; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; McDonald DC, 2014, PHARMACOEPIDEM DR S, V23, P1258, DOI 10.1002/pds.3690; McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007; Meiler A, 2005, SCHWEIZ ARCH NEUROL, V156, P310, DOI DOI 10.4414/sanp.2005.01626; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Ojima T, 2004, PEDIATR INT, V46, P264, DOI 10.1111/j.1442-200x.2004.01881.x; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2011, PAIN MED, V12, P747, DOI 10.1111/j.1526-4637.2011.01062.x; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Raebel MA, 2013, JAMA-J AM MED ASSOC, V310, P1369, DOI 10.1001/jama.2013.278344; Ross J, 2000, ADDICTION, V95, P1785, DOI 10.1046/j.1360-0443.2000.951217858.x; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Saunders KW, 2012, J PAIN, V13, P266, DOI 10.1016/j.jpain.2011.11.004; Sehgal N, 2013, J PAIN, V14, pS85, DOI 10.1016/j.jpain.2013.01.676; Vazan P, 2013, SUBST USE MISUSE, V48, P880, DOI 10.3109/10826084.2013.796989; WAGNER TH, 2007, PSYCHOL SERVICES, V0004	44	272	273	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	2017	356								j760	10.1136/bmj.j760	http://dx.doi.org/10.1136/bmj.j760			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO9NH	28292769	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000397014900002
J	Fritz, Z; Slowther, AM; Perkins, GD				Fritz, Zoe; Slowther, Anne-Marie; Perkins, Gavin D.			Resuscitation policy should focus on the patient, not the decision	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE-SUSTAINING TREATMENT; CARDIOPULMONARY-RESUSCITATION; ORDERS; PREFERENCES; SURVIVAL; IMPACT		[Fritz, Zoe] Warwick Med Sch, Div Hlth Sci, Soc & Eth, Gibbet Hill Campus, Coventry CV4 7AL, W Midlands, England; [Fritz, Zoe] Warwick Med Sch, Div Hlth Sci, Acute Med, Gibbet Hill Campus, Coventry CV4 7AL, W Midlands, England; [Slowther, Anne-Marie] Warwick Med Sch, Div Hlth Sci, Clin Eth, Gibbet Hill Campus, Coventry CV4 7AL, W Midlands, England; [Perkins, Gavin D.] Warwick Med Sch, Div Hlth Sci, Crit Care Med, Gibbet Hill Campus, Coventry CV4 7AL, W Midlands, England; [Fritz, Zoe] Cambridge Univ Hosp, Soc & Eth, Cambridge, England; [Fritz, Zoe] Cambridge Univ Hosp, Acute Med, Cambridge, England; [Perkins, Gavin D.] Univ Warwick, Heart England NHS Fdn Trust, Crit Care Med, Coventry, W Midlands, England	University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Cambridge; University of Cambridge; Heart of England NHS Foundation Trust; University of Warwick	Fritz, Z (corresponding author), Warwick Med Sch, Div Hlth Sci, Soc & Eth, Gibbet Hill Campus, Coventry CV4 7AL, W Midlands, England.	zoe.fritz@addenbrookes.nhs.uk	Perkins, Gavin/E-7613-2010	Perkins, Gavin/0000-0003-3027-7548; Fritz, Zoe/0000-0001-9403-409X	National Institute for Health Research Health Service Delivery Research Programme [12/5001/55, 15/15/09]; Wellcome Trust [WT100577MA]; National Institute for Health Research [15/15/09, NF-SI-0514-10139, 12/5001/55] Funding Source: researchfish	National Institute for Health Research Health Service Delivery Research Programme; Wellcome Trust(Wellcome Trust); National Institute for Health Research(National Institute for Health Research (NIHR))	Some of the research reported in this paper was funded by the National Institute for Health Research Health Service Delivery Research Programme (project number 12/5001/55 and 15/15/09); some from the Wellcome Trust Grant WT100577MA.	Andrew E, 2017, RESUSCITATION, V110, P42, DOI 10.1016/j.resuscitation.2016.10.018; Aune S, 2005, RESUSCITATION, V65, P291, DOI 10.1016/j.resuscitation.2004.11.028; Beach MC, 2002, J AM GERIATR SOC, V50, P2057, DOI 10.1046/j.1532-5415.2002.50620.x; Chen JLT, 2008, AM HEART J, V156, P78, DOI 10.1016/j.ahj.2008.01.030; Cohen RI, 2009, J CRIT CARE, V24, P311, DOI 10.1016/j.jcrc.2008.01.007; Cohn S, 2013, QJM-INT J MED, V106, P165, DOI 10.1093/qjmed/hcs222; Findlay G, 2012, COMMUNICATION; Fried TR, 2006, ARCH INTERN MED, V166, P890, DOI 10.1001/archinte.166.8.890; Fritz Z, 2015, J EVAL CLIN PRACT, V21, P109, DOI 10.1111/jep.12256; Fritz Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070977; Fritz ZBM, 2014, RESUSCITATION, V85, P444, DOI 10.1016/j.resuscitation.2014.01.016; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Grasner JT, 2016, RESUSCITATI IN PRESS, DOI [10.1016/j.resuscitation.2016.10.001, DOI 10.1016/J.RESUSCITATION.2016.10.001]; Halpern SD, 2015, NEW ENGL J MED, V373, P2001, DOI 10.1056/NEJMp1509664; Henneman E A, 1994, Am J Crit Care, V3, P467; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Janssen DJA, 2012, CHEST, V141, P1251, DOI 10.1378/chest.11-1472; JUDE JR, 1961, JAMA-J AM MED ASSOC, V178, P1063, DOI 10.1001/jama.1961.03040500005002; Mentzelopoulos SD, 2016, RESUSCITATION, V100, P11, DOI 10.1016/j.resuscitation.2015.12.010; Perkins GD, 2016, DO NOT ATTEMPT CARDI; Pitcher D, 2017, BMJ-BRIT MED J, V356, P876; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; Rosoff PM, 2017, AM J BIOETHICS, V17, P26, DOI 10.1080/15265161.2016.1265163; Sivakumar R, 2004, J MED ETHICS, V30, P311, DOI 10.1136/jme.2002.002915; Sulzgruber P, 2016, EUR HEART J-ACUTE CA	25	49	48	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2017	356								j813	10.1136/bmj.j813	http://dx.doi.org/10.1136/bmj.j813			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EM9JQ	28246084	Green Published, hybrid			2023-01-03	WOS:000395628100016
J	Srikanok, S; Parker, DM; Parker, AL; Lee, T; Min, AM; Ontuwong, P; Tan, SO; Sirinonthachai, S; McGready, R				Srikanok, Somjet; Parker, Daniel M.; Parker, Amber L.; Lee, Tracey; Min, Aung Myat; Ontuwong, Pranee; Tan, Saw Oo; Sirinonthachai, Supachai; McGready, Rose			Empirical lessons regarding contraception in a protracted refugee setting: A descriptive study from Maela camp on the Thai-Myanmar border 1996-2015	PLOS ONE			English	Article							REPRODUCTIVE HEALTH; INFANT-MORTALITY; CHILD HEALTH; PREGNANCY; MALARIA; KAREN; FERTILITY; SERVICES; ECOLOGY; WOMEN	Conflict settings and refugee camps can be chaotic places, with large and rapid population movements, exacerbated public health problems, and ad hoc health services. Reproductive health care that includes family planning is of heightened importance in such settings, however, funding and resources tend to be constrained and geared towards acute health services such as trauma management and infectious disease containment. Here we report on the complexities and challenges of providing family planning in a post-emergency refugee setting, using the example of the largest refugee camp on the Thai-Myanmar border, in existence now for over 30 years. Data from 2009 demonstrates an upward trend in uptake of all contraceptives, especially long acting reversible contraception (LARC) and permanent methods (e.g.sterilization) over time. Increased uptake occurred during periods of time when there were boosts in funding or when barriers to access were alleviated. For example a surgeon fluent in local languages is correlated with increased uptake of tubal ligation in females. These data indicate that funding directed toward contraceptives in this refugee setting led to increases in contraceptives use. However, contraceptive uptake estimates depend on the baseline population which is difficult to measure in this setting. As far as we are aware, this is the longest reported review of family planning services for a refugee camp setting to date. The lessons learned from this setting may be valuable given the current global refugee crisis.	[Srikanok, Somjet; Ontuwong, Pranee; Sirinonthachai, Supachai] Planned Parenthood Assoc Thailand, Bangkok, Thailand; [Parker, Daniel M.; Parker, Amber L.; Lee, Tracey; Min, Aung Myat; Tan, Saw Oo; McGready, Rose] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand; [McGready, Rose] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Old Rd Campus, Oxford, England	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford	Parker, DM (corresponding author), Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand.	daniel@shoklo-unit.com	McGready, Rose/A-3290-2014; Parker, Daniel M./B-5471-2013	McGready, Rose/0000-0003-1621-3257; Parker, Daniel M./0000-0002-5352-7338; Parker, Amber/0000-0002-6248-3904	UNHCR; International Planned Parenthood Federation East and South East Asia and Oceania Region (IPPF ESEAOR); Malariadokters (The Netherlands); Wellcome Trust [WT-106698]	UNHCR; International Planned Parenthood Federation East and South East Asia and Oceania Region (IPPF ESEAOR); Malariadokters (The Netherlands)(Netherlands Government); Wellcome Trust(Wellcome TrustEuropean Commission)	We are grateful for the support received by PPAT under the patronage of H.R.H the Princess Mother, from UNHCR in 2008, and International Planned Parenthood Federation East and South East Asia and Oceania Region (IPPF ESEAOR) in 2009, and Malariadokters (The Netherlands) in 2011. We are grateful to the organizations that have supported supplies of contraceptives to SMRU including Thailand Department of Public Health, Family Planning Australia, and other private donors. SMRU is part of the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Program funded by the Wellcome Trust (WT-106698). The funding bodies had no role in the design, collection, analysis or interpretation of data, nor in the writing or submission of the manuscript for publication.r We are grateful to the women and men from Maela camp who attended SMRU or PPAT over the years and who participated in family planning, antenatal and birth services. We are grateful for the support received by PPAT under the patronage of H.R.H the Princess Mother, from UNHCR in 2008, and International Planned Parenthood Federation East and South East Asia and Oceania Region (IPPF ESEAOR) in 2009, and Malariadokters (The Netherlands) in 2011 and Stichting Vluchteling in 2015. We are grateful to the organizations that have supported supplies of contraceptives to SMRU including Thailand Department of Public Health, Family Planning Australia, and other private donors. SMRU is part of the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Program funded by the Wellcome Trust (WT 106698). The funding bodies had no role in the design, collection, analysis or interpretation of data, nor in the writing or submission of the manuscript for publication.	BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111; Black BO, 2014, OBSTET GYNAECOL, V16, P153, DOI 10.1111/tog.12114; BOSS LP, 1994, JAMA-J AM MED ASSOC, V272, P371, DOI 10.1001/jama.272.5.371; CALDWELL JC, 1976, POPUL DEV REV, V2, P321, DOI 10.2307/1971615; Carrara VI, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-45; Casey SE, 2015, CONFL HEALTH, V9, DOI 10.1186/1752-1505-9-S1-S3; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Coale A J, 1984, Pak Dev Rev, V23, P531; Corak Miles, 2006, IZA DISCUSSION PAPER; Cottrell MP, 2015, REFUG SURV Q, V34, P20, DOI 10.1093/rsq/hdv015; Curry DW, 2015, GLOB HEALTH, V3, P14, DOI 10.9745/GHSP-D-14-00164; Curtin S. C., 2013, NCHS DATA BRIEF; Dixon-Mueller R, 2007, AM J PUBLIC HEALTH, V97, P45, DOI 10.2105/AJPH.2005.068056; Gedeon J, 2015, CONFL HEALTH, V9, DOI 10.1186/s13031-015-0034-9; GUHA-SAPIR D, 1991, World Health Statistics Quarterly, V44, P171; Hegde S, 2012, ASIA-PAC J PUBLIC HE, V24, P989, DOI 10.1177/1010539511409024; Helweg-Larsen K, 1994, Ugeskr Laeger, V156, P1475; Hobstetter Margaret, 2015, Int J Gynaecol Obstet, V130 Suppl 3, pE37, DOI 10.1016/j.ijgo.2015.05.008; Hunter P, 2016, EMBO REP, V17, P492, DOI 10.15252/embr.201642171; Hynes M, 2002, JAMA-J AM MED ASSOC, V288, P595, DOI 10.1001/jama.288.5.595; Kobori E, 2007, AIDS BEHAV, V11, P611, DOI 10.1007/s10461-006-9167-6; Krause SK, 2000, INT FAM PLAN PERSPEC, V26, P181, DOI 10.2307/2648256; Lee T, 2000, REPROD HLTH REFUGEES, P23; Luxemburger C, 2003, T ROY SOC TROP MED H, V97, P251, DOI 10.1016/S0035-9203(03)90134-9; Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459; MBAGO MCY, 1994, J BIOSOC SCI, V26, P451, DOI 10.1017/S0021932000021593; McGready R, 2015, F1000RESEARCH, V3, P123, DOI 10.12688/f1000research.4190.2; McGready R, 2012, PLOS ONE, V7; Moss WJ, 2006, B WORLD HEALTH ORGAN, V84, P58, DOI 10.2471/BLT.04.019570; Tran NT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137412; NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D; O'Hare BAM, 2007, J ROY SOC MED, V100, P564, DOI 10.1258/jrsm.100.12.564; Parker DM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0921-y; Parker DM, 2014, DEMOGR RES, V30, P1129, DOI 10.4054/DemRes.2014.30.39; Patel P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000090; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Plewes K, 2008, INT J STD AIDS, V19, P833, DOI 10.1258/ijsa.2008.008034; Radelet S, 1998, BROOKINGS PAP ECO AC, P1; Raheel H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048760; Rochat RW, 2011, AM J EPIDEMIOL, V174, pS80, DOI 10.1093/aje/kwr304; Salisbury P, 2016, BMC REPROD HEAL; Schreck L, 2000, INT FAM PLAN PERSPEC, V26, P162, DOI 10.2307/2648253; Short RV, 2001, REPROD FERT DEVELOP, V13, P405, DOI 10.1071/RD01107; TBC, 2015, REF IDP CAMP POP; TBC, 2004, WORLDS 20 YEARS BORD; UNCHR, 2016, OV UNHCRS OP AS PAC; UNHCR Women's Refugee Commission, 2011, WOM REF COMM REF FAM; van Min M., 2009, FORCED MIGRATION REV, P68; Ventura SJ, 1999, NATL VITAL STAT REPO; Wagmiller R.L., 2009, CHILDHOOD INTERGENER; Weerasuriya Chathika K, 2012, Confl Health, V6, P5, DOI 10.1186/1752-1505-6-5; World Health Organization, 2014, MAT MORT; World Health Organization, 2015, FAM PLANN CONTR	53	9	9	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0172007	10.1371/journal.pone.0172007	http://dx.doi.org/10.1371/journal.pone.0172007			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL5SX	28231251	Green Published, gold			2023-01-03	WOS:000394682400025
J	Wong, J; Motulsky, A; Abrahamowicz, M; Eguale, T; Buckeridge, DL; Tamblyn, R				Wong, Jenna; Motulsky, Aude; Abrahamowicz, Michal; Eguale, Tewodros; Buckeridge, David L.; Tamblyn, Robyn			Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEROTONIN REUPTAKE INHIBITORS; BRITISH ASSOCIATION; DRUG-USE; GUIDELINES; APPROVAL; PATIENT; QUEBEC; CANADA; SAFETY; RISK	OBJECTIVE To examine off-label indications for antidepressants in primary care and determine the level of scientific support for off-label prescribing. DESIGN Descriptive study of antidepressant prescriptions written by primary care physicians using an indication based electronic prescribing system. SETTING Primary care practices in and around two major urban centres in Quebec, Canada. PARTICIPANTS Patients aged 18 years or older who visited a study physician between 1 January 2003 and 30 September 2015 and were prescribed an antidepressant through the electronic prescribing system. MAIN OUTCOME MEASURES Prevalence of off-label indications for antidepressant prescriptions by class and by individual drug. Among off-label antidepressant prescriptions, the proportion of prescriptions in each of the following categories was measured: strong evidence supporting use of the prescribed drug for the respective indication; no strong evidence for the prescribed drug but strong evidence supporting use of another drug in the same class for the indication; or no strong evidence supporting use of the prescribed drug and all other drugs in the same class for the indication. RESULTS 106 850 antidepressant prescriptions were written by 174 physicians for 20 920 adults. By class, tricyclic antidepressants had the highest prevalence of off-label indications (81.4%, 95% confidence interval, 77.3% to 85.5%), largely due to a high off-label prescribing rate for amitriptyline (93%, 89.6% to 95.7%). Trazodone use for insomnia was the most common off-label use for antidepressants, accounting for 26.2% (21.9% to 30.4%) of all off-label prescriptions. For only 15.9% (13.0% to 19.3%) of all off-label prescriptions, the prescribed drug had strong scientific evidence for the respective indication. For 39.6% (35.7% to 43.2%) of off-label prescriptions, the prescribed drug did not have strong evidence but another antidepressant in the same class had strong evidence for the respective indication. For the remaining 44.6% (40.2% to 49.0%) of off-label prescriptions, neither the prescribed drug nor any other drugs in the class had strong evidence for the indication. CONCLUSIONS When primary care physicians prescribed antidepressants for off-label indications, these indications were usually not supported by strong scientific evidence, yet often another antidepressant in the same class existed that had strong evidence for the respective indication. There is an important need to generate and provide physicians with evidence on off-label antidepressant use to optimise prescribing decisions.	[Wong, Jenna; Motulsky, Aude; Abrahamowicz, Michal; Buckeridge, David L.; Tamblyn, Robyn] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Motulsky, Aude] Univ Montreal, Sch Publ Hlth, Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada; [Eguale, Tewodros] Massachusetts Coll Pharm & Hlth Sci Univ, Boston, MA USA	McGill University; Universite de Montreal	Wong, J (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.	jenna.wong@mail.mcgill.ca		Abrahamowicz, Michal/0000-0002-3172-3952	Canadian Institutes of Health Research (CIHR) [IOP-112675]; Vanier Canada Graduate Scholarship (CIHR); Max E Binz Fellowship (Faculty of Medicine, McGill University)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship (CIHR)(Canadian Institutes of Health Research (CIHR)); Max E Binz Fellowship (Faculty of Medicine, McGill University)(Eli Lilly)	This study was funded by the Canadian Institutes of Health Research (CIHR; grant IOP-112675). JW is supported by the Vanier Canada Graduate Scholarship (CIHR) and the Max E Binz Fellowship (Faculty of Medicine, McGill University). MA is a James McGill professor of biostatistics at McGill University. The funders had no role in the study design; collection, analysis, interpretation of the data; writing of the manuscript; or in the decision to submit the manuscript for publication.	Anglin R, 2014, AM J GASTROENTEROL, V109, P810, DOI 10.1038/ajg.2014.82; Baldwin DS, 2014, J PSYCHOPHARMACOL, V28, P403, DOI 10.1177/0269881114525674; Bartlett Gillian, 2005, Acta bioeth., V11, P145, DOI 10.4067/S1726-569X2005000200005; Carvalho AF, 2016, PSYCHOTHER PSYCHOSOM, V85, P270, DOI 10.1159/000447034; Cascade Elisa, 2009, Psychiatry (Edgmont), V6, P16; Center for Medicare Advocacy, 2010, CMA REP MED COV OFF; Chen DT, 2009, PHARMACOEPIDEM DR S, V18, P1094, DOI 10.1002/pds.1825; Chen H, 2006, J CLIN PSYCHIAT, V67, P972, DOI 10.4088/JCP.v67n0615; Dall M, 2009, CLIN GASTROENTEROL H, V7, P1314, DOI 10.1016/j.cgh.2009.08.019; Dieleman JP, 2005, CURR MED RES OPIN, V21, P1461, DOI 10.1185/030079905X61866; Downing NS, 2014, JAMA-J AM MED ASSOC, V311, P368, DOI 10.1001/jama.2013.282034; Dresser R, 2009, J LAW MED ETHICS, V37, P476, DOI 10.1111/j.1748-720X.2009.00408.x; Eguale T, 2016, JAMA INTERN MED, V176, P55, DOI 10.1001/jamainternmed.2015.6058; Eguale T, 2012, ARCH INTERN MED, V172, P781, DOI 10.1001/archinternmed.2012.340; Eguale T, 2010, DRUG SAFETY, V33, P559, DOI 10.2165/11534580-000000000-00000; Eom CS, 2012, J BONE MINER RES, V27, P1186, DOI 10.1002/jbmr.1554; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Furberg CD, 2001, CURR CONTR TRIALS C, V2, P205, DOI 10.1186/CVM-2-5-205; Ghinea N, 2015, THER INNOV REGUL SCI, V49, P359, DOI 10.1177/2168479015570337; Godwin Marshall, 2003, BMC Med Educ, V3, P10, DOI 10.1186/1472-6920-3-10; Hemels MEH, 2002, ANN PHARMACOTHER, V36, P1375, DOI 10.1345/aph.1A331; Hu XH, 2004, J CLIN PSYCHIAT, V65, P959; Johnston A, 2010, BRIT J CLIN PHARMACO, V70, P320, DOI 10.1111/j.1365-2125.2010.03681.x; Katzman MA, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-S1-S1; Largent EA, 2009, ARCH INTERN MED, V169, P1745, DOI 10.1001/archinternmed.2009.314; Li Ying, 2011, AMIA Annu Symp Proc, V2011, P768; McAlister FA, 1999, JAMA-J AM MED ASSOC, V282, P1371, DOI 10.1001/jama.282.14.1371; Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999; National Center forHealth Statistics, 2011, HLTH US 2010 SPEC FE; O'Malley PG, 2012, ARCH INTERN MED, V172, P759, DOI 10.1001/archinternmed.2012.789; Pomey MP, 2007, MILBANK Q, V85, P469, DOI 10.1111/j.1468-0009.2007.00496.x; Prescribing and Medicines Team, 2016, PRESCR DISP COMM ENG; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Rost K, 1994, Arch Fam Med, V3, P333, DOI 10.1001/archfami.3.4.333; Sbarbaro JA, 2001, CLIN INFECT DIS, V33, pS240, DOI 10.1086/321856; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107; Stone KJ, 2003, AM FAM PHYSICIAN, V68, P498; Tamblyn R, 2006, J AM MED INFORM ASSN, V13, P148, DOI 10.1197/jamia.M1887; Thomson Micromedex, DRUGD SYST INT DAT; Walton SN, 2008, PHARMACOTHERAPY, V28, P1443, DOI 10.1592/phco.28.12.1443; Wang B, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4679; Wilson SJ, 2010, J PSYCHOPHARMACOL, V24, P1577, DOI 10.1177/0269881110379307; Wittich CM, 2012, MAYO CLIN PROC, V87, P982, DOI 10.1016/j.mayocp.2012.04.017; Wong J, 2016, JAMA-J AM MED ASSOC, V315, P2230, DOI 10.1001/jama.2016.3445; Xiao YL, 2010, STAT MED, V29, P915, DOI 10.1002/sim.3807	45	105	110	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2017	356								j603	10.1136/bmj.j603	http://dx.doi.org/10.1136/bmj.j603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EM9KS	28228380	Green Published, hybrid			2023-01-03	WOS:000395631000003
J	Zeriouh, W; Nani, A; Belarbi, M; Dumont, A; de Rosny, C; Aboura, I; Ghanemi, FZ; Murtaza, B; Patoli, D; Thomas, C; Apetoh, L; Rebe, C; Delmas, D; Khan, NA; Ghiringhelli, F; Rialland, M; Hichami, A				Zeriouh, Wafa; Nani, Abdelhafid; Belarbi, Meriem; Dumont, Adelie; de Rosny, Charlotte; Aboura, Ikram; Ghanemi, Fatima Zahra; Murtaza, Babar; Patoli, Danish; Thomas, Charles; Apetoh, Lionel; Rebe, Cedric; Delmas, Dominique; Khan, Naim Akhtar; Ghiringhelli, Francois; Rialland, Mickael; Hichami, Aziz			Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway	PLOS ONE			English	Article							OLIVE LEAF EXTRACT; COLORECTAL-CANCER; CARCINOMA CELLS; CYTOCHROME-C; CALCIUM; P53; POLYPHENOLS; ACTIVATION; DISEASE; PROTEIN	Dietary polyphenols, derived from natural products, have received a great interest for their chemopreventive properties against cancer. In this study, we investigated the effects of phenolic extract of the oleaster leaves ( PEOL) on tumor growth in mouse model and on cell death in colon cancer cell lines. We assessed the effect of oleaster leaf infusion on HCT116 ( human colon cancer cell line) xenograft growth in athymic nude mice. We observed that oleaster leaf polyphenol-rich infusion limited HCT116 tumor growth in vivo. Investigations of PEOL on two human CRC cell lines showed that PEOL induced apoptosis in HCT116 and HCT8 cells. We demonstrated an activation of caspase-3, -7 and -9 by PEOL and that pretreatment with the pan-caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone ( z-VAD-fmk), prevented PEOL-induced cell death. We observed an involvement of the mitochondrial pathway in PEOL-induced apoptosis evidenced by reactive oxygen species ( ROS) production, a decrease of mitochondrial membrane potential, and cytochrome c release. Increase in intracellular Ca2+ concentration induced by PEOL represents the early event involved in mitochondrial dysfunction, ROS-induced endoplasmic reticulum ( ER) stress and apoptosis induced by PEOL, as ruthenium red, an inhibitor of mitochondrial calcium uptake inhibited apoptotic effect of PEOL, BAPTA/AM inhibited PEOL-induced ROS generation and finally, N-acetyl-L-cysteine reversed ER stress and apoptotic effect of PEOL. These results demonstrate that polyphenols from oleaster leaves might have a strong potential as chemopreventive agent in colorectal cancer.	[Zeriouh, Wafa; Nani, Abdelhafid; Belarbi, Meriem; Aboura, Ikram; Ghanemi, Fatima Zahra] Aboubekr Belkaid Univ, Lab Nat Prod, Tilimsen, Algeria; [Nani, Abdelhafid] African Univ Ahmed Draia, Dept Nat & Life Sci, Adrar, Algeria; [Nani, Abdelhafid; Dumont, Adelie; de Rosny, Charlotte; Aboura, Ikram; Ghanemi, Fatima Zahra; Murtaza, Babar; Patoli, Danish; Thomas, Charles; Apetoh, Lionel; Rebe, Cedric; Delmas, Dominique; Khan, Naim Akhtar; Ghiringhelli, Francois; Rialland, Mickael; Hichami, Aziz] Univ Bourgogne Franche Comte, INSERM U1231, Dijon, France; [Rebe, Cedric; Ghiringhelli, Francois] Ctr Georges Francois Leclerc, Dijon, France	Universite Abou Bekr Belkaid; Universite d'Adrar; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc	Hichami, A (corresponding author), Univ Bourgogne Franche Comte, INSERM U1231, Dijon, France.	aziz.hichami@u-bourgogne.fr	Apetoh, Lionel/G-3310-2014; Delmas, Dominique/AAD-9749-2019; Apetoh, Lionel/AIC-2384-2022; Murtaza, Babar/AAR-8200-2021; REBE, Cédric/AAD-4316-2019; Thomas, charles/C-7130-2019	Apetoh, Lionel/0000-0002-2774-438X; Delmas, Dominique/0000-0003-3576-0248; Apetoh, Lionel/0000-0002-2774-438X; REBE, Cédric/0000-0001-8831-145X; Thomas, charles/0000-0001-9998-6698; NANI, ABDELHAFID/0000-0002-8665-0447; Delmas, Dominique/0000-0002-8911-8499; Khan, Naim Akhtar/0000-0002-8930-9332; Patoli, Danish/0000-0002-6837-336X; ghiringhelli, francois/0000-0002-5465-8305; Rialland, Mickael/0000-0001-9693-9351	Inserm, Labex LipSTIC INSERM	Inserm, Labex LipSTIC INSERM	This study was supported by Inserm, Labex LipSTIC INSERM U866, bilateral Franco-Algerian collaborative project "Tassili."	Abaza L, 2007, BIOSCI BIOTECH BIOCH, V71, P1306, DOI 10.1271/bbb.60716; Aires V, 2004, MOL CELL BIOCHEM, V260, P103, DOI 10.1023/B:MCBI.0000026061.57326.28; Armutcu F, 2011, SPAT DD PER REV J CO, V1, P159; Banerjee A, 2016, ONCOTARGET IMPACT J, V5; Bennani-Kabchi N., 2000, Annales Pharmaceutiques Francaises, V58, P271; Boehning D, 2004, CELL CYCLE, V3, P252; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chen CY, 2007, J AGR FOOD CHEM, V55, P948, DOI 10.1021/jf0624594; Corsi L, 2002, FITOTERAPIA, V73, P674, DOI 10.1016/S0367-326X(02)00227-7; Cottet-Rousselle C, 2011, CYTOM PART A, V79A, P405, DOI 10.1002/cyto.a.21061; Dramane G, 2012, J CLIN INVEST, V122, P2267, DOI 10.1172/JCI59953; Fares R, 2011, PLANT FOOD HUM NUTR, V66, P58, DOI 10.1007/s11130-011-0213-9; Giovannini C, 2012, NUTR NEUROSCI, V15, P134, DOI 10.1179/1476830512Y.0000000006; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Hajiaghaalipour F, 2015, FOOD CHEM, V169, P401, DOI 10.1016/j.foodchem.2014.07.005; Han J, 2009, CYTOTECHNOLOGY, V59, P45, DOI 10.1007/s10616-009-9191-2; Hanene G, 2015, INT J PHARM PHARM SC, V7; Hannachi H, 2013, PAK J PHARM SCI, V26, P503; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Katiyar Santosh K., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P17; Kim ER, 2014, WORLD J GASTROENTERO, V20, P9872, DOI 10.3748/wjg.v20.i29.9872; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lafka TI, 2013, FOODS, V2, P18, DOI 10.3390/foods2010018; Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018; Marchetti C, 2002, HUM REPROD, V17, P1257, DOI 10.1093/humrep/17.5.1257; McGuire S, 2014, ADV NUTR, V5, P456, DOI 10.3945/an.114.006171; Middleton E, 2000, PHARMACOL REV, V52, P673; Mijatovic SA, 2011, INT J CANCER, V128, P1955, DOI 10.1002/ijc.25526; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Nakazato T, 2005, HEMATOL J, V90; Nani A, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0946-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oak MH, 2005, J NUTR BIOCHEM, V16, P1, DOI 10.1016/j.jnutbio.2004.09.004; Obrenovich ME, 2010, REJUV RES, V13, P631, DOI 10.1089/rej.2010.1043; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Reyes FJ, 2006, FEBS LETT, V580, P6302, DOI 10.1016/j.febslet.2006.10.038; Rodriguez M.L., 2013, J CARCINOG MUTAGEN, V6; Rodriguez ML, 2013, AFRIQUE SCI, V09, P159; Roy AM, 2005, MOL CANCER THER, V4, P81; Soni MG, 2006, FOOD CHEM TOXICOL, V44, P903, DOI 10.1016/j.fct.2006.01.008; Vasen HFA, 2015, NAT REV GASTRO HEPAT, V12, P88, DOI 10.1038/nrgastro.2014.229; Watson JL, 2010, MOL CARCINOGEN, V49, P13, DOI 10.1002/mc.20571; Zhong Y, 2010, EUR J CANCER, V46, P3365, DOI 10.1016/j.ejca.2010.07.007	48	22	23	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2017	12	2							e0170823	10.1371/journal.pone.0170823	http://dx.doi.org/10.1371/journal.pone.0170823			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BI	28212423	gold, Green Published, Green Submitted			2023-01-03	WOS:000394424700003
J	Moore, N; Blouin, B; Razuri, H; Casapia, M; Gyorkos, TW				Moore, Nora; Blouin, Brittany; Razuri, Hugo; Casapia, Martin; Gyorkos, Theresa W.			Determinants of first trimester attendance at antenatal care clinics in the Amazon region of Peru: A case-control study	PLOS ONE			English	Article							MATERNAL HEALTH-CARE; DEVELOPING-COUNTRIES; ANEMIA	Objective To identify determinants which influence the timing of the first antenatal care (ANC) visit in pregnant women. Design Retrospective matched nested case-control study. Setting Two health centres, Belen and 6 de Octubre, in the Peruvian Amazon. Population All pregnant women who had attended ANC during the years 2010, 2011, and 2012. Methods All cases (819 women initiating ANC in their first trimester) were selected from ANC registries from 2010 to 2012. A random sample of controls (819 women initiating ANC in their second or third trimester) was matched 1: 1 to cases on health centre and date of first ANC visit. Data were obtained from ANC registries. Conditional logistic regression analyses were performed. Main outcome measure Case-control status of each woman determined by the gestational age at first ANC visit. Results Cases had higher odds of: 1) being married or cohabiting (aOR = 1.69; 95% CI: 1.19, 2.41); 2) completing secondary school or attending post-secondary school (aOR = 1.45; 95% CI: 1.02, 2.06); 3) living in an urban environment (aOR = 1.79; 95% CI: 1.04, 3.10) and 4) having had a previous miscarriage (aOR = 1.56; 95% CI: 1.13, 2.15), compared to controls. No statistically significant difference in odds was found for parity (aOR = 1.08; 95% CI: 0.85, 1.36). Conclusions This study provides empirical evidence of determinants of first ANC attendance. These findings are crucial to the planning and timing of local interventions, like deworming, aimed at pregnant women so that they can access and benefit fully from all government-provided ANC services.	[Moore, Nora; Blouin, Brittany; Gyorkos, Theresa W.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Moore, Nora; Blouin, Brittany; Razuri, Hugo; Gyorkos, Theresa W.] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada; [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru	McGill University; McGill University	Gyorkos, TW (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Gyorkos, TW (corresponding author), McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada.	theresa.gyorkos@mcgill.ca	Razuri, Hugo/C-1542-2013	Razuri, Hugo/0000-0003-4571-5520; Blouin, Brittany/0000-0001-7447-7467; Casapia Morales, Wilfredo Martin/0000-0002-5972-0948	National Institutes of Health (NIH) grant [1P50A1098574-01]	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by a National Institutes of Health (NIH) grant [Grant # 1P50A1098574-01, to M.C. and T.W.G.); https:// grants.nih.gov/funding/index.htm. Additional support includes: travel awards from McGill University Faculty of Medicine and the Axe de recherche en sante mondiale of the Reseau de recherche en sante des populations du Quebec (to N.M.). URLs: http//www.mcgill.calmedresearch/students-postdocs/graduate-funding/graduate mobility-award-2016-2017; http://www.santepop. qc.ca/en. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Ayala LSH, 2013, MATERN CHILD HLTH J, V17, P1112, DOI 10.1007/s10995-012-1113-9; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; Casapia Martin, 2007, Int J Equity Health, V6, P6, DOI 10.1186/1475-9276-6-6; Crompton D, 2006, PREVENTATIVE CHEMOTH; Habibov NN, 2011, HEALTH ECON POLICY L, V6, P175, DOI 10.1017/S1744133110000174; Hawley NL, 2014, MATERN CHILD HLTH J, V18, P2284, DOI 10.1007/s10995-013-1368-9; Instituto Nacional de Estadistica E Informatica, 2013, POBL EST GRUP ED SEG; Instituto Nacional de Estadistica E Informatica, 2013, PER ENC DEM SAL FAM; Jewell RT, 2009, APPL ECON, V41, P10; Kasiulevicius V, 2006, GERONTOLOGIJA, V7, P6; Larocque R, 2005, AM J TROP MED HYG, V73, P783, DOI 10.4269/ajtmh.2005.73.783; Larocque R, 2006, TROP MED INT HEALTH, V11, P1485, DOI 10.1111/j.1365-3156.2006.01706.x; Larocque R, 2006, CAN J PUBLIC HEALTH, V97, P222, DOI 10.1007/BF03405590; Mishra SCK, 2014, NATL GUIDELINES DEWO; Munoz DC, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0042-z; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Ryan JA, 2009, INT J GYNECOL OBSTET, V107, P162, DOI 10.1016/j.ijgo.2009.06.014; Say L, 2007, B WORLD HEALTH ORGAN, V85, P812, DOI 10.2471/BLT.06.035659; Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; Villar J, 2002, WHO ANTENATAL CARE R; WHO, 2005, 3 GLOB M PARTN PAR C	24	13	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0171136	10.1371/journal.pone.0171136	http://dx.doi.org/10.1371/journal.pone.0171136			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BG	28207749	Green Published, Green Submitted, gold			2023-01-03	WOS:000394424500016
J	Han, B; Bhowmick, N; Qu, Y; Chung, S; Giuliano, AE; Cui, X				Han, B.; Bhowmick, N.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.			FOXC1: an emerging marker and therapeutic target for cancer	ONCOGENE			English	Review							TO-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; GENE-EXPRESSION SIGNATURE; SUPERIOR PROGNOSTIC VALUE; BREAST-CANCER; DNA METHYLATION; ESTROGEN-RECEPTOR; HEPATOCELLULAR-CARCINOMA; CELL NICHE; HELIX GENE	The Forkhead box C1 (FOXC1) transcription factor is involved in normal embryonic development and regulates the development and function of many organs. Most recently, a large body of literature has shown that FOXC1 plays a critical role in tumor development and metastasis. Clinical studies have demonstrated that elevated FOXC1 expression is associated with poor prognosis in many cancer subtypes, such as basal-like breast cancer (BLBC). FOXC1 is highly and specifically expressed in BLBC as opposed to other breast cancer subtypes. Its functions in breast cancer have been extensively explored. This review will summarize current knowledge on the function and regulation of FOXC1 in tumor development and progression with a focus on BLBC, as well as the implications of these new findings in cancer diagnosis and treatment.	[Han, B.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Los Angeles, CA 90048 USA; [Bhowmick, N.] Cedars Sinai Med Ctr, Dept Med, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063), David Salomon Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy to Xiaojiang Cui, and the Fashion Footwear Charitable Foundation of New York, Inc., the Entertainment Industry Foundation, the Margie and Robert E Petersen Foundation and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Aldinger KA, 2009, NAT GENET, V41, P1037, DOI 10.1038/ng.422; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berry FB, 2006, J BIOL CHEM, V281, P10098, DOI 10.1074/jbc.M513629200; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Blonska M, 2015, BLOOD, V125, P981, DOI 10.1182/blood-2014-04-568188; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060; De Val S, 2008, CELL, V135, P1053, DOI 10.1016/j.cell.2008.10.049; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Duan S., 2012, ABSTRACT APPL ANAL, V2012, P1, DOI DOI 10.1109/SPC0M.2012.6290252; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Haldipur P, 2014, ELIFE, V3, DOI 10.7554/eLife.03962; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Jia BX, 2012, J NANOMATER, V2012, DOI 10.1155/2012/796815; Jin YL, 2014, ANN SURG ONCOL, V21, pS758, DOI 10.1245/s10434-014-3980-3; Kaestner KH, 2000, GENE DEV, V14, P142; Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lay K, 2016, P NATL ACAD SCI USA, V113, pE1506, DOI 10.1073/pnas.1601569113; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Li C, 2013, COMPUT BIOL CHEM, V47, P192, DOI 10.1016/j.compbiolchem.2013.08.010; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin ZY, 2014, CANCER SCI, V105, P1288, DOI 10.1111/cas.12499; Lines MA, 2002, HUM MOL GENET, V11, P1177, DOI 10.1093/hmg/11.10.1177; Mattiske D, 2006, DEV BIOL, V290, P447, DOI 10.1016/j.ydbio.2005.12.007; Mayeuf-Louchart A, 2016, DEVELOPMENT, V143, P872, DOI 10.1242/dev.128017; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Mirzayans F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049095; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Omatsu Y, 2014, NATURE, V508, P536, DOI 10.1038/nature13071; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Peraldo-Neia C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-31; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788; Prasitsak T, 2015, DEV DYNAM, V244, P703, DOI 10.1002/dvdy.24269; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Ray PS, 2011, ANN SURG ONCOL, V18, P3839, DOI 10.1245/s10434-011-1657-8; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012-1606(03)00355-5; SASAKI H, 1993, DEVELOPMENT, V118, P47; Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035; Siegenthaler JA, 2013, BIOL OPEN, V2, P647, DOI 10.1242/bio.20135009; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Sizemore GM, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.108001; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Skarie JM, 2009, INVEST OPHTH VIS SCI, V50, P5026, DOI 10.1167/iovs.09-3447; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Stute P, 2012, BREAST CANCER RES TR, V133, P617, DOI 10.1007/s10549-011-1811-9; Sun JJ, 2013, DEVELOPMENT, V140, P1034, DOI 10.1242/dev.085225; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; Tribulo C, 2003, DEVELOPMENT, V130, P6441, DOI 10.1242/dev.00878; Tumer Z, 2009, EUR J HUM GENET, V17, P1527, DOI 10.1038/ejhg.2009.93; van der Heul-Nieuwenhuijsen L, 2009, BJU INT, V103, P1574, DOI 10.1111/j.1464-410X.2009.08351.x; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang JH, 2016, ONCOTARGET, V7, P84375, DOI 10.18632/oncotarget.11224; Wang L, 2016, SCIENCE, V351, P613, DOI 10.1126/science.aad5440; Wang YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2906-9; Wei Li, 2013, Zoological Research, V34, P14, DOI 10.3724/SP.J.1141.2013.01014; Wilm B, 2004, DEV BIOL, V271, P176, DOI 10.1016/j.ydbio.2004.03.034; Wu JM, 2008, CLIN CANCER RES, V14, P1938, DOI 10.1158/1078-0432.CCR-07-4082; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu YY, 2016, TUMOR BIOL, V37, P239, DOI 10.1007/s13277-015-3686-6; Xu Y, 2014, INT J DISTRIB SENS N, DOI 10.1155/2014/594782; Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769; Yao T, 2016, ONCOL LETT, V12, P73, DOI 10.3892/ol.2016.4573; Yoshida M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7653; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu-Rice Y, 2016, ONCOGENE, V35, P5400, DOI 10.1038/onc.2016.78; Zarbalis K, 2007, P NATL ACAD SCI USA, V104, P14002, DOI 10.1073/pnas.0702618104; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860; Zvelebil M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3403	99	67	77	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3957	3963		10.1038/onc.2017.48	http://dx.doi.org/10.1038/onc.2017.48			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288141	Green Accepted			2023-01-03	WOS:000405379900002
J	Rowan, KM; Angus, DC; Bailey, M; Barnato, AE; Bellomo, R; Canter, RR; Coats, TJ; Delaney, A; Gimbel, E; Grieve, RD; Harrison, DA; Higgins, AM; Howe, B; Huang, DT; Kellum, JA; Mouncey, PR; Music, E; Peake, SL; Pike, F; Reade, MC; Sadique, MZ; Singer, M; Yealy, DM				Rowan, Kathryn M.; Angus, Derek C.; Bailey, Michael; Barnato, Amber E.; Bellomo, Rinaldo; Canter, Ruth R.; Coats, Timothy J.; Delaney, Anthony; Gimbel, Elizabeth; Grieve, Richard D.; Harrison, David A.; Higgins, Alisa M.; Howe, Belinda; Huang, David T.; Kellum, John A.; Mouncey, Paul R.; Music, Edvin; Peake, Sandra L.; Pike, Francis; Reade, Michael C.; Sadique, M. Zia; Singer, Mervyn; Yealy, Donald M.		PRISM Investigators	Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE SEPSIS; PERSONALIZED MEDICINE; OUTCOMES; TRIAL	BACKGROUND After a single-center trial and observational studies suggesting that early, goal-directed therapy (EGDT) reduced mortality from septic shock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed no benefit. This meta-analysis of individual patient data from the three recent trials was designed prospectively to improve statistical power and explore heterogeneity of treatment effect of EGDT. METHODS We harmonized entry criteria, intervention protocols, outcomes, resource-use measures, and data collection across the trials and specified all analyses before unblinding. After completion of the trials, we pooled data, excluding the protocol-based standard-therapy group from the ProCESS trial, and resolved residual differences. The primary outcome was 90-day mortality. Secondary outcomes included 1-year survival, organ support, and hospitalization costs. We tested for treatment-by-subgroup interactions for 16 patient characteristics and 6 care-delivery characteristics. RESULTS We studied 3723 patients at 138 hospitals in seven countries. Mortality at 90 days was similar for EGDT (462 of 1852 patients [24.9%]) and usual care (475 of 1871 patients [25.4%]); the adjusted odds ratio was 0.97 (95% confidence interval, 0.82 to 1.14; P = 0.68). EGDT was associated with greater mean (+/-SD) use of intensive care (5.3+/-7.1 vs. 4.9+/-7.0 days, P = 0.04) and cardiovascular support (1.9+/-3.7 vs. 1.6+/-2.9 days, P = 0.01) than was usual care; other outcomes did not differ significantly, although average costs were higher with EGDT. Subgroup analyses showed no benefit from EGDT for patients with worse shock (higher serum lactate level, combined hypotension and hyperlactatemia, or higher predicted risk of death) or for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation. CONCLUSIONS In this meta-analysis of individual patient data, EGDT did not result in better outcomes than usual care and was associated with higher hospitalization costs across a broad range of patient and hospital characteristics.	[Rowan, Kathryn M.; Canter, Ruth R.; Harrison, David A.; Mouncey, Paul R.] Intens Care Natl Audit & Res Ctr, Napier House,24 High Holborn, London WC1V 6AZ, England; [Grieve, Richard D.; Sadique, M. Zia] London Sch Hyg & Trop Med, London, England; [Singer, Mervyn] UCL, London, England; [Coats, Timothy J.] Univ Leicester, Leicester, Leics, England; [Angus, Derek C.; Barnato, Amber E.; Gimbel, Elizabeth; Huang, David T.; Kellum, John A.; Music, Edvin; Yealy, Donald M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Bailey, Michael; Bellomo, Rinaldo; Higgins, Alisa M.; Howe, Belinda; Peake, Sandra L.] Monash Univ, Melbourne, Vic, Australia; [Delaney, Anthony] Univ Sydney, Sydney, NSW, Australia; [Peake, Sandra L.] Univ Adelaide, Adelaide, SA, Australia; [Peake, Sandra L.] Queen Elizabeth Hosp, Adelaide, SA, Australia; [Reade, Michael C.] Univ Queensland, Brisbane, Qld, Australia; [Pike, Francis] Eli Lilly, Indianapolis, IN USA	Intensive Care National Audit & Research Centre; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of Leicester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Monash University; University of Sydney; University of Adelaide; University of Queensland; Eli Lilly	Rowan, KM (corresponding author), Intens Care Natl Audit & Res Ctr, Napier House,24 High Holborn, London WC1V 6AZ, England.	kathy.rowan@icnarc.org	Delaney, Anthony/AAE-3365-2019; Kellum, John/AAP-3072-2020; McCurdy, Michael/T-5518-2019; Bailey, Michael J/A-4499-2012; Reade, Michael/G-7035-2012; Coats, Timothy/AAW-1254-2021; Harrison, David A/O-4355-2018; Angus, Derek C/E-9671-2012; Singer, Mervyn/Q-6142-2019; Higgins, Alisa/AAM-8088-2020; Limkakeng, Alexander T./AAH-7733-2020; Kellum, John A/HCH-2944-2022	Kellum, John/0000-0003-1995-2653; McCurdy, Michael/0000-0001-5319-0475; Bailey, Michael J/0000-0002-5551-1401; Reade, Michael/0000-0003-1570-0707; Coats, Timothy/0000-0003-2736-2784; Harrison, David A/0000-0002-9002-9098; Singer, Mervyn/0000-0002-1042-6350; Higgins, Alisa/0000-0001-8295-7559; Limkakeng, Alexander T./0000-0002-9822-5595; Kellum, John A/0000-0003-1995-2653; Chawla, Lakhmir/0000-0001-5987-8318; Sadique, Zia/0000-0001-5814-0258; Mouncey, Paul/0000-0002-8510-8517; Brealey, David/0000-0002-1982-3379; Rajbhandari, Dorrilyn/0000-0001-8883-0428; Self, Wesley/0000-0002-9300-3045; Kulstad, Erik/0000-0002-9331-8266; Rowan, Kathryn/0000-0001-8217-5602; Nichol, Alistair/0000-0002-4689-1238; Wilkman, Erika/0000-0003-4250-7523; Bion, Julian/0000-0003-0344-5403; Myburgh, John/0000-0003-4088-7016; Harvey, Daniel/0000-0002-5165-3277; Grieve, Richard/0000-0001-8899-1301; Micallef, Sharon/0000-0002-8496-2324; Bajwa, Ednan/0000-0001-9026-1009; Huang, David/0000-0001-7649-1633; Delaney, Anthony/0000-0002-1015-7146	National Institute of General Medical Sciences; National Institute for Health Research [07/37/47] Funding Source: researchfish; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076659] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the National Institute of General Medical Sciences and others; PRISM ClinicalTrials.gov number, NCT02030158.	Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Davenport EE, 2016, LANCET RESP MED, V4, P259, DOI 10.1016/S2213-2600(16)00046-1; De Backer D, 2016, INTENS CARE MED, V42, P1048, DOI 10.1007/s00134-016-4295-6; Grieve R, 2005, HEALTH ECON, V14, P185, DOI 10.1002/hec.916; Huang DT, 2013, INTENS CARE MED, V39, P1760, DOI 10.1007/s00134-013-3024-7; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Nguyen HB, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1288-3; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Puskarich MA, 2009, CRIT CARE, V13, DOI 10.1186/cc8138; Reade MC, 2010, INTENS CARE MED, V36, P11, DOI 10.1007/s00134-009-1650-x; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Shankar-Hari M, 2016, CRIT CARE MED, V44, P2223, DOI 10.1097/CCM.0000000000001876; Sivayoham N, 2012, EUR J EMERG MED, V19, P235, DOI 10.1097/MEJ.0b013e32834bbea6; Vincent JL, 2016, LANCET RESP MED, V4, P242, DOI 10.1016/S2213-2600(16)00068-0; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Willan AR, 2004, HEALTH ECON, V13, P461, DOI 10.1002/hec.843; Wong HR, 2015, AM J RESP CRIT CARE, V191, P309, DOI 10.1164/rccm.201410-1864OC; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	20	282	296	2	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	2017	376	23					2223	2234		10.1056/NEJMoa1701380	http://dx.doi.org/10.1056/NEJMoa1701380			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW8WG	28320242	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000402798200006
J	Rubin, EJ				Rubin, Eric J.			Reviving a Drug for Tuberculosis?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ETHIONAMIDE		[Rubin, Eric J.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Rubin, EJ (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.							Blondiaux N, 2017, SCIENCE, V355, P1206, DOI 10.1126/science.aag1006; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Willand N, 2009, NAT MED, V15, P537, DOI 10.1038/nm.1950	3	4	6	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	2017	376	23					2292	2294		10.1056/NEJMcibr1703502	http://dx.doi.org/10.1056/NEJMcibr1703502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EW8WG	28591540				2023-01-03	WOS:000402798200017
J	Moran, GJ; Krishnadasan, A; Mower, WR; Abrahamian, FM; LoVecchio, F; Steele, MT; Rothman, RE; Karras, DJ; Hoagland, R; Pettibone, S; Talan, DA				Moran, Gregory J.; Krishnadasan, Anusha; Mower, William R.; Abrahamian, Fredrick M.; LoVecchio, Frank; Steele, Mark T.; Rothman, Richard E.; Karras, David J.; Hoagland, Rebecca; Pettibone, Stephanie; Talan, David A.			Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOFT-TISSUE INFECTIONS; SKIN; PLACEBO; VISITS	IMPORTANCE Emergency department visits for skin infections in the United States have increased with the emergence of methicillin-resistant Staphylococcus aureus (MRSA). For cellulitis without purulent drainage, beta-hemolytic streptococci are presumed to be the predominant pathogens. It is unknown if antimicrobial regimens possessing in vitro MRSA activity provide improved outcomes compared with treatments lacking MRSA activity. OBJECTIVE To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than cephalexin alone. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized superiority trial in 5 US emergency departments among outpatients older than 12 years with cellulitis and no wound, purulent drainage, or abscess enrolled from April 2009 through June 2012. All participants had soft tissue ultrasound performed at the time of enrollment to exclude abscess. Final follow-up was August 2012. INTERVENTIONS Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice daily, for 7 days (n = 248 participants) or cephalexin plus placebo for 7 days (n = 248 participants). MAIN OUTCOMES AND MEASURES The primary outcome determined a priori in the per-protocol group was clinical cure, defined as absence of these clinical failure criteria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21). A clinically significant difference was defined as greater than 10%. RESULTS Among 500 randomized participants, 496 (99%) were included in the modified intention-to-treat analysis and 411 (82.2%) in the per-protocol analysis (median age, 40 years [range, 15-78 years]; 58.4% male; 10.9% had diabetes). Median length and width of erythema were 13.0 cm and 10.0 cm. In the per-protocol population, clinical cure occurred in 182 (83.5%) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 193 in the cephalexin group (difference, -2.0%; 95% CI, -9.7% to 5.7%; P = .50). In the modified intention-to-treat population, clinical cure occurred in 189 (76.2%) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 248 in the cephalexin group (difference, 7.3%; 95% CI, -1.0% to 15.5%; P = .07). Between-group adverse event rates and secondary outcomes through 7 to 9 weeks, including overnight hospitalization, recurrent skin infections, and similar infection in household contacts, did not differ significantly. CONCLUSIONS AND RELEVANCE Among patients with uncomplicated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alone did not result in higher rates of clinical resolution of cellulitis in the per-protocol analysis. However, because imprecision around the findings in the modified intention-to-treat analysis included a clinically important difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be needed.	[Moran, Gregory J.; Krishnadasan, Anusha; Abrahamian, Fredrick M.; Talan, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Olive View UCLA Med Ctr, Dept Emergency Med, Los Angeles, CA 90095 USA; [Moran, Gregory J.; Talan, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Olive View UCLA Med Ctr, Div Infect Dis,Dept Med, Los Angeles, CA 90095 USA; [Mower, William R.] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan Med Ctr, Dept Emergency Med, Los Angeles, CA 90095 USA; [LoVecchio, Frank] Univ Arizona, Maricopa Med Ctr, Dept Emergency Med, Phoenix, AZ USA; [LoVecchio, Frank] Mayo Clin & Mayo Grad Sch Med, Phoenix, AZ USA; [Steele, Mark T.] Univ Missouri, Truman Med Ctr, Sch Med, Dept Emergency Med, Kansas City, MO 64108 USA; [Rothman, Richard E.] Johns Hopkins Sch Med, Dept Emergency Med, Johns Hopkins Med Ctr, Baltimore, MD USA; [Karras, David J.] Temple Univ, Lewis Katz Sch Med, Dept Emergency Med, Philadelphia, PA 19122 USA; [Hoagland, Rebecca] Cota Enterprises Inc, Mclouth, KS USA; [Pettibone, Stephanie] EMMES Corp, Rockville, MD USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ronald Reagan UCLA Medical Center; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; University of Missouri System; University of Missouri Kansas City; Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Emmes Corporation	Moran, GJ (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.	idnet@ucla.edu			National Institute of Allergy and Infectious Diseases [1U01 HHSN272200700032C]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by grant 1U01 HHSN272200700032C to Drs Moran and Talan from the National Institute of Allergy and Infectious Diseases.	Chira S, 2010, EPIDEMIOL INFECT, V138, P313, DOI 10.1017/S0950268809990483; Crisp JG, 2015, CLIN INFECT DIS, V61, P1679, DOI 10.1093/cid/civ655; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Elliott DJ, 2009, PEDIATRICS, V123, pE959, DOI 10.1542/peds.2008-2428; Gunderson CG, 2012, J INFECTION, V64, P148, DOI 10.1016/j.jinf.2011.11.004; Hersh AL, 2008, ARCH INTERN MED, V168, P1585, DOI 10.1001/archinte.168.14.1585; Jeng A, 2010, MEDICINE, V89, P217, DOI 10.1097/MD.0b013e3181e8d635; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Pallin DJ, 2008, ANN EMERG MED, V51, P291, DOI 10.1016/j.annemergmed.2007.12.004; Pallin DJ, 2014, WEST J EMERG MED, V15, P282, DOI 10.5811/westjem.2013.8.18040; Pallin DJ, 2013, CLIN INFECT DIS, V56, P1754, DOI 10.1093/cid/cit122; Spellberg B, 2009, CLIN INFECT DIS, V49, P383, DOI 10.1086/600296; Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu296, 10.1093/cid/ciu444]; US Food and Drug Administration, 2013, GID IND ACUT BACT SK; Weng QY, 2017, JAMA DERMATOL, V153, P141, DOI 10.1001/jamadermatol.2016.3816	16	56	58	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2017	317	20					2088	2096		10.1001/jama.2017.5653	http://dx.doi.org/10.1001/jama.2017.5653			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV5JJ	28535235	Green Published			2023-01-03	WOS:000401800600019
J	Baeza-Yates, R; Sangal, PM; Villoslada, P				Baeza-Yates, Ricardo; Sangal, Puneet Mohan; Villoslada, Pablo			Burden of neurological diseases in the US revealed by web searches	PLOS ONE			English	Article							MULTIPLE-SCLEROSIS; BEHAVIOR; PEOPLE; EPILEPSY; TRENDS	Background Analyzing the disease-related web searches of Internet users provides insight into the interests of the general population as well as the healthcare industry, which can be used to shape health care policies. Methods We analyzed the searches related to neurological diseases and drugs used in neurology using the most popular search engines in the US, Google and Bing/Yahoo. Results We found that the most frequently searched diseases were common diseases such as dementia or Attention Deficit/Hyperactivity Disorder (ADHD), as well as medium frequency diseases with high social impact such as Parkinson's disease, MS and ALS. The most frequently searched CNS drugs were generic drugs used for pain, followed by sleep disorders, dementia, ADHD, stroke and Parkinson's disease. Regarding the interests of the healthcare industry, ADHD, Alzheimer's disease, MS, ALS, meningitis, and hypersomnia received the higher advertising bids for neurological diseases, while painkillers and drugs for neuropathic pain, drugs for dementia or insomnia, and triptans had the highest advertising bidding prices. Conclusions Web searches reflect the interest of people and the healthcare industry, and are based either on the frequency or social impact of the disease.	[Baeza-Yates, Ricardo] Univ Pompeu Fabra, Barcelona, Spain; [Sangal, Puneet Mohan] Amazon, Seattle, WA USA; [Villoslada, Pablo] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Villoslada, Pablo] Univ Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain	Pompeu Fabra University; Amazon.com; University of California System; University of California San Francisco; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Villoslada, P (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Villoslada, P (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain.	Pablo.VillosladaDiaz@ucsf.edu	Villoslada, Pablo/AAF-9547-2019; Villoslada, Pablo/O-1757-2019; Baeza-Yates, Ricardo/H-5692-2015	Villoslada, Pablo/0000-0002-8735-6119; Baeza-Yates, Ricardo/0000-0003-3208-9778	CERCA Program / Generalitat de Catalunya; Amazon Inc.	CERCA Program / Generalitat de Catalunya; Amazon Inc.	This study was funded by CERCA Program / Generalitat de Catalunya to PV. Funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Amazon Inc., a commercial company provided support in the form of salaries for author PS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions.	Agarwal Vibhu, 2016, AMIA Jt Summits Transl Sci Proc, V2016, P15; Brigo F, 2016, NEUROL SCI, V37, P781, DOI 10.1007/s10072-016-2501-5; Brigo F, 2015, J PUBLIC HEALTH-UK, V37, P555, DOI 10.1093/pubmed/fdu083; Brigo F, 2015, EPILEPSY BEHAV, V49, P146, DOI 10.1016/j.yebeh.2015.02.029; Brigo F, 2015, J CLIN NEUROSCI, V22, P1170, DOI 10.1016/j.jocn.2015.02.006; Brigo F, 2014, MULT SCLER RELAT DIS, V3, P440, DOI 10.1016/j.msard.2014.02.005; Brigo F, 2014, EPILEPSY BEHAV, V31, P67, DOI 10.1016/j.yebeh.2013.11.020; Cerminara C, 2014, EPILEPSY BEHAV, V41, P119, DOI 10.1016/j.yebeh.2014.09.053; Colombo C, 2014, INTERACT J MED RES, V3, P2, DOI 10.2196/ijmr.3034; De Lott LB, 2016, NEUROLOGY, V86, P1491, DOI 10.1212/WNL.0000000000002589; Eysenbach Gunther, 2006, AMIA Annu Symp Proc, P244; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Jansen Bernard J., 2008, International Journal of Electronic Business, V6, P114, DOI 10.1504/IJEB.2008.018068; Moccia M, 2016, J NEUROL NEUROSUR PS, V87, P1028, DOI 10.1136/jnnp-2016-313260; Otte WM, 2013, EPILEPSY BEHAV, V29, P571, DOI 10.1016/j.yebeh.2013.10.013; Vera C, 2012, TECH VASC INTERV RAD, V15, P153, DOI 10.1053/j.tvir.2012.02.009; White RW, 2013, J AM MED INFORM ASSN, V20, P404, DOI 10.1136/amiajnl-2012-001482; World Health Organization (OMS), 2006, NEUR DIS PUBL HLTH C	18	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2017	12	5							e0178019	10.1371/journal.pone.0178019	http://dx.doi.org/10.1371/journal.pone.0178019			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UA	28531237	Green Submitted, Green Published, gold			2023-01-03	WOS:000402058400050
J	Joly, P; Maho-Vaillant, M; Prost-Squarcioni, C; Hebert, V; Houivet, E; Calbo, S; Caillot, F; Golinski, ML; Labeille, B; Picard-Dahan, C; Paul, C; Richard, MA; Bouaziz, JD; Duvert-Lehembre, S; Bernard, P; Caux, F; Alexandre, M; Ingen-Housz-Oro, S; Vabres, P; Delaporte, E; Quereux, G; Dupuy, A; Debarbieux, S; Avenel-Audran, M; D'Incan, M; Bedane, C; Beneton, N; Jullien, D; Dupin, N; Misery, L; Machet, L; Beylot-Barry, M; Dereure, O; Sassolas, B; Vermeulin, T; Benichou, J; Musette, P				Joly, Pascal; Maho-Vaillant, Maud; Prost-Squarcioni, Catherine; Hebert, Vivien; Houivet, Estelle; Calbo, Sebastien; Caillot, Frederique; Golinski, Marie Laure; Labeille, Bruno; Picard-Dahan, Catherine; Paul, Carle; Richard, Marie-Aleth; Bouaziz, Jean David; Duvert-Lehembre, Sophie; Bernard, Philippe; Caux, Frederic; Alexandre, Marina; Ingen-Housz-Oro, Saskia; Vabres, Pierre; Delaporte, Emmanuel; Quereux, Gaelle; Dupuy, Alain; Debarbieux, Sebastien; Avenel-Audran, Martine; D'Incan, Michel; Bedane, Christophe; Beneton, Nathalie; Jullien, Denis; Dupin, Nicolas; Misery, Laurent; Machet, Laurent; Beylot-Barry, Marie; Dereure, Olivier; Sassolas, Bruno; Vermeulin, Thomas; Benichou, Jacques; Musette, Philippe		French Study Grp Autoimmune	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial	LANCET			English	Article							INTENSITY SCORE ABSIS; MYCOPHENOLATE-MOFETIL; SINGLE-CYCLE; VULGARIS; THERAPY; DISEASE; ADJUVANT; CORTICOSTEROIDS; COMBINATION; DERMATOLOGY	Background High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with corticosteroid treatment alone, while decreasing treatment side-effects of corticosteroids. Methods We did a prospective, multicentre, parallel-group, open-label, randomised trial in 25 dermatology hospital departments in France (Ritux 3). Eligible participants were patients with newly diagnosed pemphigus aged 18-80 years being treated for the first time (not at the time of a relapse). We randomly assigned participants (1: 1) to receive either oral prednisone alone, 1.0 or 1.5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0.5 or 1.0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24, then an additional visit at month 36). Treatment was assigned through central computer-generated randomisation, with stratification according to disease-severity (severe or moderate, based on Harman's criteria). The primary endpoint was the proportion of patients who achieved complete remission off-therapy at month 24 (intention-to-treat analysis). This study is registered with ClinicalTrials.gov, number NCT00784589. Findings Between May 10, 2010, and Dec 7, 2012, we enrolled 91 patients and randomly assigned 90 to treatment (90 were analysed; 1 patient withdrew consent before the random assignment). At month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (absolute difference 55 percentage points, 95% CI 38.4-71.7; p<0.0001. This difference corresponded to a relative risk of success of 2.61 (95% CI 1.71-3.99, p<0.0001), corresponding to 1.82 patients (95% CI 1.39-2.60) who would need to be treated with rituximab plus prednisone (rather than prednisone alone) for one additional success. No patient died during the study. More severe adverse events of grade 3-4 were reported in the prednisone-alone group (53 events in 29 patients; mean 1.20 [SD 1.25]) than in the rituximab plus prednisone group (27 events in 16 patients; mean 0.59 [1.15]; p=0.0021). The most common of these events in both groups were diabetes and endocrine disorder (11 [21%] with prednisone alone vs six [22%] with rituximab plus prednisone), myopathy (ten [19%] vs three [11%]), and bone disorders (five [9%] vs five [19%]). Interpretation Data from our trial suggest that first-line use of rituximab plus short-term prednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events.	[Joly, Pascal; Maho-Vaillant, Maud; Hebert, Vivien; Calbo, Sebastien; Caillot, Frederique; Golinski, Marie Laure; Duvert-Lehembre, Sophie; Musette, Philippe] Normandie Univ, Rouen Univ Hosp, Dept Dermatol, Rouen, France; [Joly, Pascal; Maho-Vaillant, Maud; Hebert, Vivien; Calbo, Sebastien; Caillot, Frederique; Golinski, Marie Laure; Duvert-Lehembre, Sophie; Musette, Philippe] Normandie Univ, Ctr Reference Malad Bulleuses Autoimmunes, INSERM U1234, Rouen, France; [Prost-Squarcioni, Catherine; Caux, Frederic; Alexandre, Marina] Univ Paris VIII, Dept Dermatol, Bobigny, France; [Houivet, Estelle; Benichou, Jacques] Normandie Univ, Rouen Univ Hosp, Dept Biostat, Rouen, France; [Houivet, Estelle; Benichou, Jacques] Normandie Univ, INSERM U1219, Rouen, France; [Labeille, Bruno] Univ St Etienne, Dept Dermatol, St Etienne, France; [Picard-Dahan, Catherine] Univ Paris X, Bichat Hosp, Dept Dermatol, Paris, France; [Paul, Carle] Univ Toulouse, Dept Dermatol, Toulouse, France; [Richard, Marie-Aleth] Aix Marseille Univ, UMR 911, INSERM CRO2, Dept Dermatol,AP HM, Marseille, France; [Bouaziz, Jean David] Paris 7 Sorbonne Paris Cite Univ, Dept Dermatol, St Louis Hosp, Paris, France; [Bernard, Philippe] Univ Reims, Dept Dermatol, Reims, France; [Ingen-Housz-Oro, Saskia] Henri Mondor Hosp, APHP, Dept Dermatol, Creteil, France; [Vabres, Pierre] Dijon Univ Hosp, Dept Dermatol, Dijon, France; [Delaporte, Emmanuel] Univ Lille, Dept Dermatol, Lille, France; [Quereux, Gaelle] Univ Nantes, Dept Dermatol, Nantes, France; [Dupuy, Alain] Univ Rennes, Dept Dermatol, Rennes, France; [Debarbieux, Sebastien] Ctr Hosp Lyon Sud, Dept Dermatol, Lyon, France; [Avenel-Audran, Martine] Univ Angers, Dept Dermatol, Angers, France; [D'Incan, Michel] Univ Clermont Ferrand, Dept Dermatol, Clermont Ferrand, France; [Bedane, Christophe] Univ Limoges, Dept Dermatol, Limoges, France; [Beneton, Nathalie] Le Mans Gen Hosp, Dept Dermatol, Le Mans, France; [Jullien, Denis] Lyon Claude Bernard Univ, Edouard Herriot Hosp, Dept Dermatol, Lyon, France; [Dupin, Nicolas] Univ Paris V, Dept Dermatol, Paris, France; [Misery, Laurent] Brest Univ Hosp, Dept Dermatol, Brest, France; [Machet, Laurent] Tours Univ Hosp, Dept Dermatol, Tours, France; [Beylot-Barry, Marie] Univ Bordeaux, Dept Dermatol, Bordeaux, France; [Dereure, Olivier] Univ Montpellier, Dept Dermatol, Montpellier, France; [Sassolas, Bruno] Brest Univ Hosp, Dept Internal Med, Brest, France; [Vermeulin, Thomas] Rouen Univ Hosp, Dept Med Informat & Informat, Rouen, France	CHU de Rouen; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Nanterre; Universite de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Dijon Bourgogne; Universite de Lille - ISITE; Universite de Lille; Nantes Universite; Universite de Rennes; CHU Lyon; Universite d'Angers; Universite de Limoges; Centre Hospitalier Le Mans; CHU Lyon; UDICE-French Research Universities; Universite Paris Cite; CHU Brest; CHU Tours; UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier; CHU Brest; CHU de Rouen	Joly, P (corresponding author), Rouen Univ Hosp, Clin Dermatol, F-76031 Rouen, France.	Pascal.Joly@chu-rouen.fr	Machet, Laurent/A-2976-2010; Vabres, Pierre/V-3850-2019; JULLIEN, Denis/D-5654-2014; Vermeulin, Thomas/AAG-3741-2020; Beylot-Barry, Marie/AHC-3163-2022; Dupuy, Alain/AFU-6822-2022; Misery, Laurent/I-1186-2019; Musette, Philippe/AAY-9916-2021; Vabres, Pierre/D-3906-2011	Machet, Laurent/0000-0001-5985-878X; Vabres, Pierre/0000-0001-8693-3183; JULLIEN, Denis/0000-0002-2995-7928; Vabres, Pierre/0000-0001-8693-3183; Beylot-Barry, Marie/0000-0001-6150-1229; Paul, Carle/0000-0003-0165-5263; Sempe, Christine/0000-0001-6903-1575; Dupin, Nicolas/0000-0002-6237-4951	French Ministry of Health; French Society of Dermatology; Roche; Programme Hospitalier de Recherche Clinique, French Ministry of Health [2008-005266-31]	French Ministry of Health; French Society of Dermatology; Roche(Roche Holding); Programme Hospitalier de Recherche Clinique, French Ministry of Health	French Ministry of Health, French Society of Dermatology, Roche.; The study was supported by a grant from the Programme Hospitalier de Recherche Clinique, French Ministry of Health (No 2008-005266-31), and a grant from the French Society of Dermatology. We thank Jean Claude Roujeau, and Jean Claude Guillaume for their help in designing the study, Michael Hertl and Rudiger Eming (Marburg Germany) who provided the recombinant desmoglein 1 and 3, Vincent Ferranti and Natacha Colliou for technical assistance, Rob Stern for commenting on the results, and Nikki Sabourin-Gibbs for her help with editing the manuscript.	Ahmed AR, 2016, INT IMMUNOPHARMACOL, V34, P25, DOI 10.1016/j.intimp.2016.02.013; Ahmed AR, 2015, AUTOIMMUN REV, V14, P323, DOI 10.1016/j.autrev.2014.12.002; Ahmed AR, 2006, NEW ENGL J MED, V355, P1772, DOI 10.1056/NEJMoa062930; Almugairen N, 2013, J AM ACAD DERMATOL, V69, P583, DOI 10.1016/j.jaad.2013.05.016; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Atzmony L, 2015, J AM ACAD DERMATOL, V73, P264, DOI 10.1016/j.jaad.2015.04.038; Beissert S, 2010, J INVEST DERMATOL, V130, P2041, DOI 10.1038/jid.2010.91; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Boulard C, 2016, BRIT J DERMATOL, V175, P142, DOI 10.1111/bjd.14405; Chams-Davatchi C, 2007, J AM ACAD DERMATOL, V57, P622, DOI 10.1016/j.jaad.2007.05.024; Cho YT, 2014, ACTA DERM-VENEREOL, V94, P472, DOI 10.2340/00015555-1746; Chrysomallis Fotis, 1994, International Journal of Dermatology, V33, P803, DOI 10.1111/j.1365-4362.1994.tb01003.x; Cianchini G, 2012, J AM ACAD DERMATOL, V67, P617, DOI 10.1016/j.jaad.2011.11.007; Colliou N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005166; Common Terminology Criteria for Adverse Events version 4. 0, 2009, COMM TERM CRIT ADV E; Deddens JA, 2003, P 28 ANN SAS US GROU, V30, P270; Eming R, 2008, J INVEST DERMATOL, V128, P2850, DOI 10.1038/jid.2008.172; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Guillevin L, 2014, NEW ENGL J MED, V371, P1771, DOI 10.1056/NEJMoa1404231; Hammers CM, 2015, J INVEST DERMATOL, V135, P742, DOI 10.1038/jid.2014.291; Harman KE, 2001, BRIT J DERMATOL, V144, P775, DOI 10.1046/j.1365-2133.2001.04132.x; Heelan K, 2015, J CUTAN MED SURG, V19, P274, DOI 10.2310/7750.2014.14092; Heelan K, 2014, JAMA DERMATOL, V150, P703, DOI 10.1001/jamadermatol.2013.6739; Hertl M, 2006, J CLIN INVEST, V116, P1159, DOI 10.1172/JCI28547; Hertl M, 2015, J EUR ACAD DERMATOL, V29, P405, DOI 10.1111/jdv.12772; Ingen-Housz-Oro S, 2015, JAMA DERMATOL, V151, P200, DOI 10.1001/jamadermatol.2014.2421; Ioannides D, 2000, ARCH DERMATOL, V136, P868, DOI 10.1001/archderm.136.7.868; Ioannides D, 2012, J EUR ACAD DERMATOL, V26, P855, DOI 10.1111/j.1468-3083.2011.04170.x; Joly P, 2007, NEW ENGL J MED, V357, P545, DOI 10.1056/NEJMoa067752; Kim JH, 2011, BRIT J DERMATOL, V165, P646, DOI 10.1111/j.1365-2133.2011.10411.x; Langan SM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a180; Leplege A, 2003, ANN DERMATOL VENER, V130, P177; Leshem YA, 2014, J AM ACAD DERMATOL, V71, P284, DOI 10.1016/j.jaad.2014.03.020; Leshem YA, 2013, J AM ACAD DERMATOL, V68, P404, DOI 10.1016/j.jaad.2012.08.010; LEVER WF, 1969, ARCH DERMATOL, V100, P70, DOI 10.1001/archderm.100.1.70; Lott JP, 2014, J AM ACAD DERMATOL, V70, P47, DOI 10.1016/j.jaad.2013.09.039; Lunardon L, 2012, ARCH DERMATOL, V148, P1031, DOI 10.1001/archdermatol.2012.1522; Martin LK, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006263.pub2; Matsukura S, 2012, ARCH DERMATOL, V148, P734, DOI 10.1001/archdermatol.2011.3320; Murrell DE, 2008, J AM ACAD DERMATOL, V58, P1043, DOI 10.1016/j.jaad.2008.01.012; Pfutze M, 2007, EUR J DERMATOL, V17, P4; Rosenbach M, 2009, J INVEST DERMATOL, V129, P2404, DOI 10.1038/jid.2009.72; Sharma VK, 2013, CLIN EXP DERMATOL, V38, P659, DOI 10.1111/ced.12073; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; Wu H, 2000, NEW ENGL J MED, V343, P31, DOI 10.1056/NEJM200007063430105; Zambruno G, 2008, J INVEST DERMATOL, V128, P2745, DOI 10.1038/jid.2008.330; Zhao CY, 2015, DRUGS, V75, P271, DOI 10.1007/s40265-015-0353-6	49	299	308	4	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2017	389	10083					2031	2040		10.1016/S0140-6736(17)30070-3	http://dx.doi.org/10.1016/S0140-6736(17)30070-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV1OH	28342637				2023-01-03	WOS:000401515300025
J	Hanafusa, N; Isoai, A; Ishihara, T; Inoue, T; Ishitani, K; Utsugisawa, T; Yamaka, T; Ito, T; Sugiyama, H; Arakawa, A; Yamada, Y; Itano, Y; Onodera, H; Kobayashi, R; Torii, N; Numata, T; Kashiwabara, T; Matsuno, Y; Kato, M				Hanafusa, Norio; Isoai, Ayako; Ishihara, Tomoaki; Inoue, Tetsuya; Ishitani, Ken; Utsugisawa, Taiju; Yamaka, Toshihiko; Ito, Tetsuya; Sugiyama, Hiroshi; Arakawa, Atsushi; Yamada, Yosuke; Itano, Yasuo; Onodera, Hirokazu; Kobayashi, Ryosuke; Torii, Naoko; Numata, Toyoko; Kashiwabara, Taihei; Matsuno, Yoshihiro; Kato, Michio			Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results	PLOS ONE			English	Article							MALIGNANCY-RELATED ASCITES; CANCER-PATIENTS; ALBUMIN; FLUID	We performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of ascites collected was 3.7 L, and mean concentration ratio was 9.2. Mean amount of reinfused protein was 67.8 g (recovery rate, 72.0%). Performance status, dietary intake, urine volume, body weight and abdominal circumference were significantly improved after CART. Body temperature increased significantly, by 0.3 degrees C on average. Concomitant steroids and/or NSAIDs use before reinfusion was significantly and negatively associated with increases in body temperature. Most adverse events were fever and chills. This study examined a large number of patients compared with previous studies, and showed that CART is an effective and relatively safe treatment for refractory ascites, such as malignant ascites.	[Hanafusa, Norio] Tokyo Womens Med Univ, Dept Blood Purificat, Kidney Ctr, Tokyo, Japan; [Isoai, Ayako; Onodera, Hirokazu; Kobayashi, Ryosuke; Torii, Naoko; Numata, Toyoko; Matsuno, Yoshihiro] Asahi Kasei Med Co Ltd, Blood Purificat Div, Tokyo, Japan; [Ishihara, Tomoaki] Yokkaichi Digest Dis Ctr, Dept Gastroenterol & Hepatol, Yokaichi, Mie, Japan; [Inoue, Tetsuya] Hita Cent Hosp, Dept Surg, Oita, Japan; [Ishitani, Ken] Kitasato Univ, Dept Gynecol, Kitasato Inst Hosp, Tokyo, Japan; [Utsugisawa, Taiju] Tokyo Womens Med Univ, Dept Transfus Med & Cell Proc, Tokyo, Japan; [Yamaka, Toshihiko] Kanagawa Inst Technol, Dept Clin Engn, Fac Engn, Kanagawa, Japan; [Ito, Tetsuya] Japanese Red Cross Med Ctr, Dept Palliat Care, Tokyo, Japan; [Sugiyama, Hiroshi] Kizawa Mem Hosp, Dept Gastroenterol, Gifu, Japan; [Arakawa, Atsushi] Nagoya City Univ, Dept Obstet & Gynecol, Grad Sch Med Sci, Aichi, Japan; [Yamada, Yosuke] Shinshu Univ Hosp, Div Nephrol, Nagano, Japan; [Itano, Yasuo] Okayama Kyoritsu Gen Hosp, Dept Internal Med, Okayama, Japan; [Kashiwabara, Taihei] Asahi Kasei Med Co Ltd, Vigilance & Qual Assurance Div, Prod Vigilance & Qual Assurance Dept, Regulatory Affairs, Tokyo, Japan; [Kato, Michio] Kato Michio Clin Liver Dis, Med Corp, Kenseikai, Hyogo, Japan	Tokyo Women's Medical University; Kitasato University; Tokyo Women's Medical University; Kanagawa Institute Technology; Japanese Red Cross Medical Center; University of Tokyo; Nagoya City University; Shinshu University	Hanafusa, N (corresponding author), Tokyo Womens Med Univ, Dept Blood Purificat, Kidney Ctr, Tokyo, Japan.	hanafusa@twmu.ac.jp	Utsugisawa, Taiju/ABD-7059-2021	Ito, Tetsuya/0000-0002-3872-4632; Hanafusa, Norio/0000-0002-0563-3320				[Anonymous], 2014, PRACT GUID MAN TRANS, P41; BRADLEY SE, 1947, J CLIN INVEST, V26, P1010, DOI 10.1172/JCI101867; DASCOMBE MJ, 1985, PROG NEUROBIOL, V25, P327, DOI 10.1016/0301-0082(85)90019-X; Davis HA, 1939, J CLIN INVEST, V18, P219, DOI 10.1172/JCI101037; Ernest D, 1999, CRIT CARE MED, V27, P46, DOI 10.1097/00003246-199901000-00025; HALLOWELL P, 1978, ANN THORAC SURG, V25, P22, DOI 10.1016/S0003-4975(10)63481-9; Ito T, 2015, INT J CLIN ONCOL, V20, P623, DOI 10.1007/s10147-014-0750-y; Ito T, 2014, THER APHER DIAL, V18, P87, DOI 10.1111/1744-9987.12049; Light RW, 2002, NEW ENGL J MED, V346, P1971, DOI 10.1056/NEJMcp010731; Maeda O, 2014, MOL CLIN ONCOL, V2, P1103, DOI 10.3892/mco.2014.335; Maeda S, 2015, THER APHER DIAL, V19, P342, DOI 10.1111/1744-9987.12343; Matsusaki K, 2011, INT J CLIN ONCOL, V16, P395, DOI 10.1007/s10147-011-0199-1; Mullens W, 2008, J AM COLL CARDIOL, V51, P300, DOI 10.1016/j.jacc.2007.09.043; Nakajima F, 2001, J JPN SOC DIAL THER, V34, P335, DOI DOI 10.4009/jsdt.34.335; Oda T, 1974, JPN J CLIN EXP MED, V51, P343; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Orimi S, 2011, THER APHER DIAL, V15, P411, DOI 10.1111/j.1744-9987.2011.00973.x; Ronco C, 2012, J AM COLL CARDIOL, V60, P1031, DOI 10.1016/j.jacc.2012.01.077; RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215; SCHNEDITZ D, 1992, KIDNEY INT, V42, P1425, DOI 10.1038/ki.1992.437; Takamatsu S, 2003, KAN TAN SUI, V46, P663; Ueda T, 2012, ANTICANCER RES, V32, P2353; Wang LC, 2015, J OBSTET GYNAECOL RE, V41, P1614, DOI 10.1111/jog.12763; Yamaguchi H, 2015, EJSO-EUR J SURG ONC, V41, P875, DOI 10.1016/j.ejso.2015.04.013; Zaak D, 2001, Z GASTROENTEROL, V39, P5, DOI 10.1055/s-2001-10707	25	29	29	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177303	10.1371/journal.pone.0177303	http://dx.doi.org/10.1371/journal.pone.0177303			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DC	28510606	Green Published, gold, Green Submitted			2023-01-03	WOS:000401485500022
J	Baker, KE				Baker, Kellan E.			The Future of Transgender Coverage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Baker, Kellan E.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Baker, Kellan E.] Ctr Amer Progress, Washington, DC 20005 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Baker, KE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.; Baker, KE (corresponding author), Ctr Amer Progress, Washington, DC 20005 USA.							Coleman E, 2012, INT J TRANSGENDERISM, V13, P165, DOI 10.1080/15532739.2011.700873; Herman JL, 2017, AGE INDIVIDUALS WHO, DOI DOI 10.1177/0011128717714204; Human Rights Campaign Foundation, 2017, CORP EQ IND 2017 RAT; James S. E., 2016, REPORT US TRANSGENDE; Padula WV, 2016, J GEN INTERN MED, V31, P394, DOI 10.1007/s11606-015-3529-6	5	68	68	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2017	376	19					1801	1804		10.1056/NEJMp1702427	http://dx.doi.org/10.1056/NEJMp1702427			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU2WR	28402247				2023-01-03	WOS:000400891100001
J	Kragholm, K; Wissenberg, M; Mortensen, RN; Hansen, SM; Hansen, CM; Thorsteinsson, K; Rajan, S; Lippert, F; Folke, F; Gislason, G; Kober, L; Fonager, K; Jensen, SE; Gerds, TA; Torp-Pedersen, C; Rasmussen, BS				Kragholm, Kristian; Wissenberg, Mads; Mortensen, Rikke N.; Hansen, Steen M.; Hansen, Carolina Malta; Thorsteinsson, Kristinn; Rajan, Shahzleen; Lippert, Freddy; Folke, Fredrik; Gislason, Gunnar; Kober, Lars; Fonager, Kirsten; Jensen, Svend E.; Gerds, Thomas A.; Torp-Pedersen, Christian; Rasmussen, Bodil S.			Bystander Efforts and 1-Year Outcomes in Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOPULMONARY-RESUSCITATION; SURVIVAL; LIFE; REGISTER; INTERVENTION; ASSOCIATION; TRENDS; COHORT; RATES	BACKGROUND The effect of bystander interventions on long-term functional outcomes among survivors of out-of-hospital cardiac arrest has not been extensively studied. METHODS We linked nationwide data on out-of-hospital cardiac arrests in Denmark to functional outcome data and reported the 1-year risks of anoxic brain damage or nursing home admission and of death from any cause among patients who survived to day 30 after an out-of-hospital cardiac arrest. We analyzed risks according to whether bystander cardiopulmonary resuscitation (CPR) or defibrillation was performed and evaluated temporal changes in bystander interventions and outcomes. RESULTS Among the 2855 patients who were 30-day survivors of an out-of-hospital cardiac arrest during the period from 2001 through 2012, a total of 10.5% had brain damage or were admitted to a nursing home and 9.7% died during the 1-year follow-up period. During the study period, among the 2084 patients who had cardiac arrests that were not witnessed by emergency medical services (EMS) personnel, the rate of bystander CPR increased from 66.7% to 80.6% (P<0.001), the rate of bystander defibrillation increased from 2.1% to 16.8% (P<0.001), the rate of brain damage or nursing home admission decreased from 10.0% to 7.6% (P<0.001), and all-cause mortality decreased from 18.0% to 7.9% (P = 0.002). In adjusted analyses, bystander CPR was associated with a risk of brain damage or nursing home admission that was significantly lower than that associated with no bystander resuscitation (hazard ratio, 0.62; 95% confidence interval [CI], 0.47 to 0.82), as well as a lower risk of death from any cause (hazard ratio, 0.70; 95% CI, 0.50 to 0.99) and a lower risk of the composite end point of brain damage, nursing home admission, or death (hazard ratio, 0.67; 95% CI, 0.53 to 0.84). The risks of these outcomes were even lower among patients who received bystander defibrillation as compared with no bystander resuscitation. CONCLUSIONS In our study, we found that bystander CPR and defibrillation were associated with risks of brain damage or nursing home admission and of death from any cause that were significantly lower than those associated with no bystander resuscitation.	[Kragholm, Kristian; Rasmussen, Bodil S.] Aalborg Univ Hosp, Dept Anesthesiol & Intens Care Med, Sdr Skovvej 15, DK-9000 Aalborg, Denmark; [Mortensen, Rikke N.; Hansen, Steen M.; Torp-Pedersen, Christian] Aalborg Univ Hosp, Dept Clin Epidemiol, Aalborg, Denmark; [Thorsteinsson, Kristinn] Aalborg Univ Hosp, Dept Cardiothorac Surg, Aalborg, Denmark; [Fonager, Kirsten] Aalborg Univ Hosp, Dept Social Med, Aalborg, Denmark; [Jensen, Svend E.] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark; [Kragholm, Kristian; Rasmussen, Bodil S.] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Hansen, Steen M.; Fonager, Kirsten; Jensen, Svend E.; Torp-Pedersen, Christian; Rasmussen, Bodil S.] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark; [Kragholm, Kristian; Rasmussen, Bodil S.] Aarhus Univ, Clin Inst Med, Aarhus, Denmark; [Wissenberg, Mads] Copenhagen Univ Hosp, Emergency Med Serv Copenhagen, Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark; [Kober, Lars] Copenhagen Univ Hosp, Emergency Med Serv Copenhagen, Rigshosp, Dept Cardiol, Copenhagen, Denmark; [Wissenberg, Mads; Lippert, Freddy; Folke, Fredrik] Univ Copenhagen, Copenhagen, Denmark; [Hansen, Carolina Malta; Rajan, Shahzleen; Folke, Fredrik; Gislason, Gunnar] Copenhagen Univ Hosp Gentofte, Dept Cardiol, Copenhagen, Denmark; [Gislason, Gunnar] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark; [Gerds, Thomas A.] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; [Hansen, Carolina Malta] Duke Clin Res Inst, Durham, NC USA	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University; Aarhus University; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Southern Denmark; University of Copenhagen; Duke University	Kragholm, K (corresponding author), Aalborg Univ Hosp, Dept Anesthesiol & Intens Care Med, Sdr Skovvej 15, DK-9000 Aalborg, Denmark.	kdks@rn.dk	Gislason, Gunnar/B-7561-2009; Folke, Fredrik/P-3601-2014	Gislason, Gunnar/0000-0002-0548-402X; Lippert, Freddy/0000-0002-2356-8809; Kragholm, Kristian/0000-0001-9629-8670; Kober, Lars/0000-0002-6635-1466; Rasmussen, Bodil Steen/0000-0003-2190-145X; Gerds, Thomas Alexander/0000-0002-5955-816X; Folke, Fredrik/0000-0002-2284-7857; Fonager, Kirsten/0000-0001-9641-992X	TrygFonden; Danish Heart Foundation	TrygFonden; Danish Heart Foundation	Funded by TrygFonden and the Danish Heart Foundation.	Andersen Christian K, 2004, Health Qual Life Outcomes, V2, P52, DOI 10.1186/1477-7525-2-52; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Bartlett JW, 2015, STAT METHODS MED RES, V24, P462, DOI 10.1177/0962280214521348; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Beesems SG, 2014, RESUSCITATION, V85, P1269, DOI 10.1016/j.resuscitation.2014.05.027; BENICHOU J, 1990, BIOMETRICS, V46, P813, DOI 10.2307/2532098; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bunch TJ, 2003, NEW ENGL J MED, V348, P2626, DOI 10.1056/NEJMoa023053; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Daya MR, 2015, RESUSCITATION, V91, P108, DOI 10.1016/j.resuscitation.2015.02.003; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hansen CM, 2015, JAMA-J AM MED ASSOC, V314, P255, DOI 10.1001/jama.2015.7938; Hansen CM, 2014, CIRCULATION, V130, P1859, DOI 10.1161/CIRCULATIONAHA.114.008850; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Jacobsen A., 2016, DANMARKS STAT; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kragholm K, 2015, CIRCULATION, V131, P1682, DOI 10.1161/CIRCULATIONAHA.114.011366; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Middelkamp W, 2007, CLIN REHABIL, V21, P425, DOI 10.1177/0269215507075307; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; . R: A Language and Environment for Statistical Computing, 2012, R LANG ENV STAT COMP; Reynolds JC, 2013, CIRCULATION, V128, P2488, DOI 10.1161/CIRCULATIONAHA.113.002408; Smith K, 2015, CIRCULATION, V131, P174, DOI 10.1161/CIRCULATIONAHA.114.011200; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83; van Houwelingen HC, 2007, SCAND J STAT, V34, P70, DOI 10.1111/j.1467-9469.2006.00529.x; Verbunt JA, 2009, RESUSCITATION, V80, P297; Vest MT, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-9; Wilson JTL, 2005, STROKE, V36, P777, DOI 10.1161/01.STR.0000157596.13234.95; Wissenberg M, 2015, CIRCULATION, V131, P1536, DOI 10.1161/CIRCULATIONAHA.114.013122; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483	34	204	215	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2017	376	18					1737	1747		10.1056/NEJMoa1601891	http://dx.doi.org/10.1056/NEJMoa1601891			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET6ZH	28467879				2023-01-03	WOS:000400442300007
J	Greenway, T; Ross, JS				Greenway, Tyler; Ross, Joseph S.			US drug marketing: how does promotion correspond with health value?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Greenway, Tyler] Yale Univ, Sch Med, New Haven, CT USA; [Ross, Joseph S.] Yale Univ, Sch Med, Gen Internal Med Sect, 333 Cedar St, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, 333 Cedar St, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA	Yale University; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Yale University	Ross, JS (corresponding author), Yale Univ, Sch Med, Gen Internal Med Sect, 333 Cedar St, New Haven, CT 06520 USA.; Ross, JS (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, 333 Cedar St, New Haven, CT 06520 USA.; Ross, JS (corresponding author), Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT 06520 USA.; Ross, JS (corresponding author), Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.	joseph.ross@yale.edu		Ross, Joseph/0000-0002-9218-3320				Agency for Healthcare Research and Quality US Department of Health and Human Services, NAT GUID CLEAR; Agrawal S, 2016, NEW ENGL J MED, V374, P906, DOI 10.1056/NEJMp1509103; Avorn J, 2011, NEW ENGL J MED, V364, P1185, DOI 10.1056/NEJMp1011713; Campbell EG, 2007, NEW ENGL J MED, V356, P1742, DOI 10.1056/NEJMsa064508; Centers for Medicare and Medicaid Services, OPEN PAYM; DeJong C, 2016, JAMA INTERN MED, V176, P1114, DOI 10.1001/jamainternmed.2016.2765; Epstein AJ, 2013, MED CARE, V51, P199, DOI 10.1097/MLR.0b013e318277eb19; Fleischman W, 2016, J EPIDEMIOL COMMUNIT; Fleischman W, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4189; IMS Health, 2014, MED US SPEND US REV; King M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f264; Lanthier M, 2013, HEALTH AFFAIR, V32, P1433, DOI 10.1377/hlthaff.2012.0541; Ornstein C, 2014, WHAT WEVE LEARNED 4; Prescrire International, PRESCR ENGL; ProPublica, OP PAYM EXPL; Ross JS, 2007, JAMA-J AM MED ASSOC, V297, P1216, DOI 10.1001/jama.297.11.1216; Yeh JS, 2016, JAMA INTERN MED, V176, P763, DOI 10.1001/jamainternmed.2016.1709	17	19	19	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	2017	357								j1855	10.1136/bmj.j1855	http://dx.doi.org/10.1136/bmj.j1855			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU2WB	28465309				2023-01-03	WOS:000400889500001
J	O'Neil, K				O'Neil, Kathleen			S&T Policy Forum examines evolving opioid epidemic	SCIENCE			English	Editorial Material																			0	1	1	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2017	356	6336					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ET2YU	28450608				2023-01-03	WOS:000400143000041
J	Orkin, AM; Zhan, C; Buick, JE; Drennan, IR; Kleiman, M; Leese, P; Morrison, LJ				Orkin, Aaron M.; Zhan, Chun; Buick, Jason E.; Drennan, Ian R.; Kleiman, Michelle; Leese, Pamela; Morrison, Laurie J.			Out-of-hospital cardiac arrest survival in drugrelated versus cardiac causes in Ontario: A retrospective cohort study	PLOS ONE			English	Article							RESUSCITATION; OUTCOMES; ASSOCIATION; OVERDOSES; PHYSICIAN; UPDATE	Background Drug overdose causes approximately 183,000 deaths worldwide annually and 50,000 deaths in Canada and the United States combined. Drug-related deaths are concentrated among young people, leading to a substantial burden of disease and loss of potential life years. Understanding the epidemiology, patterns of care, and prognosis of drug-related prehospital emergencies may lead to improved outcomes. Methods We conducted a retrospective cohort study of out-of-hospital cardiac arrests with drugrelated and presumed cardiac causes between 2007 and 2013 using the Toronto Regional RescuNet Epistry database. The primary outcome was survival to hospital discharge. We computed standardized case fatality rates, and odds ratios of survival to hospital discharge for cardiac arrests with drug-related versus presumed cardiac causes, adjusting for confounders using logistic regression. Results The analysis involved 21,497 cardiac arrests, including 378 (1.8%) drug-related and 21,119 (98.2%) presumed cardiac. Compared with the presumed cardiac group, drug-related arrest patients were younger and less likely to receive bystander resuscitation, have initial shockable cardiac rhythms, or be transported to hospital. There were no significant differences in emergency medical service response times, return of spontaneous circulation, or survival to discharge. Standardized case fatality rates confirmed that these effects were not due to age or sex differences. Adjusting for known predictors of survival, drug-related cardiac arrest was associated with increased odds of survival to hospital discharge (OR1.44, 95% CI 1.15 - 1.81). Interpretation In out-of-hospital cardiac arrest, patients with drug-related causes are less likely than those with presumed cardiac causes to receive bystander resuscitation or have an initial shockable rhythm, but are more likely to survive after accounting for predictors of survival. The demographics and outcomes among drug-related cardiac arrest patients offers unique opportunities for prehospital intervention.	[Orkin, Aaron M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Orkin, Aaron M.; Zhan, Chun; Buick, Jason E.; Drennan, Ian R.; Morrison, Laurie J.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Orkin, Aaron M.] Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada; [Orkin, Aaron M.; Morrison, Laurie J.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Orkin, Aaron M.; Leese, Pamela] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Drennan, Ian R.] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada; [Kleiman, Michelle; Morrison, Laurie J.] Univ Toronto, St Michaels Hosp, Div Emergency Med, Toronto, ON, Canada; [Leese, Pamela] Publ Hlth Ontario, Toronto, ON, Canada	University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Orkin, AM (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Orkin, AM (corresponding author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada.; Orkin, AM (corresponding author), Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada.; Orkin, AM (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Orkin, AM (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.	aaron.orkin@mail.utoronto.ca	Drennan, Ian R/K-3046-2013; Buick, Jason E/K-4816-2013; Orkin, Aaron/K-2500-2014; Morrison, Laurie Jean/A-6325-2012; Drennan, Ian/GQH-9137-2022	Drennan, Ian R/0000-0001-8033-4382; Buick, Jason E/0000-0002-1859-1713; Orkin, Aaron/0000-0002-1111-8720; Morrison, Laurie Jean/0000-0001-8369-9774; 	Dalla Lana School of Public Health; Ontario Ministry of Health and Long-Term Care Clinician Investigator Program; Canadian Institutes of Health Research Fellowship Program; Canadian Institutes of Health Research Banting and Best Doctoral Research Award	Dalla Lana School of Public Health; Ontario Ministry of Health and Long-Term Care Clinician Investigator Program; Canadian Institutes of Health Research Fellowship Program(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research Banting and Best Doctoral Research Award(Canadian Institutes of Health Research (CIHR))	This study received no specific funding. The Dalla Lana School of Public Health, Ontario Ministry of Health and Long-Term Care Clinician Investigator Program, and the Canadian Institutes of Health Research Fellowship Program fund AMO's research and the Canadian Institutes of Health Research Banting and Best Doctoral Research Award funds IRD's research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	British Columbia Coroners Service, 2007, ILLICIT DRUG OVERDOS; British Columbia Government, PROV HLTH OFF DECL P; Buick JE, 2012, CJEM, V15, P1; Centers for Disease Control and Prevention, 2015, NAT VIT STAT SYST MO; Centers for Disease Control and Prevention, 2014, WEB BAS INJ STAT QUE; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Drennan IR, 2016, CMAJ; Elmer J, 2015, RESUSCITATION, V89, P177, DOI 10.1016/j.resuscitation.2015.01.028; Fischer B, 2006, CANADIAN J PUBLIC HL, P384; Gladstone E, 2015, CMAJ; Gomes T, 2014, ADDICTION, V109, P1482, DOI 10.1111/add.12598; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Health Canada Prescription Drug Status Committee, NOT PRESCR DRUG LIST; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Katz AZ, 2015, RESUSCITATION, V94, P23, DOI 10.1016/j.resuscitation.2015.06.015; Koller AC, 2014, RESUSCITATION; Koller AC, 2014, PREHOSP EMERG CARE, V18, P483, DOI 10.3109/10903127.2014.897780; Lavonas EJ, 2015, CIRCULATION, V132, pS501, DOI 10.1161/CIR.0000000000000264; Lin S, 2011, RESUSCITATION, V82, P419, DOI 10.1016/j.resuscitation.2010.12.006; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Morrison LJ, 2008, RESUSCITATION, V78, P161, DOI 10.1016/j.resuscitation.2008.02.020; Murphy Y, 2015, PAIN PHYSICIAN, V18, pE605; National Institute on Drug Abuse (NIDA), 2006, EP TRENDS DRUG AB; Nielsen K, 2011, RESUSCITATION, V82, P1410, DOI 10.1016/j.resuscitation.2011.05.027; Office for National Statistics (United Kingdom), 2013, DEATHS REL DRUG POIS; Ontario Ministry of Health and Long-Term Care, 2010, DEC PAT STAND; Ontario Ministry of Health and Long-Term Care, 2011, ADV LIF SUPP PAT CAR; Penington Institute Australia, 2014, ANN REV 2014; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Rittenberger JC, 2011, RESUSCITATION, V82, P1036, DOI 10.1016/j.resuscitation.2011.03.034; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Salcido DD, 2016, RESUSCITATION, V99, P13, DOI 10.1016/j.resuscitation.2015.11.010; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; SIMS M, 1973, AM J PUBLIC HEALTH, V63, P215, DOI 10.2105/AJPH.63.3.215; Soholm H, 2015, ANN EMERG MED, V65, P523, DOI 10.1016/j.annemergmed.2014.12.009; Sporer KA, 1996, ACAD EMERG MED, V3, P660, DOI 10.1111/j.1553-2712.1996.tb03487.x; Statistics Canada, POP DWELL COUNTS CAN; United Nations Office on Drugs and Crime (UNDOC), 2014, WORLD DRUG REP 2014; Vanden Hoek TL, 2010, CIRCULATION, V122, pS829, DOI 10.1161/CIRCULATIONAHA.110.971069; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; Wolfenden HH, 1923, J R STAT SOC, V86, P399, DOI 10.2307/2341622	42	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2017	12	4							e0176441	10.1371/journal.pone.0176441	http://dx.doi.org/10.1371/journal.pone.0176441			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET5FI	28445501	Green Published, gold, Green Submitted			2023-01-03	WOS:000400309200061
J	Breitenstein, C; Grewe, T; Floel, A; Ziegler, W; Springer, L; Martus, P; Huber, W; Willmes, K; Ringelstein, EB; Haeusler, KG; Abel, S; Glindemann, R; Domahs, F; Regenbrecht, F; Schlenck, KJ; Thomas, M; Obrig, H; de Langen, E; Rocker, R; Wigbers, F; Ruehmkorf, C; Hempen, I; List, J				Breitenstein, Caterina; Grewe, Tanja; Floeel, Agnes; Ziegler, Wolfram; Springer, Luise; Martus, Peter; Huber, Walter; Willmes, Klaus; Ringelstein, E. Bernd; Haeusler, Karl Georg; Abel, Stefanie; Glindemann, Ralf; Domahs, Frank; Regenbrecht, Frank; Schlenck, Klaus-Juergen; Thomas, Marion; Obrig, Hellmuth; de Langen, Ernst; Rocker, Roman; Wigbers, Franziska; Ruehmkorf, Christina; Hempen, Indra; List, Jonathan			Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting	LANCET			English	Article							PARALLEL-GROUP; COMMUNICATION; REHABILITATION; RELIABILITY; IMPACT; LIFE	Background Treatment guidelines for aphasia recommend intensive speech and language therapy for chronic (>= 6 months) aphasia after stroke, but large-scale, class 1 randomised controlled trials on treatment effectiveness are scarce. We aimed to examine whether 3 weeks of intensive speech and language therapy under routine clinical conditions improved verbal communication in daily-life situations in people with chronic aphasia after stroke. Methods In this multicentre, parallel group, superiority, open-label, blinded-endpoint, randomised controlled trial, patients aged 70 years or younger with aphasia after stroke lasting for 6 months or more were recruited from 19 inpatient or outpatient rehabilitation centres in Germany. An external biostatistician used a computer-generated permuted block randomisation method, stratified by treatment centre, to randomly assign participants to either 3 weeks or more of intensive speech and language therapy (>= 10 h per week) or 3 weeks deferral of intensive speech and language therapy. The primary endpoint was between-group difference in the change in verbal communication effectiveness in everyday life scenarios (Amsterdam-Nijmegen Everyday Language Test A-scale) from baseline to immediately after 3 weeks of treatment or treatment deferral. All analyses were done using the modified intention-to-treat population (those who received 1 day or more of intensive treatment or treatment deferral). This study is registered with ClinicalTrials.gov, number NCT01540383. Findings We randomly assigned 158 patients between April 1, 2012, and May 31, 2014. The modified intention-to-treat population comprised 156 patients (78 per group). Verbal communication was significantly improved from baseline to after intensive speech and language treatment (mean difference 2.61 points [SD 4.94]; 95% CI 1.49 to 3.72), but not from baseline to after treatment deferral (-0.03 points [4.04]; -0.94 to 0.88; between-group difference Cohen's d 0.58; p=0.0004). Eight patients had adverse events during therapy or treatment deferral (one car accident [in the control group], two common cold [one patient per group], three gastrointestinal or cardiac symptoms [all intervention group], two recurrent stroke [one in intervention group before initiation of treatment, and one before group assignment had occurred]); all were unrelated to study participation. Interpretation 3 weeks of intensive speech and language therapy significantly enhanced verbal communication in people aged 70 years or younger with chronic aphasia after stroke, providing an effective evidence-based treatment approach in this population. Future studies should examine the minimum treatment intensity required for meaningful treatment effects, and determine whether treatment effects cumulate over repeated intervention periods.	[Breitenstein, Caterina; Ringelstein, E. Bernd; Thomas, Marion; Rocker, Roman; Wigbers, Franziska; Ruehmkorf, Christina; Hempen, Indra] Univ Munster, Dept Gen Neurol, Munster, Germany; [Breitenstein, Caterina; Ringelstein, E. Bernd; Thomas, Marion; Rocker, Roman; Wigbers, Franziska; Ruehmkorf, Christina; Hempen, Indra] Univ Munster, Dept Neurol, Munster, Germany; [Grewe, Tanja] Fresenius Univ Appl Sci, Fac Hlth & Social Sci, Idstein, Germany; [Grewe, Tanja] Fresenius Univ Appl Sci, Fac Hlth & Social Sci, Hamburg, Germany; [Floeel, Agnes; Haeusler, Karl Georg; List, Jonathan] NeuroCure Clin Res Ctr, Washington, DC USA; [Floeel, Agnes; Haeusler, Karl Georg; List, Jonathan] Ctr Stroke Res Berlin, Washington, DC USA; [Floeel, Agnes; Haeusler, Karl Georg; List, Jonathan] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Floeel, Agnes] Ernst Moritz Arndt Univ Greifswald, Dept Neurol, Greifswald, Germany; [Ziegler, Wolfram] Ludwig Maximilians Univ Munchen, Inst Phonet & Speech Proc, Clin Neuropsychol Res Grp, Munich, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biostatist, Tubingen, Germany; [Willmes, Klaus; Abel, Stefanie] Rhein Westfal TH Aachen, Clin & Cognit Neurosci, Aachen, Germany; [Willmes, Klaus] Rhein Westfal TH Aachen, Clin & Neuropsychol, Aachen, Germany; [Abel, Stefanie] Rhein Westfal TH Aachen, Univ Hosp, Dept Neurol, Aachen, Germany; [Abel, Stefanie] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; [Glindemann, Ralf] Bogenhausen Hosp, Neuropsychol Dept, Munich, Germany; [Domahs, Frank] Univ Marburg, Inst German Linguist, Marburg, Germany; [Regenbrecht, Frank; Obrig, Hellmuth] Univ Leipzig, Max Planck Inst Cognit & Brain Sci, Clin Cognit Neurol, Leipzig, Germany; [Schlenck, Klaus-Juergen] M&I Fachklinik Enzensberg, Fuessen, Germany; [de Langen, Ernst] Reha Ctr Passauer Wolf, Bad Griesbach, Germany	University of Munster; University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ernst Moritz Arndt Universitat Greifswald; University of Munich; Eberhard Karls University of Tubingen; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital; University of Manchester; Munchen Klinik; Philipps University Marburg; Leipzig University; Max Planck Society	Breitenstein, C (corresponding author), Univ Munster, Dept Gen Neurol, Munster, Germany.	caterina.breitenstein@uni-muenster.de	Häusler, Karl Georg/AAS-5962-2021; Floel, Agnes/A-9426-2017; Willmes, Klaus F/A-1268-2014; Schulz, Jorg B./D-9786-2012; Bruehl, Stefanie/D-3059-2017	Willmes, Klaus F/0000-0002-9012-0553; Schulz, Jorg B./0000-0002-8903-0593; Villringer, Arno/0000-0003-2604-2404; Bruehl, Stefanie/0000-0003-4826-1990	German Federal Ministry of Education and Research; German Society for Aphasia Research and Treatment; German Federal Ministry of Education and Research (BMBF) [01GY1144]; German Society for Aphasia Research and Treatment (GAB)	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Society for Aphasia Research and Treatment; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Society for Aphasia Research and Treatment (GAB)	German Federal Ministry of Education and Research and the German Society for Aphasia Research and Treatment.; This investigator-initiated trial was funded by the German Federal Ministry of Education and Research (BMBF; identifier, 01GY1144) and the German Society for Aphasia Research and Treatment (GAB). Further acknowledgements are given in the appendix.	Allen L, 2012, TOP STROKE REHABIL, V19, P523, DOI 10.1310/tsr1906-523; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Baumgaertner A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-308; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; BLOMERT L, 1994, APHASIOLOGY, V8, P381, DOI 10.1080/02687039408248666; Bowen A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4407; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Cherney LR, 2011, CURR NEUROL NEUROSCI, V11, P560, DOI 10.1007/s11910-011-0227-6; de Jong-Hagelstein M, 2011, J NEUROL NEUROSUR PS, V82, P399, DOI 10.1136/jnnp.2010.210559; Dickey L, 2010, ARCH PHYS MED REHAB, V91, P196, DOI 10.1016/j.apmr.2009.09.020; Dignam J, 2015, STROKE, V46, P2206, DOI 10.1161/STROKEAHA.115.009522; Dijkerman HC, 1996, J ROY COLL PHYS LOND, V30, P538; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Doucet T., 2012, Annals of Physical and Rehabilitation Medicine, V55, P112, DOI 10.1016/j.rehab.2012.01.007; Ellis C, 2012, STROKE, V43, P1429, DOI 10.1161/STROKEAHA.111.647339; Fisher A, 2014, J STROKE CEREBROVASC, V23, P759, DOI 10.1016/j.jstrokecerebrovasdis.2013.06.035; Hilari K, 2003, STROKE, V34, P1944, DOI 10.1161/01.STR.0000081987.46660.ED; Hilari K, 2011, DISABIL REHABIL, V33, P211, DOI 10.3109/09638288.2010.508829; Huber W, 1984, Adv Neurol, V42, P291; Knecht S, 2016, J NEUROL NEUROSUR PS, V87, P526, DOI 10.1136/jnnp-2015-310344; Laska AC, 2011, CEREBROVASC DIS EXTR, V1, P66, DOI 10.1159/000329835; LOMAS J, 1989, J SPEECH HEAR DISORD, V54, P113, DOI 10.1044/jshd.5401.113; Meinzer M, 2005, STROKE, V36, P1462, DOI 10.1161/01.STR.0000169941.29831.2a; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Ramos-Murguialday A, 2013, ANN NEUROL, V74, P100, DOI 10.1002/ana.23879; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P172, DOI 10.1044/jslhr.4101.172; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008; Willmes K., 1999, VERBALER NONVERBALER	31	142	146	4	58	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2017	389	10078					1528	1538		10.1016/S0140-6736(17)30067-3	http://dx.doi.org/10.1016/S0140-6736(17)30067-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER7OP	28256356	Green Submitted			2023-01-03	WOS:000399002900026
J	Chen, LY; Xu, AL; Yin, NN; Zhao, M; Wang, ZG; Chen, T; Gao, YS; Chen, ZB				Chen, Longyun; Xu, Anli; Yin, Nina; Zhao, Min; Wang, Zhigang; Chen, Tao; Gao, Yisheng; Chen, Zebin			Enhancement of immune cytokines and splenic CD4+T cells by electroacupuncture at ST36 acupoint of SD rats	PLOS ONE			English	Article							IL-2 RECEPTOR EXPRESSION; INTERFERON-GAMMA; ACUPUNCTURE; CALCIUM; STIMULATION; PAIN; CYTOTOXICITY; MECHANISM; TISSUE	Electroacupuncture at the ST36 acupoint can enhance the body's immune function. However, the mechanism for this enhancement has not been fully described. Our study was designed to investigate the effect of electroacupuncture on the immune function of Sprague-Dawley (SD) rats. The rats were randomly divided into three groups: a control group, a non-acupoint group (abdominal muscle acupuntured) and a ST36 acupoint group. Our results showed that successive electroacupuncture at the ST36 acupoint for 3 d significantly enhanced the interferon-gamma (IFN-gamma) level in the serum of SD rats. The results also showed that the serum and extracts from spleen cells of the ST36 acupoint group contained higher levels of interleukin (IL)-2 and IL-17 compared to those of the other two groups. Immunohistochemical analysis showed that electroacupuncture applied to the ST36 acupoint enhanced the expression level of CD4 in spleen cells. Furthermore, it was observed that CD4 co-localized with transient receptor potential vanilloid (TRPV) channels at the membrane of splenic CD4+ T cells and the expression level of CD4 was related to TRPV channels in the electroacupuncture treatment. These observations indicated that electroacupuncture stimulation at the ST36 acupoint enhanced the level of immune cytokines and splenic CD4+ T cells through TRPV channels in this system.	[Chen, Longyun; Xu, Anli; Zhao, Min] Hubei Univ Chinese Med, Dept Biochem, Basic Med Coll, Wuhan, Peoples R China; [Yin, Nina; Chen, Tao; Gao, Yisheng; Chen, Zebin] Hubei Univ Chinese Med, Dept Anat, Basic Med Coll, Wuhan, Peoples R China; [Wang, Zhigang] Hubei Univ Chinese Med, Dept Pathogen Biol, Basic Med Coll, Wuhan, Peoples R China	Hubei University of Chinese Medicine; Hubei University of Chinese Medicine; Hubei University of Chinese Medicine	Chen, ZB (corresponding author), Hubei Univ Chinese Med, Dept Anat, Basic Med Coll, Wuhan, Peoples R China.	chenzebin-hbtcm@outlook.com			Health and Family Planning Commission of Hubei Province [2013Z-Z01]; Hubei Provincial Department of Education [B2016112]	Health and Family Planning Commission of Hubei Province; Hubei Provincial Department of Education	This study was supported by grants from the Health and Family Planning Commission of Hubei Province (no. 2013Z-Z01) and Hubei Provincial Department of Education (no. B2016112). The funders' websites are http://www.hbwsjs.gov.cn/ and http://www.hbe.gov.cn/. Zebin Chen received the funding. He had a role in the study design.	Chen WH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/636848; Chen WH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-82; Deknuydt F, 2009, CLIN IMMUNOL, V131, P298, DOI 10.1016/j.clim.2008.12.008; DENG QS, 1995, AM J CHINESE MED, V23, P1, DOI 10.1142/S0192415X9500002X; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Komada H, 1996, CELL IMMUNOL, V173, P215, DOI 10.1006/cimm.1996.0270; Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0; Lin JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114948; LU GW, 1983, AM J PHYSIOL, V245, pR606, DOI 10.1152/ajpregu.1983.245.4.R606; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Majhi RK, 2015, FEBS J, V282, P2661, DOI 10.1111/febs.13306; Monchanok C, 2015, SCI REPORTS, P1; Oh-Hora M, 2008, CURR OPIN IMMUNOL, V20, P250, DOI 10.1016/j.coi.2008.04.004; Park JY, 2014, J PAIN, V15, P535, DOI 10.1016/j.jpain.2014.01.498; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; RICHARDSON PH, 1986, PAIN, V24, P15, DOI 10.1016/0304-3959(86)90023-0; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Rogers P A, 1992, Probl Vet Med, V4, P162; Sato T, 1996, JPN J PHYSIOL, V46, P131, DOI 10.2170/jjphysiol.46.131; SHALABY MR, 1985, J INTERFERON RES, V5, P571, DOI 10.1089/jir.1985.5.571; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Vig M, 2009, NAT IMMUNOL, V10, P21, DOI 10.1038/ni.f.220; WATMAN NP, 1988, CELL IMMUNOL, V111, P158, DOI 10.1016/0008-8749(88)90060-3; Wu B, 1996, Zhongguo Zhong Xi Yi Jie He Za Zhi, V16, P139; Wu B, 1994, Zhongguo Zhong Xi Yi Jie He Za Zhi, V14, P537; YE JP, 1995, J LEUKOCYTE BIOL, V58, P225, DOI 10.1002/jlb.58.2.225; Yu Y, 1998, J NEUROIMMUNOL, V90, P176, DOI 10.1016/S0165-5728(98)00143-X; Yu Y, 1997, JPN J PHYSIOL, V47, P173, DOI 10.2170/jjphysiol.47.173	32	17	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2017	12	4							e0175568	10.1371/journal.pone.0175568	http://dx.doi.org/10.1371/journal.pone.0175568			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MB	28406959	Green Published, Green Submitted, gold			2023-01-03	WOS:000399955400070
J	Kato, S; Murakami, H; Inaki, A; Mochizuki, T; Demura, S; Nakase, J; Yoshioka, K; Yokogawa, N; Igarashi, T; Takahashi, N; Yonezawa, N; Kinuya, S; Tsuchiya, H				Kato, Satoshi; Murakami, Hideki; Inaki, Anri; Mochizuki, Takafumi; Demura, Satoru; Nakase, Junsuke; Yoshioka, Katsuhito; Yokogawa, Noriaki; Igarashi, Takashi; Takahashi, Naoki; Yonezawa, Noritaka; Kinuya, Seigo; Tsuchiya, Hiroyuki			Innovative exercise device for the abdominal trunk muscles: An early validation study	PLOS ONE			English	Article							LOW-BACK-PAIN; EVIDENCE-INFORMED MANAGEMENT; GLUCOSE-UPTAKE; OLDER-ADULTS; REHABILITATION; STIMULATION; DISABILITY	Background Exercise is one of the few treatments that provide significant improvements in chronic low back pain (CLBP). We developed an innovative exercise device for abdominal trunk muscles. This device can be used in a sitting or standing position and contains a built-in system to measure abdominal trunk muscle strength. We examined whether subjects can adequately use the device to perform the exercises and measure their abdominal trunk muscle strength. Methods We collected data on the body height, body weight, body mass index, and girth of 30 healthy male volunteers, and measured their grip power and trunk extensor muscle strength using a dynamometer. The volunteers performed a sit-up test as an indicator of trunk flexor muscle strength, and we measured their abdominal muscle strength using the device. We then evaluated the correlations between abdominal trunk muscle strength and anthropometric parameters as well as the strength of other muscles. In subsequent tests, 5 of the 30 subjects participated in two positron emission tomography (PET) series consisting of examinations after a resting period (control study) and during exercise (exercise study). For the exercise study, the subjects performed 2 sets of exercises for 20 minutes using the device before and after an injection of 18 F-fluorodeoxyglucose (FDG). PET-computed tomography images were obtained 60 minutes after FDG injection in each study. We compared the skeletal muscle metabolism of the participants in both studies using the standardized uptake value. Results The muscle strength measured by the device and the 30-second sit-up frequency were correlated. FDG accumulation within the diaphragm and abdominal rectus muscles was significantly higher in the exercise study. Conclusion Our innovative exercise device facilitates a coordinated contraction of the abdominal trunk muscles at the anterior aspect and the roof of the core, and enables subjects to measure the strength of these muscles.	[Kato, Satoshi; Murakami, Hideki; Demura, Satoru; Nakase, Junsuke; Yoshioka, Katsuhito; Yokogawa, Noriaki; Igarashi, Takashi; Takahashi, Naoki; Yonezawa, Noritaka; Tsuchiya, Hiroyuki] Kanazawa Univ, Dept Orthopaed Surg, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan; [Inaki, Anri; Kinuya, Seigo] Kanazawa Univ, Dept Nucl Med Biotracer Med, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan; [Mochizuki, Takafumi] Kanazawa Adv Med Ctr, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University	Kato, S (corresponding author), Kanazawa Univ, Dept Orthopaed Surg, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan.	skato323@gmail.com	DEMURA, Satoru/X-8589-2019	Kato, Satoshi/0000-0003-4762-5932	Daiwa Securities Health Foundation [42-18]; Suzuken Memorial Foundation [15-011]	Daiwa Securities Health Foundation; Suzuken Memorial Foundation	This research was supported by the Daiwa Securities Health Foundation (grant number:42-18, http://www.daiwa-grp.jp/dsh/) and the Suzuken Memorial Foundation (grant number:15-011, http://www.suzukenzaidan.or.jp/ index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparetion of the manuscript.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Akuthota V, 2004, ARCH PHYS MED REHAB, V85, pS86, DOI 10.1053/j.apmr.2003.12.005; Akuthota V, 2008, CURR SPORT MED REP, V7, P39, DOI 10.1097/01.CSMR.0000308663.13278.69; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Bojsen-Moller J, 2010, J APPL PHYSIOL, V109, P1895, DOI 10.1152/japplphysiol.00671.2010; Bronfort G, 2008, SPINE J, V8, P213, DOI 10.1016/j.spinee.2007.10.023; Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012; Cohen J., 2013, STAT POWER ANAL BEHA; Coyle PC, 2016, PAIN MED; Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005; Dagenais S, 2010, SPINE J, V10, P514, DOI 10.1016/j.spinee.2010.03.032; Fatemi R, 2015, J BACK MUSCULOSKELET, V28, P591, DOI 10.3233/BMR-150585; Fujimoto T, 2000, EUR J APPL PHYSIOL, V83, P297, DOI 10.1007/s004210000254; Hayden J A, 2005, Cochrane Database Syst Rev, pCD000335; Iversen MD, 2003, ARCH PHYS MED REHAB, V84, P1324, DOI 10.1016/S0003-9993(03)00198-9; Kavcic N, 2004, SPINE, V29, P1254, DOI 10.1097/00007632-200406010-00016; Kemppainen J, 2002, J PHYSIOL-LONDON, V542, P403, DOI 10.1113/jphysiol.2002.018135; Kolt GS, 2003, MANUAL THER, V8, P110, DOI 10.1016/S1356-689X(02)00156-X; Lizier DT, 2012, REV BRAS ANESTESIOL, V62, P838, DOI 10.1590/S0034-70942012000600008; Mannion AF, 2009, EUR SPINE J, V18, P1881, DOI 10.1007/s00586-009-1093-7; Mayer J, 2008, SPINE J, V8, P96, DOI 10.1016/j.spinee.2007.09.008; McGill S, 2007, LOW BACK DISORDERS E; Meng XG, 2015, AM J PHYS MED REHAB, V94, P358, DOI 10.1097/PHM.0000000000000188; Nakase J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073898; Numata H, 2016, J ORTHOP SCI, V21, P53, DOI 10.1016/j.jos.2015.09.003; Oesch P, 2010, J REHABIL MED, V42, P193, DOI 10.2340/16501977-0524; Ohnuma M, 2006, J ORTHOP SCI, V11, P42, DOI 10.1007/s00776-005-0972-y; Pappas GP, 2001, J APPL PHYSIOL, V90, P329, DOI 10.1152/jappl.2001.90.1.329; Patti A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000383; Phillips EM, 2004, ARCH PHYS MED REHAB, V85, pS52, DOI 10.1016/j.apmr.2004.03.012; Poitras S, 2008, SPINE J, V8, P226, DOI 10.1016/j.spinee.2007.10.022; Richardson C A, 1995, Man Ther, V1, P2, DOI 10.1054/math.1995.0243; Rudy TE, 2007, PAIN, V131, P293, DOI 10.1016/j.pain.2007.01.012; Saragiotto BT, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012004; Slade SC, 2006, J MANIP PHYSIOL THER, V29, P163, DOI 10.1016/j.jmpt.2005.12.011; Standaert CJ, 2008, SPINE J, V8, P114, DOI 10.1016/j.spinee.2007.10.015; Stanton TR, 2010, EUR SPINE J, V19, P533, DOI 10.1007/s00586-009-1214-3	37	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0172934	10.1371/journal.pone.0172934	http://dx.doi.org/10.1371/journal.pone.0172934			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28235060	Green Submitted, Green Published, gold			2023-01-03	WOS:000394688200173
J	McInnes, IB; Schett, G				McInnes, Iain B.; Schett, Georg			Pathogenetic insights from the treatment of rheumatoid arthritis	LANCET			English	Article							FIBROBLAST-LIKE SYNOVIOCYTES; ALPHA MONOCLONAL-ANTIBODY; CLINICAL-RESPONSE; DOUBLE-BLIND; B-CELL; INADEQUATE RESPONSE; RITUXIMAB TREATMENT; GENE-EXPRESSION; PARALLEL-GROUP; BONE LOSS	Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular damage, functional loss, and comorbidity. The development of effective biologics and small-molecule kinase inhibitors in the past two decades has substantially improved clinical outcomes. Just as understanding of pathogenesis has led in large part to the development of drugs, so have mode-of-action studies of these specific immune-targeted agents revealed which immune pathways drive articular inflammation and related comorbidities. Cytokine inhibitors have definitively proven a critical role for tumour necrosis factor a and interleukin 6 in disease pathogenesis and possibly also for granulocyte-macrophage colony-stimulating factor. More recently, clinical trials with Janus kinase (JAK) inhibitors have shown that cytokine receptors that signal through the JAK/STAT signalling pathway are important for disease, informing the pathogenetic function of additional cytokines (such as the interferons). Finally, successful use of costimulatory blockade and B-cell depletion in the clinic has revealed that the adaptive immune response and the downstream events initiated by these cells participate directly in synovial inflammation. Taken together, it becomes apparent that understanding the effects of specific immune interventions can elucidate definitive molecular or cellular nodes that are essential to maintain complex inflammatory networks that subserve diseases like rheumatoid arthritis.	[McInnes, Iain B.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8QQ, Lanark, Scotland; [Schett, Georg] Friedrich Alexander Univ Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany; [Schett, Georg] Univ Klinikum Erlangen, Erlangen, Germany	University of Glasgow; University of Erlangen Nuremberg; University of Erlangen Nuremberg	McInnes, IB (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8QQ, Lanark, Scotland.	iain.mcinnes@glasgow.ac.uk	Duarte, Graziela Biude Silva/Q-7728-2016		Abbvie; BMS; Janssen; MSD; Astra Zeneca; Pfizer; Roche; UCB; Celgene; Chugai; Novartis; MRC [MR/N005813/1] Funding Source: UKRI; Medical Research Council [MR/N005813/1] Funding Source: researchfish	Abbvie(AbbVie); BMS(Bristol-Myers Squibb); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); MSD; Astra Zeneca(AstraZeneca); Pfizer(Pfizer); Roche(Roche Holding); UCB(UCB Pharma SA); Celgene(Bristol-Myers SquibbCelgene Corporation); Chugai; Novartis(Novartis); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	IBM declares honoraria or research grants from Abbvie, BMS, Janssen, MSD, Astra Zeneca, Pfizer, Roche, UCB. GS declares honoraria or research grants from Abbvie, BMS, Celgene, Chugai, Novartis, Roche, UCB.	Aletaha D, 2017, LANCET, V389, P1206, DOI 10.1016/S0140-6736(17)30401-4; Alvaro-Gracia JM, 2017, ANN RHEUM DIS, V76, P196, DOI 10.1136/annrheumdis-2015-208918; Amano T, 2003, GENE DEV, V17, P2436, DOI 10.1101/gad.1096603; Angiolilli C, 2017, ANN RHEUM DIS, V76, P277, DOI 10.1136/annrheumdis-2015-209064; Bell GM, 2017, ANN RHEUM DIS, V76, P227, DOI 10.1136/annrheumdis-2015-208456; Benham H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9301; Blume J, 2011, BRAIN BEHAV IMMUN, V25, P221, DOI 10.1016/j.bbi.2010.10.008; Bonelli M, 2016, RHEUMATOLOGY, V55, P710, DOI 10.1093/rheumatology/kev403; Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190; Boyle DL, 2015, ANN RHEUM DIS, V74, P1311, DOI 10.1136/annrheumdis-2014-206028; Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764; Bresnihan B, 2009, J RHEUMATOL, V36, P1800, DOI 10.3899/jrheum.090348; Brink M, 2013, ARTHRITIS RHEUM; Buch MH, 2008, RHEUMATOLOGY, V47, P1469, DOI 10.1093/rheumatology/ken261; Buch MH, 2009, ANN RHEUM DIS, V68, P1220, DOI 10.1136/ard.2008.091876; Buckley CD, 2015, ANNU REV IMMUNOL, V33, P715, DOI 10.1146/annurev-immunol-032713-120252; Burger D, 2006, BEST PRACT RES CL RH, V20, P879, DOI 10.1016/j.berh.2006.06.004; Burmester GR, 2017, ANN RHEUM DIS, V76, P1020, DOI 10.1136/annrheumdis-2016-210624; Canete JD, 2009, ANN RHEUM DIS, V68, P751, DOI 10.1136/ard.2008.089284; Carmona L, 2007, ANN RHEUM DIS, V66, P880, DOI 10.1136/ard.2006.067660; Catrina AI, 2016, IMMUNOL REV, V269, P162, DOI 10.1111/imr.12379; Cavanagh J, 2010, ANN RHEUM DIS, V69, P1251, DOI 10.1136/ard.2009.107912; Charles P, 1999, J IMMUNOL, V163, P1521; Charles-Schoeman C, 2015, ARTHRITIS RHEUMATOL, V67, P616, DOI 10.1002/art.38974; Chatzidionysiou K, 2011, ANN RHEUM DIS, V70, P1575, DOI 10.1136/ard.2010.148759; Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962; Cutolo M, 2016, EXPERT REV CLIN IMMU, V12, P417, DOI 10.1586/1744666X.2016.1133295; Das S, 2014, ANN RHEUM DIS, V73, P909, DOI 10.1136/annrheumdis-2013-204417; De Vita S, 2002, ARTHRITIS RHEUM, V46, P2029, DOI 10.1002/art.10467; Di Giuseppe D, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4218; Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481; Ducreux J, 2014, ARTHRITIS RHEUMATOL, V66, P15, DOI 10.1002/art.38202; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Figueiredo CP, 2017, ANN RHEUM DIS, V76, P399, DOI 10.1136/annrheumdis-2016-209297; Gabay C, 2016, ANN RHEUM DIS, V75, P1806, DOI 10.1136/annrheumdis-2015-207872; Gerlag DM, 2008, BEST PRACT RES CL RH, V22, P311, DOI 10.1016/j.berh.2008.02.002; Gerlag DM, 2016, RHEUMATOLOGY, V55, P607, DOI 10.1093/rheumatology/kev347; Giles JT, 2016, 2016 AM COLL RHEUM A; Greenberg JD, 2011, ANN RHEUM DIS, V70, P576, DOI 10.1136/ard.2010.129916; Gutierrez-Roelens I, 2011, ARTHRITIS RHEUM-US, V63, P1246, DOI 10.1002/art.30292; Hamilton JA, 2017, NAT REV DRUG DISCOV, V16, P53, DOI 10.1038/nrd.2016.231; Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975; Herenius MMJ, 2011, ANN RHEUM DIS, V70, P1160, DOI 10.1136/ard.2010.141549; Hess A, 2011, P NATL ACAD SCI USA, V108, P3731, DOI 10.1073/pnas.1011774108; Hodge JA, 2016, CLIN EXP RHEUMATOL, V34, P318; Hogan VE, 2012, ANN RHEUM DIS, V71, P1888, DOI 10.1136/annrheumdis-2011-201115; Izquierdo E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008131; Kallberg H, 2011, ANN RHEUM DIS, V70, P508, DOI 10.1136/ard.2009.120899; Kanbe K, 2013, RHEUMATOL INT, V33, P1883, DOI 10.1007/s00296-011-2326-8; Kapoor SR, 2013, ARTHRITIS RHEUM-US, V65, P1448, DOI 10.1002/art.37921; Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477; Kavanaugh A, 2008, ANN RHEUM DIS, V67, P402, DOI 10.1136/ard.2007.074229; Klaasen R, 2009, ARTHRITIS RHEUM-US, V60, P3217, DOI 10.1002/art.24913; Klein K, 2016, ANN RHEUM DIS, V75, P422, DOI 10.1136/annrheumdis-2014-205809; Klein K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4074; Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis-2012-202958; Konig MF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaj1921; Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis-2015-208093; Kunwar S, 2016, RHEUMATOL INT, V36, P1065, DOI 10.1007/s00296-016-3480-9; Lewis HD, 2015, NAT CHEM BIOL, V11, P189, DOI 10.1038/nchembio.1735; Lindberg J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011310; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Maeshima K, 2012, ARTHRITIS RHEUM-US, V64, P1790, DOI 10.1002/art.34329; McInnes IB, 2016, NAT REV RHEUMATOL, V12, P63, DOI 10.1038/nrrheum.2015.171; McInnes IB, 2015, ANN RHEUM DIS, V74, P694, DOI 10.1136/annrheumdis-2013-204345; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Meune C, 2010, ARCH CARDIOVASC DIS, V103, P253, DOI 10.1016/j.acvd.2010.03.007; Micha R, 2011, AM J CARDIOL, V108, P1362, DOI 10.1016/j.amjcard.2011.06.054; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Patakas A, ABATACEPT INHIBITION; Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM; Robertson J, 2013, NAT REV RHEUMATOL, V9, P513, DOI 10.1038/nrrheum.2013.91; Rosengren S, 2012, ANN RHEUM DIS, V71, P440, DOI 10.1136/ard.2011.150284; Rosengren S, 2011, RHEUMATOLOGY, V50, P603, DOI 10.1093/rheumatology/keq337; Rosengren S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2497; Ruiz-Heiland G, 2014, ANN RHEUM DIS, V73, P771, DOI 10.1136/annrheumdis-2012-202907; Sanayama Y, 2014, ARTHRITIS RHEUMATOL, V66, P1421, DOI 10.1002/art.38400; Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202; Schett G, 2008, ARTHRITIS RHEUM-US, V58, P2936, DOI 10.1002/art.23951; Schett G, 2017, MOD RHEUMATOL, V27, P193, DOI 10.1080/14397595.2016.1265907; Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153; Sellam J, 2013, ARTHRITIS RHEUM-US, V65, P2253, DOI 10.1002/art.38023; Siebert S, 2017, SCI REP-UK, V7, DOI 10.1038/srep40473; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Smolen JS, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209831; Smolen JS, 2013, ANN RHEUM DIS, V72, P3, DOI 10.1136/annrheumdis-2012-202361; Solomon DH, 2015, ARTHRITIS RHEUMATOL, V67, P1995, DOI 10.1002/art.39195; Tak PP, 2012, ARTHRITIS RHEUM-US, V64, P360, DOI 10.1002/art.33353; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis-2015-208052; Tan EM, 2016, J EXP MED, V213, P1937, DOI 10.1084/jem.20160792; Teng YKO, 2009, ANN RHEUM DIS, V68, P1011, DOI 10.1136/ard.2008.092791; Thurlings RM, 2010, ANN RHEUM DIS, V69, P409, DOI 10.1136/ard.2009.109041; Valencia X, 2004, J EXP MED, V200, P1673, DOI 10.1084/jem.20041545; van Vollenhoven RF, 2011, ARTHRITIS RHEUM-US, V63, P1782, DOI 10.1002/art.30372; Vos K, 2007, ARTHRITIS RHEUM, V56, P772, DOI 10.1002/art.22400; Walsh CAE, 2008, CLIN EXP RHEUMATOL, V26, P656; Weinblatt ME, 2014, ARTHRITIS RHEUMATOL, V66, P3255, DOI 10.1002/art.38851; Wenink MH, 2012, ANN RHEUM DIS, V71, P80, DOI 10.1136/annrheumdis-2011-200348; Wright HL, 2015, RHEUMATOLOGY, V54, P743, DOI 10.1093/rheumatology/keu488; Wunderlich C, 2017, SEMIN ARTHRITIS RHEU, V46, P709, DOI 10.1016/j.semarthrit.2016.09.011	102	656	721	17	259	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2017	389	10086					2328	2337		10.1016/S0140-6736(17)31472-1	http://dx.doi.org/10.1016/S0140-6736(17)31472-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW9XM	28612747	Green Accepted			2023-01-03	WOS:000402872700027
J	Seymour, CW; Gesten, F; Prescott, HC; Friedrich, ME; Iwashyna, TJ; Phillips, GS; Lemeshow, S; Osborn, T; Terry, KM; Levy, MM				Seymour, Christopher W.; Gesten, Foster; Prescott, Hallie C.; Friedrich, Marcus E.; Iwashyna, Theodore J.; Phillips, Gary S.; Lemeshow, Stanley; Osborn, Tiffany; Terry, Kathleen M.; Levy, Mitchell M.			Time to Treatment and Mortality during Mandated Emergency Care for Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEPTIC SHOCK; ANTIBIOTIC-TREATMENT; DEFINITIONS; DETERMINANT; IMPROVEMENT; OUTCOMES; THERAPY; LACTATE	BACKGROUND In 2013, New York began requiring hospitals to follow protocols for the early identification and treatment of sepsis. However, there is controversy about whether more rapid treatment of sepsis improves outcomes in patients. METHODS We studied data from patients with sepsis and septic shock that were reported to the New York State Department of Health from April 1, 2014, to June 30, 2016. Patients had a sepsis protocol initiated within 6 hours after arrival in the emergency department and had all items in a 3-hour bundle of care for patients with sepsis (i.e., blood cultures, broad-spectrum antibiotic agents, and lactate measurement) completed within 12 hours. Multilevel models were used to assess the associations between the time until completion of the 3-hour bundle and risk-adjusted mortality. We also examined the times to the administration of antibiotics and to the completion of an initial bolus of intravenous fluid. RESULTS Among 49,331 patients at 149 hospitals, 40,696 (82.5%) had the 3-hour bundle completed within 3 hours. The median time to completion of the 3-hour bundle was 1.30 hours (interquartile range, 0.65 to 2.35), the median time to the administration of antibiotics was 0.95 hours (interquartile range, 0.35 to 1.95), and the median time to completion of the fluid bolus was 2.56 hours (interquartile range, 1.33 to 4.20). Among patients who had the 3-hour bundle completed within 12 hours, a longer time to the completion of the bundle was associated with higher risk-adjusted in-hospital mortality (odds ratio, 1.04 per hour; 95% confidence interval [CI], 1.02 to 1.05; P<0.001), as was a longer time to the administration of antibiotics (odds ratio, 1.04 per hour; 95% CI, 1.03 to 1.06; P<0.001) but not a longer time to the completion of a bolus of intravenous fluids (odds ratio, 1.01 per hour; 95% CI, 0.99 to 1.02; P = 0.21). CONCLUSIONS More rapid completion of a 3-hour bundle of sepsis care and rapid administration of antibiotics, but not rapid completion of an initial bolus of intravenous fluids, were associated with lower risk-adjusted in-hospital mortality.	[Seymour, Christopher W.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, 3550 Terrace St,Scaife Hall,Rm 639, Pittsburgh, PA 15261 USA; [Seymour, Christopher W.] Univ Pittsburgh, Sch Med, Dept Emergency Med, 3550 Terrace St,Scaife Hall,Rm 639, Pittsburgh, PA 15261 USA; [Seymour, Christopher W.] Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA; [Gesten, Foster; Friedrich, Marcus E.] New York State Dept Hlth, Albany, NY USA; [Phillips, Gary S.; Terry, Kathleen M.] IPRO, Lake Success, NY USA; [Prescott, Hallie C.; Iwashyna, Theodore J.] Univ Michigan, Ann Arbor, MI 48109 USA; [Prescott, Hallie C.; Iwashyna, Theodore J.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA; [Lemeshow, Stanley] Ohio State Univ, Div Biostat, Coll Publ Hlth, Columbus, OH 43210 USA; [Osborn, Tiffany] Washington Univ, St Louis, MO USA; [Levy, Mitchell M.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University; Washington University (WUSTL); Brown University	Seymour, CW (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Sch Med, 3550 Terrace St,Scaife Hall,Rm 639, Pittsburgh, PA 15261 USA.; Seymour, CW (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, 3550 Terrace St,Scaife Hall,Rm 639, Pittsburgh, PA 15261 USA.	seymourcw@upmc.edu	Osborn, Tiffany/AAT-2281-2020	Prescott, Hallie/0000-0002-8442-6724	National Institutes of Health; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K08GM115859, R35GM119519] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the National Institutes of Health and others.	Banta JE, 2012, CRIT CARE MED, V40, P2960, DOI 10.1097/CCM.0b013e31825bc92f; Cooke CR, 2014, JAMA-J AM MED ASSOC, V312, P1397, DOI 10.1001/jama.2014.11350; Dimick JB, 2010, HEALTH SERV RES, V45, P1614, DOI 10.1111/j.1475-6773.2010.01158.x; Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Gaieski DF, 2013, CRIT CARE MED, V41, P1167, DOI 10.1097/CCM.0b013e31827c09f8; Gropen TI, 2006, NEUROLOGY, V67, P88, DOI 10.1212/01.wnl.0000223622.13641.6d; Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC; Kumar A, 2006, J INFECT DIS, V193, P251, DOI 10.1086/498909; Lash TL., 2009, APPL QUANTITATIVE BI; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu VX, 2017, AM J RESP CRIT CARE; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Puskarich MA, 2011, CRIT CARE MED, V39, P2066, DOI 10.1097/CCM.0b013e31821e87ab; Reineck LA, 2014, CRIT CARE MED, V42, P1055, DOI 10.1097/CCM.0000000000000132; Rhee C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1266-9; Rhee C, 2014, NEW ENGL J MED, V370, P1673, DOI 10.1056/NEJMp1400276; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Rowan KM, 2017, NEW ENGL J MED, V376, P2223, DOI 10.1056/NEJMoa1701380; Royston P, 2005, METHOD INFORM MED, V44, P561; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Sterling SA, 2015, CRIT CARE MED, V43, P1907, DOI 10.1097/CCM.0000000000001142; Vazquez-Guillamet C, 2014, CRIT CARE MED, V42, P2342, DOI 10.1097/CCM.0000000000000516; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Walkey AJ, 2014, AM J RESP CRIT CARE, V189, P548, DOI 10.1164/rccm.201311-1967OC; Wang HE, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-9	25	940	966	4	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	2017	376	23					2235	2244		10.1056/NEJMoa1703058	http://dx.doi.org/10.1056/NEJMoa1703058			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW8WG	28528569	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000402798200007
J	Ferrando, C; Suarez-Sipmann, F; Tusman, G; Leon, I; Romero, E; Gracia, E; Mugarra, A; Arocas, B; Pozo, N; Soro, M; Belda, FJ				Ferrando, Carlos; Suarez-Sipmann, Fernando; Tusman, Gerardo; Leon, Irene; Romero, Esther; Gracia, Estefania; Mugarra, Ana; Arocas, Blanca; Pozo, Natividad; Soro, Marina; Belda, Francisco J.			Open lung approach versus standard protective strategies: Effects on driving pressure and ventilatory efficiency during anesthesia - A pilot, randomized controlled trial	PLOS ONE			English	Article							END-EXPIRATORY PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR RECRUITMENT; MECHANICAL VENTILATION; GENERAL-ANESTHESIA; TIDAL-VOLUME; GAS-EXCHANGE; IMPROVES; OBESE; ATELECTASIS	Background Low tidal volume (VT) during anesthesia minimizes lung injury but may be associated to a decrease in functional lung volume impairing lung mechanics and efficiency. Lung recruitment (RM) can restore lung volume but this may critically depend on the post-RM selected PEEP. This study was a randomized, two parallel arm, open study whose primary outcome was to compare the effects on driving pressure of adding a RM to low-VT ventilation, with or without an individualized post-RM PEEP in patients without known previous lung disease during anesthesia. Methods Consecutive patients scheduled for major abdominal surgery were submitted to low-VT ventilation (6 ml.kg(-1)) and standard PEEP of 5 cmH(2)O (pre-RM, n = 36). After 30 min estabilization all patients received a RM and were randomly allocated to either continue with the same PEEP (RM-5 group, n = 18) or to an individualized open-lung PEEP (OL-PEEP) (Open Lung Approach, OLA group, n = 18) defined as the level resulting in maximal Cdyn during a decremental PEEP trial. We compared the effects on driving pressure and lung efficiency measured by volumetric capnography. Results OL-PEEP was found at 8 +/- 2 cmH(2)O. 36 patients were included in the final analysis. When compared with pre-RM, OLA resulted in a 22% increase in compliance and a 28% decrease in driving pressure when compared to pre-RM. These parameters did not improve in the RM-5. The trend of the DP was significantly different between the OLA and RM-5 groups (p = 0.002). VDalv/VTalv was significantly lower in the OLA group after the RM (p = 0.035). Conclusions Lung recruitment applied during low-VT ventilation improves driving pressure and lung efficiency only when applied as an open-lung strategy with an individualized PEEP in patients without lung diseases undergoing major abdominal surgery.	[Ferrando, Carlos; Leon, Irene; Romero, Esther; Gracia, Estefania; Mugarra, Ana; Arocas, Blanca; Soro, Marina; Belda, Francisco J.] Hosp Clin Univ, Dept Anesthesiol & Crit Care, Valencia, Spain; [Suarez-Sipmann, Fernando] Inst Salud Carlos III, GIBER Enfermedades Resp, Madrid, Spain; [Suarez-Sipmann, Fernando] Uppsala Univ Hosp, Dept Surg Sci, Hedenstierna Lab, Uppsala, Sweden; [Tusman, Gerardo] Hosp Privado Comunidad Mar Del Plata, Dept Anesthesiol, Mar Del Plata, Buenos Aires, Argentina; [Pozo, Natividad] Hosp Clin Univ, INCLIVA Clin Res Inst, Valencia, Spain	Hospital Clinic Universitari de Valencia; Instituto de Salud Carlos III; Uppsala University; Uppsala University Hospital	Ferrando, C (corresponding author), Hosp Clin Univ, Dept Anesthesiol & Crit Care, Valencia, Spain.	cafeoranestesia@gmail.com	Sipmann, Fernando Suarez/AAD-9104-2020; Leon, Irene/AAA-5711-2019; Belda, Javier/AAF-1597-2020	Sipmann, Fernando Suarez/0000-0002-7412-2970; Leon, Irene/0000-0003-2172-8933; Ferrando, Carlos/0000-0002-1907-5323	INCLIVA Biomedical Research Institute	INCLIVA Biomedical Research Institute	This work was funded by the INCLIVA Biomedical Research Institute.	Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Bohm SH, 2009, ANESTH ANALG, V109, P151, DOI 10.1213/ane.0b013e31819bcbb5; Bohr C., 1891, UBER LUNGGEATMUNG SK, V2, P236; Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-976OC; Borges JB, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1063-x; Cereda M, 2014, CRIT CARE MED, V41, P527; Duggan M, 2005, ANESTHESIOLOGY, V102, P838, DOI 10.1097/00000542-200504000-00021; Ferrando C, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0694-1; Ferrando C, 2014, ANESTH ANALG, V118, P657, DOI 10.1213/ANE.0000000000000105; FLETCHER R, 1981, BRIT J ANAESTH, V53, P77, DOI 10.1093/bja/53.1.77; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; HEDENSTIERNA G, 1976, ACTA ANAESTH SCAND, V20, P334, DOI 10.1111/j.1399-6576.1976.tb05047.x; Jabaudon M, 2015, RESPIROLOGY, V20, P1131, DOI 10.1111/resp.12583; Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383; Ladha K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3646; Maisch S, 2008, ANESTH ANALG, V106, P175, DOI 10.1213/01.ane.0000287684.74505.49; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Richard JC, 2001, AM J RESP CRIT CARE, V163, P1609, DOI 10.1164/ajrccm.163.7.2004215; Rusca M, 2003, ANESTH ANALG, V97, P1835, DOI 10.1213/01.ANE.0000087042.02266.F6; Serpa Neto A, LANCET RESP MED; Neto AS, 2015, ANESTHESIOLOGY, V123, P66, DOI 10.1097/ALN.0000000000000706; Severgnini P, 2013, ANESTHESIOLOGY, V118, P1307, DOI 10.1097/ALN.0b013e31829102de; SUTER PM, 1975, NEW ENGL J MED, V292, P284, DOI 10.1056/NEJM197502062920604; The PROVE Network Investigators, 2014, LANCET, V384, P495, DOI DOI 10.1016/S0140-6736(14)60416-5; TOKICS L, 1987, ANESTHESIOLOGY, V66, P157, DOI 10.1097/00000542-198702000-00009; Tusman G, 2004, CAN J ANAESTH, V51, P723, DOI 10.1007/BF03018433; Tusman G, 2004, ANESTH ANALG, V98, P1604, DOI 10.1213/01.ANE.0000068484.67655.1A; Tusman G, 2014, ANESTH ANALG, V118, P137, DOI 10.1213/01.ane.0000438350.29240.08; Tusman G, 2011, INTENS CARE MED, V37, P870, DOI 10.1007/s00134-011-2164-x; Tusman G, 2009, J CLIN MONIT COMPUT, V23, P197, DOI 10.1007/s10877-009-9182-z; Unzueta C, 2012, BRIT J ANAESTH, V108, P517, DOI 10.1093/bja/aer415	32	34	39	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177399	10.1371/journal.pone.0177399	http://dx.doi.org/10.1371/journal.pone.0177399			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UP	28493943	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314300102
J	Lu, Y; Figler, B; Huang, H; Tu, YC; Wang, J; Cheng, F				Lu, Yin; Figler, Bryan; Huang, Hong; Tu, Yi-Cheng; Wang, Ju; Cheng, Feng			Characterization of the mechanism of drug-drug interactions from PubMed using MeSH terms	PLOS ONE			English	Article							P-GLYCOPROTEIN; THEOPHYLLINE; METABOLISM; INHIBITION; QUINIDINE	Identifying drug-drug interaction (DDI) is an important topic for the development of safe pharmaceutical drugs and for the optimization of multidrug regimens for complex diseases such as cancer and HIV. There have been about 150,000 publications on DDIs in PubMed, which is a great resource for DDI studies. In this paper, we introduced an automatic computational method for the systematic analysis of the mechanism of DDIs using MeSH (Medical Subject Headings) terms from PubMed literature. MeSH term is a controlled vocabulary thesaurus developed by the National Library of Medicine for indexing and annotating articles. Our method can effectively identify DDI-relevant MeSH terms such as drugs, proteins and phenomena with high accuracy. The connections among these MeSH terms were investigated by using co-occurrence heatmaps and social network analysis. Our approach can be used to visualize relationships of DDI terms, which has the potential to help users better understand DDIs. As the volume of PubMed records increases, our method for automatic analysis of DDIs from the PubMed database will become more accurate.	[Lu, Yin; Figler, Bryan; Cheng, Feng] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA; [Huang, Hong] Univ S Florida, Sch Informat, Tampa, FL 33620 USA; [Tu, Yi-Cheng] Univ S Florida, Dept Comp Sci & Engn, Tampa, FL 33620 USA; [Wang, Ju] Tianjin Med Univ, Sch Biomed Engn, Tianjin, Peoples R China; [Cheng, Feng] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Tianjin Medical University; State University System of Florida; University of South Florida	Cheng, F (corresponding author), Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA.; Cheng, F (corresponding author), Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA.	fcheng1@health.usf.edu	Cheng, Feng/A-9760-2009; Huang, Hong/G-5957-2016	Cheng, Feng/0000-0003-3619-8090; Huang, Hong/0000-0002-8957-4881	National Natural Science Foundation of China [31271411]; Ed and Ethel Moore Alzheimer's Disease Research Program of Florida Department of Health [7AZ23]; National Institutes of Health (NIH) [RO1GM086707]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ed and Ethel Moore Alzheimer's Disease Research Program of Florida Department of Health; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The project was supported by a grant from National Natural Science Foundation of China (Grant No: 31271411) to Ju Wang, the Ed and Ethel Moore Alzheimer's Disease Research Program of Florida Department of Health (Award No: 7AZ23) to Feng Cheng, and in part, supported by a grant (Grant No: RO1GM086707) from National Institutes of Health (NIH), USA, to Yi-Cheng Tu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becker ML, 2007, PHARMACOEPIDEM DR S, V16, P641, DOI 10.1002/pds.1351; Chen Jiezhong, 2006, Ann Clin Microbiol Antimicrob, V5, P3, DOI 10.1186/1476-0711-5-3; Dai Y, 2004, BIOCHEM PHARMACOL, V68, P1889, DOI 10.1016/j.bcp.2004.07.012; Damkier P, 1999, PHARMACOL TOXICOL, V85, P257, DOI 10.1111/j.1600-0773.1999.tb02019.x; DuBuske LM, 2005, DRUG SAFETY, V28, P789, DOI 10.2165/00002018-200528090-00004; Duke JD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002614; FARRAR KT, 1985, LANCET, V1, P983; Gottlieb A, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.26; Huang JL, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002998; Huang SM, 2007, CLIN PHARMACOL THER, V81, P298, DOI 10.1038/sj.clpt.6100054; Hutzler JM, 2011, PHARMACOKINETICS IN DRUG DEVELOPMENT, VOL 3: ADVANCES AND APPLICATIONS, P21, DOI 10.1007/978-1-4419-7937-7_2; Isoherranen N, 2004, DRUG METAB DISPOS, V32, P1121, DOI 10.1124/dmd.104.000315; Kostoff RN, 2004, INT J MED INFORM, V73, P515, DOI 10.1016/j.ijmedinf.2004.02.008; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Lill J, 2000, AM J HEALTH-SYST PH, V57, P1579, DOI 10.1093/ajhp/57.17.1579; List AF, 2002, BLOOD, V100, P1910, DOI 10.1182/blood.V100.5.1910.h81702001910_1910_1912; Lu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17357; Luo H, 2014, NUCLEIC ACIDS RES, V42, pW46, DOI 10.1093/nar/gku433; Miyazawa Y, 2002, J INT MED RES, V30, P34, DOI 10.1177/147323000203000106; Obach RS, 2003, DRUG TODAY, V39, P301, DOI 10.1358/dot.2003.39.5.799456; Percha B, 2013, TRENDS PHARMACOL SCI, V34, P178, DOI 10.1016/j.tips.2013.01.006; Percha B, 2012, BIOCOMPUT-PAC SYM, P410; Psarra TA, 2007, J VET PHARMACOL THER, V30, P541, DOI 10.1111/j.1365-2885.2007.00904.x; Segura-Bedmar I, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S2-S1; Strandell J, 2008, BRIT J CLIN PHARMACO, V65, P144, DOI 10.1111/j.1365-2125.2007.02981.x; Takarabe M, 2011, J CHEM INF MODEL, V51, P2977, DOI 10.1021/ci200367w; Tari L, 2010, BIOINFORMATICS, V26, pi547, DOI 10.1093/bioinformatics/btq382; Tatonetti NP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003377; Tatonetti NP, 2012, J AM MED INFORM ASSN, V19, P79, DOI 10.1136/amiajnl-2011-000214; Thakrar BT, 2007, BRIT J CLIN PHARMACO, V64, P489, DOI 10.1111/j.1365-2125.2007.02900.x; TWUMBARIMA Y, 1981, NEW ENGL J MED, V304, P1466, DOI 10.1056/NEJM198106113042405; Vilar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058321; Vilar S, 2012, J AM MED INFORM ASSN, V19, P1066, DOI 10.1136/amiajnl-2012-000935; Wang ZP, 2009, J BIOMED INFORM, V42, P726, DOI 10.1016/j.jbi.2009.03.010; Wanwimolruk S, 2014, EXCLI J, V13, P347; Yan Su, 2013, Proceedings (IEEE Int Conf Bioinformatics Biomed), P349, DOI 10.1109/BIBM.2013.6732517	36	17	19	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2017	12	4							e0173548	10.1371/journal.pone.0173548	http://dx.doi.org/10.1371/journal.pone.0173548			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KK	28422961	Green Published, Green Submitted, gold			2023-01-03	WOS:000399875600010
J	Kilonzo, KG; Jones, ESW; Okpechi, IG; Wearne, N; Barday, Z; Swanepoel, CR; Yeates, K; Rayner, BL				Kilonzo, Kajiru G.; Jones, Erika S. W.; Okpechi, Ikechi G.; Wearne, Nicola; Barday, Zunaid; Swanepoel, Charles R.; Yeates, Karen; Rayner, Brian L.			Disparities in dialysis allocation: An audit from the new South Africa	PLOS ONE			English	Article							RENAL REPLACEMENT THERAPY; CHRONIC KIDNEY-DISEASE	End Stage Kidney Disease (ESKD) is a public health problem with an enormous economic burden. In resource limited settings management of ESKD is often rationed. Racial and socio-economic inequalities in selecting candidates have been previously documented in South Africa. New guidelines for dialysis developed in the Western Cape have focused on prioritizing treatment. With this in mind we aimed at exploring whether the new guidelines would improve inequalities previously documented. A retrospective study of patients presented to the selection committee was conducted at Groote Schuur Hospital. A total of 564 ESKD patients presented between 1 January 2008 and 31 December 2012 were assessed. Half of the patients came from low socioeconomic areas, and presentation was late with either overt uremia (n = 181, 44 .4%) or fluid overload (n = 179, 43 .9%). More than half (53 . 9%) of the patients were not selected for the program. Predictors of non-acceptance onto the program included age above 50 years (OR 0.3, p = 0.001), unemployment (OR 0.3, p < 0.001), substance abuse (OR 0.2, p < 0.001), diabetes (OR 0.4, p = 0.016) and a poor psychosocial assessment (OR 0.13, p < 0.001). Race, gender and marital status were not predictors. The use of new guidelines has not led to an increase in inequalities. In view of the advanced nature of presentation greater efforts need to be made to prevent early kidney disease, to allocate more resources to renal replacement therapy in view of the loss of young and potentially productive life.	[Kilonzo, Kajiru G.; Jones, Erika S. W.; Okpechi, Ikechi G.; Wearne, Nicola; Barday, Zunaid; Swanepoel, Charles R.; Rayner, Brian L.] Univ Cape Town, Fac Hlth Sci, Dept Med, Div Nephrol & Hypertens, Cape Town, Western Cape, South Africa; [Kilonzo, Kajiru G.] Kilimanjaro Christian Med Univ Coll, Internal Med Dept, Kilimanjaro, Moshi, Tanzania; [Yeates, Karen] Queens Univ, Dept Nephrol, Kingston, ON, Canada	University of Cape Town; Queens University - Canada	Kilonzo, KG (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Med, Div Nephrol & Hypertens, Cape Town, Western Cape, South Africa.; Kilonzo, KG (corresponding author), Kilimanjaro Christian Med Univ Coll, Internal Med Dept, Kilimanjaro, Moshi, Tanzania.	kajiru@yahoo.com	Rayner, Brian/AAA-3174-2021		ISN award to train in Nephrology at Groote Schuur Hospital/University of Cape Town; ISN Fellowship	ISN award to train in Nephrology at Groote Schuur Hospital/University of Cape Town; ISN Fellowship	The First Author received an ISN award to train in Nephrology at Groote Schuur Hospital/University of Cape Town. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work has been made possible through an ISN Fellowship.	Alebiosu C Olutayo, 2006, Afr Health Sci, V6, P132; Arogundade FA, 2011, AFR HEALTH SCI, V11, P594; Davids MR., 2014, S AFRICAN RENAL REGI; Goransson LG, 2001, J INTERN MED, V250, P154, DOI 10.1046/j.1365-2796.2001.00869.x; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Junod V, 2010, SWISS MED WEEKLY EUR, P1; Kausz AT, 2000, J AM SOC NEPHROL, V11, P2351, DOI 10.1681/ASN.V11122351; Moosa M, 2010, GUIDELINE PRIORITY S, P1; Moosa MR, 2006, KIDNEY INT, V70, P1107, DOI 10.1038/sj.ki.5001750; Naicker S, 2003, KIDNEY INT, V63, P119, DOI 10.1046/j.1523-1755.63.s83.25.x; Okpechi IG, 2012, J NEPHROL, V25, P551, DOI 10.5301/jn.5000032; Okpechi IG, 2010, J NATL MED ASSOC, V102, P1193, DOI 10.1016/S0027-9684(15)30774-4; Pozo ME, 2012, TRANSPL INT, V25, P652, DOI 10.1111/j.1432-2277.2012.01468.x; Rayner B, 2003, SAMJ S AFR MED J, V93, P673; Swanepoel CR, 2013, NAT REV NEPHROL, V9, P610, DOI 10.1038/nrneph.2013.168; Tamura MK, 2014, KIDNEY INT, V85, P686, DOI 10.1038/ki.2013.369; Van Zyl-smit R, 1997, S AFR MED J, V87, P3; Wauters JP, 2005, NEPHROL DIAL TRANSPL, V20, P490, DOI 10.1093/ndt/gfh709; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715	19	27	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2017	12	4							e0176041	10.1371/journal.pone.0176041	http://dx.doi.org/10.1371/journal.pone.0176041			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KH	28419150	Green Published, gold, Green Submitted			2023-01-03	WOS:000399875200063
J	Xiang, Y; Lu, LM; Chen, XK; Wen, ZH				Xiang, Yu; Lu, Liming; Chen, Xiankun; Wen, Zehuai			Does Tai Chi relieve fatigue? A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							BREAST-CANCER SURVIVORS; MULTIPLE-SCLEROSIS; EXERCISE; HEALTH; INTERVENTIONS; ARTHRITIS; QUALITY; PEOPLE; QIGONG; ADULTS	Background Fatigue is not only a familiar symptom in our daily lives, but also a common ailment that affects all of our bodily systems. Several randomized controlled trials (RCTs) have proven Tai Chi to be beneficial for patients suffering from fatigue, however conclusive evidence is still lacking. A systematic review and meta-analysis was performed on all RCTs reporting the effects of Tai Chi for fatigue. Methods In the end of April 2016, seven electronic databases were searched for RCTs involving Tai Chi for fatigue. The search terms mainly included Tai Chi, Tai-ji, Taiji, fatigue, tiredness, weary, weak, and the search was conducted without language restrictions. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 software was used for meta-analysis. Publication bias was estimated with a funnel plot and Egger's test. We also assessed the quality of evidence with the GRADE system. Results Ten trials (n = 689) were included, and there was a high risk of bias in the blinding. Two trials were determined to have had low methodological quality. Tai Chi was found to have improved fatigue more than conventional therapy (standardized mean difference (SMD): -0.45, 95% confidence interval (CI): -0.70, -0.20) overall, and have positive effects in cancer-related fatigue (SMD:-0.38, 95% CI: -0.65, -0.11). Tai Chi was also more effective on vitality (SMD: 0.63, 95% CI: 0.20, 1.07), sleep (SMD: -0.32, 95% CI: -0.61, -0.04) and depression (SMD: -0.58, 95% CI: -1.04, -0.11). However, no significant difference was found in multiple sclerosis-related fatigue (SMD: -0.77, 95% CI: -1.76, 0.22) and age-related fatigue (SMD: -0.77, 95% CI: -1.78, 0.24). No adverse events were reported among the included studies. The quality of evidence was moderate in the GRADE system. Conclusions The results suggest that Tai Chi could be an effective alternative and/or complementary approach to existing therapies for people with fatigue. However, the quality of the evidence was only moderate and may have the potential for bias. There is still absence of adverse events data to evaluate the safety of Tai Chi. Further multi-center RCTs with large sample sizes and high methodological quality, especially carefully blinded design, should be conducted in future research.	[Xiang, Yu] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China; [Lu, Liming; Chen, Xiankun; Wen, Zehuai] Guangdong Prov Hosp Chinese Med, Key Unit Methodol Clin Res, Guangzhou, Guangdong, Peoples R China; [Wen, Zehuai] Guangzhou Univ Chinese Med, Natl Ctr Design Measurement & Evaluat Clin Res, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Wen, ZH (corresponding author), Guangdong Prov Hosp Chinese Med, Key Unit Methodol Clin Res, Guangzhou, Guangdong, Peoples R China.; Wen, ZH (corresponding author), Guangzhou Univ Chinese Med, Natl Ctr Design Measurement & Evaluat Clin Res, Guangzhou, Guangdong, Peoples R China.	wenzh@gzucm.edu.cn	Wen, Zehuai/A-5103-2015	Wen, Zehuai/0000-0002-1797-2047	National Key Technology R&D Program for the 12th Five year Plan of Ministry of Science and Technology, China [2013BAI02B10]; TCM Science and Technology Project of Guangdong Provincial Hospital of Chinese Medicine [YN2015MS14, YK2013BIN05]	National Key Technology R&D Program for the 12th Five year Plan of Ministry of Science and Technology, China; TCM Science and Technology Project of Guangdong Provincial Hospital of Chinese Medicine	This work was supported by the National Key Technology R&D Program for the 12th Five year Plan of Ministry of Science and Technology, China (No.2013BAI02B10), and TCM Science and Technology Project of Guangdong Provincial Hospital of Chinese Medicine (No.YN2015MS14 and No.YK2013BIN05). This funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Bidonde J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011336; Burschka JM, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0165-4; Callahan LF, 2016, J AGING PHYS ACTIV, V24, P101, DOI 10.1123/japa.2014-0211; Chan AWK, 2013, COMPLEMENT THER MED, V21, P585, DOI 10.1016/j.ctim.2013.09.008; Crane PB, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00055; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Denman M, 2016, ANN INTERN MED, V164, pJC55, DOI 10.7326/ACPJC-2016-164-10-055; Du SZ, 2015, INT J NURS STUD, V52, P368, DOI 10.1016/j.ijnurstu.2014.05.009; Fiest Kirsten M, 2016, Int J MS Care, V18, P96, DOI 10.7224/1537-2073.2015-070; Meneses-Echavez JF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1069-4; Galantino ML, 2013, ALTERN THER HEALTH M, V19, P38; Galantino ML, 2003, REHABIL ONCOL, V21, P17, DOI DOI 10.1097/01893697-200321010-00012; Garcia-Hermoso A, 2015, J BACK MUSCULOSKELET, V28, P609, DOI 10.3233/BMR-140562; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; Hall AM, 2011, ARTHRITIS CARE RES, V63; Han A, 2004, COCHRANE DATABASE SY, V3, DOI DOI 10.1002/14651858.CD004849; Hartley L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010366.pub2; Heine M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009956.pub2; Irwin MR, 2014, SLEEP, V37, P1543, DOI 10.5665/sleep.4008; Jiang M.Y., 2013, CHIN NURS RES, V27, P420, DOI [DOI 10.3969/J.ISSN.1009-6493.2013.05.018, 10.3969/j.issn.1009]; Kim SH, 2013, J INVEST MED, V61, P827, DOI [10.231/JIM.0b013e3182906862, 10.2310/JIM.0b013e3182906862]; Kong LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25325; Larkey LK, 2015, ANN BEHAV MED, V49, P165, DOI 10.1007/s12160-014-9645-4; Lee Kang-Yi, 2006, Taehan Kanho Hakhoe Chi, V36, P278; Li C, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0723-0; Li G. F., 2011, THESIS; Li L., 2012, J COMMUNITY MED, V10, P50; Liu Xin, 2015, Evidence-based Complementary and Alternative Medicine, V2015, P879712; Liu X, 2015, COMPLEMENT THER MED, V23, P516, DOI 10.1016/j.ctim.2015.05.001; LIU Y, 2015, COCHRANE DB SYST REV, V1; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Castro-Sanchez AM, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/473963; Mercier J, 2016, SLEEP MED REV; Mock V, 2000, ONCOLOGY-NY, V14, P151; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Multiple Sclerosis Council for Clinical Practice Guidelines, 1998, FAT MULT SCLER EV BA; Ni XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099377; Pan XH, 2016, J ZHEJIANG UNIV-SC B, V17, P640, DOI 10.1631/jzus.B1600052; Payne C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008427.pub2; Persson PB, 2016, ACTA PHYSIOL, V218, P3, DOI 10.1111/apha.12756; Platta ME, 2016, ARCH PHYS MED REHAB, V97, P1564, DOI 10.1016/j.apmr.2016.01.023; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; Redwine LS, 2012, J ALTERN COMPLEM MED, V18, P744, DOI 10.1089/acm.2011.0314; Reid-Arndt Stephanie A, 2012, Complement Ther Clin Pract, V18, P26, DOI 10.1016/j.ctcp.2011.02.005; Roland NJ, 2012, CLIN OTOLARYNGOL, V37, P393, DOI 10.1111/coa.12032; Romero-Zurita A, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/614196; Savovic J, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-37; Shen JH, 2006, SLEEP MED REV, V10, P63, DOI 10.1016/j.smrv.2005.05.004; Shephard RJ, 2016, SPRINGER SER EPIDEMI, P1, DOI 10.1007/978-3-319-29577-0_1; Shi CM, 2013, WUHUN, V9, P8; Tan L, 2004, J SHE SPORT U, V23, P375; Wang Chenchen, 2010, BMC Complement Altern Med, V10, P23, DOI 10.1186/1472-6882-10-23; Wang Chenchen, 2008, V52, P218, DOI 10.1159/000134302; Wong WS, 2010, J AFFECT DISORDERS, V127, P248, DOI 10.1016/j.jad.2010.04.029; Zhang LL, 2016, J PAIN SYMPTOM MANAG, V51, P504, DOI 10.1016/j.jpainsymman.2015.11.020	56	23	23	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0174872	10.1371/journal.pone.0174872	http://dx.doi.org/10.1371/journal.pone.0174872			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2JD	28380067	gold, Green Submitted, Green Published			2023-01-03	WOS:000399353500072
J	Brodschneider, R; Libor, A; Kupelwieser, V; Crailsheim, K				Brodschneider, Robert; Libor, Anika; Kupelwieser, Vera; Crailsheim, Karl			Food consumption and food exchange of caged honey bees using a radioactive labelled sugar solution	PLOS ONE			English	Article							APIS-MELLIFERA L; NEONICOTINOID INSECTICIDES; TROPHALLAXIS; TOXICITY; WORKERS; HYMENOPTERA; PESTICIDES; VARIANCE; DECLINES; APIDAE	We measured the distribution of sugar solution within groups of caged honey bees (Apis mellifera) under standard in vitro laboratory conditions using 14C polyethylene glycol as a radioactive marker to analyze ingestion by individual bees after group feeding. We studied the impact of different experimental setups by varying the number of bees, age of bees, origin of bees, duration of experiment, the amount of available diet, and the influence of the neurotoxic pesticide imidacloprid in the diet on the feeding and food sharing behavior (trophallaxis). Sugar solution was non -uniformly distributed in bees in 36 out of 135 cages. As a measure of the extent to which the sugar diet was equally distributed between caged bees, we calculated the (inner 80%) intake ratio by dividing the intake of the 90th percentile bee by the intake of the 10th percentile bee. This intake ratio ranged from 1.3 to 94.8 in 133 individual cages, further supporting a non -uniform distribution of food among caged bees. We can expect a cage with 10 or 30 bees containing one bee that ingests, on average, the 8.8 -fold of the bee in the same cage ingesting the smallest quantity of food. Inner 80% intake ratios were lower in experiments with a permanent or chronic offering of labelled sugar solution compared to temporary or acute feedings. After pooling the data of replicates to achieve a higher statistical power we compared different experimental setups. We found that uniform food distribution is best approached with 10 newly emerged bees per cage, which originate from a brood comb from a single colony. We also investigated the trophallaxis between caged honey bees which originally consumed the diet and newly added bees. Color marked bees were starved and added to the cages in a ratio of 10:5 or 20:20 after the initial set of bees consumed all the labelled sugar solution. The distribution of the labelled sugar solution by trophallaxis within 48 hours to added bees was 25% (10:5) or 45% (20:20) of the initial sugar solution. Imidacloprid at its median lethal dose (LD50) in the sugar solution reduced this post -feeding food transmission to 27% (20:20). Our results show that differences in food intake exist within caged bees that may lead to differential exposure that can influence the interpretation of toxicity tests.	[Brodschneider, Robert; Libor, Anika; Kupelwieser, Vera; Crailsheim, Karl] Graz Univ, Inst Zool, Graz, Austria	University of Graz	Brodschneider, R (corresponding author), Graz Univ, Inst Zool, Graz, Austria.	robert.brodschneider@uni-graz.at		Brodschneider, Robert/0000-0002-2535-0280	Austrian Federal Ministry of Agriculture, Forestry, Environment and Water Management [100972]	Austrian Federal Ministry of Agriculture, Forestry, Environment and Water Management	Open access publication fee was provided by the project "Zukunft Biene" (grant number: 100972) funded by the Austrian Federal Ministry of Agriculture, Forestry, Environment and Water Management.	Abbott A., 1978, PRODUCTION ECOLOGY A, P233; [Anonymous], 2002, ANGEW STAT ANWENDUNG; [Anonymous], 2011, 230 CEB; Bevk D, 2012, APIDOLOGIE, V43, P465, DOI 10.1007/s13592-011-0113-x; Blacquiere T, 2012, ECOTOXICOLOGY, V21, P973, DOI 10.1007/s10646-012-0863-x; Brodschneider R, 2010, APIDOLOGIE, V41, P278, DOI 10.1051/apido/2010012; Crailsheim K, 1998, APIDOLOGIE, V29, P97, DOI 10.1051/apido:19980106; CRAILSHEIM K, 1991, J COMP PHYSIOL B, V161, P55, DOI 10.1007/BF00258746; CRAILSHEIM K, 1988, J INSECT PHYSIOL, V34, P85, DOI 10.1016/0022-1910(88)90158-8; CRAILSHEIM K, 1990, ZOOL JAHRB ALLG ZOOL, V94, P303; CRAILSHEIM K, 1985, J INSECT PHYSIOL, V31, P707, DOI 10.1016/0022-1910(85)90051-4; Cresswell JE, 2012, PEST MANAG SCI, V68, P819, DOI 10.1002/ps.3290; Cresswell JE, 2011, ECOTOXICOLOGY, V20, P149, DOI 10.1007/s10646-010-0566-0; Decourtye A, 2010, ADV EXP MED BIOL, V683, P85; Desmedt L, 2016, SCI REP-UK, V6, DOI 10.1038/srep31809; Doublet V, 2015, ENVIRON MICROBIOL, V17, P969, DOI 10.1111/1462-2920.12426; Evans JD, 2009, J APICULT RES, V48, P300, DOI 10.3896/IBRA.1.48.4.13; Fairbrother A, 2014, ENVIRON TOXICOL CHEM, V33, P719, DOI 10.1002/etc.2527; FARINA WM, 1991, ANIM BEHAV, V42, P389, DOI 10.1016/S0003-3472(05)80037-5; Francis RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057540; Free J. B., 1957, British Journal of Animal Behaviour, V5, P41, DOI 10.1016/S0950-5601(57)80023-9; FURGALA B., 1961, BEE WORLD, V42, P249; Goulson D, 2008, ANNU REV ENTOMOL, V53, P191, DOI 10.1146/annurev.ento.53.103106.093454; Goulson D, 2015, SCIENCE, V347, DOI 10.1126/science.1255957; Hurst V, 2014, J COMP PHYSIOL A, V200, P881, DOI 10.1007/s00359-014-0932-0; Kessler SC, 2015, NATURE, V521, P74, DOI 10.1038/nature14414; KORST PJAM, 1982, INSECT SOC, V29, P209, DOI 10.1007/BF02228753; Laurino D, 2013, B INSECTOL, V66, P119; Medrzycki P, 2013, J APICULT RES, V52, DOI 10.3896/IBRA.1.52.4.14; Meixner MD, 2004, INSECT SOC, V51, P43, DOI 10.1007/s00040-003-0701-5; MORITZ RFA, 1986, INSECT SOC, V33, P26, DOI 10.1007/BF02224032; MORITZ RFA, 1990, ANIM BEHAV, V40, P641, DOI 10.1016/S0003-3472(05)80693-1; MORITZ RFA, 1992, INSECT SOC, V39, P365, DOI 10.1007/BF01240621; Nauen R, 2001, PEST MANAG SCI, V57, P577, DOI 10.1002/ps.331; Nazzi F, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002735; NIXON HL, 1952, PROC R SOC SER B-BIO, V140, P43, DOI 10.1098/rspb.1952.0042; OECD, 1998, 213 OECD; OEPP/EPPO, 2010, B OEPP EPPO B, V40, P323; PERSHAD SHOBHA, 1967, ANN ABEILLE [PARIS], V10, P139, DOI 10.1051/apido:19670301; Potts SG, 2010, J APICULT RES, V49, P15, DOI 10.3896/IBRA.1.49.1.02; RINDERER TE, 1976, J ECON ENTOMOL, V69, P489, DOI 10.1093/jee/69.4.489; Rondeau G, 2014, SCI REP-UK, V4, DOI 10.1038/srep05566; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Simon-Delso N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103073; Sponsler DB, 2016, ENV TOXICOL CHEM; Suchail S, 2000, ENVIRON TOXICOL CHEM, V19, P1901, DOI [10.1897/1551-5028(2000)019&lt;1901:COITIT&gt;2.3.CO;2, 10.1002/etc.5620190726]; Suchail S, 2004, PEST MANAG SCI, V60, P291, DOI 10.1002/ps.772; Sudd JH, 1967, INTRO BEHAV ANTS; Williams G. R., 2013, J APICULT RES, VI, P1, DOI DOI 10.3896/IBRA.1.52.1.04	49	14	14	4	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0174684	10.1371/journal.pone.0174684	http://dx.doi.org/10.1371/journal.pone.0174684			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VG	28355267	gold, Green Published			2023-01-03	WOS:000399174600080
J	Zhao, M; Huang, X; Cheng, X; Lin, X; Zhao, T; Wu, LY; Yu, XD; Wu, KW; Fan, M; Zhu, LL				Zhao, Ming; Huang, Xin; Cheng, Xiang; Lin, Xiao; Zhao, Tong; Wu, Liying; Yu, Xiaodan; Wu, Kuiwu; Fan, Ming; Zhu, Lingling			Ketogenic diet improves the spatial memory impairment caused by exposure to hypobaric hypoxia through increased acetylation of histones in rats	PLOS ONE			English	Article							BETA-HYDROXYBUTYRATE; BRAIN; NEUROPROTECTION; INVOLVEMENT; PLASTICITY; COGNITION; ALTITUDE; NEURONS; DISEASE; MODEL	Exposure to hypobaric hypoxia causes neuron cell damage, resulting in impaired cognitive function. Effective interventions to antagonize hypobaric hypoxia-induced memory impairment are in urgent need. Ketogenic diet (KD) has been successfully used to treat drug resistant epilepsy and improves cognitive behaviors in epilepsy patients and other pathophysiological animal models. In the present study, we aimed to explore the potential beneficial effects of a KD on memory impairment caused by hypobaric hypoxia and the underlying possible mechanisms. We showed that the KD recipe used was ketogenic and increased plasma levels of ketone bodies, especially beta-hydroxybutyrate. The results of the behavior tests showed that the KD did not affect general locomotor activity but obviously promoted spatial learning. Moreover, the KD significantly improved the spatial memory impairment caused by hypobaric hypoxia (simulated altitude of 6000 m, 24 h). In addition, the improving-effect of KD was mimicked by intraperitoneal injection of BHB. The western blot and immunohistochemistry results showed that KD treatment not only increased the acetylated levels of histone H3 and histone H4 compared to that of the control group but also antagonized the decrease in the acetylated histone H3 and H4 when exposed to hypobaric hypoxia. Furthermore, KD-hypoxia treatment also promoted PKA/CREB activation and BDNF protein expression compared to the effects of hypoxia alone. These results demonstrated that KD is a promising strategy to improve spatial memory impairment caused by hypobaric hypoxia, in which increased modification of histone acetylation plays an important role.	[Zhao, Ming; Huang, Xin; Cheng, Xiang; Lin, Xiao; Zhao, Tong; Wu, Liying; Yu, Xiaodan; Wu, Kuiwu; Fan, Ming; Zhu, Lingling] Beijing Inst Basic Med Sci, Dept Cognit Sci, Beijing, Peoples R China; [Fan, Ming; Zhu, Lingling] Nantong Univ, Coinnovat Ctr Neuroregenerat, Nantong, JS, Peoples R China; [Fan, Ming] Beijing Inst Brain Disorders, 10 Xitoutiao, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Nantong University	Fan, M; Zhu, LL (corresponding author), Beijing Inst Basic Med Sci, Dept Cognit Sci, Beijing, Peoples R China.; Fan, M; Zhu, LL (corresponding author), Nantong Univ, Coinnovat Ctr Neuroregenerat, Nantong, JS, Peoples R China.; Fan, M (corresponding author), Beijing Inst Brain Disorders, 10 Xitoutiao, Beijing, Peoples R China.	fanmingchina@126.com; linglingzhu@hotmail.com		Wu, Li-Ying/0000-0001-5277-2078; Zhu, Lingling/0000-0002-6474-5875	National Natural Science Foundation of China [81430044, 31271205, 31271211]; Beijing municipal Science and Technology Commission [Z161100000216134]; National Basic Research Program of China [2012CB518200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China, Grant#81430044, 31271205, 31271211 (http://www.nsfc.gov.cn/); the Beijing municipal Science and Technology Commission, Grant #Z161100000216134 (http://www.bjkw.gov.cn/n8785584/index.html) and the National Basic Research Program of China, Grant # 2012CB518200 (http://program.most.gov.cn/.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Davidson TL, 2013, NEUROSCIENCE, V253, P110, DOI 10.1016/j.neuroscience.2013.08.044; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925; Hallbook T, 2012, EPILEPSY RES, V100, P304, DOI 10.1016/j.eplepsyres.2011.04.017; Hawk JD, 2011, LEARN MEMORY, V18, P367, DOI 10.1101/lm.2097411; Izumi Y, 1998, J CLIN INVEST, V101, P1121, DOI 10.1172/JCI1009; Jiang Y, 2016, BRAIN RES, V1646, P451, DOI 10.1016/j.brainres.2016.06.029; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Kauser H, 2016, BRAIN RES, V1636, P152, DOI 10.1016/j.brainres.2016.01.053; Krasnova IN, 2013, NEUROBIOL DIS, V58, P132, DOI 10.1016/j.nbd.2013.05.009; Krikorian R, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.10.006; Li P, 2012, PHYSIOL BEHAV, V106, P439, DOI 10.1016/j.physbeh.2012.03.002; Lin C, 2013, NEUROSCIENCE, V231, P216, DOI 10.1016/j.neuroscience.2012.11.051; Maiti P, 2008, BEHAV BRAIN RES, V189, P233, DOI 10.1016/j.bbr.2008.01.007; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; McQuown SC, 2011, J NEUROSCI, V31, P764, DOI 10.1523/JNEUROSCI.5052-10.2011; Monti B, 2013, CURR PHARM DESIGN, V19, P5065, DOI 10.2174/1381612811319280005; Muthuraju S, 2014, MALAYS J MED SCI, V21, P41; Pagani M, 1998, CORTEX, V34, P243, DOI 10.1016/S0010-9452(08)70751-2; Postulart D, 2016, EPILEPSY BEHAVIOR E, V60, P153; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Samoilov M, 2016, ACTA HISTOCHEM, V118, P80, DOI 10.1016/j.acthis.2015.11.008; Samoilova M, 2010, J NEUROCHEM, V113, P826, DOI 10.1111/j.1471-4159.2010.06645.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Shukitt-Hale B, 1998, INT J AVIAT PSYCHOL, V8, P319, DOI 10.1207/s15327108ijap0804_1; Sleiman SF, 2016, ELIFE, V5, DOI 10.7554/eLife.15092; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Thaler S, 2010, GRAEF ARCH CLIN EXP, V248, P1729, DOI 10.1007/s00417-010-1425-7; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P614; Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhang XY, 2016, NUTR RES, V36, P349, DOI 10.1016/j.nutres.2015.12.002	34	37	41	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0174477	10.1371/journal.pone.0174477	http://dx.doi.org/10.1371/journal.pone.0174477			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VG	28355243	gold, Green Published, Green Submitted			2023-01-03	WOS:000399174600054
J	Papke, B; Der, CJ				Papke, Bjoern; Der, Channing J.			Drugging RAS: Know the enemy	SCIENCE			English	Review							K-RAS; PLASMA-MEMBRANE; SMALL MOLECULES; CANCER; INHIBITION; BRAF; ERK; ASSOCIATION; DISCOVERY; ONCOGENES	The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.	[Papke, Bjoern; Der, Channing J.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Der, CJ (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Papke, Bjoern/0000-0001-8156-7508; Der, Channing/0000-0002-7751-2747	Astex Pharmaceutics; Novartis; LifeSci Advisors; Cullinan Pharmaceuticals; NATIONAL CANCER INSTITUTE [P01CA203657, U01CA199235, R01CA042978, R01CA175747] Funding Source: NIH RePORTER	Astex Pharmaceutics; Novartis(Novartis); LifeSci Advisors; Cullinan Pharmaceuticals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	C.J.D. is on the Scientific Advisory Boards of Warp Drive Bio, a company developing therapeutics for proteins that cannot be targeted by conventional drug discovery approaches, and Kyras Therapeutics, a company developing RAS-targeted drugs. C.J.D. is also a paid consultant for Astex Pharmaceutics, Novartis, LifeSci Advisors, and Cullinan Pharmaceuticals.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Athuluri-Divakar SK, 2016, CELL, V165, P643, DOI 10.1016/j.cell.2016.03.045; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Cho KJ, 2016, MOL CELL BIOL, V36, P363, DOI 10.1128/MCB.00719-15; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Cox Adrienne D, 2010, Small GTPases, V1, P2; Downward J, 2015, CLIN CANCER RES, V21, P1802, DOI 10.1158/1078-0432.CCR-14-2180; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hunter JC, 2014, P NATL ACAD SCI USA, V111, P8895, DOI 10.1073/pnas.1404639111; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Lazo JS, 2016, ANNU REV PHARMACOL, V56, P23, DOI 10.1146/annurev-pharmtox-010715-103440; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Papke B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11360; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ritt DA, 2016, MOL CELL, V64, P875, DOI 10.1016/j.molcel.2016.10.029; Ryan MB, 2015, TRENDS CANCER, V1, P183, DOI 10.1016/j.trecan.2015.10.001; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Schmick M, 2014, CELL, V157, P459, DOI 10.1016/j.cell.2014.02.051; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun Q, 2012, ANGEW CHEM INT EDIT, V51, P6140, DOI 10.1002/anie.201201358; Thompson H, 2013, NAT MED, V19, P949, DOI 10.1038/nm0813-949; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; van der Hoeven D, 2013, MOL CELL BIOL, V33, P237, DOI 10.1128/MCB.00884-12; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wang T, 2017, CELL, V168, P890, DOI 10.1016/j.cell.2017.01.013; Witkiewicz AK, 2016, CELL REP, V16, P2017, DOI 10.1016/j.celrep.2016.07.023; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zeitouni D, 2016, CANCERS, V8, DOI 10.3390/cancers8040045; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	49	216	230	5	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1158	1163		10.1126/science.aam7622	http://dx.doi.org/10.1126/science.aam7622			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9WV	28302824				2023-01-03	WOS:000396351200033
J	Stern, AD; Alexander, BM; Chandra, A				Stern, A. D.; Alexander, B. M.; Chandra, A.			BIOMEDICAL INNOVATION How economics can shape precision medicines Innovation incentives, pricing, and access are critical	SCIENCE			English	Editorial Material							BREAST-CANCER; ADAPTIVE RANDOMIZATION; MARKET-SIZE; TRIAL		[Stern, A. D.; Chandra, A.] Harvard Sch Business, Boston, MA 02163 USA; [Stern, A. D.] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02215 USA; [Stern, A. D.] Harvard TH Chan Sch Publ Hlth, Boston, MA 02215 USA; [Alexander, B. M.] Dana Farber Canc Inst, Boston, MA 02215 USA; [Alexander, B. M.] Harvard Med Sch, Harvard Program Therapeut Sci, Boston, MA 02115 USA; [Chandra, A.] Harvard Kennedy Sch, Cambridge, MA 02138 USA; [Chandra, A.] Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; National Bureau of Economic Research	Stern, AD (corresponding author), Harvard Sch Business, Boston, MA 02163 USA.; Stern, AD (corresponding author), Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02215 USA.; Stern, AD (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02215 USA.	astern@hbs.edu	Stern, Ariel Dora/AGJ-7029-2022	Stern, Ariel Dora/0000-0002-3586-1041				Acemoglu D, 2004, Q J ECON, V119, P1049, DOI 10.1162/0033553041502144; Bach PB, 2014, JAMA-J AM MED ASSOC, V312, P1629, DOI 10.1001/jama.2014.13235; Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316; Chandra A, 2015, JAMA-J AM MED ASSOC, V314, P225, DOI 10.1001/jama.2015.6170; Chandra A, 2011, J ECON PERSPECT, V25, P27, DOI 10.1257/jep.25.2.27; COCHRANE JH, 1995, J POLIT ECON, V103, P445, DOI 10.1086/261991; Dubois P, 2015, RAND J ECON, V46, P844, DOI 10.1111/1756-2171.12113; FDA, 2016, NOV DRUGS SUMM; FDA, 2012, 209 FDA GFI; Food and Drug Administration, 2014, GUID IND EXP PROGR S; Montazerhodjat V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6913; Park JW, 2016, NEW ENGL J MED, V375, P11, DOI 10.1056/NEJMoa1513750; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; The Henry J. Kaiser Family Foundation, 2016, MED PARD D PRESCR DR; Yin W, 2009, J HEALTH ECON, V28, P950, DOI 10.1016/j.jhealeco.2009.06.011	16	15	15	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1131	1133		10.1126/science.aai8707	http://dx.doi.org/10.1126/science.aai8707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN9WV	28302813				2023-01-03	WOS:000396351200023
J	McWilliams, JM; Schwartz, AL				McWilliams, J. Michael; Schwartz, Aaron L.			Focusing on High-Cost Patients - The Key to Addressing High Costs?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICARE; CARE; PROGRAM		[McWilliams, J. Michael; Schwartz, Aaron L.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [McWilliams, J. Michael] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	McWilliams, JM (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA.; McWilliams, JM (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P01AG032952] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG032952] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		McWilliams JM, 2016, JAMA-J AM MED ASSOC, V316, P1711, DOI 10.1001/jama.2016.12049; McWilliams JM, 2014, JAMA INTERN MED, V174, P938, DOI 10.1001/jamainternmed.2014.1073; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Schwartz AL, 2015, JAMA INTERN MED, V175, P1815, DOI 10.1001/jamainternmed.2015.4525; Schwartz AL, 2014, JAMA INTERN MED, V174, P1067, DOI 10.1001/jamainternmed.2014.1541	5	41	41	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2017	376	9					807	809		10.1056/NEJMp1612779	http://dx.doi.org/10.1056/NEJMp1612779			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EM9JK	28249127	Green Accepted			2023-01-03	WOS:000395627500002
J	Lown, M; Fuller, R; Lightowler, H; Fraser, A; Gallagher, A; Stuart, B; Byrne, C; Lewith, G				Lown, Mark; Fuller, Richard; Lightowler, Helen; Fraser, Ann; Gallagher, Andrew; Stuart, Beth; Byrne, Christopher; Lewith, George			Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study	PLOS ONE			English	Article							POSTPRANDIAL BLOOD-GLUCOSE; LEAF EXTRACT; MORUS-ALBA; 1-DEOXYNOJIRIMYCIN; LEAVES; FOOD; HYPERGLYCEMIA; SUPPRESSES; MEDICINES; HUMANS	Background High sugar and refined carbohydrate intake is associated with weight gain, increased incidence of diabetes and is linked with increased cardiovascular mortality. Reducing the health impact of poor quality carbohydrate intake is a public health priority. Reducose, a proprietary mulberry leaf extract (ME), may reduce blood glucose responses following dietary carbohydrate intake by reducing absorption of glucose from the gut. Methods A double-blind, randomised, repeat measure, phase 2 crossover design was used to study the glycaemic and insulinaemic response to one reference product and three test products at the Functional Food Centre, Oxford Brooks University, UK. Participants; 37 adults aged 19-59 years with a BMI >= 20kg/m(2) and <= 30kg/m(2). The objective was to determine the effect of three doses of mulberry-extract (Reducose) versus placebo on blood glucose and insulin responses when co-administered with 50g maltodextrin in normoglycaemic healthy adults. We also report the gastrointestinal tolerability of the mulberry extract. Results Thirty-seven participants completed the study: The difference in the positive Incremental Area Under the Curve (pIAUC) (glucose (mmol /L x h)) for half, normal and double dose ME compared with placebo was -6.1% (-18.2%, 5.9%; p = 0.316), -14.0% (-26.0%, -2.0%; p = 0.022) and -22.0% (-33.9%, -10.0%; p< 0.001) respectively. The difference in the pIAUC insulin (mIU/L x h)) for half, normal and double dose ME compared with placebo was -9.7% (-25.8%, 6.3%; p = 0.234), -23.8% (-39.9%, -7.8%; p = 0.004) and -24.7% (-40.8%, -8.6%; p = 0.003) respectively. There were no statistically significant differences between any of the 4 groups in the odds of experiencing one or more gastrointestinal symptoms (nausea, abdominal cramping, distension or flatulence). Conclusions Mulberry leaf extract significantly reduces total blood glucose rise after ingestion of maltodextrin over 120 minutes. The pattern of effect demonstrates a classical dose response curve with significant effects over placebo. Importantly, total insulin rises were also significantly suppressed over the same time-period. There were no statistically significant differences between any of the treatment groups (including placebo) in the odds of experiencing one or more gastrointestinal symptoms. Mulberry extract may have multiple modes of action and further studies are necessary to evaluate ME as a potential target for the prevention of type 2 diabetes and the regulation of dysglycaemia.	[Lown, Mark; Fuller, Richard; Stuart, Beth; Lewith, George] Univ Southampton, Fac Med, Primary Care & Populat Sci, Aldermoor Hlth Ctr, Southampton, Hants, England; [Lightowler, Helen; Fraser, Ann] Oxford Brooks Univ, Funct Food Ctr, Oxford, England; [Gallagher, Andrew] Phynova Grp Ltd, Long Hanborough, England; [Byrne, Christopher] Univ Southampton, Fac Med, Nutr & Metab, Southampton, Hants, England; [Byrne, Christopher] Southampton Univ Hosp, Southampton, Hants, England; [Byrne, Christopher] Southampton Univ Hosp, Biomed Res Ctr, Southampton Natl Inst Hlth Res, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton; University of Southampton	Lown, M (corresponding author), Univ Southampton, Fac Med, Primary Care & Populat Sci, Aldermoor Hlth Ctr, Southampton, Hants, England.	m.lown@soton.ac.uk	Capel, Helen/AAC-8818-2022	Gallagher, Andrew/0000-0002-5974-4093; Lown, Mark/0000-0001-8309-568X; Stuart, Beth/0000-0001-5432-7437; Byrne, Christopher D/0000-0001-6322-7753	Technology Strategy Board/Innovate UK grant [101726]; Southampton National Institute for Health Research Biomedical Research Centre; National Institute for Health Research [CL-2014-26-004(1)] Funding Source: researchfish	Technology Strategy Board/Innovate UK grant; Southampton National Institute for Health Research Biomedical Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	The work has been funded by a Technology Strategy Board/Innovate UK grant (101726). CB is supported in part by the Southampton National Institute for Health Research Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The work has been funded by a Technology Strategy Board/Innovate UK grant.; CDB is supported in part by the Southampton National Institute for Health Research Biomedical Research Centre.	Andallu B, 2001, CLIN CHIM ACTA, V314, P47, DOI 10.1016/S0009-8981(01)00632-5; BAILEY CJ, 1989, DIABETES CARE, V12, P553, DOI 10.2337/diacare.12.8.553; Banu S, 2015, SAUDI J BIOL SCI, V22, P32, DOI 10.1016/j.sjbs.2014.04.005; Basu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057873; Bensky D, 1993, CHINESE HERBAL MED M; Brouns F, 2005, NUTR RES REV, V18, P145, DOI 10.1079/NRR2005100; Chau CF, 2006, TRENDS FOOD SCI TECH, V17, P313, DOI 10.1016/j.tifs.2005.12.005; DeFronzo RA, 2011, DIABETES CARE, V34, pS202, DOI 10.2337/dc11-s221; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; Glube Natalie, 2013, Results Pharma Sci, V3, P1, DOI 10.1016/j.rinphs.2013.08.002; HotherNielsen O, 1996, METABOLISM, V45, P82, DOI 10.1016/S0026-0495(96)90204-8; Kimura T, 2007, J AGR FOOD CHEM, V55, P5869, DOI 10.1021/jf062680g; Kojima Y, 2010, J CLIN BIOCHEM NUTR, V47, P155, DOI 10.3164/jcbn.10-53; Lown M, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0997-2; Ma X, 2009, J ETHNOPHARMACOL, V122, P54, DOI 10.1016/j.jep.2008.11.022; Malhotra A., 2015, BR J SPORTS MED; Miura T, 1998, J NUTR SCI VITAMINOL, V44, P371, DOI 10.3177/jnsv.44.371; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Morenga LT, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7492; Mudra M, 2007, DIABETES CARE, V30, P1272, DOI 10.2337/dc06-2120; Nakagawa K, 2007, J AGR FOOD CHEM, V55, P8928, DOI 10.1021/jf071559m; Nakamura M, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-29; Naowaboot J, 2012, AM J CHINESE MED, V40, P163, DOI 10.1142/S0192415X12500139; National Institute for Health and Care Excellence, 2011, NICE GUID PH35 PREV; National Institute for Health and Care Excellence, 2006, NICE GUID CG43 OB GU; National Institute for Health and Care Excellence, 2012, NICE GUID PH 38 PREV; Oku T, 2006, BRIT J NUTR, V95, P933, DOI 10.1079/BJN20061746; Romaguera D, 2013, DIABETOLOGIA, V56, P1520, DOI 10.1007/s00125-013-2899-8; Schwartz S, 2006, DIABETES CARE, V29, P759, DOI 10.2337/diacare.29.04.06.dc05-1967; Srivastava S, 2003, INT J FOOD SCI NUTR, V54, P411, DOI 10.1080/09637480310001622288; THIEBAUD D, 1982, DIABETES, V31, P957, DOI 10.2337/diacare.31.11.957; Velasquez-Mieyer PA, 2003, INT J OBESITY, V27, P219, DOI 10.1038/sj.ijo.802227; Wu T, 2013, FOOD CHEM, V141, P482, DOI 10.1016/j.foodchem.2013.03.046	33	27	28	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2017	12	2							e0172239	10.1371/journal.pone.0172239	http://dx.doi.org/10.1371/journal.pone.0172239			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SK	28225835	Green Published, gold, Green Accepted			2023-01-03	WOS:000394680900032
J	Franck, JA; Smeets, RJEM; Seelen, HAM				Franck, Johan Anton; Smeets, Rob Johannes Elise Marie; Seelen, Henk Alexander Maria			Changes in arm-hand function and arm-hand skill performance in patients after stroke during and after rehabilitation	PLOS ONE			English	Article							CLINICALLY IMPORTANT DIFFERENCE; UPPER-LIMB RECOVERY; UPPER-EXTREMITY; MOTOR RECOVERY; ABILHAND QUESTIONNAIRE; INTERRATER RELIABILITY; OUTCOME MEASURES; SURVIVORS; THERAPY; IMPAIRMENT	Background Arm-hand rehabilitation programs applied in stroke rehabilitation frequently target specific populations and thus are less applicable in heterogeneous patient populations. Besides, changes in arm-hand function (AHF) and arm-hand skill performance (AHSP) during and after a specific and well-described rehabilitation treatment are often not well evaluated. Method This single-armed prospective cohort study featured three subgroups of stroke patients with either a severely, moderately or mildly impaired AHF. Rehabilitation treatment consisted of a Concise_ Arm_ and_ hand_ Rehabilitation_ Approach_ in_ Stroke (CARAS). Measurements at function and activity level were performed at admission, clinical discharge, 3, 6, 9 and 12 months after clinical discharge. Results Eighty-nine stroke patients (M/F:63/23; mean age: 57.6yr (+/-10.6); post-stroke time: 29.8 days (+/-20.1)) participated. All patients improved on AHF and arm-hand capacity during and after rehabilitation, except on grip strength in the severely affected subgroup. Largest gains occurred in patients with a moderately affected AHF. As to self-perceived AHSP, on average, all subgroups improved over time. A small percentage of patients declined regarding self-perceived AHSP post-rehabilitation. Conclusions A majority of stroke patients across the whole arm-hand impairment severity spectrum significantly improved on AHF, arm-hand capacity and self-perceived AHSP. These were maintained up to one year post-rehabilitation. Results may serve as a control condition in future studies.	[Franck, Johan Anton] Adelante Rehabil Ctr, Dept Brain Injury Rehabil, Hoensbroek, Netherlands; [Franck, Johan Anton; Seelen, Henk Alexander Maria] Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Smeets, Rob Johannes Elise Marie; Seelen, Henk Alexander Maria] Maastricht Univ, Res Sch CAPHRI, Dept Rehabil Med, Maastricht, Netherlands	Maastricht University	Franck, JA (corresponding author), Adelante Rehabil Ctr, Dept Brain Injury Rehabil, Hoensbroek, Netherlands.; Franck, JA (corresponding author), Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands.	h.franck@adelante-zorggroep.nl	Smeets, Rob JEM/D-1522-2011	Smeets, Rob JEM/0000-0002-9503-366X				Arya KN, 2012, TOP STROKE REHABIL, V19, P193, DOI 10.1310/tsr1903-193; Arya KN, 2011, TOP STROKE REHABIL, V18, P599, DOI 10.1310/tsr18s01-599; Ashford S, 2008, J REHABIL MED, V40, P787, DOI 10.2340/16501977-0276; Barker RN, 2005, DISABIL REHABIL, V27, P1213, DOI 10.1080/09638280500075717; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Combs SA, 2010, DISABIL REHABIL, V32, P669, DOI 10.3109/09638280903242716; De Weerdt WJG., 1985, PHYSIOTHER CAN, V37, P65, DOI DOI 10.3138/PTC.37.2.065; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Franck J.A., 2015, OPEN J OCCUP THER, V3, P10, DOI [10.15453/2168-6408.1164, DOI 10.15453/2168-6408.1164]; French B, 2009, STROKE; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Hamilton G. F., 1994, STIMULUS, V13, P164; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Harris-Love ML, 2016, NEUROREHAB NEURAL RE, V30, P328, DOI 10.1177/1545968315594886; Hayward K, 2010, DISABIL REHABIL, V32, P1973, DOI 10.3109/09638288.2010.481027; Hsieh CL, 1998, AGE AGEING, V27, P107, DOI 10.1093/ageing/27.2.107; Jang SH, 2003, NEUROREPORT, V14, P137, DOI 10.1097/00001756-200301200-00025; Kwah LK, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6040053; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Kwakkel G, 2015, OXFORD TXB NEUROREHA; Lang CE, 2008, ARCH PHYS MED REHAB, V89, P1693, DOI 10.1016/j.apmr.2008.02.022; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; McDonnell MN, 2007, NEUROREHAB NEURAL RE, V21, P435, DOI 10.1177/1545968307300437; Mirbagheri MM, 2008, ARCH PHYS MED REHAB, V89, P1507, DOI 10.1016/j.apmr.2008.02.017; Morris JH, 2008, ARCH PHYS MED REHAB, V89, P1237, DOI 10.1016/j.apmr.2007.11.039; Oujamaa L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P269, DOI 10.1016/j.rehab.2008.10.003; Penta M, 2001, STROKE, V32, P1627, DOI 10.1161/01.STR.32.7.1627; Penta M, 1998, ARCH PHYS MED REHAB, V79, P1038, DOI 10.1016/S0003-9993(98)90167-8; Platz T, 2005, CLIN REHABIL, V19, P714, DOI 10.1191/0269215505cr904oa; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Prabhakaran S, 2008, NEUROREHAB NEURAL RE, V22, P64, DOI 10.1177/1545968307305302; Reenen ETKV, 2009, DISABIL REHABIL, V31, P1338, DOI 10.1080/09638280902846855; Salter K, 2005, DISABIL REHABIL, V27, P191, DOI 10.1080/09638280400008537; Smania N, 2007, STROKE, V38, P1088, DOI 10.1161/01.STR.0000258077.88064.a3; Sullivan KJ, 2011, STROKE, V42, P427, DOI 10.1161/STROKEAHA.110.592766; Timmermans AAA, 2009, DISABIL REHABIL, V31, P1344, DOI 10.1080/09638280902823664; Timmermans AAA, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-1; Twisk JWR, 2003, APPL LONGITUDINAL DA; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; Verbunt JA, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-7; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Wallace AC, 2010, CLIN REHABIL, V24, P471, DOI 10.1177/0269215509358944; Wang TN, 2011, ARCH PHYS MED REHAB, V92, P1086, DOI 10.1016/j.apmr.2011.01.020; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Winstein CJ, 2006, TXB NEURAL REPAIR RE; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115; Wolf SL, 2008, LANCET NEUROL, V7, P33, DOI 10.1016/S1474-4422(07)70294-6; Yozbatiran N, 2008, NEUROREHAB NEURAL RE, V22, P78, DOI 10.1177/1545968307305353	51	15	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							e0179453	10.1371/journal.pone.0179453	http://dx.doi.org/10.1371/journal.pone.0179453			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX5KN	28614403	Green Published, Green Submitted, gold			2023-01-03	WOS:000403280900054
J	Murphy, PB; Rehal, S; Arbane, G; Bourke, S; Calverley, PMA; Crook, AM; Dowson, L; Duffy, N; Gibson, GJ; Hughes, PD; Hurst, JR; Lewis, KE; Mukherjee, R; Nickol, A; Oscroft, N; Patout, M; Pepperell, J; Smith, I; Stradling, JR; Wedzicha, JA; Polkey, MI; Elliott, M; Hart, N				Murphy, Patrick B.; Rehal, Sunita; Arbane, Gill; Bourke, Stephen; Calverley, Peter M. A.; Crook, Angela M.; Dowson, Lee; Duffy, Nicholas; Gibson, G. John; Hughes, Philip D.; Hurst, John R.; Lewis, Keir E.; Mukherjee, Rahul; Nickol, Annabel; Oscroft, Nicholas; Patout, Maxime; Pepperell, Justin; Smith, Ian; Stradling, John R.; Wedzicha, Jadwiga A.; Polkey, Michael I.; Elliott, Markw.; Hart, Nicholas			Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; POSITIVE-PRESSURE VENTILATION; RESPIRATORY-FAILURE; HYPERCAPNIC COPD; NASAL VENTILATION; CROSSOVER TRIAL; CPAP; QUESTIONNAIRE; MINIMIZATION; MULTICENTER	IMPORTANCE Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death. OBJECTIVE To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent hypercapnia after an acute COPD exacerbation. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial of patients with persistent hypercapnia (PaCO2 > 53mmHg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible. INTERVENTIONS There were 59 patients randomized to home oxygen alone (median oxygen flow rate, 1.0 L/min [interquartile range {IQR}, 0.5-2.0 L/min]) and 57 patients to home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min [IQR, 0.5-1.5 L/min]). The median home ventilator settings were an inspiratory positive airway pressure of 24 (IQR, 22-26) cm H2O, an expiratory positive airway pressure of 4 (IQR, 4-5) cmH(2)O, and a backup rate of 14 (IQR, 14-16) breaths/minute. MAIN OUTCOMES AND MEASURES Time to readmission or death within 12 months adjusted for the number of previous COPD admissions, previous use of long-term oxygen, age, and BMI. RESULTS A total of 116 patients (mean [SD] age of 67 [10] years, 53% female, mean BMI of 21.6 [IQR, 18.2-26.1], mean [SD] forced expiratory volume in the first second of expiration of 0.6 L [0.2 L], and mean [SD] PaCO2 while breathing room air of 59 [7] mmHg) were randomized. Sixty-four patients (28 in home oxygen alone and 36 in home oxygen plus home NIV) completed the 12-month study period. The median time to readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months (IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio of 0.49 (95% CI, 0.31-0.77; P = .002). The 12-month risk of readmission or death was 63.4% in the home oxygen plus home NIV group vs 80.4% in the home oxygen alone group, absolute risk reduction of 17.0%(95% CI, 0.1%-34.0%). At 12 months, 16 patients had died in the home oxygen plus home NIV group vs 19 in the home oxygen alone group. CONCLUSIONS AND RELEVANCE Among patients with persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive ventilation to home oxygen therapy prolonged the time to readmission or death within 12 months.	[Murphy, Patrick B.; Arbane, Gill; Patout, Maxime; Hart, Nicholas] Guys & St Thomas NHS Fdn Trust, Lane Fox Unit, London, England; [Murphy, Patrick B.; Hart, Nicholas] Kings Coll London, Asthma Allergy & Lung Biol, London, England; [Rehal, Sunita; Crook, Angela M.] UCL, MRC Clin Trials Unit, Inst Clin Trials & Methodol, London, England; [Bourke, Stephen] Northumbria Healthcare NHS Fdn Trust, Resp Med, Newcastle Upon Tyne, Tyne & Wear, England; [Bourke, Stephen] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Calverley, Peter M. A.] Univ Liverpool, Sch Aging & Chron Dis, Liverpool, Merseyside, England; [Dowson, Lee] Royal Wolverhampton NHS Trust, Resp Med, Wolverhampton, W Midlands, England; [Duffy, Nicholas] Aintree Univ Hosp NHS Fdn Trust, Resp Med, Liverpool, Merseyside, England; [Gibson, G. John] Newcastle Univ, Resp Med, Newcastle Upon Tyne, Tyne & Wear, England; [Hughes, Philip D.] Plymouth Hosp NHS Trust, Resp Med, Plymouth, Devon, England; [Hurst, John R.] UCL, Resp Med, Royal Free Campus, London, England; [Lewis, Keir E.] Swansea Univ, Resp Med, Swansea, W Glam, England; [Mukherjee, Rahul] Heart England NHS Trust, Resp Med, Birmingham, W Midlands, England; [Nickol, Annabel; Stradling, John R.] Univ Oxford, Oxford NIHR Biomed Res Ctr, Oxford, England; [Nickol, Annabel; Stradling, John R.] NHS Fdn Trust, Oxford, England; [Oscroft, Nicholas; Smith, Ian] Papworth Hosp, Resp Support & Ctr, Cambridge, England; [Pepperell, Justin] Taunton & Somerset NHS Trust, Resp Med, Taunton, Somerset, England; [Wedzicha, Jadwiga A.; Polkey, Michael I.] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England; [Wedzicha, Jadwiga A.; Polkey, Michael I.] Imperial Coll, London, England; [Elliott, Markw.] Leeds Univ Hosp, Dept Resp Med, Leeds, W Yorkshire, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Medical Research Council Clinical Trials Unit; University of London; University College London; Newcastle University - UK; University of Liverpool; Aintree University Hospitals NHS Foundation Trust; Newcastle University - UK; University of Plymouth; University of London; University College London; Swansea University; Heart of England NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; Papworth Hospital; Royal Brompton & Harefield NHS Foundation Trust; Imperial College London	Murphy, PB (corresponding author), St Thomas Hosp, Lane Fox Resp Unit, Westminster Bridge Rd, London SE1 7EH, England.	patrick.murphy@gstt.nhs.uk	Mukherjee, Rahul/CAA-9942-2022; Patout, Maxime/AAH-9001-2019; Hart, Nicholas/O-7076-2015	Patout, Maxime/0000-0002-1366-8726; Hart, Nicholas/0000-0002-6863-585X; Lewis, Keir/0000-0002-8248-6774; Bourke, Stephen/0000-0003-0228-0854; Hurst, John/0000-0002-7246-6040; Wedzicha, Jadwiga/0000-0001-9642-1261; Lewis, Keir/0000-0001-9756-4723; Mukherjee, Rahul/0000-0003-4466-0660	Philips Respironics; ResMed; ResMed Foundation; Guy's and St Thomas' Charity; Guy's and St Thomas' NHS Foundation Trust and King's College London; National Institute of Health Research Comprehensive Biomedical Research Centre; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; MRC [G1001365, G0800570, G1001372] Funding Source: UKRI; Medical Research Council [G1001365, G0800570, G1001372] Funding Source: researchfish; National Institute for Health Research [RP-PG-0109-10056, NF-SI-0510-10270, NF-SI-0513-10077] Funding Source: researchfish	Philips Respironics; ResMed; ResMed Foundation; Guy's and St Thomas' Charity; Guy's and St Thomas' NHS Foundation Trust and King's College London; National Institute of Health Research Comprehensive Biomedical Research Centre; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was supported by unrestricted educational grant funding from Philips Respironics, ResMed, the ResMed Foundation, and the Guy's and St Thomas' Charity. Philips Respironics provided the Harmony 2 ventilators and the Actiwatch spectrum devices used in the study. ResMed provided the VPAP IIISTa devices used in the study. The study was supported by Guy's and St Thomas' NHS Foundation Trust and King's College London, the National Institute of Health Research Comprehensive Biomedical Research Centre, and the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, which partly funded Dr Polkey's salary.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Chu CM, 2004, THORAX, V59, P1020, DOI 10.1136/thx.2004.024307; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Costello R, 1997, AM J MED, V102, P239, DOI 10.1016/S0002-9343(97)00017-X; De Backer L, 2011, INT J CHRONIC OBSTR, V6, P615, DOI 10.2147/COPD.S22823; Djavadkhani Y, 2015, THORAX, V70, P265, DOI 10.1136/thoraxjnl-2014-206354; ELLIOTT MW, 1991, EUR RESPIR J, V4, P1044; Gates KL, 2013, AM J RESP CELL MOL, V49, P821, DOI 10.1165/rcmb.2012-0487OC; Ghosh D, 2012, EUR RESPIR J, V40, P408, DOI 10.1183/09031936.00152411; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; Jones Paul W, 2005, COPD, V2, P75; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704; McEvoy RD, 2009, THORAX, V64, P561, DOI 10.1136/thx.2008.108274; Murphy PB, 2012, INT J CHRONIC OBSTR, V7, P811, DOI 10.2147/COPD.S36151; Murray I, 2011, THORAX, V66, P825, DOI 10.1136/thx.2010.152264; National Institute for Health and Care Excellence (NICE), 2019, CHRON OBSTR PULM DIS; Nickol Annabel H, 2008, Int J Chron Obstruct Pulmon Dis, V3, P453; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Rodway GW, 2010, SLEEP, V33, P260, DOI 10.1093/sleep/33.2.260; Saatci E, 2004, EUR RESPIR J, V23, P129, DOI 10.1183/09031936.03.00039503; Schwartz SW, 2012, SLEEP, V35, P1585, DOI 10.5665/sleep.2218; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Struik FM, 2014, THORAX, V69, P826, DOI 10.1136/thoraxjnl-2014-205126; Suh ES, 2015, THORAX, V70, P1123, DOI 10.1136/thoraxjnl-2015-207188; Windisch W, 2011, BREATHE, V8, P114, DOI 10.1183/20734735.011511	32	305	322	2	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2017	317	21					2177	2186		10.1001/jama.2017.4451	http://dx.doi.org/10.1001/jama.2017.4451			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW7PG	28528348	Bronze, Green Published			2023-01-03	WOS:000402706100014
J	Zheng, H; Schnabel, A; Yahiaoui-Doktor, M; Meissner, W; Van Aken, H; Zahn, P; Pogatzki-Zahn, E				Zheng, Hua; Schnabel, Alexander; Yahiaoui-Doktor, Maryam; Meissner, Winfried; Van Aken, Hugo; Zahn, Peter; Pogatzki-Zahn, Esther			Age and preoperative pain are major confounders for sex differences in postoperative pain outcome: A prospective database analysis	PLOS ONE			English	Article							RISK-FACTORS; SURGERY; ANALGESIA; GENDER; PREDICTORS; MANAGEMENT; WOMEN; QUESTIONNAIRE; REQUIREMENTS; HYSTERECTOMY	Objectives Current literature is in disagreement regarding female sex as a risk factor for pain after surgery. We hypothesized, that sex differences exist but that they are influenced by certain factors. Here, we investigated the influence of sex for different clinically relevant postoperative pain ( POP) outcome parameters and evaluated the role of assumed confounders for sex differences. Methods From 1372 screened patients undergoing orthopedic surgery at the university hospital of Muenster between March 2010 and June 2011, 890 patients were included. The validated International Pain Outcomes questionnaire was used to assess the role of sex for several aspects of POP including pain severity, physical and emotional functional interference as well as the patient's perceptions of the care they received on the first day after surgery. Assessed confounders were age, preoperative chronic pain, anesthetic technique employed and surgical procedure. All statistical analyses were performed with SPSS Statistics Software 22. Results Linear regression analysis demonstrated that sex was a statistically significant risk factor for "worst pain since surgery". Additionally, significant sex differences in "time spent in severe pain", "feeling anxious due to pain", "feeling helpless due to pain" and "opioid consumption since surgery" could be identified. An univariate general linear model showed that "age" and "preoperative pain" were significant confounders for sex differences. Further descriptive subgroup analysis revealed consistent sex differences for several POP outcome variables especially in patients older than 50 years or patients with preoperative chronic pain. However, sex differences disappeared in younger patients and in patients without preoperative pain. Discussion Our data confirmed that sex differences exist in pain intensity and frequency, pain interference with feelings and opioid consumption during the first 24 hours postoperatively. However, sex differences were significantly influenced by the factors "age" and "preoperative pain". These findings may in part explain why clinical studies get different results related to sex differences and renders specific awareness in older women and female patients with preoperative chronic pain.	[Zheng, Hua] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China; [Zheng, Hua; Schnabel, Alexander; Van Aken, Hugo; Pogatzki-Zahn, Esther] Univ Hosp Muenster, Dept Anesthesiol Intens Care & Pain Med, Munster, Germany; [Schnabel, Alexander] Univ Hosp Wuerzburg, Dept Anesthesiol & Intens Care, Wurzburg, Germany; [Yahiaoui-Doktor, Maryam] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; [Meissner, Winfried] Jena Univ Hosp, Dept Anesthesiol & Intens Care, Jena, Germany; [Zahn, Peter] Ruhr Univ Bochum, Berufsgenossenschaftl Univ Klinikum Bergmannsheil, Dept Anesthesiol & Intens Care Med Palliat Care M, Bochum, Germany	Huazhong University of Science & Technology; University of Munster; University of Wurzburg; Leipzig University; Friedrich Schiller University of Jena; Ruhr University Bochum	Pogatzki-Zahn, E (corresponding author), Univ Hosp Muenster, Dept Anesthesiol Intens Care & Pain Med, Munster, Germany.	pogatzki@anit.uni-muenster.de	Yahiaoui-Doktor, Maryam/I-5859-2019; Zahn, Peter/AAB-9377-2021	Yahiaoui-Doktor, Maryam/0000-0002-3321-1598; Pogatzki-Zahn, Esther/0000-0003-0981-3940	FP7-g rant program [42977]	FP7-g rant program	The present study was supported by the FP7-grant program (project 42977) to EP-Z and WM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aubrun F, 2005, ANESTHESIOLOGY, V103, P156, DOI 10.1097/00000542-200507000-00023; Bartley EJ, 2015, PAIN MED, V16, P99, DOI 10.1111/pme.12591; Brandsborg B, 2007, ANESTHESIOLOGY, V106, P1003, DOI 10.1097/01.anes.0000265161.39932.e8; Cepeda MS, 2003, ANESTH ANALG, V97, P1464, DOI 10.1213/01.ANE.0000080153.36643.83; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Craft RM, 2004, EUR J PAIN, V8, P397, DOI 10.1016/j.ejpain.2004.01.003; Craft RM, 2003, CLIN J PAIN, V19, P175, DOI 10.1097/00002508-200305000-00005; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gleichgerrcht E, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00243; Gramke HF, 2009, CLIN J PAIN, V25, P455, DOI 10.1097/AJP.0b013e31819a6e34; Greenspan JD, 2007, PAIN, V132, pS26, DOI 10.1016/j.pain.2007.10.014; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Kalkman CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5; Niesters M, 2010, PAIN, V151, P61, DOI 10.1016/j.pain.2010.06.012; Ochroch EA, 2002, ANESTHESIOLOGY, V97, P1234, DOI 10.1097/00000542-200211000-00029; Perttunen K, 1999, ACTA ANAESTH SCAND, V43, P563; Peters ML, 2007, ANN SURG, V245, P487, DOI 10.1097/01.sla.0000245495.79781.65; Pinto PR, 2012, J PAIN, V13, P1045, DOI 10.1016/j.jpain.2012.07.014; Rosseland LA, 2004, PAIN, V112, P248, DOI 10.1016/j.pain.2004.08.028; Rothaug J, 2013, J PAIN, V14, P1361, DOI 10.1016/j.jpain.2013.05.016; Schnabel A, 2012, PAIN, V153, P238, DOI 10.1016/j.pain.2011.10.022; Sommer M, 2010, CLIN J PAIN, V26, P87, DOI 10.1097/AJP.0b013e3181b43d68; Tighe PJ, 2014, PAIN MED, V15, P1390, DOI 10.1111/pme.12498; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Zaslansky R, 2015, EUR J PAIN, V19, P490, DOI 10.1002/ejp.571; Zaslansky R, 2012, EUR J PAIN, V16, P430, DOI 10.1002/j.1532-2149.2011.00024.x	29	29	29	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2017	12	6							e0178659	10.1371/journal.pone.0178659	http://dx.doi.org/10.1371/journal.pone.0178659			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW9YQ	28586373	Green Published, gold, Green Submitted			2023-01-03	WOS:000402875700021
J	Glod, SA				Glod, Susan A.			The Other Victims of the Opioid Epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Glod, Susan A.] Penn State Hlth, Milton S Hershey Med Ctr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Glod, SA (corresponding author), Penn State Hlth, Milton S Hershey Med Ctr, Hershey, PA 17033 USA.							Campbell JN, 1996, PAIN FORUM, V5, P85; Compton P, 2008, PAIN MED, V9, P383, DOI 10.1111/j.1526-4637.2008.00462.x; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; von Gunten CF, 2005, J PALLIAT MED, V8, P1084, DOI 10.1089/jpm.2005.8.s-88	4	21	21	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2017	376	22					2101	2102		10.1056/NEJMp1702188	http://dx.doi.org/10.1056/NEJMp1702188			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW3JB	28564563				2023-01-03	WOS:000402390400001
J	Lindahl, JR; Fisher, NE; Cooper, DJ; Rosen, RK; Britton, WB				Lindahl, Jared R.; Fisher, Nathan E.; Cooper, David J.; Rosen, Rochelle K.; Britton, Willoughby B.			The varieties of contemplative experience: A mixed-methods study of meditation-related challenges in Western Buddhists	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; RANDOMIZED-CONTROLLED-TRIAL; COGNITIVE THERAPY; PSYCHIATRIC-DISORDERS; CLINICAL-IMPLICATIONS; INTENSIVE MEDITATION; CAUSALITY ASSESSMENT; CURRENT STATE; FOLLOW-UP; DSM-IV	Buddhist-derived meditation practices are currently being employed as a popular form of health promotion. While meditation programs draw inspiration from Buddhist textual sources for the benefits of meditation, these sources also acknowledge a wide range of other effects beyond health-related outcomes. The Varieties of Contemplative Experience study investigates meditation-related experiences that are typically underreported, particularly experiences that are described as challenging, difficult, distressing, functionally impairing, and/or requiring additional support. A mixed-methods approach featured qualitative interviews with Western Buddhist meditation practitioners and experts in Theravada, Zen, and Tibetan traditions. Interview questions probed meditation experiences and influencing factors, including interpretations and management strategies. A follow-up survey provided quantitative assessments of causality, impairment and other demographic and practice-related variables. The content-driven thematic analysis of interviews yielded a taxonomy of 59 meditation-related experiences across 7 domains: cognitive, perceptual, affective, somatic, conative, sense of self, and social. Even in cases where the phenomenology was similar across participants, interpretations of and responses to the experiences differed considerably. The associated valence ranged from very positive to very negative, and the associated level of distress and functional impairment ranged from minimal and transient to severe and enduring. In order to determine what factors may influence the valence, impact, and response to any given experience, the study also identified 26 categories of influencing factors across 4 domains: practitioner-level factors, practice-level factors, relationships, and health behaviors. By identifying a broader range of experiences associated with meditation, along with the factors that contribute to the presence and management of experiences reported as challenging, difficult, distressing or functionally impairing, this study aims to increase our understanding of the effects of contemplative practices and to provide resources for mediators, clinicians, meditation researchers, and meditation teachers.	[Lindahl, Jared R.] Brown Univ, Cogut Ctr Humanities, Providence, RI 02912 USA; [Fisher, Nathan E.] Univ Calif Santa Barbara, Dept Religious Studies, Santa Barbara, CA 93106 USA; [Cooper, David J.; Britton, Willoughby B.] Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USA; [Rosen, Rochelle K.; Britton, Willoughby B.] Brown Univ, Dept Behav & Social Sci, Sch Publ Hlth, Providence, RI 02912 USA	Brown University; University of California System; University of California Santa Barbara; Brown University; Brown University	Britton, WB (corresponding author), Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USA.; Britton, WB (corresponding author), Brown Univ, Dept Behav & Social Sci, Sch Publ Hlth, Providence, RI 02912 USA.	willoughby_britton@brown.edu	/V-3995-2019		National Center for Complementary and Integrative Health at the National Institutes of Health [K23-AT006328-01A1]; Bial Foundation [256/12]; Varela Research Award from the Mind and Life Institute; 40 Foundation; National Center for Complementary & Integrative Health [K23AT006328] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health at the National Institutes of Health; Bial Foundation(Bial Foundation); Varela Research Award from the Mind and Life Institute; 40 Foundation; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by grant number K23-AT006328-01A1 from the National Center for Complementary and Integrative Health (https://nccah.nih.gov/) at the National Institutes of Health, grant number 256/12 from the Bial Foundation (www.bial.com) (WB), the Varela Research Award from the Mind and Life Institute (ww.mindandlife.org) (NF) and the 1440 Foundation (www.1440.org) (WB, JL). The funders had no role in the study design, data collection, decision to publish or preparation of the manuscript.	Agbabiaka TB, 2008, DRUG SAFETY, V31, P21, DOI 10.2165/00002018-200831010-00003; Aitken Robert., 1982, TAKING PATH ZEN; [Anonymous], 2015, NATL HLTH STAT REPOR; APA, 1994, 300 6 DEP DIS DIAGN; APA, 2013, 300 6 DEP DER DIS DI, P302; Ataria Y, 2015, PHILOS PSYCHOL, V28, P1128, DOI 10.1080/09515089.2014.969801; Ataria Y, 2015, CONSCIOUS COGN, V37, P133, DOI 10.1016/j.concog.2015.09.002; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bent S, 2006, ANN INTERN MED, V144, P257, DOI 10.7326/0003-4819-144-4-200602210-00007; Berkovich-Ohana A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00912; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Boorstein S, 1996, TXB TRANSPERSONAL PS; Bovin M. J., 2015, PSYCHOMETRIC PROPERT; Brattstrom O, 2015, EUR J EPIDEMIOL, V30, P151, DOI 10.1007/s10654-014-9969-1; Britton WB, 2014, ANN NY ACAD SCI, V1307, P64, DOI 10.1111/nyas.12279; BROWN D, 1984, PERCEPT MOTOR SKILL, V58, P775, DOI 10.2466/pms.1984.58.3.775; Buddhaghosa B., 1991, PATH PURIFICATION; Carlson LE, 2016, PSYCHO-ONCOLOGY, V25, P750, DOI 10.1002/pon.4150; Carrington P., 1977, MISUSE MEDITATION PR; CASTILLO RJ, 1990, PSYCHIATRY, V53, P158; Census Bureau US, 2014, ED ATT US 2014 DET T; Cermolacce M, 2007, CONSCIOUS COGN, V16, P703, DOI 10.1016/j.concog.2007.05.013; Chambers R, 2009, CLIN PSYCHOL REV, V29, P560, DOI 10.1016/j.cpr.2009.06.005; Chan-Ob Tinnakorn, 1999, Journal of the Medical Association of Thailand, V82, P925; Chen Z, 2011, J SCI STUD RELIG, V50, P654, DOI 10.1111/j.1468-5906.2011.01606.x; Chiesa A, 2014, SUBST USE MISUSE, V49, P492, DOI 10.3109/10826084.2013.770027; Chiesa A, 2011, PSYCHIAT RES, V187, P441, DOI 10.1016/j.psychres.2010.08.011; Chiesa A, 2011, J ALTERN COMPLEM MED, V17, P83, DOI 10.1089/acm.2009.0546; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Corbin J., 1998, BASICS QUALITATIVE R; CRAVEN JL, 1989, CAN J PSYCHIAT, V34, P648, DOI 10.1177/070674378903400705; DeCuir-Gunby JT, 2011, FIELD METHOD, V23, P136, DOI 10.1177/1525822X10388468; DeHoff SL, 2015, PASTOR PSYCHOL, V64, P21, DOI 10.1007/s11089-013-0584-y; DEIKMAN AJ, 1966, J NERV MENT DIS, V142, P101, DOI 10.1097/00005053-196602000-00001; Dein S, 2011, TRANSCULT PSYCHIATRY, V48, P318, DOI 10.1177/1363461511402723; Disayavanish C, 1984, J PSYCHIAT ASS THAIL, V29, P1; Dobkin PL, 2012, MINDFULNESS, V3, P44, DOI 10.1007/s12671-011-0079-9; Dor-Ziderman Y, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00582; Droit-Volet S, 2015, CONSCIOUS COGN, V31, P86, DOI 10.1016/j.concog.2014.10.007; Eisendrath SJ, 2016, PSYCHOTHER PSYCHOSOM, V85, P99, DOI 10.1159/000442260; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Epstein M. D., 1981, J TRANSPERSONAL PSYC, V13, P137; Faugier J, 1997, J ADV NURS, V26, P790, DOI 10.1046/j.1365-2648.1997.00371.x; FENWICK P, 1983, BRIT MED J, V287, P1401, DOI 10.1136/bmj.287.6403.1401; Follette V., 2006, J RATION-EMOT COGN-B, V24, P45, DOI [10.1007/s10942-006-0025-2, DOI 10.1007/S10942-006-0025-2]; Fonteyn ME, 2008, APPL NURS RES, V21, P165, DOI 10.1016/j.apnr.2006.08.005; Fowler FJ, 1998, PUBLIC OPIN QUART, V62, P29; Full GE, 2013, MINDFULNESS, V4, P55, DOI 10.1007/s12671-012-0173-7; Gallagher RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028096; Gallagher Sh, 2013, OXFORD HDB SELF; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Grant JA, 2014, ANN NY ACAD SCI, V1307, P55, DOI 10.1111/nyas.12282; Grant JA, 2009, PSYCHOSOM MED, V71, P106, DOI 10.1097/PSY.0b013e31818f52ee; Greenberg MT, 2012, CHILD DEV PERSPECT, V6, P161, DOI 10.1111/j.1750-8606.2011.00215.x; Gregory PN, 2001, RELIG AM CULT, V11, P233, DOI 10.1525/rac.2001.11.2.233; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Gyatso J, 1999, J AM ACAD RELIG, V67, P113; Hakuin, 2009, HAKUINS PRECIOUS MIR; Hanley AW, 2016, J COUNS DEV, V94, P103, DOI 10.1002/jcad.12066; HEIDE FJ, 1983, J CONSULT CLIN PSYCH, V51, P171, DOI 10.1037/0022-006X.51.2.171; Hickey WakohS., 2010, J GLOBAL BUDDHISM, V11, P1; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hill AB, 2015, J ROY SOC MED, V108, P32, DOI 10.1177/0141076814562718; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Hua H, 2003, SHURANGAMA SUTRA COM, V8; Huntington CW, 2015, J AM ACAD RELIG, V83, P624, DOI 10.1093/jaarel/lfv008; Davidson R, 2012, CHILD DEV PERSPECT, V6, P146, DOI 10.1111/j.1750-8606.2012.00240.x; Jardri R., 2013, NEUROSCIENCE HALLUCI, P43, DOI DOI 10.1007/978-1-4614-4121-2; Jaseja H, 2010, EPILEPSY BEHAV, V17, P124, DOI 10.1016/j.yebeh.2009.10.022; Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438; Jonsson U, 2014, CONTEMP CLIN TRIALS, V38, P1, DOI 10.1016/j.cct.2014.02.005; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Kabat-Zinn J, 2011, CONTEMP BUDDHISM, V12, P281, DOI 10.1080/14639947.2011.564844; Kaiser-Greenland S., 2010, THE MINDFUL CHILD; Kaliman P, 2014, PSYCHONEUROENDOCRINO, V40, P96, DOI 10.1016/j.psyneuen.2013.11.004; Kerr CE, 2011, CLIN PSYCHOL PSYCHOT, V18, P80, DOI 10.1002/cpp.700; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kilpatrick DG, 2013, J TRAUMA STRESS, V26, P537, DOI 10.1002/jts.21848; Kirmayer L, 2013, ADV PSYCHOSOMATIC ME, P33; Kornfield J., 1979, J TRANSPERSONAL PSY, V11, P4158; Kornfield J., 2011, BRINGING HOME DHARMA; Kriegel U., 2015, VARIETIES CONSCIOUSN; Kuijpers HJH, 2007, PSYCHOPATHOLOGY, V40, P461, DOI 10.1159/000108125; KUTZ I, 1985, PSYCHOTHER PSYCHOSOM, V43, P209; Kuyken W., 2012, MINDFULNESS BASED CO; Kuyken W., 2016, JAMA PSYCHIAT; Kuyken W, 2015, LANCET, V386, P63, DOI 10.1016/S0140-6736(14)62222-4; Lindahl J, 2011, RELIGION, V41, P79, DOI 10.1080/0048721X.2011.553135; Lindahl JR, 2015, MINDFULNESS, V6, P57, DOI 10.1007/s12671-014-0380-5; Lindahl JR, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00973; Lindahl JR, 2012, PACIFIC WORLD J I BU, V3, P231; Lomas T., 2014, MINDFULNESS, V2014, P1; Lopez D.S., 2012, SCI BUDDHA HIS SHORT; Lopez Donald S., 2009, BUDDHISM SCI GUIDE P; Luhrmann TM, 2015, TOP COGN SCI, V7, P646, DOI 10.1111/tops.12158; LUKOFF D, 1995, PSYCHIAT CLIN N AM, V18, P467, DOI 10.1016/S0193-953X(18)30035-2; Lustyk M Kathleen B, 2009, Adv Mind Body Med, V24, P20; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; MacQueen K, 1998, CULTURAL ANTHR METHO, V10; Mani M, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4328; McFarlane Alexander, 2005, Journal of Integrative Neuroscience, V4, P27, DOI 10.1142/S0219635205000689; McMahan D., 2011, HDB RELIG AUTHORITY; McMahan David L., 2008, MAKING BUDDHIST MODE; Meiklejohn J, 2012, MINDFULNESS, V3, P291, DOI 10.1007/s12671-012-0094-5; Menezes A, 2010, CURR PSYCHIAT REP, V12, P174, DOI 10.1007/s11920-010-0117-7; MILLER JJ, 1995, GEN HOSP PSYCHIAT, V17, P192, DOI 10.1016/0163-8343(95)00025-M; MILLER JJ, 1993, J TRANSPERSONAL PSY, V25, P169; Monteiro LM, 2015, MINDFULNESS, V6, P1, DOI 10.1007/s12671-014-0301-7; Nakaya M., 2010, GER J PSYCHIAT, V13, P161; Namto S., 1989, INSIGHT MEDITATION P; Naranjo C A, 1986, Drug Inf J, V20, P387; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NARANJO CA, 1982, PROG NEURO-PSYCHOPH, V6, P651, DOI 10.1016/S0278-5846(82)80162-0; NIA, 2011, NIA ADV EV SER ADV E; NIH, 2016, ADV EV SER ADV EV GU; O'Connor S, 2010, MENT HEALTH RELIG CU, V13, P171, DOI 10.1080/13674670903277984; Office for Human Research Protections (OHRP), 2007, GUID REV REP UN PROB; Olano HA, 2015, J ALTERN COMPLEM MED, V21, P100, DOI 10.1089/acm.2014.0269; Parnas J, 2005, PSYCHOPATHOLOGY, V38, P236, DOI 10.1159/000088441; Pasick RJ, 2009, HEALTH EDUC BEHAV, V36, p11S, DOI 10.1177/1090198109338917; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Perez-De-Albeniz A., 2000, INT J PSYCHOTHER, V5, P49, DOI DOI 10.1080/13569080050020263; Robins LN, 1991, PSYCHIAT DISORDERS A; Samuelson M, 2007, PRISON J, V87, P254, DOI 10.1177/0032885507303753; Sayadaw M., 2016, MANUAL OF INSIGHT; Sayadaw M., 1965, PROGR INSIGHT MODERN; Sethi S, 2003, AUST NZ J PSYCHIAT, V37, P382; Shapiro D H Jr, 1992, Int J Psychosom, V39, P62; SHAPIRO DH, 1982, AM J PSYCHIAT, V139, P267; Shapiro SL, 2011, TEACH COLL REC, V113, P493; Sharf R., 2014, TRANSCULT PSYCHIATRY, V52, P470; SHARF RH, 1995, NUMEN, V42, P228, DOI 10.1163/1568527952598549; Sharf Robert H., 1998, CRITICAL TERMS RELIG; Shimokawa K, 2010, J CONSULT CLIN PSYCH, V78, P298, DOI 10.1037/a0019247; Shonin E., 2014, CLIN PRACTICE, V11, P389, DOI DOI 10.2217/cpr.14.23; Shonin E, 2014, INT J MENT HEALTH AD, V12, P181, DOI 10.1007/s11469-013-9460-3; Shonin E, 2014, J RELIG HEALTH, V53, P849, DOI 10.1007/s10943-013-9679-0; Shonin E, 2014, AUST NZ J PSYCHIAT, V48, P124, DOI 10.1177/0004867413512688; Sierra M, 2001, J NERV MENT DIS, V189, P629, DOI 10.1097/00005053-200109000-00010; Simeon D, 2009, DISSOCIATION DISSOCI; Sogen O., 2001, INTRO ZEN TRAINING; Stanley E. A., 2009, JOINT FORCE Q, V55, P144; Stanley EA, 2011, COGN BEHAV PRACT, V18, P566, DOI 10.1016/j.cbpra.2010.08.002; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; SUDSUANG R, 1991, PHYSIOL BEHAV, V50, P543, DOI 10.1016/0031-9384(91)90543-W; Sumter Melvina T, 2009, J Correct Health Care, V15, P47, DOI 10.1177/1078345808326621; Tashakkori A., 2010, HDB MIXED METHODS SO; Tate A., 1993, AUTOBIOGRAPHY FOREST; Taves A, 2009, RELIGIOUS EXPERIENCE RECONSIDERED: A BUILDING-BLOCK APPROACH TO THE STUDY OF RELIGION AND OTHER SPECIAL THINGS, P1; Taves A, 2008, RELIGION, V38, P125, DOI 10.1016/j.religion.2008.01.005; Teasdale JD, 2011, CONTEMP BUDDHISM, V12, P103, DOI 10.1080/14639947.2011.564826; Teddlie C, 2007, J MIX METHOD RES, V1, P77, DOI 10.1177/2345678906292430; Theophile H, 2010, DRUG SAFETY, V33, P1045, DOI 10.2165/11537780-000000000-00000; Turner C. F., 1992, SURVEY MEASUREMENT D, P177; TURNER RP, 1995, J NERV MENT DIS, V183, P435, DOI 10.1097/00005053-199507000-00003; Turner W M, 1984, Drug Inf J, V18, P259; VanderKooi L., 1997, J TRANSPERSONAL PSY, V29, P31; VANNUYS D, 1973, INT J CLIN EXP HYP, V21, P59, DOI 10.1080/00207147308409306; Waelde L. C., 2004, J TRAUMA DISSOCIATIO, V5, P147, DOI [10.1300/J229v05n02_08, DOI 10.1300/J229V05N02_08]; Wallace, 2006, ATTENTION REVOLUTION; Wallace B.A., 2011, STILLING MIND SHAMAT; Wallace BA, 2015, DUDJOM LINGPAS VISIO, V3; WALSH R, 1979, AM J PSYCHIAT, V136, P1085; Walsh R., 1977, J TRANSPERSONAL PSYC, V9, P151; Walsh RN, 1978, J TRANSPERSONAL PSY, V10, P1; Weissman JS, 2008, ANN INTERN MED, V149, P100, DOI 10.7326/0003-4819-149-2-200807150-00006; Wieczner J., 2016, FORTUNE, P1; Wildman Wesley J., 2011, RELIG SPIRITUAL EXPE; Williams JMG, 2014, J CONSULT CLIN PSYCH, V82, P275, DOI 10.1037/a0035036; Wilson J., 2014, MINDFUL AM MUTUAL TR; World Health Organization, 2016, US WHO UMC SYST STAN; Yorston G.A., 2001, MENTAL HLTH RELIG CU, V4, P209, DOI DOI 10.1080/713685624	175	177	178	6	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2017	12	5							e0176239	10.1371/journal.pone.0176239	http://dx.doi.org/10.1371/journal.pone.0176239			38	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	EV8VE	28542181	Green Submitted, Green Published, gold			2023-01-03	WOS:000402061500004
J	Schubert, C; Waletzko, O; Weiss, C; Voelzke, D; Toperim, S; Roeser, A; Puccini, S; Piroth, M; Mehrens, C; Kueter, JD; Hierholz, K; Gerull, K; Fogliata, A; Block, A; Cozzi, L				Schubert, Carolin; Waletzko, Oliver; Weiss, Christian; Voelzke, Dirk; Toperim, Sevda; Roeser, Arnd; Puccini, Silvia; Piroth, Marc; Mehrens, Christian; Kueter, Jan-Dirk; Hierholz, Kirsten; Gerull, Karsten; Fogliata, Antonella; Block, Andreas; Cozzi, Luca			Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium	PLOS ONE			English	Article							RADIATION-THERAPY; OPTIMIZATION ENGINE; AT-RISK; IMRT; QUALITY; RADIOTHERAPY	Purpose To evaluate the performance of a model-based optimisation process for volumetric modulated arc therapy applied to prostate cancer in a multicentric cooperative group. The RapidPlan (RP) knowledge-based engine was tested for the planning of Volumetric modulated arc therapy with RapidArc on prostate cancer patients. The study was conducted in the frame of the German RapidPlan Consortium (GRC). Methods and materials 43 patients from one institute of the GRC were used to build and train a RP model. This was further shared with all members of the GRC plus an external site from a different country to increase the heterogeneity of the patient's sampling. An in silico multicentric validation of the model was performed at planning level by comparing RP against reference plans optimized according to institutional procedures. A total of 60 patients from 7 institutes were used. Results On average, the automated RP based plans resulted fully consistent with the manually optimised set with a modest tendency to improvement in the medium-to-high dose region. A per-site stratification allowed to identify different patterns of performance of the model with some organs at risk resulting better spared with the manual or with the automated approach but in all cases the RP data fulfilled the clinical acceptability requirements. Discrepancies in the performance were due to different contouring protocols or to different emphasis put in the optimization of the manual cases. Conclusions The multicentric validation demonstrated that it was possible to satisfactorily optimize with the knowledge based model patients from all participating centres. In the presence of possibly significant differences in the contouring protocols, the automated plans, though acceptable and fulfilling the benchmark goals, might benefit from further fine tuning of the constraints. The study demonstrates that, at least for the case of prostate cancer patients, it is possibile to share models among different clinical institutes in a cooperative framework.	[Schubert, Carolin; Toperim, Sevda] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy, Hamburg, Germany; [Schubert, Carolin; Toperim, Sevda] Univ Med Ctr Hamburg Eppendorf, Radiat Oncol Dept, Hamburg, Germany; [Waletzko, Oliver] Dr Rohn & Kollegen Klinikum Dortmund, Radiat Oncol Dept, Dortmund, Germany; [Weiss, Christian; Hierholz, Kirsten] Klinikum Darmstadt GmbH, Radiat Oncol Dept, Darmstadt, Germany; [Voelzke, Dirk; Puccini, Silvia] Strahlentherapie Bonn Rhein Sieg, Radiat Oncol Grp Practice, Bonn, Germany; [Roeser, Arnd; Piroth, Marc] Witten Herdecke Univ, Helios Univ Klinikum, Radiat Oncol Dept, Wuppertal, Germany; [Mehrens, Christian; Block, Andreas] Klinikum Dortmund, Med Phys Dept, Dortmund, Germany; [Kueter, Jan-Dirk; Gerull, Karsten] Univ Med Ctr Schleswig Holstein, Radiat Oncol Dept, Campus Luebeck, Lubeck, Germany; [Fogliata, Antonella; Cozzi, Luca] Humanitas Clin & Res Ctr, Radiotherapy & Radiosurg Dept, Rozzano, Italy	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Klinikum Darmstadt; Klinikum Dortmund; University of Kiel; Schleswig Holstein University Hospital; IRCCS Humanitas Research Hospital	Cozzi, L (corresponding author), Humanitas Clin & Res Ctr, Radiotherapy & Radiosurg Dept, Rozzano, Italy.	luca.cozzi@humanitas.it	Puccini, Silvia/AAY-8691-2020; Block, Andreas/GLU-6047-2022; cozzi, luca/GZL-4895-2022	cozzi, luca/0000-0001-7862-898X; Fogliata, Antonella/0000-0002-2282-9894				Appenzoller LM, 2012, MED PHYS, V39, P7446, DOI 10.1118/1.4761864; Aznar MC, 2010, RADIOTHER ONCOL, V97, P480, DOI 10.1016/j.radonc.2010.09.014; Berry SL, 2016, RADIOTHER ONCOL, V120, P349, DOI 10.1016/j.radonc.2016.06.010; Boero IJ, 2016, J CLIN ONCOL, V34, P684, DOI 10.1200/JCO.2015.63.9898; Chang ATY, 2016, INT J RADIAT ONCOL, V95, P981, DOI 10.1016/j.ijrobp.2016.02.017; Chanyavanich V, 2011, MED PHYS, V38, P2515, DOI 10.1118/1.3574874; Delaney A, 2017, ACTA ONCOL; Delaney AR, 2016, INT J RADIAT ONCOL, V94, P469, DOI 10.1016/j.ijrobp.2015.11.011; Fogliata A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145137; Fogliata A, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0530-5; Fogliata A, 2014, RADIOTHER ONCOL, V113, P385, DOI 10.1016/j.radonc.2014.11.009; Fogliata A, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0236-0; Good D, 2013, INT J RADIAT ONCOL, V87, P176, DOI 10.1016/j.ijrobp.2013.03.015; Hussein M, 2016, RADIOTHER ONCOL, V120, P473, DOI 10.1016/j.radonc.2016.06.022; Li N, 2017, INT J RADIAT ONCOL, V97, P164, DOI 10.1016/j.ijrobp.2016.10.005; Moore KL, 2011, INT J RADIAT ONCOL, V81, P545, DOI 10.1016/j.ijrobp.2010.11.030; Pesce GA, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-54; Snyder K, 2016, J APPL CLIN MED PHYS, V17, P6429; Tol JP, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0542-1; Wu H, 2016, J APPL CLIN MED PHYS, V17, P6410; Wu H, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0684-9; Yuan LL, 2012, MED PHYS, V39, P6868, DOI 10.1118/1.4757927; Zhu XF, 2011, MED PHYS, V38, P719, DOI 10.1118/1.3539749	23	51	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2017	12	5							e0178034	10.1371/journal.pone.0178034	http://dx.doi.org/10.1371/journal.pone.0178034			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UA	28531226	Green Submitted, Green Published, gold			2023-01-03	WOS:000402058400052
J	Suijker, JJ; MacNeil-Vroomen, JL; van Rijn, M; Buurman, BM; de Rooij, SE; van Charente, EPM; Bosmans, JE				Suijker, Jacqueline J.; MacNeil-Vroomen, Janet L.; van Rijn, Marjon; Buurman, Bianca M.; de Rooij, Sophia E.; van Charente, Eric P. Moll; Bosmans, Judith E.			Cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people: Results of a cluster randomized trial	PLOS ONE			English	Article							COMPREHENSIVE GERIATRIC ASSESSMENT; QUALITY-OF-LIFE; FUNCTIONAL DECLINE; ECONOMIC-EVALUATION; ELDERLY-PEOPLE; HOME VISITS; INTERDISCIPLINARY INTERVENTION; MANAGEMENT INTERVENTION; INTEGRATED CARE; MISSING DATA	Objective To evaluate the cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people in comparison with usual care. Methods We conducted cost-effectiveness and cost-utility analyses alongside a cluster randomized trial with one-year follow-up. Participants were aged >= 70 years and at increased risk of functional decline. Participants in the intervention group (n = 1209) received a comprehensive geriatric assessment and individually tailored multifactorial interventions coordinated by a community-care registered nurse with multiple follow-up visits. The control group (n = 1074) received usual care. Costs were assessed from a healthcare perspective. Outcome measures included disability (modified Katz-Activities of Daily Living (ADL) index score), and quality-adjusted life-years (QALYs). Statistical uncertainty surrounding Incremental Cost-Effectiveness Ratios (ICERs) was estimated using bootstrapped bivariate regression models while adjusting for confounders. Results There were no statistically significant differences in Katz-ADL index score and QALYs between the two groups. Total mean costs were significantly higher in the intervention group (EUR 6518 (SE 472) compared with usual care (EUR 5214 (SE 338); adjusted mean difference (sic) 1457 (95% CI: 572; 2537). Cost-effectiveness acceptability curves showed that the maximum probability of the intervention being cost-effective was 0.14 at a willingness to pay (WTP) of EUR 50,000 per one point improvement on the Katz-ADL index score and 0.04 at a WTP of EUR 50,000 per QALY gained. Conclusion The current intervention was not cost-effective compared to usual care to prevent or postpone new disabilities over a one-year period. Based on these findings, implementation of the evaluated multifactorial nurse-led care model is not to be recommended.	[Suijker, Jacqueline J.; van Charente, Eric P. Moll] Acad Med Ctr, Dept Gen Practice, Amsterdam, Netherlands; [MacNeil-Vroomen, Janet L.; van Rijn, Marjon; Buurman, Bianca M.; de Rooij, Sophia E.] Acad Med Ctr, Dept Internal Med, Geriatr Med Sect, Amsterdam, Netherlands; [de Rooij, Sophia E.] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Geriatr Med, Groningen, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Suijker, JJ (corresponding author), Acad Med Ctr, Dept Gen Practice, Amsterdam, Netherlands.	b.m.vanes@amc.uva.nl	Vroomen, Janet MacNeil/M-5358-2017	Vroomen, Janet MacNeil/0000-0001-6400-7189; Bosmans, Judith/0000-0002-1443-1026	ZonMW 'The Netherlands Organization for Health Research and Development' (ZonMw) [313020201]; Dutch National Care for the Elderly Programme	ZonMW 'The Netherlands Organization for Health Research and Development' (ZonMw); Dutch National Care for the Elderly Programme	This work was supported by ZonMW 'The Netherlands Organization for Health Research and Development' (ZonMw no. 313020201) and was part of the Dutch National Care for the Elderly Programme. http://www.zonmw.nl/en/.	Beaton K, 2014, GERIATRICS GERONTOLO; Bernabei R, 1998, BMJ-BRIT MED J, V316, P1348, DOI 10.1136/bmj.316.7141.1348; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Blom J, 2016, AGE AGEING, V45, P30, DOI 10.1093/ageing/afv174; Bouman A, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-74; Boumans CAM, 2010, HANDLEIDING KOSTENON; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Centraal Bureau voor de Statistiek, 2010, PRIJS; Cesari M, 2014, J GERONTOLOGY A; Counsell SR, 2009, J AM GERIATR SOC, V57, P1420, DOI 10.1111/j.1532-5415.2009.02383.x; Department of Health, 2001, NATIONAL SERVICE FRA; Drubbel I., 2013, FRAILTY SCREENING OL; Dutch College of General Practitioners, 2011, COR VAL GEN PRACT UT; Eekhout I, 2014, J CLIN EPIDEMIOL, V67, P335, DOI 10.1016/j.jclinepi.2013.09.009; Eklund K, 2009, HEALTH SOC CARE COMM, V17, P447, DOI 10.1111/j.1365-2524.2009.00844.x; Elkan R, 2001, BMJ-BRIT MED J, V323, P719, DOI 10.1136/bmj.323.7315.719; Fairhall N, 2015, J AM MED DIR ASSOC, V16, P41, DOI 10.1016/j.jamda.2014.07.006; Fairhall N, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-120; Faria R, 2014, PHARMACOECONOMICS, V32, P1157, DOI 10.1007/s40273-014-0193-3; Fenwick E, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-52; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Groessl EJ, 2007, AM J PREV MED, V33, P214, DOI 10.1016/j.amepre.2007.04.031; Hardy SE, 2006, J GERONTOL A-BIOL, V61, P272, DOI 10.1093/gerona/61.3.272; Health Counsil of the Netherlands, 2008, HLTH CAR ELD MULT; Hebert R, 2010, J GERONTOL B-PSYCHOL, V65, P107, DOI 10.1093/geronb/gbp027; Huss A, 2008, J GERONTOL A-BIOL, V63, P298, DOI 10.1093/gerona/63.3.298; Jones R, 2004, FAM PRACT, V21, P597, DOI 10.1093/fampra/cmh603; Kehusmaa S, 2010, J REHABIL MED, V42, P949, DOI 10.2340/16501977-0623; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Latour CHM, 2007, J PSYCHOSOM RES, V62, P363, DOI 10.1016/j.jpsychores.2006.10.016; Lin Jennifer S, 2012, J Am Geriatr Soc, V60, P2157, DOI 10.1111/j.1532-5415.2012.04214.x; Looman WM, 2016, FAMILY PRACTICE; Lutomski JE, 2015, J CLIN EPIDEMIOLOGY; Markle-Reid M, 2006, MED CARE RES REV, V63, P531, DOI 10.1177/1077558706290941; Mayo-Wilson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089257; Melis RJF, 2008, J GERONTOL A-BIOL, V63, P275, DOI 10.1093/gerona/63.3.275; Metzelthin SF, 2015, AGE AGEING, V44, P390, DOI 10.1093/ageing/afu200; Rechel B., 2010, CAN HLTH SYSTEMS RES; Rechel B, 2013, LANCET, V381, P1312, DOI 10.1016/S0140-6736(12)62087-X; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Stuck AE, 2000, ARCH INTERN MED, V160, P977, DOI 10.1001/archinte.160.7.977; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; Stuck AE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001889; Suijker JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158714; Suijker JJ, 2014, J CLIN EPIDEMIOL, V67, P1121, DOI 10.1016/j.jclinepi.2014.05.014; Suijker JJ, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-85; van Dalen MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093372; van Hout HPJ, 2010, J GERONTOL A-BIOL, V65, P734, DOI 10.1093/gerona/glq037; van Leeuwen KM, 2015, J AM GERIATR SOC, V63, P2494, DOI 10.1111/jgs.13834; van Leeuwen KM, 2015, VALUE HEALTH, V18, P35, DOI 10.1016/j.jval.2014.09.006; van Rijn M, 2016, AGE AGEING, V45, P894, DOI 10.1093/ageing/afw157; WEINBERGER M, 1992, J AM GERIATR SOC, V40, P585, DOI 10.1111/j.1532-5415.1992.tb02107.x; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Williamson EJ, 2014, RESPIROLOGY, V19, P303, DOI 10.1111/resp.12238	54	7	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2017	12	4							e0175272	10.1371/journal.pone.0175272	http://dx.doi.org/10.1371/journal.pone.0175272			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES9KD	28414806	Green Submitted, Green Published, gold			2023-01-03	WOS:000399874800019
J	Abdissa, D; Geleta, G; Bacha, K; Abdissa, N				Abdissa, Dele; Geleta, Girma; Bacha, Ketema; Abdissa, Negera			Phytochemical investigation of Aloe pulcherrima roots and evaluation for its antibacterial and antiplasmodial activities	PLOS ONE			English	Article							ANTHRAQUINONES	Medicinal plants with documented traditional uses remain an important source for the treatment of a wide range of ailments. Evidence shows that majority of the Ethiopian population are still dependent on traditional medicine. Aloe pulcherrima Gilbert & Sebsebe is one of the endemic Aloe species traditionally used for the treatment of malaria and wound healing in central, Southern and Northern part of Ethiopia. The aim of the current study was, therefore, to isolate active compounds from roots of A. pulcherrima and evaluate for their antibacterial and antiplasmodial activities using standard test strains. Bioassay-guided sequential extraction and column chrom-atographic separation were employed for the isolation of bioactive pure compounds. The structures of the compounds were determined by 1D and 2D NMR spectro-scopic techniques. Disk diffusion method was employed to evaluate the antibacterial activities of the isolated compounds against four bacterial strains specifically (Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 6633, Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853). The malaria SYBR Green I-based in vitro assay technique was used for in vitro antiplasmodial activity evaluation of the compounds against chloroquine resistant (D6) and -sensitive (W2) strains of P. falciparum. Three compounds, chrysophanol, aloesaponarin I and aloesaponarin II were isolated from the acetone extracts of roots of A. pulcherrima. Evaluation of antibacterial activities revealed that aloesaponarin I and aloesaponarin II had significant activities against all the bacterial strains with inhibition zone diameters ranging from 18-27 mm as compared to the reference drug (gentamicin), which displayed inhibition zone diameter ranging between 20 mm (B. subtilis) and 25 mm (P. aeruginosa). The isolated compounds showed moderate in vitro antiplasmodial activity against both chloroquine resistant (W2) -sensitive (D6) strains. Isolation of chrysophanol, aloesaponarin I and aloesaponarin II from roots of A. pulcherrima is the first report of its kind. The finding could be used for further comprehensive evaluation of the isolated compounds for their antibacterial and antimalarial activities besides consideration of the same for potent drug development.	[Abdissa, Dele; Abdissa, Negera] Jimma Univ, Coll Nat Sci, Dept Chem, Jimma, Ethiopia; [Geleta, Girma; Bacha, Ketema] Jimma Univ, Coll Nat Sci, Dept Biol, Jimma, Ethiopia	Jimma University; Jimma University	Bacha, K (corresponding author), Jimma Univ, Coll Nat Sci, Dept Biol, Jimma, Ethiopia.	ketemabacha2002@yahoo.com	Abdissa, Negera/L-3144-2019	Abdissa, Negera/0000-0002-9899-0262; /0000-0002-6286-5689				Bacha K, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0765-9; Begashaw T, 2016, AFR J MICROBIOL RES, V10, p1961 ; Cheloti M.W., 2010, THESIS U NAIROBI NAI; Chin YW, 2006, AAPS J, V8, pE239, DOI 10.1007/BF02854894; Cui HX, 2006, WORLD J MICROB BIOT, V22, P1377, DOI 10.1007/s11274-006-9197-2; Dagne E, 2000, CURR ORG CHEM, V4, P1055, DOI 10.2174/1385272003375932; Demissew S, 2010, ALOES LILIES ETHIOPI, P113; Deressa T, 2010, ETHIOP J HEALTH DEV, V24, P25; Dewick P. M., 2002, MED NATURAL PRODUCTS, P35; Harvey A., 2001, GIT LAB J, V5, P284; Ivana BS, 2006, J INFECT DIS, V10, p400 ; Jayaweera DMA, 1982, MED PLANTS INDIGEN 4, p52 ; Juma WP, 2011, PHYTOCHEM LETT, V4, P176, DOI 10.1016/j.phytol.2011.02.010; Karunamoorthi K, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-22; Monks Terrence J, 2002, Curr Drug Metab, V3, P425, DOI 10.2174/1389200023337388; Mulat M., 2015, J PHARM SCI REV RES, V32, P45; Mwitari PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065619; Nejatzadeh-Barandozi Fatemeh, 2013, Org Med Chem Lett, V3, P5, DOI 10.1186/2191-2858-3-5; Satyajit DS, 2012, NATURAL PRODUCTS ISO, V864, P619; Schripsema J, 1996, PHYTOCHEMISTRY, V42, P177, DOI 10.1016/0031-9422(95)00885-3; Sebsebe D., 1997, FLORA ETHIOPIA ERITR, V6, P117; SMITH GF, 1995, TAXON, V44, P513, DOI 10.2307/1223496; TAKEDA N, 1973, TETRAHEDRON, V29, P3703, DOI 10.1016/S0040-4020(01)93536-7; Teka T., 2014, INT J PHYTOPHARM, V5, P261, DOI [10.3390/molecules21111415, DOI 10.3390/MOLECULES21111415]; VANWYK BE, 1995, BIOCHEM SYST ECOL, V23, P267, DOI 10.1016/0305-1978(94)00094-W; Wink Michael, 2015, Medicines (Basel), V2, P251, DOI 10.3390/medicines2030251; YAGI A, 1974, CHEM PHARM BULL, V22, P1159; Yineger H, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-11	28	29	32	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2017	12	3							e0173882	10.1371/journal.pone.0173882	http://dx.doi.org/10.1371/journal.pone.0173882			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8VS	28333961	Green Submitted, Green Published, gold			2023-01-03	WOS:000399102200026
J	Kozuki, N; Oseni, L; Mtimuni, A; Sethi, R; Rashidi, T; Kachale, F; Rawlins, B; Gupta, S				Kozuki, Naoko; Oseni, Lolade; Mtimuni, Angella; Sethi, Reena; Rashidi, Tambudzai; Kachale, Fannie; Rawlins, Barbara; Gupta, Shivam			Health facility service availability and readiness for intrapartum and immediate postpartum care in Malawi: A cross-sectional survey	PLOS ONE			English	Article							PROGRAM	This analysis seeks to identify strengths and gaps in the existing facility capacity for intrapar-tum and immediate postpartum fetal and neonatal care, using data collected as a part of Malawi's Helping Babies Breath program evaluation. From August to September 2012, the Maternal and Child Health Integrated Program (MCHIP) conducted a cross-sectional survey in 84 Malawian health facilities to capture current health facility service availability and readi-ness and health worker capacity and practice pertaining to labor, delivery, and immediate postpartum care. The survey collected data on availability of equipment, supplies, and medi-cations, and health worker knowledge and performance scores on intrapartum care simula-tion and actual management of real clients at a subset of facilities. We ran linear regression models to identify predictors of high simulation performance of routine delivery care and management of asphyxiated newborns across all facilities surveyed. Key supplies for infec-tion prevention and thermal care of the newborn were found to be missing in many of the surveyed facilities. At the health center level, 75% had no clinician trained in basic emer-gency obstetric care or newborn care and 39% had no midwife trained in the same. We observed that there were no proportional increases in available transport and staff at a facility as catchment population increased. In simulations of management of newborns with breathing problems, health workers were able to complete a median of 10 out of 16 tasks for a full-term birth case scenario and 20 out of 30 tasks for a preterm birth case scenario. Health workers who had more years of experience appeared to perform worse. Our study provides a benchmark and highlights gaps for future evaluations and studies as Malawi con-tinues to make strides in improving facility-based care. Further progress in reducing the bur-den of neonatal and fetal death in Malawi will be partly predicated on guaranteeing properly equipped and staffed facilities in addition to ensuring the presence of skilled health workers.	[Kozuki, Naoko; Gupta, Shivam] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Oseni, Lolade; Rashidi, Tambudzai] Jhpiego, Lilongwe, Malawi; [Mtimuni, Angella] USAID, Lilongwe, Malawi; [Sethi, Reena; Rawlins, Barbara] Jhpiego, Washington, DC USA; [Kachale, Fannie] Malawi Minist Hlth, Lilongwe, Malawi	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jhpiego; United States Agency for International Development (USAID); Jhpiego	Gupta, S (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	sgupta23@jhu.edu		Kozuki, Naoko/0000-0003-2850-3956	USAID through the Maternal and Child Health Integrated Program; SSDI-Services bilateral program in Malawi	USAID through the Maternal and Child Health Integrated Program(United States Agency for International Development (USAID)); SSDI-Services bilateral program in Malawi	We acknowledge support from USAID through the Maternal and Child Health Integrated Program and the SSDI-Services bilateral program in Malawi.	American Academy of Pediatrics, HELP BAB BREATH; American Academy of Pediatrics, HELP BAB BREATH FAC, V2 nd; [Anonymous], 1985, LANCET, V2, P436; [Anonymous], 2015, COUNTDOWN 2015 COUNT; [Anonymous], 2007, MAN COMPL PREGN CHIL; [Anonymous], 2010, MAL DEM HLTH SURV 20; Berg A BL, 2012, EVALUATION KANGAROO; Blencowe H, 2016, LANCET GLOBAL HLTH; Blencowe H, 2013, PEDIATR RES, V74, P17, DOI 10.1038/pr.2013.204; Brenner S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123968; Callaghan-Koru JA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1052; Demographic and Health Survey, SPA OV; Ersdal HL, 2013, RESUSCITATION, V84, P1422, DOI 10.1016/j.resuscitation.2013.04.005; Goggin K, 2016, AIDS BEHAV, V20, P2141, DOI 10.1007/s10461-016-1404-z; Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3; Lee ACC, 2013, PEDIATR RES, V74, P50, DOI 10.1038/pr.2013.206; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Malawi Ministry of Health, EV NEWB ACT PLAN ACT; McPherson RA, 2013, PROCESS DOCUMENTATIO; Sethi R, 2015, MEASUREMENT QUALITY; Thorsen VC, 2011, BMC NURS, V10, DOI 10.1186/1472-6955-10-9; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; USAID, 2015, USAID MAL HLTH COMM; van Lettow M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-426; Wendo D, 2015, SUPPORT SERVICE DELI; Zimba E, 2012, HEALTH POLICY PLANN, V27, P88, DOI 10.1093/heapol/czs043	26	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0172492	10.1371/journal.pone.0172492	http://dx.doi.org/10.1371/journal.pone.0172492			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301484	Green Published, Green Submitted, gold			2023-01-03	WOS:000396318300015
J	Rossoni, RD; Fuchs, BB; de Barros, PP; Velloso, MD; Jorge, AOC; Junqueira, JC; Mylonakis, E				Rossoni, Rodnei Dennis; Fuchs, Beth Burgwyn; de Barros, Patricia Pimentel; Velloso, Marisol dos Santos; Cardoso Jorge, Antonio Olavo; Junqueira, Juliana Campos; Mylonakis, Eleftherios			Lactobacillus paracasei modulates the immune system of Galleria mellonella and protects against Candida albicans infection	PLOS ONE			English	Article							MODEL HOST; IN-VITRO; PROBIOTIC LACTOBACILLUS; ANTIMICROBIAL PEPTIDES; VIRULENCE FACTORS; GENE-EXPRESSION; INNATE IMMUNITY; LARVAE; RESPONSES; PATHOGENESIS	Probiotics have been described as a potential strategy to control opportunistic infections due to their ability to stimulate the immune system. Using the non-vertebrate model host Galleria mellonella, we evaluated whether clinical isolates of Lactobacillus spp. are able to provide protection against Candida albicans infection. Among different strains of Lactobacillus paracasei, Lactobacillus rhamnosus and Lactobacillus fermentum, we verified that L. paracasei 28.4 strain had the greatest ability to prolong the survival of larvae infected with a lethal dose of C. albicans. We found that the injection of 10(7) cells/larvae of L. paracasei into G. mellonella larvae infected by C. albicans increased the survival of these insects compared to the control group (P = 0.0001). After that, we investigated the immune mechanisms involved in the protection against C. albicans infection, evaluating the number of hemocytes and the gene expression of antifungal peptides. We found that L. paracasei increased the hemocyte quantity (2.38 x 10(6) cells/mL) in relation to the control group (1.29 x 10(6) cells/mL), indicating that this strain is capable of raising the number of circulating hemocytes into the G. mellonella hemolymph. Further, we found that L. paracasei 28.4 upregulated genes that encode the antifungal peptides galiomicin and gallerymicin. In relation to the control group, L. paracasei 28.4 increased gene expression of galiomicin by 6.67-fold and 17.29-fold for gallerymicin. Finally, we verified that the prophylactic provision of probiotic led to a significant reduction of the number of fungal cells in G. mellonella hemolymph. In conclusion, L. paracasei 28.4 can modulate the immune system of G. mellonella and protect against candidiasis.	[Rossoni, Rodnei Dennis; de Barros, Patricia Pimentel; Velloso, Marisol dos Santos; Cardoso Jorge, Antonio Olavo; Junqueira, Juliana Campos] Univ Estadual Paulista UNESP, Dept Biosci & Oral Diag, Sao Paulo, Brazil; [Rossoni, Rodnei Dennis; Fuchs, Beth Burgwyn; Mylonakis, Eleftherios] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Div Infect Dis, Providence, RI 02912 USA	Universidade Estadual Paulista; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Junqueira, JC (corresponding author), Univ Estadual Paulista UNESP, Dept Biosci & Oral Diag, Sao Paulo, Brazil.	juliana@ict.unesp.br	De Barros, Patrícia Pimentel/B-3496-2016; Rossoni, Rodnei D/K-2390-2013; Junqueira, Juliana Campos/Q-3108-2019; Junqueira, Juliana/GQZ-4509-2022; de Barros, Patrícia Pimentel/M-8160-2019	De Barros, Patrícia Pimentel/0000-0003-4885-2811; Rossoni, Rodnei D/0000-0002-9977-3040; Junqueira, Juliana Campos/0000-0001-6646-6856; de Barros, Patrícia Pimentel/0000-0003-4885-2811	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/25181-8, 2014/12458-4, 2015/09770-9]; FAPESP [2013/25181-8, 2014/12458-4, 2015/09770-9]; Brown/Brazil Initiative at Brown University	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brown/Brazil Initiative at Brown University	This study was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (2013/25181-8, 2014/12458-4 and 2015/09770-9). RDR received a doctoral fellowship from FAPESP (2013/25181-8, 2014/12458-4). JCJ received a grant from FAPESP (2015/09770-9). Funding was also made available through a grant from the Brown/Brazil Initiative at Brown University.	Abedin-Do A, 2015, IMMUNOTHERAPY-UK, V7, P1307, DOI 10.2217/imt.15.92; Aoudia N, 2016, FOOD MICROBIOL, V53, P51, DOI 10.1016/j.fm.2015.04.009; Arvanitis M, 2013, BBA-MOL BASIS DIS, V1832, P1378, DOI 10.1016/j.bbadis.2013.03.008; Barbosa JO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150457; Bergin D, 2003, MICROBES INFECT, V5, P1389, DOI 10.1016/j.micinf.2003.09.019; Bergin D, 2006, MICROBES INFECT, V8, P2105, DOI 10.1016/j.micinf.2006.03.005; Brown SE, 2009, INSECT BIOCHEM MOLEC, V39, P792, DOI 10.1016/j.ibmb.2009.09.004; Chassot F, 2010, CONTRACEPTION, V81, P331, DOI 10.1016/j.contraception.2009.12.011; Chibebe J, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-217; Chon H, 2009, J APPL MICROBIOL, V107, P1588, DOI 10.1111/j.1365-2672.2009.04343.x; Chon H, 2010, COMP IMMUNOL MICROB, V33, pE41, DOI 10.1016/j.cimid.2009.11.002; Coronado-Castellote Laura, 2013, J Clin Exp Dent, V5, pe279, DOI 10.4317/jced.51242; Fallon JP, 2011, VIRULENCE, V2, P413, DOI 10.4161/viru.2.5.17811; Fuchs BB, 2010, VIRULENCE, V1, P475, DOI 10.4161/viru.1.6.12985; Galdeano CM, 2006, CLIN VACCINE IMMUNOL, V13, P219, DOI 10.1128/CVI.13.2.219-226.2006; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; Grounta A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161263; Guarner F, 2012, J CLIN GASTROENTEROL, V46, P468, DOI 10.1097/MCG.0b013e3182549092; Hasslof P, 2010, BMC ORAL HEALTH, V10, DOI 10.1186/1472-6831-10-18; Hofs S, 2016, J MICROBIOL, V54, P149, DOI 10.1007/s12275-016-5514-0; Jiang QR, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0759-7; Jorjao Adeline Lacerda, 2015, ScientificWorldJournal, V2015, P716749, DOI 10.1155/2015/716749; Joyce SA, 2010, MICROBIOL-SGM, V156, P3456, DOI 10.1099/mic.0.040782-0; Junqueira JC, 2012, VIRULENCE, V3, P474, DOI 10.4161/viru.22493; Kim YG, 2006, MICROBES INFECT, V8, P994, DOI 10.1016/j.micinf.2005.10.019; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowenberger C, 2001, INSECT BIOCHEM MOLEC, V31, P219, DOI 10.1016/S0965-1748(00)00141-7; Martinez-Alvarez JA, 2014, REV IBEROAM MICOL, V31, P62, DOI 10.1016/j.riam.2013.09.015; Matsubara VH, 2016, APPL MICROBIOL BIOT, V100, P6415, DOI 10.1007/s00253-016-7527-3; Mayer FL, 2013, VIRULENCE, V4, P119, DOI 10.4161/viru.22913; Morales DK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000886; Mowlds P, 2008, MYCOPATHOLOGIA, V165, P5, DOI 10.1007/s11046-007-9069-9; Mowlds P, 2010, MICROBES INFECT, V12, P146, DOI 10.1016/j.micinf.2009.11.004; Mylonakis E, 2005, INFECT IMMUN, V73, P3842, DOI 10.1128/IAI.73.7.3842-3850.2005; Oliveira VMC, 2016, J APPL MICROBIOL, V121, P1737, DOI 10.1111/jam.13289; RATCLIFFE NA, 1985, IMMUNOL LETT, V10, P253, DOI 10.1016/0165-2478(85)90100-2; Ribeiro FC, 2017, J APPL MICROBIOL, V122, P201, DOI 10.1111/jam.13324; Ryan KA, 2009, J MED MICROBIOL, V58, P996, DOI 10.1099/jmm.0.009407-0; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Soloviev DA, 2011, INFECT IMMUN, V79, P1546, DOI 10.1128/IAI.00650-10; Song YL, 2000, FEMS MICROBIOL LETT, V187, P167, DOI 10.1016/S0378-1097(00)00196-8; Vilela SFG, 2015, VIRULENCE, V6, P29, DOI 10.4161/21505594.2014.981486; Vilmos P, 1998, IMMUNOL LETT, V62, P59, DOI 10.1016/S0165-2478(98)00023-6; Wagner RD, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-58; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Zdybicka-Barabas A, 2014, ARCH INSECT BIOCHEM, V87, P1, DOI 10.1002/arch.21175	47	54	56	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2017	12	3							e0173332	10.1371/journal.pone.0173332	http://dx.doi.org/10.1371/journal.pone.0173332			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5QM	28267809	Green Submitted, Green Published, gold			2023-01-03	WOS:000396060600022
J	van de Ven, RM; Buitenweg, JIV; Schmand, B; Veltman, DJ; Aaronson, JA; Nijboer, TCW; Kruiper-Doesborgh, SJC; van Bennekom, CAM; Rasquin, SMC; Ridderinkhof, KR; Murre, JMJ				van de Ven, Renate M.; Buitenweg, Jessika I. V.; Schmand, Ben; Veltman, Dick J.; Aaronson, Justine A.; Nijboer, Tanja C. W.; Kruiper-Doesborgh, Suzanne J. C.; van Bennekom, Coen A. M.; Rasquin, Sascha M. C.; Ridderinkhof, K. Richard; Murre, Jaap M. J.			Brain training improves recovery after stroke but waiting list improves equally: A multicenter randomized controlled trial of a computer-based cognitive flexibility training	PLOS ONE			English	Article							WORKING-MEMORY; IMPAIRMENT; THERAPY; DYSFUNCTION; FREQUENCY; INJURY; ADULTS; TASK; LIFE	Background Brain training is currently widely used in an attempt to improve cognitive functioning. Computer-based training can be performed at home and could therefore be an effective add-on to available rehabilitation programs aimed at improving cognitive functioning. Several studies have reported cognitive improvements after computer training, but most lacked proper active and passive control conditions. Objective Our aim was to investigate whether computer-based cognitive flexibility training improves executive functioning after stroke. We also conducted within-group analyses similar to those used in previous studies, to assess inferences about transfer effects when comparisons to proper control groups are missing. Methods We conducted a randomized controlled, double blind trial. Adults (30 - 80 years old) who had suffered a stroke within the last 5 years were assigned to either an intervention group (n = 38), active control group (i. e., mock training; n = 35), or waiting list control group (n = 24). The intervention and mock training consisted of 58 half-hour sessions within a 12-week period. Cognitive functioning was assessed using several paper-and-pencil and computerized neuropsychological tasks before the training, immediately after training, and 4 weeks after training completion. Results and conclusions Both training groups improved on training tasks, and all groups improved on several transfer tasks (three executive functioning tasks, attention, reasoning, and psychomotor speed). Improvements remained 4 weeks after training completion. However, the amount of improvement in executive and general cognitive functioning in the intervention group was similar to that of both control groups (active control and waiting list). Therefore, this improvement was likely due to training-unspecific effects. Our results stress the importance to include both active and passive control conditions in the study design and analyses. Results from studies without proper control conditions should be interpreted with care.	[van de Ven, Renate M.; Buitenweg, Jessika I. V.; Schmand, Ben; Ridderinkhof, K. Richard; Murre, Jaap M. J.] Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands; [Schmand, Ben] Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, Amsterdam, Netherlands; [Veltman, Dick J.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands; [Aaronson, Justine A.; van Bennekom, Coen A. M.] Heliomare Rehabil Ctr, Dept Res & Dev, Wijk Aan Zee, Netherlands; [Nijboer, Tanja C. W.] Univ Med Ctr Utrecht, Ctr Excellence Rehabil Med, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Nijboer, Tanja C. W.] De Hoogstr Rehabil, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Univ Utrecht, Dept Expt Psychol, Utrecht, Netherlands; [Kruiper-Doesborgh, Suzanne J. C.] Reade, Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands; [Rasquin, Sascha M. C.] Maastricht Univ, Adelante Zorggrp, Caphri, Rehabil Med, Maastricht, Netherlands; [Ridderinkhof, K. Richard] Univ Amsterdam, ABC, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Maastricht University; Maastricht University Medical Centre (MUMC); University of Amsterdam	van de Ven, RM (corresponding author), Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands.	r.m.vandeven@uva.nl	Murre, Jaap MJ/A-3813-2010	van Bennekom, coen/0000-0002-9754-261X	Netherlands Initiative Brain and Cognition part of the Organization for Scientific Research (NWO) [056-14-013]	Netherlands Initiative Brain and Cognition part of the Organization for Scientific Research (NWO)	This project is part of the research program "Treatment of cognitive disorders based on functional brain imaging" funded by the Netherlands Initiative Brain and Cognition, a part of the Organization for Scientific Research (NWO) under grant number 056-14-013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akerlund E, 2013, BRAIN INJURY, V27, P1649, DOI 10.3109/02699052.2013.830195; Benton A.L., 1989, MULTILINGUAL APHASIA, V3rd ed.; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Buitenweg JIV, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00183; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cohen J., 2013, STAT POWER ANAL BEHA; Corbett A, 2015, J AM MED DIR ASSOC, V16, P990, DOI 10.1016/j.jamda.2015.06.014; Culbertson WC., 2005, TOWER LONDON DREXEL; De Luca R, 2014, DISABIL HEALTH J, V7, P356, DOI 10.1016/j.dhjo.2014.04.003; Delis D., 2001, DELIS KAPLAN EXECUTI; Glass BD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070350; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI [10.1080/09602019208401399, DOI 10.1080/09602019208401399]; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRUBBS FE, 1950, ANN MATH STAT, V21, P27, DOI 10.1214/aoms/1177729885; Hardy JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134467; Karbach J, 2009, DEVELOPMENTAL SCI, V12, P978, DOI 10.1111/j.1467-7687.2009.00846.x; Kurland J, 2010, APHASIOLOGY, V24, P737, DOI 10.1080/02687030903524711; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; Lesniak M, 2008, DEMENT GERIATR COGN, V26, P356, DOI 10.1159/000162262; Lever AG, 2015, J ABNORM PSYCHOL, V124, P1014, DOI 10.1037/abn0000108; Lin ZC, 2014, J INT MED RES, V42, P659, DOI 10.1177/0300060513505809; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Maaijwee NAMM, 2014, J NEUROL, V261, P1300, DOI 10.1007/s00415-014-7346-3; Mayo E., 1933, HUMAN PROBLEMS IND C; Middleton LE, 2014, NEUROREHABILITATION, V34, P305, DOI 10.3233/NRE-131030; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Raven J., 1998, MANUAL RAVENS PROGRE; Roethlisberger F.J., 1939, MANAGEMENT WORKER AC; Rogers RD, 1995, J EXPT PSYCHOL GEN, V124; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Saan R, 1986, 15 WOORDENTEST A B V; Saghaei M., 2011, J BIOMED SCI ENG, V4, P734, DOI [10.4236/jbise.2011.411090, DOI 10.4236/JBISE.2011.411090]; Slagter HA, 2012, TRENDS COGN SCI, V16, P582, DOI 10.1016/j.tics.2012.10.001; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Thrane G, 2014, J REHABIL MED, V46, P833, DOI 10.2340/16501977-1859; Thurnstone LL, 1938, PRIMARY MENTAL ABILI; van de Ven RM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00150; van de Ven RM, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0397-y; Van Vleet TM, 2015, NEUROCASE, V21, P489, DOI 10.1080/13554794.2014.928329; Wechsler D, 1999, MANUAL WECHSLER ABBR; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Zachary R., 1991, SHIPLEY I LIVING SCA	44	23	24	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0172993	10.1371/journal.pone.0172993	http://dx.doi.org/10.1371/journal.pone.0172993			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN5BR	28257436	Green Submitted, Green Published, gold			2023-01-03	WOS:000396021100048
J	Dowdy, SF				Dowdy, Steven F.			Overcoming cellular barriers for RNA therapeutics	NATURE BIOTECHNOLOGY			English	Article							DOUBLE-STRANDED-RNA; HUMAN-IMMUNODEFICIENCY-VIRUS; SOLID-PHASE SYNTHESIS; LIPID-LIKE MATERIALS; IN-VIVO; ANTISENSE OLIGONUCLEOTIDES; MAMMALIAN-CELLS; MESSENGER-RNA; EFFICIENT DELIVERY; SIRNA DELIVERY	RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.	[Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Dowdy, SF (corresponding author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	sdowdy@ucsd.edu						Abe K, 2016, CURR OPIN STRUC BIOL, V39, P71, DOI 10.1016/j.sbi.2016.06.001; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402; Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; [Anonymous], 2016, ARR PHARM FOC RES SU; Baltimore D, 2015, SCIENCE, V348, P36, DOI 10.1126/science.aab1028; Beaudet AL, 2016, HUM MOL GENET, V25, pR18, DOI 10.1093/hmg/ddv476; Blain JC, 2014, ANNU REV BIOCHEM, V83, P615, DOI 10.1146/annurev-biochem-080411-124036; Brito LA, 2015, ADV GENET, V89, P179, DOI 10.1016/bs.adgen.2014.10.005; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Byrne M, 2013, J OCUL PHARMACOL TH, V29, P855, DOI 10.1089/jop.2013.0148; Castanotto D, 2015, NUCLEIC ACIDS RES, V43, P9350, DOI 10.1093/nar/gkv964; Chang CI, 2009, MOL THER, V17, P725, DOI 10.1038/mt.2008.298; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Crooke S.T., 2017, NAT BIOTECHNOL; Cu Y, 2013, VACCINES, V1, P367, DOI 10.3390/vaccines1030367; Cuellar TL, 2015, NUCLEIC ACIDS RES, V43, P1189, DOI 10.1093/nar/gku1362; Cummings RD, 2009, ESSENTIALS GLYCOBIOL; Dirin M, 2013, EXPERT OPIN BIOL TH, V13, P875, DOI 10.1517/14712598.2013.774366; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; ECKSTEIN F, 1966, J AM CHEM SOC, V88, P4292, DOI 10.1021/ja00970a054; Eckstein F, 2014, NUCLEIC ACID THER, V24, P374, DOI 10.1089/nat.2014.0506; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fitzgerald K, 2017, NEW ENGL J MED, V376, P41, DOI 10.1056/NEJMoa1609243; Fletcher S, 2006, J GENE MED, V8, P207, DOI 10.1002/jgm.838; Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808; Gantier MP, 2007, CYTOKINE GROWTH F R, V18, P363, DOI 10.1016/j.cytogfr.2007.06.016; Hache M, 2016, J CHILD NEUROL, V31, P899, DOI 10.1177/0883073815627882; Hamil AS, 2016, METHODS MOL BIOL, V1364, P1, DOI 10.1007/978-1-4939-3112-5_1; Hou KK, 2015, BIOTECHNOL ADV, V33, P931, DOI 10.1016/j.biotechadv.2015.05.005; Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310; Ipsaro JJ, 2015, NAT STRUCT MOL BIOL, V22, P20, DOI 10.1038/nsmb.2931; Iversen F, 2013, THERANOSTICS, V3, P201, DOI 10.7150/thno.5743; Jarver P, 2014, NUCLEIC ACID THER, V24, P37, DOI 10.1089/nat.2013.0454; Jiang J, 2016, NEURON, V90, P535, DOI 10.1016/j.neuron.2016.04.006; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Juliano RL, 2014, NUCLEIC ACID THER, V24, P101, DOI 10.1089/nat.2013.0463; Juliano RL, 2016, NUCLEIC ACIDS RES, V44, P6518, DOI 10.1093/nar/gkw236; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; KOCH AL, 1985, J MOL EVOL, V21, P270, DOI 10.1007/BF02102359; Kordasiewicz HB, 2012, NEURON, V74, P1031, DOI 10.1016/j.neuron.2012.05.009; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Lagier-Tourenne C, 2013, P NATL ACAD SCI USA, V110, pE4530, DOI 10.1073/pnas.1318835110; Lanphier E, 2015, NATURE, V519, P410, DOI 10.1038/519410a; Li M, 2015, J AM CHEM SOC, V137, P14084, DOI 10.1021/jacs.5b05694; Liang XH, 2016, NUCLEIC ACIDS RES, V44, P3892, DOI 10.1093/nar/gkw144; Liang XH, 2015, NUCLEIC ACIDS RES, V43, P2927, DOI 10.1093/nar/gkv143; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Liu J, 2015, NAT PROTOC, V10, P1842, DOI 10.1038/nprot.2015.117; Lonn P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32301; Lonn P, 2015, EXPERT OPIN DRUG DEL, V12, P1627, DOI 10.1517/17425247.2015.1046431; Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106; Maeda H, 2016, MICROCIRCULATION, V23, P173, DOI 10.1111/micc.12228; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUMURA Y, 1986, CANCER RES, V46, P6387; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Moulton HM, 2010, BBA-BIOMEMBRANES, V1798, P2296, DOI 10.1016/j.bbamem.2010.02.012; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Neveu M, 2013, ASTROBIOLOGY, V13, P391, DOI 10.1089/ast.2012.0868; Ohrt T, 2012, CURR TOP MED CHEM, V12, P79, DOI 10.2174/156802612798919132; Oka N, 2008, J AM CHEM SOC, V130, P16031, DOI 10.1021/ja805780u; Osborn MF, 2015, NUCLEIC ACIDS RES, V43, P8664, DOI 10.1093/nar/gkv942; Passini MA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001777; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; Polymenidou M, 2011, NAT NEUROSCI, V14, P459, DOI 10.1038/nn.2779; Prakash TP, 2014, NUCLEIC ACIDS RES, V42, P8796, DOI 10.1093/nar/gku531; Rajeev KG, 2015, CHEMBIOCHEM, V16, P903, DOI 10.1002/cbic.201500023; Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299; Rettig GR, 2012, MOL THER, V20, P483, DOI 10.1038/mt.2011.263; Rich A., 1962, HORIZONS BIOCH, P103; Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sehgal A, 2015, NAT MED, V21, P492, DOI 10.1038/nm.3847; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Stec WJ, 1998, J AM CHEM SOC, V120, P7156, DOI 10.1021/ja973801j; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Sternberg SH, 2014, NATURE, V507, P62, DOI 10.1038/nature13011; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Sun XG, 2008, NAT BIOTECHNOL, V26, P1379, DOI 10.1038/nbt.1512; Wan WB, 2014, NUCLEIC ACIDS RES, V42, P13456, DOI 10.1093/nar/gku1115; Wang M, 2016, P NATL ACAD SCI USA, V113, P2868, DOI 10.1073/pnas.1520244113; Wang YL, 2009, NATURE, V461, P754, DOI 10.1038/nature08434; WEIDNER DA, 1995, FEBS LETT, V366, P146, DOI 10.1016/0014-5793(95)00517-D; Weiner DB, 2013, MOL THER, V21, P506, DOI 10.1038/mt.2013.26; Wittrup A, 2015, NAT BIOTECHNOL, V33, P870, DOI 10.1038/nbt.3298; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wooddell CI, 2013, MOL THER, V21, P973, DOI 10.1038/mt.2013.31; Yang B, 2015, NUCLEIC ACIDS RES, V43, P1987, DOI 10.1093/nar/gkv060; Yin H, 2016, NAT BIOTECHNOL, V34, P328, DOI 10.1038/nbt.3471; Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001; Yu DB, 2012, CELL, V150, P895, DOI 10.1016/j.cell.2012.08.002; Yu RZ, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.26; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688; Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081	107	528	549	10	474	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2017	35	3					222	229		10.1038/nbt.3802	http://dx.doi.org/10.1038/nbt.3802			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	EN3RC	28244992				2023-01-03	WOS:000395924600021
J	Liu, Q; Hu, SY; He, Y; Zhang, JS; Zeng, XN; Gong, FT; Liang, LN				Liu, Qi; Hu, Shouyu; He, Yi; Zhang, Jiashu; Zeng, Xiaona; Gong, Fengtao; Liang, Li'na			The protective effects of Zhen-Wu-Tang against cisplatin-induced acute kidney injury in rats	PLOS ONE			English	Article							FIBROSIS; PATHWAY; RISK	Acute kidney injury (AKI) is a common clinical condition that confers a risk of progression of chronic kidney disease and a high risk of death. The purpose of the current study is to investigate the anti-apoptotic and anti-fibrotic effects of Zhen-Wu-Tang (ZWT) on cisplatin (CIS)-induced renal injury and elucidate the involvement of nuclear factor (erythroid-derived 2)like 2 (Nrf2), the PI3K/Akt signaling pathway, transforming growth factor (TGF)-beta and the Wnt/beta-catenin signaling pathway in the positive effects of Zhen-Wu-Tang on the kidneys. Wistar rats were randomly assigned into six groups of 6 rats each as follows: normal control 1; normal control 2; CIS 1 and CIS 2, which received single intraperitoneal injections of CIS (6 mg/kg); CIS+ZWT 4 and CIS+ZWT 10, which received ZWT (1 ml/100 g/day, ig) starting days after the CIS injection for 4 and 10 days, respectively. Hematoxylin-eosin (H&E) staining was performed to identify the amelioration of histopathological changes in the kidneys and apoptosis of the renal proximal tubular cells. Picrosirius red staining was used to evaluate renal fibrosis after ZWT treatment. The relationship between ZWT and the upregulation of Nrf2, phosphorylation of Akt, and the downregulation of TGF-beta and WNT/beta-catenin were determined by Western blotting. At the end of the experiment, serum was isolated from the orbital blood of rats, and blood urea nitrogen (BUN) and creatinine (Cr) levels were measured. The results showed that ZWT restored the histological alterations, aberrant collagen deposition in the kidneys and the BUN and Cr levels that were increased by CIS. Treatment with ZWT reduced the expression levels of TGF-beta and Wnt and increased the expression levels of Nrf2, PI3K and Akt in the CIS-exposed kidney tissues. Furthermore, ZWT downregulated apoptosis and fibrosis by modulating the expression levels of caspase-3, Bax and alpha-smooth muscle actin (alpha-SMA). In conclusion, this study provides evidence for the anti-fibrotic and anti-apoptotic roles of ZWT in CIS-induced experimental kidney injury.	[Liu, Qi; Zhang, Jiashu; Zeng, Xiaona; Gong, Fengtao] Dalian Med Univ, Coll Pharm, Dalian, Liaoning, Peoples R China; [Hu, Shouyu] Dalian Med Univ, Affiliated Hosp 2, Dept Neurol, Dalian, Liaoning, Peoples R China; [He, Yi] Dalian Med Univ, Affiliated Hosp 2, Dept Urol, Dalian, Liaoning, Peoples R China; [Liang, Li'na] Dalian Med Univ, Coll Inst Integrat Med, Dalian, Liaoning, Peoples R China	Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University	Liang, LN (corresponding author), Dalian Med Univ, Coll Inst Integrat Med, Dalian, Liaoning, Peoples R China.	lianglina304@163.com			Youth fund of national natural science fund [81302893]	Youth fund of national natural science fund	Support was provided by the Youth fund of national natural science fund (grant number: 81302893) [Receiver: LLN]. This work is technical supported from the Collegue of pharmacy and College (Institute) of Integrative Medicine of Dalian Meduical University, Dalian, Liaoning, China.	Alfiya Akhmetshina, 2011, NATURE COMMUNICATION, V3, P735; Apoznanski W, 2013, INT UROL NEPHROL, V45, P607, DOI 10.1007/s11255-013-0454-7; Atilano-Roque A, 2016, TOXICOL REP, V3, P153, DOI 10.1016/j.toxrep.2016.01.006; Bijkerk R, 2016, KIDNEY INT; Cai Y, 2010, J ETHNOPHARMACOL, V131, P88, DOI 10.1016/j.jep.2010.06.004; Nguyen CN, 2013, PHYTOTHER RES, V27, P1810, DOI 10.1002/ptr.4931; Conroy Andrea L., 2016, OPEN FORUM INFECT DI, V3; Demeng Chen, 2012, DEVELOPMENT, V139, P1522; Dhanapriya J, 2016, CLIN KIDNEY J, V9, P201, DOI 10.1093/ckj/sfw004; Erik Johansson, 2016, EXP CELL RES; Fabre V, 2011, J INFECT DIS, V203, P707, DOI 10.1093/infdis/jiq099; Ievgeniia Burlaka, 2016, KIDNEY INT; Karsdal MA, 2016, J HEPATOL, V64, P103, DOI 10.1016/j.jhep.2015.08.014; Lee J, 2015, APOPTOSIS, V20, P740, DOI 10.1007/s10495-015-1112-6; Liu Q, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0062-3; Parr SK, 2016, ADV CHRONIC KIDNEY D, V23, P186, DOI 10.1053/j.ackd.2016.01.014; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Seo MH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166913; Shen N, 2013, KIDNEY INT, V84, P64, DOI 10.1038/ki.2013.82; Tan HL, 2016, BLOOD PURIFICAT, V41, P144, DOI 10.1159/000441269; Tilyek A, 2016, J ETHNOPHARMACOL, V178, P297, DOI 10.1016/j.jep.2015.10.003; Trujillo KA, 2011, INT J CANCER, V129, P1310, DOI 10.1002/ijc.25788; Wang B, 2014, KIDNEY INT, V85, P352, DOI 10.1038/ki.2013.372; Wu JJ, 2014, EXP CELL RES, V328, P351, DOI 10.1016/j.yexcr.2014.08.030; Wu JB, 2016, INT IMMUNOPHARMACOL, V33, P33, DOI 10.1016/j.intimp.2016.01.008; Zerr P, 2016, ANN RHEUM DIS, V75, P226, DOI 10.1136/annrheumdis-2014-205740; Zhou ZM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162873	27	21	21	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2017	12	6							e0179137	10.1371/journal.pone.0179137	http://dx.doi.org/10.1371/journal.pone.0179137			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW9YQ	28586398	Green Published, Green Submitted, gold			2023-01-03	WOS:000402875700048
J	Brown, RT; Komaiko, KD; Shi, Y; Fung, KZ; Boscardin, WJ; Au-Yeung, A; Tarasovsky, G; Jacob, R; Steinman, MA				Brown, Rebecca T.; Komaiko, Kiya D.; Shi, Ying; Fung, Kathy Z.; Boscardin, W. John; Au-Yeung, Alvin; Tarasovsky, Gary; Jacob, Riya; Steinman, Michael A.			Bringing functional status into a big data world: Validation of national Veterans Affairs functional status data	PLOS ONE			English	Article							INSTRUMENTAL ACTIVITIES; DISABILITY; PATTERNS; MORTALITY; BARRIERS; FAILURE; TRENDS; INDEX; WAVE	Background The ability to perform basic daily activities ("functional status") is key to older adults' quality of life and strongly predicts health outcomes. However, data on functional status are seldom collected during routine clinical care in a way that makes them available for clinical use and research. Objectives To validate functional status data that Veterans Affairs (VA) medical centers recently started collecting during routine clinical care, compared to the same data collected in a structured research setting. Design Prospective validation study. Setting Seven VA medical centers that collected complete data on 5 activities of daily living (ADLs) and 8 instrumental activities of daily living (IADLs) from older patients attending primary care appointments. Participants Randomly selected patients aged 75 and older who had new ADL and IADL data collected during a primary care appointment (N = 252). We oversampled patients with ADL dependence and applied these sampling weights to our analyses. Measurements Telephone-based interviews using a validated measure to assess the same 5 ADLs and 8 IADLs. Results Mean age was 83 years, 96% were male, and 75% were white. Of 85 participants whom VA data identified as dependent in 1 or more ADLs, 74 (87%) reported being dependent by interview; of 167 whom VA data identified as independent in ADLs, 149 (89%) reported being independent. The sample-weighted sensitivity of the VA data for identifying ADL dependence was 45% (95% CI, 29%, 62%) compared to the reference standard, the specificity was 99% (95% CI, 99%, >99%), and the positive predictive value was 87% (95% CI, 79%, 93%). The weighted kappa statistic was 0.55 (95% CI, 0.41, 0.68) for the agreement between VA data and research-collected data in identifying ADL dependence. Conclusion Overall agreement of VA functional status data with a reference standard was moderate, with fair sensitivity but high specificity and positive predictive value.	[Brown, Rebecca T.; Komaiko, Kiya D.; Shi, Ying; Fung, Kathy Z.; Boscardin, W. John; Au-Yeung, Alvin; Tarasovsky, Gary; Jacob, Riya; Steinman, Michael A.] San Francisco Vet Affairs VA Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA; [Brown, Rebecca T.; Komaiko, Kiya D.; Boscardin, W. John; Au-Yeung, Alvin; Jacob, Riya; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Brown, RT (corresponding author), San Francisco Vet Affairs VA Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA.; Brown, RT (corresponding author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.	rebecca.brown@ucsf.edu	PAN, ZEQIANG/X-6341-2018	Brown, Rebecca/0000-0001-7483-4137	National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute [KL2TR000143]; National Institute on Aging at the National Institutes of Health [K23AG045290, P30AG044281, K24AG049057]; John A. Hartford Foundation; Tideswell at UCSF; Veterans Affairs Health Services Research & Development Measurement Science Quality Enhancement Research Initiative [QUE 15-283]; UCSF Open Access Publishing Fund; NATIONAL INSTITUTE ON AGING [K24AG049057, P30AG044281, K23AG045290] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute; National Institute on Aging at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); John A. Hartford Foundation; Tideswell at UCSF; Veterans Affairs Health Services Research & Development Measurement Science Quality Enhancement Research Initiative; UCSF Open Access Publishing Fund; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant KL2TR000143 from the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute (RTB; https://ncats.nih.gov/), by grant K23AG045290 from the National Institute on Aging at the National Institutes of Health (RTB; https://www.nia.nih.gov/), by grant P30AG044281 from the National Institute on Aging at the National Institutes of Health (RTB, MAS; https://www.nia.nillgov/), by the John A. Hartford Foundation (RTB; http://www.johnahartford.org/), by Tideswell at UCSF (RTB; http//www.johnahartford.org/), by the Veterans Affairs Health Services Research & Development Measurement Science Quality Enhancement Research Initiative (QUE 15-283; RTB, MAS; https://www.queri.research.va.gov/), and by grant K24AG049057 from the National Institute on Aging at the National Institutes of Health (MAS; https ://www.nia.nih.govi), and the UCSF Open Access Publishing Fund (RTB; http://guides.ucsf.edu/oafund/criteria). These funding sources had no role in the preparation, review, or approval of the manuscript. Drs. Brown, Shi, and Steinman and Ms. Fung are employees of the San Francisco VA Medical Center. The opinions expressed in this manuscript may not represent those of the Department of Veterans Affairs.	Berner ES, 2005, J AM MED INFORM ASSN, V12, P3, DOI 10.1197/jamia.M1664; Bierman AS, 2001, J GEN INTERN MED, V16, P785, DOI 10.1111/j.1525-1497.2001.10918.x; Bogardus ST, 2001, J GEN INTERN MED, V16, P728, DOI 10.1046/j.1525-1497.2001.00625.x; Borzecki AM, 2004, AM J MED QUAL, V19, P201, DOI 10.1177/106286060401900504; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Centers for Medicare & Medicaid Services, 2016, QUAL MEAS; Crawford SL, 1997, J AM GERIATR SOC, V45, P338, DOI 10.1111/j.1532-5415.1997.tb00950.x; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Dunlop DD, 1997, AM J PUBLIC HEALTH, V87, P378, DOI 10.2105/AJPH.87.3.378; Fonda S, 2004, DOCUMENTATION PHYS F; Freedman VA, 2004, DEMOGRAPHY, V41, P417, DOI 10.1353/dem.2004.0022; Freedman VA, 2013, DEMOGRAPHY, V50, P661, DOI 10.1007/s13524-012-0167-z; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Hung WW, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-47; Iezzoni LI, 2003, HEALTH CARE FINANC R, V24, P61; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Jagger C, 2001, J AM GERIATR SOC, V49, P404, DOI 10.1046/j.1532-5415.2001.49083.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Murtagh KN, 2004, AM J PUBLIC HEALTH, V94, P1406, DOI 10.2105/AJPH.94.8.1406; Patterson ES, 2005, J BIOMED INFORM, V38, P189, DOI 10.1016/j.jbi.2004.11.015; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; Saczynski JS, 2012, PHARMACOEPIDEM DR S, V21, P129, DOI 10.1002/pds.2313; Saleem JJ, 2005, J AM MED INFORM ASSN, V12, P438, DOI 10.1197/jamia.M1777; Simborg DW, 2013, J AM MED INFORM ASSN, V20, pE21, DOI 10.1136/amiajnl-2012-001508; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Steinman MA, 2012, J AM GERIATR SOC, V60, P1872, DOI 10.1111/j.1532-5415.2012.04158.x; Sudore RL, 2006, J GEN INTERN MED, V21, P867, DOI 10.1111/j.1525-1497.2006.00535.x; Whitson HE, 2010, J GERONTOL A-BIOL, V65, P1325, DOI 10.1093/gerona/glq139; Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895-4356(03)00246-4	31	6	6	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2017	12	6							e0178726	10.1371/journal.pone.0178726	http://dx.doi.org/10.1371/journal.pone.0178726			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EW6HZ	28570678	Green Submitted, gold, Green Published			2023-01-03	WOS:000402611800111
J	Treweeke, A; Hall, J; Lambie, S; Leslie, SJ; Megson, IL; MacRury, SM				Treweeke, A.; Hall, J.; Lambie, S.; Leslie, S. J.; Megson, I. L.; MacRury, S. M.			Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ACUTE CORONARY SYNDROMES; OXIDATIVE STRESS; PLATELET ACTIVATION; DIALYSIS PATIENTS; N-ACETYLCYSTEINE; NEPHROPATHY; INFLAMMATION; ANTIOXIDANT; GLUTATHIONE	Background Evidence points to activation of pro-inflammatory and pro-thrombotic stimuli during the haemodialysis process in end-stage renal disease (ESRD) with potential to predispose to cardiovascular events. Diabetes is associated with a higher incidence of cardiovascular disease in haemodialysis patients. We tested the hypothesis that a range of mediators and markers that modulate cardiovascular risk are elevated in haemodialysis patients with diabetes compared to those without. Methods Men and women with diabetes (n = 6) and without diabetes (n = 6) aged 18-90 years receiving haemodialysis were recruited. Blood samples were collected and analysed pre- and post-haemodialysis sessions for (platelet-monocyte conjugates (PMC), oxidised LDL (Ox-LDL), endothelin 1 (ET-1) and vascular endothelial growth factor (VEGF-A). Results PMC levels significantly increased after haemodialysis in both groups (diabetes p = 0.047; non-diabetes p = 0.005). Baseline VEGF-A was significantly higher in people with diabetes (p = 0.009) and post-dialysis levels were significantly reduced in both groups (P = 0.002). Ox-LDL and CRP concentrations were not significantly different between groups nor affected in either group post-dialysis. Similarly, ET-1 concentrations were comparable in all patients at baseline, with no change post-dialysis in either group. Conclusions In this pilot study, we have confirmed that circulating PMCs are increased following dialysis irrespective of diabetes status. This is likely to be a mechanistic process and offers a potential explanation for high rates of vascular events associated with haemodialysis. The higher VEGF-A concentrations between patients with and without diabetes is a previously unreported finding in diabetic ESRD. Further research is merited to establish whether VEGF-A is a marker or mediator (or both) of cardiovascular risk in haemodialysis.	[Treweeke, A.; Hall, J.; Leslie, S. J.; Megson, I. L.; MacRury, S. M.] Univ Highlands & Isl, Div Hlth Res, Inverness, Scotland; [Lambie, S.; Leslie, S. J.; MacRury, S. M.] Raigmore Hosp, Dept Med, Inverness, Scotland	UHI Millennium Institute	MacRury, SM (corresponding author), Univ Highlands & Isl, Div Hlth Res, Inverness, Scotland.; MacRury, SM (corresponding author), Raigmore Hosp, Dept Med, Inverness, Scotland.	Sandra.macrury@uhi.ac.uk	Megson, Ian/K-2195-2012	Megson, Ian/0000-0001-8287-2459; MacRury, Sandra/0000-0001-7599-1302	NHS Highland R&D endowment fund	NHS Highland R&D endowment fund	The authors received funding from NHS Highland R&D endowment fund to aid this research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, US RENAL DATA SYSTEM; [Anonymous], 2010, AM J KIDNEY DIS S, V55, pS269; Aslam S, 2008, CURR OPIN NEPHROL HY, V17, P99; Avci E, 2014, RENAL FAILURE, V36, P767, DOI 10.3109/0886022X.2014.890841; Becker RC, 2005, AM HEART J, V150, P189, DOI 10.1016/j.ahj.2005.04.006; Chang JJY, 2006, SEMIN DIALYSIS, V19, P297, DOI 10.1111/j.1525-139X.2006.00176.x; Couser WG, 2011, KID INT; Davenport AP, 2016, PHARMACOL REV, V68, P357, DOI 10.1124/pr.115.011833; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; Doi K, 2010, CURR VASC PHARMACOL, V8, P122, DOI 10.2174/157016110790226606; Filiopoulos V, 2009, INT J ARTIF ORGANS, V32, P872, DOI 10.1177/039139880903201206; Foley RN, 1997, DIABETOLOGIA, V40, P1307, DOI 10.1007/s001250050825; Gibson KR, 2009, J CARDIOVASC PHARM, V54, P319, DOI 10.1097/FJC.0b013e3181b6e77b; Gutierrez-Adrianzen OA, 2014, J HUM HYPERTENS, P1; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Karalliedde J, 2011, DIABETES CARE, V34, pS291, DOI 10.2337/dc11-s241; Le Brocq M, 2008, ANTIOXID REDOX SIGN, V10, P1631, DOI 10.1089/ars.2007.2013; Lim HS, 2004, DIABETES CARE, V27, P2918, DOI 10.2337/diacare.27.12.2918; MacNeil SJ, 2016, NEPHRON S1, V132, P41; Martins PD, 2004, ARTERIOSCL THROM VAS, V24, P193, DOI 10.1161/01.ATV.0000106320.40933.E5; McCullough PA, 2008, AM J KIDNEY DIS, V51, pS38, DOI 10.1053/j.ajkd.2007.12.017; Megson Ian L, 2015, J Diabetes Sci Technol, V9, P573, DOI 10.1177/1932296815570359; Morrish NJ, 2001, DIABETOLOGIA, V44, pS14, DOI 10.1007/PL00002934; Nakagawa T, 2009, DIABETES, V58, P1471, DOI 10.2337/db09-0119; Ndip A, 2010, DIABETES CARE, V33, P1811, DOI 10.2337/dc10-0255; Nitsch D, 2007, QJM-INT J MED, V100, P551, DOI 10.1093/qjmed/hcm062; Pawlak K, 2006, THROMB RES, V117, P517, DOI 10.1016/j.thromres.2005.05.001; Pernow J, 2012, LIFE SCI, V91, P507, DOI 10.1016/j.lfs.2012.03.029; Sarma J, 2002, CIRCULATION, V105, P2166, DOI 10.1161/01.CIR.0000015700.27754.6F; Shoji T, 2005, J ATHEROSCLER THROMB, V12, P344, DOI 10.5551/jat.12.344; Sirolli V, 2006, INT J IMMUNOPATH PH, V19, P461, DOI 10.1177/039463200601900302; Treweeke AT, 2012, DIABETOLOGIA, V55, P2920, DOI 10.1007/s00125-012-2685-z; Van Dijk PC, 2005, KIDNEY INT, V67, P1489, DOI DOI 10.1111/J.1523-1755.2005.00227.X; Wang JH, 2007, INT J CARDIOL, V115, P361, DOI 10.1016/j.ijcard.2006.03.019; Yuan J, 2013, ADV MATH PHYS, V2013, P1, DOI DOI 10.1093/NDT/GFT256; Zhang SZ, 2007, CLIN CARDIOL, V30, P26, DOI 10.1002/clc.2	36	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2017	12	5							e0178171	10.1371/journal.pone.0178171	http://dx.doi.org/10.1371/journal.pone.0178171			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UE	28542479	Green Submitted, gold, Green Published			2023-01-03	WOS:000402058800044
J	Schroder, H; Henke, A; Stieger, L; Beckers, S; Biermann, H; Rossaint, R; Sopka, S				Schroeder, Hanna; Henke, Alexandra; Stieger, Lina; Beckers, Stefan; Biermann, Henning; Rossaint, Rolf; Sopka, Sasa			Influence of learning styles on the practical performance after the four-step basic life support training approach - An observational cohort study	PLOS ONE			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; EUROPEAN RESUSCITATION; CHEST COMPRESSIONS; COUNCIL GUIDELINES; MEDICAL-STUDENTS; CPR PERFORMANCE; RETENTION; SKILLS	Background Learning and training basic life support (BLS)-especially external chest compressions (ECC) within the BLS-algorithm-are essential resuscitation training for laypersons as well as for health care professionals. The objective of this study was to evaluate the influence of learning styles on the performance of BLS and to identify whether all types of learners are sufficiently addressed by Peytons four-step approach for BLS training. Methods A study group of first-year medical students (n = 334) without previous medical knowledge was categorized according to learning styles using the German Lernstilinventar questionnaire based on Kolb's Learning Styles Inventory. Students' BLS performances were assessed before and after a four-step BLS training approach lasting 4 hours. Standardized BLS training was provided by an educational staff consisting of European Resuscitation Council-certified advanced life support providers and instructors. Pre- and post-intervention BLS performance was evaluated using a single-rescuer-scenario and standardized questionnaires (6-point-Likert-scales: 1 = completely agree, 6 = completely disagree). The recorded points of measurement were the time to start, depth, and frequency of ECC. Results The study population was categorized according to learning styles: diverging (5%, n = 16), assimilating (36%, n = 121), converging (41%, n = 138), and accommodating (18%, n = 59). Independent of learning styles, both male and female participants showed significant improvement in cardiopulmonary resuscitation (CPR) performance. Based on the Kolb learning styles, no significant differences between the four groups were observed in compression depth, frequency, time to start CPR, or the checklist-based assessment within the baseline assessment. A significant sex effect on the difference between pre- and post-interventional assessment points was observed for mean compression depth and mean compression frequency. Conclusions The findings of this work show that the four-step-approach for BLS training addresses all types of learners independent of their learning styles and does not lead to significant differences in the performance of CPR.	[Schroeder, Hanna; Beckers, Stefan; Rossaint, Rolf; Sopka, Sasa] Rhein Westfal TH Aachen, Univ Hosp, Dept Anaesthesiol, Aachen, North Rhine Wes, Germany; [Schroeder, Hanna; Stieger, Lina; Beckers, Stefan; Sopka, Sasa] Rhein Westfal TH Aachen, Med Fac, Aachen Interdisciplinary Training Ctr Med Educ, Aachen, North Rhine Wes, Germany; [Henke, Alexandra] Hermann Josef Hosp, Dept Internal Med, Erkelenz, North Rhine Wes, Germany; [Biermann, Henning] Agaples Elisabethenstift, Dept Internal Med, Darmstadt, Hesse, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University	Schroder, H (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anaesthesiol, Aachen, North Rhine Wes, Germany.; Schroder, H (corresponding author), Rhein Westfal TH Aachen, Med Fac, Aachen Interdisciplinary Training Ctr Med Educ, Aachen, North Rhine Wes, Germany.	hschroeder@ukaachen.de	Sopka, Sasa/M-4990-2017; Beckers, Stefan K./O-2943-2019; Schröder, Hanna/AAE-6335-2021	Sopka, Sasa/0000-0003-2165-5578; Beckers, Stefan K./0000-0002-2896-7948; 				Abella BS, 2005, CIRCULATION, V111, P428, DOI 10.1161/01.CIR.0000153811.84257.59; Al-Kadri HMF, THESIS; Barelli A, 2010, RESUSCITATION, V81, P1607, DOI 10.1016/j.resuscitation.2010.09.010; Beckers SK, 2007, RESUSCITATION, V72, P444, DOI 10.1016/j.resuscitation.2006.08.001; Beckers SK, 2007, RESUSCITATION, V72, P100, DOI 10.1016/j.resuscitation.2006.05.020; Bullock I, 2000, RESUSCITATION, V45, P139, DOI 10.1016/S0300-9572(00)00171-4; Chamberlain D, 2002, RESUSCITATION, V53, P179, DOI 10.1016/S0300-9572(02)00025-4; Chamberlain D, 2001, RESUSCITATION, V50, P27, DOI 10.1016/S0300-9572(01)00342-2; Cliffs E., 2010, KOLB EXPERIENTIAL LE; Coffield F., 2004, SHOULD WE BE USING L; Engels PT, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-51; Epstein RM, 2007, NEW ENGL J MED, V356, P4; Fabry G, 2010, GMS Z MED AUSBILD, V29, P4, DOI [10.3205/zma00826, DOI 10.3205/zma00826]; Greif R, 2010, RESUSCITATION, V81, P1692, DOI 10.1016/j.resuscitation.2010.09.478; Haller HD, PAD SEM GOTT; Handley JA, 1998, RESUSCITATION, V36, P3, DOI 10.1016/S0300-9572(97)00095-6; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Murray C, 2011, J ALLIED HLTH, V40, P67, DOI DOI 10.3109/07380577.2012.763199; Odegaard S, 2007, RESUSCITATION, V74, P127, DOI 10.1016/j.resuscitation.2006.12.006; Orde S, 2010, RESUSCITATION, V81, P1687, DOI 10.1016/j.resuscitation.2010.05.026; Pashler Harold, 2008, Psychol Sci Public Interest, V9, P105, DOI 10.1111/j.1539-6053.2009.01038.x; Peyton JWR., 1998, TEACHING LEARNING ME; Rohrer D, 2012, MED EDUC, V46, P634, DOI 10.1111/j.1365-2923.2012.04273.x; Sarac L, 2010, RESUSCITATION, V81, P555, DOI 10.1016/j.resuscitation.2009.08.030; Schwerdtfeger K, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-104; Soar J, 2010, RESUSCITATION, V81, P1434, DOI 10.1016/j.resuscitation.2010.08.014	27	14	14	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2017	12	5							e0178210	10.1371/journal.pone.0178210	http://dx.doi.org/10.1371/journal.pone.0178210			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UA	28542636	Green Published, Green Submitted, gold			2023-01-03	WOS:000402058400070
J	Bhatnagar, M; Goel, I; Roy, T; Shukla, SD; Khurana, S				Bhatnagar, Maheep; Goel, Ishan; Roy, Tathagato; Shukla, Sunil Dutt; Khurana, Sukant			Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice	PLOS ONE			English	Article							NEURONAL DENDRITIC ARBORIZATION; GROWTH SPURT PERIOD; L-DOPA; OXIDATIVE STRESS; DISEASE; MOTOR; NEUROPROTECTION; NEUROTOXICITY; SYSTEM; ASSAY	Parkinson's disease remains as one of the most common debilitating neurodegenerative disorders. With the hopes of finding agents that can cure or reduce the pace of progression of the disease, we studied two traditional medicinal plants: Centella asiatica and Withania somnifera that have been explored in some recent studies. In agreement with the previous work on ethanol extracts of these two plants in mice model, we saw an improvement in oxidative stress profile as well as behavioral performance in 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) induced Parkinson-like symptoms in Balb/c mice. Given the known potential of both the herbal extracts in improving Parkinson-like symptoms, we expected the combination of the two to show better results than either of the two but surprisingly there was no additivity in either oxidative stress or behavioural recovery. In fact, in some assays, the combination performed worse than either of the two individual constituents. This effect of mixtures highlights the need of testing mixtures in supplements market using enthomedicine. The necessity of comparing multiple groups in this study to get most information from the experiments motivated us to design a ladder-like visualization to show comparison with different groups that we call complete comparison display (CCD). In summary, we show the potential of Centella asiatica and Withania somnifera to ameliorate Parkinson's disorder.	[Bhatnagar, Maheep; Shukla, Sunil Dutt] Mohanlal Sukhadia Univ, Dept Zool, Udaipur, Rajasthan, India; [Goel, Ishan; Khurana, Sukant] Cent Drug Res Inst, Pharmacol Dept, Lucknow, Uttar Pradesh, India; [Roy, Tathagato; Khurana, Sukant] Indian Inst Sci Educ & Res Kolkata, Dept Biol Sci, Haringhata Farm, W Bengal, India; [Shukla, Sunil Dutt] Govt Meera Girls Coll, Udaipur, Rajasthan, India	Mohanlal Sukhadia University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Indian Institute of Science Education & Research (IISER) - Kolkata	Shukla, SD (corresponding author), Mohanlal Sukhadia Univ, Dept Zool, Udaipur, Rajasthan, India.; Khurana, S (corresponding author), Cent Drug Res Inst, Pharmacol Dept, Lucknow, Uttar Pradesh, India.; Khurana, S (corresponding author), Indian Inst Sci Educ & Res Kolkata, Dept Biol Sci, Haringhata Farm, W Bengal, India.; Shukla, SD (corresponding author), Govt Meera Girls Coll, Udaipur, Rajasthan, India.	sukantkhurana@gmail.com; shuklasd@gmail.com	Shukla, Sunil Dutt/M-1182-2014; Shukla, Sunil Dutt/O-1443-2019	Shukla, Sunil Dutt/0000-0002-4467-3106; Shukla, Sunil Dutt/0000-0002-4467-3106				Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI 10.1191/0906327105ht209oa; Ahmed D, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-243; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; BARBEAU A, 1969, Canadian Medical Association Journal, V101, P59; Bastide MF, 2015, PROG NEUROBIOL, V132, P96, DOI 10.1016/j.pneurobio.2015.07.002; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Blesa J, 2012, NEUROBIOL DIS, V48, P79, DOI 10.1016/j.nbd.2012.05.018; Blesa J, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00092; Brotchie JM, 2005, J NEURAL TRANSM, V112, P359, DOI 10.1007/s00702-004-0251-7; Cheng CW, 2015, J PHOTOCH PHOTOBIO B, V148, P262, DOI 10.1016/j.jphotobiol.2015.04.028; Cheng CL, 2000, LIFE SCI, V67, P2647, DOI 10.1016/S0024-3205(00)00848-1; Cools R, 2006, NEUROSCI BIOBEHAV R, V30, P1, DOI 10.1016/j.neubiorev.2005.03.024; Datusalia AK, 2012, ACTA POL PHARM, V69, P699; Dhuley JN, 1998, J ETHNOPHARMACOL, V60, P173, DOI 10.1016/S0378-8741(97)00151-7; DONNAN GA, 1987, J NEUROL SCI, V77, P185, DOI 10.1016/0022-510X(87)90121-3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; George M, 2010, AFR J TRAD COMPL ALT, V6; Gnanapragasam A, 2004, LIFE SCI, V76, P585, DOI 10.1016/j.lfs.2004.09.009; GODWINAUSTEN RB, 1969, LANCET, V2, P165; Haleagrahara N, 2010, J TOXICOL SCI, V35, P41, DOI 10.2131/jts.35.41; Horstink M, 2006, EUR J NEUROL, V13, P1186, DOI 10.1111/j.1468-1331.2006.01548.x; HYLAND K, 1992, CLIN CHEM, V38, P2405; Inamdar PK, 1996, J CHROMATOGR A, V742, P127, DOI 10.1016/0021-9673(96)00237-3; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; Jagmag SA, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00503; James JT, 2009, MOLECULES, V14, P3922, DOI 10.3390/molecules14103922; Jana U, 2010, Nepal Med Coll J, V12, P8; Jankovic J, 2005, MOVEMENT DISORD, V20, pS11, DOI 10.1002/mds.20458; Jansen RLM, 2014, PHYTOTHER RES, V28, P1789, DOI 10.1002/ptr.5199; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jeon W.K., 2012, EVID-BASED COMPL ALT, V2012, P1; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kumar Anil, 2011, Int J Alzheimers Dis, V2011, P347569, DOI 10.4061/2011/347569; Liu XX, 2000, LIFE SCI, V66, P2277, DOI 10.1016/S0024-3205(00)00557-9; MITRA N, 1992, BRAIN RES B, V28; Mohanakumar KP, 2000, BRAIN RES, V864, P281, DOI 10.1016/S0006-8993(00)02189-2; MOHANDAS J, 1984, BIOCHEM PHARMACOL, V33, P1801, DOI 10.1016/0006-2952(84)90353-8; Muralikrishnan D, 1998, FASEB J, V12, P905, DOI 10.1096/fasebj.12.10.905; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; Panda Sunanda, 1997, Indian Journal of Physiology and Pharmacology, V41, P424; Ponnusamy K, 2008, Med J Malaysia, V63 Suppl A, P102; Prakash J, 2014, NEUROCHEM RES, V39, P2527, DOI 10.1007/s11064-014-1443-7; Prakash J, 2013, NEUROCHEM RES, V38, P972, DOI 10.1007/s11064-013-1005-4; Rao KGM, 2006, EVID-BASED COMPL ALT, V3, P349, DOI 10.1093/ecam/nel024; Rao KGM, 2009, EVID-BASED COMPL ALT, V6, P203, DOI 10.1093/ecam/nem079; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sankar SR, 2007, CELL MOL BIOL LETT, V12, P473, DOI 10.2478/s11658-007-0015-0; Shinomol GK, 2010, PHYTOTHER RES, V24, P885, DOI 10.1002/ptr.3042; Shinomol GK, 2008, NEUROTOXICOLOGY, V29, P948, DOI 10.1016/j.neuro.2008.09.009; Shukla SD, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00112; Siddique YH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/382124; SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7; Tandon Neeraj, 2012, Toxicol Int, V19, P245, DOI 10.4103/0971-6580.103658; Ul Kabir A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-31; VARASTET M, 1994, NEUROSCIENCE, V63, P47, DOI 10.1016/0306-4522(94)90006-X; WEIHMULLER FB, 1989, PHARMACOL BIOCHEM BE, V34, P113, DOI 10.1016/0091-3057(89)90362-6; WEIHMULLER FB, 1988, NEUROSCI LETT, V85, P137, DOI 10.1016/0304-3940(88)90443-0; Whishaw IQ, 2003, J NEUROSCI METH, V126, P13, DOI 10.1016/S0165-0270(03)00049-9; Wijeweeraa P, PHYTOMEDICINE; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; Wong KS, 2003, J NEUROL SCI, V216, P81, DOI 10.1016/S0022-510X(03)00217-X; Xu CL, 2013, FITOTERAPIA, V90, P112, DOI 10.1016/j.fitote.2013.07.009; Xu CL, 2012, PHARMACOL BIOCHEM BE, V100, P413, DOI 10.1016/j.pbb.2011.09.014; Zaidan M R S, 2005, Trop Biomed, V22, P165; Zheng Cheng-jian, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P348	65	11	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177254	10.1371/journal.pone.0177254	http://dx.doi.org/10.1371/journal.pone.0177254			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DC	28510600	Green Submitted, gold, Green Published			2023-01-03	WOS:000401485500018
J	Han, T; Goralski, M; Gaskill, N; Capota, E; Kim, J; Ting, TC; Xie, Y; Williams, NS; Nijhawan, D				Han, Ting; Goralski, Maria; Gaskill, Nicholas; Capota, Emanuela; Kim, Jiwoong; Ting, Tabitha C.; Xie, Yang; Williams, Noelle S.; Nijhawan, Deepak			Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15	SCIENCE			English	Article							CELL LUNG-CANCER; SODIUM LY573636 SODIUM; EVERY 3 WEEKS; PHASE-I; SOLID TUMORS; CHLOROQUINOXALINE SULFONAMIDE; UBIQUITIN LIGASE; NEDD8-ACTIVATING ENZYME; METASTATIC MELANOMA; CYCLE INHIBITOR		[Han, Ting; Williams, Noelle S.; Nijhawan, Deepak] Univ Texas Southwestern Med Ctr, Dept Biochem, Dallas, TX 75390 USA; [Goralski, Maria; Gaskill, Nicholas; Capota, Emanuela; Nijhawan, Deepak] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; [Kim, Jiwoong; Xie, Yang] Univ Texas Southwestern Med Ctr, Dept Clin Sci, Quantitat Biomed Res Ctr, Dallas, TX 75390 USA; [Kim, Jiwoong; Xie, Yang; Williams, Noelle S.; Nijhawan, Deepak] Univ Texas Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Ting, Tabitha C.] Univ Texas Southwestern Med Ctr, Med Scientist Training Program, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Nijhawan, D (corresponding author), Univ Texas Southwestern Med Ctr, Dept Biochem, Dallas, TX 75390 USA.; Nijhawan, D (corresponding author), Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.; Nijhawan, D (corresponding author), Univ Texas Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.	deepak.nijhawan@utsouthwestern.edu		Ting, Tabitha/0000-0001-5206-9243; Han, Ting/0000-0003-3168-8699; Williams, Noelle/0000-0003-1894-5742	Cancer Prevention and Research Institute of Texas [RP150596]; Harold C. Simmons Cancer Center Startup Award; Disease-Oriented Clinical Scholar award; Damon Runyon Clinical Investigator award [CI-68-13]; Welch Foundation [I-1879]	Cancer Prevention and Research Institute of Texas; Harold C. Simmons Cancer Center Startup Award; Disease-Oriented Clinical Scholar award; Damon Runyon Clinical Investigator award; Welch Foundation(The Welch Foundation)	We thank J. Ready, S. McKnight, and M. Brown for critically evaluating our manuscript. We thank S. Elledge for suggesting the use of MLN4924 as a tool compound, B. Kaelin for providing the His-tagged ubiquitin construct, and D. McFadden for providing a plasmid containing the TIR1 sequence. R. Tomaino and colleagues at the Harvard Medical School Taplin Mass Spectrometry Facility performed shotgun mass spectrometry on RBM39-bound proteins. We are grateful to J. McKnight, who provided assistance in cloning RBM39 repair templates; K. Klein for support with Sf9 cell culture; Z. Otwinowski, who confirmed the presence of RBM39 mutations through an independent analysis of whole-exome sequencing data; and U. Tambar and P. Le for synthesizing and providing indisulam. CQS (NSC 339004) was obtained from the National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program. T.H. is a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. J. K. is supported by the Cancer Prevention and Research Institute of Texas (grant RP150596). D.N. is supported by a Harold C. Simmons Cancer Center Startup Award, a Disease-Oriented Clinical Scholar award, a Damon Runyon Clinical Investigator award (CI-68-13), and a grant from the Welch Foundation (I-1879). The University of Texas Southwestern Medical Center and the authors (D.N., T.H., and N.G.) have filed a patent application (U. S. Provisional Patent Application no. 62/425,732) related to the use of tasisulam, CQS, or indisulam in cancer patients whose tumors harbor mutations in splicing factors or express DCAF15. Exome-sequencing and RNA-sequencing data from this study have been deposited at the National Center for Biotechnology Information Sequence Read Archive under accession numbers SRP068238 and SRP096666. T.H. designed the study, executed experiments, made the figures, and wrote the manuscript. M.G. performed the initial HCT-116 screen and the validation experiments. N.G. purified RBM39 complex, leading to the discovery of DCAF15 as the substrate receptor for RBM39 (Figs. 2D, 3E, and 4A). E.C. expressed and purified recombinant RBM39D150 protein. J. K. and Y.X. performed bioinformatics analyses of exome sequencing and RNA sequencing. T.C.T. expressed and purified DDB1-DCAF15 and performed gel filtration analysis of DDB1-DCAF15-RBM39 complex (fig. S9). N.S.W. performed the mouse xenograft experiment (Fig. 1H) and mass spectrometry quantification of indisulam (Fig. 4D). D.N. designed and supervised the study, performed correlation analysis of indisulam sensitivity with basal gene expression and copy number variation, and wrote the manuscript.	Abbate F, 2004, BIOORG MED CHEM LETT, V14, P217, DOI 10.1016/j.bmcl.2003.09.062; Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Bekaii-Saab TS, 2006, INVEST NEW DRUG, V24, P343, DOI 10.1007/s10637-005-4827-3; Dittrich C, 2003, CLIN CANCER RES, V9, P5195; Domanski M., 2012, BIOTECHNIQUES, DOI [10.2144/000113864, DOI 10.2144/000113864(2012).]; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fukuoka K, 2001, INVEST NEW DRUG, V19, P219, DOI 10.1023/A:1010608317361; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Haddad RI, 2004, CLIN CANCER RES, V10, P4680, DOI 10.1158/1078-0432.CCR-04-0229; Han T, 2016, NAT CHEM BIOL, V12, P511, DOI [10.1038/NCHEMBIO.2082, 10.1038/nchembio.2082]; Haritunians T, 2008, ONCOL REP, V20, P1237, DOI 10.3892/or_00000135; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Jin JP, 2005, METHOD ENZYMOL, V399, P287, DOI 10.1016/S0076-6879(05)99020-4; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kirkwood JM, 2011, CANCER-AM CANCER SOC, V117, P4732, DOI 10.1002/cncr.26068; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; LaCava J, 2015, BIOTECHNIQUES, V58, P103, DOI 10.2144/000114262; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Matyskiela ME, 2016, NATURE, V535, P252, DOI 10.1038/nature18611; Miller VA, 1997, CANCER CHEMOTH PHARM, V40, P415, DOI 10.1007/s002800050679; Natsume T, 2016, CELL REP, V15, P210, DOI 10.1016/j.celrep.2016.03.001; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Owa T, 1999, J MED CHEM, V42, P3789, DOI 10.1021/jm9902638; Ozawa Y, 2001, EUR J CANCER, V37, P2275, DOI 10.1016/S0959-8049(01)00275-1; Patel RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030619; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petzold G., 2016, NATURE, V532, P127, DOI DOI 10.1038/NATURE16979;PMID:26909574; Punt CJA, 2001, ANN ONCOL, V12, P1289, DOI 10.1023/A:1012287111922; Raymond E, 2002, J CLIN ONCOL, V20, P3508, DOI 10.1200/JCO.2002.09.030; Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/NCHEMBIO.1986, 10.1038/nchembio.1986]; RIGAS JR, 1992, CANCER RES, V52, P6619; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simon GR, 2011, CANCER CHEMOTH PHARM, V68, P1233, DOI 10.1007/s00280-011-1593-0; Smyth JF, 2005, ANN ONCOL, V16, P158, DOI 10.1093/annonc/mdi016; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Talbot DC, 2007, CLIN CANCER RES, V13, P1816, DOI 10.1158/1078-0432.CCR-06-0249; Tan X, 2007, NATURE, V446, P640, DOI 10.1038/nature05731; Terret C, 2003, EUR J CANCER, V39, P1097, DOI 10.1016/S0959-8049(03)00128-X; Toth JI, 2012, CELL REP, V1, P309, DOI 10.1016/j.celrep.2012.02.006; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Yamada Y, 2005, CANCER SCI, V96, P721, DOI 10.1111/j.1349-7006.2005.00109.x; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780	53	275	281	12	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2017	356	6336							eaal3755	10.1126/science.aal3755	http://dx.doi.org/10.1126/science.aal3755			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET2YU	28302793				2023-01-03	WOS:000400143000044
J	Maesato, K; Ohtake, T; Mochida, Y; Ishioka, K; Oka, M; Moriya, H; Hidaka, S; Kobayashi, S				Maesato, Kyoko; Ohtake, Takayasu; Mochida, Yasuhiro; Ishioka, Kunihiro; Oka, Machiko; Moriya, Hidekazu; Hidaka, Sumi; Kobayashi, Shuzo			Correlation of hippocampal atrophy with hyperhomocysteinemia in hemodialysis patients: An exploratory pilot study	PLOS ONE			English	Article							VOXEL-BASED MORPHOMETRY; SMALL-VESSEL DISEASE; CEREBRAL-BLOOD-FLOW; COGNITIVE IMPAIRMENT; HOMOCYSTEINE LEVELS; ALZHEIMERS-DISEASE; FOLIC-ACID; ATHEROSCLEROSIS; DIALYSIS; BRAIN	Background Cognitive impairment is one of the important critical issues in hemodialysis (HD) patients. However, the associating factors of brain atrophy in HD patients have not been fully elucidated. Purpose and methods Brain magnetic resonance imaging (MRI) was performed in 34 of total 72 HD outpatients in our dialysis center. These MRI images were analyzed by an application software; Voxel-based Specific Regional Analysis System for Alzheimer's Disease (VSRAD). VSRAD quantitatively calculates the extent of brain atrophy (percent of volume reduction) comparing with a MRI imaging database of 80 age-matched healthy controls. The extent of both hippocampal and whole-brain atrophy was evaluated with possible contributing factors. Results In all patients, the mean extent of hippocampal atrophy was 27.3%, and the mean extent of whole-brain atrophy was 11.2%. The extent of hippocampal atrophy was significantly correlated with low body mass index (BMI), total serum homocysteine (tHcy) levels, and brachialankle pulse wave velocity (baPWV). The extent of whole-brain atrophy showed significant correlations with age, hypoalbuminemia, and baPWV. Based on the multiple regression analysis, tHcy was an independent determinant of hippocampal atrophy (beta = 0.460, R-2 = 0.189, P<0.01); while age was an independent determinant of whole-brain atrophy (beta = 0.594, R-2 = 0.333, P<0.01). Conclusions In this exploratory pilot study, hippocampal atrophy was significantly correlated with hyperhomocysteinemia in HD patients.	[Maesato, Kyoko] Shonan Kamakura Gen Hosp, Dept Kidney Dis, Kamakura, Kanagawa, Japan; Shonan Kamakura Gen Hosp, Transplant Ctr, Kamakura, Kanagawa, Japan		Maesato, K (corresponding author), Shonan Kamakura Gen Hosp, Dept Kidney Dis, Kamakura, Kanagawa, Japan.	kyoko.maesato@tokushukai.jp						Arnadottir M, 1996, SCAND J CLIN LAB INV, V56, P41, DOI 10.3109/00365519609088586; Balla S, 2013, CURR OPIN PHARMACOL, V13, P192, DOI 10.1016/j.coph.2012.12.001; Beauchet O, 2013, J HYPERTENS, V31, P1502, DOI 10.1097/HJH.0b013e32836184b5; Cacciapuoti F, 2013, J THROMB THROMBOLYS, V36, P258, DOI 10.1007/s11239-012-0856-x; Hassan A, 2004, BRAIN, V127, P212, DOI 10.1093/brain/awh023; Hirata Y, 2005, NEUROSCI LETT, V382, P269, DOI 10.1016/j.neulet.2005.03.038; Huang RFS, 2001, LIFE SCI, V68, P2799, DOI 10.1016/S0024-3205(01)01066-9; Isshiki R, 2014, THER APHER DIAL, V18, P291, DOI 10.1111/1744-9987.12107; Jardine MJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3533; Kamata T, 2000, AM J NEPHROL, V20, P27, DOI 10.1159/000013551; Kampoli AM, 2012, CURR MED CHEM, V19, P2521, DOI 10.2174/092986712800493039; Kloppenborg RP, 2014, NEUROLOGY, V82, P777, DOI 10.1212/WNL.0000000000000168; Kobayashi S, 2014, HYPERTENS RES, V37, P636, DOI 10.1038/hr.2014.57; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Matsuda H, 2012, AM J NEURORADIOL, V33, P1109, DOI 10.3174/ajnr.A2935; Nakai S, 2012, THER APHER DIAL, V16, P11, DOI 10.1111/j.1744-9987.2011.01050.x; Post JB, 2012, AM J NEPHROL, V35, P120, DOI 10.1159/000334871; Righetti M, 2012, CURR MED CHEM, V19, P3502, DOI 10.2174/092986712801323261; RODGERS GM, 1990, BLOOD, V75, P895; Shimomura T, 2011, EUR J CLIN INVEST, V41, P751, DOI 10.1111/j.1365-2362.2010.02464.x	20	8	12	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2017	12	4							e0175102	10.1371/journal.pone.0175102	http://dx.doi.org/10.1371/journal.pone.0175102			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0LV	28394902	Green Published, gold, Green Submitted			2023-01-03	WOS:000399954800017
J	Spoelstra-de Man, AME; Smorenberg, A; Groeneveld, ABJ				Spoelstra-de Man, Angelique M. E.; Smorenberg, Annemieke; Groeneveld, A. B. Johan			Different effects of fluid loading with saline, gelatine, hydroxyethyl starch or albumin solutions on acid-base status in the critically ill	PLOS ONE			English	Article							LACTATED RINGERS SOLUTION; ABDOMINAL AORTIC-ANEURYSM; MAJOR VASCULAR-SURGERY; DOUBLE-BLIND CROSSOVER; 0.9-PERCENT SALINE; HEALTHY-VOLUNTEERS; PULMONARY PERMEABILITY; CARDIAC RESPONSE; RESPONSIVENESS; INFUSIONS	Introduction Fluid administration in critically ill patients may affect acid-base balance. However, the effect of the fluid type used for resuscitation on acid-base balance remains controversial. Methods We studied the effect of fluid resuscitation of normal saline and the colloids gelatine 4%, hydroxyethyl starch (HES) 6%, and albumin 5% on acid-base balance in 115 clinically hypovolemic critically ill patients during a 90 minute filling pressure-guided fluid challenge by a post-hoc analysis of a prospective randomized clinical trial. Results About 1700 mL was infused per patient in the saline and 1500 mL in each of the colloid groups (P<0.001). Overall, fluid loading slightly decreased pH (P<0.001) and there was no intergroup difference. This mildly metabolic acidifying effect was caused by a small increase in chloride concentration and decrease in strong ion difference in the saline- and HES-, and an increase in (uncorrected) anion gap in gelatine- and albumin-loaded patients, independent of lactate concentrations. Conclusion In clinically hypovolemic, critically ill patients, fluid resuscitation by only 1500-1700 mL of normal saline, gelatine, HES or albumin, resulted in a small decrease in pH, irrespective of the type of fluid used. Therefore, a progressive metabolic acidosis, even with increased anion gap, should not be erroneously attributed to insufficient fluid resuscitation.	[Spoelstra-de Man, Angelique M. E.] Vrije Univ Amsterdam, Med Ctr, Dept Intens Care, Amsterdam, Netherlands; [Smorenberg, Annemieke] Ziekenhuis Amstelland, Dept Internal Med, Amstelland, Netherlands; [Groeneveld, A. B. Johan] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Smorenberg, A (corresponding author), Ziekenhuis Amstelland, Dept Internal Med, Amstelland, Netherlands.	a.smorenberg@vumc.nl		de Man, Angelique/0000-0001-8738-8295	B. Braun Medical Melsungen, Germany	B. Braun Medical Melsungen, Germany	This study has been supported by an unrestricted grant of B. Braun Medical Melsungen, Germany. The funder was not involved in the study design, data collection, analysis, writing, or submission of the manuscript.	Bellomo R, 2006, CRIT CARE MED, V34, P2891, DOI 10.1097/01.CCM.0000242159.32764.86; Bruegger D, 2005, CRIT CARE MED, V33, P556, DOI 10.1097/01.ccm.0000155986.01926.95; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Gattinoni L, 2013, CRIT CARE, V17, DOI 10.1186/cc11502; Groeneveld ABJ, 2011, ANN SURG, V253, P470, DOI 10.1097/SLA.0b013e318202ff00; Johansen L., 1997, INTEGRATIVE COMP PHY, V272, P549; Kraut JA, 2007, CLIN J AM SOC NEPHRO, V2, P162, DOI 10.2215/CJN.03020906; Kuiper AN, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-189; Liskaser F, 1999, CURR OPIN CRIT CARE, V5, P440; Lobo DN, 2010, CRIT CARE MED, V38, P464, DOI 10.1097/CCM.0b013e3181bc80f1; Lobo DN, 2001, CLIN SCI, V101, P173, DOI 10.1042/CS20000316; Mallat J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056635; MCFARLANE C, 1994, ANAESTHESIA, V49, P779; Morgan TJ, 2009, ANAESTH INTENS CARE, V37, P407, DOI 10.1177/0310057X0903700304; Morgan TJ, 2005, CRIT CARE, V9, P204, DOI 10.1186/cc2946; Nagaoka D, 2010, J CRIT CARE, V25, P525, DOI 10.1016/j.jcrc.2010.02.003; Rehm M, 2000, ANESTHESIOLOGY, V93, P1174, DOI 10.1097/00000542-200011000-00007; Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007; Story D A, 1999, Crit Care Resusc, V1, P156; Takil A, 2002, ANESTH ANALG, V95, P294, DOI 10.1213/01.ANE.0000020188.49502.39; Trof RJ, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-12; Trof RJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10062; Trof RJ, 2010, INTENS CARE MED, V36, P697, DOI 10.1007/s00134-010-1776-x; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Verheij J, 2006, BRIT J ANAESTH, V96, P21, DOI 10.1093/bja/aei286; Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5; Volta CA, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-29; Waters JH, 2000, ANESTHESIOLOGY, V93, P1184, DOI 10.1097/00000542-200011000-00008; Waters JH, 2001, ANESTH ANALG, V93, P817, DOI 10.1097/00000539-200110000-00004; Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003; Williams EL, 1999, ANESTH ANALG, V88, P999, DOI 10.1097/00000539-199905000-00006	31	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0174507	10.1371/journal.pone.0174507	http://dx.doi.org/10.1371/journal.pone.0174507			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28380062	Green Published, gold, Green Submitted			2023-01-03	WOS:000399353500050
J	Wubante, AA				Wubante, Amarech Asratie			Determinants of infant nutritional status in Dabat district, North Gondar, Ethiopia: A case control study	PLOS ONE			English	Article								Background Malnutrition is the top cause of global burden of disease, disability and mortality among infants. Over two-thirds of deaths of children globally occur during the first year of life (infancy). Malnutrition among infants is substantially high in Ethiopia. Therefore, this study is aimed to assess determinants of infant nutritional status. Methods A community based nested case-control study was conducted from February to June 2013 in Dabat district. A total of 80 cases and 320 controls (1: 4 ratios) were studied. Relevant data was extracted from the community based survey data set. Anthroplus software was used to identify cases and controls. Determinants of infant nutritional status were identified using multivariate analysis. Results Among the total of 80 cases and 320 controls, more than half (52.5%) of the cases and the controls (53.8%) were males and females, respectively. Breast Feeding (BF) was started immediately after birth in only 43.8% of the cases. Nearly 94% of the mothers of the cases had no breast feeding information as part of Ante Natal Care (ANC) follow up. Maternal age (AOR: 0.29; 95% CI: 0.11-0.76), having radio (AOR: 0.43; 95% CI: 0.22-0.82), lack of toilet facility (AOR: 2.24; 95% CI: 1.16-4.33), deprivation of colostrum (AOR: 1.76; 95% CI: 1.01-1.06) and method of complementary feeding (AOR: 2.82; 95% CI: 1.33-5.99) were associated with wasting. Conclusions This study has found that inappropriate infant feeding; nutritional information gap and lack of toilet facility as significant predictors of malnutrition. Hence, joint interventions, including counseling of mothers about benefits of colostrum feeding and use of appropriate feeding method, toilet utilization and mass media such as radio possession, are needed to address the problem in Dabat district.	[Wubante, Amarech Asratie] West Gojjam Zonal Hlth Dept, Finoteselam, Ethiopia		Wubante, AA (corresponding author), West Gojjam Zonal Hlth Dept, Finoteselam, Ethiopia.	asratama19@yahoo.com						[Anonymous], 2012, ETH DEM HLTH SURV 20; Assis AMO, 2005, EUR J CLIN NUTR, V59, P1317, DOI 10.1038/sj.ejcn.1602245; Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Central Statistical Agency, 2007, POP HOUS CENS ETH 20; Chicci AHM, 1998, J NUTR EDUC, V14, P99; Emond A, 2007, ARCH DIS CHILD, V92, P115, DOI 10.1136/adc.2005.091496; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, ETH HLTH SECT DEV PR; Frost MB, 2005, SOC SCI MED, V60, P395, DOI 10.1016/j.socscimed.2004.05.010; Galler JR, 2012, J NUTR, V142, P788, DOI 10.3945/jn.111.145441; Kumar Dinesh, 2006, Indian Journal of Pediatrics, V73, P417, DOI 10.1007/BF02758565; Panigrahi A, 2014, SCI WORLD J; Priyatama P., 2015, JIPBS, V2, P252; Sachdeva Sandeep, 2010, Indian J Community Med, V35, P353, DOI 10.4103/0970-0218.66889; Servili C, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-693; Shiratori S, 2011, MEDIA IMPACT NUTR IN; Solomon Amsalu, 2008, Ethiopian Journal of Health Development, V22, P21; Teshome B, 2009, ETHIOP J HEALTH DEV, V23, P98; UNICEF WHO World Bank, 2013, JOINT CHILD MALN EST; WHO-WORLD HEALTH ORGANIZATION, 2009, INF YOUNG CHILD FEED; World Health Organization, POOR SAN THREAT PUBL; World Health Organization, 2006, WHO CHILD GROWTH STA	22	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2017	12	3							e0174624	10.1371/journal.pone.0174624	http://dx.doi.org/10.1371/journal.pone.0174624			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VD	28346497	Green Published, Green Submitted, gold			2023-01-03	WOS:000399174300063
J	El Dib, R; Gomaa, H; Ortiz, A; Politei, J; Kapoor, A; Barreto, F				El Dib, Regina; Gomaa, Huda; Ortiz, Alberto; Politei, Juan; Kapoor, Anil; Barreto, Fellype			Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies	PLOS ONE			English	Article							AGALSIDASE BETA TREATMENT; NATURAL-HISTORY DATA; QUALITY-OF-LIFE; ALPHA-GALACTOSIDASE; OPEN-LABEL; GASTROINTESTINAL SYMPTOMS; CLINICAL-MANIFESTATIONS; PEDIATRIC-PATIENTS; EARLY INITIATION; RENAL-FUNCTION	Background Anderson-Fabry disease (AFD) is an X-linked recessive inborn error of glycosphingolipid metabolism caused by a deficiency of alpha-galactosidase A. Renal failure, heart and cerebrovascular involvement reduce survival. A Cochrane review provided little evidence on the use of enzyme replacement therapy (ERT). We now complement this review through a linear regression and a pooled analysis of proportions from cohort studies. Objectives To evaluate the efficacy and safety of ERT for AFD. Materials and methods For the systematic review, a literature search was performed, from inception to March 2016, using Medline, EMBASE and LILACS. Inclusion criteria were cohort studies, patients with AFD on ERT or natural history, and at least one patient-important outcome (all-cause mortality, renal, cardiovascular or cerebrovascular events, and adverse events) reported. The pooled proportion and the confidence interval (CI) are shown for each outcome. Simple linear regressions for composite endpoints were performed. Results 77 cohort studies involving 15,305 participants proved eligible. The pooled proportions were as follows: a) for renal complications, agalsidase alfa 15.3% [95% CI 0.048, 0.303; I-2 = 77.2%, p = 0.0005]; agalsidase beta 6% [95% CI 0.04, 0.07; I-2 = not applicable]; and untreated patients 21.4% [95% CI 0.1522, 0.2835; I-2 = 89.6%, p<0.0001]. Effect differences favored agalsidase beta compared to untreated patients; b) for cardiovascular complications, agalsidase alfa 28% [95% CI 0.07, 0.55; I-2 = 96.7%, p<0.0001]; agalsidase beta 7% [95% CI 0.05, 0.08; I-2 = not applicable]; and untreated patients 26.2% [95% CI 0.149, 0.394; I-2 = 98.8%, p<0.0001]. Effect differences favored agalsidase beta compared to untreated patients; and c) for cerebrovascular complications, agalsidase alfa 11.1% [95% CI 0.058, 0.179; I-2 = 70.5%, p = 0.0024]; agalsidase beta 3.5% [95% CI 0.024, 0.046; I-2 = 0%, p = 0.4209]; and untreated patients 18.3% [95% CI 0.129, 0.245; I-2 = 95% p<0.0001]. Effect differences favored agalsidase beta over agalsidase alfa or untreated patients. A linear regression showed that Fabry patients receiving agalsidase alfa are more likely to have higher rates of composite endpoints compared to those receiving agalsidase beta. Conclusions Agalsidase beta is associated to a significantly lower incidence of renal, cardiovascular and cerebrovascular events than no ERT, and to a significantly lower incidence of cerebrovascular events than agalsidase alfa. In view of these results, the use of agalsidase beta for preventing major organ complications related to AFD can be recommended.	[El Dib, Regina] Unesp Univ Estadual Paulista, Inst Sci & Technol, Sao Jose Dos Campos, Brazil; [El Dib, Regina; Kapoor, Anil] McMaster Univ, McMaster Inst Urol, Hamilton, ON, Canada; [Gomaa, Huda] Tanta Chest Hosp, Dept Pharm, Tanta, Egypt; [Ortiz, Alberto] Univ Autonoma Madrid, IIS Fdn Jimenez Diaz, Madrid, Spain; [Politei, Juan] Dr Nestor Chamoles Lab Neurochem, Neurol Serv, Buenos Aires, DF, Argentina; [Barreto, Fellype] Univ Fed Parana, Serv Nephrol, Dept Internal Med, Curitiba, Parana, Brazil	Universidade Estadual Paulista; McMaster University; Egyptian Knowledge Bank (EKB); Tanta University; Autonomous University of Madrid; Fundacion Jimenez Diaz; Universidade Federal do Parana	El Dib, R (corresponding author), Unesp Univ Estadual Paulista, Inst Sci & Technol, Sao Jose Dos Campos, Brazil.; El Dib, R (corresponding author), McMaster Univ, McMaster Inst Urol, Hamilton, ON, Canada.	eldib@ict.unesp.br	Dib, Regina El/ABC-8178-2020; ortiz, alberto/Y-7582-2018; Barreto, Fellype C/C-6517-2012; Kapoor, Anil/AAQ-7184-2021	Dib, Regina El/0000-0002-4081-803X; ortiz, alberto/0000-0002-9805-9523; Barreto, Fellype C/0000-0002-6394-9227; Kapoor, Anil/0000-0001-9180-8029; Gomaa, Huda/0000-0002-6500-1106	Spanish Government; FEDER funds Intensificacion and RETIC REDINREN [RD016/0021]; Brazilian Research Council (CNPq) [310953/2015-4]	Spanish Government(Spanish GovernmentEuropean Commission); FEDER funds Intensificacion and RETIC REDINREN; Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Alberto Ortiz has been funded by Spanish Government and FEDER funds Intensificacion and RETIC REDINREN RD016/0021. Regina El Dib received a Brazilian Research Council (CNPq) scholarship (#310953/2015-4). The funding agencies played no role in the conduct of the research or preparation of the manuscript.	Aerts JM, 2008, P NATL ACAD SCI USA, V105, P2812, DOI 10.1073/pnas.0712309105; Alderson P, 2003, BRIT MED J, V326, P475, DOI 10.1136/bmj.326.7387.475; Anderson LJ, 2014, J INHERIT METAB DIS, V37, P969, DOI 10.1007/s10545-014-9717-4; Arash-Kaps L, 2014, C PUBLICATION VAR S1, V37, pS145; Baehner F, 2003, J INHERIT METAB DIS, V26, P617, DOI 10.1023/B:BOLI.0000005658.14563.77; Banikazemi M, 2007, ANN INTERN MED, V146, P77, DOI 10.7326/0003-4819-146-2-200701160-00148; Barba-Romero MA, 2011, INT J CLIN PRACT, V65, P903, DOI 10.1111/j.1742-1241.2011.02695.x; Beer M, 2006, AM J CARDIOL, V97, P1515, DOI 10.1016/j.amjcard.2005.11.087; Borgwardt L, 2013, CLIN GENET, V83, P432, DOI 10.1111/j.1399-0004.2012.01947.x; Branton MH, 2002, MEDICINE, V81, P122, DOI 10.1097/00005792-200203000-00003; Choi JH, 2008, J KOREAN MED SCI, V23, P243, DOI 10.3346/jkms.2008.23.2.243; Collin C, 2012, EUR J PREV CARDIOL, V19, P43, DOI 10.1177/1741826710391118; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Crutchfield KE, 1998, NEUROLOGY, V50, P1746, DOI 10.1212/WNL.50.6.1746; Cybulla M, 2013, NEPHROL DIAL TRANSPL, V28, P287; Dehout F, 2004, J INHERIT METAB DIS, V27, P499, DOI 10.1023/B:BOLI.0000037342.59612.69; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dominguez RO, 2006, REV NEUROLOGIA, V43, P201, DOI 10.33588/rn.4304.2005610; DONATI D, 1987, NEPHRON, V46, P353, DOI 10.1159/000184389; Douglas GJ McKechine, 2015, MOL GENET METAB, V114, pS11; El Dib R, 2016, COCHRANE DB SYST REV; El Dib R, 2013, ACTA CIR BRAS, V28, P870, DOI 10.1590/S0102-86502013001200010; El Dib R, 2012, BJU INT, V110, P510, DOI 10.1111/j.1464-410X.2011.10885.x; El Dib RP, 2007, J EVAL CLIN PRACT, V13, P689, DOI 10.1111/j.1365-2753.2007.00886.x; Elliott PM, 2006, HEART, V92, P357, DOI 10.1136/hrt.2004.054015; Eng CM, 2007, J INHERIT METAB DIS, V30, P184, DOI 10.1007/s10545-007-0521-2; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Eto Y, 2005, J INHERIT METAB DIS, V28, P575, DOI 10.1007/s10545-005-0575-y; Feriozzi S, 2012, CLIN J AM SOC NEPHRO, V7, P60, DOI 10.2215/CJN.03130411; Boas PJFV, 2013, J EVAL CLIN PRACT, V19, P633, DOI 10.1111/j.1365-2753.2012.01877.x; Fujiwara M, 2007, TOKYO JIKEIKAI MED J, V122, P295; Germain DP, 2013, GENET MED, V15, P958, DOI 10.1038/gim.2013.53; Goto H, 2013, C PUBLICATION VAR S1, V36, pS261; Guffon N, 2004, J INHERIT METAB DIS, V27, P221, DOI 10.1023/B:BOLI.0000028726.11177.8b; Guffon N, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.4.e38; Hebert A, 2013, MOL GENET METAB, V108, pS47, DOI 10.1016/j.ymgme.2012.11.109; Hilz MJ, 2010, J HYPERTENS, V28, P1438, DOI 10.1097/HJH.0b013e328336a077; Hoffmann B, 2007, CLIN GASTROENTEROL H, V5, P1447, DOI 10.1016/j.cgh.2007.08.012; Hopkin R, 2013, MOL GENET METAB, V108, pS49, DOI 10.1016/j.ymgme.2012.11.113; Hopkin R, 2012, MOL GENET METAB, V105, pS36, DOI 10.1016/j.ymgme.2011.11.079; Hughes DA, 2011, MOL GENET METAB, V103, P207, DOI 10.1016/j.ymgme.2011.03.022; Imbriaco M, 2009, HEART, V95, P1103, DOI 10.1136/hrt.2008.162800; Jardim LB, 2006, J INHERIT METAB DIS, V29, P653, DOI 10.1007/s10545-006-0339-3; Johnson FK, 2016, MOL GENET METAB, V117, pS63, DOI 10.1016/j.ymgme.2015.12.307; Kalliokoski RJ, 2006, J INHERIT METAB DIS, V29, P112, DOI 10.1007/s10545-006-0221-3; Kampmann C, 2008, INT J CARDIOL, V130, P367, DOI 10.1016/j.ijcard.2008.03.007; Kampmann C, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0338-2; Kantola I, 2012, CLIN THER, V1, pe21; Kim JH, 2015, C PUBLICATION VAR S1, V38, pS265; Kisinovsky I, 2013, MEDICINA-BUENOS AIRE, V73, P31; Kobayashi M, 2008, J Inherit Metab Dis, V31 Suppl 3, P483, DOI 10.1007/s10545-007-0740-6; Kobayashi M, 2005, J INHERIT METAB D S1, V28; Koskenvuo JW, 2008, J INHERIT METAB DIS, V31, P432, DOI 10.1007/s10545-008-0848-3; Lin DY, 2009, AM J HUM GENET, V85, P862, DOI 10.1016/j.ajhg.2009.11.001; Lin HY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003146; Linhart A, 2007, EUR HEART J, V28, P1228, DOI 10.1093/eurheartj/ehm153; Linthorst GE, 2004, KIDNEY INT, V66, P1589, DOI 10.1111/j.1523-1755.2004.00924.x; Lobo T, 2008, INTERN MED J, V38, P407, DOI 10.1111/j.1445-5994.2008.01669.x; Lubanda JC, 2009, GENET MED, V11, P256, DOI 10.1097/GIM.0b013e3181981d82; MacDermot KD, 2001, J MED GENET, V38, P769, DOI 10.1136/jmg.38.11.769; Martins AM, 2013, GENET MOL RES, V12, P136, DOI 10.4238/2013.January.24.5; Martins AM, 2014, J YMGME; Mehta A, 2009, LANCET, V12, P374; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Motwani M, 2012, MOL GENET METAB, V107, P197, DOI 10.1016/j.ymgme.2012.05.011; Ortiz A, 2016, J MED GENET, V53, P495, DOI 10.1136/jmedgenet-2015-103486; Ortiz A, 2010, NEPHROL DIAL TRANSPL, V25, P769, DOI 10.1093/ndt/gfp554; Pano A, 2014, MOL GENET METAB, V111, pS84, DOI 10.1016/j.ymgme.2013.12.201; Parini R, 2008, CLIN GENET, V74, P260, DOI 10.1111/j.1399-0004.2008.01012.x; Pastores GM, 2007, NEPHROL DIAL TRANSPL, V22, P1920, DOI 10.1093/ndt/gfm096; Patel MR, 2011, J AM COLL CARDIOL, V57, P1093, DOI 10.1016/j.jacc.2010.11.018; Pisani A, 2005, AM J KIDNEY DIS, V46, P120, DOI 10.1053/j.ajkd.2005.03.016; Prabakaran T, 2014, NEPHROL DIAL TRANSPL, V29, P619, DOI 10.1093/ndt/gft452; Ramaswami U, 2012, CLIN GENET, V81, P485, DOI 10.1111/j.1399-0004.2011.01671.x; Ries M, 2006, PEDIATRICS, V118, P924, DOI 10.1542/peds.2005-2895; Gallego AR, 2006, MED CLIN-BARCELONA, V127, P481, DOI 10.1157/13093265; Rombach SM, 2014, J INHERIT METAB DIS, V37, P341, DOI 10.1007/s10545-014-9677-8; Rombach SM, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-47; Sanchez-Nino MD, 2015, HUM MOL GENET, V24, P5720, DOI 10.1093/hmg/ddv291; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Schiffmann R, 2007, J AM SOC NEPHROL, V18, P1576, DOI 10.1681/ASN.2006111263; Schiffmann R, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0169-6; Schiffmann R, 2009, NEPHROL DIAL TRANSPL, V24, P2102, DOI 10.1093/ndt/gfp031; Schwarting A, 2006, CLIN NEPHROL, V66, P77; Shemesh E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010324.pub2; Sims K, 2009, STROKE, V40, P788, DOI 10.1161/STROKEAHA.108.526293; Sirrs SM, 2014, MOL GENET METAB, V111, P499, DOI 10.1016/j.ymgme.2014.01.014; Spada M, 2006, AM J HUM GENET, V79, P31, DOI 10.1086/504601; Spinelli L, 2004, CLIN GENET, V66, P158, DOI 10.1111/j.1399-0004.2004.00284.x; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Talbot AS, 2015, HEART, V101, P287, DOI 10.1136/heartjnl-2014-306278; Thofehrn S, 2009, RENAL FAILURE, V31, P773, DOI 10.3109/08860220903150296; Tondel C, 2013, J AM SOC NEPHROL, V24, P137, DOI 10.1681/ASN.2012030316; Tsuboi K, 2015, C PUBLICATION VAR S1, V38, pS291; Tsuboi K, 2015, C PUBLICATION VAR S1, V38, pS292; Vedder AC, 2007, J INHERIT METAB DIS, V30, P68, DOI 10.1007/s10545-006-0484-8; Vedder AC, 2008, MOL GENET METAB, V94, P319, DOI 10.1016/j.ymgme.2008.03.003; Warnock DG, 2012, NEPHROL DIAL TRANSPL, V27, P1042, DOI 10.1093/ndt/gfr420; Watt T, 2010, GENET MED, V12, P703, DOI 10.1097/GIM.0b013e3181f13a4a; Weidemann F, 2013, J INTERN MED, V274, P331, DOI 10.1111/joim.12077; WEST M, 2013, MOL GENET METAB, V108, pS97; West M, CANADIAN FABRY DISEA; Whybra C, 2009, GENET MED, V11, P441, DOI 10.1097/GIM.0b013e3181a23bec; Wraith JE, 2008, J PEDIATR-US, V152, P563, DOI 10.1016/j.jpeds.2007.09.007; Wu JC, 2010, EUR HEART J, V31, P1088, DOI 10.1093/eurheartj/ehp588	106	53	55	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2017	12	3							e0173358	10.1371/journal.pone.0173358	http://dx.doi.org/10.1371/journal.pone.0173358			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9HQ	28296917	Green Submitted, Green Published, gold			2023-01-03	WOS:000396311700035
J	Bloom, SL; Leveno, KJ				Bloom, Steven L.; Leveno, Kenneth J.			Unproven Technologies in Maternal-Fetal Medicine and the High Cost of US Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRETERM BIRTH; DOUBLE-BLIND; SHORT CERVIX; PROGESTERONE; WOMEN; MULTICENTER; TRIAL; RISK		[Bloom, Steven L.; Leveno, Kenneth J.] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Bloom, SL (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	steven.bloom@utsouthwestern.edu						[Anonymous], 2011, LEAD HLTH IND HLTH P; Behrman RE, 2007, PRETERM BIRTH CAUSES; Berghella V, 2012, AM J OBSTET GYNECOL, V206, P376, DOI 10.1016/j.ajog.2012.03.010; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Committee on Practice BulletinsObstetrics The American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P964; Esplin MS, 2017, JAMA-J AM MED ASSOC, V317, P1047, DOI 10.1001/jama.2017.1373; Fonseca EB, 2007, NEW ENGL J MED, V357, P462, DOI 10.1056/NEJMoa067815; Frey HA, 2016, SEMIN FETAL NEONAT M, V21, P68, DOI 10.1016/j.siny.2015.12.011; Hassan SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/uog.9017; Khalifeh A, 2016, OBSTET GYNECOL, V127, p7S, DOI 10.1097/01.AOG.0000483635.97512.65; Martin AB, 2017, HEALTH AFFAIR, V36, P166, DOI 10.1377/hlthaff.2016.1330; Matthews T J, 2015, Natl Vital Stat Rep, V64, P1; McIntosh J, 2016, AM J OBSTET GYNECOL, V215, pB2, DOI 10.1016/j.ajog.2016.04.027; Norman JE, 2016, LANCET, V387, P2106, DOI 10.1016/S0140-6736(16)00350-0; Obama B, 2016, JAMA-J AM MED ASSOC, V316, P525, DOI 10.1001/jama.2016.9797; Squires D., 2015, US HLTH CARE GLOBAL	16	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2017	317	10					1025	1026		10.1001/jama.2017.1218	http://dx.doi.org/10.1001/jama.2017.1218			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO5DO	28291876				2023-01-03	WOS:000396713400014
J	Lee, S; Kang, E; Yoo, KD; Choi, Y; Kim, DK; Joo, KW; Yang, SH; Kim, YL; Kang, SW; Yang, CW; Kim, NH; Kim, YS; Lee, H				Lee, Sunhwa; Kang, Eunjeong; Yoo, Kyung Don; Choi, Yunhee; Kim, Dong Ki; Joo, Kwon Wook; Yang, Seung Hee; Kim, Yong-Lim; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam Ho; Kim, Yon Su; Lee, Hajeong			Lower serum potassium associated with increased mortality in dialysis patients: A nationwide prospective observational cohort study in Korea	PLOS ONE			English	Article							AMBULATORY PERITONEAL-DIALYSIS; RESIDUAL RENAL-FUNCTION; HEMODIALYSIS-PATIENTS; PRACTICE PATTERNS; HYPOKALEMIA; ATHEROSCLEROSIS; MALNUTRITION; INFLAMMATION; SUPPLEMENTATION; NONADHERENCE	Background Abnormal serum potassium concentration has been suggested as a risk factor for mortality in patients undergoing dialysis patients. We investigated the impact of serum potassium levels on survival according to dialysis modality. Methods A nationwide, prospective, observational cohort study for end stage renal disease patients has been ongoing in Korea since August 2008. Our analysis included patients whose records contained data regarding serum potassium levels. The relationship between serum potassium and mortality was analyzed using competing risk regression. Results A total of 3,230 patients undergoing hemodialysis (HD, 64.3%) or peritoneal dialysis (PD, 35.7%) were included. The serum potassium level was significantly lower (P < 0.001) in PD (median, 4.5 mmol/L; interquartile range, 4.0-4.9 mmol/L) than in HD patients (median, 4.9 mmol/L; interquartile range, 4.5-5.4 mmol/L). During 4.4-1.7 years of follow-up, 751 patients (23.3%) died, mainly from cardiovascular events (n = 179) and infection (n = 120). In overall, lower serum potassium level less than 4.5 mmol/L was an independent risk factor for mortality after adjusting for age, comorbidities, and nutritional status (sub-distribution hazard ratio, 1.30; 95% confidence interval 1.10-1.53; P = 0.002). HD patients showed a U-shaped survival pattern, suggesting that both lower and higher potassium levels were deleterious, although insignificant. However, in PD patients, only lower serum potassium level (<4.5 mmol/L) was an independent predictor of mortality (sub-distribution hazard ratio, 1.35; 95% confidence interval 1.00-1.80; P = 0.048). Conclusion Lower serum potassium levels (<4.5 mmol/L) occur more commonly in PD than in HD patients. It represents an independent predictor of survival in overall dialysis, especially in PD patients. Therefore, management of dialysis patients should focus especially on reducing the risk of hypokalemia, not only that of hyperkalemia.	[Lee, Sunhwa; Kang, Eunjeong; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Lee, Hajeong] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Yoo, Kyung Don] Dongguk Univ, Dept Internal Med, Gyeongju Hosp, Gyeongju, South Korea; [Choi, Yunhee] Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea; [Yang, Seung Hee; Lee, Hajeong] Seoul Natl Univ, Kidney Res Inst, Seoul, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; [Kang, Shin-Wook] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Yang, Chul Woo] Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea; [Kim, Nam Ho] Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea	Seoul National University (SNU); Seoul National University Hospital; Dongguk University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Kyungpook National University; Kyungpook National University Hospital; Yonsei University; Yonsei University Health System; Seoul St. Mary's Hospital; Chonnam National University; Chonnam National University Hospital	Lee, H (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.; Lee, H (corresponding author), Seoul Natl Univ, Kidney Res Inst, Seoul, South Korea.	mdhjlee@gmail.com	Kim, Dong Ki/J-5389-2012; Kang, Eunjeong/ABA-3646-2021; Yoo, Kyung Don/AAK-8096-2020	Kim, Dong Ki/0000-0002-5195-7852; Kang, Eunjeong/0000-0002-2191-2784; Yoo, Kyung Don/0000-0001-6545-6517	grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI); Ministry of Health & Welfare, Republic of Korea [HC15C1129]	grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI); Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC15C1129).	Avram MM, 2001, AM J KIDNEY DIS, V38, P1351, DOI 10.1053/ajkd.2001.29254; Bergstrom J, 1983, Kidney Int Suppl, V16, pS153; Bielecka-Dabrowa A, 2012, INT J CARDIOL, V158, P12, DOI 10.1016/j.ijcard.2011.06.121; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; Chattopadhyay J, 2014, ADV PERIT DIAL, V30; Ekundayo OJ, 2010, INT J CARDIOL, V141, P167, DOI 10.1016/j.ijcard.2008.11.195; ELLIOTT P, 1988, BRIT MED J, V297, P319; Glassock RJ, 2009, CLIN J AM SOC NEPHRO, V4, pS79, DOI 10.2215/CJN.04860709; GORDEN P, 1973, DIABETES, V22, P544, DOI 10.2337/diab.22.7.544; Hadi HAR, 2005, VASC HEALTH RISK MAN, V1, P183; He FJ, 2010, HYPERTENSION, V55, P681, DOI 10.1161/HYPERTENSIONAHA.109.147488; HELFANT RH, 1986, AM J MED, V80, P13, DOI 10.1016/0002-9343(86)90336-0; HODGKIN AL, 1960, J PHYSIOL-LONDON, V153, P386, DOI 10.1113/jphysiol.1960.sp006541; Hwang JC, 2011, BLOOD PURIFICAT, V32, P254, DOI 10.1159/000325226; Jadoul M, 2012, CLIN J AM SOC NEPHRO, V7, P765, DOI 10.2215/CJN.08850811; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Khan AN, 1996, PERITON DIALYSIS INT, V16, P652; Kim Hyun-Wook, 2007, Electrolyte Blood Press, V5, P102, DOI 10.5049/EBP.2007.5.2.102; Kjeldsen K, 2010, EXP CLIN CARDIOL, V15, pE96; Kovesdy CP, 2007, CLIN J AM SOC NEPHRO, V2, P999, DOI 10.2215/CJN.04451206; Lacson E, 2015, AM J KIDNEY DIS, V66, P1056, DOI 10.1053/j.ajkd.2015.06.014; Lang SM, 2001, PERITON DIALYSIS INT, V21, P52; LINDHOLM B, 1986, ACTA MED SCAND, V219, P323; Lu XH, 2009, J RENAL NUTR, V19, P469, DOI 10.1053/j.jrn.2009.04.003; Misra M, 2001, KIDNEY INT, V59, P754, DOI 10.1046/j.1523-1755.2001.059002754.x; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Musso Carlos G., 2004, International Urology and Nephrology, V36, P469, DOI 10.1007/s11255-004-6194-y; Noori N, 2010, AM J KIDNEY DIS, V56, P338, DOI 10.1053/j.ajkd.2010.03.022; Osadchii OE, 2010, FUND CLIN PHARMACOL, V24, P547, DOI 10.1111/j.1472-8206.2010.00835.x; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; PLAVINIK FL, 1992, HYPERTENSION, V19, P26; Ribeiro SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127453; ROSTAND SG, 1983, ARCH INTERN MED, V143, P377, DOI 10.1001/archinte.143.2.377; ROWE JW, 1980, METABOLISM, V29, P498, DOI 10.1016/0026-0495(80)90074-8; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; Singhi S, 1996, Indian Pediatr, V33, P9; SPITAL A, 1985, AM J KIDNEY DIS, V6, P173, DOI 10.1016/S0272-6386(85)80022-6; Stenvinkel P, 2001, PERITON DIALYSIS INT, V21, pS157; SUGIMOTO T, 1988, HYPERTENSION, V11, P579, DOI 10.1161/01.HYP.11.6.579; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015; TADDEI S, 1994, HYPERTENSION, V23, P485, DOI 10.1161/01.HYP.23.4.485; Torlen K, 2012, CLIN J AM SOC NEPHRO, V7, P1272, DOI 10.2215/CJN.00960112; Tziviskou Effie, 2003, International Urology and Nephrology, V35, P429, DOI 10.1023/B:UROL.0000022867.93739.03; Unruh ML, 2005, AM J KIDNEY DIS, V46, P1107, DOI 10.1053/j.ajkd.2005.09.002; Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891; Weiner ID, 1997, J AM SOC NEPHROL, V8, P1179; Xu QD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086750; Yi Joo-Hark, 2009, Electrolyte Blood Press, V7, P25, DOI 10.5049/EBP.2009.7.1.25; Yi Joo-Hark, 2009, Electrolyte Blood Press, V7, P79, DOI 10.5049/EBP.2009.7.2.79; Zanger R, 2010, SEMIN DIALYSIS, V23, P575, DOI 10.1111/j.1525-139X.2010.00789.x	51	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2017	12	3							e0171842	10.1371/journal.pone.0171842	http://dx.doi.org/10.1371/journal.pone.0171842			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5OE	28264031	Green Published, gold, Green Submitted			2023-01-03	WOS:000396054300004
J	Hategeka, C; Shoveller, J; Tuyisenge, L; Kenyon, C; Cechetto, DF; Lynd, LD				Hategeka, Celestin; Shoveller, Jean; Tuyisenge, Lisine; Kenyon, Cynthia; Cechetto, David F.; Lynd, Larry D.			Pediatric emergency care capacity in a low-resource setting: An assessment of district hospitals in Rwanda	PLOS ONE			English	Article							QUALITY; KENYA; INDICATORS; COUNTRIES; CHILDREN	Background Health system strengthening is crucial to improving infant and child health outcomes in low-resource countries. While the knowledge related to improving newborn and child survival has advanced remarkably over the past few decades, many healthcare systems in such settings remain unable to effectively deliver pediatric advance life support management. With the introduction of the Emergency Triage, Assessment and Treatment plus Admission care (ETAT+)-a locally adapted pediatric advanced life support management program-in Rwandan district hospitals, we undertook this study to assess the extent to which these hospitals are prepared to provide this pediatric advanced life support management. The results of the study will shed light on the resources and support that are currently available to implement ETAT+, which aims to improve care for severely ill infants and children. Methods A cross-sectional survey was undertaken in eight district hospitals across Rwanda focusing on the availability of physical and human resources, as well as hospital services organizations to provide emergency triage, assessment and treatment plus admission care for severely ill infants and children. Results Many of essential resources deemed necessary for the provision of emergency care for severely ill infants and children were readily available (e.g. drugs and laboratory services). However, only 4/8 hospitals had BVM for newborns; while nebulizer and MDI were not available in 2/8 hospitals. Only 3/8 hospitals had F-75 and ReSoMal. Moreover, there was no adequate triage system across any of the hospitals evaluated. Further, guidelines for neonatal resuscitation and management of malaria were available in 5/8 and in 7/8 hospitals, respectively; while those for child resuscitation and management of sepsis, pneumonia, dehydration and severe malnutrition were available in less than half of the hospitals evaluated. Conclusions Our assessment provides evidence to inform new strategies to enhance the capacity of Rwandan district hospitals to provide pediatric advanced life support management. Identifying key gaps in the health care system is required in order to facilitate the implementation and scale up of ETAT+ in Rwanda. These findings also highlight a need to establish an outreach/mentoring program, embedded within the ongoing ETAT+ program, to promote cross-hospital learning exchanges.	[Hategeka, Celestin; Shoveller, Jean] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Hategeka, Celestin; Lynd, Larry D.] Univ British Columbia, Fac Pharmaceut Sci, Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada; [Tuyisenge, Lisine] Univ Teaching Hosp Kigali, Dept Pediat, Kigali, Rwanda; [Kenyon, Cynthia] London Hlth Sci Ctr, Childrens Hosp, Div Neonatal Perinatal Med, London, ON, Canada; [Cechetto, David F.] Western Univ, Dept Anat & Cell Biol, Schulich Sch Med & Dent, London, ON, Canada; [Lynd, Larry D.] Providence Hlth Res Inst, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Hategeka, C (corresponding author), Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada.; Hategeka, C; Lynd, LD (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada.; Lynd, LD (corresponding author), Providence Hlth Res Inst, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada.	celestin.hategeka@alumni.ubc.ca; larry.lynd@ubc.ca		Hategeka, Celestin/0000-0001-7808-4652; Lynd, Larry/0000-0002-7622-3919	CIDA-Maternal Newborn and Child Health in Rwanda [S065358]	CIDA-Maternal Newborn and Child Health in Rwanda	DFC received a grant (CIDA-Maternal Newborn and Child Health in Rwanda, S065358) that contributed to funding the master's training for CH at the University of British Columbia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe KK, 2000, AM J EMERG MED, V18, P126, DOI 10.1016/S0735-6757(00)90001-9; Aluvaala J, 2014, ARCH DIS CHILDHOOD; Association AH, 2005, PEDIATRICS, V117, pe989, DOI [10.1542/peds.2006-0219, DOI 10.1542/PEDS.2006-0219]; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Binagwaho A, 2013, NEW ENGL J MED, V369, P2054, DOI 10.1056/NEJMsr1302176; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; English M, 2004, LANCET, V364, P1622, DOI 10.1016/S0140-6736(04)17318-2; Gathara D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117048; Hategeka C., 2012, RWANDA MED J, V69, P34; Hategekimana C., 2015, EVALUATING IMPLEMENT; Hategekimana C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152882; Irimu GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039964; Khilnani P, 2010, INDIAN J CRIT CARE M, V14, P41, DOI 10.4103/0972-5229.63029; Mabey D, 2013, PRINCIPLES MED AFRIC; Maternal Newborn and Child Health in Rwanda (MNCHR), 2010, REP QUAL HLTH CAR RW; MENGE I, 1995, E AFR MED J, V72, P165; Ministry of Health of Rwanda, 2010, LIST NAT MED ESS; Ministry of Health of Rwanda, 2011, INT HLTH SYST STRENG; Ministry of Health of Rwanda, 2008, SERV PROV ASS SURV; Ministry of Health of Rwanda, 2012, RWAND ANN HLTH STAT; Ministry of Health of Rwanda, 2011, BAS PED PROT; Ministry of Health Rwanda, 2005, RWAND HLTH SECT POL; Molyneux EM, 2010, ANN TROP PAEDIATR, V30, P165, DOI 10.1179/146532810X12703902516482; Mwakyusa Sekela, 2006, BMC Int Health Hum Rights, V6, P9, DOI 10.1186/1472-698X-6-9; National Institute of Statistics of Rwanda, 2014, RWAND POP HOUS CENS; National Institute of Statistics of Rwanda (NISR) [Rwanda]; Ministry of Health (MOH) [Rwanda]; and ICF International, 2015, RWAND DEM HLTH SURV; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Ntoburi S, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-90; Ralston ME, 2013, LANCET, V381, P256, DOI 10.1016/S0140-6736(12)61191-X; Robison JA, 2012, PEDIATRICS, V130, pE676, DOI 10.1542/peds.2012-0026; Shoveller J, 2016, CRIT PUBLIC HEALTH, V26, P487, DOI 10.1080/09581596.2015.1117577; Slusher TM, 2011, SEMINARS PERINATOLOG; United Nations, MILL DEV GOALS 2000; WHO, 1987, HOSP HLTH ALL REP WH; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C; World Health Organization (WHO), 2003, KANGAROO MOTHER CARE	36	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0173233	10.1371/journal.pone.0173233	http://dx.doi.org/10.1371/journal.pone.0173233			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5BR	28257500	Green Published, gold, Green Submitted			2023-01-03	WOS:000396021100079
J	Malik, NS; Ahmad, M; Minhas, MU				Malik, Nadia Shamshad; Ahmad, Mahmood; Minhas, Muhammad Usman			Cross-linked beta-cyclodextrin and carboxymethyl cellulose hydrogels for controlled drug delivery of acyclovir	PLOS ONE			English	Article							CONTROLLED-RELEASE; SUPERABSORBENT HYDROGEL; DICLOFENAC SODIUM; METHACRYLIC-ACID; CHITOSAN; CIPROFLOXACIN; COMPLEXATION; MICROSPHERES; DERIVATIVES; ALGINATE	To explore the potential role of polymers in the development of drug-delivery systems, this study investigated the use of beta-cyclodextrin (beta-CD), carboxymethyl cellulose (CMC), acrylic acid (AA) and N' N'-methylenebis-acrylamide (MBA) in the synthesis of hydrogels for controlled drug delivery of acyclovir (ACV). Different proportions of beta-CD, CMC, AA and MBA were blended with each other to fabricate hydrogels via free radical polymerization technique. Fourier transform infrared spectroscopy (FTIR) revealed successful grafting of components into the polymeric network. Thermal and morphological characterization confirmed the formation of thermodynamically stable hydrogels having porous structure. The pH-responsive behaviour of hydrogels has been documented by swelling dynamics and drug release behaviour in simulated gastrointestinal fluids. Drug release kinetics revealed controlled release behaviour of the antiviral drug acyclovir in developed polymeric network. Cross-linked beta-cyclodextrin and carboxymethyl cellulose hydrogels can be used as promising candidates for the design and development of controlled drug-delivery systems.	[Malik, Nadia Shamshad; Ahmad, Mahmood; Minhas, Muhammad Usman] Islamia Univ Bahawalpur, Fac Pharm & Alternat Med, Bahawalpur, Pakistan	Islamia University of Bahawalpur	Ahmad, M (corresponding author), Islamia Univ Bahawalpur, Fac Pharm & Alternat Med, Bahawalpur, Pakistan.	ma786_786@yahoo.com			Higher Education Commission of Pakistan; Islamia University of Bahawalpur, Pakistan	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); Islamia University of Bahawalpur, Pakistan	Higher Education Commission of Pakistan and The Islamia University of Bahawalpur, Pakistan funded the research. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Blanco-Fernandez B, 2011, CARBOHYD POLYM, V85, P765, DOI 10.1016/j.carbpol.2011.03.042; Cesteros LC, 2007, MACROMOL CHEM PHYS, V208, P1764, DOI 10.1002/macp.200700109; Chao GT, 2006, J POLYM RES, V13, P349, DOI 10.1007/s10965-006-9050-1; Das D, 2015, INT J BIOL MACROMOL, V72, P171, DOI 10.1016/j.ijbiomac.2014.08.007; El-Sayed S, 2011, PHYSICA B, V406, P4068, DOI 10.1016/j.physb.2011.07.050; Folch-Cano C, 2014, MOLECULES, V19, P14066, DOI 10.3390/molecules190914066; Guirguis OW, 2012, NAT SCI; Halib N, 2010, J APPL POLYM SCI, V116, P2920, DOI 10.1002/app.31857; Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002; Hosseinzadeh H, 2010, J CHEM SCI, V122, P651, DOI 10.1007/s12039-010-0100-1; Kono H, 2015, INT J BIOL MACROMOL, V72, P299, DOI 10.1016/j.ijbiomac.2014.08.030; Kono H, 2014, CARBOHYD POLYM, V106, P84, DOI 10.1016/j.carbpol.2014.02.020; Kono H, 2013, CARBOHYD POLYM, V98, P784, DOI 10.1016/j.carbpol.2013.06.065; Kopecek J, 2009, J POLYM SCI POL CHEM, V47, P5929, DOI 10.1002/pola.23607; Kumari S, 2014, IRAN POLYM J, V23, P111, DOI 10.1007/s13726-013-0206-7; Liu Y, 2015, BIORESOURCES, V10, P6479; Minhas MU, 2013, DARU, V21, DOI 10.1186/2008-2231-21-44; Park JS, 2001, POLYMER, V42, P4271, DOI 10.1016/S0032-3861(00)00768-0; Pinho E, 2014, CELLULOSE, V21, P4519, DOI 10.1007/s10570-014-0439-4; Prabaharan M, 2006, CARBOHYD POLYM, V63, P153, DOI 10.1016/j.carbpol.2005.08.051; Rashid A, 2015, TROP J PHARM RES, V14, P1121, DOI 10.4314/tjpr.v14i7.1; Rodriguez-Tenreiro C, 2006, PHARM RES-DORDR, V23, P121, DOI 10.1007/s11095-005-8924-y; Rokhade AP, 2007, CARBOHYD POLYM, V67, P605, DOI 10.1016/j.carbpol.2006.07.001; dos Santos JFR, 2008, ACTA BIOMATER, V4, P745, DOI 10.1016/j.actbio.2007.12.008; Saravanan M, 2004, INT J PHARM, V283, P71, DOI 10.1016/j.ijpharm.2004.06.023; Siemoneit U, 2006, INT J PHARMACEUT, V312, P66, DOI 10.1016/j.ijpharm.2005.12.046; Silva DA, 2006, CARBOHYD POLYM, V66, P16, DOI 10.1016/j.carbpol.2006.02.021; Siritientong T, 2015, MACROMOL RES, V23, P861, DOI 10.1007/s13233-015-3116-z; Sohail M, 2015, INT J PHARMACEUT, V487, P110, DOI 10.1016/j.ijpharm.2015.04.013; Thatiparti TR, 2010, MACROMOL BIOSCI, V10, P82, DOI 10.1002/mabi.200900204; Tsao JY, 2010, INT J PHARMACEUT, V402, P123, DOI 10.1016/j.ijpharm.2010.09.033; Wang GF, 2014, CHEM PAP, V68, P1390, DOI 10.2478/s11696-014-0574-2; Wang YZ, 2013, TURK J CHEM, V37, P149, DOI 10.3906/kim-1204-52; Xin JY, 2010, INT J PHARMACEUT, V386, P221, DOI 10.1016/j.ijpharm.2009.11.024	34	79	79	2	121	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2017	12	2							e0172727	10.1371/journal.pone.0172727	http://dx.doi.org/10.1371/journal.pone.0172727			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4LY	28245257	gold, Green Published, Green Submitted			2023-01-03	WOS:000395980200028
J	Taguchi, S; Buti, S; Fukuhara, H; Otsuka, M; Bersanelli, M; Morikawa, T; Miyazaki, H; Nakagawa, T; Fujimura, T; Kume, H; Igawa, Y; Homma, Y				Taguchi, Satoru; Buti, Sebastiano; Fukuhara, Hiroshi; Otsuka, Masafumi; Bersanelli, Melissa; Morikawa, Teppei; Miyazaki, Hideyo; Nakagawa, Tohru; Fujimura, Tetsuya; Kume, Haruki; Igawa, Yasuhiko; Homma, Yukio			Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?	PLOS ONE			English	Article							RANDOMIZED-TRIAL; INTERFERON-ALPHA; RADICAL NEPHRECTOMY; HIGH-RISK; STAGE-II; POSTOPERATIVE RADIOTHERAPY; PHASE-III; INTERLEUKIN-2; IMMUNOCHEMOTHERAPY; ADENOCARCINOMA	Background The benefit of adjuvant immunotherapy after nephrectomy in renal cell carcinoma (RCC) is controversial. The present study aimed to examine the possible benefit of adjuvant immunotherapy in various clinical settings. Methods We retrospectively reviewed 436 patients with pT1-3N0-2M0 RCC who underwent radical or partial nephrectomy with curative intent at our institution between 1981 and 2009. Of them, 98 (22.5%) patients received adjuvant interferon-alpha (IFN-alpha) after surgery (adjuvant IFN-alpha group), while 338 (77.5%) did not (control group). The primary endpoint was cancer-specific survival (CSS). Univariate and multivariate analyses were conducted using log-rank tests and Cox proportional hazards models, respectively. Results Fifty-two (11.9%) patients died from RCC with a median follow-up period of 96 months. Preliminary univariate analyses comparing CSS among treatment groups in each TNM setting revealed that CSS in the control group was equal or superior to that in the adjuvant IFN-a group in earlier stages, while the opposite trend was observed in more advanced stages. We evaluated the TNM cutoffs and demonstrated maximized benefit of adjuvant IFN-a in patients with pT2b-3cN0 (P = 0.0240). In multivariate analysis, >= pT3 and pN1-2 were independent predictors for poor CSS in all patients. In the subgroups with >= pT2 disease (n = 123), pN1-2 and no adjuvant treatment were significant poor prognostic factors. Conclusions Adjuvant immunotherapy after nephrectomy may be beneficial in pT2b-3cN0 RCC. Careful consideration is, however, required for interpretation of this observational study because of its selection bias and adverse effects of IFN-alpha.	[Taguchi, Satoru; Fukuhara, Hiroshi; Otsuka, Masafumi; Miyazaki, Hideyo; Nakagawa, Tohru; Fujimura, Tetsuya; Kume, Haruki; Igawa, Yasuhiko; Homma, Yukio] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; [Buti, Sebastiano; Bersanelli, Melissa] Univ Hosp Parma, Med Oncol Unit, Parma, Italy; [Morikawa, Teppei] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan	University of Tokyo; University of Parma; University Hospital of Parma; University of Tokyo	Fukuhara, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan.	hfukuhara-jua@umin.ac.jp	Buti, Sebastiano/S-1314-2017; Bersanelli, Melissa/AAA-2024-2020; Igawa, Yasuhiko/AAY-9505-2021	Buti, Sebastiano/0000-0003-0876-0226; Bersanelli, Melissa/0000-0002-6527-6281; 				Atzpodien J, 2005, BRIT J CANCER, V92, P843, DOI 10.1038/sj.bjc.6602443; Basting R, 1999, ANTICANCER RES, V19, P1545; Bex A, 2016, INT J UROL, V23, P5, DOI 10.1111/iju.12891; Buti S, 2012, ONCOL REV, V6, P145, DOI 10.4081/oncol.2012.e18; Clark JI, 2003, J CLIN ONCOL, V21, P3133, DOI 10.1200/JCO.2003.02.014; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Coit DG, 2016, J NATL COMPR CANC NE, V14, P450, DOI 10.6004/jnccn.2016.0051; Di Trolio R, 2015, CYTOKINE GROWTH F R, V26, P203, DOI 10.1016/j.cytogfr.2014.11.008; Eble J. N., 2004, WHO IARC CLASSIFICAT; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Haas NB, 2016, LANCET, V387, P2008, DOI 10.1016/S0140-6736(16)00559-6; Hinotsu S, 2013, INT J CLIN ONCOL, V18, P68, DOI 10.1007/s10147-011-0345-9; Hong SK, 2005, UROLOGY, V66, P518, DOI 10.1016/j.urology.2005.04.014; KJAER M, 1987, SCAND J UROL NEPHROL, V21, P285, DOI 10.3109/00365598709180784; KJAER M, 1987, INT J RADIAT ONCOL, V13, P665, DOI 10.1016/0360-3016(87)90283-5; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Levakov Ivan, 2011, Med Pregl, V64, P173; Messing EM, 2003, J CLIN ONCOL, V21, P1214, DOI 10.1200/JCO.2003.02.005; MIGLIARI R, 1995, J CHEMOTHERAPY, V7, P240, DOI 10.1179/joc.1995.7.3.240; Motzer RJ, 2014, NCCN CLIN PRACTICE G; Passalacqua R, 2014, J IMMUNOTHER, V37, P440, DOI 10.1097/CJI.0000000000000055; Pizzocaro G, 2001, J CLIN ONCOL, V19, P425, DOI 10.1200/JCO.2001.19.2.425; Smaldone MC, 2011, HEMATOL ONCOL CLIN N, V25, P765, DOI 10.1016/j.hoc.2011.06.002; The Japanese Urological Association The Japanese Society of Pathology Japan Radiological Society, 2011, GENERAL RULE FOR CLI, P522, DOI [10.1016/j.urology.2005.04.014, DOI 10.1016/J.UROLOGY.2005.04.014]; Yap TA, 2006, CLIN GENITOURIN CANC, V5, P120, DOI 10.3816/CGC.2006.n.028	26	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2017	12	2							e0172341	10.1371/journal.pone.0172341	http://dx.doi.org/10.1371/journal.pone.0172341			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN3UW	28241027	Green Submitted, gold, Green Published			2023-01-03	WOS:000395934400019
J	Donges, SC; D'Amico, JM; Butler, JE; Taylor, JL				Donges, Siobhan C.; D'Amico, Jessica M.; Butler, Jane E.; Taylor, Janet L.			The effects of cervical transcutaneous spinal direct current stimulation on motor pathways supplying the upper limb in humans	PLOS ONE			English	Article							SOLEUS H-REFLEX; POST-ACTIVATION DEPRESSION; DC STIMULATION; INDUCED PLASTICITY; CORD-INJURY; EVOKED-POTENTIALS; CORTEX; PAIN; MODULATION; EXCITABILITY	Non-invasive, weak direct current stimulation can induce changes in excitability of underlying neural tissue. Many studies have used transcranial direct current stimulation to induce changes in the brain, however more recently a number of studies have used transcutaneous spinal direct current stimulation to induce changes in the spinal cord. This study further characterises the effects following cervical transcutaneous spinal direct current stimulation on motor pathways supplying the upper limb. In Study 1, on two separate days, participants (n = 12, 5 F) received 20 minutes of either real or sham direct current stimulation at 3 mA through electrodes placed in an anterior-posterior configuration over the neck (anode anterior). Biceps brachii, flexor carpi radialis and first dorsal interosseous responses to transcranial magnetic stimulation (motor evoked potentials) and cervicomedullary stimulation (cervicomedullary motor evoked potentials) were measured before and after real or sham stimulation. In Study 2, on two separate days, participants (n = 12, 7 F) received either real or sham direct current stimulation in the same way as for Study 1. Before and after real or sham stimulation, median nerve stimulation elicited M waves and H reflexes in the flexor carpi radialis. H-reflex recruitment curves and homosynaptic depression of the H reflex were assessed. Results show that the effects of real and sham direct current stimulation did not differ for motor evoked potentials or cervicomedullary motor evoked potentials for any muscle, nor for H-reflex recruitment curve parameters or homosynaptic depression. Cervical transcutaneous spinal direct current stimulation with the parameters described here does not modify motor responses to corticospinal stimulation nor does it modify H reflexes of the upper limb. These results are important for the emerging field of transcutaneous spinal direct current stimulation.	[Donges, Siobhan C.; D'Amico, Jessica M.; Butler, Jane E.; Taylor, Janet L.] Neurosci Res Australia, Randwick, NSW, Australia; [Donges, Siobhan C.; Butler, Jane E.; Taylor, Janet L.] Univ New South Wales, Sydney, NSW, Australia	Neuroscience Research Australia; University of New South Wales Sydney	Taylor, JL (corresponding author), Neurosci Res Australia, Barker St, Randwick, NSW, Australia.	j.taylor@neura.edu.au	Butler, Jane E/D-4186-2011; Taylor, Janet/C-9667-2011	Butler, Jane/0000-0002-5834-8152; D'Amico, Jessica/0000-0002-3487-0712; Taylor, Janet/0000-0001-8976-5162	National Health and Medical Research Council of Australia [1055084]; Australian Postgraduate Award; University of New South Wales research excellence scholarship; National Health and Medical Research Council Research Fellowships	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); University of New South Wales research excellence scholarship; National Health and Medical Research Council Research Fellowships(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a Program Grant (1055084) from the National Health and Medical Research Council of Australia. SCD holds an Australian Postgraduate Award and a University of New South Wales research excellence scholarship. JLT and JEB hold National Health and Medical Research Council Research Fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar J, 2011, J PHYSIOL-LONDON, V589, P4981, DOI 10.1113/jphysiol.2011.214189; Ahmed Z, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12157; Ahmed Z, 2014, J NEUROSCI, V34, P1701, DOI 10.1523/JNEUROSCI.4445-13.2014; Ahmed Z, 2013, J NEUROSCI, V33, P14949, DOI 10.1523/JNEUROSCI.2793-13.2013; Ahmed Z, 2013, J NEUROSCI, V33, P4935, DOI 10.1523/JNEUROSCI.4930-12.2013; Ahmed Z, 2012, J APPL PHYSIOL, V112, P1576, DOI 10.1152/japplphysiol.00967.2011; Ahmed Z, 2011, J APPL PHYSIOL, V110, P1414, DOI 10.1152/japplphysiol.01390.2010; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bocci T, 2015, NEUROMODULATION, V18, P686, DOI 10.1111/ner.12298; Bocci T, 2015, J NEUROPHYSIOL, V114, P440, DOI 10.1152/jn.00490.2014; Bolzoni F, 2015, J PHYSIOL-LONDON, V593, P947, DOI 10.1113/jphysiol.2014.285940; Boudreau S, 2007, PAIN, V132, P169, DOI 10.1016/j.pain.2007.07.019; Bunday KL, 2012, CURR BIOL, V22, P2355, DOI 10.1016/j.cub.2012.10.046; Cabral ME, 2015, NEUROREPORT, V26, P618, DOI 10.1097/WNR.0000000000000397; Carroll TJ, 2001, J NEUROSCI METH, V112, P193, DOI 10.1016/S0165-0270(01)00468-X; Christie AD, 2005, J CLIN NEUROPHYSIOL, V22, P204; Cogiamanian F., 2012, FRONT PSYCHIAT, V3; Cogiamanian F, 2011, PAIN, V152, P370, DOI 10.1016/j.pain.2010.10.041; Cogiamanian F, 2008, CLIN NEUROPHYSIOL, V119, P2636, DOI 10.1016/j.clinph.2008.07.249; CREUTZFELDT O, 1962, EXP NEUROL, V5, P436, DOI 10.1016/0014-4886(62)90056-0; CRONE C, 1989, EXP BRAIN RES, V78, P28, DOI 10.1007/bf00230683; D'Amico JM, 2013, J NEUROPHYSIOL, V109, P1485, DOI 10.1152/jn.00822.2012; Fanelli D, 2012, SCIENTOMETRICS, V90, P891, DOI 10.1007/s11192-011-0494-7; Fanelli D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010271; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fitzpatrick SC, 2016, CLIN NEUROPHYSIOL, V127, P724, DOI 10.1016/j.clinph.2015.03.013; Heide AC, 2014, BRAIN STIMUL, V7, P636, DOI 10.1016/j.brs.2014.06.008; Hubli M, 2013, CLIN NEUROPHYSIOL, V124, P1187, DOI 10.1016/j.clinph.2012.11.021; Hultborn H, 1996, EXP BRAIN RES, V108, P450; Ingham D, 2011, EUR J PAIN, V15, P1028, DOI 10.1016/j.ejpain.2011.04.006; Kabakov AY, 2012, J NEUROPHYSIOL, V107, P1881, DOI 10.1152/jn.00715.2011; Klimstra M, 2008, EXP BRAIN RES, V186, P93, DOI 10.1007/s00221-007-1207-6; Kohn AF, 1997, EXP BRAIN RES, V116, P375, DOI 10.1007/PL00005765; Lamy JC, 2013, J NEUROPHYSIOL, V110, P109, DOI 10.1152/jn.00116.2013; Lamy JC, 2012, J NEUROPHYSIOL, V108, P906, DOI 10.1152/jn.10898.2011; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Lim CY, 2011, NEUROREPORT, V22, P819, DOI 10.1097/WNR.0b013e32834b939d; Lundbye-Jensen J, 2008, J APPL PHYSIOL, V105, P139, DOI 10.1152/japplphysiol.00687.2007; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; Matosin N, 2014, DIS MODEL MECH, V7, P171, DOI 10.1242/dmm.015123; Mavromatis N, 2016, NEUROSCIENCE, V330, P403, DOI 10.1016/j.neuroscience.2016.06.008; Meyer-Friessem CH, 2015, NEUROSCI LETT, V589, P153, DOI 10.1016/j.neulet.2015.01.029; Nardone R, 2015, NEUROMODULATION, V18, P580, DOI 10.1111/ner.12332; Nierat MC, 2014, J NEUROSCI, V34, P14420, DOI 10.1523/JNEUROSCI.1288-14.2014; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Parazzini M, 2014, CLIN NEUROPHYSIOL, V125, P2260, DOI 10.1016/j.clinph.2014.02.027; Perrotta A, 2016, CLIN NEUROPHYSIOL, V127, P755, DOI 10.1016/j.clinph.2015.01.031; Priori A, 2014, J PHYSIOL-LONDON, V592, P3345, DOI 10.1113/jphysiol.2013.270280; Song WG, 2015, J NEUROPHYSIOL, V113, P2801, DOI 10.1152/jn.00784.2014; Stagg CJ, 2011, NEUROPSYCHOLOGIA, V49, P800, DOI 10.1016/j.neuropsychologia.2011.02.009; Svensson P, 2003, EUR J PAIN-LONDON, V7, P55, DOI 10.1016/S1090-3801(02)00050-2; Taylor JL, 2009, J NEUROSCI, V29, P11708, DOI 10.1523/JNEUROSCI.2217-09.2009; Taylor JL, 2004, J APPL PHYSIOL, V96, P1496, DOI 10.1152/japplphysiol.01116.2003; Taylor JL, 2002, J PHYSIOL-LONDON, V541, P949, DOI 10.1113/jphysiol.2002.016782; Thirugnanasambandam N, 2011, RESTOR NEUROL NEUROS, V29, P311, DOI 10.3233/RNN-2011-0601; Truini A, 2011, EUR J PAIN, V15, P1023, DOI 10.1016/j.ejpain.2011.04.009; UGAWA Y, 1991, ANN NEUROL, V29, P418, DOI 10.1002/ana.410290413; Valeriani M, 1999, CLIN NEUROPHYSIOL, V110, P1475, DOI 10.1016/S1388-2457(99)00075-9; Winkler T, 2010, CLIN NEUROPHYSIOL, V121, P957, DOI 10.1016/j.clinph.2010.01.014; Zehr EP, 2007, NEUROSCI LETT, V419, P10, DOI 10.1016/j.neulet.2007.03.045; Zehr EP, 1999, EXP BRAIN RES, V124, P474, DOI 10.1007/s002210050643	61	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2017	12	2							e0172333	10.1371/journal.pone.0172333	http://dx.doi.org/10.1371/journal.pone.0172333			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SK	28225813	Green Submitted, Green Published, gold			2023-01-03	WOS:000394680900035
J	Budoff, MJ; Ellenberg, SS; Lewis, CE; Mohler, ER; Wenger, NK; Bhasin, S; Barrett-Connor, E; Swerdloff, RS; Stephens-Shields, A; Cauley, JA; Crandall, JP; Cunningham, GR; Ensrud, KE; Gill, TM; Matsumoto, AM; Molitch, ME; Nakanishi, R; Nezarat, N; Matsumoto, S; Hou, XL; Basaria, S; Diem, SJ; Wang, C; Cifelli, D; Snyder, PJ				Budoff, Matthew J.; Ellenberg, Susan S.; Lewis, Cora E.; Mohler, Emile R., III; Wenger, Nanette K.; Bhasin, Shalender; Barrett-Connor, Elizabeth; Swerdloff, Ronald S.; Stephens-Shields, Alisa; Cauley, Jane A.; Crandall, Jill P.; Cunningham, Glenn R.; Ensrud, Kristine E.; Gill, Thomas M.; Matsumoto, Alvin M.; Molitch, Mark E.; Nakanishi, Rine; Nezarat, Negin; Matsumoto, Suguru; Hou, Xiaoling; Basaria, Shehzad; Diem, Susan J.; Wang, Christina; Cifelli, Denise; Snyder, Peter J.			Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOGENOUS SEX-HORMONES; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PROGRESSION; CT; MORTALITY; RISK; ANGIOGRAPHY	IMPORTANCE Recent studies have yielded conflicting results as to whether testosterone treatment increases cardiovascular risk. OBJECTIVE To test the hypothesis that testosterone treatment of older men with low testosterone slows progression of noncalcified coronary artery plaque volume. DESIGN, SETTING, AND PARTICIPANTS Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism who were enrolled in the Testosterone Trials between June 24, 2010, and June 9, 2014. INTERVENTION Testosterone gel, with the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months. MAIN OUTCOMES AND MEASURES The primary outcomewas noncalcified coronary artery plaque volume, as determined by coronary computed tomographic angiography. Secondary outcomes included total coronary artery plaque volume and coronary artery calcium score (range of 0 to >400 Agatston units, with higher values indicating more severe atherosclerosis). RESULTS Of 170 men who were enrolled, 138 (73 receiving testosterone treatment and 65 receiving placebo) completed the study and were available for the primary analysis. Among the 138 men, the mean (SD) age was 71.2 (5.7) years, and 81% were white. At baseline, 70 men (50.7%) had a coronary artery calcification score higher than 300 Agatston units, reflecting severe atherosclerosis. For the primary outcome, testosterone treatment compared with placebo was associated with a significantly greater increase in noncalcified plaque volume from baseline to 12 months (from median values of 204mm3 to 232 mm(3) vs 317 mm(3) to 325 mm(3), respectively; estimated difference, 41 mm(3); 95% CI, 14 to 67 mm(3); P = .003). For the secondary outcomes, the median total plaque volume increased from baseline to 12 months from 272 mm(3) to 318 mm(3) in the testosterone group vs from 499 mm(3) to 541 mm(3) in the placebo group (estimated difference, 47 mm(3); 95% CI, 13 to 80 mm(3); P=.006), and the median coronary artery calcification score changed from 255 to 244 Agatston units in the testosterone group vs 494 to 503 Agatston units in the placebo group (estimated difference, -27 Agatston units; 95% CI, -80 to 26 Agatston units). No major adverse cardiovascular events occurred in either group. CONCLUSIONS AND RELEVANCE Among older men with symptomatic hypogonadism, treatment with testosterone gel for 1 year compared with placebo was associated with a significantly greater increase in coronary artery noncalcified plaque volume, as measured by coronary computed tomographic angiography. Larger studies are needed to understand the clinical implications of this finding.	[Budoff, Matthew J.; Nakanishi, Rine; Nezarat, Negin; Matsumoto, Suguru] Harbor UCLA Med Ctr, Div Cardiol, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Ellenberg, Susan S.; Stephens-Shields, Alisa; Hou, Xiaoling; Cifelli, Denise] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lewis, Cora E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Mohler, Emile R., III] Univ Penn, Sect Vasc Med, Div Cardiovasc Dis, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wenger, Nanette K.] Emory Univ, Sch Med, Div Cardiol, Dept Med,Emory Heart & Vasc Ctr, Atlanta, GA 30322 USA; [Bhasin, Shalender; Basaria, Shehzad] Harvard Med Sch, Brigham & Womens Hosp, Res Program Mens Hlth Aging & Metab, Boston, MA USA; [Barrett-Connor, Elizabeth] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA; [Swerdloff, Ronald S.; Wang, Christina] Harbor UCLA, Los Angeles Biomed Res Inst, Div Endocrinol, Torrance, CA USA; [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Crandall, Jill P.] Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10467 USA; [Crandall, Jill P.] Albert Einstein Coll Med, Div Geriatr, Bronx, NY 10467 USA; [Cunningham, Glenn R.] Baylor Coll Med, Dept Med, Div Diabet Endocrinol & Metab, Houston, TX 77030 USA; [Cunningham, Glenn R.] Baylor St Lukes Med Ctr, Houston, TX USA; [Cunningham, Glenn R.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA; [Ensrud, Kristine E.; Diem, Susan J.] Univ Minnesota, Dept Med, Div Epidemiol & Community Hlth, Box 736 UMHC, Minneapolis, MN 55455 USA; [Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Gill, Thomas M.] Yale Sch Med, Div Geriatr Med, New Haven, CT USA; [Matsumoto, Alvin M.] Univ Washington, Sch Med, Geriatr Res Educ & Clin Ctr, VA Puget Sound Hlth Syst, Seattle, WA USA; [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Molitch, Mark E.] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Snyder, Peter J.] Univ Penn, Div Endocrinol Diabet & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of Pennsylvania; Pennsylvania Medicine; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Emory University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Yale University; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University; Feinberg School of Medicine; University of Pennsylvania; Pennsylvania Medicine	Snyder, PJ (corresponding author), Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	pjs@mail.med.upenn.edu	Budoff, Matthew/ABD-5175-2021; Gill, Thomas M./H-7043-2019; Matsumoto, Alvin/AAH-6096-2020	Budoff, Matthew/0000-0002-9616-1946; Gill, Thomas M./0000-0002-6450-0368; Basaria, Shehzad/0000-0003-1749-8549; Ensrud, Kristine/0000-0002-9069-3036	National Institute on Aging [U01 AG030644, K07AG043587]; National Heart, Lung, and Blood Institute; National Institute of Neurological Diseases and Stroke; National Institute of Child Health and Human Development; AndroGel; placebo gel; National Institute of Diabetes and Digestive and Kidney Diseases [DK079626]; Claude D. Pepper Older Americans Independence Centers grant from the National Institute on Aging [P30-AG021342]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK079626, P30DK079626, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021342, U01AG030644, K07AG043587] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Diseases and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); AndroGel; placebo gel; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Claude D. Pepper Older Americans Independence Centers grant from the National Institute on Aging; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Testosterone Trials were supported by grant U01 AG030644 from the National Institute on Aging, supplemented by funds from the National Heart, Lung, and Blood Institute. Additional funding was provided by the National Institute of Neurological Diseases and Stroke and the National Institute of Child Health and Human Development. AbbVie provided funding, AndroGel, and placebo gel. Dr Lewis was supported by grant DK079626 from the National Institute of Diabetes and Digestive and Kidney Diseases to the University of Alabama at Birmingham Diabetes Research and Training Center. Dr Gill is the recipient of Academic Leadership Award K07AG043587 from the National Institute on Aging, and the Yale Field Center is supported in part by the Claude D. Pepper Older Americans Independence Centers grant P30-AG021342 from the National Institute on Aging.	Abd Alamir M, 2016, CORONARY ARTERY DIS, V27, P95, DOI 10.1097/MCA.0000000000000321; Arbab-Zadeh A, 2015, J AM COLL CARDIOL, V65, P846, DOI 10.1016/j.jacc.2014.11.041; Baillargeon J, 2014, ANN PHARMACOTHER, V48, P1138, DOI 10.1177/1060028014539918; Baillargeon J, 2013, JAMA INTERN MED, V173, P1465, DOI 10.1001/jamainternmed.2013.6895; BARRETTCONNOR E, 1988, CIRCULATION, V78, P539, DOI 10.1161/01.CIR.78.3.539; Basaria S, 2015, JAMA-J AM MED ASSOC, V314, P570, DOI 10.1001/jama.2015.8881; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Boogers MJ, 2012, EUR HEART J, V33, P1007, DOI 10.1093/eurheartj/ehr465; Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439; Cauley JA, 2015, J GERONTOL A-BIOL, V70, P1105, DOI 10.1093/gerona/glv031; Dalager MG, 2011, INT J CARDIOVAS IMAG, V27, P593, DOI 10.1007/s10554-010-9695-z; Finkle WD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085805; Fischer C, 2013, J CARDIOVASC COMPUT, V7, P256, DOI 10.1016/j.jcct.2013.08.006; Gaur S, 2016, EUR HEART J, V37, P1220, DOI 10.1093/eurheartj/ehv690; Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]; Hamirani YS, 2011, INT J CARDIOL, V149, P270, DOI 10.1016/j.ijcard.2011.02.056; Khaw KT, 2007, CIRCULATION, V116, P2694, DOI 10.1161/CIRCULATIONAHA.107.719005; Kloner RA, 2016, J AM COLL CARDIOL, V67, P545, DOI 10.1016/j.jacc.2015.12.005; Matsumoto S, 2016, J NUTR, V146, p427S, DOI 10.3945/jn.114.202424; Miszalski-Jamka T, 2012, INT J CARDIOVAS IMAG, V28, P621, DOI 10.1007/s10554-011-9799-0; Muraleedharan V, 2013, EUR J ENDOCRINOL, V169, P725, DOI 10.1530/EJE-13-0321; Oh JY, 2002, DIABETES CARE, V25, P55, DOI 10.2337/diacare.25.1.55; Papadopoulou SL, 2012, JACC-CARDIOVASC IMAG, V5, pS28, DOI 10.1016/j.jcmg.2012.01.009; Raff Gilbert L, 2009, J Cardiovasc Comput Tomogr, V3, P122, DOI 10.1016/j.jcct.2009.01.001; Samady H, 2011, CIRCULATION, V124, P779, DOI 10.1161/CIRCULATIONAHA.111.021824; Schuhbaeck A, 2014, EUR RADIOL, V24, P2300, DOI 10.1007/s00330-014-3253-3; Shores MM, 2012, J CLIN ENDOCR METAB, V97, P2050, DOI 10.1210/jc.2011-2591; Smith GD, 2005, CIRCULATION, V112, P332, DOI 10.1161/CIRCULATIONAHA.104.489088; Snyder PJ, 2016, NEW ENGL J MED, V374, P611, DOI 10.1056/NEJMoa1506119; Snyder PJ, 2014, CLIN TRIALS, V11, P362, DOI 10.1177/1740774514524032; Srinivas-Shankar U, 2010, J CLIN ENDOCR METAB, V95, P639, DOI 10.1210/jc.2009-1251; Vigen R, 2013, JAMA-J AM MED ASSOC, V310, P1829, DOI 10.1001/jama.2013.280386; Zeb I, 2013, ATHEROSCLEROSIS, V231, P198, DOI 10.1016/j.atherosclerosis.2013.08.019	33	216	221	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2017	317	7					708	716		10.1001/jama.2016.21043	http://dx.doi.org/10.1001/jama.2016.21043			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL8WR	28241355	Green Published, Green Accepted			2023-01-03	WOS:000394901600018
J	Beernaert, K; Smets, T; Cohen, J; Verhofstede, R; Costantini, M; Eecloo, K; Van Den Noortgate, N; Deliens, L				Beernaert, Kim; Smets, Tinne; Cohen, Joachim; Verhofstede, Rebecca; Costantini, Massimo; Eecloo, Kim; Van Den Noortgate, Nele; Deliens, Luc			Improving comfort around dying in elderly people: a cluster randomised controlled trial	LANCET			English	Article							LIVERPOOL CARE PATHWAY; OF-LIFE CARE; PALLIATIVE CARE; LAST HOURS; END; PROGRAM; CANCER	Background Over 50% of elderly people die in acute hospital settings, where the quality of end-of-life care is often suboptimum. We aimed to assess the effectiveness of the Care Programme for the Last Days of Life (CAREFuL) at improving comfort and quality of care in the dying phase in elderly people. Methods We did a cluster randomised controlled trial in acute geriatric wards in ten hospitals in Flemish Region, Belgium, between Oct 1, 2012, and March 31, 2015. Hospitals were randomly assigned to implementation of CAREFuL (CAREFuL group) or to standard care (control group) using a random number generator. Patients and families were masked to interventaion allocation; hospital staff were unmasked. CAREFuL comprised a care guide for the last days of life, training, supportive documentation, and an implementation guide. Primary outcomes were comfort around dying, measured with the End-of-Life in Dementia-Comfort Assessment in Dying (CAD-EOLD), and symptom management, measured with the End-of-Life in Dementia-Symptom Management (SM-EOLD), by nurses and family carers. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01890239. Findings 451 (11%) of 4241 beds in ten hospitals were included in the analyses. Five hospitals were randomly assigned to standard health care practice and five to the CAREFuL programme; 118 patients in the control group and 164 in the CAREFuL group were eligible for assessment. Assessments were done for 132 (80%) of 164 patients in the CAREFuL group and 109 (92%) of 118 in the control group by nurses, and 48 (29%) in the CAREFuL group and 23 (19%) in the control group by family carers. Implementation of CAREFuL compared with control significantly improved nurseassessed comfort (CAD-EOLD baseline-adjusted mean difference 4.30, 95% CI 2.07-6.53; p<0.0001). No significant differences were noted for the CAD-EOLD assessed by family carers (baseline-adjusted mean difference -0.62, 95% CI -6.07 to 4.82; p=0.82) or the SM-EOLD assessed by nurses (-0.41, -1.86 to 1.05; p=0.58) or by family carers (-0.59, -3.75 to 2.57; p=0.71). Interpretation Although a continuous monitoring of the programme is warranted, these results suggest that implementation of CAREFuL might improve care during the last days of life for patients in acute geriatric hospital wards.	[Beernaert, Kim; Smets, Tinne; Cohen, Joachim; Verhofstede, Rebecca; Eecloo, Kim; Van Den Noortgate, Nele; Deliens, Luc] Vrije Univ Brussel, End Life Care Res Grp, B-1090 Brussels, Belgium; [Beernaert, Kim; Smets, Tinne; Cohen, Joachim; Verhofstede, Rebecca; Eecloo, Kim; Van Den Noortgate, Nele; Deliens, Luc] Univ Ghent, End Life Care Res Grp, Ghent, Belgium; [Deliens, Luc] Univ Ghent, Dept Med Oncol, Ghent, Belgium; [Costantini, Massimo] Arcispedale Santa Maria Nuova IRCCS, Palliat Care Unit, Reggio Emilia, Italy; [Van Den Noortgate, Nele] Ghent Univ Hosp, Dept Geriatr Med, Ghent, Belgium	Vrije Universiteit Brussel; Ghent University; Ghent University; IRCCS Arcispedale S. Maria Nuova; Ghent University; Ghent University Hospital	Beernaert, K (corresponding author), Vrije Univ Brussel, End Life Care Res Grp, B-1090 Brussels, Belgium.	kim.beernaert@vub.ac.be	costantini, massimo/AAK-5388-2021; Cohen, Joachim/B-6803-2008	costantini, massimo/0000-0002-5293-7079; Cohen, Joachim/0000-0002-7224-9476; Beernaert, Kim/0000-0002-2520-3977; Van Den Noortgate, Nele/0000-0001-5546-5380; Smets, Tinne/0000-0003-1439-316X	Flemish Government Agency for Innovation by Science and Technology; Belgian Cancer Society "Kom Op Tegen Kanker"	Flemish Government Agency for Innovation by Science and Technology; Belgian Cancer Society "Kom Op Tegen Kanker"	The Flemish Government Agency for Innovation by Science and Technology and the Belgian Cancer Society "Kom Op Tegen Kanker".	Adams G, 2004, J CLIN EPIDEMIOL, V57, P785, DOI 10.1016/j.jclinepi.2003.12.013; Agentschap Zorg en Gezondheid, 2016, EV LIGD BEZ ZIEK; Al-Qurainy R, 2009, INT J CLIN PRACT, V63, P508, DOI 10.1111/j.1742-1241.2008.01991.x; Bailey FA, 2005, ARCH INTERN MED, V165, P1722, DOI 10.1001/archinte.165.15.1722; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; Brannstrom M, 2016, PALLIATIVE MED, V30, P54, DOI 10.1177/0269216315588007; Chan R. J., 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD008006.PUB4; Chan R, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008006.pub2, 10.1002/14651858.CD008006.pub4]; Chan RJ, 2013, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14641858.CD008006; Costantini M, 2014, LANCET, V383, P226, DOI 10.1016/S0140-6736(13)61725-0; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Ellershaw J., 2011, CARE DYING PATHWAY E; Floriani CA, 2012, PALLIAT SUPPORT CARE, V10, P295, DOI 10.1017/S1478951511001039; Gomes B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0466-5; Hall S., 2011, PALLIATIVE CARE OLDE; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; Karlawish JHT, 2003, J PAIN SYMPTOM MANAG, V25, pS14, DOI 10.1016/S0885-3924(03)00098-8; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Marie Curie Palliative Care Institute, 2009, NAT CAR DYING AUD HO; McConnell T, 2013, WORLDV EVID-BASED NU, V10, P218, DOI 10.1111/wvn.12003; Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Murray-Brown F, 2015, PALLIATIVE MED, V29, P975, DOI 10.1177/0269216315601951; Neuberger J., 2013, MORE CARE LESS PATHW; Pivodic L, 2016, J EPIDEMIOL COMMUN H, V70, P17, DOI 10.1136/jech-2014-205365; Twomey F, 2007, AGE AGEING, V36, P462, DOI 10.1093/ageing/afm031; Vacha-Haase T, 2004, J COUNS PSYCHOL, V51, P473, DOI 10.1037/0022-0167.51.4.473; Verhofstede R, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0102-y; Verhofstede R, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0025-z; Verhofstede R, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0010-7; Volicer L, 2011, ALZ DIS ASSOC DIS, V15, P194; World Health Organization, 2005, PREVENTING CHRONIC D	32	15	16	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	2017	390	10090					125	134		10.1016/S0140-6736(17)31265-5	http://dx.doi.org/10.1016/S0140-6736(17)31265-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ8LF	28526493				2023-01-03	WOS:000404976600029
J	Pai, SC; Kung, PT; Chou, WY; Kuo, T; Tsai, WC				Pai, Szu-Chi; Kung, Pei-Tseng; Chou, Wen-Yu; Kuo, Tsunghuai; Tsai, Wen-Chen			Survival and medical utilization of children and adolescents with prolonged ventilatordependent and associated factors	PLOS ONE			English	Article							TERM MECHANICAL VENTILATION; OUTCOMES; CARE; COST	Over the course of a year, more than 20,000 patients in Taiwan require prolonged mechanical ventilation (PMV). Data from the National Health Insurance Research Database for patients between 2005 and 2011 were used to conduct a retrospective analysis on ventilator dependence. The study subjects were PMV patients aged <17 years in Taiwan. A multiple regression model employing general estimating equations was applied to investigate the factors affecting the use of medical resources by children and adolescent PMV patients. A Cox proportional hazard model was incorporated to explore the factors affecting the survival of these patients. Data were collected for a total of 1,019 children and adolescent PMV patients in Taiwan. The results revealed that the average number of outpatient visits per subject was 32.1 times per year, whereas emergency treatments averaged 1.56 times per year per subject and hospitalizations averaged 160.8 days per year per subject. Regarding average annual medical costs, hospitalizations accounted for the largest portion at NT $821,703 per year per subject, followed by outpatient care at NT$123,136 per year per subject and emergency care at NT$3,806 per year per subject. The demographic results indicated that the patients were predominately male (61.24%), with those under 1 year of age accounting for the highest percentage (36.38%). According to the Kaplan D Meier curve, the 1-year and 5-year mortality rates of the patients were approximately 32% and 47%, respectively. The following factors affecting the survival rate were considered: age, the Charlson Comorbidity Index (CCI), diagnosis type necessitating ventilator use, and whether an invasive ventilator was used. This study investigated the use of medical resources and the survival rates of children and adolescent PMV patients. The findings of this study can serve as a reference for the National Health Insurance Administration in promoting its future integrated pilot projects on ventilator dependency.	[Pai, Szu-Chi; Chou, Wen-Yu; Tsai, Wen-Chen] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Pai, Szu-Chi] Show Chwan Mem Hosp, Dept Resp Therapy, Changhua, Taiwan; [Kung, Pei-Tseng] Asia Univ, Dept Hlth Adm, Taichung, Taiwan; [Kuo, Tsunghuai] Show Chwan Mem Hosp, Dept Chest Med, Changhua, Taiwan	China Medical University Taiwan; Show Chwan Memorial Hospital; Asia University Taiwan; Show Chwan Memorial Hospital	Tsai, WC (corresponding author), China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan.	wtsai@mail.cmu.edu.tw	Tsai, Wen-Chen/O-3095-2015	Tsai, Wen-Chen/0000-0002-9684-0789	China Medical University [CMU103-ASIA-23, DOH102-NH-9009]; Asia University; Ministry of Health and Welfare, Taiwan; National Health Insurance Administration, Taiwan	China Medical University(China Medical University); Asia University; Ministry of Health and Welfare, Taiwan; National Health Insurance Administration, Taiwan	This study was supported by grants (CMU103-ASIA-23, DOH102-NH-9009) from China Medical University, Asia University and the Ministry of Health and Welfare, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was supported by grants (CMU103-ASIA-23, DOH102-NH-9009) from China Medical University, Asia University and the National Health Insurance Administration, Taiwan. We are grateful for use of the National Health Insurance Research Database.	Baldwin MR, 2013, CHEST, V143, P910, DOI 10.1378/chest.12-1668; Benneyworth BD, 2011, PEDIATRICS, V127, pE1533, DOI 10.1542/peds.2010-2026; Damuth E, 2015, LANCET RESP MED, V3, P544, DOI 10.1016/S2213-2600(15)00150-2; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Edwards J. D., 2010, J PEDIAT, V157; Estenssoro E, 2005, CHEST, V127, P598, DOI 10.1378/chest.127.2.598; Fakharian Atefeh, 2013, Tanaffos, V12, P6; Frengley JD, 2014, J AM GERIATR SOC, V62, P1, DOI 10.1111/jgs.12597; Hsia SH, 2012, PEDIATR NEONATOL, V53, P304, DOI 10.1016/j.pedneo.2012.07.005; Lin MS, 2013, RESP CARE, V58, P517, DOI 10.4187/respcare.01530; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Lone NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10117; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; McDougall CM, 2013, ARCH DIS CHILD, V98, P660, DOI 10.1136/archdischild-2012-303062; National Health Insurance Administration Ministry of Health and Welfare, 2013, REG GOV EX NAT HLTH; National Health Insurance Administration Ministry of Health and Welfare, 2016, UN HLTH COV TAIW; National Health Insurance Administration Ministry of Health and Welfare, 2012, BUS IMPL REP FEBR; National Health Insurance Administration Ministry of Health and Welfare, 2014, ABSTR STAT AN NAT A; National Health Insurance Administration Ministry of Health and Welfare, 2006, EST VENT INT DEL SYS; National Health Insurance Administration Ministry of Health and Welfare. The National Health Insur- ance Statistics, 2010, ABSTR STAT AN 3 ST A, V4; National Health Insurance Administration Ministry of Health and Welfare. The National Health Insurance Statistics, 2014, NAT HLTH INS STAT B, V4; Pilcher DV, 2005, THORAX, V60, P187, DOI 10.1136/thx.2004.026500; Racca F, 2011, MINERVA ANESTESIOL, V77, P892; Tung HP, 2009, J TAIWAN EMERG MED, V11, pS14; Wallis C, 2011, ARCH DIS CHILD, V96, P998, DOI 10.1136/adc.2010.192864	25	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2017	12	6							e0179274	10.1371/journal.pone.0179274	http://dx.doi.org/10.1371/journal.pone.0179274			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY5TN	28628663	Green Published, gold, Green Submitted			2023-01-03	WOS:000404043100021
J	Taran, S; Detsky, AS				Taran, Shaurya; Detsky, Allan S.			It's a Beautiful Thing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Taran, Shaurya; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Detsky, AS (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Toronto, ON, Canada.; Detsky, AS (corresponding author), Univ Hlth Network, Toronto, ON, Canada.	allan.detsky@sinaihealthsystem.ca	Taran, Shaurya/ABF-1571-2020					McCabe K., 1989, WASHINGTONIAN    AUG	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2017	317	21					2165	2166		10.1001/jama.2017.3102	http://dx.doi.org/10.1001/jama.2017.3102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW7PG	28586891				2023-01-03	WOS:000402706100009
J	Raina, R; Chauvin, AM; Bunchman, T; Askenazi, D; Deep, A; Ensley, MJ; Krishnappa, V; Sethi, SK				Raina, Rupesh; Chauvin, Abigail M.; Bunchman, Timothy; Askenazi, David; Deep, Akash; Ensley, Michael J.; Krishnappa, Vinod; Sethi, Sidharth Kumar			Treatment of AKI in developing and developed countries: An international survey of pediatric dialysis modalities	PLOS ONE			English	Article							RENAL REPLACEMENT THERAPY; ACUTE KIDNEY INJURY; CHILDREN; ULTRAFILTRATION; EPIDEMIOLOGY; HEMODIALYSIS; METAANALYSIS; MANAGEMENT; FAILURE	Hypothesis Acute kidney injury (AKI) is a common cause of morbidity and mortality worldwide, with a pediatric incidence ranging from 19.3% to 24.1%. Treatment of pediatric AKI is a source of debate in varying geographical regions. Currently CRRT is the treatment for pediatric AKI, but limitations due to cost and accessibility force use of adult equipment and other therapeutic options such as peritoneal dialysis (PD) and hemodialysis (HD). It was hypothesized that more cost-effective measures would likely be used in developing countries due to lesser resource availability. Methods A 26-question internet-based survey was distributed to 650 pediatric Nephrologists. There was a response rate of 34.3% (223 responses). The survey was distributed via pedneph and perrt email servers, inquiring about demographics, technology, resources, pediatric-specific supplies, and preference in renal replacement therapy (RRT) in pediatric AKI. The main method of analysis was to compare responses about treatments between nephrologists in developed countries and nephrologists in developing countries using difference-of-proportions tests. Results PD was available in all centers surveyed, while HD was available in 85.1% and 54.1% (p = 0.00), CRRT was available in 60% and 33.3% (p = 0.001), and SLED was available in 20% and 25% (p = 0.45) centers of developed and developing world respectively. In developing countries, 68.5% (p = 0.000) of physicians preferred PD to costlier therapies, while in developed countries it was found that physicians favored HD (72%, p = 0.00) or CRRT (24%, p = 0.041) in infants. Conclusions Lack of availability of resources, trained physicians and funds often preclude standards of care in developing countries, and there is much development needed in terms of meeting higher global standards for treating pediatric AKI patients. PD remains the main modality of choice for treatment of AKI in infants in developing world.	[Raina, Rupesh] Akron Childrens Hosp, Dept Pediat Nephrol, Akron, OH 44308 USA; [Raina, Rupesh; Krishnappa, Vinod] Cleveland Clin Akron Gen, Dept Nephrol, Akron, OH 44307 USA; [Chauvin, Abigail M.] Northeast Ohio Med Univ, Rootstown, OH USA; [Bunchman, Timothy] VCU Sch Med, Childrens Hosp Richmond, Richmond, VA USA; [Askenazi, David] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Deep, Akash] Kings Coll Hosp London, Denmark Hill, London, England; [Ensley, Michael J.] Kent State Univ, Dept Polit Sci, Kent, OH 44242 USA; [Sethi, Sidharth Kumar] Medanta, Kidney Inst, Gurgaon, Haryana, India	Akron Children's Hospital; Northeast Ohio Medical University (NEOMED); Virginia Commonwealth University; University of Alabama System; University of Alabama Birmingham; King's College Hospital NHS Foundation Trust; King's College Hospital; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Raina, R (corresponding author), Akron Childrens Hosp, Dept Pediat Nephrol, Akron, OH 44308 USA.; Raina, R (corresponding author), Cleveland Clin Akron Gen, Dept Nephrol, Akron, OH 44307 USA.	rraina@chmca.org	Krishnappa, Vinod/Y-8213-2018; raina, rupesh/AAE-6660-2020	Krishnappa, Vinod/0000-0002-1697-4526; 				Askenazi D, 2016, PEDIATR NEPHROL, V31, P853, DOI 10.1007/s00467-015-3259-3; Basu RK, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0016-6; BELSHA CW, 1995, PEDIATR NEPHROL, V9, P361, DOI 10.1007/BF02254215; Bunchman TE, 2008, SEMIN NEPHROL, V28, P488, DOI 10.1016/j.semnephrol.2008.05.009; Cerda J, 2008, NAT CLIN PRACT NEPHR, V4, P138, DOI 10.1038/ncpneph0722; Coulthard MG, 2014, PEDIATR NEPHROL, V29, P1873, DOI 10.1007/s00467-014-2923-3; COULTHARD MG, 1995, ARCH DIS CHILD-FETAL, V73, pF162, DOI 10.1136/fn.73.3.F162; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Kidney Disease: Improving Global Outcomes (KDIGO) Group, 2012, KIDNEY INT S; McCulloch M SH, 2016, PEDIAT NEPHROLOGY, P2613; Momtaz HE, 2014, J CLIN NEONATOL, V3, P99, DOI 10.4103/2249-4847.134691; Peruzzi L, 2014, CASE REP NEPHROL DIA, V4, P113, DOI 10.1159/000363691; Ronco C, 2015, AM J KIDNEY DIS, V66, P206, DOI 10.1053/j.ajkd.2015.03.029; Ronco C, 2014, LANCET, V383, P1807, DOI 10.1016/S0140-6736(14)60799-6; Ronco C, 2012, PEDIATR NEPHROL, V27, P1203, DOI 10.1007/s00467-012-2179-8; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Sutherland SM, 2013, CLIN J AM SOC NEPHRO, V8, P1661, DOI 10.2215/CJN.00270113; Uchino S, 2007, INTENS CARE MED, V33, P1563, DOI 10.1007/s00134-007-0754-4; Vasudevan A, 2012, Indian J Nephrol, V22, P121, DOI 10.4103/0971-4065.97130; Warady BA, 2000, PEDIATR NEPHROL, V15, P11, DOI 10.1007/s004670000420	20	24	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2017	12	5							e0178233	10.1371/journal.pone.0178233	http://dx.doi.org/10.1371/journal.pone.0178233			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6GJ	28557999	Green Submitted, Green Published, gold			2023-01-03	WOS:000402607000035
J	Galan, I; Slmon, L; Boldo, E; Ortiz, C; Fernandez-Cuenca, R; Linares, C; Medrano, MJ; Pastor-Barriuso, R				Galan, Inaki; Slmon, Lorena; Boldo, Elena; Ortiz, Cristina; Fernandez-Cuenca, Rafael; Linares, Cristina; Jose Medrano, Maria; Pastor-Barriuso, Roberto			Changes in hospitalizations for chronic respiratory diseases after two successive smoking bans in Spain	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EMERGENCY-DEPARTMENT VISITS; FREE LEGISLATION; CHILDHOOD ASTHMA; SPANISH SMOKING; BAR WORKERS; IMPACT; IMPLEMENTATION; METAANALYSIS; HEALTH	Background Existing evidence on the effects of smoke-free policies on respiratory diseases is scarce and inconclusive. Spain enacted two consecutive smoke-free regulations: a partial ban in 2006 and a comprehensive ban in 2011. We estimated their impact on hospital admissions via emergency departments for chronic obstructive pulmonary disease (COPD) and asthma. Methods Data for COPD (ICD-9 490-492, 494-496) came from 2003-2012 hospital admission records from the fourteen largest provinces of Spain and from five provinces for asthma (ICD-9 493). We estimated changes in hospital admission rates within provinces using Poisson additive models adjusted for long-term linear trends and seasonality, day of the week, temperature, influenza, acute respiratory infections, and pollen counts (asthma models). We estimated immediate and gradual effects through segmented-linear models. The coefficients within each province were combined through random-effects multivariate meta-analytic models. Results The partial ban was associated with a strong significant pooled immediate decline in COPD-related admission rates (14.7%, 95% CI: 5.0, 23.4), sustained over time with a one-year decrease of 13.6% (95% CI: 2.9, 23.1). The association was consistent across age and sex groups but stronger in less economically developed Spanish provinces. Asthma-related admission rates decreased by 7.4% (95% CI: 0.2, 14.2) immediately after the comprehensive ban was implemented, although the one-year decrease was sustained only among men (9.9%, 95% CI: 3.9, 15.6). Conclusions The partial ban was associated with an immediate and sustained strong decline in COPD-related admissions, especially in less economically developed provinces. The comprehensive ban was related to an immediate decrease in asthma, sustained for the medium-term only among men.	[Galan, Inaki; Slmon, Lorena; Boldo, Elena; Ortiz, Cristina; Fernandez-Cuenca, Rafael; Jose Medrano, Maria; Pastor-Barriuso, Roberto] Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain; [Galan, Inaki] Univ Autonoma Madrid, IdiPAZ, Sch Med, Dept Prevent Med & Publ Hlth, Madrid, Spain; [Boldo, Elena; Fernandez-Cuenca, Rafael; Pastor-Barriuso, Roberto] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain; [Boldo, Elena] Puerta de Hierro Biomed Res Inst, Madrid, Spain; [Linares, Cristina] Inst Salud Carlos III, Natl Sch Publ Hlth, Madrid, Spain	Instituto de Salud Carlos III; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Instituto de Salud Carlos III	Galan, I (corresponding author), Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain.; Galan, I (corresponding author), Univ Autonoma Madrid, IdiPAZ, Sch Med, Dept Prevent Med & Publ Hlth, Madrid, Spain.	igalan@isciii.es	Galán, Ignacio/P-6451-2015; Pastor-Barriuso, Roberto/AAA-6746-2019; Boldo, Elena/L-6610-2014	Galán, Ignacio/0000-0003-0624-9993; Pastor-Barriuso, Roberto/0000-0002-7325-3960; Boldo, Elena/0000-0003-0027-1989	Institute of Health Carlos III, Ministry of Economy and Competitiveness [FIS PI11/01276]	Institute of Health Carlos III, Ministry of Economy and Competitiveness	This work was supported by Grant FIS PI11/01276 from the Institute of Health Carlos III, Ministry of Economy and Competitiveness. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allwright S, 2005, BMJ-BRIT MED J, V331, P1117, DOI 10.1136/bmj.38636.499225.55; Burke DL, 2017, STAT MED, V36, P855, DOI 10.1002/sim.7141; Hidalgo AC, 2014, GAC SANIT, V28, P456, DOI 10.1016/j.gaceta.2014.05.006; Comhair SAA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018574; Croghan IT, 2015, BMC PULM MED, V15, DOI 10.1186/1471-2466-15-6; Dusemund F, 2015, TOB CONTROL, V24, P404, DOI 10.1136/tobaccocontrol-2013-051290; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; Fernandez E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004244; Flouris AD, 2011, CURR OPIN PULM MED, V17, P110, DOI 10.1097/MCP.0b013e328343165d; Frazer K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005992.pub3; Galan I, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008892; Gan WQ, 2015, TOB CONTROL, V24, P568, DOI 10.1136/tobaccocontrol-2014-051660; Gasparrini A, 2012, STAT MED, V31, P3821, DOI 10.1002/sim.5471; Gaudreau K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056102; Gershon AS, 2012, COPD, V9, P216, DOI 10.3109/15412555.2011.648030; Goldstein E, 2012, EPIDEMIOLOGY, V23, P829, DOI 10.1097/EDE.0b013e31826c2dda; Hahn EJ, 2014, AM J PUBLIC HEALTH, V104, P1059, DOI 10.2105/AJPH.2014.301887; Hartl S, 2016, EUR RESPIR J, V47, P113, DOI 10.1183/13993003.01391-2014; Head P, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120079; Herman PM, 2011, AM J PUBLIC HEALTH, V101, P491, DOI 10.2105/AJPH.2009.179572; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Humair JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090417; Hunsberger S, 2002, BIOSTATISTICS, V3, P289, DOI 10.1093/biostatistics/3.2.289; Jimenez-Ruiz CA, 2008, EUR J PUBLIC HEALTH, V18, P622, DOI 10.1093/eurpub/ckn066; Kent BD, 2012, CHEST, V142, P673, DOI 10.1378/chest.11-2757; Landers G, 2014, AM J PUBLIC HEALTH, V104, pE74, DOI 10.2105/AJPH.2013.301697; Larrauri A., 2006, Boletin Epidemiologico Semanal, V14, P85; Lopez MJ, 2013, NICOTINE TOB RES, V15, P992, DOI 10.1093/ntr/nts218; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Millett C, 2013, PEDIATRICS, V131, pE495, DOI 10.1542/peds.2012-2592; Moraros J, 2010, INT J ENV RES PUB HE, V7, P4169, DOI 10.3390/ijerph7124169; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; Rayens MK, 2008, J ALLERGY CLIN IMMUN, V122, P537, DOI 10.1016/j.jaci.2008.06.029; Shetty KD, 2011, J POLICY ANAL MANAG, V30, P6, DOI 10.1002/pam.20548; Spanish Society of Epidemiology, ASS IMP SPAN SMOK LA; Stallings-Smith S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098617; Svanes C, 2004, THORAX, V59, P295, DOI 10.1136/thx.2003.009746; Tan CE, 2012, CIRCULATION, V126, P2177, DOI 10.1161/CIRCULATIONAHA.112.121301; US Dept of Health and Human Services, 2014, HLTH CONS SMOK 50 YE HLTH CONS SMOK 50 YE; US Surgeon General, 2006, HLTH CONS INV EXP TO; Vander W. M. W., 2012, HEALTH AFFAIR, V31, P2699, DOI DOI 10.1377/HLTHAFF.2011.0385; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wood SN, 2003, J ROY STAT SOC B, V65, P95, DOI 10.1111/1467-9868.00374	44	16	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2017	12	5							e0177979	10.1371/journal.pone.0177979	http://dx.doi.org/10.1371/journal.pone.0177979			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV8VE	28542337	Green Published, Green Submitted, gold			2023-01-03	WOS:000402061500048
J	Kao, CC; Yang, JY; Chen, L; Chao, CT; Peng, YS; Chiang, CK; Huang, JW; Hung, KY				Kao, Chih-Chin; Yang, Ju-Yeh; Chen, Likwang; Chao, Chia-Ter; Peng, Yu-Sen; Chiang, Chih-Kang; Huang, Jenq-Wen; Hung, Kuan-Yu			Factors associated with poor outcomes of continuous renal replacement therapy	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; PERITONEAL-DIALYSIS; REQUIRING CRRT; FAILURE; DISEASE; MORTALITY; RISK; HEMODIALYSIS; CIRRHOSIS	Continuous renal replacement therapy (CRRT) is one of the dialysis modalities for critically ill patients. Despite intensive dialysis care, a high mortality rate is found in these patients. Our objective was to investigate the factors associated with poor outcomes in these patients. We conducted a retrospective cohort study using the National Health Insurance Research Database. Records of critically ill patients who received CRRT between 2007 and 2011 were retrieved, and the patients were categorized into two groups: those with acute kidney injury (AKI) and those with history of end-stage renal disease (ESRD). Our primary and secondary outcomes were in-hospital mortality and long-term survival and non-renal recovery (long-term dialysis dependence), respectively, in the AKI group. We enrolled 15,453 patients, with 13,204 and 2249 in the AKI and ESRD groups, respectively. Overall, 66.5% patients died during hospitalization. In-hospital mortality did not differ significantly between groups (adjusted odds ratio, 0.93; 95% CI, 0.84-1.02). Age, chronic liver disease, and cancer history were identified as independent risk factors for in-hospital mortality in both groups. Hypertension was associated with higher risk of in-hospital mortality in patients with AKI. Age, coronary artery disease, and admission to the medical intensive care unit (MICU) were risk factors for long-term dialysis dependence in patients with AKI. Patients with AKI and ESRD have similarly poor outcomes after CRRT. Older age and presence of chronic liver disease and cancer were associated with higher mortality. Older age, presence of coronary artery disease, and admission to MICU were associated with lower renal recovery rate in patients with AKI.	[Kao, Chih-Chin] Taipei Med Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Kao, Chih-Chin] Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, Taipei, Taiwan; [Kao, Chih-Chin] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Yang, Ju-Yeh; Peng, Yu-Sen] Far Eastern Mem Hosp, Div Nephrol, New Taipei, Taiwan; [Yang, Ju-Yeh] Far Eastern Mem Hosp, Dept Qual Management Ctr, New Taipei, Taiwan; [Yang, Ju-Yeh] Oriental Inst Technol, Dept Ind Management, New Taipei, Taiwan; [Chen, Likwang] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan; [Chao, Chia-Ter; Chiang, Chih-Kang; Huang, Jenq-Wen; Hung, Kuan-Yu] Natl Taiwan Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; Asia Eastern University of Science & Technology; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital	Huang, JW (corresponding author), Natl Taiwan Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan.	jenqwen@gmail.com	peng, yu/GXW-2071-2022; Chao, Chia-Ter/H-7994-2019	Chao, Chia-Ter/0000-0003-2892-7986; Yang, Ju-Yeh/0000-0003-3034-021X; CHIANG, CHIH-KANG/0000-0001-9021-4616; HUANG, JENQ-WEN/0000-0001-8011-2317; HUNG, KUAN-YU/0000-0003-3472-5512				Allegretti AS, 2013, CRIT CARE, V17, DOI 10.1186/cc12780; Arulkumaran N, 2013, BRIT J ANAESTH, V110, P13, DOI 10.1093/bja/aes401; Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc8037; Belcher JM, 2013, HEPATOLOGY, V57, P753, DOI 10.1002/hep.25735; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Campbell GA, 2014, ADV CHRONIC KIDNEY D, V21, P64, DOI 10.1053/j.ackd.2013.08.002; Case J, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/479730; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; Durairaj L, 2005, CHEST, V128, P1682, DOI 10.1378/chest.128.3.1682; Duran PA, 2014, HEMODIAL INT, V18, pS1, DOI 10.1111/hdi.12216; Fagundes C, 2013, J HEPATOL, V59, P474, DOI 10.1016/j.jhep.2013.04.036; Faubel S, 2008, ADV CHRONIC KIDNEY D, V15, P284, DOI 10.1053/j.ackd.2008.04.008; Fortrie G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121482; GINES A, 1993, GASTROENTEROLOGY, V105, P229, DOI 10.1016/0016-5085(93)90031-7; Grams ME, 2012, KIDNEY INT, V81, P942, DOI 10.1038/ki.2011.241; Haider AW, 2003, ANN INTERN MED, V138, P10, DOI 10.7326/0003-4819-138-1-200301070-00006; Hobson EV, 2012, PERITON DIALYSIS INT, V32, P590, DOI 10.3747/pdi.2012.00152; Hsu CY, 2007, CURR OPIN NEPHROL HY, V16, P221, DOI 10.1097/MNH.0b013e3280895ad9; Ishani A, 2009, J AM SOC NEPHROL, V20, P223, DOI 10.1681/ASN.2007080837; Iwagami M, 2015, NEPHROL DIAL TRANSPL, V30, P988, DOI 10.1093/ndt/gfv069; Jung YS, 2012, HEMODIAL INT, V16, P456, DOI 10.1111/j.1542-4758.2012.00694.x; Liu JN, 2010, KIDNEY INT, V77, P141, DOI 10.1038/ki.2009.413; Oh HJ, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0454-8; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Pannu Neesh, 2005, Ther Clin Risk Manag, V1, P141, DOI 10.2147/tcrm.1.2.141.62908; Ronco C, 2001, NEPHROL DIAL TRANSPL, V16, P230, DOI 10.1093/ndt/16.2.230; Salahudeen AK, 2013, CLIN J AM SOC NEPHRO, V8, P347, DOI 10.2215/CJN.03530412; Schmitt R, 2008, AM J KIDNEY DIS, V52, P262, DOI 10.1053/j.ajkd.2008.03.005; Sligl WI, 2010, CRIT CARE MED, V38, P2126, DOI 10.1097/CCM.0b013e3181eedaeb; Srisawat N, 2010, CRIT CARE, V14, DOI 10.1186/cc8933; Strijack B, 2009, J AM SOC NEPHROL, V20, P2441, DOI 10.1681/ASN.2009040366; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Waikar SS, 2008, CLIN J AM SOC NEPHRO, V3, P844, DOI 10.2215/CJN.05191107; Walcher A, 2011, RENAL FAILURE, V33, P935, DOI 10.3109/0886022X.2011.615964; Yang JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12816	38	23	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2017	12	5							e0177759	10.1371/journal.pone.0177759	http://dx.doi.org/10.1371/journal.pone.0177759			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VE	28542272	gold, Green Submitted, Green Published			2023-01-03	WOS:000402061500037
J	McGuire, AL; Mulroney, KT; Carson, CF; Ram, R; Morahan, G; Chakera, A				McGuire, Amanda L.; Mulroney, Kieran T.; Carson, Christine F.; Ram, Ramesh; Morahan, Grant; Chakera, Aron			Analysis of early mesothelial cell responses to Staphylococcus epidermidis isolated from patients with peritoneal dialysis-associated peritonitis	PLOS ONE			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; INNATE IMMUNITY; MESSENGER-RNA; CYTOKINES; ENDOTHELIN-1; EXPRESSION; INFECTION; RECEPTOR; OUTCOMES	The major complication of peritoneal dialysis (PD) is the development of peritonitis, an infection within the abdominal cavity, primarily caused by bacteria. PD peritonitis is associated with significant morbidity, mortality and health care costs. Staphylococcus epidermidis is the most frequently isolated cause of PD-associated peritonitis. Mesothelial cells are integral to the host response to peritonitis, and subsequent clinical outcomes, yet the effects of infection on mesothelial cells are not well characterised. We systematically investigated the early mesothelial cell response to clinical and reference isolates of S. epidermidis using primary mesothelial cells and the mesothelial cell line Met-5A. Using an unbiased whole genome microarray, followed by a targeted panel of genes known to be involved in the human antibacterial response, we identified 38 differentially regulated genes (adj. p-value < 0.05) representing 35 canonical pathways after 1 hour exposure to S. epidermidis. The top 3 canonical pathways were TNFR2 signaling, IL-17A signaling, and TNFR1 signaling (adj. p-values of 0.0012, 0.0012 and 0.0019, respectively). Subsequent qPCR validation confirmed significant differences in gene expression in a number of genes not previously described in mesothelial cell responses to infection, with heterogeneity observed between clinical isolates of S. epidermidis, and between Met-5A and primary mesothelial cells. Heterogeneity between different S. epidermidis isolates suggests that specific virulence factors may play critical roles in influencing outcomes from peritonitis. This study provides new insights into early mesothelial cell responses to infection with S. epidermidis, and confirms the importance of validating findings in primary mesothelial cells.	[McGuire, Amanda L.; Mulroney, Kieran T.; Carson, Christine F.; Chakera, Aron] Harry Perkins Inst Med Res, Translat Renal Res Grp, Nedlands, WA, Australia; [McGuire, Amanda L.; Mulroney, Kieran T.; Carson, Christine F.; Chakera, Aron] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Ram, Ramesh; Morahan, Grant] Harry Perkins Inst Med Res, Ctr Diabet Res, Nedlands, WA, Australia; [Chakera, Aron] Sir Charles Gairdner Hosp, Dept Renal Med, Nedlands, WA, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; Harry Perkins Institute of Medical Research; University of Western Australia	McGuire, AL (corresponding author), Harry Perkins Inst Med Res, Translat Renal Res Grp, Nedlands, WA, Australia.; McGuire, AL (corresponding author), Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia.	Amanda.McGuire@uwa.edu.au	Morahan, Grant/T-7501-2019; Carson, Christine F/F-1521-2013	Carson, Christine F/0000-0003-3669-1651; McGuire, Amanda/0000-0002-1261-9236; Mulroney, Kieran/0000-0001-5036-1339	Sir Charles Gairdner Osborne Park Health Care Group (SCGOPHCG)'s Research Advisory Committee (RAC) [RAC 2015-16/044]; University, State and Commonwealth Governments; Diabetes Research Foundation WA, NHMRC [1069173]; NHMRC Program [53000400, 37612600]	Sir Charles Gairdner Osborne Park Health Care Group (SCGOPHCG)'s Research Advisory Committee (RAC); University, State and Commonwealth Governments; Diabetes Research Foundation WA, NHMRC; NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia)	Funding for this research was provided to AC (RAC 2015-16/044) by the Sir Charles Gairdner Osborne Park Health Care Group (SCGOPHCG)'s Research Advisory Committee (RAC), in conjunction with the Charlies Foundation for Research, http://www.scgh.health.wa.gov.au/Research/RAGFunding.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank Lavinia Gordon from the Australian Genome Research Facility (AGRF), Melbourne, Australia for bioinformatics assistance with the microarray data, Professor Tim Inglis and Kate Trojer from PathWest Laboratory Medicine WA for assistance obtaining clinical and reference isolates, and Zen-Bio Inc. for providing the human primary mesothelial cells used in this study. The authors acknowledge the facilities, and the scientific and technical assistance of Cytometry Core at the Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, a facility funded by the University, State and Commonwealth Governments. RR is supported by the Diabetes Research Foundation WA, NHMRC Project Grant 1069173 and by NHMRC Program Grants 53000400 and 37612600.	Anand S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072860; ANZDATA Registry, 2015, 37 ANZDATA REG; Barretti P, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-212; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birnie KA, 2015, MOL CANCER RES, V13, P1106, DOI 10.1158/1541-7786.MCR-14-0442; Brewis IA, 2010, NEPHROL DIAL TRANSPL, V25, P1749, DOI 10.1093/ndt/gfq145; BROWN AL, 1991, J HOSP INFECT, V18, P109, DOI 10.1016/0195-6701(91)90155-2; Brown MC, 2011, PERITON DIALYSIS INT, V31, P639, DOI 10.3747/pdi.2010.00185; Busnadiego O, 2015, J AM SOC NEPHROL, V26, P173, DOI 10.1681/ASN.2013070799; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cass A, 2010, EC IMPACT END STAGE; Chaudhry V, 2016, SCI REP-UK, V6, DOI 10.1038/srep19263; Colmont CS, 2011, NEPHROL DIAL TRANSPL, V26, P4079, DOI 10.1093/ndt/gfr217; Conlan S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-7-r64; Culhane AC, 2005, BIOINFORMATICS, V21, P2789, DOI 10.1093/bioinformatics/bti394; Davenport A, 2009, PERITON DIALYSIS INT, V29, P297; del Peso G, 2005, NEPHROL DIAL TRANSPL, V20, P1201, DOI 10.1093/ndt/gfh793; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghali JR, 2011, PERITON DIALYSIS INT, V31, P651, DOI 10.3747/pdi.2010.00131; Heath CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142773; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Jones JSP, 2001, LUNG, V179, P397, DOI 10.1007/s004080000075; JONJIC N, 1992, J EXP MED, V176, P1165, DOI 10.1084/jem.176.4.1165; Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kinnaert P, 1996, ANN SURG, V224, P749, DOI 10.1097/00000658-199612000-00010; Koussounadis A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10775; Kratochvill F, 2015, CANCER RES, V75, P3054, DOI 10.1158/0008-5472.CAN-15-0205; McGuire A, 2015, PERIT DIAL INT; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Mizgerd JP, 2001, J IMMUNOL, V166, P4042, DOI 10.4049/jimmunol.166.6.4042; Mutsaers SE, 2016, TXB PLEURAL DIS, P27; Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049; Novick RP, 2008, ANNU REV GENET, V42, P541, DOI 10.1146/annurev.genet.42.110807.091640; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Rodrigues-Diez R, 2014, KIDNEY INT; Rodriguez-Pascual F, 2014, LIFE SCI, V118, P156, DOI 10.1016/j.lfs.2013.12.024; Rutherford ST, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012427; Schieppati A, 2005, KIDNEY INT, V68, pS7, DOI 10.1111/j.1523-1755.2005.09801.x; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shin JH, 2011, PERITON DIALYSIS INT, V31, P340, DOI 10.3747/pdi.2010.00073; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Varano Della Vergiliana JF, 2013, PLOS ONE, V8; Vuong C, 2002, MICROBES INFECT, V4, P481, DOI 10.1016/S1286-4579(02)01563-0; Wang HH, 2011, J CHIN MED ASSOC, V74, P11, DOI 10.1016/j.jcma.2011.01.002; Wesener DA, 2015, NAT STRUCT MOL BIOL, V22, P603, DOI 10.1038/nsmb.3053; WEST TE, 1986, J CLIN MICROBIOL, V23, P809, DOI 10.1128/JCM.23.5.809-812.1986; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715; Wong YY, 2013, PERITON DIALYSIS INT, V33, P507, DOI 10.3747/pdi.2012.00281; Yao YF, 2005, INFECT IMMUN, V73, P1856, DOI 10.1128/IAI.73.3.1856-1860.2005; Zhou Q, 2016, KIDNEY INT, V90, P515, DOI 10.1016/j.kint.2016.03.040	55	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2017	12	5							e0178151	10.1371/journal.pone.0178151	http://dx.doi.org/10.1371/journal.pone.0178151			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VE	28542390	Green Published, Green Submitted, gold			2023-01-03	WOS:000402061500066
J	Abbasi, J				Abbasi, Jennifer			A Day in the Life: NICU Medical Director Tends to Infants With Neonatal Abstinence Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 16	2017	317	19					1937	1939		10.1001/jama.2017.3567	http://dx.doi.org/10.1001/jama.2017.3567			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU8VB	28448648				2023-01-03	WOS:000401315500001
J	Patel, S; Williams, JW; Wallace, RB				Patel, Sachin; Williams, John W., Jr.; Wallace, Robert B.			What We Do (and Don't) Know About the Health Effects of Cannabis and Whether Marijuana Is Medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vanderbilt Univ, Med Ctr, Nashville, TN USA; Duke Univ, Durham, NC USA; Durham Vet Affairs Med Ctr, Ctr Innovat Hlth Serv Res Primary Care, Durham, NC USA; Univ Iowa, Iowa City, IA USA; [Patel, Sachin] Vanderbilt Psychiat Hosp, 1601 23rd Ave South, Nashville, TN 37232 USA; [Williams, John W., Jr.] Duke Univ, Sch Med, 411 West Chapel Hill St,Suite 500, Durham, NC 27701 USA; [Wallace, Robert B.] Univ Iowa, Coll Publ Hlth, 145 Riverside Dr, Iowa City, IA 52242 USA	Vanderbilt University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of Iowa; Vanderbilt University; Duke University; University of Iowa	Patel, S (corresponding author), Vanderbilt Psychiat Hosp, 1601 23rd Ave South, Nashville, TN 37232 USA.	Sachin.patel@vanderbilt.edu	Patel, Sachin/E-5608-2012		NIEHS NIH HHS [P30 ES005605] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Belendiuk KA, 2015, ADDICT SCI CLIN PRAC, V10, DOI 10.1186/s13722-015-0032-7; Borodovsky JT, 2016, INT J DRUG POLICY, V36, P141, DOI 10.1016/j.drugpo.2016.02.022; Center for Behavioral Health Statistics and Quality, 2015, HHS PUBL; Center for Behavioral Health Statistics and Quality, 2015, NSDUH SER H; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C	5	2	2	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2017	166	10					747	+		10.7326/M17-0501	http://dx.doi.org/10.7326/M17-0501			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU7UM	28384665				2023-01-03	WOS:000401240200021
J	Murthy, SK; James, PD; Antonova, L; Chalifoux, M; Tanuseputro, P				Murthy, Sanjay K.; James, Paul D.; Antonova, Lilia; Chalifoux, Mathieu; Tanuseputro, Peter			High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study	PLOS ONE			English	Article							ADMINISTRATIVE DATA; VALIDATION; PREVALENCE; DATABASES; ONTARIO; ILLNESS; RECORDS; TRENDS	Background End of life (EOL) care is associated with greater costs, particularly for acute care services. In patients with inflammatory bowel disease (IBD), EOL costs may be accentuated due to reliance on hospital-based services and expensive diagnostic tests and treatments. We aimed to compare EOL health care use and costs between IBD and non-IBD decedents. Methods We conducted a retrospective cohort study of all decedents of Ontario, Canada between 2010 and 2013 using linked health administrative data. IBD (N = 2,214) and non-IBD (N = 262,540) decedents were compared on total direct health care costs in the last year of life and hospitalization time during the last 90 days of life. Results During the last 90 days of life, IBD patients spent an average of 16 days in hospital, equal to 2.1 greater adjusted hospital days (95% confidence interval [CI] 1.5-2.8 days) than non-IBD patients. IBD diagnosis was associated with $ 7,210 CAD (95% CI $ 5,005 -$ 9,464) higher adjusted per-patient cost in the last year of life, of which 76% was due to excess hospitalization costs. EOL cost of IBD care was higher than 15 of 16 studied chronic conditions. Health care costs rose sharply in the last 90 days of life, primarily due to escalating hospitalization costs. Conclusions IBD patients spend more time in hospital and incur substantially greater health care costs than other decedents as they approach the EOL. These excess costs could be curtailed through avoidance of unnecessary hospitalizations and expensive treatments in the setting of irreversible deterioration.	[Murthy, Sanjay K.; James, Paul D.; Tanuseputro, Peter] Ottawa Hosp, Dept Med, Div Gastroenterol, Ottawa, ON, Canada; [Murthy, Sanjay K.; James, Paul D.; Tanuseputro, Peter] Univ Ottawa, Ottawa, ON, Canada; [Murthy, Sanjay K.; James, Paul D.; Antonova, Lilia; Chalifoux, Mathieu; Tanuseputro, Peter] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Murthy, Sanjay K.; Chalifoux, Mathieu; Tanuseputro, Peter] Inst Clin Evaluat Sci ICES uOttawa, Ottawa, ON, Canada; [Tanuseputro, Peter] Bruyere Res Inst, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Murthy, SK (corresponding author), Ottawa Hosp, Dept Med, Div Gastroenterol, Ottawa, ON, Canada.; Murthy, SK (corresponding author), Univ Ottawa, Ottawa, ON, Canada.; Murthy, SK (corresponding author), Ottawa Hosp Res Inst, Ottawa, ON, Canada.; Murthy, SK (corresponding author), Inst Clin Evaluat Sci ICES uOttawa, Ottawa, ON, Canada.	smurthy@toh.on.ca		Murthy, Sanjay/0000-0002-0128-7897; Tanuseputro, Peter/0000-0002-4409-0795	Institute for Clinical Evaluative Sciences (ICES); Ontario Ministry of Health and Long-Term Care (MOHLTC); Ontario Ministry of Health and Long-Term Care; Health System Performance Research Network Grant (HSPRN) [06034]	Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Health System Performance Research Network Grant (HSPRN)	This research was supported by a research grant from the Ontario Ministry of Health and Long-Term Care to the Health System Performance Research Network Grant [grant number HSPRN #06034]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was made possible with the support of the Institute for Clinical Evaluative Sciences (ICES) which receives funding from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.	Austin PC, 2011, MED CARE, V49, P932, DOI 10.1097/MLR.0b013e318215d5e2; Bassi A, 2004, GUT, V53, P1471, DOI 10.1136/gut.2004.041616; Benchimol EI, 2009, GUT, V58, P1490, DOI 10.1136/gut.2009.188383; Benchimol EI, 2014, J CLIN EPIDEMIOL, V67, P887, DOI 10.1016/j.jclinepi.2014.02.019; Drummond D, 2012, COMMISSION REFORM ON; Felder S, 2000, J HEALTH ECON, V19, P679, DOI 10.1016/S0167-6296(00)00039-4; Gershon AS, 2009, COPD, V6, P388, DOI 10.1080/15412550903140865; Gershon AS, 2009, CAN RESPIR J, V16, P183, DOI 10.1155/2009/963098; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Jaakkimainen RL, 2016, J ALZHEIMERS DIS, V54, P337, DOI 10.3233/JAD-160105; Johnson SL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008597; Kappelman MD, 2013, DIGEST DIS SCI, V58, P519, DOI 10.1007/s10620-012-2371-5; Kappelman MD, 2008, GASTROENTEROLOGY, V135, P1907, DOI 10.1053/j.gastro.2008.09.012; Longobardi T, 2006, CLIN GASTROENTEROL H, V4, P731, DOI 10.1016/j.cgh.2006.02.013; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Mondor L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002249; Niewiadomski O, 2015, J CROHNS COLITIS; Rocchi A, 2012, CAN J GASTROENTEROL, V26, P811, DOI 10.1155/2012/984575; Schultz SE, 2013, CHRON DIS INJ CAN, V33, P160; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Tu Karen, 2007, Open Med, V1, pe18; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; Wodchis WP, 2013, GUIDELINES PERSON LE	23	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2017	12	5							e0177211	10.1371/journal.pone.0177211	http://dx.doi.org/10.1371/journal.pone.0177211			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UR	28498877	gold, Green Published, Green Submitted			2023-01-03	WOS:000401314500012
J	Rudra, S; Kalra, A; Kumar, A; Joe, W				Rudra, Shalini; Kalra, Aakshi; Kumar, Abhishek; Joe, William			Utilization of alternative systems of medicine as health care services in India: Evidence on AYUSH care from NSS 2014	PLOS ONE			English	Article							TRADITIONAL MEDICINE	AYUSH, an acronym for Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa-Rigpa and Homeopathy represents the alternative systems of medicine recognized by the Government of India. Understanding the patterns of utilization of AYUSH care has been important for various reasons including an increased focus on its mainstreaming and integration with biomedicine-based health care system. Based on a nationally representative health survey 2014, we present an analysis to understand utilization of AYUSH care across socioeconomic and demographic groups in India. Overall, 6.9% of all patients seeking outpatient care in the reference period of last two weeks have used AYUSH services without any significant differentials across rural and urban India. Importantly, public health facilities play a key role in provisioning of AYUSH care in rural areas with higher utilization in Chhattisgarh, Kerala and West Bengal. Use of AYUSH among middle-income households is lower when compared with poorer and richer households. We also find that low-income households display a greater tendency for AYUSH self-medication. AYUSH care utilization is higher among patients with chronic diseases and also for treating skin-related and musculo-skeletal ailments. Although the overall share of AYUSH prescription drugs in total medical expenditure is only about 6% but the average expenditure for drugs on AYUSH and allopathy did not differ hugely. The discussion compares our estimates and findings with other studies and also highlights major policy issues around mainstreaming of AYUSH care.	[Rudra, Shalini] Observer Res Fdn, New Delhi, India; [Kalra, Aakshi; Kumar, Abhishek; Joe, William] Delhi Univ, Populat Res Ctr, Inst Econ Growth, North Campus, Delhi, India	University of Delhi	Joe, W (corresponding author), Delhi Univ, Populat Res Ctr, Inst Econ Growth, North Campus, Delhi, India.	william@iegindia.org		Joe, William/0000-0003-3282-658X				Abraham L, 2005, INDIAN SYSTEMS MED I; Ahmad S S, 2007, INT J ALTERN MED, V6, P1; Bannerman RH, 1988, TRADITIONAL MED HLTH; BHARDWAJ SM, 1975, SOC SCI MED, V9, P603, DOI 10.1016/0037-7856(75)90174-2; BHATIA JC, 1975, SOC SCI MED, V9, P15, DOI 10.1016/0037-7856(75)90153-5; Chandra Shailaja, 2012, Ayu, V33, P461, DOI 10.4103/0974-8520.110504; Das J, 2016, AM ECON REV, V106, P3765, DOI 10.1257/aer.20151138; Ebrahimnejad H, 2009, ROY ASIAT SOC BOOKS, P1; Elwell-Sutton TM, 2013, HEALTH POLICY PLANN, V28, P467, DOI 10.1093/heapol/czs077; Erreygers G, 2009, J HEALTH ECON, V28, P504, DOI 10.1016/j.jhealeco.2008.02.003; Gautham Meenakshi, 2011, Indian J Med Res, V134, P627, DOI 10.4103/0971-5916.90987; George A, 2013, SOC SCI MED, V96, P297, DOI 10.1016/j.socscimed.2013.01.022; Gopichandran Vijayaprasad, 2012, Indian J Med Ethics, V9, P272; Government of India, 2015, KEY IND SOC CONS IND; Greene W. H., 2003, ECONOMETRIC ANAL; Harilal M. S., 2009, ECON POLIT WEEKLY, V44, P44; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046; Jaggi OP., 2000, MED INDIA MODERN PER; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Jeffery R., 1988, POLITICS HLTH INDIA; Kumar C, 2011, PUBLIC PRIVATE DICHO; Kumar Deepak, 2010, INDIAN HIST REV, V37; Kumar Deepak, 2001, DIS MED INDIA HIST O; Lakshmi JK, 2015, HEALTH POLICY PLANN, V30, P1067, DOI 10.1093/heapol/czu096; Mahal A, 2001, HNP DISCUSSION PAPER; Mazumdar PG, 2007, J BIOSOC SCI, V39, P819, DOI 10.1017/S0021932007002106; Ministry of Textiles Government of India, 2015, ANN REP 2014 15; Mira Sadgopal, 2009, Economic and Political Weekly, V44, P52; Mohanan M, 2015, JAMA PEDIATR, V169, P349, DOI 10.1001/jamapediatrics.2014.3445; Mukherjee PK, 2012, J ETHNOPHARMACOL, V143, P424, DOI 10.1016/j.jep.2012.07.036; Mushtaq Muhammad Umair, 2009, Indian J Community Med, V34, P6, DOI 10.4103/0970-0218.45369; National Rural Health Mission, 2005, INDIAN J PUBLIC HLTH, V49, P175; NEUMANN AK, 1971, SOC SCI MED, V5, P137, DOI 10.1016/0037-7856(71)90094-1; Oyebode O, 2016, USE TRADITIONAL MED; Patwardhan Bhushan, 2015, J Ayurveda Integr Med, V6, P147, DOI 10.4103/0975-9476.166389; Planning Commission of India, 2011, REP STEER COMM AYUSH; Powell-Jackson T, 2016, SCIENCE, V354, P34, DOI 10.1126/science.aai8652; Priya R., 2010, STATUS ROLE AYUSH LO; RAMESH A, 1981, SOC SCI MED-MED GEOG, V15, P69, DOI 10.1016/0160-8002(81)90017-4; Raut B, 2011, INT J RES AYURVEDA P, V2, P876; Rohde J.E., 1995, RURAL PRIVATE PRACTI; Ruchika Nandha, 2013, International Journal of Green Pharmacy, V7, P173, DOI 10.4103/0973-8258.120184; Samal J, 2015, J INTERCULT ETHNOPHA, V4, P348, DOI 10.5455/jice.20151101093011; Schensul SL, 2006, SOC SCI MED, V62, P2774, DOI 10.1016/j.socscimed.2005.11.003; Sheehan Helen E, 2009, Indian J Med Ethics, V6, P138; Shyam Ashtekar, 2001, Economic and Political Weekly, V36, P448; Singh P, 2005, INDIAN J MED RES, V122, P137; Sivaramakrishnan K., 2006, OLD POTIONS NEW BOTT; Song F, 1991, HLTH POLICY PLAN, V6, P64; Srinivasan P, 1995, World Health Forum, V16, P190; Sujatha V., 2009, Economic and Political Weekly, V44, P76; Sujatha V., 2009, Economic and Political Weekly, V44, P35; Sunil Amrith, 2007, Economic and Political Weekly, V42, P114; Thorsen RS, 2016, HEALTH POLICY PLANN, V31, P314, DOI 10.1093/heapol/czv060; Vaidya A D B National Commission on Macroeconomics and Health, 2005, EFF INT IND SYST MED; VANDEVEN WPMM, 1981, J ECONOMETRICS, V17, P229, DOI 10.1016/0304-4076(81)90028-2; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; World Health Organization, 2013, WHO TRAD MED STRAT 2; World Health Organization, 2000, US	60	38	38	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2017	12	5							e0176916	10.1371/journal.pone.0176916	http://dx.doi.org/10.1371/journal.pone.0176916			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ET9SP	28472197	Green Published, gold, Green Submitted			2023-01-03	WOS:000400648500096
J	DiRocco, DA; Ji, YN; Sherer, EC; Klapars, A; Reibarkh, M; Dropinski, J; Mathew, R; Maligres, P; Hyde, AM; Limanto, J; Brunskill, A; Ruck, RT; Campeau, LC; Davies, IW				DiRocco, Daniel A.; Ji, Yining; Sherer, Edward C.; Klapars, Artis; Reibarkh, Mikhail; Dropinski, James; Mathew, Rose; Maligres, Peter; Hyde, Alan M.; Limanto, John; Brunskill, Andrew; Ruck, Rebecca T.; Campeau, Louis-Charles; Davies, Ian W.			A multifunctional catalyst that stereoselectively assembles prodrugs	SCIENCE			English	Article							KINETIC RESOLUTION; ENANTIOSELECTIVE SYNTHESIS; FACILE SYNTHESIS; ENZYME-ACTIVITY; NUCLEOSIDE; PHOSPHORYLATION; PHOSPHATE; DISCOVERY; ANALOGS	The catalytic stereoselective synthesis of compounds with chiral phosphorus centers remains an unsolved problem. State-of-the-art methods rely on resolution or stoichiometric chiral auxiliaries. Phosphoramidate prodrugs are a critical component of pronucleotide (ProTide) therapies used in the treatment of viral disease and cancer. Here we describe the development of a catalytic stereoselective method for the installation of phosphorus-stereogenic phosphoramidates to nucleosides through a dynamic stereoselective process. Detailed mechanistic studies and computational modeling led to the rational design of a multifunctional catalyst that enables stereoselectivity as high as 99:1.	[DiRocco, Daniel A.; Ji, Yining; Sherer, Edward C.; Klapars, Artis; Reibarkh, Mikhail; Dropinski, James; Mathew, Rose; Maligres, Peter; Hyde, Alan M.; Limanto, John; Brunskill, Andrew; Ruck, Rebecca T.; Campeau, Louis-Charles; Davies, Ian W.] Merck & Co Inc, Proc Res & Dev, Rahway, NJ 07065 USA	Merck & Company	DiRocco, DA (corresponding author), Merck & Co Inc, Proc Res & Dev, Rahway, NJ 07065 USA.	daniel.dirocco@merck.com		Sherer, Edward/0000-0001-8178-9186; Reibarkh, Mikhail/0000-0002-6589-707X; Ji, Yining/0000-0002-9650-6844				ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; Blackmond DG, 2005, ANGEW CHEM INT EDIT, V44, P4302, DOI 10.1002/anie.200462544; BROWN C, 1975, J CHEM SOC CHEM COMM, P504, DOI 10.1039/c39750000504; Cahard D, 2004, MINI-REV MED CHEM, V4, P371; De Miranda AS, 2013, J MOL CATAL B-ENZYM, V91, P77, DOI 10.1016/j.molcatb.2013.02.008; Denmark SE, 2001, ANGEW CHEM INT EDIT, V40, P4759, DOI 10.1002/1521-3773(20011217)40:24<4759::AID-ANIE4759>3.0.CO;2-G; Dunn JMM, 2017, CHEM SCI, V8, P2804, DOI 10.1039/c6sc05081f; Dutartre M, 2016, CHEM SOC REV, V45, P5771, DOI 10.1039/c6cs00031b; Evans JW, 2004, J AM CHEM SOC, V126, P8134, DOI 10.1021/ja047845l; FARNHAM WB, 1970, J AM CHEM SOC, V92, P5808, DOI 10.1021/ja00722a082; Jordheim LP, 2013, NAT REV DRUG DISCOV, V12, P447, DOI 10.1038/nrd4010; Konsler RG, 1998, J AM CHEM SOC, V120, P10780, DOI 10.1021/ja982683c; Lee LC, 2006, BIOCHEM J, V397, P69, DOI 10.1042/BJ20051645; Liu S, 2012, TETRAHEDRON-ASYMMETR, V23, P329, DOI 10.1016/j.tetasy.2012.02.018; Longo CM, 2009, ANGEW CHEM INT EDIT, V48, P4158, DOI 10.1002/anie.200900480; MCGUIGAN C, 1992, BIOORG MED CHEM LETT, V2, P701, DOI 10.1016/S0960-894X(00)80395-9; Pertusati F, 2015, CHEM COMMUN, V51, P8070, DOI 10.1039/c5cc00448a; Pradere U, 2014, CHEM REV, V114, P9154, DOI 10.1021/cr5002035; Ross BS, 2011, J ORG CHEM, V76, P8311, DOI 10.1021/jo201492m; Ryan M, 2001, BIOCHEMISTRY-US, V40, P9743, DOI 10.1021/bi010958m; Sculimbrene BR, 2001, J AM CHEM SOC, V123, P10125, DOI 10.1021/ja016779+; Sofia MJ, 2010, J MED CHEM, V53, P7202, DOI 10.1021/jm100863x; Steinreiber J, 2008, CHEM-EUR J, V14, P8060, DOI 10.1002/chem.200701643; Tran K, 2015, J ORG CHEM, V80, P4994, DOI 10.1021/acs.joc.5b00392; WEINTRAUB PM, 1987, J HETEROCYCLIC CHEM, V24, P561, DOI 10.1002/jhet.5570240305; Xu SJ, 2005, CHEM-EUR J, V11, P4751, DOI 10.1002/chem.200500398; Zhang ZF, 2010, J AM CHEM SOC, V132, P15939, DOI 10.1021/ja109069k	27	83	87	2	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2017	356	6336					426	429		10.1126/science.aam7936	http://dx.doi.org/10.1126/science.aam7936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET2YU	28450641				2023-01-03	WOS:000400143000051
J	Ben-Pazi, H; Cohen, A; Kroyzer, N; Lotem-Ophir, R; Shvili, Y; Winter, G; Deutsch, L; Pollak, Y				Ben-Pazi, Hilla; Cohen, Avraham; Kroyzer, Naama; Lotem-Ophir, Renana; Shvili, Yaakov; Winter, Gidon; Deutsch, Lisa; Pollak, Yehuda			Clown-care reduces pain in children with cerebral palsy undergoing recurrent botulinum toxin injections-A quasi-randomized controlled crossover study	PLOS ONE			English	Article							NITROUS-OXIDE; PREOPERATIVE ANXIETY; EMERGENCY-DEPARTMENT; ENTERAL MIDAZOLAM; CONTROLLED-TRIAL; INTERVENTIONS; MANAGEMENT	Objective We investigated the impact of clown-care on pain in 45 children with cerebral palsy who underwent recurrent Botulinum-toxin injections (age 7.04 +/- 4.68 years). Participants were randomized to receive either clown (n = 20) or standard (n = 25) -care. Methods Pain Visual-Analogue-Scale (range 1 - 5) was reported before and after procedures. Pain assessment was lower for children undergoing Botulinum-toxin injections with clown-care (2.89 +/- 1.36) compared to standard-care (3.85 +/- 1.39; p = 0.036) even though pain anticipated prior to procedures was similar (similar to 3). Findings Children who underwent the first procedure with clown-care reported lower pain even after they crossed-over to the following procedure which was standard (p = 0.048). Carryover effect was more prominent in injection-naive children (p = 0.019) and during multiple procedures (p = 0.009). Prior pain experience correlated with pain in subsequent procedures only when first experience was standard-care (p = 0.001). Conclusions Clown-care alleviated pain sensation during Botulinum-toxin injections and initial clown-care experience reduced pain during subsequent injections even though clowns were not present.	[Ben-Pazi, Hilla; Kroyzer, Naama; Winter, Gidon] Shaare Zedek Med Ctr, Neuropediatr Unit, Jerusalem, Israel; [Cohen, Avraham; Lotem-Ophir, Renana; Shvili, Yaakov] Shaare Zedek Med Ctr, Dept Pediat, Jerusalem, Israel; [Deutsch, Lisa] Biostatist Consulting LD, Modien, Israel; [Pollak, Yehuda] Hebrew Univ Jerusalem, Sch Educ, Jerusalem, Israel	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem	Ben-Pazi, H (corresponding author), Shaare Zedek Med Ctr, Neuropediatr Unit, Jerusalem, Israel.	Benpazi@gmail.com		benpazi, hilla/0000-0002-8039-4761; Pollak, Yehuda/0000-0002-1293-499X	Magi Foundation [HB 19003249]	Magi Foundation	Shaare Zedek Medical Center partially covered study expenses (HB, AC, YS, RLO). The second phase of this study (crossover) was funded by the Magi Foundation (HB 19003249), http://132.74.7.18/showpage_new.asp?ldnn=1489&namef=Magi%20Foundation&otkuda=pass.asp&order=submission_deadline.namef&view=. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Biostatistical Consulting (owned by the author LD) provided support in the form of salary for author LD but did not have any additional role in the study design, data collection, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Bakheit AMO, 2003, EUR J NEUROL, V10, P415, DOI 10.1046/j.1468-1331.2003.00619.x; Brochard S, 2011, EUR J PAEDIATR NEURO, V15, P310, DOI 10.1016/j.ejpn.2010.12.006; Castle K, 2007, DEV MED CHILD NEUROL, V49, P445, DOI 10.1111/j.1469-8749.2007.00445.x; Charles James A, 2005, J Headache Pain, V6, P51, DOI 10.1007/s10194-005-0148-3; Crocker PJ, 2012, AM J EMERG MED, V30, P861, DOI 10.1016/j.ajem.2011.05.030; Dunbar RIM, 2012, P ROY SOC B-BIOL SCI, V279, P1161, DOI 10.1098/rspb.2011.1373; Eccleston C, COCHRANE DATABASE SY, V12; Engel Joyce M, 2005, Phys Occup Ther Pediatr, V25, P73, DOI 10.1300/J006v25n04_06; Felluga M, 2016, EUR J PEDIATR, V175, P645, DOI 10.1007/s00431-015-2688-0; Fernandes SC, 2010, J HEALTH PSYCHOL, V15, P405, DOI 10.1177/1359105309350231; Friedler S, 2011, FERTIL STERIL, V95, P2127, DOI 10.1016/j.fertnstert.2010.12.016; Golan G, 2009, PEDIATR ANESTH, V19, P262, DOI 10.1111/j.1460-9592.2008.02903.x; Gubbay A, 2009, DEV MED CHILD NEUROL, V51, P491, DOI 10.1111/j.1469-8749.2009.03297_1.x; Gulur P, 2009, J PAIN, V10, P173, DOI 10.1016/j.jpain.2008.08.005; Hagberg B, 1996, ACTA PAEDIATR, V85, P954, DOI 10.1111/j.1651-2227.1996.tb14193.x; Hansen Lars Kjaersgaard, 2011, J Pain Res, V4, P297, DOI 10.2147/JPR.S23199; Hanuka P, MEDICAL CLOWNS FACIL; Hicks CL, 2006, J PEDIATR PSYCHOL, V31, P724, DOI 10.1093/jpepsy/jsj065; Knaepen L, 2013, DEV NEUROBIOL, V73, P85, DOI 10.1002/dneu.22047; Kumar R, 2009, DEV MED CHILD NEUROL, V51, P838, DOI 10.1111/j.1469-8749.2009.03355.x; Linge L, 2013, INT J QUAL STUD HEAL, V8, DOI 10.3402/qhw.v8i0.18907; Minute M, 2012, Pediatr Med Chir, V34, P77; Noel M, 2012, PAIN MANAG, V2, P487, DOI [10.2217/pmt.12.41, 10.2217/PMT.12.41]; Novak I, 2013, DEV MED CHILD NEUROL, V55, P885, DOI 10.1111/dmcn.12246; Raphael BS, 2010, CLIN ORTHOP RELAT R, V468, P1845, DOI 10.1007/s11999-009-1167-1; Rothrock JF, 2000, HEADACHE, V40, P17, DOI 10.1046/j.1526-4610.2000.00002.x; Sanger Terence D, 2005, Curr Treat Options Neurol, V7, P427, DOI 10.1007/s11940-005-0043-x; Scheffer ART, 2010, ARCH OTOLARYNGOL, V136, P873, DOI 10.1001/archoto.2010.147; Uman LS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179; Uman LS, 2008, J PEDIATR PSYCHOL, V33, P842, DOI 10.1093/jpepsy/jsn031; Vagnoli L, 2010, PEDIATR ANESTH, V20, P937, DOI 10.1111/j.1460-9592.2010.03403.x; Voepel-Lewis T, PAIN MANAGEMENT NURS, V6, P168; Voepel-Lewis Terri, 2005, Pain Manag Nurs, V6, P168, DOI 10.1016/j.pmn.2005.08.004; von Baeyer Carl L, 2006, Pain Res Manag, V11, P157; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Wolyniez I, 2013, CLIN PEDIATR, V52, P1168, DOI 10.1177/0009922813502257	36	22	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2017	12	4							e0175028	10.1371/journal.pone.0175028	http://dx.doi.org/10.1371/journal.pone.0175028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KD	28414728	Green Submitted, Green Published, gold			2023-01-03	WOS:000399874800015
J	Moss, JA; Baum, MM; Easley, JT; Cox, DM; Smith, TJ				Moss, John A.; Baum, Marc M.; Easley, Jeremiah T.; Cox, Darren M.; Smith, Thomas J.			An intravaginal ring for real-time evaluation of adherence to therapy	PLOS ONE			English	Article							TENOFOVIR DISOPROXIL FUMARATE; HIV-PREVENTION TRIALS; PREEXPOSURE PROPHYLAXIS; SUSTAINED DELIVERY; AFRICAN WOMEN; VAGINAL RING; PHARMACOKINETICS; INFECTION; SAFETY; DRUGS	Two recent Phase III clinical trials to investigate an intravaginal ring for preventing HIV infection demonstrated that adherence to prescribed device use was a primary driver of efficacy. Surrogate methods for determining adherence in the studies were limited in their inability to monitor temporal patterns of use and allow deconvolution of the effects of adherence and device efficacy on HIV infection rates. To address this issue, we have developed functionality in an intravaginal ring to continuously monitor when the device is being used and maintain a log of adherence that can be accessed by clinicians after it is removed. An electronic module fabricated with common, inexpensive electronic components was encapsulated in a silicone intravaginal ring. The device uses temperature as a surrogate measure of periods of device insertion and removal, and stores a record of the data for subsequent retrieval. The adherence-monitoring intravaginal ring accurately recorded the device status over 33 simulated IN-OUT cycles and more than 1000 measurement cycles in vitro. Following initial in vitro testing in a temperature-controlled chamber, the device was evaluated in vivo in sheep using a predetermined insertion/removal pattern to simulate intravaginal ring use. After insertion into the vaginal cavity of a sheep, the logged data correctly indicated the device status over 29 hours of continuous measurement including three cycles of insertion and removal. The device described here is a promising, low-cost method for real-time adherence assessment in clinical trials involving medicated intravaginal rings or other intravaginal devices.	[Moss, John A.; Baum, Marc M.; Cox, Darren M.] Oak Crest Inst Sci, Dept Chem, Monrovia, CA 91016 USA; [Easley, Jeremiah T.] Colorado State Univ, Preclin Surg Res Lab, Ft Collins, CO 80523 USA; [Smith, Thomas J.] Auritec Pharmaceut Inc, Pasadena, CA USA	Colorado State University	Moss, JA (corresponding author), Oak Crest Inst Sci, Dept Chem, Monrovia, CA 91016 USA.	j.moss@oak-crest.org		Moss, John/0000-0001-8091-3245; Baum, Marc/0000-0003-1558-5649	National Institute for Allergies and Infectious Diseases of the National Institutes of Health (NIH) [1R41AI104549]; NIH Small Business Technology Transfer (STTR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI104549] Funding Source: NIH RePORTER	National Institute for Allergies and Infectious Diseases of the National Institutes of Health (NIH); NIH Small Business Technology Transfer (STTR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the National Institute for Allergies and Infectious Diseases of the National Institutes of Health (NIH) under grant 1R41AI104549 (JM). The funder provided support in the form of salaries for authors [JM, MB, JE, DC, and TS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. TS is an employee of Auritec Pharmaceuticals, a for profit pharmaceutical company that was the private sector partner in the NIH Small Business Technology Transfer (STTR) grant funding this work. The specific roles of the authors are articulated in the 'author contributions' section.	Agot K, 2015, AIDS BEHAV, V19, P743, DOI 10.1007/s10461-014-0859-z; Amico KR, 2013, AIDS BEHAV, V17, P2143, DOI 10.1007/s10461-013-0429-9; Auritec Pharmaceuticals, 2000, AURITEC PHARMACEUTIC; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baeten JM, NEW ENGL J MED; Baum MM, 2015, INT J PHARMACEUT, V495, P579, DOI 10.1016/j.ijpharm.2015.09.028; Baum MM, 2012, J PHARM SCI-US, V101, P2833, DOI 10.1002/jps.23208; Boyd P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125682; Brown E., 2016, 21 INT AIDS C AIDS 2; Farmer KC, 1999, CLIN THER, V21, P1074, DOI 10.1016/S0149-2918(99)80026-5; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gunawardana M, 2014, J PHARM SCI-US, V103, P3611, DOI 10.1002/jps.24154; Gunawardana M, 2014, ANTIMICROB AGENTS CH, V58, P2262, DOI 10.1128/AAC.02542-13; Hillier S., 2016, RINGS AND THINGS; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Keller MJ, 2012, J ANTIMICROB CHEMOTH, V67, P2005, DOI 10.1093/jac/dks151; MacQueen KM, 2014, J INT AIDS SOC S2, V17, P19158, DOI DOI 10.7448/IAS.17.3.19158; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; Montgomery ET, 2012, AIDS BEHAV, V16, P1787, DOI 10.1007/s10461-012-0248-4; Moss JA, 2014, ANTIMICROB AGENTS CH, V58, P5125, DOI 10.1128/AAC.02871-14; Moss JA, 2013, ANTIMICROB AGENTS CH, V57, P3994, DOI 10.1128/AAC.00547-13; Moss JA, 2012, AIDS, V26, P707, DOI 10.1097/QAD.0b013e3283509abb; Quittner AL, 2000, J CLIN PSYCHOL MED S, V7, P41, DOI 10.1023/A:1009545319673; RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69, DOI 10.1164/ajrccm/149.2_Pt_2.S69; Rand CS, 1998, HDB HLTH BEHAV CHANG, P114; Reece W. O., 2009, FUNCTIONAL ANATOMY P; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614	31	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e0174729	10.1371/journal.pone.0174729	http://dx.doi.org/10.1371/journal.pone.0174729			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2QB	28384179	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000399371900031
J	Yang, Y; Qiu, S; Qian, L; Tian, Y; Chen, YN; Bi, L; Chen, WP				Yang, Ye; Qiu, Shuang; Qian, Lei; Tian, Yuan; Chen, Yingna; Bi, Lei; Chen, Weiping			OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells	PLOS ONE			English	Article							SALVIANOLIC ACIDS; SIGNALING PATHWAY; PTEN; EXPRESSION; RADIATION; PI3K/AKT; ROLES; EMT	A component formula with definite compositions provides a new approach to treat various diseases. Salvia miltiorrhiza and Panax ginseng are widely used in China because of their antitumor properties. In the previous study, the optimizing component formula (OCF), prepared with salvianolic acids, ginsenosides, and ginseng polysaccharides (5, 10, and 5 mg.L-1, respectively) extracted from S. miltiorrhiza and P. ginseng on the basis of IC50 in lung cancer A549 cells and damage minimization on human bronchial epithelial cells in vitro. Currently, we also have demonstrated the inhibitory effect of OCF on A549 cell migration and invasion in vitro. According to Lewis lung cancer cells (LLC) allograft in C57BL/6 mice and A549 xenograft in nude mice experiment, we found that the anti-tumor and anti-metastasis effects of OCF treatment were related to the inhibition of epithelial-mesenchymal transition (EMT). Further studies showed that the inhibitory effect of OCF on EMT was associated with the PTEN/ PI3K/ AKT pathway. Therefore, all studies revealed that OCF could prevent cancer progression and tumor metastasis by inhibiting EMT involved PTEN/PI3K/ AKT signaling pathway in lung cancer cells.	[Yang, Ye; Qiu, Shuang; Qian, Lei; Tian, Yuan; Chen, Yingna; Bi, Lei; Chen, Weiping] Nanjing Univ Chinese Med, Dept Preclin Med, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine	Bi, L; Chen, WP (corresponding author), Nanjing Univ Chinese Med, Dept Preclin Med, Nanjing, Jiangsu, Peoples R China.	bella_nj@163.com; wp2002123@163.com	Lang, Ming/HIK-0758-2022; yang, yang/GWB-9426-2022; Chen, Wei/GZK-7348-2022	Bi, Lei/0000-0002-2951-0966	National Natural Sciences Foundation of China [81273638, 81503486]; Key Project of Science and Technology from Administration of Traditional Chinese Medicine in Jiangsu Province [ZD201502]; scientific innovation research of college graduate in Jiangsu province [KYLX15_0997, KYLX16_1153]; Priority Academic Program Development of Jiangsu Higher Education Institutions (integration of traditional Chinese and western medicine)	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Science and Technology from Administration of Traditional Chinese Medicine in Jiangsu Province; scientific innovation research of college graduate in Jiangsu province; Priority Academic Program Development of Jiangsu Higher Education Institutions (integration of traditional Chinese and western medicine)	This work was supported by: grants from National Natural Sciences Foundation of China (No. 81273638 and 81503486); the Key Project of Science and Technology from Administration of Traditional Chinese Medicine in Jiangsu Province (ZD201502); scientific innovation research of college graduate in Jiangsu province (No. KYLX15_0997 and KYLX16_1153); and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (integration of traditional Chinese and western medicine).	Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chang L, 2014, CANCER METAST REV, V33, P469, DOI 10.1007/s10555-014-9493-5; Cho YJ, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0283-1; Du GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072044; Gerets HHJ, 2012, CELL BIOL TOXICOL, V28, P69, DOI 10.1007/s10565-011-9208-4; Hellevik T, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-59; Ho JHC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-30; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Karamitopoulou E, 2011, HUM PATHOL, V42, P1888, DOI 10.1016/j.humpath.2010.06.020; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; Kim YJ, 2014, J GINSENG RES, V38, P66, DOI 10.1016/j.jgr.2013.11.001; Langdon SP, 2012, CURR DRUG TARGETS, V13, P1535; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li CL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1411-x; Li SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078902; Ma XH, 2015, MOLECULES, V20, P16235, DOI 10.3390/molecules200916235; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Pan Fuqiang, 2015, Drug Des Devel Ther, V9, P4779, DOI 10.2147/DDDT.S84628; Perez-Ramirez C, 2015, PHARMACOGENOMICS, V16, P1843, DOI 10.2217/pgs.15.122; Rammah M, 2012, TOXICOL LETT, V211, P220, DOI 10.1016/j.toxlet.2012.04.003; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shi SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089123; Shimamura T, 2004, CANCER RES, V64, P6989, DOI 10.1158/0008-5472.CAN-04-1166; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tu KS, 2016, INT J ONCOL, V48, P965, DOI 10.3892/ijo.2015.3309; Wu WY, 2012, ACTA PHARMACOL SIN, V33, P1119, DOI 10.1038/aps.2012.126; Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686; Xu XY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0096780, 10.1371/journal.pone.0109950]; [颜晓静 Yan Xiaojing], 2014, [中国中药杂志, China Journal of Chinese Materia Medica], V39, P4436; Yoo DG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033678; Yoshioka H, 2012, TOXICOL LETT, V211, P257, DOI 10.1016/j.toxlet.2012.04.005; Yuan X, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0087-z; Zhang LG, 2014, J ETHNOPHARMACOL, V155, P1424, DOI 10.1016/j.jep.2014.07.011; Zhou GJ, 2014, MOLECULES, V19, P7207, DOI 10.3390/molecules19067207	39	13	13	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0174021	10.1371/journal.pone.0174021	http://dx.doi.org/10.1371/journal.pone.0174021			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301605	Green Published, Green Submitted, gold			2023-01-03	WOS:000396318300112
J	Pitcher, D; Fritz, Z; Wang, M; Spiller, JA				Pitcher, David; Fritz, Zoe; Wang, Madeleine; Spiller, Juliet A.			PRACTICE POINTER Emergency care and resuscitation plans	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION; DECISION-MAKING; ORDERS; LIFE; END		[Pitcher, David] Resuscitat Council UK, Tavistock House, London WC1H 9HR, England; [Fritz, Zoe] Addenbrookes Hosp, Cambridge Univ Hosp, Dept Acute Med, Cambridge CB2 0QQ, England; [Spiller, Juliet A.] Marie Curie Hosp Edinburgh, Palliat Med, Edinburgh, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Pitcher, D (corresponding author), Resuscitat Council UK, Tavistock House, London WC1H 9HR, England.	david.pitcher@resus.org.uk	Spiller, Juliet/GWC-7042-2022	Fritz, Zoe/0000-0001-9403-409X				Beed M, 2015, RESUSCITATION, V86, P31, DOI 10.1016/j.resuscitation.2014.10.002; Caldwell G, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3769; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Ebell MH, 2013, JAMA INTERN MED, V173, P1872, DOI 10.1001/jamainternmed.2013.10037; Field RA, 2014, RESUSCITATION, V85, P1418, DOI 10.1016/j.resuscitation.2014.08.024; Fritz Z, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j813; Fritz Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070977; Fritz Z, 2010, J MED ETHICS, V36, P593, DOI 10.1136/jme.2010.035725; Harris D, 2009, RESUSCITATION, V80, P1275, DOI 10.1016/j.resuscitation.2009.07.008; Heslop Pauline, 2013, CONFIDENTIAL INQUIRY; Mockford C, 2015, RESUSCITATION, V88, P99, DOI 10.1016/j.resuscitation.2014.11.016; Mullick A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6064; Musa I, 2015, AGE AGEING, V44, P371, DOI 10.1093/ageing/afv041; National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 2012, TIM TO INT; Perkins GD, 2016, HLTH SERV DELIV RES, V4; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; Seymour J, 2004, SOC SCI MED, V59, P57, DOI 10.1016/j.socscimed.2003.10.005	17	16	16	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2017	356								j876	10.1136/bmj.j876	http://dx.doi.org/10.1136/bmj.j876			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM9JQ	28246080	Green Published, hybrid			2023-01-03	WOS:000395628100017
J	Jung, WM; Lee, YS; Wallraven, C; Chae, Y				Jung, Won-Mo; Lee, Ye-Seul; Wallraven, Christian; Chae, Younbyoung			Bayesian prediction of placebo analgesia in an instrumental learning model	PLOS ONE			English	Article							PERCEIVED CONTROL; PAIN; MECHANISMS; EXPECTATION; UNCERTAINTY; EVENTS; REWARD; BRAIN	Placebo analgesia can be primarily explained by the Pavlovian conditioning paradigm in which a passively applied cue becomes associated with less pain. In contrast, instrumental conditioning employs an active paradigm that might be more similar to clinical settings. In the present study, an instrumental conditioning paradigm involving a modified trust game in a simulated clinical situation was used to induce placebo analgesia. Additionally, Bayesian modeling was applied to predict the placebo responses of individuals based on their choices. Twenty-four participants engaged in a medical trust game in which decisions to receive treatment from either a doctor (more effective with high cost) or a pharmacy (less effective with low cost) were made after receiving a reference pain stimulus. In the conditioning session, the participants received lower levels of pain following both choices, while high pain stimuli were administered in the test session even after making the decision. The choice-dependent pain in the conditioning session was modulated in terms of both intensity and uncertainty. Participants reported significantly less pain when they chose the doctor or the pharmacy for treatment compared to the control trials. The predicted pain ratings based on Bayesian modeling showed significant correlations with the actual reports from participants for both of the choice categories. The instrumental conditioning paradigm allowed for the active choice of optional cues and was able to induce the placebo analgesia effect. Additionally, Bayesian modeling successfully predicted pain ratings in a simulated clinical situation that fits well with placebo analgesia induced by instrumental conditioning.	[Jung, Won-Mo; Lee, Ye-Seul; Chae, Younbyoung] Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea; [Wallraven, Christian] Korea Univ, Dept Brain Cognit Engn, Seoul, South Korea	Kyung Hee University; Korea University	Chae, Y (corresponding author), Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea.	ybchae@khu.ac.kr	Chae, Younbyoung/AAM-1243-2020	Lee, Ye-Seul/0000-0001-6127-5401; Chae, Younbyoung/0000-0001-6787-2215; Wallraven, Christian/0000-0002-2604-9115	Basic Science Research Program through the National Research Foundation of Korea [2015R1D1A1A01058033]; LG Yonam Foundation for Research Fellowship [2016]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); LG Yonam Foundation for Research Fellowship	YC was supported by the Basic Science Research Program through the National Research Foundation of Korea (grant number 2015R1D1A1A01058033; nrf.re.kr) and the LG Yonam Foundation for Research Fellowship (grant number 2016; foundation.lg.or.kr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Anchisi D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117270; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Benedetti F, 2003, J NEUROSCI, V23, P4315; Beydoun A, 1996, PAIN, V65, P189, DOI 10.1016/0304-3959(95)00161-1; Buchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042; CHAN AW, 1992, J NEUROL NEUROSUR PS, V55, P56, DOI 10.1136/jnnp.55.1.56; Colloca L, 2013, PAIN, V154, P511, DOI 10.1016/j.pain.2013.02.002; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; Doering BK, 2012, TRENDS PHARMACOL SCI, V33, P165, DOI 10.1016/j.tips.2011.12.001; Friston K, 2016, NEUROSCI BIOBEHAV R, V68, P862, DOI 10.1016/j.neubiorev.2016.06.022; Friston KJ, 2010, NAT REV NEUROSCI, V11, P127, DOI 10.1038/nrn2787; Friston KJ, 2009, PHILOS T R SOC B, V364, P1211, DOI 10.1098/rstb.2008.0300; Garrison J, 2013, NEUROSCI BIOBEHAV R, V37, P1297, DOI 10.1016/j.neubiorev.2013.03.023; Kersten D, 2004, ANNU REV PSYCHOL, V55, P271, DOI 10.1146/annurev.psych.55.090902.142005; Kessner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109014; Kessner S, 2013, JAMA INTERN MED, V173, P1468, DOI 10.1001/jamainternmed.2013.6705; Knill DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/j.tins.2004.10.007; Kong Jian, 2014, Handb Exp Pharmacol, V225, P3, DOI 10.1007/978-3-662-44519-8_1; Lee IS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17140; Meulders A, 2011, PAIN, V152, P2460, DOI 10.1016/j.pain.2011.05.015; Nolan TA, 2012, PAIN, V153, P2009, DOI 10.1016/j.pain.2012.04.026; O'Reilly JX, 2012, EUR J NEUROSCI, V35, P1169, DOI 10.1111/j.1460-9568.2012.08010.x; Pan WX, 2005, J NEUROSCI, V25, P6235, DOI 10.1523/JNEUROSCI.1478-05.2005; Patil A, 2010, J STAT SOFTW, V35, P1; Pellino TA, 1998, J PAIN SYMPTOM MANAG, V15, P110, DOI 10.1016/S0885-3924(97)00255-8; Pessiglione M, 2008, NEURON, V59, P561, DOI 10.1016/j.neuron.2008.07.005; RESCORLA RA, 1988, AM PSYCHOL, V43, P151, DOI 10.1037/0003-066X.43.3.151; Seymour B, 2007, J NEUROSCI, V27, P4826, DOI 10.1523/JNEUROSCI.0400-07.2007; Talmi D, 2008, J NEUROSCI, V28, P360, DOI 10.1523/JNEUROSCI.4028-07.2008; Talmi D, 2009, J NEUROSCI, V29, P14617, DOI 10.1523/JNEUROSCI.2026-09.2009; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; van't Wout M, 2008, COGNITION, V108, P796, DOI 10.1016/j.cognition.2008.07.002; Vlaeyen JWS, 2015, PAIN, V156, pS86, DOI 10.1097/j.pain.0000000000000107; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wardle MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068884; WEISENBERG M, 1985, PAIN, V23, P187, DOI 10.1016/0304-3959(85)90059-4; Wiech K, 2006, J NEUROSCI, V26, P11501, DOI 10.1523/JNEUROSCI.2568-06.2006; Wiech K, 2016, SCIENCE, V354, P584, DOI 10.1126/science.aaf8934; Winston JS, 2014, J NEUROSCI, V34, P14526, DOI 10.1523/JNEUROSCI.1706-14.2014; Yoshida W, 2013, J NEUROSCI, V33, P5638, DOI 10.1523/JNEUROSCI.4984-12.2013; Ziegler EA, 1999, BRAIN, V122, P2245, DOI 10.1093/brain/122.12.2245	42	12	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2017	12	2							e0172609	10.1371/journal.pone.0172609	http://dx.doi.org/10.1371/journal.pone.0172609			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL5SK	28225816	Green Published, gold, Green Submitted			2023-01-03	WOS:000394680900058
J	Kaushik, MK; Kaul, SC; Wadhwa, R; Yanagisawa, M; Urade, Y				Kaushik, Mahesh K.; Kaul, Sunil C.; Wadhwa, Renu; Yanagisawa, Masashi; Urade, Yoshihiro			Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction	PLOS ONE			English	Article							LEAF EXTRACT; OLDER-ADULTS; RATS; MICE	Insomnia is the most common sleep complaint which occurs due to difficulty in falling asleep or maintaining it. Most of currently available drugs for insomnia develop dependency and/or adverse effects. Hence natural therapies could be an alternative choice of treatment for insomnia. The root or whole plant extract of Ashwagandha (Withania somnifera) has been used to induce sleep in Indian system of traditional home medicine, Ayurveda. However, its active somnogenic components remain unidentified. We investigated the effect of various components of Ashwagandha leaf on sleep regulation by oral administration in mice. We found that the alcoholic extract that contained high amount of active withanolides was ineffective to induce sleep in mice. However, the water extract which contain triethylene glycol as a major component induced significant amount of non-rapid eye movement sleep with slight change in rapid eye movement sleep. Commercially available triethylene glycol also increased non-rapid eye movement sleep in mice in a dose-dependent (10-30 mg/mouse) manner. These results clearly demonstrated that triethylene glycol is an active sleep inducing component of Ashwagandha leaves and could potentially be useful for insomnia therapy.	[Kaushik, Mahesh K.; Urade, Yoshihiro] Univ Tsukuba, Dept Mol Sleep, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan; [Kaushik, Mahesh K.; Yanagisawa, Masashi] Univ Tsukuba, Dept Mol Genet, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan; [Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, Drug Discovery & Assets Innovat Lab, DBT AIST Int Lab Adv Biomed, Higashi 1-1-1, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Kaushik, MK; Urade, Y (corresponding author), Univ Tsukuba, Dept Mol Sleep, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.; Kaushik, MK (corresponding author), Univ Tsukuba, Dept Mol Genet, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.	kaushik.m.k.kb@u.tsukuba.ac.jp; yoshihiro.ft@u.tsukuba.ac.jp	Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; Kaushik, Mahesh K./AAD-5977-2019	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; Kaushik, Mahesh K./0000-0003-4286-1573	"Japan Society for the Promotion of Science", KAKENHI [16H01881]	"Japan Society for the Promotion of Science", KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported financially by grant from "Japan Society for the Promotion of Science", KAKENHI grant number 16H01881 to Yoshihiro Urade.	Akhoon BA, 2016, EXP GERONTOL, V78, P47, DOI 10.1016/j.exger.2016.03.004; Ballantyne B, 2007, J APPL TOXICOL, V27, P291, DOI 10.1002/jat.1220; Borron SW, 1997, VET HUM TOXICOL, V39, P26; Calcaterra NE, 2014, ACS CHEM NEUROSCI, V5, P253, DOI 10.1021/cn5000056; Chandrasekhar K, 2012, Indian J Psychol Med, V34, P255, DOI 10.4103/0253-7176.106022; Cho S, 2014, PSYCHOPHARMACOLOGY, V231, P2825, DOI 10.1007/s00213-014-3445-1; Gautam A, 2013, NEUROBIOL LEARN MEM, V106, P177, DOI 10.1016/j.nlm.2013.08.009; Gooneratne NS, 2008, CLIN GERIATR MED, V24, P121, DOI 10.1016/j.cger.2007.08.002; Gooneratne NS, 2014, CLIN GERIATR MED, V30, P591, DOI 10.1016/j.cger.2014.04.007; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; Jacobson LH, 2014, EXPERT REV CLIN PHAR, V7, P711, DOI 10.1586/17512433.2014.966813; Kaur K, 2004, FOOD CHEM TOXICOL, V42, P2015, DOI 10.1016/j.fct.2004.07.015; Kaushik MK, 2014, EXP NEUROL, V253, P82, DOI 10.1016/j.expneurol.2013.12.002; Kohtoh S, 2008, SLEEP BIOL RHYTHMS, V6, P163, DOI 10.1111/j.1479-8425.2008.00355.x; Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265; Kumar A, 2008, INDIAN J PHARM SCI, V70, P806, DOI 10.4103/0250-474X.49130; Kumar A, 2007, INDIAN J EXP BIOL, V45, P524; Manchanda S, 2016, MOL NEUROBIOL; MCKENNIS H, 1962, TOXICOL APPL PHARM, V4, P411, DOI 10.1016/0041-008X(62)90029-7; Murthy M. R. Ven, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P238; PATCHEV V, 1991, HOMEOSTASIS HLTH DIS, V33, P97; Rani G, 2005, FOOD CHEM TOXICOL, V43, P95, DOI 10.1016/j.fct.2004.07.021; Reddy M S, 2011, Indian J Psychol Med, V33, P1, DOI 10.4103/0253-7176.85388; Schwartz Thomas L, 2013, Drugs Context, V2013, P212257, DOI 10.7573/dic.212257; Vassiliadis J, 1999, J TOXICOL-CLIN TOXIC, V37, P773, DOI 10.1081/CLT-100102455; Verma SK., 2011, ASIAN J PHARM CLIN R, V4, P1; Wadhwa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077189; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; ZAKUSOV VV, 1977, ARCH INT PHARMACOD T, V229, P313; Zhang DY, 2010, J CLIN PSYCHOPHARM, V30, P694, DOI 10.1097/JCP.0b013e3181fa8526	31	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0172508	10.1371/journal.pone.0172508	http://dx.doi.org/10.1371/journal.pone.0172508			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BG	28207892	gold, Green Published, Green Submitted			2023-01-03	WOS:000394424500143
J	Amdahl, J; Diaz, J; Sharma, A; Park, J; Chandiwana, D; Delea, TE				Amdahl, Jordan; Diaz, Jose; Sharma, Arati; Park, Jinhee; Chandiwana, David; Delea, Thomas E.			Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom	PLOS ONE			English	Article							CANCER; TRIAL; UNCERTAINTY; THERAPY; CANADA	Background Sunitinib and pazopanib are the only two targeted therapies for the first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) recommended by the United Kingdom's National Institute for Health and Care Excellence. Pazopanib demonstrated non-inferior efficacy and a differentiated safety profile versus sunitinib in the phase III COMPARZ trial. The current analysis provides a direct comparison of the cost-effectiveness of pazopanib versus sunitinib from the perspective of the United Kingdom's National Health Service based on data from COMPARZ and other sources. Methods A partitioned-survival analysis model with three health states (alive with no progression, alive with progression, or dead) was used to estimate the incremental cost per qualityadjusted life-year (QALY) gained for pazopanib versus sunitinib over five years (duration of follow-up for final survival analysis in COMPARZ). The proportion of patients in each health state over time was based on Kaplan-Meier distributions for progression-free and overall survival from COMPARZ. Utility values were based on EQ-5D data from the pivotal study of pazopanib versus placebo. Costs were based on medical resource utilisation data from COMPARZ and unit costs from secondary sources. Probabilistic and deterministic sensitivity analyses were conducted to assess uncertainty of model results. Results In the base case, pazopanib was estimated to provide more QALYs (0.0565, 95% credible interval [CrI]: -0.0920 to 0.2126) at a lower cost (-1,061 pound, 95% CrI: -4,328 pound to 2,067) pound versus sunitinib. The probability that pazopanib yields more QALYs than sunitinib was estimated to be 76%. For a threshold value of 30,000 pound per QALY gained, the probability that pazopanib is cost-effective versus sunitinib was estimated to be 95%. Pazopanib was dominant in most scenarios examined in deterministic sensitivity analyses. Conclusions Pazopanib is likely to be a cost-effective treatment option compared with sunitinib as firstline treatment of mRCC in the United Kingdom.	[Amdahl, Jordan; Sharma, Arati; Delea, Thomas E.] Policy Anal Inc, Res, Brookline, MA 02445 USA; [Diaz, Jose] GlaxoSmithKline, Global Hlth Outcomes Oncol, Stockley Pk West, Uxbridge, Middx, England; [Park, Jinhee] Novartis Pharmaceut, Worldwide Hlth Outcomes Value & Access, E Hanover, NJ USA; [Chandiwana, David] Novartis Pharmaceut UK Ltd, Worldwide Hlth Outcomes Value & Access, Camberley, Surrey, England; [Diaz, Jose] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res Markets, Twickenham, Greater London, England	Policy Analysis Inc; GlaxoSmithKline; Novartis; Novartis; Bristol-Myers Squibb	Delea, TE (corresponding author), Policy Anal Inc, Res, Brookline, MA 02445 USA.	tdelea@pai2.com		Sharma, Arati/0000-0002-2831-2941	Glaxo Smith Kline; Novartis Pharmaceuticals Corporation; GSK; Novartis	Glaxo Smith Kline(GlaxoSmithKline); Novartis Pharmaceuticals Corporation(Novartis); GSK(GlaxoSmithKline); Novartis(Novartis)	Funding for this study was provided to PAI by Glaxo Smith Kline and Novartis Pharmaceuticals Corporation. Pazopanib is an asset of Novartis AG as of March 2,2015. The funders provided support in the form of salaries for authors; JD receiveda salary from both GSK and Novartis, and JP and DC received a salary from Novartis. The funders were involved in the concept and design of the study, as well as the interpretation of the data, writing and approval of the manuscript and the decision to submit.	Amdahl J, 2016, CURR ONCOL, V23, pE340, DOI 10.3747/co.23.2244; [Anonymous], 2016, VOTRIENT PACKAGE INS; Auguste P, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15180; Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006; Chabot I, 2010, VALUE HEALTH, V13, P837, DOI 10.1111/j.1524-4733.2010.00738.x; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Curtis L., 2012, UNIT COSTS HLTH SOCI; Delea TE, 2015, J MANAG CARE SPEC PH, V21, P46, DOI 10.18553/jmcp.2015.21.1.46; Dodd LE, 2008, J CLIN ONCOL, V26, P3791, DOI 10.1200/JCO.2008.16.1711; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Egton Medical Information Systems Limited, 2016, REN CANC; Escudier B, 2014, J CLIN ONCOL, V32, P1412, DOI 10.1200/JCO.2013.50.8267; GlaxoSmithKline, 2013, RAND DOUBL BLIND CRO; Hansen RN, 2015, J MANAG CARE SPEC PH, V21, P37, DOI 10.18553/jmcp.2015.21.1.37; Keisner SV, 2011, DRUGS, V71, P443, DOI 10.2165/11588960-000000000-00000; Lothgren M, 2000, HEALTH ECON, V9, P623, DOI 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V; Mitchell AP, 2015, J ONCOL PRACT, V11, P491, DOI 10.1200/JOP.2015.004929; Motzer R, 2012, ANN ONCOL, V23; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR; National Institute for Health and Clinical Excellence (NICE), 2009, SUN 1 LIN TREATM ADV; NHS Department of Health, 2012, REF COSTS 2011 12; NHS National Institute for Health and Care Excellence (NICE), 2011, PAZ 1 LIN TREAT ADV; Sonpavde Guru, 2007, Curr Oncol Rep, V9, P115, DOI 10.1007/s11912-007-0007-2; Spiegelhalter D, 2004, BAYESIAN APPROACHES, P65; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Thompson R, 2010, 10030 CEP	30	20	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2017	12	6							e0175920	10.1371/journal.pone.0175920	http://dx.doi.org/10.1371/journal.pone.0175920			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY6UH	28636648	gold, Green Published, Green Submitted			2023-01-03	WOS:000404118300002
J	Mason, C; Weber, J; Atasoy, S; Sabariego, C; Cieza, A				Mason, Catherine; Weber, Joerg; Atasoy, Seryan; Sabariego, Carla; Cieza, Alarcos			Development of indicators for monitoring Community-Based Rehabilitation	PLOS ONE			English	Article							PROGRAMS	Background Community-Based Rehabilitation (CBR) is a multi-sectoral approach working to equalize opportunities and include people with disability in all aspects of community life. Reliable and internationally comparable data needed to monitor and evaluate CBR are scarce, partially due to the absence of standardized indicators. The objective of this manuscript is to describe the collaborative development process which led to the World Health Organization's (WHO) recently launched set of standardized CBR outcome indicators. Methods The WHO's CBR Guidelines recognize CBR as a comprehensive and multi-sectoral strategy, and were therefore used as the starting point for the development of the indicators, in a consensus process involving WHO and International Disability and Development Consortium. Pilot implementations in Guatemala, Egypt and China using a specifically developed mobile phone application to collect data, and an online expert survey were completed to assess validity and feasibility of the indicators and their corresponding questions. Results The indicator set includes 13 Base Indicators which are broad enough to capture the situation of people with disability in settings where CBR is carried out, independently of the specific CBR activities carried out in a community; and 27 Supplementary Indicators that provide more specific coverage and can be selected based on the specific goals of a CBR program. Conclusion The indicators were suitable to assess differences in health, education, social life, livelihood and empowerment between people with disability and other community members. This comparability provides valuable information to CBR managers, donors and government agencies, to guide decision making, support advocacy and improve accountability. The CBR indicators will support WHO and its member states in their efforts towards strengthening CBR, by generating evidence on its effectiveness.	[Mason, Catherine; Atasoy, Seryan; Sabariego, Carla] Ludwig Maximilians Univ Munchen, Publ Hlth & Hlth Serv Res, Dept Med Informat Biometry & Epidemiol IBE, Munich, Germany; [Weber, Joerg] London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England; [Cieza, Alarcos] WHO, Disabil & Rehabil Unit, Geneva, Switzerland	University of Munich; University of London; London School of Hygiene & Tropical Medicine; World Health Organization	Mason, C (corresponding author), Ludwig Maximilians Univ Munchen, Publ Hlth & Hlth Serv Res, Dept Med Informat Biometry & Epidemiol IBE, Munich, Germany.	catherine.mason@med.uni-muenchen.de		Mason, Catherine/0000-0002-6859-4373	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Adeoye A, 2011, DISABIL REHABIL, V33, P1110, DOI 10.3109/09638288.2010.521613; [Anonymous], 1996, WORKSH COMM BAS REH; Chung EYH, 2011, DISABIL REHABIL, V33, P1668, DOI 10.3109/09638288.2010.541545; Cornielje H, 2000, LEPROSY REV, V71, P472; Cornielje H, 2008, LEPROSY REV, V79, P36; CRPD, 2006, CONV RIGHTS PERS DIS; Finkenflugel H, 2008, DISABIL REHABIL, V30, P348, DOI 10.1080/09638280701257288; GALLUP, 2013, POLL SOC SER CONS HA; Gibson L., 2015, CAMPBELL SYSTEMATIC, V15; Grandisson M, 2014, DISABIL REHABIL, V36, P265, DOI 10.3109/09638288.2013.785602; International Labour Organization United Nations Educational Scientific and Cultural Organization and the World Health Organization, 2004, CBR STRAT REH EQ OPP; Kendall E, 2000, DISABIL REHABIL, V22, P435, DOI 10.1080/09638280050045901; Kuipers P, 2004, Rural Remote Health, V4, P291; Kuipers P, 2003, J REHABIL, V69, P4; Lukersmith S, 2013, DISABIL REHABIL, V35, P1941, DOI 10.3109/09638288.2013.770078; Madden R.H., 2015, DISABIL CBR INC DEV, V26, P26, DOI [10.5463/dcid.v26i4.472, DOI 10.5463/DCID.V26I4.472]; Meadows D., 1998, EARTHSCAN READER SUS; Organisation for Economic Co-operation and Development, 2004, GLOS KEY TERMS EV RE; Robb A, 2012, TECHN M DEV CBR M E; Sharma M., 2007, ASIA PAC DISABIL REH, V18, P46; Thomas M, 2011, PSYCHOL DEV SOC, V23, P277, DOI 10.1177/097133361102300206; Weltgesundheitsorganisation, 2015, WHO GLOB DIS ACT PLA; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WHO, 2015, CAPT DIFF WE MAK COM; Wirz S, 2002, INT J REHABIL RES, V25, P163, DOI 10.1097/00004356-200209000-00001; World Health Organization, 2012, WHO QUAL LIF BREF WH; World Health Organization, 2010, COMM BAS REH CBR GUI	27	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178418	10.1371/journal.pone.0178418	http://dx.doi.org/10.1371/journal.pone.0178418			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EW6MJ	28575102	gold, Green Published			2023-01-03	WOS:000402624300050
J	Bardelli, A				Bardelli, Alberto			MEDICAL RESEARCH Personalized test tracks cancer relapse	NATURE			English	Editorial Material							CIRCULATING TUMOR DNA; LIQUID BIOPSIES		[Bardelli, Alberto] Univ Torino, Dept Oncol, I-10060 Candiolo, Italy; [Bardelli, Alberto] IRCCS, Candiolo Canc Inst FPO, Bari, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia	Bardelli, A (corresponding author), Univ Torino, Dept Oncol, I-10060 Candiolo, Italy.; Bardelli, A (corresponding author), IRCCS, Candiolo Canc Inst FPO, Bari, Italy.	alberto.bardelli@unito.it	BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070				Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Beaver JA, 2014, CLIN CANCER RES, V20, P2643, DOI 10.1158/1078-0432.CCR-13-2933; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Jamal-Hanjani M., 2017, NEW ENGL J MED, V376, P2109; Siravegna G., 2017, NATURE REV CLIN ONCO; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7	8	10	11	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 25	2017	545	7655					417	418		10.1038/545417a	http://dx.doi.org/10.1038/545417a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV6TH	28541318				2023-01-03	WOS:000401906500038
J	Sumner, J; Harrison, A; Doherty, P				Sumner, Jennifer; Harrison, Alexander; Doherty, Patrick			The effectiveness of modern cardiac rehabilitation: A systematic review of recent observational studies in non-attenders versus attenders	PLOS ONE			English	Review							HEALTH-CARE PROFESSIONALS; LIFE-STYLE MODIFICATION; MYOCARDIAL-INFARCTION; SHORT-TERM; 1-YEAR; STATEMENT; PROGRAMS; OUTCOMES; IMPACT; TRIAL	Background The beneficial effects of cardiac rehabilitation (CR) have been challenged in recent years and there is now a need to investigate whether current CR programmes, delivered in the context of modern cardiology, still benefit patients. Methods A systematic review of non-randomised controlled studies was conducted. Electronic searches of Medline, Embase, CINAHL, science citation index (web of science), CIRRIE and Open Grey were undertaken. Non-randomised studies investigating the effects of CR were included when recruitment occurred from the year 2000 onwards in accordance with significant CR guidance changes from the late 1990' s. Adult patients diagnosed with acute myocardial infarction (AMI) were included. Non-English articles were considered. Two reviewers independently screened articles according to pre-defined selection criteria as reported in the PROSPERO database (CRD42015024021). Results Out of 2,656 articles, 8 studies involving 9,836 AMI patients were included. Studies were conducted in 6 countries. CR was found to reduce the risk of all-cause and cardiac-related mortality and improve Health-Related Quality of Life (HRQOL) significantly in at least one domain. The benefits of CR in terms of recurrent MI were inconsistent and no significant effects were found regarding re-vascularisation or re-hospitalisation following AMI. Conclusion Recent observational evidence draws different conclusions to the most current reviews of trial data with respect to total mortality and re-hospitalisation, questioning the representativeness of historic data in the modern cardiological era. Future work should seek to clarify which patient and service level factors determine the likelihood of achieving improved all-cause and cardiac mortality and reduced hospital re-admissions.	[Sumner, Jennifer; Harrison, Alexander; Doherty, Patrick] Univ York, Dept Hlth Sci, York, N Yorkshire, England	University of York - UK	Sumner, J (corresponding author), Univ York, Dept Hlth Sci, York, N Yorkshire, England.	Jenny.sumner@york.ac.uk	Sumner, Jennifer/AAT-3319-2021	Sumner, Jennifer/0000-0002-2200-3275; Doherty, Patrick Joseph/0000-0002-1887-0237				Alberti G, 2000, CORONARY HEART DIS N; Aldana SG, 2006, BEHAV MODIF, V30, P507, DOI 10.1177/0145445504267797; Aldana SG, 2003, HEART LUNG, V32, P374, DOI 10.1016/S0147-9563(03)00106-7; BALADY GJ, 1994, CIRCULATION, V90, P1602; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Benzer W, 2017, INT J CARDIOL, V228, P58, DOI 10.1016/j.ijcard.2016.11.059; Bjarnason-Wehrens B, 2010, EUR J CARDIOV PREV R, V17, P410, DOI 10.1097/HJR.0b013e328334f42d; Boulay P, 2004, PREV MED, V38, P586, DOI 10.1016/j.ypmed.2003.11.028; British Association for Cardiovascular Prevention and Rehabilitation, 2012, BACPR STANDARDS CORE; British Heart Foundation, 2016, CARDIOVASCULAR DIS S; Caliani SE, 2004, REV ESP CARDIOL, V57, P53; Coll-Fernandez R, 2014, ARCH PHYS MED REHAB, V95, P322, DOI 10.1016/j.apmr.2013.09.020; Department of Health, 2013, CARD DIS OUTC STRAT; Doherty P, 2013, HEART, V99, P593, DOI 10.1136/heartjnl-2012-303365; Doherty P, 2012, HEART, V98, P605, DOI 10.1136/heartjnl-2012-301728; Giannuzzi P, 2003, EUR HEART J, V24, P1273, DOI 10.1016/S0195-668X(03)00198-2; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jolliffe JA, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001800; Junger C, 2010, CURR MED RES OPIN, V26, P803, DOI 10.1185/03007991003604216; Karmali KN, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007131.pub3; Kim C, 2011, ANN REHABIL MED-ARM, V35, P375, DOI 10.5535/arm.2011.35.3.375; Lawler PR, 2011, AM HEART J, V162, P571, DOI 10.1016/j.ahj.2011.07.017; Listerman J, 2011, J CARDIOPULM REHABIL, V31, P342, DOI 10.1097/HCR.0b013e31822f189c; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Martin BJ, 2012, CIRCULATION, V126, P677, DOI 10.1161/CIRCULATIONAHA.111.066738; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; NICE, 2013, MI SEC PREV GUID 172; NICE, 2011, CARD REH SERV COMM G; Nielsen KM, 2008, EUR J PUBLIC HEALTH, V18, P479, DOI 10.1093/eurpub/ckn060; Piepoli MF, 2014, EUR J PREV CARDIOL, V21, P664, DOI 10.1177/2047487312449597; Rashid MA, 2012, HEART BRIT CARDIAC S, V98; Rauch B, 2016, EUR J PREV CARDIOL; Rauch B, 2014, EUR J PREV CARDIOL, V21, P1060, DOI 10.1177/2047487313486040; Salzwedel A, 2015, AGING CLIN EXP RES, V27, P315, DOI 10.1007/s40520-014-0283-2; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sumner JA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003930; Anderson Lindsey, 2017, Cochrane Database Syst Rev, V6, pCD007130, DOI [10.1002/14651858.CD007130.pub3, 10.1002/14651858.CD007130.pub4]; Taylor RS, 2012, HEART BRITISH CARDIA, V98; The National Audit of Cardiac Rehabilitation (NACR), 2016, NAT AUD CARD REH NAC; Wells GA, 2013, RES SYNTH METHODS, V4, P63, DOI 10.1002/jrsm.1077; West RR, 2012, HEART, V98, P637, DOI 10.1136/heartjnl-2011-300302; Wood D, 2012, HEART, V98, P607, DOI 10.1136/heartjnl-2012-301811; Zwisler AD, 2016, INT J CARDIOL, V221, P963, DOI 10.1016/j.ijcard.2016.06.207	44	30	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2017	12	5							e0177658	10.1371/journal.pone.0177658	http://dx.doi.org/10.1371/journal.pone.0177658			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UR	28498869	gold, Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000401314500039
J	Pennisi, M; Lanza, G; Cantone, M; Ricceri, R; Ferri, R; D'Agate, CC; Pennisi, G; Di Lazzaro, V; Bella, R				Pennisi, Manuela; Lanza, Giuseppe; Cantone, Mariagiovanna; Ricceri, Riccardo; Ferri, Raffaele; D'Agate, Carmela Cinzia; Pennisi, Giovanni; Di Lazzaro, Vincenzo; Bella, Rita			Cortical involvement in celiac disease before and after long-term gluten-free diet: A Transcranial Magnetic Stimulation study	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR CORTEX EXCITABILITY; SLEEP-APNEA SYNDROME; INTRACORTICAL INHIBITION; SILENT PERIOD; DIAGNOSIS; ANTIBODIES; AUTOANTIBODIES; DISTURBANCES; VARIABILITY	Objective Transcranial Magnetic Stimulation in de novo patients with Celiac Disease previously revealed an imbalance in the excitability of cortical facilitatory and inhibitory circuits. After a median period of 16 months of gluten-free diet, a global increase of cortical excitability was reported, suggesting a glutamate-mediated compensation for disease progression. We have now evaluated cross-sectionally the changes of cortical excitability to TMS after a much longer gluten-free diet. Methods Twenty patients on adequate gluten-free diet for a mean period of 8.35 years were enrolled and compared with 20 de novo patients and 20 healthy controls. Transcranial Magnetic Stimulation measures, recorded from the first dorsal interosseous muscle of the dominant hand, consisted of: resting motor threshold, cortical silent period, motor evoked potentials, central motor conduction time, mean short-latency intracortical inhibition and intracortical facilitation. Results The cortical silent period was shorter in de novo patients, whereas in gluten-free diet participants it was similar to controls. The amplitude of motor responses was significantly smaller in all patients than in controls, regardless of the dietary regimen. Notwithstanding the diet, all patients exhibited a statistically significant decrease of mean short-latency intracortical inhibition and enhancement of intracortical facilitation with respect to controls; more intracortical facilitation in gluten-restricted compared to non-restricted patients was also observed. Neurological examination and celiac disease-related antibodies were negative. Conclusions In this new investigation, the length of dietary regimen was able to modulate the electrocortical changes in celiac disease. Nevertheless, an intracortical synaptic dysfunction, mostly involving excitatory and inhibitory interneurons within the motor cortex, may persist. The clinical significance of subtle neurophysiological changes in celiac disease needs to be further investigated.	[Pennisi, Manuela] Emergency Hosp Cannizzaro, Spinal Unit, Catania, Italy; [Lanza, Giuseppe; Cantone, Mariagiovanna; Ferri, Raffaele] IRCCS Oasi Maria SS, Dept Neurol IC, Troina, Enna, Italy; [Ricceri, Riccardo; Bella, Rita] Univ Catania, Dept Med & Surg Sci & Adv Technol, Sect Neurosci, Catania, Italy; [D'Agate, Carmela Cinzia] Univ Catania, Gastroenterol & Endoscopy Unit, Catania, Italy; [Pennisi, Giovanni] Univ Catania, Dept Specialita Med Chirurg, Catania, Italy; [Di Lazzaro, Vincenzo] Campus Biomed Univ, Inst Neurol, Rome, Italy	IRCCS Oasi Maria SS; University of Catania; University of Catania; University of Catania; University Campus Bio-Medico - Rome Italy	Lanza, G (corresponding author), IRCCS Oasi Maria SS, Dept Neurol IC, Troina, Enna, Italy.	glanza@oasi.en.it	Di Lazzaro, Vincenzo/L-3731-2018; Lanza, Giuseppe/R-3065-2017; Cantone, Mariagiovanna/C-9392-2017; Ferri, Raffaele/B-5439-2013; Pennisi, Manuela/AAC-2362-2019	Di Lazzaro, Vincenzo/0000-0002-9113-5925; Lanza, Giuseppe/0000-0002-5659-662X; Cantone, Mariagiovanna/0000-0002-9072-4971; Ferri, Raffaele/0000-0001-6937-3065; Pennisi, Manuela/0000-0003-0776-1411				Alaedini A, 2007, J IMMUNOL, V178, P6590, DOI 10.4049/jimmunol.178.10.6590; Bella R, 2016, BRAIN STIMUL, V9, P225, DOI 10.1016/j.brs.2015.09.013; Bella R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129218; Bella R, 2011, INT J PSYCHOPHYSIOL, V82, P248, DOI 10.1016/j.ijpsycho.2011.09.006; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Biagi F, 2012, BRIT J NUTR, V108, P1884, DOI 10.1017/S0007114511007367; Bilgic B, 2013, NEUROL SCI, V34, P2199, DOI 10.1007/s10072-013-1448-z; Brown KJ, 2010, AM J NEURORADIOL, V31, P880, DOI 10.3174/ajnr.A1826; Cantello R, 2002, J CLIN NEUROPHYSIOL, V19, P272, DOI 10.1097/00004691-200208000-00003; Cantone M, 2014, CLIN NEUROPHYSIOL, V125, P1509, DOI 10.1016/j.clinph.2014.04.010; Chin Russell L, 2005, Curr Treat Options Neurol, V7, P43, DOI 10.1007/s11940-005-0005-3; Concerto C, 2015, INT J PSYCHIAT CLIN, V19, P253, DOI 10.3109/13651501.2015.1084329; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Currie S, 2012, J NEUROL NEUROSUR PS, V83, P1216, DOI 10.1136/jnnp-2012-303281; Di Lazzaro V, 2001, EXP BRAIN RES, V141, P121; Di Lazzaro V, 2014, J PHYSIOL-LONDON, V592, P4115, DOI 10.1113/jphysiol.2014.274316; Di Lazzaro V, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00018; Di Lazzaro V, 2010, LANCET, V376, P1798, DOI 10.1016/S0140-6736(10)61163-4; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; Freeman HJ, 2008, CAN J GASTROENTEROL, V22, P273, DOI 10.1155/2008/905325; Gadoth A, 2015, JAMA NEUROL, V72, P676, DOI 10.1001/jamaneurol.2015.48; Giordano D, 2012, COMPUT METH PROG BIO, V107, P4, DOI 10.1016/j.cmpb.2011.10.008; Green PHR, 2003, LANCET, V362, P383, DOI 10.1016/S0140-6736(03)14027-5; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hadjivassiliou M, 2004, P 11 INT S CEL DIS B; Hadjivassiliou M, 2008, ANN NEUROL, V64, P332, DOI 10.1002/ana.21450; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Humeau Y, 2001, J NEUROSCI, V21, P4195, DOI 10.1523/JNEUROSCI.21-12-04195.2001; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Jackson JR, 2012, PSYCHIAT QUART, V83, P91, DOI 10.1007/s11126-011-9186-y; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lanza G, 2015, SLEEP MED REV, V19, P39, DOI 10.1016/j.smrv.2014.04.001; Lanza G, 2015, SLEEP MED, V16, P138, DOI 10.1016/j.sleep.2014.08.016; Ludvigsson JF, 2014, EUR J NEUROL, V21, P976, DOI 10.1111/ene.12419; Luostarinen L, 2003, J NEUROL NEUROSUR PS, V74, P490, DOI 10.1136/jnnp.74.4.490; Mavroudi A, 2005, PEDIATR NEUROL, V33, P292, DOI 10.1016/j.pediatrneurol.2005.05.010; Mesrati F, 2004, NEUROPHYSIOL CLIN, V34, P217, DOI 10.1016/j.neucli.2004.09.005; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Orth M, 2004, CLIN NEUROPHYSIOL, V115, P1076, DOI 10.1016/j.clinph.2003.12.025; Orth M, 2003, CLIN NEUROPHYSIOL, V114, P2362, DOI 10.1016/S1388-2457(03)00243-8; Parisi P, 2015, SEIZURE-EUR J EPILEP, V25, P181, DOI 10.1016/j.seizure.2014.09.016; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pennisi G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102790; Pennisi M, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8154969; Rigamonti A, 2007, MUSCLE NERVE, V35, P675, DOI 10.1002/mus.20727; Roshan L, 2003, EXP BRAIN RES, V151, P330, DOI 10.1007/s00221-003-1502-9; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Sanders DS, 2003, EUR J GASTROEN HEPAT, V15, P407, DOI 10.1097/00042737-200304000-00012; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Spampinato C, 2013, IEEE T NEUR SYS REH, V21, P391, DOI 10.1109/TNSRE.2013.2256432; Takenoshita H, 2001, J NEUROL NEUROSUR PS, V70, P386, DOI 10.1136/jnnp.70.3.386; Tijssen MAJ, 2000, NEUROLOGY, V54, P1350, DOI 10.1212/WNL.54.6.1350; Turner MR, 2007, NAT CLIN PRACT NEURO, V3, P581, DOI 10.1038/ncpneuro0631; Turner MR, 2013, NEUROLOGY, V81, P1222, DOI 10.1212/WNL.0b013e3182a6cc13; Tursi A, 2006, DIGEST DIS SCI, V51, P1869, DOI 10.1007/s10620-005-9054-4; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; WILLIAMSON S, 1995, J AUTONOM NERV SYST, V55, P18, DOI 10.1016/0165-1838(95)00028-V; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 1996, EXP BRAIN RES, V109, P127; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028	65	30	30	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2017	12	5							e0177560	10.1371/journal.pone.0177560	http://dx.doi.org/10.1371/journal.pone.0177560			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UN	28489931	Green Submitted, Green Published, gold			2023-01-03	WOS:000401314100079
J	Worrall, L; Foster, A				Worrall, Linda; Foster, Abby			Does intensity matter in aphasia rehabilitation?	LANCET			English	Editorial Material							TOP 10; STROKE; PEOPLE; LIFE		[Worrall, Linda; Foster, Abby] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Worrall, Linda; Foster, Abby] La Trobe Univ, Sch Allied Hlth, Discipline Speech Pathol, Melbourne, Vic, Australia	University of Queensland; La Trobe University	Worrall, L (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.; Worrall, L (corresponding author), La Trobe Univ, Sch Allied Hlth, Discipline Speech Pathol, Melbourne, Vic, Australia.	l.worrall@uq.edu.au	Foster, Abby/AAL-6420-2021	Foster, Abby/0000-0002-7787-8765				Allen L, 2012, TOP STROKE REHABIL, V19, P523, DOI 10.1310/tsr1906-523; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Breitenstein C, 2016, LANCET; Cherney LR, 2011, CURR NEUROL NEUROSCI, V11, P560, DOI 10.1007/s11910-011-0227-6; Davidson B, 2008, TOP STROKE REHABIL, V15, P325, DOI 10.1310/tsr1504-325; El Hachioui H, 2013, J NEUROL NEUROSUR PS, V84, P310, DOI 10.1136/jnnp-2012-302596; Ellis C, 2012, STROKE, V43, P1429, DOI 10.1161/STROKEAHA.111.647339; Engelter ST, 2006, STROKE, V37, P1379, DOI 10.1161/01.STR.0000221815.64093.8c; Hilari K, 2009, INT J LANG COMM DIS, V44, P193, DOI 10.1080/13682820802008820; Katz RC, 2000, INT J LANG COMM DIS, V35, P303; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; Rose M, 2014, INT J SPEECH-LANG PA, V16, P169, DOI 10.3109/17549507.2013.794474; Simmons-Mackie N, 2017, APHASIOLOGY, V31, P131, DOI 10.1080/02687038.2016.1180662	13	7	8	2	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2017	389	10078					1494	1495		10.1016/S0140-6736(17)30546-9	http://dx.doi.org/10.1016/S0140-6736(17)30546-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER7OP	28256354				2023-01-03	WOS:000399002900005
J	Requena-Morales, R; Palazon-Bru, A; Rizo-Baeza, MM; Adsuar-Quesada, JM; Gil-Guillen, VF; Cortes-Castell, E				Requena-Morales, Rosa; Palazon-Bru, Antonio; Mercedes Rizo-Baeza, Maria; Manuel Adsuar-Quesada, Jose; Francisco Gil-Guillen, Vicente; Cortes-Castell, Ernesto			Mortality after out-of-hospital cardiac arrest in a Spanish Region	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; SURVIVAL; GUIDELINES; AGE	Aims To determine out-of-hospital cardiac arrest mortality in the province of Alicante (Spain) and its associated factors. Methods Cross-sectional observational study of all patients who received cardiopulmonary resuscitation (CPR) by the Emergency Medical Services (EMS) (n = 422) in the province of Alicante in 2013. To determine associated factors, a binary logistic regression model was constructed. Primary outcome: death before arriving at the hospital. Predictive variables: gender, age, artificial respiration, prior functional status, asystole, cardiogenic aetiology, bystander CPR, time from the cardiac arrest to the arrival of the EMS and location of cardiac arrest. Results There were 337 deaths (79.9%; 95% Cl: 76.0-83.7%). Factors independently associated (p<0.05) with death were: male gender (OR = 2.11; 95% Cl: 1.20-3.72; p = 0.010), asystole (OR = 1.99, 95% Cl: 1.17-3.39; p = 0.012), cardiac arrest at home (OR = 2.44; 95% Cl: 1.42-4.18; p = 0.001) and an increased time between arrest and EMS arrival (OR = 1.05, 95% Cl: 1.01-1.09, p = 0.009). Having a worse prior functional status had a tendency towards significance (OR = 0.56, 95% Cl: 0.31-1.02, p = 0.059). Conclusions Mortality was high. The associated factors were: male gender, asystole, worse prior functional status, longer time from the cardiac arrest to the arrival of the EMS and having the cardiac arrest at home. The clearly negative impact of experiencing a cardiac arrest at home necessitates modifying training policies in Spain. These policies should be focused on providing information about CPR in schools in order to decrease the mortality of these events.	[Requena-Morales, Rosa; Mercedes Rizo-Baeza, Maria] Univ Alicante, Dept Nursing, Alicante, Spain; [Requena-Morales, Rosa; Manuel Adsuar-Quesada, Jose] Valencian Reg Minist Hlth, Emergency Med Serv, Alicante, Spain; [Palazon-Bru, Antonio; Francisco Gil-Guillen, Vicente] Miguel Hernandez Univ, Dept Clin Med, Alicante, Spain; [Cortes-Castell, Ernesto] Miguel Hernandez Univ, Dept Pharmacol Pediat & Organ Chem, Alicante, Spain	Universitat d'Alacant; Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche	Palazon-Bru, A (corresponding author), Miguel Hernandez Univ, Dept Clin Med, Alicante, Spain.	antonio.pb23@gmail.com	Cortés-Castell, Ernesto/H-8528-2019; Rizo-Baeza, Mercedes/J-3974-2017; Guillén, Vicente Francisco Gil/AAE-8201-2019	Rizo-Baeza, Mercedes/0000-0002-6754-6505; Palazon-Bru, Antonio/0000-0002-5959-9631; Gil-Guillen, Vicente F/0000-0003-3793-9786; CORTES CASTELL, ERNESTO/0000-0002-8079-1695				[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Ballesteros-Pena S, 2013, EMERGENCIAS, V25, P137; Ballesteros-Pena S, 2013, REV ESP CARDIOL, V66, P269, DOI 10.1016/j.rec.2012.09.014; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bottiger BW, 2015, LANCET, V385, P2353, DOI 10.1016/S0140-6736(15)61099-6; Clark Angela P, 2005, Crit Care Nurs Clin North Am, V17, P23, DOI 10.1016/j.ccell.2004.09.004; Curos Abadal A, 2001, Rev Esp Cardiol, V54, P827; Escorial Hernandez V, 2001, Rev Esp Cardiol, V54, P832; Fothergill RT, 2013, RESUSCITATION, V84, P1089, DOI 10.1016/j.resuscitation.2013.03.034; Grasner JT, 2013, BEST PRAC RES-CL ANA, V27, P293, DOI 10.1016/j.bpa.2013.07.008; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Iqbal MB, 2015, AM J CARDIOL, V115, P730, DOI 10.1016/j.amjcard.2014.12.033; JENNETT B, 1975, LANCET, V1, P480; Kwok H, 2013, RESUSCITATION, V84, P1353, DOI 10.1016/j.resuscitation.2013.04.015; Marijon E, 2015, CIRCULATION, V131, P1546, DOI 10.1161/CIRCULATIONAHA.114.010498; Montgomery W H, 1992, Ann Acad Med Singap, V21, P69; Nakanishi N, 2011, PREHOSP EMERG CARE, V15, P271, DOI 10.3109/10903127.2010.545475; Nehme Z, 2015, CIRC-CARDIOVASC QUAL, V8, P56, DOI 10.1161/CIRCOUTCOMES.114.001185; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Ringh M, 2015, NEW ENGL J MED, V372, P2316, DOI 10.1056/NEJMoa1406038; Safdar B, 2014, ACAD EMERG MED, V21, P1503, DOI 10.1111/acem.12540; Sasson C, 2014, ACAD EMERG MED, V21, P1042, DOI 10.1111/acem.12455; Silfvast T, 1996, RESUSCITATION, V31, P101, DOI 10.1016/0300-9572(95)00915-9; Wissenberg M, 2015, CIRCULATION, V131, P1536, DOI 10.1161/CIRCULATIONAHA.114.013122	25	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2017	12	4							e0175818	10.1371/journal.pone.0175818	http://dx.doi.org/10.1371/journal.pone.0175818			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MB	28407020	gold, Green Published, Green Submitted			2023-01-03	WOS:000399955400101
J	Cherniak, W; Anguyo, G; Meaney, C; Kong, LY; Malhame, I; Pace, R; Sodhi, S; Silverman, M				Cherniak, William; Anguyo, Geoffrey; Meaney, Christopher; Kong, Ling Yuan; Malhame, Isabelle; Pace, Romina; Sodhi, Sumeet; Silverman, Michael			Effectiveness of advertising availability of prenatal ultrasound on uptake of antenatal care in rural Uganda: A cluster randomized trial	PLOS ONE			English	Article							LOW-INCOME COUNTRIES; MATERNITY SERVICES; HEALTH; DELIVERY; IMPACT; WOMEN; PREGNANCY; COMMUNITY; SETTINGS; BENEFITS	In rural Uganda pregnant women often lack access to health services, do not attend antenatal care, and tend to utilize traditional healers/birth attendants. We hypothesized that receiving a message advertising that "you will be able to see your baby by ultrasound" would motivate rural Ugandan women who otherwise might use a traditional birth attendant to attend antenatal care, and that those women would subsequently be more satisfied with care. A cluster randomized trial was conducted across eight rural sub-counties in southwestern Uganda. Sub-counties were randomized to a control arm, with advertisement of antenatal care with no mention of portable obstetric ultrasound (four communities, n = 59), or an intervention arm, with advertisement of portable obstetric ultrasound. Advertisement of portable obstetric ultrasound was further divided into intervention A) word of mouth advertisement of portable obstetric ultrasound and antenatal care (one communitity, n = 16), B) radio advertisement of only antenatal care and word of mouth advertisement of antenatal care and portable obstetric ultrasound (one community, n = 7), or C) word of mouth + radio advertisement of both antenatal care and portable obstetric ultrasound (two communities, n = 75). The primary outcome was attendance to antenatal care. 159 women presented to antenatal care across eight sub-counties. The rate of attendance was 65.1 (per 1000 pregnant women, 95% CI 38.3-110.4) where portable obstetric ultrasound was advertised by radio and word of mouth, as compared to a rate of 11.1 (95% CI 6.1-20.1) in control communities (rate ratio 5.9, 95% CI 2.6-13.0, p<0.0001). Attendance was also improved in women who had previously seen a traditional healer (13.0, 95% CI 5.4-31.2) compared to control (1.5, 95% CI 0.5-5.0, rate ratio 8.7, 95% CI 2.0-38.1, p = 0.004). By advertising antenatal care and portable obstetric ultrasound by radio attendance was significantly improved. This study suggests that women can be motivated to attend antenatal care when offered the concrete incentive of seeing their baby.	[Cherniak, William; Meaney, Christopher; Sodhi, Sumeet] Univ Toronto, Markham Stouffville Hosp, Div Emergency Med, Dept Family & Community Med, Toronto, ON, Canada; [Cherniak, William; Kong, Ling Yuan; Malhame, Isabelle; Pace, Romina; Silverman, Michael] Bridge Hlth Med & Dent, Toronto, ON, Canada; [Anguyo, Geoffrey] Kigezi Healthcare Fdn, Kabale, Uganda; [Anguyo, Geoffrey] Mbarara Univ Sci & Technol, Kabale, Uganda; [Kong, Ling Yuan; Malhame, Isabelle; Pace, Romina] McGill Univ, Dept Internal Med, Montreal, PQ, Canada; [Sodhi, Sumeet] Univ Hlth Network, Toronto Western Hosp, Dept Family & Community Med, Toronto, ON, Canada; [Silverman, Michael] Western Univ, Div Infect Dis, London, ON, Canada	University of Toronto; Mbarara University of Science & Technology; McGill University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Western University (University of Western Ontario)	Cherniak, W (corresponding author), Univ Toronto, Markham Stouffville Hosp, Div Emergency Med, Dept Family & Community Med, Toronto, ON, Canada.; Cherniak, W (corresponding author), Bridge Hlth Med & Dent, Toronto, ON, Canada.	w.cherniak@mail.utoronto.ca	Meaney, Christopher/R-8349-2018; Silverman, Michael/J-3776-2014	Meaney, Christopher/0000-0002-5429-5233; Silverman, Michael/0000-0002-0389-7656; Pace, Romina/0000-0002-3976-2753	Bridge to Health Medical and Dental (BTH); BTH	Bridge to Health Medical and Dental (BTH); BTH	The funding source of this study was provided by Bridge to Health Medical and Dental (BTH), www.bridgetohealth.ca. BTH is primarily funded through unrestricted donations from Canadian corporations (such as Cole Engineering, Lebovic Enterprises and other smaller donors), Canadian Rotary Clubs, and small private donors. None of the donors had any conflicts of interest. None of the Canadian investigators received any personal compensation for their work on this project. The organization has no proprietary holdings on the technology used in this study nor does it, or its investigators, receive any financial compensation for sales of portable ultrasound technology. Some compensation for time spent was provided by BTH to the Ugandan research team.	[Anonymous], 2010, WORLD HLTH STAT 2010; [Anonymous], 2010, REP WHO TECHN CONS T; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Conrad P, 2012, QUAL HEALTH RES, V22, P619, DOI 10.1177/1049732311431897; Dixon J, 2014, TROP MED INT HEALTH, V19, P98, DOI 10.1111/tmi.12223; Ediau M, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-189; El Arifeen S, 2013, LANCET, V382, P2012, DOI 10.1016/S0140-6736(13)62149-2; Firth Emma Rebecca, 2011, Afr J Reprod Health, V15, P91; Glei DA, 2003, SOC SCI MED, V57, P2447, DOI 10.1016/S0277-9536(03)00140-0; Guliani H, 2014, HEALTH POLICY PLANN, V29, P589, DOI 10.1093/heapol/czt045; Guliani H, 2012, SOC SCI MED, V74, P1882, DOI 10.1016/j.socscimed.2012.02.008; Halim N, 2011, HEALTH POLICY PLANN, V26, P242, DOI 10.1093/heapol/czq040; Harris RD, 2009, J ULTRAS MED, V28, P1067, DOI 10.7863/jum.2009.28.8.1067; Houweling TAJ, 2007, B WORLD HEALTH ORGAN, V85, P745, DOI 10.2471/BLT.06.038588; Kakaire O, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-12; Kiwuwa MS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-44; Kyomuhendo GB, 2003, REPROD HEALTH MATTER, V11, P16, DOI 10.1016/S0968-8080(03)02176-1; Lincetto O, 2006, ANTENATAL CARE OPPOR, P55; McClure EM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-73; Ministry of Health, 2012, HLTH SYST 2020 MAK U; Ndyomugyenyi R, 1998, HEALTH POLICY PLANN, V13, P94, DOI 10.1093/heapol/13.1.94; Ross AB, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0424-9; Ross AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078450; Rutanga M, 2011, RELIG POWER GREAT LA; Shah SP, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-4; Stolz LA, 2015, TROP MED INT HEALTH, V20, P1067, DOI 10.1111/tmi.12511; The Partnership for Maternal, NEWB CHILD HLTH WORL; The Women and Girls Empowerment Project (WOGE), KAB DISTR UG FACT SH; WHO, GLOBAL HEALTH OBSERV; Yaw AW, ULTRASOUND IMAGING D	30	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2017	12	4							e0175440	10.1371/journal.pone.0175440	http://dx.doi.org/10.1371/journal.pone.0175440			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ET0LZ	28403187	Green Submitted, Green Published, gold			2023-01-03	WOS:000399955200068
J	Du, HX; Yang, JJ; Bai, JY; Ming, K; Shi, JT; Yao, FK; Zhang, W; Yu, Y; Chen, Y; Xiong, W; Wu, Y; Wang, DY; Hu, YL; Liu, JG				Du, Hongxu; Yang, Jingjing; Bai, Jingying; Ming, Ke; Shi, Jintong; Yao, Fangke; Zhang, Wei; Yu, Yang; Chen, Yun; Xiong, Wen; Wu, Yi; Wang, Deyun; Hu, Yuanliang; Liu, Jiaguo			A flavone-polysaccharide based prescription attenuates the mitochondrial dysfunction induced by duck hepatitis A virus type	PLOS ONE			English	Article							OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; LIVER-INJURY; CELL-DEATH; MEDICINE; SEROTYPE; PROTEIN	The principal target organ of duck hepatitis A virus type 1 (DHAV-1) is duckling liver, which is an energy-intensive organ and plays important roles in body's energy metabolism and conversion. As the "power house" of the hepatocytes, mitochondria provide more than 90% of the energy. However, mitochondria are much vulnerable to the oxidative stress for their rich in polyunsaturated fatty acids. Although previous researches have demonstrated that DHAV-1 could induce the oxidative stress in the serum of the infected ducklings, no related study on the mitochondria during the pathological process of DVH has been reported by far. To address this issue, we examined the HE stained tissue pathological slices, detected the hepatic SOD, CAT and GPX activities and MDA contents and analyzed the ATP content, mitochondrial ultrastructure and the mitochondrial SOD, GPX activities and MDA content in the liver tissues. The results showed that the hepatic redox status was significantly disturbed so that causing the mitochondrial dysfunction, ATP depletion and mitochondrial oxidative stress during the process of the DHAV-1 infection, and a prescription formulated with Hypericum japonicum flavone, Radix Rehmanniae Recens polysaccharide and Salvia plebeia flavone (HRS), which had been demonstrated with good anti-oxidative activity in serum, could effectively alleviate the hepatic injury and the oxidative stress in liver tissue induced by DHAV-1 thus alleviating the mitochondrial injury and oxidative stress. In a word, this research discovers the oxidative stress induced mitochondrial dysfunction and oxidative stress during the DVH pathological process and demonstrates HRS exerts good anti-oxidative activity in liver tissue to protect mitochondria against reactive oxygen species (ROS).	[Du, Hongxu; Yang, Jingjing; Bai, Jingying; Ming, Ke; Shi, Jintong; Yao, Fangke; Zhang, Wei; Yu, Yang; Chen, Yun; Xiong, Wen; Wu, Yi; Wang, Deyun; Hu, Yuanliang; Liu, Jiaguo] Nanjing Agr Univ, Coll Vet Med, Inst Tradit Chinese Vet Med, Nanjing, Peoples R China	Nanjing Agricultural University	Liu, JG (corresponding author), Nanjing Agr Univ, Coll Vet Med, Inst Tradit Chinese Vet Med, Nanjing, Peoples R China.	liujiaguo@njau.edu.cn			National Natural Science Foundation of China [31172355, 31572557]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Special Funds for Agro-scientific Research of Public Interest [201303040, 201403051]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Special Funds for Agro-scientific Research of Public Interest	This work was supported by the National Natural Science Foundation of China (grant no. 31172355, 31572557, URLs: http://isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list), Project Funds from the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Special Funds for Agro-scientific Research of Public Interest (201303040 and 201403051, URLs: http://www.moa.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbar M, 2016, BRAIN RES, V1637, P34, DOI 10.1016/j.brainres.2016.02.016; Al-Qabandi W, 2012, MED PRIN PRACT, V21, P264, DOI 10.1159/000334491; Arakawa S, 2015, BIOCHEM BIOPH RES CO, V467, P1006, DOI 10.1016/j.bbrc.2015.10.022; ASPLIN FD, 1965, VET REC, V77, P1529; Auger C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00040; Bacchetta R, 2016, ENVIRON RES, V148, P376, DOI 10.1016/j.envres.2016.04.028; Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Chan Katie, 2005, Expert Opin Drug Metab Toxicol, V1, P655, DOI 10.1517/17425255.1.4.655; Chen X, 2006, BRIT J PHARMACOL, V149, P1092, DOI 10.1038/sj.bjp.0706945; Chen Y, 2015, VIRUS RES, V204, P58, DOI 10.1016/j.virusres.2015.04.013; Chen Y, 2014, INT J BIOL MACROMOL, V66, P186, DOI 10.1016/j.ijbiomac.2014.02.038; Chen ZG, 2015, J ETHNOPHARMACOL, V162, P287, DOI 10.1016/j.jep.2015.01.002; Cichoz-Lach H, 2014, WORLD J GASTROENTERO, V20, P8082, DOI 10.3748/wjg.v20.i25.8082; Clark R, 2005, J INVEST DERMATOL, V125, P629, DOI 10.1111/j.0022-202X.2005.23856.x; Du HX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146046; Gui SY, 2005, WORLD J GASTROENTERO, V11, P2984, DOI 10.3748/wjg.v11.i19.2984; HAIDER SA, 1979, AVIAN DIS, V23, P715, DOI 10.2307/1589748; Khan M, 2015, BBA-MOL CELL RES, V1853, P2822, DOI 10.1016/j.bbamcr.2014.12.040; Kim MC, 2007, ARCH VIROL, V152, P2059, DOI 10.1007/s00705-007-1023-0; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LEVINE PP, 1950, CORNELL VET, V40, P71; Li-Weber M, 2013, CANCER LETT, V332, P304, DOI 10.1016/j.canlet.2010.07.015; Liu P, 2005, WORLD J GASTROENTERO, V11, P2892, DOI 10.3748/wjg.v11.i19.2892; Lopez-Armada MJ, 2013, MITOCHONDRION, V13, P106, DOI 10.1016/j.mito.2013.01.003; Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188; Polo M, 2015, BRIT J PHARMACOL, V172, P1713, DOI 10.1111/bph.13018; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Sanz A, 2016, BBA-BIOENERGETICS, V1857, P1116, DOI 10.1016/j.bbabio.2016.03.018; Sekine S, 2015, TOXICOL APPL PHARM, V282, P237, DOI 10.1016/j.taap.2014.12.004; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tang YH, 2012, FOOD CHEM TOXICOL, V50, P1194, DOI 10.1016/j.fct.2012.02.008; Tseng CH, 2007, VIRUS RES, V126, P19, DOI 10.1016/j.virusres.2007.01.012; Tseng CH, 2007, VIRUS RES, V123, P190, DOI 10.1016/j.virusres.2006.09.007; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang LQ, 2015, ACTA PHARM SIN B, V5, P310, DOI [10.1016//j.apsb.2015.05.005, 10.1016/j.apsb.2015.05.005]; Wiesenfeld PW, 2006, FOOD CHEM TOXICOL, V44, P579, DOI 10.1016/j.fct.2005.09.005; Zeng T, 2008, TOXICOLOGY, V252, P86, DOI 10.1016/j.tox.2008.07.062; Zhang R, 2010, FOOD CHEM TOXICOL, V48, P922, DOI 10.1016/j.fct.2010.01.001	39	3	4	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2017	12	4							e0175495	10.1371/journal.pone.0175495	http://dx.doi.org/10.1371/journal.pone.0175495			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0LV	28394931	Green Published, Green Submitted, gold			2023-01-03	WOS:000399954800039
J	Paal, P; Bukki, J				Paal, Piret; Buekki, Johannes			"If I had stayed back home, I would not be alive any more..." - Exploring end-of-life preferences in patients with migration background	PLOS ONE			English	Article							PALLIATIVE CARE; UNITED-KINGDOM; ETHNIC-GROUPS; PHYSICIANS; MIGRANTS	Background In patients with life-limiting conditions and a history of migration, a higher risk of not dying at home and limited access to palliative care services has been reported. Aim To explore the views and end-of-life preferences of patients with a migration history in Germany and to identify migration specific themes. Design Two-armed study using Kaufmann's 'understanding interview' ('focused interview') method and grounded theory approach. Thematic content analysis was applied using MaxQDA 12 software. Setting/Participants Migrant and non-migrant adult patients with far advanced, life-limiting disease receiving palliative care in different specialist level settings (specialist home palliative care, palliative care inpatient unit, inpatient hospice). Results The 37 interviewees (19 native Germans and 18 patients from Europe and the U.S., Israel, Turkey, and Indonesia) expressed eleven themes covering health care-and patient-related issues, of which four emerged to be specific for migrants: worse survival in home country; the perception of an altered identity and 'not belonging'; language skills as prerequisite to survive; and longing for 'home' while being attached to Germany. From these categories, three overarching themes were derived: (1) a limited understanding of the concept of 'palliative care'; (2) the suppression of end of life discussions for its association with suffering and loss of autonomy; and (3) the significance of complex individual migration histories. Conclusions Based on these findings, the concept of a 'double home' experience is proposed. Barriers to access to palliative care should be minimized for all patients while cultural stereotyping has to be avoided.	[Paal, Piret; Buekki, Johannes] Hospice Care DaSein, Dept Res & Dev, Munich, Germany; [Buekki, Johannes] Paracelsus Med Univ, Inst Nursing Sci & Palliat Care, Salzburg, Austria	Paracelsus Private Medical University	Bukki, J (corresponding author), Hospice Care DaSein, Dept Res & Dev, Munich, Germany.	dr.j.buekki@hospiz-da-sein.de	Paal, Piret/J-4565-2019; Bukki, Johannes/D-4980-2015	Bukki, Johannes/0000-0003-1232-1103; Paal, Piret/0000-0002-1341-3248	Bavarian Ministry of Health (Bayerisches Staatsministerium fur Gesundheit und Pflege) [VI 5/33454/20/15]; Bavarian Ministry of Health officials	Bavarian Ministry of Health (Bayerisches Staatsministerium fur Gesundheit und Pflege); Bavarian Ministry of Health officials	This work has been kindly funded by the Bavarian Ministry of Health (Bayerisches Staatsministerium fur Gesundheit und Pflege https://www.stmgp.bayern.de), grant number: VI 5/33454/20/15. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are indebted to Iemkje Stiemer and Iryna Tretiakova who diligently conducted the transcriptions, and to the Bavarian Ministry of Health officials who generously supported this research project and provided administrative advice.	Bade KJ, 2010, CYCLOPEDIA MIGRATION; Bosma H, 2010, PALLIATIVE MED, V24, P510, DOI 10.1177/0269216309351380; Briggs C. L., 1986, LEARNING ASK; Buiting HM, 2008, EUR J PUBLIC HEALTH, V18, P681, DOI 10.1093/eurpub/ckn084; Burt R. S., 2005, BROKERAGE CLOSURE IN; Ceuterick M, 2017, SOC SCI MED, V177, P43, DOI 10.1016/j.socscimed.2017.01.026; Coupland VH, 2011, PALLIATIVE MED, V25, P314, DOI 10.1177/0269216310395986; Crawley LaVera M, 2005, J Palliat Med, V8 Suppl 1, pS58; de Graaff Fuusje M, 2010, BMC Palliat Care, V9, P19, DOI 10.1186/1472-684X-9-19; Epner DE, 2012, ANN ONCOL, V23, P33, DOI 10.1093/annonc/mds086; Evans N, 2012, J PAIN SYMPTOM MANAG, V43, P261, DOI 10.1016/j.jpainsymman.2011.04.012; Gunaratnam Y, 2014, SUBJECTIVITY, V7, P74, DOI 10.1057/sub.2013.21; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Holloway I., 2003, QUALITATIVE RES, V3, P345, DOI [10.1177/1468794103033004, DOI 10.1177/1468794103033004]; Jansky M, 2015, PALLIATIVE HOSPICE C; Jansky M, 2017, BUNDESGESUNDHEITSBLA, V60, P45, DOI 10.1007/s00103-016-2473-x; Kars MC, 2016, PALLIATIVE MED, V30, P533, DOI 10.1177/0269216315616759; Kaufmann Jean-Claude, 1999, UNDERSTANDING INTERV; LeBlanc TW, 2013, J ONCOL PRACT, V9, P277, DOI 10.1200/JOP.2013.000996; Milberg A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165452; Razum O, 2016, BUNDESGESUNDHEITSBLA, V59, P259, DOI 10.1007/s00103-015-2286-3; Salis Gross C, 2014, PALLIATIVE CARE SENS; Searight HR, 2005, AM FAM PHYSICIAN, V71, P515; Taylor B, 2011, QUAL HEALTH RES, V21, P1576, DOI 10.1177/1049732311415288; Torres S, 2016, J INTERCULT STUD, V37, P103, DOI 10.1080/07256868.2016.1141756; United Nations Department of Economic and Social Affairs report, 2016, TRENDS INT MIGRANT S; Vaismoradi M., 2016, J NURS ED PRACT, V6, P100, DOI [DOI 10.5430/JNEP.V6N5P100, 10.5430/jnep.v6n5p100]; van Dijk TA, 2006, DISCOURSE STUD, V8, P159, DOI 10.1177/1461445606059565; Venkatasalu MR, 2014, PALLIATIVE MED, V28, P264, DOI 10.1177/0269216313506765; Volker Deborah L, 2005, Am J Hosp Palliat Care, V22, P442, DOI 10.1177/104990910502200610	30	3	3	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e175314	10.1371/journal.pone.0175314	http://dx.doi.org/10.1371/journal.pone.0175314			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2QB	28384309	Green Published, gold, Green Submitted			2023-01-03	WOS:000399371900154
J	Ishiguro, S; Uppalapati, D; Goldsmith, Z; Robertson, D; Hodge, J; Holt, H; Nakashima, A; Turner, K; Tamura, M				Ishiguro, Susumu; Uppalapati, Deepthi; Goldsmith, Zachary; Robertson, Dana; Hodge, Jacob; Holt, Hayley; Nakashima, Arashi; Turner, Katie; Tamura, Masaaki			Exopolysaccharides extracted from Parachlorella kessleri inhibit colon carcinoma growth in mice via stimulation of host antitumor immune responses	PLOS ONE			English	Article							UNICELLULAR GREEN-ALGAE; CHLORELLA-VULGARIS; ATTENUATES GROWTH; CELL-WALL; TUMOR; POLYSACCHARIDES; GLYCOPROTEIN; RESISTANCE; LIPOPOLYSACCHARIDE; STRAIN	The newly purified extracellular polysaccharides (exopolysaccharides) from Parachlorella kessleri (PCEPS) were evaluated on their antitumor and immunomodulatory effects in cell culture and mouse colon carcinoma peritoneal dissemination model. In two-dimensional cell culture, the PCEPS treatment inhibited cell growth of both murine and human colon carcinoma cells in a dose- and time-dependent manner. In contrast, the growth of mouse splenocytes (SPLs) and bone marrow cells (BMCs) were stimulated by the treatment with PCEPS. The treatment with PCEPS also increased specific subpopulations of the cells in BMCs: antigen presenting cells (CD19(+) B cells, 33D1(+) dendritic cells and CD68(+) macrophage) and CD8(+) cytotoxic T cells. In three-dimensional spheroid culture, spheroid growth of CT26 cells co-cultured with HL-60 human neutrophilic promyeloblasts and Jurkat cells (human lymphoblasts), but not THP1 human monocyte/macrophage was significantly attenuated by PCEPS treatment. In a mouse CT26 colon carcinoma peritoneal dissemination model, intraperitoneal injection of PCEPS (10 mg/kg, twice per week) significantly attenuated the growth of CT26 colon carcinoma in syngeneic mice. The present study suggests that PCEPS inhibits colon carcinoma growth via direct cell growth inhibition and a stimulation of the host antitumor immune responses. Taken together, the current study suggests that exopolysaccharides derived from Parachlorella kessleri contain significant bioactive materials that inhibit colon carcinoma growth.	[Tamura, Masaaki] Kansas State Univ, Coll Vet Med, Dept Anat, Manhattan, KS 66506 USA; Kansas State Univ, Coll Vet Med, Dept Physiol, Manhattan, KS 66506 USA	Kansas State University; Kansas State University	Tamura, M (corresponding author), Kansas State Univ, Coll Vet Med, Dept Anat, Manhattan, KS 66506 USA.	mtamura@vet.ksu.edu		Tamura, Masaaki/0000-0003-4863-3379; Ishiguro, Susumu/0000-0002-3268-7754	Kansas State University Johnson Cancer Research Center [2011JCRCEQ, 2014CRA, 2015CRA, 2016CRA]; College of Veterinary Medicine Dean's funds [2010CVM-EQ]; NIH [P20 RR017686]	Kansas State University Johnson Cancer Research Center; College of Veterinary Medicine Dean's funds; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by funds from Kansas State University Johnson Cancer Research Center 2011JCRCEQ (MT), 2014CRA (ZG and MT), 2015CRA (JH, HH, AN and MT), 2016CRA (HH and MT), College of Veterinary Medicine Dean's funds 2010CVM-EQ (MT), and NIH grant P20 RR017686 (MT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Cancer Society, 2014, COLORECTAL CANCER FA; Armstrong MT, 2006, FASEB J, V20, P2145, DOI 10.1096/fj.05-5484fje; Armstrong PB, 2002, BIOL BULL, V203, P203, DOI 10.2307/1543397; Bot J, 2003, PATHOL RES PRACT, V199, P341, DOI 10.1078/0344-0338-00427; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Buono S, 2014, FOOD FUNCT, V5, P1669, DOI [10.1039/c4fo00125g, 10.1039/C4FO00125G]; Coragliotti A. FS, 2012, Microalgal polysaccharide compositions. United States patent US, Patent No. 20120202768; Raposo MFD, 2013, MAR DRUGS, V11, P233, DOI 10.3390/md11010233; Doi C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-67; Donot F, 2012, CARBOHYD POLYM, V87, P951, DOI 10.1016/j.carbpol.2011.08.083; El-Sheekh MM, 2012, IRAN J ENVIRON HEALT, V9, DOI 10.1186/1735-2746-9-10; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Hasegawa T, 2002, INT IMMUNOPHARMACOL, V2, P579, DOI 10.1016/S1567-5769(02)00002-4; HASEGAWA T, 1995, INT J IMMUNOPHARMACO, V17, P505, DOI 10.1016/0192-0561(95)00035-Z; Huang CJ, 2006, J IMMUNOL, V176, P4173, DOI 10.4049/jimmunol.176.7.4173; IBUSUKI K, 1990, NAT IMMUN CELL GROW, V9, P121; Ishiguro S, 2016, PHARM RES-DORDR, V33, P2517, DOI 10.1007/s11095-016-1976-3; Ishiguro S, 2015, CANCER BIOL THER, V16, P307, DOI 10.1080/15384047.2014.1002357; Justo GZ, 2001, IMMUNOPHARM IMMUNOT, V23, P119, DOI 10.1081/IPH-100102573; Kawabata A, 2012, CANCER BIOL THER, V13, P880, DOI 10.4161/cbt.20840; Kawakami T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084704; KONISHI F, 1985, CANCER IMMUNOL IMMUN, V19, P73; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Li P, 2001, Biotechnol Genet Eng Rev, V18, P375; Lu HL, 2011, CLIN CANCER RES, V17, P67, DOI 10.1158/1078-0432.CCR-10-1763; Matsuzuka T, 2010, LUNG CANCER, V70, P28, DOI 10.1016/j.lungcan.2010.01.003; Merchant Randall E., 2002, Journal of Medicinal Food, V5, P141, DOI 10.1089/10966200260398170; MIKHEYSKAYA LV, 1977, J BACTERIOL, V130, P1; MIYAZAWA Y, 1988, J ETHNOPHARMACOL, V24, P135, DOI 10.1016/0378-8741(88)90145-6; Mohamed ZA, 2008, ECOTOXICOLOGY, V17, P504, DOI 10.1007/s10646-008-0204-2; Noda K, 1996, PLANTA MED, V62, P423, DOI 10.1055/s-2006-957931; Ohta N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123756; OKAMOTO K, 1978, JPN HEART J, V19, P622; OSBORN MJ, 1964, SCIENCE, V145, P783, DOI 10.1126/science.145.3634.783; Ou Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087223; PANAC CO. LTD, 2014, Japan patent, Patent No. [JP2014-025035A, 2014025035]; Ramos AL, 2010, NUTR CANCER, V62, P1170, DOI 10.1080/01635581.2010.513801; Royce CL, 1996, J ENDOTOXIN RES, V3, P437, DOI 10.1177/096805199600300601; SANO T, 1987, ARTERY, V14, P76; SANO T, 1988, ARTERY, V15, P217; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; SEMPLE TU, 1978, CANCER RES, V38, P1345; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978-1-61779-012-6_9; TANAKA K, 1984, CANCER IMMUNOL IMMUN, V17, P90, DOI 10.1007/BF00200042; TANAKA K, 1990, IMMUNOPHARM IMMUNOT, V12, P277, DOI 10.3109/08923979009019673; Tanaka K, 1998, CANCER IMMUNOL IMMUN, V45, P313, DOI 10.1007/s002620050448; Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839; Zheng WF, 2006, INT IMMUNOPHARMACOL, V6, P1093, DOI 10.1016/j.intimp.2006.01.020	49	17	17	5	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0175064	10.1371/journal.pone.0175064	http://dx.doi.org/10.1371/journal.pone.0175064			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28380056	gold, Green Published			2023-01-03	WOS:000399353500091
J	Travers, CP; Clark, RH; Spitzer, AR; Das, A; Garite, TJ; Carlo, WA				Travers, Colm P.; Clark, Reese H.; Spitzer, Alan R.; Das, Abhik; Garite, Thomas J.; Carlo, Waldemar A.			Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRONCHOPULMONARY DYSPLASIA; PERIVIABLE BIRTH; PERINATAL-CARE; RISK; BORN; METAANALYSIS; ASSOCIATION; MATURATION; SURVIVAL; DEATH	OBJECTIVE To determine whether exposure to any antenatal corticosteroids is associated with a lower rate of death at each gestational age at which administration is currently recommended. DESIGN Prospective cohort study. SETTINGS 300 participating neonatal intensive care units of the Pediatrix Medical Group in the United States. PARTICIPANTS 117 941 infants 23 0/7 to 34 6/7 weeks' gestational age born between 1 January 2009 and 31 December 2013. EXPOSURE Any antenatal corticosteroids. MAIN OUTCOMES MEASURES Death or major hospital morbidities analyzed by gestational age and exposure to antenatal corticosteroids with models adjusted for birth weight, sex, mode of delivery, and multiple births. RESULTS Infants exposed to antenatal corticosteroids (n= 81 832) had a significantly lower rate of death before discharge at each gestation 29 weeks or less, 31 weeks, and 33-34 weeks compared with infants without exposure (range of adjusted odds ratios 0.32 to 0.55). The number needed to treat with antenatal corticosteroids to prevent one death before discharge increased from six at 23 and 24 weeks' gestation to 798 at 34 weeks' gestation. The rate of survival without major hospital morbidity was higher among infants exposed to antenatal corticosteroids at the lowest gestations. Infants exposed to antenatal corticosteroids had lower rates of severe intracranial hemorrhage or death, necrotizing enterocolitis stage 2 or above or death, and severe retinopathy of prematurity or death compared with infants without exposure at all gestations less than 30 weeks and most gestations for infants born at 30 weeks' gestation or later. CONCLUSION Among infants born from 23 to 34 weeks' gestation, antenatal exposure to corticosteroids compared with no exposure was associated with lower mortality and morbidity at most gestations. The effect size of exposure to antenatal corticosteroids on mortality seems to be larger in infants born at the lowest gestations.	[Travers, Colm P.; Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL 35233 USA; [Clark, Reese H.; Spitzer, Alan R.; Garite, Thomas J.] Pediatrix Med Grp, Ctr Res Educ & Qual, Sunrise, FL USA; [Clark, Reese H.; Spitzer, Alan R.; Garite, Thomas J.] MEDNAX, Sunrise, FL USA; [Das, Abhik] RTI Int, Social Stat & Environm Sci Unit, Res Triangle Pk, NC USA; [Garite, Thomas J.] Univ Calif Irvine, Dept Obstet & Gynecol, Irvine, CA 92717 USA	University of Alabama System; University of Alabama Birmingham; Research Triangle Institute; University of California System; University of California Irvine	Carlo, WA (corresponding author), Univ Alabama Birmingham, Div Neonatol, Birmingham, AL 35233 USA.	wcarlo@peds.uab.edu	Das, Abhik/AAF-1883-2020; Clark, Reese/L-5392-2019	Das, Abhik/0000-0003-2722-0479; Clark, Reese/0000-0002-7363-4640	Agency for Healthcare Research and Quality [5T32HS013852-14]; Perinatal Health and Human Development Research Program of the University of Alabama at Birmingham; Children's of Alabama Centennial Scholar Fund; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS013852] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Perinatal Health and Human Development Research Program of the University of Alabama at Birmingham; Children's of Alabama Centennial Scholar Fund; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	CPT is supported by the Agency for Healthcare Research and Quality grant number 5T32HS013852-14, the Perinatal Health and Human Development Research Program of the University of Alabama at Birmingham, and the Children's of Alabama Centennial Scholar Fund. These funders had no role in: the study design; the collection, analysis, or interpretation of data; the writing of the report; or in the decision to submit the article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.	Ambalavanan N, 2008, J PERINATOL, V28, P420, DOI 10.1038/jp.2008.18; Austeng D, 2010, ACTA PAEDIATR, V99, P978, DOI 10.1111/j.1651-2227.2010.01846.x; Bottoms SF, 1997, AM J OBSTET GYNECOL, V176, P960, DOI 10.1016/S0002-9378(97)70386-7; Brownfoot FC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006764.pub3; Carlo WA, 2011, JAMA-J AM MED ASSOC, V306, P2348, DOI 10.1001/jama.2011.1752; Davidson C, 2010, J REPROD MED, V55, P14; Ecker JL, 2015, AM J OBSTET GYNECOL, V213, P604, DOI 10.1016/j.ajog.2015.08.035; Ellsbury DL, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-0389; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Fischer HS, 2013, PEDIATRICS, V132, pE1351, DOI 10.1542/peds.2013-1880; GARITE TJ, 1992, AM J OBSTET GYNECOL, V166, P646, DOI 10.1016/0002-9378(92)91691-3; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Manktelow BN, 2010, ARCH DIS CHILD-FETAL, V95, pF95, DOI 10.1136/adc.2009.170340; McKinlay CJD, 2012, AM J OBSTET GYNECOL, V206, P187, DOI 10.1016/j.ajog.2011.07.042; Melamed N, 2015, OBSTET GYNECOL, V125, P1377, DOI 10.1097/AOG.0000000000000840; Mori R, 2011, J PEDIATR-US, V159, P110, DOI 10.1016/j.jpeds.2010.12.039; Onland W, 2011, AM J PERINAT, V28, P33, DOI 10.1055/s-0030-1262509; Park CK, 2016, OBSTET GYNECOL, V127, P715, DOI 10.1097/AOG.0000000000001355; Patel RM, 2015, NEW ENGL J MED, V372, P331, DOI 10.1056/NEJMoa1403489; Raju TNK, 2014, AM J OBSTET GYNECOL, V210, P406, DOI 10.1016/j.ajog.2014.02.027; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Royal College of Obstetricians and Gynaecologists, 2010, ANT CORT RED NEON MO; Rysavy MA, 2015, NEW ENGL J MED, V372, P1801, DOI 10.1056/NEJMoa1410689; Serenius F, 2015, PEDIATRICS, V135, pE1163, DOI 10.1542/peds.2014-2988; Smith PB, 2012, PEDIATRICS, V129, pE1508, DOI 10.1542/peds.2011-2216; Spitzer AR, 2015, INDIAN J PEDIATR, V82, P71, DOI 10.1007/s12098-014-1585-2; Tolia VN, 2015, NEW ENGL J MED, V372, P2118, DOI 10.1056/NEJMsa1500439; Tyson JE, 2008, NEW ENGL J MED, V358, P1672, DOI 10.1056/NEJMoa073059; Walsh Michele C, 2003, J Perinatol, V23, P451, DOI 10.1038/sj.jp.7210963; Wong D, 2014, ARCH DIS CHILD-FETAL, V99, pF12, DOI 10.1136/archdischild-2013-304705; Zephyrin LC, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.06.009	32	79	82	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2017	356								j1039	10.1136/bmj.j1039	http://dx.doi.org/10.1136/bmj.j1039			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY4WY	28351838	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000426829100001
J	Zhou, JZ; Li, SY; Wang, YP; Lei, Y; Foreman, RD; Yin, JY; Chen, JDZ				Zhou, Jingzhu; Li, Shiying; Wang, Yinping; Lei, Yong; Foreman, Robert D.; Yin, Jieyun; Chen, Jiande D. Z.			Effects and mechanisms of auricular electroacupuncture on gastric hypersensitivity in a rodent model of functional dyspepsia	PLOS ONE			English	Article							VISCERAL HYPERSENSITIVITY; ELECTRICAL-STIMULATION; RECTAL DISTENSION; AUTONOMIC FUNCTION; ACUPUNCTURE; MOTILITY; MANAGEMENT; SYMPTOMS; MIGRAINE; STRESS	Background Functional dyspepsia (FD) is a common functional gastrointestinal disease, and abdominal pain is one of the main symptoms. The aim of this study was to explore the effects and mechanisms of auricular electro-acupuncture (AEA) on gastric hypersensitivity in a rodent model of FD. Methods Ten-day-old pups were gavaged with 0.2 ml of 0.1% iodoacetamide daily for 6 days. AEA at the "stomach" point with different parameters or sham-EA was performed on 8-week-old animals. Gastric sensitivity to gastric distention was measured under different conditions. Autonomic functions were assessed from the spectral analysis of heart rate variability (HRV) derived from the electrocardiogram. Naloxone was injected intraperitoneally before AEA to explore the opioid mechanism. Gastric emptying was measured at the end of the study. Results 1) Gastric sensitivity to gastric distention was higher in the FD rats. AEA with parameters of 0.1s on, 0.4s off, 100Hz, 0.3ms and 0.4-0.5mA, but not other parameters or sham- EA, decreased gastric hypersensitivity in the FD rats. Naloxone did not block the effect of AEA. 2) Lower vagal activity and higher sympathovagal ratio were noted in the FD rats, compared with the controls. AEA increased vagal activity and improved sympathovagal imbalance. Conclusions AEA ameliorates gastric hypersensitivity in FD rats and this effect may be attributed to the improvement of sympathovagal balance.	[Zhou, Jingzhu; Li, Shiying; Lei, Yong; Yin, Jieyun; Chen, Jiande D. Z.] VA Med Ctr, Vet Res & Educ Fdn, Oklahoma City, OK 73104 USA; [Zhou, Jingzhu; Foreman, Robert D.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA; [Zhou, Jingzhu; Wang, Yinping] Nanjing Med Univ, Affiliated Hosp 1, Dept Acupuncture & Moxibust, Nanjing, Jiangsu, Peoples R China; [Chen, Jiande D. Z.] Ningbo Pace Translat Med Res Ctr, Ningbo, Zhejiang, Peoples R China; [Chen, Jiande D. Z.] Johns Hopkins Univ, Ctr Neurogastroenterol, Baltimore, MD 21218 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Nanjing Medical University; Johns Hopkins University	Chen, JDZ (corresponding author), VA Med Ctr, Vet Res & Educ Fdn, Oklahoma City, OK 73104 USA.; Chen, JDZ (corresponding author), Ningbo Pace Translat Med Res Ctr, Ningbo, Zhejiang, Peoples R China.; Chen, JDZ (corresponding author), Johns Hopkins Univ, Ctr Neurogastroenterol, Baltimore, MD 21218 USA.	JiandeDZChen@gmail.com	Wang, Yin/HCI-9352-2022					Al-Chaer ED, 2000, GASTROENTEROLOGY, V119, P1276, DOI 10.1053/gast.2000.19576; Arai YCP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/945063; Camilleri M, 2013, NAT REV GASTRO HEPAT, V10, P187, DOI 10.1038/nrgastro.2013.11; Carbone F, 2014, DIGEST DIS, V32, P222, DOI 10.1159/000357854; Ceccherelli F, 2012, ACUPUNCTURE ELECTRO, V37, P277; Chen Jian-yong, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P880; Chen J, 2008, AM J PHYSIOL-GASTR L, V295, pG614, DOI 10.1152/ajpgi.90322.2008; Dai F, 2013, AM J PHYSIOL-GASTR L, V305, pG333, DOI 10.1152/ajpgi.00224.2012; Gao XY, 2008, AUTON NEUROSCI-BASIC, V138, P50, DOI 10.1016/j.autneu.2007.10.003; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; HAUSKEN T, 1993, PSYCHOSOM MED, V55, P12, DOI 10.1097/00006842-199301000-00004; He BJ, 2013, PAIN MED, V14, P1608, DOI 10.1111/pme.12197; He W, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/786839; Hveem K, 1998, SCAND J GASTROENTERO, V33, P123; Jia CS, 2009, J TRADIT CHIN MED, V29, P43, DOI 10.1016/S0254-6272(09)60030-3; KAMETANI H, 1979, J PHYSIOL-LONDON, V294, P407, DOI 10.1113/jphysiol.1979.sp012937; Kienbaum P, 2001, CIRCULATION, V103, P850, DOI 10.1161/01.CIR.103.6.850; Kim SE, 2013, J NEUROGASTROENTEROL, V19, P233, DOI 10.5056/jnm.2013.19.2.233; La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264; Lacy BE, 2013, ALIMENT PHARM THER, V38, P170, DOI 10.1111/apt.12355; Lacy BE, 2012, ALIMENT PHARM THER, V36, P3, DOI 10.1111/j.1365-2036.2012.05128.x; Lee KJ, 2004, BEST PRACT RES CL GA, V18, P707, DOI 10.1016/j.bpg.2004.04.007; Li H, 2013, ACUPUNCT MED, V31, P57, DOI 10.1136/acupmed-2012-010173; Lin Yuan, 2011, J ACUPUNC TUINA SCI, V9, P39; Liu JS, 2012, AM J PHYSIOL-REG I, V303, pR209, DOI 10.1152/ajpregu.00301.2010; Liu JS, 2004, DIGEST DIS SCI, V49, P729, DOI 10.1023/B:DDAS.0000030081.91006.86; Liu LS, 2008, GASTROENTEROLOGY, V134, P2070, DOI 10.1053/j.gastro.2008.02.093; Liu Yue-dong, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P887; Lorena SLS, 2002, DIGEST DIS SCI, V47, P27; Ma TT, 2012, ALIMENT PHARM THER, V35, P552, DOI 10.1111/j.1365-2036.2011.04979.x; Mahadeva S, 2006, WORLD J GASTROENTERO, V12, P2661, DOI 10.3748/wjg.v12.i17.2661; Nogier P., 1981, ACURICULOTHERAPY AUR AURICULOTHERAPY AURI; Peuker ET, 2002, CLIN ANAT, V15, P35, DOI 10.1002/ca.1089; Samsom M, 1999, GASTROENTEROLOGY, V116, P515, DOI 10.1016/S0016-5085(99)70171-X; Sator-Katzenschlager SM, 2007, EXPERT REV MED DEVIC, V4, P23, DOI 10.1586/17434440.4.1.23; Song J, 2013, NEUROGASTROENT MOTIL, V25, P807, DOI 10.1111/nmo.12183; Sun Y, 2014, NEUROGASTROENT MOTIL, V26, P176, DOI 10.1111/nmo.12248; Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x; Wang Y, 2013, EUR J PAIN, V17, P1447, DOI 10.1002/j.1532-2149.2013.00325.x; Wang Yan-Gang, 2007, Zhongguo Zhen Jiu, V27, P245; Wong TM, 2001, J BIOMED SCI, V8, P299, DOI 10.1159/000054047; Wu SJ, 2011, J RES MED SCI, V16, P39; Xu SP, 2006, DIGEST DIS SCI, V51, P2154, DOI 10.1007/s10620-006-9412-x; Yin JY, 2011, AM J PHYSIOL-REG I, V301, pR465, DOI 10.1152/ajpregu.00271.2010; Yin JY, 2010, AM J PHYSIOL-GASTR L, V298, pG563, DOI 10.1152/ajpgi.00252.2009; Zhang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114226; Zhou YY, 2012, WORLD J GASTROENTERO, V18, P7201, DOI 10.3748/wjg.v18.i48.7201	47	21	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2017	12	3							e0174568	10.1371/journal.pone.0174568	http://dx.doi.org/10.1371/journal.pone.0174568			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VE	28350818	Green Published, gold, Green Submitted			2023-01-03	WOS:000399174400058
J	Wakeman, SE				Wakeman, Sarah E.			Another Senseless Death - The Case for Supervised Injection Facilities	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OVERDOSE DEATHS; DRUG		[Wakeman, Sarah E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wakeman, Sarah E.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wakeman, SE (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Wakeman, SE (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Bayoumi AM, 2008, CAN MED ASSOC J, V179, P1143, DOI 10.1503/cmaj.080808; Kinnard EN, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-29; Milloy MJS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003351; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1	5	9	9	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2017	376	11					1011	1013		10.1056/NEJMp1613651	http://dx.doi.org/10.1056/NEJMp1613651			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO0QT	28296603				2023-01-03	WOS:000396403700005
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: Are we too captivated by precision medicine?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				[Anonymous], 2015, WASHINGTON POST; Catapult Precision Medicine, CYT; Health Education England, 2015, PREC MED WHAT IS IT; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Hoffmann TC, 2017, JAMA INTERN MED, V177, P407, DOI 10.1001/jamainternmed.2016.8254; NHS England, 2015, PERS MED STRAT; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; US National Library of Medicine, WHAT IS PREC MED IN	8	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2017	356								j1168	10.1136/bmj.j1168	http://dx.doi.org/10.1136/bmj.j1168			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BU	28279961	Bronze, Green Published			2023-01-03	WOS:000396433400004
J	Sellam, A; Lode, N; Ayachi, A; Jourdain, G; Dauger, S; Jones, P				Sellam, Aurelie; Lode, Noella; Ayachi, Azzedine; Jourdain, Gilles; Dauger, Stephane; Jones, Peter			Passive hypothermia (>= 35-< 36 degrees C) during transport of newborns with hypoxic-ischaemic encephalopathy	PLOS ONE			English	Article							WHOLE-BODY HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; MODERATE HYPOTHERMIA; ASPHYXIA; INFANTS; TERM	Background Hypothermia initiated in the first six hours of life in term infants with hypoxic ischemic encephalopathy reduces the risk of death and severe neurological sequelae. Our study's principal objective was to evaluate transport predictors potentially influencing arrival in NICU (Neonatal Intensive Care Unit) at a temperature >= 35-<36 degrees C. Methodology/Principal findings A multi-centric, prospective cohort study was conducted during 18 months by the three Neonatal Transport Teams and 13 NICUs. Newborns were selected for inclusion according to biological and clinical criteria before transport using passive hypothermia using a target temperature of >= 35-<36 degrees C. Data on 120 of 126 inclusions were available for analysis. Thirty-three percent of the children arrived in NICU with the target temperature of >= 35-<36 degrees C. The mean temperature for the whole group of infants on arrival in NICU was 35.4 degrees C (34.3-36.5). The median age of all infants on arrival in NICU was 3h03min [2h25min-3h56min]. Three infants arrived in NICU with a temperature of <33 degrees C and eleven with a temperature >= 37 degrees C. Adrenaline during resuscitation was associated with a lower mean temperature on arrival in NICU. Conclusions/Significance Our strategy using >= 35-<36 degrees C passive hypothermia combined with short transport times had little effect on temperature after the arrival of Neonatal Transport Team although did reduce numbers of infants arriving in NICU in deep hypothermia. For those infants where hypothermia was discontinued in NICU our strategy facilitated re-warming. Re-adjustment to a lower target temperature to >= 34.5-<35.5 degrees C may reduce the proportion of infants with high/normothermic temperatures.	[Sellam, Aurelie; Lode, Noella; Jones, Peter] Hop Robert Debre, AP HP, SMUR Pediat, Paris, France; [Ayachi, Azzedine] Hop Andre Gregoire, AP HP, SMUR Pediat, Montreuil, France; [Jourdain, Gilles] Hop Clamart, SMUR Pediat, Clamart, France; [Dauger, Stephane; Jones, Peter] Hop Robert Debre, Reanimat Pediat PICU, Paris, France; [Jones, Peter] UCL, Inst Child Hlth, Portex Unit, Crit Care Grp,Portex Unit, London, England; [Jones, Peter] London Sch Hyg & Trop Med, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Jones, P (corresponding author), Hop Robert Debre, AP HP, SMUR Pediat, Paris, France.; Jones, P (corresponding author), Hop Robert Debre, Reanimat Pediat PICU, Paris, France.; Jones, P (corresponding author), UCL, Inst Child Hlth, Portex Unit, Crit Care Grp,Portex Unit, London, England.; Jones, P (corresponding author), London Sch Hyg & Trop Med, London, England.	sejjprj@ucl.ac.uk	Dauger, Stéphane/AAX-9669-2021					Akula VP, 2012, AM J PERINAT, V29, P319, DOI 10.1055/s-0031-1295661; Azzopardi D, NEW ENGL J MED, V371, P140, DOI [10.1056/NEJMeal315788, DOI 10.1056/NEJMEAL315788]; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BURNARD ED, 1958, BRIT MED J, V2, P1197, DOI 10.1136/bmj.2.5106.1197; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Fairchild K, 2010, J PERINATOL, V30, P324, DOI 10.1038/jp.2009.168; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1999, PEDIATR RES, V46, P274, DOI 10.1203/00006450-199909000-00005; Hallberg B, 2009, ACTA PAEDIATR, V98, P942, DOI 10.1111/j.1651-2227.2009.01303.x; Hobson Andrea, 2011, Air Med J, V30, P197, DOI 10.1016/j.amj.2011.03.010; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Johnston ED, 2010, ARCH DIS CHILD-FETAL, V97, pF365; Kendall GS, 2010, ARCH DIS CHILD-FETAL, V95, pF408, DOI 10.1136/adc.2010.187211; Khurshid F, 2011, PAED CHILD HEALT-CAN, V16, P153, DOI 10.1093/pch/16.3.153; Laptook AR, 2013, ANN NEUROL, V73, P520, DOI 10.1002/ana.23843; Laptook AR, 2010, PEDIATRICS, V126, pE965, DOI 10.1542/peds.2010-2075; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Merchant N, 2015, DEV MED CHILD NEUROL, V57, P8, DOI 10.1111/dmcn.12726; MYERS RE, 1975, BIOL NEONATE, V26, P21; O'Reilly D, 2013, J PERINATOL, V33, P435, DOI 10.1038/jp.2012.138; Oncel MY, 2013, PEDIATR HEMAT ONCOL, V30, P246, DOI 10.3109/08880018.2013.771240; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Savarese I, 2015, J MATERN-FETAL NEO M, V14, P1; Schierholz Elizabeth, 2014, Adv Neonatal Care, V14 Suppl 5, pS24, DOI 10.1097/ANC.0000000000000121; Shah NA, 2015, AM J PERINAT, V32, P755, DOI 10.1055/s-0034-1395483; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Thoresen M, 2013, NEONATOLOGY, V104, P228, DOI 10.1159/000353948; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Weiss M D, 2014, J Neonatal Perinatal Med, V7, P173, DOI 10.3233/NPM-14814018	32	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2017	12	3							e0170100	10.1371/journal.pone.0170100	http://dx.doi.org/10.1371/journal.pone.0170100			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6AW	28278217	gold, Green Published, Green Submitted			2023-01-03	WOS:000396087900105
J	Jewell, JA; Hillier, S				Jewell, J. A.; Hillier, Sheila			Kan-Wen Ma OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																		MA KW, PUBLICATION LIST, P99767	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2017	356								j810	10.1136/bmj.j810	http://dx.doi.org/10.1136/bmj.j810			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL4GP	28213350				2023-01-03	WOS:000394580000007
J	Zhang, H; Dasbiswas, K; Ludwig, NB; Han, G; Lee, B; Vaikuntanathan, S; Talapin, DV				Zhang, Hao; Dasbiswas, Kinjal; Ludwig, Nicholas B.; Han, Gang; Lee, Byeongdu; Vaikuntanathan, Suri; Talapin, Dmitri V.			Stable colloids in molten inorganic salts	NATURE			English	Article							SURFACE; NANOCRYSTALS; SEMICONDUCTOR; NANOPARTICLES; STABILITY; HYDRATION; HALIDE; ROUTE	A colloidal solution is a homogeneous dispersion of particles or droplets of one phase (solute) in a second, typically liquid, phase (solvent). Colloids are ubiquitous in biological, chemical and technological processes(1,2), homogenizing highly dissimilar constituents. To stabilize a colloidal system against coalescence and aggregation, the surface of each solute particle is engineered to impose repulsive forces strong enough to overpower van der Waals attraction and keep the particles separated from each other(2). Electrostatic stabilization(3,4) of charged solutes works well in solvents with high dielectric constants, such as water (dielectric constant of 80). In contrast, colloidal stabilization in solvents with low polarity, such as hexane (dielectric constant of about 2), can be achieved by decorating the surface of each particle of the solute with molecules (surfactants) containing flexible, brush-like chains(2,5). Here we report a class of colloidal systems in which solute particles (including metals, semiconductors and magnetic materials) form stable colloids in various molten inorganic salts. The stability of such colloids cannot be explained by traditional electrostatic and steric mechanisms. Screening of many solute-solvent combinations shows that colloidal stability can be traced to the strength of chemical bonding at the solute-solvent interface. Theoretical analysis and molecular dynamics modelling suggest that a layer of surface-bound solvent ions produces long-ranged charge-density oscillations in the molten salt around solute particles, preventing their aggregation. Colloids composed of inorganic particles in inorganic melts offer opportunities for introducing colloidal techniques to solid-state science and engineering applications.	[Zhang, Hao; Dasbiswas, Kinjal; Ludwig, Nicholas B.; Vaikuntanathan, Suri; Talapin, Dmitri V.] Univ Chicago, Dept Chem, Chicago, IL 60637 USA; [Zhang, Hao; Dasbiswas, Kinjal; Ludwig, Nicholas B.; Vaikuntanathan, Suri; Talapin, Dmitri V.] Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; [Han, Gang] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; [Lee, Byeongdu] Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; [Talapin, Dmitri V.] Argonne Natl Lab, Ctr Nanoscale Mat, Argonne, IL 60439 USA	University of Chicago; University of Chicago; University of Massachusetts System; University of Massachusetts Worcester; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory	Talapin, DV (corresponding author), Univ Chicago, Dept Chem, Chicago, IL 60637 USA.; Talapin, DV (corresponding author), Univ Chicago, James Franck Inst, Chicago, IL 60637 USA.; Talapin, DV (corresponding author), Argonne Natl Lab, Ctr Nanoscale Mat, Argonne, IL 60439 USA.	dvtalapin@uchicago.edu		Ludwig, Nicholas/0000-0002-7345-659X; Dasbiswas, Kinjal/0000-0002-5741-8200	National Science Foundation (NSF) [DMR-1611371]; Air Force Office of Scientific Research (AFOSR) [FA9550-14-1-0367]; Department of Defense (DOD) Office of Naval Research [N00014-13-1-0490]; II-VI Foundation; National Institutes of Health (NIH) [R01 MH103133]; Human Frontier Science Program [RGY-0090/2014]; University of Chicago Research Computing Center; NSF MRSEC [DMR-14-20703]; Center for Nanoscale Materials and Advanced Photon Source; DOE Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH103133] Funding Source: NIH RePORTER; Division Of Materials Research [1611371] Funding Source: National Science Foundation	National Science Foundation (NSF)(National Science Foundation (NSF)); Air Force Office of Scientific Research (AFOSR)(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Department of Defense (DOD) Office of Naval Research; II-VI Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program(Human Frontier Science Program); University of Chicago Research Computing Center; NSF MRSEC(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); Center for Nanoscale Materials and Advanced Photon Source; DOE Office of Science by Argonne National Laboratory(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Division Of Materials Research(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We thank P. Guyot-Sionnest for discussions, L. Wang for help with taking photographs, V. Srivastava for providing data on GaAs NCs in molten salts, A. Filatov for discussions and help with XPS measurements, F. Zhai and T.-Y. Zheng for help with NMR measurements, Z. Li and M.H. Hudson for providing UCNP5 and Fe<INF>3</INF>O<INF>4</INF>NCs, and T Shpigel for reading the manuscript. This work was supported by the National Science Foundation (NSF; DMR-1611371), Air Force Office of Scientific Research (AFOSR; FA9550-14-1-0367), Department of Defense (DOD) Office of Naval Research (grant number N00014-13-1-0490), and by the II-VI Foundation. G.H. acknowledges support from the National Institutes of Health (NIH; R01 MH103133) and the Human Frontier Science Program (RGY-0090/2014). N.B.L acknowledges support from the University of Chicago Research Computing Center. The work used facilities supported by the NSF MRSEC (DMR-14-20703), and resources of the Center for Nanoscale Materials and Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory (DE-AC02-06CH11357).	Amgoune A, 2011, CHEM COMMUN, V47, P859, DOI 10.1039/c0cc04109b; Andreu-Cabedo P, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-582; [Anonymous], ACTA PHYSICOCHIM USS; Boles MA, 2016, NAT MATER, V15, P141, DOI [10.1038/NMAT4526, 10.1038/nmat4526]; Chen LY, 2015, NATURE, V528, P539, DOI 10.1038/nature16445; Dong AG, 2011, J AM CHEM SOC, V133, P998, DOI 10.1021/ja108948z; Erwin SC, 2005, NATURE, V436, P91, DOI 10.1038/nature03832; Evans D, 1999, COLLOIDAL DOMAIN PHY, P1; Fafarman AT, 2011, J AM CHEM SOC, V133, P15753, DOI 10.1021/ja206303g; FANNIN AA, 1972, J ELECTROCHEM SOC, V119, P801, DOI 10.1149/1.2404344; Frenkel D., 2002, UNDERSTANDING MOL SI, P165; Gao JS, 2015, ACS NANO, V9, P3243, DOI 10.1021/acsnano.5b00354; Gebbie MA, 2015, P NATL ACAD SCI USA, V112, P7432, DOI 10.1073/pnas.1508366112; Huang J, 2014, ACS NANO, V8, P9388, DOI 10.1021/nn503458y; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1; KOHN HW, 1969, SCIENCE, V163, P924, DOI 10.1126/science.163.3870.924; Kovalenko MV, 2009, SCIENCE, V324, P1417, DOI 10.1126/science.1170524; Lanning OJ, 2004, J PHYS CHEM B, V108, P11069, DOI 10.1021/jp048102p; Li CJ, 2014, AIMS ENERGY, V2, P133, DOI 10.3934/energy.2014.2.133; Limmer DT, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.256102; Mezger M, 2008, SCIENCE, V322, P424, DOI 10.1126/science.1164502; Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545; NAPPER DH, 1977, J COLLOID INTERF SCI, V58, P390, DOI 10.1016/0021-9797(77)90150-3; Ning ZJ, 2015, NATURE, V523, P324, DOI 10.1038/nature14563; Ozerinc S, 2010, MICROFLUID NANOFLUID, V8, P145, DOI 10.1007/s10404-009-0524-4; Rodriguez R, 2008, ADV MATER, V20, P4353, DOI 10.1002/adma.200801975; Rosen EL, 2012, ANGEW CHEM INT EDIT, V51, P684, DOI 10.1002/anie.201105996; Schneck E, 2012, P NATL ACAD SCI USA, V109, P14405, DOI 10.1073/pnas.1205811109; Shirts MR, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2978177; Smith AM, 2016, J PHYS CHEM LETT, V7, P2157, DOI 10.1021/acs.jpclett.6b00867; Ueno K, 2008, LANGMUIR, V24, P5253, DOI 10.1021/la704066v; Verwey E. J. W., 1948, THEORY STABILITY LYO, P1; Warren SC, 2006, J AM CHEM SOC, V128, P12074, DOI 10.1021/ja064469r; Zhang H, 2014, ACS NANO, V8, P7359, DOI 10.1021/nn502470v; Zobel M, 2015, SCIENCE, V347, P292, DOI 10.1126/science.1261412	37	121	122	19	375	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2017	542	7641					328	+		10.1038/nature21041	http://dx.doi.org/10.1038/nature21041			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2LQ	28202966				2023-01-03	WOS:000394451600032
J	Greene, JA; Padula, WV				Greene, Jeremy A.; Padula, William V.			Perspective Targeting Unconscionable Prescription-Drug Prices Maryland's Anti-Price-Gouging Law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GENERIC DRUGS		[Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD USA; [Padula, William V.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Greene, JA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.; Greene, JA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD USA.		Padula, Bill/AGB-4625-2022					Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; [Anonymous], 2016, SUDD PRIC SPIK OFF P; Berndt ER, 2007, HEALTH AFFAIR, V26, P790, DOI 10.1377/hlthaff.26.3.790; Korobkin Russell, 2004, U HAW L REV, V26, P458; Tribble S. J., 2017, WASHINGTON POST	5	19	19	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2017	377	2					101	103		10.1056/NEJMp1704907	http://dx.doi.org/10.1056/NEJMp1704907			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA2PC	28591520				2023-01-03	WOS:000405282300001
J	Oh, EH; Oh, K; Han, M; Seo, H; Chang, K; Lee, SH; Kim, GU; Song, EM; Seo, M; Lee, HS; Hwang, SW; Park, SH; Yang, DH; Kim, KJ; Byeon, JS; Myung, SJ; Yang, SK; Ye, BD				Oh, Eun Hye; Oh, Kyunghwan; Han, Minkyu; Seo, Hyungil; Chang, Kiju; Lee, Sun-Ho; Kim, Gwang-Un; Song, Eun Mi; Seo, Myeongsook; Lee, Ho-Su; Hwang, Sung Wook; Park, Sang Hyoung; Yang, Dong-Hoon; Kim, Kyung-Jo; Byeon, Jeong-Sik; Myung, Seung-Jae; Yang, Suk-Kyun; Ye, Byong Duk			Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors	PLOS ONE			English	Article							EARLY COMBINED IMMUNOSUPPRESSION; RANDOMIZED CONTROLLED-TRIAL; INFLAMMATORY-BOWEL-DISEASE; HOSPITAL-BASED COHORT; CONVENTIONAL MANAGEMENT; COMBINATION THERAPY; CERTOLIZUMAB PEGOL; INFLIXIMAB; AZATHIOPRINE; MAINTENANCE	Although early treatment of Crohn's disease (CD) patients with anti-tumor necrosis factor (TNF) agents or immunomodulators (IMs) may improve long-term outcomes, especially those with poor prognostic factors, their effectiveness in Asians remains unclear. In this study, Korean patients with CD naive to both intestinal surgery and intestinal complications, and with at least two risk factors for progression (diagnosis at age <40 years, systemic corticosteroid treatment <3 months after diagnosis, and perianal fistula at diagnosis) were retrospectively analyzed. Patients were classified into those who started anti-TNFs, or IMs but not anti-TNFs, within 2 years of diagnosis, and those who started anti-TNFs and/or IMs later. Their probabilities of intestinal surgery and intestinal complications were compared. A total of 670 patients were enrolled, 79 in the early anti-TNF, 286 in the early IM, and 305 in the late treatment group. Kaplan-Meier analysis with the log-rank test showed that from starting anti-TNFs/IMs, times to intestinal surgery (P < 0.001), stricturing complications (P = 0.002), and penetrating complications (P < 0.001) were significantly longer in the early anti-TNF/IM groups than in the late treatment group. Multivariate Cox regression analysis showed that, from starting anti-TNFs/IMs, late anti-TNF/IM treatment was independently associated with higher risks of intestinal surgery (adjusted hazard ratio [aHR] 2.321, 95% confidence interval [CI] 1.503-3.584, P < 0.001), behavioral progression (aHR 2.001, 95% CI 1.449-2.763, P < 0.001), stricturing complications (aHR 1.736, 95% CI 1.209-2.493, P = 0.003), and penetrating complications (aHR 3.315, 95% CI 2.094-5.249, P < 0.001) than early treatment. In conclusion, treatment of Asian CD patients having poor prognostic factors with anti-TNFs/IMs within 2 years of diagnosis is associated with better clinical outcomes than later treatment.	[Oh, Eun Hye; Oh, Kyunghwan] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea; [Han, Minkyu] Univ Ulsan, Coll Med, Dept Clin Epidemiol & Biostat, Seoul, South Korea; [Seo, Hyungil; Chang, Kiju; Lee, Sun-Ho; Kim, Gwang-Un; Song, Eun Mi; Seo, Myeongsook; Hwang, Sung Wook; Park, Sang Hyoung; Yang, Dong-Hoon; Kim, Kyung-Jo; Byeon, Jeong-Sik; Myung, Seung-Jae; Yang, Suk-Kyun; Ye, Byong Duk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea; [Lee, Ho-Su] Univ Ulsan, Coll Med, Asan Med Ctr, Hlth Screening & Promot Ctr, Seoul, South Korea; [Hwang, Sung Wook; Park, Sang Hyoung; Kim, Kyung-Jo; Yang, Suk-Kyun; Ye, Byong Duk] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Ye, BD (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea.; Ye, BD (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea.	bdye@amc.seoul.kr	Ye, Byong Duk/AAF-4955-2020; Park, Sang Hyoung/CAH-4735-2022; Yang, Dong-Hoon/B-3437-2015	Ye, Byong Duk/0000-0001-6647-6325; Yang, Dong-Hoon/0000-0001-7756-2704				Aberra FN, 2015, CLIN GASTROENTEROL H, V13, P1702, DOI 10.1016/j.cgh.2015.02.032; Antunes O, 2014, BEST PRACT RES CL GA, V28, P473, DOI 10.1016/j.bpg.2014.05.001; Baert F, 2010, GASTROENTEROLOGY, V138, P463, DOI 10.1053/j.gastro.2009.09.056; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Beaugerie L, 2006, GASTROENTEROLOGY, V130, P650, DOI 10.1053/j.gastro.2005.12.019; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Colombel JF, 2014, CLIN GASTROENTEROL H, V12, P414, DOI 10.1016/j.cgh.2013.06.019; Cosnes J, 2002, INFLAMM BOWEL DIS, V8, P244, DOI 10.1097/00054725-200207000-00002; Cosnes J, 2013, GASTROENTEROLOGY, V145, P758, DOI 10.1053/j.gastro.2013.04.048; D'Haens G, 2008, LANCET, V371, P660, DOI 10.1016/S0140-6736(08)60304-9; Danese S, 2011, ALIMENT PHARM THER, V33, P857, DOI 10.1111/j.1365-2036.2011.04598.x; De Cruz P, 2015, LANCET, V385, P1406, DOI 10.1016/S0140-6736(14)61908-5; Franchimont DP, 1998, EUR J GASTROEN HEPAT, V10, P821, DOI 10.1097/00042737-199810000-00001; Gomollon F, 2017, J CROHNS COLITIS, V11, P3, DOI 10.1093/ecco-jcc/jjw168; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Khanna R, 2015, LANCET, V386, P1825, DOI 10.1016/S0140-6736(15)00068-9; Lakatos PL, 2012, AM J GASTROENTEROL, V107, P579, DOI 10.1038/ajg.2011.448; Lakatos PL, 2009, WORLD J GASTROENTERO, V15, P3504, DOI 10.3748/wjg.15.3504; Lichtenstein GR, 2006, AM J GASTROENTEROL, V101, P1030, DOI 10.1111/j.1572-0241.2006.00463.x; Lichtenstein GR, 2006, CLIN GASTROENTEROL H, V4, P621, DOI 10.1016/j.cgh.2006.03.002; Loly C, 2008, SCAND J GASTROENTERO, V43, P948, DOI 10.1080/00365520801957149; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Ng WK, 2016, INTEST RES, V14, P111, DOI 10.5217/ir.2016.14.2.111; Ordas I, 2011, GUT, V60, P1754, DOI 10.1136/gutjnl-2011-300934; Osterman MT, 2015, CLIN GASTROENTEROL H, V13, P1293, DOI 10.1016/j.cgh.2015.02.017; Osterman MT, 2015, CLIN GASTROENTEROL H, V13, pe1272; Ott C, 2014, INT J COLORECTAL DIS, V29, P1329, DOI 10.1007/s00384-014-2002-z; Panaccione R, 2014, GASTROENTEROLOGY, V146, P392, DOI 10.1053/j.gastro.2013.10.052; Panes J, 2013, GASTROENTEROLOGY, V145, P766, DOI 10.1053/j.gastro.2013.06.009; Park SH, 2016, DIGEST DIS SCI, V61, P2060, DOI 10.1007/s10620-016-4105-6; Park SH, 2014, INFLAMM BOWEL DIS, V20, P488, DOI 10.1097/01.MIB.0000441203.56196.46; Qiu Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001148; Rogler G, 2013, J CROHNS COLITIS, V7, P670, DOI [10.1016/j.crohns.2012.10.012, 10.1016/j.crohns.2013.02.014]; Rogler G, 2013, DIGEST DIS, V31, P83, DOI 10.1159/000347190; Romberg-Camps MJL, 2009, AM J GASTROENTEROL, V104, P371, DOI 10.1038/ajg.2008.38; Rubin DT, 2012, INFLAMM BOWEL DIS, V18, P2225, DOI 10.1002/ibd.22925; Rutgeerts P, 2012, GASTROENTEROLOGY, V142, P1102, DOI 10.1053/j.gastro.2012.01.035; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2014, J CROHNS COLITIS, V8, P927, DOI 10.1016/j.crohns.2014.02.021; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Solberg IC, 2007, CLIN GASTROENTEROL H, V5, P1430, DOI 10.1016/j.cgh.2007.09.002; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Yang SK, 2008, INFLAMM BOWEL DIS, V14, P542, DOI 10.1002/ibd.20310; Yang SK, 2016, DIGEST DIS, V34, P165, DOI 10.1159/000443134	46	31	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2017	12	5							e0177479	10.1371/journal.pone.0177479	http://dx.doi.org/10.1371/journal.pone.0177479			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UE	28542298	Green Submitted, gold, Green Published			2023-01-03	WOS:000402058800018
J	Parikh, RB; Schwartz, JS; Navathe, AS				Parikh, Ravi B.; Schwartz, J. Sanford; Navathe, Amol S.			Beyond Genes and Molecules - A Precision Delivery Initiative for Precision Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Parikh, Ravi B.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Schwartz, J. Sanford; Navathe, Amol S.] Univ Penn, Wharton Sch Business, Perelman Sch Med, Philadelphia, PA 19104 USA; [Schwartz, J. Sanford; Navathe, Amol S.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Navathe, Amol S.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA	Harvard University; Brigham & Women's Hospital; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Parikh, RB (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.			Navathe, Amol/0000-0001-7182-4988				Amarasingham R, 2013, BMJ QUAL SAF, V22, P998, DOI 10.1136/bmjqs-2013-001901; [Anonymous], GENES; Medicine Institute of, 2011, PREC MED BUILD KNOWL; Poulin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085733; Salathe M, 2013, NEW ENGL J MED, V369, P401, DOI 10.1056/NEJMp1307752	5	22	22	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2017	376	17					1609	1612		10.1056/NEJMp1613224	http://dx.doi.org/10.1056/NEJMp1613224			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET2AY	28445664				2023-01-03	WOS:000400071900003
J	Favini, N; Hockenberry, JM; Gilman, M; Jain, S; Ong, MK; Adams, EK; Becker, ER				Favini, Nathan; Hockenberry, Jason M.; Gilman, Matlin; Jain, Sanjula; Ong, Michael K.; Adams, E. Kathleen; Becker, Edmund R.			Comparative Trends in Payment Adjustments Between Safety-Net and Other Hospitals Since the Introduction of the Hospital Readmission Reduction Program and Value-Based Purchasing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Favini, Nathan] Univ Calif Los Angeles, Robert Wood Johnson Fdn, Los Angeles, CA USA; [Hockenberry, Jason M.; Gilman, Matlin; Jain, Sanjula; Adams, E. Kathleen; Becker, Edmund R.] Emory Univ, Dept Hlth Management & Policy, 1518 Clifton Rd,GCR 622, Atlanta, GA 30322 USA; [Ong, Michael K.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA	Robert Wood Johnson Foundation (RWJF); University of California System; University of California Los Angeles; Emory University; University of California System; University of California Los Angeles	Hockenberry, JM (corresponding author), Emory Univ, Dept Hlth Management & Policy, 1518 Clifton Rd,GCR 622, Atlanta, GA 30322 USA.	jason.hockenberry@emory.edu	Ong, Michael/AAR-3310-2020; Ong, Michael K/F-7397-2013	Ong, Michael/0000-0001-8530-7754; 	Robert Wood Johnson Foundation	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	Dr Favini was supported by the Robert Wood Johnson Foundation Clinical Scholars program during the course of the study.	Carey K, 2016, HEALTH AFFAIR, V35, P1918, DOI 10.1377/hlthaff.2016.0537; Gilman M, 2015, ANN INTERN MED, V163, P427, DOI 10.7326/M14-2813; Gilman M, 2015, HEALTH AFFAIR, V34, P398, DOI 10.1377/hlthaff.2014.1059; Gilman M, 2014, HEALTH AFFAIR, V33, P1314, DOI 10.1377/hlthaff.2014.0138; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150	5	10	10	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2017	317	15					1578	1580		10.1001/jama.2017.1469	http://dx.doi.org/10.1001/jama.2017.1469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ES2YN	28418474				2023-01-03	WOS:000399393900023
J	Rademaker, RL; de Ven, VGV; Tong, F; Sack, AT				Rademaker, Rosanne L.; de Ven, Vincent G. van; Tong, Frank; Sack, Alexander T.			The impact of early visual cortex transcranial magnetic stimulation on visual working memory precision and guess rate	PLOS ONE			English	Article							SHORT-TERM-MEMORY; FEATURE-BASED ATTENTION; NEURAL MECHANISMS; STATE-DEPENDENCY; PARIETAL CORTEX; CAPACITY LIMIT; CONSOLIDATION; REPRESENTATIONS; INFORMATION; REVEALS	Neuroimaging studies have demonstrated that activity patterns in early visual areas predict stimulus properties actively maintained in visual working memory. Yet, the mechanisms by which such information is represented remain largely unknown. In this study, observers remembered the orientations of 4 briefly presented gratings, one in each quadrant of the visual field. A 10Hz Transcranial Magnetic Stimulation (TMS) triplet was applied directly at stimulus offset, or midway through a 2-second delay, targeting early visual cortex corresponding retinotopically to a sample item in the lower hemifield. Memory for one of the four gratings was probed at random, and participants reported this orientation via method of adjustment. Recall errors were smaller when the visual field location targeted by TMS over-lapped with that of the cued memory item, compared to errors for stimuli probed diagonally to TMS. This implied topographic storage of orientation information, and a memory-enhancing effect at the targeted location. Furthermore, early pulses impaired performance at all four locations, compared to late pulses. Next, response errors were fit empirically using a mixture model to characterize memory precision and guess rates. Memory was more precise for items proximal to the pulse location, irrespective of pulse timing. Guesses were more probable with early TMS pulses, regardless of stimulus location. Thus, while TMS administered at the offset of the stimulus array might disrupt early-phase consolidation in a non-topographic manner, TMS also boosts the precise representation of an item at its targeted retinotopic location, possibly by increasing attentional resources or by injecting a beneficial amount of noise.	[Rademaker, Rosanne L.] Univ Calif San Diego, Psychol Dept, San Diego, CA 92103 USA; [Rademaker, Rosanne L.; de Ven, Vincent G. van; Sack, Alexander T.] Maastricht Univ, Cognit Neurosci Dept, Maastricht, Netherlands; [Tong, Frank] Vanderbilt Univ, Psychol Dept, Nashville, TN USA	University of California System; University of California San Diego; Maastricht University; Vanderbilt University	Rademaker, RL (corresponding author), Univ Calif San Diego, Psychol Dept, San Diego, CA 92103 USA.	rosanne.rademaker@gmail.com		Sack, Alexander/0000-0002-1471-0885	Netherlands Organization for Scientific Research (Graduate School for Cognitive and Clinical Neuroscience) [NWO 22.001.036]; European Research Council; ERC Grant [263472]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD083211] Funding Source: NIH RePORTER	Netherlands Organization for Scientific Research (Graduate School for Cognitive and Clinical Neuroscience); European Research Council(European Research Council (ERC)European Commission); ERC Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	RLR was supported by a grant from the Netherlands Organization for Scientific Research (Graduate School for Cognitive and Clinical Neuroscience, NWO 22.001.036). ATS was supported by the European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013) / ERC Grant agreement n [263472].	Abrahamyan A, 2011, J NEUROSCI, V31, P3290, DOI 10.1523/JNEUROSCI.6256-10.2011; Abrams J, 2012, VISION RES, V52, P70, DOI 10.1016/j.visres.2011.10.016; Awh E, 2001, TRENDS COGN SCI, V5, P119, DOI 10.1016/S1364-6613(00)01593-X; Bays PM, 2008, SCIENCE, V321, P851, DOI 10.1126/science.1158023; Bays PM, 2015, TRENDS COGN SCI, V19, P431, DOI 10.1016/j.tics.2015.06.004; Bays PM, 2014, J NEUROSCI, V34, P3632, DOI 10.1523/JNEUROSCI.3204-13.2014; Bays PM, 2009, J VISION, V9, DOI 10.1167/9.10.7; BERLUCCHI G, 1968, SCIENCE, V159, P308, DOI 10.1126/science.159.3812.308; Bettencourt KC, 2016, NAT NEUROSCI, V19, P150, DOI 10.1038/nn.4174; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Brady TF, 2013, PSYCHOL REV, V120, P85, DOI 10.1037/a0030779; Brady TF, 2009, J EXP PSYCHOL GEN, V138, P487, DOI 10.1037/a0016797; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Carandini M, 2012, NAT REV NEUROSCI, V13, P51, DOI 10.1038/nrn3136; Cattaneo Z, 2009, EUR J NEUROSCI, V30, P1393, DOI 10.1111/j.1460-9568.2009.06911.x; Chen YZ, 2012, NEURON, V74, P557, DOI 10.1016/j.neuron.2012.03.033; Christophel TB, 2012, J NEUROSCI, V32, P12983, DOI 10.1523/JNEUROSCI.0184-12.2012; CHUN MM, 1995, J EXP PSYCHOL HUMAN, V21, P109; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; de Graaf TA, 2014, NEUROSCI BIOBEHAV R, V45, P295, DOI 10.1016/j.neubiorev.2014.06.017; De Weerd P, 2012, J NEUROSCI, V32, P1981, DOI 10.1523/JNEUROSCI.3712-11.2011; Duecker F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073813; Edin F, 2009, P NATL ACAD SCI USA, V106, P6802, DOI 10.1073/pnas.0901894106; Emrich SM, 2013, J NEUROSCI, V33, P6516, DOI 10.1523/JNEUROSCI.5732-12.2013; Ester EF, 2015, NEURON, V87, P893, DOI 10.1016/j.neuron.2015.07.013; Ester EF, 2009, J NEUROSCI, V29, P15258, DOI 10.1523/JNEUROSCI.4388-09.2009; Ester EF, J COG NEUROSCI, V25, P754; Fougnie D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2237; Freeman J, 2011, NAT NEUROSCI, V14, P1195, DOI 10.1038/nn.2889; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; Hollingworth A, 2006, J EXP PSYCHOL LEARN, V32, P58, DOI 10.1037/0278-7393.32.1.58; Jacobs C, 2014, CORTEX, V59, P1, DOI 10.1016/j.cortex.2014.06.017; Jolicoeur P, 1998, COGNITIVE PSYCHOL, V36, P138, DOI 10.1006/cogp.1998.0684; Jonides J, 2005, CURR DIR PSYCHOL SCI, V14, P2, DOI 10.1111/j.0963-7214.2005.00323.x; Lamme VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X; Lee SH, 2013, NAT NEUROSCI, V16, P997, DOI 10.1038/nn.3452; Lee TG, 2012, J NEUROSCI, V32, P15458, DOI 10.1523/JNEUROSCI.0627-12.2012; Ling S, 2009, CURR BIOL, V19, P1458, DOI 10.1016/j.cub.2009.06.069; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Matthews PBC, 1999, J PHYSIOL-LONDON, V518, P867, DOI 10.1111/j.1469-7793.1999.0867p.x; Pasternak T, 2003, J NEUROPHYSIOL, V90, P2757, DOI 10.1152/jn.00422.2003; Pooresmaeili A, 2014, CURR BIOL, V24, DOI 10.1016/j.cub.2014.10.007; Pratte MS, 2017, J EXP PSYCHOL HUMAN, V43, P6, DOI 10.1037/xhp0000302; Pratte MS, 2014, J VISION, V14, DOI 10.1167/14.3.22; Riggall AC, 2012, J NEUROSCI, V32, P12990, DOI 10.1523/JNEUROSCI.1892-12.2012; Rose NS, 2016, SCIENCE, V354, P1136, DOI 10.1126/science.aah7011; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; ROVAMO J, 1982, INVEST OPHTH VIS SCI, V23, P666; Sack AT, 2009, J COGNITIVE NEUROSCI, V21, P207, DOI 10.1162/jocn.2009.21126; Schwarzkopf DS, 2011, J NEUROSCI, V31, P3143, DOI 10.1523/JNEUROSCI.4863-10.2011; Serences JT, 2007, NEURON, V55, P301, DOI 10.1016/j.neuron.2007.06.015; Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x; Siebner HR, 2009, CORTEX, V45, P1035, DOI 10.1016/j.cortex.2009.02.007; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Silvanto J, 2012, NEUROIMAGE, V59, P840, DOI 10.1016/j.neuroimage.2011.07.062; Silvanto J, 2010, NEUROIMAGE, V50, P1683, DOI 10.1016/j.neuroimage.2010.01.021; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Sneve MH, 2015, NEUROPSYCHOLOGIA, V66, P1, DOI 10.1016/j.neuropsychologia.2014.11.004; Soto D, 2012, J NEUROSCI, V32, P3447, DOI 10.1523/JNEUROSCI.6243-11.2012; Sreenivasan KK, 2014, J COGNITIVE NEUROSCI, V26, P1141, DOI 10.1162/jocn_a_00556; Sreenivasan KK, 2014, TRENDS COGN SCI, V18, P82, DOI 10.1016/j.tics.2013.12.001; Stokes MG, 2015, TRENDS COGN SCI, V19, P394, DOI 10.1016/j.tics.2015.05.004; Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; van Bergen RS, 2015, NAT NEUROSCI, V18, P1728, DOI 10.1038/nn.4150; van de Ven V, 2012, J NEUROSCI, V32, P4, DOI 10.1523/JNEUROSCI.3261-11.2012; van den Berg R, 2012, P NATL ACAD SCI USA, V109, P8780, DOI 10.1073/pnas.1117465109; Vogel EK, 2006, J EXP PSYCHOL HUMAN, V32, P1436, DOI 10.1037/0096-1523.32.6.1436; Wolff MJ, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00123; Woodman GF, 2012, VIS COGN, V20, P1, DOI 10.1080/13506285.2011.630694; Xu YD, 2006, NATURE, V440, P91, DOI 10.1038/nature04262; Zaksas D, 2001, J NEUROPHYSIOL, V86, P912, DOI 10.1152/jn.2001.86.2.912; Zhang WW, 2008, NATURE, V453, P233, DOI 10.1038/nature06860	76	19	19	5	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e0175230	10.1371/journal.pone.0175230	http://dx.doi.org/10.1371/journal.pone.0175230			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2QB	28384347	Green Submitted, Green Published, gold			2023-01-03	WOS:000399371900129
J	Zhang, W; Ma, LY; Bauer, BA; Liu, ZS; Lu, Y				Zhang, Wei; Ma, Liyan; Bauer, Brent A.; Liu, Zhishun; Lu, Yao			Acupuncture for benign prostatic hyperplasia: A systematic review and meta-analysis	PLOS ONE			English	Article							TRIALS; NEEDLE	Purpose This systematic review and meta-analysis aims to assess the therapeutic and adverse effects of acupuncture for benign prostatic hyperplasia (BPH) in randomized controlled trials (RCTs). Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, the Chinese Biomedical Database, the China National Knowledge Infrastructure, the VIP Database and the Wanfang Database. Parallelgroup RCTs of acupuncture for men with symptomatic BPH were included. Data from the included trials were extracted by two independent reviewers and were analyzed with The Cochrane Collaboration Review Manager software (RevMan 5.3.5) after risk of bias judgments. The primary outcome measure of this review was a change in urological symptoms. Results Eight RCTs, which involved 661 men with BPH, were included. Follow-up varied from 4 weeks to 18 months. Pooling of the data from three trials that compared acupuncture with sham-acupuncture revealed that in the short term (4-6 weeks), acupuncture can significantly improve IPSS (MD -1.90, 95% CI -3.58 to -0.21). A sensitivity analysis of the shortterm endpoint showed the same result (MD -3.01, 95% CI -5.19 to -0.84) with a borderline minimal clinical important difference (MCID). Qmax of the short-term endpoint indicated statistically positive beneficial effects of acupuncture (MD -1.78, 95% CI -3.43, -0.14). A metaanalysis after medium-term follow-up (12-18 weeks) indicated no significant effect on IPSS when the data from two trials were combined (MD -2.04, 95% CI -4.19, 0.10). Conclusion Statistically significant changes were observed in favor of acupuncture in moderate to severe BPH with respect to short-term follow-up endpoints. The clinical significance of these changes needs to be tested by further studies with rigorous designs and longer follow-up times.	[Zhang, Wei; Liu, Zhishun; Lu, Yao] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, Beijing, Peoples R China; [Ma, Liyan] Capital Med Univ, Beijing Friendship Hosp, Clin Lab Ctr, Beijing, Peoples R China; [Bauer, Brent A.] Mayo Clin, Dept Med, Rochester, MN USA	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Capital Medical University; Mayo Clinic	Zhang, W (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, Beijing, Peoples R China.	zhangwei_7108@126.com						Abrams P, 2009, J UROLOGY, V181, P1779, DOI 10.1016/j.juro.2008.11.127; Bonnerman R., 1979, ACUPUNCTURE WORLD HL; Chen R., 2013, CHINA J ORTHOP TRAUM, V26, P54; [陈元武 Chen Yuanwu], 2010, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V25, P902; Cimentepe E, 2003, J ENDOUROL, V17, P103, DOI 10.1089/08927790360587432; Du L., 2012, J INTEGR TRADIT CHIN, V21, P1637; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hino K, 2010, UROLOGY, V75, P730, DOI 10.1016/j.urology.2009.04.025; Huang L., 2003, ILLUSTRATED HIST CHI; Kevin TM, AM UROLOGICAL ASS GU; Kramer G, 2007, EUR UROL, V51, P1202, DOI 10.1016/j.eururo.2006.12.011; Liu X., 2012, ENERGY METALLURGICAL, V1, P5; MacPherson H, 2001, COMPLEMENT THER MED, V9, P246, DOI 10.1054/ctim.2001.0488; McConnell J, 2006, 6 INT CONS NEW DEV P; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Institute for Health and Clinical Excellence, 2010, MAN LOW UR TRACT SYM; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Robert G, 2009, EUR UROL SUPPL, V8, P879, DOI 10.1016/j.eursup.2009.11.004; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Traditional Chinese Medicine Publication Center, 1963, YELL EMP CLASS INT M; Victor W., 2005, REV UROL, V7, P14; Wang KM., 2006, THESIS; WANG Y, 2013, PLOS ONE, V2013; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; Yang T., 2010, THESIS CHINA ACAD CH; Yu J-S., 2011, EVID-BASED COMPL ALT, V2011; Yun Q, 2006, CHINESE J CLIN REHAB, V10, P132; Zhang F.-S., 2005, MICR C P 2005 APMC 2, V3, P3; Zhang W, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007009; Zheng R., 2016, THESIS, P611	33	12	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2017	12	4							e0174586	10.1371/journal.pone.0174586	http://dx.doi.org/10.1371/journal.pone.0174586			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2IO	28376120	Green Submitted, Green Published, gold			2023-01-03	WOS:000399352000009
J	Bodemer, C; Guillet, G; Cambazard, F; Boralevi, F; Ballarini, S; Milliet, C; Bertuccio, P; La Vecchia, C; Bach, JF; de Prost, Y				Bodemer, Christine; Guillet, Gerard; Cambazard, Frederic; Boralevi, Franck; Ballarini, Stefania; Milliet, Christian; Bertuccio, Paola; La Vecchia, Carlo; Bach, Jean-Francois; de Prost, Yves			Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study	PLOS ONE			English	Article							MYCOBACTERIUM-VACCAE SUSPENSION; REMITTING MULTIPLE-SCLEROSIS; DOUBLE-BLIND; HYGIENE HYPOTHESIS; RESPIRATORY-TRACT; T-CELLS; CHILDREN; PROBIOTICS; DISEASE; ASTHMA	Background Environmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend. Objective This study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom (R), Broncho-Munal (R), Ommunal (R), Paxoral (R), Vaxoral (R)), in the treatment of established AD in children. Methods Children aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with emollients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9 months. The primary end-point was the difference between groups in the occurrence of new flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional Cox proportional hazard regression models accounting for repeated events. Results Among the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the placebo group. As expected most children in both treatment groups experienced at least 1 NF during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67-0.96), also when potential confounding factors, as family history of atopy and corticosteroids use, were taken into account (HR = 0.82; 95% CI: 0.69-0.98). No major side effect was reported, with comparable and good tolerability for OM-85 and placebo. Conclusions Results show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85 on established AD.	[Bodemer, Christine; de Prost, Yves] Hop Necker Enfants Malad, AP HP, Dept Dermatol, Paris, France; [Guillet, Gerard] Univ Poitiers, Dept Dermatol, Poitiers, France; [Cambazard, Frederic] Univ St Etienne, Hop St Etienne, Dept Dermatol, St Etienne, France; [Boralevi, Franck] Univ Bordeaux, Hop Pellegrin Enfants, Pediat Dermatol Unit, Bordeaux, France; [Ballarini, Stefania; Milliet, Christian] Vifor Pharma OM Pharma, Meyrin, Switzerland; [Bertuccio, Paola; La Vecchia, Carlo] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [Bach, Jean-Francois] Univ Paris 05, Sorbone Paris Cite, Paris, France; [Bach, Jean-Francois] INEM, CNRS, INSERM, U1151,UMR 8253, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Poitiers; CHU de St Etienne; Universite Jean Monnet; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of Milan; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bach, JF (corresponding author), Univ Paris 05, Sorbone Paris Cite, Paris, France.; Bach, JF (corresponding author), INEM, CNRS, INSERM, U1151,UMR 8253, Paris, France.	jean-francois.bach@academie-sciences.fr	La Vecchia, Carlo/Z-1710-2019	La Vecchia, Carlo/0000-0003-1441-897X; boralevi, franck/0000-0002-0477-5909	European Research Council [250290]; ViforPharma/OM Pharma [BV-2002/1]	European Research Council(European Research Council (ERC)European Commission); ViforPharma/OM Pharma(Dexcel Pharma)	This work was supported by the European Research Council, grant agreement number 250290. The funder (ViforPharma/OM Pharma), inquality of official sponsor of the clinical study (Sponsor's Protocol Code Number BV-2002/1),had a relevant role in the study design, data collection and analysis and decision to publish; the funders' employees since 2011 (StefaniaBallarini and ChristianMilliet) had a role in the preparation and review of the manuscript.	Ahrens B, 2011, INT ARCH ALLERGY IMM, V156, P196, DOI 10.1159/000322352; Alyanakian MA, 2006, DIABETES, V55, P179, DOI 10.2337/diabetes.55.1.179; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Arkwright PD, 2003, BRIT J DERMATOL, V149, P1029, DOI 10.1111/j.1365-2133.2003.05557.x; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Aumeunier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011484; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Berth-Jones J, 2006, CLIN EXP ALLERGY, V36, P1115, DOI 10.1111/j.1365-2222.2006.02558.x; Boyle RJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006135.pub2; Brooks C, 2013, CURR OPIN ALLERGY CL, V13, P70, DOI 10.1097/ACI.0b013e32835ad0d2; Brothers S, 2009, CLIN EXP DERMATOL, V34, P770, DOI 10.1111/j.1365-2230.2008.03153.x; Davies MG, 2006, J DERMATOL TREAT, V17, P74, DOI 10.1080/09546630500515321; Donaldson DS, 2013, MUCOSAL IMMUNOL, V6, P535, DOI 10.1038/mi.2012.93; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Figueiredo CA, 2013, J ALLERGY CLIN IMMUN, V131, P1064, DOI 10.1016/j.jaci.2013.01.016; Fiocchi A, 2012, WORLD ALLERGY ORGAN, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Gerasimov SV, 2010, AM J CLIN DERMATOL, V11, P351, DOI 10.2165/11531420-000000000-00000; Gueniche A, 2006, EUR J DERMATOL, V16, P380; Han L, 2014, AM J RHINOL ALLERGY, V28, P110, DOI 10.2500/ajra.2013.27.4021; Hopewell S, 2008, LANCET, V371, P281, DOI 10.1016/S0140-6736(07)61835-2; Isolauri E, 2012, GASTROENTEROL CLIN N, V41, P747, DOI 10.1016/j.gtc.2012.08.007; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kelly PJ, 2000, STAT MED, V19, P13, DOI 10.1002/(SICI)1097-0258(20000115)19:1&lt;13::AID-SIM279&gt;3.0.CO;2-5; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Rosche B, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-112; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sayers I, 2004, J ALLERGY CLIN IMMUN, V114, P302, DOI 10.1016/j.jaci.2004.03.057; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Schaad UB, 2010, WORLD J PEDIATR, V6, P5, DOI 10.1007/s12519-010-0001-x; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Sutton A.J., 2000, METHODS METAANALYSIS; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Thorburn AN, 2012, J IMMUNOL, V188, P4611, DOI 10.4049/jimmunol.1101299; Versalovic J, 2013, ANN NUTR METAB, V63, P42, DOI 10.1159/000354899; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356; Yang HJ, 2014, ALLERGY ASTHMA IMMUN, V6, P208, DOI 10.4168/aair.2014.6.3.208; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	50	15	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2017	12	3							e0161555	10.1371/journal.pone.0161555	http://dx.doi.org/10.1371/journal.pone.0161555			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8VS	28333952	Green Published, Green Submitted, gold			2023-01-03	WOS:000399102200001
J	Deddens, JC; Feyen, DA; Zwetsloot, PP; Brans, MA; Siddiqi, S; van Laake, LW; Doevendans, PA; Sluijter, JP				Deddens, Janine C.; Feyen, Dries A.; Zwetsloot, Peter-Paul; Brans, Maike A.; Siddiqi, Sailay; van Laake, Linda W.; Doevendans, Pieter A.; Sluijter, Joost P.			Targeting chronic cardiac remodeling with cardiac progenitor cells in a murine model of ischemia/reperfusion injury	PLOS ONE			English	Article							SPECKLE TRACKING ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; MYOCARDIAL-INFARCTION; STEM-CELLS; HEART REGENERATION; THERAPY; TRANSPLANTATION; REPAIR; GUIDELINES; DISEASE	Background Translational failure for cardiovascular disease is a substantial problem involving both high research costs and an ongoing lack of novel treatment modalities. Despite the progress already made, cell therapy for chronic heart failure in the clinical setting is still hampered by poor translation. We used a murine model of chronic ischemia/reperfusion injury to examine the effect of minimally invasive application of cardiac progenitor cells (CPC) in cardiac remodeling and to improve clinical translation. Methods 28 days after the induction of I/R injury, mice were randomized to receive either CPC (0.5 million) or vehicle by echo-guided intra-myocardial injection. To determine retention, CPC were localized in vivo by bioluminescence imaging (BLI) two days after injection. Cardiac function was assessed by 3D echocardiography and speckle tracking analysis to quantify left ventricular geometry and regional myocardial deformation. Results BLI demonstrated successful injection of CPC (18/23), which were mainly located along the needle track in the anterior/septal wall. Although CPC treatment did not result in overall restoration of cardiac function, a relative preservation of the left ventricular end-diastolic volume was observed at 4 weeks follow-up compared to vehicle control (+ 5.3 +/- 2.1 mu l vs. + 10.8 +/- 1.5 mu l). This difference was reflected in an increased strain rate (+ 16%) in CPC treated mice. Conclusions CPC transplantation can be adequately studied in chronic cardiac remodeling using this study set-up and by that provide a translatable murine model facilitating advances in research for new therapeutic approaches to ultimately improve therapy for chronic heart failure.	[Deddens, Janine C.; Feyen, Dries A.; Zwetsloot, Peter-Paul; Brans, Maike A.; Siddiqi, Sailay; van Laake, Linda W.; Doevendans, Pieter A.; Sluijter, Joost P.] Univ Med Ctr Utrecht, Dept Cardiol, Expt Cardiol Lab, Utrecht, Netherlands; [Deddens, Janine C.; Doevendans, Pieter A.; Sluijter, Joost P.] Netherlands Heart Inst ICIN, Utrecht, Netherlands; [Feyen, Dries A.; van Laake, Linda W.; Doevendans, Pieter A.; Sluijter, Joost P.] Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Sluijter, JP (corresponding author), Univ Med Ctr Utrecht, Dept Cardiol, Expt Cardiol Lab, Utrecht, Netherlands.; Sluijter, JP (corresponding author), Netherlands Heart Inst ICIN, Utrecht, Netherlands.; Sluijter, JP (corresponding author), Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands.	J.Sluijter@umcutrecht.nl	Zwetsloot, Peter-Paul/N-8846-2019	Zwetsloot, Peter-Paul/0000-0002-2634-4667; Doevendans, Pieter/0000-0002-6257-7169	Innovation and the Netherlands Cardio Vascular Research Initiative (CVON): The Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organization for Health Research and Development; Royal Netherlands Academy of Science; Alexandre Suerman program for MD/PhD students of the University Medical Center Utrecht, the Netherlands; ZonMW Translational Adult Stem Cell [1161002016]	Innovation and the Netherlands Cardio Vascular Research Initiative (CVON): The Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Royal Netherlands Academy of Science; Alexandre Suerman program for MD/PhD students of the University Medical Center Utrecht, the Netherlands; ZonMW Translational Adult Stem Cell	We acknowledge the support from Innovation and the Netherlands Cardio Vascular Research Initiative (CVON): The Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Science and the Alexandre Suerman program for MD/PhD students of the University Medical Center Utrecht, the Netherlands. Additionally, the ZonMW Translational Adult Stem Cell grant 1161002016.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Aguirre A, 2013, CELL STEM CELL, V12, P275, DOI 10.1016/j.stem.2013.02.008; Baranyai T, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0313-1; Bauer M, 2011, CIRC RES, V108, P908, DOI 10.1161/CIRCRESAHA.110.239574; Bhan A, 2014, AM J PHYSIOL-HEART C, V306, pH1371, DOI 10.1152/ajpheart.00553.2013; Bolli R, 2015, J AM COLL CARDIOL, V66, P2000, DOI 10.1016/j.jacc.2015.09.002; Clifford DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037373; Delewi R, 2014, EUR HEART J, V35, P989, DOI 10.1093/eurheartj/eht372; Eding JEC, 2015, CIRC RES, V116, P80, DOI 10.1161/CIRCRESAHA.116.304872; Feyen DAM, 2016, ADV HEALTHC MAT; Feyen D, 2013, CARDIOVASC RES, V99, P83, DOI 10.1093/cvr/cvt078; Gaetani R, 2014, J CELL MOL MED, V18, P2147, DOI 10.1111/jcmm.12458; Giricz Z, 2006, J PHARMACOL EXP THER, V316, P154, DOI 10.1124/jpet.105.091140; Goumans MJ, 2014, HEART, V100, P1153, DOI 10.1136/heartjnl-2014-305646; Goumans MJ, 2008, STEM CELL RES, V1, P138, DOI 10.1016/j.scr.2008.02.003; Johnston PV, 2009, CIRCULATION, V120, P1075, DOI 10.1161/CIRCULATIONAHA.108.816058; Lara-Pezzi E, 2015, J CARDIOVASC TRANSL, V8, P3, DOI 10.1007/s12265-015-9606-8; Latham N, 2013, CIRCULATION, V128, pS105, DOI 10.1161/CIRCULATIONAHA.112.000374; Lecour S, 2014, CARDIOVASC RES, V104, P399, DOI 10.1093/cvr/cvu225; Lorkeers S. J., 2015, PLOS ONE, V10; Madonna R, 2016, EUR HEART J; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; McCafferty K, 2014, DIS MODEL MECH, V7, P1321, DOI 10.1242/dmm.016741; McMurray JJV, 2012, EUR J HEART FAIL, V14, P803, DOI 10.1093/eurjhf/hfs105; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Motulsky HJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-123; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Oskouei BN, 2012, STEM CELL TRANSL MED, V1, P116, DOI 10.5966/sctm.2011-0015; Peng Y, 2009, AM J PHYSIOL-HEART C, V297, pH811, DOI 10.1152/ajpheart.00385.2009; Prendiville TW, 2014, JOVE-J VIS EXP, DOI 10.3791/51566; Rota M, 2008, CIRC RES, V103, P107, DOI 10.1161/CIRCRESAHA.108.178525; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Smits AM, 2009, NAT PROTOC, V4, P232, DOI 10.1038/nprot.2008.229; Smits AM, 2009, CARDIOVASC RES, V83, P527, DOI 10.1093/cvr/cvp146; Springer ML, 2005, AM J PHYSIOL-HEART C, V289, pH1307, DOI 10.1152/ajpheart.00164.2005; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tang X- L, 2016, CIRC RES; Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905; Thibault H, 2007, AM J PHYSIOL-HEART C, V293, pH496, DOI 10.1152/ajpheart.00087.2007; Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018; Tseliou E, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0443-8; van den Akker F, 2013, BBA-GEN SUBJECTS, V1830, P2449, DOI 10.1016/j.bbagen.2012.08.026; van den Akker F., 2016, EUR HEART J; van Laake LW, 2007, NAT PROTOC, V2, P2551, DOI 10.1038/nprot.2007.371; van Zuylen VL, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1128-y; Xu ZB, 2014, JOVE-J VIS EXP, DOI 10.3791/51329; Yamada S, 2013, J PHYSIOL-LONDON, V591, P4335, DOI 10.1113/jphysiol.2013.252288; Ye ZY, 2011, ADV DRUG DELIVER REV, V63, P688, DOI 10.1016/j.addr.2011.02.007; Yee K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113805; Zwetsloot PP, 2016, CIRC RES	50	7	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2017	12	3							e0173657	10.1371/journal.pone.0173657	http://dx.doi.org/10.1371/journal.pone.0173657			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER6VC	28319168	Green Published, Green Submitted, gold			2023-01-03	WOS:000398945800021
J	Dawson, MA				Dawson, Mark A.			The cancer epigenome: Concepts, challenges, and therapeutic opportunities	SCIENCE			English	Review							TERT PROMOTER MUTATIONS; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; MYELODYSPLASTIC SYNDROME; SELECTIVE-INHIBITION; CLONAL HEMATOPOIESIS; HISTONE METHYLATION; CBX FAMILY; RESISTANCE; PLASTICITY	Cancer biology is profoundly influenced by changes in the epigenome. Because the dynamic plasticity of the epigenome lends itself well to therapeutic manipulation, the past few years have witnessed an unprecedented investment in the development, characterization, and translation of targeted epigenetic therapies. In this review, I provide a broad context for recent developments that offer a greater understanding of how epigenetic regulators facilitate the initiation, maintenance, and evolution of cancer. I discuss newly developed epigenetic therapies and the cellular and molecular mechanisms that may govern sensitivity and resistance to these agents. I also review the rationale for future combination therapies involving existing and emerging epigenetic drugs.	[Dawson, Mark A.] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia; [Dawson, Mark A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Dawson, Mark A.] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia; [Dawson, Mark A.] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center	Dawson, MA (corresponding author), Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia.; Dawson, MA (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.; Dawson, MA (corresponding author), Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia.; Dawson, MA (corresponding author), Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia.	mark.dawson@petermac.org	Dawson, Mark A/B-9317-2017	Dawson, Mark A/0000-0002-5464-5029	National Health and Medical Research Council of Australia; Cancer Council Victoria; Snowdome Foundation; Celgene; Pfizer	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Snowdome Foundation; Celgene(Bristol-Myers SquibbCelgene Corporation); Pfizer(Pfizer)	The scope and space limitations of this review have unfortunately meant that I have not been able to separately cite many of the original publications that have contributed substantially to the literature. I sincerely apologize to the authors of these publications. I thank S.-J. Dawson for critical appraisal of the manuscript and all of the members of the Dawson laboratory for helpful discussions. M.A.D. is the senior fellow for Leukaemia Foundation Australia. The National Health and Medical Research Council of Australia, Cancer Council Victoria, and the Snowdome Foundation support research in the Dawson laboratory. M.A.D. is on the scientific advisory board of Cancer Therapeutics CRC (CTx), a company developing new cancer drugs, and is a paid consultant for Celgene and Pfizer.	Allis C, 2015, EPIGENETICS-US; Alvarado AS, 2014, CELL, V157, P110, DOI 10.1016/j.cell.2014.02.041; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Cerchietti L., 2017, J CLIN ONCOL; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Daley GQ, 2012, CELL, V151, P1151, DOI 10.1016/j.cell.2012.11.016; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deplus R, 2013, EMBO J, V32, P645, DOI 10.1038/emboj.2012.357; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fellmann C, 2014, NAT CELL BIOL, V16, P10, DOI 10.1038/ncb2895; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Gilan O, 2016, NAT STRUCT MOL BIOL, V23, P673, DOI 10.1038/nsmb.3249; Groschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019; Halley-Stott RP, 2013, BRIEF FUNCT GENOMICS, V12, P164, DOI 10.1093/bfgp/elt011; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Issa JP, 2015, CANCER-AM CANCER SOC, V121, P556, DOI 10.1002/cncr.29085; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kagoya Y, 2016, J CLIN INVEST, V126, P3479, DOI 10.1172/JCI86437; Katainen R, 2015, NAT GENET, V47, P818, DOI 10.1038/ng.3335; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lu C, 2016, SCIENCE, V352, P844, DOI 10.1126/science.aac7272; Luger K, 2012, NAT REV MOL CELL BIO, V13, P436, DOI 10.1038/nrm3382; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Oldridge DA, 2015, NATURE, V528, P418, DOI 10.1038/nature15540; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Perera D, 2016, NATURE, V532, P259, DOI 10.1038/nature17437; Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780; Pleyer L, 2015, DRUG METAB REV, V47, P252, DOI 10.3109/03602532.2014.995379; Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Rodriguez R, 2014, NAT REV GENET, V15, P783, DOI 10.1038/nrg3796; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Sanchez-Rivera FJ, 2015, NAT REV CANCER, V15, P387, DOI 10.1038/nrc3950; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Sigalotti L, 2014, PHARMACOL THERAPEUT, V142, P339, DOI 10.1016/j.pharmthera.2013.12.015; Stein EM, 2016, BLOOD, V127, P71, DOI 10.1182/blood-2015-07-604538; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Woods BA, 2015, IMMUNOL REV, V263, P22, DOI 10.1111/imr.12246; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Yamazaki H, 2014, CANCER CELL, V25, P415, DOI 10.1016/j.ccr.2014.02.008; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	74	210	214	3	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1147	1152		10.1126/science.aam7304	http://dx.doi.org/10.1126/science.aam7304			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9WV	28302822				2023-01-03	WOS:000396351200031
J	Orban, JC; Novain, M; Cattet, F; Plattier, R; Nefzaoui, M; Hyvernat, H; Raguin, O; Kaidomar, M; Kerever, S; Ichai, C				Orban, Jean-Christophe; Novain, Michael; Cattet, Florian; Plattier, Remi; Nefzaoui, Mohamed; Hyvernat, Herve; Raguin, Olivier; Kaidomar, Michel; Kerever, Sebastien; Ichai, Carole			Association of serum lactate with outcome after out-of-hospital cardiac arrest treated with therapeutic hypothermia	PLOS ONE			English	Article							EUROPEAN-RESUSCITATION-COUNCIL; INTENSIVE-CARE MEDICINE; SURVIVORS; PREDICTION; GUIDELINES; CLEARANCE; INJURY; SHOCK; MORTALITY; SOCIETY	Aims Lactate reflects hypoxic insult in many conditions and is considered as a prognosis factor. But, after cardiac arrest, its interest is still debated. Our study aimed to assess the prognosis value of lactate in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia. Methods This retrospective observational study included out-of-hospital cardiac arrest patients treated with therapeutic hypothermia in four ICUs. Lactate levels were compared at different times during the first 24 hours according to outcome at ICU discharge and to the type of death (multiorgan or neurologic failure). Results Two hundred and seventy-two patients were included, 89 good outcome and 183 poor outcome. In the latter group, 171 patients died, from multiorgan failure in 30% and neurologic failure in 70%. Lactate levels were higher in the poor compared to the good outcome patients at admission (5.4 (3.3-9.4) vs. 2.2 (1.5-3.6) mmol/L; p<0.01), 12 hours (2.5 (1.6-4.7) vs. 1.4 (1.0-2.2) mmol/L; p<0.01) and 24 hours (1.8 (1.1-2.8) vs. 1.3 (0.9-2.1) mmol/L; p<0.01). Patients succumbing from multiorgan failure exhibited higher lactate levels compared to those dying from neurologic failure at admission (7.9 (3.9-12.0) vs. 5.2 (3.3-8.8) mmol/L; p<0.01), H12 (4.9 (2.1-8.9) vs. 2.2 (1.4-3.4) mmol/L; p<0.01) and H24 (3.3 (1.8-5.5) vs. 1.4 (1.1-2.5) mmol/L; p<0.01). Initial lactate levels showed an increasing proportion of poor outcome from the first to fourth quartile. Conclusions After out-of-hospital cardiac arrest treated with therapeutic hypothermia, lactate levels during the first 24 hours seem linked with ICU outcome. Patients dying from multiorgan failure exhibit higher initial lactate concentrations than patients succumbing from neurological failure.	[Orban, Jean-Christophe; Novain, Michael; Cattet, Florian; Plattier, Remi; Nefzaoui, Mohamed; Ichai, Carole] Nice Univ Hosp, Pasteur Hosp 2, Med Surg ICU, 30 Voie Romaine, Nice, France; [Hyvernat, Herve] Nice Univ Hosp, Med ICU, Archet Hosp, 151 Route St Antoine, Nice, France; [Raguin, Olivier] Antibes Gen Hosp, Intens Care Unit, 107 Ave Nice, Antibes, France; [Kaidomar, Michel] Frejus St Raphael Gen Hosp, Intens Care Unit, 240 Ave St Lambert, Frejus, France; [Kerever, Sebastien] Lariboisiere Univ Hosp, Dept Anesthesiol, 2 Rue Ambroise Pare, Paris, France; [Kerever, Sebastien] Lariboisiere Univ Hosp, Dept Crit Care, 2 Rue Ambroise Pare, Paris, France	CHU Nice; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Orban, JC (corresponding author), Nice Univ Hosp, Pasteur Hosp 2, Med Surg ICU, 30 Voie Romaine, Nice, France.	orban.jc@chu-nice.fr	Kerever, Sébastien/S-1620-2019	Kerever, Sébastien/0000-0003-0764-4370; Orban, Jean-Christophe/0000-0002-8004-4809				Abella BS, 2005, RESUSCITATION, V64, P181, DOI 10.1016/j.resuscitation.2004.09.014; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Bougouin W, 2014, INTENS CARE MED, V40, P846, DOI 10.1007/s00134-014-3252-5; CARDEN DL, 1985, AM J EMERG MED, V3, P120, DOI 10.1016/0735-6757(85)90033-6; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; Cocchi MN, 2011, MINERVA ANESTESIOL, V77, P1063; Contenti J, 2015, AM J EMERG MED, V33, P167, DOI 10.1016/j.ajem.2014.11.003; Dankiewicz J, 2014, CRIT CARE MED, V42, P2537, DOI 10.1097/CCM.0000000000000543; de Vreede-Swagemakers JJM, 1998, HEART, V79, P356, DOI 10.1136/hrt.79.4.356; Donnino MW, 2007, RESUSCITATION, V75, P229, DOI 10.1016/j.resuscitation.2007.03.021; Donnino MW, 2014, CRIT CARE MED, V42, P1804, DOI 10.1097/CCM.0000000000000332; Gasparetto N, 2014, RESUSCITATION, V85, P376, DOI 10.1016/j.resuscitation.2013.11.014; Grimaldi D, 2013, RESUSCITATION, V84, P60, DOI 10.1016/j.resuscitation.2012.06.010; Han F, 2008, CRIT CARE MED, V36, pS447, DOI 10.1097/CCM.0b013e31818a8a51; James JH, 1999, LANCET, V354, P505, DOI 10.1016/S0140-6736(98)91132-1; Kliegel A, 2004, MEDICINE, V83, P274, DOI 10.1097/01.md.0000141098.46118.4c; Korth U, 2003, RESUSCITATION, V58, P209, DOI 10.1016/S0300-9572(03)00119-9; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Lee TR, 2013, CRIT CARE, V17, DOI 10.1186/cc13090; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Levraut J, 1998, AM J RESP CRIT CARE, V157, P1021, DOI 10.1164/ajrccm.157.4.9705037; Mullner M, 1997, INTENS CARE MED, V23, P1138, DOI 10.1007/s001340050470; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Oddo M, 2014, CRIT CARE MED, V42, P1340, DOI 10.1097/CCM.0000000000000211; Orban JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045284; Revelly JP, 2005, CRIT CARE MED, V33, P2235, DOI 10.1097/01.CCM.0000181525.99295.8F; Sandroni C, 2014, INTENS CARE MED, V40, P1816, DOI 10.1007/s00134-014-3470-x; Shinozaki K, 2011, RESUSCITATION, V82, P404, DOI 10.1016/j.resuscitation.2010.10.026; Starodub R, 2013, RESUSCITATION, V84, P1078, DOI 10.1016/j.resuscitation.2013.02.001; Wolfrum S, 2007, RESUSCITATION, V72, P207, DOI 10.1016/j.resuscitation.2006.06.033; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021	35	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2017	12	3							e0173239	10.1371/journal.pone.0173239	http://dx.doi.org/10.1371/journal.pone.0173239			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6CJ	28282398	Green Published, gold, Green Submitted			2023-01-03	WOS:000396091800024
J	Channin, DS				Channin, David S.			Why Physician Leaders of Health Care Organizations Should Participate in Direct Patient Care	ANNALS OF INTERNAL MEDICINE			English	Letter									[Channin, David S.] Insightful Med Informat, Vestal, NY USA		Channin, DS (corresponding author), Insightful Med Informat, Vestal, NY USA.							Detsky AS, 2016, ANN INTERN MED, V165, P519, DOI 10.7326/M16-0820	1	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					376	376		10.7326/L16-0625	http://dx.doi.org/10.7326/L16-0625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265661				2023-01-03	WOS:000396432800014
J	Terawaki, K; Kashiwase, Y; Sawada, Y; Hashimoto, H; Yoshimura, M; Ohbuchi, K; Sudo, Y; Suzuki, M; Miyano, K; Shiraishi, S; Higami, Y; Yanagihara, K; Hattori, T; Kase, Y; Ueta, Y; Uezono, Y				Terawaki, Kiyoshi; Kashiwase, Yohei; Sawada, Yumi; Hashimoto, Hirofumi; Yoshimura, Mitsuhiro; Ohbuchi, Katsuya; Sudo, Yuka; Suzuki, Masami; Miyano, Kanako; Shiraishi, Seiji; Higami, Yoshikazu; Yanagihara, Kazuyoshi; Hattori, Tomohisa; Kase, Yoshio; Ueta, Yoichi; Uezono, Yasuhito			Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model	PLOS ONE			English	Article							HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; NEUROPEPTIDE-Y-INNERVATION; LEUKEMIA-INHIBITORY FACTOR; CISPLATIN-INDUCED ANOREXIA; NUDE-MICE; ARCUATE NUCLEUS; HERBAL MEDICINE; 5-HT2C RECEPTOR; PLASMA GHRELIN; MELANOMA-CELLS	Cancer cachexia (CC) is a multifactorial disease characterized by decreased food intake and loss of body weight due to reduced musculature with or without loss of fat mass. Patients with gastric cancer have a high incidence of cachexia. We previously established a novel CC rat model induced by human gastric cancer-derived 85As2 cells in order to examine the pathophysiology of CC and identify potential therapeutics. In patients with CC, anorexia is often observed, despite elevation of ghrelin, suggesting that ghrelin resistance may develop in these patients. In this study, we aimed to clarify the occurrence of ghrelin resistance in CC rats accompanied by anorexia and we investigated whether rikkunshito (RKT), a traditional Japanese Kampo medicine that potentiates ghrelin signaling, ameliorated CC-related anorexia through alleviation of ghrelin resistance. 85As2-tumor-bearing rats developed severe CC symptoms, including anorexia and loss of body weight/musculature, with the latter symptoms being greater in cachectic rats than in non-tumor-bearing or pair-fed rats. CC rats showed poor responses to intraperitoneal injection of ghrelin. In CC rats, plasma ghrelin levels were elevated and hypothalamic anorexigenic peptide mRNA levels were decreased, whereas hypothalamic growth hormone secretagogue receptor (GHS-R) mRNA was not affected. In vitro, RKT directly enhanced ghrelin-induced GHS-R activation. RKT administrated orally for 7 days partly alleviated the poor response to ghrelin and ameliorated anorexia without affecting the elevation of plasma ghrelin levels in CC rats. The expression of hypothalamic orexigenic neuropeptide Y mRNA but not hypothalamic GHS-R mRNA was increased by RKT. Thus, the 85As2 cell-induced CC rat model developed ghrelin resistance, possibly contributing to anorexia and body weight loss. The mechanism through which RKT ameliorated anorexia in the CC rat model may involve alleviation of ghrelin resistance by enhancement of ghrelin signaling. These findings suggest that RKT may be a promising agent for the treatment of CC.	[Terawaki, Kiyoshi; Kashiwase, Yohei; Sawada, Yumi; Ohbuchi, Katsuya; Sudo, Yuka; Suzuki, Masami; Miyano, Kanako; Shiraishi, Seiji; Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Div Canc Pathophysiol, Chuo Ku, Tokyo, Japan; [Terawaki, Kiyoshi; Ohbuchi, Katsuya; Hattori, Tomohisa; Kase, Yoshio] Tsumura & Co, Tsumura Res Labs, Kampo Sci Strategies Div, Ami, Ibaraki, Japan; [Kashiwase, Yohei; Sudo, Yuka; Higami, Yoshikazu] Tokyo Univ Sci, Lab Mol Pathol & Metab Dis, Fac Pharmaceut Sci, Noda, Chiba, Japan; [Hashimoto, Hirofumi; Yoshimura, Mitsuhiro; Ueta, Yoichi] Univ Occupat & Environm Hlth, Dept Physiol, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka, Japan; [Yanagihara, Kazuyoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Biomarker Discovery, Kashiwa, Chiba, Japan; [Uezono, Yasuhito] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Support Canc Res, Chuo Ku, Tokyo, Japan; [Uezono, Yasuhito] Natl Canc Ctr, Innovat Ctr Support Palliat & Psychosocial Care, Chuo Ku, Tokyo, Japan	National Cancer Center - Japan; Tsumura & Company; Tokyo University of Science; University of Occupational & Environmental Health - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Uezono, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Canc Pathophysiol, Chuo Ku, Tokyo, Japan.; Uezono, Y (corresponding author), Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Support Canc Res, Chuo Ku, Tokyo, Japan.; Uezono, Y (corresponding author), Natl Canc Ctr, Innovat Ctr Support Palliat & Psychosocial Care, Chuo Ku, Tokyo, Japan.	yuezono@ncc.go.jp	Shiraishi, Seiji/GPX-5566-2022	Hashimoto, Hirofumi/0000-0003-1575-836X; Higami, Yoshikazu/0000-0003-1381-0777; Miyano, Kanako/0000-0003-1673-6074	Ministry of Education, Culture, Sports, Science and Technology, Japan [22590510, 24590740]; Foundation for Promotion of Cancer Research in Japan; Ministry of Health, Labour and Welfare, Japan [H22-General-035]; Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine [15lk0310003h0001, 16lk0310020h0001]; Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED [15ck0106059h0002, 16nk0101311h0002]; National Cancer Center Research and Development Fund [23-A-2, 23-A-29, 23-A-38]; Tsumura & Co. (Ibaraki, Japan); Grants-in-Aid for Scientific Research [16K08537] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Foundation for Promotion of Cancer Research in Japan; Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine; Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Tsumura & Co. (Ibaraki, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Grant support was provided to KT by: 1. Grants-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology, Japan [http://www.jsps.go.jp/j-grantsinaid/index.html] Grant no. 22590510. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 2. The Foundation for Promotion of Cancer Research in Japan [http://www.ncc.go.jp/jp/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Grant support was provided to Y. Uezono by: 1. The Third-term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, Japan; [http://www.mhlw.go.jp/] Grant no. H22-General-035. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 2. Grants-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology, Japan; [http://www.jsps.go.jp/j-grantsinaid/index.html] Grant no. 24590740. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 3. Grants from the Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine [http://www.amed.go.jp/] Grant no. 15lk0310003h0001, 16lk0310020h0001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 4. The Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED; [http://www.amed.go.jp/] Grant no. 15ck0106059h0002, 16nk0101311h0002. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 5. The National Cancer Center Research and Development Fund [http://www.ncc.go.jp/jp/] Grant nos. 23-A-2, 23-A-29, and 23-A-38. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 6. A grant from Tsumura & Co. (Ibaraki, Japan) [https://www.tsumura.co.jp/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai M, 2012, HEPATO-GASTROENTEROL, V59, P62, DOI 10.5754/hge11246; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Broberger C, 1999, NEUROENDOCRINOLOGY, V70, P295, DOI 10.1159/000054490; Chang JWC, 2003, J ENDOCRINOL, V179, P387, DOI 10.1677/joe.0.1790387; Currie PJ, 2005, AM J PHYSIOL-REG I, V289, pR353, DOI 10.1152/ajpregu.00756.2004; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; Ebrahimi B, 2004, CANCER-AM CANCER SOC, V101, P2727, DOI 10.1002/cncr.20672; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Fekete C, 2001, ENDOCRINOLOGY, V142, P2606, DOI 10.1210/en.142.6.2606; Fujitsuka N, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.25; Fujitsuka N, 2016, MOL PSYCHIATR; Fujitsuka N, 2009, BIOL PSYCHIAT, V65, P748, DOI 10.1016/j.biopsych.2008.10.031; Garcia JM, 2005, J CLIN ENDOCR METAB, V90, P2920, DOI 10.1210/jc.2004-1788; Grossberg AJ, 2010, ENDOCRINOLOGY, V151, P606, DOI 10.1210/en.2009-1135; Hanada T, 2003, BIOCHEM BIOPH RES CO, V301, P275, DOI 10.1016/S0006-291X(02)03028-0; Hayakawa T, 1999, DRUG EXP CLIN RES, V25, P211; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Laviano A, 2005, NAT CLIN PRACT ONCOL, V2, P158, DOI 10.1038/ncponc0112; Legradi G, 1998, ENDOCRINOLOGY, V139, P3262, DOI 10.1210/en.139.7.3262; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsumura T, 2010, J GASTROENTEROL, V45, P300, DOI 10.1007/s00535-009-0166-z; Miyano K, 2014, J PHARMACOL SCI, V126, P302, DOI 10.1254/jphs.14R13CP; MORI M, 1991, CANCER RES, V51, P6656; Muscaritoli M, 2006, EUR J CANCER, V42, P31, DOI 10.1016/j.ejca.2005.07.026; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Neary NM, 2004, J CLIN ENDOCR METAB, V89, P2832, DOI 10.1210/jc.2003-031768; PAXINOS G, 1982, THE RAT BRAIN IN STE; Peters MF, 2010, ASSAY DRUG DEV TECHN, V8, P219, DOI 10.1089/adt.2009.0232; Ramos EJB, 2004, CURR OPIN CLIN NUTR, V7, P427, DOI 10.1097/01.mco.0000134363.53782.cb; Ravasco P, 2004, SUPPORT CARE CANCER, V12, P246, DOI 10.1007/s00520-003-0568-z; Scott CW, 2010, DRUG DISCOV TODAY, V15, P704, DOI 10.1016/j.drudis.2010.06.008; Shimizu Y, 2003, CLIN CANCER RES, V9, P774; Suzuki H, 2014, NEUROGASTROENT MOTIL, V26, P950, DOI 10.1111/nmo.12348; Suzuki H, 2009, NEUROGASTROENT MOTIL, V21, P688, DOI 10.1111/j.1365-2982.2009.01290.x; Suzuki M, 2012, SYNAPSE, V66, P747, DOI 10.1002/syn.21559; Tack J, 2006, GUT, V55, P327, DOI 10.1136/gut.2004.060426; Takeda H, 2008, GASTROENTEROLOGY, V134, P2004, DOI 10.1053/j.gastro.2008.02.078; Terawaki K, 2014, AM J PHYSIOL-ENDOC M, V306, pE373, DOI 10.1152/ajpendo.00116.2013; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Tominaga K, 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1093/ECAM/NEP173; TONI R, 1990, ENDOCRINOLOGY, V126, P2444, DOI 10.1210/endo-126-5-2444; Toshinai K, 2001, BIOCHEM BIOPH RES CO, V281, P1220, DOI 10.1006/bbrc.2001.4518; Tschop M, 2001, J ENDOCRINOL INVEST, V24, pRC19, DOI 10.1007/BF03351037; Vettor R, 2002, J ENDOCRINOL INVEST, V25, P836, DOI 10.1007/BF03344047; Walsh D, 2002, SUPPORT CARE CANCER, V10, P385, DOI 10.1007/s00520-001-0318-z; Wang W, 2006, INT J ONCOL, V28, P1393; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Yakabi K, 2010, REGUL PEPTIDES, V161, P97, DOI 10.1016/j.regpep.2010.02.003; Yanagihara K, 2013, NUTR CANCER, V65, P578, DOI 10.1080/01635581.2013.776089; Yanai M, 2013, J GASTROENTEROL, V48, P611, DOI 10.1007/s00535-012-0687-8; Yoshimura M, 2013, PEPTIDES, V46, P13, DOI 10.1016/j.peptides.2013.04.019; Zaki MH, 2004, INT J CANCER, V111, P592, DOI 10.1002/ijc.20270	52	30	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0173113	10.1371/journal.pone.0173113	http://dx.doi.org/10.1371/journal.pone.0173113			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4NF	28249026	gold, Green Published, Green Submitted			2023-01-03	WOS:000395983500077
J	Li, YH; Zheng, XZ; Ru, GM; Ding, QN; Hahn, RG				Li, Yuhong; Zheng Xiaozhu; Ru Guomei; Ding Qiannan; Hahn, Robert G.			Effects of vasoactive drugs on crystalloid fluid kinetics in septic sheep	PLOS ONE			English	Article							VOLUME KINETICS; INFUSION; MANAGEMENT; SALINE; SHOCK	Purpose Crystalloid fluid and vasoactive drugs are used in the early treatment of sepsis. The purpose of the present study was to examine how these drugs alter plasma volume expansion, peripheral edema, and urinary excretion. Methods Twenty-five anesthetized sheep were made septic by cecal puncture and a short infusion of lipopolysaccharide. After 50 min, a slow infusion of isotonic saline was initiated: the saline either contained no drug, norepinephrine (1 mu g/kg/min), phenylephrine (3 mu g/kg/min), dopamine (50 mu g/kg/min), or esmolol (50 mu g/kg/min). Ten min later, 20 mL/kg Ringer A s lactate solution was given over 30 min. Central hemodynamics, acid-base balance, and the urinary excretion were monitored. Frequent measurements of the blood hemoglobin concentration were used as input in a kinetic analysis, using a mixed effects modeling software. Results The fluid kinetic analysis showed slow distribution and elimination of Ringer A s lactate, although phenylephrine and dopamine accelerated the distribution. Once distributed, the fluid remained in the peripheral tissues and did not equilibrate adequately with the plasma. Overall, stimulation of adrenergic alpha(1)-receptors accelerated, while beta(1)-receptors retarded, the distribution and elimination of fluid. A pharmacodynamic E-max model showed that Ringer A s lactate increased stroke volume by 13 ml/beat. Alpha(1)-receptors, but not beta(1)-receptors, further increased stroke volume, while both raised the mean arterial pressure. Modulation of the beta1-receptors limited the acidosis. Conclusions Stimulation of adrenergic alpha(1)-receptors with vasoactive drugs accelerated, while beta1receptors retarded, the distribution and elimination of fluid. The tendency for peripheral accumulation of fluid was pronounced, in particular when phenylephrine was given.	[Li, Yuhong] Shaoxing Peoples Hosp, Dept Anesthesiol, Shaoxing, Zhejiang, Peoples R China; [Li, Yuhong; Ru Guomei; Ding Qiannan] Shaoxing Peoples Hosp, Res Ctr, Shaoxing, Zhejiang, Peoples R China; [Zheng Xiaozhu] Zhejiang Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China; [Hahn, Robert G.] Sodertalje Hosp, Res Unit, Sodertalje, Sweden		Hahn, RG (corresponding author), Sodertalje Hosp, Res Unit, Sodertalje, Sweden.	r.hahn@telia.com	li, Yu/HCI-9086-2022	Hahn, Robert/0000-0002-1528-3803	Medical Health Science and Technology Project of Zhejiang province [2014KYB277]; Zhejiang Provincial Science Foundation [LY15H030013]	Medical Health Science and Technology Project of Zhejiang province; Zhejiang Provincial Science Foundation	The project was supported by Medical Health Science and Technology Project of Zhejiang province (No 2014KYB277) and Zhejiang Provincial Science Foundation (No LY15H030013).	Beale Richard J, 2004, Crit Care Med, V32, pS455, DOI 10.1097/01.CCM.0000142909.86238.B1; Brauer KI, 2002, ANESTHESIOLOGY, V96, P442, DOI 10.1097/00000542-200202000-00033; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Ewaldsson CA, 2006, J SURG RES, V131, P7, DOI 10.1016/j.jss.2005.09.012; Hahn RG, 2016, ACTA ANAESTH SCAND, V60, P569, DOI 10.1111/aas.12686; Hahn RG, 2016, EUR J ANAESTH, V33, P475, DOI 10.1097/EJA.0000000000000436; Hahn RG, 2014, CLINICS, V69, P120, DOI 10.6061/clinics/2014(02)08; Hahn RG, 2010, ANESTHESIOLOGY, V113, P470, DOI 10.1097/ALN.0b013e3181dcd88f; Heeremans EH, 2010, CURR OPIN ANESTHESIO, V23, P479, DOI 10.1097/ACO.0b013e32833a1d2f; Li Y, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-16; Patel GP, 2010, SHOCK, V33, P375, DOI 10.1097/SHK.0b013e3181c6ba6f; Stowe T, 2011, ANESTHETIC PHARM, P648; Svensen C, 1997, ANESTHESIOLOGY, V87, P204, DOI 10.1097/00000542-199708000-00006; [No title captured]	14	13	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0172361	10.1371/journal.pone.0172361	http://dx.doi.org/10.1371/journal.pone.0172361			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SX	28231305	gold, Green Published, Green Submitted			2023-01-03	WOS:000394682400038
J	James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Miliman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR				James, N. D.; de Bono, J. S.; Spears, M. R.; Clarke, N. W.; Mason, M. D.; Dearnaley, D. P.; Ritchie, A. W. S.; Amos, C. L.; Gilson, C.; Jones, R. J.; Matheson, D.; Miliman, R.; Attard, G.; Chowdhury, S.; Cross, W. R.; Gillessen, S.; Parker, C. C.; Russell, J. M.; Berthold, D. R.; Brawley, C.; Adab, F.; Aung, S.; Birtle, A. J.; Bowen, J.; Brock, S.; Chakraborti, P.; Ferguson, C.; Gale, J.; Gray, E.; Hingorani, M.; Hoskin, P. J.; Lester, J. F.; Malik, Z. I.; McKinna, F.; McPhail, N.; Money-Kyrle, J.; O'Sullivan, J.; Parikh, O.; Protheroe, A.; Robinson, A.; Srihari, N. N.; Thomas, C.; Wagstaff, J.; Wylie, J.; Zarkar, A.; Parmar, M. K. B.; Sydes, M. R.		STAMPEDE Investigators	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ZOLEDRONIC ACID; PLUS PREDNISONE; STAMPEDE TRIAL; CONTROL ARM; OPEN-LABEL; SURVIVAL; MULTISTAGE; DOCETAXEL; MULTIARM	BACKGROUND Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. METHODS We randomly assigned patients in a 1: 1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, whichever came first. The primary outcome measure was overall survival. The intermediate primary outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA progression or death from prostate cancer). RESULTS A total of 1917 patients underwent randomization from November 2011 through January 2014. The median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic disease. There were 248 treatment-failure events in the combination group as compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% of the patients in the ADT-alone group (with three grade 5 events). CONCLUSIONS Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone.	[James, N. D.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England; [Zarkar, A.] Univ Hosp Birmingham, Birmingham, W Midlands, England; [de Bono, J. S.; Dearnaley, D. P.; Attard, G.] Inst Canc Res, London, England; [Spears, M. R.; Amos, C. L.; Gilson, C.; Brawley, C.; Parmar, M. K. B.; Sydes, M. R.] UCL, MRC, Clin Trials Unit, London, England; [Chowdhury, S.] Kings Coll London, London, England; [Chowdhury, S.] Guys & St Thomas NHS Fdn Trust, London, England; [Parker, C. C.] Royal Marsden NHS Fdn Trust, London, England; [Clarke, N. W.] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Mason, M. D.] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales; [Lester, J. F.] Velindre Canc Ctr, Cardiff, S Glam, Wales; [Ritchie, A. W. S.] Gloucestershire Royal Hosp, Gloucester, England; [Bowen, J.] Gloucestershire Hosp NHS Fdn Trust, Gloucester, England; [Jones, R. J.; Russell, J. M.] Univ Glasgow, Glasgow, Lanark, Scotland; [Cross, W. R.] St James Univ Hosp, Leeds, W Yorkshire, England; [Adab, F.] Univ Hosp North Midlands, Stoke On Trent, Staffs, England; [Aung, S.] Royal Devon & Exeter Hosp NHS Fdn Trust Exeter, Exeter, Devon, England; [Birtle, A. J.] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England; [Brock, S.] Poole Hosp, Dorset Canc Ctr, Poole, Dorset, England; [Chakraborti, P.] Royal Derby Hosp, Derby, England; [Ferguson, C.] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Gale, J.] Queen Alexandra Hosp, Portsmouth Oncol Ctr, Portsmouth, Hants, England; [Gray, E.] Musgrove Pk Hosp, Taunton, Somerset, England; [Hingorani, M.] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England; [Hoskin, P. J.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Malik, Z. I.] Clatterbridge Canc Ctr, Wirral, Merseyside, England; [McKinna, F.] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England; [Robinson, A.] Royal Sussex Cty Hosp, Sussex Canc Ctr, Brighton, E Sussex, England; [McPhail, N.] NHS Highland, Inverness, Scotland; [Money-Kyrle, J.] Royal Surrey Cty Hosp, Guildford, Surrey, England; [O'Sullivan, J.] Northern Ireland Canc & Queens Univ, Belfast, Antrim, North Ireland; [Parikh, O.] Lancashire Teaching Hosp NHS Trust, Preston, Lancs, England; [Protheroe, A.] Churchill Hosp, Oxford, England; [Srihari, N. N.] Shrewsbury & Telford Hosp NHS Trust, Shrewsbury, Salop, England; [Thomas, C.] East Kent Hosp NHS Trust, Canterbury, Kent, England; [Wagstaff, J.] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Wylie, J.] Christie NHS Fdn Trust, Manchester, Lancs, England; [Gillessen, S.] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland; [Berthold, D. R.] Univ Lausanne Hosp, Lausanne, Switzerland	University of Birmingham; University of Birmingham; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Medical Research Council Clinical Trials Unit; University of London; University College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Salford Royal NHS Foundation Trust; Cardiff University; Velindre Cancer Centre; Gloucestershire Royal Hospital; Gloucestershire Hospitals NHS Foundation Trust; University of Glasgow; Saint James's University Hospital; Royal Preston Hospital; Poole Hospital; University of Nottingham; Weston Park Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Musgrove Park Hospital; Mount Vernon Cancer Centre; Clatterbridge Cancer Centre; Brighton and Sussex University Hospitals NHS Trust; University of Brighton; University of Brighton; Royal Surrey County Hospital; University of Oxford; Swansea University; Christie NHS Foundation Trust; Kantonsspital St. Gallen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	James, ND (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.	mrcctu.stampede_publications@ucl.ac.uk	Sydes, Matthew/C-3373-2008; Dearnaley, David P/J-2318-2014; Hingorani, M./AAQ-3416-2020; Mason, Malcolm D/H-6979-2013; James, Nick/AAL-6802-2020; Gillessen, Silke/C-6093-2019	Sydes, Matthew/0000-0002-9323-1371; Dearnaley, David P/0000-0002-3954-2806; Hingorani, M./0000-0003-4877-5174; de Bono, Johann S/0000-0002-2034-595X; Gillessen, Silke/0000-0001-5746-6555; James, Nicholas/0000-0002-7314-8204; Wagstaff, John/0000-0002-1140-5981; O'Sullivan, Joe/0000-0001-6999-2739; Brawley, Christopher/0000-0003-3641-278X; Hoskin, Peter/0000-0001-8323-9567	Cancer Research U.K.; Cancer Research UK [3804] Funding Source: researchfish; Medical Research Council [MC_UU_12023/25] Funding Source: researchfish	Cancer Research U.K.(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, NCT00268476, and Current Controlled Trials number, ISRCTN78818544.	Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Barthel FMS, 2009, STATA J, V9, P505, DOI 10.1177/1536867X0900900401; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Fitzpatrick JM, 2014, EUR UROL, V65, P1198, DOI 10.1016/j.eururo.2013.07.022; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; James ND, 2016, JAMA ONCOL, V2, P348, DOI 10.1001/jamaoncol.2015.4350; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; James ND, 2009, BJU INT, V103, P464, DOI 10.1111/j.1464-410X.2008.08034.x; James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002; Mason MD, 2017, J CLIN ONCOL, V35, P1530, DOI 10.1200/JCO.2016.69.0677; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Parmar MKB, 2008, JNCI-J NATL CANCER I, V100, P1204, DOI 10.1093/jnci/djn267; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Sydes M.R., 2011, TRIALS, Vvol. 12, pA3; Sydes MR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-168; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1	29	959	974	2	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2017	377	4					338	351		10.1056/NEJMoa1702900	http://dx.doi.org/10.1056/NEJMoa1702900			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BB	28578639	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000406295000006
J	Austin, L; Ewing, G; Grande, G				Austin, Lynn; Ewing, Gail; Grande, Gunn			Factors influencing practitioner adoption of carer-led assessment in palliative homecare: A qualitative study of the use of the Carer Support Needs Assessment Tool (CSNAT)	PLOS ONE			English	Article							OF-LIFE CARE; CAREGIVERS	Introduction Informal caregivers play a pivotal role in supporting patients approaching the end of life. The Carer Support Needs Assessment Tool (CSNAT) is designed to facilitate person-centred assessment and support through a process that is practitioner-facilitated, but carer-led. This study explored practitioners' experiences of implementing the CSNAT in palliative homecare. Methods We conducted qualitative interviews/focus groups with 20 practitioners in one UK hospice homecare service (18 nurses, two healthcare assistants) before and after the implementation of the CSNAT. Thematic analysis of the data was underpinned by framework analysis. Results Not all practitioners appreciated that using the CSNAT required a shift towards a more person-centred approach to assessment; consequently they tagged the tool onto their existing practitioner-led practice. Practitioners who did use the CSNAT as intended were able to act as role models and support their colleagues in making this transition. Practitioners' comments revealed a number of contradictions: 1) Most felt that they 'already do' identify carer support needs, but feared using the CSNAT could increase their workload; 2) some worried about introducing the CSNAT 'too soon', but recognised that it was 'too late' once patients were close to the end of life; 3) whilst practitioners stated 'they were there for the family as well as the patient', care provision was overtly centred around patients. Conclusion This study provides vital insights into barriers and facilitators to implementing the CSNAT as part of a person-centred approach to assessment. The findings identified the training and support required to help practitioners make this transition to this new way of working.	[Austin, Lynn] Univ Manchester, Fac Biol Med & Hlth Sci, Ctr Primary Care, Manchester, Lancs, England; [Ewing, Gail] Univ Cambridge, Ctr Family Res, Cambridge, England; [Grande, Gunn] Univ Manchester, Fac Biol Med & Hlth, Div Nursing Midwifery & Social Work, Manchester, Lancs, England	University of Manchester; University of Cambridge; University of Manchester	Austin, L (corresponding author), Univ Manchester, Fac Biol Med & Hlth Sci, Ctr Primary Care, Manchester, Lancs, England.	lynn.austin@manchester.ac.uk	Austin, Lynn/P-1255-2014	Austin, Lynn/0000-0003-4399-4554	Dimbleby Cancer Care	Dimbleby Cancer Care	This work was supported by the Dimbleby Cancer Care - grant number not allocated. Sole role was to fund the research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boot M, 2014, INT J PALLIAT NURS, V20, P9, DOI 10.12968/ijpn.2014.20.1.9; Canadian HPCA, 2013, MOD GUID HOSP PALL C; Connolly M, 2010, PATIENT EDUC COUNS, V79, P87, DOI 10.1016/j.pec.2009.06.004; Deeken JF, 2003, J PAIN SYMPTOM MANAG, V26, P922, DOI 10.1016/S0885-3924(03)00327-0; DH, 2009, END LIF CAR STRAT QU; DH, 2014, TRANSF PRIM CAR SAF; Ewing G, 2016, PALLIATIVE MED, V30, P392, DOI 10.1177/0269216315596662; Ewing Gail, 2015, Br J Community Nurs, V20, P580, DOI 10.12968/bjcn.2015.20.12.580; Ewing G, 2013, J PAIN SYMPTOM MANAG, V46, P395, DOI 10.1016/j.jpainsymman.2012.09.008; Ewing G, 2013, PALLIATIVE MED, V27, P244, DOI 10.1177/0269216312440607; Fields A, 2013, INT J PALLIAT NURS, V19, P558, DOI 10.12968/ijpn.2013.19.11.558; Hileman J W, 1992, Oncol Nurs Forum, V19, P771; Hill HC, 2014, PALLIATIVE MED, V28, P256, DOI 10.1177/0269216313499960; HM Government, 2008, CAR HEART 21 CENT FA; HTH, 2009, ID CAR NEEDS PALL SE; Hudson PL, 2010, PALLIATIVE MED, V24, P656, DOI 10.1177/0269216310373167; Levesque L, 2010, INT J NURS STUD, V47, P876, DOI 10.1016/j.ijnurstu.2009.12.006; National Cancer Action Team, 2010, PROGRAM NATL END LIF; National Council for Palliative Care (NCPC), 2012, WHO CAR SUPP CAR PEO; National Institute for Health and Care Excellence (NICE), 2004, IMPR SUPP PALL CAR A; NCAT, 2011, HOL NEEDS ASS PEOPL; NHS England, 2014, NHS ENG COMM CAR; NHS Improving Quality, 2014, COMM CAR REP FIND OU; NHS Institute for Innovation and Improvement, 2009, SUST GUID; Osse BHP, 2006, CANCER NURS, V29, P378, DOI 10.1097/00002820-200609000-00005; Palliative Care Australia, 2005, STAND PROV QUAL PALL; Payne S., 2013, SUPPORTING FAMILY CA; Ritchie J, 2003, QUALITATIVE RES; Salmon Jennifer R, 2005, Am J Hosp Palliat Care, V22, P188, DOI 10.1177/104990910502200307; Stajduhar KI, 2010, PALLIATIVE MED, V24, P573, DOI 10.1177/0269216310371412; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042	31	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2017	12	6							e0179287	10.1371/journal.pone.0179287	http://dx.doi.org/10.1371/journal.pone.0179287			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX8NF	28622348	Green Submitted, gold, Green Published			2023-01-03	WOS:000403506300019
J	Prada, ETA; Orth, M; Nolting, S; Spottl, G; Maurer, J; Auernhammer, C				Prada, Elke Tatjana Aristizabal; Orth, Michael; Noelting, Svenja; Spoettl, Gerald; Maurer, Julian; Auernhammer, Christoph			The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells	PLOS ONE			English	Article							OXIDATIVE STRESS; RADIATION ONCOLOGY; CANCER-TREATMENT; MTOR INHIBITORS; DNA-DAMAGE; DNTP POOL; PATHWAY; RESISTANCE; THERAPY; GROWTH	Modulation of the redox system in cancer cells has been considered a promising target for anti-cancer therapy. The novel MTH1 inhibitor TH588 proved tremendous potential in terms of cancer cell eradication, yet its specificity has been questioned by recent reports, indicating that TH588 may also induce cancer cell death by alternative mechanisms than MTH1 inhibition. Here we used a panel of heterogeneous neuroendocrine tumor cells in order to assess cellular mechanisms and molecular signaling pathways implicated in the effects of TH588 alone as well as dual-targeting approaches combining TH588 with everolimus, cytotoxic 5-fluorouracil or Y-irradiation. Our results reflect that TH588 alone efficiently decreased the survival of neuroendocrine cancer cells by PI3K-Akt-mTOR axis downregulation, increased apoptosis and oxidative stress. However, in the dual-targeting approaches cell survival was further decreased due to an even stronger downregulation of the PI3K-Akt-mTOR axis and augmentation of apoptosis but not oxidative stress. Furthermore, we could attribute TH588 chemo- and radio-sensitizing properties. Collectively our data not only provide insights into how TH588 exactly kills cancer cells but also depict novel perspectives for combinatorial treatment approaches encompassing TH588.	[Prada, Elke Tatjana Aristizabal; Noelting, Svenja; Spoettl, Gerald; Maurer, Julian; Auernhammer, Christoph] Ludwig Maximilians Univ Munchen, Interdisciplinary Ctr Neuroendocrine Tumours Gast, Univ Hosp, Dept Internal Med 2, Campus Grosshadern, Bavaria, Germany; [Orth, Michael] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Campus Grosshadern, Bavaria, Germany	University of Munich; University of Munich	Auernhammer, C (corresponding author), Ludwig Maximilians Univ Munchen, Interdisciplinary Ctr Neuroendocrine Tumours Gast, Univ Hosp, Dept Internal Med 2, Campus Grosshadern, Bavaria, Germany.	christoph.auernhammer@med.uni-muenchen.de	Orth, Michael/AAQ-7299-2021	Orth, Michael/0000-0002-4608-7151; Nolting, Svenja/0000-0002-7064-590X				Babu V, 2013, PANCREAS, V42, P912, DOI 10.1097/MPA.0b013e31827ae993; Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451; Cakir M, 2011, EXPERT OPIN THER TAR, V15, P457, DOI 10.1517/14728222.2011.555403; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Capozzi M, 2015, INT J SURG, V21, pS89, DOI 10.1016/j.ijsu.2015.06.064; Chan DL, 2017, THER ADV GASTROENTER, V10, P132, DOI 10.1177/1756283X16674660; CHENG KC, 1992, J BIOL CHEM, V267, P166; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; EVERS BM, 1991, GASTROENTEROLOGY, V101, P303, DOI 10.1016/0016-5085(91)90004-5; Fujikawa K, 2001, NUCLEIC ACIDS RES, V29, P449, DOI 10.1093/nar/29.2.449; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Georgakilas AG, 2012, CANCER LETT, V327, P3, DOI 10.1016/j.canlet.2012.03.032; Haghdoost S, 2006, FREE RADICAL BIO MED, V41, P620, DOI 10.1016/j.freeradbiomed.2006.05.003; He K, 2016, ONCOTARGET; Hennel R, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-85; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Kawamura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26521; Kettle JG, 2016, J MED CHEM, V59, P2346, DOI 10.1021/acs.jmedchem.5b01760; Klaunig JE, 2011, TOXICOL APPL PHARM, V254, P86, DOI 10.1016/j.taap.2009.11.028; Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453; Kolby L, 2001, AM J PATHOL, V158, P745, DOI 10.1016/S0002-9440(10)64017-5; Kong LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137888; Leung EY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131400; Luo MH, 2010, ANTIOXID REDOX SIGN, V12, P1247, DOI 10.1089/ars.2009.2698; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nolting S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143830; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Orth M, 2014, RADIAT ENVIRON BIOPH, V53, P1, DOI 10.1007/s00411-013-0497-2; Pavel ME, 2011, LANCET, V378, P2005, DOI 10.1016/S0140-6736(11)61742-X; Petrocchi A, 2016, BIOORG MED CHEM LETT, V26, P1503, DOI 10.1016/j.bmcl.2016.02.026; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Reuther C, 2016, NEUROENDOCRINOLOGY, V103, P383, DOI 10.1159/000439431; Ringborg U, 2003, ACTA ONCOL, V42, P357, DOI 10.1080/02841860310010826; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shipkova M, 2016, THER DRUG MONIT, V38, P143, DOI 10.1097/FTD.0000000000000260; Spampatti M, 2014, WORLD J GASTROENTERO, V20, P10038, DOI 10.3748/wjg.v20.i29.10038; Tong LY, 2015, CANCER LETT, V367, P18, DOI 10.1016/j.canlet.2015.07.008; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tu YY, 2016, AM J TRANSL RES, V8, P2803; Vandamme T, 2016, BRIT J CANCER, V114, P650, DOI 10.1038/bjc.2016.25; Vera-Ramirez L, 2012, CANCER LETT, V327, P134, DOI 10.1016/j.canlet.2011.12.029; Wagle N, 2014, NEW ENGL J MED, V371, P1426, DOI 10.1056/NEJMoa1403352; Wang JY, 2016, J INVESTIGATIVE DERM; Warpman Berglund U, 2016, ANN ONCOLOGY OFFICIA; Wolin EM, 2013, CANCER LETT, V335, P1, DOI 10.1016/j.canlet.2013.02.016; Yao JC, 2016, LANCET, V387, P968, DOI 10.1016/S0140-6736(15)00817-X; Yao JC, 2016, J CLIN ONCOLOGY OFFI; Zatelli MC, 2016, ENDOCR-RELAT CANCER, V23, pR173, DOI 10.1530/ERC-15-0413; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005; Zitzmann K, 2007, NEUROENDOCRINOLOGY, V85, P54, DOI 10.1159/000100057	51	11	12	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2017	12	5							e0178375	10.1371/journal.pone.0178375	http://dx.doi.org/10.1371/journal.pone.0178375			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VR	28542590	Green Published, Green Accepted, gold			2023-01-03	WOS:000402062800083
J	Rafacho, BPM; dos Santos, PP; Goncalves, AD; Fernandes, AAH; Okoshi, K; Chiuso-Minicucci, F; Azevedo, PS; Zornoff, LAM; Minicucci, MF; Wang, XD; de Paiva, SAR				Murino Rafacho, Bruna Paola; dos Santos, Priscila Portugal; Goncalves, Andrea de Freitas; Henrique Fernandes, Ana Angelica; Okoshi, Katashi; Chiuso-Minicucci, Fernanda; Azevedo, Paula S.; Mamede Zornoff, Leonardo Antonio; Minicucci, Marcos Ferreira; Wang, Xiang-Dong; Rupp de Paiva, Sergio Alberto			Rosemary supplementation (Rosmarinus oficinallis L.) attenuates cardiac remodeling after myocardial infarction in rats	PLOS ONE			English	Article							OXIDATIVE STRESS; DIASTOLIC DYSFUNCTION; HEART-FAILURE; ANTIOXIDANT; ACID; SIZE; RECOMMENDATIONS; OFFICINALIS; ASSOCIATION; INHIBITION	Background Myocardial infarction (MI) is one of the leading causes of morbidity and mortality worldwide. Dietary intervention on adverse cardiac remodeling after MI has significant clinical relevance. Rosemary leaves are a natural product with antioxidant/anti-inflammatory properties, but its effect on morphology and ventricular function after MI is unknown. Methods and results To determine the effect of the dietary supplementation of rosemary leaves on cardiac remodeling after MI, male Wistar rats were divided into 6 groups after sham procedure or experimental induced MI: 1) Sham group fed standard chow (SR0, n = 23); 2) Sham group fed standard chow supplemented with 0.02% rosemary (R002) (SR002, n = 23); 3) Sham group fed standard chow supplemented with 0.2% rosemary (R02) (SR02, n = 22); 4) group submitted to MI and fed standard chow (IR0, n = 13); 5) group submitted to MI and fed standard chow supplemented with R002 (IR002, n = 8); and 6) group submitted to MI and fed standard chow supplemented with R02 (IR02, n = 9). After 3 months of the treatment, systolic pressure evaluation, echocardiography and euthanasia were performed. Left ventricular samples were evaluated for: fibrosis, cytokine levels, apoptosis, energy metabolism enzymes, and oxidative stress. Rosemary dietary supplementation attenuated cardiac remodeling by improving energy metabolism and decreasing oxidative stress. Rosemary supplementation of 0.02% improved diastolic function and reduced hypertrophy after MI. Regarding rosemary dose, 0.02% and 0.2% for rats are equivalent to 11 mg and 110 mg for humans, respectively. Conclusion Our findings support further investigations of the rosemary use as adjuvant therapy in adverse cardiac remodeling.	[Murino Rafacho, Bruna Paola; dos Santos, Priscila Portugal; Goncalves, Andrea de Freitas; Okoshi, Katashi; Chiuso-Minicucci, Fernanda; Azevedo, Paula S.; Mamede Zornoff, Leonardo Antonio; Minicucci, Marcos Ferreira; Rupp de Paiva, Sergio Alberto] UNESP, Internal Med Dept, Botucatu Med Sch, Botucatu, SP, Brazil; [Henrique Fernandes, Ana Angelica] UNESP, Dept Biochem, Botucatu Biosci Inst, Botucatu, SP, Brazil; [Chiuso-Minicucci, Fernanda] UNESP, Dept Microbiol & Immunol, Botucatu Biosci Inst, Botucatu, SP, Brazil; [Wang, Xiang-Dong] Tufts Univ, Nutr & Canc Biol Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista; Tufts University; United States Department of Agriculture (USDA)	Rafacho, BPM (corresponding author), UNESP, Internal Med Dept, Botucatu Med Sch, Botucatu, SP, Brazil.	bpmrafacho@alunos.fmb.unesp.br	Rafacho, Bruna Paola Murino/B-5460-2013; Rafacho, Bruna Paola Murino/AGW-5794-2022; Fernandes, Ana Angelica Henrique/D-5291-2012; Minicucci, Fernanda C/A-9220-2015; wang, xiao/HGB-7081-2022; Minicucci, Marcos F/A-9094-2008; Zornoff, Leonardo/A-5612-2008; Paiva, Sergio AR/A-5101-2008; Okoshi, Katashi/A-3955-2011; Azevedo, Paula Schmidt/S-1597-2019; dos Santos, Priscila Portugal/U-5345-2018	Rafacho, Bruna Paola Murino/0000-0001-8825-6980; Rafacho, Bruna Paola Murino/0000-0001-8825-6980; Minicucci, Fernanda C/0000-0002-4155-6414; wang, xiao/0000-0002-4088-3341; Minicucci, Marcos F/0000-0002-5980-4367; Zornoff, Leonardo/0000-0002-9831-8820; Paiva, Sergio AR/0000-0003-4412-1990; Okoshi, Katashi/0000-0001-8980-8839; Azevedo, Paula Schmidt/0000-0002-5843-6232; dos Santos, Priscila Portugal/0000-0003-1159-5030	National Council of Technological and Scientific Development [CNPq 140262/2011-3]; Sao Paulo Research Foundation [FAPESP 2011/08956-0, 2011/15059-5]	National Council of Technological and Scientific Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was funded by National Council of Technological and Scientific Development (CNPq 140262/2011-3) and Sao Paulo Research Foundation (FAPESP 2011/08956-0 and 2011/15059-5), Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, GUIDE CARE USE LAB A; Assalin HB, 2013, CIRC-HEART FAIL, V6, P809, DOI 10.1161/CIRCHEARTFAILURE.112.000298; Baba K, 2013, J BIOL CHEM, V288, P18393, DOI 10.1074/jbc.M112.438762; Bai NS, 2010, J AGR FOOD CHEM, V58, P5363, DOI 10.1021/jf100332w; Botsoglou N, 2010, FOOD CHEM TOXICOL, V48, P944, DOI 10.1016/j.fct.2010.01.004; Burneiko RCM, 2006, FOOD CHEM TOXICOL, V44, P1167, DOI 10.1016/j.fct.2006.01.004; Buttros JB, 2009, PHARMACOLOGY, V84, P29, DOI 10.1159/000222245; Cheung S, 2007, ONCOL REP, V17, P1525; Chohan M, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-578; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Csonka C, 2010, J PHARMACOL TOX MET, V61, P163, DOI 10.1016/j.vascn.2010.02.014; de Paiva SAR, 2003, AM J PHYSIOL-HEART C, V284, pH2242, DOI 10.1152/ajpheart.00646.2002; dos Santos PP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098895; Eilat-Adar S, 2013, NUTRIENTS, V5, P3646, DOI 10.3390/nu5093646; Ewing JF, 1995, ANAL BIOCHEM, V232, P243, DOI 10.1006/abio.1995.0014; Forman HJ, 2014, FREE RADICAL BIO MED, V66, P24, DOI 10.1016/j.freeradbiomed.2013.05.045; Genena AK, 2008, CIENCIA TECNOL ALIME, V28, P463, DOI 10.1590/S0101-20612008000200030; Gilbert B, 2003, CURR MED CHEM, V10, P13, DOI 10.2174/0929867033368583; Goncalves AF, 2015, CELL PHYSIOL BIOCHEM, V35, P259, DOI 10.1159/000369693; HARAGUCHI H, 1995, PLANTA MED, V61, P333, DOI 10.1055/s-2006-958094; Hori M, 2009, CARDIOVASC RES, V81, P457, DOI 10.1093/cvr/cvn335; Idikio HA, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/836806; Jeong EM, 2015, CIRC J, V79, P470, DOI 10.1253/circj.CJ-15-0064; Karthik D, 2011, J CARDIOVASC PHARM, V58, P514, DOI 10.1097/FJC.0b013e31822c265d; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lian KC, 2010, TOXICOL APPL PHARM, V245, P21, DOI 10.1016/j.taap.2010.01.003; Liu QF, 2016, J AGR FOOD CHEM, V64, P6716, DOI 10.1021/acs.jafc.6b03001; Liu TT, 2014, LIFE SCI, V101, P27, DOI 10.1016/j.lfs.2014.02.004; Lustosa BB, 2016, INT J CARDIOL, V225, P147, DOI 10.1016/j.ijcard.2016.09.092; Madamanchi NR, 2013, FREE RADICAL BIO MED, V61, P473, DOI 10.1016/j.freeradbiomed.2013.04.001; Minicucci MF, 2014, ARQ BRAS CARDIOL, V102, P549, DOI 10.5935/abc.20140051; Minicucci MF, 2011, INT J CARDIOL, V151, P242, DOI 10.1016/j.ijcard.2011.06.068; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Mozaffarian D, 2011, CIRCULATION, V123, P2870, DOI 10.1161/CIRCULATIONAHA.110.968735; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Paiva SAR, 2005, J NUTR, V135, P2109, DOI 10.1093/jn/135.9.2109; Peng CH, 2007, BIOSCI BIOTECH BIOCH, V71, P2223, DOI 10.1271/bbb.70199; Perez-Fons L, 2010, J AGR FOOD CHEM, V58, P161, DOI 10.1021/jf9026487; Pfeffer JM, 2000, CARDIOVASC DRUG THER, V14, P579, DOI 10.1023/A:1007890126061; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; Polegato BF, 2016, ARQ BRAS CARDIOL, V106, P105, DOI 10.5935/abc.20160015; Posadas SJ, 2009, EXP GERONTOL, V44, P383, DOI 10.1016/j.exger.2009.02.015; Punithavathi VR, 2010, LIFE SCI, V86, P178, DOI 10.1016/j.lfs.2009.11.021; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Retelny VS, 2008, NUTR CLIN PRACT, V23, P468, DOI 10.1177/0884533608323425; Ristow M, 2014, DOSE-RESPONSE, V12, P288, DOI 10.2203/dose-response.13-035.Ristow; Rustin P, 2002, EUR J HUM GENET, V10, P289, DOI 10.1038/sj.ejhg.5200793; Sadzuka Y, 1997, TOXICOL LETT, V92, P1, DOI 10.1016/S0378-4274(97)00028-3; Sahu BD, 2014, MOL CELL BIOCHEM, V394, P163, DOI 10.1007/s11010-014-2092-5; Saks V, 2006, J PHYSIOL-LONDON, V577, P769, DOI 10.1113/jphysiol.2006.120584; Scheckel KA, 2008, J NUTR, V138, P2098, DOI 10.3945/jn.108.090431; SPADARO J, 1980, ARCH PATHOL LAB MED, V104, P179; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; Sun DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033491; Sun GB, 2012, TOXICOL APPL PHARM, V265, P229, DOI 10.1016/j.taap.2012.10.002; Sun Y, 2009, CARDIOVASC RES, V81, P482, DOI 10.1093/cvr/cvn333; Tamaki Y, 2010, PLANTA MED, V76, P683, DOI 10.1055/s-0029-1240622; van Deel ED, 2008, FREE RADICAL BIO MED, V44, P1305, DOI 10.1016/j.freeradbiomed.2007.12.007; WEBER KT, 1994, J MOL CELL CARDIOL, V26, P279, DOI 10.1006/jmcc.1994.1036; WOLFE CL, 1993, CIRCULATION, V87, P881, DOI 10.1161/01.CIR.87.3.881; Zhou SS, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/260429; Zhu YZ, 2004, NAT PROD REP, V21, P478, DOI 10.1039/b304821g; Zornoff LAM, 2006, NUTRITION, V22, P146, DOI 10.1016/j.nut.2005.05.008; Zornoff LAM, 2009, ARQ BRAS CARDIOL, V93, P434, DOI 10.1590/S0066-782X2009001000018; Zornoff LAM, 2009, ARQ BRAS CARDIOL, V92, P157, DOI 10.1590/S0066-782X2009000200013	65	15	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177521	10.1371/journal.pone.0177521	http://dx.doi.org/10.1371/journal.pone.0177521			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UP	28494028	Green Submitted, Green Published, gold			2023-01-03	WOS:000401314300128
J	Rohaut, B; Porcher, R; Hissem, T; Heming, N; Chillet, P; Djedaini, K; Moneger, G; Kandelman, S; Allary, J; Cariou, A; Sonneville, R; Polito, A; Antona, M; Azabou, E; Annane, D; Siami, S; Chretien, F; Mantz, J; Sharshar, T				Rohaut, Benjamin; Porcher, Raphael; Hissem, Tarik; Heming, Nicholas; Chillet, Patrick; Djedaini, Kamel; Moneger, Guy; Kandelman, Stanislas; Allary, Jeremy; Cariou, Alain; Sonneville, Romain; Polito, Andrea; Antona, Marion; Azabou, Eric; Annane, Djillali; Siami, Shidasp; Chretien, Fabrice; Mantz, Jean; Sharshar, Tarek		Grp Exploration Neurologique	Brainstem response patterns in deeply-sedated critically-ill patients predict 28-day mortality	PLOS ONE			English	Article							MECHANICALLY VENTILATED PATIENTS; INTENSIVE-CARE SEDATION; LONG-TERM MORTALITY; POINT-PREVALENCE; ICU PATIENTS; COMA SCALE; DELIRIUM; MULTICENTER; RELIABILITY; VALIDATION	Background and purpose Deep sedation is associated with acute brain dysfunction and increased mortality. We had previously shown that early-assessed brainstem reflexes may predict outcome in deeply sedated patients. The primary objective was to determine whether patterns of brainstem reflexes might predict mortality in deeply sedated patients. The secondary objective was to generate a score predicting mortality in these patients. Methods Observational prospective multicenter cohort study of 148 non-brain injured deeply sedated patients, defined by a Richmond Assessment sedation Scale ( RASS) <-3. Brainstem reflexes and Glasgow Coma Scale were assessed within 24 hours of sedation and categorized using latent class analysis. The Full Outline Of Unresponsiveness score ( FOUR) was also assessed. Primary outcome measure was 28-day mortality. A "Brainstem Responses Assessment Sedation Score " (BRASS) was generated. Results Two distinct sub-phenotypes referred as homogeneous and heterogeneous brainstem reactivity were identified (accounting for respectively 54.6% and 45.4% of patients). Homogeneous brainstem reactivity was characterized by preserved reactivity to nociceptive stimuli and a partial and topographically homogenous depression of brainstem reflexes. Heterogeneous brainstem reactivity was characterized by a loss of reactivity to nociceptive stimuli associated with heterogeneous brainstem reflexes depression. Heterogeneous sub-phenotype was a predictor of increased risk of 28-day mortality after adjustment to Simplified Acute Physiology Score-II (SAPS-II) and RASS (Odds Ratio [95% confidence interval] = 6.44 [2.63-15.8]; p< 0.0001) or Sequential Organ Failure Assessment (SOFA) and RASS (OR [95% CI] = 5.02 [2.01-12.5]; p = 0.0005). The BRASS (and marginally the FOUR) predicted 28-day mortality (c-index [95% CI] = 0.69 [0.54-0.84] and 0.65 [0.49- 0.80] respectively). Conclusion In this prospective cohort study, around half of all deeply sedated critically ill patients displayed an early particular neurological sub-phenotype predicting 28-day mortality, which may reflect a dysfunction of the brainstem.	[Rohaut, Benjamin] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Intens Care Unit, Paris, France; [Rohaut, Benjamin] UPMC Univ Paris 06, Sorbonne Univ, Fac Med Pitie Salpetriere, Paris, France; [Rohaut, Benjamin] Inst Cerveau & Moelle Epiniere, ICM, PICNIC Lab, Paris, France; [Rohaut, Benjamin] INSERM, U1127, Paris, France; [Porcher, Raphael] Descartes Univ, Hotel Dieu Hosp, AP HP, Ctr Clin Epidemiol, Paris, France; [Hissem, Tarik; Siami, Shidasp] Sud Essonne Hosp, Gen Intens Care Unit, Etampes, France; [Heming, Nicholas; Moneger, Guy; Polito, Andrea; Annane, Djillali; Sharshar, Tarek] Univ Versailles St Quentin Yvelines, Raymond Poincare Hosp, AP HP, Gen Intens Care Unit, Garches, France; [Chillet, Patrick] Chalons En Champagne Hosp, Gen Intens Care Unit, Chalons Sur Marne, France; [Djedaini, Kamel] Geoffroy St Hilaire Hosp, Gen Intens Care Unit, Paris, France; [Kandelman, Stanislas; Allary, Jeremy] Diderot Univ, Beaujon Claude Bernard Hosp, AP HP, Dept Anesthesiol, Paris, France; [Kandelman, Stanislas; Allary, Jeremy] Diderot Univ, Beaujon Claude Bernard Hosp, AP HP, Intens Care Unit, Paris, France; [Cariou, Alain] Descartes Univ, Cochin Hosp, AP HP, Intens Care Unit, Paris, France; [Sonneville, Romain] Diderot Univ, Bichat Claude Bernard Hosp, AP HP, Med Intens Care Unit, Paris, France; [Antona, Marion] Descartes Univ, Cochin Hosp, AP HP, Surg Intens Care Unit, Paris, France; [Azabou, Eric] Univ Versailles St Quentin Yvelines, Raymond Poincare Hosp, AP HP, Dept Physiol, Garches, France; [Chretien, Fabrice; Mantz, Jean; Sharshar, Tarek] Pasteur Inst, Lab Human Histopathol & Anim Models, Paris, France; [Chretien, Fabrice] Descartes Univ, St Anne Hosp, Dept Neuropathol, Paris, France; [Mantz, Jean] Descartes Univ, Georges Pompidou European Hosp, AP HP, Dept Anesthesiol, Paris, France; [Mantz, Jean] Descartes Univ, Georges Pompidou European Hosp, AP HP, Intens Care Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Sharshar, T (corresponding author), Univ Versailles St Quentin Yvelines, Raymond Poincare Hosp, AP HP, Gen Intens Care Unit, Garches, France.; Sharshar, T (corresponding author), Pasteur Inst, Lab Human Histopathol & Anim Models, Paris, France.	tsharshar@gmail.com	Sonneville, Romain/AAE-7039-2020; Annane, Djillali/R-7947-2019; Rohaut, Benjamin/O-9250-2017; Chretien, fabrice B/D-4035-2018; Sharshar, Tarek/ABF-4117-2021	Sonneville, Romain/0000-0003-0245-309X; Rohaut, Benjamin/0000-0001-6752-8756; Chretien, fabrice B/0000-0002-2794-1383; Porcher, Raphael/0000-0002-5277-4679				Annane D, 1999, AM J RESP CRIT CARE, V160, P458, DOI 10.1164/ajrccm.160.2.9810073; [Anonymous], 2012, R LANG ENV STAT COMP; Balzer F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0929-2; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Boisseau N, 2002, BRIT J ANAESTH, V88, P785, DOI 10.1093/bja/88.6.785; Collins L. M., 2013, LATENT CLASS LATENT, V718; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Elliott D, 2013, CRIT CARE RESUSC, V15, P213; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Grap MJ, 2012, AM J CRIT CARE, V21, pE53, DOI 10.4037/ajcc2012301; Grp ST, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-24; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Lazarsfeld PF, 1968, LATENT STRUCTURE ANA; Le Gall JR, 2005, CRIT CARE, V9, pR645, DOI 10.1186/cc3821; LECESSIE S, 1991, BIOMETRICS, V47, P1267, DOI 10.2307/2532385; Linzer DA, 2011, J STAT SOFTW, V42, P1, DOI 10.18637/jss.v042.i10; Liu EHC, 2005, BRIT J ANAESTH, V94, P193, DOI 10.1093/bja/aei003; Nydahl P, 2014, CRIT CARE MED, V42, P1178, DOI 10.1097/CCM.0000000000000149; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Rotheray KR, 2012, RESUSCITATION, V83, P86, DOI 10.1016/j.resuscitation.2011.07.017; Sauder P, 2008, ANN FR ANESTH, V27, P541, DOI 10.1016/j.annfar.2008.04.021; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4; Sharshar T, 2002, CRIT CARE MED, V30, P2371, DOI 10.1097/00003246-200210000-00031; Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b; Shehabi Y, 2013, CRIT CARE, V17, DOI 10.1186/cc12679; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Treggiari MM, 2009, CRIT CARE MED, V37, P2527, DOI 10.1097/CCM.0b013e3181a5689f; van den Boogaard M, 2014, INTENS CARE MED, V40, P361, DOI 10.1007/s00134-013-3202-7; van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wurpts IC, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00920	39	23	23	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2017	12	4							e0176012	10.1371/journal.pone.0176012	http://dx.doi.org/10.1371/journal.pone.0176012			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET5FE	28441453	Green Submitted, Green Published, gold			2023-01-03	WOS:000400308800018
J	Belinova, L; Kahleova, H; Malinska, H; Topolcan, O; Windrichova, J; Oliyarnyk, O; Kazdova, L; Hill, M; Pelikanova, T				Belinova, Lenka; Kahleova, Hana; Malinska, Hana; Topolcan, Ondrej; Windrichova, Jindra; Oliyarnyk, Olena; Kazdova, Ludmila; Hill, Martin; Pelikanova, Terezie			The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study	PLOS ONE			English	Article							DEPENDENT INSULINOTROPIC POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; INDUCED WEIGHT-LOSS; GASTRIC BYPASS-SURGERY; PLASMA GHRELIN LEVELS; DIET-INDUCED OBESITY; BETA-CELL FUNCTION; FOOD-INTAKE; GENDER-DIFFERENCES; PHYSICAL-ACTIVITY	Background Appetite and gastrointestinal hormones (GIHs) participate in energy homeostasis, feeding behavior and regulation of body weight. We demonstrated previously the superior effect of a hypocaloric diet regimen with lower meal frequency (B2) on body weight, hepatic fat content, insulin sensitivity and feelings of hunger compared to the same diet divided into six smaller meals a day (A6). Studies with isoenergetic diet regimens indicate that lower meal frequency should also have an effect on fasting and postprandial responses of GIHs. The aim of this secondary analysis was to explore the effect of two hypocaloric diet regimens on fasting levels of appetite and GIHs and on their postprandial responses after a standard meal. It was hypothesized that lower meal frequency in a reduced-energy regimen leading to greater body weight reduction and reduced hunger would be associated with decreased plasma concentrations of GIHs: gastric inhibitory peptide (GIP), glucagon-like peptide-1(GLP-1), peptide YY(PYY), pancreatic polypeptide (PP) and leptin and increased plasma concentration of ghrelin. The postprandial response of satiety hormones (GLP-1, PYY and PP) and postprandial suppression of ghrelin will be improved. Methods In a randomized crossover study, 54 patients suffering from type 2 diabetes (T2D) underwent both regimens. The concentrations of GLP-1, GIP, PP, PYY, amylin, leptin and ghrelin were determined using multiplex immunoanalyses. Results Fasting leptin and GIP decreased in response to both regimens with no difference between the treatments (p = 0.37 and p = 0.83, respectively). Fasting ghrelin decreased in A6 and increased in B2 (with difference between regimens p = 0.023). Fasting PP increased in B2with no significant difference between regimens (p = 0.17). Neither GLP-1 nor PYY did change in either regimen. The decrease in body weight correlated negatively with changes in fasting ghrelin (r = -0.4, p<0.043) and the postprandial reduction of ghrelin correlated positively with its fasting level (r = 0.9, p<0.001). The postprandial responses of GIHs and appetite hormones were similar after both diet regimens. Conclusions Both hypocaloric diet regimens reduced fasting leptin and GIP and postprandial response of GIP comparably. The postprandial responses of GIHs and appetite hormones were similar after both diet regimens. Eating only breakfast and lunch increased fasting plasma ghrelin more than the same caloric restriction split into six meals. The changes in fasting ghrelin correlated negatively with the decrease in body weight. These results suggest that for type 2 diabetic patients on a hypocaloric diet, eating larger breakfast and lunch may be more efficient than six smaller meals during the day.	[Belinova, Lenka; Kahleova, Hana; Malinska, Hana; Oliyarnyk, Olena; Kazdova, Ludmila; Pelikanova, Terezie] Inst Clin & Expt Med Prague, Dept Diabetol, Prague, Czech Republic; [Belinova, Lenka] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Topolcan, Ondrej; Windrichova, Jindra] Univ Hosp Plzen, Lab Immunoanal, Plzen, Czech Republic; [Hill, Martin] Inst Endocrinol, Dept Steroid Hormones & Proteohormones, Prague, Czech Republic	Institute for Clinical & Experimental Medicine (IKEM); Charles University Prague; University Hospital Plzen; Institute of Endocrinology - Prague	Belinova, L (corresponding author), Inst Clin & Expt Med Prague, Dept Diabetol, Prague, Czech Republic.; Belinova, L (corresponding author), Charles Univ Prague, Fac Med 1, Prague, Czech Republic.	bell@ikem.cz	Hill, Martin/G-7699-2019; Topolcan, Ondrej/K-7753-2017	Windrichova, Jindra/0000-0003-0365-0968; Topolcan, Ondrej/0000-0001-6622-390X; Hill, Martin/0000-0002-1705-0835; Oliyarnyk, Olena/0000-0002-4912-6187				de Luis DA, 2008, NUTRITION, V24, P162, DOI 10.1016/j.nut.2007.11.001; Aronne L, 2007, J CLIN ENDOCR METAB, V92, P2977, DOI 10.1210/jc.2006-2003; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Batterham RL, 2007, NATURE, V450, P106, DOI 10.1038/nature06212; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Batterham RL, 2003, J CLIN ENDOCR METAB, V88, P3989, DOI 10.1210/jc.2003-030630; Belinova L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107561; Blom WAM, 2009, PHYSIOL BEHAV, V96, P742, DOI 10.1016/j.physbeh.2009.01.016; Chan JL, 2006, DIABETOLOGIA, V49, P169, DOI 10.1007/s00125-005-0041-2; Chandarana K, 2009, GASTROENTEROLOGY, V136, P2115, DOI 10.1053/j.gastro.2009.02.047; Cummings DE, 2004, AM J PHYSIOL-ENDOC M, V287, pE297, DOI 10.1152/ajpendo.00582.2003; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; de Luis DA, 2007, ANN NUTR METAB, V51, P134, DOI 10.1159/000103273; DelPparigi A, 2002, J CLIN ENDOCR METAB, V87, P5461, DOI 10.1210/jc.2002-020871; DePaula AL, 2008, SURG ENDOSC, V22, P706, DOI 10.1007/s00464-007-9472-9; Duval K, 2008, AM J CLIN NUTR, V88, P1200, DOI 10.3945/ajcn.2008.26220; English PJ, 2006, DIABETOLOGIA, V49, P2219, DOI 10.1007/s00125-006-0344-y; English PJ, 2002, J CLIN ENDOCR METAB, V87, P2984, DOI 10.1210/jc.87.6.2984; Enriori PJ, 2007, CELL METAB, V5, P181, DOI 10.1016/j.cmet.2007.02.004; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; Gerner T, 2014, SCAND J CLIN LAB INV, V74, P213, DOI 10.3109/00365513.2013.877594; Hagstromer M, 2006, PUBLIC HEALTH NUTR, V9, P755, DOI 10.1079/PHN2005898; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hellstrom L, 2000, J INTERN MED, V247, P457, DOI 10.1046/j.1365-2796.2000.00678.x; Hickey MS, 1996, BIOCHEM MOL MED, V59, P1, DOI 10.1006/bmme.1996.0056; Howarth NC, 2007, INT J OBESITY, V31, P675, DOI 10.1038/sj.ijo.0803456; Iepsen EW, 2016, EUR J ENDOCRINOL, V174, P775, DOI 10.1530/EJE-15-1116; Ishii S, 2016, J NUTR SCI VITAMINOL, V62, P40, DOI 10.3177/jnsv.62.40; Jakubowicz D, 2015, DIABETOLOGIA, V58, P912, DOI 10.1007/s00125-015-3524-9; Kahleova H, 2015, EUR J CLIN NUTR, V69, P755, DOI 10.1038/ejcn.2015.46; Kahleova H, 2014, DIABETOLOGIA, V57, P1552, DOI 10.1007/s00125-014-3253-5; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; Kellar KL, 2002, EXP HEMATOL, V30, P1227, DOI 10.1016/S0301-472X(02)00922-0; Kelly KR, 2009, AM J PHYSIOL-ENDOC M, V296, pE1269, DOI 10.1152/ajpendo.00112.2009; Kim BJ, 2005, J CLIN ENDOCR METAB, V90, P6665, DOI 10.1210/jc.2005-0409; le Roux CW, 2006, ENDOCRINOLOGY, V147, P3, DOI 10.1210/en.2005-0972; Leidy HJ, 2011, J NUTR, V141, P154, DOI 10.3945/jn.109.114389; Lutz TA, 2013, DIABETES OBES METAB, V15, P99, DOI 10.1111/j.1463-1326.2012.01670.x; Lutz TA, 2006, PHYSIOL BEHAV, V89, P465, DOI 10.1016/j.physbeh.2006.04.001; Malinska H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103565; Mann JI, 2004, NUTR METAB CARDIOVAS, V14, P373, DOI 10.1016/S0939-4753(04)80028-0; Mauvais-Jarvis F, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0033-y; McClean PL, 2007, AM J PHYSIOL-ENDOC M, V293, pE1746, DOI 10.1152/ajpendo.00460.2007; McCrory MA, 2011, J NUTR, V141, P144, DOI 10.3945/jn.109.114918; Meier JJ, 2010, DIABETES, V59, P1117, DOI 10.2337/db09-1899; Meier JJ, 2009, BEST PRACT RES CL EN, V23, P433, DOI 10.1016/j.beem.2009.03.007; Mekary RA, 2012, AM J CLIN NUTR, V95, P1182, DOI 10.3945/ajcn.111.028209; Meloun M, 2000, CLIN CHEM LAB MED, V38, P553, DOI 10.1515/CCLM.2000.081; Mishra AK, 2016, METABOLISM, V65, P48, DOI 10.1016/j.metabol.2015.10.008; Moran LJ, 2005, J CLIN ENDOCR METAB, V90, P5205, DOI 10.1210/jc.2005-0701; Munsters MJM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038632; Neary NM, 2005, ENDOCRINOLOGY, V146, P5120, DOI 10.1210/en.2005-0237; Nicklas BJ, 1997, OBES RES, V5, P62, DOI 10.1002/j.1550-8528.1997.tb00284.x; Palmer MA, 2009, NUTR REV, V67, P379, DOI 10.1111/j.1753-4887.2009.00204.x; Perry B, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2011.21; Purnell JQ, 2007, INT J OBESITY, V31, P385, DOI 10.1038/sj.ijo.0803401; Raynor Hollie A, 2015, Front Nutr, V2, P38, DOI 10.3389/fnut.2015.00038; Reinehr T, 2007, J PEDIATR GASTR NUTR, V44, P608, DOI 10.1097/MPG.0b013e3180406a24; Reutrakul S, 2014, CHRONOBIOL INT, V31, P64, DOI 10.3109/07420528.2013.821614; Roth JD, 2008, P NATL ACAD SCI USA, V105, P7257, DOI 10.1073/pnas.0706473105; SALERA M, 1982, J CLIN ENDOCR METAB, V55, P329, DOI 10.1210/jcem-55-2-329; Scharf MT, 2004, SEMIN LIVER DIS, V24, P335, DOI 10.1055/s-2004-860863; Schindler K, 2004, EUR J CLIN INVEST, V34, P549, DOI 10.1111/j.1365-2362.2004.01382.x; Skrha J, 2010, PHYSIOL RES, V59, P749, DOI 10.33549/physiolres.931893; Solomon TPJ, 2010, DIABETES CARE, V33, P1561, DOI 10.2337/dc09-2021; Stock S, 2005, J CLIN ENDOCR METAB, V90, P2161, DOI 10.1210/jc.2004-1251; TAI MM, 1991, AM J CLIN NUTR, V54, P783, DOI 10.1093/ajcn/54.5.783; Verdich C, 2001, INT J OBESITY, V25, P1206, DOI 10.1038/sj.ijo.0801655; Verdich C, 2001, J CLIN ENDOCR METAB, V86, P4382, DOI 10.1210/jc.86.9.4382; Wagenknecht M, 2007, Cas Lek Cesk, V146, P284; Wauters M, 2003, HORM METAB RES, V35, P92, DOI 10.1055/s-2003-39054; Weiss EP, 2015, DIABETES CARE, V38, P1253, DOI 10.2337/dc14-2913; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yildiz BO, 2004, P NATL ACAD SCI USA, V101, P10434, DOI 10.1073/pnas.0403465101; Young Andrew, 2005, Adv Pharmacol, V52, P79, DOI 10.1016/S1054-3589(05)52005-2	75	15	16	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2017	12	4							e0174820	10.1371/journal.pone.0174820	http://dx.doi.org/10.1371/journal.pone.0174820			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2IH	28369078	gold, Green Published, Green Submitted			2023-01-03	WOS:000399351000050
J	Ramdas, K; Darzi, A				Ramdas, Kamalini; Darzi, Ara			Adopting Innovations in Care Delivery - The Case of Shared Medical Appointments	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ramdas, Kamalini] London Business Sch, London, England; [Darzi, Ara] Imperial Coll London, St Marys Hosp, Dept Surg, London, England	University of London; London Business School; Imperial College London	Ramdas, K (corresponding author), London Business Sch, London, England.		ramdas, kamalini/M-9798-2014					ANGRIST JD, 1991, Q J ECON, V106, P979, DOI 10.2307/2937954; Miller AR, 2011, J POLIT ECON, V119, P289, DOI 10.1086/660083; Oddone E, 2012, SHARED MED APPOINTME; Ramdas K, 2012, HARVARD BUS REV, V90, P98	4	26	27	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2017	376	12					1105	1107		10.1056/NEJMp1612803	http://dx.doi.org/10.1056/NEJMp1612803			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO9NB	28328325	Green Published, Green Accepted			2023-01-03	WOS:000397014300005
J	Ma, JN; Meng, XL; Guo, XH; Lan, YR; Zhang, SS				Ma, Junnan; Meng, Xianglong; Guo, Xiaohui; Lan, Yaru; Zhang, Shuosheng			Thermal analysis during partial carbonizing process of rhubarb, moutan and burnet	PLOS ONE			English	Article							ISOCONVERSION METHODS; CELLULOSE PYROLYSIS; ACTIVATION-ENERGY; KINETIC-ANALYSIS; THERMOGRAVIMETRY; DECOMPOSITION; MODEL	Control of temperature and duration of partial carbonization for Chinese medicines have been mainly based on experience of the processors. No quantitative methods and parameters are available that can be used to precisely control the temperature and determine the energy changes during the process. In our research, with a simulated atmosphere air condition, the partial carbonization processes of three Chinese herb medicines rhubarb, moutan and burnet were simulated at different heating rates (5, 10 and 20 degrees C . min(-1)) and analyzed by thermal gravimetric analysis (TGA) to quantify the upper limits of the temperature. The activation energy was calculated with Friedman, Kissinger-Akahira-Sunose (KAS) method and Ozawa-Flynn- Wall (OFW) methods in iso-conversional models and independent parallel reaction model (IPR). The upper temperatures were calculated to be 280, 184 and 246 degrees C for rhubarb, moutan and burnet, respectively, at corresponding conversion rates of 0.4, 0.2 and 0.1. Calculation of the activation energy has been found impossible with the IPR model. Results obtained from the three iso-conversional methods were different. For rhubarb and burnet, the conversion rates at the upper temperature limits were at the highest or second highest activation energy, while for moutan, it was at the lowest value of activation energy. These results confirmed scientific rationales of traditional Chinese medicine theory that rhubarb and burnet be prepared at high temperature and moutan be prepared at medium temperature. Application of thermal analysis techniques would broaden and deepen traditional Chinese medicine research, and are applicable to the processing of medicinal materials including traditional Chinese medicines. Results obtained from the study could provide new ideas and methods for research to modernize the preparation of traditional Chinese medicines.	[Ma, Junnan; Meng, Xianglong] Dongguk Univ, Coll Oriental Med, Dept Herbol, Gyeongju, South Korea; [Ma, Junnan; Meng, Xianglong; Lan, Yaru; Zhang, Shuosheng] Shanxi Univ Tradit Chinese Med, Inst Pharmaceut & Food Engn, Jinzhong, Shanxi, Peoples R China; [Guo, Xiaohui] Chinese Acad Sci, Key Lab Carbon Mat, Inst Coal Chem, Taiyuan, Shanxi, Peoples R China	Dongguk University; Chinese Academy of Sciences; Institute of Coal Chemistry, CAS	Zhang, SS (corresponding author), Shanxi Univ Tradit Chinese Med, Inst Pharmaceut & Food Engn, Jinzhong, Shanxi, Peoples R China.	zhangshuosheng@aliyun.com	Meng, Xiang-Long/GXV-5867-2022		National Natural Science Foundation of China [81173555]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Support was provided by the National Natural Science Foundation of China (81173555)	Bian J, 2013, THESIS; Brown ME, 2000, THERMOCHIM ACTA, V355, P125, DOI 10.1016/S0040-6031(00)00443-3; Brown ME, 1997, J THERM ANAL, V49, P17, DOI 10.1007/BF01987418; Cai BC, 2009, PREPARATION TRADITIO, P1; Cai JM, 2008, ENERG FUEL, V22, P867, DOI 10.1021/ef7006672; Chen JY, 2010, MODERNIZATION TRADIT, V04, P511; [陈佩东 CHEN Peidong], 2006, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V22, P302; Chen XJ, 2013, CHINESE ARCH TRADITI, V07, P1671; China Pharmacopoeia Committee, 2010, CHINESE PHARMACOPOEI, P62; Chunxiu G, 2004, J THERM ANAL CALORIM, V76, P203, DOI 10.1023/B:JTAN.0000027819.43154.52; Damartzis T, 2011, BIORESOURCE TECHNOL, V102, P6230, DOI 10.1016/j.biortech.2011.02.060; Deng GH, 2013, CHINESE J EXPT TRADI, V7, P35; Fan XF, 2012, CHINESE J GRASSLAND, V1, P48; FLYNN JH, 1990, J THERM ANAL, V36, P1579, DOI 10.1007/BF01914077; Flynn JH, 1997, THERMOCHIM ACTA, V300, P83, DOI 10.1016/S0040-6031(97)00046-4; FRIEDMAN HL, 1964, J POLYM SCI POL SYM, P183; Hill J.O, 1991, INT CONFEDERATION TH, Vthird; Hu FL, 2009, THESIS; Jiang T, 2013, CHINA J CHINESE MAT, V7, P1000; Ke J, 2013, FUEL, V104, P781, DOI 10.1016/j.fuel.2012.06.066; KEATTCH CJ, 1991, J THERM ANAL, V37, P2089, DOI 10.1007/BF01905580; Kim S, 2006, KOREAN J CHEM ENG, V23, P409, DOI 10.1007/BF02706742; Li X, 2012, PLANT DIS PEST, V3, P34; Li ZQ, 2008, BIORESOURCE TECHNOL, V99, P7616, DOI 10.1016/j.biortech.2008.02.003; Liao Q, 2013, PHARM CLINICS CHINES, V2, P21; Lin T.C., 2010, THESIS; Lopez R. J., 2001, ADV ENG MATH; Lu LM, 2012, THERM ANAL, P112; Ma JN, 2013, WORLD J INTEGRATED T, V8, P468; Meng X.J., 2013, THESIS; Meng XL, 2014, CHIN J NAT MEDICINES, V12, P55, DOI [10.3724/SP.J.1009.2014.00055, 10.1016/S1875-5364(14)60010-8]; Meng XL, 2012, CHINA J CHINESE MAT, V23, P3558; Orfao JJM, 1999, FUEL, V78, P349, DOI 10.1016/S0016-2361(98)00156-2; OZAWA T, 1992, THERMOCHIM ACTA, V203, P159, DOI 10.1016/0040-6031(92)85192-X; [彭凯 Peng Kai], 2013, [中成药, Chinese Traditional Patent Medicine], V35, P140; [宋爱新 Song Aixin], 2003, [中草药, Chinese Traditional and Herbal Drugs], V34, P169; Starink MJ, 2003, THERMOCHIM ACTA, V404, P163, DOI 10.1016/S0040-6031(03)00144-8; Su M., 2013, CHINESE J EXPT TRADI, V19, P190, DOI [10.11653/syfj2013090190, DOI 10.11653/SYFJ2013090190]; Sun FJ, 2011, LIAONING J TRADITION, V1, P177; Tang S, 2013, CHINESE J EXPT TRADI, V8, P10, DOI DOI 10.1371/J0URNAL.P0NE; Tu YS, 2013, CHINESE J EXPT TRADI, V5, P13; Varhegyi G, 1997, J ANAL APPL PYROL, V42, P73, DOI 10.1016/S0165-2370(96)00971-0; Vyazovkin S, 1997, J PHYS CHEM A, V101, P8279, DOI 10.1021/jp971889h; Wang DZ, 2013, J CHINESE MED MAT, V1, P35; Wang Shu-Jun, 2007, Zhongguo Zhong Yao Za Zhi, V32, P296; Ye F, 2013, CHINESE J EXPT TRADI, V12, P83; Yu FR, 2012, THESIS; Yu LiPing, 2011, Acta Scientiarum Naturalium Universitatis Sunyatseni, V50, P94; Zeng JJ, 2011, INT BIODETER BIODEGR, V65, P410, DOI 10.1016/j.ibiod.2011.01.004; Zeng LY, 2013, CHINESE TRADITIONAL, V12, P1584; Zhou YF, 2012, CHINESE J EXPT TRADI, V16, P16; Zhuang G, 2013, CHINA J CHINESE MAT, V10, P1526	52	15	18	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2017	12	3							e0173946	10.1371/journal.pone.0173946	http://dx.doi.org/10.1371/journal.pone.0173946			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8RG	28323877	Green Published, gold, Green Submitted			2023-01-03	WOS:000399089000047
J	Roets-Merken, L; Zuidema, S; Vernooij-Dassen, M; Dees, M; Hermsen, P; Kempen, G; Graff, M				Roets-Merken, Lieve; Zuidema, Sytse; Vernooij-Dassen, Myrra; Dees, Marianne; Hermsen, Pieter; Kempen, Gertrudis; Graff, Maud			Problems identified by dual sensory impaired older adults in long-term care when using a self-management program: A qualitative study	PLOS ONE			English	Article							NURSING-HOME; DEAFBLINDNESS; COMMUNICATION; RESIDENTS; HEARING; RECORDS; PEOPLE	Objective To gain insights into the problems of dual sensory impaired older adults in long-term care. Insights into these problems are essential for developing adequate policies which address the needs of the increasing population of dual sensory impaired older adults in long-term care. Methods A qualitative study was conducted in parallel with a cluster randomized controlled trial. Dual sensory impaired older adults in the intervention group (n = 47, age range 82-98) were invited by a familiar nurse to identify the problems they wanted to address. Data were taken from the semi-structured intervention diaries in which nurses noted the older adults' verbal responses during a five-month intervention period in 17 long-term care homes across the Netherlands. The data were analyzed using descriptive statistics and qualitative content analysis based on the Grounded Theory. Findings The 47 dual sensory impaired older adults identified a total of 122 problems. Qualitative content analysis showed that the older adults encountered participation problems and problems controlling what happens in their personal environment. Three categories of participation problems emerged: (1) existential concerns of not belonging or not being able to connect with other people, (2) lack of access to communication, information and mobility, and (3) the desire to be actively involved in care delivery. Two categories of control-in-personal-space problems emerged: (1) lack of control of their own physical belongings, and (2) lack of control regarding the behavior of nurses providing daily care in their personal environment. Conclusions The invasive problems identified indicate that dual sensory impaired older adults experience great existential pressures on their lives. Long-term care providers need to develop and implement policies that identify and address these problems, and be aware of adverse consequences of usual care, in order to improve dual sensory impaired residents' autonomy and quality of life.	[Roets-Merken, Lieve; Vernooij-Dassen, Myrra; Graff, Maud] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Donders Inst Cognit Brain & Behav, Nijmegen, Netherlands; [Roets-Merken, Lieve] Kalorama Fdn, Beek Ubbergen, Netherlands; [Zuidema, Sytse] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Groningen, Netherlands; [Dees, Marianne; Graff, Maud] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, IQ Healthcare, Nijmegen, Netherlands; [Hermsen, Pieter] Severinus Fdn, Veldhoven, Netherlands; [Kempen, Gertrudis] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Hlth Serv Res, Maastricht, Netherlands	Radboud University Nijmegen; University of Groningen; Radboud University Nijmegen; Maastricht University	Roets-Merken, L (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Donders Inst Cognit Brain & Behav, Nijmegen, Netherlands.; Roets-Merken, L (corresponding author), Kalorama Fdn, Beek Ubbergen, Netherlands.	lieve.roets-merken@radboudumc.nl	Dees, marianne/E-5608-2016; Kempen, Gertrudis/Y-8796-2019; Graff, M.J.L./L-4333-2015; Dees, Marianne/AAL-2814-2021; Kempen, Gertrudis I/H-5978-2016	Dees, marianne/0000-0001-9749-880X; Kempen, Gertrudis/0000-0002-7053-2198; Kempen, Gertrudis I/0000-0002-7053-2198; Roets-Merken, Lieve/0000-0002-7248-7968	Joannes de Deo Foundation; Mother Catharina Fund in the Netherlands	Joannes de Deo Foundation; Mother Catharina Fund in the Netherlands	This study is made possible by the financial support from the Joannes de Deo Foundation and the Mother Catharina Fund in the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bakker-de Pree B, 1983, CONSTRUCTIONELE GEDR; Brennan M, 2005, GERONTOLOGIST, V45, P337, DOI 10.1093/geront/45.3.337; Centraal Indicatieorgaan Zorg, 2014, TRENDR 2013; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Dammeyer J, 2014, SCAND J PUBLIC HEALT, V42, P554, DOI 10.1177/1403494814544399; Danermark B, 2008, INT J AUDIOL, V47, pS119, DOI 10.1080/14992020802307388; de Boer MR, 2005, EUR J OPHTHALMOL, V15, P400, DOI 10.1177/112067210501500314; Dullard B, 2016, GERONTOLOGIST, V56, P313, DOI 10.1093/geront/gnu032; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Goll JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116664; Gopinath B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055054; Gustavsson M, 2015, SCAND J OCCUP THER, V22, P435, DOI 10.3109/11038128.2015.1044907; Guthrie DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155073; Heine C, 2004, AGEING SOC, V24, P113, DOI 10.1017/S0144686X03001491; Hersh M, 2013, J DEAF STUD DEAF EDU, V18, P446, DOI 10.1093/deafed/ent022; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Larsen FA, 2014, RES DEV DISABIL, V35, P2568, DOI 10.1016/j.ridd.2014.05.029; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689; Roets-Merken LM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013122; Roets-Merken LM, 2015, CLIN REHABIL, V29, P107, DOI 10.1177/0269215514542639; Roets-Merken LM, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-321; Schneider JM, 2011, J AGING HEALTH, V23, P1309, DOI 10.1177/0898264311408418; Sinoo MM, 2012, J CLIN NURS, V21, P1913, DOI 10.1111/j.1365-2702.2012.04128.x; Theurer K, 2015, J AGING STUD, V35, P201, DOI 10.1016/j.jaging.2015.08.011; Vaal J, 2007, Ned Tijdschr Geneeskd, V151, P1459; WHO, HEAR IMP GRAD 2016; Yamada Y, 2015, J GERONTOL A; Yamada Y, 2017, J OCEANOGR, V73, P11, DOI 10.1007/s10872-015-0336-y	30	9	9	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2017	12	3							e0173601	10.1371/journal.pone.0173601	http://dx.doi.org/10.1371/journal.pone.0173601			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER8RG	28323846	Green Published, gold			2023-01-03	WOS:000399089000021
J	Couzin-Frankel, J				Couzin-Frankel, Jennifer			Supply of promising T cell therapy is strained	SCIENCE			English	News Item																			0	12	19	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	2017	356	6343								10.1126/science.356.6343.1112	http://dx.doi.org/10.1126/science.356.6343.1112			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX6BO	28619895				2023-01-03	WOS:000403327400010
J	Hohlbaum, K; Bert, B; Dietze, S; Palme, R; Fink, H; Thone-Reineke, C				Hohlbaum, Katharina; Bert, Bettina; Dietze, Silke; Palme, Rupert; Fink, Heidrun; Thoene-Reineke, Christa			Severity classification of repeated isoflurane anesthesia in C57BL/6JRj mice-Assessing the degree of distress	PLOS ONE			English	Article							FECAL CORTICOSTERONE METABOLITES; LABORATORY RODENTS; STRESS-RESPONSE; MESSENGER-RNA; PAIN; BEHAVIOR; RATS; ANXIETY; HAIR; SEX	According to the EU Directive 2010/63, the severity of a procedure has to be classified as mild, moderate or severe. General anesthesia is thought to be mild, but the Directive does not differentiate between single and repeated anesthesia. Therefore, we investigated the impact of repeated administration of isoflurane, the most commonly used inhalation anesthetic, on the well-being of adult C57BL/6JRj mice, in comparison to single administrations and to untreated animals, when applied six times for 45 min at an interval of 3-4 days. For the animals anesthetized, excitations, phases of anesthesia, and vital parameters were monitored. Well-being after anesthesia was assessed using a behavioral test battery including luxury behavior like burrowing and nest building behavior, the Mouse Grimace Scale (MGS), the free exploratory paradigm for anxiety-related behavior, home cage activity and the rotarod test for activity, as well as food intake and body weight. Additionally, hair corticosterone and fecal corticosterone metabolites were measured. Our results show that nest building behavior, home cage activity, body weight, and corticosterone concentrations were not influenced by anesthesia, whereas changes in burrowing behavior, the MGS, food intake, and the free exploratory behavior indicated that the well-being of the mice was more affected by repeated than single isoflurane anesthesia. This effect depended on the sex of the animals, with female mice being more susceptible than male mice. However, repeated isoflurane anesthesia caused only short-term mild distress and impairment of well-being, mainly in the immediate postanesthetic period. Well-being stabilized at 8 days after the last anesthesia, at the latest. Therefore, we conclude that when using our anesthesia protocol, the severity of both single and repeated isoflurane anesthesia in C57BL/6JRj mice can be classified as mild. However, within the mild severity category, repeated isoflurane anesthesia ranks higher than single isoflurane anesthesia. Additionally, our results imply that male and female mice can differently perceive the severity of a procedure.	[Hohlbaum, Katharina; Thoene-Reineke, Christa] Free Univ Berlin, Inst Anim Welf Anim Behav & Lab Anim Sci, Dept Vet Med, Berlin, Germany; [Hohlbaum, Katharina; Bert, Bettina; Dietze, Silke; Fink, Heidrun] Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, Berlin, Germany; [Palme, Rupert] Univ Vet Med, Unit Physiol Pathophysiol & Expt Endocrinol, Dept Biomed Sci, Vienna, Austria; [Bert, Bettina] BfR Fed Inst Risk Assessment, Berlin, Germany	Free University of Berlin; Free University of Berlin; University of Veterinary Medicine Vienna; Federal Institute for Risk Assessment	Hohlbaum, K (corresponding author), Free Univ Berlin, Inst Anim Welf Anim Behav & Lab Anim Sci, Dept Vet Med, Berlin, Germany.; Hohlbaum, K (corresponding author), Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, Berlin, Germany.	katharina.hohlbaum@fu-berlin.de	Palme, Rupert/A-3499-2008	Palme, Rupert/0000-0001-9466-3662; Bert, Bettina/0000-0002-8202-9290	German Federal Ministry of Education and Research [031A262A]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	The study is part of the Berlin Brandenburg research platform BB3R (www bb3r de) and was funded by the German Federal Ministry of Education and Research (grant number: 031A262A) (www.bmbf.de/en/index.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albrecht M., 2014, BMC VET RES, V10, P963; Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Altholtz LY, 2006, J AM ASSOC LAB ANIM, V45, P17; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; Atanasov NA, 2015, J AM ASSOC LAB ANIM, V54, P737; Bekhbat M, 2016, BEHAV BRAIN RES, V305, P122, DOI 10.1016/j.bbr.2016.03.003; Bert B, 2013, J PHARMACOL TOX MET, V68, P240, DOI 10.1016/j.vascn.2013.01.001; Bryant CD, 2008, J NEUROGENET, V22, P315, DOI 10.1080/01677060802357388; Cozzoli DK, 2014, ALCOHOL, V48, P741, DOI 10.1016/j.alcohol.2014.07.015; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; Di S, 2003, J NEUROSCI, V23, P4850; Ding F, 2016, J ANESTH, V30, P684, DOI 10.1007/s00540-016-2189-y; Finlayson K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166446; Flaishon R, 2003, ANESTH ANALG, V97, P1046, DOI 10.1213/01.ANE.0000080202.70592.A7; Flaishon R, 1999, BRAIN RES, V815, P287, DOI 10.1016/S0006-8993(98)01120-2; Flecknell P., 2016, LAB ANIMAL ANAESTHES; Flecknell PA, 1999, LAB ANIM-UK, V33, P41, DOI 10.1258/002367799780578516; Gao W, 2013, J CHROMATOGR B, V928, P1, DOI 10.1016/j.jchromb.2013.03.008; Gargiulo S, 2012, ILAR J, V53, pE55, DOI 10.1093/ilar.53.1.55; GRAD B, 1968, J GERONTOL, V23, P522, DOI 10.1093/geronj/23.4.522; Gunther L, 2011, NEUROPHARMACOLOGY, V61, P433, DOI 10.1016/j.neuropharm.2011.03.004; Harrison NL, 2003, ANESTH ANALG, V97, P616, DOI 10.1213/01.ANE.0000086120.30172.12; Hayase T, 2016, MED GAS RES, V6, P70, DOI 10.4103/2045-9912.184715; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; Hildebrandt IJ, 2008, ILAR J, V49, P17, DOI 10.1093/ilar.49.1.17; Hurst JL, 2010, NAT METHODS, V7, P825, DOI [10.1038/nmeth.1500, 10.1038/NMETH.1500]; Jacobsen KR, 2012, J AM ASSOC LAB ANIM, V51, P69; Jarcho MR, 2016, HORM BEHAV, V78, P135, DOI 10.1016/j.yhbeh.2015.11.004; Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001; Jirkof P, 2013, LAB ANIM-UK, V47, P153, DOI 10.1177/0023677213475603; Jirkof P, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00165; Kalueff AV, 2004, BRAIN RES PROTOC, V13, P151, DOI 10.1016/j.brainresprot.2004.04.002; Kikuchi T, 2013, NEUROSCIENCE, V237, P151, DOI 10.1016/j.neuroscience.2013.01.062; Kita M, 2013, ADV BIOMED ENG RES, V1, P24; Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]; Li FX, 2015, ANESTHESIOLOGY, V122, P768, DOI 10.1097/ALN.0000000000000607; Long RP, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8524560; MARTIN DC, 1990, NEUROCHEM RES, V15, P969, DOI 10.1007/BF00965741; Matta JA, 2008, P NATL ACAD SCI USA, V105, P8784, DOI 10.1073/pnas.0711038105; Miller A, 2015, APPL ANIM BEHAV SCI, V172, P58, DOI 10.1016/j.applanim.2015.08.038; Miller AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166652; Moody CM, 2014, APPL ANIM BEHAV SCI, V158, P95, DOI 10.1016/j.applanim.2014.04.011; Mukaida K, 2007, ANESTH ANALG, V104, P836, DOI 10.1213/01.ane.0000255200.42574.22; Neumaier JF, 2000, MOL BRAIN RES, V82, P65, DOI 10.1016/S0169-328X(00)00181-9; Palme R, 2013, WIEN TIERARZTL MONAT, V100, P238; Paylor R, 2006, PHYSIOL BEHAV, V87, P95, DOI 10.1016/j.physbeh.2005.09.002; Raap DK, 2002, NEUROENDOCRINOLOGY, V76, P348, DOI 10.1159/000067582; Rex A, 2005, EUR J NEUROSCI, V22, P1185, DOI 10.1111/j.1460-9568.2005.04251.x; Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207; Russel W. M. S., 1959, PRINC HUM EXP TECH; Schuettler J, 2008, HDB EXPT PHARM; Scorrano F, 2015, FASEB J, V29, P859, DOI 10.1096/fj.14-254474; Solomonow J, 2015, TULA UNDERGRAD RES J, V2, P14; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; TerRiet MF, 2000, BRIT J ANAESTH, V85, P305, DOI 10.1093/bja/85.2.305; Thomson S, 2010, EXP CLIN ENDOCR DIAB, V118, P133, DOI 10.1055/s-0029-1220771; Touma C, 2004, HORM BEHAV, V45, P10, DOI 10.1016/j.yhbeh.2003.07.002; Touma C, 2003, GEN COMP ENDOCR, V130, P267, DOI 10.1016/S0016-6480(02)00620-2; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; Tsuji M, 2000, PSYCHOPHARMACOLOGY, V152, P157, DOI 10.1007/s002130000514; Voigt CC, 2013, ANIM WELFARE, V22, P449, DOI 10.7120/09627286.22.4.449; Walker MK, 2012, TOXICOL APPL PHARM, V260, P65, DOI 10.1016/j.taap.2012.01.025; Whittington RA, 2006, ANESTH ANALG, V103, P92, DOI 10.1213/01.ane.0000221488.48352.61; WYRWICZ AM, 1987, BIOCHIM BIOPHYS ACTA, V927, P86, DOI 10.1016/0167-4889(87)90069-3; Yokoyama C, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw079; Yonezaki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122118; Yu T, 2015, J CHROMATOGR B, V1002, P267, DOI 10.1016/j.jchromb.2015.08.035	69	81	81	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2017	12	6							e0179588	10.1371/journal.pone.0179588	http://dx.doi.org/10.1371/journal.pone.0179588			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX6PQ	28617851	Green Submitted, Green Published, gold			2023-01-03	WOS:000403364600049
J	Smith, OM; Chant, C; Burns, KEA; Kaur, M; Ashraf, S; DosSantos, CC; Hwang, SW; Friedrich, JO				Smith, Orla M.; Chant, Clarence; Burns, Karen E. A.; Kaur, Maninder; Ashraf, Said; DosSantos, Claudia C.; Hwang, Stephen W.; Friedrich, Jan O.			Characteristics, clinical course, and outcomes of homeless and non-homeless patients admitted to ICU: A retrospective cohort study	PLOS ONE			English	Article							NEIGHBORHOOD POVERTY RATE; ADULTS; HOSPITALIZATION; POPULATION; HEALTH; COSTS	Background Little is known about homeless patients in intensive care units (ICUs). Objectives To compare clinical characteristics, treatments, and outcomes of homeless to non-homeless patients admitted to four ICUs in a large inner-city academic hospital. Methods 63 randomly-selected homeless compared to 63 age-, sex-, and admitting-ICU-matched non-homeless patients. Results Compared to matched non-homeless, homeless patients (average age 48 +/- 12 years, 90% male, 87% admitted by ambulance, 56% mechanically ventilated, average APACHE II 17) had similar comorbidities and illness severity except for increased alcohol (70% vs 17%, p<0.001) and illicit drug(46% vs 8%, p<0.001) use and less documented hypertension (16% vs 40%, p = 0.005) or prescription medications (48% vs 67%, p<0.05). Intensity of ICU interventions was similar except for higher thiamine (71% vs 21%, p<0.0001) and nicotine (38% vs 14%, p = 0.004) prescriptions. Homeless patients exhibited significantly lower Glasgow Coma Scores and significantly more bacterial respiratory cultures. Longer durations of antibiotics, vasopressors/ inotropes, ventilation, ICU and hospital lengths of stay were not statistically different, but homeless patients had higher hospital mortality (29% vs 8%, p = 0.005). Review of all deaths disclosed that withdrawal of life-sustaining therapy occurred in similar clinical circumstances and proportions in both groups, regardless of family involvement. Using multivariable logistic regression, homelessness did not appear to be an independent predictor of hospital mortality. Conclusions Homeless patients, admitted to ICU matched to non-homeless patients by age and sex (characteristics most commonly used by clinicians), have higher hospital mortality despite similar comorbidities and illness severity. Trends to longer durations of life supports may have contributed to the higher mortality. Additional research is required to validate this higher mortality and develop strategies to improve outcomes in this vulnerable population.	[Smith, Orla M.; Burns, Karen E. A.; Kaur, Maninder; Ashraf, Said; DosSantos, Claudia C.; Friedrich, Jan O.] St Michaels Hosp, Crit Care Dept, Toronto, ON, Canada; [Smith, Orla M.; Chant, Clarence; Burns, Karen E. A.; DosSantos, Claudia C.; Friedrich, Jan O.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Smith, Orla M.] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON, Canada; [Chant, Clarence] St Michaels Hosp, Pharm Dept, Toronto, ON, Canada; [Burns, Karen E. A.; DosSantos, Claudia C.; Hwang, Stephen W.; Friedrich, Jan O.] St Michaels Hosp, Dept Med, Toronto, ON, Canada; [Burns, Karen E. A.; DosSantos, Claudia C.; Hwang, Stephen W.; Friedrich, Jan O.] Univ Toronto, Toronto, ON, Canada; [Burns, Karen E. A.; DosSantos, Claudia C.; Friedrich, Jan O.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Hwang, Stephen W.] St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada; [Kaur, Maninder] Univ Hosp Conway, Family Med Dept, Monroe, LA USA; [Ashraf, Said] Wayne State Univ, Dept Internal Med, Detroit Med Ctr, Detroit, MI 48202 USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Detroit Medical Center; Wayne State University	Friedrich, JO (corresponding author), St Michaels Hosp, Crit Care Dept, Toronto, ON, Canada.; Friedrich, JO (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.; Friedrich, JO (corresponding author), St Michaels Hosp, Dept Med, Toronto, ON, Canada.; Friedrich, JO (corresponding author), Univ Toronto, Toronto, ON, Canada.; Friedrich, JO (corresponding author), Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.	friedrichj@smh.ca	Hwang, Stephen W./GVR-7773-2022; Hwang, Stephen/D-2297-2011	Friedrich, Jan/0000-0001-7248-2350; Hwang, Stephen/0000-0002-1276-1101	Clinician Scientist Award from Canadian Institutes of Health Research (CIHR); Ministry of Research and Innovation; CIHR Clinician Scientist Award	Clinician Scientist Award from Canadian Institutes of Health Research (CIHR); Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario); CIHR Clinician Scientist Award(Canadian Institutes of Health Research (CIHR))	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Burns is supported by a Clinician Scientist Award from the Canadian Institutes of Health Research (CIHR) and an Early Researcher Award from the Ministry of Research and Innovation. Dr. Friedrich is supported by a CIHR Clinician Scientist Award. None of the funding agencies had any direct involvement in the design and conduct of this study.	Bein T, 2012, INTENS CARE MED, V38, P612, DOI 10.1007/s00134-012-2463-x; Bige N, 2015, CRIT CARE MED, V43, P1246, DOI 10.1097/CCM.0000000000000944; Chant C, 2014, INTENS CARE MED, V40, P123, DOI 10.1007/s00134-013-3124-4; GELBERG L, 1990, J AM GERIATR SOC, V38, P1220, DOI 10.1111/j.1532-5415.1990.tb01503.x; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; Human Resources and Skills Development Canada, HOM SHELT BEDS HOUS; Hwang SW, 2011, MED CARE, V49, P350, DOI 10.1097/MLR.0b013e318206c50d; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; MARTELL JV, 1992, ANN INTERN MED, V116, P299, DOI 10.7326/0003-4819-116-4-299; Mendu ML, 2012, CRIT CARE MED, V40, P1427, DOI 10.1097/CCM.0b013e318241e51e; Plevneshi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007255; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; US Department of Housing and Urban Development, 2012 ANN HOM ASS REP; Zager S, 2011, CHEST, V139, P1368, DOI 10.1378/chest.10-2594	15	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2017	12	6							e0179207	10.1371/journal.pone.0179207	http://dx.doi.org/10.1371/journal.pone.0179207			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX2VR	28604792	gold, Green Published, Green Submitted			2023-01-03	WOS:000403088400035
J	Warren, P				Warren, Penny			Brian Webb OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																		WEBB B, PUBLICATION LIST	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2017	357								j2829	10.1136/bmj.j2829	http://dx.doi.org/10.1136/bmj.j2829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY1UJ	28607122				2023-01-03	WOS:000403752200006
J	Berger, RE; Rivers, E; Levy, MM				Berger, Rebecca E.; Rivers, Emanuel; Levy, Mitchell M.			Management of Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GOAL-DIRECTED THERAPY; VENOUS OXYGEN-SATURATION; SEVERE SEPSIS; RESUSCITATION; MORTALITY		[Rivers, Emanuel] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA; [Levy, Mitchell M.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Levy, Mitchell M.] Rhode Isl Hosp, Providence, RI USA	Henry Ford Health System; Henry Ford Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								Boulain T, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0609-7; Engoren Milo, 2012, J Intensive Care Med, V27, P112, DOI 10.1177/0885066610394326; Grissom CK, 2009, CRIT CARE MED, V37, P2720, DOI 10.1097/CCM.0b013e3181a59532; Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Mark DG, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0496-y; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Nguyen HB, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1288-3; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rowan KM, 2017, NEW ENGL J MED, V376, P2223, DOI 10.1056/NEJMoa1701380; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	13	15	15	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	2017	376	23					2282	2285		10.1056/NEJMclde1705277	http://dx.doi.org/10.1056/NEJMclde1705277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW8WG	28591533				2023-01-03	WOS:000402798200015
J	Bove, GM; Chapelle, SL; Hanlon, KE; Diamond, MP; Mokler, DJ				Bove, Geoffrey M.; Chapelle, Susan L.; Hanlon, Katherine E.; Diamond, Michael P.; Mokler, David J.			Attenuation of postoperative adhesions using a modeled manual therapy	PLOS ONE			English	Article							CHRONIC PELVIC PAIN; SMALL-BOWEL OBSTRUCTION; LAPAROSCOPIC ADHESIOLYSIS; COLORECTAL SURGERY; ABDOMINAL MASSAGE; PHYSICAL-THERAPY; RISK-FACTORS; RAT; PREVENTION; ILEUS	Postoperative adhesions are pathological attachments that develop between abdominopelvic structures following surgery. Considered unavoidable and ubiquitous, postoperative adhesions lead to bowel obstructions, infertility, pain, and reoperations. As such, they represent a substantial health care challenge. Despite over a century of research, no preventive treatment exists. We hypothesized that postoperative adhesions develop from a lack of movement of the abdominopelvic organs in the immediate postoperative period while rendered immobile by surgery and opiates, and tested whether manual therapy would prevent their development. In a modified rat cecal abrasion model, rats were allocated to receive treatment with manual therapy or not, and their resulting adhesions were quantified. We also characterized macrophage phenotype. In separate experiments we tested the safety of the treatment on a strictureplasty model, and also the efficacy of the treatment following adhesiolysis. We show that the treatment led to reduced frequency and size of cohesive adhesions, but not other types of adhesions, such as those involving intraperitoneal fatty structures. This effect was associated with a delay in the appearance of trophic macrophages. The treatment did not inhibit healing or induce undesirable complications following strictureplasty. Our results support that that maintained movements of damaged structures in the immediate postoperative period has potential to act as an effective preventive for attenuating cohesive postoperative adhesion development. Our findings lay the groundwork for further research, including mechanical and pharmacologic approaches to maintain movements during healing.	[Bove, Geoffrey M.; Hanlon, Katherine E.; Mokler, David J.] Univ New England, Coll Osteopath Med, Dept Biomed Sci, Stella Maris 102, Biddeford, ME 04005 USA; [Chapelle, Susan L.] Squamish Integrated Hlth, Squamish, BC, Canada; [Diamond, Michael P.] Augusta Univ, Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA USA	University of New England - Maine; University System of Georgia; Augusta University	Bove, GM (corresponding author), Univ New England, Coll Osteopath Med, Dept Biomed Sci, Stella Maris 102, Biddeford, ME 04005 USA.	gbove@une.edu	Mokler, David J./H-3114-2019	Mokler, David J./0000-0001-7340-3431	National Institute General Medical Sciences of the National Institutes of Health [R01GM108041]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108041] Funding Source: NIH RePORTER	National Institute General Medical Sciences of the National Institutes of Health; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported in this publication was supported by the National Institute General Medical Sciences of the National Institutes of Health under award number R01GM108041 to GMB. The content does not necessarily represent the views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Artinyan A, 2008, WORLD J SURG, V32, P1495, DOI 10.1007/s00268-008-9491-2; Attard JAP, 2007, CAN J SURG, V50, P291; Beck DE, 1999, DIS COLON RECTUM, V42, P241, DOI 10.1007/BF02237135; Bolnick A, 2015, J MINIM INVAS GYN, V22, P549, DOI 10.1016/j.jmig.2014.12.009; Bove GM, 2015, J PHARMACOL TOX MET, V74, P1, DOI 10.1016/j.vascn.2015.04.004; Bove GM, 2012, J BODYW MOV THER, V16, P76, DOI 10.1016/j.jbmt.2011.02.004; Bove GM, 2016, J INVEST SURG, P1; Bruggmann D, 2010, DTSCH ARZTEBL INT, V107, P789, DOI 10.3238/arztebl.2010.0769; Cedergren J, 2003, APMIS, V111, P963, DOI 10.1034/j.1600-0463.2003.1111008.x; Chapelle SL, 2013, J BODYW MOV THER, V17, P83, DOI 10.1016/j.jbmt.2012.05.004; Chaturvedi AA, 2014, INT J COLORECTAL DIS, V29, P1411, DOI 10.1007/s00384-014-2009-5; CONE DF, 1959, B JOHNS HOPKINS HOSP, V105, P8; Cravedi P, 2014, J AM SOC NEPHROL, V25, P2003, DOI 10.1681/ASN.2013090945; Cubukcu A, 2002, SURGERY, V131, P81, DOI 10.1067/msy.2002.118316; Davey AK, 2007, J MINIM INVAS GYN, V14, P15, DOI 10.1016/j.jmig.2006.07.013; Diamond MP, 2011, AM J OBSTET GYNECOL, V205, pS1, DOI 10.1016/j.ajog.2011.09.027; DIAMOND MP, 1994, FERTIL STERIL, V62, P984; Diamond MP, 2001, HUM REPROD UPDATE, V7, P567, DOI 10.1093/humupd/7.6.567; DiZerega, 2000, PERITONEAL SURG; Ernst E, 1999, FORSCH KOMPLEMENTMED, V6, P149, DOI 10.1159/000021240; Gomel V, 1996, J REPROD MED, V41, P35; Hammoud A, 2004, FERTIL STERIL, V82, P1483, DOI 10.1016/j.fertnstert.2004.07.948; Hellebrekers BWJ, 2011, BRIT J SURG, V98, P1503, DOI 10.1002/bjs.7657; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; KRESCH AJ, 1984, OBSTET GYNECOL, V64, P672; Kumar S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005080.pub2; Kutuk MS, 2012, HUM REPROD, V27, P733, DOI 10.1093/humrep/der439; Le Blanc-Louvry I, 2002, J GASTROINTEST SURG, V6, P43, DOI 10.1016/S1091-255X(01)00009-9; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Liu Z, 2005, J NEUROL, V252, P1280, DOI 10.1007/s00415-005-0825-9; LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233; Maeda K, 1997, INT IMMUNOL, V9, P993, DOI 10.1093/intimm/9.7.993; Metwally M, 2008, CURR OPIN OBSTET GYN, V20, P345, DOI 10.1097/GCO.0b013e3283073a6c; Nezhat F R, 2000, JSLS, V4, P281; Parker MC, 2007, COLORECTAL DIS, V9, P66, DOI 10.1111/j.1463-1318.2007.01342.x; PETERS AAW, 1992, BRIT J OBSTET GYNAEC, V99, P59, DOI 10.1111/j.1471-0528.1992.tb14394.x; Rice AD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7610387; Rice AD, 2015, ALTERN THER HEALTH M, V21, P36; Richardson EH, 1911, ANN SURG, V54, P758, DOI 10.1097/00000658-191112000-00004; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; Saravelos HG, 1995, HUM REPROD, V10, P2895, DOI 10.1093/oxfordjournals.humrep.a135814; Sato Y, 2001, GASTROINTEST ENDOSC, V54, P476, DOI 10.1067/mge.2001.117760; SCHIFF CA, 1949, SURGERY, V25, P257; SCOTTCOOMBES DM, 1993, ANN ROY COLL SURG, V75, P123; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96, DOI 10.1002/jlb.46.2.96; Stanciu D, 2007, COLORECTAL DIS, V9, P35, DOI 10.1111/j.1463-1318.2007.01346.x; Tou JCL, 2002, EXP BIOL MED, V227, P587, DOI 10.1177/153537020222700806; Vather R, 2013, INT J COLORECTAL DIS, V28, P1385, DOI 10.1007/s00384-013-1704-y; WILLIAMS AF, 1977, CELL, V12, P663, DOI 10.1016/0092-8674(77)90266-5; Wong YY, 2015, J ORTHOP SPORT PHYS, V45, P1006, DOI 10.2519/jospt.2015.5766; Wurn BF, 2008, ALTERN THER HEALTH M, V14, P18	51	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178407	10.1371/journal.pone.0178407	http://dx.doi.org/10.1371/journal.pone.0178407			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6MJ	28574997	Green Published, gold, Green Submitted			2023-01-03	WOS:000402624300048
J	Kirkland, KB				Kirkland, Kathryn B.			Finding Joy in Practice Cocreation in Palliative Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH		[Kirkland, Kathryn B.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Hanover, NH 03766 USA; [Kirkland, Kathryn B.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College	Kirkland, KB (corresponding author), Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Hanover, NH 03766 USA.; Kirkland, KB (corresponding author), Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Lebanon, NH 03766 USA.	kathryn.kirkland@dartmouth.edu						Batalden M, 2016, BMJ QUAL SAF, V25, P509, DOI 10.1136/bmjqs-2015-004315; Charon R., 2006, NARRATIVE MED HONORI; Kinnell G, 2006, AM POETRY REV, V35, P3; Lynch T, 2016, VALUE COCREATION HEA; Mulley AG, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6572; Sikka R, 2015, BMJ QUAL SAF, V24, P608, DOI 10.1136/bmjqs-2015-004160	6	1	1	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2017	317	20					2065	2066		10.1001/jama.2017.1109	http://dx.doi.org/10.1001/jama.2017.1109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV5JJ	28535240				2023-01-03	WOS:000401800600015
J	Rose, AJ; Fischer, SH; Paasche-Orlow, MK				Rose, Adam J.; Fischer, Shira H.; Paasche-Orlow, Michael K.			Beyond Medication Reconciliation The Correct Medication List	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rose, Adam J.; Fischer, Shira H.] RAND Corp, 20 Pk Plaza,Ste 920, Boston, MA 02116 USA; [Rose, Adam J.; Paasche-Orlow, Michael K.] Boston Univ, Sch Med, Dept Med, Sect Gen Internal Med, Boston, MA 02118 USA	RAND Corporation; Boston University	Rose, AJ (corresponding author), RAND Corp, 20 Pk Plaza,Ste 920, Boston, MA 02116 USA.	arose@rand.org	Fischer, Shira/ABC-4293-2021; Paasche-Orlow, Michael/ABF-7919-2020; Rose, Adam/HHY-9078-2022	Fischer, Shira/0000-0002-1124-4962; Paasche-Orlow, Michael/0000-0002-9276-7190; Rose, Adam/0000-0001-8681-6155				Fischer S, 2017, JAMA-J AM MED ASSOC, V317, P469, DOI 10.1001/jama.2016.19908; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Wolf MS, 2016, J GEN INTERN MED, V31, P1482, DOI 10.1007/s11606-016-3816-x; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	5	50	50	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2017	317	20					2057	2058		10.1001/jama.2017.4628	http://dx.doi.org/10.1001/jama.2017.4628			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV5JJ	28426844				2023-01-03	WOS:000401800600011
J	Lamberti, MJ; Pansa, MF; Vera, RE; Fernandez-Zapico, ME; Vittar, NBR; Rivarola, VA				Julia Lamberti, Maria; Florencia Pansa, Maria; Emanuel Vera, Renzo; Fernandez-Zapico, Martin Ernesto; Rumie Vittar, Natalia Belen; Alicia Rivarola, Viviana			Transcriptional activation of HIF-1 by a ROS-ERK axis underlies the resistance to photodynamic therapy	PLOS ONE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; MITOCHONDRIAL COMPLEX-III; 5-AMINOLEVULINIC ACID; COLORECTAL-CANCER; OXIDATIVE STRESS; PROTEIN-KINASE; CELL; INDUCTION; IDENTIFICATION; HIF-1-ALPHA	Photodynamic therapy ( PDT), a promising treatment option for cancer, involves the activation of a photosensitizer (PS) by local irradiation with visible light. Excitation of the PS leads to a series of photochemical reactions and consequently the local generation of harmful reactive oxygen species (ROS) causing limited or none systemic defects. However, the development of resistance to this promising therapy has slowed down its translation into the clinical practice. Thus, there is an increase need in understanding of the molecular mechanism underlying resistance to PDT. Here, we aimed to examine whether a relationship exists between PDT outcome and ROS-involvement in the resistance mechanism in photosensitized cancer cells. In order to recapitulate tumor architecture of the respective original tumor, we developed a multicellular three-dimensional spheroid system comprising a normoxic periphery, surrounding a hypoxic core. Using Me-ALA, a prodrug of the PS PpIX, in human colorectal spheroids we demonstrate that HIF-1 transcriptional activity was strongly up-regulated and mediates PDT resistant phenotype. RNAi knockdown of HIF-1 impairs resistance to PDT. Oxidative stress-mediated activation of ERK1/2 followed PDT was involved on positive modulation of HIF-1 transcriptional activity after photodynamic treatment. ROS scavenging and MEK/ERK pathway inhibition abrogated the PDT-mediated HIF-1 upregulation. Together our data demonstrate that resistance to PDT is in part mediated by the activation of a ROS-ERK1/2-HIF-1 axis, thus, identifying novel therapeutic targets that could be used in combination with PDT.	[Julia Lamberti, Maria; Florencia Pansa, Maria; Emanuel Vera, Renzo; Rumie Vittar, Natalia Belen; Alicia Rivarola, Viviana] Univ Nacl Rio Cuarto, Fac Ciencias Exactas Fis Quim & Nat, Dept Biol Mol, Cordoba, Argentina; [Fernandez-Zapico, Martin Ernesto] Mayo Clin, Schulze Ctr Novel Therapeut, Rochester, MN USA	Universidad Nacional Rio Cuarto; Mayo Clinic	Vittar, NBR; Rivarola, VA (corresponding author), Univ Nacl Rio Cuarto, Fac Ciencias Exactas Fis Quim & Nat, Dept Biol Mol, Cordoba, Argentina.	belenrumie@gmail.com; vrivarola@exa.unrc.edu.ar	Lamberti, María Julia/AAM-4911-2020	Lamberti, María Julia/0000-0001-7162-0520	FONCyT [PICT-2013-2667]; CONICET [PIP 112-201101-00453]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Agencia Nacional de Promocion Cientifica y Tecnologica (PICT); Secretaria de Ciencia y Tecnica (SECyT); Universidad Nacional de Rio Cuarto, Argentina; Fulbright-Ministerio de Educacion de Argentina	FONCyT(FONCyT); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica (PICT)(ANPCyT); Secretaria de Ciencia y Tecnica (SECyT)(Secretaria de Ciencia y Tecnologia (SECYT)); Universidad Nacional de Rio Cuarto, Argentina; Fulbright-Ministerio de Educacion de Argentina	This work was supported PICT-2013-2667, FONCyT (http://www.agencia.mincyt.gob.ar/ frontend/ageocia/fondo/foncyt) to VAR; PIP 112-201101-00453, CONICET (http://www.conicet.gov.art) to VAR; PPI, SECyT, UNRC (https://www.unrc.edu.ar/cyt/) to VAR; and CONICET-NIH (http://www.conicet.gov.ar/) to NBRV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Agencia Nacional de Promocion Cientifica y Tecnologica (PICT), Secretaria de Ciencia y Tecnica (SECyT), Universidad Nacional de Rio Cuarto, Argentina, Fulbright-Ministerio de Educacion de Argentina. VAR and NBRV are members of the Scientific Researcher Career at CONICET. MJL, MFP and REV hold fellowship from CONICET.	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24; BARR H, 1990, BRIT J SURG, V77, P93, DOI 10.1002/bjs.1800770132; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bhuvaneswari R, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-56; Biswas S, 2013, BBA-MOL BASIS DIS, V1832, P293, DOI 10.1016/j.bbadis.2012.11.003; Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc; Bown SG, 2002, GUT, V50, P549, DOI 10.1136/gut.50.4.549; Broekgaarden M, 2015, CANCER METAST REV, V34, P643, DOI 10.1007/s10555-015-9588-7; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052; Chetty NC, 2008, CLIN EXP DERMATOL, V33, P204, DOI 10.1111/j.1365-2230.2007.02600.x; Cosserat-Gerardin I, 2000, J PHOTOCH PHOTOBIO B, V59, P72, DOI 10.1016/S1011-1344(00)00142-1; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1; Donnelly RF, 2007, PERSPECT MED CHEM, V1, P49; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ducrest AL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf064; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINGAR VH, 1992, J SURG RES, V53, P524, DOI 10.1016/0022-4804(92)90101-5; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Galanis A, 2008, CANCER LETT, V266, P12, DOI 10.1016/j.canlet.2008.02.028; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Ji ZY, 2006, CANCER LETT, V244, P182, DOI 10.1016/j.canlet.2005.12.010; Jin FY, 2012, MOL CANCER RES, V10, P1021, DOI 10.1158/1541-7786.MCR-11-0498; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kashtan H, 1996, DIS COLON RECTUM, V39, P379, DOI 10.1007/BF02054050; Kelty CJ, 2002, PHOTOCH PHOTOBIO SCI, V1, P158, DOI 10.1039/b201027p; Koderhold G, 1996, J PHOTOCH PHOTOBIO B, V36, P221, DOI 10.1016/S1011-1344(96)07376-9; Krieg RC, 2002, PHOTOCHEM PHOTOBIOL, V76, P518, DOI 10.1562/0031-8655(2002)076<0518:MCOTCS>2.0.CO;2; Lamberti M, 2014, LASER PHYS, V24, P8; Lamberti MJ, 2013, PHYTOMEDICINE, V20, P1007, DOI 10.1016/j.phymed.2013.04.018; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liu YYL, 2004, LIFE SCI, V75, P2035, DOI 10.1016/j.lfs.2004.03.027; Marchetti P, 1996, J IMMUNOL, V157, P4830; Martin CM, 2008, CIRC RES, V102, P1075, DOI 10.1161/CIRCRESAHA.107.161729; Mathupala SP, 2009, BIOTECHNIQUES, V46, P305, DOI 10.2144/000113079; Metzger W, 2011, CYTOTHERAPY, V13, P1000, DOI 10.3109/14653249.2011.583233; Mitra S, 2000, BIOPHYS J, V78, P2597, DOI 10.1016/S0006-3495(00)76804-4; Mitra S, 2006, MOL CANCER THER, V5, P3268, DOI 10.1158/1535-7163.MCT-06-0421; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Nakamura M, 2015, WORLD J GASTROENTERO, V21, P6706, DOI 10.3748/wjg.v21.i21.6706; Ong QX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153487; Pialoux V, 2009, FREE RADICAL BIO MED, V46, P321, DOI 10.1016/j.freeradbiomed.2008.10.047; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Sheleg SV, 2004, PHOTODERMATOL PHOTO, V20, P21, DOI 10.1111/j.1600-0781.2004.00078.x; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Weijer R, 2016, ONCOTARGET, V7, P3331, DOI 10.18632/oncotarget.6490; Wyld L, 1998, BRIT J CANCER, V77, P1621, DOI 10.1038/bjc.1998.265; Xiang L, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-32; Yamamoto M, 2013, ACTA MED OKAYAMA, V67, P153; Yeh LH, 2004, ANTIOXID REDOX SIGN, V6, P944, DOI 10.1089/ars.2004.6.944	61	32	34	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2017	12	5							e0177801	10.1371/journal.pone.0177801	http://dx.doi.org/10.1371/journal.pone.0177801			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DX	28545088	Green Published, gold, Green Submitted			2023-01-03	WOS:000401487700082
J	Theocharopoulos, G; Danis, K; Greig, J; Hoffmann, A; De Valk, H; Jimissa, A; Tejan, S; Sankoh, M; Kleijer, K; Turner, W; Achar, J; Duncombe, J; Lokuge, K; Gayton, I; Broeder, R; Kremer, R; Caleo, G				Theocharopoulos, Georgios; Danis, Kostas; Greig, Jane; Hoffmann, Alexandra; De Valk, Henriette; Jimissa, Augustine; Tejan, Sumaila; Sankoh, Mohammed; Kleijer, Karline; Turner, Will; Achar, Jay; Duncombe, Jennifer; Lokuge, Kamalini; Gayton, Ivan; Broeder, Rob; Kremer, Ronald; Caleo, Grazia			Ebola management centre proximity associated with reduced delays of healthcare of Ebola Virus Disease (EVD) patients, Tonkolili, Sierra Leone, 2014-15	PLOS ONE			English	Article							TRANSMISSION	Between August-December 2014, Ebola Virus Disease (EVD) patients from Tonkolili District were referred for care to two Medecins Sans Frontieres (MSF) Ebola Management Centres (EMCs) outside the district (distant EMCs). In December 2014, MSF opened an EMC in Tonkolili District (district EMC). We examined the effect of opening a district-based EMC on time to admission and number of suspect cases dead on arrival (DOA), and identified factors associated with fatality in EVD patients, residents in Tonkolili District. Residents of Tonkolili district who presented between 12 September 2014 and 23 February 2015 to the district EMC and the two distant EMCs were identified from EMC line-lists. EVD cases were confirmed by a positive Ebola PCR test. We calculated time to admission since the onset of symptoms, case-fatality and adjusted Risk Ratios (aRR) using Binomial regression. Of 249 confirmed Ebola cases, 206 (83%) were admitted to the distant EMCs and 43 (17%) to the district EMC. Of them 110 (45%) have died. Confirmed cases dead on arrival (n = 10) were observed only in the distant EMCs. The median time from symptom onset to admission was 6 days (IQR 4,8) in distant EMCs and 3 days (IQR 2,7) in the district EMC (p<0.001). Cases were 2.0 (95% CI 1.4-2.9) times more likely to have delayed admission (>3 days after symptom onset) in the distant compared with the district EMC, but were less likely (aRR = 0.8; 95% CI 0.6-1.0) to have a high viral load (cycle threshold <= 22). A fatal outcome was associated with a high viral load (aRR 2.6; 95% CI 1.8-3.6) and vomiting at first presentation (aRR 1.4; 95% CI 1.0-2.0). The opening of a district EMC was associated with earlier admission of cases to appropriate care facilities, an essential component of reducing EVD transmission. High viral load and vomiting at admission predicted fatality. Healthcare providers should consider the location of EMCs to ensure equitable access during Ebola outbreaks.	[Theocharopoulos, Georgios; Danis, Kostas; Hoffmann, Alexandra] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training, Stockholm, Sweden; [Tejan, Sumaila; Duncombe, Jennifer; Kremer, Ronald] Inst Veille Sanitaire, St Martin Dheres, France; [Hoffmann, Alexandra; Tejan, Sumaila; Kleijer, Karline; Lokuge, Kamalini] Med Sans Frontieres, Magburaka, Sierra Leone; [Duncombe, Jennifer; Lokuge, Kamalini; Broeder, Rob; Kremer, Ronald] Manson Unit, Medecins Sans Frontieres, London, ON, Canada; [Danis, Kostas; De Valk, Henriette; Sankoh, Mohammed; Turner, Will; Duncombe, Jennifer; Broeder, Rob] State Off Hlth & Social Affairs, Berlin, Germany; [Tejan, Sumaila; Kleijer, Karline; Gayton, Ivan] Dist Hlth Management Team, Hlth & Sanitat, Magburaka, Magburaka, Sierra Leone	European Centre for Disease Prevention & Control; Institute of Public Health Surveillance; Ministry of Health & Sanitation Sierra Leone	Theocharopoulos, G (corresponding author), European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training, Stockholm, Sweden.	theocharopoulos1@yahoo.com	Danis, Kostas/ABD-7357-2020; Achar, Jay/AAB-2710-2022	Achar, Jay/0000-0002-2521-4422; Greig, Jane/0000-0003-2732-0023; Lokuge, Kamalini/0000-0002-6287-1296; de Valk, Henriette/0000-0002-5928-7689				Agua-Agum J, 2015, W AFR EB EP ONE YEAR, V372; [Anonymous], 2014, WHO STAT M INT HLTH; Borchert M, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-357; Brainard J, 2016, INT J EPIDEMIOL, V45, P102, DOI 10.1093/ije/dyv307; Centers for Disease Control and Prevention, 2015, INT REC AMB SERV PRO; Crowe SJ, 2016, EMERG INFECT DIS, V22, P217, DOI 10.3201/eid2202.151250; Dallatomasina S, 2015, TROP MED INT HEALTH, V20, P448, DOI 10.1111/tmi.12454; de La Vega MA, 2016, EXPERT REV ANTI-INFE, V14, P557, DOI 10.1080/14787210.2016.1176912; Faye O, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001908; Fitzpatrick G, 2015, J INFECT DIS, V212, P1752, DOI 10.1093/infdis/jiv304; Flint M, 2015, J INFECT DIS, V212, pS350, DOI 10.1093/infdis/jiv361; Frieden TR, 2014, NEW ENGL J MED, V371, P1177, DOI 10.1056/NEJMp1409903; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; Kutalek R, 2015, LANCET GLOB HEALTH, V3, pE131, DOI 10.1016/S2214-109X(15)70010-0; Lindblade KA, 2015, EMERG INFECT DIS, V21, P1800, DOI 10.3201/eid2110.150912; Lokuge K, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004498; Marzi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036192; Medecins Sans Frontieres, 2013, ETH REV BOARD STAND; MMWRC, 2014, UPD EB VIR DIS EPI W; Muyembe-Tamfum JJ, 1999, J INFECT DIS S1, V179; Olu O, 2015, PAN AFR MED J, V22, DOI 10.11694/pamj.supp.2015.22.1.6521; Osterholm MT, 2015, MBIO, V6, DOI 10.1128/mBio.00137-15; Pathmanathan I, 2014, RAPID ASSESSMENT EBO; Spengler JR, 2015, J INFECT DIS S2, V212; WHO, 2014, 1 WHO; Wolz A, 2014, NEW ENGL J MED, V371, P1081, DOI 10.1056/NEJMp1410179; World Health Organization, 2014, 2 WHO; Yan T, 2015, EUR J CLIN MICROBIOL, V34, P2089, DOI 10.1007/s10096-015-2457-z	28	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2017	12	5							e0176692	10.1371/journal.pone.0176692	http://dx.doi.org/10.1371/journal.pone.0176692			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9RJ	28459838	Green Published, Green Submitted, gold			2023-01-03	WOS:000400645000048
J	Donaldson, LJ; Kelley, ET; Dhingra-Kumar, N; Kieny, MP; Sheikh, A				Donaldson, Liam J.; Kelley, Edward T.; Dhingra-Kumar, Neelam; Kieny, Marie-Paule; Sheikh, Aziz			Medication Without Harm: WHO's Third Global Patient Safety Challenge	LANCET			English	Editorial Material									[Donaldson, Liam J.] London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, London, England; [Kelley, Edward T.; Dhingra-Kumar, Neelam; Kieny, Marie-Paule] World Hlth Org, Geneva, Switzerland; [Sheikh, Aziz] Univ Edinburgh, Med Informat Ctr, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; World Health Organization; University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Med Informat Ctr, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Kieny, Marie-Paule/Q-1238-2019; Kieny, Marie-Paule/N-3914-2017	Kieny, Marie-Paule/0000-0002-5943-6488; Sheikh, Aziz/0000-0001-7022-3056	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Aitken M., 2012, ADV RESPONSIBLE USE; Allegranzi B, 2007, J HOSP INFECT, V65, P115, DOI 10.1016/S0195-6701(07)60027-9; Allegranzi B, 2013, LANCET INFECT DIS, V13, P843, DOI 10.1016/S1473-3099(13)70163-4; Aspden P, 2007, PREVENTING MEDICATIO; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; SAFREN M A, 1960, Hospitals, V34, ppassim; SAFREN M A, 1960, Hospitals, V34, P32; Safren M.A., 1960, HOSPITALS, V34, P57; Safren M. A., 1960, HOSPITALS, V34, p[53, 65]; Safren MA, 1960, HOSPITALS, V34, P62; Safren MA, 1960, HOSPITALS 1, V34, P60; SAFREN MA, 1960, HOSPITALS, V34, P66; Safren MA, 1960, HOSPITALS, V34, P64; Safren MA, 1960, HOSPITALS, V34, P68; World Alliance for Patient Safety, 2008, INT J RISK SAFETY ME, V20, P181; Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5	16	165	173	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2017	389	10080					1680	+		10.1016/S0140-6736(17)31047-4	http://dx.doi.org/10.1016/S0140-6736(17)31047-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET3BG	28463129	Green Published, Bronze			2023-01-03	WOS:000400151000009
J	Patel, H; Lissoos, T; Rubin, DT				Patel, Haridarshan; Lissoos, Trevor; Rubin, David T.			Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB DOSE INTENSIFICATION; ANTI-TNF THERAPY; MANAGEMENT; CARE; ADULTS	This study assessed the occurrence of indicators for suboptimal biologic therapy among ulcerative colitis (UC) and Crohn's disease (CD) patients over time in the United States (US). Data from a large US claims database (2005-2013) were used to retrospectively identify patients with diagnosed with either UC or CD who were new biologic users. Indicators of suboptimal biologic therapy included: dose escalation during the maintenance phase, discontinuation of the initial biologic, switch to another biologic within 90 days following the last day of supply of the initial biologic, augmentation with a non-biologic systemic therapy, UC-or CD-related surgery, UC-or CD-related urgent care, and development of fistula (for CD only). Kaplan-Meier analyses were used. A total of 1,699 UC and 4,569 CD patients were included. Among UC patients, 51.1% and 90.9% experienced >= 1 indicator of suboptimal biologic therapy within 6 months and 36 months of biologic therapy initiation, respectively. Among CD patients, 54.3% and 91.4% experienced >= 1 indicator of suboptimal biologic therapy within 6 and 36 months of biologic therapy initiation, respectively. For both UC and CD patients, the most frequent indicators of suboptimal biologic therapy were discontinuation, dose escalation and augmentation. In conclusion, this study found that the occurrence of suboptimal biologic therapy is common among patients with UC and CD, with approximately 90% of patients experiencing at least one indicator of suboptimal biologic therapy within 36 months of biologic treatment initiation.	[Patel, Haridarshan] Immens Consulting Inc, Chicago, IL USA; [Lissoos, Trevor] Takeda Pharmaceut USA Inc, Chicago, IL USA; [Rubin, David T.] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL 60637 USA	Takeda Pharmaceutical Company Ltd; Takeda Pharmaceuticals USA Inc. (TPUSA)	Rubin, DT (corresponding author), Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL 60637 USA.	drubin@medicine.bsd.uchicago.edu		Rubin, David/0000-0001-5647-1723	Takeda Pharmaceuticals International, Inc.	Takeda Pharmaceuticals International, Inc.(Takeda Pharmaceutical Company Ltd)	This study was funded in full by Takeda Pharmaceuticals International, Inc. The funder provided support in the form of salary for Trevor Lissoos, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The design, analysis, reporting of findings, and intent to publish represent the views and opinions of the authors and do not represent the views and opinions of their respective organizations/companies. The specific roles of these authors are articulated in the 'author contributions' section.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Baran B, 2013, ISRN GASTROENTEROLOG, V2013, P12; Ben-Horin S, 2011, ALIMENT PHARM THER, V33, P987, DOI 10.1111/j.1365-2036.2011.04612.x; Billioud V, 2011, AM J GASTROENTEROL, V106, P674, DOI 10.1038/ajg.2011.60; Colletti RB, 2009, J PEDIATR GASTR NUTR, V49, P297, DOI 10.1097/MPG.0b013e3181919695; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Ding NS, 2016, ALIMENT PHARM THER, V43, P30, DOI 10.1111/apt.13445; Esrailian E, 2007, ALIMENT PHARM THER, V26, P1005, DOI 10.1111/j.1365-2036.2007.03445.x; Ghosh Subrata, 2010, Therap Adv Gastroenterol, V3, P239, DOI 10.1177/1756283X10373176; Gisbert JP, 2009, AM J GASTROENTEROL, V104, P760, DOI 10.1038/ajg.2008.88; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Hilsden R, 2002, CAN J GASTROENTEROL, V16, P865, DOI 10.1155/2002/463015; Jung SA, 2012, CLIN ENDOSC, V45, P254, DOI 10.5946/ce.2012.45.3.254; Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727; Lichtenstein GR, 2009, AM J GASTROENTEROL, V104, P465, DOI 10.1038/ajg.2008.168; Lichtenstein GR, 2005, GASTROENTEROLOGY, V128, P862, DOI 10.1053/j.gastro.2005.01.048; Lin KK, 2012, DIGEST DIS SCI, V57, P1013, DOI 10.1007/s10620-011-1969-3; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Nguyen DL, 2015, THER ADV CHRONIC DIS, V6, P147, DOI 10.1177/2040622315579621; Panaccione Remo, 2010, Therap Adv Gastroenterol, V3, P179, DOI 10.1177/1756283X09357579; Park SC, 2015, GUT LIVER, V9, P18, DOI 10.5009/gnl14226; Reddy SI, 2005, AM J GASTROENTEROL, V100, P1357, DOI 10.1111/j.1572-0241.2005.40849.x; Regueiro M, 2007, INFLAMM BOWEL DIS, V13, P1093, DOI 10.1002/ibd.20177; Rubin DT, 2014, ALIMENT PHARM THER, V39, P1143, DOI 10.1111/apt.12727; Rubin DT, 2017, INFLAMM BOWEL DIS, V23, P224, DOI 10.1097/MIB.0000000000000994; Sales-Campos H, 2015, BRAZ J MED BIOL RES, V48, P96, DOI [10.1590/1414-431x20143774, 10.1590/1414-431X20143774]; Sandborn WJ, 2014, GASTROENTEROLOGY, V147, P702, DOI 10.1053/j.gastro.2014.07.022; Schreiber Stefan, 2011, Therap Adv Gastroenterol, V4, P375, DOI 10.1177/1756283X11413315; Steenholdt C, 2016, INFLAMM BOWEL DIS, V22, P1999, DOI 10.1097/MIB.0000000000000772; Strik AS, 2016, EXPERT REV CLIN PHAR, V9, P429, DOI 10.1586/17512433.2016.1133288; Travis SPL, 2008, J CROHNS COLITIS, V2, P24, DOI 10.1016/j.crohns.2007.11.002; Travis SPL, 2006, GUT, V55, DOI 10.1136/gut.2005.081950b; Zampeli Evanthia, 2014, World J Gastrointest Pathophysiol, V5, P293, DOI 10.4291/wjgp.v5.i3.293	33	22	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2017	12	4							e0175099	10.1371/journal.pone.0175099	http://dx.doi.org/10.1371/journal.pone.0175099			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KM	28426675	Green Submitted, Green Published, gold			2023-01-03	WOS:000399875900019
J	Hori, S; Miyake, M; Tatsumi, Y; Onishi, S; Morizawa, Y; Nakai, Y; Tanaka, N; Fujimoto, K				Hori, Shunta; Miyake, Makito; Tatsumi, Yoshihiro; Onishi, Sayuri; Morizawa, Yosuke; Nakai, Yasushi; Tanaka, Nobumichi; Fujimoto, Kiyohide			Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model	PLOS ONE			English	Article							BACILLUS-CALMETTE-GUERIN; REGULATORY T-CELLS; SUPPRESSOR-CELLS; TUMOR-IMMUNITY; CARCINOMA; THERAPY; GROWTH; IMMUNOTHERAPY; SURVIVAL; GEMCITABINE	Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer (NMIBC). Although the immunoreaction elicited by BCG treatment is well documented, those induced by intravesical treatment with chemotherapeutic agents are much less known. We investigated the immunological profiles caused by mitomycin C, gemcitabine, adriamycin and docetaxel in the N-butylN-( 4-hydroxybutyl) nitrosamine (BBN)-induced orthotopic bladder cancer mouse model. Ninety mice bearing orthotopic bladder cancer induced by BBN were randomly divided into six groups and treated with chemotherapeutic agents once a week for four weeks. After last treatment, bladder and serum samples were analyzed for cell surface and immunological markers (CD4, CD8, CD56, CD204, Foxp3, and PD-L1) using immunohistochemistry staining. Serum and urine cytokine levels were evaluated by ELISA. All chemotherapeutic agents presented antitumor properties similar to those of BCG. These included changes in immune cells that resulted in fewer M2 macrophages and regulatory T cells around tumors. This result was compatible with those in human samples. Intravesical chemotherapy also induced systemic changes in cytokines, especially urinary interleukin (IL)-17A and granulocyte colony stimulating factor (G-CSF), as well as in the distribution of blood neutrophils, lymphocytes, and monocytes. Our findings suggest that intravesical treatment with mitomycin C and adriamycin suppresses protumoral immunity while enhancing anti-tumor immunity, possibly through the action of specific cytokines. A better understanding of the immunoreaction induced by chemotherapeutic agents can lead to improved outcomes and fewer side effects in intravesical chemotherapy against NMIBC.	[Hori, Shunta; Miyake, Makito; Tatsumi, Yoshihiro; Onishi, Sayuri; Morizawa, Yosuke; Nakai, Yasushi; Tanaka, Nobumichi; Fujimoto, Kiyohide] Nara Med Univ, Dept Urol, Nara, Japan	Nara Medical University	Fujimoto, K (corresponding author), Nara Med Univ, Dept Urol, Nara, Japan.	kiyokun@naramed-u.ac.ip	Morizawa, Yosuke/AAJ-3343-2021		JSPS KAKENHI [15K10605]; Nara Medical University; Fiscal Years	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Nara Medical University; Fiscal Years	This work was supported by JSPS KAKENHI grant number 15K10605 (KF) and Fiscal Years 2015-2016 Nara Medical University Grant-in Aid for Collaborative Research Projects (KF and MM).	Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545; Askeland EJ, 2012, ADV UROL, V2012, DOI 10.1155/2012/181987; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; Barlow LJ, 2013, J UROLOGY, V189, P834, DOI 10.1016/j.juro.2012.10.068; BECICH MJ, 1991, J UROLOGY, V145, P1316, DOI 10.1016/S0022-5347(17)38622-6; Bevers RFM, 2004, BRIT J CANCER, V91, P607, DOI 10.1038/sj.bjc.6602026; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; BOHLE A, 1990, J UROLOGY, V144, P53, DOI 10.1016/S0022-5347(17)39365-5; Clark PE, 2013, J NATL COMPR CANC NE, V11, P446, DOI 10.6004/jnccn.2013.0059; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Hayata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053131; Hendricksen K, 2007, CURR OPIN UROL, V17, P352, DOI 10.1097/MOU.0b013e3281c55f2b; Herr HW, 2008, J UROLOGY, V179, P53, DOI 10.1016/j.juro.2007.08.122; Herr HW, 2012, J UROLOGY, V187, P435, DOI 10.1016/j.juro.2011.10.032; Hirahara N, 2001, ONCOLOGY-BASEL, V61, P79, DOI 10.1159/000055357; Kan S, 2012, ANTICANCER RES, V32, P5363; Kikuchi E, 2009, INT J UROL, V16, P279, DOI 10.1111/j.1442-2042.2008.02235.x; Kitamura Hiroshi, 2011, Cancers (Basel), V3, P3055, DOI 10.3390/cancers3033055; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170; Loskog A, 2007, J UROLOGY, V177, P353, DOI 10.1016/j.juro.2006.08.078; Ludwig AT, 2004, CANCER RES, V64, P3386, DOI 10.1158/0008-5472.CAN-04-0374; Matsushima M, 2011, ONCOL LETT, V2, P13, DOI 10.3892/ol.2010.217; Mattarollo SR, 2011, CANCER RES, V71, P4809, DOI 10.1158/0008-5472.CAN-11-0753; Miyake M, 2010, UROL INT, V85, P355, DOI 10.1159/000317785; Nakamura R, 2009, EUR J CANCER, V45, P2123, DOI 10.1016/j.ejca.2009.03.024; Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206; Nepple Kenneth G, 2009, Can Urol Assoc J, V3, pS188; Numasaki M, 2005, J IMMUNOL, V175, P6177, DOI 10.4049/jimmunol.175.9.6177; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Peyromaure M, 2003, J UROLOGY, V169, P2110, DOI 10.1097/01.ju.0000066840.42991.4a; Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269; Saban MR, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-6; Saint F, 2003, INT J CANCER, V107, P434, DOI 10.1002/ijc.11352; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Shahin O, 2003, J UROLOGY, V169, P96, DOI 10.1016/S0022-5347(05)64044-X; Shevchenko I, 2013, INT J CANCER, V133, P98, DOI 10.1002/ijc.27990; Shintani Y, 2007, INT J UROL, V14, P140, DOI 10.1111/j.1442-2042.2007.01696.x; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Simons MP, 2007, IMMUNOL RES, V39, P79, DOI 10.1007/s12026-007-0084-1; Svatek RS, 2015, CLIN CANCER RES, V21, P303, DOI 10.1158/1078-0432.CCR-14-1781; Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012; Temraz S, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-76; Terabe M, 2004, CURR OPIN IMMUNOL, V16, P157, DOI 10.1016/j.coi.2004.01.010; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Wei Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092079; Zhao Y, 2015, ONCOTARGET, V6, P39196, DOI 10.18632/oncotarget.5538; Zheng YW, 2015, CELL IMMUNOL, V294, P54, DOI 10.1016/j.cellimm.2015.02.003	50	9	9	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2017	12	4							e0175494	10.1371/journal.pone.0175494	http://dx.doi.org/10.1371/journal.pone.0175494			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MB	28406993	Green Published, gold, Green Submitted			2023-01-03	WOS:000399955400063
J	Nauffal, V; Zhang, YY; Tanawuttiwat, T; Blasco-Colmenares, E; Rickard, J; Marine, JE; Butcher, B; Norgard, S; Dickfeld, TM; Ellenbogen, KA; Guallar, E; Tomaselli, GF; Cheng, AA				Nauffal, Victor; Zhang, Yiyi; Tanawuttiwat, Tanyanan; Blasco-Colmenares, Elena; Rickard, John; Marine, Joseph E.; Butcher, Barbara; Norgard, Sanaz; Dickfeld, Timm-Michael; Ellenbogen, Kenneth A.; Guallar, Eliseo; Tomaselli, Gordon F.; Cheng, Alan			Clinical decision tool for CRT-P vs. CRT-D implantation: Findings from PROSE-ICD	PLOS ONE			English	Article							CARDIAC-RESYNCHRONIZATION THERAPY; C-REACTIVE PROTEIN; HEART-FAILURE; CARDIOVERTER-DEFIBRILLATOR; BROAD-SPECTRUM; PACEMAKER; ANEMIA; DYSFUNCTION; PREDICTOR; MORBIDITY	Background Cardiac resynchronization therapy (CRT) devices reduce mortality through pacing-induced cardiac resynchronization and implantable cardioverter defibrillator (ICD) therapy for ventricular arrhythmias (VAs). Whether certain factors can predict if patients will benefit more from implantation of CRT pacemakers (CRT-P) or CRT defibrillators (CRT-D) remains unclear. Methods and results We followed 305 primary prevention CRT-D recipients for the two primary outcomes of HF hospitalization and ICD therapy for VAs. Serum biomarkers, electrocardiographic and clinical variables were collected prior to implant. Multivariable analysis using Cox-proportional hazards model was used to fit the final models. Among 282 patients with follow-up outcome data, 75 (26.6%) were hospitalized for HF and 31 (11%) received appropriate ICD therapy. Independent predictors of HF hospitalization were atrial fibrillation (HR = 1.8 (1.1,2.9)), NYHA class III/IV (HR = 2.2 (1.3,3.6)), ejection fraction < 20% (HR = 1.7 (1.1,2.7)), HS-IL6 > 4.03pg/ml (HR = 1.7 (1.1,2.9)) and hemoglobin (< 12g/dl) (HR = 2.2 (1.3,3.6)). Independent predictors of appropriate therapy included BUN > 20mg/dL (HR = 3.0 (1.3,7.1)), HS-CRP > 9.42mg/L (HR = 2.3 (1.1,4.7)), no beta blocker therapy (HR = 3.2 (1.4,7.1)) and hematocrit >= 38% (HR = 2.7 (1.03,7.0)). Patients with 0-1 risk factors for appropriate therapy (IR 1 per 100 person-years) and >= 3 risk factors for HF hospitalization (IR 23 per 100-person-years) were more likely to die prior to receiving an appropriate ICD therapy. Conclusions Clinical and biomarker data can risk stratify CRT patients for HF progression and VAs. These findings may help characterize subgroups of patients that may benefit more from the use of CRT-P vs. CRT-D systems.	[Nauffal, Victor; Tanawuttiwat, Tanyanan; Rickard, John; Marine, Joseph E.; Butcher, Barbara; Norgard, Sanaz; Tomaselli, Gordon F.; Cheng, Alan] Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; [Zhang, Yiyi; Blasco-Colmenares, Elena; Guallar, Eliseo] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Dickfeld, Timm-Michael] Univ Maryland, Dept Med, Baltimore, MD 21201 USA; [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore; Virginia Commonwealth University	Cheng, AA (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA.	alcheng@jhmi.edu	Ellenbogen, Kenneth/AAJ-3992-2021; Tanawuttiwat, Tanyanan/AAA-5694-2020		National Institutes of Health [R01 HL091062, R01 HL103946]; Johns Hopkins Murex Research Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL132181] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Johns Hopkins Murex Research Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding was provided by National Institutes of Health R01 HL091062 to GT and National Institutes of Health R01 HL103946 to AC. VN was supported by the Johns Hopkins Murex Research Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand IS, 2008, J AM COLL CARDIOL, V52, P501, DOI 10.1016/j.jacc.2008.04.044; Bogale N, 2012, EUR J HEART FAIL, V14, P61, DOI 10.1093/eurjhf/hfr158; Braunwald E, 2008, NEW ENGL J MED, V358, P2148, DOI 10.1056/NEJMra0800239; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cheng A, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000083; Choi EY, 2012, AM HEART J, V164, P251, DOI 10.1016/j.ahj.2012.05.010; Ellenbogen KA, 2010, CIRCULATION, V122, P2660, DOI 10.1161/CIRCULATIONAHA.110.992552; Epstein AE, 2013, J AM COLL CARDIOL, V61, pE6, DOI 10.1016/j.jacc.2012.11.007; Hjalmarson A, 1999, LANCET, V353, P2001; Kleijn L, 2012, HEART, V98, P1237, DOI 10.1136/heartjnl-2012-301954; Looi KL, 2014, HEART, V100, P794, DOI 10.1136/heartjnl-2014-305537; McAlister FA, 2007, JAMA-J AM MED ASSOC, V297, P2502, DOI 10.1001/jama.297.22.2502; Michelucci A, 2007, J CARD FAIL, V13, P207, DOI 10.1016/j.cardfail.2006.11.013; Morani G, 2013, EUROPACE, V15, P1273, DOI 10.1093/europace/eut032; Mozaffarian D, 2007, CIRCULATION, V116, P392, DOI 10.1161/CIRCULATIONAHA.106.687103; Nauffal V, 2015, J AM COLL CARDIOL, V66, P2911, DOI 10.1016/j.jacc.2015.10.048; O'Meara E, 2006, CIRCULATION, V113, P986, DOI 10.1161/CIRCULATIONAHA.105.582577; Poole JE, 2010, CIRCULATION, V122, P1553, DOI 10.1161/CIRCULATIONAHA.110.976076; Rao RK, 2007, CIRCULATION, V115, P2136, DOI 10.1161/CIRCULATIONAHA.106.634444; Santini M, 2011, J AM COLL CARDIOL, V57, P167, DOI 10.1016/j.jacc.2010.08.624; Saxon LA, 2006, CIRCULATION, V114, P2766, DOI 10.1161/CIRCULATIONAHA.106.642892; Seta Y, 1996, J Card Fail, V2, P243, DOI 10.1016/S1071-9164(96)80047-9; Singh JP, 2011, CIRCULATION, V123, P1159, DOI 10.1161/CIRCULATIONAHA.110.000646; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Theuns DAMJ, 2012, PACE, V35, P275, DOI 10.1111/j.1540-8159.2011.03289.x; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4; van Bommel RJ, 2010, EUR HEART J, V31, P2783, DOI 10.1093/eurheartj/ehq252; Verma SK, 2012, CIRCULATION, V126, P418, DOI 10.1161/CIRCULATIONAHA.112.112185; Wu KC, 2012, CIRC-CARDIOVASC IMAG, V5, P178, DOI 10.1161/CIRCIMAGING.111.968024	30	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2017	12	4							0175205	10.1371/journal.pone.0175205	http://dx.doi.org/10.1371/journal.pone.0175205			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2RO	28388657	Green Submitted, gold, Green Published			2023-01-03	WOS:000399375800028
J	Krimpenfort, P; Berns, A				Krimpenfort, Paul; Berns, Anton			Rejuvenation by Therapeutic Elimination of Senescent Cells	CELL			English	Editorial Material							SECRETION	In this issue of Cell, Baar et al. show how FOXO4 protects senescent cell viability by keeping p53 sequestered in nuclear bodies, preventing it from inducing apoptosis. Disrupting this interaction with an all-D amino acid peptide (FOXO4-DRI) restores p53' s apoptotic role and ameliorates the consequences of senescence-associated loss of tissue homeostasis.	[Krimpenfort, Paul; Berns, Anton] Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands.	a.berns@nki.nl						Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; DiLoreto R, 2015, MOL BIOL CELL, V26, P4524, DOI 10.1091/mbc.E14-06-1084; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Martins R, 2016, AGING CELL, V15, P196, DOI 10.1111/acel.12427; Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340	9	7	9	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 23	2017	169	1					3	5		10.1016/j.cell.2017.03.014	http://dx.doi.org/10.1016/j.cell.2017.03.014			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EP0PU	28340347	Bronze			2023-01-03	WOS:000397090000002
J	Normile, D				Normile, Dennis			REGENERATIVE MEDICINE iPS cell therapy reported safe Researchers no longer envision replacement tissues tailor-made from each patient's cells	SCIENCE			English	News Item																			0	11	11	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1109	1110		10.1126/science.355.6330.1109	http://dx.doi.org/10.1126/science.355.6330.1109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9WV	28302802				2023-01-03	WOS:000396351200012
J	Salami, J; Crews, CM				Salami, Jemilat; Crews, Craig M.			Waste disposal-An attractive strategy for cancer therapy	SCIENCE			English	Review							RESISTANT PROSTATE-CANCER; BET BROMODOMAIN PROTEIN; MULTIPLE-MYELOMA CELLS; ANDROGEN RECEPTOR; BREAST-CANCER; SELECTIVE DEGRADATION; MEDIATED DEGRADATION; SMALL MOLECULES; TARGET; UBIQUITINATION	Targeted therapies for cancer are typically small molecules or monoclonal antibodies that act by inhibiting the activity of specific proteins that drive tumor growth. Although many of these drugs are effective in cancer patients, the response is often not durable because tumor cells develop resistance to the drugs. Another limitation of this strategy is that not all oncogenic driver proteins are "druggable" enzymes or receptors with activities that can be inhibited. Here we describe an alternative approach to targeted therapy that is based on co-opting the cellular quality-control machinery-the ubiquitin-proteasome system-to remove specific cancer-causing proteins from the cell. We first discuss examples of existing cancer drugs that work by degrading specific proteins and then review recent progress in the rational design and preclinical testing of small molecules that induce selective degradation of specific target proteins.	[Salami, Jemilat; Crews, Craig M.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Crews, Craig M.] Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA; [Crews, Craig M.] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Crews, CM (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.; Crews, CM (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.; Crews, CM (corresponding author), Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA.	craig.crews@yale.edu	Crews, Craig M./ABH-9346-2020; 高, 雨莉/HGU-8187-2022	Crews, Craig M./0000-0002-8456-2005; 	Leukemia and Lymphoma Society; NIH [R35CA197589]; Arvinas; NATIONAL CANCER INSTITUTE [R35CA197589] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arvinas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	C.M.C. is the chief scientific adviser of and is a shareholder in Arvinas, a biotechnology company focused on developing protein degradation therapeutics for cancer and other diseases. C.M.C. is an inventor on patent US7041298 B2 and patent applications PCT/US2013/040551, PCT/US2013/021136, EP20150180508, and PCT/US2011/063401 (submitted by Yale University) and PCT/US2015/025813 (submitted by Arvinas), which cover targeted protein degradation. C.M.C. acknowledges support from the Leukemia and Lymphoma Society and the NIH (grant R35CA197589). C.M.C. also receives research funding from Arvinas.	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Bill A, 2014, J BIOL CHEM, V289, P11029, DOI 10.1074/jbc.M114.549188; Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/nchembio.1858, 10.1038/NCHEMBIO.1858]; Buckley DL, 2012, ANGEW CHEM INT EDIT, V51, P11463, DOI 10.1002/anie.201206231; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Cyrus K, 2010, CHEMBIOCHEM, V11, P1531, DOI 10.1002/cbic.201000222; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; Garner F, 2015, ANTI-CANCER DRUG, V26, P948, DOI 10.1097/CAD.0000000000000271; Gustafson JL, 2015, ANGEW CHEM INT EDIT, V54, P9659, DOI 10.1002/anie.201503720; Howell A, 2003, CANCER CHEMOTH PHARM, V52, pS39, DOI 10.1007/s00280-003-0645-5; Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Itoh Y, 2010, J AM CHEM SOC, V132, P5820, DOI 10.1021/ja100691p; Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Lebraud H, 2016, ACS CENTRAL SCI, V2, P927, DOI 10.1021/acscentsci.6b00280; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mi LX, 2009, J BIOL CHEM, V284, P17039, DOI 10.1074/jbc.M901789200; Neklesa TK, 2011, NAT CHEM BIOL, V7, P538, DOI [10.1038/NCHEMBIO.597, 10.1038/nchembio.597]; Okuhira K, 2013, CANCER SCI, V104, P1492, DOI 10.1111/cas.12272; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113; Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Schneekloth AR, 2008, BIOORG MED CHEM LETT, V18, P5904, DOI 10.1016/j.bmcl.2008.07.114; Sekine K, 2008, J BIOL CHEM, V283, P8961, DOI 10.1074/jbc.M709525200; Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432; Teicher BA, 2015, BIOCHEM PHARMACOL, V96, P1, DOI 10.1016/j.bcp.2015.04.008; Tovar C, 2013, CANCER RES, V73, P2587, DOI 10.1158/0008-5472.CAN-12-2807; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Xie T, 2014, NAT CHEM BIOL, V10, P1006, DOI 10.1038/nchembio.1658; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhou Y, 2015, J MOL ENDOCRINOL, V54, pR15, DOI 10.1530/JME-14-0203	49	144	169	9	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1163	1167		10.1126/science.aam7340	http://dx.doi.org/10.1126/science.aam7340			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9WV	28302825				2023-01-03	WOS:000396351200034
J	Tolle, SW; Teno, JM				Tolle, Susan W.; Teno, Joan M.			Lessons from Oregon in Embracing Complexity in End-of-Life Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUSTAINING TREATMENT; PHYSICIAN ORDERS; TRANSITIONS; RESIDENTS; SURVIVAL; DEATH		[Tolle, Susan W.] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA; [Tolle, Susan W.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; [Teno, Joan M.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; [Teno, Joan M.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA	Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tolle, SW (corresponding author), Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.; Tolle, SW (corresponding author), Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA.							Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fromme EK, 2014, J AM GERIATR SOC, V62, P1246, DOI 10.1111/jgs.12889; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Hickman SE, 2011, J AM GERIATR SOC, V59, P2091, DOI 10.1111/j.1532-5415.2011.03656.x; Institute of Medicine, 2015, DYING AM IMPR QUAL H; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Mitchell SL, 2000, J GERONTOL A-BIOL, V55, pM735, DOI 10.1093/gerona/55.12.M735; Teno JM, 2014, JAMA-J AM MED ASSOC, V312, P1868, DOI 10.1001/jama.2014.14949; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Teno JM, 2012, J AM GERIATR SOC, V60, P1918, DOI 10.1111/j.1532-5415.2012.04148.x; Teno JM, 2012, ARCH INTERN MED, V172, P697, DOI 10.1001/archinternmed.2012.1200; The Dartmouth Atlas of Health Care, 2012, PERC DEC DEM REC FEE; Tolle S, 1994, SUNDAY OREGONIA 1113, pC1; Tolle S., 1994, SUNDAY OREGONIA 1113, pC4; Tolle SW, 2015, NEW ENGL J MED, V372, P667, DOI 10.1056/NEJMclde1411152; Zive DM, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0605-3	16	30	30	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2017	376	11					1078	1082		10.1056/NEJMsb1612511	http://dx.doi.org/10.1056/NEJMsb1612511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO0QT	28296604				2023-01-03	WOS:000396403700015
J	Horibe, R; Hirohashi, Y; Asano, T; Mariya, T; Suzuki, T; Takaya, A; Saijo, H; Shionoya, Y; Kubo, T; Nakatsugawa, M; Kanaseki, T; Tsukahara, T; Watanabe, K; Atsuyama, E; Toji, S; Hirano, H; Hasegawa, T; Takahashi, H; Sato, N; Torigoe, T				Horibe, Ryota; Hirohashi, Yoshihiko; Asano, Takuya; Mariya, Tasuku; Suzuki, Takeshi; Takaya, Akari; Saijo, Hiroshi; Shionoya, Yosuke; Kubo, Terufumi; Nakatsugawa, Munehide; Kanaseki, Takayuki; Tsukahara, Tomohide; Watanabe, Kazue; Atsuyama, Eri; Toji, Shingo; Hirano, Hiroshi; Hasegawa, Tadashi; Takahashi, Hiroki; Sato, Noriyuki; Torigoe, Toshihiko			Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy	PLOS ONE			English	Article							ACQUIRED-RESISTANCE; GENE-EXPRESSION; T-LYMPHOCYTES; THERAPIES; ANTIGEN; PROTEIN; MARKER; DOCETAXEL; NIVOLUMAB; ABILITY	Lung cancer is one of the most common malignancies with a high rate of mortality. Lung cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) play major role in resistance to treatments, recurrence and distant metastasis and eradication of CSCs/CICs is crucial to improve recent therapy. Cytotoxic T lymphocytes (CTLs) are major effectors of cancer immunotherapy, and CTLs recognize antigenic peptides derived from antigens that are presented by major histocompatibility complex (MHC) class I molecules. In this study, we analyzed the potency of a cancer-testis (CT) antigen, brother of the regulator of the imprinted site variant subfamily 6 (BORIS sf6), in lung CSC/CIC immunotherapy. BORIS sf6 mRNA was expressed in lung carcinoma cells (9/19), especially in sphere-cultured lung cancer stem-like cells, and in primary lung carcinoma tissues (4/9) by RT-PCR. Immunohistochemical staining using BORIS sf6-specific antibody revealed that high expression of BORIS sf6 is related to poorer prognosis. CTLs could be induced by using a human leukocyte antigen, (HLA)-A2 restricted antigenic peptide (BORIS C34_24(9)), from all of 3 HLA-A2-positive individuals, and CTL clone cells specific for BORIS C34_24(9) peptide could recognize BORIS sf6-positive, HLA-A2-positive lung carcinoma cells. These results indicate that BORIS sf6 is a novel target of lung cancer immunotherapy that might be useful for targeting treatment-resistant lung cancer stem-like cells.	[Horibe, Ryota; Hirohashi, Yoshihiko; Asano, Takuya; Mariya, Tasuku; Takaya, Akari; Saijo, Hiroshi; Shionoya, Yosuke; Kubo, Terufumi; Nakatsugawa, Munehide; Kanaseki, Takayuki; Tsukahara, Tomohide; Watanabe, Kazue; Sato, Noriyuki; Torigoe, Toshihiko] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan; [Horibe, Ryota; Saijo, Hiroshi; Shionoya, Yosuke; Takahashi, Hiroki] Sapporo Med Univ, Sch Med, Dept Resp Med & Allergol, Sapporo, Hokkaido, Japan; [Asano, Takuya; Mariya, Tasuku] Sapporo Med Univ, Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Suzuki, Takeshi] Sapporo Med Univ, Sch Med, Dept Biol, Sapporo, Hokkaido, Japan; [Watanabe, Kazue; Atsuyama, Eri; Toji, Shingo] MED & BIOL LABS CO LTD, Nagoya, Aichi, Japan; [Hirano, Hiroshi; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Torigoe, T (corresponding author), Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan.	hirohash@sapmed.ac.jp; torigoe@sapmed.ac.jp	Hirohashi, Yoshihiko/AFQ-4227-2022	Torigoe, Toshihiko/0000-0002-9463-5917; Kanaseki, Takayuki/0000-0001-7294-6880	Ministry of Education, Culture, Sports, Science and Technology of Japan; Health and Labor Sciences Research Grants; Ono Cancer Research Fund; Suharakinenzaidan Co., Ltd.; Northern Advancement Center for Science & Technology of Hokkaido Japan; Japan Agency for Medical Research and Development; AMED; MEDICAL and BIOLOGICAL LABORATORIES CO., LTD.; MEDICAL and BIOLOGICAL LABORATORIES CO., LTD	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Health and Labor Sciences Research Grants(Ministry of Health, Labour and Welfare, Japan); Ono Cancer Research Fund(Ono Cancer Research Fund); Suharakinenzaidan Co., Ltd.; Northern Advancement Center for Science & Technology of Hokkaido Japan; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); AMED; MEDICAL and BIOLOGICAL LABORATORIES CO., LTD.; MEDICAL and BIOLOGICAL LABORATORIES CO., LTD	This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to NS), program for developing the supporting system for upgrading education and research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to NS), Health and Labor Sciences Research Grants, a grant-in-aid of Ono Cancer Research Fund (to TTo), Suharakinenzaidan Co., Ltd. (to YH), Grants-in-Aid for Regional R&D Proposal-Based Program from Northern Advancement Center for Science & Technology of Hokkaido Japan (to YH and TTo) and the project for development of innovative research on cancer therapeutics from Japan Agency for Medical Research and Development, AMED and MEDICAL and BIOLOGICAL LABORATORIES CO., LTD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MEDICAL and BIOLOGICAL LABORATORIES CO., LTD provided support in the form of salaries for authors KW, EA and ST, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions section.	Asano T, 2016, ONCOTARGET; Boolell V, 2015, CANCERS, V7, P1815, DOI 10.3390/cancers7030864; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Cuffel C, 2011, INT J CANCER, V128, P2625, DOI 10.1002/ijc.25607; D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181; Darcy V, 2006, CLIN CANCER RES, V12, P5978, DOI 10.1158/1078-0432.CCR-05-2731; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Hashida S, 2015, CANCER SCI, V106, P1377, DOI 10.1111/cas.12749; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; Hirohashi Y, 2016, CANCER SCI, V107, P12, DOI 10.1111/cas.12830; Hirohashi Y, 2010, EXP MOL PATHOL, V88, P128, DOI 10.1016/j.yexmp.2009.09.021; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hoivik EA, 2014, ONCOTARGET, V5, P1052, DOI 10.18632/oncotarget.1697; Huang CP, 2013, CANCER LETT, V328, P144, DOI 10.1016/j.canlet.2012.08.021; Inoda S, 2011, AM J PATHOL, V178, P1805, DOI 10.1016/j.ajpath.2011.01.004; Inoda S, 2009, J IMMUNOTHER, V32, P474, DOI 10.1097/CJI.0b013e3181a1d109; INOUE Y, 1990, JPN J CANCER RES, V81, P1012, DOI 10.1111/j.1349-7006.1990.tb03339.x; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Kholmanskikh O, 2008, INT J CANCER, V122, P777, DOI 10.1002/ijc.23140; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062; Morita R, 2014, CANCER SCI, V105, P389, DOI 10.1111/cas.12362; Morita R, 2014, METHODS MOL BIOL, V1139, P345, DOI 10.1007/978-1-4939-0345-0_28; Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140; Nakatsugawa M, 2009, CANCER SCI, V100, P1485, DOI 10.1111/j.1349-7006.2009.01187.x; Nishizawa S, 2012, CANCER RES, V72, P2844, DOI 10.1158/0008-5472.CAN-11-3062; Okabayashi K, 2012, CANCER SCI, V103, P1617, DOI 10.1111/j.1349-7006.2012.02355.x; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Freitas MRP, 2013, ONCOTARGET, V4, P636, DOI 10.18632/oncotarget.950; Qiu XF, 2012, CANCER LETT, V323, P161, DOI 10.1016/j.canlet.2012.04.004; Renaud S, 2011, NUCLEIC ACIDS RES, V39, P862, DOI 10.1093/nar/gkq827; Reungwetwattana T, 2012, CLIN LUNG CANCER, V13, P252, DOI 10.1016/j.cllc.2011.09.004; Risinger JI, 2007, CLIN CANCER RES, V13, P1713, DOI 10.1158/1078-0432.CCR-05-2569; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Saijo H, 2016, ONCOTARGET; Shapiro M, 2013, CHEST, V144, P1615, DOI 10.1378/chest.12-3069; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sun FF, 2015, INT J CLIN EXP PATHO, V8, P6287; Takahashi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069095; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Woloszynska-Read Anna, 2007, Cancer Immun, V7, P21; Yamada R, 2013, TISSUE ANTIGENS; Yasuda K, 2014, LAB INVESTIGATION J; Zampieri M, 2014, BBA-GENE REGUL MECH, V1839, P813, DOI 10.1016/j.bbagrm.2014.06.017; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050	50	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0171460	10.1371/journal.pone.0171460	http://dx.doi.org/10.1371/journal.pone.0171460			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4NF	28248963	gold, Green Published, Green Submitted			2023-01-03	WOS:000395983500014
J	Sanhueza, L; Melo, R; Montero, R; Maisey, K; Mendoza, L; Wilkens, M				Sanhueza, Loreto; Melo, Ricardo; Montero, Ruth; Maisey, Kevin; Mendoza, Leonora; Wilkens, Marcela			Synergistic interactions between phenolic compounds identified in grape pomace extract with antibiotics of different classes against Staphylococcus aureus and Escherichia coli	PLOS ONE			English	Article							IN-VITRO; ANTIBACTERIAL ACTIVITIES; BIOLOGICAL-ACTIVITY; DRUG-RESISTANCE; VITIS-VINIFERA; SEED EXTRACT; BETA-LACTAMS; BY-PRODUCTS; METHICILLIN; POTENTIATION	Synergy could be an effective strategy to potentiate and recover antibiotics nowadays useless in clinical treatments against multi-resistant bacteria. In this study, synergic interactions between antibiotics and grape pomace extract that contains high concentration of phenolic compounds were evaluated by the checkerboard method in clinical isolates of Staphylococcus aureus and Escherichia coli. To define which component of the extract is responsible for the synergic effect, phenolic compounds were identified by RP-HPLC and their relative abundance was determined. Combinations of extract with pure compounds identified there in were also evaluated. Results showed that the grape pomace extract combined with representatives of different classes of antibiotics as beta-lactam, quinolone, fluoroquinolone, tetracycline and amphenicol act in synergy in all S. aureus and E. coli strains tested with FICI values varying from 0.031 to 0.155. The minimal inhibitory concentration (MIC) was reduced 4 to 75 times. The most abundant phenolic compounds identified in the extract were quercetin, gallic acid, protocatechuic acid and luteolin with relative abundance of 26.3, 24.4, 16.7 and 11.4%, respectively. All combinations of the extract with the components also showed synergy with FICI values varying from 0.031 to 0.5 and MIC reductions of 4 to 125 times with both bacteria strains. The relative abundance of phenolic compounds has no correlation with the obtained synergic effect, suggesting that the mechanism by which the synergic effect occurs is by a multi-objective action. It was also shown that combinations of grape pomace extract with antibiotics are not toxic for the HeLa cell line at concentrations in which the synergistic effect was observed (47 mu g/mL of extract and 0.6-375 mu g/mL antibiotics). Therefore, these combinations are good candidates for testing in animal models in order to enhance the effect of antibiotics of different classes and thus restore the currently unused clinical antibiotics due to the phenomenon of resistance. Moreover, the use of grape pomace is a good and low-cost alternative for this purpose being a waste residue of the wine industry.	[Sanhueza, Loreto; Melo, Ricardo] Univ Mayor, Fac Ciencias, Nucleo Quim & Bioquim, Santiago, Chile; [Montero, Ruth; Maisey, Kevin] Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Lab Inmunol Comparat, Santiago, Chile; [Mendoza, Leonora] Univ Santiago Chile, Fac Quim & Biol, Dept Quim Mat, Lab Micol, Santiago, Chile; [Wilkens, Marcela] Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Lab Microbiol Basica & Aplicada, Santiago, Chile	Universidad Mayor; Universidad de Santiago de Chile; Universidad de Santiago de Chile; Universidad de Santiago de Chile	Wilkens, M (corresponding author), Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Lab Microbiol Basica & Aplicada, Santiago, Chile.	marcela.wilkens@usach.cl	Maisey, Kevin/AAP-2886-2021; Wilkens, Marcela/G-5928-2019	Maisey, Kevin/0000-0002-7423-6329; Montero, Ruth Tamara/0000-0002-3019-1800	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [1130389]; Direccion de Investigacion en Ciencia y Tecnologia (DICYT-USACH); Comision Nacional de Ciencia y Tecnologia (CONICYT)	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Direccion de Investigacion en Ciencia y Tecnologia (DICYT-USACH); Comision Nacional de Ciencia y Tecnologia (CONICYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT))	This study was supported financially under Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) project 1130389 and by the Direccion de Investigacion en Ciencia y Tecnologia (DICYT-USACH). L.Sanhueza thanks the Comision Nacional de Ciencia y Tecnologia (CONICYT) for its support of her doctoral studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin MU, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0580-0; Anastasiadi M, 2009, J AGR FOOD CHEM, V57, P457, DOI 10.1021/jf8024979; de Almeida MRA, 2013, PAK J PHARM SCI, V26, P881; Betoni JEC, 2006, MEM I OSWALDO CRUZ, V101, P387, DOI 10.1590/S0074-02762006000400007; Braga LKA, 2011, AFR J PHARM PHARMACO, V5, P2145, DOI 10.5897/AJPP11.414; Brown JC, 2009, APPL ENVIRON MICROB, V75, P848, DOI 10.1128/AEM.01595-08; Casagrande JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112748; *CLSI, 2005, PERF STAND ANT SUSC; Corrales M, 2010, FOOD CHEM TOXICOL, V48, P3471, DOI 10.1016/j.fct.2010.09.025; Coutinho HDM, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-13; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002; Eumkeb G, 2012, J PHOTOCH PHOTOBIO B, V117, P247, DOI 10.1016/j.jphotobiol.2012.10.006; Eumkeb G, 2012, J APPL MICROBIOL, V112, P55, DOI 10.1111/j.1365-2672.2011.05190.x; Fujita M, 2005, MICROBIOL IMMUNOL, V49, P391, DOI 10.1111/j.1348-0421.2005.tb03732.x; Furiga A, 2009, FOOD CHEM, V113, P1037, DOI 10.1016/j.foodchem.2008.08.059; Garvey MI, 2011, INT J ANTIMICROB AG, V37, P145, DOI 10.1016/j.ijantimicag.2010.10.027; Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008; Isogai E, 2001, CURR MICROBIOL, V42, P248, DOI 10.1007/s002840010212; Kammerer D, 2004, J AGR FOOD CHEM, V52, P4360, DOI 10.1021/jf049613b; Kao TT, 2010, INT J FOOD MICROBIOL, V141, P17, DOI 10.1016/j.ijfoodmicro.2010.04.025; Kourtesi Christina, 2013, Open Microbiol J, V7, P34, DOI 10.2174/1874285801307010034; Kuete V, 2011, INT J ANTIMICROB AG, V37, P156, DOI 10.1016/j.ijantimicag.2010.10.020; Lafka TI, 2007, FOOD CHEM, V104, P1206, DOI 10.1016/j.foodchem.2007.01.068; Li XZ, 2009, DRUGS, V69, P1555, DOI 10.2165/11317030-000000000-00000; Mendoza L, 2013, IND CROP PROD, V43, P360, DOI [10.1016/j.indcrop.2012.07.048, 10.1016/j.indcroP.2012.07.048]; Motyl M., 2005, CURRENT PROTOCOLS PH; Mun SH, 2013, PHYTOMEDICINE, V20, P714, DOI 10.1016/j.phymed.2013.02.006; Nicoletti I, 2008, J AGR FOOD CHEM, V56, P8801, DOI 10.1021/jf801411m; Ozkan G, 2004, J SCI FOOD AGR, V84, P1807, DOI 10.1002/jsfa.1901; Rockenbach II, 2011, FOOD CHEM, V127, P174, DOI 10.1016/j.foodchem.2010.12.137; Sagdic O, 2011, FOOD CHEM, V126, P1749, DOI 10.1016/j.foodchem.2010.12.075; Sanhueza L, 2014, J ADV MICROBIOLOGY, V4, P225, DOI [DOI 10.4236/AIM.2014.45029, 10.4236/aim.2014.45029]; Shibata H, 2009, ANTIMICROB AGENTS CH, V53, P2218, DOI 10.1128/AAC.00829-08; Shiota S, 2004, MICROBIOL IMMUNOL, V48, P67, DOI 10.1111/j.1348-0421.2004.tb03489.x; Stapleton PD, 2004, INT J ANTIMICROB AG, V23, P462, DOI 10.1016/j.ijantimicag.2003.09.027; Stefanovic O, 2011, J MED PLANTS RES, V5, P4074; Thimothe J, 2007, J AGR FOOD CHEM, V55, P10200, DOI 10.1021/jf0722405; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Wilkens M, 2002, PLANTA MED, V68, P452, DOI 10.1055/s-2002-32086; Xia EQ, 2010, INT J MOL SCI, V11, P622, DOI 10.3390/ijms11020622; Xie YX, 2015, CURR MED CHEM, V22, P132	42	89	95	4	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0172273	10.1371/journal.pone.0172273	http://dx.doi.org/10.1371/journal.pone.0172273			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28235054	Green Published, Green Submitted, gold			2023-01-03	WOS:000394688200061
J	DeLoughery, T				DeLoughery, Thomas			Guideline: A hemoglobin threshold of 7 to 8 g/dL is recommended for hemodynamically stable hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[DeLoughery, Thomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	DeLoughery, T (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.							Adams RC., 1942, SURG GYNECOL OBSTET, V3, P603; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Heddle NM, 2016, NEW ENGL J MED, V375, P1937, DOI 10.1056/NEJMoa1609014	3	1	1	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2017	166	4					JC15	JC15		10.7326/ACPJC-2017-166-4-015	http://dx.doi.org/10.7326/ACPJC-2017-166-4-015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL7FO	28241288				2023-01-03	WOS:000394786700003
J	Liao, JM; Schapira, MS; Navathe, AS; Mitra, N; Weissman, A; Asch, DA				Liao, Joshua M.; Schapira, Marilyn S.; Navathe, Amol S.; Mitra, Nandita; Weissman, Arlene; Asch, David A.			The Effect of Emphasizing Patient, Societal, and Institutional Harms of Inappropriate Antibiotic Prescribing on Physician Support of Financial Penalties: A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Letter									[Liao, Joshua M.; Schapira, Marilyn S.; Navathe, Amol S.; Mitra, Nandita; Asch, David A.] Univ Penn, Philadelphia, PA 19104 USA; [Schapira, Marilyn S.; Navathe, Amol S.; Asch, David A.] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Weissman, Arlene] Amer Coll Physicians, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; American College of Physicians	Liao, JM (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X; Navathe, Amol/0000-0001-7182-4988	Leonard Davis Institute of Health Economics at the University of Pennsylvania	Leonard Davis Institute of Health Economics at the University of Pennsylvania	By the Leonard Davis Institute of Health Economics at the University of Pennsylvania, which had no role in the study design, data collection, analysis, or interpretation of results.	American Board of Internal Medicine Foundation, 2017, CHOOS WISELY; Berwick DM, 2017, LANCET, P32570, DOI [10.1016/S0140-6736, DOI 10.1016/S0140-6736]; Centers for Medicare & Medicaid Services, 2016, CMS RESP PUBL COMM N; Mafi JN, 2016, ANN INTERN MED, V165, P237, DOI 10.7326/M15-2152; Rosenberg A, 2015, JAMA INTERN MED, V175, P1913, DOI 10.1001/jamainternmed.2015.5441	5	14	14	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2017	167	3					215	216		10.7326/L17-0102	http://dx.doi.org/10.7326/L17-0102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC1XN	28631001				2023-01-03	WOS:000406631400017
J	Lam, KYC; Yao, P; Wang, HY; Duan, R; Dong, TTX; Tsim, KWK				Lam, Kelly Y. C.; Yao, Ping; Wang, Huaiyou; Duan, Ran; Dong, Tina T. X.; Tsim, Karl W. K.			Asarone from Acori Tatarinowii Rhizome prevents oxidative stress-induced cell injury in cultured astrocytes: A signaling triggered by Akt activation	PLOS ONE			English	Article							ALPHA-ASARONE; GENE-EXPRESSION; ANTIOXIDANT; INDUCTION; REGIONS; CALAMUS	Acori Tatarinowii Rhizome (ATR; the dried rhizome of Acori tatarinowii Schott) is a well-known herb being used for mental disorder in China and Asia. Volatile oil is considered as the active ingredient of ATR, and asarones account for more than 90% of total volatile oil. Here, the protective effects of ATR oil and asarones, both alpha-asarone and beta-asarone, were probed in cultured rat astrocytes. The cyto-protective effect of ATR oil and asarones against tBHP-induced astrocyte injury was revealed, and additionally ATR oil and asarones reduced the tBHP-induced intracellular reactive oxygen species (ROS) accumulation. In parallel, the activity of anti-oxidant response element (ARE) promoter construct (pARE-Luc), being transfected in cultured astrocytes, was markedly induced by application of ATR oil and asarones. The mRNAs encoding anti-oxidant enzymes, e.g. glutathione S-transferase (GST), glutamate-cysteine ligase modulatory subunit (GCLM), glutamate-cysteine ligase catalytic subunit (GCLC) and NAD(P) H quinone oxidoreductase (NQO1) were induced by ATR oil and asarones in a dose-dependent manner. The ATR oil/asarone-induced gene expression could be mediated by Akt phosphorylation; because the applied LY294002, a phosphoinositide 3-kinase inhibitor, fully abolished the induction. These results demonstrated that a-asarone and beta-asarone could account, at least partly, the function of ATR being a Chinese medicinal herb.	[Lam, Kelly Y. C.; Yao, Ping; Wang, Huaiyou; Duan, Ran; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Wang, Huaiyou; Duan, Ran; Dong, Tina T. X.; Tsim, Karl W. K.] HKUST Shenzhen Res Inst, Hitech Pk, Shenzhen, Guangdong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Ctr Chinese Med, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.; Tsim, KWK (corresponding author), HKUST Shenzhen Res Inst, Hitech Pk, Shenzhen, Guangdong, Peoples R China.	botsim@ust.hk		Tsim, Karl/0000-0003-4808-1674; Wang, Huai-You/0000-0003-1407-9912	Hong Kong Research Grants Council [T13-607/12R, 663012, 662713, M-HKUST604/13, TUYF15SC01]; Hong Kong Jockey Club Charities Trust [HKJCCT12SC01]; Foundation of The Awareness of Nature [TAON12SC01, JCYJ20160229205726699, JCYJ20160229205812004]; Lee's Pharmaceutical Co. Ltd.	Hong Kong Research Grants Council(Hong Kong Research Grants Council); Hong Kong Jockey Club Charities Trust; Foundation of The Awareness of Nature; Lee's Pharmaceutical Co. Ltd.	This research was supported by Hong Kong Research Grants Council Theme-based Research Scheme (T13-607/12R), GRF (663012, 662713, M-HKUST604/13), TUYF15SC01, The Hong Kong Jockey Club Charities Trust (HKJCCT12SC01) and Foundation of The Awareness of Nature (TAON12SC01) to Karl TSIM, JCYJ20160229205726699 to Prof. Tsim, JCYJ20160229205812004 to Dr. Dong and JCYJ20160229210027564 to Dr. Wang. Kelly Y.C. LAM received a Kanya Lee Scholarship from Lee's Pharmaceutical Co. Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn Jee-Yin, 2014, Exp Neurobiol, V23, P200, DOI 10.5607/en.2014.23.3.200; Chen JP, 2014, PHYTOTHER RES, V28, P1727, DOI 10.1002/ptr.5202; Chen JP, 2013, J AGR FOOD CHEM, V61, P7315, DOI 10.1021/jf402379u; Chong ZZ, 2012, FUTUR NEUROL, V7, P733, DOI 10.2217/FNL.12.72; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Limon ID, 2009, NEUROSCI LETT, V453, P98, DOI 10.1016/j.neulet.2009.02.011; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dowell JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070163; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal Y, 2015, PLANTA MED, V81, P333, DOI 10.1055/s-0035-1545694; Keenoy BMY, 2001, LIFE SCI, V68, P2037, DOI 10.1016/S0024-3205(01)01001-3; Kovacic P, 2012, CURR NEUROPHARMACOL, V10, P289, DOI 10.2174/157015912804143487; Kumar H, 2012, BIOSCI BIOTECH BIOCH, V76, P1518, DOI 10.1271/bbb.120247; Lam KYC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163337; Lam KYC, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0113-x; Liang L, 2013, J AGR FOOD CHEM, V61, P2755, DOI 10.1021/jf304768p; Maiwulanjiang M, 2014, J ETHNOPHARMACOL, V153, P491, DOI 10.1016/j.jep.2014.03.010; Maiwulanjiang M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/687958; Manikandan S, 2005, BIOL PHARM BULL, V28, P2327, DOI 10.1248/bpb.28.2327; Manikandan S, 2005, PHARMACOL RES, V52, P467, DOI 10.1016/j.phrs.2005.07.007; Meuillet EJ, 2011, CURR MED CHEM, V18, P2727; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Pages N, 2010, NEUROSCI RES, V68, P337, DOI 10.1016/j.neures.2010.08.011; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Yang YX, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-236; Zhang L, 2010, BRAIN RES, V1357, P157, DOI 10.1016/j.brainres.2010.08.007; Zhu JTT, 2007, J AGR FOOD CHEM, V55, P2438, DOI 10.1021/jf063299z; ZHU KY, 2013, EVID-BASED COMPL ALT, V2013, P31385	29	26	26	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2017	12	6							e0179077	10.1371/journal.pone.0179077	http://dx.doi.org/10.1371/journal.pone.0179077			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX1NV	28598994	Green Published, Green Submitted, gold			2023-01-03	WOS:000402992000022
J	Fernandez-Sanchez, L; Bravo-Osuna, I; Lax, P; Arranz-Romera, A; Maneu, V; Esteban-Perez, S; Pinilla, I; Puebla-Gonzalez, MD; Herrero-Vanrell, R; Cuenca, N				Fernandez-Sanchez, Laura; Bravo-Osuna, Irene; Lax, Pedro; Arranz-Romera, Alicia; Maneu, Victoria; Esteban-Perez, Sergio; Pinilla, Isabel; del Mar Puebla-Gonzalez, Maria; Herrero-Vanrell, Rocio; Cuenca, Nicolas			Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats	PLOS ONE			English	Article							PHOTORECEPTOR CELL-DEATH; CONTROLLED DRUG-DELIVERY; RETINITIS-PIGMENTOSA; GANGLION-CELLS; MOUSE MODELS; RHODOPSIN; TUDCA; PLGA; BILE; SURVIVAL	Successful drug therapies for treating ocular diseases require effective concentrations of neuroprotective compounds maintained over time at the site of action. The purpose of this work was to assess the efficacy of intravitreal controlled delivery of tauroursodeoxycholic acid (TUDCA) encapsulated in poly(D, L-lactic-co-glycolic acid) (PLGA) microspheres for the treatment of the retina in a rat model of retinitis pigmentosa. PLGA microspheres (MSs) containing TUDCA were produced by the O/W emulsion-solvent evaporation technique. Particle size and morphology were assessed by light scattering and scanning electronic microscopy, respectively. Homozygous P23H line 3 rats received a treatment of intravitreal injections of TUDCA-PLGA MSs. Retinal function was assessed by electroretinography at P30, P60, P90 and P120. The density, structure and synaptic contacts of retinal neurons were analyzed using immunofluorescence and confocal microscopy at P90 and P120. TUDCA-loaded PLGA MSs were spherical, with a smooth surface. The production yield was 78%, the MSs mean particle size was 23 mu m and the drug loading resulted 12.5 +/- 0.8 mu g TUDCA/mg MSs. MSs were able to deliver the loaded active compound in a gradual and progressive manner over the 28-day in vitro release study. Scotopic electroretinografic responses showed increased ERG a- and b-wave amplitudes in TUDCA-PLGA-MSstreated eyes as compared to those injected with unloaded PLGA particles.TUDCA-PLGAMSs- treated eyes showed more photoreceptor rows than controls. The synaptic contacts of photoreceptors with bipolar and horizontal cells were also preserved in P23H rats treated with TUDCA-PLGA MSs. This work indicates that the slow and continuous delivery of TUDCA from PLGA-MSs has potential neuroprotective effects that could constitute a suitable therapy to prevent neurodegeneration and visual loss in retinitis pigmentosa.	[Fernandez-Sanchez, Laura; Lax, Pedro; Cuenca, Nicolas] Univ Alicante, Dept Physiol Genet & Microbiol, Alicante, Spain; [Bravo-Osuna, Irene; Arranz-Romera, Alicia; Esteban-Perez, Sergio; del Mar Puebla-Gonzalez, Maria; Herrero-Vanrell, Rocio] Univ Complutense Madrid, Fac Pharm, Dept Pharm & Pharmaceut Technol, Madrid, Spain; [Maneu, Victoria] Univ Alicante, Dept Opt Pharmacol & Anat, Alicante, Spain; [Pinilla, Isabel] Lozano Blesa Univ Hosp, Dept Ophthalmol, Zaragoza, Spain; [Pinilla, Isabel] Aragon Inst Hlth Res IIS Aragon, Zaragoza, Spain; [Herrero-Vanrell, Rocio] San Carlos Clin Hosp IdISSC, Sanit Res Inst, Madrid, Spain; [Herrero-Vanrell, Rocio] Univ Complutense Madrid, Ind Pharm Inst, Madrid, Spain; [Cuenca, Nicolas] Univ Alicante, Inst Ramon Margalef, Alicante, Spain	Universitat d'Alacant; Complutense University of Madrid; Universitat d'Alacant; Lozano Blesa University Clinical Hospital; Complutense University of Madrid; Universitat d'Alacant	Cuenca, N (corresponding author), Univ Alicante, Dept Physiol Genet & Microbiol, Alicante, Spain.; Herrero-Vanrell, R (corresponding author), Univ Complutense Madrid, Fac Pharm, Dept Pharm & Pharmaceut Technol, Madrid, Spain.; Herrero-Vanrell, R (corresponding author), San Carlos Clin Hosp IdISSC, Sanit Res Inst, Madrid, Spain.; Herrero-Vanrell, R (corresponding author), Univ Complutense Madrid, Ind Pharm Inst, Madrid, Spain.; Cuenca, N (corresponding author), Univ Alicante, Inst Ramon Margalef, Alicante, Spain.	rociohv@ucm.es; cuenca@ua.es	bravo-osuna, irene/M-3469-2015; Cuenca, Nicolas/I-2007-2015; Pérez, Sergio Esteban/K-6400-2017; Maneu, Victoria/N-4147-2014; Lax, Pedro/M-9074-2014; Fernandez-Sanchez, Laura/AAB-5663-2019	bravo-osuna, irene/0000-0003-3133-7872; Cuenca, Nicolas/0000-0002-6767-5710; Pérez, Sergio Esteban/0000-0003-4832-0778; Maneu, Victoria/0000-0002-5265-1361; Lax, Pedro/0000-0001-6931-1008; Fernandez-Sanchez, Laura/0000-0002-3629-0156	Spanish Ministry of Economy and Competitiveness [MINECO-FEDER BFU2015-67139-R, MICINN-FEDER MAT 2013-43127R]; Institute de Salud Carlos III [RETICS-FEDER RD16/0008/0016, RD16/0008/0009]; Complutense Research Group [UCM920415]; Generalitat Valenciana [PROMETEO/2016/158]	Spanish Ministry of Economy and Competitiveness(Spanish Government); Institute de Salud Carlos III(Instituto de Salud Carlos III); Complutense Research Group; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission)	This work was supported by The Spanish Ministry of Economy and Competitiveness (MINECO-FEDER BFU2015-67139-R, to NC; MICINN-FEDER MAT 2013-43127R to RH-V) (http://www.mineco.gob.es); Institute de Salud Carlos III (RETICS-FEDER RD16/0008/0016, to NC; RD16/0008/0009 to RH-V) (http://www.oftared.com/); Complutense Research Group (UCM920415) to RH-V (https://www.ucm.es/); and Generalitat Valenciana PROMETEO/2016/158 to NC (http://www.gva.es).	Abrego G, 2015, EUR J PHARM BIOPHARM, V95, P261, DOI 10.1016/j.ejpb.2015.01.026; Andres-Guerrero V, 2015, J CONTROL RELEASE, V211, P105, DOI 10.1016/j.jconrel.2015.05.279; Arango-Gonzalez B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112142; Boatright JH, 2006, MOL VIS, V12, P1706; Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149; Castro-Caldas M, 2012, MOL NEUROBIOL, V46, P475, DOI 10.1007/s12035-012-8295-4; Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8; Checa-Casalengua P, 2011, J CONTROL RELEASE, V156, P92, DOI 10.1016/j.jconrel.2011.06.023; Chennamaneni SR, 2013, J CONTROL RELEASE, V167, P53, DOI 10.1016/j.jconrel.2013.01.007; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; Cortez LM, 2015, J VIROL, V89, P7660, DOI 10.1128/JVI.01165-15; Cuenca N, 2004, NEUROSCIENCE, V127, P301, DOI 10.1016/j.neuroscience.2004.04.042; Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001; Doonan F, 2005, INVEST OPHTH VIS SCI, V46, P3530, DOI 10.1167/iovs.05-0248; Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Duan WM, 2002, CELL TRANSPLANT, V11, P195; Elia AE, 2015, EUR J NEUROL; Esquiva G, 2013, INVEST OPHTH VIS SCI, V54, P4605, DOI 10.1167/iovs.13-12120; Fernandez-Sanchez L, 2015, MOLECULES, V20, P13875, DOI 10.3390/molecules200813875; Fernaandez-Saanchez L, 2014, INVEST OPHTH VIS SCI, V55, P6059, DOI 10.1167/iovs.14-14421; Fernandez-Sanchez L, 2012, HUM GENE THER, V23, P1290, DOI 10.1089/hum.2012.067; Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074; Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496; Fu YB, 2014, ADV EXP MED BIOL, V801, P791, DOI 10.1007/978-1-4614-3209-8_99; Garcia-Ayuso D, 2010, EXP EYE RES; Garcia-Ayuso D, 2015, INVEST OPHTH VIS SCI, V56, P4592, DOI 10.1167/iovs.15-16808; Gaspar JM, 2013, NEUROSCIENCE, V253, P380, DOI 10.1016/j.neuroscience.2013.08.053; Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3; GIORDANO GG, 1995, CURR EYE RES, V14, P761, DOI 10.3109/02713689508995797; Gomez-Vicente V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137826; Gong J, 2006, BRAIN RES, V1082, P73, DOI 10.1016/j.brainres.2006.01.111; Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7; Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9; Herrero-Vanrell R, 2011, INVEST OPHTHALMOL, V52, P3251, DOI 10.1016/i.exer.2015.10.012; Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jiang C, 2007, MOL VIS, V13, P1783; Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2; Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006; Kaur J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022181; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; KHOOBEHI B, 1991, OPHTHALMIC SURG LAS, V22, P175; Kolomiets B, 2010, NEUROBIOL DIS, V38, P47, DOI 10.1016/j.nbd.2009.12.025; Lawson EC, 2016, ADV EXP MED BIOL, V854, P431, DOI 10.1007/978-3-319-17121-0_57; Lax P, 2011, J PINEAL RES, V50, P183, DOI 10.1111/j.1600-079X.2010.00827.x; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245; Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363; Muller LPD, 2015, J COMP NEUROL, V523, P1443, DOI 10.1002/cne.23751; Noailles A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0186-3; Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x; Paganelli F, 2010, EXPERT OPIN DRUG DEL, V7, P955, DOI 10.1517/17425247.2010.498817; Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012; Pinilla I, 2005, NEUROSCI LETT, V382, P16, DOI 10.1016/j.neulet.2005.02.055; Pinilla I, 2016, EXP EYE RES, V150, P122, DOI 10.1016/j.exer.2015.10.012; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Puthussery T, 2010, ADV EXP MED BIOL, V664, P525, DOI 10.1007/978-1-4419-1399-9_60; RADOMSKY ML, 1990, BIOMATERIALS, V11, P619, DOI 10.1016/0142-9612(90)90018-L; Ran X, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau047; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Rong XF, 2014, INT J NANOMED, V9, P3057, DOI 10.2147/IJN.S64100; Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Veloso Jr AA., 1997, INVEST OPHTHALMOL, V38; Viana RJS, 2009, CELL MOL LIFE SCI, V66, P1094, DOI 10.1007/s00018-009-8746-x; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003; Zhang HB, 2003, INVEST OPHTH VIS SCI, V44, P2858, DOI 10.1167/iovs.03-0072; Zhang T, 2012, INVEST OPHTH VIS SCI, V53, P3349, DOI 10.1167/iovs.12-9851	73	36	36	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2017	12	5							e0177998	10.1371/journal.pone.0177998	http://dx.doi.org/10.1371/journal.pone.0177998			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VR	28542454	Green Submitted, Green Published, gold			2023-01-03	WOS:000402062800034
J	Afiatin; Khoe, LC; Kristin, E; Masytoh, LS; Herlinawaty, E; Werayingyong, P; Nadjib, M; Sastroasmoro, S; Teerawattananon, Y				Afiatin; Khoe, Levina Chandra; Kristin, Erna; Masytoh, Lusiana Siti; Herlinawaty, Eva; Werayingyong, Pitsaphun; Nadjib, Mardiati; Sastroasmoro, Sudigdo; Teerawattananon, Yot			Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia	PLOS ONE			English	Article							PERITONEAL-DIALYSIS; CENTER HEMODIALYSIS; KIDNEY-DISEASE	Objectives This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD) in Indonesia. Methods A Markov model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Three policy options were compared, i.e., the PD-first policy, HD-first policy, and supportive care. Results The PD-first policy for ESRD patients resulted in 5.93 life years, equal to the HD-first policy, with a slightly higher QALY gained (4.40 vs 4.34). The total lifetime cost for a patient under the PD-first policy is around 700 million IDR, which is lower than the cost under the HD-first policy, i.e. 735 million IDR per patient. Compared to supportive care, the incremental cost-effectiveness ratio of the PD-first policy is 193 million IDR per QALY, while the HD-first policy resulted in 207 million IDR per QALY. Budget impact analysis indicated that the required budget for the PD-first policy is 43 trillion IDR for 53% coverage and 75 trillion IDR for 100% coverage in five years, which is less than the HD-first policy, i.e. 88 trillion IDR and 166 trillion IDR. Conclusions The PD-first policy was found to be more cost-effective compared to the HD-first policy. Budget impact analysis provided evidence on the enormous financial burden for the country if the current practice, where HD dominates PD, continues for the next five years.	[Afiatin] Univ Padjadjaran, Fac Med, Dept Internal Med, Bandung, Indonesia; [Khoe, Levina Chandra] Univ Indonesia, Fac Med, Dept Community Med, Jakarta, Indonesia; [Kristin, Erna] Univ Gadjah Mada, Fac Med, Dept Pharmacol & Therapy, Yogyakarta, Indonesia; [Masytoh, Lusiana Siti; Herlinawaty, Eva] Minist Hlth, Ctr Hlth Financing & Secur, Jakarta, Indonesia; [Werayingyong, Pitsaphun; Teerawattananon, Yot] Minist Publ Hlth, HITAP, Bangkok, Thailand; [Nadjib, Mardiati; Sastroasmoro, Sudigdo] Indonesian Hlth Technol Assessment Comm, Jakarta, Indonesia	Universitas Padjadjaran; University of Indonesia; Gadjah Mada University; Ministry of Health - Indonesia; Ministry of Public Health - Thailand	Khoe, LC (corresponding author), Univ Indonesia, Fac Med, Dept Community Med, Jakarta, Indonesia.	levinachandramd@gmail.com	Kristin, Erna/AAB-7461-2021	Kristin, Erna/0000-0002-5609-6078; Teerawattananon, Yot/0000-0003-2217-2930; Khoe, Levina/0000-0002-2050-392X	Ministry of Health, Indonesia; Australian Indonesian Partnership for Health Systems Strengthening (AIPHSS) under the Department of Foreign Affairs Trade, Australia; International Decision Support Initiative (iDSI); Bill & Melinda Gates Foundation; UK's Department for International Development; Rockefeller Foundation	Ministry of Health, Indonesia; Australian Indonesian Partnership for Health Systems Strengthening (AIPHSS) under the Department of Foreign Affairs Trade, Australia; International Decision Support Initiative (iDSI); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK's Department for International Development; Rockefeller Foundation	This work received funding support from the state budget from the Ministry of Health, Indonesia and the Australian Indonesian Partnership for Health Systems Strengthening (AIPHSS) under the Department of Foreign Affairs Trade, Australia. Technical assistance from the Health Intervention and Technology Assessment Program (HITAP) International Unit was supported by International Decision Support Initiative (iDSI) to provide technical assistance on health intervention and technology assessment to governments in low- and middle-income countries. iDSI is funded by the Bill & Melinda Gates Foundation, the UK's Department for International Development, and the Rockefeller Foundation. The HITAP team provided technical assistance to the authors throughout the conduct of the research, the writing of the report, and the publication process. The other funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, STAND TAR HLTH SERV; Berns JS, 2015, PATIENT INFORM HEMOD; BPJS-K, 2014, INF BPJS KES; Chanouzas D, 2012, NEPHROL DIAL TRANSPL, V27, P1542, DOI 10.1093/ndt/gfr452; de Wit GA, 2002, NEPHROL DIAL TRANSPL, V17, P86, DOI 10.1093/ndt/17.1.86; de Wit GA, 1998, HEALTH POLICY, V44, P215, DOI 10.1016/S0168-8510(98)00017-7; Hooi LS, 2005, NEPHROLOGY, V10, P25, DOI 10.1111/j.1440-1797.2005.00360.x; Indonesian Renal Registry, 2014, 7 IND REN REG; Indonesian Renal Registry, 2013, 6 IND REN REG; Just PM, 2008, HEALTH POLICY, V86, P163, DOI 10.1016/j.healthpol.2007.12.004; KARLBERG I, 1995, INT J TECHNOL ASSESS, V11, P611, DOI 10.1017/S026646230000876X; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Li PKT, 2001, PERITON DIALYSIS INT, V21, pS307; Lim T O, 1999, Med J Malaysia, V54, P442; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; National Healthcare Security Agency, 2015, MIN HLTH; National Institute of Health Research and Development, 2013, BAS HLTH SURV; Novelia E., 2014, THESIS; Sennfalt K, 2001, PERITON DIALYSIS INT, V22, P39; Smith C, 2003, NEPHRON CLIN PRACT, V95, pC40, DOI 10.1159/000073708; Stanley M, 2010, NEPHROLOGY, V15, pS24, DOI 10.1111/j.1440-1797.2010.01228.x; Teerawattananon Y, 2007, VALUE HEALTH, V10, P61, DOI 10.1111/j.1524-4733.2006.00145.x; Teerawattananon Y, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0090-7; Tongsiri S, 2011, VALUE HEALTH, V14, P1142, DOI 10.1016/j.jval.2011.06.005; Treharne C, 2014, APPL HEALTH ECON HEA, V12, P409, DOI 10.1007/s40258-014-0108-7; Vale L, 2004, COCHRANE DATABASE SY; Wasserfallen JB, 2004, NEPHROL DIAL TRANSPL, V19, P1594, DOI 10.1093/ndt/gfh175; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Wong CF, 2007, RENAL FAILURE, V29, P653, DOI 10.1080/08860220701459634	31	29	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2017	12	5							e0177436	10.1371/journal.pone.0177436	http://dx.doi.org/10.1371/journal.pone.0177436			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV3PV	28545094	Green Published, gold, Green Submitted			2023-01-03	WOS:000401672400043
J	Beyreuther, E; Bruchner, K; Krause, M; Schmidt, M; Szabo, R; Pawelke, J				Beyreuther, Elke; Bruechner, Kerstin; Krause, Mechthild; Schmidt, Margret; Szabo, Rita; Pawelke, Joerg			An optimized small animal tumour model for experimentation with low energy protons	PLOS ONE			English	Article							LASER-DRIVEN; CELL-LINE; CANCER; MATRIGEL; FADU	Background The long-term aim of developing laser based particle acceleration towards clinical application requires not only substantial technological progress, but also the radiobiological characterization of the resulting ultra-short and ultra-intensive particle beam pulses. After comprehensive cell studies a mouse ear tumour model was established allowing for the penetration of low energy protons (similar to 20 MeV) currently available at laser driven accelerators. The model was successfully applied for a first tumour growth delay study with laser driven electrons, whereby the need of improvements crop out. Methods To optimise the mouse ear tumour model with respect to a stable, high take rate and a lower number of secondary tumours, Matrigel was introduced for tumour cell injection. Different concentrations of two human tumour cell lines (FaDu, LN229) and Matrigel were evaluated for stable tumour growth and fulfilling the allocation criteria for irradiation experiments. The originally applied cell injection with PBS was performed for comparison and to assess the long-term stability of the model. Finally, the optimum suspension of cells and Matrigel was applied to determine applicable dose ranges for tumour growth delay studies by 200 kV Xray irradiation. Results Both human tumour models showed a high take rate and exponential tumour growth starting at a volume of similar to 10 mm(3). As disclosed by immunofluorescence analysis these small tumours already interact with the surrounding tissue and activate endothelial cells to form vessels. The formation of delimited, solid tumours at irradiation size was shown by standard H&E staining and a realistic dose range for inducing tumour growth delay without permanent tumour control was obtained for both tumour entities. Conclusion The already established mouse ear tumour model was successfully upgraded now providing stable tumour growth with high take rate for two tumour entities (HNSCC, glioblastoma) that are of interest for future irradiation experiments at experimental accelerators.	[Beyreuther, Elke; Bruechner, Kerstin; Krause, Mechthild; Pawelke, Joerg] Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany; [Beyreuther, Elke; Bruechner, Kerstin; Krause, Mechthild; Schmidt, Margret; Pawelke, Joerg] Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany; [Beyreuther, Elke; Bruechner, Kerstin; Krause, Mechthild; Schmidt, Margret; Pawelke, Joerg] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Bruechner, Kerstin] Tech Univ Dresden, Dresden, Germany; [Krause, Mechthild] Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany; [Krause, Mechthild] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Krause, Mechthild] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Krause, Mechthild] German Canc Res Ctr, Heidelberg, Germany; [Krause, Mechthild; Schmidt, Margret] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany; [Szabo, Rita] ELI HU Nonprofit Ltd, Attosecond Light Pulse Source, Szeged, Hungary	Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Technische Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; ELI-HU Research & Development Non-Profit	Beyreuther, E (corresponding author), Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany.; Beyreuther, E (corresponding author), Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany.; Beyreuther, E (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany.	E.Beyreuther@hzdr.de		Krause, Mechthild/0000-0003-1776-9556; Beyreuther, Elke/0000-0002-0582-1444	German Federal Ministry of Education and Research (BMBF) [03ZIK445, 03Z1N511]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The work was supported by the German Federal Ministry of Education and Research (BMBF), grant nos. 03ZIK445 and 03Z1N511.	Benton G, 2014, ADV DRUG DELIVER REV, V79-80, P3, DOI 10.1016/j.addr.2014.06.005; Bin JH, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4769372; Daido H, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/5/056401; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; Doria D, 2012, AIP ADV, V2, DOI 10.1063/1.3699063; Fernandez-Palomo C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119924; Fliedner FP, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0105-4; Helbig L, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-207; Jermann M., 2015, INT J PART THER, V2, P50, DOI 10.14338/IJPT-15-00013; Kraft SD, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/8/085003; Krause M, 2007, RADIOTHER ONCOL, V83, P316, DOI 10.1016/j.radonc.2007.04.014; Ledingham KWD, 2007, BRIT J RADIOL, V80, P855, DOI 10.1259/bjr/29504942; Oppelt M, 2015, RADIAT ENVIRON BIOPH, V54, P155, DOI 10.1007/s00411-014-0582-1; RANGAN SRS, 1972, CANCER, V29, P117, DOI 10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schurer M, 2012, BIOMED ENG-BIOMED TE, V57, P62, DOI 10.1515/bmt-2012-4244; SUIT HD, 1965, CELLULAR RAD BIOL, P514; Yaromina A, 2010, RADIOTHER ONCOL, V96, P116, DOI 10.1016/j.radonc.2010.04.020; Yogo A, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3551623; Zeil K, 2013, APPL PHYS B-LASERS O, V110, P437, DOI 10.1007/s00340-012-5275-3	21	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2017	12	5							e0177428	10.1371/journal.pone.0177428	http://dx.doi.org/10.1371/journal.pone.0177428			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV3PV	28545054	Green Published, Green Submitted, gold			2023-01-03	WOS:000401672400042
J	Crow, D				Crow, Diana			Silicon Valley Meets Biomedical Research in the Chan Zuckerberg Initiative	CELL			English	Editorial Material								The Chan Zuckerberg Initiative, the philanthropy launched by Facebook CEO Mark Zuckerberg and his wife Priscilla Chan, drew attention with its stated goal of helping to "cure, manage, or treat all diseases" by the end of the century. They intend to do it through funding basic research and addressing gaps in biomedical technology.											0	0	0	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 18	2017	169	5					767	769		10.1016/j.cell.2017.05.013	http://dx.doi.org/10.1016/j.cell.2017.05.013			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV1OM	28525746	Bronze			2023-01-03	WOS:000401515900001
J	Canizares, M; Hogg-Johnson, S; Gignac, MAM; Glazier, RH; Badley, EM				Canizares, Mayilee; Hogg-Johnson, Sheilah; Gignac, Monique A. M.; Glazier, Richard H.; Badley, Elizabeth M.			Changes in the use practitioner-based complementary and alternative medicine over time in Canada: Cohort and period effects	PLOS ONE			English	Article							HEALTH-CARE; CAM USE; UNITED-STATES; AGE; ADULTS; PAIN; THERAPIES; TRENDS; SELF; PREVALENCE	Background The use of complementary and alternative medicine (CAM) is growing. However the factors contributing to changes over time and to birth cohort differences in CAM use are not well understood. Setting We used data from 10186 participants, who were aged 20-69 years at the first cycle of data collection in the longitudinal component of the Canadian National Population Health Survey (1994/95-2010/11). We examined chiropractic and other practitioner-based CAM use with a focus on five birth cohorts: pre-World War II (born 1925-1934); World War II (born 1935-1944); older baby boomers (born 1945-1954); younger baby boomers (born 1955-1964); and Gen Xers (born 1965-1974). The survey collected data every two years on predisposing (e.g., sex, education), enabling (e.g., income), behavior-related factors (e.g., obesity), need (e.g., chronic conditions), and use of conventional care (primary care and specialists). Results The findings suggest that, at corresponding ages, more recent cohorts reported greater CAM (OR = 25.9, 95% CI: 20.0; 33.6 for Gen Xers vs. pre-World War) and chiropractic use than their predecessors (OR = 2.2, 95% CI: 1.7; 2.8 for Gen Xers vs. pre-World War). There was also a secular trend of increasing CAM use, but not chiropractic use, over time (period effect) across all ages. Factors associated with cohort differences were different for CAM and chiropractic use. Cohort differences in CAM use were partially related to a period effect of increasing CAM use over time across all ages while cohort differences in chiropractic use were related to the higher prevalence of chronic conditions among recent cohorts. The use of conventional care was positively related to greater CAM use (OR = 1.8, 95% CI: 1.6; 2.0)	[Canizares, Mayilee] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Canizares, Mayilee; Gignac, Monique A. M.; Badley, Elizabeth M.] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada; [Hogg-Johnson, Sheilah; Gignac, Monique A. M.; Glazier, Richard H.; Badley, Elizabeth M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Hogg-Johnson, Sheilah; Gignac, Monique A. M.] Inst Work & Hlth, Toronto, ON, Canada; [Glazier, Richard H.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Glazier, Richard H.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Glazier, Richard H.] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada	University of Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Institute for Work & Health; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Canizares, M (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.; Canizares, M (corresponding author), Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada.	mcanizar@uhnres.utoronto.ca		Badley, Elizabeth/0000-0002-6045-2549	CIHR Operating Grant Secondary Analysis of Databases [SEC 117113]	CIHR Operating Grant Secondary Analysis of Databases	Access to the data is through the Statistics Canada Research Data Centres (RDC) Program. RDCs are operated under the provisions of the Statistics Act in accordance with all the confidentiality rules. The findings and conclusions of this paper are those of the authors and do not represent the official position of Statistics Canada. This study was partially supported by a CIHR Operating Grant Secondary Analysis of Databases (SEC 117113). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshar S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2008-7; Ahn AC, 2006, AM J PUBLIC HEALTH, V96, P647, DOI 10.2105/AJPH.2004.048496; Astin JA, 1998, ARCH INTERN MED, V158, P2303, DOI 10.1001/archinte.158.21.2303; Ayers SL, 2012, HEALTH SERV RES, V47, P2081, DOI 10.1111/j.1475-6773.2012.01406.x; Ayers SL, 2010, HEALTH-LONDON, V14, P234, DOI 10.1177/1363459309347491; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bell A, 2014, SOC SCI MED, V120, P21, DOI 10.1016/j.socscimed.2014.09.008; Bell A, 2013, SOC SCI MED, V93, P163, DOI 10.1016/j.socscimed.2013.04.029; Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023; Brown C, 2009, J ALTERN COMPLEM MED, V15, P911, DOI 10.1089/acm.2008.0561; Busse JW, 2005, MAYO CLIN P, P80; Canadian Institute for Health Information, CANADAS HEALTH CARE; Canizares M, 2017, J GERONTOL B-PSYCHOL; Carle AC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-49; Clarke TC, 2015, NATL HLTH STAT REPOR, P1; Coulter ID, 2004, MED J AUSTRALIA, V180, P587, DOI 10.5694/j.1326-5377.2004.tb06099.x; Davis MA, 2011, HEALTH SERV RES, V46, P1402, DOI 10.1111/j.1475-6773.2011.01270.x; Deloitte Center for Health Solutions, THE QUEST FOR VALUE; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Esmail N, 2007, COMPLEMENTARY AND AL; Faith J, 2015, ALTERN THER HEALTH M, V21, P30; Feinglass J, 2007, CLIN J PAIN, V23, P744, DOI 10.1097/AJP.0b013e31815349d4; Foster MM, 2010, HEALTH POLICY, V97, P105, DOI 10.1016/j.healthpol.2010.04.005; Fries C. J., 2012, Issues in health and health care related to race/ethnicity, immigration, SES and gender, P113; Fries CJ, 2013, HEALTH SOCIOL REV, V22, P37, DOI 10.5172/hesr.2013.22.1.37; Grzywacz JG, 2008, AM J HEALTH BEHAV, V32, P650, DOI 10.5555/ajhb.2008.32.6.650; Grzywacz JG, 2007, J HEALTH SOC BEHAV, V48, P84, DOI 10.1177/002214650704800106; Harris PE, 2012, INT J CLIN PRACT, V66, P924, DOI 10.1111/j.1742-1241.2012.02945.x; Hirschkorn KA, 2009, CAN REV SOCIOL, V46, P143, DOI 10.1111/j.1755-618X.2009.01208.x; Ho TF, 2014, J AM BOARD FAM MED, V27, P465, DOI 10.3122/jabfm.2014.04.130238; Kelner M, 1997, SOC SCI MED, V45, P203, DOI 10.1016/S0277-9536(96)00334-6; Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011; Lapane KL, 2012, OSTEOARTHR CARTILAGE, V20, P22, DOI 10.1016/j.joca.2011.10.005; Lawrence Dana J, 2007, Chiropr Osteopat, V15, P2, DOI 10.1186/1746-1340-15-2; Lind BK, 2010, J ALTERN COMPLEM MED, V16, P411, DOI 10.1089/acm.2009.0261; McFarland B, 2002, AM J PUBLIC HEALTH, V92, P1616, DOI 10.2105/AJPH.92.10.1616; Metcalfe A, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-58; Mior SA, 2008, J MANIP PHYSIOL THER, V31, P104, DOI 10.1016/j.jmpt.2007.12.007; Moffatt S, 2012, AGEING SOC, V32, P725, DOI 10.1017/S0144686X11000602; Murthy V, 2014, CLIN RHEUMATOL, V33, P253, DOI 10.1007/s10067-013-2357-5; Nahin RL, 2010, BMC HEALTH SERV RES, P10; Neiberg RH, 2011, J ALTERN COMPLEM MED, V17, P363, DOI 10.1089/acm.2009.0157; Pagan JA, 2005, HEALTH AFFAIR, V24, P255, DOI 10.1377/hlthaff.24.1.255; Rabe-Hesketh S, 2006, J R STAT SOC A STAT, V169, P805, DOI 10.1111/j.1467-985X.2006.00426.x; Redwood D, 2008, J ALTERN COMPLEM MED, V14, P361, DOI 10.1089/acm.2007.0766; Reither EN, 2015, SOC SCI MED, V128, P356, DOI 10.1016/j.socscimed.2015.01.011; Rochelle TL, 2010, BRIT J HEALTH PSYCH, V15, P715, DOI 10.1348/135910709X479195; Rosenthal M, 2002, MILBANK Q, V80, P41, DOI 10.1111/1468-0009.00003; SAS Institute Inc, 2013, SAS STAT 9 3 US GUID; Sirois FM, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-16; Statistics Canada, 2011, INFORMATION ABOUT TH; Sulik GA, 2008, NO LONGER PATIENT SO, P3; Suzuki E, 2012, SOC SCI MED, V75, P452, DOI 10.1016/j.socscimed.2012.03.036; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; Vallerand AH, 2003, AM J PUBLIC HEALTH, V93, P923, DOI 10.2105/AJPH.93.6.923; Ventola C Lee, 2010, P T, V35, P461; Villanueva-Russell Y, 2011, SOC SCI MED, V72, P1826, DOI 10.1016/j.socscimed.2011.03.038; Votova K, 2010, J ALTERN COMPLEM MED, V16, P995, DOI 10.1089/acm.2009.0628; Weigel P, 2010, CHIROPR OSTEO, V18, P1; Yang SB, 2013, CLIN THER, V35, P1690, DOI 10.1016/j.clinthera.2013.09.022; Yang Y, 2013, AGE PERIOD COHORT AN, Vxiii	62	21	21	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177307	10.1371/journal.pone.0177307	http://dx.doi.org/10.1371/journal.pone.0177307			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EU8UP	28494011	gold, Green Submitted, Green Published			2023-01-03	WOS:000401314300084
J	Carreras-Planella, L; Soler-Majoral, J; Rubio-Esteve, C; Lozano-Ramos, SI; Franquesa, M; Bonet, J; Troya-Saborido, MI; Borras, FE				Carreras-Planella, Laura; Soler-Majoral, Jordi; Rubio-Esteve, Cristina; Ines Lozano-Ramos, Sara; Franquesa, Marcella; Bonet, Josep; Isabel Troya-Saborido, Maria; Enric Borras, Francesc			Characterization and proteomic profile of extracellular vesicles from peritoneal dialysis efflux	PLOS ONE			English	Article							HEMODIALYSIS; BIOMARKERS; FLUID; MODEL	Peritoneal Dialysis (PD) is considered the best option for a cost-effective mid-term dialysis in patients with Chronic Renal Failure. However, functional failure of the peritoneal membrane (PM) force many patients to stop PD treatment and start haemodialysis. Currently, PM functionality is monitored by the peritoneal equilibration test, a tedious technique that often show changes when the membrane damage is advanced. As in other pathologies, the identification and characterization of extracellular vesicles (EVs) in the peritoneal dialysis efflux (PDE) may represent a non-invasive alternative to identify biomarkers of membrane failure. Using size-exclusion chromatography, we isolated EVs from PDE in a group of patients. Vesicles were characterized by the presence of tetraspanin markers, nanoparticle tracking analysis profile, cryo-electron microscopy and mass spectrometry. Here, we report the isolation and characterization of PDE-EVs. Based on mass spectrometry, we have found a set of well-conserved proteins among patients. Interestingly, the peptide profile also revealed remarkable changes between newly enrolled and longer-treated PD patients. These results are the first step to the identification of PDE-EVs based new markers of PM damage, which could support clinicians in their decision-making in a non-invasive manner.	[Carreras-Planella, Laura; Soler-Majoral, Jordi; Rubio-Esteve, Cristina; Ines Lozano-Ramos, Sara; Franquesa, Marcella; Bonet, Josep; Isabel Troya-Saborido, Maria; Enric Borras, Francesc] Germans Trias & Pujol Hlth Sci Res Inst, REMAR IVECAT Grp, Can Ruti Campus, Badalona, Spain; [Carreras-Planella, Laura; Ines Lozano-Ramos, Sara; Enric Borras, Francesc] Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Soler-Majoral, Jordi; Rubio-Esteve, Cristina; Franquesa, Marcella; Bonet, Josep; Isabel Troya-Saborido, Maria; Enric Borras, Francesc] Germans Trias & Pujol Univ Hosp, Nephrol Dept, Can Ruti Campus, Badalona, Spain; [Soler-Majoral, Jordi] Autonomous Univ Barcelona, Dept Med, Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Troya-Saborido, MI; Borras, FE (corresponding author), Germans Trias & Pujol Hlth Sci Res Inst, REMAR IVECAT Grp, Can Ruti Campus, Badalona, Spain.; Borras, FE (corresponding author), Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain.; Troya-Saborido, MI; Borras, FE (corresponding author), Germans Trias & Pujol Univ Hosp, Nephrol Dept, Can Ruti Campus, Badalona, Spain.	mitroya.germanstrias@gencat.cat; feborras@igtp.cat	Franquesa, Marcella/A-7231-2017; Borràs, Francesc E/P-2287-2017	Franquesa, Marcella/0000-0002-1287-8908; Borràs, Francesc E/0000-0003-4038-1912; Franquesa/0000-0001-6251-8575; Soler, Jordi/0000-0001-6693-4859; Carreras-Planella, Laura/0000-0003-3512-0849	National R+D+I [PI16/00072]; ISCIII; European Regional Development Fund [2014SGR804]; Instituto de Salud Carlos III-Red de Investigacion Renal (REDinREN) [RD16/0009]; Fundacio Cellex; Beatriu de Pinos-B contract from Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya [2014BPB00118]; Spanish "Sistema Nacionalde Salud" (SNS-ISCIII); "Direccio d'Estrategia i Coordinacio" Catalan Health Department [CES07/015]	National R+D+I; ISCIII(Instituto de Salud Carlos III); European Regional Development Fund(European Commission); Instituto de Salud Carlos III-Red de Investigacion Renal (REDinREN)(Instituto de Salud Carlos III); Fundacio Cellex(Foundation CELLEX); Beatriu de Pinos-B contract from Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya; Spanish "Sistema Nacionalde Salud" (SNS-ISCIII); "Direccio d'Estrategia i Coordinacio" Catalan Health Department	This work was supported by the PI16/00072 project, integrated in the National R+D+I and funded by the ISCIII and the European Regional Development Fund http://www.isciii.es), "Suport Grups de Recerca" programme of Generalitat de Catalunya (2014SGR804, Group REMAR, http://agaur.gencat.cat), Instituto de Salud Carlos III-Red de Investigacion Renal (REDinREN) (RD16/0009 Feder Funds, http://www.isciii.es, http://redinren.org), and Fundacio Cellex. MF is sponsored by the Beatriu de Pinos-B contract (2014BPB00118, http://agaur.gencat.cat) from Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya. FEB is sponsored by the "Researchers Stabilization Program" from the Spanish "Sistema Nacionalde Salud" (SNS-ISCIII, http://www.isciii.es) and "Direccio d'Estrategia i Coordinacio" Catalan Health Department (CES07/015, http://salutweb.gencat.cat). The funders had no role in study design,data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera Abelardo, 2005, Curr Opin Investig Drugs, V6, P262; Aroeira L, 2008, PERIT DIAL, V28, P29; Atapour A, 2015, SAUDI J KIDNEY DIS T, V26, P962, DOI 10.4103/1319-2442.164578; Barreto DL, 2013, AM J KIDNEY DIS, V62, P823, DOI 10.1053/j.ajkd.2013.01.031; Boukouris S, 2015, PROTEOM CLIN APPL, V9, P358, DOI 10.1002/prca.201400114; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Erdbrugger U, 2015, J AM SOC NEPHROL, P1; Fais S, 2016, ACS NANO, V10, P3886, DOI 10.1021/acsnano.5b08015; Gamez-Valero A, 2016, SCI REP-UK, V6, DOI 10.1038/srep33641; Gamez-Valero A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00006; Heaf JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090119; Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Kim DK, 2015, BIOINFORMATICS, V31, P933, DOI 10.1093/bioinformatics/btu741; Lechner M, 2010, J PROTEOME RES, V9, P2472, DOI 10.1021/pr9011574; Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087; Lin F, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0039-z; Lozano-Ramos I, 2015, J EXTRACELL VESICLES, P1; Lozano-Ramos I, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27369; Lukowsky LR, 2013, CLIN J AM SOC NEPHRO, V8, P619, DOI 10.2215/CJN.04810512; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351; Mujais S, 2000, PERITON DIALYSIS INT, V20, pS5; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Sritippayawain S, 2007, J PROTEOME RES, V6, P4356, DOI 10.1021/pr0702969; Treharne C, 2014, APPL HEALTH ECON HEA, V12, P409, DOI 10.1007/s40258-014-0108-7; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Wang HY, 2010, NEPHROL DIAL TRANSPL, V25, P1955, DOI 10.1093/ndt/gfp696; WANIEWSKI J, 1991, BLOOD PURIFICAT, V9, P129, DOI 10.1159/000170009; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066	31	16	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2017	12	5							e0176987	10.1371/journal.pone.0176987	http://dx.doi.org/10.1371/journal.pone.0176987			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UN	28489901	gold, Green Submitted, Green Published			2023-01-03	WOS:000401314100041
J	Takayama, K; Kaneko, H; Kataoka, K; Hattori, K; Ra, E; Tsunekawa, T; Fukukita, H; Haga, F; Ito, Y; Terasaki, H				Takayama, Kei; Kaneko, Hiroki; Kataoka, Keiko; Hattori, Kyoko; Ra, Eimei; Tsunekawa, Taichi; Fukukita, Hiroshi; Haga, Fuminori; Ito, Yasuki; Terasaki, Hiroko			Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study	PLOS ONE			English	Article							SUBTENON TRIAMCINOLONE ACETONIDE; INTRAVITREAL RANIBIZUMAB; THICKNESS; COMBINATION; BEVACIZUMAB; MONOTHERAPY; INJECTIONS	Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with naive PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with naive PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both P < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both P < 0.05) but not in the IAI group. A mean of 3.7 +/- 0.9 and 5.6 +/- 2.0 injections was administered to the combination and IAI groups, respectively (P = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.	[Takayama, Kei; Kaneko, Hiroki; Kataoka, Keiko; Hattori, Kyoko; Ra, Eimei; Tsunekawa, Taichi; Fukukita, Hiroshi; Haga, Fuminori; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan; [Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan	Nagoya University; National Defense Medical College - Japan	Kaneko, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.	h-kaneko@med.nagoya-u.ac.jp	Kaneko, Hiroki/AHA-2461-2022; Kaneko, Hiroki/O-7695-2015; Ito, Yasuki/M-4876-2014; Kataoka, Keiko/B-2806-2016	Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465; Ito, Yasuki/0000-0001-9219-9261; Kataoka, Keiko/0000-0002-8795-6536; Takayama, Kei/0000-0002-1477-9014	Chukyo longevity medical and promotion foundation [15H04994, 16K20313, 17K16964]; Takeda Medical Research Foundation	Chukyo longevity medical and promotion foundation; Takeda Medical Research Foundation	The study was supported by a grant from the Grants-in-Aid for Scientific Research B (H. Terasaki, 15H04994), Grant-in-Aid for Young Scientists B (K. Kataoka, 16K20313), Grant-in-Aid for Young Scientists B (K. Takayama,17K16964), Chukyo longevity medical and promotion foundation (H. Kaneko), and Takeda Medical Research Foundation (H.Kaneko). There are no patents, products in development or marketed products to declare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was supported by a grant from the Grants-in-Aid for Scientific Research B (H. Terasaki, 15H04994), Grant-in-Aid for Young Scientists B (K. Kataoka, 16K20313), Grant-in-Aid for Young Scientists B (K. Takayama,17K16964), Chukyo longevity medical and promotion foundation (H. Kaneko), and Takeda Medical Research Foundation (H.Kaneko).	Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020; Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007; Coppens G, 2011, Bull Soc Belge Ophtalmol, P39; Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028; Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526; Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04; Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767; Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe; Ho M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36870; Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1; Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179; Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x; Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019; Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y; Kim H, 2015, GRAEFES ARCH CLIN EX; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446; Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432; Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f; Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001; Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051; Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041; Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030; Matsumiya W, 2016, GRAEFES ARCH CLIN EX; Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z; Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003; Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x; Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189; Sakurada Y, 2016, RETINA; Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466; Takayama K, 2016, GRAEFES ARCH CLIN EX; Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6; Wang WF, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004154; Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359; Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024; Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005; YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001	39	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2017	12	5							e0176100	10.1371/journal.pone.0176100	http://dx.doi.org/10.1371/journal.pone.0176100			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9SB	28467427	Green Published, gold, Green Submitted			2023-01-03	WOS:000400647000035
J	Lye, DC; Archuleta, S; Syed-Omar, SF; Low, JG; Oh, HM; Wei, Y; Fisher, D; Ponnampalavanar, SSL; Wijaya, L; Lee, LK; Ooi, EE; Kamarulzaman, A; Lum, LC; Tambyah, PA; Leo, YS				Lye, David C.; Archuleta, Sophia; Syed-Omar, Sharifah F.; Low, Jenny G.; Oh, Helen M.; Wei, Yuan; Fisher, Dale; Ponnampalavanar, Sasheela S. L.; Wijaya, Limin; Lee, Linda K.; Ooi, Eng-Eong; Kamarulzaman, Adeeba; Lum, Lucy C.; Tambyah, Paul A.; Leo, Yee-Sin			Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial	LANCET			English	Article							GLOBAL DISTRIBUTION; HEMORRHAGIC-FEVER; INFECTION; INDIA	Background Dengue is the commonest vector-borne infection worldwide. It is often associated with thrombocytopenia, and prophylactic platelet transfusion is widely used despite the dearth of robust evidence. We aimed to assess the efficacy and safety of prophylactic platelet transfusion in the prevention of bleeding in adults with dengue and thrombocytopenia. Methods We did an open-label, randomised, superiority trial in five hospitals in Singapore and Malaysia. We recruited patients aged at least 21 years who had laboratory-confirmed dengue (confirmed or probable) and thrombocytopenia (<= 20 000 platelets per mu L), without persistent mild bleeding or any severe bleeding. Patients were assigned (1: 1), with randomly permuted block sizes of four or six and stratified by centre, to receive prophylactic platelet transfusion in addition to supportive care (transfusion group) or supportive care alone (control group). In the transfusion group, 4 units of pooled platelets were given each day when platelet count was 20 000 per mu L or lower; supportive care consisted of bed rest, fluid therapy, and fever and pain medications. The primary endpoint was clinical bleeding (excluding petechiae) by study day 7 or hospital discharge (whichever was earlier), analysed by intention to treat. Safety outcomes were analysed according to the actual treatment received. This study was registered with ClinicalTrials.gov, number NCT01030211, and is completed. Findings Between April 29, 2010, and Dec 9, 2014, we randomly assigned 372 patients to the transfusion group (n=188) or the control group (n=184). The intention-to-treat analysis included 187 patients in the transfusion group (one patient was withdrawn immediately) and 182 in the control group (one was withdrawn immediately and one did not have confirmed or probable dengue). Clinical bleeding by day 7 or hospital discharge occurred in 40 (21%) patients in the transfusion group and 48 (26%) patients in the control group (risk difference -4.98% [95% CI -15.08 to 5.34]; relative risk 0.81 [95% CI 0.56 to 1.17]; p=0.16). 13 adverse events occurred in the transfusion group and two occurred in the control group (5.81% [-4.42 to 16.01]; 6.26 [1.43 to 27.34]; p=0.0064). Adverse events that were possibly, probably, or definitely related to transfusion included three cases of urticaria, one maculopapular rash, one pruritus, and one chest pain, as well as one case each of anaphylaxis, transfusion-related acute lung injury, and fluid overload that resulted in serious adverse events. No death was reported. Interpretation In adult patients with dengue and thrombocytopenia, prophylactic platelet transfusion was not superior to supportive care in preventing bleeding, and might be associated with adverse events.	[Lye, David C.; Lee, Linda K.; Leo, Yee-Sin] Tan Tock Seng Hosp, Inst Infect Dis & Epidemiol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; [Lye, David C.; Archuleta, Sophia; Fisher, Dale; Tambyah, Paul A.; Leo, Yee-Sin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Leo, Yee-Sin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Archuleta, Sophia; Fisher, Dale; Tambyah, Paul A.] Natl Univ Hlth Syst, Natl Univ Hosp, Div Infect Dis, Singapore, Singapore; [Syed-Omar, Sharifah F.; Ponnampalavanar, Sasheela S. L.; Kamarulzaman, Adeeba; Lum, Lucy C.] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Low, Jenny G.; Wijaya, Limin] Singapore Gen Hosp, Singapore, Singapore; [Low, Jenny G.; Ooi, Eng-Eong] Duke NUS Med Sch, Singapore, Singapore; [Oh, Helen M.] Changi Gen Hosp, Singapore, Singapore; [Wei, Yuan] Singapore Clin Res Inst, Singapore, Singapore; [Leo, Yee-Sin] Lee Kong Chian Sch Med, Singapore, Singapore	Tan Tock Seng Hospital; National University of Singapore; National University of Singapore; National University of Singapore; Universiti Malaya; Singapore General Hospital; National University of Singapore; Changi General Hospital; Singapore Clinical Research Institute; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Lye, DC (corresponding author), Tan Tock Seng Hosp, Inst Infect Dis & Epidemiol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	david_lye@ttsh.com.sg	Lum, Lucy/Q-9871-2017; Lye, David/ABF-4402-2021; OMAR, SHARIFAH FARIDAH SFSO SYED/B-9752-2010; LA SRI PONNAMPALAVANAR, SASHEELA SRI/B-9703-2010	Lum, Lucy/0000-0002-7452-4208; Archuleta, Sophia/0000-0002-8414-6327; Syed Omar, Sharifah Faridah/0000-0002-4947-4878; Ooi, Eng Eong/0000-0002-0520-1544; Lye, David/0000-0003-0324-0205; sri la sri ponnampalavanar, sasheela/0000-0002-4506-1304	National Medical Research Council, Singapore; National Medical Research Council, Singapore (STOP dengue grant) [NMRC/TCR/005/2008]	National Medical Research Council, Singapore(National Medical Research Council, Singapore); National Medical Research Council, Singapore (STOP dengue grant)(National Medical Research Council, Singapore)	National Medical Research Council, Singapore.; We thank all the doctors and research staff whose enthusiasm and work have made this clinical trial possible. This study was funded by the National Medical Research Council, Singapore (STOP dengue grant NMRC/TCR/005/2008).	Adalja AA, 2012, EMERG INFECT DIS, V18, P608, DOI 10.3201/eid1804.110968; Assir MZK, 2013, TRANSFUS MED HEMOTH, V40, P362, DOI 10.1159/000354837; Bhaskar E, 2015, J INFECT DEV COUNTR, V9, P105, DOI 10.3855/jidc.5031; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Cardier JE, 2006, CYTOKINE, V34, P155, DOI 10.1016/j.cyto.2006.04.002; Chamnanchanunt S, 2012, SE ASIAN J TROP MED, V43, P890; Chaudhary R, 2006, TRANSFUS APHER SCI, V35, P239, DOI 10.1016/j.transci.2006.08.007; Chaurasia R, 2015, TRANSFUS MED HEMOTH, V42, P227, DOI 10.1159/000371500; Chuansumrit A, 2014, THROMB RES, V133, P10, DOI 10.1016/j.thromres.2013.09.028; Chuansumrit Ampaiwan, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P10; Delaflor-Weiss E, 2000, TRANSFUS MED REV, V14, P180, DOI 10.1016/S0887-7963(00)80007-3; Fujimoto Denys Eiti, 2014, Rev. Bras. Hematol. Hemoter., V36, P115, DOI 10.5581/1516-8484.20140027; Gould EA, 2010, CLIN MICROBIOL INFEC, V16, P1702, DOI 10.1111/j.1469-0691.2010.03386.x; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Kutsuna S, 2015, EMERG INFECT DIS, V21, P517, DOI [10.3201/eid2103.141662, 10.3201/eid2103/141662]; Lee Min-Sheng, 2006, Journal of Microbiology Immunology and Infection, V39, P121; Lee TH, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004576; Lum LCS, 2003, J PEDIATR-US, V143, P682, DOI 10.1067/S0022-3476(03)00503-1; Lum LCSL, 2002, J PEDIATR-US, V140, P629, DOI 10.1067/mpd.2002.123665; Lye DC, 2009, CLIN INFECT DIS, V48, P1262, DOI 10.1086/597773; Sang SW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003808; Sharma A, 2012, AM J TROP MED HYG, V86, P531, DOI 10.4269/ajtmh.2012.10-0209; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846; Teo D, 2009, TRANSFUSION MED, V19, P66, DOI 10.1111/j.1365-3148.2009.00916.x; Wang SF, 2016, AM J TROP MED HYG, V94, P193, DOI 10.4269/ajtmh.15-0422; Whitehorn J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001716; (WHO) WHO, 1997, DENG HAEM FEV DIAGN; World Health Organization, 2009, DENG GUID TREATM PRE	30	40	46	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2017	389	10079					1611	1618		10.1016/S0140-6736(17)30269-6	http://dx.doi.org/10.1016/S0140-6736(17)30269-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ES5EK	28283286				2023-01-03	WOS:000399560000028
J	Shirai, K; Kawashima, M; Saitoh, J; Abe, T; Fukata, K; Shigeta, Y; Irie, D; Shiba, S; Okano, N; Ohno, T; Nakano, T				Shirai, Katsuyuki; Kawashima, Motohiro; Saitoh, Jun-ichi; Abe, Takanori; Fukata, Kyohei; Shigeta, Yuka; Irie, Daisuke; Shiba, Shintaro; Okano, Naoko; Ohno, Tatsuya; Nakano, Takashi			Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; ELDERLY-PATIENTS; IRRADIATION; JAPAN; METAANALYSIS; COMBINATION; SURGERY; REGIMEN	The safety and efficacy of carbon-ion radiotherapy for advanced non-small cell lung cancer have not been established. We evaluated the clinical outcomes and dose-volume histogram parameters of carbon-ion radiotherapy compared with photon therapy in T2b-4N0M0 non-small cell lung cancer. Twenty-three patients were treated with carbon-ion radiotherapy between May 2011 and December 2015. Seven, 14, and 2 patients had T2b, T3, and T4, respectively. The median age was 78 (range, 53-91) years, with 22 male patients. There were 12 adenocarcinomas, 8 squamous cell carcinomas, 1 non-small cell lung carcinoma, and 2 clinically diagnosed lung cancers. Eleven patients were operable, and 12 patients were inoperable. Most patients (91%) were treated with carbon-ion radiotherapy of 60.0 Gy relative biological effectiveness (RBE) in 4 fractions or 64.0 Gy (RBE) in 16 fractions. Local control and overall survival rates were calculated. Dose-volume histogram parameters of normal lung and tumor coverages were compared between carbon-ion radiotherapy and photon therapies, including three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The median follow-up of surviving patients was 25 months. Three patients experienced local recurrence, and the 2-year local control rate was 81%. During follow-up, 5 patients died of lung cancer, and 1 died of intercurrent disease. The 2-year overall survival rate was 70%. Operable patients had a better overall survival rate compared with inoperable patients (100% vs. 43%; P = 0.04). There was no grade >= 2 radiation pneumonitis. In dose-volume histogram analysis, carbon-ion radiotherapy had a significantly lower dose to normal lung and greater tumor coverage compared with photon therapies. Carbon-ion radiotherapy was effectively and safely performed for T2b-4N0M0 non-small cell lung cancer, and the dose distribution was superior compared with those for photon therapies. A Japanese multi-institutional study is ongoing to prospectively evaluate these patients and establish the use of carbon-ion radiotherapy.	[Shirai, Katsuyuki; Kawashima, Motohiro; Saitoh, Jun-ichi; Abe, Takanori; Fukata, Kyohei; Shigeta, Yuka; Irie, Daisuke; Shiba, Shintaro; Okano, Naoko; Ohno, Tatsuya; Nakano, Takashi] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma, Japan	Gunma University	Shirai, K (corresponding author), Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma, Japan.	kshirai@gunma-u.ac.jp	Fukata, Kyohei/G-9011-2018	Fukata, Kyohei/0000-0003-4015-6969; Shiba, Shintaro/0000-0002-1293-4113	Japan Society for the Promotion of Science (JSPS) [26461878]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) Grant Number 26461878 (https://www.jsps.go.jp/index.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anagnostou VK, 2015, CLIN CANCER RES, V21, P976, DOI 10.1158/1078-0432.CCR-14-1187; Atagi S, 2012, LANCET ONCOL, V13, P671, DOI 10.1016/S1470-2045(12)70139-0; Bradley J, 2012, INT J RADIAT ONCOL, V82, P435, DOI 10.1016/j.ijrobp.2010.09.033; Ebara T, 2014, ANTICANCER RES, V34, P5099; Eriguchi T, 2016, J RADIAT RES, V57, P265, DOI 10.1093/jrr/rrw023; Fakiris AJ, 2009, INT J RADIAT ONCOL, V75, P677, DOI 10.1016/j.ijrobp.2008.11.042; Fennell DA, 2016, CANCER TREAT REV, V44, P42, DOI 10.1016/j.ctrv.2016.01.003; Gajra A, 2014, J CLIN ONCOL, V32, P2562, DOI 10.1200/JCO.2014.55.3099; Kamada T, 2015, LANCET ONCOL, V16, pE93, DOI 10.1016/S1470-2045(14)70412-7; Kanai T, 1999, INT J RADIAT ONCOL, V44, P201, DOI 10.1016/S0360-3016(98)00544-6; Kubo N, 2016, J RADIAT RES, V57, P548, DOI 10.1093/jrr/rrw041; Loeffler JS, 2013, NAT REV CLIN ONCOL, V10, P411, DOI 10.1038/nrclinonc.2013.79; MARINO P, 1995, CANCER, V76, P593, DOI 10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N; Meng MB, 2015, ONCOTARGET, V6, P15690, DOI 10.18632/oncotarget.3704; Miyamoto T, 2007, J THORAC ONCOL, V2, P916, DOI 10.1097/JTO.0b013e3181560a68; Miyamoto T, 2007, INT J RADIAT ONCOL, V67, P750, DOI 10.1016/j.ijrobp.2006.10.006; Mizobuchi T, 2016, EUR J CARDIO-THORAC, V49, P1503, DOI 10.1093/ejcts/ezv348; Nagata Y, 2015, INT J RADIAT ONCOL, V93, P989, DOI 10.1016/j.ijrobp.2015.07.2278; Onishi H, 2004, LUNG CANCER, V45, P45, DOI 10.1016/j.lungcan.2004.01.004; Pritchard RS, 1996, ANN INTERN MED, V125, P723, DOI 10.7326/0003-4819-125-9-199611010-00003; Nguyen QN, 2015, RADIOTHER ONCOL, V115, P367, DOI 10.1016/j.radonc.2015.05.014; Rosenzweig KE, 2007, J CLIN ONCOL, V25, P5557, DOI 10.1200/JCO.2007.13.2191; Rowell NP, 2001, THORAX, V56, P628, DOI 10.1136/thorax.56.8.628; Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2; Shirai K, 2012, INT J MOL IMAGING, V2012; Shirai K, 2016, ONCOL LETT IN PRESS; Takahashi W, 2015, CANCER-AM CANCER SOC, V121, P1321, DOI 10.1002/cncr.29195; Tan CS, 2016, LUNG CANCER, V93, P59, DOI 10.1016/j.lungcan.2016.01.003; Tashiro M, 2013, RADIOL PHYS TECHNOL, V6, P356, DOI 10.1007/s12194-013-0208-3; Walraven I, 2016, RADIOTHER ONCOL, V118, P442, DOI 10.1016/j.radonc.2016.02.011; Yuan SH, 2007, AM J CLIN ONCOL-CANC, V30, P239, DOI 10.1097/01.coc.0000256691.27796.24	31	19	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2017	12	4							e0175589	10.1371/journal.pone.0175589	http://dx.doi.org/10.1371/journal.pone.0175589			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0JS	28399182	Green Submitted, Green Published, gold			2023-01-03	WOS:000399949000051
J	He, CB; Lin, XJ				He, Chao-Bin; Lin, Xiao-Jun			Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; P53 GENE-THERAPY; CANCER; REPLICATION; CELLS; CYCLOOXYGENASE-2; COMBINATION; EFFICACY; IMPROVES; ONYX-015	Background The systemic inflammatory response plays an important role in cancer development and progression. An original inflammation-based staging system for predicting survival in patients undergoing transarterial chemoembolization (TACE) combined with recombinant human type-5 adenovirus H101 is not available. This study aimed to validate the prognostic value of inflammation scores for patients with hepatocellular carcinoma (HCC) who were treated with TACE combined with H101. Methods The data from 216 patients with HCC who underwent TACE combined with H101 from January 2007 to July 2015 were retrospectively collected, and the association of the inflammation scores with overall survival (OS) was analyzed. Univariate and multivariate analyses were performed to identify variables associated with OS. The prognostic value of the inflammation scores, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), neutrophil/ platelet-to-lymphocyte ratio (NLR-PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), prognostic index (PI), tumor-node-metastasis (TNM), Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) staging systems were analyzed and compared using the areas under the receiver operating characteristic curves (AUROCs). Results The estimated 1-, 2-, and 3-year OS rates were 61.3%, 44.2%, and 40.5% for the entire study cohort, respectively; the median OS was 17 months. According to the multivariate Cox proportional hazards model, the pretreatment NLR, tumor diameter and pretreatment alpha-fetoprotein (AFP) levels were independent predictors of OS. The CLIP score had superior discriminative abilities compared with other staging systems, and the NLR-PLR score consistently displayed a higher AUROC value than the other inflammation-based prognostic scores. The combination of the NLR-PLR and CLIP scores exhibited a superior prognostic ability for OS compared to the NLR-PLR or CLIP scores alone. Conclusions The NLR-PLR score is a more powerful predictive system than the other inflammation based scores for patients with HCC who were treated with TACE and H101. The predictive ability may be improved by utilizing a combination of the NLR-PLR and CLIP scores.	[He, Chao-Bin; Lin, Xiao-Jun] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hepatobiliary Oncol,Canc Ctr, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Lin, XJ (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hepatobiliary Oncol,Canc Ctr, Guangzhou, Guangdong, Peoples R China.	linxj@sysucc.org.cn		He, Chaobin/0000-0002-8149-1264				Abe T, 2016, HEPATOL RES, V46, P622, DOI 10.1111/hepr.12597; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cillo U, 2006, J HEPATOL, V44, P723, DOI 10.1016/j.jhep.2005.12.015; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; COWELL JK, 1992, ANN ONCOL, V3, P693, DOI 10.1093/oxfordjournals.annonc.a058319; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Fernandez M, 2009, J HEPATOL, V50, P604, DOI 10.1016/j.jhep.2008.12.011; Fu S, 2016, ONCOTARGET; Guan YS, 2011, WORLD J GASTROENTERO, V17, P2143, DOI 10.3748/wjg.v17.i16.2143; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Honda K, 1998, BRIT J CANCER, V77, P776, DOI 10.1038/bjc.1998.126; Hsu CY, 2016, ANN SURG ONCOL, V23, P994, DOI 10.1245/s10434-015-4929-x; Hsu CY, 2010, CANCER-AM CANCER SOC, V116, P3006, DOI 10.1002/cncr.25044; Huitzil-Melendez FD, 2010, J CLIN ONCOL, V28, P2889, DOI 10.1200/JCO.2009.25.9895; Ishigami S, 2000, CANCER, V88, P577, DOI 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.3.CO;2-M; Jaiswal M, 2000, CANCER RES, V60, P184; Kasuya H, 2007, CURR CANCER DRUG TAR, V7, P123, DOI 10.2174/156800907780058826; Kasymjanova G, 2010, CURR ONCOL, V17, P52; Ke M., 2016, ONCOTARGET; Lee YH, 2014, J CLIN GASTROENTEROL, V48, P734, DOI 10.1097/MCG.0b013e3182a8a254; Lei J, 2015, INT J ONCOL, V47, P555, DOI 10.3892/ijo.2015.3045; Li C, 2015, J SURG RES, V198, P73, DOI 10.1016/j.jss.2015.05.003; Lin XJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1715-x; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2008, J HEPATOL, V48, pS20, DOI 10.1016/j.jhep.2008.01.022; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Manghisi G, 1998, HEPATOLOGY, V28, P751; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Reid T, 2002, CANCER RES, V62, P6070; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shen A, 2015, J GASTROEN HEPATOL, V30, P1651, DOI 10.1111/jgh.13009; Song W, 2016, ONCOTARGET; Song X, 2010, INVEST OPHTH VIS SCI, V51, P2626, DOI 10.1167/iovs.09-3516; Tian G, 2009, ANTI-CANCER DRUG, V20, P389, DOI 10.1097/CAD.0b013e32832a2df9; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tu KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068574; Yang ZX, 2010, J CANCER RES CLIN, V136, P625, DOI 10.1007/s00432-009-0701-6; Yoshimitsu K, 2014, HEPATIC MED-EVID RES, V6, P89, DOI 10.2147/HMER.S31440; Zhang H, 2009, MOL THER, V17, P57, DOI 10.1038/mt.2008.236; Zhang N, 2016, ONCOTARGET; Zhou DS, 2015, WORLD J GASTROENTERO, V21, P5582, DOI 10.3748/wjg.v21.i18.5582; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	55	40	42	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0174769	10.1371/journal.pone.0174769	http://dx.doi.org/10.1371/journal.pone.0174769			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VG	28355305	Green Published, Green Submitted, gold			2023-01-03	WOS:000399174600087
J	Le, B; Powers, GL; Tam, YT; Schumacher, N; Malinowski, RL; Steinke, L; Kwon, G; Marker, PC				Le, Bao; Powers, Ginny L.; Tam, Yu Tong; Schumacher, Nicholas; Malinowski, Rita L.; Steinke, Laura; Kwon, Glen; Marker, Paul C.			Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer	PLOS ONE			English	Article							ANDROGEN RECEPTOR; MOLECULAR ASPECTS; IN-VIVO; CELL; AKT; COMPLEX; PHOSPHORYLATION; PROGRESSION; INHIBITION; GENERATION	Background Advanced prostate cancers that are resistant to all current therapies create a need for new therapeutic strategies. One recent innovative approach to cancer therapy is the simultaneous use of multiple FDA-approved drugs to target multiple pathways. A challenge for this approach is caused by the different solubility requirements of each individual drug, resulting in the need for a drug vehicle that is non-toxic and capable of carrying multiple water-insoluble antitumor drugs. Micelles have recently been shown to be new candidate drug solubilizers for anti cancer therapy. Methods This study set out to examine the potential use of multi-drug loaded micelles for prostate cancer treatment in preclinical models including cell line and mouse models for prostate cancers with Pten deletions. Specifically antimitotic agent (d) under barocetaxel, mTOR inhibitor (r) under barapamycin, and HSP90 inhibitor (17) under bar-N-allylamino-17-demethoxygeldanamycin were incorporated into the micelle system (DR17) and tested for antitumor efficacy. Results In vitro growth inhibition of prostate cancer cells was greater when all three drugs were used in combination compared to each individual drug, and packaging the drugs into micelles enhanced the cytotoxic effects. At the molecular level DR17 targeted simultaneously several molecular signaling axes important in prostate cancer including androgen receptor, mTOR, and PI3K/AKT. In a mouse genetic model of prostate cancer, DR17 treatment decreased prostate weight, which was achieved by both increasing caspase-dependent cell death and decreasing cell proliferation. Similar effects were also observed when DR17 was administered to nude mice bearing prostate cancer cells xenografts. Conclusion These results suggest that combining these three cancer drugs in multi-drug loaded micelles may be a promising strategy for prostate cancer therapy.	[Le, Bao; Powers, Ginny L.; Tam, Yu Tong; Schumacher, Nicholas; Malinowski, Rita L.; Steinke, Laura; Kwon, Glen; Marker, Paul C.] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 425 N Charter St, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Marker, PC (corresponding author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 425 N Charter St, Madison, WI 53706 USA.	marker@wisc.edu		Tam, Yu Tong/0000-0002-2661-5412	National Institute of Health [R21CA195313]; National Cancer Institute [R01CA140217]; NCI [R21CA195313, R01CA140217]; NATIONAL CANCER INSTITUTE [R21CA195313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U54DK104310] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by: National Institute of Health, https://www.nih.gov, National Cancer Institute, Grantnumber: R01CA140217; National Institute of Health, https://www.nih.gov, Grantnumber: R21CA195313.The funders had no role in study design, data collection and analysis, decision to publish,or preparation of the manuscript.; We thank veterinary pathologist Dr. Ruth Sullivan for her help in the assessment of histopathology of mouse tissues. This work is supported by NCI grants R01CA140217 and R21CA195313.	Amato R, 2013, CANCER CHEMOTH PHARM, V71, P1629, DOI 10.1007/s00280-013-2163-4; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Buresh-Stiemke RA, 2012, DEV DYNAM, V241, P2005, DOI 10.1002/dvdy.23886; Charles-River, NU NU MOUS HEM; Chen XG, 2010, MOL CARCINOGEN, V49, P603, DOI 10.1002/mc.20628; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311; Hasenstein JR, 2012, MOL CANCER THER, V11, P2233, DOI 10.1158/1535-7163.MCT-11-0987; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kosaka T, 2011, J UROLOGY, V185, P2376, DOI 10.1016/j.juro.2011.02.016; Kwon GS, 2008, PHARM RES-DORD, V25, P2053, DOI 10.1007/s11095-008-9644-x; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Maroto P, 2015, CRIT REV ONCOL HEMAT; MCKINNEY TD, 1976, J REPROD FERTIL, V47, P115, DOI 10.1530/jrf.0.0470115; Morgan TM, 2009, CURR CANCER DRUG TAR, V9, P237, DOI 10.2174/156800909787580999; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; OKADA H, 1992, VIRCHOWS ARCH A, V421, P157, DOI 10.1007/BF01607049; Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shin HC, 2011, MOL PHARMACEUT, V8, P1257, DOI 10.1021/mp2000549; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Wang ZA, 2014, CELL REP, V8, P1339, DOI 10.1016/j.celrep.2014.08.002; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	33	18	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2017	12	3							e0174658	10.1371/journal.pone.0174658	http://dx.doi.org/10.1371/journal.pone.0174658			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VE	28350865	Green Published, gold, Green Submitted			2023-01-03	WOS:000399174400070
J	Kawai, E; Nakahara, H; Ueda, SY; Manabe, K; Miyamoto, T				Kawai, Eriko; Nakahara, Hidehiro; Ueda, Shin-ya; Manabe, Kou; Miyamoto, Tadayoshi			A novel approach for evaluating the effects of odor stimulation on dynamic cardiorespiratory functions	PLOS ONE			English	Article							OLFACTORY STIMULATION; GRAPEFRUIT OIL; BLOOD-PRESSURE; INHALATION; HUMANS; SYSTEM; SCENT; RATS	We aimed to develop a novel method to quantitatively evaluate the effects of odor stimulation on cardiorespiratory functions over time, and to examine the potential usefulness of clinical aromatherapy. Eighteen subjects participated. Nine people were assigned to each of the two resting protocols. Protocol 1: After resting for 2 min in a sitting position breathing room air, the subject inhaled either air or air containing sweet marjoram essential oil from the Douglas bag for 6 min, Protocol 2: After resting for 5 min in a supine position, the subject inhaled the essential oil for 10 min, and then recovered for 10 min breathing room air. All subjects inhaled the essential oil through a face mask attached to one-way valve, and beat-to-beat heart rate (HR) and arterial blood pressure (BP) as well as breath-by-breath respiratory variables were continuously recorded. In both protocols, during fragrance inhalation of the essential oil, time-dependent decrease in mean BP and HR were observed (P< 0.05). During post-inhalation recovery, the significant fragrance-induced bradycardic effect lasted at least 5 min (-3.1 +/- 3.9% vs. pre-inhalation baseline value, p< 0.05). The mean BP response at the start of odor stimulation was approximated by a first-order exponential model. However, such fragrance-induced changes were not observed in the respiratory variables. We established a novel approach to quantitatively and accurately evaluate the effects of quantitative odor stimulation on dynamic cardiorespiratory functions, and the duration of the effect. This methodological approach may be useful for scientific evaluation of aromatherapy as an approach to integrated medicine, and the mechanisms of action of physiological effects in fragrance compounds.	[Kawai, Eriko; Nakahara, Hidehiro; Ueda, Shin-ya; Manabe, Kou; Miyamoto, Tadayoshi] Morinomiya Univ Med Sci, Grad Sch Hlth Sci, Osaka, Osaka, Japan		Kawai, E (corresponding author), Morinomiya Univ Med Sci, Grad Sch Hlth Sci, Osaka, Osaka, Japan.	kawai@respiratorycontrol.com		miyamoto, tadayoshi/0000-0001-5504-6119	Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine from Japan Agency for Medical Research and Development, AMED	Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED))	This research was partially supported by the Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine from Japan Agency for Medical Research and Development, AMED.	Asano K, 2009, INFLUENCE ODOR STIMU, V8, P17; Cha JH, 2013, J KOREAN ACAD NURS, V40, P705; Dalton P, 1996, PERCEPT PSYCHOPHYS, V58, P781, DOI 10.3758/BF03213109; Goes TC, 2012, J ALTERN COMPLEM MED, V18, P798, DOI 10.1089/acm.2011.0551; Haze S, 2002, JPN J PHARMACOL, V90, P247, DOI 10.1254/jjp.90.247; Hongratanaworakit T, 2009, NAT PROD COMMUN, V4, P291; Ilmberger J, 2001, CHEM SENSES, V26, P239, DOI 10.1093/chemse/26.3.239; Ito A, 2010, PROMOTION SALIVATION, V14, P134; Niijima A, 2003, EXP BIOL MED, V228, P1190, DOI 10.1177/153537020322801014; Peng SM, 2009, J ALTERN COMPLEM MED, V15, P53, DOI 10.1089/acm.2008.0243; Pluznick JL, 2013, P NATL ACAD SCI USA, V110, P4410, DOI 10.1073/pnas.1215927110; Pluznick JL, 2009, P NATL ACAD SCI USA, V106, P2059, DOI 10.1073/pnas.0812859106; Sayorwan Winai, 2012, Journal of the Medical Association of Thailand, V95, P598; Shen J, 2005, NEUROSCI LETT, V380, P289, DOI 10.1016/j.neulet.2005.01.058; Shiina Y, 2008, INT J CARDIOL, V129, P193, DOI 10.1016/j.ijcard.2007.06.064; Tanida M, 2006, NEUROSCI LETT, V398, P155, DOI 10.1016/j.neulet.2005.12.076; Umeno K, 2008, BRIT J CLIN PHARMACO, V65, P188, DOI 10.1111/j.1365-2125.2007.02992.x; VieIllard S, 2008, COGNITION EMOTION, V22, P720, DOI 10.1080/02699930701503567; Yamamoto Y., 2003, J JPN SOC PHYSL ANTH, V8, P25	19	3	3	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0172841	10.1371/journal.pone.0172841	http://dx.doi.org/10.1371/journal.pone.0172841			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5BR	28257441	Green Published, gold, Green Submitted			2023-01-03	WOS:000396021100030
J	Caberlotto, E; Ruiz, L; Miller, Z; Poletti, M; Tadlock, L				Caberlotto, Elisa; Ruiz, Laetitia; Miller, Zane; Poletti, Mickael; Tadlock, Lauri			Effects of a skin-massaging device on the ex-vivo expression of human dermis proteins and in-vivo facial wrinkles	PLOS ONE			English	Article							GENE-EXPRESSION; VII COLLAGEN; FIBROBLASTS; CULTURE	Mechanical and geometrical cues influence cell behaviour. At the tissue level, almost all organs exhibit immediate mechanical responsiveness, in particular by increasing their stiffness in direct proportion to an applied mechanical stress. It was recently shown in cultured-cell models, in particular with fibroblasts, that the frequency of the applied stress is a fundamental stimulating parameter. However, the influence of the stimulus frequency at the tissue level has remained elusive. Using a device to deliver an oscillating torque that generates cyclic strain at different frequencies, we studied the effect(s) of mild skin massage in an ex vivo model and in vivo. Skin explants were maintained ex vivo for 10 days and massaged twice daily for one minute at various frequencies within the range of 65-85 Hz. Biopsies were analysed at D0, D5 and D10 and processed for immuno-histological staining specific to various dermal proteins. As compared to untreated skin explants, the massaging procedure clearly led to higher rates of expression, in particular for decorin, fibrillin, tropoelastin, and procollagen-1. The mechanical stimulus thus evoked an anti-aging response. Strikingly, the expression was found to depend on the stimulus frequency with maximum expression at 75Hz. We then tested whether this mechanical stimulus had an anti-aging effect in vivo. Twenty Caucasian women (aged 65-75y) applied a commercial anti-aging cream to the face and neck, followed by daily treatments using the anti-aging massage device for 8 weeks. A control group of twenty-two women, with similar ages to the first group, applied the cream alone. At W0, W4 and W8, a blinded evaluator assessed the global facial wrinkles, skin texture, lip area, cheek wrinkles, neck sagging and neck texture using a clinical grading scale. We found that combining the massaging device with a skin anti-aging formulation amplified the beneficial effects of the cream.	[Caberlotto, Elisa] LOreal Res & Innovat, Chevilly Larue, France; [Ruiz, Laetitia] LOreal Res & Innovat, Aulnay Sous Bois, France; [Miller, Zane; Poletti, Mickael; Tadlock, Lauri] LOreal Res & Innovat, Redmond, WA USA	L'Oreal Group; L'Oreal Group; L'Oreal Group	Caberlotto, E (corresponding author), LOreal Res & Innovat, Chevilly Larue, France.	ecaberlotto@rd.loreal.com			L'Oreal Research Innovation	L'Oreal Research Innovation	This work was supported by L'Oreal Research & Innovation. EC, LR, ZM, MP, and LT are employed by L'Oreal. L'Oreal was the sole funder for this study and all research, study design, data collection and analysis, decisions to publish and manuscript preparation was performed by L'Oreal employees or contractors.	Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; Balestrini JL, 2006, J BIOMECH, V39, P2983, DOI 10.1016/j.jbiomech.2005.10.025; Behrens DT, 2012, J BIOL CHEM, V287, P18700, DOI 10.1074/jbc.M111.336073; Bercoff J, 2004, IEEE T ULTRASON FERR, V51, P396, DOI 10.1109/TUFFC.2004.1295425; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; Chung HJ, 2010, DERMATOL CLIN, V28, P93, DOI 10.1016/j.det.2009.10.011; Crane JD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002882; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; Eastwood M, 1998, P I MECH ENG H, V212, P85, DOI 10.1243/0954411981533854; El-Domyati M, 2002, EXP DERMATOL, V11, P398, DOI 10.1034/j.1600-0625.2002.110502.x; Farran AJE, 2013, J TISSUE ENG REGEN M, V7, P213, DOI 10.1002/term.514; Hamed SH, 2012, J COSMET DERMATOL-US, V11, P239, DOI 10.1111/j.1473-2165.2012.00626.x; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HOFFMAN H, 1952, AUST J EXP BIOL MED, V30, P541, DOI 10.1038/icb.1952.52; Huang CY, 2013, TRENDS MOL MED, V19, P555, DOI 10.1016/j.molmed.2013.05.005; Humbert P, 2015, CLIN INTERV AGING, V10, P387, DOI 10.2147/CIA.S69752; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Jiang YY, 2015, PREP BIOCHEM BIOTECH, V45, P476, DOI 10.1080/10826068.2014.923444; Jungbauer S, 2008, BIOPHYS J, V95, P3470, DOI 10.1529/biophysj.107.128611; Khan S, 1997, ANNU REV BIOCHEM, V66, P785, DOI 10.1146/annurev.biochem.66.1.785; Kielty CM, 1997, MICROSC RES TECHNIQ, V38, P413, DOI 10.1002/(SICI)1097-0029(19970815)38:4<413::AID-JEMT9>3.0.CO;2-J; Kutty JK, 2010, J TISSUE ENG REGEN M, V4, P62, DOI 10.1002/term.219; Langton A. K., 2010, International Journal of Cosmetic Science, V32, P330, DOI 10.1111/j.1468-2494.2010.00574.x; Lee YH, 2011, YONSEI MED J, V52, P982, DOI 10.3349/ymj.2011.52.6.982; McMahon TA, 1984, MUSCLES REFLEXES AND; Phuong C, 2016, CUTAN OCUL TOXICOL, V35, P153, DOI 10.3109/15569527.2015.1065501; Portillo-Soto A, 2014, J ALTERN COMPLEM MED, V20, P932, DOI 10.1089/acm.2014.0160; Shin MS, 2015, J STRENGTH COND RES, V29, P2255, DOI 10.1519/JSC.0000000000000688; Skobowiat C, 2013, BRIT J DERMATOL, V168, P595, DOI 10.1111/bjd.12096; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; SLOMINSKI A, 2013, J STEROID BIOCHEM, V137, P107, DOI [DOI 10.1016/j.jsbmb.2013.02.006, 10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092; Sukharev Sergei, 2004, Sci STKE, V2004, pre4, DOI 10.1126/stke.2192004re4; Tong ZX, 2014, TISSUE ENG PT A, V20, P1922, DOI [10.1089/ten.tea.2013.0496, 10.1089/ten.TEA.2013.0496]; Trauer S, 2014, EUR J PHARM BIOPHARM, V86, P301, DOI 10.1016/j.ejpb.2013.11.004; Tunay VB, 2010, J EUR ACAD DERMATOL, V24, P138, DOI 10.1111/j.1468-3083.2009.03355.x; Van Agtmael T, 2010, CELL TISSUE RES, V339, P167, DOI 10.1007/s00441-009-0866-y; Walchli C, 2014, J ALTERN COMPLEM MED, V20, P507, DOI 10.1089/acm.2012.0833; Willand MP, 2016, NEUROREHAB NEURAL RE, V30, P490, DOI 10.1177/1545968315604399; Zerdoum AB, 2014, JOVE-J VIS EXP, DOI 10.3791/51594	44	11	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0172624	10.1371/journal.pone.0172624	http://dx.doi.org/10.1371/journal.pone.0172624			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4NF	28249037	Green Submitted, Green Published, gold			2023-01-03	WOS:000395983500049
J	den Hartigh, LJ; Wang, SR; Goodspeed, L; Wietecha, T; Houston, B; Omer, M; Ogimoto, K; Subramanian, S; Gowda, GAN; O'Brien, KD; Kaiyala, KJ; Morton, GJ; Chait, A				den Hartigh, Laura J.; Wang, Shari; Goodspeed, Leela; Wietecha, Tomasz; Houston, Barbara; Omer, Mohamed; Ogimoto, Kayoko; Subramanian, Savitha; Gowda, G. A. Nagana; O'Brien, Kevin D.; Kaiyala, Karl J.; Morton, Gregory J.; Chait, Alan			Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice	PLOS ONE			English	Article							CONJUGATED LINOLEIC-ACID; RECEPTOR-DEFICIENT MICE; ENERGY-EXPENDITURE; INSULIN-RESISTANCE; BODY-COMPOSITION; RISK MARKERS; OBESE HUMANS; SUPPLEMENTATION; TRANS-10; FAT	Background Widely used as a weight loss supplement, trans-10, cis-12 conjugated linoleic acid (10,12 CLA) promotes fat loss in obese mice and humans, but has also been associated with insulin resistance. Objective We therefore sought to directly compare weight loss by 10,12 CLA versus caloric restriction (CR, 15-25%), an acceptable healthy method of weight loss, to determine how 10,12 CLA-mediated weight loss fails to improve glucose metabolism. Methods Obese mice with characteristics of human metabolic syndrome were either supplemented with 10,12 CLA or subjected to CR to promote weight loss. Metabolic endpoints such as energy expenditure, glucose and insulin tolerance testing, and trunk fat distribution were measured. Results By design, 10,12 CLA and CR caused equivalent weight loss, with greater fat loss by 10,12 CLA accompanied by increased energy expenditure, reduced respiratory quotient, increased fat oxidation, accumulation of alternatively activated macrophages, and browning of subcutaneous white adipose tissue (WAT). Moreover, 10,12 CLA-supplemented mice better defended their body temperature against a cold challenge. However, 10,12 CLA concurrently induced the detrimental loss of subcutaneous WAT without reducing visceral WAT, promoted reduced plasma and WAT adipokine levels, worsened hepatic steatosis, and failed to improve glucose metabolism. Obese mice undergoing CR were protected from subcutaneous-specific fat loss, had improved hepatic steatosis, and subsequently showed the expected improvements in WAT adipokines, glucose metabolism and WAT inflammation. Conclusions These results suggest that 10,12 CLA mediates the preferential loss of subcutaneous fat that likely contributes to hepatic steatosis and maintained insulin resistance, despite significant weight loss and WAT browning in mice. Collectively, we have shown that weight loss due to 10,12 CLA supplementation or CR results in dramatically different metabolic phenotypes, with the latter promoting a healthier form of weight loss.	[den Hartigh, Laura J.; Wang, Shari; Goodspeed, Leela; Houston, Barbara; Omer, Mohamed; Ogimoto, Kayoko; Subramanian, Savitha; Morton, Gregory J.; Chait, Alan] Univ Washington, Dept Med, Metab, Seattle, WA 98105 USA; [Wietecha, Tomasz; O'Brien, Kevin D.] Univ Washington, Dept Med, Cardiol, Seattle, WA USA; [Gowda, G. A. Nagana] Univ Washington, Dept Anesthesiol & Pain Med, Northwest Metabol Res Ctr, Seattle, WA 98195 USA; [Kaiyala, Karl J.] Univ Washington, Dept Oral Hlth Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	den Hartigh, LJ (corresponding author), Univ Washington, Dept Med, Metab, Seattle, WA 98105 USA.	lauradh@u.washington.edu	O'Brien, Kevin/CAH-4638-2022; O'Brien, Kevin Douglas/HDO-1461-2022	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Subramanian, Savitha/0000-0002-4866-2009	NIH National Center for Complimentary and Integrative Health [K01 AT007177]; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30 DK035816, P30 DK017047, U24 DK097153, P30 DK089503]; NIH National Heart, Lung, and Blood Institute [T32 HL007312]; University of Washington Nutrition Obesity Research Center; NIH Common Funds Project; Nutrition Obesity Research Center; University of Michigan; National Center for Complementary & Integrative Health [K01AT007177] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL092969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816, P30DK017047] Funding Source: NIH RePORTER	NIH National Center for Complimentary and Integrative Health; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Washington Nutrition Obesity Research Center; NIH Common Funds Project(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nutrition Obesity Research Center; University of Michigan(University of Michigan System); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by funding from the NIH National Center for Complimentary and Integrative Health (K01 AT007177), NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (University of Washington Nutrition Obesity Research Center Pilot and Feasibility Award: P30 DK035816; University of Washington Diabetes Research Center Pilot and Feasibility Award: P30 DK017047; University of Michigan Pilot and Feasibility Award: U24 DK097153; and University of Michigan Nutrition Obesity Research Center: P30 DK089503), and NIH National Heart, Lung, and Blood Institute (T32 HL007312).; The following core facilities of the University of Washington Nutrition Obesity Research Center supported this work: Energy Balance and Glucose Metabolism Core, Metabolomics sub core, and Atherosclerosis subcore. Jarrell Nelson from the Energy Balance and Glucose Metabolism Core contributed significant work to calorimetry analyses. The authors also utilized Metabolomics Core Services supported by the NIH Common Funds Project and the Nutrition Obesity Research Center, both from the University of Michigan, with particular contribution of expertise from Arun Das.	Abdgawad M, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032439, 10.1371/journal.pone.0046057]; Aprile M, 2014, PPAR RES, V2014, DOI 10.1155/2014/537865; Bahceci M, 2007, J ENDOCRINOL INVEST, V30, P210, DOI 10.1007/BF03347427; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Blanchard PG, 2016, ACTA PHYSL OXF; Blanck HM, 2007, J AM DIET ASSOC, V107, P441, DOI 10.1016/j.jada.2006.12.009; Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cai DM, 2012, BIOCHEM BIOPH RES CO, V422, P621, DOI 10.1016/j.bbrc.2012.05.038; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Close RN, 2007, AM J CLIN NUTR, V86, P797, DOI 10.1093/ajcn/86.3.797; den Hartigh LJ, 2013, J LIPID RES, V54, P2964, DOI 10.1194/jlr.M035188; Dong J, 2016, INT J OBESITY, V40, P434, DOI 10.1038/ijo.2015.200; Evans M, 2002, J NUTR, V132, P450, DOI 10.1093/jn/132.3.450; Fisher FM, 2002, HORM METAB RES, V34, P650, DOI 10.1055/s-2002-38246; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355; Gonzalez-Plaza J J, 2015, SURG OBES RELAT DIS; Gwang-woong G, 2013, J MICROBIOL BIOTECHN, V23, P1569, DOI 10.4014/jmb.1308.08008; Hamilton M, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0122-2; Hamm JK, 1999, ANN NY ACAD SCI, V892, P134, DOI 10.1111/j.1749-6632.1999.tb07792.x; Harvie M, 2013, BRIT J NUTR, V110, P1534, DOI 10.1017/S0007114513000792; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jones JG, 2016, DIABETOLOGIA, V59, P1098, DOI 10.1007/s00125-016-3940-5; Kaiyala KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119391; Kaiyala KJ, 2011, DIABETES, V60, P17, DOI 10.2337/db10-0909; Kamphuis MMJW, 2003, INT J OBESITY, V27, P840, DOI 10.1038/sj.ijo.0802304; Kennedy A, 2010, J LIPID RES, V51, P1906, DOI 10.1194/jlr.M005447; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Komatsu M, 2010, GENES CELLS, V15, P91, DOI 10.1111/j.1365-2443.2009.01368.x; Kostogrys RB, 2012, J NUTR HEALTH AGING, V16, P482, DOI 10.1007/s12603-011-0354-4; Magkos F, 2016, CELL METAB; Meyer LK, 2013, ADIPOCYTE, V2, P217, DOI 10.4161/adip.24953; MORRISON WR, 1964, J LIPID RES, V5, P600; Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Perry RJ, 2014, NATURE, V510, P84, DOI 10.1038/nature13478; Pini M, 2016, FASEB J, V30, P241, DOI 10.1096/fj.15-276675; Poirier H, 2006, DIABETES, V55, P1634, DOI 10.2337/db06-0036; Qiu YF, 2014, CELL, V157, P1292, DOI 10.1016/j.cell.2014.03.066; Rachid TL, 2015, MOL CELL ENDOCRINOL, V402, P86, DOI 10.1016/j.mce.2014.12.027; Raff M, 2008, J NUTR, V138, P509, DOI 10.1093/jn/138.3.509; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Riserus U, 2004, DIABETOLOGIA, V47, P1016, DOI 10.1007/s00125-004-1421-8; Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516; Riserus U, 2001, INT J OBESITY, V25, P1129, DOI 10.1038/sj.ijo.0801659; Saraf N, 2012, J PHARM PHARMACOL, V64, P161, DOI 10.1111/j.2042-7158.2011.01366.x; Schwartz A, 2010, OBES REV, V11, P531, DOI 10.1111/j.1467-789X.2009.00654.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shen W, 2013, J LIPID RES; Shen W, 2016, ANNU REV NUTR, V36, P183, DOI 10.1146/annurev-nutr-071715-050924; Shen W, 2015, J NUTR BIOCHEM, V26, P616, DOI 10.1016/j.jnutbio.2014.12.016; Shimizu I, 2015, CURR OBES REP, V4, P224, DOI 10.1007/s13679-015-0157-8; Silveira MB, 2007, PUBLIC HEALTH NUTR, V10, P1181, DOI 10.1017/S1368980007000687; Steck SE, 2007, J NUTR, V137, P1188, DOI 10.1093/jn/137.5.1188; Subramanian S, 2008, ARTERIOSCL THROM VAS, V28, P685, DOI 10.1161/ATVBAHA.107.157685; Subramanian S, 2011, J LIPID RES, V52, P1626, DOI 10.1194/jlr.M016246; Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; West DB, 2000, J NUTR, V130, P2471, DOI 10.1093/jn/130.10.2471; Yen M, 2012, J MED TOXICOL, V8, P145, DOI 10.1007/s13181-012-0213-7	65	24	24	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2017	12	2							e0172912	10.1371/journal.pone.0172912	http://dx.doi.org/10.1371/journal.pone.0172912			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4LY	28245284	gold, Green Published, Green Submitted			2023-01-03	WOS:000395980200041
J	Kiewiet, MBG; Dekkers, R; Gros, M; van Neerven, RJJ; Groeneveld, A; de Vos, P; Faas, MM				Kiewiet, M. B. Gea; Dekkers, Renske; Gros, Marjan; van Neerven, R. J. Joost; Groeneveld, Andre; de Vos, Paul; Faas, Marijke M.			Toll-like receptor mediated activation is possibly involved in immunoregulating properties of cow's milk hydrolysates	PLOS ONE			English	Article							BOVINE BETA-CASEIN; PATTERN-RECOGNITION RECEPTORS; LIMULUS AMEBOCYTE LYSATE; PROTEIN HYDROLYSATE; BIOACTIVE PEPTIDES; IN-VITRO; ENHANCES PROLIFERATION; IMMUNE-RESPONSES; EPITHELIAL-CELLS; IL-8 SECRETION	Immunomodulating proteins and peptides are formed during the hydrolysis of cow's milk proteins. These proteins are potential ingredients in functional foods used for the management of a range of immune related problems, both in infants and adults. However, the mechanism behind these effects is unknown. We hypothesize that the interaction of peptides with Toll-like receptors (TLRs) can induce immune effects, since these receptors are known to sample many dietary molecules in the intestine in order to regulate immune effects. To investigate this, we compared the immune effects and TLR activation and inhibition by whey and casein hydrolysates with different hydrolysis levels. We first measured cytokine production in primary peripheral blood mononuclear cells stimulated with either whey, casein, or their hydrolysates. IL-10 and TNF alpha were induced by whey hydrolysates (decreasing with increasing hydrolysis level), but not by casein hydrolysates. Next, the activation of TLR 2, 3, 5 and 9 receptors were observed by intact and mildly hydrolysed whey proteins only and not by casein hydrolysates in TLR reporter cell lines. Many casein hydrolysates inhibited TLR signaling (mainly TLR 5 and 9). These results demonstrate that the effects of cow's milk proteins on the immune system are protein type and hydrolysis dependent. TLR signaling is suggested as a possible mechanism for differences in effect. This knowledge contributes to a better understanding of the immune effects of hydrolysates and the design of infant formula, and nutrition in general, with specific immunoregulatory effects.	[Kiewiet, M. B. Gea; de Vos, Paul; Faas, Marijke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Immunoendocrinol,Div Med Biol, Groningen, Netherlands; [Dekkers, Renske; Gros, Marjan; van Neerven, R. J. Joost; Groeneveld, Andre] FrieslandCampina, Amersfoort, Netherlands; [Faas, Marijke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands	University of Groningen; University of Groningen	Kiewiet, MBG (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Immunoendocrinol,Div Med Biol, Groningen, Netherlands.	m.b.g.kiewiet@umcg.nl	de Vos, Paul/A-3170-2013; van Neerven, Joost/GWZ-3214-2022	van Neerven, R.J.Joost/0000-0002-3991-5297; de vos, paul/0000-0001-9618-2408				Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Baldi A, 2005, J DAIRY RES, V72, P66, DOI 10.1017/S002202990500110X; Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Bermudez-Brito M, 2015, MOL NUTR FOOD RES, V23; Chabance B, 1998, BIOCHIMIE, V80, P155, DOI 10.1016/S0300-9084(98)80022-9; Chen L, 2013, J PHARMACEUT BIOMED, V80, P180, DOI 10.1016/j.jpba.2013.03.011; Cheng X, 2015, NUTRIENTS, V7, P3119, DOI 10.3390/nu7053119; Duan CC, 2012, ASIAN PAC J ALLERGY, V30, P32; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Hill M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023995; Iskandar MM, 2013, BRIT J NUTR, V110, P58, DOI 10.1017/S0007114512004655; Kazlauskaite J, 2005, INT IMMUNOPHARMACOL, V5, P1936, DOI 10.1016/j.intimp.2005.06.015; Lahart N, 2011, INT DAIRY J, V21, P777, DOI 10.1016/j.idairyj.2011.03.014; Lebrun I, 2004, MEDIAT INFLAMM, V13, P263, DOI 10.1080/09629350400003068; Ledoux N, 1999, NAHRUNG, V43, P196, DOI 10.1002/(SICI)1521-3803(19990601)43:3&lt;196::AID-FOOD196&gt;3.0.CO;2-N; Magalhaes PO, 2007, J PHARM PHARM SCI, V10, P388; Malinowski J, 2014, FOOD CHEM, V165, P129, DOI 10.1016/j.foodchem.2014.05.075; Mao XY, 2005, MILCHWISSENSCHAFT, V60, P119; Martinez-Maqueda D, 2013, INT DAIRY J, V32, P13, DOI 10.1016/j.idairyj.2013.03.010; Meisel H, 2004, BIOFACTORS, V21, P55, DOI 10.1002/biof.552210111; Michallet MC, 2013, CURR OPIN MICROBIOL, V16, P296, DOI 10.1016/j.mib.2013.04.003; Mukhopadhya A, 2015, FOOD FUNCT, V6, P612, DOI 10.1039/c4fo00689e; NANDAN R, 1977, J LAB CLIN MED, V89, P910; Ndiaye F, 2012, EUR J NUTR, V51, P29, DOI 10.1007/s00394-011-0186-3; Nielsen DSG, 2012, J ANIM SCI, V90, P403, DOI 10.2527/jas.53953; Ortega-Gonzalez M, 2014, BRIT J NUTR, V111, P1202, DOI 10.1017/S0007114513003590; Pan DD, 2013, J DAIRY SCI, V96, P4958, DOI 10.3168/jds.2013-6758; Paredes-Juarez GA, 2014, MATERIALS, V7, P2087, DOI 10.3390/ma7032087; Perez-Cano FJ, 2007, BRIT J NUTR, V98, pS80, DOI 10.1017/S0007114507838074; Piccolomini AF, 2012, FOOD NUTR RES, V56, DOI 10.3402/fnr.v56i0.17549; Prioult G, 2004, CLIN DIAGN LAB IMMUN, V11, P266, DOI 10.1128/CDLI.11.2.266-271.2004; Raikos V, 2014, DAIRY SCI TECHNOL, V94, P91, DOI 10.1007/s13594-013-0152-3; Ren CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34561; Rodriguez-Carrio J, 2014, INT DAIRY J, V34, P65, DOI 10.1016/j.idairyj.2013.07.004; Sahasrabudhe NM, 2015, MOL NUTR FOOD RES, V23; Sandre C, 2001, J NUTR, V131, P2936, DOI 10.1093/jn/131.11.2936; Sutas Y, 1996, J ALLERGY CLIN IMMUN, V98, P216, DOI 10.1016/S0091-6749(96)70245-2; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tavares TG, 2013, INT DAIRY J, V32, P156, DOI 10.1016/j.idairyj.2013.05.010; Tobita K, 2006, J AGR FOOD CHEM, V54, P8013, DOI 10.1021/jf0610864; Trompette A, 2003, J NUTR, V133, P3499, DOI 10.1093/jn/133.11.3499; van Neerven RJ, 2009, J PERINATOL, V29, P79; Vogt L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068367; Wada Y, 2015, PEDIATR RES, V77, P546, DOI 10.1038/pr.2015.10; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Wong CW, 1996, IMMUNOL CELL BIOL, V74, P323, DOI 10.1038/icb.1996.58; Wong KF, 1998, J DAIRY SCI, V81, P1825, DOI 10.3168/jds.S0022-0302(98)75752-2; Wynn JL, 2009, J PERINATOL, V29, P79, DOI 10.1038/jp.2008.132; Zaczynska E, 2014, ADV CLIN EXP MED, V23, P871, DOI 10.17219/acem/30168	50	28	30	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e0178191	10.1371/journal.pone.0178191	http://dx.doi.org/10.1371/journal.pone.0178191			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0PL	28594834	Green Published, gold, Green Submitted			2023-01-03	WOS:000402923200020
J	Li, M; Watt, S; Escaf, M; Gardam, M; Heesters, A; O'Leary, G; Rodin, G				Li, Madeline; Watt, Sarah; Escaf, Marnie; Gardam, Michael; Heesters, Ann; O'Leary, Gerald; Rodin, Gary			Medical Assistance in Dying - Implementing a Hospital-Based Program in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; NETHERLANDS; SUICIDE; CANCER		[Li, Madeline; Watt, Sarah; Rodin, Gary] Univ Toronto, Princess Margaret Canc Ctr, Dept Support Care, Toronto, ON, Canada; [Li, Madeline; Gardam, Michael; O'Leary, Gerald; Rodin, Gary] Univ Toronto, Fac Med, Toronto, ON, Canada; [Heesters, Ann] Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada; [Li, Madeline; Watt, Sarah; Escaf, Marnie; Gardam, Michael; Heesters, Ann; O'Leary, Gerald; Rodin, Gary] Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Li, M (corresponding author), Univ Toronto, Princess Margaret Canc Ctr, Dept Support Care, Toronto, ON, Canada.; Li, M (corresponding author), Univ Toronto, Fac Med, Toronto, ON, Canada.			Rodin, Gary/0000-0002-6626-6974				Clark D, 2007, LANCET ONCOL, V8, P430, DOI 10.1016/S1470-2045(07)70138-9; College of Physicians and Surgeons od Ontario, 2016, POL STAT 4 16 MED AS; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Hendry M, 2013, PALLIATIVE MED, V27, P13, DOI 10.1177/0269216312463623; Huxley A., 1932, BRAVE NEW WORLD; Loggers ET, 2013, NEW ENGL J MED, V368, P1417, DOI 10.1056/NEJMsa1213398; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Oregon Health Authority, 2016, DEATH DIGN ACT DAT S; Shakespeare W., 1909, THE HARVARD CLASSICS, VXLVI; Snijdewind MC, 2015, JAMA INTERN MED, V175, P1633, DOI 10.1001/jamainternmed.2015.3978; Upshur R, 2016, LANCET, V388, P545, DOI 10.1016/S0140-6736(16)31255-7; Woodthorpe K, 2010, SOCIOL COMPASS, V4, P283, DOI 10.1111/j.1751-9020.2010.00279.x	13	83	83	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2017	376	21					2082	2088		10.1056/NEJMms1700606	http://dx.doi.org/10.1056/NEJMms1700606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV7MC	28538128				2023-01-03	WOS:000401959600015
J	Honda, H; Hirano, T; Ueda, M; Kojima, S; Mashiba, S; Hayase, Y; Michihata, T; Shishido, K; Takahashi, K; Hosaka, N; Ikeda, M; Sanada, D; Shibata, T				Honda, Hirokazu; Hirano, Tsutomu; Ueda, Masashi; Kojima, Shiho; Mashiba, Shinichi; Hayase, Yasuyuki; Michihata, Tetsuo; Shishido, Kanji; Takahashi, Keiko; Hosaka, Nozomu; Ikeda, Misa; Sanada, Daisuke; Shibata, Takanori			Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis	PLOS ONE			English	Article							A-II; CHOLESTEROL EFFLUX; HDL; RISK; DISEASE; ATHEROSCLEROSIS; METABOLISM; MORTALITY; PROTEIN	Apolipoproteins are associated with survival among patients on hemodialysis (HD), but these associations might be influenced by dysfunctional (oxidized) high-density lipoprotein (HDL). We assessed associations among apolipoproteins and oxidized HDL, mortality and cardiovascular disease (CVD) events in patients on HD. This prospective observational study examined 412 patients on prevalent HD. Blood samples were obtained before dialysis at baseline to measure lipids, apolipoproteins, oxidized LDL, oxidized HDL, high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6 at baseline, and HDL-C and hs-CRP were measured 12 months later. Patients were then prospectively followed-up (mean, 40 months) and all-cause mortality and composite CVD events were analyzed. Associations between variables at baseline and clinical outcome were assessed by Cox proportional hazards modeling (n = 412) and Cox hazards modeling with a time-varying covariate with HDL-C and hs-CRP (n = 369). Quartiles of apolipoproteins and oxidized HDL were not associated with all-cause mortality. However, Cox proportional hazards models with quartiles of each variable adjusted for confounders and hs-CRP or IL-6 identified apolipoprotein (apo) B-to-apoA-I ratio (apoB/apoA-I) and oxidized HDL, but not apoA-I or apoA-II, as independent risk factors for composite CVD events. These associations were confirmed by Cox proportional hazards modeling with time-varying covariates for hs-CRP. ApoB/apoA-I was independently associated with composite CVD events in 1-standard deviation (SD) increase-of-variables models adjusted for the confounders, oxidized HDL and hs-CRP. However, these associations disappeared from the model adjusted with IL-6 instead of hs-CRP, and oxidized HDL and IL-6 were independently associated with composite CVD events. Findings resembled those from Cox proportional hazards modeling using time-varying covariates with HDL-C adjusted with IL-6. In conclusion, both oxidized HDL and apoB/apoA-I might be associated with CVD events in patients on prevalent HD, while associations of apoB/apoA-I with CVD events differed between models of apoB/apoA-I quartiles and 1-SD increases, and were influenced by IL-6.	[Honda, Hirokazu; Hosaka, Nozomu] Showa Univ, Koto Toyosu Hosp, Dept Med, Div Nephrol, Tokyo, Japan; [Honda, Hirokazu; Hosaka, Nozomu; Ikeda, Misa; Sanada, Daisuke; Shibata, Takanori] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan; [Hirano, Tsutomu] Showa Univ, Sch Med, Dept Med, Div Diabet Metab & Endocrinol, Tokyo, Japan; [Ueda, Masashi; Kojima, Shiho; Mashiba, Shinichi; Hayase, Yasuyuki] Ikagaku, Res Dev, Kyoto, Japan; [Michihata, Tetsuo] Ebara Clin, Dept Dialysis, Tokyo, Japan; [Shishido, Kanji] Kawasaki Clin, Dept Dialysis, Kawasaki, Kanagawa, Japan; [Takahashi, Keiko] Kitami Higashiyama Clin, Div Dialysis, Tokyo, Japan	Showa University; Showa University; Showa University	Honda, H (corresponding author), Showa Univ, Koto Toyosu Hosp, Dept Med, Div Nephrol, Tokyo, Japan.; Honda, H (corresponding author), Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan.	hondah@med.showa-u.ac.jp		Honda, Hirokazu/0000-0002-5634-6145				Alaupovic P, 1997, ARTERIOSCL THROM VAS, V17, P715, DOI 10.1161/01.ATV.17.4.715; Birjmohun RS, 2007, CIRCULATION, V116, P2029, DOI 10.1161/CIRCULATIONAHA.107.704031; Chadwick AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123138; Corsetti JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039110; Gugliucci A, 2015, CLIN CHIM ACTA, V439, P5, DOI 10.1016/j.cca.2014.09.016; Gugliucci A, 2012, J LIPIDS, V2012, DOI 10.1155/2012/726048; Holzer M, 2011, J AM SOC NEPHROL, V22, P1631, DOI 10.1681/ASN.2010111144; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Honda H, 2016, J ATHEROSCLER THROMB, V23, P81, DOI 10.5551/jat.30015; Honda H, 2012, ATHEROSCLEROSIS, V220, P493, DOI 10.1016/j.atherosclerosis.2011.10.038; Honda H, 2010, CLIN J AM SOC NEPHRO, V5, P1021, DOI 10.2215/CJN.06110809; HUANG YD, 1995, ARTERIOSCL THROM VAS, V15, P1412, DOI 10.1161/01.ATV.15.9.1412; Huang Y, 2014, NAT MED, V20, P193, DOI 10.1038/nm.3459; Ikewaki K, 2014, CLIN EXP NEPHROL, V18, P261, DOI 10.1007/s10157-013-0881-x; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; K/ DOQI National Kidney Foundation, 2000, AM J KIDNEY DIS, V35, pS1, DOI DOI 10.1053/AJKD.2000.V35.AAJKD03517; Kalantar-Zadeh K, 2007, KIDNEY INT, V72, P1149, DOI 10.1038/sj.ki.5002491; Kaysen GA, 2014, NEPHROL DIAL TRANSPL, V29, P430, DOI 10.1093/ndt/gft370; Keane WF, 2013, J ATHEROSCLER THROMB, V20, P123, DOI 10.5551/jat.12849; Kennedy DJ, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000104; Kidney Disease Outcomes Quality Initiative (K/DOQI) Group, 2003, AM J KIDNEY DIS S, V41, pI; Kollerits B, 2016, NEPHROL DIAL TRANSPL, V31, P1901, DOI 10.1093/ndt/gfv428; Lubrano Valter, 2015, World J Exp Med, V5, P218, DOI 10.5493/wjem.v5.i4.218; Malle E, 2006, ARCH BIOCHEM BIOPHYS, V445, P245, DOI 10.1016/j.abb.2005.08.008; Nakajima T, 2000, ANN CLIN BIOCHEM, V37, P179, DOI 10.1258/0004563001899186; Navab KD, 2011, CURR PHARM DESIGN, V17, P17; Navab M, 2009, J LIPID RES, V50, pS145, DOI 10.1194/jlr.R800036-JLR200; Sato Y, 2016, CLIN J AM SOC NEPHRO, V11, P840, DOI 10.2215/CJN.09830915; Silbernagel G, 2015, J AM SOC NEPHROL, V26, P484, DOI 10.1681/ASN.2013080816; Sun J, 2016, CLIN J AM SOC NEPHRO, V11, P1163, DOI 10.2215/CJN.10441015; Sweetnam PM, 2000, EUR J CLIN INVEST, V30, P947, DOI 10.1046/j.1365-2362.2000.00725.x; Ueda M, 2007, CLIN CHIM ACTA, V378, P105, DOI 10.1016/j.cca.2006.11.002; Umemoto T, 2013, CIRC RES, V112, P1345, DOI 10.1161/CIRCRESAHA.111.300581; Vaziri ND, 2010, NAT REV NEPHROL, V6, P287, DOI 10.1038/nrneph.2010.36; Wang Y, 2013, ARTERIOSCL THROM VAS, V33, P224, DOI 10.1161/ATVBAHA.112.300445; Wiswedel I, 2008, BIOMARK INSIGHTS, V3, P419; Yamamoto S, 2012, J AM COLL CARDIOL, V60, P2372, DOI 10.1016/j.jacc.2012.09.013	37	9	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2017	12	5							e0177980	10.1371/journal.pone.0177980	http://dx.doi.org/10.1371/journal.pone.0177980			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV3PV	28542510	gold, Green Published, Green Submitted			2023-01-03	WOS:000401672400125
J	Yen, YH; Chen, JB; Cheng, BC; Chen, JF; Chang, KC; Tseng, PL; Wu, CK; Tsai, MC; Lin, MT; Hu, TH				Yen, Yi-Hao; Chen, Jin-Bor; Cheng, Ben-Chung; Chen, Jung-Fu; Chang, Kuo-Chin; Tseng, Po-Lin; Wu, Cheng-Kun; Tsai, Ming-Chao; Lin, Ming-Tsung; Hu, Tsung-Hui			Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study	PLOS ONE			English	Article							METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; HEPATIC STEATOSIS; RISK-FACTORS; DIAGNOSIS; SEVERITY; ASSOCIATION; MARKERS; BIOPSY	Background and aims Controlled attenuation parameter (CAP) is a non-invasive method for measuring hepatic steatosis (HS). Non-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVDs). CVDs are the leading cause of morbidity and mortality in hemodialysis patients. The aim of this study was to investigate the prevalence of NAFLD in hemodialysis patients. Method We prospectively enrolled patients undergoing chronic hemodialysis, as well as patients with normal renal function who served as controls. The control group patients were referred by an endocrinologist to be tested for NAFLD; most of these patients had diabetes, hypertension, or dyslipidemia. We excluded those with excess alcohol intake, use of drugs known to induce HS, chronic viral hepatitis, or CAP failure. CAP >= 238 dB/m was used as a cutoff suggesting HS. An increased liver kidney contrast, as defined by ultrasound, was used to make the diagnosis of HS. Results Three hundred and forty-three hemodialysis patients and 252 control group patients were enrolled. Among the hemodialysis patients, 192 (56.0%) had CAP- or ultrasound-identified HS compared with 91 (26.5%) who only had ultrasound-identified HS (P < 0.001). Among the control group patients, 212 (84.1%) had CAP- or ultrasound-identified HS compared with 180 (71.4%) who only had ultrasound-identified HS (P < 0.001). Conclusions The prevalence of NAFLD in the hemodialysis patients was 56%. The number of diagnoses of NAFLD made by using CAP combined with ultrasound was more than 2 times the number made with ultrasound alone in the hemodialysis patients. Therefore, we suggest the use of CAP combined with ultrasound to screen for NAFLD in hemodialysis patients.	[Yen, Yi-Hao; Chang, Kuo-Chin; Tseng, Po-Lin; Wu, Cheng-Kun; Tsai, Ming-Chao; Lin, Ming-Tsung; Hu, Tsung-Hui] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepato Gastroenterol, Kaohsiung, Taiwan; [Yen, Yi-Hao; Chen, Jin-Bor; Cheng, Ben-Chung; Chen, Jung-Fu; Chang, Kuo-Chin; Tseng, Po-Lin; Wu, Cheng-Kun; Tsai, Ming-Chao; Lin, Ming-Tsung; Hu, Tsung-Hui] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Chen, Jin-Bor; Cheng, Ben-Chung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Cheng, Ben-Chung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Endocrinol & Metab, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Hu, TH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepato Gastroenterol, Kaohsiung, Taiwan.; Chen, JB; Hu, TH (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Chen, JB (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.	chenjb1019@gmail.com; dr.hu@msa.hinet.net	Tsai, Ming Chao/ABA-9806-2020	, Ming-Chao/0000-0002-3613-2051	Chang Gung Memorial Hospital-Kaohsiung Medical Center; Taiwan [CMRPG8B1171]	Chang Gung Memorial Hospital-Kaohsiung Medical Center; Taiwan	This work was supported by Grant CMRPG8B1171 from Chang Gung Memorial Hospital-Kaohsiung Medical Center; Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Brophy DF, 2007, THROMB RES, V119, P723, DOI 10.1016/j.thromres.2006.02.013; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Chen CH, 2015, HEMATOLOGY, V20, P304, DOI 10.1179/1607845414Y.0000000199; Cheng YF, 2014, TRANSPLANTATION, V97, pS3, DOI [10.1097/TP.0000000000000060, 10.1097/01.tp.0000446265.42019.f3]; D'Adamo E, 2010, DIABETES CARE, V33, P1817, DOI 10.2337/dc10-0284; Dasarathy S, 2009, J HEPATOL, V51, P1061, DOI 10.1016/j.jhep.2009.09.001; de Ledinghen V, 2014, J HEPATOL, V60, P1026, DOI 10.1016/j.jhep.2013.12.018; Hamad Asma A, 2012, Arab J Gastroenterol, V13, P161, DOI 10.1016/j.ajg.2012.06.010; Hamaguchi M, 2007, AM J GASTROENTEROL, V102, P2708, DOI 10.1111/j.1572-0241.2007.01526.x; Hanley AJG, 2005, DIABETES, V54, P3140, DOI 10.2337/diabetes.54.11.3140; Kotronen A, 2009, DIABETOLOGIA, V52, P684, DOI 10.1007/s00125-009-1282-2; Kotronen A, 2008, ARTERIOSCL THROM VAS, V28, P27, DOI 10.1161/ATVBAHA.107.147538; Lai Yu-Cheng, 2013, Nephron Clin Pract, V124, P218, DOI 10.1159/000357952; Lee K, 2013, METAB SYNDR RELAT D, V11, P229, DOI 10.1089/met.2012.0153; Locatelli F, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1072; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Marchesini G, 2016, J HEPATOL, V64, P1388, DOI 10.1016/j.jhep.2015.11.004; Mikolasevic I, 2014, MED HYPOTHESES, V82, P205, DOI 10.1016/j.mehy.2013.11.039; Mikolasevic I, 2015, HEMODIAL INT, V19, P472, DOI 10.1111/hdi.12280; Mikolasevic I, 2015, WIEN KLIN WOCHENSCHR, V127, P451, DOI 10.1007/s00508-015-0757-z; Mikolasevic I, 2014, BLOOD PURIFICAT, V37, P259, DOI 10.1159/000360270; Mikolasevic I, 2014, CLIN INTERV AGING, V9, P1295, DOI 10.2147/CIA.S65382; Pacifico L, 2011, WORLD J GASTROENTERO, V17, P3082, DOI 10.3748/wjg.v17.i26.3082; Petta S, 2016, HEPATOLOGY; Petta S, 2015, HEPATOLOGY, V62, P1101, DOI 10.1002/hep.27844; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Sasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005; Schwimmer JB, 2008, CIRCULATION, V118, P277, DOI 10.1161/CIRCULATIONAHA.107.739920; Shi KQ, 2014, J GASTROEN HEPATOL, V29, P1149, DOI 10.1111/jgh.12519; Sniderman AD, 2010, CLIN J AM SOC NEPHRO, V5, P335, DOI 10.2215/CJN.06300909; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063; Vanholder R, 2005, NEPHROL DIAL TRANSPL, V20, P1048, DOI 10.1093/ndt/gfh813; Yilmaz Y, 2013, EUR J GASTROEN HEPAT, V25, P1330, DOI 10.1097/MEG.0b013e3283623a16	37	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2017	12	4							e0176027	10.1371/journal.pone.0176027	http://dx.doi.org/10.1371/journal.pone.0176027			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KM	28426815	Green Published, gold, Green Submitted			2023-01-03	WOS:000399875900088
J	Ahn, C; Lee, J; Oh, J; Song, Y; Chee, Y; Lim, TH; Kong, H; Shin, H				Ahn, Chiwon; Lee, Juncheol; Oh, Jaehoon; Song, Yeongtak; Chee, Youngjoon; Lim, Tae Ho; Kong, Hyunggoo; Shin, Hyungoo			Effectiveness of feedback with a smartwatch for high-quality chest compressions during adult cardiac arrest: A randomized controlled simulation study	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; CPR PERFORMANCE; LAY PERSONS; DEPTH; DEVICE; IMPROVEMENT; CAPABILITY; TARGET; SKILLS	Previous studies have demonstrated the potential for using smartwatches with a built-in accelerometer as feedback devices for high-quality chest compression during cardiopulmonary resuscitation. However, to the best of our knowledge, no previous study has reported the effects of this feedback on chest compressions in action. A randomized, parallel controlled study of 40 senior medical students was conducted to examine the effect of chest compression feedback via a smartwatch during cardiopulmonary resuscitation of manikins. A feedback application was developed for the smartwatch, in which visual feedback was provided for chest compression depth and rate. Vibrations from smartwatch were used to indicate the chest compression rate. The participants were randomly allocated to the intervention and control groups, and they performed chest compressions on manikins for 2 min continuously with or without feedback, respectively. The proportion of accurate chest compression depth (>= 5 cm and <= 6 cm) was assessed as the primary outcome, and the chest compression depth, chest compression rate, and the proportion of complete chest decompression (<= 1 cm of residual leaning) were recorded as secondary outcomes. The proportion of accurate chest compression depth in the intervention group was significantly higher than that in the control group (64.6 +/- 7.8% versus 43.1 +/- 28.3%; p = 0.02). The mean compression depth and rate and the proportion of complete chest decompressions did not differ significantly between the two groups (all p>0.05). Cardiopulmonary resuscitation-related feedback via a smartwatch could provide assistance with respect to the ideal range of chest compression depth, and this can easily be applied to patients with out-of-hospital arrest by rescuers who wear smartwatches.	[Ahn, Chiwon; Lee, Juncheol; Oh, Jaehoon; Lim, Tae Ho; Kong, Hyunggoo; Shin, Hyungoo] Hanyang Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Ahn, Chiwon] Hanyang Univ, Grad Sch Med, Dept Biomed Engn, Seoul, South Korea; [Oh, Jaehoon; Song, Yeongtak; Lim, Tae Ho; Kong, Hyunggoo] Hanyang Univ, Convergence Technol Ctr Disaster Preparedness, Seoul, South Korea; [Chee, Youngjoon] Univ Ulsan, Sch Elect Engn, Ulsan, South Korea	Hanyang University; Hanyang University; Hanyang University; University of Ulsan	Oh, J (corresponding author), Hanyang Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.; Oh, J (corresponding author), Hanyang Univ, Convergence Technol Ctr Disaster Preparedness, Seoul, South Korea.	ojjai@hanmail.net	Ahn, Chiwon/ABG-4142-2021; Oh, Jaehoon/P-1698-2015; Shin, Hyungoo/R-7752-2016	Oh, Jaehoon/0000-0001-8055-1467; Kang, Hyunggoo/0000-0002-9522-2532; Ahn, Chiwon/0000-0002-1813-1098; Shin, Hyungoo/0000-0003-3203-1672	Bumsuk Academic Research Fund	Bumsuk Academic Research Fund	This paper was supported by Bumsuk Academic Research Fund in 2015, http://www.bumsuk.or.kr/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This paper was supported by the Bumsuk Academic Research Fund in 2015.	Abella BS, 2007, RESUSCITATION, V73, P54, DOI 10.1016/j.resuscitation.2006.10.027; Ashton A, 2002, RESUSCITATION, V55, P151, DOI 10.1016/S0300-9572(02)00168-5; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; BIRNBAUM ML, 1994, CRIT CARE MED, V22, P741, DOI 10.1097/00003246-199405000-00007; Bland JM, 2015, AM J CLIN NUTR, V102, P991, DOI 10.3945/ajcn.115.119768; Bohn A, 2011, RESUSCITATION, V82, P257, DOI 10.1016/j.resuscitation.2010.11.006; Buleon C, 2013, AM J EMERG MED, V31, P1457, DOI 10.1016/j.ajem.2013.07.029; Gruber J, 2012, TRENDS ANAESTH CRIT, V2, P287, DOI 10.1016/j.tacc.2012.09.004; Hellevuo H, 2013, RESUSCITATION, V84, P760, DOI 10.1016/j.resuscitation.2013.02.015; Hoke RS, 2004, RESUSCITATION, V63, P327, DOI 10.1016/j.resuscitation.2004.05.019; Hostler David, 2011, BMJ, V342, pd512, DOI 10.1136/bmj.d512; Jensen ML, 2009, RESUSCITATION, V80, P238, DOI 10.1016/j.resuscitation.2008.10.026; Kim MJ, 2013, RESUSCITATION, V84, P361, DOI 10.1016/j.resuscitation.2012.07.011; Kirkbright S, 2014, RESUSCITATION, V85, P460, DOI 10.1016/j.resuscitation.2013.12.012; Kramer-Johansen J, 2006, RESUSCITATION, V71, P283, DOI 10.1016/j.resuscitation.2006.05.011; Krasteva V, 2011, PHYSIOL MEAS, V32, P687, DOI 10.1088/0967-3334/32/6/006; Lee S, 2015, AM J EMERG MED, V33, P1425, DOI 10.1016/j.ajem.2015.07.010; Li Q, 2011, MED TEACH, V33, pE549, DOI 10.3109/0142159X.2011.600360; Neset A, 2010, RESUSCITATION, V81, P887, DOI 10.1016/j.resuscitation.2010.03.028; Nolan JP, 2014, CURR OPIN CRIT CARE, V20, P227, DOI 10.1097/MCC.0000000000000083; Peberdy MA, 2009, RESUSCITATION, V80, P1169, DOI 10.1016/j.resuscitation.2009.07.003; Riegel B, 2005, AM HEART J, V150, P927, DOI 10.1016/j.ahj.2005.01.042; Skorning M, 2010, RESUSCITATION, V81, P53, DOI 10.1016/j.resuscitation.2009.10.005; Song Y, 2016, RESUSCITATION, V103, P20, DOI 10.1016/j.resuscitation.2016.03.014; Song Y, 2015, TELEMED E-HEALTH, V21, P36, DOI 10.1089/tmj.2014.0051; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; van Tulder R, 2015, RESUSCITATION, V89, P137, DOI 10.1016/j.resuscitation.2015.01.031; Verplancke T, 2008, RESUSCITATION, V77, P75, DOI 10.1016/j.resuscitation.2007.10.006; Yang CW, 2012, RESUSCITATION, V83, P1055, DOI 10.1016/j.resuscitation.2012.02.027; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012	32	18	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2017	12	4							e0169046	10.1371/journal.pone.0169046	http://dx.doi.org/10.1371/journal.pone.0169046			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2IH	28369055	Green Published, Green Submitted, gold			2023-01-03	WOS:000399351000004
J	Zhou, X; Ma, TT; Zhang, YC; Zhou, N; Li, J				Zhou, Xuan; Ma, Tingting; Zhang, Yichan; Zhou, Na; Li, Juan			Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; FOLLICULAR LYMPHOMA; MALE GENDER; CHOP; CHEMOTHERAPY; SURVIVAL; TRANSPLANTATION; OUTCOMES; TRIAL	Purpose The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and provide survival benefits for patients with follicular or mantle cell lymphoma. However, the effects of rituximab in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear. Two new studies involving rituximab in the treatment of DLBCL were performed this past year. We performed a meta analysis to evaluate the effects of rituximab maintenance treatment of patients with DLBCL. Methods Several databases (PubMed, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials) databases were reviewed for relevant randomized controlled trials published prior to May, 2016. Two reviewers assessed the quality of the included studies and extracted data independently. The hazard ratios (HRs) for time-to-event data and relative risks (RRs) for the other data were pooled and estimated. Results Totally 5 studies including 1740 patients were eligible for the meta-analysis. Compared to the observation group, patients who received rituximab maintenance therapy had significantly improved event-free survival (EFS) (HR = 0.80, 95% CI: 0.65-0.98) and progression free survival (PFS) (HR = 0.72, 95% CI: 0.54-0.94). However, there was no statistically significant difference in overall survival (OS) (HR = 0.66, 95% CI: 0.27-1.29). A subgroup analysis suggested that male patients may benefit from rituximab maintenance therapy with a better EFS (HR = 0.53, 95% CI: 0.34-0.82-), while this advantage was not observed in female patients (HR = 0.99, 95% CI: 0.64-1.52). Conclusions Rituximab maintenance may provide survival benefits beyond that afforded by first- and second -line chemotherapy alone, especially in male patients. However, maintenance rituximab treatment may cause more adverse events. It is recommended that both survival benefits and adverse events should be taken into consideration when making treatment decisions.	[Zhou, Xuan; Ma, Tingting; Zhang, Yichan; Zhou, Na; Li, Juan] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Hematol, Nanjing, Jiangsu, Peoples R China	Nanjing University	Li, J (corresponding author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Hematol, Nanjing, Jiangsu, Peoples R China.	juanli2003@163.com			National Natural Science Foundation of China [31371399]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China(31371399). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, CLIN LYMPHOMA MYELOM, V7, P456; Badin F, 2010, CLINICOECONOMIC OUTC, V2, P37; Cheung MC, 2007, CANCER TREAT REV, V33, P161, DOI 10.1016/j.ctrv.2006.10.005; Epperla N, 2015, BONE MARROW TRANSPL, V50, P1393, DOI 10.1038/bmt.2015.184; Foa R, 2011, ONKOLOGIE, V34, P98; Gisselbrecht C, 2012, J CLIN ONCOL, V30, P4462, DOI 10.1200/JCO.2012.41.9416; Habermann TM, 2012, HEMATOLOGY, V17, pS93, DOI 10.1179/102453312X13336169156014; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hainsworth JD, 2010, CL LYMPH MYELOM LEUK, V10, P44, DOI 10.3816/CLML.2010.n.004; Haioun C, 2009, ANN ONCOL, V20, P1985, DOI 10.1093/annonc/mdp237; Hedstrom G, 2015, ACTA ONCOL, V54, P924, DOI 10.3109/0284186X.2015.1026455; Heutte N, 2011, LEUKEMIA LYMPHOMA, V52, P1239, DOI 10.3109/10428194.2011.566951; Hosein PJ, 2015, AM J HEMATOL, V90, pE111, DOI 10.1002/ajh.23996; Huang BT, 2012, J CANCER RES CLIN, V138, P125, DOI 10.1007/s00432-011-1074-1; Jaeger U, 2015, HAEMATOLOGICA, V100, P955, DOI 10.3324/haematol.2015.125344; Jung HA, 2012, ANN HEMATOL, V91, P1747, DOI 10.1007/s00277-012-1516-0; Lindenmeyer LP, 2013, ANN HEMATOL, V92, P1451, DOI 10.1007/s00277-013-1811-4; Morschhauser F, 2014, BLOOD, V124; Muller C, 2012, BLOOD, V119, P3276, DOI 10.1182/blood-2011-09-380949; Mytelka DS, 2015, HEMATOLOGY, V20, P442, DOI 10.1179/1607845414Y.0000000228; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pfreundschuh M, 2014, BLOOD, V123, P640, DOI 10.1182/blood-2013-07-517037; Ren YR, 2015, CHINESE MED J-PEKING, V128, P378, DOI 10.4103/0366-6999.150111; Riihijarvi S, 2011, EUR J HAEMATOL, V86, P124, DOI 10.1111/j.1600-0609.2010.01541.x; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Vassilakopoulos TP, 2015, HAEMATOLOGICA, V100, pE480, DOI 10.3324/haematol.2015.133223; Witzens-Harig M, 2015, BRIT J HAEMATOL, V171, P710, DOI 10.1111/bjh.13652; Zhong H J, 2016, Zhonghua Xue Ye Xue Za Zhi, V37, P756, DOI 10.3760/cma.j.issn.0253-2727.2016.09.006	29	8	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0174648	10.1371/journal.pone.0174648	http://dx.doi.org/10.1371/journal.pone.0174648			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VG	28355276	gold, Green Submitted, Green Published			2023-01-03	WOS:000399174600075
J	Kaiser, J				Kaiser, Jocelyn			WHEN LESS IS MORE Some cancer therapies may work better if doses are timed to thwart tumor evolution	SCIENCE			English	Editorial Material																			0	12	12	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2017	355	6330			SI		1144	1146		10.1126/science.355.6330.1144	http://dx.doi.org/10.1126/science.355.6330.1144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN9WV	28302821				2023-01-03	WOS:000396351200030
J	Lu, YA; Tu, KH; Lee, CC; Wu, PW; Chang, CJ; Tian, YC; Yang, CW; Chu, PH				Lu, Yueh-An; Tu, Kun-Hua; Lee, Cheng-Chia; Wu, Patricia W.; Chang, Chee-Jen; Tian, Ya-Chung; Yang, Chih-Wei; Chu, Pao-Hsien			Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan	PLOS ONE			English	Article							SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; LIVER-CIRRHOSIS; DIALYSIS; MORTALITY; SURVIVAL; OUTCOMES; PREVALENCE; PREDICTORS	Background Peritonitis has been independently associated with increased morbidity and mortality in peritoneal dialysis patients. However, there are few reports on peritonitis in hemodialysis patients. We aim at investigating both the risk profiles and prognostic impact of peritonitis in hemodialysis patients. Methods This nation-wide longitudinal study uses claims data obtained from the Taiwan National Health Insurance Research Database. A total of 80,733 incident hemodialysis patients of age >= 20 years without a history of peritonitis were identified between January 1, 1998 and December 31, 2009. Predictors of peritonitis events were estimated using Cox proportional hazard models. Time-dependent Cox proportional hazard models were used to estimate hazard ratio for mortality attributed to peritonitis exposure. Results Of 80,733 incident hemodialysis patients over a 13-year study period, peritonitis was diagnosed in 935 (1.16%), yielding an incidence rate of 2.91 per 1000 person-years. Female gender, liver cirrhosis and polycystic kidney disease were three of the most significant factors for peritonitis in both non -diabetic and diabetic hemodialysis patients. The cumulative survival rate of patients with peritonitis was 38.8% at 1 year and 10.1% at 5 years. A time dependent Cox multivariate analysis showed that peritonitis had significantly increased hazard ratio for all cause mortality. Additionally, the risk of mortality remained significantly higher for non-diabetic hemodialysis patients that experienced peritonitis. Conclusions The risk of peritonitis in hemodialysis patients is higher in female gender, liver cirrhosis and polycystic kidney disease. Although peritonitis is a rare condition, it is associated with significantly poorer outcome in hemodialysis patients.	[Lu, Yueh-An; Tu, Kun-Hua; Lee, Cheng-Chia; Tian, Ya-Chung; Yang, Chih-Wei] Linkou Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Taipei, Taiwan; [Lu, Yueh-An; Tu, Kun-Hua; Lee, Cheng-Chia; Tian, Ya-Chung; Yang, Chih-Wei] Chang Gung Univ, Dept Med, Taoyuan, Taiwan; [Tu, Kun-Hua; Lee, Cheng-Chia; Yang, Chih-Wei] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan; [Wu, Patricia W.] Chang Gung Mem Hosp, Dept Radiol, Linkou, Taiwan; [Chang, Chee-Jen] Chang Gung Univ, Grad Inst Clin Med, Taoyuan, Taiwan; [Chang, Chee-Jen] Chang Gung Univ, Res Serv Ctr Hlth Informat, Taoyuan, Taiwan; [Chang, Chee-Jen] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Chang, Chee-Jen; Chu, Pao-Hsien] Chang Gung Univ, Chang Gung Mem Hosp, Dept Cardiol, Coll Med, Taipei, Taiwan; [Chu, Pao-Hsien] Chang Gung Univ, Coll Med, Healthcare Ctr, Chang Gung Mem Hosp, Taipei, Taiwan; [Chu, Pao-Hsien] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Heart Failure Ctr, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University	Chu, PH (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Cardiol, Coll Med, Taipei, Taiwan.; Chu, PH (corresponding author), Chang Gung Univ, Coll Med, Healthcare Ctr, Chang Gung Mem Hosp, Taipei, Taiwan.; Chu, PH (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Heart Failure Ctr, Taipei, Taiwan.	taipei.chu@gmail.com	Tu, Kun-Hua/ABD-1751-2021; Chu, Pao-Hsien/P-5249-2019	Tu, Kun-Hua/0000-0002-7146-4481; Chu, Pao-Hsien/0000-0003-0361-6348; Wu, Patricia/0000-0002-7453-0368; Lu, Yueh-An/0000-0002-5486-2357; Lee, Cheng-Chia/0000-0002-6973-5908	Linkou Chang-Gung Memorial Hospital [CMRPG3F2691, CMRPG3B1352, CORPG3F581]; Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital [CLRPG3D0042]; Research Services Center For Health Information, Chang Gung University [CIRPD1D0031]	Linkou Chang-Gung Memorial Hospital; Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital; Research Services Center For Health Information, Chang Gung University	This work was supported by the Research Grant of Linkou Chang-Gung Memorial Hospital, grant number CMRPG3F2691, CMRPG3B1352 and CORPG3F581. The authors wish to acknowledge the Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital (Grant CLRPG3D0042) and Research Services Center For Health Information, Chang Gung University (Grant CIRPD1D0031) for statistical consultation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou Dagher G, 2015, BMC EMERG MED, V15, DOI 10.1186/s12873-015-0057-y; [Anonymous], 2016, 2015 ANN REPORT KIDN; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Chen CH, 2007, J FORMOS MED ASSOC, V106, P148, DOI 10.1016/S0929-6646(09)60231-X; Chiu YL, 2008, NEPHRON CLIN PRACT, V109, pC109, DOI 10.1159/000145453; Dalrymple LS, 2015, AM J KIDNEY DIS, V65, P754, DOI 10.1053/j.ajkd.2014.11.030; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; De Vecchi AF, 2002, AM J KIDNEY DIS, V40, P161, DOI 10.1053/ajkd.2002.33925; Doklestic S K, 2014, J Med Life, V7, P132; Eleftheriadis T, 2007, SEMIN DIALYSIS, V20, P440, DOI 10.1111/J.1525-139X.2007.00283.x; Fontan MP, 2005, PERITON DIALYSIS INT, V25, P274; Fried LF, 1996, J AM SOC NEPHROL, V7, P2176; Gunjaca I, 2010, ACTA CLIN CROAT, V49, P11; Hammami M, 2010, N AM J MED SCI, V2, P238; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Kim HW, 2011, CLIN EXP NEPHROL, V15, P258, DOI 10.1007/s10157-010-0379-8; Klaric D, 2013, INT UROL NEPHROL, V45, P519, DOI 10.1007/s11255-012-0257-2; Kotwal S, 2015, NEPHROLOGY; Kraja B, 2012, GASTROENTEROL RES PR, V2012; Lantinga MA, 2016, NEPHROLOGY DIALYSIS; Litjens NHR, 2008, J AM SOC NEPHROL, V19, P1483, DOI 10.1681/ASN.2007090971; de Bustillo EM, 2011, NEFROLOGIA, V31, P723, DOI 10.3265/Nefrologia.pre2011.Oct.10987; Nessim SJ, 2009, CLIN J AM SOC NEPHRO, V4, P1195, DOI 10.2215/CJN.00910209; Ono Yasuo, 2004, Journal of Infection and Chemotherapy, V10, P200; Ra G, 2015, J CLIN GASTROENTEROL, V49, P858, DOI 10.1097/MCG.0000000000000311; Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014; Schirren CA, 1997, CLIN EXP IMMUNOL, V108, P144, DOI 10.1046/j.1365-2249.1997.d01-985.x; Selgas R, 2008, PERITON DIALYSIS INT, V28, P118; SKLAR AH, 1987, AM J KIDNEY DIS, V10, P81, DOI 10.1016/S0272-6386(87)80036-7; Suwabe T, 2015, EUR J CLIN MICROBIOL, V34, P1369, DOI 10.1007/s10096-015-2361-6; Taylor NJ, 2014, ALIMENT PHARM THER, V40, P705, DOI 10.1111/apt.12886; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Tsung PC, 2013, CLIN MOL HEPATOL, V19, P131, DOI 10.3350/cmh.2013.19.2.131; van Esch S, 2014, PERITON DIALYSIS INT, V34, P162, DOI 10.3747/pdi.2013.00275; van Manen JG, 2002, AM J KIDNEY DIS, V40, P82, DOI 10.1053/ajkd.2002.33916; Wen CP, 2008, LANCET, V371, P2173, DOI 10.1016/S0140-6736(08)60952-6; Wiest R, 2014, J HEPATOL, V60, P197, DOI 10.1016/j.jhep.2013.07.044; Zahir M, 2013, CASE REP UROL, V2013; Zimmerman D, 2012, NEPHROL DIAL TRANSPL, V27, P3816, DOI 10.1093/ndt/gfs416	39	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173710	10.1371/journal.pone.0173710	http://dx.doi.org/10.1371/journal.pone.0173710			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301536	Green Submitted, Green Published, gold			2023-01-03	WOS:000396318300064
J	Raihan, MJ; Farzana, FD; Sultana, S; Haque, MA; Rahman, AS; Waid, JL; McCormick, B; Choudhury, N; Ahmed, T				Raihan, Mohammad Jyoti; Farzana, Fahmida Dil; Sultana, Sabiha; Haque, Md Ahshanul; Rahman, Ahmed Shafiqur; Waid, Jillian L.; McCormick, Ben; Choudhury, Nuzhat; Ahmed, Tahmeed			Examining the relationship between socio-economic status, WASH practices and wasting	PLOS ONE			English	Article							CHILD UNDERNUTRITION; ACUTE MALNUTRITION; WATER; INTERVENTION; ENTEROPATHY; PREVENTION; DIARRHEA; DISINFECTION; PREVALENCE; SANITATION	Childhood wasting is a global problem and is significantly more pronounced in low and middle income countries like Bangladesh. Socio Economic Status (SES) and Water, Sanitation and Hygiene (WASH) practices may be significantly associated with wasting. Most previous research is consistent about the role of SES, but the significance of WASH in the context of wasting remains ambiguous. The effect of SES and WASH on weight for length (WHZ) is examined using a Structural Equation Model (SEM) to explicitly describe the direct and indirect role of WASH in the context of SES. A nationally representative survey of 10,478 Bangladeshi children under 5 were examined. An expert defined SEM was used to construct latent variables for SES and WASH. The SEM included a direct pathway from SES to WHZ and an indirect pathway from SES to WHZ via WASH along with regression of relevant covariates on the outcome WHZ and the latent variables. Both SES (p<0.01) and WASH (p<0.05) significantly affect WHZ. SES (p<0.01) also significantly affects WASH. Other structural components showed that child's age (p<0.01) affects WHZ and types of residence (p<0.01) affects SES. WASH practices at least partially mediate the association between SES and wasting status. WASH and SES are both significantly associated with WHZ.	[Raihan, Mohammad Jyoti; Farzana, Fahmida Dil; Haque, Md Ahshanul; Rahman, Ahmed Shafiqur; Choudhury, Nuzhat; Ahmed, Tahmeed] Int Ctr Diarrhoeal Dis Res, Nutr & Clin Serv Div, Dhaka, Bangladesh; [Sultana, Sabiha; Ahmed, Tahmeed] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh; [Waid, Jillian L.] Helen Keller Int, Dhaka, Bangladesh; [McCormick, Ben] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA	International Centre for Diarrhoeal Disease Research (ICDDR); Bangladesh Rural Advancement Committee BRAC; BRAC University; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Ahmed, T (corresponding author), Int Ctr Diarrhoeal Dis Res, Nutr & Clin Serv Div, Dhaka, Bangladesh.; Ahmed, T (corresponding author), BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh.	tahmeed@icddrb.org	Waid, Jillian/HJB-0908-2022	McCormick, Ben/0000-0002-8060-0502	European Commission; EU	European Commission(European CommissionEuropean Commission Joint Research Centre); EU(European Commission)	This study was made possible by the committed contribution and partnership of James P Grant School of Public Health (JPGSPH), BRAC University and icddr,b. This project itself is a joint partnership between JPGSPH, BRAC University, Bangladesh Bureau of Statistics and Helen Keller International (HKI), Bangladesh and funded by European Commission.; This manuscript was made possible by the committed contribution and partnership of James P Grant School of Public Health (JPGSPH), BRAG University (BU) and icddr,b. The manuscript is based on data collected and shared by FSNSP, implemented by JPGSPH, BU, Helen Keller International, Bangladesh and Bangladesh Bureau of Statistics and funded by EU. This manuscript has been reviewed by FSNSP technical reviewers for scientific content and consistency of data interpretation with previous FSNSP publications and significant comments have been incorporated prior to submission for publication. We acknowledge the following donors for providing unrestricted support to icddr,b's effort and advancement to its strategic plan: Government of the People's Republic of Bangladesh; Canada (Global Affairs, Canada-GAC), Sweden (Sida), and the United Kingdom (DFID).	Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Arnold B, 2009, INT J EPIDEMIOL, V38, P1651, DOI 10.1093/ije/dyp241; Arnold BF, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003476; Banda K, 2007, T ROY SOC TROP MED H, V101, P1124, DOI 10.1016/j.trstmh.2007.05.004; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; Bloss E, 2004, J TROP PEDIATRICS, V50, P260, DOI 10.1093/tropej/50.5.260; Chavance M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-37; Coates J., 2007, FOOD NUTR TECHNICAL, V3, DOI 10.1007/s13398-014-0173-7.2; Cogill B, 2003, ANTHROPOMETRIC INDIC; Costello A., 2005, PRACTICAL ASSESSMENT, V10, P1, DOI [10.4135/9781412995627.d8, DOI 10.4135/9781412995627.D8]; Dangour AD, 2013, COCHRANE DATABASE SY, V8; de Pee S, 2015, FOOD NUTR BULL, V36, pS24, DOI 10.1177/15648265150361S104; du Preez M, 2011, ENVIRON SCI TECHNOL, V45, P9315, DOI 10.1021/es2018835; Ehiri J, 2003, HAND WASHING PREVENT; Frozanfar MK, 2016, NAGOYA J MED SCI, V78, P41; Fuchs C, 2014, INT J PEDIAT, V2014, DOI 10.1155/2014/267806; Gross R, 2006, LANCET, V367, P1209, DOI 10.1016/S0140-6736(06)68509-7; Gunzler Douglas, 2013, Shanghai Arch Psychiatry, V25, P390, DOI 10.3969/j.issn.1002-0829.2013.06.009; GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; Helen Keller International B, 2014, FSNSP HIST; Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8; Imdad A, 2011, CURR OPIN CLIN NUTR, V14, P276, DOI 10.1097/MCO.0b013e328345364a; Isunju JB, 2011, PUBLIC HEALTH, V125, P368, DOI 10.1016/j.puhe.2011.03.008; Kennedy E, 2015, FOOD NUTR BULL, V36, pS9, DOI 10.1177/15648265150361S102; Khan NZ, 2009, J TROP PEDIATRICS, V55, P177, DOI 10.1093/tropej/fmn108; Langford R, 2011, AM J HUM BIOL, V23, P621, DOI 10.1002/ajhb.21189; Lin A, 2013, AM J TROP MED HYG, V89, P130, DOI 10.4269/ajtmh.12-0629; LOWBURY EJL, 1964, BMJ-BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5403.230; Luby SP, 2004, JAMA-J AM MED ASSOC, V291, P2547, DOI 10.1001/jama.291.21.2547; Luby SP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001052; Manary MJ, 2008, BMJ, V337; MITTERMAYER H, 1975, ZBL BAKT MIK HYG B, V160, P163; Mohsena M, 2010, PUBLIC HEALTH NUTR, V13, P1498, DOI 10.1017/S1368980010001758; Ngure FM, 2014, ANN NY ACAD SCI, V1308, P118, DOI 10.1111/nyas.12330; Pelletier David L., 2002, COMMON UNDERSTANDING; Psaki SR, 2014, POPUL HEALTH METR, V12, DOI 10.1186/1478-7954-12-8; Rayhan M.I., 2006, PAK J NUTR, V5, P558, DOI [10.3923/pjn.2006.558.562, DOI 10.3923/PJN.2006.558.562]; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; Sharma K, 2012, JOURNAL OF NEPAL HEA; Shekar M, 2006, REPOSITIONING NUTR C; Siddiqi M.N.A., 2011, ASIAN J MED SCI, V2, P113, DOI [10.3126/ajms.v2i2.3662, DOI 10.3126/AJMS.V2I2.3662]; Smith LC, 2005, WORLD DEV, V33, P1285, DOI 10.1016/j.worlddev.2005.03.002; VanderWeele TJ, 2012, AM J EPIDEMIOL; Vidal M, 2005, J CLIN MICROBIOL, V43, P5362, DOI 10.1128/JCM.43.10.5362-5365.2005; Waddington H., 2009, WATER SANITATION HYG; Walker JE, 1925, J INFECT DIS, V37, P181, DOI 10.1093/infdis/37.2.181; Wang YF, 2006, FOOD NUTR BULL, V27, pS175, DOI 10.1177/15648265060274S502; WHO, 2015, CHILD GROWTH IND THE; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA	49	20	20	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2017	12	3							e0172134	10.1371/journal.pone.0172134	http://dx.doi.org/10.1371/journal.pone.0172134			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6AW	28278161	Green Published, gold			2023-01-03	WOS:000396087900115
J	Figueiredo, PHS; Lima, MMO; Costa, HS; Gomes, RT; Neves, CDC; de Oliveira, ES; Alves, FL; Rodrigues, VGB; Maciel, EHB; Balthazar, CH				Scheidt Figueiredo, Pedro Henrique; Oliveira Lima, Marcia Maria; Costa, Henrique Silveira; Gomes, Rosalina Tossige; Cunha Neves, Camila Danielle; de Oliveira, Evandro Silveira; Alves, Frederico Lopes; Brandao Rodrigues, Vanessa Gomes; Barroso Maciel, Emilio Henrique; Balthazar, Claudio Heitor			The role of the inspiratory muscle weakness in functional capacity in hemodialysis patients	PLOS ONE			English	Article							SHUTTLE WALK TEST; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; EXERCISE CAPACITY; REFERENCE VALUES; HEART-FAILURE; MORTALITY; STRENGTH; DISEASE; CKD	Introduction Inspiratory muscle function may be affected in patients with End-Stage Renal Disease (ESRD), further worsening the functional loss in these individuals. However, the impact of inspiratory muscle weakness (IMW) on the functional capacity (FC) of hemodialysis patients remains unknown. Thus, the present study aimed to evaluate the impact of IMW on FC in ESRD patients undergoing hemodialysis. Materials and methods ESRD patients on hemodialysis treatment for more than six months were evaluated for inspiratory muscle strength and FC. Inspiratory muscle strength was evaluated based on maximal inspiratory pressure (MIP). IMW was defined as MIP values less than 70% of the predicted value. FC was evaluated using the Incremental Shuttle Walk test (ISWT). Patients whose predicted peak oxygen uptake (VO(2)peak) over the distance walked during the ISWT was less than 16mL/kg/min were considered to have FC impairment. Associations between variables were assessed by linear and logistic regression, with adjustment for age, sex, body mass index (BMI), presence of diabetes and hemoglobin level. Receiver-operating characteristic (ROC) analysis was used to determine different cutoff values of the MIP for normal inspiratory muscle strength and FC. Results Sixty-five ERSD patients (67.7% male), aged 48.2 (44.5-51.9) years were evaluated. MIP was an independent predictor of the distance walked during the ISWT (R (2) = 0.44). IMW was an independent predictor of VO(2)peak < 16mL/kg/min. (OR = 5.7; p = 0.048) in adjusted logistic regression models. ROC curves showed that the MIP cutoff value of 82cmH(2)O had a sensitivity of 73.5% and specificity of 93.7% in predicting normal inspiratory strength and a sensitivity and specificity of 76.3% and 70.4%, respectively, in predicting VO(2)peak >= 16mL/ kg/min. Conclusions IMW is associated with reduced FC in hemodialysis patients. Evaluation of the MIP may be important to functional monitoring in clinical practice and can help in the stratification of patients eligible to perform exercise testing.	[Scheidt Figueiredo, Pedro Henrique] Univ Fed Vales Jequitinhonha & Mucuri, Postgrad Course Physiol Sci, Multicentr Program Physiol Sci, Diamantina, MG, Brazil; [Scheidt Figueiredo, Pedro Henrique; Oliveira Lima, Marcia Maria; Gomes, Rosalina Tossige; Cunha Neves, Camila Danielle; de Oliveira, Evandro Silveira; Balthazar, Claudio Heitor] Univ Fed Vales Jequitinhonha & Mucuri, Phys Therapy Sch, Cardiovasc Rehabil Lab LABCAR, Diamantina, MG, Brazil; [Costa, Henrique Silveira] Univ Fed Minas Gerais, Sch Med, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, Brazil; [Alves, Frederico Lopes; Brandao Rodrigues, Vanessa Gomes; Barroso Maciel, Emilio Henrique] Santa Casa Caridade Diamantina Hosp, Hemodialysis Unit, Diamantina, MG, Brazil; [Scheidt Figueiredo, Pedro Henrique; Balthazar, Claudio Heitor] Rodovia MGT 367,Km 583,5000,Alto da Jacuba,39, Diamantina, MG, Brazil	Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal de Minas Gerais	Figueiredo, PHS (corresponding author), Univ Fed Vales Jequitinhonha & Mucuri, Postgrad Course Physiol Sci, Multicentr Program Physiol Sci, Diamantina, MG, Brazil.; Figueiredo, PHS (corresponding author), Univ Fed Vales Jequitinhonha & Mucuri, Phys Therapy Sch, Cardiovasc Rehabil Lab LABCAR, Diamantina, MG, Brazil.; Figueiredo, PHS (corresponding author), Rodovia MGT 367,Km 583,5000,Alto da Jacuba,39, Diamantina, MG, Brazil.	phsfig@yahoo.com.br	Figueiredo, Pedro Henrique/AAP-2158-2020; Costa, Henrique Silveira/H-8286-2014	Costa, Henrique Silveira/0000-0002-1426-7246				Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; Alves R, 2016, EUR J PHYS REHAB MED, V52, P20; Axelsson J, 2004, AM J CLIN NUTR, V80, P1222, DOI 10.1093/ajcn/80.5.1222; Cahalin LP, 2015, HEART FAIL CLIN, V11, P149, DOI 10.1016/j.hfc.2014.09.002; Carrero JJ, 2008, CLIN NUTR, V27, P557, DOI 10.1016/j.clnu.2008.04.007; Chen CT, 2013, SCI WORLD J, DOI 10.1155/2013/643954; Cury JL, 2010, BRAZ J PHYS THER, V14, P91, DOI 10.1590/S1413-35552010005000008; Dempsey JA, 2006, RESP PHYSIOL NEUROBI, V151, P242, DOI 10.1016/j.resp.2005.12.015; Dipp T, 2010, REV BRAS MED ESPORTE, V16, P246, DOI 10.1590/S1517-86922010000400002; Dourado VZ, 2013, J BRAS PNEUMOL, V39, P190, DOI 10.1590/S1806-37132013000200010; Eknoyan G, 2004, KIDNEY INT, V66, P1310, DOI 10.1111/j.1523-1755.2004.00894.x; Fassbinder Tânia Regina Cavinatto, 2015, Braz. J. Nephrol., V37, P47, DOI 10.5935/0101-2800.20150008; Finkelstein FO, 2009, KIDNEY INT, V76, P946, DOI 10.1038/ki.2009.307; Fragoso CAV, 2014, J AM GERIATR SOC, V62, P622, DOI 10.1111/jgs.12738; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14; Hart N, 2002, AM J RESP CRIT CARE, V165, P1265, DOI 10.1164/rccm.2110016; Hill K, 2012, RESPIROLOGY, V17, P278, DOI 10.1111/j.1440-1843.2011.02089.x; Ikizler TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE107, DOI 10.1152/ajpendo.2002.282.1.E107; Iyasere O, 2014, POSTGRAD MED J, V90, P340, DOI 10.1136/postgradmedj-2013-132251; Johansen KL, 2010, KIDNEY INT, V78, P1164, DOI 10.1038/ki.2010.312; Johansen KL, 2012, CLIN J AM SOC NEPHRO; Kaminski DM, 2011, CLIN AUTON RES, V21, P29, DOI 10.1007/s10286-010-0087-1; Katayama A, 2014, ENVIRON HEALTH PREV, V19, P220, DOI 10.1007/s12199-014-0380-z; Kovelis Demetria, 2008, J. bras. pneumol., V34, P907, DOI 10.1590/S1806-37132008001100004; Kutner NG, 2015, AM J KIDNEY DIS, V66, P297, DOI 10.1053/j.ajkd.2015.01.024; Moreno AM, 2014, BRAZ J MED BIOL RES, V47, P972, DOI 10.1590/1414-431X20143896; Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007; Neves CDC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117563; Painter P, 2012, CLIN J AM SOC NEPHRO; Painter P, 2009, ADV CHRONIC KIDNEY D, V16, P437, DOI 10.1053/j.ackd.2009.09.002; Parreira VF, 2014, CHEST, V145, P1357, DOI 10.1378/chest.13-2071; Petchey WG, 2011, CLIN J AM SOC NEPHRO, V6, P512, DOI 10.2215/CJN.06880810; Pinheiro MB, 2014, EUR J PHYS REHAB MED, V50, P301; Polkey MI, 2016, AM J RESP CRITICAL C; Pomidori L, 2016, J NEPHROL, P1; Reis MS, 2014, PHYSIOTHER RES INT, V19, P16, DOI 10.1002/pri.1552; Reis MS, 2010, CLINICS, V65, P369, DOI 10.1590/S1807-59322010000400004; Rosa CSC, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0183-5; Silva Vanessa Giendruczak da, 2011, Braz. J. Nephrol., V33, P62; Singer J, 2011, J CARDIOPULM REHABIL, V31, P111, DOI 10.1097/HCR.0b013e3182033663; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Stack AG, 2005, AM J KIDNEY DIS, V45, P690, DOI 10.1053/j.ajkd.2004.12.013; Tavana Sasan, 2015, Tanaffos, V14, P128; Torino C, 2014, KIDNEY BLOOD PRESS R, V39, P205, DOI 10.1159/000355798; van der Palen J, 2004, THORAX, V59, P1063, DOI 10.1136/thx.2004.021915; WEBER KT, 1985, AM J CARDIOL, V55, pA22, DOI 10.1016/0002-9149(85)90792-1; Weiner DE, 2006, AM J KIDNEY DIS, V48, P392, DOI 10.1053/j.ajkd.2006.05.021; Yamada K, 2016, J CARD FAIL, V22, P38, DOI 10.1016/j.cardfail.2015.10.010	48	14	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2017	12	3							e0173159	10.1371/journal.pone.0173159	http://dx.doi.org/10.1371/journal.pone.0173159			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6AW	28278163	Green Published, Green Submitted, gold			2023-01-03	WOS:000396087900051
J	Detsky, AS; Gropper, MA				Detsky, Allan S.; Gropper, Michael A.			Why Physician Leaders of Health Care Organizations Should Participate in Direct Patient Care RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Detsky, Allan S.] Univ Toronto, Toronto, ON, Canada; [Gropper, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Toronto; University of California System; University of California San Francisco	Detsky, AS (corresponding author), Univ Toronto, Toronto, ON, Canada.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					376	377		10.7326/L16-0624	http://dx.doi.org/10.7326/L16-0624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265660				2023-01-03	WOS:000396432800016
J	Kebede, HK; Gesesew, HA; Woldehaimanot, TE; Goro, KK				Kebede, Hafte Kahsay; Gesesew, Hailay Abrha; Woldehaimanot, Tewodros Eyob; Goro, Kabaye Kumela			Antimicrobial use in paediatric patients in a teaching hospital in Ethiopia	PLOS ONE			English	Article							ANTIBIOTIC USE; PRESCRIPTIONS; SURVEILLANCE; CHILDREN; EUROPE	Background Antibiotics use in in children are different from adults due to a lack of data on pharmacokinetics, pharmacodynamics, efficacy and safety of drugs, different physiological spectrum, pediatrics populations being vulnerable to the majority of the illnesses, and the adverse effect of their irrational use is more serious. However, antibiotic use is not explored much in a paediatric population. The current study focused on antibiotic use among pediatric population using data from a tertiary hospital in Ethiopia. Methods A retrospective cross-sectional study collated data from 614 pediatrics patients admitted in pediatrics ward at Jimma University Teaching Hospital, Southwest Ethiopia. Descriptive analyses were performed to describe the type and pattern of antibiotics. The number of prescriptions per a patient was also compared with the WHO standard. Data analysis was carried out using SPSS version 20 for mackintosh. Results Antimicrobials were prescribed for 407(86.4%) patients of which 85.9% were in the form of injectables. A total of 1241 (90%) medicines were administered parenterally followed by oral 110 (8%). The maximum number of medicines per prescription was eight for all types of drugs in general, and five for antimicrobials in particular. All antimicrobials were prescribed empirically without any microbiological evidence. Pneumonia, sepsis and meningitis were the main reasons for antimicrobial use in the ward. Out of the total of 812 antibiotics prescribed; Penicillin G crystalline was the most (20%) frequently prescribed, followed by gentamicin (19%) and ampicillin (16). Conclusions Majority of the prescribed antibiotics were antimicrobials, and was in the form of injectables. Antimicrobials were over prescribed and the number of drugs per prescription was also far from WHO recommendation. Strict prescribing standard guidelines and treatment habits should be developed in the country, to prevent antimicrobial resistance.	[Kebede, Hafte Kahsay] Filtu Hosp, Somali, Ethiopia; [Gesesew, Hailay Abrha] Jimma Univ, Dept Epidemiol, Coll Hlth Sci, Jimma, Ethiopia; [Gesesew, Hailay Abrha] Flinders Univ S Australia, Discipline Publ Hlth, Fac Med Nursing & Hlth Sci, Adelaide, SA, Australia; [Woldehaimanot, Tewodros Eyob; Goro, Kabaye Kumela] Jimma Univ, Dept Clin Pharm, Coll Hlth Sci, Jimma, Ethiopia	Jimma University; Flinders University South Australia; Jimma University	Gesesew, HA (corresponding author), Jimma Univ, Dept Epidemiol, Coll Hlth Sci, Jimma, Ethiopia.; Gesesew, HA (corresponding author), Flinders Univ S Australia, Discipline Publ Hlth, Fac Med Nursing & Hlth Sci, Adelaide, SA, Australia.	hailushepi@gmail.com	Gesesew, Hailay/AAF-6486-2020	Gesesew, Hailay/0000-0002-3531-4400	Jimma University	Jimma University	This research was funded by Jimma University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulgafar O J, 2011, J CLIN DIAGNOSTIC RE, V5, P566; Abula T., 1999, Ethiopian Journal of Health Development, V13, P135; Adriaenssens N, 2011, J ANTIMICROB CHEMOTH, V66, P47, DOI 10.1093/jac/dkr457; Ansam S, 2006, AN NAJAH U J RES, V20, P191; Bozic B, 2015, ARCH DIS CHILD, V100, P966, DOI 10.1136/archdischild-2015-308274; Buccellato E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139097; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Ceyhan M, 2010, INT J INFECT DIS, V14, pE55, DOI 10.1016/j.ijid.2009.03.013; Desta Z, 1997, E AFR MED J, V74, P758; DiPiro JT, 2002, PHARMACOTHERAPY PATH; FDRE, 2010, HLTH SECT DEV PROGR; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Isah AO, 2004, DEV STANDARD VALUES; Jan D, 2001, HLTH ISSUES, V69, P1; Katzung B G, 2001, BASIC CLIN PHARMACOL, P200; Majed A-A, 2015, EUROPEAN SCI J, V11, P253; Mathew B, 2013, IRJIPS, V1; Menassie K, 2004, CROSS SECTIONAL SURV; Mestawot F, 2013, INT J BASIC CLIN PHA, V2, P718; Minyahil A., 2013, J APPL PHARM SCI, V3, P93; Mukonzo JK, 2013, J MULTIDISCIP HEALTH, V6, P303, DOI 10.2147/JMDH.S49075; Nwolisa CE, 2006, J TROP PEDIATRICS, V52, P197, DOI 10.1093/tropej/fmi095; Palikhe N, 2004, Kathmandu Univ Med J (KUMJ), V2, P6; Paruk F, 2012, SAMJ S AFR MED J, V102, P613, DOI 10.7196/SAMJ.5833; Raveh D, 2001, QJM-INT J MED, V94, P141, DOI 10.1093/qjmed/94.3.141; Resi D, 2003, J ANTIMICROB CHEMOTH, V52, P282, DOI 10.1093/jac/dkg302; SCHOLLENBERG E, 1980, CAN MED ASSOC J, V122, P49; Thrane N, 1999, PEDIATR INFECT DIS J, V18, P333, DOI 10.1097/00006454-199904000-00004; [WHO MoH], 2003, BAS ASS PHARM SECT E; [WHO AHO], 2016, AFR HLTH OBS WHO AN; WHO, 1985, C EXP NAIR 25 29 NOV; WHO. World Health Organization, 2010, MED RAT US MED; Wubante Y, 2005, S W ETHIOPIA ETHIOPI, V15, P147	33	15	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2017	12	3							e0173290	10.1371/journal.pone.0173290	http://dx.doi.org/10.1371/journal.pone.0173290			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5OE	28264021	Green Published, Green Submitted, gold			2023-01-03	WOS:000396054300049
J	Chim, L; Salkeld, G; Kelly, P; Lipworth, W; Hughes, DA; Stockler, MR				Chim, Lesley; Salkeld, Glenn; Kelly, Patrick; Lipworth, Wendy; Hughes, Dyfrig A.; Stockler, Martin R.			Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia	PLOS ONE			English	Article							DISCRETE-CHOICE; CANCER DRUGS; PREFERENCES; HEALTH; COSTS; LIFE; CARE; END	Background Around the world government agencies responsible for the selection and reimbursement of prescribed medicines and other health technologies are considering how best to bring community preferences into their decision making. In particular, community views about the distribution or equity of funding across the population. These official committees and agencies often have access to the best available and latest evidence on clinical effectiveness, safety and cost from large clinical trials and population-based studies. All too often they do not have access to high quality evidence about community views. We therefore, conducted a large and representative population-based survey in Australia to determine what community members think about the factors that do and should influence government spending on prescribed medicines. Methods A choice-based survey was designed to elicit the importance of individual criteria when considering the equity of government spending on prescribed medicines. A representative sample of 3080 adult Australians completed the survey by allocating a hypothetical budget to different combinations of money spent on two patient populations. Societal preferences were inferred from absolute majority responses i.e. populations with more than 50% of respondents' allocation for a particular allocation criterion. Results This study shows that, all else being equal, severity of disease, diseases for which there is no alternative treatment available on the government formulary, diseases that affect patients who are not financially well off, and life-style unrelated diseases are supported by the public as resource allocation criteria. Where 'all else is not equal', participants allocated more resources to the patient population that gained considerable improvement in health and fewer resources to those that gained little improvement in health. This result held under all scenarios except for 'end-of-life treatments'. Responses to cost (and corresponding number of patients treated) trade-off scenarios indicated a significant reduction in the proportion of respondents choosing to divide resources equally and a shift in preference towards devoting resources to the population that were more costly to treat for all criteria with the exception of severity of disease. Conclusions The general public have clear views on what's fair in terms of government spending on prescribed medicines. In addition to supporting the application of the 'rule of rescue', important considerations for government spending included the severity of disease being treated, diseases for which there is no alternative treatment available on the government formulary, diseases that affect patients who are not financially well off and life-style unrelated diseases. This study shows that the general public are willing to share their views on what constitutes an equitable allocation of the government's drug budget. The challenge remains to how best to consider those views alongside clinical and economic considerations.	[Chim, Lesley; Kelly, Patrick] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia; [Chim, Lesley] Alex Pharmaceut, Sydney, NSW, Australia; [Salkeld, Glenn] Univ Wollongong, Fac Social Sci, Wollongong, NSW, Australia; [Lipworth, Wendy] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW, Australia; [Hughes, Dyfrig A.] Bangor Univ, Bangor Inst Hlth & Med Res, Ctr Hlth Econ & Med Evaluat, Bangor, Gwynedd, Wales; [Stockler, Martin R.] Univ Sydney, NHMRC, Clin Trials Ctr, Sydney, NSW, Australia; [Stockler, Martin R.] Concord Hosp, Concord Canc Ctr, Sydney, NSW, Australia; [Stockler, Martin R.] Chris OBrien Lifehouse, Sydney, NSW, Australia	University of Sydney; University of Wollongong; University of Sydney; Bangor University; University of Sydney; Concord Repatriation General Hospital; University of Sydney	Chim, L (corresponding author), Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.; Chim, L (corresponding author), Alex Pharmaceut, Sydney, NSW, Australia.	lesleychim@gmail.com	Hughes, Dyfrig/H-5252-2012	Hughes, Dyfrig/0000-0001-8247-7459; Kelly, Patrick/0000-0002-5015-0977; Lipworth, Wendy/0000-0002-0234-657X	National Health and Medical Research Council of Australia [6633003]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was undertaken as part of the Screening and Diagnostic Test Evaluation Program funded by the National Health and Medical Research Council of Australia under Program Grant number 6633003. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PHARM BEN SCHEM QUIC; Australian Government Department of Health, 2015, GUID PREP SUBM PHARM; Campaigns, CAMP; Cancer Drugs Alliance, 2015, CANC DRUGS ALL SUBM; Chim L, 2010, PHARMACOECONOMICS, V28, P463, DOI 10.2165/11533000-000000000-00000; Daroudi R, 2016, INT J HEALTH POLICY, V5, P99, DOI 10.15171/ijhpm.2015.186; Department of Health, LIF SAV DRUGS PROGR; Desser AS, 2013, PHARMACOECONOMICS, V31, P1051, DOI 10.1007/s40273-013-0093-y; Dolan P, 2005, HEALTH ECON, P14; Finkelstein EA, 2015, HEALTH POLICY, V119, P1482, DOI 10.1016/j.healthpol.2015.09.001; Gallego G, 2007, HEALTH EXPECT, V10, P224, DOI 10.1111/j.1369-7625.2007.00439.x; George B, 2001, PHARMACOECONOMICS, V19, P1103, DOI 10.2165/00019053-200119110-00004; Ghinea N, 2016, MED J AUSTRALIA, V204, P214, DOI 10.5694/mja15.01309; Harris AH, 2008, MED DECIS MAKING, V28, P713, DOI 10.1177/0272989X08315247; Hosmer D, 2000, APPL LOGISTIC RERESS; Lees Ann, 2002, Health Expect, V5, P47, DOI 10.1046/j.1369-6513.2002.00157.x; Linley WG, 2013, HEALTH ECON, V22, P948, DOI 10.1002/hec.2872; MacKenzie R, 2008, J ROY SOC MED, V101, P1; MacLeod TE, 2016, PATIENT, V9, P201, DOI 10.1007/s40271-015-0139-7; McKie John, 2009, Aust New Zealand Health Policy, V6, P11, DOI 10.1186/1743-8462-6-11; Mileshkin L, 2009, J CLIN ONCOL, V27, P5830, DOI 10.1200/JCO.2009.22.7793; Neumann PJ, 2010, HEALTH AFFAIR, V29, P196, DOI 10.1377/hlthaff.2009.0077; NHS England, 2015, GUID SUPP OP CDF 201; Pharmaceutical Benfits Advisory Committee, 2015, PHARM BEN ADV COMM S; PharmaDispatch, 2015, PAT HAV SUFF SYST NE; Rare Cancer Australia, 2015, RAR CANC AUSTR SUBM; Senate Community Affairs Reference Committee, 2015, AV NEW INN SPEC CANC; Shah KK, 2015, SOC SCI MED, V124, P48, DOI 10.1016/j.socscimed.2014.11.022; Shah KK, 2009, HEALTH POLICY, V93, P77, DOI 10.1016/j.healthpol.2009.08.005; Tordrup D, 2013, APPL HEALTH ECON HEA, V11, P639, DOI 10.1007/s40258-013-0056-7; van Exel J, 2015, SOC SCI MED, V126, P128, DOI 10.1016/j.socscimed.2014.12.023; Vogler S, 2016, HEALTH POLICY TECHN, V5, P213, DOI 10.1016/j.hlpt.2016.03.009; Whitty JA, 2012, VALUE HEALTH, V15, pA306, DOI 10.1016/j.jval.2012.08.642; Whitty JA, 2011, APPL HEALTH ECON HEA, V9, P73, DOI 10.2165/11537150-000000000-00000; Whitty JA, 2015, HEALTH POLICY, V119, P127, DOI 10.1016/j.healthpol.2014.09.003; Whitty JA, 2014, MED DECIS MAKING, V34, P638, DOI 10.1177/0272989X14526640; Wilson A, 2011, VALUE HEALTH, V14, P944, DOI 10.1016/j.jval.2011.05.004; Wortley S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010265	38	19	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0172971	10.1371/journal.pone.0172971	http://dx.doi.org/10.1371/journal.pone.0172971			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN4NF	28249013	Green Published, Green Submitted, gold			2023-01-03	WOS:000395983500066
J	Xu, LY; Munir, K; Kanabkaew, C; Le Coeur, S				Xu, Luyi; Munir, Kerim; Kanabkaew, Cheeraya; Le Coeur, Sophie			Factors influencing antiretroviral treatment suboptimal adherence among perinatally HIV-infected adolescents in Thailand	PLOS ONE			English	Article							DIAGNOSIS DISCLOSURE; MEDICATION ADHERENCE; POSITIVE CHILDREN; THERAPY; OUTCOMES; YOUTH; PREDICTORS; CHALLENGES; BARRIERS; HIV/AIDS	Background Existing studies have suggested decreased adherence and rebound in mortality in perinatally HIV-infected adolescents receiving antiretroviral therapy (ART) as compared to adults and young children. Methods We used both quantitative and qualitative approaches to identify factors influencing adherence among perinatally infected adolescents in Thailand. We analyzed data from 568 pairs of perinatally infected adolescents (aged 12-19) and their primary caregivers in the Teens Living With Antiretrovirals (TEEWA) study, a cross-sectional survey conducted in 2010-2012. We also conducted 12 in-depth interviews in 2014 with infected adolescents or their primary caregivers to elicit experiences of living with long-term ART. Results From the quantitative analysis, a total of 275 (48.4%) adolescents had evidence of suboptimal adherence based on this composite outcome: adolescents self-reported missing doses in the past 7 days, caregiver rating of overall adherence as suboptimal, or latest HIV-RNA viral load >= 1000 copies/ml. In multivariate logistic regression analysis, younger age, having grandparents or extended family members as the primary caregiver, caregiver-assessed poor intellectual ability, having a boy/girlfriend, frequent online chatting, self-reported unhappiness and easiness in asking doctors questions were significantly associated with suboptimal adherence. From the in-depth interviews, tensed relationships with caregivers, forgetfulness due to busy schedules, and fear of disclosing HIV status to others, especially boy/girlfriends, were important contributors to suboptimal adherence. Social and emotional support and counseling from peer group was consistently reported as a strong adherence-promoting factor. Conclusion Our findings highlight unique barriers of ART adherence among the perinatally infected adolescents. Future interventions should be targeted at helping adolescents to improve interpersonal relationships and build adaptive skills in recognizing and addressing challenging situations related to ART taking.	[Xu, Luyi; Munir, Kerim] Harvard Med Sch, Boston, MA 02115 USA; [Munir, Kerim] Boston Childrens Hosp, Div Dev Med, Dev Med Ctr, Boston, MA USA; [Kanabkaew, Cheeraya; Le Coeur, Sophie] Inst Rech Dev IRD 174 PHPT, Chiang Mai, Thailand; [Kanabkaew, Cheeraya; Le Coeur, Sophie] Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai, Thailand; [Le Coeur, Sophie] INED, Paris, France; [Le Coeur, Sophie] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Chiang Mai University; Harvard University; Harvard T.H. Chan School of Public Health	Xu, LY (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	luyi_xu@hms.harvard.edu	Munir, Kerim/D-6910-2015	Munir, Kerim/0000-0002-2404-1806	Sidaction [AI22-1/01855]; Oxfam Great Britain, Thailand [THAA51]; Scholars in Medicine, Harvard Medical School, Boston, USA; Thai Studies Fund, Harvard University Asia Center, Boston, USA; NIMH / Fogarty International Center, National Institutes of Health NCD-LIFESPAN Global Mental Health/Developmental Disorders Research Program [D43TW009680]; FOGARTY INTERNATIONAL CENTER [D43TW009680] Funding Source: NIH RePORTER	Sidaction; Oxfam Great Britain, Thailand; Scholars in Medicine, Harvard Medical School, Boston, USA; Thai Studies Fund, Harvard University Asia Center, Boston, USA; NIMH / Fogarty International Center, National Institutes of Health NCD-LIFESPAN Global Mental Health/Developmental Disorders Research Program; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by Sidaction, grant AI22-1/01855, (https://www.sidaction.org/) - receiver: SL; Oxfam Great Britain, Thailand, grant THAA51, (http://www.oxfam.org.uk/) -receiver: Marc Lallemant; Scholars in Medicine, Harvard Medical School, Boston, USA, (http://hms.harvard.edu/departments/medical-education/student-services/scholars-medicine-sim) -receiver: LX; Thai Studies Fund, Harvard University Asia Center, Boston, USA, (http://asiacenter.harvard.edu/grants/students/southeastasia) -receiver: LX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NIMH / Fogarty International Center, National Institutes of Health NCD-LIFESPAN Global Mental Health/Developmental Disorders Research Program, grant D43TW009680, (www.fic.nih.gov) -receiver: KM The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agwu AL, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18579; Bernays S, 2014, LANCET, V383, P1355, DOI 10.1016/S0140-6736(13)62328-4; Boon-yasidhi V, 2016, INT J STD AIDS, V27, P288, DOI 10.1177/0956462415579590; Boon-Yasidhi V, 2013, AIDS CARE, V25, P756, DOI 10.1080/09540121.2012.749331; Boussari O, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/1471-2288-15-10; Chandler CN AE, 2013, LOST TRANSITIONS CUR, DOI [10.1007/s10461-012-0364-1, DOI 10.1007/S10461-012-0364-1]; Chandwani S, 2012, J ADOLESCENT HEALTH, V51, P242, DOI 10.1016/j.jadohealth.2011.12.013; Cluver Lucie D, 2015, AIDS, V29 Suppl 1, pS57, DOI 10.1097/QAD.0000000000000695; Denison JA, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19358; Evans SD, 2015, AIDS PATIENT CARE ST, V29, P43, DOI 10.1089/apc.2014.0058; Falagas ME, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-13; FESTINGER L, 1962, SCI AM, V207, P93, DOI 10.1038/scientificamerican1062-93; Fetzer BC, 2011, AIDS PATIENT CARE ST, V25, P611, DOI 10.1089/apc.2011.0083; Hudelson C, 2015, AIDS CARE, V27, P805, DOI 10.1080/09540121.2015.1011073; Kanabkaew C, 2012, C AM PUBL HLTH ASS S; Kang E, 2015, INT J STD AIDS, V26, P534, DOI 10.1177/0956462414545524; Katz IT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18640; Kawuma R, 2014, AJAR-AFR J AIDS RES, V13, P189, DOI 10.2989/16085906.2014.927778; Konstantopoulos C, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu119; Li JZ, 2014, AIDS, V28, P181, DOI 10.1097/QAD.0000000000000123; Louthrenoo O, 2013, J INT ASS PROVIDERS; Lowenthal ED, 2014, LANCET INFECT DIS; Lowenthal ED, 2015, JAMA PEDIATR, V169, P498, DOI 10.1001/jamapediatrics.2014.3785; MacDonell K, 2013, AIDS BEHAV, V17, P86, DOI 10.1007/s10461-012-0364-1; Manosuthi W, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0053-z; Mavhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070254; Mellins CA, 2004, PEDIATR INFECT DIS J, V23, P1035, DOI 10.1097/01.inf.0000143646.15240.ac; Mellins CA, 2011, AIDS PATIENT CARE ST, V25, P413, DOI 10.1089/apc.2011.0025; Mofenson LM, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18650; Mupambireyi Z, 2014, CHILD YOUTH SERV REV, V45, P106, DOI 10.1016/j.childyouth.2014.03.026; Murphy DA, 2003, ARCH PEDIAT ADOL MED, V157, P249, DOI 10.1001/archpedi.157.3.249; Mutwa PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060073; Naar-King S, 2013, J PEDIATR PSYCHOL, V38, P664, DOI 10.1093/jpepsy/jst017; Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e; Nyogea D, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0753-y; Petersen I, 2010, AIDS CARE, V22, P970, DOI 10.1080/09540121003623693; Reisner Sari L, 2009, Top HIV Med, V17, P14; Rongkavilit Chokechai, 2007, J Adolesc Health, V40, DOI 10.1016/j.jadohealth.2006.11.004; Simoni JM, 2007, PEDIATRICS, V119, pE1371, DOI 10.1542/peds.2006-1232; Sirikum C, 2014, AIDS CARE, V26, P1144, DOI 10.1080/09540121.2014.894614; Sohn AH, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18555; Tulloch O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099061; UNAIDS, 2015, 2014 HIV AIDS EST; UNICEF, 2015, AD RAD AS PAC AIDS R; Vreeman RC, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18466; White YRG, 2008, W INDIAN MED J, V57, P231; Williams PL, 2006, PEDIATRICS, V118, pE1745, DOI 10.1542/peds.2006-0493	47	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0172392	10.1371/journal.pone.0172392	http://dx.doi.org/10.1371/journal.pone.0172392			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL2BG	28207891	Green Published, Green Submitted, gold			2023-01-03	WOS:000394424500130
J	Edwards, ST; Dorr, DA; Landon, BE				Edwards, Samuel T.; Dorr, David A.; Landon, Bruce E.			Can Personalized Care Planning Improve Primary Care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LONG-TERM CONDITIONS; MANAGEMENT		[Edwards, Samuel T.] Vet Affairs VA Portland Hlth Care Syst, Sect Gen Internal Med, Portland, OR USA; [Edwards, Samuel T.] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA; [Dorr, David A.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Landon, Bruce E.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Internal Med & Primary Care, Boston, MA 02215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Edwards, ST (corresponding author), VA Portland Hlth Care Syst, Sect Gen Internal Med, 3710 SW US Vet Hosp Rd,R&D199, Portland, OR 97239 USA.	samuel.edwards@va.gov			Research Triangle Institute International; UpToDate Inc; Evidera; American Board of Internal Medicine; Freedman Healthcare Consulting	Research Triangle Institute International; UpToDate Inc; Evidera; American Board of Internal Medicine; Freedman Healthcare Consulting	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Landon reported receiving travel support from the Meyers-JDC Brookdale Institute and EagleDream Health; receiving personal fees from Research Triangle Institute International, UpToDate Inc, Evidera, the American Board of Internal Medicine, and Freedman Healthcare Consulting; and serving as a member of the Newton, Massachusetts, Healthcare Advisory Committee. No other authors reported disclosures.	Agency for Healthcare Research and Quality (AHRQ), INT BEH HLTH PRIM CA; Baker A, 2017, MAKING COMPREHENSIVE; Centers for Medicare & Medicaid Services (CMS). HHS, 2014, FED REGISTER, V79, P67547; Chase Dian A, 2014, AMIA Annu Symp Proc, V2014, P1718; Coulter A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010523.pub2; Edwards ST, 2014, NEW ENGL J MED, V371, P2049, DOI 10.1056/NEJMp1410790; Newbould J, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-71; Reeves D, 2014, BRIT J GEN PRACT, V64, pE568, DOI 10.3399/bjgp14X681385; Tinetti ME, 2016, JAMA CARDIOL, V1, P9, DOI 10.1001/jamacardio.2015.0248	9	22	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2017	318	1					25	26		10.1001/jama.2017.6953	http://dx.doi.org/10.1001/jama.2017.6953			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ4YF	28594991				2023-01-03	WOS:000404717700009
J	Pauwels, K; Aerts, S; Muijzers, E; De Jaegere, E; van Heeringen, K; Portzky, G				Pauwels, Kirsten; Aerts, Saskia; Muijzers, Ekke; De Jaegere, Eva; van Heeringen, Kees; Portzky, Gwendolyn			BackUp: Development and evaluation of a smart-phone application for coping with suicidal crises	PLOS ONE			English	Article							MOBILE PHONE; HEALTH; TECHNOLOGY; INTERVENTION; MHEALTH	Background Suicide is a major public health issue and has large impact on the lives of many people. Innovative technologies such as smartphones could create new possibilities for suicide prevention, such as helping to overcome the barriers and stigma on help seeking in case of suicidal ideation. Due to their omnipresence, smartphone apps can offer suicide prevention tools very fast, they are easily-accessible, low-threshold and can help overcome some of the help-seeking barriers suicidal people experience. This article describes the development, testing and implementation of a mobile application for coping with suicidal crisis: BackUp. Methods Based on the analysis of literature and existing suicide prevention apps several tools were identified as relevant to include in a suicide prevention app. The selected tools (a safety planning tool, a hope box, a coping cards module, and a module to reach out) are evidence based in a face to face context, and could be easily transferred into a mobile app. The testing of existing apps and the literature also revealed important guidelines for the technical development of the application. Results BackUp was developed and tested by an expert panel (n = 9) and a panel of end users (n = 21). Both groups rated BackUp as valuable for suicide prevention. Suicidal ideation of the end user group was measured using the Beck Scale for Suicidal Ideation before and after testing BackUp, and showed a small but non-significant decrease. The majority of the testers used BackUp several times. All tools were evaluated as rather or very useable in times of suicidal crisis. Conclusion BackUp was positively evaluated and indicates that self-help tools can have a positive impact on suicidal ideation. Apps in particular create opportunities in approaching people that are not reached by traditional interventions; on the other hand they can contribute to suicide prevention in addition to regular care. However, more research is needed on the impact and effect of suicide prevention apps.	[Pauwels, Kirsten; Aerts, Saskia; Muijzers, Ekke; De Jaegere, Eva; van Heeringen, Kees; Portzky, Gwendolyn] Flemish Ctr Expertise Suicide Prevent, Ghent, Flanders, Belgium; [Pauwels, Kirsten; Aerts, Saskia; Muijzers, Ekke] Flemish Suicide Prevent Ctr, Brussels, Belgium; [De Jaegere, Eva; van Heeringen, Kees; Portzky, Gwendolyn] Univ Ghent, Unit Suicide Res, Ghent, Flanders, Belgium	Ghent University	Pauwels, K (corresponding author), Flemish Ctr Expertise Suicide Prevent, Ghent, Flanders, Belgium.; Pauwels, K (corresponding author), Flemish Suicide Prevent Ctr, Brussels, Belgium.	kirsten.pauwels@preventiezelfdoding.be	Aerts, Saskia/AAG-7955-2020; van Heeringen, Kees/H-2384-2013	van Heeringen, Kees/0000-0001-5801-194X; Pauwels, Kirsten/0000-0002-1407-1614	Flemish Government	Flemish Government(European Commission)	The funder was the Flemish Government, Zorg en Gezondheid, www.zorgengezondheid.be. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Aguirre RTP, 2013, J TECHNOL HUMAN SERV, V31, P269, DOI 10.1080/15228835.2013.814750; BECK AT, 1988, J CLIN PSYCHOL, V44, P499, DOI 10.1002/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6; Berrouiguet S, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5066; Bush NE, 2015, SUICIDE LIFE-THREAT, V45, P1, DOI 10.1111/sltb.12103; Christensen H, 2014, INT J ENV RES PUB HE, V11, P8193, DOI 10.3390/ijerph110808193; de Beurs D, 2015, CRISIS, V36, P79, DOI 10.1027/0227-5910/a000316; De Jaegere E, 2013, ETHICAL GUIDELINES T, V5; Donker T, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2791; Gregory JM, 2017, J CAN ACAD CHILD ADO, V26, P45; Gulliver A, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-113; Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Horgan A, 2010, J PSYCHIATR MENT HLT, V17, P117, DOI 10.1111/j.1365-2850.2009.01497.x; Kennard BD, 2015, J TECHNOL HUMAN SERV, V33, P345, DOI 10.1080/15228835.2015.1106384; Labelle R, 2013, SUICIDE PREVENTION AND NEW TECHNOLOGIES: EVIDENCE BASED PRACTICE, P166; Larsen ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152285; Luxton D.D., 2015, CURR TREAT OPT PSYCH, V2, P349, DOI DOI 10.1007/S40501-015-0057-2; Luxton DD, 2011, PROF PSYCHOL-RES PR, V42, P505, DOI 10.1037/a0024485; Luxton DD, 2011, TELEMED E-HEALTH, V17, P50, DOI 10.1089/tmj.2010.0091; Reynders A, 2011, SUICIDE VLAANDEREN N; Rickwood D, 2005, ADV MENT HEALTH, V4, P218, DOI 10.5172/jamh.4.3.218; Shand FL, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-396; Stanley B, 2012, COGN BEHAV PRACT, V19, P256, DOI 10.1016/j.cbpra.2011.01.001; Taylor PJ, 2011, PSYCHOL BULL, V137, P391, DOI 10.1037/a0022935; Tighe J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013518; Vanhaelewyn B, TELEFONIE SMARTPHONE; Wenzel A., 2009, COGNITIVE THERAPY SU; World Health Organization, 2016, PREV SUIC GLOB IMP; Zorg en Gezondheid, 2014, EV STERFT DOOR ZELFD	29	16	17	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2017	12	6							e0178144	10.1371/journal.pone.0178144	http://dx.doi.org/10.1371/journal.pone.0178144			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EY6UH	28636617	Green Published, gold, Green Submitted			2023-01-03	WOS:000404118300010
J	Feng, ZY; Lugtenberg, M; Franse, C; Fang, XY; Hu, SL; Jin, CL; Raat, H				Feng, Zeyun; Lugtenberg, Marjolein; Franse, Carmen; Fang, Xinye; Hu, Shanlian; Jin, Chunlin; Raat, Hein			Risk factors and protective factors associated with incident or increase of frailty among community-dwelling older adults: A systematic review of longitudinal studies	PLOS ONE			English	Review							WOMEN AGED 65; PROSPECTIVE COHORT; DEPRESSIVE SYMPTOMS; MEXICAN-AMERICANS; URIC-ACID; HEALTH; MEN; PEOPLE; CONSUMPTION; DETERMINANTS	Introduction Frailty is one of the greatest challenges facing our aging population, as it can lead to adverse outcomes such as institutionalization, hospitalization, and mortality. However, the factors that are associated with frailty are poorly understood. We performed a systematic review of longitudinal studies in order to identify the sociodemographic, physical, biological, lifestyle-related, and psychological risk or protective factors that are associated with frailty among community-dwelling older adults. Methods A systematic literature search was conducted in the following databases in order to identify studies that assessed the factors associated with of frailty among community-dwelling older adults: Embase, Medline Ovid, Web of Science, Cochrane, PsychINFO Ovid, CINAHL EBS-COhost, and Google Scholar. Studies were selected if they included a longitudinal design, focused on community-dwelling older adults aged 60 years and older, and used a tool to assess frailty. The methodological quality of each study was assessed using the Quality of Reporting of Observational Longitudinal Research checklist. Results Twenty-three studies were included. Significant associations were reported between the following types of factors and frailty: sociodemographic factors (7/7 studies), physical factors (5/6 studies), biological factors (5/7 studies), lifestyle factors (11/13 studies), and psychological factors (7/8 studies). Significant sociodemographic factors included older age, ethnic background, neighborhood, and access to private insurance or Medicare; significant physical factors included obesity and activities of daily living (ADL) functional status; significant biological factors included serum uric acid; significant lifestyle factors included a higher Diet Quality Index International (DQI) score, higher fruit/vegetable consumption and higher tertile of all measures of habitual dietary resveratrol exposure; significant psychological factors included depressive symptoms. Conclusions A broad range of sociodemographic, physical, biological, lifestyle, and psychological factors show a longitudinal association with frailty. These factors should be considered when developing interventions aimed at preventing and/or reducing the burden associated with frailty among community-dwelling older adults.	[Feng, Zeyun; Lugtenberg, Marjolein; Franse, Carmen; Fang, Xinye; Raat, Hein] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Feng, Zeyun; Fang, Xinye; Hu, Shanlian; Jin, Chunlin] Shanghai Med Informat Ctr, Shanghai Hlth Dev Res Ctr, Shanghai, Peoples R China; [Jin, Chunlin] Shanghai Populat Dev Res Ctr, Shanghai, Peoples R China	Erasmus University Rotterdam; Erasmus MC	Raat, H (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.	h.raat@erasmusmc.nl	Feng, Zeyun/O-9644-2019	Feng, Zeyun/0000-0003-4723-6283	China Medical Board-Collaborating Program in Evidence-based Health Policy-making [CMB-CP14-190]	China Medical Board-Collaborating Program in Evidence-based Health Policy-making	ZF is supported by a fellowship from the China Medical Board-Collaborating Program in Evidence-based Health Policy-making (grant number: CMB-CP14-190, https://www.chinamedicalboard.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views presented here are those of the authors and should not be attributed to the China Medical Board or its directors, officers, or staff.	Ade C. Mello, 2014, CAD SAUDE PUBLICA, V30, P1143; Alonso-Bouzon C, 2014, AGE, V36, P495, DOI 10.1007/s11357-013-9576-1; [Anonymous], 2016, BMJ, V353, pi2229, DOI 10.1136/bmj.i2229; Aranda MP, 2011, J AGING HEALTH, V23, P1189, DOI 10.1177/0898264311421961; Baylis D, 2013, AGE, V35, P963, DOI 10.1007/s11357-012-9396-8; Bergman H, 2007, J GERONTOL A-BIOL, V62, P731, DOI 10.1093/gerona/62.7.731; Buttery AK, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0022-3; Cawthon PM, 2009, J CLIN ENDOCR METAB, V94, P3806, DOI 10.1210/jc.2009-0417; Chan R, 2015, NUTRIENTS, V7, P7070, DOI 10.3390/nu7085326; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; Coelho T, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00056; Dent E, 2016, EUR J INTERN MED, V31, P3, DOI 10.1016/j.ejim.2016.03.007; Ensrud KE, 2011, J AM GERIATR SOC, V59, P101, DOI 10.1111/j.1532-5415.2010.03201.x; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Frachot A., 2003, LOSS DISTRIBUTION AP, P369; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Fried LP, 1998, PRINCIPLES GERIATRIC, V4, P1387; Gale CR, 2013, AGE, V35, P2493, DOI 10.1007/s11357-013-9528-9; Garcia-Esquinas E, 2016, EXP GERONTOL, V82, P160, DOI 10.1016/j.exger.2016.07.002; Garcia-Esquinas E, 2016, AM J CLIN NUTR, V104, P132, DOI 10.3945/ajcn.115.125781; Gobbens RJJ, 2014, QUAL LIFE RES, V23, P2289, DOI 10.1007/s11136-014-0672-1; Gobbens RJJ, 2010, J NUTR HEALTH AGING, V14, P175, DOI 10.1007/s12603-010-0045-6; Gobbens RJJ, 2010, J AM MED DIR ASSOC, V11, P344, DOI 10.1016/j.jamda.2009.11.003; Gruenewald TL, 2009, J AM GERIATR SOC, V57, P1525, DOI 10.1111/j.1532-5415.2009.02389.x; Hoogendijk EO, 2014, ANN EPIDEMIOL, V24, P628, DOI 10.1016/j.annepidem.2014.07.003; Hyde Z, 2010, J CLIN ENDOCR METAB, V95, P3165, DOI 10.1210/jc.2009-2754; Ingles M, 2014, J AM GERIATR SOC, V62, P1324, DOI 10.1111/jgs.12876; Lakey SL, 2012, J AM GERIATR SOC, V60, P854, DOI 10.1111/j.1532-5415.2012.03940.x; Lana A, 2015, J AM GERIATR SOC, V63, P1852, DOI 10.1111/jgs.13626; Leon-Munoz LM, 2014, J AM MED DIR ASSOC, V15, P899, DOI 10.1016/j.jamda.2014.06.013; McHugh J. E., 2016, Irish Journal of Psychological Medicine, V33, P111, DOI 10.1017/ipm.2015.67; Monin J, 2016, J AM GERIATR SOC, V64, P824, DOI 10.1111/jgs.14023; Myers V, 2014, INT J CARDIOL, V170, P338, DOI 10.1016/j.ijcard.2013.11.009; Ortola R, 2016, J GERONTOL A-BIOL, V71, P251, DOI 10.1093/gerona/glv125; Ottenbacher KJ, 2009, AM J PUBLIC HEALTH, V99, P673, DOI 10.2105/AJPH.2008.143958; Poli S, 2016, AGING CLIN EXP RES; Rabassa M, 2015, AM J CLIN NUTR, V102, P1534, DOI 10.3945/ajcn.115.118976; Sandoval-Insausti H, 2016, J GERONTOL A-BIOL, V71, P1329, DOI 10.1093/gerona/glw033; Sautin YY, 2008, NUCLEOS NUCLEOT NUCL, V27, P608, DOI 10.1080/15257770802138558; Semba RD, 2006, J GERONTOL A-BIOL, V61, P594, DOI 10.1093/gerona/61.6.594; Singh AS, 2008, OBES REV, V9, P474, DOI 10.1111/j.1467-789X.2008.00475.x; Talegawkar SA, 2012, J NUTR, V142, P2161, DOI 10.3945/jn.112.165498; Tooth L, 2005, AM J EPIDEMIOL, V161, P280, DOI 10.1093/aje/kwi042; Vaughan L, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S69632; Woo J, 2005, GERONTOLOGY, V51, P402, DOI 10.1159/000088705; Woods NF, 2005, J AM GERIATR SOC, V53, P1321, DOI 10.1111/j.1532-5415.2005.53405.x	46	189	195	8	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2017	12	6							e0178383	10.1371/journal.pone.0178383	http://dx.doi.org/10.1371/journal.pone.0178383			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX6PQ	28617837	gold, Green Submitted, Green Published			2023-01-03	WOS:000403364600010
J	Liu, MM; Li, ST; Shu, Y; Zhan, HQ				Liu, Meng-Meng; Li, Shu-Ting; Shu, Yan; Zhan, He-Qin			Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials	PLOS ONE			English	Article							GASTROINTESTINAL SYMPTOMS; DISTRESSFUL SYMPTOMS; RADICAL RADIOTHERAPY; SYSTEMATIC REVIEWS; PUBLICATION BIAS; FLORA; HETEROGENEITY; PREBIOTICS; PATTERNS; EFFICACY	Background Radiotherapy is commonly used for abdominal or pelvic cancer, and patients receiving radiotherapy have a high risk developing to an acute radiation-induced diarrhea. Several previous studies have discussed the effect of probiotics on prevention of radiation-induced diarrhea, but the results are still inconsistent. Objective We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of probiotic supplementation for prevention the radiation-induced diarrhea. Methods Relevant RCTs studies assessing the effect of probiotic supplementation on clinical outcomes compared with placebo were searched in PubMed, EMBASE, and the Cochrane Library databases (up to March 30 2016). Heterogeneity was assessed with I-2 and H-2, and publication bias was evaluated using sensitive analysis. Results Six trials, a total of 917 participants (490 participants received prophylactic probiotics and 427 participants received placebo), were included in this meta-analysis. Compared with placebo, probiotics were associated with a lower incidence of radiation-induced diarrhea (RR: 0.55; 95% CI: 0.34-0.88; P= 0.01; I-2: 87%; 95% CI: 75%-94%; H-2: 2.8; 95% CI: 2.0-4.0). However, there is no significant difference in the anti-diarrheal medication use (RR: 0.68; 95% CI: 0.40-1.14; P= 0.14) or bristol scale on stool form (RR: 0.64; 95% CI: 0.35-1.17; P= 0.14). Conclusion Probiotics may be beneficial to prevent radiation-induced diarrhea in patients who suffered from abdominal or pelvic cancers during radiotherapy period.	[Liu, Meng-Meng; Li, Shu-Ting; Shu, Yan; Zhan, He-Qin] Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Anhui Medical University	Zhan, HQ (corresponding author), Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China.	heqinzh@163.com			National Natural Science Foundation of China [81202006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (no. 81202006).; This work was supported by National Natural Science Foundation of China. (No. 81202006).	al-Albany M, 2002, ACTA ONCOL, V41, P532; Barraud D, 2013, CHEST, V143, P646, DOI 10.1378/chest.12-1745; Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P19, DOI 10.1016/S0936-6555(05)80689-2; Berg RD, 1999, ADV EXP MED BIOL, V473, P11; Bergmark K, 2002, ACTA OBSTET GYN SCAN, V81, P443, DOI 10.1034/j.1600-0412.2002.810512.x; Bismar Mike M, 2002, Curr Gastroenterol Rep, V4, P361, DOI 10.1007/s11894-002-0005-3; Blanarova C, 2009, BRATISL MED J, V110, P98; Chitapanarux I, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-31; Ciorba MA, 2012, CLIN GASTROENTEROL H, V10, P960, DOI 10.1016/j.cgh.2012.03.024; Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912; Demers M, 2014, CLIN NUTR, V33, P761, DOI 10.1016/j.clnu.2013.10.015; Denham JW, 2002, RADIOTHER ONCOL, V63, P129, DOI 10.1016/S0167-8140(02)00060-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Deshpande G, 2007, LANCET, V369, P1614, DOI 10.1016/S0140-6736(07)60748-X; Eddins C, 2008, J WOUND OSTOMY CONT, V35, P50, DOI 10.1097/01.WON.0000308619.01756.16; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Famularo G, 2003, CURR PHARM DESIGN, V9, P1973, DOI 10.2174/1381612033454207; Famularo G, 1999, BIODRUGS, V12, P455, DOI 10.2165/00063030-199912060-00005; Fedorak RN, 2008, J CLIN GASTROENTEROL, V42, pS111, DOI 10.1097/MCG.0b013e31816d922c; Floch MH, 2005, GASTROENTEROL CLIN N, V34, P547, DOI 10.1016/j.gtc.2005.05.004; Fokdal L, 2004, RADIOTHER ONCOL, V72, P139, DOI 10.1016/j.radonc.2004.05.006; Frazzoni L, 2015, WORLD J CLIN ONCOL, V6, P272, DOI 10.5306/wjco.v6.i6.272; Fuccio L, 2009, J CLIN GASTROENTEROL, V43, P506, DOI 10.1097/MCG.0b013e3181a1f59c; Gami B, 2003, ALIMENT PHARM THER, V18, P987, DOI 10.1046/j.1365-2036.2003.01760.x; Gibson RJ, 2006, SUPPORT CARE CANCER, V14, P890, DOI 10.1007/s00520-006-0040-y; Giralt J, 2008, INT J RADIAT ONCOL, V71, P1213, DOI 10.1016/j.ijrobp.2007.11.009; Gorbach SL, 2002, DIGEST LIVER DIS, V34, pS2, DOI 10.1016/S1590-8658(02)80155-4; Gu WJ, 2013, JPEN-PARENTER ENTER, V37, P310, DOI 10.1177/0148607112463245; Guandalini S, 2011, J CLIN GASTROENTEROL, V45, pS149, DOI 10.1097/MCG.0b013e3182257e98; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hanson WR, 1994, RAD GASTROINTESTINAL, P171; HASLETON PS, 1985, HISTOPATHOLOGY, V9, P517, DOI 10.1111/j.1365-2559.1985.tb02833.x; Hempel S, 2012, JAMA-J AM MED ASSOC, V307, P1959, DOI 10.1001/jama.2012.3507; Henningsohn L, 2002, RADIOTHER ONCOL, V62, P215, DOI 10.1016/S0167-8140(01)00455-8; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hovdenak N, 2000, INT J RADIAT ONCOL, V48, P1111, DOI 10.1016/S0360-3016(00)00744-6; Hovdenak N, 2002, INT J RADIAT ONCOL, V53, P919, DOI 10.1016/S0360-3016(02)02808-0; HUSEBYE E, 1995, GASTROENTEROLOGY, V109, P1078, DOI 10.1016/0016-5085(95)90565-0; Johnston BC, 2012, ANN INTERN MED, V157, P878, DOI 10.7326/0003-4819-157-12-201212180-00563; Kicinski M, 2015, STAT MED, V34, P2781, DOI 10.1002/sim.6525; Larsen A, 2007, ACTA ONCOL, V46, P639, DOI 10.1080/02841860601099241; LINKAMSTER H, 1994, FEMS IMMUNOL MED MIC, V10, P55, DOI 10.1111/j.1574-695X.1994.tb00011.x; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Marteau P, 2003, BEST PRACT RES CL GA, V17, P47, DOI 10.1053/bega.2002.0344; Mittlbock M, 2006, STAT MED, V25, P4321, DOI 10.1002/sim.2692; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Molla M, 2007, WORLD J GASTROENTERO, V13, P3043, DOI 10.3748/wjg.v13.i22.3043; Olopade FA, 2005, BRIT J CANCER, V92, P1663, DOI 10.1038/sj.bjc.6602552; Packey CD, 2010, CURR OPIN GASTROEN, V26, P88, DOI 10.1097/MOG.0b013e3283361927; Picard C, 2001, NEUROGASTROENT MOTIL, V13, P19, DOI 10.1046/j.1365-2982.2001.00236.x; Quigley EMM, 2006, GASTROENTEROLOGY, V130, pS78, DOI 10.1053/j.gastro.2005.11.046; Rijkers GT, 2010, J NUTR, V140, p671S, DOI 10.3945/jn.109.113779; Ritchie ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034938; SALMINEN E, 1988, CLIN RADIOL, V39, P435, DOI 10.1016/S0009-9260(88)80296-4; Salminen S, 1996, ANTON LEEUW INT J G, V70, P347, DOI 10.1007/BF00395941; Scartoni D, 2015, ANTICANCER RES, V35, P5687; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Stewart BW, 2014, WORLD CANC REPORT 20, P505; Stringer AM, 2009, CURR DRUG METAB, V10, P79, DOI 10.2174/138920009787048419; Sullivan A, 2005, J INTERN MED, V257, P78, DOI 10.1111/j.1365-2796.2004.01410.x; SUMMERS RW, 1991, AM J PHYSIOL, V261, pG145, DOI 10.1152/ajpgi.1991.261.1.G145; Touchefeu Y, 2014, ALIMENT PHARM THER, V40, P409, DOI 10.1111/apt.12878; Urbancsek H, 2001, EUR J GASTROEN HEPAT, V13, P391, DOI 10.1097/00042737-200104000-00015; Visich KL, 2010, CLIN J ONCOL NURS, V14, P467, DOI 10.1188/10.CJON.467-473; Wedlake LJ, 2013, ALIMENT PHARM THER, V37, P1046, DOI 10.1111/apt.12316; Whelan K, 2014, AM J GASTROENTEROL, V109, P1563, DOI 10.1038/ajg.2014.258; Wu XD, 2018, CLIN NUTR, V37, P505, DOI 10.1016/j.clnu.2016.10.015	70	44	48	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178870	10.1371/journal.pone.0178870	http://dx.doi.org/10.1371/journal.pone.0178870			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6MJ	28575095	Green Submitted, Green Published, gold			2023-01-03	WOS:000402624300128
J	Ferreiro, JLL; Otero, JA; Gonzalez, LG; Lamazares, LN; Blanco, AA; Sanjurjo, JRB; Conde, IR; Soneira, MF; Aguado, JD				Lamas Ferreiro, Jose Luis; Alvarez Otero, Judith; Gonzalez Gonzalez, Lucia; Novoa Lamazares, Luis; Arca Blanco, Alexandra; Bermudez Sanjurjo, Jose Ramon; Rodriguez Conde, Irene; Fernandez Soneira, Maria; de la Fuente Aguado, Javier			Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors	PLOS ONE			English	Article							COMBINATION ANTIMICROBIAL THERAPY; RISK-FACTORS; 30-DAY MORTALITY; BACTEREMIA; RESISTANCE; IMPACT; ANTIBIOTICS	Background The aim of this study was to analyze the mortality and predictors of 30-day mortality among hospitalized patients with Pseudomonas aeruginosa urinary tract infection (PAUTI) and the impact of antibiotic treatment on survival. Methods Patients admitted to our hospital with PAUTI or those diagnosed of PAUTI during hospitalization for other disease between September 2012 and September 2014 were included. Repeated episodes from the same patient were excluded. Database with demographic, clinical and laboratory items was created. Empirical and definitive antibiotic therapy, antimicrobial resistance and all-cause mortality at 30 and 90 days were included. Results 62 patients were included, with a mean age of 75 years. 51% were male. Mortality was 17.7% at 30 days and 33.9% at 90 days. Factors associated with reduced survival at 30 days were chronic liver disease with portal hypertension (P<0,01), diabetes mellitus (P = 0,04) chronic renal failure (P = 0,02), severe sepsis or septic shock (P<0,01), Charlson index > 3 (P = 0.02) and inadequated definitive antibiotic treatment (P<0,01). Independent risk factors for mortality in multivariate analysis were advanced chronic liver disease (HR 77,4; P<0,01), diabetes mellitus (HR 3,6; P = 0,04), chronic renal failure (HR 4,1; P = 0,03) and inadequated definitive antimicrobial treatment (HR 6,8; P = 0,01). Conclusions PAUTI are associated with high mortality in hospitalized patients, which increases significantly in those with severe comorbidity such as chronic renal failure, advanced liver disease or diabetes mellitus. Inadequated antibiotic treatment is associated with poor outcome, which remarks the importance of adjusting empirical antibiotic treatment based on the microbiological susceptibility results.	[Lamas Ferreiro, Jose Luis; Alvarez Otero, Judith; Gonzalez Gonzalez, Lucia; Novoa Lamazares, Luis; Arca Blanco, Alexandra; Bermudez Sanjurjo, Jose Ramon; de la Fuente Aguado, Javier] Povisa Hosp, Internal Med, Vigo, Spain; [Rodriguez Conde, Irene; Fernandez Soneira, Maria] Povisa Hosp, Microbiol, Vigo, Spain		Ferreiro, JLL (corresponding author), Povisa Hosp, Internal Med, Vigo, Spain.	jlamfer@gmail.com	de la Fuente Aguado, Javier/I-1431-2019					Aliaga L, 2000, EUR J CLIN MICROBIOL, V19, P871, DOI 10.1007/s100960000392; Almagro P, 2012, RESPIRATION, V84, P36, DOI 10.1159/000331224; Ammerlaan H, 2009, CLIN INFECT DIS, V49, P997, DOI 10.1086/605555; Bouza E, 2001, CLIN MICROBIOL INFEC, V7, P523, DOI 10.1046/j.1198-743x.2001.00326.x; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; Chamot E, 2003, ANTIMICROB AGENTS CH, V47, P2756, DOI 10.1128/AAC.47.9.2756-2764.2003; Cheong HS, 2008, EUR J CLIN MICROBIOL, V27, P1219, DOI 10.1007/s10096-008-0568-5; Dantas RC, 2014, J MED MICROBIOL, V63, P1679, DOI 10.1099/jmm.0.073262-0; Djordjevic Z, 2013, AM J INFECT CONTROL, V41, P1182, DOI 10.1016/j.ajic.2013.02.018; Gastmeier P, 2001, CLIN MICROBIOL INFEC, V7, P521, DOI 10.1111/j.1469-0691.2001.00353.x; Horcajada JP, 2013, CLIN MICROBIOL INFEC, V19, P962, DOI 10.1111/1469-0691.12089; Horino T, 2012, INTERNAL MED, V51, P59, DOI 10.2169/internalmedicine.51.5698; Joo EJ, 2011, INFECTION, V39, P309, DOI 10.1007/s15010-011-0124-6; Kang CI, 2003, CLIN INFECT DIS, V37, P745, DOI 10.1086/377200; Kim YJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-161; Gonzalez AL, 2014, BIOMEDICA, V34, P58, DOI [10.1590/S0120-41572014000500008, 10.7705/biomedica.v34i0.1691]; Liu QQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11715; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3510, DOI 10.1128/AAC.00338-07; Micek ST, 2005, ANTIMICROB AGENTS CH, V49, P1306, DOI 10.1128/AAC.49.4.1306-1311.2005; Morata L, 2012, ANTIMICROB AGENTS CH, V56, P4833, DOI 10.1128/AAC.00750-12; Osih RB, 2007, ANTIMICROB AGENTS CH, V51, P839, DOI 10.1128/AAC.00901-06; Schechner V, 2011, DIAGN MICR INFEC DIS, V71, P38, DOI 10.1016/j.diagmicrobio.2011.05.010; Vitkauskiene A, 2010, MEDICINA-LITHUANIA, V46, P490, DOI 10.3390/medicina46070071	23	43	43	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2017	12	5							e0178178	10.1371/journal.pone.0178178	http://dx.doi.org/10.1371/journal.pone.0178178			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VT	28552972	Green Submitted, Green Published, gold			2023-01-03	WOS:000402063000024
J	Santos, CL; Santos, RS; Moraes, L; Samary, CS; Felix, NS; Silva, JD; Morales, MM; Huhle, R; Abreu, MG; Schanaider, A; Silva, PL; Pelosi, P; Rocco, PRM				Santos, Cintia L.; Santos, Raquel S.; Moraes, Lillian; Samary, Cynthia S.; Felix, Nathane S.; Silva, Johnatas D.; Morales, Marcelo M.; Huhle, Robert; Abreu, Marcelo G.; Schanaider, Alberto; Silva, Pedro L.; Pelosi, Paolo; Rocco, Patricia R. M.			Effects of pressure support and pressure-controlled ventilation on lung damage in a model of mild extrapulmonary acute lung injury with intra-abdominal hypertension	PLOS ONE			English	Article							ABDOMINAL COMPARTMENT SYNDROME; END-EXPIRATORY PRESSURE; CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; BIOLOGICAL IMPACT; PULMONARY; AIRWAY; OXYGENATION; VOLUME; INFLAMMATION	Intra-abdominal hypertension (IAH) may co-occur with the acute respiratory distress syndrome (ARDS), with significant impact on morbidity and mortality. Lung-protective controlled mechanical ventilation with low tidal volume and positive end-expiratory pressure (PEEP) has been recommended in ARDS. However, mechanical ventilation with spontaneous breathing activity may be beneficial to lung function and reduce lung damage in mild ARDS. We hypothesized that preserving spontaneous breathing activity during pressure support ventilation (PSV) would improve respiratory function and minimize ventilator-induced lung injury (VILI) compared to pressure-controlled ventilation (PCV) in mild extrapulmonary acute lung injury (ALI) with IAH. Thirty Wistar rats (334 +/- 55g) received Escherichia coli lipopolysaccharide intraperitoneally (1000 mu g) to induce mild extrapulmonary ALI. After 24h, animals were anesthetized and randomized to receive PCV or PSV. They were then further randomized into subgroups without or with IAH (15 mmHg) and ventilated with PCV or PSV (PEEP = 5cmH(2)O, driving pressure adjusted to achieve tidal volume = 6mL/kg) for 1h. Six of the 30 rats were used for molecular biology analysis and were not mechanically ventilated. The main outcome was the effect of PCV versus PSV on mRNA expression of interleukin (IL)-6 in lung tissue. Regardless of whether IAH was present, PSV resulted in lower mean airway pressure (with no differences in peak airway or peak and mean transpulmonary pressures) and less mRNA expression of biomarkers associated with lung inflammation (IL-6) and fibrogenesis (type III procollagen) than PCV. In the presence of IAH, PSV improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to PCV. In this experimental model of mild extrapulmonary ALI associated with IAH, PSV compared to PCV improved lung function and morphology and reduced type 2 epithelial cell damage.	[Santos, Cintia L.; Santos, Raquel S.; Moraes, Lillian; Samary, Cynthia S.; Felix, Nathane S.; Silva, Johnatas D.; Silva, Pedro L.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Lab Pulm Invest, Carlos Chagas Filho Inst Biophys, Av Carlos Chagas Filho S-N,Bloco G-014, Rio De Janeiro, RJ, Brazil; [Santos, Cintia L.; Schanaider, Alberto] Univ Fed Rio de Janeiro, Lab Expt Surg, Fac Med, Av Prof Rodolpho Paulo Rocco 225, Rio De Janeiro, RJ, Brazil; [Morales, Marcelo M.] Univ Fed Rio de Janeiro, Lab Cellular & Mol Physiol, Carlos Chagas Filho Inst Biophys, Av Carlos Chagas Filho S-N,Bloco G2-048, Rio De Janeiro, RJ, Brazil; [Huhle, Robert; Abreu, Marcelo G.] Tech Univ Dresden, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, Univ Hosp Carl Gustav Carus, Fetschertsr 74, Dresden, Germany; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, IRCCS AOU San Martino IST, Largo Rosanna Benzi 8, Genoa, Italy	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Genoa; IRCCS AOU San Martino IST	Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Lab Pulm Invest, Carlos Chagas Filho Inst Biophys, Av Carlos Chagas Filho S-N,Bloco G-014, Rio De Janeiro, RJ, Brazil.	prmrocco@gmail.com	Rocco, Patricia/I-7460-2012; Silva, Johnatas D/I-6478-2017; Silva, Pedro Leme/AAD-8236-2019; Huhle, Robert/GYQ-7985-2022	Rocco, Patricia/0000-0003-1412-7136; Silva, Johnatas D/0000-0003-4379-4237; Silva, Pedro Leme/0000-0001-5838-4949; samary, cynthia/0000-0002-1860-4166; Pelosi, Paolo/0000-0001-5055-3023	Carlos Chagas Filho Rio de Janeiro State Research Foundation (FAPERJ), Rio de Janeiro, Brazil [E-26/103.118/2014]; Brazilian Council for Scientific and Technological Development (CNPq)), Brasilia, Brazil [471438/2012-0]	Carlos Chagas Filho Rio de Janeiro State Research Foundation (FAPERJ), Rio de Janeiro, Brazil(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Brazilian Council for Scientific and Technological Development (CNPq)), Brasilia, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from the Carlos Chagas Filho Rio de Janeiro State Research Foundation (FAPERJ; grant number E-26/103.118/2014), Rio de Janeiro, Brazil; and the Brazilian Council for Scientific and Technological Development (CNPq; grant number 471438/2012-0), Brasilia, Brazil.	Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Blanch L, 2015, INTENS CARE MED, V41, P633, DOI 10.1007/s00134-015-3692-6; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Carvalho AR, 2009, ANESTH ANALG, V109, P856, DOI 10.1213/ane.0b013e3181aff245; Carvalho NC, 2014, CRIT CARE MED, V42, pE702, DOI 10.1097/CCM.0000000000000605; Cortes-Puentes GA, 2015, CRIT CARE MED, V43, pE287, DOI 10.1097/CCM.0000000000001036; Cortes-Puentes GA, 2013, J TRAUMA ACUTE CARE, V74, P1468, DOI 10.1097/TA.0b013e31829243a7; De Waele JJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0879-8; Deeren DH, 2005, INTENS CARE MED, V31, P1577, DOI 10.1007/s00134-005-2802-2; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Grasso F, 2008, AM J RESP CRIT CARE, V177, P412, DOI 10.1164/rccm.200707-1004OC; Guldner A, 2016, CRIT CARE MED, V44, pE854, DOI 10.1097/CCM.0000000000001721; Guldner A, 2014, ANESTHESIOLOGY, V120, P673, DOI 10.1097/ALN.0000000000000124; Henzler D, 2010, INTENS CARE MED, V36, P1427, DOI 10.1007/s00134-010-1827-3; Holodinsky JK, 2013, CRIT CARE, V17, DOI 10.1186/cc13075; Ke L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033125; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Kiss T, 2016, BRIT J ANAESTH, V116, P708, DOI 10.1093/bja/aew093; Kopernik G, 1998, AM J OBSTET GYNECOL, V179, P1503, DOI 10.1016/S0002-9378(98)70016-X; Lima Ricardo Antonio Correia, 2011, Rev Col Bras Cir, V38, P417; Malbrain MLNG, 2014, MINERVA ANESTESIOL, V80, P293; Malbrain MLNG, 2004, INTENS CARE MED, V30, P822, DOI 10.1007/s00134-004-2169-9; Malbrain MLNG, 2005, CRIT CARE MED, V33, P315, DOI 10.1097/01.CCM.0000153408.09806.1B; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Moraes L, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0474-4; MUTOH T, 1992, J APPL PHYSIOL, V72, P575, DOI 10.1152/jappl.1992.72.2.575; Neumann P, 2005, CRIT CARE MED, V33, P1090, DOI 10.1097/01.CCM.0000163226.34868.0A; Padilha Gisele de A, 2016, Intensive Care Med Exp, V4, P35; Pellegrini M, 2016, AM J RESP CRIT CARE; Pelosi P, 2007, ACTA CLIN BELG, V62, P78, DOI 10.1179/acb.2007.62.s1.011; Pelosi P, 2012, CRIT CARE, V16, DOI 10.1186/cc11874; Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011; Quintel M, 2004, AM J RESP CRIT CARE, V169, P534, DOI 10.1164/rccm.200209-1060OC; Regli A, 2012, CRIT CARE, V16, DOI 10.1186/cc11840; Regli A, 2012, CRIT CARE MED, V40, P1879, DOI 10.1097/CCM.0b013e31824e0e80; Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d; Roberts DJ, 2016, CURR OPIN CRIT CARE, V22, P174, DOI 10.1097/MCC.0000000000000289; Rocco PRM, 2012, CURR OPIN ANESTHESIO, V25, P123, DOI 10.1097/ACO.0b013e32834f8c7f; Rocco PRM, 2001, AM J RESP CRIT CARE, V164, P1067, DOI 10.1164/ajrccm.164.6.2007062; Saddy F, 2013, CRIT CARE, V17, DOI 10.1186/cc13051; Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6; Samary CS, 2015, ANESTHESIOLOGY, V123, P423, DOI 10.1097/ALN.0000000000000716; Santos CL, 2012, INTENS CARE MED, V38, P499, DOI 10.1007/s00134-011-2451-6; Santos CL, 2014, CRIT CARE, V18, DOI 10.1186/cc13920; Santos CL SR, 2015, INTENS CARE MED, V3, pA806; Schmittgen Thomas D., 2008, V429, P89, DOI 10.1007/978-1-60327-040-3_7; Silva PL, 2016, EXPERT REV RESP MED, V10, P1243, DOI 10.1080/17476348.2016.1251842; Spieth PM, 2015, ANESTHESIOLOGY, V122, P106, DOI 10.1097/ALN.0000000000000415; Spieth PM, 2011, CRIT CARE MED, V39, P746, DOI 10.1097/CCM.0b013e318206bda6; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Vidal MG, 2008, CRIT CARE MED, V36, P1823, DOI 10.1097/CCM.0b013e31817c7a4d; Wrigge H, 2005, CRIT CARE, V9, pR780, DOI 10.1186/cc3908; Wrigge H, 2003, ANESTHESIOLOGY, V99, P376, DOI 10.1097/00000542-200308000-00019; Yoshida T, 2016, AM J RESP CRIT CARE; Yoshida T, 2017, AM J RESP CRIT CARE, V195, P985, DOI 10.1164/rccm.201604-0748CP; Yoshida T, 2016, CRIT CARE MED, V44, pE678, DOI 10.1097/CCM.0000000000001649; Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC; Yoshida T, 2012, CRIT CARE MED, V40, P1578, DOI 10.1097/CCM.0b013e3182451c40	59	5	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2017	12	5							e0178207	10.1371/journal.pone.0178207	http://dx.doi.org/10.1371/journal.pone.0178207			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VR	28542443	gold, Green Published, Green Submitted			2023-01-03	WOS:000402062800053
J	Chen, Q; Hu, CY; Liu, Y; Liu, Y; Wang, W; Zheng, HC; Rong, LC; Jia, JY; Sun, SX; Yu, C; Liu, YM				Chen, Qian; Hu, Chaoying; Liu, Ye; Liu, Yun; Wang, Wei; Zheng, Hongchao; Rong, Lianchen; Jia, Jingying; Sun, Shixuan; Yu, Chen; Liu, Yan Mei			Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study	PLOS ONE			English	Article							URINARY TRYPSIN-INHIBITOR; PROTEASE INHIBITOR; STRESS; INJURY; RATS	Ulinastatin, is a broad-spectrum protease inhibitor purified from human urine, inhibits endogenous proteases such as trypsin, a-chymotrypsin, hyaluronidase, and plasmin. It is widely being used at increasingly higher doses for the treatment of acute or chronic pancreatitis, severe infection, and acute organ failure. We aimed to evaluate the safety and tolerability of high-dose ulinastatin in healthy volunteers in our single center, randomized, double-blind, placebo-controlled, single-dose escalation study. Fifty-one healthy Chinese subjects were enrolled in 9 dose cohorts (3x10(5) U, 6x10(5) U, 12x10(5) U, 20x10(5) U, 30x10(5) U, 45x10(5) U, 60x10(5) U, 70x10(5) U, or 80x10(5) U of ulinastatin) and randomized to UTI or matching placebo (n = 1). Each dose cohort was composed of 3-7 subjects. All subjects were required to have 2 h of intravenous infusion. Safety and tolerability were assessed throughout the study via monitoring of vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and interviews with the subjects about adverse events. Fifty-one subjects (35 men and 16 women) completed the study. A total of 13 AEs were reported by 10 subjects: 11 adverse events in the ulinastatin groups and 2 adverse events in the placebo group. Twelve of the adverse events were possibly related to the study drug. The most common drug-related adverse events included dizziness, pain at injection site, and a decrease in white blood cell count. All adverse events were of mild severity; none were serious. In conclusion, 2 hours of intravenous infusion of ulinastatin (3x10(5) to 80x10(5) U) was well tolerated by healthy Chinese subjects.	[Chen, Qian; Hu, Chaoying; Liu, Ye; Liu, Yun; Jia, Jingying; Sun, Shixuan; Yu, Chen; Liu, Yan Mei] Fudan Univ, Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China; [Chen, Qian; Hu, Chaoying; Liu, Ye; Liu, Yun; Wang, Wei; Zheng, Hongchao; Jia, Jingying; Sun, Shixuan; Yu, Chen; Liu, Yan Mei] Fudan Univ, Zhongshan Xuhui Hosp, Shanghai, Peoples R China; [Wang, Wei] Fudan Univ, Shanghai Xuhui Cent Hosp, Dept Emergency, Shanghai, Peoples R China; [Zheng, Hongchao] Fudan Univ, Shanghai Xuhui Cent Hosp, Dept Cardiol, Shanghai, Peoples R China; [Rong, Lianchen] Techpool Biopharma Co Ltd, Clin Dev Dept, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Liu, YM (corresponding author), Fudan Univ, Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China.; Liu, YM (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Shanghai, Peoples R China.	ymliu@shxh-centerlab.com		Jia, Jingying/0000-0002-2492-3219	Guangdong Techpool Bio-pharma Co., Ltd.; Techpool Bio-pharma Company, Limited	Guangdong Techpool Bio-pharma Co., Ltd.; Techpool Bio-pharma Company, Limited	This study was funded by Guangdong Techpool Bio-pharma Co., Ltd., who provided the study drug and financial support for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Lianchen Rong is employed by Techpool Bio-pharma Company, Limited, Shanghai, China. Techpool Bio-pharma Company, Limited provided support in the form of salary for author LR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; All authors are grateful to the sponsor, Guangdong Techpool Bio-pharma Co., Ltd., who provided the study drug and financial support for this study. We would also like to thank Shanghai Clinical Research Center for performing the data analysis.	Bao PT, 2009, EUR J PHARMACOL, V603, P114, DOI 10.1016/j.ejphar.2008.12.007; [冯国辉 FENG Guo-hui], 2009, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V29, P296; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Jeong CW, 2012, KOREAN J ANESTHESIOL, V63, P120, DOI 10.4097/kjae.2012.63.2.120; Koga Y, 2010, NEUROL RES, V32, P925, DOI 10.1179/016164110X12645013515133; Pugia MJ, 2005, CLIN CHEM LAB MED, V43, P1, DOI 10.1515/CCLM.2005.001; Sato N, 2002, DIGEST SURG, V19, P300, DOI 10.1159/000064578; Song J, 2013, KOREAN J ANESTHESIOL, V64, P334, DOI 10.4097/kjae.2013.64.4.334; State Food and Drug Administration of China, GUID GOOD CLIN PRINC; Umeadi C, 2008, TRANSPL P, V40, P387, DOI 10.1016/j.transproceed.2008.01.034; WMA, 1964, WMA DECL HELS ETH PR; Wu CY, 2007, CHIN J CLIN PHARM, V12, P103; Yang HY, 2011, AM J SURG, V202, P151, DOI 10.1016/j.amjsurg.2010.07.044; [张安 ZHANG An], 2008, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V24, P104; [张献全 ZHANG Xianquan], 2008, [中国急救医学, Chinese Journal of Critical Care Medicine], V28, P1060; Zhong DF, 2011, CHIN J CLIN RATIONAL, V4, P41	16	16	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177425	10.1371/journal.pone.0177425	http://dx.doi.org/10.1371/journal.pone.0177425			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UP	28493932	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314300105
J	Wu, CH; Yang, YW; Hung, SC; Kuo, KL; Wu, KD; Wu, VC; Hsieh, TC				Wu, Che-Hsiung; Yang, Ya-Wen; Hung, Szu-Chun; Kuo, Ko-Lin; Wu, Kwan-Dun; Wu, Vin-Cent; Hsieh, Tsung-Cheng		Natl Taiwan Univ Study Grp Acute	Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease	PLOS ONE			English	Article							LOW-PROTEIN-DIET; CHRONIC-RENAL-FAILURE; IMPROVES NUTRITIONAL-STATUS; NATIONAL-HEALTH INSURANCE; AMINO-ACID SUPPLEMENT; PREDIALYSIS PATIENTS; CONTROLLED-TRIAL; SERUM PHOSPHATE; TAIWAN; PROGRESSION	Background The benefit of alpha-Ketoanalogues (KA) supplementation for chronic kidney disease (CKD) patients that followed low-protein diet (LPD) remains undetermined. Methods We extracted longitudinal data for all CKD patients in the Taiwan National Health Insurance from January 1, 2000 through December 31, 2010. A total of 1483 patients with anemic advanced CKD treated with LPD, who started KA supplementation, were enrolled in this study. We analyzed the risks of end stage renal disease and all-cause mortality using Cox proportional hazard models with influential drugs as time-dependent variables. Results A total of 1113 events of initiating long-term dialysis and 1228 events of the composite outcome of long-term dialysis or death occurred in patients with advanced CKD after a mean follow-up of 1.57 years. Data analysis suggests KA supplementation is associated with a lower risk for long-term dialysis and the composite outcome when daily dosage is more than 5.5 tablets. The beneficial effect was consistent in subgroup analysis, independent of age, sex, and comorbidities. Conclusions Among advanced CKD patients that followed LPD, KA supplementation at an appropriate dosage may substantially reduce the risk of initiating long-term dialysis or of developing the composite outcome. KA supplementation represents an additional therapeutic strategy to slow the progression of CKD.	[Wu, Che-Hsiung; Hung, Szu-Chun; Kuo, Ko-Lin] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Div Nephrol, Taipei, Taiwan; [Wu, Che-Hsiung; Hsieh, Tsung-Cheng] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Wu, Che-Hsiung] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Yang, Ya-Wen] Natl Taiwan Univ Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Wu, Kwan-Dun; Wu, Vin-Cent] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan	Tzu Chi University; Tzu Chi University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Hsieh, TC (corresponding author), Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan.; Wu, VC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan.	q91421028@ntu.edu.tw; tchsieh@mail.tcu.edu.tw		YANG, YA-WEN/0000-0003-0412-584X; WU, VIN-CENT/0000-0001-7935-0991; Wu, Che-Hsiung/0000-0001-6164-6655; Hsieh, Tsung-Cheng/0000-0003-3024-8675; Kuo, Ko-Lin/0000-0002-7477-0388				Aparicio M, 2012, J RENAL NUTR, V22, pS1, DOI 10.1053/j.jrn.2011.09.005; Bellizzi V, 2007, KIDNEY INT, V71, P245, DOI 10.1038/sj.ki.5001955; Brunori G, 2007, AM J KIDNEY DIS, V49, P569, DOI 10.1053/j.ajkd.2007.02.278; Buckley JP, 2015, EPIDEMIOLOGY, V26, P204, DOI 10.1097/EDE.0000000000000217; Chang JH, 2009, NEPHROLOGY, V14, P750, DOI 10.1111/j.1440-1797.2009.01115.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chauveau P, 2007, J RENAL NUTR, V17, P250, DOI 10.1053/j.jrn.2007.02.007; Chen JB C B, 2012, KIDNEY RES CLIN PRAC, pA24; Chen YR, 2013, NEPHROL DIAL TRANSPL, V28, P671, DOI 10.1093/ndt/gfs469; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Collins Allan J, 2014, Am J Kidney Dis, V63, pA7, DOI 10.1053/j.ajkd.2013.11.001; Cupisti A, 2014, KIDNEY BLOOD PRESS R, V39, P107, DOI 10.1159/000355784; de Brito-Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205; de Zeeuw D, 2004, CIRCULATION, V110, P921, DOI 10.1161/01.CIR.0000139860.33974.28; DRUML W, 1986, INFUSIONSTHERAPIE, V13, P262; Eddington H, 2010, CLIN J AM SOC NEPHRO, V5, P2251, DOI 10.2215/CJN.00810110; Gao X, 2010, BRIT J NUTR, V103, P608, DOI 10.1017/S0007114509992108; Garneata L, 2016, J AM SOC NEPHROL, V27, P2164, DOI 10.1681/ASN.2015040369; Hiroshige K, 2001, NEPHROL DIAL TRANSPL, V16, P1856, DOI 10.1093/ndt/16.9.1856; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; Hsu TW, 2014, JAMA INTERN MED, V174, P347, DOI 10.1001/jamainternmed.2013.12700; Huang JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126668; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; Hwang SJ, 2010, NEPHROLOGY, V15, P3, DOI 10.1111/j.1440-1797.2010.01304.x; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602; KING AJ, 1993, J AM SOC NEPHROL, V3, P1723; Kovesdy CP, 2013, AM J CLIN NUTR, V97, P1163, DOI 10.3945/ajcn.112.036418; Lai TS, 2013, CRIT CARE, V17, DOI 10.1186/cc13054; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; LEWIS NJW, 1993, PHARMACOECONOMICS, V4, P323, DOI 10.2165/00019053-199304050-00003; Lin CC, 2005, J FORMOS MED ASSOC, V104, P157; Mircescu G, 2007, J RENAL NUTR, V17, P179, DOI 10.1053/j.jrn.2006.12.012; MITCH WE, 1984, NEW ENGL J MED, V311, P623, DOI 10.1056/NEJM198409063111002; MITCH WE, 1984, BIOCHEM J, V222, P579, DOI 10.1042/bj2220579; NATH KA, 1986, J CLIN INVEST, V78, P1199, DOI 10.1172/JCI112703; Ou SM, 2013, KIDNEY INT, V84, P198, DOI 10.1038/ki.2013.79; Prakash S, 2004, J RENAL NUTR, V14, P89, DOI 10.1053/j.jrn.2004.01.008; Scalone L, 2010, NEPHROL DIAL TRANSPL, V25, P907, DOI 10.1093/ndt/gfp572; Shiao C-C, 2015, NEPHROLOGY; Shih CJ, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0169-3; Teplan V, 2008, WIEN KLIN WOCHENSCHR, V120, P478, DOI 10.1007/s00508-008-0987-4; Voormolen N, 2007, NEPHROL DIAL TRANSPL, V22, P2909, DOI 10.1093/ndt/gfm286; Walser M, 1999, J AM SOC NEPHROL, V10, P110; Walser M, 1999, KIDNEY INT, V55, P771, DOI 10.1046/j.1523-1755.1999.055003771.x; WALSER M, 1993, KIDNEY INT, V43, P933, DOI 10.1038/ki.1993.131; WALSER M, 1992, J AM SOC NEPHROL, V2, P1178; Wang WJ, 2014, J BONE MINER RES, V29, P676, DOI 10.1002/jbmr.2061; Woo MJ, 2008, STAT MED, V27, P3805, DOI 10.1002/sim.3278; Wu CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112257; Wu IW, 2009, NEPHROL DIAL TRANSPL, V24, P3426, DOI 10.1093/ndt/gfp259; Wu PC, 2015, CLIN PHARMACOL THER, V98, P442, DOI 10.1002/cpt.173; Wu VC, 2014, J CLIN EPIDEMIOL, V67, P1139, DOI 10.1016/j.jclinepi.2014.05.012; Wu VC, 2014, J AM SOC NEPHROL, V25, P595, DOI 10.1681/ASN.2013060610; Wu VC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030836; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	56	17	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2017	12	5							e0176847	10.1371/journal.pone.0176847	http://dx.doi.org/10.1371/journal.pone.0176847			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9SX	28475591	Green Published, Green Submitted, gold			2023-01-03	WOS:000400649500018
J	Paige, NM; Miake-Lye, IM; Booth, MS; Beroes, JM; Mardian, AS; Dougherty, P; Branson, R; Tang, BR; Morton, SC; Shekelle, PG				Paige, Neil M.; Miake-Lye, Isomi M.; Booth, Marika Suttorp; Beroes, Jessica M.; Mardian, Aram S.; Dougherty, Paul; Branson, Richard; Tang, Baron; Morton, Sally C.; Shekelle, Paul G.			Association of Spinal Manipulative Therapy With Clinical Benefit and Harm for Acute LowBack Pain Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; RANDOMIZED-CONTROLLED-TRIAL; STAY-ACTIVE CARE; MANUAL THERAPY; ADVERSE EVENTS; PHYSICAL-THERAPY; PREDICTION RULE; STEROID INJECTIONS; EFFECT SIZE; PROGRAM	IMPORTANCE Acute low back pain is common and spinal manipulative therapy (SMT) is a treatment option. Randomized clinical trials (RCTs) and meta-analyses have reported different conclusions about the effectiveness of SMT. OBJECTIVE To systematically review studies of the effectiveness and harms of SMT for acute (<= 6 weeks) low back pain. DATA SOURCES Search of MEDLINE, Cochrane Database of Systematic Reviews, EMBASE, and Current Nursing and Allied Health Literature from January 1, 2011, through February 6, 2017, as well as identified systematic reviews and RCTs, for RCTs of adults with low back pain treated in ambulatory settings with SMT compared with sham or alternative treatments, and that measured pain or function outcomes for up to 6 weeks. Observational studies were included to assess harms. DATA EXTRACTION AND SYNTHESIS Data extractionwas done in duplicate. Study qualitywas assessed using the Cochrane Back and Neck (CBN) Risk of Bias tool. This tool has 11 items in the following domains: randomization, concealment, baseline differences, blinding (patient), blinding (care provider [care provider is a specific qualitymetric used by the CBN Risk of Bias tool]), blinding (outcome), co-interventions, compliance, dropouts, timing, and intention to treat. Prior research has shown the CBN Risk of Bias tool identifies studies at an increased risk of bias using a threshold of 5 or 6 as a summary score. The evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. MAIN OUTCOMES AND MEASURES Pain (measured by either the 100-mm visual analog scale, 11-point numeric rating scale, or other numeric pain scale), function (measured by the 24-point Roland Morris Disability Questionnaire or Oswestry Disability Index [range, 0-100]), or any harms measured within 6 weeks. FINDINGS Of 26 eligible RCTs identified, 15 RCTs (1711 patients) provided moderate-quality evidence that SMT has a statistically significant association with improvements in pain (pooled mean improvement in the 100-mm visual analog pain scale, -9.95 [95% CI, -15.6 to -4.3]). Twelve RCTs (1381 patients) produced moderate-quality evidence that SMT has a statistically significant association with improvements in function (pooled mean effect size, -0.39 [95% CI, -0.71 to -0.07]). Heterogeneity was not explained by type of clinician performing SMT, type of manipulation, study quality, or whether SMT was given alone or as part of a package of therapies. No RCT reported any serious adverse event. Minor transient adverse events such as increased pain, muscle stiffness, and headache were reported 50% to 67% of the time in large case series of patients treated with SMT. CONCLUSIONS AND RELEVANCE Among patients with acute low back pain, spinal manipulative therapy was associated with modest improvements in pain and function at up to 6 weeks, with transient minor musculoskeletal harms. However, heterogeneity in study results was large.	[Paige, Neil M.; Miake-Lye, Isomi M.; Beroes, Jessica M.; Shekelle, Paul G.] West Los Angeles Vet Affairs Med Ctr, 111G,11301 Wilshire Blvd, Los Angeles, CA 90076 USA; [Miake-Lye, Isomi M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Booth, Marika Suttorp; Shekelle, Paul G.] RAND Corp, Southern Calif Evidence Based Practice Ctr, Santa Monica, CA USA; [Mardian, Aram S.] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Dougherty, Paul] Canandaigua Vet Affairs Med Ctr, Rochester, NY USA; [Branson, Richard] Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN USA; [Tang, Baron] White River Junct Vet Affairs Med Ctr, White River Jct, VT USA; [Morton, Sally C.] Virginia Tech, Blacksburg, VA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; RAND Corporation; Virginia Polytechnic Institute & State University	Shekelle, PG (corresponding author), West Los Angeles Vet Affairs Med Ctr, 111G,11301 Wilshire Blvd, Los Angeles, CA 90076 USA.	paul.shekelle@va.gov	Mardian, Aram/ABD-3079-2021	Gravis, Ainars/0000-0002-0337-5559; Mardian, Aram/0000-0001-6920-8537	Veterans Affairs Quality Enhancement Research Initiative as part of the Evidence Synthesis Program	Veterans Affairs Quality Enhancement Research Initiative as part of the Evidence Synthesis Program	This work was funded by the Veterans Affairs Quality Enhancement Research Initiative as part of the Evidence Synthesis Program.	[Anonymous], 2011, STAT STAT SOFTW REL; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Avery S, 2004, PHYS THER REV, P146; Barrett AJ, 2000, J ROY SOC MED, V93, P258, DOI 10.1177/014107680009300511; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND, P9; Blomberg S, 1994, Eur Spine J, V3, P246, DOI 10.1007/BF02226573; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BLOMBERG S, 1992, Scandinavian Journal of Primary Health Care, V10, P170, DOI 10.3109/02813439209014057; Blomberg S, 1993, CLIN REHABIL, V7, P49; Blomberg Stefan, 1993, Scandinavian Journal of Primary Health Care, V11, P83, DOI 10.3109/02813439308994908; Bogefeldt J, 2008, CLIN REHABIL, V22, P529, DOI 10.1177/0269215507087294; Brennan GP, 2006, SPINE, V31, P623, DOI 10.1097/01.brs.0000202807.72292.a8; Cagnie B, 2004, MANUAL THER, V9, P151, DOI 10.1016/j.math.2004.03.001; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Chou R, 2015, ANN INTERN MED, V163, P373, DOI 10.7326/M15-0934; Chou R, 2009, SPINE, V34, P1078, DOI 10.1097/BRS.0b013e3181a103b1; Cleland JA, 2009, SPINE, V34, P2720, DOI 10.1097/BRS.0b013e3181b48809; CRAMER GD, 1993, J MANIP PHYSIOL THER, V16, P7; Cruser D, 2012, J MAN MANIP THER, V20, P5, DOI 10.1179/2042618611Y.0000000016; DELITTO A, 1993, PHYS THER, V73, P216, DOI 10.1093/ptj/73.4.216; DELITTO A, 1993, PHYS THER, V73, P226, DOI 10.1093/ptj/73.4.226; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Ferreira ML, 2003, J MANIP PHYSIOL THER, V26, P593, DOI 10.1016/j.jmpt.2003.08.010; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Fritz JM, 2015, JAMA-J AM MED ASSOC, V314, P1459, DOI 10.1001/jama.2015.11648; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; Goertz CM, 2013, SPINE, V38, P627, DOI 10.1097/BRS.0b013e31827733e7; Grunnesjo MI, 2011, CLIN REHABIL, V25, P999, DOI 10.1177/0269215511403512; Grunnesjo MI, 2004, J MANIP PHYSIOL THER, V27, P431, DOI 10.1016/j.jmpt.2004.06.001; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Hallegraeff HJM, 2009, PERCEPT MOTOR SKILL, V108, P196, DOI 10.2466/PMS.108.1.196-208; Hancock MJ, 2007, LANCET, V370, P1638, DOI 10.1016/S0140-6736(07)61686-9; Hebert JJ, 2015, J MANIP PHYSIOL THER, V38, P677, DOI 10.1016/j.jmpt.2013.05.009; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoiriis KT, 2004, J MANIP PHYSIOL THER, V27, P388, DOI 10.1016/j.jmpt.2004.05.003; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; Hussain I, 2013, RAWAL MED J, V38, P358; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Juni P, 2009, ANN RHEUM DIS, V68, P1420, DOI 10.1136/ard.2008.093757; Leboeuf-Yde C, 1997, J Manipulative Physiol Ther, V20, P511; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Maiers M, 2015, MANUAL THER, V20, P335, DOI 10.1016/j.math.2014.10.003; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MATHEWS W, 1988, Physiotherapy Practice, V4, P201; Morton JE., 1999, J MANUAL MANIP THER, V7, P182; Oliphant D, 2004, J MANIP PHYSIOL THER, V27, P197, DOI 10.1016/j.jmpt.2003.12.023; Paanalahti K, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-77; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; Roelofs PDDM, 2008, SPINE, V33, P1766, DOI 10.1097/BRS.0b013e31817e69d3; Rubinstein SM, 2008, J MANIP PHYSIOL THER, V31, P94, DOI 10.1016/j.jmpt.2007.12.006; Rubinstein SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008880.pub2; Sanchez-Meca J, 2008, PSYCHOL METHODS, V13, P31, DOI 10.1037/1082-989X.13.1.31; Santilli Valter, 2006, Spine J, V6, P131, DOI 10.1016/j.spinee.2005.08.001; Seferlis T, 1998, Eur Spine J, V7, P461; Senstad O, 1997, SPINE, V22, P435, DOI 10.1097/00007632-199702150-00017; Shekelle PG, 2017, EFFECTIVENESS HARMS; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; van Tulder MW, 2009, SPINE, V34, P1685, DOI 10.1097/BRS.0b013e3181ab6a78; von Heymann WJ, 2013, SPINE, V38, P540, DOI 10.1097/BRS.0b013e318275d09c; Walker BF, 2013, SPINE, V38, P1723, DOI 10.1097/BRS.0b013e31829fefe4; Walker BF, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005427.pub2; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080	72	112	115	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 11	2017	317	14					1451	1460		10.1001/jama.2017.3086	http://dx.doi.org/10.1001/jama.2017.3086			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER6FQ	28399251	Bronze, Green Published			2023-01-03	WOS:000398901200019
J	Bouchie, A; DeFrancesco, L; Sheridan, C; Webb, S				Bouchie, Aaron; DeFrancesco, Laura; Sheridan, Cormac; Webb, Sarah			Nature Biotechnology's academic spinouts of 2016	NATURE BIOTECHNOLOGY			English	Article							T-CELL-RECEPTOR; STEM-CELLS; TARGET; CD47; PHAGOCYTOSIS; INFLAMMATION; DEGRADATION; MECHANISM; FIBROSIS; STRATEGY	Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging.	[DeFrancesco, Laura] Nat Biotechnology, New York, NY 10004 USA		DeFrancesco, L (corresponding author), Nat Biotechnology, New York, NY 10004 USA.							Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Choi CHJ, 2013, P NATL ACAD SCI USA, V110, P7625, DOI 10.1073/pnas.1305804110; Dai HR, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv439; Fournie JJ, 2013, CELL MOL IMMUNOL, V10, P35, DOI 10.1038/cmi.2012.39; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Horrigan SK, 2017, ELIFE, V6, DOI 10.7554/eLife.18173; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Kojima Y, 2016, NATURE, V536, P86, DOI 10.1038/nature18935; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lee JH, 2014, SCIENCE, V343, P1360, DOI 10.1126/science.1250212; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Marcu-Malina V, 2011, BLOOD, V118, P50, DOI 10.1182/blood-2010-12-325993; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Palchaudhuri R, 2016, NAT BIOTECHNOL, V34, P738, DOI 10.1038/nbt.3584; Radovic-Moreno AF, 2015, P NATL ACAD SCI USA, V112, P3892, DOI 10.1073/pnas.1502850112; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sebestyen Z, 2016, CELL REP, V15, P1973, DOI 10.1016/j.celrep.2016.04.081; Wang JB, 2014, P NATL ACAD SCI USA, V111, P13157, DOI 10.1073/pnas.1410785111; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433	24	4	4	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2017	35	4					322	333		10.1038/nbt.3847	http://dx.doi.org/10.1038/nbt.3847			12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ER4OT	28398323				2023-01-03	WOS:000398780600019
J	McLaughlin, K				McLaughlin, Kathleen			DEADLY CHEMISTRY	SCIENCE			English	Editorial Material																			0	7	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2017	355	6332					1364	1366		10.1126/science.355.6332.1364	http://dx.doi.org/10.1126/science.355.6332.1364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EQ1DL	28360278				2023-01-03	WOS:000397809500016
J	Lu, X; Horner, JW; Paul, E; Shang, XY; Troncoso, P; Deng, PN; Jiang, S; Chang, Q; Spring, DJ; Sharma, P; Zebala, JA; Maeda, DY; Wang, YA; DePinho, RA				Lu, Xin; Horner, James W.; Paul, Erin; Shang, Xiaoying; Troncoso, Patricia; Deng, Pingna; Jiang, Shan; Chang, Qing; Spring, Denise J.; Sharma, Padmanee; Zebala, John A.; Maeda, Dean Y.; Wang, Y. Alan; DePinho, Ronald A.			Effective combinatorial immunotherapy for castration-resistant prostate cancer	NATURE			English	Article							TYROSINE KINASE INHIBITOR; SUPPRESSOR-CELLS; DOUBLE-BLIND; CHECKPOINT BLOCKADE; PHASE-III; DASATINIB; PLACEBO; MICROSATELLITE; IPILIMUMAB; SENESCENCE	A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC)(1). Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types(2). However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade(3-5), motivating a search for targeted therapies that overcome this resistance. Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumour immune evasion(6). The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer(7-9). Mouse models of prostate cancer show that MDSCs (CD11b(+)Gr1(+)) promote tumour initiation(10) and progression(11). These observations prompted us to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function. Here we develop a novel chimaeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting. Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy. Targeted therapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumour activities. Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy. Mechanistically, combination therapy efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDSC-promoting cytokines secreted by prostate cancer cells. These observations illuminate a clinical path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.	[Lu, Xin; Shang, Xiaoying; Deng, Pingna; Spring, Denise J.; Wang, Y. Alan; DePinho, Ronald A.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Horner, James W.; Paul, Erin; Jiang, Shan; Chang, Qing] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Troncoso, Patricia] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Zebala, John A.; Maeda, Dean Y.] Syntrix Biosyst Inc, Auburn, WA 98001 USA; [Lu, Xin] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Notre Dame	Wang, YA; DePinho, RA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	yalanwang@mdanderson.org; rdepinho@mdanderson.org	Maeda, Dean/AAB-8973-2020	Maeda, Dean/0000-0002-9304-6846; Spring, Denise J./0000-0002-4593-0901	Department of Defense Prostate Cancer Research Program (PCRP) Idea Development Award-New Investigator Option [W81XWH-14-1-0576]; National Institutes of Health [R44HL072614]; Clayton & Modesta Williams Cancer Research Fund; Cancer Center Support Grant [P30CA016672];  [U01CA141508];  [P01CA117969]; NATIONAL CANCER INSTITUTE [U01CA141508, P01CA117969, P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL072614] Funding Source: NIH RePORTER	Department of Defense Prostate Cancer Research Program (PCRP) Idea Development Award-New Investigator Option; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clayton & Modesta Williams Cancer Research Fund; Cancer Center Support Grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank N. Feng for advice on preclinical drug dosing; X. Xu and K. O'Connor for technical support on mES cells and chimaera generation; P. Jones and C. Carroll for providing <SUP>19</SUP>F NMR spectroscopy data; K. Zhao, Z. Xu, and Z. Fang for animal husbandry; F. Giancotti for suggestions on manuscript writing; A. Varma and J. W. Han for technical assistance; G. Wang, E.-J. Jin, P. Dey, and all members of the DePinho laboratory for a variety of technical support and suggestions. The project was supported by U01CA141508 (R.A.D.), P01CA117969 (R.A.D.), Department of Defense Prostate Cancer Research Program (PCRP) Idea Development Award-New Investigator Option W81XWH-14-1-0576 (X.L.), National Institutes of Health grant R44HL072614 (D.Y.M.), and the Clayton & Modesta Williams Cancer Research Fund (R.A.D.). Facility-based experimental support was provided by the Small Animal Imaging Facility (C. Kingsley, V. Tran, K. Maldonado, C. Kaffes), Flow Cytometry and Cellular Imaging Core Facility (J. Burks, D. Mak, and K. Dwyer), and Laboratory Animal Genetic Services (F. Benavides) at The University of Texas MD Anderson Cancer Center (Cancer Center Support Grant P30CA016672).	Ali K, 2014, NATURE, V510, P407, DOI 10.1038/nature13444; Araujo JC, 2013, LANCET ONCOL, V14, P1307, DOI 10.1016/S1470-2045(13)70479-0; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Benavides F, 2000, MOL CARCINOGEN, V28, P191, DOI 10.1002/1098-2744(200008)28:4<191::AID-MC1>3.0.CO;2-K; Birbach A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053501; Bjornson ZB, 2013, CURR OPIN IMMUNOL, V25, P484, DOI 10.1016/j.coi.2013.07.004; Brusa D, 2013, INT J UROL, V20, P971, DOI 10.1111/iju.12086; Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; De Henau O, 2016, NATURE, V539, P443, DOI 10.1038/nature20554; Di Mitri D, 2014, NATURE, V515, P134, DOI 10.1038/nature13638; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Fazio N, 2016, ANTICANCER RES, V36, P713; Frick A, 2015, PHARMACOGEN PERS MED, V8, P81, DOI 10.2147/PGPM.S73312; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219; Hossain DMS, 2015, CLIN CANCER RES, V21, P3771, DOI 10.1158/1078-0432.CCR-14-3145; Jia SD, 2013, CANCER DISCOV, V3, P44, DOI 10.1158/2159-8290.CD-12-0262; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Rivera LB, 2015, CELL REP, V11, P577, DOI 10.1016/j.celrep.2015.03.055; Saha BK, 1996, J IMMUNOL METHODS, V194, P77, DOI 10.1016/0022-1759(96)00065-8; Schade AE, 2008, BLOOD, V111, P1366, DOI 10.1182/blood-2007-04-084814; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Vitali R, 2009, INT J CANCER, V125, P2547, DOI 10.1002/ijc.24606; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Yuen AKL, 2005, TETRAHEDRON LETT, V46, P7899, DOI 10.1016/j.tetlet.2005.09.101	43	300	319	7	243	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2017	543	7647					728	+		10.1038/nature21676	http://dx.doi.org/10.1038/nature21676			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP8IS	28321130	Green Accepted			2023-01-03	WOS:000397619700058
J	Palmer, R; Hughes, H; Chater, T				Palmer, Rebecca; Hughes, Helen; Chater, Tim			What do people with aphasia want to be able to say? A content analysis of words identified as personally relevant by people with aphasia	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NAMING DISORDERS; COMPUTER THERAPY; STROKE; PROTOCOL; ANOMIA	Background Word finding is a common difficulty for people with aphasia. Targeting words that are relevant to the individual could maximise the usefulness and impact of word finding therapy. Aims To provide insights into words that people with aphasia perceive to be personally relevant. Methods and procedures 100 people with aphasia were each asked to identify 100 words that would be particularly important for them to be able to say. Two speech and language therapist researchers conducted a quantitative content analysis of the words selected. The words were coded into a framework of topics and subtopics. The frequency with which different words and topics were selected was then calculated. Outcomes and results 100 participants representing 20 areas of the United Kingdom ranged in age from 23 to 85 years. Word finding difficulties ranged from mild to severe. The sample of 9999 words selected for practice included 3095 different words in 27 topics. The majority of words selected (79.4%) were from the topics 'food and drink' (30.6%), 'nature and gardening' (10.3%), 'entertainment' (9.4%), 'places' (7.3%), 'people' (6.7%), 'house' (6.5%), 'clothes' (5.2%) and 'travel' (3.5%). The 100 words types chosen with the greatest frequency were identified. These account for 27 percent of the 9999 words chosen by the participants. Discussion Personally relevant vocabulary is unique to each individual and is likely to contain specific or specialist words for which material needs to be individually prepared. However there is some commonality in the words chosen by people with aphasia. This could inform pre-prepared materials for use in word finding therapy from which personally relevant words could be selected for practice.	[Palmer, Rebecca; Chater, Tim] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Palmer, Rebecca; Hughes, Helen] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England	University of Sheffield; University of Sheffield	Palmer, R (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England.; Palmer, R (corresponding author), Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.	r.l.palmer@sheffield.ac.uk	; Chater, Tim/Q-4355-2016	Palmer, Rebecca/0000-0002-2335-7104; Chater, Tim/0000-0002-1138-0147	National Institute for Health Research [12/21/01AB]; NIHR/HEFCE; Tavistock Trust	National Institute for Health Research(National Institute for Health Research (NIHR)); NIHR/HEFCE; Tavistock Trust	This report is independent research funded by the National Institute for Health Research (Health Technology Assessment - 12/21/01AB Clinical and cost effectiveness of aphasia computer therapy compared with usual stimulation or attention control long term post stroke (CACTUS)). RP is partially funded by an NIHR/HEFCE senior academic clinical lectureship. The Tavistock Trust for Aphasia also provides additional funding. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The views expressed in this article are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health.	Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781; Best W, 2008, INT J LANG COMM DIS, V43, P390, DOI 10.1080/13682820701608001; Best W, 2013, CORTEX, V49, P2345, DOI 10.1016/j.cortex.2013.01.005; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); Fink RB, 2002, APHASIOLOGY, V16, P1061, DOI 10.1080/02687030244000400; Jayes M, 2014, INT J SPEECH-LANG PA, V16, P159, DOI 10.3109/17549507.2013.795999; List D, 2007, KNOW YOUR AUDIENCE P; Mortley J, 2004, APHASIOLOGY, V18, P193, DOI 10.1080/02687030344000553; Nickels L, 2002, APHASIOLOGY, V16, P935, DOI 10.1080/02687030244000563; Palmer R, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0527-7; Palmer R, 2013, INT J LANG COMM DIS, V48, P508, DOI 10.1111/1460-6984.12024; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Raymer AM, 2008, J SPEECH LANG HEAR R, V51, pS259, DOI 10.1044/1092-4388(2008/020); Swinburn K., 2004, COMPREHENSIVE APHASI; Swinburn K, 2010, CONNECT COMMUNICATIO; Worrall L, 2011, APHASIOLOGY, V25, P309, DOI 10.1080/02687038.2010.508530	17	4	4	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2017	12	3							e0174065	10.1371/journal.pone.0174065	http://dx.doi.org/10.1371/journal.pone.0174065			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VD	28346518	Green Published, Green Accepted, gold			2023-01-03	WOS:000399174300021
J	Perez-Vidal, C; Gracia, L; Carmona, C; Alorda, B; Salinas, A				Perez-Vidal, Carlos; Gracia, Luis; Carmona, Cristian; Alorda, Bartomeu; Salinas, Antonio			Wireless transmission of biosignals for hyperbaric chamber applications	PLOS ONE			English	Article							SENSOR PLATFORM	This paper presents a wireless system to send biosignals outside a hyperbaric chamber avoiding wires going through the chamber walls. Hyperbaric chambers are becoming more and more common due to new indications of hyperbaric oxygen treatments. Metallic walls physically isolate patients inside the chamber, where getting a patient's vital signs turns into a painstaking task. The paper proposes using a ZigBee-based network to wirelessly transmit the patient's biosignals to the outside of the chamber. In particular, a wearable battery supported device has been designed, implemented and tested. Although the implementation has been conducted to transmit the electrocardiography signal, the device can be easily adapted to consider other biosignals.	[Perez-Vidal, Carlos] Miguel Hernandez Univ, Dept Syst Engn & Automat, Elche, Spain; [Gracia, Luis] Univ Politecn Valencia, Inst IDF, Valencia, Spain; [Carmona, Cristian; Alorda, Bartomeu] Univ Illes Balears, Dept Phys, Palma De Mallorca, Spain; [Salinas, Antonio] Perpetuo Socorro Hosp, MEDIBAROX Hyperbar Unit, Alicante, Spain	Universidad Miguel Hernandez de Elche; Universitat Politecnica de Valencia; Universitat de les Illes Balears	Perez-Vidal, C (corresponding author), Miguel Hernandez Univ, Dept Syst Engn & Automat, Elche, Spain.	carlos.perez@umh.es	Carmona, Cristian/S-5180-2018; Alorda, Bartomeu/X-8716-2018	Carmona, Cristian/0000-0001-7872-535X; Alorda, Bartomeu/0000-0002-5617-6254	Miguel Hernandez University	Miguel Hernandez University	This research has been carried out with funding and promotion of "Catedra de Medicina Hiperbarica" of the Miguel Hernandez University. http://nbio.umh.es/es/2010/12/01/catedra-de-medicina-hiperbarica-medibarox/.	Barea-Navarro R., BIOMEDICAL INSTRUMEN; Brubakk AO, 2004, UNDERSEA HYPERBAR M, V31, P73; Burns A, 2010, IEEE SENS J, V10, P1527, DOI 10.1109/JSEN.2010.2045498; Chen C., 2013, J MOD INT THINGS, V2, P24; Chung WY, 2008, IEEE ENG MED BIO, P1529, DOI 10.1109/IEMBS.2008.4649460; Fadlullah ZM, 2011, IEEE COMMUN MAG, V49, P60, DOI 10.1109/MCOM.2011.5741147; Gesell L.B., 2008, HYPERBARIC OXYGEN TH, V12th ed.; Gil Y, 2012, SENSORS-BASEL, V12, P10381, DOI 10.3390/s120810381; Hu S, 2012, SENSORS-BASEL, V12, P12844, DOI 10.3390/s120912844; Lee JS, 2007, IEEE IND ELEC, P46; Lin BS, 2006, IEEE T INF TECHNOL B, V10, P647, DOI 10.1109/TITB.2006.874194; Lin CT, 2010, IEEE T INF TECHNOL B, V14, P726, DOI 10.1109/TITB.2010.2047401; Lindell K., HYPERBARIC OXIGEN TH; Branco BHM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150517; Mahmood A, 2015, RENEW SUST ENERG REV, V41, P248, DOI 10.1016/j.rser.2014.08.036; Marks Robert J., 1991, SPRINGER TEXTS ELECT, pxiii; Olteanu AC, 2013, I C CONTR SYS COMP S, P189, DOI 10.1109/CSCS.2013.63; Parikh P.P., 2010, IEEE PES GEN M, P1, DOI DOI 10.1109/PES.2010.5589988; Semmlow J. L., 2011, BIOSIGNAL MED IMAGE; Shang YL, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.012813; Sidhu B, 2007, PROC WRLD ACAD SCI E, V19, P308; Sureda A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163371; Tortora G.J., 2009, PRINCIPLES ANATOMY P, P729; Xu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148324	24	1	1	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2017	12	3							e0172768	10.1371/journal.pone.0172768	http://dx.doi.org/10.1371/journal.pone.0172768			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9HQ	28296900	Green Published, Green Submitted, gold			2023-01-03	WOS:000396311700013
J	Tudor, D; Nenu, I; Filip, GA; Olteanu, D; Cenariu, M; Tabaran, F; Ion, RM; Gligor, L; Baldea, I				Tudor, Diana; Nenu, Iuliana; Filip, Gabriela Adriana; Olteanu, Diana; Cenariu, Mihai; Tabaran, Flaviu; Ion, Rodica Mariana; Gligor, Lucian; Baldea, Ioana			Combined regimen of photodynamic therapy mediated by Gallium phthalocyanine chloride and Metformin enhances anti-melanoma efficacy	PLOS ONE			English	Article							IN-VITRO; PHOTOPHYSICAL PROPERTIES; ALUMINUM-PHTHALOCYANINE; NITRIC-OXIDE; CANCER-CELLS; TNF-ALPHA; KAPPA-B; ALA-PDT; MELANOMA; APOPTOSIS	Background Melanoma therapy is challenging, especially in advanced cases, due to multiple developed tumor defense mechanisms. Photodynamic therapy (PDT) might represent an adjuvant treatment, because of its bimodal action: tumor destruction and immune system awakening. In this study, a combination of PDT mediated by a metal substituted phthalocyanine-Gal-lium phthalocyanine chloride (GaPc) and Metformin was used against melanoma. The study aimed to: (1) find the anti-melanoma efficacy of GaPc-PDT, (2) assess possible bene-ficial effects of Metformin addition to PDT, (3) uncover some of the mechanisms underlining cell killing and anti-angiogenic effects. Methods Two human lightly pigmented melanoma cell lines: WM35 and M1/15 subjected to previous Metformin exposure were treated by GaPc-PDT. Cell viability, death mechanism, cytoskele-ton alterations, oxidative damage, were assessed by means of colorimetry, flowcytometry, confocal microscopy, spectrophotometry, ELISA, Western Blotting. Results GaPc proved an efficient photosensitizer. Metformin addition enhanced cell killing by mech-anisms dependent on the cell line, namely apoptosis in the metastatic M1/15 and necrosis in the radial growth phase, WM35. Cell death mechanism relied on the inhibition of nuclear transcription factor (NF)-kappa B activation and tumor necrosis factor (TNF) D related apoptosis-inducing ligand (TRAIL) sensitization, leading to TRAIL and TNF-alpha induced apoptosis. Met-formin diminished the anti-angiogenic effect of PDT. Conclusions Metformin addition to GaPc-PDT increased tumor cell killing through enhanced oxidative damage and induction of proapoptotic mechanisms, but altered PDT anti-angiogenic effects. General significance Combination of Metformin and PDT might represent a solution to enhance the efficacy, lead-ing to a potential adjuvant role of PDT in melanoma therapy.	[Tudor, Diana; Nenu, Iuliana; Filip, Gabriela Adriana; Olteanu, Diana; Baldea, Ioana] Univ Med & Pharm, Dept Physiol, Cluj Napoca, Romania; [Cenariu, Mihai] Univ Agr Sci & Vet Med, Dept Biochem, Cluj Napoca, Romania; [Tabaran, Flaviu] Univ Agr Sci & Vet Med, Dept Pathol, Cluj Napoca, Romania; [Ion, Rodica Mariana] Natl Inst Res & Dev Chem & Petrochem ICECHIM, Nanomed Res Grp, Bucharest, Romania; [Gligor, Lucian] OSRAM Romania, OSRAM Opto Semicond, Global City Business Pk, Voluntari, Ilfov, Romania	Iuliu Hatieganu University of Medicine & Pharmacy; University of Agricultural Sciences & Veterinary Medicine Cluj Napoca; University of Agricultural Sciences & Veterinary Medicine Cluj Napoca; National Institute Research & Development in Chemistry & Petrochemistry; Osram	Filip, GA (corresponding author), Univ Med & Pharm, Dept Physiol, Cluj Napoca, Romania.	adrianafilip33@yahoo.com	Ion, Rodica-Mariana/B-2839-2008; Adriana, Filip Gabriela/AAB-7418-2019; Tudor, Diana Valentina/O-5516-2017; Tabaran, Flaviu/D-8562-2011; Olteanu, Elena Diana/A-4750-2017; Ioana, Baldea/Y-6129-2019; Cenariu, Mihai Cosmin/C-2558-2012; Tudor, Diana/ABB-8826-2020; Baldea, Ioana/C-4360-2011	Ion, Rodica-Mariana/0000-0002-9842-3321; Adriana, Filip Gabriela/0000-0002-7447-4925; Tudor, Diana Valentina/0000-0002-5997-8586; Tabaran, Flaviu/0000-0001-5744-0451; Olteanu, Elena Diana/0000-0002-3034-3659; Cenariu, Mihai Cosmin/0000-0001-6501-0128; Baldea, Ioana/0000-0003-4046-7310	University of Medicine and Pharmacy, Cluj-Napoca, Romania [1493/4/28.01.2014, 4945/4/08.03.2016]; OSRAM Opto Semiconductors, OSRAM Romania;  [PN-III-P2-2.1-PED-2016-1521]	University of Medicine and Pharmacy, Cluj-Napoca, Romania; OSRAM Opto Semiconductors, OSRAM Romania; 	This paper was supported by 1493/4/28.01.2014, 4945/4/08.03.2016 Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania and National Grant PN-III-P2-2.1-PED-2016-1521. We also affirm that the paper doesn't have any grants or contracts from a government agency, a non profit foundation, or a company supporting the preparation of the manuscript or the described research. The OSRAM Opto Semiconductors, OSRAM Romania provided support in the form of salaries for authors [LG], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acedo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.77; Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Ali H, 1999, CHEM REV, V99, P2379, DOI 10.1021/cr980439y; Baldea I, 2012, J PHYSIOL PHARMACOL, V63, P109; Baldea I, 2016, J PHOTOCH PHOTOBIO B, V161, P402, DOI 10.1016/j.jphotobiol.2016.06.012; Baldea Ioana, 2015, Clujul Med, V88, P175, DOI 10.15386/cjmed-419; Baldea I, 2015, J PHOTOCH PHOTOBIO B, V151, P142, DOI 10.1016/j.jphotobiol.2015.07.019; Baldea I, 2013, J DERMATOL SCI, V72, P168, DOI 10.1016/j.jdermsci.2013.06.004; Berwick M, MELANOMA 2016, P17; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bonnett R, 2001, TETRAHEDRON, V57, P9513, DOI 10.1016/S0040-4020(01)00952-8; Bro?yna AA, 2016, J CUTANEOUS PATHOLOG; Brozyna AA, 2008, INT J CANCER, V123, P1448, DOI 10.1002/ijc.23664; Brozyna AA, 2016, ONCOTARGET, V7, P17844, DOI 10.18632/oncotarget.7528; Brozyna AA, 2013, HUM PATHOL, V44, P2071, DOI 10.1016/j.humpath.2013.02.022; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Cerezo M, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12267; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Chen B, 2006, CRITICAL REV EUKARVO, V16; Collins-Gold L., 2000, MOD DRUG DISCOVERY, V3, P44; Cretney E, 2006, IMMUNOL CELL BIOL, V84, P87, DOI 10.1111/j.1440-1711.2005.01413.x; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Eggermont AMM, 2014, LANCET, V383, P816, DOI 10.1016/S0140-6736(13)60802-8; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Filip A, 2011, J MED FOOD, V14, P761, DOI 10.1089/jmf.2010.0142; Alvarez MG, 2004, PHOTODIAGN PHOTODYN, V1, P335, DOI 10.1016/S1572-1000(04)00068-7; Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920; Griffith TS, 1998, J IMMUNOL, V161, P2833; Guldi DM, 2000, J AM CHEM SOC, V122, P8289, DOI 10.1021/ja001578b; Hegyesi H, 2001, J INVEST DERMATOL, V117, P151, DOI 10.1046/j.0022-202x.2001.01406.x; Hirsch HA, 2009, CANCER RES, V69, P8832, DOI 10.1158/0008-5472.CAN-09-3869; Isoda K, 2006, ARTERIOSCL THROM VAS, V26, P611, DOI 10.1161/01.ATV.0000201938.78044.75; Jakubowska M, 2013, NITRIC OXIDE-BIOL CH, V35, P79, DOI 10.1016/j.niox.2013.08.004; Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004; Kleemann B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103762; Kumar R, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-27; Lang K, 2004, COORDIN CHEM REV, V248, P321, DOI 10.1016/j.ccr.2004.02.004; Leanne B J, 2008, METAL BASED DRUGS, V2008; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; LINSKY JP, 1980, INORG CHEM, V19, P3131, DOI 10.1021/ic50212a061; Liu F, 2009, J INVEST DERMATOL, V129, P422, DOI 10.1038/jid.2008.255; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Maduray K, 2013, J PHOTOCH PHOTOBIO B, V128, P58, DOI 10.1016/j.jphotobiol.2013.08.003; Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159-8290.CD-11-0280; Medina VA, 2010, BRIT J PHARMACOL, V161, P755, DOI 10.1111/j.1476-5381.2010.00961.x; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Menendez JA, 2015, CELL CYCLE, V14, P3801, DOI 10.1080/15384101.2015.1022697; Moiseeva O, 2013, AGING-US, V5, P330, DOI 10.18632/aging.100556; Monge-Fuentes V, 2014, NANO REV EXP, V5, DOI 10.3402/nano.v5.24381; Muehlmann LA, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951-015-0095-3; Muehlmann LA, 2014, INT J NANOMED, V9, P1199, DOI 10.2147/IJN.S57420; Nenu I, 2015, TUMOR BIOL, V36, P6589, DOI 10.1007/s13277-015-3639-0; Nenu I, 2014, J PHOTOCH PHOTOBIO B, V138, P80, DOI 10.1016/j.jphotobiol.2014.04.027; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Nombona N, 2012, J PHOTOCH PHOTOBIO B, V107, P35, DOI 10.1016/j.jphotobiol.2011.11.007; Nyman ES, 2004, J PHOTOCH PHOTOBIO B, V73, P1, DOI 10.1016/j.jphotobiol.2003.10.002; Ochoa-Gonzalez F, 2016, PLOS ONE, V11; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Olteanu D, 2014, J PHOTOCH PHOTOBIO B, V136, P54, DOI 10.1016/j.jphotobiol.2014.04.018; Pan XB, 2015, COLLOID SURFACE B, V130, P292, DOI 10.1016/j.colsurfb.2015.04.028; Plonka PM, 2003, EXP DERMATOL, V12, P356, DOI 10.1034/j.1600-0625.2002.120401.x; Pluskalova M, 2006, J PHOTOCH PHOTOBIO B, V83, P205, DOI 10.1016/j.jphotobiol.2006.01.003; Popescu T, 2014, LIFE SCI, V117, P75, DOI 10.1016/j.lfs.2014.09.022; Pustelny K, 2007, NITRIC OXIDE-BIOL CH, V16, P202, DOI 10.1016/j.niox.2006.10.002; Raghunath Arathi, 2015, BMC Res Notes, V8, P170, DOI 10.1186/s13104-015-1128-6; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Salani B, 2014, ENDOCR-RELAT CANCER, V21, pR461, DOI 10.1530/ERC-14-0284; Schallreuter KU, 2008, EXP DERMATOL, V17, P395, DOI 10.1111/j.1600-0625.2007.00675.x; Sharma KV, 2012, PHOTODIAGN PHOTODYN, V9, P156, DOI 10.1016/j.pdpdt.2011.09.003; Sharma SK, RESISTANCE PHOTODYNA, P229; Slattery ML, 2010, CARCINOGENESIS; Slominski A, 2014, ARCH BIOCHEM BIOPHYS, V563, P79, DOI 10.1016/j.abb.2014.06.030; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; SLOMINSKI A, 1985, ANTICANCER RES, V5, P403; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Slominski A, 2009, INT J CANCER, V124, P1470, DOI 10.1002/ijc.24005; Song CW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00362; Spagnolo F, 2012, ARCH DERMATOL RES, V304, P177, DOI 10.1007/s00403-012-1223-7; SPIKES JD, 1986, PHOTOCHEM PHOTOBIOL, V43, P691, DOI 10.1111/j.1751-1097.1986.tb05648.x; Swavey S., 2013, RECENT ADV BIOL THER; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Uzdensky A, 2005, BBA-GEN SUBJECTS, V1722, P43, DOI 10.1016/j.bbagen.2004.11.011; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Wolnicka-Glubisz A, 2015, ARCH DERMATOL RES, V307, P89, DOI 10.1007/s00403-014-1523-1; Wood JM, 2004, BIOCHEM BIOPH RES CO, V325, P1412, DOI 10.1016/j.bbrc.2004.10.185; Yuan CY, 2015, TISSUE ENG PT A, V21, P1163, DOI [10.1089/ten.tea.2014.0058, 10.1089/ten.TEA.2014.0058]; Zabierowski SE, 2008, J CLIN ONCOL, V26, P2890, DOI 10.1200/JCO.2007.15.5465; Zhuang LQ, 2006, HUM PATHOL, V37, P1286, DOI 10.1016/j.humpath.2006.04.026	91	20	20	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2017	12	3							e0173241	10.1371/journal.pone.0173241	http://dx.doi.org/10.1371/journal.pone.0173241			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6AW	28278159	Green Published, Green Submitted, gold			2023-01-03	WOS:000396087900057
J	Friedman, D; Fryzek, J; Jiang, XH; Bloomfield, A; Ambrose, CS; Wong, PC				Friedman, Deborah; Fryzek, Jon; Jiang, Xiaohui; Bloomfield, Adam; Ambrose, Christopher S.; Wong, Pierre C.			Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses	PLOS ONE			English	Article							YOUNG-CHILDREN; PALIVIZUMAB PROPHYLAXIS; INFANTS; EPIDEMIOLOGY; CONTEMPORARY; GUIDELINES; INFECTION; MORBIDITY; RATES	Children with hemodynamically significant congenital heart disease (CHD) are at elevated risk of morbidity and mortality due to respiratory syncytial virus (RSV) disease compared to their healthy peers. Previous studies have demonstrated lower RSV hospitalization risk among all children with CHD at 12-23 months of age versus 0-11 months of age. However, RSV hospitalization risk at 12-23 months of age by specific CHD diagnosis has not been characterized. Both case-control and cohort studies were conducted using data from the US National Inpatient Sample from 1997 to 2013 to characterize relative risk of RSV hospitalization among children 12-23 months of age with CHD. Related CHD diagnoses were combined for analysis. Hospitalizations for RSV and unspecified bronchiolitis were described by length of stay, mechanical ventilation use, mortality, and total charges. Over the 17-year period, 1,168,886 live birth hospitalizations with CHD were identified. Multiple specific CHD conditions had an elevated odds ratio or relative risk of RSV hospitalization. Mean total RSV hospitalization charges were significantly higher among children with CHD relative to those without CHD ($19,650 vs $7,939 in 2015 dollars) for this period. Compared to children without CHD, children with Ebstein's anomaly, transposition of the great arteries, aortic stenosis, heterotaxia, and aortic arch anomalies had 367-, 344-, 203-, 117- and 47-fold increased risk of inpatient RSV mortality, respectively. Unspecified bronchiolitis hospitalization odds and relative risk across CHD diagnoses were similar to those observed with RSV hospitalization; however, unspecified bronchiolitis hospitalizations were associated with shorter mean days of stay and less frequently associated with mechanical ventilation or mortality. Among children with more severe CHD diagnoses, RSV disease remains an important health risk through the second year of life. These data can help inform decisions regarding interventions to protect children with CHD from severe RSV disease during their second year of life.	[Friedman, Deborah] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; [Fryzek, Jon; Jiang, Xiaohui] EpidStat Inst, Rockville, MD USA; [Bloomfield, Adam; Ambrose, Christopher S.] AstraZeneca, Gaithersburg, MD 20878 USA; [Wong, Pierre C.] Childrens Hosp, Div Cardiol, Los Angeles, CA USA	New York Medical College; AstraZeneca; Children's Hospital Los Angeles	Friedman, D (corresponding author), New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.; Bloomfield, A (corresponding author), AstraZeneca, Gaithersburg, MD 20878 USA.	Deborah_Friedman@NYMC.edu; Adam.Bloomfield@astrazeneca.com		Bloomfield, Adam/0000-0002-5429-7378; Ambrose, Christopher/0000-0003-4175-7336	AstraZeneca	AstraZeneca(AstraZeneca)	This research was funded by AstraZeneca. DF is a consultant to AstraZeneca and a member of the Speakers Bureau. JF and XJ provided consultant/research support for AstraZeneca, as employees of EpidStat. AstraZeneca provided Epidstat with research support for this study. AB and CSA are employees of AstraZeneca and hold stock or stock options. PCW has received grant/research support through his institution from AstraZeneca. The specific roles of these authors are articulated in the 'author contributions' section. Editorial assistance was provided by The Lockwood Group (Stamford, CT, USA) and funded by AstraZeneca. Palivizumab is marketed by MedImmune, a specialty care division of AstraZeneca. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson JS, 2003, PEDIATRICS, V112, P1442; Agency for Healthcare Research and Quality, 2012, PED QUAL IND 7 TECHN; Agency for Healthcare Research and Quality, 2006, MEAS PED HLTH CAR QU; Altman CA, 2000, PEDIATR CARDIOL, V21, P433, DOI 10.1007/s002460010103; American Academy of Pediatrics, 2012, RED BOOK REP COMM IN; Bollani L, 2015, RECOMMENDATIONS PROP; Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Cheng HH, 2016, CONGENIT HEART DIS, V11, P80, DOI 10.1111/chd.12293; Chu PY, 2016, CARDIOL YOUNG, V10, P1; Doucette A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152208; Feinstein JA, 2014, PEDIATRICS, V133, pE1575, DOI 10.1542/peds.2013-3060; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Figueras Aloy J, 2015, AN PEDIAT BARC, V82; Forster J, 2012, GUIDELINE PREVENTION; Friedman DM, 2016, CLIN PEDIATR, V55, P724, DOI 10.1177/0009922815604598; Frohnert Barbara Kathleen, 2005, J Perinatol, V25, P737, DOI 10.1038/sj.jp.7211382; Granbom E, 2016, PEDIAT CARDIOL; Granbom E, 2014, ACTA PAEDIATR, V103, P840, DOI 10.1111/apa.12658; Hon KL, 2012, J CRIT CARE, V27, P464, DOI 10.1016/j.jcrc.2011.12.001; Jung Jo Won, 2011, Korean J Pediatr, V54, P192, DOI 10.3345/kjp.2011.54.5.192; Langley GF, 2011, PEDIATR INFECT DIS J, V30, P510, DOI 10.1097/INF.0b013e3182184ae7; Li A, 2016, PEDIAT INFECT DIS J; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Makari D, 2015, CLIN PEDIATR, V54, P594, DOI 10.1177/0009922814546040; MOLER FW, 1992, CRIT CARE MED, V20, P1406, DOI 10.1097/00003246-199210000-00008; Nakazawa M, 2006, PEDIATR INT, V48, P190, DOI 10.1111/j.1442-200X.2006.02179.x; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Ozyurt A, 2015, PEDIATR PULM, V50, P1025, DOI 10.1002/ppul.23102; Paes BA, 2011, CAN RESPIR J, V18, pE10, DOI 10.1155/2011/493056; Panozzo CA, 2010, PEDIATRICS, V126, pE116, DOI 10.1542/peds.2009-3221; Peter G, 1997, RED BOOK REP COMM IF; Public Health England, 2013, IMM INF DIS RESP SYN; Robinson Joan L, 2015, Paediatr Child Health, V20, P321; Simon A, 2007, EUR J PEDIATR, V166, P1273, DOI 10.1007/s00431-007-0426-y; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Strickland MJ, 2008, CARDIOL YOUNG, V18, P92, DOI 10.1017/S1047951108002515; Svensson B, 2011, ACTA PAEDIATR, V100, P407, DOI 10.1111/j.1651-2227.2010.02029.x; Welke KF, 2009, ANN THORAC SURG, V87, P216, DOI 10.1016/j.athoracsur.2008.10.032; Whelan Barbara, 2016, Drugs Ther Perspect, V32, P119	41	15	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2017	12	3							e0172512	10.1371/journal.pone.0172512	http://dx.doi.org/10.1371/journal.pone.0172512			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4XX	28253361	Green Published, Green Submitted, gold			2023-01-03	WOS:000396011300023
J	Schandelmaier, S; Kaushal, A; Lytvyn, L; Heels-Ansdell, D; Siemieniuk, RAC; Agoritsas, T; Guyatt, GH; Vandvik, PO; Couban, R; Mollon, B; Busse, JW				Schandelmaier, Stefan; Kaushal, Alka; Lytvyn, Lyubov; Heels-Ansdell, Diane; Siemieniuk, Reed A. C.; Agoritsas, Thomas; Guyatt, Gordon H.; Vandvik, Per O.; Couban, Rachel; Mollon, Brent; Busse, Jason W.			Low intensity pulsed ultrasound for bone healing: systematic review of randomized controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DOUBLE-BLIND; LATERAL MALLEOLAR; DISTRACTION OSTEOGENESIS; ELECTRICAL-STIMULATION; ELECTROMAGNETIC-FIELDS; TREATMENT TIME; FRACTURES; METAANALYSIS; MULTICENTER; QUALITY	Objective To determine the efficacy of low intensity pulsed ultrasound (LIPUS) for healing of fracture or osteotomy. Design Systematic review and meta-analysis. Data sources Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials, and trial registries up to November 2016. Study selection Randomized controlled trials of LIPUS compared with sham device or no device in patients with any kind of fracture or osteotomy. Review methods Two independent reviewers identified studies, extracted data, and assessed risk of bias. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. The GRADE system was used to assess the quality of evidence. Results 26 randomized controlled trials with a median sample size of 30 (range 8-501) were included. The most trustworthy evidence came from four trials at low risk of bias that included patients with tibia or clavicle fractures. Compared with control, LIPUS did not reduce time to return to work (percentage difference: 2.7% later with LIPUS, 95% confidence interval 7.7% earlier to 14.3% later; moderate certainty) or the number of subsequent operations (risk ratio 0.80, 95% confidence interval 0.55 to 1.16; moderate certainty). For pain, days to weight bearing, and radiographic healing, effects varied substantially among studies. For all three outcomes, trials at low risk of bias failed to show a benefit with LIPUS, while trials at high risk of bias suggested a benefit (interaction P<0.001). When only trials at low risk of bias trials were considered, LIPUS did not reduce days to weight bearing (4.8% later, 4.0% earlier to 14.4% later; high certainty), pain at four to six weeks (mean difference on 0-100 visual analogue scale: 0.93 lower, 2.51 lower to 0.64 higher; high certainty), and days to radiographic healing (1.7% earlier, 11.2% earlier to 8.8% later; moderate certainty). Conclusions Based on moderate to high quality evidence from studies in patients with fresh fracture, LIPUS does not improve outcomes important to patients and probably has no effect on radiographic bone healing. The applicability to other types of fracture or osteotomy is open to debate.	[Schandelmaier, Stefan; Kaushal, Alka; Heels-Ansdell, Diane; Siemieniuk, Reed A. C.; Agoritsas, Thomas; Guyatt, Gordon H.; Busse, Jason W.] McMaster Univ, Dept Clin Epidemiol & Biostat, 1280 Main St West, Hamilton, ON L8S 4L8, Canada; [Schandelmaier, Stefan] Univ Basel Hosp, Inst Clin Epidemiol & Biostat, Spitalstr 12, CH-4031 Basel, Switzerland; [Kaushal, Alka; Couban, Rachel; Busse, Jason W.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON L8S 4K1, Canada; [Lytvyn, Lyubov] Oslo Univ Hosp, Forskningsveien 2b,Postboks 1089, N-0317 Oslo, Norway; [Siemieniuk, Reed A. C.] Univ Toronto, Dept Med, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada; [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland; [Guyatt, Gordon H.] McMaster Univ, Dept Med, 1280 Main St West, Hamilton, ON L8S 4L8, Canada; [Vandvik, Per O.] Univ Oslo, Inst Hlth & Soc, Fac Med, N-0318 Oslo, Norway; [Vandvik, Per O.] Innlandet Hosp Trust Div, Dept Med, Gjovik, Norway; [Mollon, Brent] Orillia Soldiers Mem Hosp, 41 Frederick St, Orillia, ON L3V 5W6, Canada; [Busse, Jason W.] McMaster Univ, Dept Anesthesia, Hamilton, ON L8S 4K1, Canada	McMaster University; University of Basel; McMaster University; University of Oslo; University of Toronto; University of Geneva; University of Geneva; McMaster University; University of Oslo; Innlandet Hospital Trust; McMaster University	Schandelmaier, S (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.	schandes@mcmaster.ca	Agoritsas, Thomas/F-4321-2014; Busse, Jason/CAH-3696-2022; Schandelmaier, Stefan/GLV-3722-2022; Couban, Rachel/AAV-1568-2021	Agoritsas, Thomas/0000-0002-6182-9969; Busse, Jason/0000-0002-0178-8712; Schandelmaier, Stefan/0000-0002-8429-0337; Couban, Rachel/0000-0001-8672-2845				Akl EA, 2012, J CLIN EPIDEMIOL, V65, P262, DOI 10.1016/j.jclinepi.2011.04.015; Aleem IS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31724; Busse JW, 2008, ACTA ORTHOP, V79, P689, DOI 10.1080/17453670810016722; Busse JW, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5351; Busse JW, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-206; Busse JW, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b351; Dudda M, 2011, J TRAUMA, V71, P1376, DOI 10.1097/TA.0b013e31821912b2; Ebrahim S, 2014, CAN J SURG, V57, pE105, DOI 10.1503/cjs.010113; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Mowafi H, 2005, INT ORTHOP, V29, P121, DOI 10.1007/s00264-004-0625-3; Emami A, 1999, CLIN ORTHOP RELAT R, P220; Emami A, 1999, J ORTHOP TRAUMA, V13, P252, DOI 10.1097/00005131-199905000-00005; Food and Drug Administration, 2000, APPR ORD EX DEV; Gan TY, 2014, CLIN J SPORT MED, V24, P457, DOI 10.1097/JSM.0000000000000084; Griffin XL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008579.pub3; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Handolin L, 2005, J ORTHOP SCI, V10, P391, DOI 10.1007/s00776-005-0901-0; Handolin L, 2005, ARCH ORTHOP TRAUM SU, V125, P317, DOI 10.1007/s00402-005-0801-y; Handolin L, 2005, SCAND J SURG, V94, P239, DOI 10.1177/145749690509400312; Hannemann PEW, 2014, BONE JOINT J, V96B, P1070, DOI 10.1302/0301-620X.96B8.33767; Hannemann PFW, 2014, ARCH ORTHOP TRAUM SU, V134, P1093, DOI 10.1007/s00402-014-2014-8; Hannemann PFW, 2012, J BONE JOINT SURG BR, V94B, P1403, DOI 10.1302/0301-620X.94B10.28844; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623-199401000-00004; Kamath JB, 2015, MULLER J MED SCI RES, V6, P49, DOI [10.4103/0975-9727.146426, DOI 10.4103/0975-9727.146426]; Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623-199707000-00002; Leung KS, 2004, ULTRASOUND MED BIOL, V30, P389, DOI 10.1016/j.ultrasmedbio.2003.11.008; Liu YW, 2014, ACTA CIR BRAS, V29, P765, DOI 10.1590/S0102-86502014001800012; Lubbert PHW, 2008, INJURY, V39, P1444, DOI 10.1016/j.injury.2008.04.004; MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246; de Albornoz PM, 2011, BRIT MED BULL, V100, P39, DOI 10.1093/bmb/ldr006; Martinez-Rondanelli A, 2014, COLOMB MEDICA, V45, P67; Mayr E, 2000, Handchir Mikrochir Plast Chir, V32, P115, DOI 10.1055/s-2000-19253; National Institute for Health and Care Excellence, 2010, LOW INT PULS ULTR PR; Nolte PA, 2002, NONUNIONS SURG LOW I, P96; Patel K, 2015, CRANIOMAXILLOFACIAL, V8, P299, DOI 10.1055/s-0034-1544104; Poolman RW, 2017, BMJ IN PRESS; Raza H, 2016, J ULTRAS MED, V35, P349, DOI 10.7863/ultra.15.02043; Ricardo M, 2006, INT ORTHOP, V30, P123, DOI 10.1007/s00264-005-0034-2; Rue JPH, 2004, ORTHOPEDICS, V27, P1192, DOI 10.3928/0147-7447-20041101-18; Rutten S, 2012, THESIS; Rutten S, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.O.00027; Salem KH, 2014, INT ORTHOP, V38, P1477, DOI 10.1007/s00264-013-2254-1; Schofer M. D., 2010, BIOMEDICAL CENTRAL M, V11, P229, DOI DOI 10.1186/1471-2474-11-229; Schortinghuis J, 2005, ARCH ORAL BIOL, V50, P411, DOI 10.1016/j.archoralbio.2004.09.005; Schortinghuis J, 2008, INT J ORAL MAX SURG, V37, P1014, DOI 10.1016/j.ijom.2008.07.004; Siemieniuk RA, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i5191; Snyder Benjamin M, 2012, Am J Orthop (Belle Mead NJ), V41, pE12; SUN X, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C117; Tajali SB, 2012, AM J PHYS MED REHAB, V91, P349, DOI 10.1097/PHM.0b013e31822419ba; Thorlund K, 2011, RES SYNTH METHODS, V2, P188, DOI 10.1002/jrsm.46; Tsumaki N, 2004, J BONE JOINT SURG AM, V86A, P2399, DOI 10.2106/00004623-200411000-00006; Urita A, 2013, J HAND SURG-AM, V38A, P498, DOI 10.1016/j.jhsa.2012.11.032; Wachovia Capital Markets, 2007, EQ RES BON GROWTH ST; Watanabe Y, 2010, J ORTHOP TRAUMA, V24, pS56, DOI 10.1097/BOT.0b013e3181d2efaf; Zacherl M, 2009, ULTRASOUND MED BIOL, V35, P1290, DOI 10.1016/j.ultrasmedbio.2009.03.008	56	40	48	2	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	2017	356								j656	10.1136/bmj.j656	http://dx.doi.org/10.1136/bmj.j656			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM9KV	28348110	Green Published, hybrid			2023-01-03	WOS:000395631300001
J	von Minckwitz, G; Procter, M; de Azambuja, E; Zardavas, D; Benyunes, M; Viale, G; Suter, T; Arahmani, A; Rouchet, N; Clark, E; Knott, A; Lang, I; Levy, C; Yardley, DA; Bines, J; Gelber, RD; Piccart, M; Baselga, J				von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Lang, Istvan; Levy, Christelle; Yardley, Denise A.; Bines, Jose; Gelber, Richard D.; Piccart, Martine; Baselga, Jose		APHINITY Steering Comm	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLUS DOCETAXEL; CHEMOTHERAPY; EFFICACY	BACKGROUND Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer. METHODS We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab. We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with placebo. RESULTS In the trial population, 63% of the patients who were randomly assigned to receive pertuzumab (2400 patients) or placebo (2405 patients) had node-positive disease and 36% had hormone-receptor-negative disease. Disease recurrence occurred in 171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P = 0.045). The estimates of the 3-year rates of invasive-disease-free survival were 94.1% in the pertuzumab group and 93.2% in the placebo group. In the cohort of patients with node-positive disease, the 3-year rate of invasive-disease-free survival was 92.0% in the pertuzumab group, as compared with 90.2% in the placebo group (hazard ratio for an invasive-disease event, 0.77; 95% CI, 0.62 to 0.96; P = 0.02). In the cohort of patients with node-negative disease, the 3-year rate of invasive-disease-free survival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard ratio for an invasive-disease event, 1.13; 95% CI, 0.68 to 1.86; P = 0.64). Heart failure, cardiac death, and cardiac dysfunction were infrequent in both treatment groups. Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%). CONCLUSIONS Pertuzumab significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. (Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877.)	[von Minckwitz, Gunter] German Breast Grp, Neu Isenburg, Germany; [Procter, Marion] Frontier Sci Scotland, Kincraig, Scotland; [de Azambuja, Evandro; Rouchet, Nathalie] Breast European Adjuvant Study Team BrEAST, Ctr Data, Brussels, Belgium; [Zardavas, Dimitrios; Arahmani, Amal] Breast Int Grp, Brussels, Belgium; [Piccart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium; [Benyunes, Mark; Clark, Emma; Knott, Adam] Roche Pharma, Bern, Switzerland; [Suter, Thomas] Bern Univ Hosp, Dept Cardiol, Cardiooncol, Bern, Switzerland; [Viale, Giuseppe] Univ Milan, European Inst Oncol, Dept Pathol, Milan, Italy; [Lang, Istvan] Natl Inst Oncol, Budapest, Hungary; [Levy, Christelle] Ctr Francois Baclesse, Caen, France; [Yardley, Denise A.] Sarah Cannon Res Inst, Nashville, TN USA; [Yardley, Denise A.] Tennessee Oncol, Nashville, TN USA; [Bines, Jose] Inst Nacl Canc, Rio De Janeiro, Brazil; [Gelber, Richard D.] Harvard Med Sch, Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA USA; [Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA; [Baselga, Jose] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	German Breast Group; Breast International Group; Institut Jules Bordet; Universite Libre de Bruxelles; University of Bern; University Hospital of Bern; IRCCS European Institute of Oncology (IEO); University of Milan; National Institute of Oncology Hungary; UNICANCER; Centre Francois Baclesse; Sarah Cannon Research Institute; Tennessee Oncology; National Cancer Institute (Inca); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard T.H. Chan School of Public Health; Frontier Science Foundation; Memorial Sloan Kettering Cancer Center	von Minckwitz, G (corresponding author), GBG Forschungs, German Breast Grp, Martin Behaim Str 12, D-63263 Neu Isenburg, Germany.; Baselga, J (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.	gunter.vonminckwitz@gbg.de; baselgaj@mskcc.org	Wardley, Andrew/N-8135-2015; Viale, Giuseppe/AAE-8921-2019; Watanabe, Junichiro/AAI-8481-2021; Khasraw, Mustafa/ABH-5962-2020; Loi, Sherene/H-1979-2016; Garcia-Saenz, Jose Angel/AAW-8662-2020; Perren, Timothy/D-5387-2013	Wardley, Andrew/0000-0002-9639-0888; Watanabe, Junichiro/0000-0001-9226-895X; Khasraw, Mustafa/0000-0003-3249-9849; Loi, Sherene/0000-0001-6137-9171; Garcia-Saenz, Jose Angel/0000-0001-6880-0301; Coudert, Bruno/0000-0001-9445-2216; Haba Rodriguez, Juan Rafael de la/0000-0001-5111-1702; Biganzoli, Laura/0000-0001-7989-8658; Pienkowski, Tadeusz/0000-0002-0110-5950; LEVY, Christelle/0000-0003-0572-5222; Perren, Timothy/0000-0001-8472-8856; Di Leo, Angelo/0000-0002-3665-9056; Bedard, Philippe/0000-0002-6771-2999; Horvath, Zsolt/0000-0002-5376-7737; Hennessy, Bryan/0000-0002-7871-6477; Bliss, Judith/0000-0001-7957-7424; Antolin Novoa, Silvia/0000-0002-0110-3349; Fernandez-Morales, Luis Antonio/0000-0003-2120-6457	F. Hoffmann-La Roche/Genentech; Cancer Research UK [15955] Funding Source: researchfish; National Institute for Health Research [NF-SI-0616-10107] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	F. Hoffmann-La Roche/Genentech(Hoffmann-La RocheRoche HoldingGenentech); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877.	[Anonymous], 2016, LANCET ONCOL, V17, P791; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; De Mattos-Arruda L, 2016, NAT REV CLIN ONCOL, V13, P566, DOI 10.1038/nrclinonc.2016.35; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Swain SM, 2013, ONCOLOGIST, V18, P257, DOI 10.1634/theoncologist.2012-0448; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Zardavas D, 2015, BREAST, V24, pS143, DOI 10.1016/j.breast.2015.07.034	14	642	651	8	130	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2017	377	2					122	131		10.1056/NEJMoa1703643	http://dx.doi.org/10.1056/NEJMoa1703643			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA2PC	28581356	Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000405282300006
J	Roberts, KM; Conwell, D				Roberts, Kristen M.; Conwell, Darwin			Acute Pancreatitis: How Soon Should We Feed Patients?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ENTERAL NUTRITION; SUPPORT		[Roberts, Kristen M.; Conwell, Darwin] Ohio State Univ, 395 West 12th Ave,Second Floor, Columbus, OH 43210 USA	Ohio State University	Roberts, KM (corresponding author), Ohio State Univ, 395 West 12th Ave,Second Floor, Columbus, OH 43210 USA.	Kristen.Roberts@osumc.edu						Cao YF, 2008, ANN NUTR METAB, V53, P268, DOI 10.1159/000189382; Chang YS, 2013, CRIT CARE, V17, DOI 10.1186/cc12790; Chokkalingam A, 1998, SYSTEMATIC REV EVIDE; Lasztity N, 2005, CLIN NUTR, V24, P198, DOI 10.1016/j.clnu.2004.12.008; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; McClave SA, 2006, JPEN-PARENTER ENTER, V30, P143, DOI 10.1177/0148607106030002143; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Vaughn VM, 2017, ANN INTERN MED, V166, P883, DOI 10.7326/M16-2533; Wang GL, 2013, J SURG RES, V183, P592, DOI 10.1016/j.jss.2012.12.010	9	3	3	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 20	2017	166	12					903	+		10.7326/M17-1123	http://dx.doi.org/10.7326/M17-1123			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX9LG	28505666				2023-01-03	WOS:000403579000022
J	Lee, SMK; Kim, HS; Park, J; Woo, JS; Leem, J; Park, JH; Lee, S; Chung, H; Lee, JM; Kim, JB; Kim, WS; Kim, KS; Kim, W				Lee, Seung Min Kathy; Kim, Hyun Soo; Park, Jimin; Woo, Jong Shin; Leem, Jungtae; Park, Jun Hyeong; Lee, Sanghoon; Chung, Hyemoon; Lee, Jung Myung; Kim, Jin-Bae; Kim, Woo-Shik; Kim, Kwon Sam; Kim, Weon			Electroacupuncture prevents endothelial dysfunction induced by ischemia-reperfusion injury via a cyclooxygenase-2-dependent mechanism: A randomized controlled crossover trial	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROGENITOR CELLS; UP-REGULATION; IN-VIVO; ACUPUNCTURE; HEART; CARDIOPROTECTION; HYPERTENSION; ATORVASTATIN	Objective Exploring clinically effective methods to reduce ischemia-reperfusion (IR) injury in humans is critical. Several drugs have shown protective effects, but studies using other interventions have been rare. Electroacupuncture (EA) has induced similar protection in several animal studies but no study has investigated how the effects could be translated and reproduced in humans. This study aimed to explore the potential effect and mechanisms of EA in IRinduced endothelial dysfunction in humans. Methods This is a prospective, randomized, crossover, sham-controlled trial consisting of two protocols. Protocol 1 was a crossover study to investigate the effect of EA on IR-induced endothelial dysfunction. Twenty healthy volunteers were randomly assigned to EA or sham EA (sham). Flow mediated dilation (FMD) of the brachial artery (BA), nitroglycerin-mediated endothelial independent dilation, blood pressure before and after IR were measured. In protocol 2, seven volunteers were administered COX-2 inhibitor celecoxib (200 mg orally twice daily) for five days. After consumption, volunteers underwent FMD before and after IR identical to protocol 1. Results In protocol 1, baseline BA diameter, Pre-IR BA diameter and FMD were similar between the two groups (p = NS). After IR, sham group showed significantly blunted FMD (Pre-IR: 11.41 +/- 3.10%, Post-IR: 4.49 +/- 2.04%, p < 0.001). However, EA protected this blunted FMD (Pre-IR: 10.96 +/- 5.30%, Post-IR: 9.47 +/- 5.23%, p = NS, p < 0.05 compared with sham EA after IR). In protocol 2, this protective effect was completely abolished by pre-treatment with celecoxib (Pre-IR: 11.05 +/- 3.27%; Post-IR: 4.20 +/- 1.68%, p = 0.001). Conclusion EA may prevent IR-induced endothelial dysfunction via a COX-2 dependent mechanism.	[Lee, Seung Min Kathy; Leem, Jungtae; Park, Jun Hyeong; Lee, Sanghoon] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea; [Lee, Seung Min Kathy; Lee, Sanghoon; Kim, Weon] Kyung Hee Univ, East West Med Res Inst, Seoul, South Korea; [Lee, Seung Min Kathy; Park, Jimin; Park, Jun Hyeong; Lee, Sanghoon] Kyung Hee Univ, Dept Acupuncture & Moxibust, Coll Korean Med, Seoul, South Korea; [Kim, Hyun Soo; Woo, Jong Shin; Chung, Hyemoon; Lee, Jung Myung; Kim, Jin-Bae; Kim, Woo-Shik; Kim, Kwon Sam; Kim, Weon] Kyung Hee Univ, Kyung Hee Univ Hosp, Div Cardiol, Dept Internal Med, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University Hospital	Kim, W (corresponding author), Kyung Hee Univ, East West Med Res Inst, Seoul, South Korea.; Kim, W (corresponding author), Kyung Hee Univ, Kyung Hee Univ Hosp, Div Cardiol, Dept Internal Med, Seoul, South Korea.	mylovekw@hanmail.net	Lee, Jung Myung/ABZ-8907-2022	Lee, Jung Myung/0000-0002-1904-5335; Lee, Seung Min/0000-0002-4478-3081; Leem, Jungtae/0000-0003-3300-5556	Traditional Korean Medicine R&D Project, Ministry of Health & Welfare, Republic of Korea [HI13C0580, HI15C0166]; JSW [HI13C0580, HI15C0166]	Traditional Korean Medicine R&D Project, Ministry of Health & Welfare, Republic of Korea; JSW	This study was supported by a grant of the Traditional Korean Medicine R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C0580 and HI15C0166). WK received grant number HI13C0580 and JSW received grant number HI15C0166. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atar S, 2006, AM J PHYSIOL-HEART C, V290, pH1960, DOI 10.1152/ajpheart.01137.2005; Birnbaum Y, 2005, CARDIOVASC RES, V65, P345, DOI 10.1016/j.cardiores.2004.10.018; Choi EY, 2015, NUTRITION, V31, P1131, DOI 10.1016/j.nut.2015.04.020; Chun KS, 2004, CARCINOGENESIS, V25, P445, DOI 10.1093/carcin/bgh021; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Gori T, 2005, CIRCULATION, V111, P742, DOI 10.1161/01.CIR.0000155252.23933.2D; Ha SJ, 2012, ARTERIOSCL THROM VAS, V32, P474, DOI 10.1161/ATVBAHA.110.222653; Inoue M, 2003, ANTIOXID REDOX SIGN, V5, P475, DOI 10.1089/152308603768295221; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; Kim DD, 2006, MICROCIRCULATION, V13, P577, DOI 10.1080/10739680600885210; Kim JH, 2013, PLOS ONE, V8; Kim W, 2006, CIRC J, V70, P1052, DOI 10.1253/circj.70.1052; Kristen AV, 2010, HEART, V96, P1396, DOI 10.1136/hrt.2009.187930; Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016; Laude K, 2002, CARDIOVASC RES, V55, P466, DOI 10.1016/S0008-6363(02)00277-8; Lee S, 2015, CLIN EXP PHARMACOL P, V42, P822, DOI 10.1111/1440-1681.12413; Lee S, 2010, AUTON NEUROSCI-BASIC, V155, P5, DOI 10.1016/j.autneu.2010.02.003; Liuni A, 2010, J AM COLL CARDIOL, V55, P1002, DOI 10.1016/j.jacc.2009.11.046; Lomuscio A, 2011, J CARDIOVASC ELECTR, V22, P241, DOI 10.1111/j.1540-8167.2010.01878.x; Longhurst J, 2013, MED ACUPUNCT, V25, P101, DOI 10.1089/acu.2013.0960; Mehta PK, 2014, INT J CARDIOL, V176, P367, DOI 10.1016/j.ijcard.2014.07.011; O'Rourke B, 2004, CIRC RES, V94, P420, DOI 10.1161/01.RES.0000117583.66950.43; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Park JM, 2010, J ALTERN COMPLEM MED, V16, P883, DOI 10.1089/acm.2009.0427; Shinmura K, 2002, CIRC RES, V90, P602, DOI 10.1161/01.RES.0000012202.52809.40; Wang J, 2013, INT J CARDIOL, V169, P317, DOI 10.1016/j.ijcard.2013.09.001; Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058; Xue XH, 2014, NEUROSCI LETT, V558, P14, DOI 10.1016/j.neulet.2013.10.029; Yang LF, 2010, ANN THORAC SURG, V89, P781, DOI 10.1016/j.athoracsur.2009.12.003; Ye YM, 2008, AM J PHYSIOL-HEART C, V295, pH343, DOI 10.1152/ajpheart.01350.2007	31	2	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2017	12	6							e0178838	10.1371/journal.pone.0178838	http://dx.doi.org/10.1371/journal.pone.0178838			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0AO	28591155	Green Published, gold, Green Submitted			2023-01-03	WOS:000402880700051
J	Chover-Sierra, E; Martinez-Sabater, A; Lapena-Monux, YR				Chover-Sierra, Elena; Martinez-Sabater, Antonio; Lapena-Monux, Yolanda Raquel			An instrument to measure nurses' knowledge in palliative care: Validation of the Spanish version of Palliative Care Quiz for Nurses	PLOS ONE			English	Article							CONTENT VALIDITY; NURSING PCQN	Background Palliative care is nowadays essential in nursing care, due to the increasing number of patients who require attention in final stages of their life. Nurses need to acquire specific knowledge and abilities to provide quality palliative care. Palliative Care Quiz for Nurses is a questionnaire that evaluates their basic knowledge about palliative care. The Palliative Care Quiz for Nurses (PCQN) is useful to evaluate basic knowledge about palliative care, but its adaptation into the Spanish language and the analysis of its effectiveness and utility for Spanish culture is lacking. Purpose To report the adaptation into the Spanish language and the psychometric analysis of the Palliative Care Quiz for Nurses. Method The Palliative Care Quiz for Nurses-Spanish Version (PCQN-SV) was obtained from a process including translation, back-translation, comparison with versions in other languages, revision by experts, and pilot study. Content validity and reliability of questionnaire were analyzed. Difficulty and discrimination indexes of each item were also calculated according to Item Response Theory (IRT). Findings Adequate internal consistency was found (S-CVI = 0.83); Cronbach's alpha coefficient of 0.67 and KR-20 test result of 0,72 reflected the reliability of PCQN-SV. The questionnaire had a global difficulty index of 0,55, with six items which could be considered as difficult or very difficult, and five items with could be considered easy or very easy. The discrimination indexes of the 20 items, show us that eight items are good or very good while six items are bad to discriminate between good and bad respondents. Discussion Although in shows internal consistency, reliability and difficulty indexes similar to those obtained by versions of PCQN in other languages, a reformulation of the items with lowest content validity or discrimination indexes and those showing difficulties with their comprehension is an aspect to take into account in order to improve the PCQN-SV. Conclusion The PCQN-SV is a useful Spanish language instrument for measuring Spanish nurses' knowledge in palliative care and it is adequate to establish international comparisons.	[Chover-Sierra, Elena] Univ Valencia, Dept Nursing, Valencia, Spain; [Chover-Sierra, Elena; Martinez-Sabater, Antonio] Hosp Gen Univ Valencia, Valencia, Spain; [Lapena-Monux, Yolanda Raquel] Univ Jaume 1, Dept Nursing, Castellon De La Plana, Spain	University of Valencia; Hospital Clinic Universitari de Valencia; Universitat Jaume I	Chover-Sierra, E (corresponding author), Univ Valencia, Dept Nursing, Valencia, Spain.; Chover-Sierra, E (corresponding author), Hosp Gen Univ Valencia, Valencia, Spain.	elena.chover@uv.es	Chover-Sierra, Elena/GQH-1530-2022; Chover-Sierra, Elena/L-9665-2019	Chover-Sierra, Elena/0000-0002-4141-6956; Martinez-Sabater, Antonio/0000-0002-6440-1431				Adriaansen MJM, 2004, INT J NURS STUD, V41, P107, DOI 10.1016/S0020-7489(03)00073-7; Autor SH, 2013, J HOSP PALLIAT NURS, V15, P307, DOI 10.1097/NJH.0b013e3182930800; Barrio-Cantalejo IM, 2009, REV CALID ASSIST, V24, P192, DOI 10.1016/j.cali.2009.02.003; Brajtman S, 2007, INT J PALLIAT NURS, V13, P213, DOI 10.12968/ijpn.2007.13.5.23491; Brazil K, 2012, INT J PALLIAT NURS, V18, P77, DOI 10.12968/ijpn.2012.18.2.77; Calculo M., 2015, PUBLICANDO, V2, P62; Cardoso Ribeiro C., 2010, FISIOTERAPIA, V32, P264, DOI [10.1016/j.ft.2010.05.001, DOI 10.1016/J.FT.2010.05.001]; Carroll G, 2005, J PALLIAT CARE, V21, P27, DOI 10.1177/082585970502100105; Choi M, 2012, J CONTIN EDUC NURS, V43, P379, DOI 10.3928/00220124-20120615-35; Chover-Sierra E, 2017, REV LAT AM ENFERMAGE, V25; Escobar-Bravo M. A., 2004, ENFERM CLIN, V14, P102; Gaite L, 1997, ARCH NEUROBIOL, V60, P91; Gomez-Batiste X, 2013, BMJ SUPPORT PALLIAT, V3, P300, DOI 10.1136/bmjspcare-2012-000211; González-Consuegra Renata Virginia, 2010, Gerokomos, V21, P80, DOI 10.4321/s1134-928x2010000200007; Iranmanesh S, 2014, PALLIAT SUPPORT CARE, V12, P203, DOI 10.1017/S1478951512001058; Kim Boon Han, 2012, [Korean Journal of Adult Nursing, 성인간호학회지], V24, P390; Kim HS, 2011, J HOSP PALLIAT NURS, V13, P222, DOI 10.1097/NJH.0b013e318210fdec; Knapp CA, 2009, INT J PALLIAT NURS, V15, P432, DOI 10.12968/ijpn.2009.15.9.44255; Larkin P, 2005, INT J PALLIAT NURS, V11, P420, DOI 10.12968/ijpn.2005.11.8.19610; Romero-Sanchez JM, 2013, J ADV NURS, V69, P2759, DOI 10.1111/jan.12128; Martin-Moreno JM, 2008, PALLIATIVE CARE EURO; Ministry of Health (Spain), 2007, ESTR CUID PAL SIST N; Ministry of Health (Spain), 2011, ESTR CUID PAL SIST N; Orts-Cortes Maria Isabel, 2013, Appl Nurs Res, V26, pe5, DOI 10.1016/j.apnr.2013.08.006; Orts-Cortes MI, 2011, THESIS; Pessini L., 2006, ACTA BIOETH, V12, P231, DOI DOI 10.4067/S1726-569X2006000200012; Polit DF, 2007, RES NURS HEALTH, V30, P459, DOI 10.1002/nur.20199; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Praena Crespo M, 2009, AN PEDIAT, V70; Radbruch L, 2010, EUR J PALLIAT CARE, V17, P22; Radbruch L, 2010, EUROPEAN J PALLIATIV, V16, P278; Raudonis BM, 2002, GERIATR NURS, V23, P296, DOI 10.1067/mgn.2002.130270; Ronaldson S, 2008, INT J OLDER PEOPLE N, V3, P258, DOI 10.1111/j.1748-3743.2008.00136.x; Ross MM, 1996, J ADV NURS, V23, P126; Sirera-Vercher M.J., 2010, REV ESP CIR ORTOP TR, V54, P211, DOI [10.1016/j.recot.2010.02.006, DOI 10.1016/J.RECOT.2010.02.006]; Squires A, 2013, INT J NURS STUD, V50, P264, DOI 10.1016/j.ijnurstu.2012.02.015; Valles-Fernandez P., 2013, MED PALIAT, V12, DOI [10.1016/j.medipa.2013.03.003., DOI 10.1016/J.MEDIPA.2013.03.003]; World Health Organization, 2004, PALL CAR SOL FACTS	38	16	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2017	12	5							e0177000	10.1371/journal.pone.0177000	http://dx.doi.org/10.1371/journal.pone.0177000			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV3PV	28545037	Green Submitted, Green Published, gold			2023-01-03	WOS:000401672400016
J	Ricciardi, A; Gentilotti, E; Coppola, L; Maffongelli, G; Cerva, C; Malagnino, V; Mari, A; Di Veroli, A; Berrilli, F; Apice, F; Toschi, N; Di Cave, D; Parisi, SG; Andreoni, M; Sarmati, L				Ricciardi, Alessandra; Gentilotti, Elisa; Coppola, Luigi; Maffongelli, Gaetano; Cerva, Carlotta; Malagnino, Vincenzo; Mari, Alessia; Di Veroli, Ambra; Berrilli, Federica; Apice, Fabiana; Toschi, Nicola; Di Cave, David; Parisi, Saverio Giuseppe; Andreoni, Massimo; Sarmati, Loredana			Infectious disease ward admission positively influences P.jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients	PLOS ONE			English	Article							PNEUMOCYSTIS-JIROVECII PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; HEMATOLOGICAL MALIGNANCIES; RESPIRATORY SPECIMENS; CARINII; DNA; EPIDEMIOLOGY	P. jiroveci (Pj) causes a potentially fatal pneumonia in immunocompromised patients and the factors associated with a bad outcome are poorly understood. A retrospective analysis on Pj pneumonia (PjP) cases occurring in Tor Vergata University Hospital, Italy, during the period 2011-2015. The patients' demographic, clinical and radiological characteristics and the Pj genotypes were considered. The study population included 116 patients, 37.9% of whom had haematological malignancy or underwent haematological stem cell transplantation (HSCT), 22.4% had HIV infection, 16.4% had chronic lung diseases (CLD), 7.8% had a solid cancer, and 3.4% underwent a solid organ transplant (SOT). The remaining 12.1% had a miscellaneous other condition. At univariate analysis, being older than 60 years was significantly correlated with a severe PjP (OR [95% CI] 2.52 [0.10-5.76]; p = 0.031) and death (OR [95% CI] 2.44 [1.05-5.70]; p = 0.036), while a previous trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis were significantly associated with a less severe pneumonia (OR [95% CI] 0.35 [0.15-0.84], p = 0.023); moreover, death due to PjP was significantly more frequent in patients with CLD (OR[95% CI] 3.26 [1.17-9.05]; p = 0.019) while, admission to the Infectious Diseases Unit was significantly associated with fewer deaths (OR[95% CI] 0.10 [0.03-0.36], p = 0.002). At multivariate analysis, a better PjP outcome was observed in patients taking TMP/ SMX prophylaxis and that were admitted to the Infectious Diseases Unit (OR[95% CI] 0.27 [0.07-1.03], p = 0.055, OR[95% CI] 0.16 [0.05-0.55]; p = 0.004, respectively).	[Ricciardi, Alessandra; Gentilotti, Elisa; Coppola, Luigi; Maffongelli, Gaetano; Cerva, Carlotta; Malagnino, Vincenzo; Andreoni, Massimo; Sarmati, Loredana] Tor Vergata Univ, Infect Dis, Rome, Italy; [Mari, Alessia] Tor Vergata Univ, Resp Dis Unit, Rome, Italy; [Di Veroli, Ambra] Tor Vergata Univ, Dept Haematol, Rome, Italy; [Berrilli, Federica; Apice, Fabiana; Di Cave, David] Tor Vergata Univ, Dept Clin Sci & Translat Med, Rome, Italy; [Toschi, Nicola] Tor Vergata Univ, Dept Biomed & Prevent, Rome, Italy; [Toschi, Nicola] Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA USA; [Toschi, Nicola] Harvard Med Sch, Boston, MA USA; [Parisi, Saverio Giuseppe] Univ Padua, Dept Mol Med, Padua, Italy; [Parisi, Saverio Giuseppe] Padua Univ Hosp, Clin Microbiol & Virol Unit, Padua, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Harvard University; Harvard Medical School; University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova	Sarmati, L (corresponding author), Tor Vergata Univ, Infect Dis, Rome, Italy.	sarmati@med.uniroma2.it	Andreoni, Masimo/AAL-2214-2020; Toschi, Nicola/J-2555-2012; Maffongelli, Gaetano/AAB-8651-2022	Toschi, Nicola/0000-0003-1929-5833; sarmati, loredana/0000-0003-1452-0333; Cerva, Carlotta/0000-0001-9060-7313; Gentilotti, Elisa/0000-0001-6018-5295; Malagnino, Vincenzo/0000-0002-6561-5298; MAFFONGELLI, GAETANO/0000-0001-7784-2511	Abbvie; Bristol-Myers Squibb; Gilead Sciences; Merck Sharp Dohme; ViiV Healthcare; Janssen-Cilag; Gilead	Abbvie(AbbVie); Bristol-Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); Merck Sharp Dohme(Merck & Company); ViiV Healthcare; Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Gilead(Gilead Sciences)	MA and SGP have received speaker fees, travel grants, and consulting fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare, and Janssen-Cilag. LS has received travel grants from Gilead Sciences and Merck Sharp & Dohme, payment for lectures from Gilead Sciences, Merck Sharp & Dohme and Abbvie and researcher funding from Gilead. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All the other authors have no disclosures.	Alanio A, 2016, J ANTIMICROB CHEMOTH, V71, P2075, DOI 10.1093/jac/dkw036; Beard CB, 2000, EMERG INFECT DIS, V6, P265, DOI 10.3201/eid0603.000306; Bitar D, 2014, EMERG INFECT DIS, V20, P1149, DOI 10.3201/eid2007.140087; Catherinot E, 2010, INFECT DIS CLIN N AM, V24, P107, DOI 10.1016/j.idc.2009.10.010; Cordonnier C, 2016, J ANTIMICROB CHEMOTH, V71, P2379, DOI 10.1093/jac/dkw155; Crothers K, 2005, AIDS, V19, P801, DOI 10.1097/01.aids.0000168974.67090.70; Curtis JR, 2000, AM J RESP CRIT CARE, V162, P393, DOI 10.1164/ajrccm.162.2.9909014; Esteves F, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.03.013; Fei MW, 2009, THORAX, V64, P1070, DOI 10.1136/thx.2009.117846; Flori P, 2004, J MED MICROBIOL, V53, P603, DOI 10.1099/jmm.0.45528-0; Gupta R, 2009, DIAGN MICR INFEC DIS, V64, P381, DOI 10.1016/j.diagmicrobio.2009.04.008; Hardak E, 2012, RESPIROLOGY, V17, P681, DOI 10.1111/j.1440-1843.2012.02158.x; Hauser PM, 2011, J CLIN MICROBIOL, V49, P1872, DOI 10.1128/JCM.02390-10; Huggett JF, 2008, THORAX, V63, P154, DOI 10.1136/thx.2007.081687; Kanne JP, 2012, AM J ROENTGENOL, V198, pW555, DOI 10.2214/AJR.11.7329; LEIBOVITZ E, 1995, J CLIN MICROBIOL, V33, P3004, DOI 10.1128/JCM.33.11.3004-3007.1995; Li MC, 2014, J MICROBIOL IMMUNOL, V47, P42, DOI 10.1016/j.jmii.2012.08.024; Lopez-Sanchez C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000681; Maini R, 2013, EMERG INFECT DIS, V19, P386, DOI 10.3201/eid1903.121151; Matos O, 2010, FUTURE MICROBIOL, V5, P1257, DOI [10.2217/fmb.10.75, 10.2217/FMB.10.75]; McQuillen DP, 2008, CLIN INFECT DIS, V47, P1051, DOI 10.1086/592067; Morris A, 2004, EMERG INFECT DIS, V10, P1713, DOI 10.3201/eid1010.030985; Morris A, 2008, COPD, V5, P43, DOI 10.1080/15412550701817656; Morris A, 2012, CLIN MICROBIOL REV, V25, P297, DOI 10.1128/CMR.00013-12; Procop GW, 2004, J CLIN MICROBIOL, V42, P3333, DOI 10.1128/JCM.42.7.3333-3335.2004; Roux A, 2014, EMERG INFECT DIS, V20, P1490, DOI 10.3201/eid2009.131668; Schmitt S, 2014, CLIN INFECT DIS, V58, P22, DOI 10.1093/cid/cit610; Sing A, 2000, J CLIN MICROBIOL, V38, P1461, DOI 10.1128/JCM.38.4.1461-1467.2000; Stern A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005590.pub3; Thomas CF, 2004, NEW ENGL J MED, V350, P2487, DOI 10.1056/NEJMra032588; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6; Wakefield AE, 1996, J CLIN MICROBIOL, V34, P1754, DOI 10.1128/JCM.34.7.1754-1759.1996; Walzer PD, 2008, CLIN INFECT DIS, V46, P625, DOI 10.1086/526778	33	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2017	12	5							e0176881	10.1371/journal.pone.0176881	http://dx.doi.org/10.1371/journal.pone.0176881			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV0YN	28505159	gold, Green Published, Green Submitted			2023-01-03	WOS:000401473500010
J	Smith, KE; Norman, GJ				Smith, Karen E.; Norman, Greg J.			Brief relaxation training is not sufficient to alter tolerance to experimental pain in novices	PLOS ONE			English	Article							MINDFULNESS-BASED INTERVENTIONS; PROGRESSIVE MUSCLE-RELAXATION; RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; BARORECEPTOR ACTIVATION; ANXIETY DISORDERS; MASSAGE THERAPY; AUTONOMIC SPACE; MEDITATION; BRAIN	Relaxation techniques, such as deep breathing and muscle relaxation, are aspects common to most forms of mindfulness training. There is now an abundance of research demonstrating that mindfulness training has beneficial effects across a wide range of clinical conditions, making it an important tool for clinical intervention. One area of extensive research is on the beneficial effects of mindfulness on experiences of pain. However, the mechanisms of these effects are still not well understood. One hypothesis is that the relaxation components of mindfulness training, through alterations in breathing and muscle tension, leads to changes in parasympathetic and sympathetic nervous system functioning which influences pain circuits. The current study seeks to examine how two of the relaxation subcomponents of mindfulness training, deep breathing and muscle relaxation, influence experiences of pain in healthy individuals. Participants were randomized to either a 10 minute deep breathing, progressive muscle relaxation, or control condition after which they were exposed to a cold pain task. Throughout the experiment, measures of parasympathetic and sympathetic nervous system activity were collected to assess how deep breathing and progressive muscle relaxation alter physiological responses, and if these changes moderate any effects of these interventions on responses to pain. There were no differences in participants' pain tolerances or self-reported pain ratings during the cold pain task or in participants' physiological responses to the task. Additionally, individual differences in physiological functioning were not related to differences in pain tolerance or pain ratings. Overall this study suggests that the mechanisms through which mindfulness exerts its effects on pain are more complex than merely through physiological changes brought about by altering breathing or muscle tension. This indicates a need for more research examining the specific subcomponents of mindfulness, and how these subcomponents might be acting, to better understand their utility as a clinical treatment.	[Smith, Karen E.; Norman, Greg J.] Univ Chicago, Dept Psychol, Integrat Neurosci Area, 5848 S Univ Ave, Chicago, IL 60637 USA; [Norman, Greg J.] Univ Chicago, Grossman Inst Neurosci, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Smith, KE (corresponding author), Univ Chicago, Dept Psychol, Integrat Neurosci Area, 5848 S Univ Ave, Chicago, IL 60637 USA.	kelsmith@uchicago.edu						Arch JJ, 2006, BEHAV RES THER, V44, P1849, DOI 10.1016/j.brat.2005.12.007; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; BERNTSON GG, 1994, PSYCHOPHYSIOLOGY, V31, P599, DOI 10.1111/j.1469-8986.1994.tb02352.x; BERNTSON GG, 1991, PSYCHOL REV, V98, P459, DOI 10.1037/0033-295X.98.4.459; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Brown CA, 2013, CLIN J PAIN, V29, P233, DOI 10.1097/AJP.0b013e31824c5d9f; Brown CA, 2010, PAIN, V150, P428, DOI 10.1016/j.pain.2010.04.017; Busch V, 2012, PAIN MED, V13, P215, DOI 10.1111/j.1526-4637.2011.01243.x; Carson JW, 2005, J HOLIST NURS, V23, P287, DOI 10.1177/0898010105277651; Chiesa A, 2011, J ALTERN COMPLEM MED, V17, P83, DOI 10.1089/acm.2009.0546; CLARK WC, 1980, SCIENCE, V209, P410, DOI 10.1126/science.7384815; COGAN R, 1981, J PSYCHOSOM RES, V25, P535, DOI 10.1016/0022-3999(81)90107-0; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Conrad A, 2007, J ANXIETY DISORD, V21, P243, DOI 10.1016/j.janxdis.2006.08.001; Critchley HD, 2013, NEURON, V77, P624, DOI 10.1016/j.neuron.2013.02.008; de Wied M, 2001, PAIN, V90, P163, DOI 10.1016/S0304-3959(00)00400-0; Dolbier CL, 2012, INT J STRESS MANAGE, V19, P48, DOI 10.1037/a0027326; DWORKIN BR, 1994, P NATL ACAD SCI USA, V91, P6329, DOI 10.1073/pnas.91.14.6329; Emery CF, 2008, PAIN, V138, P375, DOI 10.1016/j.pain.2008.01.015; Gard T, 2012, CEREB CORTEX, V22, P2692, DOI 10.1093/cercor/bhr352; Grant JA, 2009, PSYCHOSOM MED, V71, P106, DOI 10.1097/PSY.0b013e31818f52ee; Gray MA, 2010, PAIN, V151, P853, DOI 10.1016/j.pain.2010.09.028; Gu J, 2015, CLIN PSYCHOL REV, V37, P1, DOI 10.1016/j.cpr.2015.01.006; HAPIDOU EG, 1988, PAIN, V34, P277, DOI 10.1016/0304-3959(88)90123-6; Heenan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099902; Hernandez-Reif M, 2001, INT J NEUROSCI, V106, P131, DOI 10.3109/00207450109149744; Hoffman JW, 2009, REDUCED SYMPATHETIC, V215, P190; Jain S, 2007, ANN BEHAV MED, V33, P11, DOI 10.1207/s15324796abm3301_2; Johnson MH, 1997, PAIN, V69, P43, DOI 10.1016/S0304-3959(96)03272-1; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Kakigi R, 2005, EUR J PAIN, V9, P581, DOI 10.1016/j.ejpain.2004.12.006; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Kwekkeboom KL, 2006, J NURS SCHOLARSHIP, V38, P269, DOI 10.1111/j.1547-5069.2006.00113.x; Lancaster SL, 2016, MINDFULNESS, V7, P614, DOI 10.1007/s12671-016-0496-x; Liu XH, 2013, STRESS HEALTH, V29, P199, DOI 10.1002/smi.2446; Lucas SJE, 2013, J APPL PHYSIOL, V115, P202, DOI 10.1152/japplphysiol.00128.2013; Manzoni GM, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-41; McClernon FJ, 2004, ADDICT BEHAV, V29, P765, DOI 10.1016/j.addbeh.2004.02.005; Porges S., 1993, BODY PERCEPTION QUES; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Radloff LS, 1977, APPL PSYCH MEAS, V1, P385, DOI DOI 10.1177/014662167700100306; Reiner K, 2013, PAIN MED, V14, P230, DOI 10.1111/pme.12006; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; SHERWOOD A, 1990, PSYCHOPHYSIOLOGY, V27, P1, DOI 10.1111/j.1469-8986.1990.tb02171.x; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Stabell N, 2013, PAIN, V154, P385, DOI 10.1016/j.pain.2012.11.012; Tang YY, 2012, CHILD DEV PERSPECT, V6, P361, DOI 10.1111/j.1750-8606.2012.00250.x; Travis F, 2009, INT J PSYCHOPHYSIOL, V71, P170, DOI 10.1016/j.ijpsycho.2008.09.007; Veehof MM, 2016, COGN BEHAV THERAPY, V45, P5, DOI 10.1080/16506073.2015.1098724; Vollestad J, 2012, BRIT J CLIN PSYCHOL, V51, P239, DOI 10.1111/j.2044-8260.2011.02024.x; Wanden-Berghe Rocio Guardiola, 2011, Eat Disord, V19, P34, DOI 10.1080/10640266.2011.533604; Zeidan F, 2012, NEUROSCI LETT, V520, P165, DOI 10.1016/j.neulet.2012.03.082; Zeidan F, 2010, J PAIN, V11, P199, DOI 10.1016/j.jpain.2009.07.015	55	6	6	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177228	10.1371/journal.pone.0177228	http://dx.doi.org/10.1371/journal.pone.0177228			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EU8UP	28493923	Green Submitted, Green Published, gold			2023-01-03	WOS:000401314300076
J	Gould, JF; Treyvaud, K; Yelland, LN; Anderson, PJ; Smithers, LG; McPhee, AJ; Makrides, M				Gould, Jacqueline F.; Treyvaud, Karli; Yelland, Lisa N.; Anderson, Peter J.; Smithers, Lisa G.; McPhee, Andrew J.; Makrides, Maria			Seven-Year Follow-up of Children Born to Women in a Randomized Trial of Prenatal DHA Supplementation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PREGNANCY		[Gould, Jacqueline F.; Makrides, Maria] South Australian Hlth & Med Res Inst, Child Nutr Res Ctr, Adelaide, SA, Australia; [Treyvaud, Karli] La Trobe Univ, Dept Psychol & Counselling, Melbourne, Vic, Australia; [Yelland, Lisa N.; Smithers, Lisa G.] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia; [Anderson, Peter J.] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [McPhee, Andrew J.] Womens & Childrens Hosp, Neonatal Serv, Adelaide, SA, Australia	South Australian Health & Medical Research Institute (SAHMRI); La Trobe University; University of Adelaide; Monash University	Makrides, M (corresponding author), South Australian Hlth & Med Res Inst, Child Nutr Res Ctr, 72 King William Rd, Adelaide, SA 5006, Australia.	maria.makrides@sahmri.com	Smithers, Lisa/D-1605-2009; Treyvaud, Karli/GXV-4561-2022; Anderson, Peter John/O-5302-2019; Yelland, Lisa N/GPP-4533-2022	Smithers, Lisa/0000-0002-6585-7836; Anderson, Peter John/0000-0001-7430-868X; Yelland, Lisa N/0000-0003-3803-8728	National Health and Medical Research Council [349301, 1048493]; Australian National Health and Medical Research Council [1061704, 1081288, 1052388]; Women's and Children's Hospital Foundation	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Women's and Children's Hospital Foundation	The original randomized trial of DHA in Pregnancy to Prevent Postnatal Depressive Symptoms and Enhance Neurodevelopment in Children (DOMInO) trial and the 7-year follow-up study were funded by National Health and Medical Research Council grants 349301 (DOMInO) and 1048493 (7-year follow-up). DOMInO trial treatment and control capsules were donated by Croda Chemicals. This work was supported by Australian National Health and Medical Research Council through senior research fellowship grants 1061704 (Dr Makrides) and 1081288 (Dr Anderson) and an early career fellowship grant 1052388 (Dr Yelland) and by a MS McLeod postdoctoral research fellowship grant from the Women's and Children's Hospital Foundation (Dr Gould).	Gould JF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011465; Gould JF, 2013, AM J CLIN NUTR, V97, P531, DOI 10.3945/ajcn.112.045781; Makrides M, 2014, JAMA-J AM MED ASSOC, V311, P1802, DOI 10.1001/jama.2014.2194; Makrides M, 2010, JAMA-J AM MED ASSOC, V304, P1675, DOI 10.1001/jama.2010.1507	4	35	36	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2017	317	11					1173	1175		10.1001/jama.2016.21303	http://dx.doi.org/10.1001/jama.2016.21303			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO9CQ	28324081				2023-01-03	WOS:000396987200024
J	Al-Rais, A				Al-Rais, Andrew			Why we should avoid handover hostility No patient has died from lack of manners, but rudeness among staff can affect performance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												andrew.al-rais@nhs.net						Porath CL, 2007, ACAD MANAGE J, V50, P1181, DOI 10.2307/20159919; Riskin A, 2015, PEDIATRICS, V136, P487, DOI 10.1542/peds.2015-1385	2	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2017	356								j1272	10.1136/bmj.j1272	http://dx.doi.org/10.1136/bmj.j1272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP4IR	28320693				2023-01-03	WOS:000397344700001
J	Puttkammer, N; Domercant, JW; Adler, M; Yuhas, K; Myrtil, M; Young, P; Francois, K; Grand'Pierre, R; Lowrance, D				Puttkammer, Nancy; Domercant, Jean Wysler; Adler, Michelle; Yuhas, Krista; Myrtil, Martine; Young, Paul; Francois, Kesner; Grand'Pierre, Reynold; Lowrance, David			ART attrition and risk factors among Option B plus patients in Haiti: A retrospective cohort study	PLOS ONE			English	Article							POISSON REGRESSION APPROACH; CLUSTER RANDOMIZED-TRIAL; TO-CHILD-TRANSMISSION; ANTIRETROVIRAL THERAPY; MALAWI; CARE; HIV; RETENTION; IMPACT; PROGRAM	Objectives In October 2012, the Haitian Ministry of Health endorsed the "Option B+" strategy to eliminate mother-to-child transmission of HIV and achieve HIV epidemic control. The objective of this paper is to assess and identify risk factors for attrition from the national ART program among Option B+ patients in the 12 months after ART initiation. Design This retrospective cohort study included patients newly initiating ART from October 2012-August 2013 at 68 ART sites covering 45% of all newly enrolled ART patients in all regions of Haiti. Methods With data from electronic medical records, we carried out descriptive analysis of sociodemographic, clinical, and pregnancy-related correlates of ART attrition, and used a modified Poisson regression approach to estimate relative risks in a multivariable model. Results There were 2,166 Option B+ patients who initiated ART, of whom 1,023 were not retained by 12 months (47.2%). One quarter (25.3%) dropped out within 3 months of ART initiation. Protective factors included older age, more advanced HIV disease progression, and any adherence counseling prior to ART initiation, while risk factors included starting ART late in gestation, starting ART within 7 days of HIV testing, and using an atypical ART regimen. Discussion Our study demonstrates early ART attrition among Option B+ patients and contributes evidence on the characteristics of women who are most at risk of attrition in Haiti. Our findings highlight the importance of targeted strategies to support retention among Option B+ patients.	[Puttkammer, Nancy] Univ Washington, Dept Global Hlth, Int Training & Educ Ctr Hlth I TECH, Seattle, WA 98195 USA; [Domercant, Jean Wysler; Lowrance, David] US Ctr Dis Control & Prevent, Port Au Prince, Haiti; [Adler, Michelle] US Ctr Dis Control & Prevent, Kampala, Uganda; [Yuhas, Krista] Univ Washington, Ctr AIDS Res, Seattle, WA 98195 USA; [Myrtil, Martine] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Young, Paul] US Ctr Dis Control & Prevent, Atlanta, GA USA; [Francois, Kesner; Grand'Pierre, Reynold] Govt Haiti, Minist Publ Hlth & Populat, Port Au Prince, Haiti	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA	Puttkammer, N (corresponding author), Univ Washington, Dept Global Hlth, Int Training & Educ Ctr Hlth I TECH, Seattle, WA 98195 USA.	nputt@uw.edu		Puttkammer, Nancy/0000-0002-6693-9278	Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration [U91HA0680]; US Centers for Disease Control and Prevention [NU2GGH001130-04-00]; International Training and Education Center for Health (I-TECH) at the University of Washington; NIAID of the National Institute of Health; NCI of the National Institute of Health; NIMH of the National Institute of Health; NIDA of the National Institute of Health; NICHD of the National Institute of Health; NHLBI of the National Institute of Health; NIA of the National Institute of Health; NIGMS of the National Institute of Health; NIDDK of the National Institute of Health [AI027757]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER	Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration; US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); International Training and Education Center for Health (I-TECH) at the University of Washington; NIAID of the National Institute of Health; NCI of the National Institute of Health; NIMH of the National Institute of Health; NIDA of the National Institute of Health; NICHD of the National Institute of Health; NHLBI of the National Institute of Health; NIA of the National Institute of Health; NIGMS of the National Institute of Health; NIDDK of the National Institute of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research has been supported by the Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration, under award number U91HA0680, and the US Centers for Disease Control and Prevention (https://www.cdc.gov/), under award number NU2GGH001130-04-00, to the International Training and Education Center for Health (I-TECH) at the University of Washington. Research reported in this publication was also supported by NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK of the National Institutes of Health (https://www.nih.gov/) under award number AI027757 to the University of Washington Center for AIDS Research (CFAR). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Institutes of Health, or the Health Resources and Services Administration.	Cataldo F, 2016, J ACQUIR IMMUNE DEFI; Cayemittes M, 2013, ENQUETE MORTALITE MO; Chan AK, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20672; Chimbwandira F, 2013, MMWR-MORBID MORTAL W, V62, P148; Desinor O, 2011, B EPIDEMIOLOGIQUE PR; Dionne-Odom J, 2016, AIDS RES TREAT, V2016, DOI 10.1155/2016/6284290; Domercant J, 2015, ATTRITION ANTIRETROV; Domercant JW, 2015, MMWR-MORBID MORTAL W, V64, P137; Ebuy H, 2015, INT J INFECT DIS, V33, P123, DOI 10.1016/j.ijid.2014.12.026; Ford D, 2016, J ACQUIRED IMMUNE DE; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Herce ME, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1065-y; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Kieffer MP, 2014, JAIDS-J ACQ IMM DEF, V67, pS188, DOI 10.1097/QAI.0000000000000372; Kim MH, 2015, JAIDS-J ACQ IMM DEF, V68, pE77, DOI 10.1097/QAI.0000000000000517; Kim MH, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.4.17389; Kim MH, 2015, WHY DID I STOP BARRI; Llenas-Garcia J, 2015, RETENTION CARE HIV I; Lober William B, 2008, AMIA Annu Symp Proc, P434; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Matheson AI, 2012, INT J MED INFORM, V81, P244, DOI 10.1016/j.ijmedinf.2012.01.011; Moga T, 2015, TAKING LESSONS LEARN; (MSPP) M.d.l.S.P.e.d.l.P., 2015, ET OP DEP CAS CASC P; Mukherjee JS, 2006, JAIDS-J ACQ IMM DEF, V43, pS123, DOI 10.1097/01.qai.0000248348.25630.74; Mutede BR, 2015, IMPROVING RETENTION; Ortblad KF, 2013, AIDS, V27, P2003, DOI 10.1097/QAD.0b013e328362ba67; [PNLS MSPP], 2014, DECL ENG VIH SIDA; Price AJ, 2014, SEX TRANSM INFECT, V90, P309, DOI 10.1136/sextrans-2013-051336; Rosenberg NE, 2015, LANCET HIV, V2, pE483, DOI 10.1016/S2352-3018(15)00182-4; Rosenberg NE, 2014, JAIDS-J ACQ IMM DEF, V67, pS114, DOI 10.1097/QAI.0000000000000319; Sam-Agudu NA, 2014, JAIDS-J ACQ IMM DEF, V67, pS132, DOI 10.1097/QAI.0000000000000331; Schmitz K, 2015, RETAINING MOTHER BAB; Sherr K, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-55; Tenthani L, 2014, AIDS, V28, P589, DOI 10.1097/QAD.0000000000000143; UNAIDS, 2014, 90 90 90 AMB TREATM; UNAIDS, 2014, THE GAP REP; UNICEF, 2014, UNICEF DAT MON HLTH; van Lettow M, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18994; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; World Health Organization, 2015, GUIDELINE ON WHEN TO; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	42	15	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2017	12	3							e0173123	10.1371/journal.pone.0173123	http://dx.doi.org/10.1371/journal.pone.0173123			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5OE	28264045	Green Published, gold, Green Submitted			2023-01-03	WOS:000396054300039
J	Li, L; Sawashita, J; Ding, X; Yang, M; Xu, Z; Miyahara, H; Mori, M; Higuchi, K				Li, Lin; Sawashita, Jinko; Ding, Xin; Yang, Mu; Xu, Zhe; Miyahara, Hiroki; Mori, Masayuki; Higuchi, Keiichi			Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis	PLOS ONE			English	Article							APOLIPOPROTEIN-A-II; SENESCENCE-ACCELERATED MOUSE; HIGH-DENSITY-LIPOPROTEINS; LIFE-SPAN EXTENSION; STOP-CODON MUTATION; SENILE AMYLOIDOSIS; APOA-II; ALZHEIMERS-DISEASE; INBRED STRAINS; MICE	In mouse senile amyloidosis, apolipoprotein (Apo) A-II is deposited extracellularly in many organs in the form of amyloid fibrils (AApoAII). Reduction of caloric intake, known as caloric restriction (CR), slows the progress of senescence and age-related disorders in mice. In this study, we intravenously injected 1 mu g of isolated AApoAII fibrils into R1. P1-Apoa2c mice to induce experimental amyloidosis and investigated the effects of CR for the next 16 weeks. In the CR group, AApoAII amyloid deposits in the liver, tongue, small intestine and skin were significantly reduced compared to those of the ad libitum feeding group. CR treatment led to obvious reduction in body weight, improvement in glucose metabolism and reduction in the plasma concentration of ApoA-II. Our molecular biological analyses of the liver suggested that CR treatment might improve the symptoms of inflammation, the unfolded protein response induced by amyloid deposits and oxidative stress. Furthermore, we suggest that CR treatment might improve mitochondrial functions via the sirtuin 1-peroxisome proliferator- activated receptor. coactivator 1 alpha (SIRT1-PGC-1 alpha) pathway. We suggest that CR is a promising approach for treating the onset and/or progression of amyloidosis, especially for systemic amyloidosis such as senile AApoAII amyloidosis. Our analysis of CR treatment for amyloidosis should provide useful information for determining the cause of amyloidosis and developing effective preventive treatments.	[Li, Lin; Sawashita, Jinko; Ding, Xin; Yang, Mu; Xu, Zhe; Miyahara, Hiroki; Mori, Masayuki; Higuchi, Keiichi] Shinshu Univ, Grad Sch Med, Inst Pathogenesis & Dis Prevent, Dept Aging Biol, Matsumoto, Nagano, Japan; [Sawashita, Jinko; Higuchi, Keiichi] Shinshu Univ, Dept Biol Sci Intractable Neurol Dis, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Matsumoto, Nagano, Japan; [Mori, Masayuki] Shinshu Univ, Dept Adv Med Hlth Promot, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Matsumoto, Nagano, Japan	Shinshu University; Shinshu University; Shinshu University	Sawashita, J (corresponding author), Shinshu Univ, Grad Sch Med, Inst Pathogenesis & Dis Prevent, Dept Aging Biol, Matsumoto, Nagano, Japan.; Sawashita, J (corresponding author), Shinshu Univ, Dept Biol Sci Intractable Neurol Dis, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Matsumoto, Nagano, Japan.	jinkos@shinshu-u.ac.jp		Sawashita, Jinko/0000-0001-8016-6649	Ministry of Education, Culture, Sports, Science, and Technology of Japan [23390093, 26293084, 24500849, 26670152]; Intractable Disease Division, the Ministry of Health, Labor, and Welfare	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Intractable Disease Division, the Ministry of Health, Labor, and Welfare	This research was supported by Grants-in-Aid for Scientific Research (B) (23390093 and 26293084) (KH), Scientific Research (C) (24500849) (JS), and Challenging Exploratory Research (26670152) (KH) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and by grants (KH) from the Intractable Disease Division, the Ministry of Health, Labor, and Welfare to the Research Committees for Amyloidosis, Japan.	Alwaili K, 2012, BBA-MOL CELL BIOL L, V1821, P405, DOI 10.1016/j.bbalip.2011.07.013; Anderson RM, 2009, TOXICOL PATHOL, V37, P47, DOI 10.1177/0192623308329476; Baumeier C, 2015, BBA-MOL CELL BIOL L, V1851, P566, DOI 10.1016/j.bbalip.2015.01.013; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Blanco-Vaca F, 2001, J LIPID RES, V42, P1727; Bonda DJ, 2011, LANCET NEUROL, V10, P275, DOI 10.1016/S1474-4422(11)70013-8; Buxbaum JN, 2012, J MOL BIOL, V421, P142, DOI 10.1016/j.jmb.2012.01.024; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Chen X, 2015, SCI REP-UK, V5, DOI 10.1038/srep12115; Chiba T, 1999, AM J PATHOL, V155, P1319, DOI 10.1016/S0002-9440(10)65234-0; Cho MH, 2014, AUTOPHAGY, V10, P1761, DOI 10.4161/auto.29647; Chung KW, 2013, EXP GERONTOL, V48, P1049, DOI 10.1016/j.exger.2012.11.007; Ferreira N, 2016, SCI REP-UK, V6, DOI 10.1038/srep26623; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; FORTE TM, 1995, J LIPID RES, V36, P148; Fu XY, 2004, FEBS LETT, V563, P179, DOI 10.1016/S0014-5793(04)00295-9; Ge FX, 2007, LAB INVEST, V87, P633, DOI 10.1038/labinvest.3700559; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Hanzen S, 2016, CELL, V166, P140, DOI 10.1016/j.cell.2016.05.006; HIGUCHI K, 1991, BIOCHEM J, V279, P427, DOI 10.1042/bj2790427; HIGUCHI K, 1995, LAB INVEST, V72, P75; Higuchi K, 1998, LAB INVEST, V78, P1535; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; HIGUCHI K, 1991, VIRCHOWS ARCH B, V60, P231, DOI 10.1007/BF02899551; Jadiya P, 2011, BIOCHEM BIOPH RES CO, V413, P306, DOI 10.1016/j.bbrc.2011.08.092; Karunadharma PP, 2015, AGING CELL, V14, P547, DOI 10.1111/acel.12317; Kisilevsky R, 2007, AMYLOID, V14, P21, DOI 10.1080/13506120601116419; Kitagawa K, 2003, AMYLOID, V10, P207, DOI 10.3109/13506120309041737; KOHNO A, 1985, J NUTR, V115, P1259, DOI 10.1093/jn/115.10.1259; Korenaga T, 2006, AM J PATHOL, V168, P898, DOI 10.2353/ajpath.2006.050350; Lee HR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134486; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Lundmark K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079104; Luo HM, 2015, LAB INVEST, V95, P320, DOI 10.1038/labinvest.2014.158; Macedo B, 2010, PHARMACOL RES, V62, P514, DOI 10.1016/j.phrs.2010.08.001; Madeo F, 2015, J CLIN INVEST, V125, P85, DOI 10.1172/JCI73946; Maesako M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131199; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Mercken EM, 2014, AGING CELL, V13, P193, DOI 10.1111/acel.12151; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Mihara M, 2004, J RHEUMATOL, V31, P1132; Morten IJ, 2007, J BIOL CHEM, V282, P29691, DOI 10.1074/jbc.M705004200; NAIKI H, 1988, AM J PATHOL, V130, P579; Pasinetti GM, 2008, J NEUROCHEM, V106, P1503, DOI 10.1111/j.1471-4159.2008.05454.x; Paulsson JF, 2006, DIABETOLOGIA, V49, P1237, DOI 10.1007/s00125-006-0206-7; Pomin VH, 2015, EUR J MED CHEM, V92, P353, DOI 10.1016/j.ejmech.2015.01.002; PRAS M, 1969, J EXP MED, V130, P777, DOI 10.1084/jem.130.4.777; Pyo JO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3300; Qian JZ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000914; Qin WP, 2006, J ALZHEIMERS DIS, V10, P417; Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sauvaget D, 2004, DIABETES, V53, P672, DOI 10.2337/diabetes.53.3.672; Sawashita J, 2015, P NATL ACAD SCI USA, V112, pE836, DOI 10.1073/pnas.1416363112; Schafer MJ, 2015, NEUROBIOL AGING, V36, P1293, DOI 10.1016/j.neurobiolaging.2014.10.043; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Simons JP, 2013, P NATL ACAD SCI USA, V110, P16115, DOI 10.1073/pnas.1306621110; Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858; Standard J, 2014, J NUTR BIOCHEM, V25, P1317, DOI 10.1016/j.jnutbio.2014.07.010; Thompson ACS, 2016, AGING CELL, V15, P118, DOI 10.1111/acel.12414; Tian G, 2014, ANTIOXID REDOX SIGN, V20, P2606, DOI 10.1089/ars.2013.5406; Umezawa M, 2003, J LIPID RES, V44, P762, DOI 10.1194/jlr.M200405-JLR200; Umezawa M, 2009, J GERONTOL A-BIOL, V64, P646, DOI 10.1093/gerona/glp047; van der Heijden RA, 2015, SCI REP-UK, V5, DOI 10.1038/srep16474; Walsh ME, 2014, FREE RADICAL BIO MED, V66, P88, DOI 10.1016/j.freeradbiomed.2013.05.037; Wang YY, 2011, J LIPID RES, V52, P1461, DOI 10.1194/jlr.M013235; Watroba M, 2016, ADV MED SCI-POLAND, V61, P52, DOI 10.1016/j.advms.2015.09.003; Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X; Westermark P, 2002, AMYLOID, V9, P197; Xing YM, 2002, J BIOL CHEM, V277, P33164, DOI 10.1074/jbc.M111570200; Xing YM, 2001, LAB INVEST, V81, P493, DOI 10.1038/labinvest.3780257; Yan JM, 2007, AM J PATHOL, V171, P172, DOI 10.2353/ajpath.2007.060576; Yazaki M, 2003, KIDNEY INT, V64, P11, DOI 10.1046/j.1523-1755.2003.00047.x; Zhang HY, 2006, FASEB J, V20, P1012, DOI 10.1096/fj.05-4890fje; Zhao L, 2013, BIOCHEMISTRY-US, V52, P1913, DOI 10.1021/bi301313b	77	8	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2017	12	2							e0172402	10.1371/journal.pone.0172402	http://dx.doi.org/10.1371/journal.pone.0172402			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SK	28225824	Green Published, Green Submitted, gold			2023-01-03	WOS:000394680900040
J	Le, VT; Klebanoff, MA; Talavera, MM; Slaughter, JL				Le, Vi T.; Klebanoff, Mark A.; Talavera, Maria M.; Slaughter, Jonathan L.			Transient effects of transfusion and feeding advances (volumetric and caloric) on necrotizing enterocolitis development: A case-crossover study	PLOS ONE			English	Article							BLOOD-CELL TRANSFUSIONS; ASSOCIATION; ANEMIA; RISK	Objective To evaluate the short-term effects of feed fortification, feed volume increase, and PRBC transfusion on the odds of developing NEC. Study design Case-crossover study of neonatal intensive care infants born at <= 32 weeks' gestation who were admitted to 5 central Ohio intensive care units from January 2012-July 2016 and developed NEC Bell Stage >= 2. Each patient served as their own control, with exposure during the 48-hour period just prior to NEC onset (hazard period) being compared to a preceding 48-hour control period, thus eliminating confounding by patient factors fixed between both intervals. NEC onset was determined by chart review as the earliest occurrence of one of the following within 24 hours of confirmatory x-ray: (1) antibiotic initiation, (2) enteral feeding cessation, (3) physician first notified of abdominal concerns, or (4) abdominal x-ray ordered. Conditional logistic regression compared exposures to feed volume increase, fortification, and PRBC transfusion during the 48-hour period prior to NEC onset to those during a preceding 48-hour control period. Analyses were stratified by gestational age and anemia (defined: hemoglobin <= 9.3 g/dL within 7 days of NEC onset). Results We included 63 infants with confirmed NEC. Acute exposure to fortification (odds ratio [OR]: 1.67, 95% confidence interval [CI]: 0.61, 4.59), feed volume increase (OR: 0.63, 95% CI: 0.28, 1.38), and PRBC transfusion (OR: 1.80, 95% CI: 0.60, 5.37) was not associated with the onset of NEC. Gestational age and anemia did not significantly modify the associations. Sensitivity testing substituting 24- and 72-hour hazard and control periods produced similar results. Conclusion Using a case-crossover design, we did not detect an association between NEC development and feed fortification, feed volume increase, or PRBC transfusion within 48-hours prior to NEC-onset. Replication in a larger set of cases is needed.	[Le, Vi T.; Klebanoff, Mark A.; Talavera, Maria M.; Slaughter, Jonathan L.] Nationwide Childrens Hosp, Res Inst, Ctr Perinatal Res, Columbus, OH 43205 USA; [Klebanoff, Mark A.; Talavera, Maria M.; Slaughter, Jonathan L.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Slaughter, JL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Perinatal Res, Columbus, OH 43205 USA.; Slaughter, JL (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.	jonathan.slaughter@nationwidechildrens.org	Slaughter, Jonathan L/E-4102-2011	Slaughter, Jonathan L/0000-0001-6831-7520	National Institutes of Health - National Heart, Lung, and Blood Institute [K08HL121182]; The Research Institute at Nationwide Children's Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL121182] Funding Source: NIH RePORTER	National Institutes of Health - National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); The Research Institute at Nationwide Children's Hospital(Ohio State University); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health - National Heart, Lung, and Blood Institute - K08HL121182 (Slaughter): (https://researchtraining.nih.gov/programs/career-development/K08) and the Institutional funds from The Research Institute at Nationwide Children's Hospital (Le): (http://www.nationwidechildrens.org/research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott J, 2013, ARCH DIS CHILD-FETAL, V98, pF470, DOI 10.1136/archdischild-2012-303260; Bernstein D, 2003, PEDIAT MED STUDENTS; Berseth CL, 2003, PEDIATRICS, V111, P529, DOI 10.1542/peds.111.3.529; Brown JVE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000343.pub3; Christensen RD, J PEDIAT, V158, P349; DeRienzo C, 2014, EARLY HUM DEV, V90, P237, DOI 10.1016/j.earlhumdev.2014.02.003; Dutta S, 2015, NUTRIENTS, V7, P423, DOI 10.3390/nu7010423; Guillen U, 2012, SEMIN PERINATOL, V36, P244, DOI 10.1053/j.semperi.2012.04.004; Hay S, 2016, SEMIN PERINATOL; Henderson G, 2009, ARCH DIS CHILD-FETAL, V94, pF120, DOI 10.1136/adc.2007.119560; Ho TTB, 2015, J PERINATOL, V35, P837, DOI 10.1038/jp.2015.73; Kirpalani H, 2012, SEMIN PERINATOL, V36, P269, DOI 10.1053/j.semperi.2012.04.007; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Maheshwari A, 2015, CLIN PERINATOL, V42, P567, DOI 10.1016/j.clp.2015.04.014; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; Morgan J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001241.pub6; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Patel RM, 2016, JAMA-J AM MED ASSOC, V315, P889, DOI 10.1001/jama.2016.1204; Patel RM, 2015, NEW ENGL J MED, V372, P331, DOI 10.1056/NEJMoa1403489; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; Sharma R, 2006, J PERINATOL, V26, P342, DOI 10.1038/sj.jp.7211510; Singh R, 2011, J PERINATOL, V31, P176, DOI 10.1038/jp.2010.145; Talavera MM, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1119	24	13	13	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2017	12	6							e0179724	10.1371/journal.pone.0179724	http://dx.doi.org/10.1371/journal.pone.0179724			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY5UN	28632783	gold, Green Submitted, Green Published			2023-01-03	WOS:000404046100046
J	Navathe, AS; Song, ZR; Emanuel, EJ				Navathe, Amol S.; Song, Zirui; Emanuel, Ezekiel J.			The Next Generation of Episode-Based Payments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICARE		[Navathe, Amol S.] Corporal Michael J Cresencz VA Med Ctr, Philadelphia, PA USA; [Navathe, Amol S.; Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Song, Zirui] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA; [Emanuel, Ezekiel J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania	Navathe, AS (corresponding author), Univ Penn, 1108 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	amol@wharton.upenn.edu		Navathe, Amol/0000-0001-7182-4988	HMSA; Oscar Health Insurance; NATIONAL INSTITUTE ON AGING [P30AG034546] Funding Source: NIH RePORTER	HMSA; Oscar Health Insurance; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Navathe reported receiving research funding from HMSA and Oscar Health Insurance; serving as an advisor to Navvis and Company, Navigant Inc, Lynx Medical, Indegene Inc, and Sutherland Global Services; and receiving honoraria from Elsevier Press. Dr Emanuel reported being a frequent paid event speaker at numerous conventions, committee meetings, and professional health care gatherings; and being a venture partner with Oak HC/FT. No other disclosures were reported.	Centers for Medicare & Medicaid Services, ADV CAR COOED EP PAY; Chernew ME, 2011, HEALTH AFFAIR, V30, P51, DOI 10.1377/hlthaff.2010.0980; Dorr LD, 2010, J ARTHROPLASTY, V25, P501, DOI 10.1016/j.arth.2009.06.005; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Emanuel EJ., 2017, PRESCRIPTION FUTURE; McWilliams JM, 2016, NEW ENGL J MED, V374, P2357, DOI 10.1056/NEJMsa1600142; Mechanic RE, 2016, NEW ENGL J MED, V374, P1706, DOI 10.1056/NEJMp1601464; Navathe AS, 2017, JAMA INTERN MED, V177, P214, DOI 10.1001/jamainternmed.2016.8263; Song ZR, 2016, JAMA-J AM MED ASSOC, V316, P1973, DOI 10.1001/jama.2016.16146	9	14	14	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2017	317	23					2371	2372		10.1001/jama.2017.5902	http://dx.doi.org/10.1001/jama.2017.5902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY0NJ	28531242				2023-01-03	WOS:000403654600007
J	Jirschitzka, J; Kimmerle, J; Halatchliyski, I; Hancke, J; Meurers, D; Cress, U				Jirschitzka, Jens; Kimmerle, Joachim; Halatchliyski, Iassen; Hancke, Julia; Meurers, Detmar; Cress, Ulrike			A productive clash of perspectives? The interplay between articles' and authors' perspectives and their impact on Wikipedia edits in a controversial domain	PLOS ONE			English	Article							PREFERENCE-INCONSISTENT RECOMMENDATIONS; REDUCING CONFIRMATION BIAS; KNOWLEDGE CONSTRUCTION; SELECTIVE EXPOSURE; POLARIZATION; INFORMATION; SCIENCE	This study examined predictors of the development of Wikipedia articles that deal with controversial issues. We chose a corpus of articles in the German-language version of Wikipedia about alternative medicine as a representative controversial issue. We extracted edits made until March 2013 and categorized them using a supervised machine learning setup as either being pro conventional medicine, pro alternative medicine, or neutral. Based on these categories, we established relevant variables, such as the perspectives of articles and of authors at certain points in time, the (im)balance of an article's perspective, the number of non-neutral edits per article, the number of authors per article, authors' heterogeneity per article, and incongruity between authors' and articles' perspectives. The underlying objective was to predict the development of articles' perspectives with regard to the controversial topic. The empirical part of the study is embedded in theoretical considerations about editorial biases and the effectiveness of norms and rules in Wikipedia, such as the neutral point of view policy. Our findings revealed a selection bias where authors edited mainly articles with perspectives similar to their own viewpoint. Regression analyses showed that an author's perspective as well as the article's previous perspectives predicted the perspective of the resulting edits, albeit both predictors interact with each other. Further analyses indicated that articles with more non-neutral edits were altogether more balanced. We also found a positive effect of the number of authors and of the authors' heterogeneity on articles' balance. However, while the effect of the number of authors was reserved to pro-conventional medicine articles, the authors' heterogenity effect was restricted to pro-alternative medicine articles. Finally, we found a negative effect of incongruity between authors' and articles' perspectives that was pronounced for the pro-alternative medicine articles.	[Jirschitzka, Jens; Kimmerle, Joachim; Halatchliyski, Iassen; Hancke, Julia; Cress, Ulrike] Leibniz Inst Wissensmedien, Tubingen, Germany; [Kimmerle, Joachim; Cress, Ulrike] Eberhard Karls Univ Tubingen, Dept Psychol, Tubingen, Germany; [Meurers, Detmar] Eberhard Karls Univ Tubingen, Dept Linguist, Tubingen, Germany	Leibniz Institut fur Wissensmedien; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Kimmerle, J (corresponding author), Leibniz Inst Wissensmedien, Tubingen, Germany.; Kimmerle, J (corresponding author), Eberhard Karls Univ Tubingen, Dept Psychol, Tubingen, Germany.	joachim.kimmerle@uni-tuebingen.de	Cress, Ulrike/AAB-4264-2020; Meurers, Detmar/AAQ-6659-2020; Cress, Ulrike/A-5615-2013; Kimmerle, Joachim/ABE-8803-2020	Cress, Ulrike/0000-0002-8996-8303; Meurers, Detmar/0000-0002-9740-7442; Cress, Ulrike/0000-0002-8996-8303; 	Leibniz ScienceCampus Tuebingen; Deutsche Forschungsgemeinschaft; Eberhard Karls University of Tuebingen; LeibnizInstitut fOr Wissensmedien, Tuebingen; Leibniz ScienceCampus Tuebingen [WCT-TP2.2]	Leibniz ScienceCampus Tuebingen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Eberhard Karls University of Tuebingen; LeibnizInstitut fOr Wissensmedien, Tuebingen; Leibniz ScienceCampus Tuebingen	The research reported here was supported by a grant from the Leibniz ScienceCampus Tuebingen (https://www.wissenschaftscampus-tuebingen.de/www/en/index.html) awarded to Ulrike Cress (WCT-TP2.2). We also acknowledge support by Deutsche Forschungsgemeinschaft http://www.dfg.de/en/index.jsp), Open Access Publishing Fund (JK) of Eberhard Karls University of Tuebingen (http://www.uni-tuebingen.de/einrichtungen/universitaetsbibliothek/forschen-publizierer/open-access-publikationsfonds.html), and the LeibnizInstitut fOr Wissensmedien, Tuebingen (https:// MNI.V.1,vm-tuebingen.de/vmv/entindext.tml). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r We are grateful to the Wikipedia Community for creating and maintaining the wonderful Internet encyclopedia Wikipedia. The research reported here was supported by a grant from the Leibniz ScienceCampus Tuebingen awarded to Ulrike Cress (WCT-TP2.2). We also acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Eberhard Karls University of Tuebingen.	Aarts AA, 2015, SCIENCE, V349, DOI 10.1126/science.aac4716; Aiken L. S., 1991, MULTIPLE REGRESSION; Benkler Y, 2006, J POLIT PHILOS, V14, P394, DOI 10.1111/j.1467-9760.2006.00235.x; Blumenstock J., 2008, P 17 INT C WWW, DOI [10.1145/1367497.1367673, DOI 10.1145/1367497.1367673]; Bohnet B., 2010, P 23 COLING C, P89; Borra E, 2015, CHI 2015: PROCEEDINGS OF THE 33RD ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P193, DOI 10.1145/2702123.2702436; Brandes U, 2008, INFORM VISUAL, V7, P34, DOI 10.1057/palgrave.ivs.9500171; Bykau S, 2015, PROC INT CONF DATA, P1573, DOI 10.1109/ICDE.2015.7113426; Cohen J., 2003, APPL MULTIPLE REGRES, V3rd; Coxe S, 2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; Cress U, 2007, P 8 IT C COMP SUPP C, P156; Cress U, 2016, COMPUT-SUPP COLLAB L, V16, P85, DOI 10.1007/978-3-319-13536-6_5; Cress U, 2016, COMPUT-SUPP COLLAB L, V16, P3, DOI 10.1007/978-3-319-13536-6_1; Cress U, 2008, INT J COMP-SUPP COLL, V3, P105, DOI 10.1007/s11412-007-9035-z; Del Vicario M, 2016, P NATL ACAD SCI USA, V113, P554, DOI 10.1073/pnas.1517441113; Detienne F, 2016, INT J HUM-COMPUT ST, V86, P11, DOI 10.1016/j.ijhcs.2015.09.002; Eysenbach G, 2001, BRIT MED J, V323, P1103, DOI 10.1136/bmj.323.7321.1103; FESTINGER L, 1962, SCI AM, V207, P93, DOI 10.1038/scientificamerican1062-93; Greenstein S, 2012, 18167 NBER; Greenstein S, 2016, 15023 HBS; Halatchliyski I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111958; Halatchliyski I, 2014, INT J COMP-SUPP COLL, V9, P97, DOI 10.1007/s11412-013-9182-3; Hall M., 2009, SIGKDD EXPLORATIONS, V11, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]; Hampton K., 2014, SOCIAL MEDIA SPIRAL; Hart PS, 2012, COMMUN RES, V39, P701, DOI 10.1177/0093650211416646; Hewitt-Taylor J, 2012, J MED INTERNET RES, V14, P301, DOI 10.2196/jmir.2068; Holtz P, 2012, J MEDIA PSYCHOL-GER, V24, P55, DOI 10.1027/1864-1105/a000062; Hookway N, 2008, QUAL RES, V8, P91, DOI 10.1177/1468794107085298; Ibm Corp, 2011, IBM SPSS STAT WIND V; Jirschitzka J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148283; Jonas E, 2001, J PERS SOC PSYCHOL, V80, P557, DOI 10.1037/0022-3514.80.4.557; Kievit RA, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00513; Kimmerle J, 2015, EDUC PSYCHOL-US, V50, P120, DOI 10.1080/00461520.2015.1036273; Kimmerle J, 2013, COMPUT HUM BEHAV, V29, P1078, DOI 10.1016/j.chb.2012.09.010; Kimmerle J, 2011, EDUC TECHNOL SOC, V14, P138; Kimmerle J, 2010, INFORM COMMUN SOC, V13, P1099, DOI 10.1080/13691180903521547; Kittur A, 2007, CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1 AND 2, P453; Knobloch-Westerwick S, 2009, COMMUN RES, V36, P426, DOI 10.1177/0093650209333030; Kobayashi T, 2009, INFORM COMMUN SOC, V12, P929, DOI 10.1080/13691180802158490; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Li CL, 2012, SOC NETW ANAL MIN, V2, P265, DOI 10.1007/s13278-011-0037-5; Lih A., 2004, 5 INT S ONL JOURN; Liu J., 2011, ACM T MANAGE INF SYS, V2, P1, DOI DOI 10.1145/1985347.1985352; LORD CG, 1979, J PERS SOC PSYCHOL, V37, P2098, DOI 10.1037/0022-3514.37.11.2098; MacKinnon DP, 2008, HEALTH PSYCHOL, V27, pS99, DOI 10.1037/0278-6133.27.2(Suppl.).S99; Mojzisch A, 2010, EUR J SOC PSYCHOL, V40, P946, DOI 10.1002/ejsp.660; Moskaliuk J, 2009, J COMPUT ASSIST LEAR, V25, P549, DOI [10.1111/j.1365-2729.2009.00331.x, 10.1111/J.1365-2729.2009.00331.x]; Moskaliuk J, 2012, COMPUT EDUC, V58, P1049, DOI 10.1016/j.compedu.2011.11.024; Muhr T., 2004, USERS MANUAL ATLAS T; Nickerson R. S., 1998, REV GEN PSYCHOL, V2, P175, DOI [10.1037/1089-2680.2.2.175, DOI 10.1037/1089-2680.2.2.175]; Noelle-Neumann E., 1980, OFFENTLICHE MEINUNG; Oeberst A, 2014, J LEARN SCI, V23, P149, DOI 10.1080/10508406.2014.888352; Pariser E., 2011, FILTER BUBBLE WHAT I; Pritschet L, PSYCHOL SCI; Rad HS, 2012, C P 8 ANN INT S WIK; Rad HS, 2011, P 20 INT C COMP WORL, P117; ROYSTON P, 1995, APPL STAT-J ROY ST C, V44, P547, DOI 10.2307/2986146; Royston P, 1992, STAT COMPUT, V2, P117, DOI [DOI 10.1007/BF01891203, 10.1007/BF01891203]; Schwind C, 2012, COMPUT HUM BEHAV, V28, P2280, DOI 10.1016/j.chb.2012.06.035; Schwind C, 2012, COMPUT EDUC, V58, P787, DOI 10.1016/j.compedu.2011.10.003; SHINE LC, 1980, EDUC PSYCHOL MEAS, V40, P331, DOI 10.1177/001316448004000207; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; Steyer R., 2003, WAHRSCHEINLICHKEIT R; Streiner DL, 2003, CAN J PSYCHIAT, V48, P756, DOI 10.1177/070674370304801108; Sumi R., 2011, Proceedings of the 2011 IEEE Third International Conference on Privacy, Security, Risk and Trust and IEEE Third International Conference on Social Computing (PASSAT/SocialCom 2011), P724, DOI 10.1109/PASSAT/SocialCom.2011.47; Taber CS, 2006, AM J POLIT SCI, V50, P755, DOI 10.1111/j.1540-5907.2006.00214.x; Tapscott D, 2006, WIKINOMICS MASS COLL; Vuong B.-Q., 2008, MODELS AND WSDM, V2008, P171, DOI DOI 10.1145/1341531.1341556; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Wyatt S, 2016, SCI TECHNOL STUD, V29, P13; Yasseri T., 2014, GLOBAL WIKIPEDIA INT, DOI DOI 10.2139/SSRN.2269392; Yasseri T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030091, 10.1371/journal.pone.0038869]	72	13	13	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178985	10.1371/journal.pone.0178985	http://dx.doi.org/10.1371/journal.pone.0178985			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EW6MJ	28575077	Green Submitted, Green Published, gold			2023-01-03	WOS:000402624300140
J	Trifiletti, DM; Sturz, VN; Showalter, TN; Lobo, JM				Trifiletti, Daniel M.; Sturz, Vanessa N.; Showalter, Timothy N.; Lobo, Jennifer M.			Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors	PLOS ONE			English	Review							21-GENE RECURRENCE SCORE; COST-EFFECTIVENESS ANALYSIS; POSITIVE BREAST-CANCER; EARLY-STAGE ESTROGEN; RT-PCR ASSAY; ONCOTYPE DX; ADJUVANT CHEMOTHERAPY; TREATMENT RECOMMENDATIONS; DISTANT RECURRENCE; CLINICAL-PRACTICE	Recent advances in the understanding of the genetic underpinnings of cancer offer the promise to customize cancer treatments to the individual through the use of genomic classifiers (GCs). At present, routine clinical utilization of GCs is uncommon and their current scope and status, in a broad sense, are unknown. As part of a registered review (PROSPERO 2014: CRD42014013371), we systematically reviewed the literature evaluating the utility of commercially available GCs by searching Ovid Medline (PubMed), EMBASE, the Cochrane Database of Systematic Reviews, and CINAHL on September 2, 2014. We excluded articles involving pediatric malignancies, non-solid or non-invasive cancers, hereditary risk of cancer, non-validated GCs, and GCs involving fewer than 3 biomarkers. A total of 3,625 studies were screened, but only 37 met the pre-specified inclusion criteria. Of these, 15 studies evaluated outcomes and clinical utility of GCs through clinical trials, and the remainder through the use of mathematical models. Most studies (29 of 37) were specific to hormone-receptor positive breast cancer, whereas only 4 studies evaluated GCs in non-breast cancer (prostate, colon, and lung cancers). GCs have spurred excitement across disciplines in recent decades. While there are several GCs that have been validated, the general quality of the data are weak. Further research, including prospective validation is needed, particularly in the non-breast cancer GCs.	[Trifiletti, Daniel M.; Showalter, Timothy N.] Univ Virginia, Sch Med, Dept Radiat Oncol, Charlottesville, VA 22908 USA; [Sturz, Vanessa N.; Lobo, Jennifer M.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lobo, JM (corresponding author), Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA.	jem4yb@virginia.edu	Lobo, Jennifer/AAK-6713-2021	Showalter, Timothy/0000-0003-1373-8496	American Society for Radiation Oncology Comparative Effectiveness Research Award	American Society for Radiation Oncology Comparative Effectiveness Research Award	This work was supported by an American Society for Radiation Oncology Comparative Effectiveness Research Award (T.N.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agendia, 2015, AG MIL; Agendia, 2015, AG COMP OV; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Chang JC, 2008, BREAST CANCER RES TR, V108, P233, DOI 10.1007/s10549-007-9590-z; Chen E, 2010, AM J MANAG CARE, V16, pE333; Cooperberg MR, 2015, EUR UROL, V67, P326, DOI 10.1016/j.eururo.2014.05.039; de Boer RH, 2013, MED J AUSTRALIA, V199, P205, DOI 10.5694/mja12.11334; Dinan MA, 2015, JAMA ONCOL, V1, P158, DOI 10.1001/jamaoncol.2015.43; Dowsett M, 2010, J CLIN ONCOL, V28, P1829, DOI 10.1200/JCO.2009.24.4798; Garraway LA, 2013, J CLIN ONCOL, V31, P1806, DOI 10.1200/JCO.2012.46.8934; Garraway LA, 2013, J CLIN ONCOL, V31, P1803, DOI 10.1200/JCO.2013.49.4799; Goldstein LJ, 2008, J CLIN ONCOL, V26, P4063, DOI 10.1200/JCO.2007.14.4501; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hall PS, 2012, JNCI-J NATL CANCER I, V104, P56, DOI 10.1093/jnci/djr484; Hannouf MB, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-447; Hassett MJ, 2012, J CLIN ONCOL, V30, P2218, DOI 10.1200/JCO.2011.38.5740; Holt S, 2013, BRIT J CANCER, V108, P2250, DOI 10.1038/bjc.2013.207; Hornberger J, 2005, AM J MANAG CARE, V11, P313; Hornberger J, 2012, VALUE HEALTH, V15, P1014, DOI 10.1016/j.jval.2012.07.012; Hornberger J, 2011, J ONCOL PRACT, V7, pE38S, DOI 10.1200/JOP.2011.000303; Hunter DJ, 2016, NEW ENGL J MED, V375, P711, DOI 10.1056/NEJMp1608282; Iwamoto T, 2011, BREAST CANCER RES TR, V130, P155, DOI 10.1007/s10549-011-1706-9; Joh JE, 2011, ONCOLOGIST, V16, P1520, DOI 10.1634/theoncologist.2011-0045; Kelly CM, 2012, ONCOLOGIST, V17, P492, DOI 10.1634/theoncologist.2012-0007; Khoury MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2105, DOI 10.1158/1055-9965.EPI-11-0481; Klang SH, 2010, VALUE HEALTH, V13, P381, DOI 10.1111/j.1524-4733.2010.00724.x; Knauer M, 2010, BRIT J CANCER, V103, P1788, DOI 10.1038/sj.bjc.6605916; Kok M, 2009, BREAST CANCER RES TR, V113, P275, DOI 10.1007/s10549-008-9939-y; Lamond NWD, 2012, BREAST CANCER RES TR, V133, P1115, DOI 10.1007/s10549-012-1989-5; Lee JJ, 2011, AM SURGEON, V77, P1364; Lund MJ, 2012, CANCER-AM CANCER SOC, V118, P788, DOI 10.1002/cncr.26180; Lyman GH, 2007, CANCER-AM CANCER SOC, V109, P1011, DOI 10.1002/cncr.22506; Maak M, 2013, ANN SURG, V257, P1053, DOI 10.1097/SLA.0b013e31827c1180; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Mislick K, 2014, CLINICOECONOMIC OUTC, V6, P37, DOI 10.2147/CEOR.S53142; NanoString Technologies, 2013, NANOSTRING LAUNCH IT; OncotypeDx, 2016, ONCOTYPEDX BREAST RE; Orucevic A, 2016, BREAST CANCER RES TR, V157, P427, DOI 10.1007/s10549-016-3833-9; Paulden M, 2013, VALUE HEALTH, V16, P729, DOI 10.1016/j.jval.2013.03.1625; PRNewswire, 2013, GENOMEDX BIOSC CLOS; PRNewswire, 2010, CLAR LAUNCH INS DX M; Rayhanabad JA, 2008, AM SURGEON, V74, P887; Reed SD, 2013, GENET MED, V15, P203, DOI 10.1038/gim.2012.119; Retel VP, 2013, EUR J CANCER, V49, P3773, DOI 10.1016/j.ejca.2013.08.001; Retel VP, 2010, EUR J CANCER, V46, P1382, DOI 10.1016/j.ejca.2010.02.035; Roth JA, 2014, ONCOLOGIST, V19, P466, DOI 10.1634/theoncologist.2013-0357; Sgroi DC, 2013, LANCET ONCOL, V14, P1067, DOI 10.1016/S1470-2045(13)70387-5; Simon R, 2006, PHARMACOGENOMICS J, V6, P166, DOI 10.1038/sj.tpj.6500349; Simonds NI, 2013, JNCI-J NATL CANCER I, V105, P929, DOI 10.1093/jnci/djt108; Tsoi DT, 2010, ONCOLOGIST, V15, P457, DOI 10.1634/theoncologist.2009-0275; Vanderlaan BF, 2011, AM J MANAG CARE, V17, P455; Ward S, 2013, HEALTH TECHNOL ASSES, P17; Yang M, 2012, CANCER-AM CANCER SOC, V118, P5163, DOI 10.1002/cncr.27443	53	6	6	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2017	12	5							e0176388	10.1371/journal.pone.0176388	http://dx.doi.org/10.1371/journal.pone.0176388			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UM	28486497	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314000010
J	Rochon, PA; Gurwitz, JH				Rochon, Paula A.; Gurwitz, Jerry H.			The prescribing cascade revisited	LANCET			English	Editorial Material							CHOLINESTERASE-INHIBITORS; DRUG-THERAPY		[Rochon, Paula A.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B2, Canada; [Rochon, Paula A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Rochon, Paula A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Gurwitz, Jerry H.] Meyers Primary Care Inst, Worcester, MA USA; [Gurwitz, Jerry H.] Univ Massachusetts, Sch Med, Dept Med, Div Geriatr Med, Worcester, MA USA	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University of Toronto; University of Massachusetts System; University of Massachusetts Worcester	Rochon, PA (corresponding author), Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B2, Canada.; Rochon, PA (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Rochon, PA (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.	paula.rochon@wchospital.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151	Canadian Institutes of Health Research; US National Institute on Aging	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We declare no competing interests. PAR holds the Retired Teachers of Ontario/Les enseignantes et enseignants retraites de l'Ontario (RTO/ERO) Chair in Geriatric Medicine at the University of Toronto and receives funding from the Canadian Institutes of Health Research. JHG receives funding from the US National Institute on Aging.	Ball R, 2016, CLIN PHARMACOL THER, V99, P265, DOI 10.1002/cpt.320; Canadian Institute for Health Information, 2013, ADV DRUG REACT REL H; Choosing Wisely Australia, 2016, 5 THINGS CLIN CONS S; Gill SS, 2005, ARCH INTERN MED, V165, P808, DOI 10.1001/archinte.165.7.808; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Greater Manchester Shared Services National Health Service, 2016, POL DEPR TOOLK VERS; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; ROCHON PA, 1995, LANCET, V346, P32, DOI 10.1016/S0140-6736(95)92656-9; Rosenberg J, 2014, J AM GERIATR SOC, V62, P580, DOI 10.1111/jgs.12714; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324	12	101	103	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2017	389	10081					1778	1780		10.1016/S0140-6736(17)31188-1	http://dx.doi.org/10.1016/S0140-6736(17)31188-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET8KW	28495154				2023-01-03	WOS:000400549300007
J	Powell, RA; Schwartz, L; Nouvet, E; Sutton, B; Petrova, M; Marston, J; Munday, D; Radbruch, L				Powell, Richard A.; Schwartz, Lisa; Nouvet, Elysee; Sutton, Brett; Petrova, Mila; Marston, Joan; Munday, Daniel; Radbruch, Lukas			Palliative care in humanitarian crises: always something to offer	LANCET			English	Editorial Material							MASS CASUALTY EVENTS		[Powell, Richard A.] MWAPO Hlth Dev Grp, POB 459-00621,Village Market, Nairobi, Kenya; McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Burnet Inst, Melbourne, Vic, Australia; Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge CB2 1EP, England; Int Consultant, Assagay, South Africa; Int Nepal Fellowship, Palliat Med & Hlth Serv Res, Kathmandu, Nepal; Univ Hosp Bonn, Bonn, Germany; Seliger Gerhard Bonn Rhein Sieg, Malteser Hosp, Ctr Palliat Care, Bonn, Germany	McMaster University; Burnet Institute; University of Cambridge; University of Bonn	Powell, RA (corresponding author), MWAPO Hlth Dev Grp, POB 459-00621,Village Market, Nairobi, Kenya.	richard2powell@yahoo.co.uk		Nouvet, Elysee/0000-0002-1607-3453; Schwartz, Lisa/0000-0002-4959-225X; Petrova, Mila/0000-0001-7351-6815	Elrha Research for Health in Humanitarian Crises (r2hc)	Elrha Research for Health in Humanitarian Crises (r2hc)	LS and EN report grants from Elrha Research for Health in Humanitarian Crises (r2hc). All other authors have no competing interests.	Bhalla MC, 2015, AM J EMERG MED, V33, P1687, DOI 10.1016/j.ajem.2015.08.021; Development Initiatives, 2017, GLOBAL HUMANITARIAN; Dhillon Paul, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211384; Dying Matters Coalition, 2017, FIND YOUR 1 CAMP; Gillis C., 2014, MACLEANS; Goodman, 2015, PALLIAT MED HOSP CAR, V1, P24, DOI [10.17140/PMHCOJ-1-105, DOI 10.17140/PMHCOJ-1-105]; Holt GR, 2008, OTOLARYNG HEAD NECK, V139, P181, DOI 10.1016/j.otohns.2008.04.027; Institute of Medicine, 2009, REP BRIEF GUID EST C; Karunakara U, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001357; Krakauer EL, 2016, LANCET, V388, P444, DOI 10.1016/S0140-6736(16)31133-3; Mackway-Jones K., 2012, MAJOR INCIDENT MED M, V3rd; Marston J, 2015, LANCET, V386, P1940, DOI 10.1016/S0140-6736(15)00825-9; Matzo M, 2009, BIOSECUR BIOTERROR, V7, P199, DOI 10.1089/bsp.2009.0017; The Sphere Project, 2011, SPHER HDB HUM CHART; who, WHO DEF PALL CAR; World Medical Association, 2006, WMA STAT MED ETH EV	16	30	30	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2017	389	10078					1498	1499		10.1016/S0140-6736(17)30978-9	http://dx.doi.org/10.1016/S0140-6736(17)30978-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER7OP	28422014	Green Submitted			2023-01-03	WOS:000399002900007
J	Prathikanti, S; Rivera, R; Cochran, A; Tungol, JG; Fayazmanesh, N; Weinmann, E				Prathikanti, Sudha; Rivera, Renee; Cochran, Ashly; Tungol, Jose Gabriel; Fayazmanesh, Nima; Weinmann, Eva			Treating major depression with yoga: A prospective, randomized, controlled pilot trial	PLOS ONE			English	Article							STAR-ASTERISK-D; REDUCE PRENATAL DEPRESSION; MINI-MENTAL-STATE; COGNITIVE THERAPY; HATHA YOGA; UNITED-STATES; INVENTORY-II; ANTIDEPRESSANT MEDICATION; PSYCHOMETRIC PROPERTIES; SELF-EFFICACY	Background Conventional pharmacotherapies and psychotherapies for major depression are associated with limited adherence to care and relatively low remission rates. Yoga may offer an alternative treatment option, but rigorous studies are few. This randomized controlled trial with blinded outcome assessors examined an 8-week hatha yoga intervention as mono-therapy for mild-to-moderate major depression. Methods Investigators recruited 38 adults in San Francisco meeting criteria for major depression of mild-to-moderate severity, per structured psychiatric interview and scores of 14 +/- 28 on Beck Depression Inventory-II (BDI). At screening, individuals engaged in psychotherapy, antidepressant pharmacotherapy, herbal or nutraceutical mood therapies, or mind-body practices were excluded. Participants were 68% female, with mean age 43.4 years (SD = 14.8, range = 22 +/- 72), and mean BDI score 22.4 (SD = 4.5). Twenty participants were randomized to 90-minute hatha yoga practice groups twice weekly for 8 weeks. Eighteen participants were randomized to 90-minute attention control education groups twice weekly for 8 weeks. Certified yoga instructors delivered both interventions at a university clinic. Primary outcome was depression severity, measured by BDI scores every 2 weeks from baseline to 8 weeks. Secondary outcomes were self-efficacy and self-esteem, measured by scores on the General Self-Efficacy Scale (GSES) and Rosenberg Self-Esteem Scale (RSES) at baseline and at 8 weeks. Results In intent-to-treat analysis, yoga participants exhibited significantly greater 8-week decline in BDI scores than controls (p-value = 0.034). In sub-analyses of participants completing final 8-week measures, yoga participants were more likely to achieve remission, defined per final BDI score <= 9 (p-value = 0.018). Effect size of yoga in reducing BDI scores was large, per Cohen's d = -0.96 [95% CI, -1.81 to -0.12]. Intervention groups did not differ significantly in 8-week change scores for either the GSES or RSES. Conclusion In adults with mild-to-moderate major depression, an 8-week hatha yoga intervention resulted in statistically and clinically significant reductions in depression severity.	[Prathikanti, Sudha] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA; [Rivera, Renee] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA USA; [Cochran, Ashly] Cornell Univ, Dept Psychiat, Weill Cornell Med, New York, NY USA; [Tungol, Jose Gabriel] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Fayazmanesh, Nima] Vet Affairs Long Beach Healthcare Syst, Dept Psychiat, Long Beach, CA USA; [Weinmann, Eva] Svastha Yoga Therapy Program, Fuss Ueber Kopf Yoga Studio, Stuttgart, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Prathikanti, S (corresponding author), Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA.	sudha.prathikanti@gmail.com			Mental Insight Foundation [435299-86871-01]; Pritzker Family Foundation [556501-41743]; Mt. Zion Health Fund [P0035738]	Mental Insight Foundation; Pritzker Family Foundation; Mt. Zion Health Fund	SP obtained 3 grants: 1) Mental Insight Foundation 435299-86871-01, 2) Pritzker Family Foundation 556501-41743, and 3) Mt. Zion Health Fund P0035738. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	aan het Rot M, 2012, CLIN PSYCHOL REV, V32, P510, DOI 10.1016/j.cpr.2012.05.007; Alan Gelenberg, 2010, PRACTICE GUIDELINE T; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Amick HR, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6019; Anderzen-Carlsson A, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.23033; Angst J, 1999, J CLIN PSYCHIAT S, V60, P113; Arnow BA, 2007, J AFFECT DISORDERS, V97, P197, DOI 10.1016/j.jad.2006.06.017; Atkinson C, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI DOI 10.1001/JAMA.2013.13805; Balasubramaniam Meera, 2012, Front Psychiatry, V3, P117, DOI 10.3389/fpsyt.2012.00117; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barth J, 2004, PSYCHOSOM MED, V66, P802, DOI 10.1097/01.psy.0000146332.53619.b2; BECK AT, 1991, AM PSYCHOL, V46, P368, DOI 10.1037/0003-066X.46.4.368; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belisario JSM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000042.pub2; Bentley SM, 2014, MED CLIN N AM, V98, P981, DOI 10.1016/j.mcna.2014.06.013; Bertisch SM, 2009, J PSYCHOSOM RES, V66, P511, DOI 10.1016/j.jpsychores.2008.12.003; Birdee GS, 2008, J GEN INTERN MED, V23, P1653, DOI 10.1007/s11606-008-0735-5; Bonura KB, 2014, J PHYS ACT HEALTH, V11, P1334, DOI 10.1123/jpah.2012-0365; Bos FM, 2015, EUR NEUROPSYCHOPHARM, V25, P1853, DOI 10.1016/j.euroneuro.2015.08.008; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Broota A, 1990, J CLIN STUD; Brown RP, 2005, J ALTERN COMPLEM MED, V11, P189, DOI 10.1089/acm.2005.11.189; Bschor T, 2016, EXPERT REV NEUROTHER, V16, P367, DOI 10.1586/14737175.2016.1155985; Butler LD, 2008, J CLIN PSYCHOL, V64, P806, DOI 10.1002/jclp.20496; Buttner MM, 2015, COMPLEMENT THER CLIN, V21, P94, DOI 10.1016/j.ctcp.2015.03.003; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cabral Patricia, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10r01068; Canadian Agency for Drugs and Technologies in Health, 2015, YOG TREATM POSTTR ST; Casacalenda N, 2002, AM J PSYCHIAT, V159, P1354, DOI 10.1176/appi.ajp.159.8.1354; Celada P, 2004, J PSYCHIATR NEUROSCI, V29, P252; Clarke Tainya C, 2015, Natl Health Stat Report, P1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Connolly KR, 2011, DRUGS, V71, P43, DOI 10.2165/11587620-000000000-00000; Cooper AA, 2015, CLIN PSYCHOL REV, V40, P57, DOI 10.1016/j.cpr.2015.05.001; Cramer H, 2016, AM J PREV MED, V50, P230, DOI 10.1016/j.amepre.2015.07.037; Cramer H, 2015, AM J EPIDEMIOL, V182, P281, DOI 10.1093/aje/kwv071; Cramer H, 2013, DEPRESS ANXIETY, V30, P1068, DOI 10.1002/da.22166; Cramer H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075515; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cuijpers P, 2010, BRIT J PSYCHIAT, V196, P173, DOI 10.1192/bjp.bp.109.066001; da Silva TL, 2009, ASIAN J PSYCHIATR, V2, P6, DOI 10.1016/j.ajp.2008.12.002; Das M, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00062; Davis K, 2015, COMPLEMENT THER CLIN, V21, P166, DOI 10.1016/j.ctcp.2015.06.005; De Maat S, 2006, PSYCHOTHER RES, V16, P562, DOI 10.1080/10503300600756402; de Sousa RT, 2015, CURR NEUROPHARMACOL, V13, P616, DOI 10.2174/1570159X13666150630173522; Deshpande Sudheer, 2009, Int J Yoga, V2, P13, DOI 10.4103/0973-6131.43287; Dhar AK, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00033; Dimidjian S, 2011, ANNU REV CLIN PSYCHO, V7, P1, DOI 10.1146/annurev-clinpsy-032210-104535; Driessen E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137864; Dunlop BW, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-106; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Edlund MJ, 2002, AM J PSYCHIAT, V159, P845, DOI 10.1176/appi.ajp.159.5.845; Ekers D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100100; Ekkekakis P, 2015, MENT HEALTH PHYS ACT, V8, P21, DOI 10.1016/j.mhpa.2014.12.001; Epel E, 2009, ANN NY ACAD SCI, V1172, P34, DOI 10.1111/j.1749-6632.2009.04414.x; Fernandes R, 2005, NAT I MENT HLTH SUMM; Ferreira-Vorkapic C., 2015, EVID-BASED COMPL ALT, V2015, P1; Field T, 2013, J BODYW MOV THER, V17, P397, DOI 10.1016/j.jbmt.2013.03.010; Field T, 2013, COMPLEMENT THER CLIN, V19, P6, DOI 10.1016/j.ctcp.2012.10.001; Field T, 2012, J BODYW MOV THER, V16, P204, DOI 10.1016/j.jbmt.2011.08.002; Fishbein D, 2014, J ALTERN COMPLEM MED, V20, pA21, DOI DOI 10.1089/ACM.2014.5052.ABSTRACT; Flint J, 2015, Psychol Med, V45, P439, DOI 10.1017/S0033291714001421; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Freedland KE, 2015, JAMA INTERN MED, V175, P1773, DOI 10.1001/jamainternmed.2015.5220; Gaynes BN, 2008, CLEV CLIN J MED, V75, P57, DOI 10.3949/ccjm.75.1.57; Gong H, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0393-1; Gonzalez HM, 2010, ARCH GEN PSYCHIAT, V67, P37, DOI 10.1001/archgenpsychiatry.2009.168; Hedden S, 2015, NSDUH SER H, V50; Hillhouse TM, 2015, EXP CLIN PSYCHOPHARM, V23, P1, DOI 10.1037/a0038550; Hofmann M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079809; Holden SC, 2015, BIRTH-ISS PERINAT C, V42, P261, DOI 10.1111/birt.12177; Huynh Nhu N, 2008, Prim Care Companion J Clin Psychiatry, V10, P91; Israel JA, 2010, PHARMACEUTICALS, V3, P2426, DOI 10.3390/ph3082426; Iyengar B. K. S, 1979, LIGHT YOGA YOGA DIPI; Jacobs TL, 2011, PSYCHONEUROENDOCRINO, V36, P664, DOI 10.1016/j.psyneuen.2010.09.010; Jain FA, 2015, PSYCHOSOMATICS, V56, P140, DOI 10.1016/j.psym.2014.10.007; Jain S, 2007, ANN BEHAV MED, V33, P11, DOI 10.1207/s15324796abm3301_2; Janakiramaiah N, 2000, J AFFECT DISORDERS, V57, P255, DOI 10.1016/S0165-0327(99)00079-8; Javnbakht M, 2009, Complement Ther Clin Pract, V15, P102, DOI 10.1016/j.ctcp.2009.01.003; Khan A, 2002, J CLIN PSYCHOPHARM, V22, P40, DOI 10.1097/00004714-200202000-00007; Khin NA, 2011, J CLIN PSYCHIAT, V72, P464, DOI 10.4088/JCP.10m06191; Khumar S, 1993, INDIAN J CLIN PSYCH; Kingston T, 2007, PSYCHOL PSYCHOTHER-T, V80, P193, DOI 10.1348/147608306X116016; Kinser PA, 2014, ARCH PSYCHIAT NURS, V28, P377, DOI 10.1016/j.apnu.2014.08.014; Kinser PA, 2013, ARCH PSYCHIAT NURS, V27, P137, DOI 10.1016/j.apnu.2013.01.003; Kinser PA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/140467; Kinser PA, 2012, EXPLORE-NY, V8, P118, DOI 10.1016/j.explore.2011.12.005; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Kovacic T, 2011, J ALTERN COMPLEM MED, V17, P1157, DOI 10.1089/acm.2010.0653; Krishnamurthy MN, 2007, J GERONTOL NURS, V33, P17, DOI 10.3928/00989134-20070201-05; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lavretsky H, 2013, INT J GERIATR PSYCH, V28, P57, DOI 10.1002/gps.3790; Lee SW, 2004, J GEN INTERN MED, V19, P760, DOI 10.1111/j.1525-1497.2004.30011.x; Lichtman JH, 2014, CIRCULATION, V129, P1350, DOI 10.1161/CIR.0000000000000019; Lin P, 2005, ANN BEHAV MED, V30, P164, DOI 10.1207/s15324796abm3002_9; Luszczynska A, 2005, J PSYCHOL, V139, P439, DOI 10.3200/JRLP.139.5.439-457; MacCoon DG, 2012, BEHAV RES THER, V50, P3, DOI 10.1016/j.brat.2011.10.011; Masand PS, 2003, CLIN THER, V25, P2289, DOI 10.1016/S0149-2918(03)80220-5; McGrath CL, 2014, BIOL PSYCHIAT, V76, P527, DOI 10.1016/j.biopsych.2013.12.005; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; Meijer A, 2011, GEN HOSP PSYCHIAT, V33, P203, DOI 10.1016/j.genhosppsych.2011.02.007; Mitchell J., 2012, PSYCHOLOGY, V3, P782, DOI DOI 10.4236/PSYCH.2012.329118; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Mohr DC, 2006, ANN BEHAV MED, V32, P254, DOI 10.1207/s15324796abm3203_12; Moradveisi L, 2014, J BEHAV THER EXP PSY, V45, P170, DOI 10.1016/j.jbtep.2013.10.003; Moradveisi L, 2013, BRIT J PSYCHIAT, V202, P204, DOI 10.1192/bjp.bp.112.113696; Mota-Pereira J, 2011, J PSYCHIATR RES, V45, P1005, DOI 10.1016/j.jpsychires.2011.02.005; Nagarathna R, 2001, YOGA ANXIETY DEPRESS; Newham JJ, 2014, DEPRESS ANXIETY, V31, P631, DOI 10.1002/da.22268; Olfson M, 2009, PSYCHIAT SERV, V60; ORETZKY S, 2007, DISS ABSTR INT B, V67, P5458; Park M, 2013, GEN HOSP PSYCHIAT, V35, P217, DOI 10.1016/j.genhosppsych.2013.01.006; Parks SE, 2014, MMWR SURVEILL SUMM, V63, P1; Pascoe MC, 2015, J PSYCHIATR RES, V68, P270, DOI 10.1016/j.jpsychires.2015.07.013; Pence BW, 2012, CURR PSYCHIAT REP, V14, P328, DOI 10.1007/s11920-012-0274-y; Phillips ML, 2015, AM J PSYCHIAT, V172, P124, DOI 10.1176/appi.ajp.2014.14010076; Pilkington K, 2005, J AFFECT DISORDERS, V89, P13, DOI 10.1016/j.jad.2005.08.013; Purohit MP, 2013, J CLIN PSYCHIAT, V74, pE520, DOI 10.4088/JCP.12m08246; Quitkin FM, 2005, J CLIN PSYCHIAT, V66, P670, DOI 10.4088/JCP.v66n0601; Ramsey AT, 2016, J TECHNOL HUMAN SERV, V34, P209, DOI 10.1080/15228835.2016.1170649; Reeves GM, 2012, J AFFECT DISORDERS, V138, P123, DOI 10.1016/j.jad.2011.12.003; Rethorst CD, 2013, J PSYCHIATR PRACT, V19, P204, DOI 10.1097/01.pra.0000430504.16952.3e; Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004; Roberson AM, 2015, J CLIN PSYCHIAT; Rohini V., 2000, NIMHANS J, V18, P53; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1515/9781400876136; Ross A, 2010, J ALTERN COMPLEM MED, V16, P3, DOI 10.1089/acm.2009.0044; Rush AJ, 2009, CNS DRUGS, V23, P627, DOI 10.2165/00023210-200923080-00001; Rutherford BR, 2010, CURR PSYCHIATRY REV, V6, P1, DOI 10.2174/157340010790596571; Saper RB, 2004, ALTERN THER HEALTH M, V10, P44; Sarubin N, 2014, J PSYCHIATR RES, V53, P76, DOI 10.1016/j.jpsychires.2014.02.022; Satchidananda Patanjali, 2012, YOGA SUTRAS PATANJAL; Satyapriya M, 2013, COMPLEMENT THER CLIN, V19, P230, DOI 10.1016/j.ctcp.2013.06.003; Schuver KJ, 2016, COMPLEMENT THER MED, V26, P85, DOI 10.1016/j.ctim.2016.03.003; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Scult Matthew, 2015, Adv Mind Body Med, V29, P26; Sethi Jaspal Kaur, 2013, J Educ Health Promot, V2, P55, DOI 10.4103/2277-9531.119043; Shahidi M, 2011, INT J GERIATR PSYCH, V26, P322, DOI 10.1002/gps.2545; Sharf J, 2010, PSYCHOTHERAPY, V47, P637, DOI 10.1037/a0021175; Sharma V K, 2005, Indian J Physiol Pharmacol, V49, P462; Sheehan DV, 2010, J CLIN PSYCHIAT, V71, P313, DOI 10.4088/JCP.09m05305whi; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simon G, 2010, PSYCHIAT SERV, V61; Sinclair SJ, 2010, EVAL HEALTH PROF, V33, P56, DOI 10.1177/0163278709356187; Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479; Steer RA, 2001, PSYCHOL REP, V88, P1075, DOI 10.2466/PR0.88.3.1075-1076; Stewart JG, 2012, J AFFECT DISORDERS, V137, P87, DOI 10.1016/j.jad.2011.12.015; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; Streeter CC, 2012, MED HYPOTHESES, V78, P571, DOI 10.1016/j.mehy.2012.01.021; Stussman Barbara J, 2015, Natl Health Stat Report, P1; Svatmarama S, 1987, HATHAYOGAPRADIPIKA H; Swift JK, 2011, J CLIN PSYCHOL, V67, P155, DOI 10.1002/jclp.20759; Taspinar B, 2014, COMPLEMENT THER MED, V22, P433, DOI 10.1016/j.ctim.2014.03.007; Telles S, 2013, CHILD ADOL PSYCH MEN, V7, DOI 10.1186/1753-2000-7-37; Thase ME, 2003, J CLIN PSYCHIAT, V64, P3; Thase ME, 2007, AM J PSYCHIAT, V164, P739, DOI 10.1176/appi.ajp.164.5.739; Torous J, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.3889; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779; Uebelacker LA, 2015, ARCH WOMENS MENT HLT; Uebelacker LA, 2010, J PSYCHIATR PRACT, V16, P22, DOI 10.1097/01.pra.0000367775.88388.96; Uher R, 2011, J CLIN PSYCHIAT, V72, P1478, DOI 10.4088/JCP.10m06419; Upchurch DM, 2010, J WOMENS HEALTH, V19, P23, DOI 10.1089/jwh.2008.1096; van Aalderen JR, 2012, PSYCHOL MED, V42, P989, DOI 10.1017/S0033291711002054; VEALE D, 1992, J ROY SOC MED, V85, P541; Vedamurthachar A, 2006, J AFFECT DISORDERS, V94, P249, DOI 10.1016/j.jad.2006.04.025; Waelde LC, 2004, J CLIN PSYCHOL, V60, P677, DOI 10.1002/jclp.10259; Wang YP, 2013, REV BRAS PSIQUIATR, V35, P416, DOI 10.1590/1516-4446-2012-1048; Warden D, 2009, J PSYCHIATR PRACT, V15, P113, DOI 10.1097/01.pra.0000348364.88676.83; Wichers M, 2011, ACTA PSYCHIAT SCAND, V124, P262, DOI 10.1111/j.1600-0447.2011.01749.x; WIERZBICKI M, 1993, PROF PSYCHOL-RES PR, V24, P190, DOI 10.1037/0735-7028.24.2.190; Wiles N, 2014, HLTH TECHNOL ASSESS, V18; Wolsko PM, 2004, J GEN INTERN MED, V19, P43, DOI 10.1111/j.1525-1497.2004.21019.x; Woolery A, 2004, ALTERN THER HEALTH M, V10, P60; World Health Organization, 2005, HDB GOOD CLIN RES PR; Zhang XP, 2005, AM J EPIDEMIOL, V161, P652, DOI 10.1093/aje/kwi089	178	59	62	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173869	10.1371/journal.pone.0173869	http://dx.doi.org/10.1371/journal.pone.0173869			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN9KE	28301561	gold, Green Published, Green Submitted			2023-01-03	WOS:000396318300087
J	Bhattarai, A; Pant, ND; Nepal, K; Adhikari, S; Sharma, M; Parajuli, P				Bhattarai, Anupama; Pant, Narayan Dutt; Nepal, Krishus; Adhikari, Sailaja; Sharma, Mukunda; Parajuli, Pramila			Anti Japanese encephalitis virus IgM positivity among patients with acute encephalitic syndrome admitted to different hospitals from all over Nepal	PLOS ONE			English	Article								The Japanese encephalitis virus (JEV) infection is one of the major public health problems in Nepal because of its increasing disease morbidity and mortality. The main purpose of this study was to determine the anti-JEV IgM positivity among acute encephalitis syndromic cases from all over Nepal. The present study was conducted at National Public Health Laboratory, Kathmandu, Nepal from April 2015 to October 2015. A total of 671 (418 CSF and 253 serum) samples were collected from 625 patients with acute encephalitic syndrome, admitted to different hospitals from all over Nepal. IgM antibody capture enzyme linked immunosorbent assay (ELISA) was used for the detection of anti-JEV IgM positive cases. The rate of anti-JEV IgM positivity was found to be 21.12%. The majority of positive cases (50%) were from the age group below 15 years, with the highest numbers of cases occurring in September (55.30%). Among all the anti-JEV IgM positive cases, higher numbers of cases were males. Geographically, the highest numbers of anti-JEV IgM positive cases were recorded from Terai region. Similarly, largest numbers of anti-JEV IgM positive cases were reported from Kailai district followed by those from Kanchanpur. However, anti-JEV IgM positive cases were also reported from hill districts. Continuation of active surveillance and vector control measures, proper management of diagnostic facilities and expanded program of immunization in JE endemic areas should be strongly emphasized to reduce the endemicity of the disease.	[Bhattarai, Anupama; Parajuli, Pramila] St Xaviers Coll, Dept Microbiol, Kathmandu, Nepal; [Pant, Narayan Dutt] Grande Int Hosp, Dept Microbiol, Kathmandu, Nepal; [Nepal, Krishus] GoldenGate Int Coll, Dept Microbiol, Kathmandu, Nepal; [Adhikari, Sailaja; Sharma, Mukunda] Natl Publ Hlth Lab, Kathmandu, Nepal		Pant, ND (corresponding author), Grande Int Hosp, Dept Microbiol, Kathmandu, Nepal.	ndpant1987@gmail.com						[Anonymous], 2010, WEEKLY EPIDEMIOLOGIC; Batchelor Patricia, 2015, Trop Dis Travel Med Vaccines, V1, P11, DOI 10.1186/s40794-015-0013-6; Bista M B, 2005, JNMA J Nepal Med Assoc, V44, P51; Brahma B, 2015, J EVIDENCE BASED MED, V2, P8637; EDCD, 2005, ANN REP 2002 2003; Ghosh D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000437; Halstead SB, 2010, CLIN INFECT DIS, V50, P1155, DOI 10.1086/651271; Kakoti G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/152656; National Immunization Program Reaching Every Child, 2011, COMPR MULT PLAN 2063; Pandey B, 2003, EPIDEMIOL INFECT, V131, P881, DOI 10.1017/S0950268803008835; Pant S. D., 2009, Journal of Nepal Paediatric Society, V29, P35, DOI 10.3126/jnps.v29i1.1600; Partridge J, 2007, AM J TROP MED HYG, V77, P1146, DOI 10.4269/ajtmh.2007.77.1146; Priyanka Srivastava, 2014, Epidemiology: Open Access, V4, P161; Ram ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099999; Tiwari S, 2012, BRAZ J INFECT DIS, V16, P564, DOI 10.1016/j.bjid.2012.10.004	15	2	2	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2017	12	3							e0173434	10.1371/journal.pone.0173434	http://dx.doi.org/10.1371/journal.pone.0173434			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5OE	28264024	Green Submitted, Green Published, gold			2023-01-03	WOS:000396054300065
J	Lee, J; Kim, HH; Ro, SM; Yang, JH				Lee, Jieun; Kim, Hyun Ho; Ro, Sang Mi; Yang, Ji Hyun			Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer	PLOS ONE			English	Article							PLATINUM-BASED CHEMOTHERAPY; CARCINOMA PATIENTS; PLUS CAPECITABINE; PHASE-II; ANTHRACYCLINE; TAXANE; MORTALITY; RESISTANT; DOUBLET	Purpose/Objective(s) After taxane and anthracycline failure, no standard chemotherapy regimen is established in metastatic breast cancer (MBC). Capecitabine and cisplatin (XP) combination shows promising results in gastrointestinal cancer, but there are relatively scarce data in MBC. We reviewed the clinical outcome of XP regimen in anthracycline and taxane resistant, heavily pretreated MBC patients. Materials/Methods Between Jan. 2010 to Feb. 2016, 48 HER2 negative MBC patients who failed anthracycline and taxane based chemotherapy were enrolled. In 43.8% of patients, more than 4 regimens were administrated before XP. Thirty- four patients (70.8%) were hormone receptor (HR) positive MBC. Patients were treated with XP (capecitabine [ 2000mg/m (2) per oral; day 1 -14] plus cisplatin [ 60mg/m (2) IV; day 1], every 3 weeks) regimen. Results Median progression-free survival (PFS) in total population was 4.33 months (range 1.1 similar to 33.57 months). HR positive patients showed trends for superior PFS compared to triple negative breast cancer (TNBC), without statistical significance (6.53 vs. 3.83 months, P = 0.168). In HR positive group, patients receiving 3 or less lines of chemotherapy showed superior PFS compared to others (10.1 vs. 3.0 months, P = 0.039). In multivariate analysis, HR positive patients receiving 3 or less lines of regimens still showed superior PFS (HR = 2.624, 95% CI; 1.071 similar to 6.43, P = 0.032). Most common toxicity was grade 3 - 4 neutropenia, without treatment-related deaths. Conclusions XP combination regimen showed clinical benefit with tolerable toxicity in heavily pretreated patients, including HR positive patients. After anthracycline and taxane failure, early administration of XP regimen in selected patients may have improve clinical outcome in breast cancer.	[Lee, Jieun; Kim, Hyun Ho; Ro, Sang Mi; Yang, Ji Hyun] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea; [Lee, Jieun] Catholic Univ Korea, Canc Res Inst, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea	Lee, J (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea.; Lee, J (corresponding author), Catholic Univ Korea, Canc Res Inst, Seoul, South Korea.	befamiliar@catholic.ac.kr						Andreopoulou E, 2013, CURR BREAST CANCER R, V5, P42, DOI 10.1007/s12609-012-0097-1; Andres Raquel, 2005, Clin Breast Cancer, V6, P158; Cardoso F, 2012, ANN ONCOL, V23, P11, DOI 10.1093/annonc/mds232; Crown JP, 2001, SEMIN ONCOL, V28, P28, DOI 10.1053/sonc.2001.22814; Decatris MP, 2004, CANCER TREAT REV, V30, P53, DOI 10.1016/S0305-7372(03)00139-7; Donadio M, 2005, ONCOLOGY-BASEL, V69, P408, DOI 10.1159/000089995; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ghosn M, 2006, ANTICANCER RES, V26, P2451; Jung KW, 2015, CANCER RES TREAT, V47, P142, DOI 10.4143/crt.2015.066; Li Q, 2015, CANCER BIOL THER, V16, P1746, DOI 10.1080/15384047.2015.1095400; Massacesi C, 2006, ONCOLOGY-BASEL, V70, P294, DOI 10.1159/000096250; Moreno-Aspitia A, 2009, MAYO CLIN PROC, V84, P533, DOI 10.1016/S0025-6196(11)60585-5; National Comprehensive Cancer Network (NCCN), 2020, NCCN CLIN PRACT GUID; Oksuzoglu B, 2008, CHEMOTHERAPY, V54, P352, DOI 10.1159/000151630; Ozdemir N, 2013, J BUON, V18, P831; Ozkan M, 2012, NEOPLASMA, V59, P38, DOI 10.4149/neo_2012_005; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sirohi B, 2008, ANN ONCOL, V19, P1847, DOI 10.1093/annonc/mdn395; SPAETH D, 1993, B CANCER, V80, P351; Staudacher L, 2011, ANN ONCOL, V22, P848, DOI 10.1093/annonc/mdq461; Thomas ES, 2007, J CLIN ONCOL, V25, P5210, DOI 10.1200/JCO.2007.12.6557	21	3	3	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e71605	10.1371/journal.pone.0171605	http://dx.doi.org/10.1371/journal.pone.0171605			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28234911	Green Published, Green Submitted, gold			2023-01-03	WOS:000394688200027
J	Welsch, ME; Kaplan, A; Chambers, JM; Stokes, ME; Bos, PH; Zask, A; Zhang, Y; Sanchez-Martin, M; Badgley, MA; Huang, CS; Tran, TH; Akkiraju, H; Brown, LM; Nandakumar, R; Cremers, S; Yang, WS; Tong, L; Olive, KP; Ferrando, A; Stockwell, BR				Welsch, Matthew E.; Kaplan, Anna; Chambers, Jennifer M.; Stokes, Michael E.; Bos, Pieter H.; Zask, Arie; Zhang, Yan; Sanchez-Martin, Marta; Badgley, Michael A.; Huang, Christine S.; Tran, Timothy H.; Akkiraju, Hemanth; Brown, Lewis M.; Nandakumar, Renu; Cremers, Serge; Yang, Wan Seok; Tong, Liang; Olive, Kenneth P.; Ferrando, Adolfo; Stockwell, Brent R.			Multivalent Small-Molecule Pan-RAS Inhibitors	CELL			English	Article							MEDIATED NUCLEOTIDE EXCHANGE; PROTEIN-PROTEIN INTERACTIONS; K-RAS; STRUCTURAL BASIS; CANCER-THERAPY; TARGETING RAS; CELLS; ACTIVATION; DISCOVERY; ONCOGENES	Design of small molecules that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may provide chemical probes and therapeutic agents. We describe here the synthesis and testing of potential small-molecule pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS. One compound, termed 3144, was found to bind to RAS proteins using microscale thermophoresis, nuclear magnetic resonance spectroscopy, and isothermal titration calorimetry and to exhibit lethality in cells partially dependent on expression of RAS proteins. This compound was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models. These findings suggest that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure-based design of small molecules targeting multiple adjacent sites to create multivalent inhibitors may be effective for some proteins.	[Welsch, Matthew E.; Zhang, Yan; Stockwell, Brent R.] Columbia Univ, Dept Chem, New York, NY 10027 USA; [Kaplan, Anna; Chambers, Jennifer M.; Stokes, Michael E.; Bos, Pieter H.; Zask, Arie; Huang, Christine S.; Tran, Timothy H.; Akkiraju, Hemanth; Brown, Lewis M.; Tong, Liang; Stockwell, Brent R.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Sanchez-Martin, Marta; Ferrando, Adolfo] Columbia Univ, Med Ctr, Inst Canc Genet, New York, NY 10032 USA; [Stokes, Michael E.; Cremers, Serge; Olive, Kenneth P.; Ferrando, Adolfo] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA; [Badgley, Michael A.; Olive, Kenneth P.] Columbia Univ, Dept Med, Med Ctr, Div Digest & Liver Dis, New York, NY 10032 USA; [Akkiraju, Hemanth; Brown, Lewis M.] Columbia Univ, Quantitat Prote & Metabol Ctr, New York, NY 10027 USA; [Nandakumar, Renu; Cremers, Serge] Columbia Univ, Med Ctr, Irving Inst Clin & Translat Res, New York, NY 10032 USA; [Yang, Wan Seok] St Johns Univ, Dept Biol Sci, Queens, NY 11439 USA; [Ferrando, Adolfo] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Saint John's University; Columbia University	Stockwell, BR (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	bstockwell@columbia.edu	Zhang, Yan/AAC-7222-2020; Stockwell, Brent R/AAE-7200-2019	Zhang, Yan/0000-0002-8659-6321; Stockwell, Brent R/0000-0002-3532-3868; Olive, Kenneth/0000-0002-3392-8994; Huang, Christine/0000-0003-4082-3880; Badgley, Michael/0000-0002-2745-696X; Bos, Pieter/0000-0002-8710-4771; Zask, Arie/0000-0002-1991-1328; Tong, Liang/0000-0002-0563-6468	NIH [S10OD012018, 5R01CA097061, 5R01GM085081, R01CA161061, 1S10RR025431-01A1]; NSF [CHE 0840451]; NYSTAR; Training Program in Molecular Biophysics [T32GM008281]; New York State Stem Cell Science Board (NYSTEM) [C029159]; NHMRC CJ Martin Biomedical Fellowship; NATIONAL CANCER INSTITUTE [R01CA161061, R35CA209896, R35CA210065, R01CA097061, R01CA172398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR025431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008281, P41GM111244, R01GM085081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA040582] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD012018] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NYSTAR; Training Program in Molecular Biophysics; New York State Stem Cell Science Board (NYSTEM); NHMRC CJ Martin Biomedical Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Neil Whalen, Stuart Myers, and Howard Robinson for setting up the X29 beamline at the NSLS. The in-house X-ray diffraction instrument was purchased with an NIH grant to L.T. (S10OD012018). This research was supported by grants to BRS (NIH 5R01CA097061, 5R01GM085081, and R01CA161061). We thank John Decatur and the Columbia Chemistry NMR core facility (NSF grant CHE 0840451 and NIH grant 1S10RR025431-01A1) for assistance in compound characterization, Michael Gaschler for providing the RHEB protein used for microscale thermophoresis, and Michael Goger from New York Structural Biology Center (NYSBC) for assistance with 3D-NMR data acquisition. B.R.S. is a member of the New York Structural Biology Center. The data collected at NYSBC was made possible by a grant from NYSTAR. A.K. was supported by the Training Program in Molecular Biophysics T32GM008281. We thank the New York State Stem Cell Science Board (NYSTEM) for support under contract #C029159 (L.M.B.). B.R.S. is a founder, consultant, and shareholder of Kyras Therapeutics, which has licensed intellectual property described in this manuscript; B.R.S. and M.E.W. are recipients of royalty payments from this license. All animal studies were approved by the Columbia University IACUC. J.M.C. was supported by an NHMRC CJ Martin Biomedical Fellowship.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Burns MC, 2014, P NATL ACAD SCI USA, V111, P3401, DOI 10.1073/pnas.1315798111; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Colletti LM, 2008, ANAL BIOCHEM, V383, P186, DOI 10.1016/j.ab.2008.08.012; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hall BE, 2002, P NATL ACAD SCI USA, V99, P12138, DOI 10.1073/pnas.192453199; Hewitt SH, 2016, CHEM COMMUN, V52, P9745, DOI 10.1039/c6cc03457h; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Jahnke W, 2006, FRAGMENT BASED APPRO; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oberstein PE, 2013, THER ADV GASTROENTER, V6, P321, DOI 10.1177/1756283X13478680; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Sastra Stephen A, 2014, Cold Spring Harb Protoc, V2014, P47, DOI 10.1101/pdb.prot077834; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun Q, 2014, J BIOMOL NMR, V60, P11, DOI 10.1007/s10858-014-9849-8; Sun Q, 2012, ANGEW CHEM INT EDIT, V51, P6140, DOI 10.1002/anie.201201358; Tanaka T, 2010, ONCOGENE, V29, P6064, DOI 10.1038/onc.2010.346; Tsutsumi K, 2009, CELL SIGNAL, V21, P1672, DOI 10.1016/j.cellsig.2009.07.004; Urosevic J, 2009, MOL CARCINOGEN, V48, P1038, DOI 10.1002/mc.20555; van Hattum H, 2014, CHEM BIOL, V21, P1185, DOI 10.1016/j.chembiol.2014.08.001; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Vo U, 2013, BIOMOL NMR ASSIGN, V7, P215, DOI 10.1007/s12104-012-9413-y; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Wang WR, 2012, BIOORG MED CHEM LETT, V22, P5766, DOI 10.1016/j.bmcl.2012.07.082; Ward AF, 2012, BLOOD, V120, P3397, DOI 10.1182/blood-2012-05-378596; Weiwer M, 2012, BIOORG MED CHEM LETT, V22, P1822, DOI 10.1016/j.bmcl.2011.09.047; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010	55	149	156	1	72	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	2017	168	5					878	+		10.1016/j.cell.2017.02.006	http://dx.doi.org/10.1016/j.cell.2017.02.006			41	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN8YB	28235199	Green Accepted, Bronze			2023-01-03	WOS:000396284800016
J	Lu, W; Cheng, F; Yan, W; Li, X; Yao, X; Song, W; Liu, M; Shen, X; Jiang, H; Chen, J; Li, J; Huang, J				Lu, W.; Cheng, F.; Yan, W.; Li, X.; Yao, X.; Song, W.; Liu, M.; Shen, X.; Jiang, H.; Chen, J.; Li, J.; Huang, J.			Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA	ONCOGENE			English	Article							CYCLOPHILIN-A; ACQUIRED-RESISTANCE; ISOMERASE ACTIVITY; COMPLEX PROMOTES; CYCLOSPORINE-A; MUTANT P53; CISPLATIN; BINDING; SUPPRESSION; ACTIVATION	TP53 plays essential roles in tumor initiation and progression, and is frequently mutated in cancer. However, pharmacological stabilization and reactivation of p53 have not been actively explored for targeted cancer therapies. Herein, we identify a novel Cyclophilin A (CypA) small molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and apoptosis via restoring p53 expression. We find that HL001 stabilizes p53 through inhibiting the MDM2-mediated p53 ubiquitination. Further mechanistic studies reveal that the downregulation of G3BP1 and the induction of reactive oxygen species and DNA damage by HL001 contribute to p53 stabilization. Surprisingly, HL001 selectively suppresses tumor growth in p53 wildtype NSCLC harboring Arg72 homozygous alleles (p53-72R) through disrupting interaction between MDM2 and p53-72R in a CypA-dependent manner. Moreover, combining HL001 with cisplatin synergistically enhance tumor regression in orthotopic NSCLC mouse model. Collectively, this study demonstrates that pharmacologic inhibition of CypA offers a potential therapeutic strategy via specific activation of p53-72R in NSCLC.	[Lu, W.; Yan, W.; Li, X.; Yao, X.; Shen, X.; Jiang, H.; Li, J.; Huang, J.] East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Sch Life Sci, Shanghai, Peoples R China; [Cheng, F.] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Cheng, F.] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China; [Song, W.; Chen, J.] Vanderbilt Univ, Sch Med, Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Shen, X.; Jiang, H.] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai, Peoples R China; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Cheng, F.] Harvard Med Sch, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA USA; [Cheng, F.] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA	East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; Sichuan University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northeastern University	Li, J; Huang, J (corresponding author), East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China.	jianli@ecust.edu.cn; huangjin@ecust.edu.cn		Chen, Jin/0000-0002-5557-2079; XUE, YAO/0000-0002-1806-7372; Cheng, Feixiong/0000-0002-1736-2847; huang, jin/0000-0002-0698-1693	National Natural Science Foundation of China [21222211, 31371485, 81402482, 91313303, 81573020]; CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology [14ZR1411100, 15431902000]; China Postdoctoral Science Foundation [2014M551361, 2015T80415]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We are grateful to Mr Lianbiao Cheng, Miss Jiaqian Pu and Miss Ningning Dong (all from Jin Huang lab) for material and intellectual help with the design and execution of some of these experiments. The authors thank Professor Jose M Cuezva (Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid, Madrid, Spain) for providing G3BP1 plasmid; Professor Xiangshi Tan (Department of Chemistry, Fudan University, Shanghai, China) for providing the pMAL-c2x-derived MBPHT-Cherry2 vector; Professor Yi Yang (Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China) for providing H23, H838, H1703 and H2126 lung cancer cell lines. The work is supported by the National Natural Science Foundation of China (21222211, 31371485, 81402482, 91313303 and 81573020), CAS Key Laboratory of Receptor Research, the Shanghai Committee of Science and Technology (14ZR1411100 and 15431902000), China Postdoctoral Science Foundation Grant (2014M551361 and 2015T80415).	Abraham S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8286; Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123; Bai JPF, 2013, ANNU REV PHARMACOL, V53, P451, DOI 10.1146/annurev-pharmtox-011112-140248; Baum N, 2009, ONCOGENE, V28, P3915, DOI 10.1038/onc.2009.248; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Bonfils C, 2010, BIOCHEM BIOPH RES CO, V393, P325, DOI 10.1016/j.bbrc.2010.01.135; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cheng FX, 2017, TRENDS IMMUNOL, V38, P77, DOI 10.1016/j.it.2016.11.007; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Choudhury R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4078; Cohen P, 2013, ACS CHEM BIOL, V8, P96, DOI 10.1021/cb300610s; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Hamilton G, 2014, CURR CANCER DRUG TAR, V14, P46, DOI 10.2174/15680096113136660109; Hong F, 2002, FASEB J, V16, P1633, DOI 10.1096/fj.02-0060fje; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Klein DK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6800; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; MUTCH DG, 1992, GYNECOL ONCOL, V47, P28, DOI 10.1016/0090-8258(92)90070-Y; Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Puente XS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-15; Rajagopalan S, 2009, J BIOL CHEM, V284, P21728, DOI 10.1074/jbc.M109.006429; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang HR, 2007, BIOCHEM BIOPH RES CO, V361, P763, DOI 10.1016/j.bbrc.2007.07.085; Zhu D, 2015, NAT MED, V21, P572, DOI 10.1038/nm.3867; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	44	13	13	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4719	4731		10.1038/onc.2017.41	http://dx.doi.org/10.1038/onc.2017.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394340	Green Published, hybrid			2023-01-03	WOS:000407702400005
J	Huang, L; Wang, Z; Liu, C; Xu, C; Mbofung, RM; McKenzie, JA; Khong, H; Hwu, P; Peng, W				Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.			CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner	ONCOGENE			English	Article							PLASMACYTOID DENDRITIC CELLS; COMBINING TARGETED THERAPY; METASTATIC MELANOMA; IMMUNE-RESPONSES; VACCINE ADJUVANT; CANCER VACCINES; T-CELLS; TUMOR; ANTIGEN; DNA	Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumors with BRAF mutation rather than showing a synergistic antitumor effect. Our further studies demonstrated that CpG alone was sufficient to dampen BRAF inhibitor-induced antitumor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mice receiving CpG-based peptide vaccine is mainly dependent upon the use of CpG. Mechanistically, CpG increased the number of circulating B cells, which produced elevated amounts of tumor necrosis factor-alpha (TNF alpha) that contributed to the increased tumor resistance to BRAF inhibitors. More importantly, B-cell depletion or TNF alpha neutralization can restore the antitumor effect of BRAF inhibition in mice receiving CpG treatment, indicating that TNF alpha-secreting B cells play an indispensable role in BRAF inhibitor resistance induced by CpG. Taken together, our results strongly suggest that precautions must be implemented when designing combinatorial approaches for cancer treatment, because distinct regimens, despite their respective therapeutic benefit as monotherapy, may together provide antagonistic clinical outcomes.	[Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Peng, W (corresponding author), Univ Texas MD Anderson Canc Ctr, 7455 Fannin St Unit 904, Houston, TX 77054 USA.; Hwu, P (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	phwu@mdanderson.org; wpeng@mdanderson.org	Huang, Lu/I-4148-2018	Mbofung, Rina/0000-0003-3872-3143; Khong, Hiep/0000-0003-4888-7862	National Cancer Institute [R01CA116206, P01CA128913, R01CA187076, P50CA093459, P30CA016672]; NATIONAL CANCER INSTITUTE [R01CA116206, R01CA187076, P30CA016672, P50CA093459, P01CA128913] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hussein Tawbi for constructive comments on the manuscript. The research was supported in part by the following National Cancer Institute grants: R01CA116206 (to PH), P01CA128913 (to PH), R01CA187076 (to PH and MD), P50CA093459 and P30CA016672 (MDACC Melanoma SPORE and MDACC CCSG for JAM and Flow facility, respectively). By the Cancer Prevention and Research Institute of Texas (CPRIT RP140106 to JAM) and by philanthropic contributions to MDACC Melanoma Moon Shot Program; Melanoma Research Alliance Team Science Award; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Aim at Melanoma Foundation, Miriam and Jim Mulva research funds; Jurgen Sager & Transocean Melanoma Research Fund; El Paso Foundation for Melanoma Research; GillsonLogenbaugh Foundation. We thank Cherie Butts from Biogen for providing antimouse CD20 antibody.	Avalos AM, 2009, J IMMUNOL, V183, P6262, DOI 10.4049/jimmunol.0901941; Bauer S, 2002, CURR TOP MICROBIOL, V270, P145; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]; Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davila E, 2003, CANCER RES, V63, P3281; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105; Hanten JA, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-39; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Hu-Lieskovan S, 2014, J CLIN ONCOL, V32, P2248, DOI 10.1200/JCO.2013.52.1377; Jerome V, 2006, J IMMUNOTHER, V29, P294; Kim S, 2008, J IMMUNOTHER, V31, P446, DOI 10.1097/CJI.0b013e31816d1d6a; Kim Teresa, 2014, Cancer Biology Medicine, V11, P237, DOI 10.7497/j.issn.2095-3941.2014.04.002; Koya RC, 2012, CANCER RES, V72, P3928, DOI 10.1158/0008-5472.CAN-11-2837; Liu CW, 2008, J CLIN INVEST, V118, P1165, DOI 10.1172/JCI33583; Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626; Lou YY, 2011, J IMMUNOTHER, V34, P279, DOI 10.1097/CJI.0b013e31820d2a05; Mehta NK, 2015, CANCER IMMUNOL RES, V3, P836, DOI 10.1158/2326-6066.CIR-15-0112; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; Menon Dinoop R, 2013, Pigment Cell Melanoma Res, V26, P912, DOI 10.1111/pcmr.12139; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Peng WY, 2010, CLIN CANCER RES, V16, P5458, DOI 10.1158/1078-0432.CCR-10-0712; Perricone MA, 2004, J IMMUNOTHER, V27, P273, DOI 10.1097/00002371-200407000-00003; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Shirota H, 2015, VACCINES-BASEL, V3, P390, DOI 10.3390/vaccines3020390; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Smith MP, 2014, CANCER DISCOV, V4, P1214, DOI 10.1158/2159-8290.CD-13-1007; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tadmor T, 2011, CANCER IMMUNOL IMMUN, V60, P609, DOI 10.1007/s00262-011-0972-z; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833	35	7	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4081	4086		10.1038/onc.2017.35	http://dx.doi.org/10.1038/onc.2017.35			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28263973	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000405379900013
J	Kitterer, D; Biegger, D; Segerer, S; Braun, N; Alscher, MD; Latus, J				Kitterer, Daniel; Biegger, Dagmar; Segerer, Stephan; Braun, Niko; Alscher, M. Dominik; Latus, Joerg			Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis	PLOS ONE			English	Article							SOLUTE TRANSPORT; MESOTHELIAL CELLS; ULTRAFILTRATION FAILURE; INTERLEUKIN-6 SYSTEM; WATER PERMEABILITY; ENDOTHELIAL-CELLS; GENE-EXPRESSION; NUCLEAR-FACTOR; CAPD PATIENTS; ACTIVATION	Introduction A growing body of evidence from animal models and cell culture studies indicate an important role of a local regulatory complement system (CS) in peritoneal injury during peritoneal dialysis (PD). We investigated the expression of the local regulatory CS (reflected by CD46, CD55, CD59) in the peritoneal tissue of patients with different membrane function characteristics. Patients and methods Biopsies from the parietal peritoneum were taken from 24 patients on PD, 22 uremic patients prior to PD. PD patients were grouped according to the dialysate-to-plasma ratio of creatinine (D/P Cre) and ratio of dialysate glucose at 4 hours versus dialysate glucose at time zero (D/D0 glucose) into low or low-average peritoneal transport status (L/LA) and high-average or high-transport status (HA/H) groups. CD46, CD55, and CD59 RNA expression were analyzed by real-time polymerase chain reaction (RT-PCR). Further localization of membrane complement regulators (CRegs) and semiquantitatively analysis was done by immunohistochemistry (IHC). Results CD46 and CD59 expression were similar in all groups. CD55 expression was significantly decreased in the HA/H group compared to the L/LA group and to uremic controls (p < 0.05 and p = 0.05, respectively). No statistically significant differences in CD46, CD55, and CD55 expression were detected when considering the history of peritonitis. There was no statistically significant correlation between PD duration and the expressions of CD46, CD55, and CD59. IHC revealed strong CD46, CD55, and CD59 expression in mesothelial cells. CD55 and CD59 were additionally detected in the vasculature. Using IHC, CD46 was lower in PD patients compared to uremic controls (p> 0.05), but there was no difference between the L/LA compared to the H/HA group. Moreover IHC confirmed decreased expression of CD55 in the HA/H group compared to the L/LA group and uremic controls (p<0.0001 and p = 0.0001, respectively). Conclusion CD55 expression is decreased in patients with fast transporter membrane function, whereas peritonitis and PD duration do not appear to alter CReg expression.	[Kitterer, Daniel; Alscher, M. Dominik; Latus, Joerg] Robert Bosch Krankenhaus, Div Nephrol, Dept Internal Med, Stuttgart, Germany; [Biegger, Dagmar] Univ Tubingen, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany; [Segerer, Stephan] Kantonsspital Aarau, Div Nephrol Dialysis & Transplantat, Aarau, Switzerland; [Braun, Niko] Nephrol Ctr Stuttgart, Stuttgart, Germany	Bosch; Robert Bosch Krankenhaus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Kantonsspital Aarau AG (KSA)	Kitterer, D (corresponding author), Robert Bosch Krankenhaus, Div Nephrol, Dept Internal Med, Stuttgart, Germany.	Daniel.kitterer@gmail.com			Else Kroner-Fresenius Stiftung; Fundacao Pesquisa e Desenvolvimento Humanitario; Robert Bosch Foundation	Else Kroner-Fresenius Stiftung; Fundacao Pesquisa e Desenvolvimento Humanitario; Robert Bosch Foundation	This work was supported by Else Kroner-Fresenius Stiftung, Fundacao Pesquisa e Desenvolvimento Humanitario, Robert Bosch Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbano G, 1999, ADV PERIT D, V15, P253; Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Braun N, 2011, NEPHROL DIAL TRANSPL, V26, P1033, DOI 10.1093/ndt/gfq488; Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Combet S, 2000, J AM SOC NEPHROL, V11, P717, DOI 10.1681/ASN.V114717; Cueto-Manzano AM, 2009, PERITON DIALYSIS INT, V29, pS90; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; Davies SJ, 1996, NEPHROL DIAL TRANSPL, V11, P498; Devuyst O, 2013, KIDNEY INT; Diaz-Buxo JA, 1999, ADV PERIT D, V15, P96; DIMITRIADIS A, 1990, ADV PERIT D, V6, P155; Flessner MF, 2007, J AM SOC NEPHROL, V18, P2294, DOI 10.1681/ASN.2006121417; Hasler U, 2011, CELL CYCLE, V10, P364, DOI 10.4161/cc.10.3.14520; HEIMBURGER O, 1990, KIDNEY INT, V38, P495, DOI 10.1038/ki.1990.231; Higuchi C, 2006, THER APHER DIAL, V10, P372, DOI 10.1111/j.1744-9987.2006.00391.x; Honda K, 1996, NEPHRON, V72, P171, DOI 10.1159/000188837; Honda K, 2008, CLIN J AM SOC NEPHRO, V3, P720, DOI 10.2215/CJN.03630807; Johnson DW, 2004, PERITON DIALYSIS INT, V24, P460; Kinashi H, 2013, J AM SOC NEPHROL, V24, P1627, DOI 10.1681/ASN.2012030226; Kitterer D, 2015, AM J PHYSIOL-RENAL, V308, pF1247, DOI 10.1152/ajprenal.00617.2014; Krediet RT, 2013, NAT REV NEPHROL, V9, P419, DOI 10.1038/nrneph.2013.99; Kuper C, 2012, CRIT CARE MED, V40, P1887, DOI 10.1097/CCM.0b013e31824e1186; Lambie M, 2013, J AM SOC NEPHROL, V24, P2071, DOI 10.1681/ASN.2013030314; Lanaspa MA, 2010, J BIOL CHEM, V285, P31694, DOI 10.1074/jbc.M109.093690; Mizuno M, 2012, AM J PHYSIOL-RENAL, V302, pF1245, DOI 10.1152/ajprenal.00652.2011; Mizuno M, 2009, J IMMUNOL, V183, P1403, DOI 10.4049/jimmunol.0804245; Mizuno T, 2013, AM J PHYSIOL-RENAL, V305, pF1603, DOI 10.1152/ajprenal.00681.2012; Mizuno T, 2011, NEPHROL DIAL TRANSPL, V26, P1821, DOI 10.1093/ndt/gfq683; Morelle J, 2016, PERITON DIALYSIS INT, V36, P227, DOI 10.3747/pdi.2015.00188; Neusser MA, 2010, KIDNEY INT, V77, P801, DOI 10.1038/ki.2010.6; Ni J, 2006, KIDNEY INT, V69, P1518, DOI 10.1038/sj.ki.5000285; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Numata M, 2003, PERITON DIALYSIS INT, V23, P116; Oh KH, 2010, NEPHROL DIAL TRANSPL, V25, P1639, DOI 10.1093/ndt/gfp670; Okada M, 1998, ARTERIOSCL THROM VAS, V18, P894, DOI 10.1161/01.ATV.18.6.894; Parikova A, 2006, KIDNEY INT, V70, P1988, DOI 10.1038/sj.ki.5001861; Pecoits R, 2006, PERITON DIALYSIS INT, V26, P53; REDDINGIUS RE, 1995, PERITON DIALYSIS INT, V15, P49; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rumpsfeld M, 2006, J AM SOC NEPHROL, V17, P271, DOI 10.1681/ASN.2005050566; Sei Y, 2015, MOL IMMUNOL, V65, P302, DOI 10.1016/j.molimm.2015.02.005; STRUIJK DG, 1994, KIDNEY INT, V45, P1739, DOI 10.1038/ki.1994.226; Tang S, 2004, CLIN EXP IMMUNOL, V136, P85, DOI 10.1111/j.1365-2249.2004.02407.x; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; VERGER C, 1983, KIDNEY INT, V23, P823, DOI 10.1038/ki.1983.101; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yang BX, 1999, AM J PHYSIOL-CELL PH, V276, pC76, DOI 10.1152/ajpcell.1999.276.1.C76; Yool AJ, 2013, J AM SOC NEPHROL, V24, P1045, DOI 10.1681/ASN.2012080869; YOUNG GA, 1993, NEPHROL DIAL TRANSPL, V8, P1372; Yu ZZ, 2014, CLIN J AM SOC NEPHRO, V9, P326, DOI 10.2215/CJN.04420413; Zhai YH, 2012, PEDIATR NEPHROL, V27, P1165, DOI 10.1007/s00467-012-2120-1; Zhang W, 2016, MATH PROBL ENG, V2016, P1, DOI DOI 10.7554/ELIFE.11324	55	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2017	12	5							e0177487	10.1371/journal.pone.0177487	http://dx.doi.org/10.1371/journal.pone.0177487			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV3PW	28542228	Green Published, Green Submitted, gold			2023-01-03	WOS:000401672600011
J	Marini, M; Bendinelli, B; Assedi, M; Occhini, D; Castaldo, M; Fabiano, J; Petranelli, M; Migliolo, M; Monaci, M; Masala, G				Marini, Mirca; Bendinelli, Benedetta; Assedi, Melania; Occhini, Daniela; Castaldo, Maria; Fabiano, Jacopo; Petranelli, Marco; Migliolo, Mario; Monaci, Marco; Masala, Giovanna			Low back pain in healthy postmenopausal women and the effect of physical activity: A secondary analysis in a randomized trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; PRIMARY-CARE; RISK-FACTORS; EPIDEMIOLOGY; PREVALENCE; MUSCULOSKELETAL; EXERCISE; POPULATION; ADULTS; INTERVENTION	Epidemiological studies on the prevalence of musculoskeletal pain have consistently shown that this is a relevant health problem, with non-specific low back pain (LBP) being the most commonly reported in adult females. Conflicting data on the association between LBP symptoms and physical activity (PA) have been reported. Here, we investigated the prevalence of LBP and the effect of a 24-month non-specific PA intervention on changes in LBP prevalence in a series of Italian healthy postmenopausal women. We performed a secondary analysis in the frame of the DAMA trial, a factorial randomized intervention trial aimed to evaluate the ability of a 24-month intervention, based on moderate-intensity PA, and/or dietary modification, in reducing mammographic breast density in healthy postmenopausal women. The PA intervention included at least 1 hour/day of moderate PA and a more strenuous weekly activity, collective walks and theoretical group sessions. A self-administered pain questionnaire was administered at baseline and at the end of the intervention. The questionnaire was specifically structured to investigate the occurrence of musculoskeletal pain, the body localization, intensity and duration of the pain. Two hundred and ten women (102 randomized to PA intervention, 108 not receiving the PA intervention) filled out the questionnaires. At baseline LBP was present in 32.9% of the participants. Among women randomized to the PA intervention, LBP prevalence at follow up (21.6%) was lower than at baseline (33.3%) (p = 0.02), while in women who did not receive the PA intervention the LBP prevalence at baseline and follow up were 32.4% and 25.9%, respectively (p = 0.30). Overall, there was no significant between-group effect of PA intervention on LBP. Further studies are needed to understand the role of non-specific PA intervention, aimed to improve overall fitness, on LBP prevalence.	[Marini, Mirca; Fabiano, Jacopo; Monaci, Marco] Univ Florence, Sect Anat & Histol, Dept Expt & Clin Med, Florence, Italy; [Bendinelli, Benedetta; Assedi, Melania; Occhini, Daniela; Castaldo, Maria; Masala, Giovanna] Canc Res & Prevent Inst ISPO, Canc Risk Factors & Lifestyle Epidemiol, Florence, Italy; [Petranelli, Marco] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Migliolo, Mario] Florentine Sports Med Assoc FMSI CONI, Florence, Italy	University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence	Marini, M (corresponding author), Univ Florence, Sect Anat & Histol, Dept Expt & Clin Med, Florence, Italy.	mirca.marini@unifi.it	Masala, Giovanna/AAC-5474-2022	Masala, Giovanna/0000-0002-5758-9069; Bendinelli, Benedetta/0000-0002-4796-1517	Cancer Institute of Tuscany (ITT); Italian Ministry of Health (Programma Integrato Oncologia)	Cancer Institute of Tuscany (ITT); Italian Ministry of Health (Programma Integrato Oncologia)	The DAMA trial was funded by the Cancer Institute of Tuscany (ITT) and the Italian Ministry of Health (Programma Integrato Oncologia 2006).	Bachmann S, 2013, THER UMSCH, V70, P543, DOI 10.1024/0040-5930/a000444; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Bener A, 2014, ASIAN SPINE J, V8, P227, DOI 10.4184/asj.2014.8.3.227; Bingefors K, 2004, EUR J PAIN, V8, P435, DOI 10.1016/j.ejpain.2004.01.005; Bjorck-van Dijken C, 2008, J REHABIL MED, V40, P864, DOI 10.2340/16501977-0273; Bonezzi C, 2002, Minerva Anestesiol, V68, P607; Edmond SL, 2000, J RHEUMATOL, V27, P220; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gomes JL, 2015, EUR SPINE J, V24, P452, DOI 10.1007/s00586-015-3763-y; Gong GL, 2013, J CLIN NURS, V22, P1857, DOI 10.1111/jocn.12134; Gourmelen J., 2007, Annales de Readaptation et de Medecine Physique, V50, P640, DOI 10.1016/j.annrmp.2007.05.009; Grossschadl F, 2016, EUR J PUBLIC HEALTH, V26, P248, DOI 10.1093/eurpub/ckv163; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hendrick P, 2011, EUR SPINE J, V20, P464, DOI 10.1007/s00586-010-1616-2; Heneweer H, 2011, EUR SPINE J, V20, P826, DOI 10.1007/s00586-010-1680-7; Heneweer H, 2009, PAIN, V143, P21, DOI 10.1016/j.pain.2008.12.033; Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002; Hoy D, 2012, ARTHRITIS RHEUM-US, V64, P2028, DOI 10.1002/art.34347; Hussain SM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003963; Izzo R, 2015, EUR J RADIOL, V84, P746, DOI 10.1016/j.ejrad.2015.01.018; Jang JH, 2015, J PHYS THER SCI, V27, P725, DOI 10.1589/jpts.27.725; Juniper M, 2009, EXPERT OPIN PHARMACO, V10, P2581, DOI 10.1517/14656560903304063; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000335.PUB2; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000963.pub3; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Krismer M, 2007, BEST PRACT RES CL RH, V21, P77, DOI 10.1016/j.berh.2006.08.004; Lizier DT, 2012, REV BRAS ANESTESIOL, V62, P838, DOI 10.1590/S0034-70942012000600008; Manchikanti L, 2014, NEUROMODULATION, V17, P3, DOI 10.1111/ner.12018; Masala G, 2014, TUMORI J, V100, P377, DOI 10.1700/1636.17890; Masiero S, 2010, ACTA PAEDIATR, V99, P1224, DOI 10.1111/j.1651-2227.2010.01770.x; Murphy S, 2014, IRISH J MED SCI, V183, P341, DOI 10.1007/s11845-013-1013-z; Notarnicola A, 2014, EUR J PHYS REHAB MED, V50, P59; Palli D, 2003, TUMORI, V89, P586, DOI 10.1177/030089160308900602; Ramond-Roquin A, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00073; Ribaud A., 2013, Annals of Physical and Rehabilitation Medicine, V56, P576, DOI 10.1016/j.rehab.2013.08.007; Saner J, 2015, MANUAL THER, V20, P672, DOI 10.1016/j.math.2015.02.005; Santos-Eggimann B, 2000, SPINE, V25, P2473, DOI 10.1097/00007632-200010010-00009; Schaller A, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0527-0; Steffens D, 2016, JAMA INTERN MED, V176, P199, DOI 10.1001/jamainternmed.2015.7431; Taylor JB, 2014, SPINE J, V14, P2299, DOI 10.1016/j.spinee.2014.01.026; van Middelkoop M, 2010, BEST PRACT RES CL RH, V24, P193, DOI 10.1016/j.berh.2010.01.002; van Tulder M, 2002, BEST PRACT RES CL RH, V16, P761, DOI 10.1053/berh.2002.0267; Waxman R, 2000, SPINE, V25, P2085, DOI 10.1097/00007632-200008150-00013; Wijnhoven HAH, 2006, CLIN J PAIN, V22, P717, DOI 10.1097/01.ajp.0000210912.95664.53; Zelman DC, 2005, J PAIN SYMPTOM MANAG, V29, P401, DOI 10.1016/j.jpainsymman.2004.06.018	45	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2017	12	5							e0177370	10.1371/journal.pone.0177370	http://dx.doi.org/10.1371/journal.pone.0177370			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UN	28489877	Green Submitted, gold, Green Published			2023-01-03	WOS:000401314100068
J	Zeng, Y; Feng, QS; Hesketh, T; Christensen, K; Vaupel, JW				Zeng, Yi; Feng, Qiushi; Hesketh, Therese; Christensen, Kaare; Vaupel, James W.			Survival, disabilities in activities of daily living, and physical and cognitive functioning among the oldest-old in China: a cohort study	LANCET			English	Article							ELDERLY POPULATION; HEALTH; TRENDS; DEMENTIA; MORTALITY; AGES; PREVALENCE; MORBIDITY; ADULTS; RATES	Background The oldest-old (those aged >= 80 years) are the most rapidly growing age group globally, and are most in need of health care and assistance. We aimed to assess changes in mortality, disability in activities of daily living, and physical and cognitive functioning among oldest-old individuals between 1998 and 2008. Methods We used data from the Chinese Longitudinal Healthy Longevity Study. Three pairs of cohorts aged 80-89 years, 90-99 years, and 100-105 years (in total, 19 528 oldest-old participants) were examined; the two cohorts in each pair were born 10 years apart, with the same age at the time of the assessment in the 1998 and 2008 surveys. Four health outcomes were investigated: annual death rate, Activities of Daily Living (ADL), physical performance in three tests and cognitive function measured by Mini-Mental State Examination (MMSE). We used different tests and multivariate regression analyses to examine the cohort differences. Findings Controlling for various confounding factors, we noted that annual mortality among oldest-old individuals was substantially reduced between 0.2% and 1.3% in 1998-2008 compared with individuals of the same age born 10 years previously, and that disability according to activities of daily living had significantly reduced annually between 0.8% and 2.8%. However, cognitive impairment in the later cohorts increased annually between 0.7% and 2.2% and objective physical performance capacity (standing up from a chair, picking up a book from the floor, and turning around 360 degrees) decreased anually between 0.4% and 3.8%. We also noted that female mortality was substantially lower than male mortality among the oldest-old, but that women's functional capacities in activities of daily living, cognition, and physical performance were worse than their male counterparts. Interpretation Advances in medications, lifestyle, and socioeconomics might compress activities of daily living disability, that is, benefits of success, but lifespan extension might expand disability of physical and cognitive functioning as more frail, elderly individuals survive with health problems, that is, costs of success.	[Zeng, Yi] Duke Univ, Ctr Study Aging & Human Dev, Med Sch, Durham, NC 27708 USA; [Zeng, Yi] Peking Univ, Raissun Inst Adv Studies, Natl Sch Dev, Hlth Aging & Dev Studies, Beijing, Peoples R China; [Feng, Qiushi] Natl Univ Singapore, Ctr Family & Populat Res, Dept Sociol, Singapore, Singapore; [Hesketh, Therese] UCL, Inst Global Hlth, London, England; [Hesketh, Therese] Zhejiang Univ, Sch Publ Hlth, Inst Global Hlth, Hangzhou, Zhejiang, Peoples R China; [Christensen, Kaare] Univ Southern Denmark, Inst Publ Hlth, Unit Epidemiol Biostat & Biodemog, Danish Aging Res Ctr, Odense, Denmark; [Vaupel, James W.] Max Planck Inst Demog Res, Rostock, Germany	Duke University; Peking University; National University of Singapore; University of London; University College London; Zhejiang University; University of Southern Denmark; Max Planck Society	Zeng, Y (corresponding author), Duke Univ, Ctr Study Aging & Human Dev, Med Sch, Durham, NC 27708 USA.	zengyi@nsd.pku.edu.cn	Christensen, Kaare/C-2360-2009; Feng, Qiushi/A-7483-2012	Christensen, Kaare/0000-0002-5429-5292; Feng, Qiushi/0000-0002-3572-4442; Vaupel, James/0000-0003-0783-3905; Hesketh, Therese/0000-0002-7564-9221	National Natural Science Foundation of China; National Institute on Aging/National Institutes of Health; United Nations Funds for Population Activities; National Natural Science Foundation of China [71110107025, 71233001, 71490732]; National Institute on Aging/National Institutes of Health [R01AG023627-10, 2P01AG031719]; NATIONAL INSTITUTE ON AGING [P30AG034424, P01AG031719, R01AG023627] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institute on Aging/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); United Nations Funds for Population Activities; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institute on Aging/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Natural Science Foundation of China, National Institute on Aging/National Institutes of Health, United Nations Funds for Population Activities.; We thank Xiaomin Shi, Zhaoxue Yin, Jieshi Luo, and Yuebin Lv (China Center for Diseases Control and Prevention), Yuzhi Liu, Chunyuan Zhang, Yun Zhou, and Zhenzhen Zheng (Peking University), Zhenyu Xiao, Liqun Tao, Qin Xu, and Ye Yuan (Chinese Center for Aging Science Research), and Jie Zhan (China Social Science Academy) for their contributions to the Chinese Longitudinal Healthy Longevity Survey (CLHLS), and we thank all interviewees and their families for their voluntary participation in the CLHLS study. We are very grateful for comments provided by Danan Gu and research assistance provided by Huashuai Chen and Muqi Guo. This study was funded by the National Natural Science Foundation of China (71110107025, 71233001, 71490732), National Institute on Aging/National Institutes of Health (R01AG023627-10; 2P01AG031719), and United Nations Funds for Population Activities.	Chan KY, 2013, LANCET, V381, P2016, DOI 10.1016/S0140-6736(13)60221-4; Christensen K, 2013, LANCET, V382, P1507, DOI 10.1016/S0140-6736(13)60777-1; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; COALE AJ, 1991, DEMOGRAPHY, V28, P293, DOI 10.2307/2061281; Dodge Hiroko H, 2012, Int J Alzheimers Dis, V2012, P956354, DOI 10.1155/2012/956354; Engberg H, 2013, AGING CLIN EXP RES, V25, P517, DOI 10.1007/s40520-013-0122-x; Feng QS, 2010, J AM GERIATR SOC, V58, P1952, DOI 10.1111/j.1532-5415.2010.03013.x; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; Huang W, 2013, SOC SCI MED, V98, P54, DOI 10.1016/j.socscimed.2013.08.021; Liang YJ, 2015, J GERONTOL A-BIOL, V70, P739, DOI 10.1093/gerona/glu204; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; Martin LG, 2014, POPUL DEV REV, V40, P475, DOI 10.1111/j.1728-4457.2014.00694.x; Matthews FE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11398; Parker MG, 2007, GERONTOLOGIST, V47, P150, DOI 10.1093/geront/47.2.150; Parker MG, 2005, J GERONTOL A-BIOL, V60, P1351, DOI 10.1093/gerona/60.10.1351; Robine JM, 2004, J GERONTOL A-BIOL, V59, P590, DOI 10.1093/gerona/59.6.M590; Satizabal CL, 2016, NEW ENGL J MED, V374, P523, DOI 10.1056/NEJMoa1504327; Theou O, 2015, AGE AGEING, V44, P471, DOI 10.1093/ageing/afv010; Vaupel JW, 2010, NATURE, V464, P536, DOI 10.1038/nature08984; Verbrugge LM, 2016, J GERONTOL B; Vestergaard S, 2015, AGING MENT HEALTH, V19, P400, DOI 10.1080/13607863.2014.944089; WAIDMANN T, 1995, MILBANK Q, V73, P253, DOI 10.2307/3350259; Wang Z, 1998, Genus, V54, P123; Wu YT, 2014, INT J GERIATR PSYCH, V29, P1212, DOI 10.1002/gps.4148; Yi Zeng, 2007, DEMOGRAPHY, V44, P497, DOI DOI 10.1353/DEM.2007.0033; Zeng Y., 2010, SAGE HDB SOCIAL GERO, P420; Zeng Y, 2012, CHINA ECON J, V5, P131, DOI 10.1080/17538963.2013.764677	29	279	293	45	250	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2017	389	10079					1619	1629		10.1016/S0140-6736(17)30548-2	http://dx.doi.org/10.1016/S0140-6736(17)30548-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ES5EK	28285816	Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000399560000029
J	Kawazoe, Y; Miyamoto, K; Morimoto, T; Yamamoto, T; Fuke, A; Hashimoto, A; Koami, H; Beppu, S; Katayama, Y; Itoh, M; Ohta, Y; Yamamura, H				Kawazoe, Yu; Miyamoto, Kyohei; Morimoto, Takeshi; Yamamoto, Tomonori; Fuke, Akihiro; Hashimoto, Atsunori; Koami, Hiroyuki; Beppu, Satoru; Katayama, Yoichi; Itoh, Makoto; Ohta, Yoshinori; Yamamura, Hitoshi		Dexmedetomidine Sepsis Intensive	Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; ENDOTOXIN-INDUCED SHOCK; CRITICALLY-ILL PATIENTS; SEPTIC SHOCK; INFLAMMATORY RESPONSES; CARDIAC EVENTS; HEART-RATE; SEDATION; DELIRIUM; RATS	IMPORTANCE Dexmedetomidine provides sedation for patients undergoing ventilation; however, its effects onmortality and ventilator-free days have not been well studied among patients with sepsis. OBJECTIVES To examine whether a sedation strategy with dexmedetomidine can improve clinical outcomes in patients with sepsis undergoing ventilation. DESIGN, SETTING, AND PARTICIPANTS Open-label, multicenter randomized clinical trial conducted at 8 intensive care units in Japan from February 2013 until January 2016 among 201 consecutive adult patients with sepsis requiring mechanical ventilation for at least 24 hours. INTERVENTIONS Patients were randomized to receive either sedation with dexmedetomidine (n = 100) or sedation without dexmedetomidine (control group; n = 101). Other agents used in both groups were fentanyl, propofol, and midazolam. MAIN OUTCOMES AND MEASURES The co-primary outcomes were mortality and ventilator-free days (over a 28-day duration). Sequential Organ Failure Assessment score (days 1, 2, 4, 6, 8), sedation control, occurrence of delirium and coma, intensive care unit stay duration, renal function, inflammation, and nutrition state were assessed as secondary outcomes. RESULTS Of the 203 screened patients, 201 were randomized. The mean age was 69 years (SD, 14 years); 63% were male. Mortality at 28 days was not significantly different in the dexmedetomidine group vs the control group (19 patients [22.8%] vs 28 patients [30.8%]; hazard ratio, 0.69; 95% CI, 0.38-1.22; P = .20). Ventilator-free days over 28 days were not significantly different between groups (dexmedetomidine group: median, 20 [interquartile range, 5-24] days; control group: median, 18 [interquartile range, 0.5-23] days; P = .20). The dexmedetomidine group had a significantly higher rate of well-controlled sedation during mechanical ventilation (range, 17%-58% vs 20%-39%; P = .01); other outcomes were not significantly different between groups. Adverse events occurred in 8 (8%) and 3 (3%) patients in the dexmedetomidine and control groups, respectively. CONCLUSIONS AND RELEVANCE Among patients requiring mechanical ventilation, the use of dexmedetomidine compared with no dexmedetomidine did not result in statistically significant improvement in mortality or ventilator-free days. However, the study may have been underpowered for mortality, and additional research may be needed to evaluate this further.	[Kawazoe, Yu] Tohoku Univ, Grad Sch Med, Div Emergency & Crit Care Med, Sendai, Miyagi, Japan; [Miyamoto, Kyohei] Wakayama Med Univ, Dept Emergency & Crit Care Med, Wakayama, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan; [Yamamoto, Tomonori] Osaka City Univ, Grad Sch Med, Dept Trauma & Crit Care Med, Osaka, Japan; [Fuke, Akihiro] Osaka City Gen Hosp, Emergency & Urgent Med Care Ctr, Osaka, Japan; [Hashimoto, Atsunori] Hyogo Coll Med, Emergency & Crit Care Ctr, Nishinomiya, Hyogo, Japan; [Koami, Hiroyuki] Saga Univ Hosp, Adv Emergency Care Ctr, Saga, Japan; [Beppu, Satoru] Natl Hosp Org, Kyoto Med Ctr, Dept Emergency Med & Crit Care Med, Kyoto, Japan; [Katayama, Yoichi] Sapporo Med Univ, Dept Emergency Med, Sapporo, Hokkaido, Japan; [Itoh, Makoto] Yamaguchi Grand Med Ctr, Dept Anesthesiol, Hofu, Japan; [Ohta, Yoshinori] Hyogo Coll Med, Dept Internal Med, Div Gen Med, Nishinomiya, Hyogo, Japan; [Yamamura, Hitoshi] Hirosaki Univ, Grad Sch Med, Dept Disaster & Crit Care Med, 5 Zaifuchou, Hirosaki, Aomori 0368562, Japan	Tohoku University; Wakayama Medical University; Hyogo College of Medicine; Osaka Metropolitan University; Osaka City General Hospital; Hyogo College of Medicine; Saga University; Sapporo Medical University; Hyogo College of Medicine; Hirosaki University	Yamamura, H (corresponding author), Hirosaki Univ, Grad Sch Med, Dept Disaster & Crit Care Med, 5 Zaifuchou, Hirosaki, Aomori 0368562, Japan.	yamamura@hirosaki-u.ac.jp	Koami, Hiroyuki/L-7981-2018	Koami, Hiroyuki/0000-0001-6268-4602; BEPPU, SATORU/0000-0002-1434-5697	Hospira Japan	Hospira Japan	This study was supported in part by a noncontractual research grant to Wakayama Medical University provided by Hospira Japan.	Ackland GL, 2010, CRIT CARE MED, V38, P388, DOI 10.1097/CCM.0b013e3181c03dfa; Aydin C, 2009, WORLD J GASTROENTERO, V15, P1620, DOI 10.3748/wjg.15.1620; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Frumento RJ, 2006, J CLIN ANESTH, V18, P422, DOI 10.1016/j.jclinane.2006.02.005; Frumento RJ, 2013, J CLIN ANESTH, V25, P432, DOI 10.1016/j.jclinane.2013.08.001; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kushimoto S, 2008, THROMB HAEMOSTASIS, V100, P1099, DOI 10.1160/TH08-05-0306; Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477; Oda S, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0055-2; Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916; Reade MC, 2016, JAMA-J AM MED ASSOC, V315, P1460, DOI 10.1001/jama.2016.2707; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Sander O, 2005, CRIT CARE MED, V33, P81, DOI 10.1097/01.CCM.0000150028.64264.14; Schmittinger CA, 2013, SHOCK, V39, P329, DOI 10.1097/SHK.0b013e318289376b; Schmittinger CA, 2012, INTENS CARE MED, V38, P950, DOI 10.1007/s00134-012-2531-2; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Skrobik Y, 2010, ANESTH ANALG, V111, P451, DOI 10.1213/ANE.0b013e3181d7e1b8; Stolk RF, 2016, AM J RESP CRIT CARE, V194, P550, DOI 10.1164/rccm.201604-0862CP; Taniguchi T, 2004, CRIT CARE MED, V32, P1322, DOI 10.1097/01.CCM.0000128579.84228.2A; Taniguchi T, 2008, J ANESTH, V22, P221, DOI 10.1007/s00540-008-0611-9; Vasilevskis EE, 2010, CHEST, V138, P1224, DOI 10.1378/chest.10-0466; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016	31	130	138	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2017	317	13					1321	1328		10.1001/jama.2017.2088	http://dx.doi.org/10.1001/jama.2017.2088			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ9VR	28322414	Green Published			2023-01-03	WOS:000398434200016
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Punishing individuals won't prevent errors	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	2017	356								j1279	10.1136/bmj.j1279	http://dx.doi.org/10.1136/bmj.j1279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY4VK	28292771	Green Published, Bronze			2023-01-03	WOS:000426824900001
J	Sothmann, T; Gauer, T; Werner, R				Sothmann, Thilo; Gauer, Tobias; Werner, Rene			4D dose simulation in volumetric arc therapy: Accuracy and affecting parameters	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; DOSIMETRIC IMPACT; MOTION; DELIVERY; SBRT; BEAMS	Radiotherapy of lung and liver lesions has changed from normofractioned 3D-CRT to stereotactic treatment in a single or few fractions, often employing volumetric arc therapy (VMAT)-based techniques. Potential unintended interference of respiratory target motion and dynamically changing beam parameters during VMAT dose delivery motivates establishing 4D quality assurance (4D QA) procedures to assess appropriateness of generated VMAT treatment plans when taking into account patient-specific motion characteristics. Current approaches are motion phantom-based 4D QA and image-based 4D VMAT dose simulation. Whereas phantom-based 4D QA is usually restricted to a small number of measurements, the computational approaches allow simulating many motion scenarios. However, 4D VMAT dose simulation depends on various input parameters, influencing estimated doses along with mitigating simulation reliability. Thus, aiming at routine use of simulation-based 4D VMAT QA, the impact of such parameters as well as the overall accuracy of the 4D VMAT dose simulation has to be studied in detail-which is the topic of the present work. In detail, we introduce the principles of 4D VMAT dose simulation, identify influencing parameters and assess their impact on 4D dose simulation accuracy by comparison of simulated motion-affected dose distributions to corresponding dosimetric motion phantom measurements. Exploiting an ITV-based treatment planning approach, VMAT treatment plans were generated for a motion phantom and different motion scenarios (sinusoidal motion of different period/direction; regular/irregular motion). 4D VMAT dose simulation results and dose measurements were compared by local 3% / 3 mm gamma-evaluation, with the measured dose distributions serving as ground truth. Overall gamma-passing rates of simulations and dynamic measurements ranged from 97% to 100% (mean across all motion scenarios: 98% +/- 1%); corresponding values for comparison of different day repeat measurements were between 98% and 100%. Parameters of major influence on 4D VMAT dose simulation accuracy were the degree of temporal discretization of the dose delivery process (the higher, the better) and correct alignment of the assumed breathing phases at the beginning of the dose measurements and simulations. Given the high gamma-passing rates between simulated motion-affected doses and dynamic measurements, we consider the simulations to provide a reliable basis for assessment of VMAT motion effects that-in the sense of 4D QA of VMAT treatment plans-allows to verify target coverage in hypofractioned VMAT-based radiotherapy of moving targets. Remaining differences between measurements and simulations motivate, however, further detailed studies.	[Sothmann, Thilo; Werner, Rene] Univ Med Ctr Hamburg Eppendorf, Dept Computat Neurosci, Hamburg, Germany; [Gauer, Tobias] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Sothmann, T (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Computat Neurosci, Hamburg, Germany.	t.sothmann@uke.de	Werner, Rene/B-4989-2017	Werner, Rene/0000-0002-2296-3305; Sentker, Thilo/0000-0001-6663-0003	Forschungsforderungsfond of the Medical Faculty of the University of Hamburg	Forschungsforderungsfond of the Medical Faculty of the University of Hamburg	This work was supported by Forschungsforderungsfond of the Medical Faculty of the University of Hamburg (to RW; URL: https://www.uke.de/english/research/funding-opportunities/faculty-of-medicine/index.html).	Bortfeld T, 2002, PHYS MED BIOL, V47, P2203, DOI 10.1088/0031-9155/47/13/302; Dogan N, 2003, INT J RADIAT ONCOL, V57, P1480, DOI 10.1016/S0360-3016(03)01569-4; Ehrbar S, 3 DIMENSIONAL VERSUS; Gauer T, 2016, RADIOTHER ONCOL, V119, pS826, DOI 10.1016/S0167-8140(16)33014-6; Goodman KA, 2010, INT J RADIAT ONCOL, V78, P486, DOI 10.1016/j.ijrobp.2009.08.020; Grohmann C, 2015, Z MED PHYS, V25, P156, DOI 10.1016/j.zemedi.2014.09.003; Guckenberger M, 2009, RADIOTHER ONCOL, V93, P259, DOI 10.1016/j.radonc.2009.08.015; Katz AW, 2007, INT J RADIAT ONCOL, V67, P793, DOI 10.1016/j.ijrobp.2006.10.025; Keall PJ, 2006, MED PHYS, V33, P3874, DOI 10.1118/1.2349696; Korreman SS, 2012, PHYS MED BIOL, V57, pR161, DOI 10.1088/0031-9155/57/23/R161; Li X, 2013, J APPL CLIN MED PHYS, V14, P195, DOI 10.1120/jacmp.v14i6.4370; Low DA, 1998, MED PHYS, V25, P656, DOI 10.1118/1.598248; Markovic M, 2014, MED PHYS, V41, DOI 10.1118/1.4870439; McGrath SD, 2010, RADIOTHER ONCOL, V95, P153, DOI 10.1016/j.radonc.2009.12.039; Milz S, 2014, PHYS MED BIOL, V59, P6401, DOI 10.1088/0022-3727/59/21/6401; Murphy K, 2011, IEEE T MED IMAGING, V30, P1901, DOI 10.1109/TMI.2011.2158349; Ong CL, 2013, INT J RADIAT ONCOL, V86, P743, DOI 10.1016/j.ijrobp.2013.03.038; Ong C, 2011, INT J RADIAT ONCOL, V79, P305, DOI 10.1016/j.ijrobp.2010.02.059; Palma DA, 2010, CANCER TREAT REV, V36, P393, DOI 10.1016/j.ctrv.2010.01.004; Poppe B, 2013, MED PHYS, V40, DOI 10.1118/1.4816298; Poulsen PR, 2012, MED PHYS, V39, P6237, DOI 10.1118/1.4754297; Rao M, 2012, INT J RADIAT ONCOL, V83, pE251, DOI 10.1016/j.ijrobp.2011.12.001; Riley C, 2014, MED PHYS, V41, DOI 10.1118/1.4855956; Simeonova AO, 2012, TRANSL LUNG CANCER R, V1, P45, DOI 10.3978/j.issn.2218-6751.10.01; Sothmann T, 2016, PHYS MED BIOL, V61, P1677, DOI 10.1088/0031-9155/61/4/1677; Stambaugh C, 2013, MED PHYS, V40, DOI 10.1118/1.4818255; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Tsuruta Y, 2014, MED PHYS, V41, P189, DOI 10.1118/1.4890592; Werner R, 2014, PHYS MED BIOL, V59, P4247, DOI 10.1088/0031-9155/59/15/4247; Werner R, 2012, Z MED PHYS, V22, P109, DOI 10.1016/j.zemedi.2011.08.001; Zhang GG, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-152; Zou W, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0225-3	32	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0172810	10.1371/journal.pone.0172810	http://dx.doi.org/10.1371/journal.pone.0172810			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SX	28231337	Green Published, Green Submitted, gold			2023-01-03	WOS:000394682400080
J	Chang, M; Iizuka, H; Kashioka, H; Naruse, Y; Furukawa, M; Ando, H; Maeda, T				Chang, Ming; Iizuka, Hiroyuki; Kashioka, Hideki; Naruse, Yasushi; Furukawa, Masahiro; Ando, Hideyuki; Maeda, Taro			Unconscious improvement in foreign language learning using mismatch negativity neurofeedback: A preliminary study	PLOS ONE			English	Article							TRAINING JAPANESE LISTENERS; EVENT-RELATED POTENTIALS; R-VERTICAL-BAR; PHONEME REPRESENTATIONS; BRAIN RESPONSES; ENGLISH; SPEECH; SOUND; PERCEPTION; ATTENTION	When people learn foreign languages, they find it difficult to perceive speech sounds that are nonexistent in their native language, and extensive training is consequently necessary. Our previous studies have shown that by using neurofeedback based on the mismatch negativity event-related brain potential, participants could unconsciously achieve learning in the auditory discrimination of pure tones that could not be consciously discriminated without the neurofeedback. Here, we examined whether mismatch negativity neurofeedback is effective for helping someone to perceive new speech sounds in foreign language learning. We developed a task for training native Japanese speakers to discriminate between 'l' and 'r' sounds in English, as they usually cannot discriminate between these two sounds. Without participants attending to auditory stimuli or being aware of the nature of the experiment, neurofeedback training helped them to achieve significant improvement in unconscious auditory discrimination and recognition of the target words 'light' and 'right'. There was also improvement in the recognition of other words containing 'l' and 'r' (e.g., 'blight' and 'bright'), even though these words had not been presented during training. This method could be used to facilitate foreign language learning and can be extended to other fields of auditory and clinical research and even other senses.	[Chang, Ming; Kashioka, Hideki; Naruse, Yasushi; Furukawa, Masahiro; Ando, Hideyuki; Maeda, Taro] Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks CiNet, Nishi Ku, Iwaoka Cho, Kobe, Hyougo, Japan; [Chang, Ming; Kashioka, Hideki; Naruse, Yasushi; Furukawa, Masahiro; Ando, Hideyuki; Maeda, Taro] Osaka Univ, Iwaoka Cho, Kobe, Hyougo, Japan; [Chang, Ming; Furukawa, Masahiro; Ando, Hideyuki; Maeda, Taro] Osaka Univ, Grad Sch Informat Sci & Technol, Suita, Osaka, Japan; [Iizuka, Hiroyuki] Hokkaido Univ, Grad Sch Informat Sci & Technol, Kita Ku, Sapporo, Hokkaido, Japan	National Institute of Information & Communications Technology (NICT) - Japan; Osaka University; Osaka University; Hokkaido University	Chang, M (corresponding author), Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks CiNet, Nishi Ku, Iwaoka Cho, Kobe, Hyougo, Japan.; Chang, M (corresponding author), Osaka Univ, Iwaoka Cho, Kobe, Hyougo, Japan.; Chang, M (corresponding author), Osaka Univ, Grad Sch Informat Sci & Technol, Suita, Osaka, Japan.	chang.ming@nict.go.jp		Furukawa, Masahiro/0000-0003-0421-8106; ANDO, HIDEYUKI/0000-0002-8405-3120	Center of Innovation Program from Japan Science and Technology Agency, JST	Center of Innovation Program from Japan Science and Technology Agency, JST	This research is partially supported by the Center of Innovation Program from Japan Science and Technology Agency, JST. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research is partially supported by the Center of Innovation Program from Japan Science and Technology Agency, JST.	ALHO K, 1994, PSYCHOPHYSIOLOGY, V31, P469, DOI 10.1111/j.1469-8986.1994.tb01050.x; Amenedo E, 2000, EUR J NEUROSCI, V12, P2570, DOI 10.1046/j.1460-9568.2000.00114.x; Bertoli S, 2002, CLIN NEUROPHYSIOL, V113, P396, DOI 10.1016/S1388-2457(02)00013-5; Bradlow AR, 1997, J ACOUST SOC AM, V101, P2299, DOI 10.1121/1.418276; Chang M, 2014, AH; Chang M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06729; Cheour M, 1998, NAT NEUROSCI, V1, P351, DOI 10.1038/1561; Koyama S, 2000, NEUROREPORT, V11, P3765, DOI 10.1097/00001756-200011270-00034; KRAUS N, 1995, J COGNITIVE NEUROSCI, V7, P25, DOI 10.1162/jocn.1995.7.1.25; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; LIVELY SE, 1994, J ACOUST SOC AM, V96, P2076, DOI 10.1121/1.410149; LOGAN JS, 1991, J ACOUST SOC AM, V89, P874, DOI 10.1121/1.1894649; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1993, NEUROREPORT, V4, P503; Naatanen R, 1997, NATURE, V385, P432, DOI 10.1038/385432a0; NAATANEN R, 1995, EAR HEARING, V16, P6; NAATANEN R, 1993, PSYCHOPHYSIOLOGY, V30, P436, DOI 10.1111/j.1469-8986.1993.tb02067.x; Pantev C, 2001, NEUROREPORT, V12, P169, DOI 10.1097/00001756-200101220-00041; Pettigrew CM, 2004, EAR HEARING, V25, P284, DOI 10.1097/01.AUD.0000130800.88987.03; Phillips C., 1995, MIT WORKING PAPERS L, V26, P125; Russeler J, 2001, NEUROSCI LETT, V308, P33, DOI 10.1016/S0304-3940(01)01977-2; Sams M, 1990, J Cogn Neurosci, V2, P344, DOI 10.1162/jocn.1990.2.4.344; Sams M., 1985, CLIN NEUROPHYSIOL, V62, P437, DOI [10.1016/0168-5597(85)90054-1, DOI 10.1016/0168-5597(85)90054-1]; Seitz AR, 2009, NEURON, V61, P700, DOI 10.1016/j.neuron.2009.01.016; Shibata K, 2011, SCIENCE, V334, P1413, DOI 10.1126/science.1212003; Sonnadara RR, 2006, BRAIN RES, V1076, P187, DOI 10.1016/j.brainres.2005.12.093; STRANGE W, 1984, PERCEPT PSYCHOPHYS, V36, P131, DOI 10.3758/BF03202673; Sussman E, 2003, PSYCHOPHYSIOLOGY, V40, P430, DOI 10.1111/1469-8986.00045; TERVANIEMI M, 1994, BIOL PSYCHOL, V38, P157, DOI 10.1016/0301-0511(94)90036-1; Tervaniemi M, 1997, NEUROREPORT, V8, P2571, DOI 10.1097/00001756-199707280-00030; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; Tremblay K, 1998, NEUROREPORT, V9, P3557, DOI 10.1097/00001756-199811160-00003; Wang Y, 1999, J ACOUST SOC AM, V106, P3649, DOI 10.1121/1.428217; Winkler I, 1999, PSYCHOPHYSIOLOGY, V36, P638, DOI 10.1111/1469-8986.3650638; YAMADA RA, 1992, PERCEPT PSYCHOPHYS, V52, P376, DOI 10.3758/BF03206698	36	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2017	12	6							e0178694	10.1371/journal.pone.0178694	http://dx.doi.org/10.1371/journal.pone.0178694			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX6PQ	28617861	Green Published, Green Submitted, gold			2023-01-03	WOS:000403364600012
J	Brinkrolf, P; Bohn, A; Lukas, RP; Heyse, M; Dierschke, T; Van Aken, HK; Hahnenkamp, K				Brinkrolf, Peter; Bohn, Andreas; Lukas, Roman-Patrik; Heyse, Marko; Dierschke, Thomas; Van Aken, Hugo Karel; Hahnenkamp, Klaus			Senior citizens as rescuers: Is reduced knowledge the reason for omitted lay-resuscitation-attempts? Results from a representative survey with 2004 interviews	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; SURVIVAL; ASSOCIATION; RATES; CPR	Objective Resuscitation (CPR) provided by a bystander prior to the arrival of the emergency services is a beneficial factor for surviving a cardiac arrest (CA). Our registry-based data show, that older patients receive bystander-CPR less frequently. Little is known on possible reasons for this finding. We sought to investigate the hypothesis that awareness of CPR measures is lower in older laypersons being a possible reason for less CPR-attempts in senior citizens. Methods 1206 datasets on bystander resuscitations actually carried out were analyzed for age-dependent differences. Subsequently, we investigated whether the knowledge required carrying out bystander-CPR and the self-confidence to do so differ between younger and older citizens using computer-assisted telephone interviewing. 2004 interviews were performed and statistically analyzed. Results A lower level of knowledge to carry out bystander-CPR was seen in older individuals. For example, 82.4% of interviewees under 65 years of age, knew the correct emergency number. In this group, 66.6% named CPR as the relevant procedure in CA. Among older individuals these responses were only given by 75.1% and 49.5% (V = 0.082; P < 0.001 and V = 0.0157; P < 0.001). Additionally, a difference concerning participants' confidence in their own abilities was detectable. 58.0% of the persons younger than 65 years were confident that they would detect a CA in comparison to 44.6% of the participants older than 65 years (V = 0.120; P < 0.001). Similarly, 62.7% of the interviewees younger than 65 were certain to know what to do during CPR compared to 51.3% of the other group (V = 0.103; P < 0.001). Conclusions Lower levels of older bystanders' knowledge and self-confidence might provide an explanation for why older patients receive bystander-CPR less frequently. Further investigation is necessary to identify causal connections and optimum ways to empower bystander resuscitation.	[Brinkrolf, Peter; Hahnenkamp, Klaus] Greifswald Univ Hosp, Dept Anaesthesiol, Greifswald, Germany; [Bohn, Andreas] City Munster Fire Serv, Emergency Serv, Munster, Germany; [Lukas, Roman-Patrik; Van Aken, Hugo Karel] Munster Univ Hosp, Dept Anaesthesiol Intens Care & Pain Therapy, Munster, Germany; [Heyse, Marko; Dierschke, Thomas] Univ Munster, Inst Sociol, Munster, Germany	University of Munster; University of Munster	Brinkrolf, P (corresponding author), Greifswald Univ Hosp, Dept Anaesthesiol, Greifswald, Germany.	peter.brinkrolf@uni-greifswald.de						[Anonymous], 2013, MUNST SPIEG ZAHL; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Boyce LW, 2015, NETH HEART J, V23, P20, DOI 10.1007/s12471-014-0617-x; Breckwoldt J, 2009, RESUSCITATION, V80, P1108, DOI 10.1016/j.resuscitation.2009.06.028; Casper Karen, 2003, Prehosp Emerg Care, V7, P299, DOI 10.1080/10903120390936455; Grasner JT, 2011, EUR HEART J, V32, P1649, DOI 10.1093/eurheartj/ehr107; Hader S, 2006, STICHPROBENQUALITAT, P11; Hansen CM, 2015, JAMA-J AM MED ASSOC, V314, P255, DOI 10.1001/jama.2015.7938; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Herlitz J, 2005, RESUSCITATION, V66, P291, DOI 10.1016/j.resuscitation.2005.04.003; Herlitz J, 2005, AM HEART J, V149, P61, DOI 10.1016/j.ahj.2004.07.014; Hofmann O., 2012, QUALITATSSICHERUNG U, P139; Iwami T, 2006, RESUSCITATION, V69, P221, DOI 10.1016/j.resuscitation.2005.08.018; Jackson RE, 1997, ACAD EMERG MED, V4, P540, DOI 10.1111/j.1553-2712.1997.tb03574.x; Kitamura T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006462; Moriwaki Yoshihiro, 2014, J Emerg Trauma Shock, V7, P285, DOI 10.4103/0974-2700.142763; Nakahara S, 2015, JAMA-J AM MED ASSOC, V314, P247, DOI 10.1001/jama.2015.8068; Orimo Hajime, 2006, Nihon Ronen Igakkai Zasshi, V43, P27; Papalexopoulou K, 2014, HEART LUNG, V43, P66, DOI 10.1016/j.hrtlng.2013.09.008; Safdar B, 2014, ACAD EMERG MED, V21, P1503, DOI 10.1111/acem.12540; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Smith K, 2015, CIRCULATION, V131, P174, DOI 10.1161/CIRCULATIONAHA.114.011200; Statistisches Bundesamt, 2013, BEV ERW STERB 2009 1; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; Tanaka Y, 2015, RESUSCITATION, V86, P74, DOI 10.1016/j.resuscitation.2014.11.004; Wong MKY, 2014, CIRCULATION, V130, P1883, DOI 10.1161/CIRCULATIONAHA.114.010633	27	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2017	12	6							e0178938	10.1371/journal.pone.0178938	http://dx.doi.org/10.1371/journal.pone.0178938			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX2VR	28604793	Green Published, Green Submitted, gold			2023-01-03	WOS:000403088400021
J	Nordmann, S; Vilotitch, A; Lions, C; Michel, L; Mora, M; Spire, B; Maradan, G; Bendiane, MK; Morel, A; Roux, P; Carrieri, P				Nordmann, Sandra; Vilotitch, Antoine; Lions, Caroline; Michel, Laurent; Mora, Marion; Spire, Bruno; Maradan, Gwenaelle; Bendiane, Marc-Karim; Morel, Alain; Roux, Perrine; Carrieri, Patrizia		ANRS Methaville Study Gp	Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial)	PLOS ONE			English	Article							USE DISORDER PATIENTS; SELF-REPORT SCALE; MAINTENANCE TREATMENT; SUBSTANCE USE; CANCER PAIN; DEPENDENT PATIENTS; PERSISTENT PAIN; FRENCH VERSION; PRIMARY-CARE; ADULT ADHD	Background Pain in opioid-dependent patients is common but data measuring the course of pain (and its correlates) using validated scales in patients initiating methadone treatment are sparse. We aimed to assess pain and its interference in daily life, associated correlates, and undertreatment before and during methadone treatment. Methods This is a secondary analysis using longitudinal data of a randomized trial comparing two methadone initiation models. We assessed the effect of methadone initiation and other correlates on pain intensity and interference (using the Brief Pain Inventory) at months 0, 6 and 12 using a mixed multinomial logistic regression model. Results The study group comprised 168 patients who had data for either pain intensity or interference for at least one visit. Moderate to severe pain was reported in 12.9% of patients at M0, 5.4% at M6 and 7.3% at M12. Substantial interference with daily functioning was reported in 36.0% at M0, 14.5% at M6 and 17.1% at M12. Of the 98 visits where patients reported moderate to severe pain or substantial interference, 55.1% reported no treatment for pain relief, non-opioid analgesics were reported by 34.7%, opioid analgesics by 3.1% and both opioid and non-opioid analgesics by 7.1%. Methadone was associated with decreased pain intensity at 6 months (OR = 0.29, p = 0.04) and 12 months (OR = 0.30, p = 0.05) of follow-up and tended to be associated with substantial pain interference. Suicide risk was associated with both pain intensity and pain interference. Conclusions Methadone in opioid-dependent patients can reduce pain. However, undertreatment of pain in methadone patients remains a major clinical concern. Patients with pain are at higher risk of suicide. Adequate screening and management of pain in this population is a priority and needs to be integrated into routine comprehensive care.	[Nordmann, Sandra; Vilotitch, Antoine; Lions, Caroline; Mora, Marion; Spire, Bruno; Maradan, Gwenaelle; Bendiane, Marc-Karim; Roux, Perrine; Carrieri, Patrizia] Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France; [Nordmann, Sandra; Vilotitch, Antoine; Lions, Caroline; Mora, Marion; Spire, Bruno; Maradan, Gwenaelle; Bendiane, Marc-Karim; Roux, Perrine; Carrieri, Patrizia] ORS PACA, Marseille, France; [Michel, Laurent] INSERM, UMR S 669, Paris, France; [Michel, Laurent] Univ Paris Sud, Paris, France; [Michel, Laurent] Univ Paris 05, UMR S 669, Paris, France; [Michel, Laurent] Ctr Pierre Nicole, Paris, France; [Morel, Alain] Oppelia, Paris, France	Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Carrieri, P (corresponding author), Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.; Carrieri, P (corresponding author), ORS PACA, Marseille, France.	maria-patrizia.carrieri@inserm.fr	Spire, Bruno/F-5546-2013; Bendiane, Marc-Karim K/F-5414-2010; Bendiane, Marc-Karim/M-7060-2019	Spire, Bruno/0000-0002-3546-8020; Bendiane, Marc-Karim K/0000-0003-4329-8807; MICHEL, laurent/0000-0002-2000-7838; Carrieri, Patrizia/0000-0002-6794-4837	French National Agency for Research on Aids and Viral Hepatitis (ANRS); French Ministry of Health	French National Agency for Research on Aids and Viral Hepatitis (ANRS)(ANRSFrench National Research Agency (ANR)); French Ministry of Health	This study received external funding from the French National Agency for Research on Aids and Viral Hepatitis (ANRS) and the French Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Barry DT, 2009, J CLIN PSYCHIAT, V70, P1213, DOI 10.4088/JCP.08m04367; Barry DT, 2009, AM J ADDICTION, V18, P117, DOI 10.1080/10550490902772470; Beck A T, 1990, Crisis, V11, P22; Blinderman Craig D, 2009, J Opioid Manag, V5, P107; Bounes V, 2013, PAIN PHYSICIAN, V16, pE739; Breitbart W, 1997, PAIN, V72, P235, DOI 10.1016/S0304-3959(97)00039-0; Caldeiro RM, 2008, ADDICTION, V103, P1996, DOI 10.1111/j.1360-0443.2008.02358.x; Carrieri PM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112328; Center for Substance Abuse Treatment, 2011, TREATMENT IMPROVEMEN, V54; Center for Substance Abuse Treatment, 2005, TREATM IMPR PROT TIP, V43; Center for Substance Abuse Treatment, 2004, TREATMENT IMPROVEMEN, V40; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; Daigre C, 2015, J ATTEN DISORD, V19, P328, DOI 10.1177/1087054714529819; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Darke S, 1991, OPIATE TREATMENT IND, P1; Dhingra L, 2015, DRUG ALCOHOL DEPEN, V149, P285, DOI 10.1016/j.drugalcdep.2015.02.007; Dhingra L, 2013, DRUG ALCOHOL DEPEN, V128, P161, DOI 10.1016/j.drugalcdep.2012.08.003; Dunn KE, 2014, PAIN MED, V15, P1540, DOI 10.1111/pme.12430; Edwards RR, 2006, PAIN, V126, P272, DOI 10.1016/j.pain.2006.07.004; Eisenberger NI, 2012, PSYCHOSOM MED, V74, P126, DOI 10.1097/PSY.0b013e3182464dd1; Eyler ECH, 2013, AM J ADDICTION, V22, P75, DOI 10.1111/j.1521-0391.2013.00308.x; Fishman SM, 2002, PAIN MED, V3, P339, DOI 10.1046/j.1526-4637.2002.02047.x; FUHRER R, 1989, Psychiatrie and Psychobiologie, V4, P163; Gache P, 2005, ALCOHOL CLIN EXP RES, V29, P2001, DOI 10.1097/01.alc.0000187034.58955.64; HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hines S, 2008, DRUG ALCOHOL REV, V27, P519, DOI 10.1080/09595230802245519; Jamison RN, 2000, J PAIN SYMPTOM MANAG, V19, P53, DOI 10.1016/S0885-3924(99)00144-X; Karasz A, 2004, J PAIN SYMPTOM MANAG, V28, P517, DOI 10.1016/j.jpainsymman.2004.02.025; Keane H, 2013, INT J DRUG POLICY, V24, P189, DOI [10.1016/j.drugpo.2013.05.007, 10.1016/j.drugpo.2013.01.011]; Larson MJ, 2007, ADDICTION, V102, P752, DOI 10.1111/j.1360-0443.2007.01759.x; Michel L, 2015, COMPR PSYCHIAT, V62, P123, DOI 10.1016/j.comppsych.2015.07.004; Miller LR, 2009, J PAIN, V10, P619, DOI 10.1016/j.jpain.2008.12.007; Nielsen S, 2013, DRUG ALCOHOL REV, V32, P489, DOI 10.1111/dar.12041; Nordmann S, 2016, PSYCHOPHARMACOLOGY, V233, P1203, DOI 10.1007/s00213-016-4202-4; Peles E, 2005, PAIN, V113, P340, DOI 10.1016/j.pain.2004.11.011; Potter JS, 2008, AM J DRUG ALCOHOL AB, V34, P101, DOI 10.1080/00952990701523706; Poundja J, 2007, J PAIN SYMPTOM MANAG, V33, P720, DOI 10.1016/j.jpainsymman.2006.09.031; Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289, P2370, DOI 10.1001/jama.289.18.2370; Roux P, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-488; Rowley D, 2011, AM J HOSP PALLIAT ME, V28, P183, DOI 10.1177/1049909110380897; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sheu R, 2008, PAIN MED, V9, P911, DOI 10.1111/j.1526-4637.2008.00420.x; St Marie B, 2014, PAIN MED, V15, P2075, DOI 10.1111/pme.12493; Stickley A, 2016, PSYCHIAT RES, V246, P326, DOI 10.1016/j.psychres.2016.10.004; Tang NKY, 2016, CLIN J PAIN, V32, P411, DOI 10.1097/AJP.0000000000000276; Trafton JA, 2004, DRUG ALCOHOL DEPEN, V73, P23, DOI 10.1016/j.drugalcdep.2003.08.007; Turner JA, 2002, PAIN, V98, P127, DOI 10.1016/S0304-3959(02)00045-3; van de Glind G, 2013, DRUG ALCOHOL DEPEN, V132, P587, DOI 10.1016/j.drugalcdep.2013.04.010; Voon P, 2015, J PAIN, V16, P887, DOI 10.1016/j.jpain.2015.06.003; Voon P, 2015, DRUG ALCOHOL REV, V34, P221, DOI 10.1111/dar.12226	53	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2017	12	5							e0176288	10.1371/journal.pone.0176288	http://dx.doi.org/10.1371/journal.pone.0176288			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DX	28520735	Green Published, gold, Green Submitted			2023-01-03	WOS:000401487700012
J	Ramachandran, SK; Thompson, A; Pandit, JJ; Devine, S; Shanks, AM				Ramachandran, Satya Krishna; Thompson, Aleda; Pandit, Jaideep J.; Devine, Scott; Shanks, Amy M.			Retrospective observational evaluation of postoperative oxygen saturation levels and associated postoperative respiratory complications and hospital resource utilization	PLOS ONE			English	Article							OBSTRUCTIVE SLEEP-APNEA; PERIOPERATIVE-OUTCOMES-GROUP; NATIONWIDE INPATIENT SAMPLE; RANDOMIZED CONTROLLED-TRIAL; PULSE OXIMETRY; CONSTANT HYPOXEMIA; SUPPLEMENTAL OXYGEN; NONCARDIAC SURGERY; EPISODIC HYPOXEMIA; RISK	Introduction The clinical importance of postoperative episodic hypoxemia is still unclear, and therefore largely under-studied. As a result, there is limited understanding of its relationship with early postoperative respiratory complications (PRC, defined as intubation within three days of surgery) and hospital resource utilization. Materials and methods This single center study was performed using a retrospective observational design. We described population based definitions of desaturation from continuous SpO(2) monitoring data captured in the post anesthesia care unit (PACU), namely median SpO(2) in PACU, duration of desaturation below median, nadir desaturation, and length of oxygen therapy relative to PACU duration. These measures were evaluated against the occurrence of early PRC in logistic regression models. Measures that were independently associated with early PRC were accepted as the primary study exposures. Stratified logistic regression models were planned if significant interaction occurred with high risk surgical procedures. Models were adjusted by including several patient conditions, procedural, and anesthesia risk factors. Propensity matching on desaturation occurrence was planned to evaluate the relationship with postoperative resource utilization. Results Among 125,740 patients included in the univariate analyses, 351 patients (0.3%) developed early PRC. Nadir desaturation < 89% [14.3% of patients; adjusted odds ratio 2.02; 95% CI 1.52, 2.68; p < 0.001] and PACU oxygen therapy requirements greater than 60 min [adjusted odds ratio 1.92 (> 60 min) to 3.04 (> 90 min); p < 0.001] were identified as independent predictors of early PRC occurrence. A modest interaction was observed between desaturation and higher surgical risk. Propensity matching for postoperative oxygen requirement was performed in 37,354 matched patients. Matched analysis demonstrated significant increase in day of surgery charges, respiratory charges, total charges, hospital length of stay, reintubation and use of invasive or non-invasive ventilatory support. Conclusions In summary, we report that prolonged PACU oxygen therapy and nadir desaturation < 89% in PACU as captured in a retrospective database are independently associated with early PRC. This study describes resource implications of PACU desaturation in a large academic medical center in North America.	[Ramachandran, Satya Krishna] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Ramachandran, Satya Krishna] Harvard Med Sch, Boston, MA 02115 USA; [Thompson, Aleda; Shanks, Amy M.] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; [Pandit, Jaideep J.] Nuffield Dept Anaesthesia, Oxford, Oxon, England; [Devine, Scott] Merck Sharpe & Dohme, Ctr Observat & Real World Evidence US Evidence &, Whitehouse Stn, NJ USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Oxford	Ramachandran, SK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.; Ramachandran, SK (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	skrama@bidmc.harvard.edu	Ramachandran, Satya Krishna/P-6636-2016; (Thompson) Leis, Aleda/J-1066-2016	Ramachandran, Satya Krishna/0000-0002-7176-6375; (Thompson) Leis, Aleda/0000-0003-2867-9062	Merck; Sharpe and Dohme; White house Station, NJ, USA, through the University of Michigan	Merck(Merck & Company); Sharpe and Dohme; White house Station, NJ, USA, through the University of Michigan	This research project was funded by Merck, Sharpe and Dohme, White house Station, NJ, USA, through the University of Michigan. No funds were paid directly to any of the authors. The funder provided support in the form of salaries for authors [SKR, SD, AS], but did not have any additional role in the study design, data collection and analysis, decision to publish,or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Amer Soc Anesthesiologists, 2006, ANESTHESIOLOGY, V104, P1081; Bateman BT, 2013, ANESTH ANALG, V116, P1380, DOI 10.1213/ANE.0b013e318251daed; Belcher AW, 2016, ANESTH ANALG, V123, P1471, DOI 10.1213/ANE.0000000000001534; Bender SP, 2015, ANESTH ANALG, V121, P1231, DOI 10.1213/ANE.0000000000000940; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; CANET J, 1989, ANESTH ANALG, V69, P207; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Chung F, 2014, ANESTHESIOLOGY, V120, P287, DOI 10.1097/ALN.0000000000000040; Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276; Fu ES, 2004, CHEST, V126, P1552, DOI 10.1378/chest.126.5.1552; Gami AS, 2013, J AM COLL CARDIOL, V62, P610, DOI 10.1016/j.jacc.2013.04.080; Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832; Gogenur I, 2008, BRIT J ANAESTH, V100, P45, DOI 10.1093/bja/aem340; Isono S, 1998, BRIT J ANAESTH, V80, P602, DOI 10.1093/bja/80.5.602; Kheterpal S, 2013, ANESTHESIOLOGY, V119, P1360, DOI 10.1097/ALN.0000435832.39353.20; Kheterpal Sachin, 2011, Anesthesiol Clin, V29, P377, DOI 10.1016/j.anclin.2011.06.002; Liao P, 2017, CHEST, V151, P597, DOI 10.1016/j.chest.2016.12.005; Loredo JS, 2006, SLEEP, V29, P564, DOI 10.1093/sleep/29.4.564; Mashour GA, 2009, J CLIN MONIT COMPUT, V23, P273, DOI 10.1007/s10877-009-9193-9; Mathis MR, 2013, ANESTHESIOLOGY, V119, P1310, DOI 10.1097/ALN.0000000000000005; McLean DJ, 2015, ANESTHESIOLOGY, V122, P1201, DOI 10.1097/ALN.0000000000000674; Mokhlesi B, 2013, OBES SURG, V23, P1842, DOI 10.1007/s11695-013-0991-2; Mokhlesi B, 2013, CHEST, V144, P903, DOI 10.1378/chest.12-2905; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; Mutter TC, 2014, ANESTHESIOLOGY, V121, P707, DOI 10.1097/ALN.0000000000000407; Netzer N, 2001, CHEST, V120, P625, DOI 10.1378/chest.120.2.625; Pedersen T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002013.pub3; Ramachandran SK, 2011, ANESTHESIOLOGY, V115, P44, DOI 10.1097/ALN.0b013e31821cf6de; Raval MV, 2010, J AM COLL SURGEONS, V211, P715, DOI 10.1016/j.jamcollsurg.2010.07.021; ROSENBERG J, 1994, EUR J SURG, V160, P137; Rosenberg J, 1999, ANAESTHESIA, V54, P323, DOI 10.1046/j.1365-2044.1999.00744.x; ROSENBERG J, 1990, ACTA CHIR SCAND, V156, P585; ROSENBERG J, 1990, BRIT J ANAESTH, V65, P684, DOI 10.1093/bja/65.5.684; ROSENBERG J, 1992, BRIT J ANAESTH, V68, P18, DOI 10.1093/bja/68.1.18; ROSENBERG J, 1994, BRIT J ANAESTH, V72, P145, DOI 10.1093/bja/72.2.145; ROSENBERG J, 1994, J CLIN ANESTH, V6, P212, DOI 10.1016/0952-8180(94)90061-2; RosenbergAdamsen S, 1997, ANAESTHESIA, V52, P589; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; Tarassenko L, 2006, BRIT J ANAESTH, V97, P64, DOI 10.1093/bja/ael113; Taylor S, 2005, AM J SURG, V190, P752, DOI 10.1016/j.amjsurg.2005.07.015; Valencia-Flores M, 2000, OBES RES, V8, P262, DOI 10.1038/oby.2000.31; Voepel-Lewis T, 2013, INT J NURS STUD, V50, P1351, DOI 10.1016/j.ijnurstu.2013.02.006; Watkinson PJ, 2006, ANAESTHESIA, V61, P1031, DOI 10.1111/j.1365-2044.2006.04818.x; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	44	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2017	12	5							e0175408	10.1371/journal.pone.0175408	http://dx.doi.org/10.1371/journal.pone.0175408			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DX	28520718	Green Published, Green Submitted, gold			2023-01-03	WOS:000401487700003
J	Janne, PA; van den Heuvel, MM; Barlesi, F; Cobo, M; Mazieres, J; Crino, L; Orlov, S; Blackhall, F; Wolf, J; Garrido, P; Poltoratskiy, A; Mariani, G; Ghiorghiu, D; Kilgour, E; Smith, P; Kohlmann, A; Carlile, DJ; Lawrence, D; Bowen, K; Vansteenkiste, J				Janne, Pasi A.; van den Heuvel, Michel M.; Barlesi, Fabrice; Cobo, Manuel; Mazieres, Julien; Crino, Lucio; Orlov, Sergey; Blackhall, Fiona; Wolf, Juergen; Garrido, Pilar; Poltoratskiy, Artem; Mariani, Gabriella; Ghiorghiu, Dana; Kilgour, Elaine; Smith, Paul; Kohlmann, Alexander; Carlile, David J.; Lawrence, David; Bowen, Karin; Vansteenkiste, Johan			Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AZD6244 ARRY-142886; PHASE-II; MULTICENTER; MUTATIONS	IMPORTANCE There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. OBJECTIVE To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC. DESIGN, SETTING, AND PARTICIPANTS Multinational, randomized clinical trial conducted at 202 sites across 25 countries from October 2013 through January 2016. Of 3323 patients with advanced NSCLC and disease progression following first-line anticancer therapy tested for a KRAS mutation, 866 were enrolled and 510 randomized. Primary reason for exclusion was ineligibility. The data cutoff date for analysis was June 7, 2016. INTERVENTIONS Patients were randomized 1: 1; 254 to receive selumetinib + docetaxel and 256 to receive placebo + docetaxel. MAIN OUTCOMES AND MEASURES Primary end point was investigator assessed progression-free survival. Secondary end points included overall survival, objective response rate, duration of response, effects on disease-related symptoms, safety, and tolerability. RESULTS Of 510 randomized patients (mean age, 61.4 years [SD, 8.3]; women, 207 [41%]), 505 patients (99%) received treatment and completed the study (251 received selumetinib + docetaxel; 254 received placebo + docetaxel). At the time of data cutoff, 447 patients (88%) had experienced a progression event and 346 deaths (68%) had occurred. Median progression-free survival was 3.9 months (interquartile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.93 [95% CI, 0.77-1.12]; P =.44). Median overall survivalwas 8.7 months (IQR, 3.6-16.8) with selumetinib + docetaxel and 7.9 months (IQR, 3.8-20.1) with placebo + docetaxel (difference, 0.9 months; HR, 1.05 [95% CI, 0.85-1.30]; P =.64). Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel (difference, 6.4%; odds ratio, 1.61 [95% CI, 1.00-2.62]; P =.05). Median duration of response was 2.9 months (IQR, 1.7-4.8; 95% CI, 2.7-4.1) with selumetinib + docetaxel and 4.5 months (IQR, 2.3-7.3; 95% CI, 2.8-5.6) with placebo + docetaxel. Adverse events of grade 3 or higher were more frequent with selumetinib + docetaxel (169 adverse events [67%] for selumetinib + docetaxel vs 115 adverse events [45%] for placebo + docetaxel; difference, 22%). CONCLUSIONS AND RELEVANCE Among patients with previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival compared with docetaxel alone.	[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,LC4114, Boston, MA 02215 USA; [Janne, Pasi A.] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, 450 Brookline Ave,LC4114, Boston, MA 02215 USA; [van den Heuvel, Michel M.] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands; [Barlesi, Fabrice] Aix Marseille Univ, AP HP, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France; [Cobo, Manuel] Hosp Univ Malaga, Dept Med Oncol, Malaga, Spain; Toulouse Univ Hosp, Dept Pulmonol, Toulouse, France; [Crino, Lucio] Ist Ricovero Cura Carattere Sci Meldola, Ist Sci Romagnolo Studio Cura Tumori, Meldola, Italy; [Orlov, Sergey] Pavlov Med Univ, Dept Med, St Petersburg, Russia; [Blackhall, Fiona] Manchester Univ & Christie Hosp NHS Fdn Trust, Manchester, Lancs, England; [Wolf, Juergen] Univ Hosp Cologne, Dept Internal Med, Ctr Integrated Oncol, Cologne, Germany; [Garrido, Pilar] Univ Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain; [Mariani, Gabriella; Ghiorghiu, Dana; Kilgour, Elaine; Smith, Paul; Kohlmann, Alexander; Carlile, David J.; Lawrence, David] AstraZeneca, Cambridge, England; [Kohlmann, Alexander] AstraZeneca, Macclesfield, Cheshire, England; [Bowen, Karin] AstraZeneca, Gaithersburg, MD USA; [Vansteenkiste, Johan] Univ Leuven, Dept Resp Dis, Resp Oncol Unit, Univ Hosp Katholieke, Leuven, Belgium	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Netherlands Cancer Institute; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; CHU de Toulouse; IRCCS Meldola (IRST); Pavlov First Saint Petersburg State Medical University; Christie NHS Foundation Trust; Christie Hospital; University of Cologne; Hospital Universitario Ramon y Cajal; AstraZeneca; AstraZeneca; KU Leuven	Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,LC4114, Boston, MA 02215 USA.; Janne, PA (corresponding author), Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, 450 Brookline Ave,LC4114, Boston, MA 02215 USA.	pasi_janne@dfci.harvard.edu	Mariani, Gabriella Lucia/AAA-4112-2021; Vansteenkiste, Johan F/B-8191-2014; van den Heuvel, Michel M/D-9491-2017; GARRIDO, PILAR/D-5187-2017; MAZIERES, JULIEN/M-3986-2014; Orlov, Sergey/AAC-8379-2022; Blackhall, Fiona/N-2186-2015	Mariani, Gabriella Lucia/0000-0001-6882-4944; Vansteenkiste, Johan F/0000-0002-6721-2775; van den Heuvel, Michel M/0000-0002-6372-2153; GARRIDO, PILAR/0000-0002-5899-6125; Blackhall, Fiona/0000-0001-8716-3395; Orlov, Sergey/0000-0001-6080-8042	AstraZeneca; Cancer Research UK [20465] Funding Source: researchfish	AstraZeneca(AstraZeneca); Cancer Research UK(Cancer Research UK)	This study was funded by AstraZeneca. Roche Molecular Systems provided management in testing the formalin- fixed, paraffinembedded tissue samples.	[Anonymous], 1966, JAMA-J AM MED ASSOC, V197, P32, DOI [10.1001/jama.1966.03110110016005, DOI 10.1001/JAMA.1966.03110110016005]; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Burman CF, 2009, STAT MED, V28, P739, DOI 10.1002/sim.3513; Carter CA, 2016, ANN ONCOL, V27, P693, DOI 10.1093/annonc/mdw008; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Denton CL, 2011, CANCER CHEMOTH PHARM, V67, P349, DOI 10.1007/s00280-010-1323-z; Janne PA, 2015, BRIT J CANCER, V113, P199, DOI 10.1038/bjc.2015.215; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Johnson ML, 2013, CANCER-AM CANCER SOC, V119, P356, DOI 10.1002/cncr.27730; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Li D, 2016, J CLIN ONCOL S, V34; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Stone A, 2015, PHARM STAT, V14, P455, DOI 10.1002/pst.1707; Wood K, 2016, JAMA ONCOL, V2, P805, DOI 10.1001/jamaoncol.2016.0405; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150	23	228	233	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 9	2017	317	18					1844	1853		10.1001/jama.2017.3438	http://dx.doi.org/10.1001/jama.2017.3438			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU2FK	28492898	Green Published			2023-01-03	WOS:000400842400015
J	Rubin, R				Rubin, Rita			Medical Marijuana Is Legal in Most States, but Physicians Have Little Evidence to Guide Them	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item													Rubin, Rita/AAD-1259-2020						0	15	16	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2017	317	16					1611	1613		10.1001/jama.2017.0813	http://dx.doi.org/10.1001/jama.2017.0813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET1FW	28384774				2023-01-03	WOS:000400014000002
J	Thomas, T; Amouroux, F; Vincent, P				Thomas, Thierry; Amouroux, Francoise; Vincent, Patrice			Intra articular hyaluronic acid in the management of knee osteoarthritis: Pharmaco-economic study from the perspective of the national health insurance system	PLOS ONE			English	Article							CONTROLLED-TRIALS; METAANALYSIS; VISCOSUPPLEMENTATION; EFFICACY; PAIN; INJECTIONS; WOMAC; COST; HIP	Introduction Pharmaco-economic data on the management of knee osteoarthritis (OA) with intra articular hyaluronic acid (IA HA) viscosupplementation is limited. We contrasted IA HA with non-steroidal anti-inflammatory drugs (NSAIDs). Methods Observational, prospective and multicenter study comparing treatments of knee OA costs and efficacy with either NSAIDs alone, or hyaluronic acid (Arthrum H 2%(R)), during a 6-month follow-up period. The investigators were pharmacists who recorded data on disease, drug consumption and healthcare circuit. Retrospectively, the 6-month period preceding inclusion was also studied, to ensure the comparability of groups. Results 199 patients were analyzed in a NSAIDs group and 202 in an IA HA group. Any of the WOMAC sub-scores and the EQ-5D Quality of Life index were significantly improved in the IA HA group (p<0.0001) at 3 and 6 months. Clinical results were therefore in favor of the IA HA group. The total drug expenses per 6-month period were comparable before and after inclusion, sic96 and sic98 for NSAIDs group vs sic94 and sic101 for IA HA group, which indicates no evidence of additional cost from IA HA. For the active part of the population, the incidence of sick leave was lower in the IA HA group, indicating a better maintenance of patient activity. The overall expense on 12 months (6 months before and 6 months after inclusion) for the national health insurance system was comparable for NSAIDs and IA HA groups: sic528 and sic526, respectively. The number of patients taking NSAIDs significantly decreased in IA HA group (from 100% at inclusion to 66% at 1-3 months and 44% at 4-6 months), but remained unchanged (100%) during the follow-up period, in NSAIDs group. Conclusion Treatment with IA HA did not generate additional cost for the national health insurance and was associated with a functional improvement of knee osteoarthritis and Quality of Life. The cost- utility analysis was in favor of IA HA, with a gain of QALY equivalent to half a month, after the 6-month follow-up period comparing both treatments. The NSAIDs consumption was decreased in the IA HA group, resulting in an improved estimated benefit/risk ratio.	[Thomas, Thierry] CHU, Serv Rhumatol, St Etienne, France; [Amouroux, Francoise] UFR Sci Pharmaceut, Bordeaux, France; [Vincent, Patrice] LCA Pharmaceut, Chartres, France	CHU de St Etienne	Vincent, P (corresponding author), LCA Pharmaceut, Chartres, France.	pvincent@lca-pharma.com			LCA Pharmaceutical	LCA Pharmaceutical	This research was entirely funded by LCA Pharmaceutical. PV is employed by LCA Pharmaceutical. LCA Pharmaceutical provided support in the form of salary for PV but did not have any additional role in the study design, data collection and analysis and final report of the study. The only role was the participation to the article.	Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; [Anonymous], 2016, CLIN TRIALS REG REC; Arramon JY, 2008, MINERVA ORTOP TRAUMA, V59, P69; Bannuru RR, 2011, OSTEOARTHR CARTILAGE, V19, P611, DOI 10.1016/j.joca.2010.09.014; Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14-1231; Bannuru RR, 2014, SEMIN ARTHRITIS RHEU, V43, P593, DOI 10.1016/j.semarthrit.2013.10.002; Bannuru RR, 2009, ARTHRIT RHEUM-ARTHR, V61, P1704, DOI 10.1002/art.24925; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2; Bruyere O, 2014, SEMIN ARTHRITIS RHEU, V44, P253, DOI 10.1016/j.semarthrit.2014.05.014; Campbell KA, 2015, J ARTHROSCOPIC RELAT, P1; Cheung K, 2009, EUROQOL GROUP 2009; Germonville T, 2015, MINERVA ORTOP TRAUMA, V66, P235; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; Guillemin F, 2011, OSTEOARTHR CARTILAGE, V19, P1314, DOI 10.1016/j.joca.2011.08.004; Gupta S, 2005, RHEUMATOLOGY, V44, P1531, DOI 10.1093/rheumatology/kei049; Hatoum Hind T, 2014, J Med Econ, V17, P326, DOI 10.3111/13696998.2014.902843; Henrotin Y, 2015, SEMIN ARTHRITIS RHEU, V45, P140, DOI 10.1016/j.semarthrit.2015.04.011; Hilliquin P., 2016, REFLEXIONS RHUMATOLO, V181, P41; Kahan A, 2003, JOINT BONE SPINE, V70, P276, DOI 10.1016/S1297-319X(03)00043-5; Le Pen C, 2005, JOINT BONE SPINE, V72, P567, DOI 10.1016/j.jbspin.2005.01.011; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Mazieres B, 2007, JOINT BONE SPINE, V74, P453, DOI 10.1016/j.jbspin.2007.01.037; McAlindon TE, NATURE REV RHEUMATOL, V2012, P635; McConnell S, 2001, ARTHRIT RHEUM-ARTHR, V45, P453, DOI 10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W; Medina JM, 2006, J FAM PRACTICE, V55, P669; Miller LE, 2013, CLIN MED INSIGHTS-AR, V6, P57, DOI 10.4137/CMAMD.S12743; Modawal A, 2005, J FAM PRACTICE, V54, P758; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Roth SH, 2011, PHYSICIAN SPORTSMED, V39, P62, DOI 10.3810/psm.2011.09.1922; Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003-4819-157-3-201208070-00473; Societe Francaise de Rhumatologie, 2006, EP MAL RHUM; Waddell DD, 2007, DRUG AGING, V24, P629, DOI 10.2165/00002512-200724080-00002; Wang CT, 2004, J BONE JOINT SURG AM, V86A, P538, DOI 10.2106/00004623-200403000-00012; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	34	20	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0173683	10.1371/journal.pone.0173683	http://dx.doi.org/10.1371/journal.pone.0173683			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8SZ	28328935	Green Submitted, Green Published, gold			2023-01-03	WOS:000399094700029
J	Maki, C; Funakoshi-Tago, M; Aoyagi, R; Ueda, F; Kimura, M; Kobata, K; Tago, K; Tamura, H				Maki, Chihiro; Funakoshi-Tago, Megumi; Aoyagi, Ryohei; Ueda, Fumihito; Kimura, Masaki; Kobata, Kenji; Tago, Kenji; Tamura, Hiroomi			Coffee extract inhibits adipogenesis in 3T3-L1 preadipocyes by interrupting insulin signaling through the downregulation of IRS1	PLOS ONE			English	Article							MITOTIC CLONAL EXPANSION; DIFFERENTIATION-INDUCED GENE; BINDING-PROTEIN; C/EBP-BETA; EARLY PHASE; EXPRESSION; ACID; FAT; FIBROBLASTS; CONSUMPTION	Although epidemiological data have indicated that a strong negative association exists between coffee consumption and the prevalence of obesity-associated diseases, the molecular mechanisms by which coffee intake prevents obesity-associated diseases has not yet been elucidated. In this study, we found that coffee intake significantly suppressed high-fat diet (HFD)-induced metabolic alternations such as increases in body weight and the accumulation of adipose tissue, and up-regulation of glucose, free fatty acid, total cholesterol and insulin levels in the blood. We also found that coffee extract significantly inhibited adipogenesis in 3T3-L1 preadipocytes. In the early phase of adipogenesis, 3T3-L1 cells treated with coffee extract displayed the retardation of cell cycle entry into the G2/M phase called as mitotic clonal expansion (MCE). Coffee extract also inhibited the activation of CCAAT/enhancer-binding protein beta (C/EBP beta) by preventing its phosphorylation by ERK. Furthermore, the coffee extract suppressed the adipogenesis-related events such as MCE and C/EBP beta activation through the down-regulation of insulin receptor substrate 1 (IRS1). The stability of the IRS1 protein was markedly decreased by the treatment with coffee extract due to proteasomal degradation. These results have revealed an anti-adipogenic function for coffee intake and identified IRS1 as a novel target for coffee extract in adipogenesis.	[Maki, Chihiro; Funakoshi-Tago, Megumi; Aoyagi, Ryohei; Ueda, Fumihito; Kimura, Masaki; Tamura, Hiroomi] Keio Univ, Grad Sch Pharmaceut Sci, Minato Ku, Tokyo, Japan; [Kobata, Kenji] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama, Japan; [Tago, Kenji] Jichi Med Univ, Dept Biochem, Div Struct Biochem, Shimotsuke, Japan	Keio University; Josai University; Jichi Medical University	Funakoshi-Tago, M (corresponding author), Keio Univ, Grad Sch Pharmaceut Sci, Minato Ku, Tokyo, Japan.	tago-mg@pha.keio.ac.jp		Ueda, Fumihito/0000-0003-1241-1643	MEXT [15K00883]; Mishima Kaiun Memorial Foundation; Informatics, Tobemaki Scholarship Foundation; Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan [25460073]	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mishima Kaiun Memorial Foundation(Mishima Kaiun Memorial Foundation); Informatics, Tobemaki Scholarship Foundation; Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was supported in part by grants (15K00883) from MEXT, Mishima Kaiun Memorial Foundation and Informatics, Tobemaki Scholarship Foundation, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan (25460073).	Aoyagi R, 2014, BIOL PHARM BULL, V37, P1820, DOI 10.1248/bpb.b14-00378; Aparicio T, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-18; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Berg T, 2005, BIOCHEM BIOPH RES CO, V334, P638, DOI 10.1016/j.bbrc.2005.06.146; Bohn SK, 2012, FOOD FUNCT, V3, P575, DOI 10.1039/c2fo10288a; Bohn SK, 2014, MOL NUTR FOOD RES, V58, P915, DOI 10.1002/mnfr.201300526; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cho AS, 2010, FOOD CHEM TOXICOL, V48, P937, DOI 10.1016/j.fct.2010.01.003; Choi BK, 2016, ASIAN PAC J TROP MED, V9, P616, DOI 10.1016/j.apjtm.2016.05.017; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Funakoshi-Tago M, 2010, J BIOL CHEM, V285, P5296, DOI 10.1074/jbc.M109.040733; Guo L, 2012, CELL DEATH DIFFER, V19, P1917, DOI 10.1038/cdd.2012.75; Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439; Krebs DL, 2000, J CELL SCI, V113, P2813; Kwon JY, 2012, NUTR RES, V32, P607, DOI 10.1016/j.nutres.2012.06.014; Kwon JY, 2012, J BIOL CHEM, V287, P11566, DOI 10.1074/jbc.M111.259721; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; Ludwig IA, 2014, FOOD FUNCT, V5, P1695, DOI [10.1039/c4fo00042k, 10.1039/C4FO00042K]; Ma YJ, 2015, PHARM RES-DORDR, V32, P1200, DOI 10.1007/s11095-014-1526-9; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Myneni R. B., 2012, ENVIRON RES LETT, V7, P1, DOI DOI 10.1074/JBC.M112.405209; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Shimocka II, 2006, BMC COMPLEM ALTERN M, V6, P9, DOI [10.1186/1472-6882-6-9, DOI 10.1186/1472-6882-6-9]; Song SJ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/718379; Stephens JM, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001436; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Xu XS, 2008, MOL CELL, V30, P403, DOI 10.1016/j.molcel.2008.03.009; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	45	37	36	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2017	12	3							e0173264	10.1371/journal.pone.0173264	http://dx.doi.org/10.1371/journal.pone.0173264			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6CJ	28282409	Green Published, gold, Green Submitted			2023-01-03	WOS:000396091800025
J	Matsubara, Y; Kimachi, M; Fukuma, S; Onishi, Y; Fukuhara, S				Matsubara, Yukiko; Kimachi, Miho; Fukuma, Shingo; Onishi, Yoshihiro; Fukuhara, Shunichi			Development of a new risk model for predicting cardiovascular events among hemodialysis patients: Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS)	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CONGESTIVE-HEART-FAILURE; CORONARY-ARTERY DISEASE; MORTALITY RISK; MINERAL METABOLISM; UNITED-STATES; ATHEROSCLEROSIS; ASSOCIATION; CALCIUM; ANEMIA	Background Cardiovascular (CV) events are the primary cause of death and becoming bedridden among hemodialysis (HD) patients. The Framingham risk score (FRS) is useful for predicting incidence of CV events in the general population, but is considerd to be unsuitable for the prediction of the incidence of CV events in HD patients, given their characteristics due to atypical relationships between conventional risk factors and outcomes. We therefore aimed to develop a new prognostic prediction model for prevention and early detection of CV events among hemodialysis patients. Methods We enrolled 3,601 maintenance HD patients based on their data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS), phases 3 and 4. We longitudinaly assessed the association between several potential candidate predictors and composite CV events in the year after study initiation. Potential candidate predictors included the component factors of FRS and other HD-specific risk factors. We used multivariable logistic regression with backward stepwise selection to develop our new prediction model and generated a calibration plot. Additinially, we performed bootstrapping to assess the internal validity. Results We observed 328 composite CV events during 1-year follow-up. The final prediction model contained six variables: age, diabetes status, history of CV events, dialysis time per session, and serum phosphorus and albumin levels. The new model showed significantly better discrimination than the FRS, in both men (c-statistics: 0.76 for new model, 0.64 for FRS) and women (c-statistics: 0.77 for new model, 0.60 for FRS). Additionally, we confirmed the consistency between the observed results and predicted results using the calibration plot. Further, we found similar discrimination and calibration to the derivation model in the boot-strapping cohort. Conclusions We developed a new risk model consisting of only six predictors. Our new model predicted CV events more accurately than the FRS.	[Matsubara, Yukiko] Akane Fdn Omachi Tsuchiya Clin, Dept Artificial Organs, Hiroshima, Japan; [Matsubara, Yukiko] Hiroshima Med Univ, Hiroshima, Japan; [Kimachi, Miho; Fukuma, Shingo; Fukuhara, Shunichi] Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Healthcare Epidemiol, Kyoto, Japan; [Kimachi, Miho; Fukuma, Shingo; Onishi, Yoshihiro] IHope Int, Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Japan; [Fukuma, Shingo; Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima, Japan	Hiroshima University; Kyoto University; Fukushima Medical University	Fukuma, S (corresponding author), Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Healthcare Epidemiol, Kyoto, Japan.	fukuma.shingo.3m@kyoto-u.ac.jp	Fukuma, Shingo/S-6584-2019	Fukuma, Shingo/0000-0002-8379-8761				Akdag I, 2008, NEPHRON CLIN PRACT, V108, pC99, DOI 10.1159/000113526; Beddhu S, 2004, J AM SOC NEPHROL, V15, P733, DOI 10.1097/01.ASN.0000113319.57131.28; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Brindle P, 2006, HEART, V92, P1752, DOI 10.1136/hrt.2006.087932; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Cavanaugh KL, 2008, AM J KIDNEY DIS, V52, P118, DOI 10.1053/j.ajkd.2008.02.001; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; Floege J, 2015, KIDNEY INT, V87, P996, DOI 10.1038/ki.2014.419; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Frank H, 2004, KIDNEY INT, V66, P832, DOI 10.1111/j.1523-1755.2004.00810.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223; Huang JC, 2013, NEPHROLOGY, V18, P510, DOI 10.1111/nep.12094; Iaina A, 2005, NAT CLIN PRACT CARD, V2, P95, DOI 10.1038/ncpcardio0094; Johansen KL, 2015, BLOOD PURIFICAT, V40, P288, DOI 10.1159/000441575; Joki N, 1997, NEPHROL DIAL TRANSPL, V12, P718, DOI 10.1093/ndt/12.4.718; Jurkovitz C, 2006, CURR OPIN NEPHROL HY, V15, P117, DOI 10.1097/01.mnh.0000214769.11609.2d; KNOTTNERUS JA, 1995, PRIMARY CARE, V22, P341; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Ohtake T, 2005, J AM SOC NEPHROL, V16, P1141, DOI 10.1681/ASN.2004090765; Okwuosa TM, 2011, J AM COLL CARDIOL, V57, P1838, DOI 10.1016/j.jacc.2010.11.053; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Silverberg DS, 2003, KIDNEY INT, V64, pS40, DOI 10.1046/j.1523-1755.64.s87.7.x; Silverberg DS, 2003, NEPHROL DIAL TRANSPL, V18, P141, DOI 10.1093/ndt/18.1.141; Stack AG, 2001, J AM SOC NEPHROL, V12, P1516, DOI 10.1681/ASN.V1271516; Steyerberg EW, 2005, J CLIN EPIDEMIOL, V58, P383, DOI 10.1016/j.jclinepi.2004.07.008; Steyerberg EW, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.07.008; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; Sumida K, 2016, NEPHROL DIAL TRANSPL, V31, P298, DOI 10.1093/ndt/gfv402; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Wang JL, 2012, NEPHRON CLIN PRACT, V121, pC102, DOI 10.1159/000345159; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Xiao JB, 2014, PLOS ONE, V9, DOI [10.1155/2014/584164, 10.1371/journal.pone.0089097, 10.1371/journal.pone.0093842]; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	45	7	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2017	12	3							e0173468	10.1371/journal.pone.0173468	http://dx.doi.org/10.1371/journal.pone.0173468			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5VL	28273175	Green Published, gold, Green Submitted			2023-01-03	WOS:000396073700008
J	Tornbom, K; Sunnerhagen, KS; Danielsson, A				Tornbom, Karin; Sunnerhagen, Katharina S.; Danielsson, Anna			Perceptions of physical activity and walking in an early stage after stroke or acquired brain injury	PLOS ONE			English	Article							QUALITATIVE CONTENT-ANALYSIS; PERCEIVED BARRIERS; REHABILITATION; EXERCISE; SURVIVORS; FACILITATORS; INDIVIDUALS; PERFORMANCE; POPULATION; INTERVIEWS	Background Physical activity has been established as being highly beneficial for health after stroke. There are considerable global efforts to find rehabilitation programs that encourage increased physical activity for persons with stroke. However, many persons with stroke or acquired brain injury do not reach recommended levels of physical activity and increased knowledge about why is needed. We aimed to explore views and experiences of physical activity and walking among persons with stroke or acquired brain injury. Method A qualitative study was conducted, among persons with stroke (n = 8) or acquired brain injury (n = 2) from a rehabilitation unit at Sahlgrenska University Hospital in Sweden. Semi-structured in-depth interviews were held about perceptions and experiences of walking and physical activity in general. Data were analyzed using qualitative content analysis, with categories that were determined inductively. Results Physical activity in general and walking ability more specifically were considered very important by the participants. However, physical activity was, regardless of exercising habits pre-injury, associated with different kinds of negative feelings and experiences. Commonly reported internal barriers in the current study were; fatigue, fear of falling or getting hurt in traffic, lack of motivation and depression. Reported external barriers were mostly related to walking, for example; bad weather, uneven ground, lack of company or noisy or too busy surroundings. Conclusion Persons with stroke or acquired brain injury found it difficult to engage in and sustain an eligible level of physical activity. Understanding individual concerns about motivators and barriers surrounding physical activity may facilitate the work of forming tailor-made rehabilitation for these groups, so that the levels of physical activity and walking can increase.	[Tornbom, Karin; Sunnerhagen, Katharina S.; Danielsson, Anna] Univ Gothenburg, Sahlgrenska Acad, Res Grp Rehabil Med, Inst Neurosci & Physiol,Dept Clin Neurosci, Gothenburg, Sweden; [Tornbom, Karin; Sunnerhagen, Katharina S.] Univ Gothenburg, Ctr Person Ctr Care GPCC, Gothenburg, Sweden; [Danielsson, Anna] Univ Gothenburg, Dept Hlth & Rehabil, Unit Physiotherapy, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Tornbom, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Res Grp Rehabil Med, Inst Neurosci & Physiol,Dept Clin Neurosci, Gothenburg, Sweden.; Tornbom, K (corresponding author), Univ Gothenburg, Ctr Person Ctr Care GPCC, Gothenburg, Sweden.	karin.tornbom@neuro.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400; Danielsson, Anna/0000-0002-6496-4066	John and Brit Wennerstrom foundation for Neurological Research; Norrbacka-Eugenia foundation [808-12]; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Hjalmar Svensson foundation [HJSV2012056]; Swedish Stroke Centre West	John and Brit Wennerstrom foundation for Neurological Research; Norrbacka-Eugenia foundation; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Hjalmar Svensson foundation; Swedish Stroke Centre West	John and Brit Wennerstrom foundation for Neurological Research; The Norrbacka-Eugenia foundation, 808-12; Rune and Ulla Amlovs foundation for Neurological Research; The Swedish Stroke association; Hjalmar Svensson foundation, HJSV2012056; and The Swedish Stroke Centre West. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; BOHANNON RW, 1988, INT J REHABIL RES, V11, P181, DOI 10.1097/00004356-198806000-00012; Bonner NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164120; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; Combs SA, 2013, DISABIL REHABIL, V35, P860, DOI 10.3109/09638288.2012.717575; Damush TM, 2007, REHABIL NURS, V32, P253, DOI 10.1002/j.2048-7940.2007.tb00183.x; Danielsson A, 2014, PM&R, V6, P139, DOI 10.1016/j.pmrj.2013.08.593; Driver S, 2012, DISABIL HEALTH J, V5, P117, DOI 10.1016/j.dhjo.2011.11.002; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; English C, 2016, TOP STROKE REHABIL, V23, P62, DOI 10.1179/1945511915Y.0000000009; English C, 2016, PHYS THER, V96, P193, DOI 10.2522/ptj.20140522; Evenson KR, 2014, J CARDIOPULM REHABIL, V34, P406, DOI 10.1097/HCR.0000000000000064; Gallagher Patti, 2011, Can J Neurosci Nurs, V33, P24; Galvin R, 2009, INT J REHABIL RES, V32, P238, DOI 10.1097/MRR.0b013e32832b083c; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Hankey GJ, 2003, CEREBROVASC DIS, V16, P14, DOI 10.1159/000069936; Harris Jocelyn E, 2004, Physiother Can, V56, P171, DOI 10.2310/6640.2004.00017; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Idowu OA, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.274.6669; Ivey FM, 2008, J CARDIOPULM REHABIL, V28, P2, DOI 10.1097/01.HCR.0000311501.57022.a8; Jaracz K, 2014, NEUROL NEUROCHIR POL, V48, P280, DOI 10.1016/j.pjnns.2014.07.004; Kirkevold Marit, 2014, BMC Psychol, V2, P4, DOI 10.1186/2050-7283-2-4; Kucukdeveci AA, 2011, J REHABIL MED, V43, P661, DOI 10.2340/16501977-0844; Luker J, 2015, ARCH PHYS MED REHAB, V96, P1698, DOI 10.1016/j.apmr.2015.03.017; Maclean N, 2000, SOC SCI MED, V50, P495; Maclean N, 2000, BMJ-BRIT MED J, V321, P1051, DOI 10.1136/bmj.321.7268.1051; Mead GE, 2007, J AM GERIATR SOC, V55, P892, DOI 10.1111/j.1532-5415.2007.01185.x; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Nadeau SE, 2016, NEUROREHAB NEURAL RE, V30, P615, DOI 10.1177/1545968315613851; Nicholson S, 2013, INT J STROKE, V8, P357, DOI 10.1111/j.1747-4949.2012.00880.x; Nicholson SL, 2014, DISABIL REHABIL, V36, P1857, DOI 10.3109/09638288.2013.874506; Ohman A, 2005, J REHABIL MED, V37, P273, DOI 10.1080/16501970510040056; Patterson S, 2009, INT J THER REHABIL, V16, P659, DOI 10.12968/ijtr.2009.16.12.45422; Peters K, 2015, NURSE RES, V22, P6, DOI 10.7748/nr.22.4.6.s2; Resnick B, 2008, TOP STROKE REHABIL, V15, P494, DOI 10.1310/tsr1505-494; Riks-Stroke, 2015, RIKS STROK YEARL RAP; Rimmer JH, 2008, J REHABIL RES DEV, V45, P315, DOI 10.1682/JRRD.2007.02.0042; Rimmer JH, 2010, AM J PHYS MED REHAB, V89, P249, DOI 10.1097/PHM.0b013e3181c9fa9d; Robison J, 2009, DISABIL REHABIL, V31, P1555, DOI 10.1080/09638280802639327; Salbach NM, 2009, PHYS THER, V89, P556, DOI 10.2522/ptj.20080249; Sunnehagen KS, 2000, SCAND J REHABIL MED, V32, P159; Vanroy C, 2016, TOP STROKE REHABIL, V23, P98, DOI 10.1080/10749357.2015.1116227; Veluswamy SK, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-27; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Witte US, 1997, SCAND J REHABIL MED, V29, P161; World Health Organization (WHO), 2016, PHYS ACTIVITY	48	21	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2017	12	3							e0173463	10.1371/journal.pone.0173463	http://dx.doi.org/10.1371/journal.pone.0173463			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN5VL	28273158	Green Published, gold			2023-01-03	WOS:000396073700005
J	Lyon, J				Lyon, Jeff			Alzheimer Outlook Far From Bleak	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	6	8	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2017	317	9					896	898		10.1001/jama.2017.0276	http://dx.doi.org/10.1001/jama.2017.0276			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM8DM	28199483				2023-01-03	WOS:000395541500002
J	Majeed, M; Bani, S; Natarajan, S; Pandey, A; Naveed, S				Majeed, Muhammed; Bani, Sarang; Natarajan, Sankaran; Pandey, Anjali; Naveed, S.			Evaluation of 90 day repeated dose oral toxicity and reproductive/developmental toxicity of 3 '-hydroxypterostilbene in experimental animals	PLOS ONE			English	Article							APOPTOSIS-INDUCING AGENTS; SPHAEROPHYSA-SALSULA; ANTIOXIDANT; PTEROSTILBENE	3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium. Despite many proposed therapeutic applications, the safety profile of 3'-HPT has not been established. The present work investigated 90 day repeated oral dose and reproductive (developmental) toxicity of 3'-HPT as a test substance in rats as per OECD guidelines. 90 day toxicity was conducted in sixty Sprague Dawley rats of each sex (120 rats), grouped into six dosage groups of 0 (control), 0 (control recovery), 20 (low dose), 80 (mid dose), 200 (high dose) and 200 (high dose recovery) mg/kg bwt/day (body weight/day) respectively. For the reproductive toxicity study forty Wistar rats of each sex (80 rats) divided into four dosage groups received 0 (vehicle control), 20 (low dose), 100 (mid dose) and 200 (high dose) mg/kg bwt/day of 3'-HPT respectively for a period of two weeks while pre-mating, mating, on the day before sacrifice, in females during pregnancy and four days of lactation period. Results showed no significant differences in body weight, food intake, absolute organ weight, haematology, with no adverse effects (toxicity) on biochemical values nor any abnormal clinical signs or behavioural changes were observed in any of the control/treatment groups, including reproductive and developmental parameters, gross and histopathological changes. In conclusion, the results suggested a No-Observed-Adverse-Effect-Level (NOAEL) of 200 mg/kg bwt/day in rats after oral administration, implying 3'-HPT did not exhibit any toxicity under the study conditions employed.	[Majeed, Muhammed] Sami Labs Ltd, Bangalore, Karnataka, India; [Bani, Sarang; Pandey, Anjali] Sami Labs Ltd, Dept Biol Res, Bangalore, Karnataka, India; [Natarajan, Sankaran] Sami Labs Ltd, Ctr Res & Dev, Bangalore, Karnataka, India; [Naveed, S.] ClinWorld Private Ltd, ClinWorld, Bangalore, Karnataka, India		Naveed, S (corresponding author), ClinWorld Private Ltd, ClinWorld, Bangalore, Karnataka, India.	naveed@clinworld.org			Sami Labs Limited; ClinWorld (P) Limited	Sami Labs Limited; ClinWorld (P) Limited	This work was sponsored by Sami Labs Limited. There was no external funding involved. The funder provided support in the form of salaries for authors of both Sami Labs Limited and ClinWorld (P) Limited [MM, SB, AP, SN and NVS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors affiliated to Sami Labs or ClinWorld are articulated in the 'author contributions' section.	GILL MT, 1987, J NAT PROD, V50, P36, DOI 10.1021/np50049a006; Ma ZJ, 2002, FITOTERAPIA, V73, P313, DOI 10.1016/S0367-326X(02)00074-6; Majeed M, 2015, United States patent US, Patent No. [9050284 B2, 9050284]; Majeed M, 2016, United States Patent US, Patent No. [9458075 B1, 9458075]; Monagas M, 2006, J AGR FOOD CHEM, V54, P319, DOI 10.1021/jf051807j; Nagabhushanam K., 2009, PharmaChem, V8, P2; OECD, 1995, OECD GUID TEST CHEM; OECD (Organization for Economic Co-operation and Development), 1998, FISH SHORT TERM TOX; Roberti M, 2003, J MED CHEM, V46, P3546, DOI 10.1021/jm030785u; Roupe KA, 2006, CURR CLIN PHARMACOL, V1, P81, DOI 10.2174/157488406775268246; Shao X, 2010, RAPID COMMUN MASS SP, V24, P1770, DOI 10.1002/rcm.4579; Takemotoa JK, 2015, J PHARM PHARM SCI, V18, P713, DOI 10.18433/J33W4C; Tolomeo M, 2005, INT J BIOCHEM CELL B, V37, P1709, DOI 10.1016/j.biocel.2005.03.004; Venkateswarlu S, 2003, BIOSCI BIOTECH BIOCH, V67, P2463, DOI 10.1271/bbb.67.2463	14	5	5	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0172770	10.1371/journal.pone.0172770	http://dx.doi.org/10.1371/journal.pone.0172770			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5BR	28257483	Green Submitted, gold, Green Published			2023-01-03	WOS:000396021100026
J	Leao, ER; Dal Fabbro, DR; de Oliveira, RB; dos Santos, IR; Victor, ED; Aquarone, RL; Andrade, CB; Ribeiro, VF; de Oliveira, RC; Friedlander, R; Ferreira, DS				Leao, Eliseth Ribeiro; Dal Fabbro, Daniela Reis; de Oliveira, Rebeca Barqueiro; dos Santos, Ingrid Ribeiro; Victor, Elivane da Silva; Aquarone, Rita Lacerda; Andrade, Cristiane Benvenuto; Ribeiro, Vivian Finotti; de Oliveira, Roselaine Coelho; Friedlander, Rosa; Ferreira, Daniela Santos			Stress, self-esteem and well-being among female health professionals: A randomized clinical trial on the impact of a self-care intervention mediated by the senses	PLOS ONE			English	Article							LOW-BACK-PAIN; LIFE SATISFACTION; MASSAGE; NURSES	Background Stress levels are evident among health professionals. However, there are few studies on sensory-based self-care aimed at stress management, self-esteem and subjective wellbeing in this group of professionals. Objective To assess the impact of a self-care intervention mediated by the senses on the stress levels, self-esteem and well-being of health professionals in a hospital environment. Methods A total of 93 health professionals participated in an unblinded clinical trial, randomized into four groups: 1) control (no intervention); 2) Monosensory-daily body moisturizing (DBM) with odorless cream; 3) Bisensory-DBM with scented cream; 4) Multisensory-DBM with scented cream associated with audiovisual material. Participants answered specific questionnaires to assess stress, self-esteem and well-being and cortisol samples were collected at baseline, 15 and 30 days following intervention, and at the 30-day follow-up. Results Self-care was characterized as neglected, with most participants reporting inadequate hours of sleep (74%), irregular physical activity (68%), and inadequate nutrition (45%). Compared to the other groups, the Bisensory group had lower stress on all three assessments (p = 0.017; 0.012; 0.036), a life satisfaction 8% higher at follow-up than at baseline (95% CI: 2% to 15%, p = 0.016), a 10% increase in positive affect (95% CI: 2% to 19%, p = 0.011) and a 12% reduction in negative affect (95% CI: 3% to 21% less, p = 0.014) after 30 days. The Multisensory group showed improvement in self-esteem (p = 0.012) and reduced cortisol (p = 0.036) after 30 days of intervention. The control group showed no changes in the variables studied, except for cortisol: an increase at the 15-day evaluation (denoting higher risk for stress, p = 0.009) and a reduction at follow-up (p = 0.028), which was nevertheless within normal levels.	[Leao, Eliseth Ribeiro; Dal Fabbro, Daniela Reis; de Oliveira, Rebeca Barqueiro; dos Santos, Ingrid Ribeiro; Victor, Elivane da Silva; Andrade, Cristiane Benvenuto] Hosp Israelita Albert Einstein, Res Inst, Sao Paulo, Brazil; [Aquarone, Rita Lacerda] Univ Sao Paulo, Sao Paulo, Brazil; [Ribeiro, Vivian Finotti] Hosp Israelita Albert Einstein, Israeli Fac Heath Sci Albert Einstein, Sao Paulo, Brazil; [de Oliveira, Roselaine Coelho] Hosp Israelita Albert Einstein, Qual & Safety, Sao Paulo, Brazil; [Friedlander, Rosa; Ferreira, Daniela Santos] Nat Cosmet, Sao Paulo, Brazil	Hospital Israelita Albert Einstein; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Hospital Israelita Albert Einstein	Leao, ER (corresponding author), Hosp Israelita Albert Einstein, Res Inst, Sao Paulo, Brazil.	eliseth.leao@einstein.br	Ribeiro, Vivian/AAD-6172-2021; Leao, Eliseth R/J-7143-2012	Leao, Eliseth R/0000-0003-0352-0549	Natura Cosmeticos	Natura Cosmeticos	Natura Cosmeticos provided support in the form of salaries for authors RF and DSF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Almeida MCP, 1989, SABER ENFERMAGEM SUA; Bagglio Maria Aparecida, 2007, Rev Gaucha Enferm, V28, P233; Barros Dalton de Souza, 2008, Rev. bras. ter. intensiva, V20, P235, DOI 10.1590/S0103-507X2008000300005; BLEGEN MA, 1993, NURS RES, V42, P36; Borda RG, 1997, INT J NURS STUD, V34, P385, DOI 10.1016/S0020-7489(97)00031-X; Borges TP, 2012, REV LAT-AM ENFERM, V20, P511, DOI 10.1590/S0104-11692012000300012; Cady SH, 1997, PERCEPT MOTOR SKILL, V84, P157, DOI 10.2466/pms.1997.84.1.157; Camelo Silvia H. Henriques, 2004, Rev. Latino-Am. Enfermagem, V12, P14, DOI 10.1590/S0104-11692004000100003; CASCIO WF, 1995, AM PSYCHOL, V50, P928, DOI 10.1037/0003-066X.50.11.928; Castro Margaret, 2003, Arq Bras Endocrinol Metab, V47, P358, DOI 10.1590/S0004-27302003000400008; Chaves S. S. S., 2003, DISSERTACAO MESTRADO; Chaves SSS, 2007, THESIS; Cooper Marcus C., 1995, GARDENS HEALTHCARE F; Core-Team, 2015, LANG ENV STAT COMP; de Carvalho V T, 1999, Rev Lat Am Enfermagem, V7, P67; De Martino Milva Maria Figueiredo, 2004, Rev. esc. enferm. USP, V38, P161; Barbosa de Oliveira Luciana C, 2008, Rev. salud pública, V10, P405, DOI 10.1590/S0124-00642008000300005; DIENER E, 1995, J PERS SOC PSYCHOL, V68, P653, DOI 10.1037/0022-3514.68.4.653; Diener E, 1996, PSYCHOL SCI, V7, P181, DOI 10.1111/j.1467-9280.1996.tb00354.x; DIENER E, 1984, J PERS SOC PSYCHOL, V47, P1105, DOI 10.1037/0022-3514.47.5.1105; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkstra K, 2006, J ADV NURS, V56, P166, DOI 10.1111/j.1365-2648.2006.03990.x; Drahota A, COCHRANE DATABASE SY, V201, P23; Furlan AD, 2009, SPINE, V34, P1669, DOI 10.1097/BRS.0b013e3181ad7bd6; Ganzini L, 2013, PALLIAT SUPPORT CARE, V13, P1; Garcia-Huidobro D, 2008, REV MED CHILE, V136, P809, DOI /S0034-98872008000600019; Giuberti Ana Carolina, 2005, Econ. Apl., V9, P369, DOI 10.1590/S1413-80502005000300002; GOATS GC, 1994, BRIT J SPORT MED, V28, P153, DOI 10.1136/bjsm.28.3.153; Goncalves S., 2004, PSICOL ESTUD, V9, P499, DOI DOI 10.1590/S1413-73722004000300018; Gouveia VV, 2009, SOC INDIC RES, V90, P267, DOI 10.1007/s11205-008-9257-0; Grant F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067395; Guido LD, 2011, REV ESC ENFERM USP, V45, P1427; Headey B., 1991, SUBJECTIVE WELL BEIN, P49; Hutz CS, 2011, AVALIACAO PSICOLOGIC, V10, P41; Ignatt C, 2012, NURSES SUFFERING PSY; Kravits K, 2010, APPL NURS RES, V23, P130, DOI 10.1016/j.apnr.2008.08.002; Regis LFLV, 2011, REV ESC ENFERM USP, V45, P332; Lai HL, 2011, J ADV NURS, V67, P2414, DOI 10.1111/j.1365-2648.2011.05670.x; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lipp MEN, 1994, ESTUD PSICOL-MADRID, V11; Liu SH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/853809; Lopes Guerrer FJ, 2011, ENFERM GLOB, V10, P1; Maslow A.H., 1987, MOTIVATION PERSONALI; Mc Cabe C, 2011, PSYCHOL ONCOLOGY; MCGEE RA, 1989, J COUNS PSYCHOL, V36, P345, DOI 10.1037/0022-0167.36.3.345; McGrath M., 1992, MY GENTLE HARP IRISH; Moraska A, 2010, EVID-BASED COMPL ALT, V7, P409, DOI 10.1093/ecam/nen029; Negeliskii C, 2011, REV LAT-AM ENFERM, V19, P606, DOI 10.1590/S0104-11692011000300021; Nilsson U., 2010, EUROPEAN J CARDIOVAS, V10, P73; Nooraee N, 2014, COMPUT STAT DATA AN, V77, P70, DOI 10.1016/j.csda.2014.03.009; Pafaro Roberta Cova, 2004, Rev. esc. enferm. USP, V38, P152, DOI 10.1590/S0080-62342004000200005; Rana D, 2013, PSYCHOL NURSES, P640; Randle J, 2003, LEARNING HLTH SOCIAL, V2, P51; Ribeiro Vivian F, 2014, Int Arch Med, V7, P22, DOI 10.1186/1755-7682-7-22; Rosenberg M, 1989, SOC ADOLESCENT SELF; Silva ID, 2009, REV ESC ENFERM USP, V43, P697; Silva Maria da Conceição de Melo, 2009, Estud. psicol. (Natal), V14, P239, DOI 10.1590/S1413-294X2009000300008; Stigsdotter U.A., 2003, J THERAPEUTIC HORTIC, V14, P38; Tsai YC, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-199; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; VIEIRA A. B. D., 2007, TEXTO CONTEXTO ENFER, V16, P15, DOI DOI 10.1590/S0104-07072007000100002; Wu JJ, 2014, COMPLEMENT THER MED, V22, P456, DOI 10.1016/j.ctim.2014.04.001	62	13	18	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2017	12	2							e0172455	10.1371/journal.pone.0172455	http://dx.doi.org/10.1371/journal.pone.0172455			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN3UW	28241070	Green Published, gold, Green Submitted			2023-01-03	WOS:000395934400021
J	Jin, YB; Zhang, GY; Lin, KR; Chen, XP; Cui, JH; Wang, YJ; Luo, W				Jin, Ya-bin; Zhang, Guo-yi; Lin, Kai-Rong; Chen, Xiang-ping; Cui, Jin-Huan; Wang, Yue-jian; Luo, Wei			Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT)	PLOS ONE			English	Article							PROSTATE-CANCER GROWTH; METASTASIS; CCL2	Background Potential clinical application values of certain cytokines and chemokines that participate in the process of tumor growth, invasion, and metastasis have been reported. However, there still lack of biomarkers for a great many of malignancy. This study identified cytokines or chemokines involved in the occurrence and development of nasopharyngeal carcinoma (NPC), which might be a biomarker for noninvasive early diagnosis. Methods The plasma levels of 19 cytokines and chemokines were detected by the luminex liquid array-based multiplexed immunoassays in 39 NPC patients before and after treatment by definitive intensity-modulated radiotherapy (IMRT). Results Plasma levels of almost all of the 19 cytokines and chemokines in NPC patients were higher than healthy controls, while only IFN-y, IL-1b IL-6, MCP-1, TNF-alpha, FKN, IL-12P70, IL-2, IL-5 and IP-10 showed significant differences. However, expression levels of most of the 19 cytokines and chemokines decreased after therapy, especially IFN-y, IL-10, IL-1b, IL-6, IL-8, MCP-1, TNF-a, VEGF, IL-17A, IL-2, IL-5 and MIP-1 b, have a dramatic decline. Taking together, plasma levels of IFN-y, IL-1b, IL-6, MCP-1, TNF-a, IL-2 and IL-5 are significantly increased in NPC patients and dramatically decreased after treatment, suggesting these cytokines and chemokines might play important roles in the progress of NPC. More interestingly, the expression level of MPC-1 is significantly associated with clinical stage. Conclusion MCP-1 might involve in the genesis and development process of NPC, which might serve as a noninvasive biomarker for early diagnosis.	[Jin, Ya-bin; Lin, Kai-Rong; Chen, Xiang-ping; Cui, Jin-Huan; Luo, Wei] Sun Yat Sen Univ, Foshan Hosp, Clin Res Inst, Foshan, Guangdong, Peoples R China; [Jin, Ya-bin; Zhang, Guo-yi; Lin, Kai-Rong; Chen, Xiang-ping; Cui, Jin-Huan; Wang, Yue-jian; Luo, Wei] Sun Yat Sen Univ, Foshan Hosp, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res, Foshan, Guangdong, Peoples R China; [Zhang, Guo-yi] Sun Yat Sen Univ, Foshan Hosp, Ctr Canc, Foshan, Guangdong, Peoples R China; [Wang, Yue-jian] Sun Yat Sen Univ, Foshan Hosp, Otolaryngol Head & Neck Surg, Foshan, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Luo, W (corresponding author), Sun Yat Sen Univ, Foshan Hosp, Clin Res Inst, Foshan, Guangdong, Peoples R China.; Wang, YJ; Luo, W (corresponding author), Sun Yat Sen Univ, Foshan Hosp, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res, Foshan, Guangdong, Peoples R China.; Wang, YJ (corresponding author), Sun Yat Sen Univ, Foshan Hosp, Otolaryngol Head & Neck Surg, Foshan, Guangdong, Peoples R China.	wyjian@fsyyy.com; luowei_421@163.com		Wang, Yuejian/0000-0002-7300-8367	National Natural Science Foundation of China [81402255]; Guangdong Province Natural Science Funds for Distinguished Young Scholar [2016A030306050]; Guangdong Province Natural Science Funds [2014A030313803]; Science and technology innovation platform in Foshan city [2015AG10002]; Science and Technology Planning Project of Guangdong Province [2016A020215005]; "Guangdong TeZhi program" youth science and technology talent of project [2015TQ01R462]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Natural Science Funds for Distinguished Young Scholar; Guangdong Province Natural Science Funds; Science and technology innovation platform in Foshan city; Science and Technology Planning Project of Guangdong Province; "Guangdong TeZhi program" youth science and technology talent of project	This work was funded by Grants from National Natural Science Foundation of China (81402255; Wei Luo) & Guangdong Province Natural Science Funds for Distinguished Young Scholar (2016A030306050; Wei Luo) & Guangdong Province Natural Science Funds (2014A030313803; Wei Luo) & Science and technology innovation platform in Foshan city (2015AG10002; Wei Luo) & Science and Technology Planning Project of Guangdong Province (2016A020215005; Yue-jian Wang) & "Guangdong TeZhi program" youth science and technology talent of project (2015TQ01R462; Wei Luo).	Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chang KP, 2011, HEAD NECK-J SCI SPEC, V33, P886, DOI 10.1002/hed.21557; Guo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129679; Kan R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127239; Lin JC, 1998, CANCER-AM CANCER SOC, V83, P635, DOI 10.1002/(SICI)1097-0142(19980815)83:4<635::AID-CNCR2>3.0.CO;2-J; Liu SY, 2014, ADV MECH ENG, DOI 10.1155/2014/868041; Liu X, 2012, CURR CANCER DRUG TAR, V12, P561, DOI 10.2174/156800912800673293; Liu Y, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.83; Lu X, 2011, EUR J CANCER, V47, P339, DOI 10.1016/j.ejca.2010.09.025; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Salazar N, 2013, CRIT REV EUKAR GENE, V23, P77, DOI 10.1615/CritRevEukaryotGeneExpr.2013006905; Savitri Eka, 2015, Glob J Health Sci, V7, P364, DOI 10.5539/gjhs.v7n3p364; Vitiello PF, 2004, IMMUNOL LETT, V91, P239, DOI 10.1016/j.imlet.2003.12.009; Yang ZH, 2012, CANCER SCI, V103, P653, DOI 10.1111/j.1349-7006.2012.02210.x; Zhu ZQ, 2013, CANCER RES, V73, P595, DOI 10.1158/0008-5472.CAN-12-1123	17	13	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0172264	10.1371/journal.pone.0172264	http://dx.doi.org/10.1371/journal.pone.0172264			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BG	28207826	Green Published, gold, Green Submitted			2023-01-03	WOS:000394424500109
J	Hu, YX; Bai, Y; Hua, ZY; Yang, J; Yang, HH; Chen, WJ; Xu, JW; Zhao, ZQ				Hu, Yunxia; Bai, Yu; Hua, Zhiyun; Yang, Jie; Yang, Huahui; Chen, Wenjun; Xu, Junwei; Zhao, Zhiqiang			Effect of Chinese patent medicine Si-Mo-Tang oral liquid for functional dyspepsia: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Article							PATHOGENESIS; EXTRACT	Background Si-Mo-Tang oral liquid (SMT) has been widely used to treat functional dyspepsia (FD), but the effectiveness is still controversial. A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to assess the efficacy and adverse effects of SMT for FD. Methods Investigators searched for articles with publication dates to June 21, 2016, from 9 English and Chinese electronic databases. Comparisons were SMT alone or SMT in combination with western medicine as experimental intervention, and western medicine or placebo as the control. We used the Cochrane collaboration tool for assessing risk of bias to evaluate methodologies. Data were synthesized with RevMan 5.3 software. (PROSPERO Registration #CRD42016042003) Results Twenty-seven RCTs were included in the review, involving 2,713 participants: 1,383 subjects were in the experimental group and 1,330 in the control group. SMT showed a significant improvement in clinical efficacy (RR 1.14; 95% CI 1.09, 1.20; P<0.00001), but the heterogeneity was also significant (P = 0.0002,I-2 = 56%). Because of the different interventions in the 2 groups, we performed subgroup and sensitivity analyses to investigate potential sources of heterogeneity. The heterogeneity was smaller after subgroup analysis and the exclusion of a study by Zhu from 2009. The corresponding pooled RR has no obvious change (RR 1.17; 95% CI 1.13, 1.21; P<0.00001). Subgroup analysis by age and drugs administered in control interventions between SMT and western medicine also showed improvement in the efficacy rate. But a data synthesis that excluded high risk of bias in the blinding of participants and personnel showed no significant difference (RR 1.14; 95% CI 0.97, 1.35; P = 0.12). Three studies measured gastric emptying. Two of these studies reported no significant difference between the experimental and control groups, while 1 study showed that SMT reduced the time of gastric emptying. The relapse rate and adverse effects had no difference between 2 groups. Conclusions This meta-analysis suggests that SMT is an effective and safe therapy option for patients with FD. However, because of the high clinical heterogeneity, poor quality, high risk of bias and small sample size of some included studies, further standardized large-scale and strictly designed studies are needed.	[Hu, Yunxia; Bai, Yu; Xu, Junwei; Zhao, Zhiqiang] Nanjing Univ Chinese Med, Coll Clin Med 1, Nanjing, Jiangsu, Peoples R China; [Hua, Zhiyun] Zhenjiang Hosp Tradit Chinese Med, Dept Respirat, Zhenjiang, Jiangsu, Peoples R China; [Yang, Jie] Liyang Hosp Tradit Chinese Med, Dept Intens Care Unit, Changzhou, Jiangsu, Peoples R China; [Yang, Huahui] Chinese Univ Hong Kong, Jockey Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China; [Chen, Wenjun] Zhejiang Hosp Tradit Chinese Med, Dept Obstet & Gynecol, Hangzhou, Zhejiang, Peoples R China	Nanjing University of Chinese Medicine; Chinese University of Hong Kong; Zhejiang Chinese Medical University	Zhao, ZQ (corresponding author), Nanjing Univ Chinese Med, Coll Clin Med 1, Nanjing, Jiangsu, Peoples R China.	zzq11142004@126.com			National Natural Science Foundation of China [81373608]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (grant number: 81373608). The website is http/:/www.nsfc.gov.cn/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[蔡光先 Cai Guangxian], 2010, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V25, P856; Guo HM, 2014, PHARM BIOL, V52, P1141, DOI 10.3109/13880209.2013.879601; Guo JS, 2012, LISHIZHEN MED MAT ME, P56; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2016, COCHRANE HDB SYSTEMA; Hu P, 2015, CHINESE J MODERN DRU, V9, P143; Huang JD, 2015, J CLIN MED, P4341; Ji XH, 2010, CHINESE MODERN DOCTO, V48, P157; Jiang HS, 2010, CHINESE J MODERN DRU, V04, P187; Jiang YH, 2014, PHARM BIOL, V52, P581, DOI 10.3109/13880209.2013.854396; Jie Luo, 2013, THEORY PRACTICE SYST; Kazemi MH, 2015, UNITED EUR GASTROENT, V3, P11, DOI 10.1177/2050640614563373; Lacy BE, 2013, ALIMENT PHARM THER, V38, P170, DOI 10.1111/apt.12355; Lahner E, 2013, UNITED EUR GASTROENT, V1, P385, DOI 10.1177/2050640613499567; Li H, 2013, CHINESE J TRADITIONA, V20, P222; Li SX, 2011, CLIN J CHINESE MED, V03, P59; Li Y., 2012, ARCH ANIM NUTR, V1, P1, DOI DOI 10.1099/VIR.0.039289-0; Ling W, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001111; Longstreth GF, 2016, FUNCTIONAL DYSPEPSIA; Meng F., 2014, HUNAN J TRADITIONAL, V30, P65; Ohno T, 2010, INT J PEPTIDES, V2010; Sander GB, 2011, VALUE HEALTH, V14, pS126, DOI 10.1016/j.jval.2011.05.021; Shen ZD, 2012, FRONTIERMED, P316; Sheng YZ, 1995, China, Patent No. [94110842.2, 941108422]; Talley NJ, 2016, KOREAN J INTERN MED, V31, P444, DOI 10.3904/kjim.2016.091; Talley NJ, 2015, NEW ENGL J MED, V373, P1853, DOI 10.1056/NEJMra1501505; Tang W, 2010, GUIDING J TRADITIONA, V16, P33; Tian LX, 2014, MED PEOPLE, V27, P222; Tu Y, 2009, JIANGXI J TRADITIONA, V40, P50; Wang JH, 2003, CLIN J PRACTICAL INT, V3, P33; Wang QZ, 2000, CHIN J INTEGR TRADIT, V8, P29; Wang YC, 2005, FEMS IMMUNOL MED MIC, V43, P295, DOI 10.1016/j.femsim.2004.09.008; Wei SH, 1999, ACTA MED SIN, V12, P758; Wen H, 2011, MED J IND ENTERPRISE, V24, P60; Wu L, 2014, J N PHARM, P92; Xiao Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122397; Xiao ZH, 2012, J GUIYANG COLL TRADI, V34, P14; Xie YB, 2016, STRAIT PHARM J, P211; Ye S, 2005, HERALD MED, V24, P679; Yi YN, 2012, PHARM BIOL, V50, P832, DOI 10.3109/13880209.2011.637505; Yu DH, 2011, CHINESE COMMUNITY PH, V13, P148; Zhang K, 2015, CHINESE MED INNOVATI, P126; Zhang MM, 2016, NEW TRADITIONAL CHIN, P83; Zhang Y, 2011, CHINA HEALTHCARE INN, V06, P22; Zhang Y, 2011, CHINA HEALTHCARE INN, V06, P44; Zheng Y, 2005, HEBEI J TRADITIONAL, V27, P815; Zhou S, 2014, J EMERGENCY TRADITIO, V23, P1791; Zhu YL, 2009, WORLD CHINESE J DIGE, V17, P3028; 李玲, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P2853	49	6	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2017	12	2							e0171878	10.1371/journal.pone.0171878	http://dx.doi.org/10.1371/journal.pone.0171878			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BF	28199409	gold, Green Published, Green Submitted			2023-01-03	WOS:000394424400056
J	Decuypere, F; Sermon, J; Geerts, P; Denee, TR; De Vos, C; Malfait, B; Lamotte, M; Mulder, CL				Decuypere, Flore; Sermon, Jan; Geerts, Paul; Denee, Tom R.; De Vos, Cedric; Malfait, Bart; Lamotte, Mark; Mulder, Cornelis L.			Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study	PLOS ONE			English	Article							TREATING CHRONIC-SCHIZOPHRENIA; PALIPERIDONE PALMITATE; MAINTENANCE TREATMENT; ORAL ANTIPSYCHOTICS; COST-EFFECTIVENESS; FOLLOW-UP; RELAPSE; RISPERIDONE; DEPOT; INJECTION	Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly, risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied. This study demonstrated significantly higher treatment continuation of paliperidone palmitate once monthly compared to risperidone microspheres (p-value< 0,01) and haloperidol decanoate (p-value< 0,01) in both countries, a significantly higher treatment continuation of paliperidone palmitate once monthly compared to olanzapine pamoate in the Netherlands (p-value< 0,01), and a general trend towards better treatment continuation versus olanzapine pamoate in Belgium. Analysing the subgroup of patients without previous exposure to long-acting antipsychotic treatment revealed the positive impact of previous exposure on treatment continuation with a subsequent long acting treatment. Additionally, the probability of restarting the index therapy was higher among patients treated with paliperidone palmitate once monthly compared to patients treated with risperidone microspheres and haloperidol decanoate. The data source used and the methodology defined ensured for the first time a comparison of treatment continuation in a non-interventional study design for the four long-acting injectable antipsychotics studied.	[Decuypere, Flore] QuintilesIMS, Commercial Serv, Zaventem, Belgium; [Sermon, Jan; De Vos, Cedric; Malfait, Bart] Janssen Cilag NV, Hlth Econ, Market Access, Reimbursement, Beerse, Belgium; [Geerts, Paul] Janssen Cilag NV, Med Affairs, Beerse, Belgium; [Denee, Tom R.] Janssen Cilag BV, Hlth Econ, Market Access, Reimbursement, Tilburg, Netherlands; [Lamotte, Mark] QuintilesIMS, Real World Evidence Solut, Zaventem, Belgium; [Mulder, Cornelis L.] Erasmus MC, Dept Psychiat, Rotterdam, Netherlands	IQVIA; Johnson & Johnson; IQVIA; Erasmus University Rotterdam; Erasmus MC	Lamotte, M (corresponding author), QuintilesIMS, Commercial Serv, Zaventem, Belgium.	flore.decuypere@quintilesims.com; jsermon@its.jnj.com; pgeerts@its.jnj.com; tdenee@its.jnj.com; cdevos4@its.jnj.com; bmalfait@its.jnj.com; mark.lamotte@quintilesims.com	Mulder, Cornelis Lambert/HGU-3446-2022	Denee, Tom/0000-0002-0150-2091	Janssen-Cilag	Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	This study was funded by Janssen-Cilag. QuintilesIMS, the employer of F. Decuypere and M. Lamotte, received consulting fees for the performance of the study and the writing of the manuscript. J. Sermon, P. Geerts, T.R. Denee, C. De Vos and B. Malfait are employed by JanssenCilag. Janssen-Cilag provided support in the form of salaries for authors J. Sermon, P. Geerts, T.R. Denee, C. De Vos and B. Malfait and QuintilesIMS provided support in the form of salaries for authors F. Decuypere and M. Lamotte. Janssen-Cilag participated in collaboration with QuintilesIMS to design the study; Janssen-Cilag had no role in the collection and analysis of the data; Janssen-Cilag participated in collaboration with QuintilesIMS in the interpretation of the data, in the writing of the report and in the decision to submit the paper for publication.	Alonso S Sanchez, 2013, 17 C NAC PSIQ SEV; Alphs L, 2014, SCHIZOPHR RES, V156, P228, DOI 10.1016/j.schres.2014.04.024; Andreasen NC, 2013, AM J PSYCHIAT, V170, P609, DOI 10.1176/appi.ajp.2013.12050674; Annemans L, 2012, ACTA CLIN BELG, V67, P108, DOI 10.2143/ACB.67.2.2062640; Attard A, 2014, ACTA PSYCHIAT SCAND, V130, P46, DOI 10.1111/acps.12201; Bera Rimal, 2013, J Med Econ, V16, P522, DOI 10.3111/13696998.2013.771641; Birchwood M, 1998, BRIT J PSYCHIAT, V172, P53, DOI 10.1192/S0007125000297663; Bitter I, 2013, EUR NEUROPSYCHOPHARM, V23, P1383, DOI 10.1016/j.euroneuro.2013.02.003; Bossie CA, 2015, INT CLIN PSYCHOPHARM, V30, P272, DOI 10.1097/YIC.0000000000000082; Burns T, 2000, INT J SOC PSYCHIATR, V46, P220, DOI 10.1177/002076400004600308; Case M, 2011, PSYCHOL MED, V41, P1291, DOI 10.1017/S0033291710001893; Catts SV, 2016, AUST NZ J PSYCHIAT, V50, P1128, DOI 10.1177/0004867416672725; De Hert M, 1998, SCHIZOPHRENIA BULL, V24, P519, DOI 10.1093/oxfordjournals.schbul.a033346; De Hert M, 2007, SCHIZOPHR RES, V92, P68, DOI 10.1016/j.schres.2007.01.010; De Hert M, 2015, CNS DRUGS, V29, P637, DOI 10.1007/s40263-015-0269-4; Divino V, 2014, DIABETES THER, V5, P499, DOI 10.1007/s13300-014-0087-6; Einarson TR, 2014, NORD J PSYCHIAT, V68, P416, DOI 10.3109/08039488.2013.852243; Einarson Thomas R, 2013, J Med Econ, V16, P1089, DOI 10.3111/13696998.2013.820193; Einarson Thomas R, 2013, J Med Econ, V16, P1096, DOI 10.3111/13696998.2013.823869; Einarson TR, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-18; Emsley R, 2013, J CLIN PSYCHOPHARM, V33, P80, DOI 10.1097/JCP.0b013e31827bfcc1; Fazel S, 2014, LANCET, V384, P1206, DOI 10.1016/S0140-6736(14)60379-2; Fleischhacker WW, 2014, JAMA-J AM MED ASSOC, V312, P1467, DOI 10.1001/jama.2014.10109; Fleischhacker WW, 2012, INT J NEUROPSYCHOPH, V15, P107, DOI 10.1017/S1461145711001076; Gallardo R Martinez, 2012, 16 C NAC PSIQ BILB; Goff DC, 2014, JAMA-J AM MED ASSOC, V311, P1973, DOI 10.1001/jama.2014.4311; Grimaldi-Bensouda L, 2012, SCHIZOPHR RES, V134, P187, DOI 10.1016/j.schres.2011.10.022; Haddad PM, 2010, MIND BRAIN, V1, P33; Jukic Vlado, 2013, Value Health Reg Issues, V2, P181, DOI 10.1016/j.vhri.2013.06.008; Kane J, 2013, JOURNAL OF CLINICAL, V66, P37; Kim E, 2016, AUST NZ J PSYCHIAT, V50, P166; Kirson NY, 2013, J CLIN PSYCHIAT, V74, P568, DOI 10.4088/JCP.12r08167; Kishimoto T, 2013, J CLIN PSYCHIAT, V74, P957, DOI 10.4088/JCP.13r08440; Leucht S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008016.pub2; Li HF, 2011, PROG NEURO-PSYCHOPH, V35, P1002, DOI 10.1016/j.pnpbp.2011.02.001; Lieberman JA, 1996, J CLIN PSYCHIAT, V57, P5; Lieberman JA, 1996, J CLIN PSYCHIAT, V57, P68; McEvoy JP, 2014, JAMA-J AM MED ASSOC, V311, P1978, DOI 10.1001/jama.2014.4310; Mehnert Angelika, 2012, J Med Econ, V15, P844, DOI 10.3111/13696998.2012.681531; Morrens M, 2015, J PSYCHIATR PRACT, V21, P248, DOI 10.1097/PRA.0000000000000085; Mouaddin N EL, 2014, ISPOR 17 ANN EUR C; Munro J, 2011, PSYCHIATR BULL, V35, P95, DOI 10.1192/pb.bp.109.027714; Offord S, 2013, J MED ECON, V16, P1; Olfson M, 2007, SCHIZOPHRENIA BULL, V33, P1379, DOI 10.1093/schbul/sbm033; Olivares JM, 2009, CURR MED RES OPIN, V25, P2197, DOI 10.1185/03007990903149306; Osborne RH, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-35; Pandina G, 2011, PROG NEURO-PSYCHOPH, V35, P218, DOI 10.1016/j.pnpbp.2010.11.008; Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241; Sampson S., 2013, COCHRANE DB SYST REV, V20, P7; Samtani MN, 2012, CLIN PHARMACOL-ADV A, V4, P25, DOI 10.2147/CPAA.S32735; Stroup TS, 2003, SCHIZOPHRENIA BULL, V29, P15, DOI 10.1093/oxfordjournals.schbul.a006986; Suzuki T, 2014, JAMA-J AM MED ASSOC, V312, P1468, DOI 10.1001/jama.2014.10103; Taylor D, 2014, INT CLIN PSYCHOPHARM, V29, P229, DOI 10.1097/YIC.0000000000000028; Thomas P, 2013, ENCEPHALE S2, V39, P79; Tiihonen J, 2011, AM J PSYCHIAT, V168, P603, DOI 10.1176/appi.ajp.2011.10081224; Vlaams Patientenplatform, 2008, RES VRAG MED ROL AP; Weiden PJ, 2004, PSYCHIAT SERV, V55, P886, DOI 10.1176/appi.ps.55.8.886; Wiersma D, 1998, SCHIZOPHRENIA BULL, V24, P75, DOI 10.1093/oxfordjournals.schbul.a033315; Willis M, 2010, EUR J HEALTH ECON, V11, P585, DOI 10.1007/s10198-009-0215-9; Zeidler J, 2013, APPL HEALTH ECON HEA, V11, P509, DOI 10.1007/s40258-013-0050-0; Zipursky RB, 2014, SCHIZOPHR RES, V152, P408, DOI 10.1016/j.schres.2013.08.001	61	24	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							e0179049	10.1371/journal.pone.0179049	http://dx.doi.org/10.1371/journal.pone.0179049			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX5KN	28614404	gold, Green Published, Green Submitted			2023-01-03	WOS:000403280900031
J	Dziedzic, M; Powrozek, T; Orlowska, E; Koch, W; Kukula-Koch, W; Gawel, K; Bednarek-Skublewska, A; Malecka-Massalska, T; Milanowski, J; Petkowicz, B; Solski, J				Dziedzic, Marcin; Powrozek, Tomasz; Orlowska, Ewelina; Koch, Wojciech; Kukula-Koch, Wirginia; Gawel, Kinga; Bednarek-Skublewska, Anna; Malecka-Massalska, Teresa; Milanowski, Janusz; Petkowicz, Beata; Solski, Janusz			Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients	PLOS ONE			English	Article							CIRCULATING MICRORNAS; CARDIAC-FUNCTION; KIDNEY-FUNCTION; HYPERTENSION; BIOMARKERS; MEDIATORS; DISEASE; GENE; IMMUNITY; MIR-146	Background microRNA (miRNA) belongs to the non-coding RNAs family responsible for the regulation of gene expression. Renalase is a protein composed of 342 amino acids, secreted by the kidneys and possibly plays an important role in the regulation of sympathetic tone and blood pressure. The aim of the present study was to investigate plasma renalase concentration, and explore the relationship between miRNA-146a-5p expression and plasma renalase levels in hemodialyzed patients. Methods The study population comprised 55 subjects who succumbed to various cardiac events, 27 women and 28 men, aged 65-70 years. The total RNA including miRNA fraction was isolated using QiagenmiRNEasy Serum/Plasma kit according to the manufacturer's protocol. The isolated miRNAs were analyzed using a quantitative polymerase chain reaction (qRT-PCR) technique. The plasma renalase levels were measured using a commercial ELISA kit. Results In the group of patients with high levels of renalase, higher miRNA-146a expression was found, compared with those with low concentration of renalase. Patients with simultaneous low miRNA-146a expression and high level of renalase were confirmed to deliver a significantly longer survival time compared with other patients. Conclusions miRNA-146a and plasma renalase levels were estimated as independent prognostic factors of hemodialyzed patients' survival time. Patients with low miRNA-146a expression demonstrated a significantly longer survival time in contrast to the patients with a high expression level of miRNA-146a. Moreover, a significantly longer survival time was found in patients with high renalase activity compared with patients with low activity of the enzyme.	[Dziedzic, Marcin; Solski, Janusz] Med Univ Lublin, Dept Lab Diagnost, Lublin, Poland; [Powrozek, Tomasz; Malecka-Massalska, Teresa] Med Univ Lublin, Dept Human Physiol, Lublin, Poland; [Orlowska, Ewelina; Bednarek-Skublewska, Anna] Med Univ Lublin, Dept Nephrol, Lublin, Poland; [Koch, Wojciech] Med Univ Lublin, Chair & Dept Bromatol, Lublin, Poland; [Kukula-Koch, Wirginia] Med Univ Lublin, Chair & Dept Pharmacognosy, Med Plants Unit, Lublin, Poland; [Gawel, Kinga] Med Univ Lublin, Dept Expt & Clin Pharmacol, Lublin, Poland; [Milanowski, Janusz] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland; [Petkowicz, Beata] Med Univ Lublin, Dept Oral Med, Lublin, Poland	Medical University of Lublin; Medical University of Lublin; Medical University of Lublin; Medical University of Lublin; Medical University of Lublin; Medical University of Lublin; Medical University of Lublin; Medical University of Lublin	Dziedzic, M (corresponding author), Med Univ Lublin, Dept Lab Diagnost, Lublin, Poland.	marcindziedzic@live.com	Koch, Wojciech/AAF-8967-2019; Kukula-Koch, Wirginia/I-5468-2019	Koch, Wojciech/0000-0001-8749-9657; Kukula-Koch, Wirginia/0000-0001-7076-600X; Malecka-Massalska, Teresa/0000-0003-3384-0324				Agarwal R, 2003, AM J MED, V115, P291, DOI 10.1016/S0002-9343(03)00366-8; Beaupre BA, 2015, ARCH BIOCHEM BIOPHYS, V579, P62, DOI 10.1016/j.abb.2015.05.016; Beaupre BA, 2013, J AM CHEM SOC, V135, P13980, DOI 10.1021/ja407384h; Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042; Buraczynska M, 2011, NEUROMOL MED, V13, P321, DOI 10.1007/s12017-011-8158-6; Catalucci D, 2009, CIRC-CARDIOVASC GENE, V2, P402, DOI 10.1161/CIRCGENETICS.109.857425; Charlson ME, 1987, J CHRON DIS, V40; Chen NX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064558; Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Desir GV, 2014, NEPHROL DIAL TRANSPL, V29, P22, DOI 10.1093/ndt/gft083; Desir GV, 2007, J AM SOC HYPERTENS, V1, P99, DOI 10.1016/j.jash.2006.12.001; Dziedzic M, 2014, ANN AGR ENV MED, V21, P132; Eikelis N, 2011, KIDNEY INT, V79, P1380, DOI 10.1038/ki.2011.90; Emilian C, 2012, CLIN J AM SOC NEPHRO, V7, P619, DOI 10.2215/CJN.10471011; Farzaneh-Far R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008612; Felekkis K, 2010, HIPPOKRATIA, V14, P236; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363; Hao Yi, 2016, J Clin Exp Ophthalmol, V7; Kalyani A, 2015, J MOL BIOL, V427, P2629, DOI 10.1016/j.jmb.2015.07.003; Kopple JD, 2001, AM J KIDNEY DIS, V38, pS68, DOI 10.1053/ajkd.2001.27578; Kutty RK, 2013, MOL VIS, V19, P737; Li G, 2008, CIRCULATION, V117, P1277, DOI 10.1161/CIRCULATIONAHA.107.732032; Malyszko J, 2015, CURR VASC PHARMACOL, V13, P134, DOI 10.2174/1570161113666141217141805; Malyszko J, 2012, J HYPERTENS, V30, P457, DOI 10.1097/HJH.0b013e32834f0bb7; Martino F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038269; METZINGERLEMEUT.V, 2012, CURRENT BASIC PATHOL, V17, P183; Moran GR, 2016, BBA-PROTEINS PROTEOM, V1864, P177, DOI 10.1016/j.bbapap.2015.04.010; Neal CS, 2011, NEPHROL DIAL TRANSPL, V26, P3794, DOI 10.1093/ndt/gfr485; Olivieri F, 2013, AGE, V35, P1157, DOI 10.1007/s11357-012-9440-8; Ono K, 2011, FEBS J, V278, P1619, DOI 10.1111/j.1742-4658.2011.08090.x; Quelhas-Santos J, 2015, AM J PHYSIOL-RENAL, V308, pF84, DOI 10.1152/ajprenal.00274.2014; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Rutkowski B, 2009, REPORT RENAL REPLACE, P1; Sarnak MJ, 2000, J THROMB THROMBOLYS, V10, P169, DOI 10.1023/A:1018718727634; Scharer K, 1999, PEDIATR NEPHROL, V13, P951, DOI 10.1007/s004670050737; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386; Stec A, 2016, INT UROL NEPHROL, V48, P871, DOI 10.1007/s11255-016-1270-7; Szeto CC, 2012, DIS MARKERS, V33, P137, DOI 10.1155/2012/842764; Taganov KD, 2007, IMMUNITY, V26, P133, DOI 10.1016/j.immuni.2007.02.005; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Workgroup, 2004, AM J KIDNEY DIS, V43, P11, DOI [10.1053/j.ajkd.2004.03.003, DOI 10.1053/J.AJKD.2004.03.003]; Wang F, 2015, J CELL MOL MED, V19, P1400, DOI 10.1111/jcmm.12527; Wang F, 2015, CLIN EXP NEPHROL, V19, P92, DOI 10.1007/s10157-014-0951-8; Wang HL, 2012, BRAZ J MED BIOL RES, V45, P1308, DOI 10.1590/S0100-879X2012007500165; Wang J, 2008, MOL BIOL REP, V35, P613, DOI 10.1007/s11033-007-9131-1; Wilflingseder J, 2015, NEPHROL DIAL TRANSPL, V30, P910, DOI 10.1093/ndt/gfu280; Xu JC, 2005, J CLIN INVEST, V115, P1275, DOI 10.1172/JCI200524066; Zampetaki A, 2012, CARDIOVASC RES, V93, P555, DOI 10.1093/cvr/cvr266; Zbroch E, 2012, KIDNEY BLOOD PRESS R, V35, P395, DOI 10.1159/000338178; Zbroch E, 2012, POL ARCH MED WEWN, V122, P40, DOI 10.20452/pamw.1132	54	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							e0179218	10.1371/journal.pone.0179218	http://dx.doi.org/10.1371/journal.pone.0179218			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX5KN	28614373	Green Published, Green Submitted, gold			2023-01-03	WOS:000403280900036
J	Baston, J				Baston, John			Daphne Marsh Baston OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	2017	357								j2887	10.1136/bmj.j2887	http://dx.doi.org/10.1136/bmj.j2887			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY1UL	28611059				2023-01-03	WOS:000403752500011
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Prescribing incentives feel grubby because they are	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Dumbreck S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h949; Lind S., 2013, PULSE, V357; Oxfordshire CCG, 2017, PRESCR INC	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2017	357								j2695	10.1136/bmj.j2695	http://dx.doi.org/10.1136/bmj.j2695			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY4VU	28584026	Bronze, Green Published			2023-01-03	WOS:000426826000001
J	Cyranoski, D				Cyranoski, David			THE SECRET WAR AGAINST COUNTERFEIT SCIENCE CHINA HAS A LUCRATIVE MARKET FOR FAKE RESEARCH REAGENTS. NOW SOME SCIENTISTS ARE FIGHTING BACK	NATURE			English	News Item							HEMOJUVELIN											Gutierrez OM, 2012, AM J NEPHROL, V36, P332, DOI 10.1159/000342519; Prassas I, 2014, CLIN CHEM LAB MED, V52, P765, DOI 10.1515/cclm-2013-1078; Rumjon A, 2012, AM J NEPHROL, V35, P295, DOI 10.1159/000336528	3	4	4	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	2017	545	7653					148	150		10.1038/545148a	http://dx.doi.org/10.1038/545148a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU3XG	28492262	Bronze			2023-01-03	WOS:000400963800010
J	Sullivan, MR; Heiden, MGV				Sullivan, Mark R.; Heiden, Matthew G. Vander			When cancer needs what's non-essential	NATURE CELL BIOLOGY			English	Editorial Material							MAMMALIAN-CELLS; SERINE; PROLIFERATION; METABOLISM; GLYCINE	The non-essential amino acids serine and glycine are critical for proliferative metabolism. A study in Nature now finds that dietary serine and glycine deprivation inhibits growth of some tumours. Whether this dietary intervention is effective depends on both the oncogenic context and tumour tissue of origin.	[Sullivan, Mark R.; Heiden, Matthew G. Vander] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Sullivan, Mark R.; Heiden, Matthew G. Vander] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Heiden, Matthew G. Vander] Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute	Heiden, MGV (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Heiden, MGV (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Heiden, MGV (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	mvh@mit.edu		/0000-0001-5765-0459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007287] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Hursting SD, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-10; Imai K, 1998, AMINO ACIDS, V15, P351, DOI 10.1007/BF01320899; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Maddocks O. D. K., 2017, NATURE; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250	15	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2017	19	5					418	420		10.1038/ncb3523	http://dx.doi.org/10.1038/ncb3523			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	ET6BR	28422952				2023-01-03	WOS:000400376100006
J	McNairy, ML; Joseph, P; Unterbrink, M; Galbaud, S; Mathon, JE; Rivera, V; Jannat-Khah, D; Reif, L; Koenig, SP; Domercant, JW; Johnson, W; Fitzgerald, DW; Pape, JW				McNairy, Margaret L.; Joseph, Patrice; Unterbrink, Michelle; Galbaud, Stanislas; Mathon, Jean-Edouard; Rivera, Vanessa; Jannat-Khah, Deanna; Reif, Lindsey; Koenig, Serena P.; Domercant, Jean Wysler; Johnson, Warren; Fitzgerald, Daniel W.; Pape, Jean W.			Outcomes after antiretroviral therapy during the expansion of HIV services in Haiti	PLOS ONE			English	Article							ELECTRONIC MEDICAL-RECORD; TREATMENT PROGRAMS; FOLLOW-UP; HIV-1-INFECTED PATIENTS; INFECTED PATIENTS; ADULT PATIENTS; LATIN-AMERICA; 1ST YEAR; CARE; MORTALITY	Background We report patient outcomes after antiretroviral therapy (ART) initiation in a network of HIV facilities in Haiti, including temporal trends and differences across clinics, during the expansion of HIV services in the country. Methods We assessed outcomes at 12 months after ART initiation (baseline) using routinely collected data on adults (>= 15 years) in 11 HIV facilities from July 2007-December 2013. Outcomes include death (ascertained from medical records), lost to follow-up (LTF) defined as no visit > 365 days from ART initiation, and retention defined as being alive and attending care >= 365 days from ART initiation. Outcomes were compared across calendar year of ART initiation and across facilities. Risk factors for death and LTF were assessed using Cox proportional hazards and competing risk regression models. Results Cumulatively, 9,718 adults initiated ART with median age 37 years (IQR 3-46). Median CD4 count was 254 cells/ uL (IQR 139-350). Twelve months after ART initiation, 4.4% (95% CI 4.0-4.8) of patients died, 21.7% (95% CI 20.9-22.6) were LTF, and 73.9% (95% CI 73.0-74.8) were retained in care. Twelve-month mortality decreased from 13.8% among adults who started ART in 2007 to 4.4% in 2013 (p< 0.001). Twelve-month LTF after ART start was 29.2% in 2007, 18.7% in 2008, and increased to 30.1% in 2013 (p< 0.001). Overall, twelve-month retention after ART start did not change over time but varied widely across facilities from 61.1% to 86.5%. Conclusion Expansion of HIV services across Haiti has been successful with increasing numbers of patients initiating ART and decreasing twelve-month mortality rates. However, overall retention has not improved, despite differences across facilities, suggesting additional strategies to improve engagement in care are needed.	[McNairy, Margaret L.; Reif, Lindsey; Johnson, Warren; Fitzgerald, Daniel W.; Pape, Jean W.] Weill Cornell Med Coll, Ctr Global Hlth, New York, NY 10065 USA; [McNairy, Margaret L.; Unterbrink, Michelle; Jannat-Khah, Deanna] Weill Cornell Med Coll, Div Gen Med, New York, NY 10065 USA; [Joseph, Patrice; Galbaud, Stanislas; Mathon, Jean-Edouard; Rivera, Vanessa; Pape, Jean W.] Haitian Study Grp Kaposis Sarcoma & Opportunist I, Port Au Prince, Haiti; [Koenig, Serena P.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Domercant, Jean Wysler] Ctr Dis Control & Prevent, Port Au Prince, Haiti	Cornell University; Cornell University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	McNairy, ML (corresponding author), Weill Cornell Med Coll, Ctr Global Hlth, New York, NY 10065 USA.; McNairy, ML (corresponding author), Weill Cornell Med Coll, Div Gen Med, New York, NY 10065 USA.	Mam9365@med.cornell.edu	Jannat-Khah, Deanna/L-9701-2019	Jannat-Khah, Deanna/0000-0002-1091-379X	Centers for Disease Control Grants [U2GGH000545, U2GGH000541]; National Institutes of Allergy and Infectious Diseases [R01A1104344]; President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under the terms of the cooperative agreements [U2GGH000545, U2GGH000541]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069421, K24AI098627, R01AI104344] Funding Source: NIH RePORTER	Centers for Disease Control Grants; National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under the terms of the cooperative agreements; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for this analysis is supported by Centers for Disease Control Grants U2GGH000545 and U2GGH000541 and the National Institutes of Allergy and Infectious Diseases grant number R01A1104344. CDC Disclaimer: The findings and conclusion of this report or (research, article, publication, poster etc.) are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. PEPFAR Attribution: This report or (research, article, publication, poster etc.) has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under the terms of the cooperative agreements: U2GGH000545 and U2GGH000541.	Aliyu MH, 2015, PATHOG GLOB HEALTH, V109, P75, DOI 10.1179/2047773215Y.0000000007; [Anonymous], 2013, UNAIDS REP GLOB AIDS; Auld AF, 2014, MMWR-MORBID MORTAL W, V63, P1097; Auld AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098183; Auld AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018453; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Coviello V, 2004, STATA J, V4, P103, DOI 10.1177/1536867X0400400201; Farahani M, 2016, TROP MED INT HEALTH, V21, P18, DOI 10.1111/tmi.12623; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng EH, 2016, CLIN INFECT DIS, V62, P935, DOI 10.1093/cid/civ1004; Grimsrud A, 2014, JAIDS-J ACQ IMM DEF, V67, pE55, DOI 10.1097/QAI.0000000000000268; Johnson LF, 2014, AM J EPIDEMIOL, V180, P1208, DOI 10.1093/aje/kwu295; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Joint United Nations Programme on HIV/AIDS, 2021, YOUNG PEOPL HIV; Koenig SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146903; Koenig SP, 2012, JAIDS-J ACQ IMM DEF, V59, pE60, DOI 10.1097/QAI.0b013e318245d3c1; Koole O, 2014, TROP MED INT HEALTH, V19, P1397, DOI 10.1111/tmi.12386; Leger P, 2009, NEW ENGL J MED, V361, P828, DOI 10.1056/NEJMc0809485; Matheson AI, 2012, INT J MED INFORM, V81, P244, DOI 10.1016/j.ijmedinf.2012.01.011; McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073; McNairy ML, 2015, JAIDS-J ACQ IMM DEF, V70, pE44, DOI 10.1097/QAI.0000000000000745; Moise C BC, 2016, C RETR OPP INF BOST; Nglazi MD, 2011, JAIDS-J ACQ IMM DEF, V56, pE1, DOI 10.1097/QAI.0b013e3181ff0bdc; Pape JW, 2014, JAIDS-J ACQ IMM DEF, V65, pS5, DOI 10.1097/QAI.0000000000000031; Pierre S, 2016, NEW ENGL J MED, V374, P397, DOI 10.1056/NEJMc1508934; Puttkammer N, 2016, INT J MED INFORM, V86, P104, DOI 10.1016/j.ijmedinf.2015.11.003; Puttkammer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112261; Reif LK, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20859; Rouzier V, 2014, ANTIVIR THER, V19, P91, DOI 10.3851/IMP2904; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a; UNAIDS, 2014, DECL ENG VIH SIDA RA; UNAIDS, 2014, HAIT EP FACT SHEET; WHO, 2016, WHO BMI CLASS; *WHO, SUMM COUNTR PROF HIV; WHO, 2006, AN THER HIV INF AD A; World Health Organization, 2009, RAP ADV ANT THER HIV	45	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2017	12	4							e0175521	10.1371/journal.pone.0175521	http://dx.doi.org/10.1371/journal.pone.0175521			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET4XE	28437477	Green Published, Green Submitted, gold			2023-01-03	WOS:000400287600008
J	Davies, BJ; Hwang, TJ; Kesselheim, AS				Davies, Benjamin J.; Hwang, Thomas J.; Kesselheim, Aaron S.			Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SHORTAGES		[Davies, Benjamin J.] Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15260 USA; [Davies, Benjamin J.] Hillman Canc Ctr, Pittsburgh, PA 15232 USA; [Hwang, Thomas J.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, PORTAL, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Hwang, Thomas J.; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Davies, BJ (corresponding author), Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15260 USA.; Davies, BJ (corresponding author), Hillman Canc Ctr, Pittsburgh, PA 15232 USA.		Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Hwang, Thomas/0000-0003-0717-1497				Centers for Medicare and Medicaid Services, 2015, CMS DRUG SPEND MED D; Chen SI, 2016, HEALTH AFFAIR, V35, P798, DOI 10.1377/hlthaff.2015.1157; Davies B., 2016, FORBES; Government Accountability Office, 2016, DRUG SHORT CERT FACT; Metzger ML, 2012, NEW ENGL J MED, V367, P2461, DOI 10.1056/NEJMp1212468	5	35	35	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2017	376	15					1401	1403		10.1056/NEJMp1615697	http://dx.doi.org/10.1056/NEJMp1615697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER6EX	28402764				2023-01-03	WOS:000398899200003
J	Nordling, L				Nordling, Linda			PUTTING GENOMES TO WORK IN AFRICA Investment promises to bring precision medicine to Africans. But will it help?	NATURE			English	Editorial Material																		Chen GJ, 2017, OBESITY, V25, P794, DOI 10.1002/oby.21804; Mayosi BM, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.116.001605; Nyakutira C, 2008, EUR J CLIN PHARMACOL, V64, P357, DOI 10.1007/s00228-007-0412-3; Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345; Popejoy AB, 2016, NATURE, V538, P161, DOI 10.1038/538161a	5	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2017	544	7648					20	22		10.1038/544020a	http://dx.doi.org/10.1038/544020a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EQ8GQ	28383002	Bronze			2023-01-03	WOS:000398323300011
J	Shin, S; Cho, SR; Kim, S; Choi, JR; Lee, KA				Shin, Saeam; Cho, Sung Ran; Kim, Sinyoung; Choi, Jong Rak; Lee, Kyung-A			Identification of cell morphology parameters from automatic hematology analyzers to predict the peripheral blood CD34-positive cell count after mobilization	PLOS ONE			English	Article							PROGENITOR-CELL; TRANSPLANTATION; INFECTION; HARVEST; MARKER; VOLUME	Optimal timing of apheresis initiation is important for maximizing the hematopoietic stem cell (HSC) yield. This study aimed to identify useful parameters from automatic hematology analyzers for predicting the peripheral blood CD34+ cell count after mobilization. We prospectively enrolled 53 healthy donors and 72 patients, and evaluated 43 cell morphology parameters from Unicel DxH800 (Beckman Coulter, USA) and Advia 2120i (Siemens Healthcare Diagnostics, USA). The correlation of each parameter with the CD34+ cell count in pre-apheresis blood samples was analyzed. The delta neutrophil index (DNI) from Advia 2120i, standard deviation of volume of neutrophils and monocytes (SD-V-NE and SD-V MO), standard deviation of conductivity of neutrophils and monocytes (SD-C-NE and SD-C MO), mean conductivity of neutrophils and monocytes (MN-C-NE and MN-C-MO), and standard deviation of axial light loss of neutrophils and monocytes (SD-AL2-NE and SD-AL2-MO) from DxH800 showed significant correlations with the CD34+ cell count. SD-V-NE, SD-C-NE, and SD-C-MO showed good or fair area under the curve values for the prediction of the CD34+ cell count. SD-V-NE, SD-C-NE, and SD-C-MO from DxH800 will provide rapid, useful information for the initiation of apheresis after mobilization.	[Shin, Saeam; Kim, Sinyoung; Choi, Jong Rak; Lee, Kyung-A] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea; [Shin, Saeam] Hallym Univ, Kangnam Sacred Heart Hosp, Coll Med, Dept Lab Med, Seoul, South Korea; [Cho, Sung Ran] Ajou Univ, Sch Med, Dept Lab Med, Suwon, South Korea	Yonsei University; Yonsei University Health System; Hallym University; Ajou University	Lee, KA (corresponding author), Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea.	KAL1119@yuhs.ac	Cho, Sung-Ran/AAK-9950-2021	Shin, Saeam/0000-0003-1501-3923; Kim, Sinyoung/0000-0002-2609-8945; Lee, Kyung-A/0000-0001-5320-6705	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120030]	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120030, http//www.htdream.kr/, KAL). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baron F, 2005, LEUKEMIA, V19, P822, DOI 10.1038/sj.leu.2403718; Charafeddine KM, 2011, SCAND J INFECT DIS, V43, P777, DOI 10.3109/00365548.2011.585179; Chaves F, 2005, AM J CLIN PATHOL, V124, P440, DOI 10.1309/LLF75W0FWQQ8TCC5; Gokcebay DG, 2011, INT J LAB HEMATOL, V33, P651, DOI 10.1111/j.1751-553X.2011.01333.x; Golubeva V, 2014, TRANSFUS APHER SCI, V50, P39, DOI 10.1016/j.transci.2013.12.004; HO AD, 1993, LEUKEMIA, V7, P1738; Jun YH, 2008, ANN CLIN LAB SCI, V38, P88; Keeney M, 1998, CYTOMETRY, V34, P61, DOI 10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F; Koca E, 2008, CURR OPIN ONCOL, V20, P220, DOI 10.1097/CCO.0b013e3282f5100b; Lee SE, 2012, J CLIN LAB ANAL, V26, P194, DOI 10.1002/jcla.21493; Luna-Herrera J, 2003, EUR J CLIN MICROBIOL, V22, P21, DOI 10.1007/s10096-002-0855-5; Padmanabhan A, 2009, VOX SANG, V97, P153, DOI 10.1111/j.1423-0410.2009.01183.x; Pavone V, 2006, BONE MARROW TRANSPL, V37, P719, DOI 10.1038/sj.bmt.1705298; Seok Y, 2012, SHOCK, V37, P242, DOI 10.1097/SHK.0b013e3182454acf; Suh C, 2004, TRANSFUSION, V44, P1762, DOI 10.1111/j.0041-1132.2004.04166.x; To LB, 2011, BLOOD, V118, P4530, DOI 10.1182/blood-2011-06-318220; Ward PCJ, 2000, CLIN CHEM, V46, P1215; Wu CY, 2016, TRANSFUSION, V56, P2042, DOI 10.1111/trf.13666	18	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2017	12	3							e0174286	10.1371/journal.pone.0174286	http://dx.doi.org/10.1371/journal.pone.0174286			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER6VC	28319139	gold, Green Submitted, Green Published			2023-01-03	WOS:000398945800065
J	Zhang, W; Lu, MZ; Zhang, CL; Zhang, RW; Ou, XF; Zhou, JJ; Li, Y; Kang, Y				Zhang, Wei; Lu, Meizhu; Zhang, Chenlong; Zhang, Ruwen; Ou, Xiaofeng; Zhou, Jianju; Li, Yan; Kang, Yan			Therapeutic hypothermia increases the risk of cardiac arrhythmia for perinatal hypoxic ischaemic encephalopathy: A meta-analysis	PLOS ONE			English	Article							SYSTEMIC HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; MILD HYPOTHERMIA; NEWBORN-INFANTS; ASPHYXIA; SETTINGS	Objective To determine whether therapeutic hypothermia after hypoxic ischaemic encephalopathy (HIE) in neonates increases the risk of cardiac arrhythmia during intervention. Design A meta-analysis was conducted using a fixed-effect model. Risk ratios, risk differences, and 95% confidence intervals, were measured. Data sources Studies identified from the Cochrane Central Register of Controlled Trials, MEDLI NE, EMBASE, Google Scholar, previous reviews, and abstracts from onset to August, 2016. Review methods Reports that compared therapeutic hypothermia with normal care for neonates with HIE and that included data on safety or cardiac arrhythmia, which is of interest to patients and clinicians, were selected. Results We found seven trials, encompassing 1322 infants that included information on safety or cardiac arrhythmia during intervention. Therapeutic hypothermia considerably increased the combined rate of cardiac arrhythmia in the seven trials (risk ratio 2.42, 95% confidence interval 1.23 to 4.76. p = 0.01; risk difference 0.02, 95% CI 0.01 to 0.04) during intervention. Conclusions In infants with hypoxic ischaemic encephalopathy, therapeutic hypothermia is associated with a consistent increase in cardiac arrhythmia during intervention.	[Zhang, Wei; Lu, Meizhu; Zhang, Chenlong; Zhang, Ruwen; Ou, Xiaofeng; Kang, Yan] Sichuan Univ, West China Med Ctr, Dept Crit Care Med, Chengdu, Sichuan, Peoples R China; [Zhang, Wei; Zhou, Jianju] Zunyi Med Coll, Clin Hosp 3, Peoples Hosp Zunyi Guizhou Prov 1, Dept Crit Care Med, Zunyi, Guizhou, Peoples R China; [Li, Yan] Peoples Hosp Yishui Cty, Dept Neurol, Yishui, Shandong, Peoples R China	Sichuan University; Zunyi Medical University	Kang, Y (corresponding author), Sichuan Univ, West China Med Ctr, Dept Crit Care Med, Chengdu, Sichuan, Peoples R China.	kangyan_hxicu@163.com						Akisu M, 2003, PROSTAG LEUKOTR ESS, V69, P45, DOI 10.1016/S0952-3278(03)00055-3; Akula V, 2014, J INVEST MED, V62, P210; Al Faleh K, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-38; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Bharadwaj SK, 2012, J TROP PEDIATRICS, V58, P382, DOI 10.1093/tropej/fms005; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Hassell KJ, 2015, ARCH DIS CHILD-FETAL, V100, pF541, DOI 10.1136/archdischild-2014-306284; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Joy R, 2013, J TROP PEDIATRICS, V59, P17, DOI 10.1093/tropej/fms036; Li Tongchuan, 2009, Hosp Pract (1995), V37, P147, DOI 10.3810/hp.2009.12.269; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Moler FW, 2015, NEW ENGL J MED, V372, P1898, DOI 10.1056/NEJMoa1411480; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Roka A, 2010, EARLY HUM DEV, V86, P361, DOI 10.1016/j.earlhumdev.2010.05.013; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	23	25	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2017	12	3							e0173006	10.1371/journal.pone.0173006	http://dx.doi.org/10.1371/journal.pone.0173006			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5VL	28273115	Green Published, Green Submitted, gold			2023-01-03	WOS:000396073700035
J	Nielsen, S; Larance, B; Lintzeris, N				Nielsen, Suzanne; Larance, Briony; Lintzeris, Nicholas			Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; GUIDELINE	CLINICAL QUESTION Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid agonist treatment associated with differences in efficacy compared with opioid taper or psychological treatments alone? BOTTOM LINE For patients who are dependent on prescription opioids, long-term maintenance of opioid agonists is associated with less prescription opioid use and better adherence to medication and psychological therapies for opioid dependence compared with opioid taper or psychological treatments alone. Methadone maintenance was not associated with differences in therapeutic efficacy compared with buprenorphine maintenance treatment. Evidence quality was low to moderate.	[Nielsen, Suzanne; Larance, Briony] Univ New South Wales, Natl Drug & Alcohol Ctr, Sydney, NSW, Australia; [Lintzeris, Nicholas] Univ Sydney, Discipline Addict Med, Sydney, NSW, Australia	University of New South Wales Sydney; University of Sydney	Nielsen, S (corresponding author), Univ New South Wales, Natl Drug & Alcohol Res Ctr, 22-32 King St, Randwick, NSW 2031, Australia.	suzanne.nielsen@unsw.edu.au			Reckitt Benckiser (Indivior); Mundipharma	Reckitt Benckiser (Indivior); Mundipharma	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Nielsen, Larance, and Lintzeris have received grant funding from Reckitt Benckiser (Indivior), which had no conditions on the work or the way the findings were reported. Drs Larance and Lintzeris reported receiving grant funding from Mundipharma for postmarketing surveillance studies of reformulated OxyContin. Dr Lintzeris reported receiving honoraria from Pharmacomedia.	Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Nielsen S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011117.pub2; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; US Center for Substance Abuse Treatment, 2004, CLIN GUID US BUPR TR, V40; Wood EA, GUIDELINE CLIN MANAG	7	44	44	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2017	317	9					967	968		10.1001/jama.2017.0001	http://dx.doi.org/10.1001/jama.2017.0001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM8DM	28267837	Green Published			2023-01-03	WOS:000395541500016
J	Masters, K				Masters, Kate			PERSONAL VIEW My mum's care means that decisions not to resuscitate must now be discussed with patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												katemasters67@sky.com							0	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	2017	356								j1084	10.1136/bmj.j1084	http://dx.doi.org/10.1136/bmj.j1084			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM9JW	28254811				2023-01-03	WOS:000395628700008
J	Vedam, S; Stoll, K; Martin, K; Rubashkin, N; Partridge, S; Thordarson, D; Jolicoeur, G				Vedam, Saraswathi; Stoll, Kathrin; Martin, Kelsey; Rubashkin, Nicholas; Partridge, Sarah; Thordarson, Dana; Jolicoeur, Ganga		Changing Childbirth BC Steering	The Mother's Autonomy in Decision Making (MADM) scale: Patient-led development and psychometric testing of a new instrument to evaluate experience of maternity care	PLOS ONE			English	Article							CHILDBIRTH; DELIVERY; HEALTH; LABOR	Shared decision making (SDM) is core to person-centered care and is associated with improved health outcomes. Despite this, there are no validated scales measuring women's agency and ability to lead decision making during maternity care. Objective To develop and validate a new instrument that assesses women's autonomy and role in decision making during maternity care. Design Through a community-based participatory research process, service users designed, content validated, and administered a cross-sectional quantitative survey, including 31 items on the experience of decision-making. Setting and participants Pregnancy experiences (n = 2514) were reported by 1672 women who saw a single type of primary maternity care provider in British Columbia. They described care by a midwife, family physician or obstetrician during 1, 2 or 3 maternity care cycles. We conducted psychometric testing in three separate samples. Main outcome measures We assessed reliability, item-to-total correlations, and the factor structure of the The Mothers' Autonomy in Decision Making (MADM) scale. We report MADM scores by care provider type, length of prenatal appointments, preferences for role in decision-making, and satisfaction with experience of decision-making. Results The MADM scale measures a single construct: autonomy in decision-making during maternity care. Cronbach alphas for the scale exceeded 0.90 for all samples and all provider groups. All item-to-total correlations were replicable across three samples and exceeded 0.7. Eigenvalue and scree plots exhibited a clear 90-degree angle, and factor analysis generated a one factor scale. MADM median scores were highest among women who were cared for by midwives, and 10 or more points lower for those who saw physicians. Increased time for prenatal appointments was associated with higher scale scores, and there were significant differences between providers with respect to average time spent in prenatal appointments. Midwifery care was associated with higher MADM scores, even during short prenatal appointments (<15 minutes). Among women who preferred to lead decisions around their care (90.8%), and who were dissatisfied with their experience of decision making, MADM scores were very low (median 14). Women with physician carers were consistently more likely to report dissatisfaction with their involvement in decision making. Discussion The Mothers Autonomy in Decision Making (MADM) scale is a reliable instrument for assessment of the experience of decision making during maternity care. This new scale was developed and content validated by community members representing various populations of childbearing women in BC including women from vulnerable populations. MADM measures women's ability to lead decision making, whether they are given enough time to consider their options, and whether their choices are respected. Women who experienced midwifery care reported greater autonomy than women under physician care, when engaging in decision-making around maternity care options. Differences in models of care, professional education, regulatory standards, and compensation for prenatal visits between midwives and physicians likely affect the time available for these discussions and prioritization of a shared decision making process. Conclusion The MADM scale reflects person-driven priorities, and reliably assesses interactions with maternity providers related to a person's ability to lead decision-making over the course of maternity care.	[Vedam, Saraswathi; Stoll, Kathrin; Martin, Kelsey; Thordarson, Dana] Univ British Columbia Vancouver, Div Midwifery, Birth Pl Res Lab, Vancouver, BC, Canada; [Stoll, Kathrin] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Rubashkin, Nicholas] Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; [Partridge, Sarah] Univ British Columbia, Dept Family Practice, Residency Program, Vancouver, BC, Canada; [Jolicoeur, Ganga] Midwives Assoc British Columbia, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of California System; University of California San Francisco; University of British Columbia	Vedam, S (corresponding author), Univ British Columbia Vancouver, Div Midwifery, Birth Pl Res Lab, Vancouver, BC, Canada.	vedam@midwifery.ubc.ca		Vedam, Saraswathi/0000-0001-6396-3638	Vancouver Foundation (NPO) [UNR12-0701]	Vancouver Foundation (NPO)	Vancouver Foundation (NPO) https://www.vancouverfoundation.ca/ This work was partially supported by operating grant #UNR12-0701 for the provincial community based participatory Changing Childbirth in BC study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2001, CROSSING QUALITY CHA; [Anonymous], 2014, INTR HLTH WOM BAB CL; [Anonymous], J CLIN EPIDEMIOLOGY, V51, P399; [Anonymous], 2015, STATEMENT POLICY GLO; Baker SR, 2005, FEM PSYCHOL, V15, P315, DOI 10.1177/0959-353505054718; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Caron-Flinterman JF, 2005, SOC SCI MED, V60, P2575, DOI 10.1016/j.socscimed.2004.11.023; Cheyney M, 2014, BIRTH-ISS PERINAT C, V41, P1, DOI 10.1111/birt.12099; CMA, 2007, GUID PHYS INT IND, P1; Coxon K, 2014, DISCOURSES RISK BLAM; Duncan E, 1996, COCHRANE DATABASE SY; Edwards A, 2001, Health Expect, V4, P151, DOI 10.1046/j.1369-6513.2001.00116.x; GITHENS PB, 1993, BIRTH-ISS PERINAT C, V20, P136, DOI 10.1111/j.1523-536X.1993.tb00438.x; Grzybowski S, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-147; Hack TF, 2006, PSYCHO-ONCOL, V15, P9, DOI 10.1002/pon.907; Hall WA, 2012, QUAL HEALTH RES, V22, P575, DOI 10.1177/1049732311424292; Harris SJ, 2012, CAN MED ASSOC J, V184, P1885, DOI 10.1503/cmaj.111753; Heaman MI, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-188; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Kriston L, 2010, PATIENT EDUC COUNS, V80, P94, DOI 10.1016/j.pec.2009.09.034; Kukla R, 2009, BIOETHICS, V23, P1, DOI 10.1111/j.1467-8519.2008.00677.x; Lalonde A, 2015, INT J GYNECOL OBSTET, V128, P95, DOI 10.1016/j.ijgo.2014.10.013; Lawrence HC, 2012, AM J OBSTET GYNECOL, V207, P147, DOI 10.1016/j.ajog.2012.07.018; Legare F, 2012, PATIENT, V5, P1, DOI 10.2165/11592180-000000000-00000; Legare F, 2008, PATIENT EDUC COUNS, V73, P526, DOI 10.1016/j.pec.2008.07.018; Lewin SA, 2001, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858, DOI 10.1002/14651858.CD003267]; Lyerly Anne., 2013, GOOD BIRTH FINDING P; Regan Mary, 2013, J Clin Ethics, V24, P239; Reis V, 2012, RESPECTFUL MATERNITY; ROBERTS AR, 2004, EVIDENCE BASED PRACT; Sandall J., 2015, COCHRANE DB SYST REV, V9, P1, DOI DOI 10.1002/14651858.CD004667.PUB4; Shay LA, 2015, MED DECIS MAKING, V35, P114, DOI 10.1177/0272989X14551638; Stacey D, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub4, 10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3]; ten Hoope-Bender P, 2014, LANCET, V384, P1226, DOI 10.1016/S0140-6736(14)60930-2; Wendland CL, 2007, MED ANTHROPOL Q, V21, P218, DOI 10.1525/MAQ.2007.21.2.218	35	61	61	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0171804	10.1371/journal.pone.0171804	http://dx.doi.org/10.1371/journal.pone.0171804			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL5SX	28231285	Green Published, Green Submitted, gold			2023-01-03	WOS:000394682400020
J	Hajiluian, G; Farhangi, MA; Jahangiry, L				Hajiluian, Ghazaleh; Farhangi, Mahdieh Abbasalizad; Jahangiry, Leila			Mediterranean dietary pattern and VEGF+405 G/C gene polymorphisms in patients with metabolic syndrome: An aspect of gene-nutrient interaction	PLOS ONE			English	Article							SERUM TRIGLYCERIDE RESPONSES; CORONARY-ARTERY-DISEASE; LIFE-STYLE MODIFICATION; RISK-FACTORS; IRANIAN ADULTS; FAT; CHOLESTEROL; PLASMA; FRUIT; MEN	Aims To evaluate the relationship between Mediterranean dietary pattern, anthropometric and metabolic biomarkers and vascular endothelial growth factor ( VEGF) +405 G/C gene polymorphism in patient with metabolic syndrome ( Mets). Materials and methods In this study 150 patients with Mets and 50 healthy subjects were enrolled. Dietary intakes were evaluated with a semi-quantitative food-frequency questionnaire ( FFQ) and Mediterranean dietary quality index ( Med-DQI) was assessed. Anthropometric assessments and blood pressure measurement were performed. Biochemical assays including fasting serum glucose ( FSG), matrix metalloproteinase-3 ( MMP-3), liver enzymes and lipid profiles were also assessed. Polymorphism of +405 G/C VEGF gene was determined utilizing polymerase chain reaction-restriction fragments length polymorphism ( PCR-RFLP) method. Results Serum high density lipoprotein-cholesterol ( HDL-C) was significantly lower and low density lipoprotein cholesterol ( LDL-C), triglyceride ( TG), total cholesterol ( TC) concentrations and FSG were significantly higher in metabolic syndrome patients compared with control group ( P < 0.05). Metabolic syndrome group with high consumption of "cholesterol" had significantly upper serum TG; also high consumption of "fish" and "vegetables-fruits" was associated with a significantly lower serum LDL concentrations. In metabolic syndrome patients with CC genotype, mean score of "saturated fatty acid" subgroup was significantly higher compared with other genotypes; whereas, in healthy individuals, mean score of "fruit-vegetable" subgroup in individuals of CC and GG genotype was significantly higher ( P<0.05). Conclusion Our findings indicated a significant relationship between Mediterranean dietary quality index and both anthropometric and metabolic risk factors. We also indicated a higher "saturated fatty acid" intake in CC genotype among metabolic syndrome patients.	[Hajiluian, Ghazaleh] Tabriz Univ Med Sci, Student Res Comm, Nutr Res Ctr, Fac Nutr, Tabriz, Iran; [Farhangi, Mahdieh Abbasalizad] Tabriz Univ Med Sci, Nutr Res Ctr, Drug Appl Res Ctr, Dept Community Nutr, Tabriz, Iran; [Jahangiry, Leila] Tabriz Univ Med Sci, Hlth Educ & Hlth Promot Dept, Sch Publ Hlth, Tabriz, Iran	Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science	Farhangi, MA (corresponding author), Tabriz Univ Med Sci, Nutr Res Ctr, Drug Appl Res Ctr, Dept Community Nutr, Tabriz, Iran.	abbasalizad_m@yahoo.com	, ../J-9427-2017; Jahangiry, Leila/F-9880-2017; Farhangi, Mahdieh Abbasalizad/AAC-6758-2019	, ../0000-0002-0491-5764; Jahangiry, Leila/0000-0002-0491-5764; 				Aggarwal A, 2014, J CARDIOVASC THORAC, V6, P169, DOI 10.15171/jcvtr.2014.006; Aggarwal A, 2014, J CARDIOVASC THORAC, V6, P15, DOI 10.5681/jcvtr.2014.003; Azizi F, 2003, DIABETES RES CLIN PR, V61, P29, DOI 10.1016/S0168-8227(03)00066-4; Azizi F, 2010, ARCH IRAN MED, V13, P243; Barylski M, 2009, ANGIOLOGY, V60, P87, DOI 10.1177/0003319708327165; Brown L, 1999, AM J CLIN NUTR, V69, P30; Carr DB, 2004, DIABETES, V53, P2087, DOI 10.2337/diabetes.53.8.2087; Carter P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4229; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COHEN JC, 1988, AM J CLIN NUTR, V47, P825, DOI 10.1093/ajcn/47.5.825; Delavar MA, 2009, ASIA PAC J CLIN NUTR, V18, P285; Esfahani FH, 2010, J EPIDEMIOL, V20, P150, DOI 10.2188/jea.JE20090083; Esposito K, 2007, MOL NUTR FOOD RES, V51, P1268, DOI 10.1002/mnfr.200600297; Esteghamati A, 2009, DIABETIC MED, V26, P745, DOI 10.1111/j.1464-5491.2009.02756.x; Farhangi MA, ORCP 2015; Farhangi MA, 2015, INT J DIABETES DEV C, P1; Farzi A, 2014, ASS VASCULAR ENDOTHE, V8, P122; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Georgoulis M, 2015, J HUM NUTR DIET, V28, P409, DOI 10.1111/jhn.12323; Gerber M, 2001, J NUTR, V131, p3051S, DOI 10.1093/jn/131.11.3051S; Gerber MJ, 2000, J AM DIET ASSOC, V100, P1164, DOI 10.1016/S0002-8223(00)00340-0; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; He K, 2004, INT J OBESITY, V28, P1569, DOI 10.1038/sj.ijo.0802795; Jacobs B, 2004, J NUTR, V134, P1400, DOI 10.1093/jn/134.6.1400; Jahangiry L, 2014, BMC PUBLIC HEALTH, V14, P1; Loktionov A, 2003, J NUTR BIOCHEM, V14, P426, DOI 10.1016/S0955-2863(03)00032-9; Mirmiran P, 2009, METABOLISM, V58, P460, DOI 10.1016/j.metabol.2008.11.002; Mohseni T, 2016, CURR TOP NUTRACEUT R, V14, P49; Moradzadegan A, 2015, J RENIN-ANGIO-ALDO S, V16, P672, DOI 10.1177/1470320313497819; Nunez-Cordoba JM, 2009, AM J EPIDEMIOL, V169, P339, DOI 10.1093/aje/kwn335; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; Reaven G, 2002, CIRCULATION, V106, P286, DOI 10.1161/01.CIR.0000019884.36724.D9; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Romaguera D, 2009, J NUTR, V139, P1728, DOI 10.3945/jn.109.108902; Takahashi MM, 2010, ARCH LATINOAM NUTR, V60, P148; Tur JA, 2005, BRIT J NUTR, V93, P369, DOI 10.1079/BJN20041363; Tzima N, 2007, LIPIDS HEALTH DIS, V6, DOI 10.1186/1476-511X-6-22; Williams DEM, 2000, BRIT J NUTR, V83, P257, DOI 10.1017/S0007114500000337; Yamaoka K, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-138; Yolanda BL, 2006, J NUTR BIOCH, V17, P1, DOI DOI 10.1016/J.JNUTBI0.2005.08.002; Zabetian A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-138	41	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2017	12	2							e0171637	10.1371/journal.pone.0171637	http://dx.doi.org/10.1371/journal.pone.0171637			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BI	28212431	Green Published, gold, Green Submitted			2023-01-03	WOS:000394424700009
J	Bao, YH; Fan, GR; Zou, DD; Wang, T; Xue, D				Bao, Yuhua; Fan, Guanrong; Zou, Dongdong; Wang, Tong; Xue, Di			Patient experience with outpatient encounters at public hospitals in Shanghai: Examining different aspects of physician services and implications of overcrowding	PLOS ONE			English	Article							CARE; PERFORMANCE; OUTCOMES; QUALITY; TIME	Background Over 90% of outpatient care in China was delivered at public hospitals, making outpatient experience in this setting an important aspect of quality of care. Objective To assess outpatient experience with different aspects of physician services at China's public hospitals and its association with overcrowding of the hospital outpatient departments. Research design Retrospective analysis of a large survey of outpatient experience in Shanghai, China. We tested the hypotheses that patient experience was poorer with physician-patient communication, education, and shared decision-making and where and when there was greater overcrowding of the hospital outpatient departments. Ordered logistic models were estimated separately for general and specialty hospitals. Subjects 7,147 outpatients at 40 public hospitals in Shanghai, China, in 2014. Measures Patient experience with physician services were self-reported based on 12 questions as part of a validated instrument. Indicators of overcrowding included time of visit (morning vs. afternoon, Monday vs. rest of the week) and hospital outpatient volume in the first half of 2014. Results Overall, patients reported very favorable experience with physician services. Two out of the 12 questions pertaining to both communication and shared decision-making consistently received lower ratings. Hospitals whose outpatient volumes were in the top two quartiles received lower patient ratings, but the relationship achieved statistical significance among specialty hospitals only. Conclusions Inadequate physician-patient communication and shared decision-making and hospital overcrowding compromise outpatient experience with physician services at Chinese public hospitals. Effective diversion of patients with chronic and less complex conditions to community health centers will be critical to alleviate the extreme workloads at hospitals with high patient volumes and, in turn, improve patient experience.	[Bao, Yuhua] Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY USA; [Bao, Yuhua] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA; [Fan, Guanrong; Zou, Dongdong] Shanghai Med Ethos Assoc, Shanghai, Peoples R China; [Wang, Tong] Shanghai Hlth & Family Planning Commiss, Shanghai, Peoples R China; [Xue, Di] Fudan Univ, Sch Publ Hlth, Dept Hosp Management, Shanghai, Peoples R China; [Xue, Di] Fudan Univ, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China	Cornell University; Cornell University; Fudan University; Fudan University	Xue, D (corresponding author), Fudan Univ, Sch Publ Hlth, Dept Hosp Management, Shanghai, Peoples R China.; Xue, D (corresponding author), Fudan Univ, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China.	xuedi@shmu.edu.cn			Weill Cornell Medical College; Shanghai Health and Family Planning Commission	Weill Cornell Medical College; Shanghai Health and Family Planning Commission	The Shanghai Health and Family Planning Commission (www.wsjsw.gov.cn) funded the patient experience survey in 2014, which provided data for this study. The sponsor of the study facilitated the study team's access to the public hospitals included in the survey and provided input in interpretation of data. YB was supported by Weill Cornell Medical College (weill.cornell.edu) sabbatical fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2015, CLIN GROUP SURV CG C; [Anonymous], 2015, CHINESE HLTH RESOURC, V18, P115; CAREY RG, 1993, MED CARE, V31, P834, DOI 10.1097/00005650-199309000-00008; Centers for Medicare and Medicaid Services, 2014, CONS ASS HEALTHC PRO; Chen T, 2015, CHINA HOSP CEO, P38; Coulter A, 2011, ENGAGING PATIENTS HE; de Silva A, MEASURING RESPONSIVE; Department of Health, 2008, US COMM QUAL INN CQU; Doyle C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001570; Fenton JJ, 2012, ARCH INTERN MED, V172, P405, DOI 10.1001/archinternmed.2011.1662; Guangyu H, 2016, CHIN J HOSP ADM, V32, P423; Hays RD, 2003, AM J MED QUAL, V18, P190, DOI 10.1177/106286060301800503; He JA, 2016, HEALTH ECON POLICY L, V28, P1; Henderson JW, 2002, EDUC PSYCHOL MEAS, V62, P995, DOI 10.1177/0013164402238086; Hsiao WC, 2008, HEALTH AFFAIR, V27, P949, DOI 10.1377/hlthaff.27.4.949; IOM Quality of Health Care Committee, 2001, CROSSING QUALITY CHA; Isaac T, 2010, HEALTH SERV RES, V45, P1024, DOI 10.1111/j.1475-6773.2010.01122.x; Janssen PPM, 1999, J ADV NURS, V29, P1360, DOI 10.1046/j.1365-2648.1999.01022.x; Kahn KL, 2007, HEALTH SERV RES, V42, P63, DOI 10.1111/j.1475-6773.2006.00604.x; Li H., 2014, OXID MED CELL LONGEV, V2014, P1, DOI DOI 10.1016/J.BI0MATERIALS.2014.01.039; Liebman BL, 2013, COLUMBIA LAW REV, V113, P181; Liu YH, 2013, BREAST CANCER RES TR, V137, P829, DOI 10.1007/s10549-012-2387-8; National Health and Family Planning Commision of the People's Republic of China, 2014, 2014 CHIN HLTH FAM P; Nichols A, 2007, RES PAPERS EC; Price RA, 2014, MED CARE RES REV, V71, P522, DOI 10.1177/1077558714541480; Ratanawongsa N, 2013, JAMA INTERN MED, V173, P210, DOI 10.1001/jamainternmed.2013.1216; Safran DG, 1998, J FAM PRACTICE, V47, P213; Saman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061097; Tai-Seale M, 2007, HEALTH SERV RES, V42, P1871, DOI 10.1111/j.1475-6773.2006.00689.x; Tai-Seale M, 2012, HEALTH ECON, V21, P457, DOI 10.1002/hec.1726; Wang XQ, 2012, LANCET, V380, P647, DOI 10.1016/S0140-6736(12)61367-1; Wei W, 2017, CHINA MED ARCH, V14, P18; Wu Q., 2014, J TRADITIONAL CHINES, V22, P653; Xue D, 2013, HEALTH CARE MANAGE R, V38, P258, DOI 10.1097/HMR.0b013e3182678f9a; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; 张丹, 2014, [中国卫生统计, Chinese Journal of Health Statistics], V31, P671	36	28	30	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0171684	10.1371/journal.pone.0171684	http://dx.doi.org/10.1371/journal.pone.0171684			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL2BG	28207783	gold, Green Published, Green Submitted			2023-01-03	WOS:000394424500047
J	El-Maouche, D; Arlt, W; Merke, DP				El-Maouche, Diala; Arlt, Wiebke; Merke, Deborah P.			Congenital adrenal hyperplasia	LANCET			English	Review							CLASSIC 21-HYDROXYLASE DEFICIENCY; ACUTE-REGULATORY-PROTEIN; 3-BETA-HYDROXYSTEROID DEHYDROGENASE-DEFICIENCY; PRENATAL DEXAMETHASONE TREATMENT; P450 OXIDOREDUCTASE DEFICIENCY; EHLERS-DANLOS-SYNDROME; CHAIN CLEAVAGE ENZYME; BONE-MINERAL DENSITY; STEROID 11-BETA-HYDROXYLASE DEFICIENCY; SUBCUTANEOUS HYDROCORTISONE INFUSION	Congenital adrenal hyperplasia is a group of autosomal recessive disorders encompassing enzyme deficiencies in the adrenal steroidogenesis pathway that lead to impaired cortisol biosynthesis. Depending on the type and severity of steroid block, patients can have various alterations in glucocorticoid, mineralocorticoid, and sex steroid production that require hormone replacement therapy. Presentations vary from neonatal salt wasting and atypical genitalia, to adult presentation of hirsutism and irregular menses. Screening of neonates with elevated 17-hydroxyprogesterone concentrations for classic (severe) 21-hydroxylase deficiency, the most common type of congenital adrenal hyperplasia, is in place in many countries, however cosyntropin stimulation testing might be needed to confirm the diagnosis or establish non-classic (milder) subtypes. Challenges in the treatment of congenital adrenal hyperplasia include avoidance of glucocorticoid overtreatment and control of sex hormone imbalances. Long-term complications include abnormal growth and development, adverse effects on bone and the cardiovascular system, and infertility. Novel treatments aim to reduce glucocorticoid exposure, improve excess hormone control, and mimic physiological hormone patterns.	[El-Maouche, Diala; Merke, Deborah P.] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Arlt, Wiebke] Univ Birmingham, Inst Metab & Syst Res IMSR, Birmingham, W Midlands, England; [Arlt, Wiebke] Birmingham Hlth Partners, Ctr Endocrinol Diabet & Metab CEDAM, Birmingham, W Midlands, England; [Merke, Deborah P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Birmingham; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Merke, DP (corresponding author), NIH, Ctr Clin, Bethesda, MD 20892 USA.	dmerke@nih.gov	Loke, Kah Yin/E-6586-2015; Arlt, Wiebke/B-6310-2009	Arlt, Wiebke/0000-0001-5106-9719; El-Maouche, Diala/0000-0002-0936-2249	Bayer AG; Diurnal and Millendo Therapeutics through National Institutes of Health Cooperative Research and Development Agreement; MRC [G0900567] Funding Source: UKRI; Medical Research Council [G116/172, G0900567] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008934] Funding Source: NIH RePORTER	Bayer AG(Bayer AG); Diurnal and Millendo Therapeutics through National Institutes of Health Cooperative Research and Development Agreement; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	WA reports licensing of a patent by Alta Biosciences, research grants from Diurnal and Millendo, scientific consultancy fees from Bayer AG, and a patent pending for a computational algorithm for rapid interpretation of steroid data pending. DPM received research funds from Diurnal and Millendo Therapeutics through the National Institutes of Health Cooperative Research and Development Agreement.	Abdulhadi-Atwan M, 2007, J CLIN ENDOCR METAB, V92, P4000, DOI 10.1210/jc.2007-1306; Albarel F, 2016, HUM REPROD, V31, P2609, DOI 10.1093/humrep/dew239; Arlt W, 2004, LANCET, V363, P2128, DOI 10.1016/S0140-6736(04)16503-3; Arlt W, 2010, J CLIN ENDOCR METAB, V95, P5110, DOI 10.1210/jc.2010-0917; Auchus RJ, 2017, J STEROID BIOCHEM, V165, P71, DOI 10.1016/j.jsbmb.2016.02.002; Auchus RJ, 2014, J CLIN ENDOCR METAB, V99, P2763, DOI 10.1210/jc.2014-1258; Auchus RJ, 2013, J CLIN ENDOCR METAB, V98, P2645, DOI 10.1210/jc.2013-1440; Aycan Z, 2013, CLIN ENDOCRINOL, V78, P667, DOI 10.1111/cen.12033; Azziz R, 1999, FERTIL STERIL, V72, P915, DOI 10.1016/S0015-0282(99)00383-0; Baker BY, 2006, J CLIN ENDOCR METAB, V91, P4781, DOI 10.1210/jc.2006-1565; Balyura M, 2015, P NATL ACAD SCI USA, V112, P2527, DOI 10.1073/pnas.1500242112; BARTTER FC, 1951, J CLIN INVEST, V30, P237, DOI 10.1172/JCI102438; Bidet M, 2010, J CLIN ENDOCR METAB, V95, P1182, DOI 10.1210/jc.2009-1383; Bidet M, 2009, J CLIN ENDOCR METAB, V94, P1570, DOI 10.1210/jc.2008-1582; BIGLIERI EG, 1966, J CLIN INVEST, V45, P1946, DOI 10.1172/JCI105499; BONGIOVANNI AM, 1963, NEW ENGL J MED, V268, P1391, DOI 10.1056/NEJM196306202682505; BONGIOVANNI AM, 1963, NEW ENGL J MED, V268, P1342, DOI 10.1056/NEJM196306132682406; BONGIOVANNI AM, 1962, J CLIN INVEST, V41, P2086, DOI 10.1172/JCI104666; BONGIOVANNI AM, 1963, NEW ENGL J MED, V268, P1283, DOI 10.1056/NEJM196306062682308; Bornstein SR, 2016, J CLIN ENDOCR METAB, V101, P364, DOI 10.1210/jc.2015-1710; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Bose HS, 2000, J CLIN ENDOCR METAB, V85, P3636, DOI 10.1210/jc.85.10.3636; Bry-Gauillard H, 2014, NEW ENGL J MED, V371, P2042, DOI 10.1056/NEJMc1410041; Bryan SM, 2009, J CLIN ENDOCR METAB, V94, P3477, DOI 10.1210/jc.2009-0630; Bulsari K, 2017, ENDOCRINE, V55, P28, DOI 10.1007/s12020-016-1189-x; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; Casteras A, 2009, CLIN ENDOCRINOL, V70, P833, DOI 10.1111/j.1365-2265.2009.03563.x; Caulfield MP, 2002, J CLIN ENDOCR METAB, V87, P3682, DOI 10.1210/jc.87.8.3682; Chabre O, 2000, J CLIN ENDOCR METAB, V85, P4060, DOI 10.1210/jc.85.11.4060; CHANG YT, 1995, PEDIATR RES, V37, P820, DOI 10.1203/00006450-199506000-00024; Chen X, 2005, J CLIN ENDOCR METAB, V90, P835, DOI 10.1210/jc.2004-1323; Cheng YH, 2016, ENDOCR-RELAT CANCER, V23, P1, DOI 10.1530/ERC-15-0527; Chihaoui M, 2016, ANDROLOGIA, V48, P45, DOI 10.1111/and.12416; Claahsen-van der Grinten HL, 2009, BEST PRACT RES CL EN, V23, P209, DOI [10.1016/j.beem.2008.09.007, 10.1155/2009/624823]; Claahsen-van der Grinten HL, 2007, J CLIN ENDOCR METAB, V92, P612, DOI 10.1210/jc.2006-1311; Cordeiro GV, 2013, ARQ BRAS ENDOCRINOL, V57, P126, DOI 10.1590/S0004-27302013000200005; Costa-Santos M, 2004, J CLIN ENDOCR METAB, V89, P49, DOI 10.1210/jc.2003-031021; Coulm B, 2012, ARCH PEDIAT ADOL MED, V166, P113, DOI 10.1001/archpediatrics.2011.774; Crocker MK, 2012, J CLIN ENDOCR METAB, V97, pE2084, DOI 10.1210/jc.2012-2298; Dagalakis U, 2016, INT J PEDIATR ENDOCR, DOI 10.1186/s13633-016-0028-4; Bianchi PHD, 2016, J CLIN ENDOCR METAB, V101, P345, DOI 10.1210/jc.2015-3201; Delle Piane L, 2015, ENDOCRINOLOGY, V156, P1210, DOI 10.1210/en.2014-1879; DiSandro M, 2015, HORM METAB RES, V47, P321, DOI 10.1055/s-0035-1547292; EBERLEIN WR, 1955, J CLIN ENDOCR METAB, V15, P1531, DOI 10.1210/jcem-15-12-1531; EBERLEIN WR, 1955, J CLIN INVEST, V34, P1337, DOI 10.1172/JCI103181; El-Maouche D, 2015, CLIN ENDOCRINOL, V82, P330, DOI 10.1111/cen.12507; Falhammar H, 2007, J CLIN ENDOCR METAB, V92, P4643, DOI 10.1210/jc.2007-0744; Falhammar H, 2015, J CLIN ENDOCR METAB, V100, P3520, DOI 10.1210/JC.2015-2093; Falhammar H, 2014, J CLIN ENDOCR METAB, V99, pE2715, DOI 10.1210/jc.2014-2957; Falhammar H, 2013, EUR J ENDOCRINOL, V168, P331, DOI 10.1530/EJE-12-0865; Falhammar H, 2012, EUR J ENDOCRINOL, V166, P441, DOI 10.1530/EJE-11-0828; Finkielstain GP, 2012, J CLIN ENDOCR METAB, V97, P4429, DOI 10.1210/jc.2012-2102; Finkielstain GP, 2011, J CLIN ENDOCR METAB, V96, pE161, DOI 10.1210/jc.2010-0319; Fisher AD, 2016, J ENDOCRINOL INVEST, V39, P1207, DOI 10.1007/s40618-016-0482-0; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; Fluck CE, 2011, AM J HUM GENET, V89, P201, DOI 10.1016/j.ajhg.2011.06.009; Fluck CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020178; FOREST MG, 1993, J STEROID BIOCHEM, V45, P75, DOI 10.1016/0960-0760(93)90125-G; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; Gomes LG, 2009, J CLIN ENDOCR METAB, V94, P89, DOI 10.1210/jc.2008-1174; Grinten HLCVD, 2008, EUR J ENDOCRINOL, V159, P489, DOI 10.1530/EJE-08-0311; Guran T, 2016, J CLIN ENDOCR METAB, V101, P283, DOI 10.1210/jc.2015-3250; Hannah-Shmouni F, 2017, GENET MED, V19, P1276, DOI 10.1038/gim.2017.46; Hirvikoski T, 2007, J CLIN ENDOCR METAB, V92, P542, DOI 10.1210/jc.2006-1340; Hirvikoski T, 2012, J CLIN ENDOCR METAB, V97, P1881, DOI 10.1210/jc.2012-1222; Homma K, 2006, J CLIN ENDOCR METAB, V91, P2643, DOI 10.1210/jc.2005-2460; Idkowiak J, 2012, J CLIN ENDOCR METAB, V97, pE465, DOI 10.1210/jc.2011-2413; Idkowiak J, 2011, J CLIN ENDOCR METAB, V96, pE453, DOI 10.1210/jc.2010-1607; Janzen N, 2007, J CLIN ENDOCR METAB, V92, P2581, DOI 10.1210/jc.2006-2890; Janzen N, 2012, HORM RES PAEDIAT, V77, P195, DOI 10.1159/000337974; Jin HY, 2011, EUR J PEDIATR, V170, P535, DOI 10.1007/s00431-010-1342-0; Jones CM, 2017, J CLIN ENDOCR METAB, V102, P1797, DOI 10.1210/jc.2016-2855; KAGIMOTO M, 1988, MOL ENDOCRINOL, V2, P564, DOI 10.1210/mend-2-6-564; Kamrath C, 2012, J CLIN ENDOCR METAB, V97, pE367, DOI 10.1210/jc.2011-1997; Kaupert LC, 2013, CLIN GENET, V84, P482, DOI 10.1111/cge.12016; Kavoussi PK, 2016, J ASSIST REPROD GEN, V33, P545, DOI 10.1007/s10815-016-0665-9; Khattab A, 2017, P NATL ACAD SCI USA, V114, pE1933, DOI 10.1073/pnas.1621082114; Khoury K, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00527; Koyama Y, 2012, CLIN CHEM, V58, P741, DOI 10.1373/clinchem.2011.173286; Krone N, 2012, J CLIN ENDOCR METAB, V97, pE257, DOI 10.1210/jc.2011-0640; Labarta E, 2011, HUM REPROD, V26, P1813, DOI 10.1093/humrep/der126; Lajic S, 2011, ENDOCR DEV, V20, P96, DOI 10.1159/000321228; Laue K, 2011, AM J HUM GENET, V89, P595, DOI 10.1016/j.ajhg.2011.09.015; Lekarev O, 2015, ENDOCRIN METAB CLIN, V44, P705, DOI 10.1016/j.ecl.2015.07.009; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Livadas S, 2015, CLIN ENDOCRINOL, V82, P543, DOI 10.1111/cen.12543; Mallappa A, 2015, J CLIN ENDOCR METAB, V100, P1137, DOI 10.1210/jc.2014-3809; Manoli I, 2002, CLIN ENDOCRINOL, V57, P669, DOI 10.1046/j.1365-2265.2002.01645.x; Martinerie L, 2009, PEDIATR RES, V66, P323, DOI 10.1203/PDR.0b013e3181b1bbec; Martinez-Aguayo A, 2007, J CLIN ENDOCR METAB, V92, P4583, DOI 10.1210/jc.2007-0383; Merke DP, 2013, LANCET DIABETES ENDO, V1, P341, DOI 10.1016/S2213-8587(13)70138-4; Merke DP, 2013, J CLIN ENDOCR METAB, V98, pE379, DOI 10.1210/jc.2012-3148; Merke DP, 2000, NEW ENGL J MED, V343, P1362, DOI 10.1056/NEJM200011093431903; Merke DP, 2000, J CLIN ENDOCR METAB, V85, P1114, DOI 10.1210/jc.85.3.1114; Mermejo LM, 2005, J CLIN ENDOCR METAB, V90, P1287, DOI 10.1210/jc.2004-1552; Metherell LA, 2009, J CLIN ENDOCR METAB, V94, P3865, DOI 10.1210/jc.2009-0467; Miller WL, 2017, J STEROID BIOCHEM, V165, P18, DOI 10.1016/j.jsbmb.2016.03.009; Miller WL, 2011, ENDOCR REV, V32, P81, DOI 10.1210/er.2010-0013; Mnif Mouna Feki, 2013, Indian J Endocrinol Metab, V17, P790, DOI 10.4103/2230-8210.117196; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Morel Y, 2014, GENETIC STEROID DISORDERS, P99, DOI 10.1016/B978-0-12-416006-4.00008-9; Morissette R, 2015, J CLIN ENDOCR METAB, V100, pE1143, DOI 10.1210/jc.2015-2232; Mouriquand PDE, 2016, J PEDIATR UROL, V12, P139, DOI 10.1016/j.jpurol.2016.04.001; Mushtaq T, 2002, ARCH DIS CHILD, V87, P93, DOI 10.1136/adc.87.2.93; Muthusamy K, 2010, J CLIN ENDOCR METAB, V95, P4161, DOI 10.1210/jc.2009-2616; Nandagopal R, 2011, EUR J ENDOCRINOL, V164, P977, DOI 10.1530/EJE-11-0019; Nella AA, 2016, J CLIN ENDOCR METAB, V101, P4690, DOI 10.1210/jc.2016-1916; New MI, 2006, J CLIN ENDOCR METAB, V91, P4205, DOI 10.1210/jc.2006-1645; New MI, 2014, J CLIN ENDOCR METAB, V99, pE1022, DOI 10.1210/jc.2014-1118; New MI, 2013, P NATL ACAD SCI USA, V110, P2611, DOI 10.1073/pnas.1300057110; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; Nordenskjold A, 2008, J CLIN ENDOCR METAB, V93, P380, DOI 10.1210/jc.2007-0556; Otto DME, 2003, MOL CELL BIOL, V23, P6103, DOI 10.1128/MCB.23.17.6103-6116.2003; PANG S, 1982, J CLIN ENDOCR METAB, V55, P413, DOI 10.1210/jcem-55-3-413; Pang SY, 1998, TRENDS ENDOCRIN MET, V9, P82, DOI 10.1016/S1043-2760(98)00015-0; Paperna T, 2005, J CLIN ENDOCR METAB, V90, P5463, DOI 10.1210/jc.2005-1145; Parajes S, 2011, J CLIN ENDOCR METAB, V96, pE1798, DOI 10.1210/jc.2011-1277; PETERSON RE, 1985, NEW ENGL J MED, V313, P1182, DOI 10.1056/NEJM198511073131903; PRADER A, 1962, HELV PAEDIATR ACTA, V17, P285; Pretorius E, 2017, MOL CELL ENDOCRINOL, V441, P76, DOI 10.1016/j.mce.2016.08.014; Pretorius E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159867; Raju TNK, 1999, LANCET, V353, P1370, DOI 10.1016/S0140-6736(05)74374-9; Reisch N, 2013, J CLIN ENDOCR METAB, V98, pE1620, DOI 10.1210/jc.2013-1306; Reisch N, 2013, J CLIN ENDOCR METAB, V98, pE528, DOI 10.1210/jc.2012-3449; Reisch N, 2012, EUR J ENDOCRINOL, V167, P35, DOI 10.1530/EJE-12-0161; Reisch N, 2009, J CLIN ENDOCR METAB, V94, P1665, DOI 10.1210/jc.2008-1414; RHEAUME E, 1992, NAT GENET, V1, P239, DOI 10.1038/ng0792-239; Rocha RO, 2008, CLIN ENDOCRINOL, V68, P226, DOI 10.1111/j.1365-2265.2007.03023.x; ROGER M, 1982, HORM RES, V16, P23, DOI 10.1159/000179481; Rubtsov P, 2009, J CLIN ENDOCR METAB, V94, P936, DOI 10.1210/jc.2008-1118; Ruiz-Babot G, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00070; Russo G, 1998, NEW ENGL J MED, V339, P853, DOI 10.1056/NEJM199809173391220; Sahakitrungruang T, 2011, J CLIN ENDOCR METAB, V96, P792, DOI 10.1210/jc.2010-1828; Sahakitrungruang T, 2009, J CLIN ENDOCR METAB, V94, P4992, DOI 10.1210/jc.2009-1460; Sarafoglou K, 2014, J PEDIATR-US, V164, P1141, DOI 10.1016/j.jpeds.2014.01.011; Speiser PW, 2010, J CLIN ENDOCR METAB, V95, P4133, DOI 10.1210/jc.2009-2631; Speiser PW, 2003, NEW ENGL J MED, V349, P776, DOI 10.1056/NEJMra021561; Stikkelbroeck NMML, 2004, J PEDIATR ENDOCR MET, V17, P645; Stikkelbroeck NMML, 2001, J CLIN ENDOCR METAB, V86, P5721, DOI 10.1210/jc.86.12.5721; Storbeck KH, 2013, MOL CELL ENDOCRINOL, V377, P135, DOI 10.1016/j.mce.2013.07.006; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Tajima T, 2001, J CLIN ENDOCR METAB, V86, P3820, DOI 10.1210/jc.86.8.3820; Tardy-Guidollet V, 2014, J CLIN ENDOCR METAB, V99, P1180, DOI 10.1210/jc.2013-2895; Tee MK, 2013, J CLIN ENDOCR METAB, V98, P713, DOI 10.1210/jc.2012-2828; Therrell BL, 2001, ENDOCRIN METAB CLIN, V30, P15, DOI 10.1016/S0889-8529(08)70017-3; Tomalik-Scharte D, 2010, EUR J ENDOCRINOL, V163, P919, DOI 10.1530/EJE-10-0764; Trakakis E, 2011, FERTIL STERIL, V96, P1048, DOI 10.1016/j.fertnstert.2011.07.1103; Turcu AF, 2016, EUR J ENDOCRINOL, V174, P601, DOI 10.1530/EJE-15-1181; Turcu AF, 2016, J CLIN ENDOCR METAB, V101, P1174, DOI 10.1210/jc.2015-3574; van der Kamp HJ, 2005, J CLIN ENDOCR METAB, V90, P3904, DOI 10.1210/jc.2004-2136; Van Wyk JJ, 2003, J CLIN ENDOCR METAB, V88, P2993, DOI 10.1210/jc.2002-022026; Walker BR, 1997, J UROLOGY, V157, P1460, DOI 10.1016/S0022-5347(01)65023-7; Wallensteen L, 2016, J CLIN ENDOCR METAB, V101, P3838, DOI 10.1210/jc.2016-1543; Wallensteen L, 2016, HORM BEHAV, V85, P5, DOI 10.1016/j.yhbeh.2016.06.011; WHITE PC, 1991, J CLIN INVEST, V87, P1664, DOI 10.1172/JCI115182; WHITE PC, 1994, ENDOCR REV, V15, P421, DOI 10.1210/er.15.4.421; WHITE PC, 1985, P NATL ACAD SCI USA, V82, P1089, DOI 10.1073/pnas.82.4.1089; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; White PC, 2011, ADV EXP MED BIOL, V707, P7, DOI 10.1007/978-1-4419-8002-1_2; White PC, 2009, NAT REV ENDOCRINOL, V5, P490, DOI 10.1038/nrendo.2009.148; WILKINS L, 1951, J CLIN ENDOCRINOL, V11, P1; Yu Min Kyung, 2015, Ann Pediatr Endocrinol Metab, V20, P155, DOI 10.6065/apem.2015.20.3.155	162	247	271	6	56	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2017	390	10108					2194	2210		10.1016/S0140-6736(17)31431-9	http://dx.doi.org/10.1016/S0140-6736(17)31431-9			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN0CL	28576284	Green Submitted			2023-01-03	WOS:000415642200024
J	Benrick, A; Kokosar, M; Hu, M; Larsson, M; Maliqueo, M; Marcondes, RR; Soligo, M; Protto, V; Jerlhag, E; Sazonova, A; Behre, CJ; Hojlund, K; Thoren, P; Stener-Victorin, E				Benrick, Anna; Kokosar, Milana; Hu, Min; Larsson, Martin; Maliqueo, Manuel; Marcondes, Rodrigo Rodrigues; Soligo, Marzia; Protto, Virginia; Jerlhag, Elisabet; Sazonova, Antonina; Behre, Carl Johan; Hojlund, Kurt; Thoren, Peter; Stener-Victorin, Elisabet			Autonomic nervous system activation mediates the increase in whole-body glucose uptake in response to electroacupuncture	FASEB JOURNAL			English	Article						glucose homeostasis; polycystic ovary syndrome; insulin resistance; muscle contraction	POLYCYSTIC-OVARY-SYNDROME; BLOOD-FLOW RESPONSES; INSULIN SENSITIVITY; GROWTH-FACTOR; STIMULATION; ACUPUNCTURE; FREQUENCY; PRONGF; EXPRESSION; PLASTICITY	A single bout of low-frequency electroacupuncture (EA) causing muscle contractions increases whole-body glucose uptake in insulin-resistant rats. We explored the underlying mechanism of this finding and whether it can be translated into clinical settings. Changes in glucose infusion rate (GIR) were measured by euglycemic-hyperinsulinemic clamp during and after 45 min of low-frequency EA in 21 overweight/obese women with polycystic ovary syndrome (PCOS) and 21 controls matched for age, weight, and body mass index (experiment 1) and in rats receiving autonomic receptor blockers (experiment 2). GIR was higher after EA in controls and women with PCOS. Plasma serotonin levels and homovanillic acid, markers of vagal activity, decreased in both controls and patients with PCOS. Adipose tissue expression of pro-nerve growth factor (proNGF) decreased, and the mature NGF/proNGF ratio increased after EA in PCOS, but not in controls, suggesting increased sympathetic-driven adipose tissue metabolism. Administration of alpha-/beta-adrenergic receptor blockers in rats blocked the increase in GIR in response to EA. Muscarinic and dopamine receptor antagonist also blocked the response but with slower onset. In conclusion, a single bout of EA increases whole-body glucose uptake by activation of the sympathetic and partly the parasympathetic nervous systems, which could have important clinical implications for the treatment of insulin resistance.	[Benrick, Anna; Kokosar, Milana; Hu, Min; Larsson, Martin; Thoren, Peter] Univ Gothenburg, Sahlgrenska Acad, Dept Physiol, Gothenburg, Sweden; [Jerlhag, Elisabet] Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, Inst Neurosci & Physiol, Gothenburg, Sweden; [Sazonova, Antonina] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, Inst Clin Sci, Gothenburg, Sweden; [Behre, Carl Johan] Univ Gothenburg, Sahlgrenska Acad, Dept Cardiol, Inst Med, Gothenburg, Sweden; [Benrick, Anna] Univ Skovde, Sch Hlth & Educ, Skovde, Sweden; [Maliqueo, Manuel] Univ Chile, Endocrinol & Metab Lab, West Div, Sch Med, Santiago, Chile; [Marcondes, Rodrigo Rodrigues; Stener-Victorin, Elisabet] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Marcondes, Rodrigo Rodrigues] Univ Sao Paulo, Fac Med, Disciplina Ginecol, Lab Ginecol Estrutural & Mol LIM 58, Sao Paulo, Brazil; [Soligo, Marzia; Protto, Virginia] CNR, Inst Translat Pharmacol, Rome, Italy; [Hojlund, Kurt] Odense Univ Hosp, Dept Endocrinol, Odense, Denmark	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Skovde; Universidad de Chile; Karolinska Institutet; Universidade de Sao Paulo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Farmacologia Traslazionale (IFT-CNR); University of Southern Denmark; Odense University Hospital	Stener-Victorin, E (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	elisabet.stener-victorin@ki.se	Soligo, Marzia/AAC-1543-2019; Stener-Victorin, Elisabet/W-6322-2018; Protto, Virginia/R-1117-2016; Marcondes, Rodrigo/Q-3510-2017	Stener-Victorin, Elisabet/0000-0002-3424-1502; Marcondes, Rodrigo/0000-0002-5391-0230; Protto, Virginia/0000-0003-1723-405X; Hojlund, Kurt/0000-0002-0891-4224; Hu, Min/0000-0002-7731-5874	Swedish Medical Research Council [2014-2775]; Jane and Dan Ohlsson Foundation; Wilhelm and Martina Lundgrens's Science Fund; Hjalmar Svensson Foundation; Adlerbert Research Foundation; Novo Nordisk Foundation [NNF16OC0020744]; Strategic Research Programme in Diabetes at Karolinska Institutet; Royal Society of Arts and Sciences in Gothenburg; Swedish federal government under the LUA/ALF [ALFGBG-429501]; Stockholm County Council; Karolinska Institutet; Becas Chile Programme; University of Chile; Italian National Research Council (CNR); Novo Nordisk Fonden [NNF16OC0020744, NNF16OC0021282, NNF17OC0026724, NNF15OC0015902] Funding Source: researchfish	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Jane and Dan Ohlsson Foundation; Wilhelm and Martina Lundgrens's Science Fund; Hjalmar Svensson Foundation; Adlerbert Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Strategic Research Programme in Diabetes at Karolinska Institutet; Royal Society of Arts and Sciences in Gothenburg; Swedish federal government under the LUA/ALF; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Becas Chile Programme; University of Chile; Italian National Research Council (CNR)(Consiglio Nazionale delle Ricerche (CNR)); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank Carola Gustafsson (University of Gothenburg) for performing all euglycemic hyperinsulinemic clamp studies in the human experiment as well as tissue biopsies. Professor Elisabet Stener-Victorin (Karolinska Institutet) is the guarantor of this study and had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. This work was supported by the Swedish Medical Research Council (Project 2014-2775, to E.S.V.); the Jane and Dan Ohlsson Foundation (to E.S.V.); Wilhelm and Martina Lundgrens's Science Fund (to E.S.V. and A.B.); the Hjalmar Svensson Foundation (to E.S.V. and A.B.); the Adlerbert Research Foundation (to E.S.V. and A.B.); the Novo Nordisk Foundation (NNF16OC0020744) (to E.S.V.); Strategic Research Programme in Diabetes at Karolinska Institutet (to E.S.V.); The Royal Society of Arts and Sciences in Gothenburg (to A.B.), the Swedish federal government under the LUA/ALF agreement ALFGBG-429501 (to E.S.V.); and the regional agreement on medical training and clinical research (to A.L.F.) between Stockholm County Council and Karolinska Institutet (to E.S.V.). M.M. thanks the Becas Chile Programme and the University of Chile for financial support through a postdoctoral fellowship. M.S. and V.P. thank the Italian National Research Council (CNR) Short Mobility Program 2015 for mobility fellowships. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.	Al-Shawi R, 2008, EUR J NEUROSCI, V27, P2103, DOI 10.1111/j.1460-9568.2008.06152.x; Al-Shawi R, 2007, ANN NY ACAD SCI, V1119, P208, DOI 10.1196/annals.1404.024; Belivani M, 2015, ACUPUNCT MED, V33, P110, DOI 10.1136/acupmed-2014-010662; Bello NT, 2006, PHYSIOL BEHAV, V88, P138, DOI 10.1016/j.physbeh.2006.03.027; Benrick A, 2014, ACTA DIABETOL, V51, P963, DOI 10.1007/s00592-014-0645-4; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; Bruno MA, 2006, P NATL ACAD SCI USA, V103, P6735, DOI 10.1073/pnas.0510645103; Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004; Chang SL, 1999, DIABETOLOGIA, V42, P250, DOI 10.1007/s001250051146; CURRY DL, 1987, LIFE SCI, V40, P2053, DOI 10.1016/0024-3205(87)90097-X; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dehvari N, 2012, BRIT J PHARMACOL, V165, P1442, DOI 10.1111/j.1476-5381.2011.01647.x; Diamanti-Kandarakis E, 2012, ENDOCR REV, V33, P981, DOI 10.1210/er.2011-1034; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Hamada T, 2003, J APPL PHYSIOL, V94, P2107, DOI 10.1152/japplphysiol.00486.2002; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Hasegawa Y, 2002, THROMB RES, V107, P319, DOI 10.1016/S0049-3848(02)00348-1; Hawley JA, 2014, CELL, V159, P738, DOI 10.1016/j.cell.2014.10.029; Higashimura Y, 2009, AUTON NEUROSCI-BASIC, V150, P100, DOI 10.1016/j.autneu.2009.06.003; Holz RW, 2016, P NATL ACAD SCI USA, V113, P5766, DOI 10.1073/pnas.1605618113; Howard L, 2013, DEVELOPMENT, V140, P2108, DOI 10.1242/dev.085266; Ishizaki N, 2009, METABOLISM, V58, P1372, DOI 10.1016/j.metabol.2009.05.001; Johansson J, 2010, AM J PHYSIOL-ENDOC M, V299, pE551, DOI 10.1152/ajpendo.00323.2010; Kagitani F, 2010, AUTON NEUROSCI-BASIC, V157, P2, DOI 10.1016/j.autneu.2010.03.004; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; Lee YC, 2011, EXP DIABETES RES, DOI 10.1155/2011/947138; Liang F, 2010, DIABETES OBES METAB, V12, P555, DOI 10.1111/j.1463-1326.2009.01192.x; Lin JG, 2004, NEUROSCI LETT, V366, P39, DOI 10.1016/j.neulet.2004.05.003; Lorentz CU, 2013, EXP NEUROL, V249, P111, DOI 10.1016/j.expneurol.2013.08.015; Manneras L, 2009, AM J PHYSIOL-REG I, V296, pR1124, DOI 10.1152/ajpregu.90947.2008; Masoudi R, 2009, J BIOL CHEM, V284, P18424, DOI 10.1074/jbc.M109.007104; Nahin RL, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-217; NG TB, 1985, COMP BIOCHEM PHYS B, V81, P687, DOI 10.1016/0305-0491(85)90387-6; Nilsson ME, 2015, ENDOCRINOLOGY, V156, P2492, DOI 10.1210/en.2014-1890; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; Pedersen SB, 2001, BIOCHEM BIOPH RES CO, V283, P19, DOI 10.1006/bbrc.2001.4736; Prieto-Garcia L, 2015, PSYCHONEUROENDOCRINO, V62, P392, DOI 10.1016/j.psyneuen.2015.09.009; Schlaich M, 2015, LANCET DIABETES ENDO, V3, P148, DOI 10.1016/S2213-8587(14)70033-6; Shimoju-Kobayashi R, 2004, AUTON NEUROSCI-BASIC, V115, P7, DOI 10.1016/j.autneu.2004.07.002; Soligo M, 2015, BRAIN RES, V1624, P455, DOI 10.1016/j.brainres.2015.08.005; Stener-Victorin E, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-44; Stener-Victorin E, 2016, OBES SCI PRACT, V2, P426, DOI 10.1002/osp4.78; Stener-Victorin E, 2003, AUTON NEUROSCI-BASIC, V108, P50, DOI 10.1016/j.autneu.2003.08.006; Stener-Victorin E, 2006, J APPL PHYSIOL, V101, P84, DOI 10.1152/japplphysiol.01593.2005; Stener-Victorin E, 2009, AM J PHYSIOL-REG I, V297, pR387, DOI 10.1152/ajpregu.00197.2009; TABRIZCHI R, 1990, BRIT J PHARMACOL, V101, P358, DOI 10.1111/j.1476-5381.1990.tb12714.x; Thorens B, 2014, DIABETES OBES METAB, V16, P87, DOI 10.1111/dom.12346; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Wang MQ, 2016, P NATL ACAD SCI USA, V113, pE3029, DOI 10.1073/pnas.1517275113	49	26	27	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2017	31	8					3288	3297		10.1096/fj.201601381R	http://dx.doi.org/10.1096/fj.201601381R			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FB1VS	28404742	Green Submitted			2023-01-03	WOS:000405932400009
J	Ruzafa, D; Hernandez-Gomez, YS; Bisello, G; Broersen, K; Morel, B; Conejero-Lara, F				Ruzafa, David; Hernandez-Gomez, Yuriko S.; Bisello, Giovanni; Broersen, Kerensa; Morel, Bertrand; Conejero-Lara, Francisco			The influence of N-terminal acetylation on micelle-induced conformational changes and aggregation of alpha-Synuclein	PLOS ONE			English	Article							PARKINSONS-DISEASE; HELICAL CONFORMATION; EXTENDED-HELIX; COMPLEX-FORMATION; MEMBRANE-BINDING; LIPID VESICLES; WILD-TYPE; MUTATION; FORMS; FIBRILLATION	The biological function of alpha-Synuclein has been related to binding to lipids and membranes but these interactions can also mediate alpha-Synuclein aggregation, which is associated to Parkinson's disease and other neuropathologies. In brain tissue alpha-Synuclein is constitutively N-acetylated, a modification that plays an important role in its conformational propensity, lipid and membrane binding, and aggregation propensity. We studied the interactions of the lipid-mimetic SDS with N-acetylated and non-acetylated alpha-Synuclein, as well as their early onset Parkinson's disease variants A30P, E46K and A53T. At low SDS/protein ratios aSynuclein forms oligomeric complexes with SDS micelles with relatively low alpha-helical structure. These micellar oligomers can efficiently nucleate aggregation of monomeric alpha-Synuclein, with successive formation of oligomers, protofibrils, curly fibrils and mature amyloid fibrils. N-acetylation reduces considerably the rate of aggregation of WT alpha-Synuclein. However, in presence of any of the early-onset Parkinson's disease mutations the protective effect of N-acetylation against micelle-induced aggregation becomes impaired. At higher SDS/protein ratios, N-acetylation favors another conformational transition, in which a second type of alpha-helix-rich, non-aggregating oligomers become stabilized. Once again, the Parkinson's disease mutations disconnect the influence of N-acetylation in promoting this transition. These results suggest a cooperative link between the N-terminus and the region of the mutations that may be important for alpha-Synuclein function.	[Ruzafa, David; Hernandez-Gomez, Yuriko S.; Bisello, Giovanni; Morel, Bertrand; Conejero-Lara, Francisco] Univ Granada, Fac Ciencias, Dept Quim Fis, Granada, Spain; [Ruzafa, David; Hernandez-Gomez, Yuriko S.; Bisello, Giovanni; Morel, Bertrand; Conejero-Lara, Francisco] Univ Granada, Fac Ciencias, Inst Biotecnol, Granada, Spain; [Broersen, Kerensa] Univ Twente, Fac Sci & Technol, MIRA Inst Biomed Technol & Tech Med, Nanobiophys Grp, Enschede, Netherlands	University of Granada; University of Granada; University of Twente	Conejero-Lara, F (corresponding author), Univ Granada, Fac Ciencias, Dept Quim Fis, Granada, Spain.; Conejero-Lara, F (corresponding author), Univ Granada, Fac Ciencias, Inst Biotecnol, Granada, Spain.	conejero@ugr.es	Lara, Francisco Conejero/F-2962-2016	Lara, Francisco Conejero/0000-0002-8282-2168; Morel, Bertrand/0000-0002-2708-8589; Bisello, Giovanni/0000-0002-3803-9555	Spanish Ministry of Economy and Competitivity [BIO2009-07317, BIO2013-40697-R]; Andalusian Government [FQM-02838]; Research Program of the University of Granada [PP2012-PI06]; European Regional Development Fund of the European Union	Spanish Ministry of Economy and Competitivity(Spanish Government); Andalusian Government; Research Program of the University of Granada; European Regional Development Fund of the European Union	This research was funded by Grants BIO2009-07317 and BIO2013-40697-R from the Spanish Ministry of Economy and Competitivity (http://www.mineco.gob.es), Grant FQM-02838 from the Andalusian Government (http://www.juntadeandalucia.es), Grant PP2012-PI06 from the Research Program of the University of Granada (http://investigacion.ugr.es) and by the European Regional Development Fund of the European Union.	Ahmad MF, 2006, J MOL BIOL, V364, P1061, DOI 10.1016/j.jmb.2006.09.085; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Appel-Cresswell S, 2013, MOVEMENT DISORD, V28, P811, DOI 10.1002/mds.25421; Barhoum S, 2013, EUR BIOPHYS J BIOPHY, V42, P405, DOI 10.1007/s00249-013-0890-4; Bartels T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103727; Bartels T, 2011, NATURE, V477, P107, DOI 10.1038/nature10324; Bisaglia M, 2005, BIOCHEMISTRY-US, V44, P329, DOI 10.1021/bi048448q; Bodner CR, 2010, BIOCHEMISTRY-US, V49, P862, DOI 10.1021/bi901723p; Broersen K, 2006, BIOCHEMISTRY-US, V45, P15610, DOI 10.1021/bi061743l; Burre J, 2014, P NATL ACAD SCI USA, V111, pE4274, DOI 10.1073/pnas.1416598111; Butterfield SM, 2010, ANGEW CHEM INT EDIT, V49, P5628, DOI 10.1002/anie.200906670; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Cheng FR, 2011, J CHEM NEUROANAT, V42, P242, DOI 10.1016/j.jchemneu.2010.12.001; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Darios F, 2010, EMBO REP, V11, P528, DOI 10.1038/embor.2010.66; De Franceschi G, 2009, J MOL BIOL, V394, P94, DOI 10.1016/j.jmb.2009.09.008; Dettmer U, 2016, CURR OPIN NEUROBIOL, V36, P15, DOI 10.1016/j.conb.2015.07.007; Dikiy I, 2014, J BIOL CHEM, V289, P3652, DOI 10.1074/jbc.M113.512459; Ferreon ACM, 2007, BIOCHEMISTRY-US, V46, P4499, DOI 10.1021/bi602461y; Ferreon ACM, 2010, ANGEW CHEM INT EDIT, V49, P3469, DOI 10.1002/anie.201000378; Ferreon ACM, 2009, P NATL ACAD SCI USA, V106, P5645, DOI 10.1073/pnas.0809232106; Flagmeier P, 2016, P NATL ACAD SCI USA, V113, P10328, DOI 10.1073/pnas.1604645113; Galvagnion C, 2015, NAT CHEM BIOL, V11, P229, DOI [10.1038/NCHEMBIO.1750, 10.1038/nchembio.1750]; Georgieva ER, 2008, J AM CHEM SOC, V130, P12856, DOI 10.1021/ja804517m; Georgieva ER, 2010, J BIOL CHEM, V285, P28261, DOI 10.1074/jbc.M110.157214; Giehm L, 2010, J MOL BIOL, V401, P115, DOI 10.1016/j.jmb.2010.05.060; Golovko MY, 2006, BIOCHEMISTRY-US, V45, P6956, DOI 10.1021/bi0600289; Iljina M., 2016, SCI REP, V6; Iyer A, 2016, J BIOL CHEM, V291, P21110, DOI 10.1074/jbc.M116.726612; Jan A, 2008, J BIOL CHEM, V283, P28176, DOI 10.1074/jbc.M803159200; Jao CC, 2008, P NATL ACAD SCI USA, V105, P19666, DOI 10.1073/pnas.0807826105; Johnson M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015801; Kang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075018; Kang LJ, 2012, PROTEIN SCI, V21, P911, DOI 10.1002/pro.2088; Kiely AP, 2013, ACTA NEUROPATHOL, V125, P753, DOI 10.1007/s00401-013-1096-7; Kim HY, 2009, J AM CHEM SOC, V131, P17482, DOI 10.1021/ja9077599; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lendel C, 2009, BIOCHEMISTRY-US, V48, P8322, DOI 10.1021/bi901285x; Lorenzen N, 2014, FEBS LETT, V588, P497, DOI 10.1016/j.febslet.2013.12.015; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Maltsev AS, 2013, J AM CHEM SOC, V135, P2943, DOI 10.1021/ja312415q; Maltsev AS, 2012, BIOCHEMISTRY-US, V51, P5004, DOI 10.1021/bi300642h; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Martinez Z, 2007, BIOCHEMISTRY-US, V46, P1868, DOI 10.1021/bi061749a; Mizuno N, 2012, J BIOL CHEM, V287, P29301, DOI 10.1074/jbc.M112.365817; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Otzen DE, 2010, CURR PROTEIN PEPT SC, V11, P355; Ouberai MM, 2013, J BIOL CHEM, V288, P20883, DOI 10.1074/jbc.M113.478297; Perlmutter JD, 2009, J BIOL CHEM, V284, P7177, DOI 10.1074/jbc.M808895200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Price WS, 1997, CONCEPT MAGNETIC RES, V9, P299, DOI 10.1002/(SICI)1099-0534(1997)9:5<299::AID-CMR2>3.3.CO;2-2; Rao JN, 2009, J MOL BIOL, V390, P516, DOI 10.1016/j.jmb.2009.05.058; Rivers RC, 2008, PROTEIN SCI, V17, P887, DOI 10.1110/ps.073181508; Ruzafa D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049690; Serra-Batiste M, 2016, P NATL ACAD SCI USA, V113, P10866, DOI 10.1073/pnas.1605104113; Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stockl M, 2008, J MOL BIOL, V375, P1394, DOI 10.1016/j.jmb.2007.11.051; Trexler AJ, 2012, PROTEIN SCI, V21, P601, DOI 10.1002/pro.2056; Trexler AJ, 2009, BIOCHEMISTRY-US, V48, P2304, DOI 10.1021/bi900114z; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2007, J NEUROCHEM, V103, P17, DOI 10.1111/j.1471-4159.2007.04764.x; Varkey J, 2013, J BIOL CHEM, V288, P17620, DOI 10.1074/jbc.M113.476697; Varkey J, 2010, J BIOL CHEM, V285, P32486, DOI 10.1074/jbc.M110.139576; Veldhuis G, 2009, CHEMBIOCHEM, V10, P436, DOI 10.1002/cbic.200800644; Wang LN, 2014, CURR BIOL, V24, P2319, DOI 10.1016/j.cub.2014.08.027; Wang W, 2011, P NATL ACAD SCI USA, V108, P17797, DOI 10.1073/pnas.1113260108; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	71	20	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2017	12	5							e0178576	10.1371/journal.pone.0178576	http://dx.doi.org/10.1371/journal.pone.0178576			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6GY	28562630	gold, Green Submitted, Green Published			2023-01-03	WOS:000402608700075
J	Clapp, MA; Little, SE; Zheng, J; Kaimal, AJ; Robinson, JN				Clapp, Mark A.; Little, Sarah E.; Zheng, Jie; Kaimal, Anjali J.; Robinson, Julian N.			Hospital-Level Variation in Postpartum Readmissions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Clapp, Mark A.; Kaimal, Anjali J.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA; [Little, Sarah E.; Robinson, Julian N.] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA; [Zheng, Jie] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Clapp, MA (corresponding author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.	mark.clapp@mgh.harvard.edu	Clapp, Mark/AAD-6926-2022	Clapp, Mark/0000-0001-5568-4444	Department of Obstetrics and Gynecology at Brigham and Women's Hospital	Department of Obstetrics and Gynecology at Brigham and Women's Hospital	This study was supported in part by the Department of Obstetrics and Gynecology at Brigham and Women's Hospital through an intradepartmental research grant, which was used for data acquisition, database processing, and statistical analysis support.	Bailit JL, 2016, AM J OBSTET GYNECOL, V215, pB8, DOI 10.1016/j.ajog.2016.06.048; Haymart MR, 2011, JAMA-J AM MED ASSOC, V306, P721, DOI 10.1001/jama.2011.1139; Kuklina EV, 2008, MATERN CHILD HLTH J, V12, P469, DOI 10.1007/s10995-007-0256-6; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	4	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2017	317	20					2128	2129		10.1001/jama.2017.2830	http://dx.doi.org/10.1001/jama.2017.2830			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV5JJ	28535223	Green Published			2023-01-03	WOS:000401800600025
J	Provencio, M; Sabin, P; Gomez-Codina, J; Torrente, M; Calvo, V; Llanos, M; Guma, J; Quero, C; Blasco, A; Cruz, MA; Aguiar, D; Garcia-Arroyo, F; Lavernia, J; Martinez, N; Morales, M; Saez-Cusi, A; Rodriguez, D; de la Cruz, L; Sanchez, JJ; Rueda, A				Provencio, Mariano; Sabin, Pilar; Gomez-Codina, Jose; Torrente, Maria; Calvo, Virginia; Llanos, Marta; Guma, Josep; Quero, Cristina; Blasco, Ana; Angel Cruz, Miguel; Aguiar, David; Garcia-Arroyo, Francisco; Lavernia, Javier; Martinez, Natividad; Morales, Manuel; Saez-Cusi, Alvaro; Rodriguez, Delvys; de la Cruz, Luis; Javier Sanchez, Jose; Rueda, Antonio		GOTEL Spanish Lymphoma Oncology Gr	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry	PLOS ONE			English	Article							NON-HODGKINS-LYMPHOMAS; PROGNOSTIC-FACTORS; TRANSFORMATION; OUTCOMES; TIME	Background Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. Patients and methods A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. Results Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal beta 2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthra-cyclines and rituximab (p <0.001), or rituximab (p <0.0001). Conclusions A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.	[Provencio, Mariano; Torrente, Maria; Calvo, Virginia] Hosp Univ Puerta de Hierro Majadahonda, Dept Med Oncol, Madrid, Spain; [Sabin, Pilar] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain; [Gomez-Codina, Jose] Hosp Univ La Fe, Dept Med Oncol, Valencia, Spain; [Llanos, Marta] Hosp Univ Canarias, Dept Med Oncol, Tenerife, Spain; [Guma, Josep] Hosp Univ San Joan de Reus, Dept Med Oncol, Tarragona, Spain; [Quero, Cristina] Hosp Univ Virgen de la Victoria, Dept Med Oncol, Malaga, Spain; [Blasco, Ana] Hosp Gen Univ, Dept Med Oncol, Valencia, Spain; [Angel Cruz, Miguel] Hosp Virgen de la Salud, Dept Med Oncol, Toledo, Spain; [Aguiar, David] Hosp Univ Gran Canaria Doctor Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Spain; [Garcia-Arroyo, Francisco] Complejo Hosp Pontevedra, Dept Med Oncol, Pontevedra, Spain; [Lavernia, Javier] Inst Valenciano Oncol, Dept Oncol, Valencia, Spain; [Martinez, Natividad] Hosp Gen Univ Elche, Dept Med Oncol, Alicante, Spain; [Morales, Manuel] Hosp Univ Nuestra Senora de Candelaria, Dept Med Oncol, Santa Cruz De Tenerife, Spain; [Saez-Cusi, Alvaro] Hosp Clin Univ Lozano Blesa, Dept Med Oncol, Zaragoza, Spain; [Rodriguez, Delvys] Hosp Univ Insular Gran Canaria, Dept Med Oncol, Las Palmas Gran Canaria, Spain; [de la Cruz, Luis] Hosp Univ Virgen de la Macarena, Dept Med Oncol, Seville, Spain; [Javier Sanchez, Jose] Univ Autonoma Nuevo Leon, Monterrey, Mexico; [Rueda, Antonio] Hosp Costa Sol, Dept Med Oncol, Marbella, Spain	Hospital Puerta de Hierro-Majadahonda; General University Gregorio Maranon Hospital; Hospital Universitari i Politecnic La Fe; Universidad de la Laguna; Hospital Virgen de la Victoria; Universidad de Malaga; Hospital Clinic Universitari de Valencia; Complejo Hospitalario de Toledo; Complexo Hospitalario Universitario de Pontevedra; Instituto Valenciano De Oncologia; Lozano Blesa University Clinical Hospital; Universidad Autonoma de Nuevo Leon	Provencio, M (corresponding author), Hosp Univ Puerta de Hierro Majadahonda, Dept Med Oncol, Madrid, Spain.	mariano.provencio@salud.madrid.org	Martínez Madrid, Natividad/Y-2636-2018; de Juan, Virginia Calvo/AAD-4505-2021; Blasco, Ana/D-7970-2018; Morales, Manuel/ABG-4659-2021; Provencio, Mariano/ABE-8586-2020	Martínez Madrid, Natividad/0000-0003-1965-9481; Blasco, Ana/0000-0002-5625-235X; Provencio, Mariano/0000-0001-9053-9197; TORRENTE, MARIA/0000-0001-8791-7660; Calvo de Juan, Virginia/0000-0002-3503-4847; Blasco Cordellat, Ana/0000-0001-5889-0382; Provencio Pulla, Mariano/0000-0001-6315-7919; Martinez-Banaclocha, Natividad/0000-0002-7515-5037				Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Chan WC, 1997, BLOOD, V89, P3909; Chau I, 2003, BRIT J CANCER, V89, P36, DOI 10.1038/sj.bjc.6601006; COIFFIER B, 1993, SEMIN ONCOL, V20, P89; Conconi A, 2015, ANN ONCOL, V26, P2317, DOI 10.1093/annonc/mdv376; Conconi A, 2010, LEUKEMIA LYMPHOMA, V51, P1028, DOI 10.3109/10428191003743460; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; Curado M., 2009, CANC INCIDENCE 5 CON, VIX; De Sanjose S., 2008, MED CLIN BARC S1, V131, p72 ; Denham JW, 1996, EUR J CANCER, V32A, P480, DOI 10.1016/0959-8049(95)00635-4; Dreyling M, 2014, ANN ONCOL, V25, P76, DOI [10.1093/annonc/mdu200, 10.1093/annonc/mdx020]; Federico M, 2013, J CLIN ONCOL, V31, P1506, DOI 10.1200/JCO.2012.45.0866; Federico M, 2009, J CLIN ONCOL, V27, P4555, DOI 10.1200/JCO.2008.21.3991; Fisher RI, 2005, J CLIN ONCOL, V23, P8447, DOI 10.1200/JCO.2005.03.1674; Gangatharan SA, 2015, BRIT J HAEMATOL, V170, P384, DOI 10.1111/bjh.13451; GARVIN AJ, 1983, CANCER-AM CANCER SOC, V52, P393, DOI 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; Nabhan C, 2014, AM J HEMATOL, V89, P633, DOI 10.1002/ajh.23708; Nastoupil LJ, 2014, CANCER-AM CANCER SOC, V120, P1830, DOI 10.1002/cncr.28659; Provencio M, 2012, CLIN TRANSL ONCOL, V14, P386, DOI 10.1007/s12094-012-0813-3; Relander T, 2010, J CLIN ONCOL, V28, P2902, DOI 10.1200/JCO.2009.26.1693; Sarkozy C, 2016, J CLIN ONCOL, V34, P2575, DOI 10.1200/JCO.2015.65.7163; Sebban C, 2008, J CLIN ONCOL, V26, P3614, DOI 10.1200/JCO.2007.15.5358; Solal-Celigny P, 2012, J CLIN ONCOL, V30, P3848, DOI 10.1200/JCO.2010.33.4474; SOUBEYRAN P, 1991, EUR J CANCER, V27, P1606, DOI 10.1016/0277-5379(91)90425-D; Swenson WT, 2005, J CLIN ONCOL, V23, P5019, DOI 10.1200/JCO.2005.04.503; Swerdlow SH, 2008, WHO CLASSIFICATION T, P200; van de Schans SAM, 2009, ANN ONCOL, V20, P1697, DOI 10.1093/annonc/mdp053; YOUNG RC, 1988, SEMIN HEMATOL, V25, P11	29	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177204	10.1371/journal.pone.0177204	http://dx.doi.org/10.1371/journal.pone.0177204			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UP	28493986	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314300071
J	Chen, JH; Pelka, K; Hacohen, N				Chen, Jonathan H.; Pelka, Karin; Hacohen, Nir			Heavy Metal Enlightens Tumor Immunity	CELL			English	Editorial Material							CANCER; IMMUNOTHERAPY	A deep understanding of the immune landscape in human cancer is essential for guiding the development of immunotherapy to benefit more patients with long-lasting efficacy. Now, two studies from Lavin et al. and Chevrier et al. employ mass cytometry to study immune infiltrates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.	[Chen, Jonathan H.; Pelka, Karin; Hacohen, Nir] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Chen, Jonathan H.; Pelka, Karin; Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Ctr Canc Res, Boston, MA 02114 USA; [Chen, Jonathan H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hacohen, N (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Hacohen, N (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Canc Res, Boston, MA 02114 USA.	nhacohen@mgh.harvard.edu			NIH/NCI [T32CA207021, 1R01CA208756]; NATIONAL CANCER INSTITUTE [R01CA208756, T32CA207021] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	J.H.C. is supported by NIH/NCI training grant T32CA207021. K.P. and N.H. are supported by NIH/NCI 1R01CA208756.	Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001	7	5	5	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 4	2017	169	4					567	569		10.1016/j.cell.2017.04.017	http://dx.doi.org/10.1016/j.cell.2017.04.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET8PD	28475889	Bronze, Green Accepted			2023-01-03	WOS:000400560900004
J	Dou, RK; Liu, ZY; Yuan, X; Xiangfei, DZ; Bai, RX; Bi, ZF; Yang, PA; Yang, YL; Dong, YS; Su, W; Li, DQ; Mao, CQ				Dou, Rongkun; Liu, Zongying; Yuan, Xue; Xiangfei, Danzhou; Bai, Ruixue; Bi, Zhenfei; Yang, Piao; Yang, Yalan; Dong, Yinsong; Su, Wei; Li, Diqiang; Mao, Canquan			PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-kappa B and production of inflammatory cytokines	PLOS ONE			English	Article							KERATINOCYTES; EXPRESSION; MEDICINE; PATHOGENESIS; ADHESION; GAMMA	Psoriasis is a chronic and persistent inflammatory skin disease seriously affecting the quality of human life. In this study, we reported an ancient formula of Chinese folk medicine, the natural plant antimicrobial solution (PAMs) for its anti-inflammatory effects and proposed the primary mechanisms on inhibiting the inflammatory response in TNF-alpha/IFN-gamma-induced HaCaT cells and imiquimod-induced psoriasis-like skin disease mouse model. Two main functional components of hydroxysafflor Yellow A and allantoin in PAMs were quantified by HPLC to be 94.2 +/- 2.2 and 262.9 +/- 12.5 mu g/mL respectively. PAMs could significantly reduce the gene expression and inflammatory cytokines production of Macrophage-Derived Chemokine (MDC), IL-8 and IL-6 in TNF-alpha/IFN-gamma-induced HaCaT cells. PAMs also significantly ameliorates the psoriatic-like symptoms in a mouse model with the evaluation scores for both the single (scales, thickness, erythema) and cumulative features were in the order of blank control < Dexamethasone < PAMs < 50% ethanol < model groups. The results were further confirmed by hematoxylin-eosin staining, RT-qPCR and immunohistochemistry. The down-regulated gene expression of IL-8, TNF-alpha, ICAM-1 and IL-23 in mouse tissues was consistent with the results from those of the HaCaT cells. The inhibition of psoriasis-like skin inflammation by PAMs was correlated with the inactivation of the translocation of P65 protein into cellular nucleus, indicating the inhibition of the inflammatory NF-kappa B signaling pathway. Taken together, these findings suggest that PAMs may be a promising drug candidate for the treatment of inflammatory skin disorders, such as psoriasis.	[Dou, Rongkun; Liu, Zongying; Yuan, Xue; Bai, Ruixue; Bi, Zhenfei; Yang, Piao; Yang, Yalan; Mao, Canquan] Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu, Peoples R China; [Xiangfei, Danzhou; Dong, Yinsong; Su, Wei] Inst Yunnan Folk Med Co Ltd, Kunming, Peoples R China; [Li, Diqiang] Chinese Acad Forestry, Inst Forest Ecol Environm & Protect, Beijing, Peoples R China	Southwest Jiaotong University; Chinese Academy of Forestry; Research Institute of Forest Ecology, Environment and Protection, CAF	Mao, CQ (corresponding author), Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu, Peoples R China.; Li, DQ (corresponding author), Chinese Acad Forestry, Inst Forest Ecol Environm & Protect, Beijing, Peoples R China.	lidq@caf.ac.cn; maocq@swjtu.edu.cn	mao, canquan/AAZ-9694-2020		Son Program of Fundamental Platform of Science and Technology Resource Condition, Ministry of Science and Technology of China [2005DKA21404]; Institute of Yunnan Folk Medicine Co. Ltd	Son Program of Fundamental Platform of Science and Technology Resource Condition, Ministry of Science and Technology of China; Institute of Yunnan Folk Medicine Co. Ltd	The work was financially supported by the Son Program of Fundamental Platform of Science and Technology Resource Condition, Ministry of Science and Technology of China (2005DKA21404, Diqiang Li, Danzhou Xiangfei, and Canquan Mao). Institute of Yunnan Folk Medicine Co. Ltd provided support in the form of salary for Ms Danzhou Xiangfei (who is a Co-PI of the funded project), Mr. Yinsong Dong and Wei Su, whose main roles are the preparation and the quality control of PAMs. The company did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of these three authors is articulated in the 'author contributions' section.	Bito T, 2000, FREE RADICAL BIO MED, V28, P219, DOI 10.1016/S0891-5849(99)00229-4; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; Deng SQ, 2013, ARCH DERMATOL RES, V305, P179, DOI 10.1007/s00403-013-1316-y; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; Farzaneh V, 2015, IND CROP PROD, V65, P247, DOI 10.1016/j.indcrop.2014.10.057; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; Hwang ST, 2017, J INVEST DERMATOL, V137, P550, DOI 10.1016/j.jid.2016.11.007; Jin M, 2016, CHIN J INTEGR MED, V22, P36, DOI 10.1007/s11655-015-1976-x; Kim HN, 2012, J PHARMACOPUNCT, V15, P7, DOI 10.3831/KPI.2012.15.2.007; Ko J, 2006, ANN ALLERG ASTHMA IM, V97, P365, DOI 10.1016/S1081-1206(10)60802-2; Lee JH, 2009, J DERMATOL SCI, V56, P64, DOI 10.1016/j.jdermsci.2009.07.001; Lizzul PF, 2005, J INVEST DERMATOL, V124, P1275, DOI 10.1111/j.0022-202X.2005.23735.x; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; McInturff JE, 2005, J INVEST DERMATOL, V125, P1, DOI 10.1111/j.0022-202X.2004.23459.x; Mizuno K, 2015, J DERMATOL SCI, V80, P45, DOI 10.1016/j.jdermsci.2015.06.016; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Novak N, 2008, DRUG NEWS PERSPECT, V21, P158, DOI 10.1358/dnp.2008.21.3.1203412; Peng WB, 2016, BIOMED CHROMATOGR, V30, P1854, DOI 10.1002/bmc.3772; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Rahman Mahfoozur, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P287; Saeki H, 2006, J DERMATOL SCI, V43, P75, DOI 10.1016/j.jdermsci.2006.06.002; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2015, STEROIDS, V103, P72, DOI 10.1016/j.steroids.2015.04.006; Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092; Szeimies RM, 2004, J AM ACAD DERMATOL, V51, P547, DOI 10.1016/j.jaad.2004.02.022; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Weng ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090739; Williamson EM, 2013, J ETHNOPHARMACOL, V149, P453, DOI 10.1016/j.jep.2013.06.050; Xiong H, 2015, CELL PHYSIOL BIOCHEM, V35, P1335, DOI 10.1159/000373955; Ye J, 2009, J PHARMACEUT BIOMED, V49, P638, DOI 10.1016/j.jpba.2008.12.009; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	36	21	24	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2017	12	5							e0176823	10.1371/journal.pone.0176823	http://dx.doi.org/10.1371/journal.pone.0176823			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9RV	28464025	gold, Green Submitted, Green Published			2023-01-03	WOS:000400646300061
J	Murray-Stewart, T; Ferrari, E; Xie, Y; Yu, F; Marton, LJ; Oupicky, D; Casero, RA				Murray-Stewart, Tracy; Ferrari, Elena; Xie, Ying; Yu, Fei; Marton, Laurence J.; Oupicky, David; Casero, Robert A., Jr.			Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047	PLOS ONE			English	Article							SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; ANTIZYME INHIBITOR; CANCER-CELLS; DELIVERY; METABOLISM; SPERMINE; ANALOGS; OXIDASE; BIOSYNTHESIS; POLYCATIONS	Synthesizing polycationic polymers directly from existing drugs overcomes the drug-loading limitations often associated with pharmacologically inert nanocarriers. We recently described nanocarriers formed from a first-generation polyamine analogue, bis(ethyl) norspermine (BENSpm), that could simultaneously target polyamine metabolism while delivering therapeutic nucleic acids. In the current study, we describe the synthesis and evaluation of self-immolative nanocarriers derived from the second-generation polyamine analogue PG-11047. Polyamines are absolutely essential for proliferation and their metabolism is frequently dysregulated in cancer. Through its effects on polyamine metabolism, PG-11047 effectively inhibits tumor growth in cancer cell lines of multiple origins as well as in human tumor mouse xenografts. Promising clinical trials have been completed verifying the safety and tolerance of this rotationally restricted polyamine analogue. We therefore used PG-11047 as the basis for Nano11047, a biodegradable, prodrug nanocarrier capable of targeting polyamine metabolism. Following exposure of lung cancer cell lines to Nano11047, uptake and intracellular degradation into the parent compound PG-11047 was observed. The release of PG-11047 highly induced the polyamine catabolic enzyme activities of spermidine/spermine N-1-acetyltransferase (SSAT) and spermine oxidase (SMOX). By contrast, the activity of ornithine decarboxylase (ODC), a rate-limiting enzyme in polyamine biosynthesis and a putative oncogene, was decreased. Consequently, intracellular levels of the natural polyamines were depleted concurrent with tumor cell growth inhibition. This availability of Nano11047 as a novel drug form and potential nucleic acid delivery vector will potentially benefit and encourage future clinical studies.	[Murray-Stewart, Tracy; Casero, Robert A., Jr.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Ferrari, Elena; Xie, Ying; Yu, Fei; Oupicky, David] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Dept Pharmaceut Sci, Omaha, NE USA; [Marton, Laurence J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska System; University of Nebraska Medical Center; University of California System; University of California San Francisco	Casero, RA (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.	rcasero@jhmi.edu	Stewart, Tracy Murray/B-6137-2017; Oupicky, David/AAR-1655-2021	Stewart, Tracy Murray/0000-0001-8679-6414; Casero, Robert/0000-0001-5653-3306; Yu, Fei/0000-0003-4367-2707; Oupicky, David/0000-0003-4710-861X	National Institutes of Health [EB015216, EB014570, R01-CA204345, S30-CA006973]; Maryland Cigarette Restitution Fund; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA204345] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Maryland Cigarette Restitution Fund; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by the National Institutes of Health (www.nih.gov) grants EB015216 (DO), EB014570 (DO), R01-CA204345 (RAC), S30-CA006973 (RAC), the Maryland Cigarette Restitution Fund (http://crf.maryland.gov/) (RAC), and the Samuel Waxman Cancer Research Foundation (http://www.waxmancancer.gov/) (RAC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babbar N, 2006, J BIOL CHEM, V281, P24182, DOI 10.1074/jbc.M601871200; BALASUNDARAM D, 1991, MOL CELL BIOCHEM, V100, P129; Battaglia V, 2014, AMINO ACIDS, V46, P511, DOI 10.1007/s00726-013-1529-6; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casero RA, 2003, BIOCHEM SOC T, V31, P361, DOI 10.1042/BST0310361; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1994, CANCER RES, V54, P3955; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598; Cirenajwis H, 2010, ANTI-CANCER DRUG, V21, P897, DOI 10.1097/CAD.0b013e32833f2f77; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Devereux W, 2003, CANCER CHEMOTH PHARM, V52, P383, DOI 10.1007/s00280-003-0662-4; Dong YM, 2012, MOL PHARMACEUT, V9, P1654, DOI 10.1021/mp300001m; Dredge K, 2009, CANCER CHEMOTH PHARM, V65, P191, DOI 10.1007/s00280-009-1105-7; Erdmann L, 2000, BIOMATERIALS, V21, P1941, DOI 10.1016/S0142-9612(00)00073-9; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hacker A, 2008, CANCER CHEMOTH PHARM, V63, P45, DOI 10.1007/s00280-008-0706-x; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Holst CM, 2006, TOXICOLOGY, V223, P71, DOI 10.1016/j.tox.2006.03.009; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Ignatenko Natalia A., 2009, Cancer Genomics & Proteomics, V6, P161; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Kopecek J, 2000, EUR J PHARM BIOPHARM, V50, P61, DOI 10.1016/S0939-6411(00)00075-8; Kuo WL, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-77; Li J, 2013, J CONTROL RELEASE, V172, P589, DOI 10.1016/j.jconrel.2013.04.010; Liechty WB, 2010, ANNU REV CHEM BIOMOL, V1, P149, DOI 10.1146/annurev-chembioeng-073009-100847; Mitchell JLA, 2007, AMINO ACIDS, V33, P291, DOI 10.1007/s00726-007-0523-2; Murray-Stewart T, 2015, POLYAMINES, P61; Murray-Stewart T, 2008, FEBS J, V275, P2795, DOI 10.1111/j.1742-4658.2008.06419.x; Murray-Stewart T, 2013, MOL CANCER THER, V12, P2088, DOI 10.1158/1535-7163.MCT-13-0418; Murray-Stewart TR, 2016, BIOCHEM J, V473, P2937, DOI 10.1042/BCJ20160383; Olsen RR, 2011, MOL CANCER RES, V9, P1285, DOI 10.1158/1541-7786.MCR-11-0178; Oupicky D, 2014, MACROMOL BIOSCI, V14, P908, DOI 10.1002/mabi.201400061; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; PORTER CW, 1986, ANTICANCER RES, V6, P525; PORTER CW, 1987, CANCER RES, V47, P2821; Reddy VK, 1998, J MED CHEM, V41, P4723, DOI 10.1021/jm980172v; Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; Smith MA, 2011, PEDIATR BLOOD CANCER, V57, P268, DOI 10.1002/pbc.22797; Stebbins ND, 2014, ADV DRUG DELIVER REV, V78, P77, DOI 10.1016/j.addr.2014.04.006; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas TJ, 2016, AMINO ACIDS, V48, P2423, DOI 10.1007/s00726-016-2246-8; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022; Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7; Xie Y, 2017, J CONTROL RELEASE, V246, P110, DOI 10.1016/j.jconrel.2016.12.017; Zhu Y, 2015, MOL PHARMACEUT, V12, P332, DOI 10.1021/mp500469n	49	12	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2017	12	4							e0175917	10.1371/journal.pone.0175917	http://dx.doi.org/10.1371/journal.pone.0175917			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KK	28423064	Green Published, Green Submitted, gold			2023-01-03	WOS:000399875600063
J	Zank, S; Hanazaki, N				Zank, Sofia; Hanazaki, Natalia			The coexistence of traditional medicine and biomedicine: A study with local health experts in two Brazilian regions	PLOS ONE			English	Article							BOLIVIAN ANDES; KNOWLEDGE; PLANTS; COMMUNITIES; ETHNOBOTANY; HEALERS; FOREST; CARE	This study investigated the combined use of traditional medicine and biomedicine by local experts in Chapada do Araripe communities (Ceara A State) and maroon communities (Santa Catarina State), Brazil. The objective was to understand the perception of local health specialists regarding the number of healers, demand for healers and use of medicinal plants, and the dependence of different environments to obtain such plants. We also aimed to understand the role of medicinal plants to treat different categories of diseases and if there is a complementary use of medicinal plants and allopathic biomedicine, according to the context of each group. The research was conducted with local health specialists that answered structured interviews, created free lists and participated in guided tours to collect cited plants. Sixty-six local health specialists were identified in the Araripe communities and 22 specialists in the maroon communities. In the maroon communities, a greater number of specialists thought there was a decrease in the number and demand for healers, as well as the use of medicinal plants, due to changes in traditional livelihoods, since they are located in a region where the effects of the modernization were more intense. In the Chapada do Araripe communities the specialists knew more plants extracted from native vegetation, whereas in the maroon communities cultivated plants were better known, which may reflect the environmental conditions and the history of each region. Medicinal plants are preferred to treat simpler health problems that do not require medical care, such as gastrointestinal problems, general pain, flues and colds. The biomedicine is used principally for problems with blood pressure, general pains and endocrine and nutritional diseases. Even with the particularities of each region, in general the use of medicinal plants and biomedicines occurred in a complementary form in both regions; however, this coexistence may result from these different contexts. This study also found that there was knowledge and appreciation for traditional health practices in both regions.	[Zank, Sofia; Hanazaki, Natalia] Univ Fed Santa Catarina, Lab Human Ecol & Ethnobot, Dept Ecol & Zool, Florianopolis, SC, Brazil	Universidade Federal de Santa Catarina (UFSC)	Zank, S (corresponding author), Univ Fed Santa Catarina, Lab Human Ecol & Ethnobot, Dept Ecol & Zool, Florianopolis, SC, Brazil.	sofiazank@gmail.com	Zank, Sofia/E-6838-2017; Hanazaki, Natalia/AAT-3830-2021	Hanazaki, Natalia/0000-0002-7876-6044; Zank, Sofia/0000-0003-0779-423X	CNPq [306478/2012-9]; CAPES	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Our research received finnancial support of CNPq through productivity grant supporting the research of N. Hanazaki (306478/2012-9) and of CAPES through PhD grant for S. Zank and financial support for fieldwork.	Albuquerque UP., 2010, METODOS TECNICAS PES, P21; Amorozo M C., 1999, REV SAUDE AMBIENTE, V2, P48; Amorozo M.D.M., 2004, J ETHNOBIOL, V24, P139; [Anonymous], 2002, APPL ETHNOBOTANY PEO; [Anonymous], 2008, PLANTAS MED BRASIL N; Avila J. V. da C., 2015, Ethnobotany Research and Applications, V14, P453; Azevedo Sheila Karla Santos de, 2006, Acta Bot. Bras., V20, P185, DOI 10.1590/S0102-33062006000100017; Baldauf C, 2013, ECON BOT, V67, P110, DOI 10.1007/s12231-013-9228-5; Benitez G, 2010, J ETHNOPHARMACOL, V129, P87, DOI 10.1016/j.jep.2010.02.016; Bennett BC, 2000, ECON BOT, V54, P90, DOI 10.1007/BF02866603; Boing L, 2013, ATELIE HIST UEPG, V1, P85; Calvet-Mir L, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-18; Cheikhyoussef A, 2011, J ETHNOBIOL ETHNOMED, V7, DOI 10.1186/1746-4269-7-10; Costa IR, ACTA BOT BRASILICA, V18, P759; Da Silva GS, 2010, REV MOSAICO, V3, P33; de Albuquerque UP, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-30; de Albuquerque UP, 2007, J ETHNOPHARMACOL, V110, P76, DOI 10.1016/j.jep.2006.09.010; de Medeiros PM, 2013, J ETHNOPHARMACOL, V150, P729, DOI 10.1016/j.jep.2013.09.026; Campos LZD, 2015, J ARID ENVIRON, V115, P53, DOI 10.1016/j.jaridenv.2015.01.002; de Wet H, 2016, S AFR J BOT, V103, P78, DOI 10.1016/j.sajb.2015.08.011; Fundacao Cultural Palmares, 2015, FUND CULT PALM; Giovannini P, 2011, SOC SCI MED, V72, P928, DOI 10.1016/j.socscimed.2011.01.007; Giovannini P, 2009, J ETHNOPHARMACOL, V121, P383, DOI 10.1016/j.jep.2008.11.003; Giraldi M, 2016, ETHNOSCIENTIA, V1; Giraldi M, 2010, ACTA BOT BRAS, V24, P395, DOI 10.1590/S0102-33062010000200010; Lorenzi H., 2000, PLANTAS DANINHAS BRA, V3rd ed.; Lozano A, J ETHNOBIOLOGY ETHNO; Lunyera J, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1262-2; Maciel Márcia Regina Antunes, 2006, Bol. Mus. Para. Emílio Goeldi. Ciênc. hum., V1, P61; Maneenoon K, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0031-5; Mathez-Stiefel SL, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-26; Monteiro JM, 2010, ECON BOT, V64, P352, DOI 10.1007/s12231-010-9132-1; NGOKWEY N, 1995, SOC SCI MED, V40, P1141, DOI 10.1016/0277-9536(94)00241-K; Oliveira D.R., 2012, REV BRASILEIRA PROMO, V25, P278; Oliveira E.C.S., 2009, REV BRAS BIOCIENC, V7, P245; Pouliot M, 2011, SOC SCI MED, V73, P1498, DOI 10.1016/j.socscimed.2011.08.037; Reeve ME, 2000, MED ANTHROPOL Q, V14, P96, DOI 10.1525/maq.2000.14.1.96; Saethre EJ, 2007, OCEANIA, V77, P95, DOI 10.1002/j.1834-4461.2007.tb00007.x; Soldati GT, 2012, EVIDENCE BASED COMPL; Sousa JR, 2013, ECON BOT, V67, P225, DOI 10.1007/s12231-013-9241-8; Vandebroek I, 2004, SOC SCI MED, V59, P837, DOI 10.1016/j.socscimed.2003.11.030; Vandebroek I, 2004, B WORLD HEALTH ORGAN, V82, P243; Vandebroek I, 2013, J ETHNOPHARMACOL, V148, P746, DOI 10.1016/j.jep.2013.05.039; WHO, 2014, INT STAT CLASS DIS R; Williams VL, 2000, ECON BOT, V54, P310, DOI 10.1007/BF02864784; ZANK S., 2016, Rev. bras. plantas med., V18, P157, DOI 10.1590/1983-084X/15_142; Zank S, 2012, EVIDENCE BASED COMPL, V10; Zank S, 2016, ETHNOBIOL CONSERV, V5, DOI 10.15451/ec2016-6-5.3-1-15; Zank S, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/1746-4269-11-11	49	28	30	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2017	12	4							e0174731	10.1371/journal.pone.0174731	http://dx.doi.org/10.1371/journal.pone.0174731			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES9KD	28414735	gold, Green Published, Green Submitted			2023-01-03	WOS:000399874800008
J	Scolnick, EM				Scolnick, Edward M.			The Path to New Therapies for Schizophrenia and Bipolar Illness	FASEB JOURNAL			English	Article						genetics; pharmacology; progress	DE-NOVO MUTATIONS; AUTISM; VARIANTS; DISORDER; FAMINE	Schizophrenia and bipolar illness are two of the most serious forms of mental illness. Until relatively recently, almost nothing was known about the molecular pathogenesis of either illness. The single largest risk factor that predisposes people to schizophrenia or bipolar illness is genetic risk. Heritability is high, and the incidence is significantly higher in identical twins than in nonidentical twins. Despite decades of work aimed at identifying the genes involved in these two illnesses, virtually no progress had beenmade until the past decade. With the knowledge and technologies that have been gained from theHumanGenome Project, ithas been possible to begin to understand the underlying genetics and to use the new information to begin the effort to discover new and better medicines to treat these illnesses. This articlewilldescribe the past decade of work toward this goal and articulate both the promise thatnowexists andwhat is still neededto bringdramatic andtangible change topatients-Scolnick, E. M. Thepath to new therapies for schizophrenia and bipolar illness.	[Scolnick, Edward M.] Broad Inst, Stanley Ctr Psychiat Res, 75 Ames St, Cambridge, MA 02142 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Scolnick, EM (corresponding author), Broad Inst, Stanley Ctr Psychiat Res, 75 Ames St, Cambridge, MA 02142 USA.	scolnick@broadinstitute.org						Andrade A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34233; Anonymous, 2016, MED LETT DRUGS THER, p1510b; Bundy H, 2011, ACTA PSYCHIAT SCAND, V123, P98, DOI 10.1111/j.1600-0447.2010.01623.x; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Genovese G, 2016, NAT NEUROSCI, V19, P1433, DOI 10.1038/nn.4402; Glausier JR, 2013, NEUROSCIENCE, V251, P90, DOI 10.1016/j.neuroscience.2012.04.044; Gulsuner S, 2013, CELL, V154, P518, DOI 10.1016/j.cell.2013.06.049; Hoek HW, 1998, SOC PSYCH PSYCH EPID, V33, P373, DOI 10.1007/s001270050068; Kim MJ, 2017, MOL PSYCHIATR, V22, P417, DOI 10.1038/mp.2016.98; Lichtenstein P, 2009, LANCET, V373, P234, DOI 10.1016/S0140-6736(09)60072-6; McCarthy SE, 2014, MOL PSYCHIATR, V19, P652, DOI 10.1038/mp.2014.29; Power RA, 2013, JAMA PSYCHIAT, V70, P22, DOI 10.1001/jamapsychiatry.2013.268; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Samocha KE, 2014, NAT GENET, V46, P944, DOI 10.1038/ng.3050; Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549; Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; Tsuang MT, 2001, BRIT J PSYCHIAT, V178, pS18, DOI 10.1192/bjp.178.40.s18	20	2	2	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2017	31	4					1254	1259		10.1096/fj.201700028	http://dx.doi.org/10.1096/fj.201700028			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ER0UR	28360375				2023-01-03	WOS:000398504300002
J	Ramirez-Lopez, MT; Vazquez, M; Lomazzo, E; Hofmann, C; Blanco, RN; Alen, F; Anton, M; Decara, J; Arco, R; Orio, L; Suarez, J; Lutz, B; de Heras, RG; Bindila, L; de Fonseca, FR				Teresa Ramirez-Lopez, Maria; Vazquez, Mariam; Lomazzo, Ermelinda; Hofmann, Clementine; Noemi Blanco, Rosario; Alen, Francisco; Anton, Maria; Decara, Juan; Arco, Rocio; Orio, Laura; Suarez, Juan; Lutz, Beat; Gomez de Heras, Raquel; Bindila, Laura; Rodriguez de Fonseca, Fernando			A moderate diet restriction during pregnancy alters the levels of endocannabinoids and endocannabinoid-related lipids in the hypothalamus, hippocampus and olfactory bulb of rat offspring in a sex-specific manner	PLOS ONE			English	Article							ANXIETY-LIKE BEHAVIORS; LOW-BIRTH-WEIGHT; FATTY-ACIDS; PRENATAL EXPOSURE; CALORIC RESTRICTION; PROTEIN RESTRICTION; ENERGY HOMEOSTASIS; EATING-DISORDERS; DUTCH FAMINE; BODY-WEIGHT	Undernutrition during pregnancy has been associated to increased vulnerability to develop metabolic and behavior alterations later in life. The endocannabinoid system might play an important role in these processes. Therefore, we investigated the effects of a moderate maternal calorie-restricted diet on the levels of the endocannabinoid 2-arachidonoyl glycerol (2-AG), arachidonic acid (AA) and the N-acylethanolamines (NAEs) anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) in the brain of newborn rat offspring. We focused on brain structures involved in metabolism, feeding behavior, as well as emotional and cognitive responses. Female Wistar rats were assigned during the entire pregnancy to either control diet (C) or restriction diet (R), consisting of a 20% calorierestricted diet. Weight gain and caloric intake of rat dams were monitored and birth outcomes were assessed. 2-AG, AA and NAE levels were measured in hypothalamus, hippocampus and olfactory bulb of the offspring. R dams displayed lower gain weight from the middle pregnancy and consumed less calories during the entire pregnancy. Offspring from R dams were underweight at birth, but litter size was unaffected. In hypothalamus, R male offspring displayed decreased levels of AA and OEA, with no change in the levels of the endocannabinoids 2-AG and AEA. R female exhibited decreased 2-AG and PEA levels. The opposite was found in the hippocampus, where R male displayed increased 2-AG and AA levels, and R female exhibited elevated levels of AEA, AA and PEA. In the olfactory bulb, only R female presented decreased levels of AEA, AA and PEA. Therefore, a moderate diet restriction during the entire pregnancy alters differentially the endocannabinoids and/or endocannabinoid-related lipids in hypothalamus and hippocampus of the underweight offspring, similarly in both sexes, whereas sex-specific alterations occur in the olfactory bulb. Consequently, endocannabinoid and endocannabinoid-related lipid signaling alterations might be involved in the long-term and sexual dimorphism effects commonly observed after undernutrition and low birth weight.	[Teresa Ramirez-Lopez, Maria; Vazquez, Mariam; Noemi Blanco, Rosario; Alen, Francisco; Anton, Maria; Orio, Laura; Gomez de Heras, Raquel; Rodriguez de Fonseca, Fernando] Univ Complutense Madrid, Fac Psicol, Dept Psicobiol, Campus Somosaguas S-N, Madrid, Spain; [Vazquez, Mariam; Decara, Juan; Arco, Rocio; Suarez, Juan; Rodriguez de Fonseca, Fernando] Univ Malaga, Hosp Reg Univ Malaga, Unidad Gest Clin Salud Mental, IBIMA, Malaga, Spain; [Lomazzo, Ermelinda; Hofmann, Clementine; Lutz, Beat; Bindila, Laura] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, Mainz, Germany; [Suarez, Juan] Univ Malaga, Fac Ciencias, IBIMA, Dept Biol Celular Genet & Fisiol, Campus Teatinos S-N, Malaga, Spain	Complutense University of Madrid; Universidad de Malaga; Johannes Gutenberg University of Mainz; Universidad de Malaga	de Heras, RG; de Fonseca, FR (corresponding author), Univ Complutense Madrid, Fac Psicol, Dept Psicobiol, Campus Somosaguas S-N, Madrid, Spain.; de Fonseca, FR (corresponding author), Univ Malaga, Hosp Reg Univ Malaga, Unidad Gest Clin Salud Mental, IBIMA, Malaga, Spain.	rgomezhe@psi.ucm.es; fernando.rodriguez@ibima.eu	Alen, Francisco/I-3890-2017; de Heras, Raquel Gomez/F-3484-2016; Ramírez-López, María Teresa/AAB-5705-2021; Lutz, Beat/AAG-4538-2022; Suarez, Juan/I-5188-2015; Orio, Laura/F-4827-2016; Lutz, Beat/AFK-6229-2022; Anton, Maria/A-9767-2016; Decara Del Olmo, Juan Manuel/I-1931-2015	Alen, Francisco/0000-0002-3847-3503; de Heras, Raquel Gomez/0000-0002-5846-1059; Ramírez-López, María Teresa/0000-0002-3944-5264; Suarez, Juan/0000-0001-5254-9802; Orio, Laura/0000-0002-9614-4062; Anton, Maria/0000-0002-7232-6291; Decara Del Olmo, Juan Manuel/0000-0002-9868-015X; RODRIGUEZ DE FONSECA, FERNANDO/0000-0002-4516-5795; Blanco Velilla, Rosario Noemi/0000-0003-0265-6655; Arco Gonzalez, Rocio/0000-0002-5618-5687	Institute de Salud Carlos III, Ministerio de Economia y Competitividad [PI12/02261, PI16/11698, PI16/01374, CP12/03109, PSI 2012-35388]; Red de Trastornos Adictivos UE/ERDF [RD12/0028/0001]; CIBERobn; Consejeria de Economia, Innovacion y Ciencia; Junta de Andalucia; UE/ERDF [PI45403, CTS-8221, CTS-433]; Consejeria de Salud, Junta de Andalucia [SAS111224]; German Research Foundation DFG [FOR926, CRC1080]; FPU predoctoral fellowship of the Spanish Ministerio de Educacion, Cultura y Deporte [AP-2009-0225]; National System of Health, ISCIII [CP12/03109]	Institute de Salud Carlos III, Ministerio de Economia y Competitividad; Red de Trastornos Adictivos UE/ERDF; CIBERobn; Consejeria de Economia, Innovacion y Ciencia; Junta de Andalucia(Junta de Andalucia); UE/ERDF; Consejeria de Salud, Junta de Andalucia(Junta de Andalucia); German Research Foundation DFG(German Research Foundation (DFG)); FPU predoctoral fellowship of the Spanish Ministerio de Educacion, Cultura y Deporte; National System of Health, ISCIII	This work was supported by the Institute de Salud Carlos III, Ministerio de Economia y Competitividad (PI12/02261 and PI16/11698 to FRF, PI16/01374 and CP12/03109 to JS, and PSI 2012-35388 to RGH), Red de Trastornos Adictivos UE/ERDF (RD12/0028/0001 to FRF), CIBERobn, Consejeria de Economia, Innovacion y Ciencia, Junta de Andalucia, UE/ERDF (PI45403, CTS-8221, CTS-433 to FRF), Consejeria de Salud, Junta de Andalucia (SAS111224 to FRF), and the German Research Foundation DFG (FOR926, project CP1 to BL; CRC1080, subproject B08 to BL). MTRL has been funded by a FPU predoctoral fellowship of the Spanish Ministerio de Educacion, Cultura y Deporte (AP-2009-0225); JS holds "Miguel Servet" research contract from the National System of Health, ISCIII (grant numbers CP12/03109). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken CE, 2013, REPRODUCTION, V145, pR1, DOI 10.1530/REP-11-0489; Akitake Y, 2015, NUTR RES, V35, P76, DOI 10.1016/j.nutres.2014.10.014; Almeida SS, 1996, PHYSIOL BEHAV, V60, P675, DOI 10.1016/S0031-9384(96)80047-3; Amusquivar E, 2003, BIOL NEONATE, V83, P136, DOI 10.1159/000067963; Antonelli T, 2005, CEREB CORTEX, V15, P2013, DOI 10.1093/cercor/bhi076; Artmann A, 2008, BBA-MOL CELL BIOL L, V1781, P200, DOI 10.1016/j.bbalip.2008.01.006; Avraham Y, 2011, J NUTR BIOCHEM, V22, P766, DOI 10.1016/j.jnutbio.2010.07.001; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Bernard C, 2005, P NATL ACAD SCI USA, V102, P9388, DOI 10.1073/pnas.0409641102; Berrendero F, 1999, SYNAPSE, V33, P181, DOI 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R; Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151; Bindila L, 2016, METHODS MOL BIOL, V1412, P9, DOI 10.1007/978-1-4939-3539-0_2; Bolton JL, 2014, DIALOGUES CLIN NEURO, V16, P307; Campos AC, 2010, NEUROSCIENCE, V167, P238, DOI 10.1016/j.neuroscience.2010.01.062; Cetin I, 2009, J PHYSIOL-LONDON, V587, P3441, DOI 10.1113/jphysiol.2009.173062; Clarke DJ, 2017, PROG NEURO-PSYCHOPH, V72, P9, DOI 10.1016/j.pnpbp.2016.08.006; CoupE B, 2009, J NEUROENDOCRINOL, V21, P40, DOI 10.1111/j.1365-2826.2008.01806.x; Coupe B, 2010, ENDOCRINOLOGY, V151, P702, DOI 10.1210/en.2009-0893; Cristino L, 2014, BIOFACTORS, V40, P389, DOI 10.1002/biof.1168; D'Asti E, 2010, ENDOCRINOLOGY, V151, P1685, DOI 10.1210/en.2009-1092; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; de Salas-Quiroga A, 2015, P NATL ACAD SCI USA, V112, P13693, DOI 10.1073/pnas.1514962112; de Souza MA, 2012, PHYSIOL BEHAV, V105, P850, DOI 10.1016/j.physbeh.2011.10.012; DEFONSECA FR, 1991, NEUROSCIENCE, V43, P713, DOI 10.1016/0306-4522(91)90329-M; Delahaye F, 2008, ENDOCRINOLOGY, V149, P470, DOI 10.1210/en.2007-1263; Desai M, 2005, AM J PHYSIOL-REG I, V288, pR91, DOI 10.1152/ajpregu.00340.2004; Desai M, 2007, AM J PHYSIOL-REG I, V293, pR2306, DOI 10.1152/ajpregu.00783.2006; DeVader SR, 2007, OBSTET GYNECOL, V110, P745, DOI 10.1097/01.AOG.0000284451.37882.85; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Dyall SC, 2016, NEUROPHARMACOLOGY, V107, P387, DOI 10.1016/j.neuropharm.2016.03.055; Easter A, 2013, EUR EAT DISORD REV, V21, P340, DOI 10.1002/erv.2229; Fezza F, 2014, MOLECULES, V19, P17078, DOI 10.3390/molecules191117078; Gabory A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047986; Gallou-Kabani C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014398; Garcia AP, 2010, DIABETES OBES METAB, V12, P403, DOI 10.1111/j.1463-1326.2009.01174.x; Guggenhuber S, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv091; Hadley KB, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040216; Hansen HS, 2008, J NEUROENDOCRINOL, V20, P94, DOI 10.1111/j.1365-2826.2008.01687.x; Hansen HS, 2013, CNS NEUROL DISORD-DR, V12, P17; Herrera E, 2002, PLACENTA, V23, pS9, DOI 10.1053/plac.2002.0771; Hoareau L, 2010, DRUG DISCOVERY TODAY, V7, pe205, DOI [10.1016/j.ddmec.2011.01.002, DOI 10.1016/J.DDMEC.2011.01.002]; Jamshidi N, 2001, BRIT J PHARMACOL, V134, P1151, DOI 10.1038/sj.bjp.0704379; Jenniches I, 2016, BIOL PSYCHIAT, V79, P858, DOI 10.1016/j.biopsych.2015.03.033; Keimpema E, 2014, EUR J NEUROSCI, V39, P334, DOI 10.1111/ejn.12431; Keimpema E, 2013, BIOCHEM SOC T, V41, P1569, DOI 10.1042/BST20130117; Lafourcade M, 2011, NAT NEUROSCI, V14, P345, DOI 10.1038/nn.2736; Larrieu T, 2012, J PHYSIOL BIOCHEM, V68, P671, DOI 10.1007/s13105-012-0179-6; Levay EA, 2008, BEHAV BRAIN RES, V191, P164, DOI 10.1016/j.bbr.2008.03.021; LUCAS A, 1991, CIBA F SYMP, V156, P38; Lukaszewski MA, 2011, AM J PHYSIOL-ENDOC M, V301, pE548, DOI 10.1152/ajpendo.00011.2011; Lussana F, 2008, AM J CLIN NUTR, V88, P1648, DOI 10.3945/ajcn.2008.26140; Lutz B, 2015, NAT REV NEUROSCI, V16, P705, DOI 10.1038/nrn4036; Lutz B, 2009, CURR OPIN PHARMACOL, V9, P46, DOI 10.1016/j.coph.2008.12.001; Maccarrone M, 2014, NAT REV NEUROSCI, V15, P786, DOI 10.1038/nrn3846; Madore C, 2014, BRAIN BEHAV IMMUN, V41, P22, DOI 10.1016/j.bbi.2014.03.021; Marques AH, 2015, BRAIN RES, V1617, P28, DOI 10.1016/j.brainres.2014.10.051; Matias I, 2003, CELL MOL LIFE SCI, V60, P382, DOI 10.1007/s000180300031; McMillen IC, 2004, ENDOCR RES, V30, P845, DOI 10.1081/ERC-200044106; Micali N, 2007, J PSYCHOSOM RES, V63, P297, DOI 10.1016/j.jpsychores.2007.05.003; Micali N, 2007, BRIT J PSYCHIAT, V190, P255, DOI 10.1192/bjp.bp.106.020768; Moreno M, 2005, BEHAV PHARMACOL, V16, P423, DOI 10.1097/00008877-200509000-00015; Morgese MG, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6030024; Morgese MG, 2016, MOL NEUROBIOL; Nomura Y, 2007, COMPR PSYCHIAT, V48, P470, DOI 10.1016/j.comppsych.2007.04.005; Palou M, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-69; Garcia AP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017313; Pu SH, 2016, BRIT J NUTR, V115, P1012, DOI 10.1017/S0007114515005425; Ramirez-Lopez MT, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00241; Ramirez-Lopez MT, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00208; Rana JS, 2007, DIABETES OBES METAB, V9, P218, DOI 10.1111/j.1463-1326.2006.00594.x; Raso GM, 2014, ENDOCRINOLOGY, V155, P1291, DOI 10.1210/en.2013-1823; Reyes-Castro LA, 2012, BEHAV BRAIN RES, V227, P324, DOI 10.1016/j.bbr.2011.06.008; Reyes-Castro LA, 2012, INT J DEV NEUROSCI, V30, P39, DOI 10.1016/j.ijdevneu.2011.10.002; Rickards AL, 2001, J DEV BEHAV PEDIATR, V22, P11, DOI 10.1097/00004703-200102000-00002; Rivera P, 2013, EUR J NEUROSCI, V37, P105, DOI 10.1111/ejn.12012; Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001; Soria-Gomez E, 2014, NAT NEUROSCI, V17, P407, DOI 10.1038/nn.3647; Suzuki M, 2010, J NUTR SCI VITAMINOL, V56, P293, DOI 10.3177/jnsv.56.293; Ramirez-Lopez MT, 2016, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00339; Tibirica E, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-5; Watanabe S, 2003, PROSTAG LEUKOTR ESS, V69, P51, DOI 10.1016/S0952-3278(03)00056-5; Wenzel D, 2013, P NATL ACAD SCI USA, V110, P18710, DOI 10.1073/pnas.1308130110; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; Williams CM, 1999, PSYCHOPHARMACOLOGY, V143, P315, DOI 10.1007/s002130050953; Zhang S, 2013, REPRODUCTION, V146, P443, DOI 10.1530/REP-13-0219	85	9	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2017	12	3							e0174307	10.1371/journal.pone.0174307	http://dx.doi.org/10.1371/journal.pone.0174307			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER9VD	28346523	gold, Green Submitted, Green Published			2023-01-03	WOS:000399174300037
J	Gupta, N; Kabahizi, J; Mukabatsinda, C; Walker, TD; Musabeyezu, E; Kiromera, A; Van Nuil, JI; Steiner, K; Mukherjee, J; Nsanzimana, S; Mbituyumuremyi, A				Gupta, Neil; Kabahizi, Jules; Mukabatsinda, Constance; Walker, Timothy David; Musabeyezu, Emmanuel; Kiromera, Athanase; Van Nuil, Jennifer Ilo; Steiner, Kevin; Mukherjee, Joia; Nsanzimana, Sabin; Mbituyumuremyi, Aimable			"Waiting for DAAs" : A retrospective chart review of patients with untreated hepatitis C in Rwanda	PLOS ONE			English	Review							SEROPREVALENCE; AFRICA	Background Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background and characteristics of a national cohort of patients with HCV infection enrolled in care and awaiting therapy with DAAs. Methods and findings We conducted a retrospective chart review of all adult patients with confirmed HCV infection who were currently enrolled in care and treatment at the four existing hepatitis referral centers in Rwanda. Patient charts at these centers were reviewed, and routinely collected data were recorded and analyzed. Overall, 253 patients were identified; median age was 56 years (IQR: 43, 65), and 149 (58.9%) were female. Median viral load was 688,736 IU/ml and 96.7% were HCV genotype 4. As classified by FIB-4 score, 64.8% of the patients had moderate to severe fibrosis. Fibrosis stage was associated with age (OR 1.12, CI 1.09-1.17), but not with time since diagnosis, gender, treatment center, or type of insurance. There was a low frequency of documented co-morbid conditions, including hypertension, diabetes, HIV, and hepatitis B virus. Conclusions Compared to an estimated 55,000 patients eligible for HCV treatment in Rwanda, this study identified only 253 patients currently diagnosed and engaged in care, highlighting an immense treatment gap in HCV, likely due to the lack of accessible and affordable screening, diagnostic, and treatment modalities. The patients that were enrolled in care had a disproportionately advanced fibrosis stage, possibly indicating late presentation to care or lack of treatment options. In the context of newly available and effective treatment options, this study supports the overall need to accelerate access to HCV screening, diagnostics, and care and treatment services in resource-limited settings in sub-Saharan Africa.	[Gupta, Neil; Steiner, Kevin; Mukherjee, Joia] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA; [Gupta, Neil; Van Nuil, Jennifer Ilo; Mukherjee, Joia] Partners Hlth, Inshuti Mu Buzima, Rwinkwavu, Rwanda; [Kabahizi, Jules] Rwanda Mil Hosp, Kanombe, Rwanda; [Mukabatsinda, Constance] Univ Teaching Hosp Kigali, Kigali, Rwanda; [Walker, Timothy David] Univ Teaching Hosp Butare, Butare, Rwanda; [Musabeyezu, Emmanuel] King Faisal Hosp, Kigali, Rwanda; [Kiromera, Athanase] Maryland Global Initiat Corp, Kigali, Rwanda; [Nsanzimana, Sabin; Mbituyumuremyi, Aimable] Rwanda Biomed Ctr, Kigali, Rwanda	Harvard University; Brigham & Women's Hospital; Rwanda Biomedical Center	Gupta, N (corresponding author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.; Gupta, N (corresponding author), Partners Hlth, Inshuti Mu Buzima, Rwinkwavu, Rwanda.	ngupta@pih.org		Gupta, Neil/0000-0003-3470-5351	Rwanda Ministry of Health; Rwanda Biomedical Center; University Teaching Hospital of Kigali; University Teaching Hospital of Butare; Rwanda Military Hospital; King Faisal Hospital	Rwanda Ministry of Health; Rwanda Biomedical Center; University Teaching Hospital of Kigali; University Teaching Hospital of Butare; Rwanda Military Hospital; King Faisal Hospital	The authors acknowledge the support and contributions of the Rwanda Ministry of Health, Rwanda Biomedical Center, University Teaching Hospital of Kigali, University Teaching Hospital of Butare, Rwanda Military Hospital, and King Faisal Hospital in the establishment of HCV treatment centers and access to registry data. Finally, we are grateful to Partners In Health and Brigham & Women's Hospital for in-kind support of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antaki N, 2010, LIVER INT, V30, P342, DOI 10.1111/j.1478-3231.2009.02188.x; Binagwaho A, 2014, LANCET, V383, P3, DOI 10.1016/S0140-6736(13)62423-X; Bolton P, 2002, J NERV MENT DIS, V190, P631, DOI 10.1097/00005053-200209000-00009; Ford N, 2012, CLIN INFECT DIS, V54, P1465, DOI 10.1093/cid/cis227; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Graham CS, 2015, ANTIVIRAL RES; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Heim L, 2014, INT J MENT HEALTH SY, V8, DOI 10.1186/1752-4458-8-37; Karoney MJ, 2013, PAN AFR MED J, V14, DOI 10.11604/pamj.2013.14.44.2199; Kateera F, 2015, T ROY SOC TROP MED H, V109, P203, DOI 10.1093/trstmh/trv004; Layden JE, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu065; Liu Zhihua, 2006, Int J Med Sci, V3, P57; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; National Institute of Statistics of Rwanda (NISR) [Rwanda] Ministry of Health (MOH) [ Rwanda] and ICF International, 2010, RWAND DEM HLTH SURV; NSIR, 2016, RWAND DEM HLTH SURV; Pawlotsky JM, 2014, GASTROENTEROLOGY, V146, P1176, DOI 10.1053/j.gastro.2014.03.003; Pirillo MF, 2007, J MED VIROL, V79, P1797, DOI 10.1002/jmv.21007; Platt L, 2016, LANCET INFECT DIS; Rao VB, 2015, LANCET INFECT DIS, V15, P819, DOI 10.1016/S1473-3099(15)00006-7; Riou J, 2015, J VIRAL HEPATITIS; Rusine J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063303; Rwanda Biomedical Center, 2016, RWAND VIR HEP NAT OP; Rwanda Biomedical Center, 2015, RWAND NONC DIS RISK; Rwanda Military Hospital. Laboratory Costs for Viral Tests, 2012, LAB COSTS VIR TESTS; Rwanda Ministry of Health, 2013, NAT GUID PREV MAN HI; Rwanda Ministry of Health, 2013, MIN HLTH ANN REP JUL; Rwanda Ministry of Health, 2015, NAT HIV ANN REP 2014; WHO, 2014, GUID SCREEN CAR TREA	28	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2017	12	3							e0174148	10.1371/journal.pone.0174148	http://dx.doi.org/10.1371/journal.pone.0174148			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8RG	28323868	gold, Green Submitted, Green Published			2023-01-03	WOS:000399089000067
J	Vaughn, VM; Shuster, D; Rogers, MAM; Mann, J; Conte, ML; Saint, S; Chopra, V				Vaughn, Valerie M.; Shuster, Dmitry; Rogers, Mary A. M.; Mann, Jason; Conte, Marisa L.; Saint, Sanjay; Chopra, Vineet			Early Versus Delayed Feeding in Patients With Acute Pancreatitis A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							EARLY ENTERAL NUTRITION; MILD ACUTE-PANCREATITIS; PARENTERAL-NUTRITION; GUT; METAANALYSIS; MORTALITY; MODERATE; SUPPORT; DIET	Background: Acute pancreatitis is among the most common and costly reasons for hospitalization in the United States. Bowel rest, pain control, and intravenous fluids are the cornerstones of treatment, but early feeding might also be beneficial. Purpose: To compare length of hospital stay, mortality, and readmission in adults hospitalized with pancreatitis who received early versus delayed feeding. Data Sources: MEDLINE via Ovid, EMBASE, the Cochrane Library, CINAHL, and Web of Science through January 2017. Study Selection: Two authors independently reviewed and selected studies if they were randomized clinical trials, included adults hospitalized with acute pancreatitis, and compared early versus delayed feeding (<= 48 vs. >48 hours after hospitalization). Data Extraction: Two investigators independently extracted study data and rated risk of bias using the Cochrane Collaboration tool. Data Synthesis: Eleven randomized trials (8 peer-reviewed publications, 3 abstract-only presentations) that included 948 patients were eligible. Seven trials (3 with low risk of bias) enrolled patients with mild to moderate pancreatitis. Four trials (1 with low risk of bias) included patients with predicted severe pancreatitis. Routes used for early feeding included oral (4 studies), nasogastric (2 studies), nasojejunal (4 studies), and oral or nasoenteric (1 study). Among patients with mild to moderate pancreatitis, early feeding was associated with reduced length of stay in 4 of 7 studies (including 2 of 3 with low risk of bias). Other outcomes were heterogeneous and variably reported, but no study showed an increase in adverse events with early feeding. Among patients with severe pancreatitis, limited evidence revealed no statistically significant difference in outcomes between early and delayed feeding. Limitation: Heterogeneity of feeding protocols and outcomes, scant data, and unclear or high risk of bias in several studies. Conclusion: Limited data suggest that early feeding in patients with acute pancreatitis does not seem to increase adverse events and, for patients with mild to moderate pancreatitis, may reduce length of hospital stay.	[Vaughn, Valerie M.] Michigan Med, Div Hosp Med, Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA; [Shuster, Dmitry] Michigan Med, Dept Internal Med, Div Gastroenterol, 3912 Taubman Ctr,SPC 5362, Ann Arbor, MI 48109 USA; [Rogers, Mary A. M.; Mann, Jason; Saint, Sanjay] Michigan Med, Dept Internal Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA; [Conte, Marisa L.] Michigan Med, Taubman Hlth Sci Lib, 1135 East Catherine St, Ann Arbor, MI 48109 USA; [Chopra, Vineet] Michigan Med, Div Hosp Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA		Chopra, V (corresponding author), Michigan Med, Div Hosp Med, Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA.	vineetc@umich.edu	Saint, Sanjay/AAF-5126-2019; Vaughn, Valerie M/L-3649-2018	Chopra, Vineet/0000-0001-8670-9376; Conte, Marisa/0000-0001-7377-163X; Rogers, Mary/0000-0001-5519-3223; Vaughn, Valerie/0000-0003-4362-7842	Agency for Healthcare Research and Quality [1-K08-HS022835-01]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Dr. Chopra is supported by a career development award from the Agency for Healthcare Research and Quality (1-K08-HS022835-01).	Al Samaraee A, 2010, SURG-J R COLL SURG E, V8, P105, DOI 10.1016/j.surge.2009.10.006; Ammori BJ, 2003, PANCREAS, V26, P122, DOI 10.1097/00006676-200303000-00006; Badalov NL, 2007, AM J GASTROENTEROL, V102, pS192, DOI 10.14309/00000434-200709002-00208; Bakker OJ, 2014, NEW ENGL J MED, V371, P1983, DOI 10.1056/NEJMoa1404393; Bakker OJ, 2014, PANCREATOLOGY, V14, P340, DOI 10.1016/j.pan.2014.07.008; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; BUCHMAN AL, 1995, JPEN-PARENTER ENTER, V19, P453, DOI 10.1177/0148607195019006453; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Dua MM, 2015, J SURG RES, V199, P44, DOI 10.1016/j.jss.2015.04.054; Eckerwall GE, 2007, CLIN NUTR, V26, P758, DOI 10.1016/j.clnu.2007.04.007; Flint R S, 2003, HPB (Oxford), V5, P69, DOI 10.1080/13651820310001108; Greenberg JA, 2016, J GASTROINTEST SURG, V20, P392, DOI 10.1007/s11605-015-3023-9; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Harrison TR, 1950, PRINCIPLES INTERNAL; Hernandez G, 1999, J CRIT CARE, V14, P73, DOI 10.1016/S0883-9441(99)90017-5; Horibe M, 2016, UNITED EUR GASTROENT, V4, P725, DOI 10.1177/2050640615612368; Karabulut U, 2014, GASTROENTEROLOGY, V146, pS621; Jiang K, 2007, WORLD J GASTROENTERO, V13, P5253, DOI 10.3748/wjg.v13.i39.5253; Kurti F, 2015, PANCREATOLOGY, V15, pS62; Larino-Noia J, 2014, PANCREATOLOGY, V14, P167, DOI 10.1016/j.pan.2014.02.008; Li JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064926; Li J, 2013, PANCREAS, V42, P88, DOI 10.1097/MPA.0b013e3182575fb5; Li W, 2010, PANCREATOLOGY, V10, P264; Li XP, 2014, MED SCI MONITOR, V20, P2327, DOI 10.12659/MSM.892770; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Marta K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101691; McClave SA, 2006, JPEN-PARENTER ENTER, V30, P143, DOI 10.1177/0148607106030002143; McClave SA, 2014, CRIT CARE MED, V42, P2600, DOI 10.1097/CCM.0000000000000654; McClure RJ, 2000, ARCH DIS CHILD-FETAL, V82, pF29, DOI 10.1136/fn.82.1.F29; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Olah A, 2014, WORLD J GASTROENTERO, V20, P16123, DOI 10.3748/wjg.v20.i43.16123; Olh A, 2010, ARCH SURG-CHICAGO, V395, P309, DOI [10.1007/s00423-010-0631-4, DOI 10.1007/S00423-010-0631-4]; Peery AF, 2015, GASTROENTEROLOGY, V149, P1731, DOI 10.1053/j.gastro.2015.08.045; Petrov MS, 2008, ALIMENT PHARM THER, V28, P704, DOI 10.1111/j.1365-2036.2008.03786.x; Petrov MS, 2013, CLIN NUTR, V32, P697, DOI 10.1016/j.clnu.2012.12.011; Powell JJ, 2000, BRIT J SURG, V87, P1375, DOI 10.1046/j.1365-2168.2000.01558.x; Stimac D, 2016, PANCREATOLOGY, V16, P523, DOI 10.1016/j.pan.2016.04.003; Teich N, 2010, PANCREAS, V39, P1088, DOI 10.1097/MPA.0b013e3181d3ce05; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Wereszczynska-Siemiatkowska U, 2013, PANCREAS, V42, P640, DOI 10.1097/MPA.0b013e318271bb61; [吴大成 WU Dacheng], 2008, [肠外与肠内营养, Parenteral & Enteral Nutrition], V15, P285; Wu Y, 1999, ANN SURG, V229, P662, DOI 10.1097/00000658-199905000-00008; Yadav D, 2006, PANCREAS, V33, P323, DOI 10.1097/01.mpa.0000236733.31617.52; Zhao XL, 2015, NUTRITION, V31, P171, DOI 10.1016/j.nut.2014.07.002	45	52	57	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 20	2017	166	12					883	+		10.7326/M16-2533	http://dx.doi.org/10.7326/M16-2533			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX9LG	28505667				2023-01-03	WOS:000403579000016
J	Villareal, DT; Aguirre, L; Gurney, AB; Waters, DL; Sinacore, DR; Colombo, E; Armamento-Villareal, R; Qualls, C				Villareal, Dennis T.; Aguirre, Lina; Gurney, A. Burke; Waters, Debra L.; Sinacore, David R.; Colombo, Elizabeth; Armamento-Villareal, Reina; Qualls, Clifford			Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT-LOSS; PHYSICAL PERFORMANCE; CALORIC RESTRICTION; SARCOPENIC OBESITY; FRAILTY; INTERFERENCE; ASSOCIATION; DISABILITY; CAPACITY; STRENGTH	BACKGROUND Obesity causes frailty in older adults; however, weight loss might accelerate age-related loss of muscle and bone mass and resultant sarcopenia and osteopenia. METHODS In this clinical trial involving 160 obese older adults, we evaluated the effectiveness of several exercise modes in reversing frailty and preventing reduction in muscle and bone mass induced by weight loss. Participants were randomly assigned to a weight-management program plus one of three exercise programs - aerobic training, resistance training, or combined aerobic and resistance training - or to a control group (no weight-management or exercise program). The primary outcome was the change in Physical Performance Test score from baseline to 6 months (scores range from 0 to 36 points; higher scores indicate better performance). Secondary outcomes included changes in other frailty measures, body composition, bone mineral density, and physical functions. RESULTS A total of 141 participants completed the study. The Physical Performance Test score increased more in the combination group than in the aerobic and resistance groups (27.9 to 33.4 points [21% increase] vs. 29.3 to 33.2 points [14% increase] and 28.8 to 32.7 points [14% increase], respectively; P=0.01 and P=0.02 after Bonferroni correction); the scores increased more in all exercise groups than in the control group (P<0.001 for between-group comparisons). Peak oxygen consumption (milliliters per kilogram of body weight per minute) increased more in the combination and aerobic groups (17.2 to 20.3 [17% increase] and 17.6 to 20.9 [18% increase], respectively) than in the resistance group (17.0 to 18.3 [8% increase]) (P<0.001 for both comparisons). Strength increased more in the combination and resistance groups (272 to 320 kg [18% increase] and 288 to 337 kg [19% increase], respectively) than in the aerobic group (265 to 270 kg [4% increase]) (P<0.001 for both comparisons). Body weight decreased by 9% in all exercise groups but did not change significantly in the control group. Lean mass decreased less in the combination and resistance groups than in the aerobic group (56.5 to 54.8 kg [3% decrease] and 58.1 to 57.1 kg [2% decrease], respectively, vs. 55.0 to 52.3 kg [5% decrease]), as did bone mineral density at the total hip (grams per square centimeter; 1.010 to 0.996 [1% decrease] and 1.047 to 1.041 [0.5% decrease], respectively, vs. 1.018 to 0.991 [3% decrease]) (P<0.05 for all comparisons). Exercise-related adverse events included musculoskeletal injuries. CONCLUSIONS Of the methods tested, weight loss plus combined aerobic and resistance exercise was the most effective in improving functional status of obese older adults. (Funded by the National Institutes of Health; LITOE ClinicalTrials. gov number, NCT01065636.)	[Villareal, Dennis T.; Armamento-Villareal, Reina] Baylor Coll Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA; [Villareal, Dennis T.; Armamento-Villareal, Reina] Michael E DeBakey Vet Affairs VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA; [Aguirre, Lina; Waters, Debra L.; Colombo, Elizabeth] New Mexico VA Hlth Care Syst, Med Care Line, Albuquerque, NM USA; [Aguirre, Lina; Colombo, Elizabeth] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA; [Gurney, A. Burke] Univ New Mexico, Sch Med, Div Phys Therapy, Albuquerque, NM 87131 USA; [Qualls, Clifford] Univ New Mexico, Sch Med, Dept Math & Stat, Albuquerque, NM 87131 USA; [Waters, Debra L.] Univ Otago, Sch Physiotherapy, Dept Med, Dunedin, New Zealand; [Sinacore, David R.] Washington Univ, Sch Med, Program Phys Therapy, St Louis, MO USA	Baylor College of Medicine; University of New Mexico; University of New Mexico; University of New Mexico; University of Otago; Washington University (WUSTL)	Villareal, DT (corresponding author), Baylor Coll Med, Michael E DeBakey VA Med Ctr, 2002 Holcombe Ave, Houston, TX 77030 USA.	dennis.villareal@bcm.edu	Villareal, Reina/AAH-6028-2019; PT, David R. Sinacore/AAS-3377-2020	PT, David R. Sinacore/0000-0002-7242-3585; Zare, Morteza/0000-0001-7157-9265	National Institutes of Health [RO1-AG031176, UL1-TR000041, P30-DK020579]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001449, UL1TR000041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG031176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the National Institutes of Health (RO1-AG031176, UL1-TR000041, and P30-DK020579).	Aguirre LE, 2015, NESTLE NUTR WORKS SE, V83, P83, DOI 10.1159/000382065; Batsis JA, 2017, J AM GERIATR SOC, V65, P257, DOI 10.1111/jgs.14514; Binder EF, 2002, J AM GERIATR SOC, V50, P1921, DOI 10.1046/j.1532-5415.2002.50601.x; Binder EF, 1999, J GERONTOL A-BIOL, V54, pM353, DOI 10.1093/gerona/54.7.M353; Blaum CS, 2005, J AM GERIATR SOC, V53, P927, DOI 10.1111/j.1532-5415.2005.53300.x; Bouchonville MF, 2013, CURR OPIN ENDOCRINOL, V20, P412, DOI 10.1097/01.med.0000433071.11466.7f; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Cadore EL, 2010, INT J SPORTS MED, V31, P689, DOI 10.1055/s-0030-1261895; Centers for Medicare and Medicaid Services, 2011, DEC MEM INT BEH THER; Dmitrienko A, 2011, STAT MED, V30, P1473, DOI 10.1002/sim.4008; Evans WJ, 2002, J GERONTOL A-BIOL, V57, pM260, DOI 10.1093/gerona/57.5.M260; Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HAYTER AJ, 1986, J AM STAT ASSOC, V81, P1000; HICKSON RC, 1980, EUR J APPL PHYSIOL O, V45, P255, DOI 10.1007/BF00421333; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; Lambert CP, 2005, REV ENDOCR METAB DIS, V6, P137, DOI 10.1007/s11154-005-6726-5; Liu CJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002759.pub2; Locher JL, 2016, EXP GERONTOL, V86, P4, DOI 10.1016/j.exger.2016.03.009; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; Maruish ME, 2011, USERS MANUAL SF 36V2, V3rd; Miller SL, 2008, J NUTR HEALTH AGING, V12, P487, DOI 10.1007/BF02982710; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Nguyen HQ, 2008, DIABETES CARE, V31, P1562, DOI 10.2337/dc08-0624; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; Roubenoff R, 2004, OBES RES, V12, P887, DOI 10.1038/oby.2004.107; Shah K, 2008, J AM GERIATR SOC, V56, P1157, DOI 10.1111/j.1532-5415.2008.01699.x; Shapses SA, 2012, ANNU REV NUTR, V32, P287, DOI 10.1146/annurev.nutr.012809.104655; Starr KNP, 2014, J AM MED DIR ASSOC, V15, P240, DOI 10.1016/j.jamda.2013.11.008; Svetkey LP, 2014, OBESITY, V22, P39, DOI 10.1002/oby.20506; Theou Olga, 2011, J Aging Res, V2011, P569194, DOI 10.4061/2011/569194; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; Villareal DT, 2006, ARCH INTERN MED, V166, P2502, DOI 10.1001/archinte.166.22.2502; Villareal DT, 2004, OBES RES, V12, P913, DOI 10.1038/oby.2004.111; Villareal DT, 2005, AM J CLIN NUTR, V82, P923, DOI 10.1093/ajcn/82.5.923; Waters DL, 2013, EXP GERONTOL, V48, P1054, DOI 10.1016/j.exger.2013.02.005; Weiss EP, 2007, J APPL PHYSIOL, V102, P634, DOI 10.1152/japplphysiol.00853.2006; Wilson JM, 2012, J STRENGTH COND RES, V26, P2293, DOI 10.1519/JSC.0b013e31823a3e2d	39	269	288	10	111	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2017	376	20					1943	1955		10.1056/NEJMoa1616338	http://dx.doi.org/10.1056/NEJMoa1616338			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV0DB	28514618	Green Accepted			2023-01-03	WOS:000401407500008
J	Abdulrahman, SA; Rampal, L; Ibrahim, F; Radhakrishnan, AP; Shahar, HK; Othman, N				Abdulrahman, Surajudeen Abiola; Rampal, Lekhraj; Ibrahim, Faisal; Radhakrishnan, Anuradha P.; Shahar, Hayati Kadir; Othman, Norlijah			Mobile phone reminders and peer counseling improve adherence and treatment outcomes of patients on ART in Malaysia: A randomized clinical trial	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT; TERM; CARE; THERAPY	Background Adherence to treatment remains the cornerstone of long term viral suppression and successful treatment outcomes among patients receiving Antiretroviral Therapy (ART). Objective(s) Evaluate the effectiveness of mobile phone reminders and peer counseling in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia. Methods A single-blind, parallel group RCT conducted in Hospital Sungai Buloh, Malaysia in which 242 adult Malaysian patients were randomized to intervention or control groups. Intervention consisted of a reminder module delivered through SMS and telephone call reminders by trained research assistants for 24 consecutive weeks (starting from date of ART initiation), in addition to adherence counseling at every clinic visit. The length of intended follow up for each patient was 6 months. Data on adherence behavior of patients was collected using specialized, pre-validated Adult AIDS Clinical Trial Group (AACTG) adherence questionnaires. Data on weight, clinical symptoms, CD4 count and viral load tests were also collected. Data was analyzed using SPSS version 22 and R software. Repeated measures ANOVA, Friedman's ANOVA and Multivariate regression models were used to evaluate efficacy of the intervention. Results The response rate after 6 months follow up was 93%. There were no significant differences at baseline in gender, employment status, income distribution and residential location of respondents between the intervention and control group. After 6 months follow up, the mean adherence was significantly higher in the intervention group (95.7; 95% CI: 94.39-96.97) as compared to the control group (87.5; 95% CI: 86.14-88.81). The proportion of respondents who had Good (>95%) adherence was significantly higher in the intervention group (92.2%) compared to the control group (54.6%). A significantly lower frequency in missed appointments (14.0% vs 35.5%) (p = 0.001), lower viral load (p = 0.001), higher rise in CD4 count (p = 0.017), lower incidence of tuberculosis (p = 0.001) and OIs (p = 0.001) at 6 months follow up, was observed among patients in the intervention group. Conclusion Mobile phone reminders (SMS and telephone call reminders) and peer counseling are effective in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia. These findings may be of potential benefit for collaborative adherence planning between patients and health care providers at ART commencement.	[Abdulrahman, Surajudeen Abiola; Rampal, Lekhraj; Ibrahim, Faisal; Shahar, Hayati Kadir] Univ Putra Malaysia, Dept Community Hlth, Fac Med & Hlth Sci, Upm Serdang, Selangor Darul, Malaysia; [Abdulrahman, Surajudeen Abiola] Penang Med Coll, Dept Publ Hlth Med, George Town, Penang, Malaysia; [Radhakrishnan, Anuradha P.] Hosp Sungai Buloh, Infect Dis Clin, Sungai Buloh, Selangor Darul, Malaysia; [Othman, Norlijah] Univ Putra Malaysia, Dept Pediat, Fac Med & Hlth Sci, Upm Serdang, Selangor Darul, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia	Rampal, L (corresponding author), Univ Putra Malaysia, Dept Community Hlth, Fac Med & Hlth Sci, Upm Serdang, Selangor Darul, Malaysia.	lekhraj@upm.edu.my		Abdulrahman, Surajudeen/0000-0003-4445-1295				Collier AC, 2005, J INFECT DIS, V192, P1398, DOI 10.1086/466526; da Costa TM, 2012, INT J MED INFORM, V81, P257, DOI 10.1016/j.ijmedinf.2011.10.002; Downer SR, 2005, MED J AUSTRALIA, V183, P366, DOI 10.5694/j.1326-5377.2005.tb07085.x; Egbewale Bolaji Emmanuel, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P354, DOI 10.1016/S2221-1691(15)30367-1; Fairley CK, 2005, HIV MED, V6, P366, DOI 10.1111/j.1468-1293.2005.00322.x; Hardy H, 2011, AIDS PATIENT CARE ST, V25, P153, DOI 10.1089/apc.2010.0006; Hovart T, 2012, COCHRANE DB SYST REV; Jani A.A., 2004, ADHERENCE HIV TREATM, P3; Kunutsor S, 2010, AIDS RES TREAT, V2010, DOI 10.1155/2010/872396; Kunutsor S, 2010, AIDS BEHAV, V14, P1347, DOI 10.1007/s10461-010-9780-2; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; March K, 2007, AM J HEALTH-SYST PH, V64, P2574, DOI 10.2146/ajhp070048; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Ndubuka NO, 2011, INT J NURS STUD, V48, P1323, DOI 10.1016/j.ijnurstu.2011.04.006; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Preininger L, 2011, CURR HIV RES, V9, P253, DOI 10.2174/157016211796320351; Reynolds NR, 2007, JAIDS-J ACQ IMM DEF, V46, P402, DOI 10.1097/QAI.0b013e318158a44f; Rich ML, 2012, JAIDS-J ACQ IMM DEF, V59, pE35, DOI 10.1097/QAI.0b013e31824476c4; Roberts C, 1999, BRIT MED J, V319, P185, DOI 10.1136/bmj.319.7203.185; Sabin LL, 2015, JAIDS-J ACQ IMM DEF, V69, P551, DOI 10.1097/QAI.0000000000000651; Sabin LL, 2010, AIDS BEHAV, V14, P580, DOI 10.1007/s10461-009-9615-1; Saple D., 2005, INDIA J DERMATOLOGY; Sarna A, 2008, JAIDS-J ACQ IMM DEF, V48, P611, DOI 10.1097/QAI.0b013e3181806bf1; van Velthoven MHMMT, 2013, PSYCHOL HEALTH MED, V18, P182, DOI 10.1080/13548506.2012.701310; World Health Organization, 2007, WHO WORK GROUP M 21	27	32	36	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177698	10.1371/journal.pone.0177698	http://dx.doi.org/10.1371/journal.pone.0177698			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV1DC	28520768	Green Submitted, Green Published, gold			2023-01-03	WOS:000401485500058
J	Savulescu, J				Savulescu, Julian			Is it in Charlie Gard's best interest to die?	LANCET			English	Editorial Material									[Savulescu, Julian] Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford OX1 1PT, England	University of Oxford	Savulescu, J (corresponding author), Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford OX1 1PT, England.	julian.savulescu@philosophy.ox.ac.uk						[Anonymous], 2017, BBC NEWS; Bruno MA, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000039; Judiciary of England and Wales, 2017, DEC SHORT REAS REL M; Rawls J., 1951, OUTLINE DECISION PRO, V60, P177, DOI DOI 10.2307/2181696; Rawls J., 1972, THEORY JUSTICE; Savulescu J, 2006, MEDICINE, V33, P11; Wilkinson D, 2017, LANCET; Wilkinson DJC, 2011, CURR OPIN ANESTHESIO, V24, P160, DOI 10.1097/ACO.0b013e328343c5af; Yan EG, 2007, J PERINATOL, V27, P307, DOI 10.1038/sj.jp.7211694	9	15	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	2017	389	10082					1868	1869		10.1016/S0140-6736(17)31204-7	http://dx.doi.org/10.1016/S0140-6736(17)31204-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU4AZ	28478974	Green Submitted			2023-01-03	WOS:000400973500008
J	Yi, Z; Huang, YS; Wang, L; Zhao, YT				Yi, Zhong; Huang, Yen Shu; Wang, Lei; Zhao, Yun-Tao			CASE REVIEW A man with chest tightness and burning limbs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Yi, Zhong; Huang, Yen Shu; Wang, Lei; Zhao, Yun-Tao] Aerosp Ctr Hosp, Cardiac Dept, Beijing, Peoples R China		Zhao, YT (corresponding author), Aerosp Ctr Hosp, Cardiac Dept, Beijing, Peoples R China.	raas@hsc.pku.edu.cn						Dispenzieri A, 2015, MAYO CLIN PROC, V90, P1054, DOI 10.1016/j.mayocp.2015.06.009; Falk RH, 2016, J AM COLL CARDIOL, V68, P1324, DOI 10.1016/j.jacc.2016.06.053; Martinelli N, 2011, CIRCULATION, V123, pE583, DOI 10.1161/CIRCULATIONAHA.110.011601; Quarta CC, 2012, CIRCULATION, V126, pE178, DOI 10.1161/CIRCULATIONAHA.111.069195; Ritts AJ, 2017, HEART FAIL CLIN, V13, P409, DOI 10.1016/j.hfc.2016.12.003; Sperry BW, 2016, J AM COLL CARDIOL, V67, P2941, DOI 10.1016/j.jacc.2016.03.593; Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X; Wechalekar AD, 2015, BRIT J HAEMATOL, V168, P186, DOI 10.1111/bjh.13155; Yilmaz A, 2014, HEART, V100, P662, DOI 10.1136/heartjnl-2011-301528	9	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	2017	357								j1979	10.1136/bmj.j1979	http://dx.doi.org/10.1136/bmj.j1979			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU6UK	28495887				2023-01-03	WOS:000401170200002
J	Jha, V; Martin, DE; Bargman, JM; Davies, S; Feehally, J; Finkelstein, F; Harris, D; Misra, M; Remuzzi, G; Levin, A				Jha, Vivekanand; Martin, Dominique E.; Bargman, Joanne M.; Davies, Simon; Feehally, John; Finkelstein, Fred; Harris, David; Misra, Madhukar; Remuzzi, Giuseppe; Levin, Adeera		Int Soc Nephrology Ethical Dialysi	Ethical issues in dialysis therapy	LANCET			English	Article							KIDNEY-DISEASE; DECISION-MAKING; CARE; ACCESS; TRANSPLANTATION; HEMODIALYSIS; COST; ESRD	Treatment for end-stage kidney disease is a major economic challenge and a public health concern worldwide. Renal-replacement therapy poses several practical and ethical dilemmas of global relevance for patients, clinicians, and policy makers. These include how to: promote patients' best interests; increase access to dialysis while maintaining procedural and distributive justice; minimise the influence of financial incentives and competing interests; ensure quality of care in service delivery and access to non-dialytic supportive care when needed; minimise the financial burden on patients and health-care system; and protect the interests of vulnerable groups during crisis situations. These issues have received comparatively little attention, and there is scant ethical analysis and guidance available to decision makers. In this Health Policy, we provide an overview of the major ethical issues related to dialysis provision worldwide, identify priorities for further investigation and management, and present preliminary recommendations to guide practice and policy.	[Jha, Vivekanand] George Inst Global Hlth, New Delhi 110025, India; [Jha, Vivekanand] Univ Oxford, Oxford, England; [Martin, Dominique E.] Deakin Univ, Sch Med, Melbourne, Vic, Australia; [Bargman, Joanne M.] Univ Toronto, Toronto, ON, Canada; [Davies, Simon] Keele Univ, Inst Appl Clin Sci, Keele, Staffs, England; [Feehally, John] Univ Leicester, Leicester, Leics, England; [Finkelstein, Fred] Yale Univ, New Haven, CT USA; [Harris, David] Univ Sydney, Sydney, NSW, Australia; [Misra, Madhukar] Univ Missouri, Columbia, MO USA; [Remuzzi, Giuseppe] Ist Ric Farmacol Mario Negri, Bergamo, Italy; [Levin, Adeera] Univ British Columbia, Vancouver, BC, Canada	University of Oxford; Deakin University; University of Toronto; Keele University; University of Leicester; Yale University; University of Sydney; University of Missouri System; University of Missouri Columbia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of British Columbia	Jha, V (corresponding author), George Inst Global Hlth, New Delhi 110025, India.	vivek.jha@georgeinstitute.ox.ac.uk	Harris, David/W-4786-2019; Remuzzi, Giuseppe/V-9766-2017	Jha, Vivekanand/0000-0002-8015-9470; Martin, Dominique/0000-0001-9363-0770; Remuzzi, Giuseppe/0000-0002-6194-3446	Baxter Healthcare; GlaxoSmithKline; NephroPlus; Fresenius Medical Care	Baxter Healthcare; GlaxoSmithKline(GlaxoSmithKline); NephroPlus; Fresenius Medical Care	VJ reports grants from Baxter Healthcare and GlaxoSmithKline and personal fees from NephroPlus; NephroPlus is a dialysis provider. DEM reports personal fees from WHO, outside the submitted work. SD reports grants and personal fees from Baxter Healthcare and Fresenius Medical Care; both are dialysis providers. JMB reports institutional support from Baxter Healthcare for education in home dialysis. DH reports personal fees from Roche Myanmar, outside the submitted work. JF, FF, MM, GR, and AL declare no competing interests.	[Anonymous], 2010, B WORLD HEALTH ORGAN, V88, P81; Chou SH, 2006, CLIN J AM SOC NEPHRO, V1, P58, DOI 10.2215/CJN.00560705; Collins A, 2006, KIDNEY INT, V69, P781, DOI 10.1038/sj.ki.5000250; Collins A, 2014, AM J KIDNEY DIS, V63, pE1; Combs SA, 2015, AM J KIDNEY DIS, V65, P233, DOI 10.1053/j.ajkd.2014.07.018; Davison SN, 2015, KIDNEY INT, V88, P447, DOI 10.1038/ki.2015.110; Etheredge H, 2015, DEV WORLD BIOETH, V15, P233, DOI 10.1111/dewb.12067; Evans NG, 2015, CLIN J AM SOC NEPHRO, V10, P2263, DOI 10.2215/CJN.03730415; Hussain JA, 2015, CLIN J AM SOC NEPHRO, V10, P1201, DOI 10.2215/CJN.11091114; Jensen CE, 2014, DAN MED J, V61; Jha V, 1996, NEPHROLOGY, V2, P65, DOI 10.1111/j.1440-1797.1996.tb00068.x; Jha V, 2015, CLIN NEPHROL, V83, pS7, DOI 10.5414/CNP83S007; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Just PM, 2008, NEPHROL DIAL TRANSPL, V23, P2365, DOI 10.1093/ndt/gfm939; Karopadi AN, 2013, NEPHROL DIAL TRANSPL, V28, P2553, DOI 10.1093/ndt/gft214; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Morton RL, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c112; Moss AH, 2010, CLIN J AM SOC NEPHRO, V5, P2380, DOI 10.2215/CJN.07170810; Murray MA, 2009, PATIENT EDUC COUNS, V76, P149, DOI 10.1016/j.pec.2008.12.010; Operations and Business Environment, ANN REPORT; Ozar DT, 2013, CLIN J AM SOC NEPHRO, V8, P840, DOI 10.2215/CJN.08490812; Parker JC, 2011, SEMIN DIALYSIS, V24, P5, DOI 10.1111/j.1525-139X.2010.00806.x; Ramachandran R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067812; Rinehart A, 2013, CLIN J AM SOC NEPHRO, V8, P2000, DOI 10.2215/CJN.12191212; Rodriguez RA, 2015, ADV CHRONIC KIDNEY D, V22, P60, DOI 10.1053/j.ackd.2014.07.003; Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014; Saunders MR, 2014, J RACIAL ETHN HEALTH, V1, P291, DOI 10.1007/s40615-014-0036-0; SINGER P, 1995, J MED ETHICS, V21, P144, DOI 10.1136/jme.21.3.144; Thompson A.K., 2006, BMC MED ETHICS, V7, P12, DOI [10.1186/1472-6939-7-12, DOI 10.1186/1472-6939-7-12]; Tonelli M, 2011, AM J TRANSPLANT, V11, P2093, DOI 10.1111/j.1600-6143.2011.03686.x	30	30	31	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2017	389	10081					1851	1856		10.1016/S0140-6736(16)32408-4	http://dx.doi.org/10.1016/S0140-6736(16)32408-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET8KW	28238456	Green Submitted			2023-01-03	WOS:000400549300034
J	Honda, H; Michihata, T; Shishido, K; Takahashi, K; Takahashi, G; Hosaka, N; Ikeda, M; Sanada, D; Shibata, T				Honda, Hirokazu; Michihata, Tetsuo; Shishido, Kanji; Takahashi, Keiko; Takahashi, Go; Hosaka, Nozomu; Ikeda, Misa; Sanada, Daisuke; Shibata, Takanori			High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients	PLOS ONE			English	Article							DOMINANT HYPOPHOSPHATEMIC RICKETS; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; DEFICIENCY ANEMIA; DIALYSIS-THERAPY; JAPANESE-SOCIETY; DOUBLE-BLIND; FGF23; PHOSPHATE; METABOLISM	A recent study demonstrated the association between inflammation, iron metabolism and fibroblast growth factor (FGF) 23. The present clinical study aimed to assess associations between anemia, iron metabolism and FGF23 in hemodialysis (HD) patients. This prospective observational study examined a cohort of prevalent HD patients (n = 282). Blood samples were obtained before dialysis sessions to measure baseline levels of hemoglobin (Hb), transferrin saturation (TSAT), ferritin, albumin-adjusted calcium (Ca), phosphate (P), intact (i)-PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact (i)-FGF23, high sensitive (hs)-CRP, and interleukin-6. After the baseline measurement, study patients were followed-up for 6 months. Biochemical measurements were subsequently performed at 1 (Hb), 2 (TSAT and ferritin) or 3 (Ca, P and hs-CRP) month intervals. Doses of ESAs and intravenous iron supplementation during the study period were recorded. i-FGF23 was positively correlated with Ca, P, i-PTH and inversely correlated with TSAT and ferritin. However, levels of Hb and hs-CRP and doses of ESAs during the study period did not differ among the i-FGF23 tertiles, with levels of ferritin and TSAT in the higher i-FGF23 tertile being consistently lower than in the middle to lower i-FGF23 tertiles. Multivariate repeated measures analysis indicated that the higher i-FGF23 tertile was independently associated with repeated measurements of ferritin, but not of TSAT. Doses of intravenous iron supplementation were significantly increased in the higher i-FGF23 tertile in multivariate models. In conclusion, high i-FGF23 levels may be associated with prolongation of low levels of ferritin, resulting in increased usages of iron supplementation in HD patients.	[Honda, Hirokazu; Hosaka, Nozomu] Showa Univ, Koto Toyosu Hosp, Dept Med, Div Nephrol, Tokyo, Japan; [Honda, Hirokazu; Hosaka, Nozomu; Ikeda, Misa; Sanada, Daisuke] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan; [Michihata, Tetsuo] Ebara Clin, Dept Dialysis, Tokyo, Japan; [Shishido, Kanji] Kawasaki Clin, Dept Dialysis, Kawasaki, Kanagawa, Japan; [Takahashi, Keiko] Kitami Higashiyama Clin, Div Dialysis, Tokyo, Japan; [Takahashi, Go; Shibata, Takanori] Showa Univ Northern Yokohama Hosp, Dept Internal Med, Yokohama, Kanagawa, Japan	Showa University; Showa University	Honda, H (corresponding author), Showa Univ, Koto Toyosu Hosp, Dept Med, Div Nephrol, Tokyo, Japan.; Honda, H (corresponding author), Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan.	hondah@med.showa-u.ac.jp		Honda, Hirokazu/0000-0002-5634-6145				Block GA, 2015, AM J KIDNEY DIS, V65, P728, DOI 10.1053/j.ajkd.2014.10.014; Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223; Bozentowicz-Wikarek M, 2015, CLIN BIOCHEM, V48, P431, DOI 10.1016/j.clinbiochem.2014.12.027; Braithwaite V, 2012, BONE, V50, P1351, DOI 10.1016/j.bone.2012.03.010; Chang YM, 2017, CLIN EXP NE IN PRESS; Chonchol M, 2016, J AM SOC NEPHROL, V27, P227, DOI 10.1681/ASN.2014101009; Coe LM, 2014, J BIOL CHEM, V289, P9795, DOI 10.1074/jbc.M113.527150; David V, 2016, KIDNEY INT, V89, P135, DOI 10.1038/ki.2015.290; di Giuseppe R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133580; Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Gaweda AE, 2010, CLIN J AM SOC NEPHRO, V5, P576, DOI 10.2215/CJN.04710709; Gejyo F, 2004, THER APHER DIAL, V8, P443, DOI 10.1111/j.1774-9987.2004.00199.x; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Hanks LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122885; Hanudel MR, 2016, AM J PHYSIOL-RENAL, V311, pF1369, DOI 10.1152/ajprenal.00281.2016; Honda H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151601; Honda H, 2012, ATHEROSCLEROSIS, V220, P493, DOI 10.1016/j.atherosclerosis.2011.10.038; Imel EA, 2011, J CLIN ENDOCR METAB, V96, P3541, DOI 10.1210/jc.2011-1239; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Kazama JJ, 2007, THER APHER DIAL, V11, pS44, DOI 10.1111/j.1744-9987.2007.00516.x; Mendoza FA, 2012, CLIN J AM SOC NEPHRO, V7, P1155, DOI 10.2215/CJN.13281211; Mendoza JM, 2017, KIDNEY INT, V91, P711, DOI 10.1016/j.kint.2016.10.021; Nowak KL, 2017, J AM SOC NEPHROL, V28, P1239, DOI 10.1681/ASN.2016040401; Roberts MA, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0391-7; Scialla JJ, 2014, J AM SOC NEPHROL, V25, P349, DOI 10.1681/ASN.2013050465; Singh S, 2016, KIDNEY INT, V90, P985, DOI 10.1016/j.kint.2016.05.019; Takeda Y, 2011, AM J NEPHROL, V33, P421, DOI 10.1159/000327019; Urena-Torres P, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-71; Vaziri ND, 2016, SEMIN NEPHROL, V36, P112, DOI 10.1016/j.semnephrol.2016.02.005; Wolf M, 2013, J BONE MINER RES, V28, P1793, DOI 10.1002/jbmr.1923; Wolf M, 2010, J AM SOC NEPHROL, V21, P1427, DOI 10.1681/ASN.2009121293; Yokoyama K, 2014, CLIN J AM SOC NEPHRO, V9, P543, DOI 10.2215/CJN.05170513	33	13	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2017	12	5							e0176984	10.1371/journal.pone.0176984	http://dx.doi.org/10.1371/journal.pone.0176984			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9SX	28475601	Green Published, Green Submitted, gold			2023-01-03	WOS:000400649500034
J	Chen, L; Michalsen, A				Chen, Lucy; Michalsen, Andreas			Management of chronic pain using complementary and integrative medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-BACK-PAIN; RANDOMIZED-CONTROLLED-TRIAL; CHRONIC NECK PAIN; ALEXANDER TECHNIQUE LESSONS; SHAM LASER ACUPUNCTURE; BEE VENOM ACUPUNCTURE; WILFORDII HOOK F; RHEUMATOID-ARTHRITIS; STRESS REDUCTION; DOUBLE-BLIND	Complementary and integrative medicine (CIM) encompasses both Western-style medicine and complementary health approaches as a new combined approach to treat a variety of clinical conditions. Chronic pain is the leading indication for use of CIM, and about 33% of adults and 12% of children in the US have used it in this context. Although advances have been made in treatments for chronic pain, it remains inadequately controlled for many people. Adverse effects and complications of analgesic drugs, such as addiction, kidney failure, and gastrointestinal bleeding, also limit their use. CIM offers a multimodality treatment approach that can tackle the multidimensional nature of pain with fewer or no serious adverse effects. This review focuses on the use of CIM in three conditions with a high incidence of chronic pain: back pain, neck pain, and rheumatoid arthritis. It summarizes research on the mechanisms of action and clinical studies on the efficacy of commonly used CIM modalities such as acupuncture, mind-body system, dietary interventions and fasting, and herbal medicine and nutrients.	[Chen, Lucy] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, MGH Ctr Translat Pain Res, Pain Management Ctr MGH, Boston, MA 02114 USA; [Chen, Lucy] Harvard Med Sch, Boston, MA 02115 USA; [Michalsen, Andreas] Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Michalsen, Andreas] Immanuel Hosp Berlin, Berlin, Germany; [Michalsen, Andreas] Charite Univ Med Berlin, Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Chen, L (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, MGH Ctr Translat Pain Res, Pain Management Ctr MGH, Boston, MA 02114 USA.; Chen, L (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	llchen@mgh.harvard.edu						Ahmed S, 2005, EVID-BASED COMPL ALT, V2, P301, DOI 10.1093/ecam/neh117; Ai Zhou, 2005, Zhongguo Zhen Jiu, V25, P531; Al Bedah AMN, 2016, J ALTERN COMPLEM MED, V22, P768, DOI 10.1089/acm.2016.0193; Alwhaibi M, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/2067095; Astin JA, 2003, J AM BOARD FAM PRACT, V16, P131, DOI 10.3122/jabfm.16.2.131; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Ben Hui, 2009, Zhen Ci Yan Jiu, V34, P383; Benson H, 1997, SCIENCE, V278, P1694; Berman BM, 2000, RHEUM DIS CLIN N AM, V26, P103, DOI 10.1016/S0889-857X(05)70124-1; Bernateck M, 2008, FORSCH KOMPLEMENTMED, V15, P187, DOI 10.1159/000141929; BHATTSANDERS D, 1985, SEMIN ARTHRITIS RHEU, V14, P225, DOI 10.1016/0049-0172(85)90041-1; Biegert C, 2004, J RHEUMATOL, V31, P2121; Blodt S, 2015, EUR J PAIN, V19, P123, DOI 10.1002/ejp.529; Brady SRE, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003368; Breuer GS, 2005, CLIN EXP RHEUMATOL, V23, P693; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; Calder PC, 2011, EUR J PHARMACOL, V668, pS50, DOI 10.1016/j.ejphar.2011.05.085; Cameron M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002948.pub2; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; Casimiro L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003788.pub2; Casimiro L, 2002, COCHRANE DB SYST REV; Centers for Disease Control and Prevention, 2017, TABL SUMM HLTH STAT; Chae Y, 2010, NEUROL RES, V32, pS64, DOI 10.1179/016164109X12537002794084; Chandran B, 2012, PHYTOTHER RES, V26, P1719, DOI 10.1002/ptr.4639; Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030; Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012; Chen XY, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0071-9; Chen XY, 2014, SCI REP-UK, V4, DOI 10.1038/srep06482; Chen Xing-hua, 2009, Zhongguo Zhen Jiu, V29, P884; Cherkin DC, 2016, JAMA-J AM MED ASSOC, V315, P1240, DOI 10.1001/jama.2016.2323; Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601; Choi TY, 2011, CLIN RHEUMATOL, V30, P937, DOI 10.1007/s10067-011-1706-5; Chopra A, 2012, CLIN RHEUMATOL, V31, P259, DOI 10.1007/s10067-011-1809-z; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cramer H, 2015, AM J EPIDEMIOL, V182, P281, DOI 10.1093/aje/kwv071; Cramer H, 2013, RHEUMATOLOGY, V52, P2025, DOI 10.1093/rheumatology/ket264; Cramer H, 2013, CLIN J PAIN, V29, P216, DOI 10.1097/AJP.0b013e318251026c; Cramer H, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-162; Cramer H, 2011, FORSCH KOMPLEMENTMED, V18, P327, DOI 10.1159/000335294; Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705; DARLINGTON LG, 1985, ANN RHEUM DIS, V44, P801, DOI 10.1136/ard.44.11.801; DARLINGTON LG, 1986, LANCET, V1, P236; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Duthy B., 2013, BACKGROUND PAPER 6 2; Efthimiou P, 2010, RHEUMATOL INT, V30, P571, DOI 10.1007/s00296-009-1206-y; Egorova N, 2015, NEUROIMAGE-CLIN, V9, P430, DOI 10.1016/j.nicl.2015.09.012; Emerich M, 2014, COMPLEMENT THER MED, V22, P148, DOI 10.1016/j.ctim.2013.12.013; Ernst E, 2011, CURR PAIN HEADACHE R, V15, P431, DOI 10.1007/s11916-011-0227-x; Evans S, 2013, CLIN J PAIN, V29, P988, DOI 10.1097/AJP.0b013e31827da381; Evans S, 2010, J PAIN SYMPTOM MANAG, V39, P904, DOI 10.1016/j.jpainsymman.2009.09.018; Fan De-Hui, 2007, Zhongguo Zhen Jiu, V27, P731; Fanavoll R, 2016, INT J OCCUP MED ENV, V29, P585, DOI 10.13075/ijomeh.1896.00606; Fernandez-Llanio Comella N, 2016, REUMATOL CLIN, V12, P151, DOI 10.1016/j.reuma.2015.10.011; Fogarty FA, 2015, ANN RHEUM DIS, V74, P472, DOI 10.1136/annrheumdis-2014-205946; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; Franca DLM, 2008, COMPLEMENT THER MED, V16, P268, DOI 10.1016/j.ctim.2008.02.006; Fu LM, 2009, J ALTERN COMPLEM MED, V15, P133, DOI 10.1089/acm.2008.0135; Fu LW, 2009, J APPL PHYSIOL, V106, P1800, DOI 10.1152/japplphysiol.91648.2008; Furst DE, 2011, JCR-J CLIN RHEUMATOL, V17, P185, DOI 10.1097/RHU.0b013e31821c0310; Gagnier JJ, 2016, SPINE, V41, P116, DOI 10.1097/BRS.0000000000001310; Gao Yong-Hui, 2009, Zhen Ci Yan Jiu, V34, P376; Giles LG, 2003, SPINE, V28, P1502; Giles LGF, 2003, SPINE, V28, P1490, DOI 10.1097/00007632-200307150-00003; Glazov G, 2014, ACUPUNCT MED, V32, P116, DOI 10.1136/acupmed-2013-010456; Goldbach-Mansky R, 2009, ANN INTERN MED, V151, P229, DOI 10.7326/0003-4819-151-4-200908180-00005; Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020; Grant JA, 2014, ANN NY ACAD SCI, V1307, P55, DOI 10.1111/nyas.12282; Grant JA, 2009, PSYCHOSOM MED, V71, P106, DOI 10.1097/PSY.0b013e31818f52ee; Grazio Simeon, 2003, Reumatizam, V50, P18; Guan Z, 1995, J Tradit Chin Med, V15, P102; Guo H F, 1997, Sheng Li Xue Bao, V49, P121; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Hahm ET, 2004, NEUROIMMUNOMODULAT, V11, P268, DOI 10.1159/000078446; Hall A, 2016, PHYS THER; Hall AM, 2011, ARTHRIT CARE RES, V63, P1576, DOI 10.1002/acr.20594; Hamre HJ, 2007, EUR J MED RES, V12, P302; Hamre Harald J, 2009, J Pain Res, V2, P75; Hamza MA, 1999, ANESTHESIOLOGY, V91, P1622, DOI 10.1097/00000542-199912000-00012; HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205; Han SH, 1999, PHYSIOL BEHAV, V66, P217, DOI 10.1016/S0031-9384(98)00276-5; Hasegawa TM, 2014, ACUPUNCT MED, V32, P109, DOI 10.1136/acupmed-2013-010333; HAUGEN M, 1991, CLIN RHEUMATOL, V10, P401, DOI 10.1007/BF02206660; He D, 2004, PAIN, V109, P299, DOI 10.1016/j.pain.2004.01.018; He Dong, 2005, Acupunct Med, V23, P52; He Wei, 2006, Zhongguo Zhen Jiu, V26, P331; Hoerster KD, 2012, PREV MED, V54, P13, DOI 10.1016/j.ypmed.2011.08.023; Hohmann C, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/753583; Hongwu Yu, 2016, Zhongguo Zhen Jiu, V36, P17; Hou Jing-Guo, 2002, Se Pu, V20, P140; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X; Huether G, 1997, BIOL PSYCHIAT, V41, P1174, DOI 10.1016/S0006-3223(96)00265-X; Hughes JG, 2009, COMPLEMENT THER MED, V17, P269, DOI 10.1016/j.ctim.2009.06.002; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Hunter RF, 2012, CLIN J PAIN, V28, P259, DOI 10.1097/AJP.0b013e3182274018; Hutchinson AJP, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749-799X-7-36; Inoue M, 2012, ACUPUNCT MED, V30, P103, DOI 10.1136/acupmed-2011-010122; International Association for the Study of Pain, 1994, CLASS CHRON PAIN DES; Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574; Jeitler M, 2015, J PAIN, V16, P77, DOI 10.1016/j.jpain.2014.10.009; Ji M, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/192808; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; Kelly RB, 2009, AM FAM PHYSICIAN, V80, P481; Kessler C, 2012, FORSCH KOMPLEMENTMED, V19, P65, DOI 10.1159/000338294; Khalsa SB, 2016, PRINCIPLES PRACTICE; Kim KH, 2013, COMPLEMENT THER MED, V21, P535, DOI 10.1016/j.ctim.2013.08.007; Kim ST, 2009, CLIN EXP RHEUMATOL, V27, P384; KJELDSENKRAGH J, 1991, LANCET, V338, P899, DOI 10.1016/0140-6736(91)91770-U; Konig A, 2003, Z ORTHOP GRENZGEB, V141, P395; Kumar S, 2017, J ALTERN COMPLEM MED, V23, P109, DOI 10.1089/acm.2015.0272; Lam M, 2013, SPINE, V38, P2124, DOI 10.1097/01.brs.0000435025.65564.b7; Lauche R, 2016, J PAIN, V17, P1013, DOI 10.1016/j.jpain.2016.06.004; Lauche R, 2016, CLIN REHABIL, V30, P247, DOI 10.1177/0269215515578699; Lauche R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065378; Lauche R, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-63; Lautenschlager J, 1997, Z RHEUMATOL, V56, P8, DOI 10.1007/s003930050016; Lee C, 2014, PAIN MED, V15, pS21, DOI 10.1111/pme.12383; Lee H, 2008, CLIN RHEUMATOL, V27, P641, DOI 10.1007/s10067-007-0819-3; Lee J, 2014, ANN RHEUM DIS, V73, P1078, DOI 10.1136/annrheumdis-2014-eular.3185; Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070; LEE JH, 1993, PAIN, V52, P11, DOI 10.1016/0304-3959(93)90109-3; Lee MS, 2008, RHEUMATOLOGY, V47, P1747, DOI 10.1093/rheumatology/ken330; Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012; Lee MS, 2011, CHIN J INTEGR MED, V17, P187, DOI 10.1007/s11655-011-0665-7; Lee SH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/402180; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; LEVENTHAL LJ, 1993, ANN INTERN MED, V119, P867, DOI 10.7326/0003-4819-119-9-199311010-00001; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; Liu L, 2015, EVID-BASED COMPL ALT, V2015, DOI [DOI 10.1155/2015/328196, 10.1155/2015/328196]; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Lundqvist LO, 2014, ARCH PHYS MED REHAB, V95, P1656, DOI 10.1016/j.apmr.2014.05.013; Lv QW, 2015, ANN RHEUM DIS, V74, P1078, DOI 10.1136/annrheumdis-2013-204807; Macfarlane GJ, 2012, RHEUMATOLOGY, V51, P1707, DOI 10.1093/rheumatology/kes133; MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747; MacPherson H, 2001, Acupunct Med, V19, P93; MacPherson H, 2017, ACUPUNCTURE CHRONIC; MacPherson H, 2015, ANN INTERN MED, V163, P653, DOI 10.7326/M15-0667; MacPherson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093739; Manek NJ, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-5; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; McDougall J, 2002, J ALTERN COMPLEM MED, V8, P71, DOI 10.1089/107555302753507195; McKellar G, 2007, ANN RHEUM DIS, V66, P1239, DOI 10.1136/ard.2006.065151; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Michalsen A, 2013, FORSCH KOMPLEMENTMED, V20, P444, DOI 10.1159/000357765; Michalsen A, 2012, J PAIN, V13, P1122, DOI 10.1016/j.jpain.2012.08.004; Michalsen A, 2010, CURR PAIN HEADACHE R, V14, P80, DOI 10.1007/s11916-010-0104-z; MOLINA PE, 1995, BIOCHEM BIOPH RES CO, V207, P312, DOI 10.1006/bbrc.1995.1189; Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5; Moudgil KD, 2014, EXPERT REV CLIN IMMU, V10, P819, DOI 10.1586/1744666X.2014.917963; Muller H, 2001, SCAND J RHEUMATOL, V30, P1, DOI 10.1080/030097401750065256; Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002; Nahn RL, 2016, EXPENDITURES COMPLEM; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; National Center for Complementary and Integrative Health, 2016, COMPL ALT INT HLTH W; National Institute for Health and Care Excellence, 2013, LOW BACK PAIN SCIAT; NORDSTROM DCE, 1995, RHEUMATOL INT, V14, P231, DOI 10.1007/BF00262088; Oga EF, 2016, EUR J DRUG METAB PH, V41, P93, DOI 10.1007/s13318-015-0296-z; Orme-Johnson DW, 2006, NEUROREPORT, V17, P1359, DOI 10.1097/01.wnr.0000233094.67289.a8; Ouyang BS, 2011, CHIN J INTEGR MED, V17, P505, DOI 10.1007/s11655-011-0783-2; Ouyang Ba-Si, 2010, Zhongguo Zhen Jiu, V30, P840; Paulson S, 2013, ANN NY ACAD SCI, V1303, P87, DOI 10.1111/nyas.12203; Pradhan EK, 2007, ARTHRIT RHEUM-ARTHR, V57, P1134, DOI 10.1002/art.23010; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Rendant D, 2011, SPINE, V36, P419, DOI 10.1097/BRS.0b013e3181d51fca; Roffey DM, 2011, SPINE J, V11, P197, DOI 10.1016/j.spinee.2011.01.031; Roseen EJ, 2016, PRINCIPLES PRACTICE, P137; Sander O, 1998, Z RHEUMATOL, V57, P11, DOI 10.1007/s003930050051; Sato M, 2009, ANN NUCL MED, V23, P311, DOI 10.1007/s12149-009-0238-4; Schmalzl L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00205; Sharon H, 2016, AM J MED, V129, P755, DOI 10.1016/j.amjmed.2016.03.002; Shen S, 1996, Sheng Li Xue Bao, V48, P89; Shin JS, 2013, PAIN, V154, P1030, DOI 10.1016/j.pain.2013.03.013; SINGH JA, 2016, COCHRANE DB SYST REV, DOI DOI 10.1002/; Singh Vijay Kumar, 2011, Indian J Physiol Pharmacol, V55, P329; Skoglund L, 2011, Complement Ther Clin Pract, V17, P54, DOI 10.1016/j.ctcp.2010.09.003; Skoldstam L, 2003, ANN RHEUM DIS, V62, P208, DOI 10.1136/ard.62.3.208; Smolen JS, 2016, ANN RHEUM DIS, V75, P1268, DOI 10.1136/annrheumdis-2016-209429; Stener-Victorin Elisabet, 2003, Reprod Biol Endocrinol, V1, P33, DOI 10.1186/1477-7827-1-33; Tam Lai-Shan, 2007, BMC Complement Altern Med, V7, P35, DOI 10.1186/1472-6882-7-35; Teut M, 2016, J PAIN, V17, P796, DOI 10.1016/j.jpain.2016.03.003; Tien CH, 2008, JOINT BONE SPINE, V75, P502, DOI 10.1016/j.jbspin.2007.08.010; Trigkilidas D, 2010, ANN ROY COLL SURG, V92, P595, DOI 10.1308/003588410X12699663904196; Trinh K, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD004870.PUB4; Trinh K, 2007, SPINE, V32, P236, DOI 10.1097/01.brs.0000252100.61002.d4; Tulder MW, 2014, COCHRANE DB SYST REV, V12; Urquhart DM, 2014, SPINE, V39, pE962, DOI 10.1097/BRS.0000000000000411; Urruela MA, 2012, CURR RHEUMATOL REP, V14, P589, DOI 10.1007/s11926-012-0295-x; Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; von Trott P, 2009, J PAIN, V10, P501, DOI 10.1016/j.jpain.2008.11.004; Wang CC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1249, DOI 10.1002/art.24009; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang HL, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0110-7; Wang Ruihui, 2007, J Tradit Chin Med, V27, P103; Weiss J, 2013, J ALTERN COMPLEM MED, V19, P935, DOI 10.1089/acm.2012.0338; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007; WHO, 2013, WHO TRADITIONAL MED; Wieland LS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010671.pub2; Willich SN, 2010, PHYTOMEDICINE, V17, P87, DOI 10.1016/j.phymed.2009.09.003; Willich SN, 2006, PAIN, V125, P107, DOI 10.1016/j.pain.2006.06.006; Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Wu WF, 2013, J MUSCULOSKELET PAIN, V21, P37, DOI 10.3109/10582452.2013.763394; XU M, 1990, NEUROSCI LETT, V118, P205, DOI 10.1016/0304-3940(90)90627-L; Xu M, 2013, AM J CHINESE MED, V41, P1, DOI 10.1142/S0192415X13500018; Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yun MD, 2012, J ALTERN COMPLEM MED, V18, P130, DOI 10.1089/acm.2010.0779; Zanette SD, 2008, CLIN RHEUMATOL, V27, P627, DOI 10.1007/s10067-007-0759-y; Zangi HA, 2012, ANN RHEUM DIS, V71, P911, DOI 10.1136/annrheumdis-2011-200351; Zeidan F, 2012, NEUROSCI LETT, V520, P165, DOI 10.1016/j.neulet.2012.03.082; Zeidan F, 2016, ANN NY ACAD SCI, V1373, P114, DOI 10.1111/nyas.13153; Zeidan F, 2015, J NEUROSCI, V35, P15307, DOI 10.1523/JNEUROSCI.2542-15.2015; Zeidan F, 2011, J NEUROSCI, V31, P5540, DOI 10.1523/JNEUROSCI.5791-10.2011; Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943; Zurier RB, 1996, ARTHRITIS RHEUM, V39, P1808, DOI 10.1002/art.1780391106	220	53	55	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2017	357								j1284	10.1136/bmj.j1284	http://dx.doi.org/10.1136/bmj.j1284			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET6XT	28438745				2023-01-03	WOS:000400437500001
J	Hashimoto, Y; Macri, D; Srivastava, I; McPherson, C; Felberbaum, R; Post, P; Cox, M				Hashimoto, Yoshifumi; Macri, Daniel; Srivastava, Indresh; McPherson, Clifton; Felberbaum, Rachael; Post, Penny; Cox, Manon			Complete study demonstrating the absence of rhabdovirus in a distinct Sf9 cell line	PLOS ONE			English	Article							VESICULAR STOMATITIS-VIRUS; SPODOPTERA-FRUGIPERDA; RNA VIRUSES; EVOLUTION; MICROVESICLES; INFECTION; PROTEIN; IDENTIFICATION; HEPATITIS; EXOSOMES	A putative novel rhabdovirus (SfRV) was previously identified in a Spodoptera frugiperda cell line (Sf9 cells [ATCC CRL-1711 lot 58078522]) by next generation sequencing and extensive bioinformatic analysis. We performed an extensive analysis of our Sf9 cell bank (ATCC CRL-1711 lot 5814 [Sf9(L5814)]) to determine whether this virus was already present in cells obtained from ATCC in 1987. Inverse PCR of DNA isolated from Sf9(L5814) cellular DNA revealed integration of SfRV sequences in the cellular genome. RT-PCR of total RNA showed a deletion of 320 nucleotides in the SfRV RNA that includes the transcriptional motifs for genes X and L. Concentrated cell culture supernatant was analyzed by sucrose density gradient centrifugation and revealed a single band at a density of 1.14 g/ml. This fraction was further analysed by electron microscopy and showed amorphous and particulate debris that did not resemble a rhabdovirus in morphology or size. SDS-PAGE analysis confirmed that the protein composition did not contain the typical five rhabdovirus structural proteins and LC-MS/MS analysis revealed primarily of exosomal marker proteins, the SfRV N protein, and truncated forms of SfRV N, P, and G proteins. The SfRV L gene fragment RNA sequence was recovered from the supernatant after ultracentrifugation of the 1.14 g/ml fraction treated with diethyl ether suggesting that the SfRV L gene fragment sequence is not associated with a diethyl ether resistant nucleocapsid. Interestingly, the 1.14 g/ml fraction was able to transfer baculovirus DNA into Sf9(L5814) cells, consistent with the presence of functional exosomes. Our results demonstrate the absence of viral particles in ATCC CRL-1711 lot 5814 Sf9 cells in contrast to a previous study that suggested the presence of infectious rhabdoviral particles in Sf9 cells from a different lot. This study highlights how cell lines with different lineages may present different virosomes and therefore no general conclusions can be drawn across Sf9 cells from different laboratories.	[Hashimoto, Yoshifumi; Macri, Daniel; Srivastava, Indresh; McPherson, Clifton; Felberbaum, Rachael; Post, Penny; Cox, Manon] Prot Sci Corp, Meriden, CT 06450 USA		Hashimoto, Y (corresponding author), Prot Sci Corp, Meriden, CT 06450 USA.	yoshihashimoto@gmail.com			Protein Sciences Corporation (PSC)	Protein Sciences Corporation (PSC)	All authors are (or were at the time the research was conducted) employees of Protein Sciences Corporation (PSC). PSC is the manufacturer of Flublok - an FDA recombinant influenza vaccine manufactured in insect cells. The safety of Flublok is extremely important to not only PSC, but also healthcare authorities. PSC has conducted and continuous to perform extensive research into the cell substrate used to manufacture Flublok and its parent cell line described in this paper. The funder provided support in the form of salaries for all authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aiewsakun P, 2015, VIROLOGY, V479, P26, DOI 10.1016/j.virol.2015.02.011; Assenberg R, 2010, J VIROL, V84, P1089, DOI 10.1128/JVI.01520-09; BLUMBERG BM, 1983, CELL, V32, P559, DOI 10.1016/0092-8674(83)90475-0; Bock JO, 2004, VIROLOGY, V319, P49, DOI 10.1016/j.virol.2003.10.017; BROWN F., 1967, J VIROL, V1, P368; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770; Cocucci E, 2015, TRENDS CELL BIOL, V25, P364, DOI 10.1016/j.tcb.2015.01.004; Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; Cui J, 2012, VIROLOGY, V427, P77, DOI 10.1016/j.virol.2012.02.014; DEZELEE S, 1987, J VIROL, V61, P1391; Dilcher M, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0410-5; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Feng ZD, 2014, ANNU REV VIROL, V1, P539, DOI 10.1146/annurev-virology-031413-085359; Fort P, 2012, MOL BIOL EVOL, V29, P381, DOI 10.1093/molbev/msr226; Holmes EC, 2011, CELL HOST MICROBE, V10, P368, DOI 10.1016/j.chom.2011.09.002; Iwanaga M, 2012, J VIROL METHODS, V179, P316, DOI 10.1016/j.jviromet.2011.11.016; Johnson JB, 2012, J VIROL, V86, P9929, DOI 10.1128/JVI.01154-12; Joubert DA, 2014, J VIROL, V88, P1591, DOI 10.1128/JVI.01812-13; Kakumani PK, 2014, GENOMICS, V104, P134, DOI 10.1016/j.ygeno.2014.06.005; Kato T., 2009, BMC BIOTECHNOL, V9; Katsuma S, 2005, J VIROL, V79, P5577, DOI 10.1128/JVI.79.9.5577-5584.2005; Koppen T, 2011, PROTEOMICS, V11, P4397, DOI 10.1002/pmic.201000774; Layrat C, 1995, PLOS PATHOG, V7; Li C, 2015, ELIFE, V4, DOI [10.7554/eLife.06587, 10.1155/2015/757269]; Li TC, 2007, J VIROL, V81, P10890, DOI 10.1128/JVI.00807-07; Liu SJ, 2014, J GEN VIROL, V95, P2809, DOI 10.1099/vir.0.069765-0; Liu SJ, 2011, VIRUSES-BASEL, V3, P1849, DOI 10.3390/v3101849; Longatti A, 2015, J VIROL, V89, P2956, DOI 10.1128/JVI.02721-14; Lovatt A, 1999, J VIROL METHODS, V82, P185, DOI 10.1016/S0166-0934(99)00111-1; Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820; Lynn Dwight E, 2002, J Insect Sci, V2, P9; Ma HL, 2014, J VIROL, V88, P6576, DOI 10.1128/JVI.00780-14; Maghodia AB, 2016, PROTEIN EXPRES PURIF, V122, P45, DOI 10.1016/j.pep.2016.02.014; McPherson CE, 2008, BIOLOGICALS, V36, P350, DOI 10.1016/j.biologicals.2008.08.001; Meckes DG, 2015, J VIROL, V89, P5200, DOI 10.1128/JVI.02470-14; Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11; Murakami R, 2013, VIRUS RES, V176, P179, DOI 10.1016/j.virusres.2013.06.005; Nadala ECB, 1997, DIS AQUAT ORGAN, V31, P141, DOI 10.3354/dao031141; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Said T, 1998, J GEN VIROL, V79, P47, DOI 10.1099/0022-1317-79-1-47; Sarkar A, 2010, VIROLOGY, V401, P61, DOI 10.1016/j.virol.2010.02.014; Shimizu A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05074; Smith G, 1987, TEXAS AGR EXP STN B, P1555; SUNAGA H, 1960, AM J TROP MED HYG, V9, P419, DOI 10.4269/ajtmh.1960.9.419; van Dongen HM, 2016, MICROBIOL MOL BIOL R, V80, P369, DOI 10.1128/MMBR.00063-15; Vasilakis N, 2014, J GEN VIROL, V95, P787, DOI 10.1099/vir.0.058685-0; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Walker PJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004664; Wilde M, 2013, TNAO38 HIGH 5 SF9 EV	51	7	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2017	12	4							e0175633	10.1371/journal.pone.0175633	http://dx.doi.org/10.1371/journal.pone.0175633			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KK	28423032	Green Submitted, Green Published, gold			2023-01-03	WOS:000399875600038
J	Li, JB; Li, CS; Yuan, W; Wu, JY; Li, J; Li, ZH; Zhao, YZ				Li, Jiebin; Li, Chunsheng; Yuan, Wei; Wu, Junyuan; Li, Jie; Li, Zhenhua; Zhao, Yongzhen			Mild hypothermia alleviates brain oedema and blood-brain barrier disruption by attenuating tight junction and adherens junction breakdown in a swine model of cardiopulmonary resuscitation	PLOS ONE			English	Article							GLOBAL CEREBRAL-ISCHEMIA; HOSPITAL CARDIAC-ARREST; VASCULAR-PERMEABILITY; NEUROLOGICAL FUNCTION; RATS; SURVIVAL; INJURY; NEUROPROTECTION; PATHOGENESIS; EXPRESSION	Mild hypothermia improves survival and neurological recovery after cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). However, the mechanism underlying this phenomenon is not fully elucidated. The aim of this study was to determine whether mild hypothermia alleviates early blood-brain barrier (BBB) disruption. We investigated the effects of mild hypothermia on neurologic outcome, survival rate, brain water content, BBB permeability and changes in tight junctions (TJs) and adherens junctions (AJs) after CA and CPR. Pigs were subjected to 8 min of untreated ventricular fibrillation followed by CPR. Mild hypothermia (33 degrees C) was intravascularly induced and maintained at this temperature for 12 h, followed by active rewarming. Mild hypothermia significantly reduced cortical water content, decreased BBB permeability and attenuated TJ ultrastructural and basement membrane breakdown in brain cortical microvessels. Mild hypothermia also attenuated the CPR-induced decreases in TJ (occludin, claudin-5, ZO-1) and AJ (VE-cadherin) protein and mRNA expression. Furthermore, mild hypothermia decreased the CA-and CPR-induced increases in matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) expression and increased angiogenin-1 (Ang-1) expression. Our findings suggest that mild hypothermia attenuates the CA-and resuscitation-induced early brain oedema and BBB disruption, and this improvement might be at least partially associated with attenuation of the breakdown of TJ and AJ, suppression of MMP-9 and VEGF expression, and upregulation of Ang-1 expression.	[Li, Jiebin; Li, Chunsheng; Yuan, Wei; Wu, Junyuan; Zhao, Yongzhen] Capital Med Univ, Beijing Chaoyang Hosp, Dept Emergency Med, Beijing Key Lab Cardiopul Cerebral Resuscitat, Beijing, Peoples R China; [Li, Jie] Capital Med Univ, Beijing FuXing Hosp, Dept Emergency Med, Beijing, Peoples R China; [Li, Zhenhua] Capital Med Univ, Beijing Friendship Hosp, Dept Emergency Med, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University	Li, CS (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Emergency Med, Beijing Key Lab Cardiopul Cerebral Resuscitat, Beijing, Peoples R China.	lcscyyy@163.com	ZHAO, YUAN/HCI-5831-2022; zhao, YZ/GXH-6401-2022		annual special cultivation and development project for Technology Innovation Base of Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation [Z151100001615056]	annual special cultivation and development project for Technology Innovation Base of Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation	This work was supported by the 2015 annual special cultivation and development project for Technology Innovation Base of Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation (No.Z151100001615056).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Almutairi MMA, 2016, CELL MOL LIFE SCI, V73, P57, DOI 10.1007/s00018-015-2050-8; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Baumann E, 2009, BRAIN RES, V1269, P185, DOI 10.1016/j.brainres.2009.02.062; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; del Zoppo GJ, 2009, CEREBROVASC DIS, V27, P65, DOI 10.1159/000200442; Derwall M, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1050-2; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Geng YJ, 2015, J CEREBR BLOOD F MET, V35, P494, DOI 10.1038/jcbfm.2014.223; Gidday JM, 1997, AM J PHYSIOL-HEART C, V272, pH2622, DOI 10.1152/ajpheart.1997.272.6.H2622; Gong P, 2013, J CEREBR BLOOD F MET, V33, P928, DOI 10.1038/jcbfm.2013.33; Gong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035313; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hang Y, 2012, J MOL NEUROSCI, V46, P236, DOI 10.1007/s12031-011-9584-5; Hsu CH, 2014, CRIT CARE MED, V42, P2575, DOI 10.1097/CCM.0000000000000547; Idris AH, 1996, RESUSCITATION, V33, P69, DOI 10.1016/S0300-9572(96)01055-6; Janata A, 2009, PROG CARDIOVASC DIS, V52, P168, DOI 10.1016/j.pcad.2009.07.001; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Katz LM, 2001, NEUROREPORT, V12, P3751, DOI 10.1097/00001756-200112040-00029; Liu WY, 2012, CNS NEUROSCI THER, V18, P609, DOI 10.1111/j.1755-5949.2012.00340.x; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Miclescu A, 2010, CRIT CARE MED, V38, P2199, DOI 10.1097/CCM.0b013e3181f26b0c; MORIMOTO Y, 1993, CRIT CARE MED, V21, P104, DOI 10.1097/00003246-199301000-00020; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Pichiule P, 1999, MOL BRAIN RES, V74, P83, DOI 10.1016/S0169-328X(99)00261-2; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; PLUTA R, 1994, BRAIN RES, V633, P41, DOI 10.1016/0006-8993(94)91520-2; Preston E, 2004, ACTA NEUROPATHOL, V108, P406, DOI 10.1007/s00401-004-0905-4; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Sawada Norimasa, 2003, Medical Electron Microscopy, V36, P147, DOI 10.1007/s00795-003-0219-y; Schultz Jason, 2011, Resuscitation, V82 Suppl 2, pS35, DOI 10.1016/S0300-9572(11)70149-6; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Sideris G, 2014, RESUSCITATION, V85, P292, DOI 10.1016/j.resuscitation.2013.10.023; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Vorbrodt AW, 2003, BRAIN RES REV, V42, P221, DOI 10.1016/S0165-0173(03)00177-2; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Xiao F, 2002, ACAD EMERG MED, V9, P933, DOI 10.1111/j.1553-2712.2002.tb02196.x; Xiao F, 2002, ACAD EMERG MED, V9, P105, DOI 10.1111/j.1553-2712.2002.tb00224.x; Xu L, 2015, GEOSCIENCE REMOTE SE, V1, P1; Zhang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082677; Zhao H, 2012, RESUSCITATION, V83, P913, DOI 10.1016/j.resuscitation.2012.01.001	54	25	31	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0174596	10.1371/journal.pone.0174596	http://dx.doi.org/10.1371/journal.pone.0174596			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VG	28355299	gold, Green Published, Green Submitted			2023-01-03	WOS:000399174600070
J	Paramsothy, S; Kamm, MA; Kaakoush, NO; Walsh, AJ; van den Bogaerde, J; Samuel, D; Leong, RWL; Connor, S; Ng, W; Paramsothy, R; Xuan, W; Lin, E; Mitchell, HM; Borody, TJ				Paramsothy, Sudarshan; Kamm, Michael A.; Kaakoush, Nadeem O.; Walsh, Alissa J.; van den Bogaerde, Johan; Samuel, Douglas; Leong, Rupert W. L.; Connor, Susan; Ng, Watson; Paramsothy, Ramesh; Xuan, Wei; Lin, Enmoore; Mitchell, Hazel M.; Borody, Thomas J.			Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial	LANCET			English	Article							INFLAMMATORY-BOWEL-DISEASE; DONOR; REMISSION; FROZEN	Background The intestinal microbiota is implicated in the pathogenesis of ulcerative colitis. Faecal microbiota transplantation is a novel form of therapeutic microbial manipulation, but its efficacy in ulcerative colitis is uncertain. We aimed to establish the efficacy of intensive-dosing, multidonor, faecal microbiota transplantation in active ulcerative colitis. Methods We conducted a multicentre, double-blind, randomised, placebo-controlled trial at three hospitals in Australia. We randomly allocated patients with active ulcerative colitis (Mayo score 4-10) in a 1: 1 ratio, using a preestablished randomisation list, to either faecal microbiota transplantation or placebo colonoscopic infusion, followed by enemas 5 days per week for 8 weeks. Patients, treating clinicians, and other study staff were unaware of the assigned treatment. Faecal microbiota transplantation enemas were each derived from between three and seven unrelated donors. The primary outcome was steroid-free clinical remission with endoscopic remission or response (Mayo score <= 2, all subscores <= 1, and <= 1 point reduction in endoscopy subscore) at week 8. Analysis was by modified intention-to-treat and included all patients receiving one study dose. We performed 16S rRNA stool analysis to assess associated microbial changes. This trial is registered with ClinicalTrials.gov, number NCT01896635. The trial has ended; this report presents the final analysis. Findings From November, 2013, to May, 2015, 85 patients were enrolled to our trial, of whom 42 were randomly assigned faecal microbiota transplantation and 43 were allocated placebo. One patient assigned faecal microbiota transplantation and three allocated placebo did not receive study treatment and were excluded from the analysis. The primary outcome was achieved in 11 (27%) of 41 patients allocated faecal microbiota transplantation versus three (8%) of 40 who were assigned placebo (risk ratio 3.6, 95% CI 1.1-11.9; p=0.021). Adverse events were reported by 32 (78%) of 41 patients allocated faecal microbiota transplantation and 33 (83%) of 40 who were assigned placebo; most were self-limiting gastrointestinal complaints, with no significant difference in number or type of adverse events between treatment groups. Serious adverse events occurred in two patients assigned faecal microbiota transplantation and in one allocated placebo. Microbial diversity increased with and persisted after faecal microbiota transplantation. Several bacterial taxa were associated with clinical outcome; in particular, the presence of Fusobacterium spp was associated with lack of remission. Interpretation Intensive-dosing, multidonor, faecal microbiota transplantation induces clinical remission and endoscopic improvement in active ulcerative colitis and is associated with distinct microbial changes that relate to outcome. Faecal microbiota transplantation is, thus, a promising new therapeutic option for ulcerative colitis. Future work should focus on precisely defining the optimum treatment intensity and the role of donor-recipient matching based on microbial profiles.	[Paramsothy, Sudarshan] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Kaakoush, Nadeem O.] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia; [Connor, Susan; Ng, Watson; Xuan, Wei] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Paramsothy, Ramesh; Mitchell, Hazel M.] Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Kamm, Michael A.] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia; [Kamm, Michael A.] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Kamm, Michael A.] Univ Melbourne, Melbourne, Vic, Australia; [Paramsothy, Sudarshan; Walsh, Alissa J.] St Vincents Hosp, Dept Gastroenterol, Sydney, NSW, Australia; [Paramsothy, Sudarshan; van den Bogaerde, Johan] Nambour Gen Hosp, Dept Gastroenterol, Nambour, Qld, Australia; [Paramsothy, Sudarshan; Samuel, Douglas; Leong, Rupert W. L.] Bankstown Lidcombe Hosp, Dept Gastroenterol, Sydney, NSW, Australia; [Connor, Susan; Ng, Watson; Paramsothy, Ramesh] Liverpool Hosp, Dept Gastroenterol, Sydney, NSW, Australia; [Connor, Susan; Xuan, Wei] Ingham Inst, Sydney, NSW, Australia; [Lin, Enmoore; Borody, Thomas J.] Ctr Digest Dis, Sydney, NSW, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; St Vincents Hospital Sydney; Liverpool Hospital; Ingham Institute for Applied Medical Research	Kamm, MA (corresponding author), St Vincents Hosp, Melbourne, Vic 3065, Australia.	mkamm@unimelb.edu.au	Kaakoush, Nadeem/ABG-9499-2020; Connor, Susan/ABF-5155-2020; Paramsothy, Sudarshan/AAN-3096-2020; Leong, Rupert WL/J-7839-2012	Connor, Susan/0000-0001-5606-0270; Leong, Rupert WL/0000-0001-5944-3488; Paramsothy, Sudarshan/0000-0002-9097-6028; Borody, Thomas/0000-0002-0519-4698; Kaakoush, Nadeem Omar/0000-0003-4017-1077; Lin, Enmoore/0000-0002-8584-7627; Walsh, Alissa/0000-0002-8994-1186	Broad Medical Research Program; Gastroenterological Society of Australia; Mount Sinai (New York) SUCCESS fund; University of New South Wales	Broad Medical Research Program; Gastroenterological Society of Australia; Mount Sinai (New York) SUCCESS fund; University of New South Wales	Broad Medical Research Program, Gastroenterological Society of Australia, Mount Sinai (New York) SUCCESS fund, University of New South Wales.	Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Borody TJ, 2014, CURR OPIN GASTROEN, V30, P97, DOI 10.1097/MOG.0000000000000027; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Kump PK, 2013, UNITED EUR GASTRO S1, V1, pA57, DOI DOI 10.1177/2050640613502899]; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Ohkusa T, 2003, GUT, V52, P79, DOI 10.1136/gut.52.1.79; Paramsothy S, 2015, INFLAMM BOWEL DIS, V21, P1600, DOI 10.1097/MIB.0000000000000405; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Sartor RB, 2010, GASTROENTEROLOGY, V139, P1816, DOI 10.1053/j.gastro.2010.10.036; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shanahan F, 2014, GASTROENTEROLOGY, V146, P1554, DOI 10.1053/j.gastro.2014.01.050; Strauss J, 2011, INFLAMM BOWEL DIS, V17, P1971, DOI 10.1002/ibd.21606; Travis SPL, 2012, GUT, V61, P535, DOI 10.1136/gutjnl-2011-300486; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vermeire S, 2016, J CROHNS COLITIS, V10, P387, DOI 10.1093/ecco-jcc/jjv203; Yilmaz P, 2014, NUCLEIC ACIDS RES, V42, pD643, DOI 10.1093/nar/gkt1209; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875	29	654	697	7	125	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2017	389	10075					1218	1228		10.1016/S0140-6736(17)30182-4	http://dx.doi.org/10.1016/S0140-6736(17)30182-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP1KL	28214091				2023-01-03	WOS:000397143700034
J	Ogama, N; Sakurai, T; Nakai, T; Niida, S; Saji, N; Toba, K; Umegaki, H; Kuzuya, M				Ogama, Noriko; Sakurai, Takashi; Nakai, Toshiharu; Niida, Shumpei; Saji, Naoki; Toba, Kenji; Umegaki, Hiroyuki; Kuzuya, Masafumi			Impact of frontal white matter hyperintensity on instrumental activities of daily living in elderly women with Alzheimer disease and amnestic mild cognitive impairment	PLOS ONE			English	Article							GLOBAL FUNCTIONAL DECLINE; DWELLING OLDER-ADULTS; SUBCORTICAL HYPERINTENSITIES; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; DEPRESSIVE SYMPTOMS; LADIS LEUKOARAIOSIS; SUNNYBROOK DEMENTIA; NATIONAL INSTITUTE; EXECUTIVE FUNCTION	Background Instrumental activities of daily living (IADL) start to decline during the progression of amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD). Cognitive and physical decline are involved in the loss of functional independence. However, little is known about AD-related neural change that leads to IADL impairment. The purpose of this study was to clarify the effects of regional white matter hyperintensity (WMH) on IADL impairment in persons with AD and aMCI. Methods The participants were 347 female subjects aged 65-85 years diagnosed with AD (n = 227), aMCI (n = 44) or normal cognition (n = 76). IADL was assessed by the Lawton Index. Cognition, mood and mobility function were evaluated by comprehensive geriatric assessment batteries. WMH and brain atrophy were analyzed with brain magnetic resonance imaging, using an automatic segmentation program. Regional WMH was measured in the frontal, temporal, occipital and parietal lobes. Results Ability to carry out IADL of shopping, food preparation, mode of transportation, responsibility for own medication, and ability to handle finances was obviously impaired in the early stage of AD. Frontal WMH was specifically associated with disability to do shopping and food preparation even after adjusting for several confounders including brain atrophy. Conclusions IADL subcategories were differentially impaired along with cognitive status in persons with AD and aMCI. Frontal WMH was an important predictor of impaired ability to do shopping and food preparation. A preventive strategy for WMH might lead to suppression of IADL disability and slow the progression of AD.	[Ogama, Noriko; Sakurai, Takashi; Saji, Naoki; Toba, Kenji] Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Japan; [Ogama, Noriko; Umegaki, Hiroyuki; Kuzuya, Masafumi] Nagoya Univ, Grad Sch Med, Dept Community Healthcare & Geriatr, Nagoya, Aichi, Japan; [Nakai, Toshiharu] Natl Ctr Geriatr & Gerontol, NeuroImaging & Informat, Obu, Japan; [Niida, Shumpei] Natl Ctr Geriatr & Gerontol, Med Genome Ctr, Obu, Japan	National Center for Geriatrics & Gerontology; Nagoya University; National Center for Geriatrics & Gerontology; National Center for Geriatrics & Gerontology	Sakurai, T (corresponding author), Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Japan.	tsakurai@ncgg.go.jp			National Center for Geriatrics and Gerontology [25-6, 27-21, 28-15]; Japanese Society for the Promotion of Science [26870765]	National Center for Geriatrics and Gerontology; Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	T.S discloses a research grant from Research Funding of Longevity Sciences (25-6, 27-21) from National Center for Geriatrics and Gerontology (http://www.ncgg.go.jp/ncgg-kenkyu/index.html). N.S discloses a research grant from Research Funding of Longevity Sciences (28-15) from the National Center for Geriatrics and Gerontology (http://www.ncgg.go.jp/ncgg-kenkyu/index.html), and Grants-in-Aid for Scientific Research (B) (No. 26870765) from the Japanese Society for the Promotion of Science (https://www.jsps.go.jp/j-grantsinaid/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Admiraal-Behloul F, 2005, NEUROIMAGE, V28, P607, DOI 10.1016/j.neuroimage.2005.06.061; Akisaki T, 2006, DIABETES-METAB RES, V22, P376, DOI 10.1002/dmrr.632; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Albert SM, 2015, J GERONTOL A-BIOL, V70, P71, DOI 10.1093/gerona/glu088; Artaud F, 2015, J AM GERIATR SOC, V63, P1129, DOI 10.1111/jgs.13442; Behl P, 2007, ARCH NEUROL-CHICAGO, V64, P266, DOI 10.1001/archneur.64.2.266; Brown PJ, 2011, ARCH GEN PSYCHIAT, V68, P617, DOI 10.1001/archgenpsychiatry.2011.57; Burton CL, 2006, CLIN NEUROPSYCHOL, V20, P432, DOI 10.1080/13854040590967063; Cahn-Weiner DA, 2007, J INT NEUROPSYCH SOC, V13, P747, DOI 10.1017/S1355617707070853; DeCarli C, 2005, STROKE, V36, P50, DOI 10.1161/01.STR.0000150668.58689.f2; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gao FQ, 2011, J ALZHEIMERS DIS, V26, P379, DOI 10.3233/JAD-2011-0058; Gobbens Robbert J J, 2014, Curr Gerontol Geriatr Res, V2014, P358137, DOI 10.1155/2014/358137; Gobbens RJJ, 2012, GERONTOLOGIST, V52, P619, DOI 10.1093/geront/gnr135; Hanyu H, 1999, EUR J NEUROL, V6, P195, DOI 10.1111/j.1468-1331.1999.tb00013.x; Honda Y, 2015, GERIATR GERONTOL INT, V15, P43, DOI 10.1111/ggi.12672; Hybels CF, 2009, PSYCHOL MED, V39, P1677, DOI 10.1017/S0033291709005650; Inzitari D, 2007, ARCH INTERN MED, V167, P81, DOI 10.1001/archinte.167.1.81; Inzitari D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2477; Kamiya M, 2014, GERIATR GERONTOL INT, V14, P45, DOI 10.1111/ggi.12260; Kim HJ, 2013, J ALZHEIMERS DIS, V35, P129, DOI 10.3233/JAD-122320; Kondo N, 2008, PREV MED, V46, P457, DOI 10.1016/j.ypmed.2007.12.007; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee JJ, 2015, PSYCHIAT INVEST, V12, P516, DOI 10.4306/pi.2015.12.4.516; MAHONEY F I, 1965, Md State Med J, V14, P61; Marshall GA, 2011, ALZHEIMERS DEMENT, V7, P300, DOI 10.1016/j.jalz.2010.04.005; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; McNeely AA, 2015, J ALZHEIMERS DIS, V43, P785, DOI 10.3233/JAD-140588; Moon SY, 2011, EUR NEUROL, V65, P223, DOI 10.1159/000318161; Nyunt MSZ, 2012, INT PSYCHOGERIATR, V24, P1633, DOI 10.1017/S1041610212000890; Ogama N, 2016, GERIATR GERONTOL INT, V16, P167, DOI 10.1111/ggi.12447; Ogama N, 2015, GERIATR GERONTOL INT, V15, P83, DOI 10.1111/ggi.12664; Ogama N, 2014, J AM MED DIR ASSOC, V15, P36, DOI 10.1016/j.jamda.2013.11.004; Okochi J., 2006, Geriatrics and Gerontology International, V6, P223, DOI 10.1111/j.1447-0594.2006.00352.x; Otsuka Y, 2012, AM J NEURORADIOL, V33, P726, DOI 10.3174/ajnr.A2853; Pantoni L, 2006, J AM GERIATR SOC, V54, P1095, DOI 10.1111/j.1532-5415.2006.00798.x; Ramirez J, 2016, FRONT AGING NEUROSCI, V8, DOI [10.3389/fnagi.2010.00062, 10.3389/fnagi.2016.00062]; Ramirez J, 2016, ALZHEIMERS DEMENT, V12, P203, DOI 10.1016/j.jalz.2015.06.1886; Roy K, 2014, J ALZHEIMERS DIS, V42, P291, DOI 10.3233/JAD-131796; Royall DR, 2007, J NEUROPSYCH CLIN N, V19, P249, DOI 10.1176/appi.neuropsych.19.3.249; Sahin A, 2015, TURK J MED SCI, V45, P1353, DOI 10.3906/sag-1406-132; Saji N, 2015, GERIATR GERONTOL INT, V15, P17, DOI 10.1111/ggi.12673; Sakurai T, 2015, GERIATR GERONTOL INT, V15, P1, DOI 10.1111/ggi.12714; Schmidt R, 2011, ACTA NEUROPATHOL, V122, P171, DOI 10.1007/s00401-011-0851-x; Seidel D, 2011, AGE AGEING, V40, P463, DOI 10.1093/ageing/afr054; Song HJ, 2014, J NUTR HEALTH AGING, V18, P765, DOI 10.1007/s12603-014-0452-1; Sugimoto T, 2016, CURR ALZHEIMER RES, V13, P718, DOI 10.2174/1567205013666160211124828; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Tomaszewski S, 2009, CLIN NEUROPSYCHOL, V23, P446, DOI 10.1080/13854040802360558; Tomimoto H, 2015, GERIATR GERONTOL INT, V15, P3, DOI 10.1111/ggi.12661; Vidoni ED, 2010, J ALZHEIMERS DIS, V19, P517, DOI 10.3233/JAD-2010-1245; Yoon B, 2014, J STROKE CEREBROVASC, V23, pE365, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.040; Yoon B, 2013, NEUROL SCI, V34, P715, DOI 10.1007/s10072-012-1120-z; Yoshita M, 2006, NEUROLOGY, V67, P2192, DOI 10.1212/01.wnl.0000249119.95747.1f	55	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2017	12	3							e0172484	10.1371/journal.pone.0172484	http://dx.doi.org/10.1371/journal.pone.0172484			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN4XX	28253275	Green Published, Green Submitted, gold			2023-01-03	WOS:000396011300021
J	Davy, BM; Winett, RA; Savla, J; Marinik, EL; Baugh, ME; Flack, KD; Halliday, TM; Kelleher, SA; Winett, SG; Williams, DM; Boshra, S				Davy, Brenda M.; Winett, Richard A.; Savla, Jyoti; Marinik, Elaina L.; Baugh, Mary Elizabeth; Flack, Kyle D.; Halliday, Tanya M.; Kelleher, Sarah A.; Winett, Sheila G.; Williams, David M.; Boshra, Soheir			Resist diabetes: A randomized clinical trial for resistance training maintenance in adults with prediabetes	PLOS ONE			English	Article							ACTIVITY PROMOTION PROGRAMS; PREVENTION PROGRAM; SELF-REGULATION; INCREASED RISK; COMBINED DIET; OLDER-ADULTS; COMMUNITY; GLUCOSE; INTERVENTION; PARTICIPATION	Objective To determine whether a social cognitive theory (SCT)-based intervention improves resistance training (RT) maintenance and strength, and reduces prediabetes prevalence. Research design and methods Sedentary, overweight/obese (BMI: 25-39.9 kg/m(2)) adults aged 50-69 (N = 170) with prediabetes participated in the 15-month trial. Participants completed a supervised 3-month RT (2x/wk) phase and were randomly assigned (N = 159) to one of two 6-month maintenance conditions: SCT or standard care. Participants continued RT at a self-selected facility. The final 6-month period involved no contact. Assessments occurred at baseline and months 3, 9, and 15. The SCT faded-contact intervention consisted of nine tailored transition (i.e., supervised training to training alone) and nine follow-up sessions. Standard care involved six generic follow-up sessions. Primary outcomes were prevalence of normoglycemia and muscular strength. Results The retention rate was 76%. Four serious adverse events were reported. After 3 months of RT, 34% of participants were no longer prediabetic. This prevalence of normoglycemia was maintained through month 15 (30%), with no group difference. There was an 18% increase in the odds of being normoglycemic for each% increase in fat-free mass. Increases in muscular strength were evident at month 3 and maintained through month 15 (P<0.001), which represented improvements of 21% and 14% for chest and leg press, respectively. Results did not demonstrate a greater reduction in prediabetes prevalence in the SCT condition. Conclusions Resistance training is an effective, maintainable strategy for reducing prediabetes prevalence and increasing muscular strength. Future research which promotes RT initiation and maintenance in clinical and community settings is warranted.	[Davy, Brenda M.; Marinik, Elaina L.; Baugh, Mary Elizabeth; Flack, Kyle D.; Halliday, Tanya M.] Virginia Tech, Dept Human Nutr Foods & Exercise, Blacksburg, VA 24061 USA; [Winett, Richard A.] Virginia Tech, Dept Psychol, Blacksburg, VA USA; [Savla, Jyoti] Virginia Tech, Dept Human Dev, Blacksburg, VA USA; [Kelleher, Sarah A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Winett, Sheila G.] PCR Inc, Blacksburg, VA USA; [Williams, David M.] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA; [Boshra, Soheir] Carilion Clin, Roanoke, VA USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Duke University; Brown University	Davy, BM (corresponding author), Virginia Tech, Dept Human Nutr Foods & Exercise, Blacksburg, VA 24061 USA.	bdavy@vt.edu	Savla, Jyoti/N-6085-2019; Williams, David M/F-8559-2011; Savla, Jyoti/J-7125-2015	Savla, Jyoti/0000-0001-7142-3770; Williams, David M/0000-0003-2335-8673; Savla, Jyoti/0000-0001-7142-3770; Halliday, Tanya/0000-0001-6178-0686; Flack, Kyle/0000-0001-7622-4770; Baugh, Mary Elizabeth/0000-0002-3469-7040	National Institutes of Health [RAW: R01DK082383]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors received funding from the National Institutes of Health (BMD, RAW: R01DK082383).	Ackermann RT, 2015, ANN INTERN MED, V163, P475, DOI 10.7326/M15-1563; Ackermann RT, 2008, AM J PREV MED, V35, P357, DOI 10.1016/j.amepre.2008.06.035; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; American College of Sport Medicine, 2005, ACSMS GUIDELINES EXE; Amundson HA, 2009, DIABETES EDUCATOR, V35, P209, DOI 10.1177/0145721709333269; Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Bray GA, 1999, DIABETES CARE, V22, P623; Centers for Disease Control and Prevention, 2014, NAT DIAB REP EST DAT; Diabetes Prevention Program Research Group, 2012, DIABETES CARE, V35, P723, DOI DOI 10.2337/DC11-1468; Dunstan DW, 2006, DIABETES CARE, V29, P2586, DOI 10.2337/dc06-1310; Eikenberg JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148009; Estabrooks PA, 2008, PATIENT EDUC COUNS, V72, P34, DOI 10.1016/j.pec.2008.01.007; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Halliday TM, 2014, EAT BEHAV, V15, P379, DOI 10.1016/j.eatbeh.2014.04.004; Herman WH, 2016, DIABETES CARE, V39, pS3, DOI 10.2337/dc16-S002; Herman WH, 2013, AM J MANAG CARE, V19, P194; Johannsen NM, 2016, SPORTS MED; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; Kraschnewski JL, 2016, PREV MED, V87, P121, DOI 10.1016/j.ypmed.2016.02.038; Li R, 2015, ANN INTERN MED, V163, P452, DOI 10.7326/M15-0469; Liu CJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002759.pub2; Loustalot F, 2013, RES Q EXERCISE SPORT, V84, P30, DOI 10.1080/02701367.2013.762289; Marinik EL, 2014, CONTEMP CLIN TRIALS, V37, P19, DOI 10.1016/j.cct.2013.11.006; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Nathan DM, 2007, DIABETES CARE, V30, P753, DOI 10.2337/dc07-9920; Payne WR, 2008, DIABETES CARE, V31, P2244, DOI 10.2337/dc08-0152; Perreault L, 2012, LANCET, V379, P2243, DOI 10.1016/S0140-6736(12)60525-X; Peterson MD, 2016, SPORTS MED, V46, P619, DOI 10.1007/s40279-015-0463-z; Pickering Thomas G, 2005, J Clin Hypertens (Greenwich), V7, P102, DOI 10.1111/j.1524-6175.2005.04377.x; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; SHIMOKATA H, 1991, DIABETES, V40, P44, DOI 10.2337/diabetes.40.1.44; Short KR, 2001, INT J SPORT NUTR EXE, V11, pS119, DOI 10.1123/ijsnem.11.s1.s119; Tabak AG, 2012, LANCET, V379, P2279, DOI 10.1016/S0140-6736(12)60283-9; Teychenne M, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0266-5; Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576; Williams DM, 2015, J AGING PHYS ACTIV, V23, P279, DOI 10.1123/japa.2013-0184; Winett RA, 2015, TRANSL BEHAV MED, V5, P149, DOI 10.1007/s13142-015-0304-5; Winett RA, 2014, TRANSL BEHAV MED, V4, P333, DOI 10.1007/s13142-014-0263-2	42	14	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0172610	10.1371/journal.pone.0172610	http://dx.doi.org/10.1371/journal.pone.0172610			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL5SX	28231265	gold, Green Published			2023-01-03	WOS:000394682400060
J	Aslakson, RA; Lorenz, K				Aslakson, Rebecca A.; Lorenz, Karl			Being CAREFuL about improving end-of-life care in hospitals	LANCET			English	Editorial Material							PALLIATIVE CARE		[Aslakson, Rebecca A.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Aslakson, Rebecca A.] Johns Hopkins Sch Med, Kimmel Canc Ctr Johns Hopkins, Palliat Care Program, Baltimore, MD 21287 USA; [Lorenz, Karl] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Lorenz, Karl] Stanford Univ, Div Primary Care & Populat Hlth, Sect Palliat Care, Stanford, CA 94305 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Stanford University; Stanford University	Aslakson, RA (corresponding author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.; Aslakson, RA (corresponding author), Johns Hopkins Sch Med, Kimmel Canc Ctr Johns Hopkins, Palliat Care Program, Baltimore, MD 21287 USA.	raslaks1@jhmi.edu		Aslakson, Rebecca A/0000-0001-7599-0625				Aslakson R, 2014, J PALLIAT MED, V17, P219, DOI 10.1089/jpm.2013.0409; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; Beernaert K, 2017, LANCET; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Casarett D, 2010, J PAIN SYMPTOM MANAG, V40, P801, DOI 10.1016/j.jpainsymman.2010.03.019; Evans N, 2012, J PAIN SYMPTOM MANAG, V43, P261, DOI 10.1016/j.jpainsymman.2011.04.012; Institute of Medicine (IOM), 2014, DYING AM IMPR QUAL H; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Lendon JP, 2015, J PAIN SYMPTOM MANAG, V49, P904, DOI 10.1016/j.jpainsymman.2014.10.018; Neuberger J., 2013, MORE CARE LESS PATHW; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; UK Department of Health, 2015, WHATS IMP ME REV CHO	12	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	2017	390	10090					97	98		10.1016/S0140-6736(17)31325-9	http://dx.doi.org/10.1016/S0140-6736(17)31325-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EZ8LF	28526494				2023-01-03	WOS:000404976600006
J	McLellan, AT				McLellan, A. Thomas			New Department of Veterans Affairs and Department of Defense Guidelines on Pain Management With Opioids: Comment and Concern	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNITED-STATES		[McLellan, A. Thomas] Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall, Philadelphia, PA 19106 USA		McLellan, AT (corresponding author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall, Philadelphia, PA 19106 USA.	tmclellan@tresearch.org						Center for Behavioral Health Statistics and Quality, 2016, RES 2015 NAT SURV DR; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS1; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Stone K, 2016, THE BALANCE     1013; U.S. Department of Health and Human Services (HHS) Office of the Surgeon General, 2016, FAC ADD AM SURG GEN; U.S. Department of Veterans Affairs/U.S. Department of Defense, 2017, VA DOD CLIN PRACT GU	9	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2017	167	1					50	+		10.7326/M17-0814	http://dx.doi.org/10.7326/M17-0814			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ3DW	28554194				2023-01-03	WOS:000404591600011
J	Cohen, BL; Sachar, DB				Cohen, Benjamin L.; Sachar, David B.			Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTI-TNF THERAPY; ACTIVE ULCERATIVE-COLITIS; SEVERE CROHNS-DISEASE; INFLIXIMAB MAINTENANCE THERAPY; PREVENTING POSTOPERATIVE RECURRENCE; NONMELANOMA SKIN CANCERS; EVIDENCE-BASED CONSENSUS; JANUS KINASE INHIBITOR; COMBINATION THERAPY; CLINICAL REMISSION	The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs. New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed.	[Cohen, Benjamin L.; Sachar, David B.] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein Inflammatory Bowel Dis, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cohen, BL (corresponding author), Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein Inflammatory Bowel Dis, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA.	benjamin.cohen@mssm.edu						Afif W, 2010, AM J GASTROENTEROL, V105, P1133, DOI 10.1038/ajg.2010.9; Alunno A, 2015, EXPERT OPIN BIOL TH, V15, P1727, DOI 10.1517/14712598.2015.1084284; Amiot A, 2016, CLIN GASTROENTEROL H, V14, P1593, DOI 10.1016/j.cgh.2016.02.016; Amiot A, 2015, THER ADV GASTROENTER, V8, P66, DOI 10.1177/1756283X14558193; Ananthakrishnan AN, 2016, INFLAMM BOWEL DIS, V22, P880, DOI 10.1097/MIB.0000000000000754; Ananthakrishnan AN, 2015, NAT REV GASTRO HEPAT, V12, P205, DOI 10.1038/nrgastro.2015.34; Araki T, 2014, SURG TODAY, V44, P291, DOI 10.1007/s00595-013-0538-0; Archer TP, 2016, IMMUNOTHERAPY-UK, V8, P495, DOI 10.2217/imt-2015-0031; Arijs I, 2018, GUT, V67, P43, DOI 10.1136/gutjnl-2016-312293; Ariyaratnam J, 2014, AM J GASTROENTEROL, V109, P163, DOI 10.1038/ajg.2013.451; Axelrad J, 2016, CLIN GASTROENTEROL H, V14, P58, DOI 10.1016/j.cgh.2015.07.037; Baert F, 2016, GUT, V65, P1126, DOI 10.1136/gutjnl-2014-307882; Baert F, 2014, CLIN GASTROENTEROL H, V12, P1474, DOI 10.1016/j.cgh.2014.01.033; Balint A, 2016, J CROHNS COLITIS, V10, P26, DOI 10.1093/ecco-jcc/jjv169; Baumgart DC, 2016, ALIMENT PHARM THER, V43, P1090, DOI 10.1111/apt.13594; Beaugerie L, 2013, GASTROENTEROLOGY, V145, P927, DOI 10.1053/j.gastro.2013.09.035; Beaugerie L, 2009, LANCET, V374, P1617, DOI 10.1016/S0140-6736(09)61302-7; Ben-Horin S, 2012, ALIMENT PHARM THER, V35, P714, DOI 10.1111/j.1365-2036.2012.04997.x; Ben-Horin S, 2016, CLIN GASTROENTEROL H, V14, P1685, DOI 10.1016/j.cgh.2016.05.023; Ben-Horin S, 2013, CLIN GASTROENTEROL H, V11, P444, DOI 10.1016/j.cgh.2012.10.020; Benitez JM, 2014, DIGEST DIS, V32, P328, DOI 10.1159/000358132; Benucci M, 2015, BIOL-TARGETS THER, V9, P7, DOI 10.2147/BTT.S69606; Benucci Maurizio, 2013, Open Rheumatol J, V7, P75, DOI 10.2174/1874312901307010075; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Billioud V, 2013, J CROHNS COLITIS, V7, P853, DOI 10.1016/j.crohns.2013.01.014; Billioud V, 2011, AM J GASTROENTEROL, V106, P674, DOI 10.1038/ajg.2011.60; Bond A, 2017, SCAND J GASTROENTERO, V52, P204, DOI 10.1080/00365521.2016.1245777; Bonovas S, 2016, CLIN GASTROENTEROL H, V14, P1385, DOI 10.1016/j.cgh.2016.04.039; Bortlik M, 2016, SCAND J GASTROENTERO, V51, P196, DOI 10.3109/00365521.2015.1079924; Bortlik M, 2013, J CROHNS COLITIS, V7, P736, DOI 10.1016/j.crohns.2012.10.019; Brandse JF, 2015, J CROHNS COLITIS, V9, P973, DOI 10.1093/ecco-jcc/jjv116; Brooks AJ, 2015, J CROHNS COLITIS, DOI [10.1016/j.crohns.2014.09.007., DOI 10.1016/J.CROHNS.2014.09.007]; Bryant RV, 2015, SCAND J GASTROENTERO, V50, P90, DOI 10.3109/00365521.2014.968864; Buisson A, 2012, ALIMENT PHARM THER, V35, P625, DOI 10.1111/j.1365-2036.2012.05002.x; Bye WA, 2017, ALIMENT PHARM THER, V46, P3, DOI 10.1111/apt.14075; Cabre E, 2012, WORLD J GASTROENTERO, V18, P3814, DOI 10.3748/wjg.v18.i29.3814; Carbonnel F, 2016, GASTROENTEROLOGY, V150, P380, DOI 10.1053/j.gastro.2015.10.050; Carla-Moreau A, 2015, DIGEST LIVER DIS, V47, P191, DOI 10.1016/j.dld.2014.11.005; Casanova MJ, 2017, AM J GASTROENTEROL, V112, P120, DOI 10.1038/ajg.2016.569; CELLIER C, 1994, GUT, V35, P231, DOI 10.1136/gut.35.2.231; Cesarini M, 2016, EXPERT REV GASTROENT, DOI [10.1080/174741, DOI 10.1080/174741]; Chiu YL, 2013, INFLAMM BOWEL DIS, V19, P1112, DOI 10.1097/MIB.0b013e3182813242; Choi GJ, 2010, J GASTROEN HEPATOL, V25, pA86; Christensen B, 2015, GASTROENTEROLOGY, V148, pS866; Cleynen I, 2016, ANN INTERN MED, V164, P10, DOI 10.7326/M15-0729; Colman RJ, 2015, J CROHNS COLITIS, V9, P312, DOI 10.1093/ecco-jcc/jjv027; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Colombel JF, 2017, GUT, V66, P839, DOI 10.1136/gutjnl-2015-311079; Cornillie F, 2014, GUT, V63, P1721, DOI 10.1136/gutjnl-2012-304094; Cote-Daigneault J, 2015, UNITED EUR GASTROENT, V3, P419, DOI 10.1177/2050640615590302; Cottone M, 2011, CLIN GASTROENTEROL H, V9, P30, DOI 10.1016/j.cgh.2010.09.026; Cross RK, 2015, EXPERT REV GASTROENT, V9, P715, DOI 10.1586/17474124.2015.1039989; D'Haens G, 2016, J CROHNS COLITIS, V10, pS17; D'Haens GR, 2011, AM J GASTROENTEROL, V106, P199, DOI 10.1038/ajg.2010.392; Danese S, 2016, J CROHNS COLITIS, V10, P1362, DOI 10.1093/ecco-jcc/jjw090; De Cruz P, 2015, LANCET, V385, P1406, DOI 10.1016/S0140-6736(14)61908-5; de Suray N, 2012, GASTROENTEROLOGY, V142, pS149; Drobne D, 2015, CLIN GASTROENTEROL H, V13, P514, DOI 10.1016/j.cgh.2014.07.027; Dubinsky MC, 2000, GASTROENTEROLOGY, V118, P705, DOI 10.1016/S0016-5085(00)70140-5; Dulai PS, 2016, AM J GASTROENTEROL, V111, P1147, DOI 10.1038/ajg.2016.236; Dulai PS, 2014, GUT, V63, P1843, DOI 10.1136/gutjnl-2014-307126; Duron C, 2015, EUR J GASTROEN HEPAT, V27, P705, DOI 10.1097/MEG.0000000000000354; Ebbers HC, 2016, BIODRUGS, V30, P1, DOI 10.1007/s40259-015-0154-1; Ellinghaus D, 2015, SCAND J GASTROENTERO, V50, P13, DOI 10.3109/00365521.2014.990507; Engel T, 2016, THER ADV CHRONIC DIS, V7, P208, DOI 10.1177/2040622316653306; Essat M, 2016, PHARMACOECONOMICS, V34, P245, DOI 10.1007/s40273-015-0334-3; Farraye FA, 2017, AM J GASTROENTEROL, V112, P241, DOI 10.1038/ajg.2016.537; Feagan BG, 2014, GASTROENTEROLOGY, V146, P681, DOI 10.1053/j.gastro.2013.11.024; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Feagan BG, 2008, CLIN GASTROENTEROL H, V6, P1370, DOI 10.1016/j.cgh.2008.06.007; Fernandes C, 2015, IMMUNOTHERAPY-UK, V7, P175, DOI 10.2217/imt.14.105; Ferrante M, 2015, J CROHNS COLITIS, V9, P617, DOI 10.1093/ecco-jcc/jjv076; Feuerstein JD, 2014, GASTROENTEROL CLIN N, V43, P543, DOI 10.1016/j.gtc.2014.05.002; Filippi J, 2015, J CROHNS COLITIS, V9, P252, DOI 10.1093/ecco-jcc/jjv001; Fiorino G, 2014, AUTOIMMUN REV, V13, P15, DOI 10.1016/j.autrev.2013.06.005; Fischer M, 2014, GASTROENTEROLOGY, V146, pS450; Ford AC, 2011, AM J GASTROENTEROL, V106, P644, DOI 10.1038/ajg.2011.73; Fornaro R, 2015, SURG-J R COLL SURG E, V13, P330, DOI 10.1016/j.surge.2015.04.002; Fumery M, 2017, AM J GASTROENTEROL, V112, P337, DOI 10.1038/ajg.2016.541; Garcia-Doval I, 2017, BRIT J DERMATOL, V176, P643, DOI 10.1111/bjd.14776; Ghazi LJ, 2013, INFLAMM BOWEL DIS, V19, P1397, DOI 10.1097/MIB.0b013e318281337d; Gibson DJ, 2015, CLIN GASTROENTEROL H, V13, P330, DOI 10.1016/j.cgh.2014.07.041; Gils A, 2014, THER DRUG MONIT, V36, P669, DOI 10.1097/FTD.0000000000000074; Gionchetti P, 2017, J CROHNS COLITIS, V11, P135, DOI 10.1093/ecco-jcc/jjw169; Gisbert JP, 2015, ALIMENT PHARM THER, V42, P391, DOI 10.1111/apt.13276; Gisbert JP, 2016, AM J GASTROENTEROL, V111, P632, DOI 10.1038/ajg.2016.54; Gisbert JP, 2009, AM J GASTROENTEROL, V104, P760, DOI 10.1038/ajg.2008.88; Gomollon F, 2017, J CROHNS COLITIS, V11, P3, DOI 10.1093/ecco-jcc/jjw168; Guerra I, 2016, INFLAMM BOWEL DIS, V22, P894, DOI 10.1097/MIB.0000000000000757; Hahn L, 2015, AM J HEALTH-SYST PH, V72, P1271, DOI 10.2146/ajhp140449; Han YM, 2016, J GASTROEN HEPATOL, V31, P1436, DOI 10.1111/jgh.13310; Hanauer SB, 2003, BEST PRACT RES CL GA, V17, P131, DOI 10.1053/bega.2003.0361; Hansen T, 2016, EXPERT REV GASTROENT, V10, P989, DOI 10.1080/17474124.2016.1215912; Harbord M, 2017, J CROHNS COLITIS, V11, P769, DOI 10.1093/ecco-jcc/jjx009; Hellstrom AE, 2016, SCAND J GASTROENTERO, V51, P563, DOI 10.3109/00365521.2015.1125524; Herfarth HH, 2016, INFLAMM BOWEL DIS, V22, P224, DOI 10.1097/MIB.0000000000000589; Herfarth HH, 2015, CLIN GASTROENTEROL H, V13, P336, DOI 10.1016/j.cgh.2014.09.045; Hirten R, 2015, AM J GASTROENTEROL, V110, P1737, DOI 10.1038/ajg.2015.355; Hordonneau C, 2014, AM J GASTROENTEROL, V109, P89, DOI 10.1038/ajg.2013.385; Jahnsen Jorgen, 2015, Expert Rev Gastroenterol Hepatol, V9 Suppl 1, P45, DOI 10.1586/17474124.2015.1091308; Jarnerot G, 2005, GASTROENTEROLOGY, V128, P1805, DOI 10.1053/j.gastro.2005.03.003; Jelsness-Jorgensen LP, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/492034; Jha A, 2015, ADV THER, V32, P742, DOI 10.1007/s12325-015-0233-1; Jones JL, 2015, CLIN GASTROENTEROL H, V13, P2233, DOI 10.1016/j.cgh.2015.06.034; Kamm MA, 2014, J CROHNS COLITIS, V8, pS13, DOI 10.1016/S1873-9946(14)60024-6; Kaplan GG, 2015, WORLD J GASTROENTERO, V21, P1251, DOI 10.3748/wjg.v21.i4.1251; Kappelman MD, 2008, GASTROENTEROLOGY, V135, P1907, DOI 10.1053/j.gastro.2008.09.012; Karmiris K, 2009, GASTROENTEROLOGY, V137, P1628, DOI 10.1053/j.gastro.2009.07.062; Karoui S, 2013, Tunis Med, V91, P230; Khan N, 2013, GASTROENTEROLOGY, V145, P1007, DOI 10.1053/j.gastro.2013.07.035; Khanna R, 2015, ALIMENT PHARM THER, V41, P77, DOI 10.1111/apt.13001; Khanna R, 2015, LANCET, V386, P1825, DOI 10.1016/S0140-6736(15)00068-9; Kirchgesner J, 2016, ALIMENT PHARM THER, V43, P838, DOI 10.1111/apt.13563; Kopylov U, 2016, THER ADV GASTROENTER, V9, P513, DOI 10.1177/1756283X16638833; Kopylov U, 2012, INFLAMM BOWEL DIS, V18, P2404, DOI 10.1002/ibd.22954; Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727; Kotlyar DS, 2011, CLIN GASTROENTEROL H, V9, P36, DOI 10.1016/j.cgh.2010.09.016; Kotze PG, 2018, CURR DRUG TARGETS, V19, P729, DOI 10.2174/1389450116666151102094922; Kotze PG, 2015, J CROHNS COLITIS, V9, P541, DOI 10.1093/ecco-jcc/jjv055; Kovacs M, 2014, WORLD J GASTROENTERO, V20, P4873, DOI 10.3748/wjg.v20.i17.4873; Kurnik D, 2003, ALIMENT PHARM THER, V18, P57, DOI 10.1046/j.1365-2036.2003.01614.x; Laharie D, 2012, LANCET, V380, P1909, DOI 10.1016/S0140-6736(12)61084-8; Lau C, 2015, ANN SURG, V261, P487, DOI 10.1097/SLA.0000000000000757; LeBlanc K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008655.pub3; Lee YM, 2015, J PEDIATR GASTR NUTR, V60, P737, DOI 10.1097/MPG.0000000000000711; Lewis JD, 2011, GASTROENTEROLOGY, V140, P1817, DOI 10.1053/j.gastro.2010.11.058; LINDBERG E, 1992, GUT, V33, P779, DOI 10.1136/gut.33.6.779; Lobaton T, 2015, ALIMENT PHARM THER, V42, P441, DOI 10.1111/apt.13294; Loftus Edward V Jr, 2016, Gastroenterol Hepatol (N Y), V12, P704; Lopez A, 2015, DIGEST LIVER DIS, V47, P356, DOI 10.1016/j.dld.2015.01.148; Louis E, 2012, GASTROENTEROLOGY, V142, P63, DOI 10.1053/j.gastro.2011.09.034; Ma C, 2017, ALIMENT PHARM THER, V45, P1232, DOI 10.1111/apt.14016; Ma C, 2016, INFLAMM BOWEL DIS, V22, P870, DOI 10.1097/MIB.0000000000000679; Ma C, 2015, J CLIN GASTROENTEROL, V49, P675, DOI 10.1097/MCG.0000000000000265; Mahadevan U, 2014, GASTROENTEROLOGY, V146, pS1; Malkonen T, 2014, INFLAMM BOWEL DIS, V20, P1309, DOI 10.1097/MIB.0000000000000088; Mantzaris GJ, 2016, DIGEST DIS, V34, P132, DOI 10.1159/000443128; Marchetti M, 2013, EUR J HEALTH ECON, V14, P853, DOI 10.1007/s10198-012-0430-7; McConnell RA, 2016, INFLAMM BOWEL DIS, V22, P213, DOI 10.1097/MIB.0000000000000596; McGovern DPB, 2015, GASTROENTEROLOGY, V149, P1163, DOI 10.1053/j.gastro.2015.08.001; McLean LP, 2016, EXPERT OPIN INV DRUG, V25, P263, DOI 10.1517/13543784.2016.1148137; Mei WQ, 2015, WORLD J GASTROENTERO, V21, P6044, DOI 10.3748/wjg.v21.i19.6044; Molander P, 2015, J CROHNS COLITIS, V9, P33, DOI 10.1016/j.crohns.2014.06.012; Molnar T, 2013, ALIMENT PHARM THER, V37, P225, DOI 10.1111/apt.12160; Monteleone G, 2015, NEW ENGL J MED, V372, P1104, DOI 10.1056/NEJMoa1407250; Moran GW, 2013, ALIMENT PHARM THER, V38, P1002, DOI 10.1111/apt.12491; Morar PS, 2015, COLORECTAL DIS, V17, pO247, DOI 10.1111/codi.13094; Moss AC, 2008, ALIMENT PHARM THER, V28, P221, DOI 10.1111/j.1365-2036.2008.03734.x; Narula N, 2013, ALIMENT PHARM THER, V37, P1057, DOI 10.1111/apt.12313; Ng SW, 2013, EXPERT REV CLIN IMMU, V9, P161, DOI [10.1586/eci.12.103, 10.1586/ECI.12.103]; Olbjorn C, 2014, SCAND J GASTROENTERO, V49, P1425, DOI 10.3109/00365521.2014.966316; Onali S, 2016, DIGEST LIVER DIS, V48, P489, DOI 10.1016/j.dld.2016.01.009; Ong DEH, 2013, J GASTROEN HEPATOL, V28, P1595, DOI 10.1111/jgh.12263; Oren R, 1996, GASTROENTEROLOGY, V110, P1416, DOI 10.1053/gast.1996.v110.pm8613046; Oussalah A, 2010, AM J GASTROENTEROL, V105, P1142, DOI 10.1038/ajg.2010.158; Panaccione R, 2015, INFLAMM BOWEL DIS, V21, P1329, DOI 10.1097/MIB.0000000000000366; Panaccione R, 2014, GASTROENTEROLOGY, V146, P392, DOI 10.1053/j.gastro.2013.10.052; Papamichael K, 2016, CLIN GASTROENTEROL H, V14, P543, DOI 10.1016/j.cgh.2015.11.014; Papamichael K, 2015, J CROHNS COLITIS, V9, P589, DOI 10.1093/ecco-jcc/jjv062; Papamichael K, 2015, CLIN GASTROENTEROL H, V13, P1103, DOI 10.1016/j.cgh.2014.11.026; Papay P, 2013, J CROHNS COLITIS, V7, P653, DOI 10.1016/j.crohns.2013.02.005; Papp M, 2014, CURR OPIN GASTROEN, V30, P359, DOI 10.1097/MOG.0000000000000076; Pariente B, 2015, GASTROENTEROLOGY, V148, P52, DOI 10.1053/j.gastro.2014.09.015; Parikh A, 2013, INFLAMM BOWEL DIS, V19, P1691, DOI 10.1097/MIB.0b013e318281f538; Park DI, 2016, INTEST RES, V14, P15, DOI 10.5217/ir.2016.14.1.15; Peyrin-Biroulet L, 2015, AM J GASTROENTEROL, V110, P1324, DOI 10.1038/ajg.2015.233; Peyrin-Biroulet L, 2011, GASTROENTEROLOGY, V141, P1621, DOI 10.1053/j.gastro.2011.06.050; Poturoglu Sule, 2016, World J Gastrointest Pharmacol Ther, V7, P490; Raaschou P, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i262; Rafia R, 2016, PHARMACOECONOMICS, V34, P1241, DOI 10.1007/s40273-016-0436-6; Regueiro M, 2014, CLIN GASTROENTEROL H, V12, P1494, DOI 10.1016/j.cgh.2013.12.035; Regueiro M, 2011, INFLAMM BOWEL DIS, V17, P118, DOI 10.1002/ibd.21355; Regueiro M, 2009, GASTROENTEROLOGY, V136, P441, DOI 10.1053/j.gastro.2008.10.051; Reinink AR, 2016, INFLAMM BOWEL DIS, V22, P1859, DOI 10.1097/MIB.0000000000000816; Reinisch Walter, 2015, Expert Rev Gastroenterol Hepatol, V9 Suppl 1, P17, DOI 10.1586/17474124.2015.1091306; Reinisch W, 2015, GASTROENTEROLOGY, V148, pS1193, DOI 10.1053/j.gastro.2015.08.023; Rogler G, 2013, DIGEST DIS, V31, P83, DOI 10.1159/000347190; Rosen MJ, 2015, ALIMENT PHARM THER, V41, P1094, DOI 10.1111/apt.13175; Rubin DT, 2012, INFLAMM BOWEL DIS, V18, P2225, DOI 10.1002/ibd.22925; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sachar DB, 2014, INFLAMM BOWEL DIS, V20, P2511, DOI 10.1097/MIB.0000000000000135; Sachar David B, 2013, Curr Gastroenterol Rep, V15, P298, DOI 10.1007/s11894-012-0298-9; Sachar DB, 2002, GUT, V51, P764, DOI 10.1136/gut.51.6.764; Sakuraba A, 2015, DIGESTION, V91, P233, DOI 10.1159/000375302; Sandborn WJ, 2016, J CROHNS COLITIS, V10, pS15; Sandborn WJ, 2007, ANN INTERN MED, V146, P829, DOI 10.7326/0003-4819-146-12-200706190-00159; Sandborn WJ, 2009, GASTROENTEROLOGY, V137, P1250, DOI 10.1053/j.gastro.2009.06.061; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Sandborn WJ, 2016, CURR MED RES OPIN, V32, P1233, DOI 10.1185/03007995.2016.1168290; Sandborn WJ, 2016, NEW ENGL J MED, V374, P1754, DOI 10.1056/NEJMoa1513248; Sandborn WJ, 2014, J CROHNS COLITIS, V8, P927, DOI 10.1016/j.crohns.2014.02.021; Sandborn WJ, 2014, CLIN GASTROENTEROL H, V12, P1485, DOI 10.1016/j.cgh.2014.01.029; Sandborn WJ, 2014, GASTROENTEROLOGY, V146, P96, DOI 10.1053/j.gastro.2013.06.010; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168; Sandborn WJ, 2010, CLIN GASTROENTEROL H, V8, P688, DOI 10.1016/j.cgh.2010.04.021; Sandborn WJ, 2009, GASTROENTEROLOGY, V136, pA520, DOI 10.1053/j.gastro.2009.06.061; Sands BE, 2005, INFLAMM BOWEL DIS, V11, P133, DOI 10.1097/00054725-200502000-00006; Sands BE, 2001, INFLAMM BOWEL DIS, V7, P83, DOI 10.1097/00054725-200105000-00001; Sands BE, 2007, INFLAMM BOWEL DIS, V13, P2, DOI 10.1002/ibd.20014; Sands BE, 2015, GASTROENTEROLOGY, V149, P1275, DOI 10.1053/j.gastro.2015.07.003; Sands BE, 2014, GASTROENTEROLOGY, V147, P618, DOI 10.1053/j.gastro.2014.05.008; Sartor RB, 2015, CLIN GASTROENTEROL H, V13, P936, DOI 10.1016/j.cgh.2014.12.027; Savarino E, 2013, AM J GASTROENTEROL, V108, P1731, DOI 10.1038/ajg.2013.287; Schreiber S, 2013, J CROHNS COLITIS, V7, P213, DOI 10.1016/j.crohns.2012.05.015; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Schulze K, 2016, BIOLOGICALS, V44, P463, DOI 10.1016/j.biologicals.2016.06.011; Scott FI, 2016, JAMA DERMATOL, V152, P164, DOI 10.1001/jamadermatol.2015.3029; Selvaggi F, 2014, INFLAMM BOWEL DIS, V20, P1296, DOI 10.1097/MIB.0000000000000026; Seow CH, 2010, GUT, V59, P49, DOI 10.1136/gut.2009.183095; Seror R, 2017, RHEUM DIS CLIN N AM, V43, P43, DOI 10.1016/j.rdc.2016.09.006; Setshedi M, 2012, J GASTROEN HEPATOL, V27, P385, DOI 10.1111/j.1440-1746.2011.06865.x; Shah ED, 2017, INFLAMM BOWEL DIS, V23, P570, DOI 10.1097/MIB.0000000000001049; Sieczkowska J, 2016, J CROHNS COLITIS, V10, P127, DOI 10.1093/ecco-jcc/jjv233; Simon EG, 2016, THER ADV GASTROENTER, V9, P26, DOI 10.1177/1756283X15618130; Singh Namita, 2015, Gastroenterol Hepatol (N Y), V11, P48; Singh S, 2016, CLIN GASTROENTEROL H, V14, P1120, DOI 10.1016/j.cgh.2016.03.038; Singh S, 2015, GASTROENTEROLOGY, V148, P64, DOI 10.1053/j.gastro.2014.09.031; Sjoberg M, 2011, GASTROENTEROLOGY, V140, pS590; Smits LJT, 2016, J CROHNS COLITIS, V10, P1287, DOI 10.1093/ecco-jcc/jjw087; Sokol H, 2009, GASTROENTEROLOGY, V136, pA187; Sorrentino D, 2006, EUR J GASTROEN HEPAT, V18, P457, DOI 10.1097/00042737-200604000-00025; Sostegni R, 2003, ALIMENT PHARM THER, V17, P11, DOI 10.1046/j.1365-2036.17.s2.17.x; Steenholdt C, 2011, ALIMENT PHARM THER, V34, P51, DOI 10.1111/j.1365-2036.2011.04682.x; Steenholdt C, 2016, INFLAMM BOWEL DIS, V22, P1999, DOI 10.1097/MIB.0000000000000772; Steenholdt C, 2016, J CLIN GASTROENTEROL, V50, P483, DOI 10.1097/MCG.0000000000000375; Steenholdt C, 2015, J CROHNS COLITIS, V9, P238, DOI 10.1093/ecco-jcc/jjv004; Steenholdt C, 2014, GUT, V63, P919, DOI 10.1136/gutjnl-2013-305279; Steenholdt C, 2012, INFLAMM BOWEL DIS, V18, P2209, DOI 10.1002/ibd.22910; Thia K, 2011, INFLAMM BOWEL DIS, V17, P105, DOI 10.1002/ibd.21400; Thorlund K, 2015, EXPERT REV GASTROENT, V9, P693, DOI 10.1586/17474124.2015.1024657; Thorlund K, 2014, J CROHNS COLITIS, V8, P571, DOI 10.1016/j.crohns.2014.01.010; Torres J, 2015, GASTROENTEROLOGY, V149, P1, DOI 10.1053/j.gastro.2015.08.055; Torres J, 2012, INFLAMM BOWEL DIS, V18, P1356, DOI 10.1002/ibd.22839; Ungar B, 2017, ALIMENT PHARM THER, V45, P276, DOI 10.1111/apt.13862; Ungar B, 2016, ALIMENT PHARM THER, V43, P1293, DOI 10.1111/apt.13631; Ungar B, 2016, CLIN GASTROENTEROL H, V14, P550, DOI 10.1016/j.cgh.2015.10.025; Ungar B, 2014, GUT, V63, P1258, DOI 10.1136/gutjnl-2013-305259; Van Assche G, 2008, GASTROENTEROLOGY, V134, P1861, DOI 10.1053/j.gastro.2008.03.004; van Schaik T, 2014, INFLAMM BOWEL DIS, V20, P2292, DOI 10.1097/MIB.0000000000000208; Vande Casteele N, 2015, GASTROENTEROLOGY, V148, P1320, DOI 10.1053/j.gastro.2015.02.031; Vande Casteele N, 2013, AM J GASTROENTEROL, V108, P962, DOI 10.1038/ajg.2013.12; Varkas G, 2016, ANN RHEUM DIS, V75, P1423, DOI 10.1136/annrheumdis-2015-208194; Vaughn BP, 2014, WORLD J GASTROENTERO, V20, P1147, DOI 10.3748/wjg.v20.i5.1147; Vaysse T, 2015, J CROHNS COLITIS, V9, P303, DOI 10.1093/ecco-jcc/jjv038; Velayos FS, 2013, CLIN GASTROENTEROL H, V11, P654, DOI 10.1016/j.cgh.2012.12.035; Velayos Fernando S, 2007, Curr Gastroenterol Rep, V9, P521, DOI 10.1007/s11894-007-0069-1; Vermeire S, 2016, J CROHNS COLITIS, V10, pS15; Vermeire S, 2007, GUT, V56, P1226, DOI 10.1136/gut.2006.099978; Vermeire S, 2017, LANCET, V389, P266, DOI 10.1016/S0140-6736(16)32537-5; Ward MG, 2015, WORLD J GASTROENTERO, V21, P11331, DOI 10.3748/wjg.v21.i40.11331; Wenger S, 2012, J CROHNS COLITIS, V6, P21, DOI 10.1016/j.crohns.2011.06.006; Yamamoto T, 2013, COLORECTAL DIS, V15, P1471, DOI 10.1111/codi.12326; Yanai H, 2015, CLIN GASTROENTEROL H, V13, P522, DOI 10.1016/j.cgh.2014.07.029; Yang Z, 2012, ALIMENT PHARM THER, V36, P922, DOI 10.1111/apt.12060; Yarur AJ, 2016, INFLAMM BOWEL DIS, V22, P409, DOI 10.1097/MIB.0000000000000689; Yarur AJ, 2015, CLIN GASTROENTEROL H, V13, P1118, DOI 10.1016/j.cgh.2014.12.026	257	90	93	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2017	357								j2505	10.1136/bmj.j2505	http://dx.doi.org/10.1136/bmj.j2505			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY7YR	28630047	Green Published			2023-01-03	WOS:000404209600001
J	Graham, KL; Dike, O; Doctoroff, L; Jupiter, M; Vanka, A; Davis, RB; Marcantonio, ER				Graham, Kelly L.; Dike, Ogechi; Doctoroff, Lauren; Jupiter, Marisa; Vanka, Anita; Davis, Roger B.; Marcantonio, Edward R.			Preventability of early vs. late readmissions in an academic medical center	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; RETROSPECTIVE COHORT; HEART-FAILURE; HOSPITAL READMISSIONS; 30-DAY READMISSIONS; ASSOCIATION; PNEUMONIA; OUTCOMES; RATES; MORTALITY	Background It is unclear if the 30-day unplanned hospital readmission rate is a plausible accountability metric. Objective Compare preventability of hospital readmissions, between an early period [0-7 days post-discharge] and a late period [8-30 days post-discharge]. Compare causes of readmission, and frequency of markers of clinical instability 24h prior to discharge between early and late readmissions. Design, setting, patients 120 patient readmissions in an academic medical center between 1/1/2009-12/31/2010 Measures Sum-score based on a standard algorithm that assesses preventability of each readmission based on blinded hospitalist review; average causation score for seven types of adverse events; rates of markers of clinical instability within 24h prior to discharge. Results Readmissions were significantly more preventable in the early compared to the late period [median preventability sum score 8.5 vs. 8.0, p = 0.03]. There were significantly more management errors as causative events for the readmission in the early compared to the late period [mean causation score [scale 1-6, 6 most causal] 2.0 vs. 1.5, p = 0.04], and these errors were significantly more preventable in the early compared to the late period [mean preventability score 1.9 vs 1.5, p = 0.03]. Patients readmitted in the early period were significantly more likely to have mental status changes documented 24h prior to hospital discharge than patients readmitted in the late period [12% vs. 0%, p = 0.01]. Conclusions Readmissions occurring in the early period were significantly more preventable. Early read-missions were associated with more management errors, and mental status changes 24h prior to discharge. Seven-day readmissions may be a better accountability measure.	[Graham, Kelly L.; Doctoroff, Lauren; Jupiter, Marisa; Vanka, Anita; Davis, Roger B.; Marcantonio, Edward R.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; [Dike, Ogechi] Univ Texas Dallas, Dept Internal Med, Southwestern Med Ctr, Dallas, TX USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graham, KL (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA.	kgraham@bidmc.harvard.edu	Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging [K24 AG035075, R01 AG030618]; Harvard University	Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging; Harvard University	EM is supported by a Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging (K24 AG035075 and R01 AG030618). This work was also conducted with support from Harvard Catalyst (NIH Award #1UL1 TR001102-01) and financial contributions from Harvard University and its affiliated academic health care centers. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Auerbach AD, 2016, JAMA INTERN MED, V176, P484, DOI 10.1001/jamainternmed.2015.7863; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Dawes AJ, 2014, J AM COLL SURGEONS, V219, P382, DOI 10.1016/j.jamcollsurg.2014.03.046; Donze J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7171; Epstein Andrew S, 2014, Hosp Pract (1995), V42, P34, DOI 10.3810/hp.2014.12.1157; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Goodwin AJ, 2015, CRIT CARE MED, V43, P738, DOI 10.1097/CCM.0000000000000859; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Graham KL, 2015, ANN INTERN MED, V162, P741, DOI 10.7326/M14-2159; Horwitz LI, ASS HOSP VOLUME READ; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kahlon S, 2015, CAN MED ASSOC J, V187, P799, DOI 10.1503/cmaj.150100; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Lindenauer PK, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f521; Marcantonio ER, 2005, J AM GERIATR SOC, V53, P963, DOI 10.1111/j.1532-5415.2005.53305.x; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7; Odonkor CA, 2015, AM J PHYS MED REHAB, V94, P555, DOI 10.1097/PHM.0000000000000213; Parina RP, 2015, J AM COLL SURGEONS, V220, P169, DOI 10.1016/j.jamcollsurg.2014.10.020; Stefan MS, 2013, J GEN INTERN MED, V28, P377, DOI 10.1007/s11606-012-2229-8; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400; Wijlaars LPMM, 2015, ARCH DIS CHILD, V100, P845, DOI 10.1136/archdischild-2014-307771	28	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2017	12	6							e0178718	10.1371/journal.pone.0178718	http://dx.doi.org/10.1371/journal.pone.0178718			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX8NF	28622384	Green Published, Green Submitted, gold			2023-01-03	WOS:000403506300006
J	Gamez-Pozo, A; Trilla-Fuertes, L; Prado-Vazquez, G; Chiva, C; Lopez-Vacas, R; Nanni, P; Berges-Soria, J; Grossmann, J; Diaz-Almiron, M; Ciruelos, E; Sabido, E; Espinosa, E; Vara, JAF				Gamez-Pozo, Angelo; Trilla-Fuertes, Lucia; Prado-Vazquez, Guillermo; Chiva, Cristina; Lopez-Vacas, Rocio; Nanni, Paolo; Berges-Soria, Julia; Grossmann, Jonas; Diaz-Almiron, Mariana; Ciruelos, Eva; Sabido, Eduard; Espinosa, Enrique; Fresno Vara, Juana Angel			Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics	PLOS ONE			English	Article							HUMAN BILIVERDIN REDUCTASE; CLINICAL-SIGNIFICANCE; EXPRESSION PROFILES; GENE; SUBTYPES; METASTASIS; IDENTIFICATION; PROGNOSIS; OVEREXPRESSION; CLASSIFICATION	Background Triple-negative breast cancer (TNBC) accounts for 15 - 20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based biomarkers that predict the response to standard adjuvant chemotherapy, so that patients at are not going to benefit from it can be offered therapeutic alternatives. Methods We analyzed the proteome of a retrospective series of formalin-fixed, paraffin-embedded TNBC tissue applying high-throughput label-free quantitative proteomics. We identified several protein signatures with predictive value, which were validated with quantitative targeted proteomics in an independent cohort of patients and further evaluated in publicly available transcriptomics data. Results Using univariate Cox analysis, a panel of 18 proteins was significantly associated with distant metastasis-free survival of patients (p< 0.01). A reduced 5-protein profile with prognostic value was identified and its prediction performance was assessed in an independent targeted proteomics experiment and a publicly available transcriptomics dataset. Predictor P5 including peptides from proteins RAC2, RAB6A, BIEA and IPYR was the best performance protein combination in predicting relapse after adjuvant chemotherapy in TNBC patients. Conclusions This study identified a protein combination signature that complements histopathological prognostic factors in TNBC treated with adjuvant chemotherapy. The protein signature can be used in paraffin-embedded samples, and after a prospective validation in independent series, it could be used as predictive clinical test in order to recommend participation in clinical trials or a more exhaustive follow-up.	[Gamez-Pozo, Angelo; Prado-Vazquez, Guillermo; Lopez-Vacas, Rocio; Berges-Soria, Julia; Fresno Vara, Juana Angel] Hosp Univ La Paz IdiPAZ, Inst Genet Med & Mol INGEMM, Mol Oncol & Pathol Lab, Madrid, Spain; [Gamez-Pozo, Angelo; Trilla-Fuertes, Lucia; Fresno Vara, Juana Angel] Biomed Mol Med SL, Madrid, Spain; [Chiva, Cristina; Sabido, Eduard] Barcelona Inst Sci & Technol, Prote Unit, Ctr Genom Regulat CRG, Barcelona, Spain; [Chiva, Cristina; Sabido, Eduard] Univ Pompeu Fabra, Prote Unit, Barcelona, Spain; [Nanni, Paolo; Grossmann, Jonas] Univ Zurich, ETH Zurich, Funct Genom Ctr Zurich, Zurich, Switzerland; [Diaz-Almiron, Mariana] Hosp Univ La Paz IdiPAZ, Biostat Unit, Madrid, Spain; [Ciruelos, Eva] Hosp Univ Doce Octubre I 12, Inst Invest, Med Oncol Serv, Madrid, Spain; [Espinosa, Enrique] Hosp Univ La Paz IdiPAZ, Med Oncol Serv, Madrid, Spain; [Espinosa, Enrique; Fresno Vara, Juana Angel] Inst Salud Carlos III, CIBERONC, Madrid, Spain	Hospital Universitario La Paz; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Hospital Universitario La Paz; Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III	Vara, JAF (corresponding author), Hosp Univ La Paz IdiPAZ, Inst Genet Med & Mol INGEMM, Mol Oncol & Pathol Lab, Madrid, Spain.; Vara, JAF (corresponding author), Biomed Mol Med SL, Madrid, Spain.; Vara, JAF (corresponding author), Inst Salud Carlos III, CIBERONC, Madrid, Spain.	juanangel.fresno@salud.madrid.org	Trilla, Lucia/AAG-8392-2019; RODRIGUEZ, CRISTINA CHIVA/AAH-7862-2020; Prado-Vazquez, Guillermo/T-1861-2017; Vara, Juan Ángel Fresno/Y-9928-2019; Gamez-Pozo, Angelo/N-2506-2014; Sabido, Eduard/F-7914-2015	Trilla, Lucia/0000-0002-4452-3474; RODRIGUEZ, CRISTINA CHIVA/0000-0001-8150-6203; Prado-Vazquez, Guillermo/0000-0003-2456-6191; Vara, Juan Ángel Fresno/0000-0003-1527-1252; Gamez-Pozo, Angelo/0000-0002-8931-0624; Espinosa Arranz, Enrique/0000-0001-6562-7902; Nanni, Paolo/0000-0001-8429-3557; Sabido, Eduard/0000-0001-6506-7714	Instituto de Salud Carlos III; Spanish Economy and Competitiveness Ministry [RD09/0076/00073, RD09/0076/00118, DI-15-07614, PT13/0001]; Farmaindustria, through the Cooperation Program in Clinical and Translational Research of the Community of Madrid; Spanish Economy and Competitiveness Ministry, Spain - FEDER program, "Una forma de hacer Europa" [PI12/00444, PI12/01016, PI15/01310]; ISCIII [PT13/0001]; Spanish Ministry of Economy and Competitiveness, "Centro de Excelencia Severo Ochoa [SEV-2012-0208]; "Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya" [2014SGR678]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Economy and Competitiveness Ministry(Spanish Government); Farmaindustria, through the Cooperation Program in Clinical and Translational Research of the Community of Madrid; Spanish Economy and Competitiveness Ministry, Spain - FEDER program, "Una forma de hacer Europa"; ISCIII(Instituto de Salud Carlos III); Spanish Ministry of Economy and Competitiveness, "Centro de Excelencia Severo Ochoa(Spanish Government); "Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya"	We want to particularly acknowledge the patients in this study for their participation and to the IdiPAZ and I+12 Biobanks for the generous gifts of clinical samples used in this work. The IdiPAZ and I+12 Biobanks are supported by Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry (RD09/0076/00073 and RD09/0076/00118 respectively) and Farmaindustria, through the Cooperation Program in Clinical and Translational Research of the Community of Madrid. This work was supported by Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain and co-funded by FEDER program, "Una forma de hacer Europa" (PI12/00444, PI12/01016 and PI15/01310). LT-F is supported by Spanish Economy and Competitiveness Ministry (DI-15-07614). The CRG/UPF Proteomics Unit is part of the "Plataforma de Recursos Biomoleculares y Bioinformaticos (ProteoRed)" supported by grant PT13/0001 of ISCIII and Spanish Ministry of Economy and Competitiveness. We acknowledge support of the Spanish Ministry of Economy and Competitiveness, "Centro de Excelencia Severo Ochoa 2013-2017", SEV-2012-0208, and from "Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya" (2014SGR678). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Albergaria A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-299; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Bianchini G, 2010, CANCER RES, V70, P8852, DOI 10.1158/0008-5472.CAN-10-1039; Chen J, 2012, J SURG ONCOL, V106, P260, DOI 10.1002/jso.22153; COX DR, 1972, J R STAT SOC B, V34, P187; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Deeb SJ, 2012, MOL CELL PROTEOMICS, V11, P77, DOI 10.1074/mcp.M111.015362; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Ellis MJ, 2013, CANCER DISCOV, V3, P1108, DOI 10.1158/2159-8290.CD-13-0219; Gamez-Pozo A, 2015, CANCER RES, P2243; Gamez-Pozo A, 2013, PROTEOM CLIN APPL, V7, P283, DOI 10.1002/prca.201200048; Gamez-Pozo A, 2011, MOL BIOSYST, V7, P2368, DOI 10.1039/c1mb05113j; Gibbs PEM, 2007, INT J CANCER, V121, P2567, DOI 10.1002/ijc.22978; Gildea JJ, 2002, CANCER RES, V62, P6418; Gong Y, 2007, LANCET ONCOL, V8, P203, DOI 10.1016/S1470-2045(07)70042-6; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207; Hirshfield KM, 2014, CURR OPIN OBSTET GYN, V26, P34, DOI 10.1097/GCO.0000000000000038; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jeong SH, 2012, TUMOR BIOL, V33, P1889, DOI 10.1007/s13277-012-0449-5; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim SS, 2013, ANTICANCER RES, V33, P4913; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee JA, 2011, J BREAST CANCER, V14, P269, DOI 10.4048/jbc.2011.14.4.269; Lee U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082125; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lerner-Marmarosh N, 2008, P NATL ACAD SCI USA, V105, P6870, DOI 10.1073/pnas.0800750105; Li HY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2680; Liu NQ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt376; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Luo DH, 2016, CANCER MED-US, V5, P2800, DOI 10.1002/cam4.894; Marguerat S, 2012, CELL, V151, P671, DOI 10.1016/j.cell.2012.09.019; Martin H, 2013, J CLIN INVEST, V123, P4449, DOI 10.1172/JCI67509; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870; Mishra DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124864; Nagaraj N, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.81; Ouyang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096228; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Raphael BJ, 2013, NAT METHODS, V10, P1077, DOI 10.1038/nmeth.2704; Laimito KR, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.632; Sanchez-Navarro I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-336; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Simon R, 2005, J CLIN ONCOL, V23, P7332, DOI 10.1200/JCO.2005.02.8712; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Yu KD, 2013, CLIN CANCER RES, V19, P2723, DOI 10.1158/1078-0432.CCR-12-2986	52	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e0178296	10.1371/journal.pone.0178296	http://dx.doi.org/10.1371/journal.pone.0178296			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0PL	28594844	Green Published, Green Submitted, gold			2023-01-03	WOS:000402923200026
J	Kurz, MC; Donnelly, JP; Wang, HE				Kurz, Michael Christopher; Donnelly, John P.; Wang, Henry E.			Variations in survival after cardiac arrest among academic medical center-affiliated hospitals	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; MORTALITY; DIAGNOSES; OUTCOMES; SEPSIS; VOLUME; CARE; CPR	Background Variation exists in cardiac arrest (CA) survival among institutions. We sought to determine institutional-level characteristics of academic medical centers (AMCs) associated with CA survival. Methods We examined discharge data from AMCs participating with Vizient clinical database-resource manager. We identified cases using ICD-9 diagnosis code 427.5 (CA) or procedure code 99.60 (CPR). We estimated hospital-specific risk-standardized survival rates (RSSRs) using mixed effects logistic regression, adjusting for individual mortality risk. Institutional and community characteristics of AMCs with higher than average survival were compared with those with lower survival. Results We analyzed data on 3,686,296 discharges in 2012, of which 33,700 (0.91%) included a CA diagnosis. Overall survival was 42.3% (95% CI 41.8-42.9) with median institutional RSSR of 42.6% (IQR 35.7-51.0; Min-Max 19.4-101.6). We identified 28 AMCs with above average survival (median RSSR 61.8%) and 20 AMCs with below average survival (median RSSR 26.8%). Compared to AMCs with below average survival, those with high CA survival had higher CA volume (median 262 vs. 119 discharges, p = 0.002), total beds (722 vs. 452, p = 0.02), and annual surgical volume (24,939 vs. 13,109, p<0.001), more likely to offer cardiac catheterization (100% vs. 72%, p = 0.007) or cardiac surgery (93% vs. 61%, p = 0.02) and cared for catchment areas with higher household income ($61,922 vs. $49,104, p = 0.004) and lower poverty rates (14.6% vs. 17.3%, p = 0.03). Conclusion Using discharge data from Vizient, we showed AMCs with higher CA and surgical case volume, cardiac catheterization and cardiac surgery facilities, and catchment areas with higher socioeconomic status had higher risk-standardized CA survival.	[Kurz, Michael Christopher; Donnelly, John P.; Wang, Henry E.] Univ Alabama Birmingham, Sch Med, Dept Emergency Med, Birmingham, AL 35294 USA; [Donnelly, John P.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Prevent Med, Birmingham, AL USA; [Donnelly, John P.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kurz, MC (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Emergency Med, Birmingham, AL 35294 USA.	mckurz@uabmc.edu		Donnelly, John/0000-0002-0646-9470	Agency for Healthcare Research and Quality, Rockville, Maryland [T32-HS013852]	Agency for Healthcare Research and Quality, Rockville, Maryland(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Mr. Donnelly's effort was supported by grant T32-HS013852 from the Agency for Healthcare Research and Quality, Rockville, Maryland.	[Anonymous], AM HEART ASS CIRC, DOI DOI 10.1161/01.CIR.95.8.2213; BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; Benjamin E.J., 2017, CIRCULATION, V135, P146; Camuglia AC, 2014, RESUSCITATION, V85, P1533, DOI 10.1016/j.resuscitation.2014.08.025; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; Carr BG, 2009, INTENS CARE MED, V35, P505, DOI 10.1007/s00134-008-1335-x; Carr BG, 2009, RESUSCITATION, V80, P30, DOI 10.1016/j.resuscitation.2008.09.001; Coppler PJ, 2016, RESUSCITATION, V98, P9, DOI 10.1016/j.resuscitation.2015.09.399; Dimick JB, 2010, HEALTH SERV RES, V45, P1614, DOI 10.1111/j.1475-6773.2010.01158.x; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fugate JE, 2012, CIRCULATION, V126, P546, DOI 10.1161/CIRCULATIONAHA.111.088807; Girotra S, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000871; International Classification of Diseases, CLIN MOD; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Morrison LJ, 2013, CIRCULATION, V127, P1538, DOI 10.1161/CIR.0b013e31828b2770; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Saposnik G, 2008, STROKE, V39, P2318, DOI 10.1161/STROKEAHA.107.510362; Sasson C, 2012, NEW ENGL J MED, V367, P1607, DOI 10.1056/NEJMoa1110700; Sutton JM, 2014, J SURG RES, V190, P484, DOI 10.1016/j.jss.2014.03.044; System NHGI, 2008, 2008 2012 AM COMM SU; Vaillancourt C, 2008, RESUSCITATION, V79, P417, DOI 10.1016/j.resuscitation.2008.07.012; Wang HE, 2015, AM J MED QUAL, V30, P328, DOI 10.1177/1062860614534461; Wang HE, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0771-6	24	20	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2017	12	6							e0178793	10.1371/journal.pone.0178793	http://dx.doi.org/10.1371/journal.pone.0178793			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW9KF	28582400	Green Published, gold, Green Submitted			2023-01-03	WOS:000402837600040
J	Straney, LD; Udy, AA; Burrell, A; Bergmeir, C; Huckson, S; Cooper, DJ; Pilcher, DV				Straney, Lahn D.; Udy, Andrew A.; Burrell, Aidan; Bergmeir, Christoph; Huckson, Sue; Cooper, D. James; Pilcher, David V.			Modelling risk-adjusted variation in length of stay among Australian and New Zealand ICUs	PLOS ONE			English	Article							INTENSIVE-CARE UNITS; HOSPITAL MORTALITY; APACHE-III; BENCHMARKING; PREDICTION; OUTCOMES	Purpose Comparisons between institutions of intensive care unit (ICU) length of stay (LOS) are significantly confounded by individual patient characteristics, and currently there is a paucity of methods available to calculate risk-adjusted metrics. Methods We extracted de-identified data from the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database for admissions between January 1 2011 and December 31 2015. We used a mixed-effects log-normal regression model to predict LOS using patient and admission characteristics. We calculated a risk-adjusted LOS ratio (RALOSR) by dividing the geometric mean observed LOS by the exponent of the expected Ln-LOS for each site and year. The RALOSR is scaled such that values <1 indicate a LOS shorter than expected, while values >1 indicate a LOS longer than expected. Secondary mixed effects regression modelling was used to assess the stability of the estimate in units over time. Results During the study there were a total of 662,525 admissions to 168 units (median annual admissions = 767, IQR:426-1121). The mean observed LOS was 3.21 days (median = 1.79 IQR = 0.92-3.52) over the entire period, and declined on average 1.97 hours per year (95% CI:1.76-2.18) from 2011 to 2015. The RALOSR varied considerably between units, ranging from 0.35 to 2.34 indicating large differences after accounting for case-mix. Conclusions There are large disparities in risk-adjusted LOS among Australian and New Zealand ICU swhich may reflect differences in resource utilization.	[Straney, Lahn D.; Udy, Andrew A.; Cooper, D. James; Pilcher, David V.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Udy, Andrew A.; Burrell, Aidan; Cooper, D. James; Pilcher, David V.] Alfred Hosp, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Bergmeir, Christoph] Monash Univ, Fac Informat Technol, Melbourne, Vic, Australia; [Huckson, Sue; Pilcher, David V.] Australian & New Zealand Intens Care Soc, Ctr Outcome & Resource Evaluat, Melbourne, Vic, Australia	Monash University; Florey Institute of Neuroscience & Mental Health; Monash University	Pilcher, DV (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.; Pilcher, DV (corresponding author), Alfred Hosp, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia.; Pilcher, DV (corresponding author), Australian & New Zealand Intens Care Soc, Ctr Outcome & Resource Evaluat, Melbourne, Vic, Australia.	d.pilcher@alfred.org.au	Cooper, D. James/G-7961-2013; Burrell, Aidan/AGY-3244-2022; Burrell, Aidan/AAE-8768-2019; Bergmeir, Christoph/Q-9911-2019; Udy, Andrew/G-2538-2010	Cooper, D. James/0000-0002-5872-9051; Burrell, Aidan/0000-0001-8430-9678; Straney, Lahn/0000-0002-2615-2366; Pilcher, David/0000-0002-8939-7985; Udy, Andrew/0000-0002-6284-2022	Monash Institute of Medica lEngineering (MIME) [2016-37]	Monash Institute of Medica lEngineering (MIME)	This research was funded in part by the Monash Institute of Medica lEngineering (MIME) under a MIME seed funding grant (2016-37). (LS, CB) [https://www.monash.edu/mime/seed]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECKER RB, 1995, J CARDIOVASC SURG, V36, P1; Heidegger CP, 2005, INTENS CARE MED, V31, P1676, DOI 10.1007/s00134-005-2831-x; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Moitra VK, 2016, CRIT CARE MED, V44, P655, DOI 10.1097/CCM.0000000000001480; Paul E, 2016, CRIT CARE RESUSC, V18, P25; Paul E, 2013, J CRIT CARE, V28, P935, DOI 10.1016/j.jcrc.2013.07.058; Power GS, 2014, CURR OPIN CRIT CARE, V20, P544, DOI 10.1097/MCC.0000000000000136; Rapoport J, 2003, MED CARE, V41, P386, DOI 10.1097/00005650-200303000-00007; Strand K, 2010, CRIT CARE, V14, DOI 10.1186/cc9279; Straney L, 2012, HEALTH SERV RES, V47, P2190, DOI 10.1111/j.1475-6773.2012.01421.x; Straney L, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.028811; Straney LD, 2010, INTENS CARE MED, V36, P1410, DOI 10.1007/s00134-010-1916-3; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Vicente FG, 2004, INTENS CARE MED, V30, P655, DOI 10.1007/s00134-003-2139-7; Zimmerman JE, 2006, CRIT CARE MED, V34, P2517, DOI 10.1097/01.CCM.0000240233.01711.D9	16	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2017	12	5							e0176570	10.1371/journal.pone.0176570	http://dx.doi.org/10.1371/journal.pone.0176570			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET9RV	28464035	gold, Green Published, Green Submitted			2023-01-03	WOS:000400646300035
J	Mujar, NMM; Dahlui, M; Emran, NA; Hadi, IA; Wai, YY; Arulanantham, S; Hooi, CC; Taib, NAM				Mujar, Noor Mastura Mohd; Dahlui, Maznah; Emran, Nor Aina; Hadi, Imisairi Abdul; Wai, Yan Yang; Arulanantham, Sarojah; Hooi, Chea Chan; Taib, Nur Aishah Mohd			Complementary and alternative medicine (CAM) use and delays in presentation and diagnosis of breast cancer patients in public hospitals in Malaysia	PLOS ONE			English	Article							SINGLE INSTITUTION; WOMEN; SURVIVAL; BARRIERS; HEALTH; PRAYER; TIME	Complementary and alternative medicine (CAM) is widely used among the breast cancer patients in Malaysia. Delays in presentation, diagnosis and treatment have been shown to impact the disease prognosis. There is considerable use of CAM amongst breast cancer patients. CAM use has been cited as a cause of delay in diagnosis and treatments in qualitative studies, however there had not been any confirmatory study that confirms its impact on delays. The purpose of this study was to evaluate whether the use of CAM among newly diagnosed breast cancer patients was associated with delays in presentation, diagnosis or treatment of breast cancer. This multi-centre cross-sectional study evaluating the time points of the individual breast cancer patients' journey from first visit, resolution of diagnosis and treatments was conducted in six public hospitals in Malaysia. All newly diagnosed breast cancer patients from 1st January to 31st December 2012 were recruited. Data were collected through medical records review and patient interview by using a structured questionnaire. Complementary and alternative medicine (CAM) was defined as the use of any methods and products not included in conventional allopathic medicine before commencement of treatments. Presentation delay was defined as time taken from symptom discovery to first presentation of more than 3 months. The time points were categorised to diagnosis delay was defined as time taken from first presentation to diagnosis of more than 1 month and treatment delay was defined as time taken from diagnosis to initial treatment of more than 1 month. Multiple logistic regression was used for analysis. A total number of 340 patients participated in this study. The prevalence of CAM use was 46.5% (n = 158). Malay ethnicity (OR 3.32; 95% CI: 1.85, 5.97) and not interpreting symptom as cancerous (OR 1.79; 95% CI: 1.10, 2.92) were significantly associated with CAM use. The use of CAM was associated with delays in presentation (OR 1.65; 95% CI: 1.05, 2.59), diagnosis (OR 2.42; 95% CI: 1.56, 3.77) and treatment of breast cancer (OR 1.74; 95% CI: 1.11, 2.72) on univariate analyses. However, after adjusting with other covariates, CAM use was associated with delays in presentation (OR 1.71; 95% CI: 1.05, 2.78) and diagnosis (OR 2.58; 95% CI: 1.59, 4.17) but not for treatment of breast cancer (OR 1.58; 95% CI: 0.98, 2.55). The prevalence of CAM use among the breast cancer patients was high. Women of Malay ethnicity and not interpreting symptom as cancerous were significantly associated with CAM use. The use of CAM is significantly associated with delay in presentation and resolution of diagnosis. This study suggests further evaluation of access to breast cancer care is needed as poor access may cause the use of CAM. However, since public hospitals in Malaysia are heavily subsidized and readily available to the population, CAM use may impact delays in presentation and diagnosis.	[Mujar, Noor Mastura Mohd] Univ Sci Malaysia, Cluster Hlth Lifestyle, Adv Med & Dent Inst, George Town, Malaysia; [Dahlui, Maznah] Univ Malaya, Dept Social & Prevent Med, Fac Med, Kuala Lumpur, Malaysia; [Emran, Nor Aina; Hadi, Imisairi Abdul; Wai, Yan Yang; Arulanantham, Sarojah; Hooi, Chea Chan] Minist Hlth, Putrajaya, Malaysia; [Taib, Nur Aishah Mohd] Univ Malaya, Dept Surg, Fac Med, Kuala Lumpur, Malaysia	Universiti Sains Malaysia; Universiti Malaya; Kementerian Kesihatan Malaysia; Universiti Malaya	Mujar, NMM (corresponding author), Univ Sci Malaysia, Cluster Hlth Lifestyle, Adv Med & Dent Inst, George Town, Malaysia.	mastura_mujar@yahoo.com	Dahlui, Maznah/F-9665-2010; Taib, Nur Aishah Mohd/B-2370-2010; DAHLUI, MAZNAH/B-8976-2010	Taib, Nur Aishah Mohd/0000-0001-8419-0478; DAHLUI, MAZNAH/0000-0003-4923-9410; Mohd Mujar, Noor Mastura/0000-0003-1773-5292	Peruntukan Penyelidikan Pascasiswazah (PPP) from the University of Malaya [UM.TNC2/IPPP/UPGP/638/PPP]; Kuala Lumpur and High Impact Research (HIR) from the Ministry of Higher Education of Malaysia [UM.C/HIR/MOHE/06]	Peruntukan Penyelidikan Pascasiswazah (PPP) from the University of Malaya; Kuala Lumpur and High Impact Research (HIR) from the Ministry of Higher Education of Malaysia	This work was supported by the Peruntukan Penyelidikan Pascasiswazah (PPP) Grant (UM.TNC2/IPPP/UPGP/638/PPP) from the University of Malaya, Kuala Lumpur and High Impact Research (HIR) Grant (UM.C/HIR/MOHE/06) from the Ministry of Higher Education of Malaysia.	Abdullah A, 2013, ASIAN PAC J CANCER P, V14, P7143, DOI 10.7314/APJCP.2013.14.12.7143; Abuduli M., 2011, MALAYS J PUBLIC HLTH, V11, P1; Al-Naggar RA., 2013, WORLD J MED SCI, V8, P157; Al-Naggar RA, 2012, ASIAN PAC J CANCER P, V13, P3595, DOI 10.7314/APJCP.2012.13.8.3595; ANDERSEN BL, 1995, BRIT J SOC PSYCHOL, V34, P33, DOI 10.1111/j.2044-8309.1995.tb01047.x; [Anonymous], 2009, REP COMM SURV; Azhar Y, 2015, PREDICTORS COMPLEMEN; Barber MD, 2004, BRIT J SURG, V91, P49, DOI 10.1002/bjs.4436; Bhoo-Pathy N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030995; Bish A, 2005, J PSYCHOSOM RES, V58, P321, DOI 10.1016/j.jpsychores.2004.10.007; Bright K, 2011, BREAST, V20, pS54, DOI 10.1016/j.breast.2011.02.012; Burgess CC, 1998, BRIT J CANCER, V77, P1343, DOI 10.1038/bjc.1998.224; Cheng ML, 2015, JOHOR MED J MALAYSIA, V70, P148; Chow WH, 2010, ANN ACAD MED SINGAP, V39, P129; Chui PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139952; Chui PL, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-425; Elmore JG, 2011, JAMA-J AM MED ASSOC, V293, P1245; Ermiah Eramah, 2012, BMC Res Notes, V5, P452, DOI 10.1186/1756-0500-5-452; Farooqui M, 2015, J TRADIT COMPLEMENT, P8; Ghazali SM, 2013, ASIAN PAC J CANCER P, V14, P1141, DOI 10.7314/APJCP.2013.14.2.1141; Hamidah A, 2009, PEDIATR BLOOD CANCER, V52, P70, DOI 10.1002/pbc.21798; Harirchi I, 2005, PUBLIC HEALTH, V119, P885, DOI 10.1016/j.puhe.2004.11.005; Hasan Syed Shahzad, 2009, Complement Ther Clin Pract, V15, P152, DOI 10.1016/j.ctcp.2009.02.003; Helyer LK, 2006, USE COMPLEMENTARY AL, V8, P1; Huo Q, 2015, ANN SURG ONCOL, V22, P883, DOI 10.1245/s10434-014-4076-9; Hwang JH, 2015, EVIDENCE BASED COMPL, V2015; Ibrahim NA, 2012, BREAST, V21, P416, DOI 10.1016/j.breast.2012.02.006; Knight Aishah, 2015, Asian Pac J Cancer Prev, V16, P3125; Leong BDK, 2007, ASIAN PAC J CANCER P, V8, P525; Lim GCC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-212; Lim JNW, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009863; Martins T, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-197; Muhamad M, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/689168; Norsa'adah B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-141; Norsa'adah B, 2012, ASIAN PAC J CANCER P, V13, P3723, DOI 10.7314/APJCP.2012.13.8.3723; Perez Gloria, 2008, Cancer Detect Prev, V32, P267, DOI 10.1016/j.cdp.2008.05.006; Plotogea A, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-125; Poum A, 2012, ASIAN PAC J CANCER P, V13, P791, DOI 10.7314/APJCP.2012.13.3.791; Puataweepong P, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/670408; Raja L, 2013, COMPLEMENTARY ALTERN, V13, P11; Rastad H, 2012, ASIAN PAC J CANCER P, V13, P4511, DOI 10.7314/APJCP.2012.13.9.4511; Richards MA, 1999, LANCET, V353, P1119, DOI 10.1016/S0140-6736(99)02143-1; Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505; Saibul N, 2012, ASIAN PAC J CANCER P, V13, P4081, DOI 10.7314/APJCP.2012.13.8.4081; Shandiz FH, 2012, EUR J CANCER, V48, pS80; Taib NA, 2007, ASIAN PAC J CANCER P, V8, P141; Taib NA, 2014, WORLD J SURG, V38, P1676, DOI 10.1007/s00268-013-2339-4; Taib NA, 2011, ASIAN PAC J CANCER P, V12, P1601; Taib NA, 2011, ASIAN PAC J CANCER P, V12, P345; Tas F, 2016, PREVALENCE DETERMINA; Weinmann S, 2005, CHARACTERISTICS WOME, P33; Whitford' HS, 2011, CANCER FORUM, V35, P27; Yew VWC, 2015, COMPLEMENTARY ALTERN, V1, P183	53	32	32	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2017	12	4							e0176394	10.1371/journal.pone.0176394	http://dx.doi.org/10.1371/journal.pone.0176394			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EL	28448541	Green Published, Green Submitted, gold			2023-01-03	WOS:000400383600073
J	Vali, P; Chandrasekharan, P; Rawat, M; Gugino, S; Koenigsknecht, C; Helman, J; Mathew, B; Berkelhamer, S; Nair, J; Wyckoff, M; Lakshminrusimha, S				Vali, Payam; Chandrasekharan, Praveen; Rawat, Munmun; Gugino, Sylvia; Koenigsknecht, Carmon; Helman, Justin; Mathew, Bobby; Berkelhamer, Sara; Nair, Jayasree; Wyckoff, Myra; Lakshminrusimha, Satyan			Hemodynamics and gas exchange during chest compressions in neonatal resuscitation	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; PERINATAL ASPHYXIA; SWINE MODEL; LAMBS; EPINEPHRINE; VENTILATION; HYPOXIA; CPR	Purpose Current knowledge about pulmonary/systemic hemodynamics and gas exchange during neonatal resuscitation in a model of transitioning fetal circulation with fetal shunts and fluid-filled alveoli is limited. Using a fetal lamb asphyxia model, we sought to determine whether hemodynamic or gas-exchange parameters predicted successful return of spontaneous circulation (ROSC). Methods The umbilical cord was occluded in 22 lambs to induce asphyxial cardiac arrest. Following five minutes of asystole, resuscitation as per AHA-Neonatal Resuscitation Program guidelines was initiated. Hemodynamic parameters and serial arterial blood gases were assessed during resuscitation. Results ROSC occurred in 18 lambs (82%) at a median (IQR) time of 120 (105-180) seconds. There were no differences in hemodynamic parameters at baseline and at any given time point during resuscitation between the lambs that achieved ROSC and those that did not. Blood gases at arrest prior to resuscitation were comparable between groups. However, lambs that achieved ROSC had lower PaO2, higher PaCO2, and lower lactate during resuscitation. Increase in diastolic blood pressures induced by epinephrine in lambs that achieved ROSC (11 +/- 4 mmHg) did not differ from those that were not resuscitated (10 +/- 6 mmHg). Low diastolic blood pressures were adequate to achieve ROSC. Conclusions Hemodynamic parameters in a neonatal lamb asphyxia model with transitioning circulation did not predict success of ROSC. Lactic acidosis, higher PaO2 and lower PaCO2 observed in the lambs that did not achieve ROSC may represent a state of inadequate tissue perfusion and/or mitochondrial dysfunction.	[Vali, Payam] Univ Calif Davis, Pediat, Sacramento, CA 95817 USA; [Chandrasekharan, Praveen; Rawat, Munmun; Gugino, Sylvia; Koenigsknecht, Carmon; Helman, Justin; Mathew, Bobby; Berkelhamer, Sara; Nair, Jayasree; Lakshminrusimha, Satyan] SUNY Buffalo, Pediat, Buffalo, NY USA; [Wyckoff, Myra] UT Southwestern, Pediat, Dallas, TX USA	University of California System; University of California Davis; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Texas System; University of Texas Southwestern Medical Center Dallas	Vali, P (corresponding author), Univ Calif Davis, Pediat, Sacramento, CA 95817 USA.	pvali@ucdavis.edu	Chandrasekharan, Praveen/X-1729-2019	Chandrasekharan, Praveen/0000-0001-8727-3017; Rawat, Munmun/0000-0001-9703-9857; Nair, Jayasree/0000-0003-3846-2027; Lakshminrusimha, Satyan/0000-0001-6098-2155	Canadian Paediatric Society -Neonatal Resuscitation Program Research Grant; American Academy of Pediatrics - Neonatal Resuscitation Program Young Investigator Award; NICHD [HD072929]	Canadian Paediatric Society -Neonatal Resuscitation Program Research Grant; American Academy of Pediatrics - Neonatal Resuscitation Program Young Investigator Award; NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was funded by the Canadian Paediatric Society -Neonatal Resuscitation Program Research Grant (SL), American Academy of Pediatrics - Neonatal Resuscitation Program Young Investigator Award (PV) and NICHD HD072929 (SL). The funders had no role study design, data collection ana analysis, decision to publish, or preparation of the manuscript.	Berg RA, 1999, CRIT CARE MED, V27, P1893, DOI 10.1097/00003246-199909000-00030; Chandrasekharan P, 2017, PEDIAT RES; Crile G, 1906, J EXP MED, V8, P713, DOI 10.1084/jem.8.6.713; Harrington DJ, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.10.877; Houri P K, 1997, Prehosp Emerg Care, V1, P65, DOI 10.1080/10903129708958789; Kapadia VS, 2013, J PEDIATR-US, V163, P949, DOI 10.1016/j.jpeds.2013.04.043; Klingenberg C, 2013, ARCH DIS CHILD-FETAL, V98, pF222, DOI 10.1136/archdischild-2012-301787; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Kuligowskia J, 2017, REDOX BIOL, V12, P1, DOI 10.1016/j.redox.2017.02.002; Perlman JM, 2015, PEDIATRICS; PREZIOSI MP, 1993, CRIT CARE MED, V21, P1901, DOI 10.1097/00003246-199312000-00018; Ramanathan T, 2005, BJA EDUC, V5, P61, DOI 10.1093/bjaceaccp/mki012; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; ROSENBERG AA, 1986, PEDIATR RES, V20, P778, DOI 10.1203/00006450-198608000-00016; ROSENBERG AA, 1989, STROKE, V20, P674, DOI 10.1161/01.STR.20.5.674; Schmolzer GM, 2014, RESUSCITATION, V85, P270, DOI 10.1016/j.resuscitation.2013.10.011; Sobotka KS, 2015, PEDIAT RES; Solberg R, 2016, PEDIATR RES, V80, P284, DOI 10.1038/pr.2016.66; Solevag AL, 2011, ARCH DIS CHILD-FETAL, V96, pF417, DOI 10.1136/adc.2010.200386; Solevag AL, 2010, RESUSCITATION, V81, P1571, DOI 10.1016/j.resuscitation.2010.06.007; Sutton RM, 2014, RESUSCITATION, V85, P983, DOI 10.1016/j.resuscitation.2014.04.015; Sutton RM, 2013, RESUSCITATION, V84, P696, DOI 10.1016/j.resuscitation.2012.10.023; TRAUB E, 1983, J PERINAT MED, V11, P103, DOI 10.1515/jpme.1983.11.2.103; Weiner GM, 2012, CLIN PERINATOL, V39, P843, DOI 10.1016/j.clp.2012.09.005; Wyckoff MH, 2008, SEMIN FETAL NEONAT M, V13, P410, DOI 10.1016/j.siny.2008.04.012; Wyckoff MH, 2015, CIRCULATION, V132, pS543, DOI 10.1161/CIR.0000000000000267; Wyckoff MH, 2012, J PEDIATR-US, V160, P239, DOI 10.1016/j.jpeds.2011.07.041	27	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2017	12	4							e0176478	10.1371/journal.pone.0176478	http://dx.doi.org/10.1371/journal.pone.0176478			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET5FE	28441439	gold, Green Published, Green Submitted			2023-01-03	WOS:000400308800063
J	Parsons, L; Cordier, R; Munro, N; Joosten, A; Speyer, R				Parsons, Lauren; Cordier, Reinie; Munro, Natalie; Joosten, Annette; Speyer, Renee			A systematic review of pragmatic language interventions for children with autism spectrum disorder	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; HIGH-FUNCTIONING AUTISM; MANAGEMENT EDUCATION-PROGRAMS; SOCIAL-SKILLS INTERVENTIONS; JOINT ATTENTION; YOUNG-CHILDREN; MUSIC-THERAPY; COMMUNICATION; SCHOOL; ADOLESCENTS	There is a need for evidence based interventions for children with autism spectrum disorder (ASD) to limit the life-long, psychosocial impact of pragmatic language impairments. This systematic review identified 22 studies reporting on 20 pragmatic language interventions for children with ASD aged 0-18 years. The characteristics of each study, components of the interventions, and the methodological quality of each study were reviewed. Meta-analysis was conducted to assess the effectiveness of 15 interventions. Results revealed some promising approaches, indicating that active inclusion of the child and parent in the intervention was a significant mediator of intervention effect. Participant age, therapy setting or modality were not significant mediators between the interventions and measures of pragmatic language. The long-term effects of these interventions and the generalisation of learning to new contexts is largely unknown. Implications for clinical practice and directions for future research are discussed.	[Parsons, Lauren; Cordier, Reinie; Munro, Natalie; Joosten, Annette] Curtin Univ, Sch Occupat Therapy & Social Work, Perth, WA, Australia; [Munro, Natalie] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia; [Speyer, Renee] James Cook Univ, Coll Healthcare Sci, Townsville, Qld, Australia	Curtin University; University of Sydney; James Cook University	Parsons, L (corresponding author), Curtin Univ, Sch Occupat Therapy & Social Work, Perth, WA, Australia.	lauren.parsons@curtin.edu.au	Cordier, Reinie/AAH-6290-2019; Munro, Natalie/J-6163-2017; Parsons, Lauren/W-9384-2019	Cordier, Reinie/0000-0002-9906-5300; Munro, Natalie/0000-0002-5870-6378; Parsons, Lauren/0000-0002-4209-7168; Joosten, Annette/0000-0003-4722-1081				Adams C., 2005, CHILD LANG TEACH THE, V21, P227, DOI DOI 10.1191/0265659005CT2900A; Adams C, 2012, INT J LANG COMM DIS, V47, P233, DOI 10.1111/j.1460-6984.2011.00146.x; [Anonymous], 2002, ADV SPEECH LANGUAGE, DOI DOI 10.1080/14417040210001669181; Baron-Cohen Simon, 2003, MIND READING INTERAC; Bauminger N, 2000, CHILD DEV, V71, P447, DOI 10.1111/1467-8624.00156; Beaumont R, 2008, J CHILD PSYCHOL PSYC, V49, P743, DOI 10.1111/j.1469-7610.2008.01920.x; Bono MA, 2004, J AUTISM DEV DISORD, V34, P495, DOI 10.1007/s10803-004-2545-x; Casenhiser DM, 2015, J AUTISM DEV DISORD, V45, P846, DOI 10.1007/s10803-014-2242-3; Casenhiser DM, 2013, AUTISM, V17, P220, DOI 10.1177/1362361311422052; Chan JM, 2009, RES AUTISM SPECT DIS, V3, P876, DOI 10.1016/j.rasd.2009.04.003; Chiang CH, 2008, J AUTISM DEV DISORD, V38, P1898, DOI 10.1007/s10803-008-0586-2; Cohen J., 2013, STAT POWER ANAL BEHA; Corbett BA, 2015, J AUTISM DEV DISORD, P1; Cordier R, 2014, RES DEV DISABIL, V35, P1588, DOI 10.1016/j.ridd.2014.03.050; DeRosier ME, 2011, J AUTISM DEV DISORD, V41, P1033, DOI 10.1007/s10803-010-1128-2; Donaldson AL., 2015, PERSPECTIVES LANGUAG, V22, P31, DOI [10.1044/lle22.1.31, DOI 10.1044/LLE22.1.31]; Fletcher-Watson S, 2015, TRIAL IPAD INTERVENT; Gabriels RL, 2015, J AM ACAD CHILD PSY, V54, P541, DOI 10.1016/j.jaac.2015.04.007; Gattino GS, 2011, NORD J MUSIC THER, V20, P142, DOI 10.1080/08098131.2011.566933; Gerenberg M, 2006, NEW YORK ACAD SCI, V1094, P139; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Hampton LH, 2016, J INTELL DISABIL RES, V60, P444, DOI 10.1111/jir.12283; Hauck M, 1995, J AUTISM DEV DISORD, V25, P579, DOI 10.1007/BF02178189; Hedges LV, 2004, PSYCHOL METHODS, V9, P426, DOI 10.1037/1082-989X.9.4.426; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hopkins IM, 2011, J AUTISM DEV DISORD, V41, P1543, DOI 10.1007/s10803-011-1179-z; Houghton K, 2013, J COMMUN DISORD, V46, P495, DOI 10.1016/j.jcomdis.2013.09.004; Ichikawa K, 2013, BIOPSYCHOSOC MED, V7, DOI 10.1186/1751-0759-7-14; Kaale A, 2014, J AM ACAD CHILD PSY, V53, P188, DOI 10.1016/j.jaac.2013.09.019; Kaale A, 2012, J CHILD PSYCHOL PSYC, V53, P97, DOI 10.1111/j.1469-7610.2011.02450.x; Kamps D, 2015, J AUTISM DEV DISORD, V45, P1809, DOI 10.1007/s10803-014-2340-2; Kasari C, 2006, J CHILD PSYCHOL PSYC, V47, P611, DOI 10.1111/j.1469-7610.2005.01567.x; Kasari C, 2014, PEDIATRICS, V134, pE72, DOI 10.1542/peds.2013-3229; Kasari C, 2012, J CHILD PSYCHOL PSYC, V53, P431, DOI 10.1111/j.1469-7610.2011.02493.x; Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5; Kim J, 2008, J AUTISM DEV DISORD, V38, P1758, DOI 10.1007/s10803-008-0566-6; Kmet LM, 2004, STANDARD QUALITY ASS, DOI DOI 10.7939/R37M04F16; Kransy L, 2002, CHILD ADOLESCENT PSY, V12, P107; Lawton K, 2012, J AUTISM DEV DISORD, V42, P307, DOI 10.1007/s10803-011-1231-z; Lee L, 2008, AUSTRALAS J AGEING, V27, P170, DOI 10.1111/j.1741-6612.2008.00298.x; Lerner MD, 2012, FOCUS AUTISM DEV DIS, V27, P147, DOI 10.1177/1088357612450613; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Locke J, 2010, J RES SPEC EDUC NEED, V10, P74, DOI 10.1111/j.1471-3802.2010.01148.x; Lopata C, 2016, RES AUTISM SPECT DIS, V21, P25, DOI 10.1016/j.rasd.2015.09.003; Lopata C, 2010, J AUTISM DEV DISORD, V40, P1297, DOI 10.1007/s10803-010-0989-8; McFadden B, 2014, RES AUTISM SPECT DIS, V8, P1699, DOI 10.1016/j.rasd.2014.08.015; McMahon CM, 2013, J AUTISM DEV DISORD, V43, P1843, DOI 10.1007/s10803-012-1733-3; Millard T, 2013, AIDS PATIENT CARE ST, V27, P103, DOI 10.1089/apc.2012.0294; MUNDY P, 1990, J AUTISM DEV DISORD, V20, P115, DOI 10.1007/BF02206861; Oono IP., 2013, EVIDENCE BASED CHILD, V8, P2380, DOI [10.1002/ebch.1952, DOI 10.1002/EBCH.1952]; Oosterling I, 2010, J AUTISM DEV DISORD, V40, P689, DOI 10.1007/s10803-009-0915-0; Paul R., 2012, LANGUAGE DISORDERS I; Paul R, 2009, J AUTISM DEV DISORD, V39, P115, DOI 10.1007/s10803-008-0607-1; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Radley KC, 2014, FOCUS AUTISM DEV DIS, V29, P216, DOI 10.1177/1088357614525660; Rao PA, 2008, J AUTISM DEV DISORD, V38, P353, DOI 10.1007/s10803-007-0402-4; Roberts J, 2011, RES AUTISM SPECT DIS, V5, P1553, DOI 10.1016/j.rasd.2011.03.001; Ryan C, 2010, J AUTISM DEV DISORD, V40, P1505, DOI 10.1007/s10803-010-1009-8; Shire SY, 2015, J AUTISM DEV DISORD, V45, P1712, DOI 10.1007/s10803-014-2329-x; Snow CE, 1996, SOC DEV, V5, P56, DOI 10.1111/j.1467-9507.1996.tb00072.x; Soorya LV, 2015, J AM ACAD CHILD PSY, V54, P208, DOI 10.1016/j.jaac.2014.12.005; Spence Susan H, 2003, Child Adolesc Ment Health, V8, P84, DOI 10.1111/1475-3588.00051; Tager-Flusberg H, 2013, AUTISM RES, V6, P468, DOI 10.1002/aur.1329; Thomeer ML, 2015, J AUTISM DEV DISORD, V45, P2115, DOI 10.1007/s10803-015-2374-0; Watkins L, 2015, J AUTISM DEV DISORD, V45, P1070, DOI 10.1007/s10803-014-2264-x; Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757; White SW, 2007, J AUTISM DEV DISORD, V37, P1858, DOI 10.1007/s10803-006-0320-x; Whitehouse AJO, 2009, INT J LANG COMM DIS, V44, P511, DOI 10.1080/13682820802708098; Wong VCN, 2010, J AUTISM DEV DISORD, V40, P677, DOI 10.1007/s10803-009-0916-z	70	54	54	2	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2017	12	4							e0172242	10.1371/journal.pone.0172242	http://dx.doi.org/10.1371/journal.pone.0172242			37	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES9KM	28426832	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000399875900002
J	Takashio, S; Nagai, T; Sugano, Y; Honda, S; Okada, A; Asaumi, Y; Aiba, T; Noguchi, T; Kusano, KF; Ogawa, H; Yasuda, S; Anzai, T				Takashio, Seiji; Nagai, Toshiyuki; Sugano, Yasuo; Honda, Satoshi; Okada, Atsushi; Asaumi, Yasuhide; Aiba, Takeshi; Noguchi, Teruo; Kusano, Kengo F.; Ogawa, Hisao; Yasuda, Satoshi; Anzai, Toshihisa		NaDEF Investigators	Persistent increase in cardiac troponin Tat hospital discharge predicts repeat hospitalization in patients with acute decompensated heart failure	PLOS ONE			English	Article							NATIONAL REGISTRY; OUTCOMES; INSIGHTS; RELEASE	Background High-sensitive cardiac troponin T (hsTnT) is a sensitive biomarker of myocardial damage and predictor of acute decompensated heart failure (ADHF). However, there is little information on changes over time in hsTnT level during ADHF management. The aim of this prospective study was to evaluate changes in hsTnT levels between admission and at discharge in patients with ADHF, and identify factors that determine such levels and their prognostic significance. Methods and results We evaluated 404 ADHF patients with abnormal hsTnT levels (>0.0135 ng/ml) on admission. The median (interquartile ranges) hsTnT levels on admission, at discharge, and percent changes in hsTnT levels were 0.038 (0.026 to 0.065), 0.032 (0.021 to 0.049) ng/ml, and -12.0 (-39.8 to 7.4) % respectively. The numbers of patients with falling (hsTnT decrease > -15%), stable (hsTnT change between-15 and +15%) and rising (hsTnT increase > +15%) hsTnT level at discharge were 190, 146, and 68, respectively. The percent change in B-type natriuretic peptide (BNP) levels was greater in the falling group, compared to the stable (p<0.001) and rising groups (p<0.001). Changes in hsTnT levels correlated significantly with changes in BNP levels (p = 0.22, p<0.001). Multivariate Cox regression analysis identified rising or stable hsTnT at discharge as a significant predictor of heart failure-related rehospitalization (hazard ratio: 1.69; 95% confidence interval: 1.06 to 2.70; p = 0.03). Conclusions Persistent increase in hsTnT levels at discharge correlated with inadequate decrease of BNP levels, and was a predictor of poor clinical outcome, with repeat heart failure hospitalizations.	[Takashio, Seiji; Nagai, Toshiyuki; Sugano, Yasuo; Honda, Satoshi; Okada, Atsushi; Asaumi, Yasuhide; Aiba, Takeshi; Noguchi, Teruo; Kusano, Kengo F.; Ogawa, Hisao; Yasuda, Satoshi; Anzai, Toshihisa; NaDEF Investigators] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan	National Cerebral & Cardiovascular Center - Japan	Anzai, T (corresponding author), Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan.	anzai@ncvc.go.jp	Honda, Satoshi/GXG-5198-2022	Asaumi, Yasuhide/0000-0002-9009-7234; Honda, Satoshi/0000-0002-1393-4270	Japan Cardiovascular Research Foundation (Toshihisa Anzai) [24-4-2]; Japan Society for the Promotion of Science (Seiji Takashio) [26860574]; Japan Agency for Medical Research and Development (Toshiyuki Nagai) [201439103A]; Japan Society for the Promotion of Science (Toshiyuki Nagai) [15K19402]	Japan Cardiovascular Research Foundation (Toshihisa Anzai); Japan Society for the Promotion of Science (Seiji Takashio)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Agency for Medical Research and Development (Toshiyuki Nagai)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science (Toshiyuki Nagai)	This work was supported by Grants-in-Aid for Young Scientists B from Japan Society for the Promotion of Science (Seiji Takashio, 26860574), Grant from the Japan Cardiovascular Research Foundation (Toshihisa Anzai, 24-4-2), Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (Toshiyuki Nagai, 15K19402), and a Grant from the Japan Agency for Medical Research and Development (Toshiyuki Nagai, 201439103A).	Braga JR, 2013, CIRC-HEART FAIL, V6, P193, DOI 10.1161/CIRCHEARTFAILURE.112.000075; Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021; Felker GM, 2015, EUR J HEART FAIL, V17, P1262, DOI 10.1002/ejhf.341; Felker GM, 2012, EUR J HEART FAIL, V14, P1257, DOI 10.1093/eurjhf/hfs110; Feng J, 2001, CIRCULATION, V103, P2035; Gheorghiade M, 2005, AM J CARDIOL, V96, p11G, DOI 10.1016/j.amjcard.2005.07.016; Giannitsis E, 2010, CLIN CHEM, V56, P254, DOI 10.1373/clinchem.2009.132654; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Espartero MEG, 2014, EUR J INTERN MED, V25, P739, DOI 10.1016/j.ejim.2014.08.005; Hessel MHM, 2008, PFLUG ARCH EUR J PHY, V455, P979, DOI 10.1007/s00424-007-0354-8; Kociol RD, 2010, J AM COLL CARDIOL, V56, P1071, DOI 10.1016/j.jacc.2010.06.016; Latini R, 2007, CIRCULATION, V116, P1242, DOI 10.1161/CIRCULATIONAHA.106.655076; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Metra M, 2013, J AM COLL CARDIOL, V61, P196, DOI 10.1016/j.jacc.2012.11.005; Nieminen MS, 2008, EUR J HEART FAIL, V10, P140, DOI 10.1016/j.ejheart.2007.12.012; O'Connor CM, 2011, CIRC-HEART FAIL, V4, P724, DOI 10.1161/CIRCHEARTFAILURE.111.961581; Peacock WF, 2008, NEW ENGL J MED, V358, P2117, DOI 10.1056/NEJMoa0706824; Sato N, 2013, CIRC J, V77, P944, DOI 10.1253/circj.CJ-13-0187; Sherwood MW, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000403; Takashio S, 2013, J AM COLL CARDIOL, V62, P632, DOI 10.1016/j.jacc.2013.03.065; Tsutamoto T, 2009, EUR J HEART FAIL, V11, P653, DOI 10.1093/eurjhf/hfp072; Xue Y, 2011, EUR J HEART FAIL, V13, P37, DOI 10.1093/eurjhf/hfq210; Yancy CW, 2006, J AM COLL CARDIOL, V47, P76, DOI 10.1016/j.jacc.2005.09.022	23	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0173336	10.1371/journal.pone.0173336	http://dx.doi.org/10.1371/journal.pone.0173336			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28379962	Green Submitted, Green Published, gold			2023-01-03	WOS:000399353500016
J	Yu, ZG; Guo, FX; Guo, YY; Zhang, ZR; Wu, F; Luo, XQ				Yu, Zugong; Guo, Fanxi; Guo, Yangyang; Zhang, Zhenrui; Wu, Feng; Luo, Xiaoqing			Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels	PLOS ONE			English	Article							IMMUNE-ENHANCING ACTIVITY; IMMUNOSUPPRESSION; MEMBRANACEUS; CYCLOPHOSPHAMIDE; DELIVERY; SYSTEM; GAMMA; MICE	The objective of this study was to develop an injectable in situ forming gel system based on Poloxamer for sustained release of Astragalus polysaccharide (APS), thus achieved once or twice administration instead of frequent dosing during long-term treatment. The optimal formulation is 10 g APS, 18 g poloxamer 407, 2 g poloxamer 188, 0.15 g CMC-Na, 0.85 g sodium chloride in 100 ml gel in situ which had a preferable sol-gel transition temperature(T sol-gel) (34.1 +/- 0.4 degrees C), and good stability. In vitro release studies, all formulations containing polymer additives had prolonged release time and decreased initial burst to some extent. The optimal formulation containing 0.15% CMC-Na showed a best sustained release profile for about 132 h with the lowest initial burst in vitro about 16.30% in 12 h). In vivo, Male BALB/c mice (18 - 20 g) were administrated with APS in-situ gel just once, the values of immune organ indices, spleen lymphocyte proliferation, and serum IgM, IgG, IL-2 and IL-6 had significant increase, which was consistent with the mice given daily APS injections (7 times), while the above indices were increased more significantly in which administrated with APS in-situ gel twice. Based on these results, it can be concluded that the Poloxamer depot is a promising carrier for the sustained release of APS with an ideal release behavior.	[Yu, Zugong; Guo, Fanxi; Guo, Yangyang; Zhang, Zhenrui; Wu, Feng; Luo, Xiaoqing] Nanjing Agr Univ, Coll Vet Med, Lab Vet Pharmacol & Toxicol, Nanjing, Jiangsu, Peoples R China	Nanjing Agricultural University	Yu, ZG (corresponding author), Nanjing Agr Univ, Coll Vet Med, Lab Vet Pharmacol & Toxicol, Nanjing, Jiangsu, Peoples R China.	yuzugong@njau.edu.cn						Asasutjarit R, 2011, INT J PHARMACEUT, V411, P128, DOI 10.1016/j.ijpharm.2011.03.054; CAO Y, 2014, OXID MED CELL LONGEV, V2014, DOI DOI 10.1155/2014/674219; Chang WT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122374; Chen XM, 2012, CARBOHYD POLYM, V90, P1114, DOI 10.1016/j.carbpol.2012.06.052; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Fan YP, 2012, INT J BIOL MACROMOL, V50, P125, DOI 10.1016/j.ijbiomac.2011.10.008; Fu J, 2014, PHYTOTHER RES, V28, P1275, DOI 10.1002/ptr.5188; Garala K, 2013, INT J PHARM INVESTIG, V3, P29, DOI 10.4103/2230-973X.108961; Guo LW, 2012, CARBOHYD POLYM, V90, P1055, DOI 10.1016/j.carbpol.2012.06.042; Klouda L, 2008, EUR J PHARM BIOPHARM, V68, P34, DOI 10.1016/j.ejpb.2007.02.025; Letsch A, 2003, METHODS, V31, P143, DOI 10.1016/S1046-2023(03)00124-5; Li MX, 2011, J ETHNOPHARMACOL, V133, P412, DOI 10.1016/j.jep.2010.10.012; Li XT, 2012, INT J MOL SCI, V13, P1747, DOI 10.3390/ijms13021747; Nguyen XN, 2010, BIOORG MED CHEM LETT, V20, P4927, DOI 10.1016/j.bmcl.2010.06.044; Qi HY, 2007, INT J PHARM, V337, P178, DOI 10.1016/j.ijpharm.2006.12.038; Ren Z, 2014, INT J BIOL MACROMOL, V70, P590, DOI 10.1016/j.ijbiomac.2014.07.044; Wei G, 2002, J CONTROL RELEASE, V83, P65, DOI 10.1016/S0168-3659(02)00175-X; Wojcikowski K, 2010, PHYTOTHER RES, V24, P875, DOI 10.1002/ptr.3038; Yu ZG, 2015, J VET PHARMACOL THER, V38, P271, DOI 10.1111/jvp.12171; Yuan HM, 2006, CANCER LETT, V243, P228, DOI 10.1016/j.canlet.2005.11.032; Yuan Y, 2009, WORLD J GASTROENTERO, V15, P3676, DOI 10.3748/wjg.15.3676; Zhang J, 2013, INT J BIOL MACROMOL, V52, P212, DOI 10.1016/j.ijbiomac.2012.09.025; Zhao XH, 2015, INT J CLIN EXP MED, V8, P558	24	9	9	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2017	12	3							e0173949	10.1371/journal.pone.0173949	http://dx.doi.org/10.1371/journal.pone.0173949			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VE	28350799	Green Published, gold, Green Submitted			2023-01-03	WOS:000399174400010
J	Melville, JM; McDonald, CA; Bischof, RJ; Polglase, GR; Lim, R; Wallace, EM; Jenkin, G; Moss, TJ				Melville, Jacqueline M.; McDonald, Courtney A.; Bischof, Robert J.; Polglase, Graeme R.; Lim, Rebecca; Wallace, Euan M.; Jenkin, Graham; Moss, Timothy J.			Human amnion epithelial cells modulate the inflammatory response to ventilation in preterm lambs	PLOS ONE			English	Article							LUNG INFLAMMATION; IMMUNE-RESPONSE; INJURY; FETAL; MACROPHAGES; MEMBRANE; TRANSPLANTATION; INTERLEUKIN-8; ACTIVATION; EXPRESSION	Ventilation of preterm neonates causes pulmonary inflammation that can contribute to lung injury, propagate systemically and result in long-term disease. Modulation of this initial response may reduce lung injury and its sequelae. We aimed to determine the effect of human amnion epithelial cells (hAECs) on immune activation and lung injury in preterm neonatal lambs. Preterm lambs received intratracheal hAECs (90x10(6)) or vehicle, prior to 2 h of mechanical ventilation. Within 5 min of ventilation onset, lambs also received intravenous hAECs (90x10(6)) or vehicle. Lung histology, bronchoalveolar lavage (BAL) cell phenotypes, and cytokine profiles were examined after 2 h of ventilation, and in unventilated controls. Histological indices of lung injury were higher than control, in vehicle-treated ventilated lambs but not in hAEC-treated ventilated lambs. Ventilation-induced pulmonary leukocyte recruitment was greater in hAEC-treated lambs than in vehicle-treated lambs. Lung IL-1 beta and IL-6 mRNA expression was higher in vehicle-and hAEC-treated ventilated lambs than in controls but IL-8 mRNA levels were greater than control only in vehicle-treated ventilated lambs. Numbers of CD44(+) and CD21(+) lymphocytes and macrophages from the lungs were altered in vehicle-and hAEC-treated ventilated lambs. Numbers of CD8(+) macrophages were lower in hAEC-treated ventilated lambs than in vehicle-treated ventilated lambs. Indices of systemic inflammation were not different between vehicle-and hAEC-treated lambs. Human amnion epithelial cells modulate the pulmonary inflammatory response to ventilation in preterm lambs, and reduce acute lung injury. Immunomodulatory effects of hAECs reduce lung injury in preterm neonates and may protect against longer-term respiratory disease.	[Melville, Jacqueline M.; McDonald, Courtney A.; Bischof, Robert J.; Polglase, Graeme R.; Lim, Rebecca; Wallace, Euan M.; Jenkin, Graham; Moss, Timothy J.] Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia; [Polglase, Graeme R.; Lim, Rebecca; Wallace, Euan M.; Jenkin, Graham; Moss, Timothy J.] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic, Australia	Hudson Institute of Medical Research; Monash University	Bischof, RJ (corresponding author), Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia.	robert.bischof@hudson.org.au	Lim, Rebecca/K-5175-2019; Moss, Timothy/A-6633-2008; Wallace, Euan M/K-6774-2015	Lim, Rebecca/0000-0002-0410-497X; Moss, Timothy/0000-0002-9408-4027; Wallace, Euan M/0000-0002-4506-5233; Polglase, Graeme/0000-0002-8906-614X; McDonald, Courtney/0000-0001-8421-461X; Bischof, Robert/0000-0002-6649-9612	National Health and Medical Research Council; State Government of Victoria	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); State Government of Victoria	This work was supported by the National Health and Medical Research Council (https://www.nhmrc.gov.au/), and the State Government of Victoria (http://www.vic.gov.au/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeynaike L, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-46; Attar Mohammad Ali, 2002, Semin Neonatol, V7, P353, DOI 10.1053/siny.2002.0129; Azuara-Blanco A, 1999, BRIT J OPHTHALMOL, V83, P399, DOI 10.1136/bjo.83.4.399; Ballabh P, 2003, AM J PERINAT, V20, P465; Barton SK, 2015, DEV NEUROSCI; Bischof RJ, 2003, CLIN EXP ALLERGY, V33, P367, DOI 10.1046/j.1365-2222.2003.01534.x; Bischof RJ, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-16; Bose CL, 2008, ARCH DIS CHILD-FETAL, V93, P1455, DOI 10.1136/adc.2007.121327; Gahler A, 2000, PEDIATR RES, V48, P299; Gien J, 2011, CURR OPIN PEDIATR, V23, P305, DOI 10.1097/MOP.0b013e328346577f; Gulbahar MY, 2009, VET PARASITOL, V160, P272, DOI 10.1016/j.vetpar.2008.11.012; Herrmann LM, 2003, AM J PATHOL, V162, P1075, DOI 10.1016/S0002-9440(10)63904-1; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V300, pL232, DOI 10.1152/ajplung.00294.2010; Hiraki K, 2009, J NEUROSCI RES, V87, P1175, DOI 10.1002/jnr.21924; Hirji N, 1997, J IMMUNOL, V158, P1833; Hodges RJ, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.038; Ilancheran S, 2007, BIOL REPROD, V77, P577, DOI 10.1095/biolreprod.106.055244; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Ko JH, 2016, P NATL ACAD SCI USA, V113, P158, DOI 10.1073/pnas.1522905113; KOTECHA S, 1995, ARCH DIS CHILD-FETAL, V72, pF90, DOI 10.1136/fn.72.2.F90; Kwong LS, 2002, VET IMMUNOL IMMUNOP, V85, P213, DOI 10.1016/S0165-2427(02)00007-7; Li Z, 2013, AUSTR MOTHERS BABIES, V28; Lin TJ, 2000, J IMMUNOL, V164, P1783, DOI 10.4049/jimmunol.164.4.1783; Liravi B, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0097-9; Makita N, 2014, INT IMMUNOL; McDonald CA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt495; Miki T, 2005, STEM CELLS, V23, P1549, DOI 10.1634/stemcells.2004-0357; Moodley Y, 2010, AM J RESP CRIT CARE, V182, P643, DOI 10.1164/rccm.201001-0014OC; Moss TJM, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.044; Murphy Sean, 2010, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01e06s13; Murphy S, 2011, CELL TRANSPLANT, V20, P909, DOI 10.3727/096368910X543385; Murphy SV, 2012, CELL TRANSPLANT, V21, P1477, DOI 10.3727/096368911X601028; Murphy SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040924; Naik AS, 2001, AM J RESP CRIT CARE, V164, P494, DOI 10.1164/ajrccm.164.3.2010127; Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007-0594; Perlman JM, 2006, PEDIATRICS, V117, pE978, DOI 10.1542/ped.2006-0350; Polglase GR, 2014, J PHYSIOL-LONDON, V592, P1993, DOI 10.1113/jphysiol.2013.270348; Polglase GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039535; Stern M, 1913, J AMER MED ASSOC, V60, P973, DOI 10.1001/jama.1913.04340130021008; Tan JL, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt542; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Turunen R, 2009, NEONATOLOGY, V96, P248, DOI 10.1159/000220764; van der Windt GJW, 2011, AM J RESP CELL MOL, V44, P377, DOI 10.1165/rcmb.2010-0158OC; Vosdoganes P, 2013, CYTOTHERAPY; Vosdoganes P, 2012, CELL TRANSPLANT; Vosdoganes P, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.054; Wallace MJ, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-19; Westover AJ, 2012, AM J PHYSIOL-LUNG C, V302, P1664, DOI 10.1152/ajplung.00297.2011; Yawno T, 2013, DEV NEUROSCI-BASEL, V35, P272, DOI 10.1159/000346683	49	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2017	12	3							e0173572	10.1371/journal.pone.0173572	http://dx.doi.org/10.1371/journal.pone.0173572			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VD	28346529	Green Published, Green Submitted, gold			2023-01-03	WOS:000399174300008
J	Frank, RG; Pollack, HA				Frank, Richard G.; Pollack, Harold A.			Addressing the Fentanyl Threat to Public Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Drug Enforcement Agency, 2016, DEA WARN POL PUBL FE; Drug Enforcement Agency, 2016, NAT HER THREAT ASS S; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Kleiman MAR, 2012, ISSUES SCI TECHNOL, V28, P79; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374	5	144	148	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2017	376	7					605	607		10.1056/NEJMp1615145	http://dx.doi.org/10.1056/NEJMp1615145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO0QJ	28199808				2023-01-03	WOS:000396402700009
J	Saper, RB; Lemaster, C; Delitto, A; Sherman, KJ; Herman, PM; Sadikova, E; Stevans, J; Keosaian, JE; Cerrada, CJ; Femia, AL; Roseen, EJ; Gardiner, P; Barnett, KG; Faulkner, C; Weinberg, J				Saper, R. B.; Lemaster, C.; Delitto, A.; Sherman, K. J.; Herman, P. M.; Sadikova, E.; Stevans, J.; Keosaian, J. E.; Cerrada, C. J.; Femia, A. L.; Roseen, E. J.; Gardiner, P.; Barnett, K. Gergen; Faulkner, C.; Weinberg, J.			Yoga, Physical Therapy, or Education for Chronic Low Back Pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													Saper, Robert B/Y-4598-2018	Saper, Robert B/0000-0002-0992-6198; Roseen, Eric/0000-0002-3240-6756					0	0	0	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2017	167	2					JC1	JC1		10.7326/P17-9039	http://dx.doi.org/10.7326/P17-9039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA6SD	28631006				2023-01-03	WOS:000405573400002
J	Fuchs, H; Rossmann, N; Schmid, MB; Hoenig, M; Thome, U; Mayer, B; Klotz, D; Hummler, HD				Fuchs, Hans; Rossmann, Nicola; Schmid, Manuel B.; Hoenig, Manfred; Thome, Ulrich; Mayer, Benjamin; Klotz, Daniel; Hummler, Helmut D.			Permissive hypercapnia for severe acute respiratory distress syndrome in immunocompromised children: A single center experience	PLOS ONE			English	Article							STEM-CELL TRANSPLANTATION; LUNG INJURY; THERAPEUTIC HYPERCAPNIA; VENTILATED PATIENTS; 6 ML/KG; ACIDOSIS; MORTALITY; PULMONARY; STRATEGY; OUTCOMES	Background Controlled hypoventilation while accepting hypercapnia has been advocated to reduce ventilator-induced lung injury. The aim of the study was to analyze outcomes of a cohort of immunocompromised children with acute respiratory distress syndrome (ARDS) ventilated with a strategy of stepwise increasing PCO2 targets up to 140 mm Hg. Methods Retrospective analysis of outcomes of a cohort of children with oncologic disease or after stem cell transplantation and severe respiratory failure in comparison with a historical control cohort. Results Out of 150 episodes of admission to the PICU 88 children underwent invasive mechanical ventilation for >24h (overall survival 75%). In a subgroup of 38 children with high ventilator requirements the PCO2 target ranges were increased stepwise. Fifteen children survived and were discharged from the PICU. Severe pulmonary hypertension was seen in two patients and no case of cerebral edema was observed. Long term outcome was available in 15 patients and 10 of these patients survived without adverse neurological sequelae. With introduction of this strategy survival of immunocompromised children undergoing mechanical ventilation for >24h increased to 48% compared to 32% prior to introduction historical cohort). Conclusions A ventilation strategy incorporating very high carbon dioxide levels to allow for low tidal volumes and limited inspiratory pressures is feasible in children. Even severe hypercapnia may be well tolerated. No severe side effects associated with hypercapnia were observed. This strategy could potentially increase survival in immunocompromised children with severe ARDS.	[Fuchs, Hans; Klotz, Daniel] Albert Ludwig Univ Freiburg, Fac Med, Med Ctr, Ctr Pediat,Dept Neonatol & Pediat Intens Care, Freiburg, Germany; [Rossmann, Nicola; Hummler, Helmut D.] Ulm Univ, Dept Pediat & Adolescent Med, Div Neonatol & Pediat Crit Care, Ulm, Germany; [Schmid, Manuel B.] Univ Zurich, Univ Hosp Zurich, Dept Neonatol, Zurich, Switzerland; [Hoenig, Manfred] Ulm Univ, Dept Pediat & Adolescent Med, Oncol & Stem Cell Transplantat, Ulm, Germany; [Thome, Ulrich] Univ Hosp Leipzig, Div Neonatol, Leipzig, Germany; [Mayer, Benjamin] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany	University of Freiburg; Ulm University; University of Zurich; University Zurich Hospital; Ulm University; Leipzig University; Ulm University	Fuchs, H (corresponding author), Albert Ludwig Univ Freiburg, Fac Med, Med Ctr, Ctr Pediat,Dept Neonatol & Pediat Intens Care, Freiburg, Germany.	hans.fuchs@uniklinik-freiburg.de	Hummler, Helmut/AAN-7297-2021; Klotz, Daniel/AAB-2585-2022	Klotz, Daniel/0000-0003-2347-3866; Bryant, Manuel/0000-0002-5981-1006				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], 2014, J INTENSIVE CARE MED, V29, P31, DOI 10.1177/0885066612457343; Bein T, 2013, INTENS CARE MED, V39, P847, DOI 10.1007/s00134-012-2787-6; Briva A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001238; Broccard AF, 2001, AM J RESP CRIT CARE, V164, P802, DOI 10.1164/ajrccm.164.5.2007060; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carvalho CRR, 1997, AM J RESP CRIT CARE, V156, P1458, DOI 10.1164/ajrccm.156.5.9604081; Chima RS, 2012, PEDIATR CRIT CARE ME, V13, pE336, DOI 10.1097/PCC.0b013e318253c945; Chonghaile MN, 2008, CRIT CARE MED, V36, P3135, DOI 10.1097/CCM.0b013e31818f0d13; Costello J, 2009, CRIT CARE MED, V37, P2412, DOI 10.1097/CCM.0b013e3181a385d3; Dellinger RP, 2013, CRIT CARE MED, V41, P637, DOI [DOI 10.1097/CCM.0b013e31827e83af, DOI 10.1007/s00134-015-3827-9]; Doerr CH, 2005, AM J RESP CRIT CARE, V171, P1371, DOI 10.1164/rccm.200309-1223OC; Fuchs H, 2015, KLIN PADIATR, V227, P322, DOI 10.1055/s-0034-1395692; Fuchs H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023816; Galluccio Steven T, 2008, Crit Care Resusc, V10, P235; Gates Khalilah L, 2013, Am J Respir Cell Mol Biol, V49, P821, DOI 10.1165/rcmb.2012-0487OC; Hummler HD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147807; Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350; Joyce Ryan R, 2011, J Med Case Rep, V5, P192, DOI 10.1186/1752-1947-5-192; Ketabchi F, 2009, AM J PHYSIOL-LUNG C, V297, pL977, DOI 10.1152/ajplung.00074.2009; Komori M, 2007, CRIT CARE MED, V35, P2171, DOI 10.1097/01.ccm.0000281445.77223.31; Kregenow DA, 2006, CRIT CARE MED, V34, P1, DOI 10.1097/01.CCM.0000194533.75481.03; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P2287, DOI 10.1164/ajrccm.162.6.2003066; Laffey JG, 2003, AM J RESP CRIT CARE, V168, P1383, DOI 10.1164/rccm.2108078; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Lheritier G, 2013, INTENS CARE MED, V39, P1734, DOI 10.1007/s00134-013-3017-6; Nichol AD, 2009, CRIT CARE MED, V37, P2953, DOI 10.1097/CCM.0b013e3181b028ce; Nin N, 2017, INTENS CARE MED, V43, P200, DOI 10.1007/s00134-016-4611-1; O'Croinin DF, 2008, CRIT CARE MED, V36, P2128, DOI 10.1097/CCM.0b013e31817d1b59; O'Toole D, 2009, THORAX, V64, P976, DOI 10.1136/thx.2008.110304; Peltekova V, 2010, INTENS CARE MED, V36, P869, DOI 10.1007/s00134-010-1787-7; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Santschi M, 2013, PEDIATR CRIT CARE ME, V14, pE332, DOI 10.1097/PCC.0b013e31828a89a2; Sinclair SE, 2002, AM J RESP CRIT CARE, V166, P403, DOI 10.1164/rccm.200112-117OC; Stubs CCM, 2013, MICROVASC RES, V90, P180, DOI 10.1016/j.mvr.2013.07.008; Tamburro RF, 2008, PEDIATR CRIT CARE ME, V9, P270, DOI 10.1097/PCC.0b013e31816c7260; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; van Gestel JPJ, 2008, CRIT CARE MED, V36, P2898, DOI 10.1097/CCM.0b013e318186a34a; van Gestel JRJ, 2008, BIOL BLOOD MARROW TR, V14, P1385, DOI 10.1016/j.bbmt.2008.09.020; Zabrocki LA, 2011, CRIT CARE MED, V39, P364, DOI 10.1097/CCM.0b013e3181fb7b35	41	6	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2017	12	6							e0179974	10.1371/journal.pone.0179974	http://dx.doi.org/10.1371/journal.pone.0179974			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY5UN	28632754	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000404046100055
J	Kraft, WK; Adeniyi-Jones, SC; Chervoneva, I; Greenspan, JS; Abatemarco, D; Kaltenbach, K; Ehrlich, ME				Kraft, Walter K.; Adeniyi-Jones, Susan C.; Chervoneva, Inna; Greenspan, Jay S.; Abatemarco, Diane; Kaltenbach, Karol; Ehrlich, Michelle E.			Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBLINGUAL BUPRENORPHINE; PRETERM; TERM	BACKGROUND Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. METHODS In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (>= 37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive either sublingual buprenorphine or oral morphine. Infants with symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phenobarbital. The primary end point was the duration of treatment for symptoms of neonatal opioid withdrawal. Secondary clinical end points were the length of hospital stay, the percentage of infants who required supplemental treatment with phenobarbital, and safety. RESULTS The median duration of treatment was significantly shorter with buprenorphine than with morphine (15 days vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered in 5 of 33 infants (15%) in the buprenorphine group and in 7 of 30 infants (23%) in the morphine group (P = 0.36). Rates of adverse events were similar in the two groups. CONCLUSIONS Among infants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphine, with similar rates of adverse events. (Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov number, NCT01452789.)	[Kraft, Walter K.; Adeniyi-Jones, Susan C.; Chervoneva, Inna; Greenspan, Jay S.; Abatemarco, Diane; Kaltenbach, Karol] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Adeniyi-Jones, Susan C.; Greenspan, Jay S.] Thomas Jefferson Univ Hosp, Nemours duPont Pediat, Philadelphia, PA 19107 USA; [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA	Jefferson University; Jefferson University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Kraft, WK (corresponding author), Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Sidney Kimmel Med Coll, 1170 Main Bldg,132 S 10th St, Philadelphia, PA 19107 USA.	walter.kraft@jefferson.edu			National Institute on Drug Abuse; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002976, R01DA029076] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov number, NCT01452789.	Anagnostis Ellena A, 2011, J Pediatr Pharmacol Ther, V16, P281, DOI 10.5863/1551-6776-16.4.281; BARRETT DA, 1993, BRIT J CLIN PHARMACO, V36, P215, DOI 10.1111/j.1365-2125.1993.tb04220.x; DOBERCZAK TM, 1991, J PEDIATR-US, V118, P933, DOI 10.1016/S0022-3476(05)82214-0; Dysart K, 2007, J PERINAT MED, V35, P344, DOI 10.1515/JPM.2007.063; Gowing L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002025.pub5; Holmes AV, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2929; Hudak ML, 2012, PEDIATRICS, V129, pE540, DOI 10.1542/peds.2011-3212; Kaltenbach K, 2016, J ADDICT MED, V10, P217, DOI 10.1097/ADM.0000000000000207; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Kraft WK, 2008, PEDIATRICS, V122, pE601, DOI 10.1542/peds.2008-0571; Kraft WK, 2011, ADDICTION, V106, P574, DOI 10.1111/j.1360-0443.2010.03170.x; Ng CM, 2015, PHARMACOTHERAPY, V35, P670, DOI 10.1002/phar.1610; Osborn DA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002059.pub3; Patrick SW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3835; Sauberan J, 2013, J ADDICT MED, V7, P113, DOI 10.1097/ADM.0b013e318280f495; Seligman NS, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.088; Short VL, 2016, BREASTFEED MED, V11, P343, DOI 10.1089/bfm.2016.0084; VANELTEREN P, 1960, B INT STATIST INST, V37, P351	18	76	77	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	2017	376	24					2341	2348		10.1056/NEJMoa1614835	http://dx.doi.org/10.1056/NEJMoa1614835			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX4UQ	28468518	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000403230800007
J	Hoben, M; Kent, A; Kobagi, N; Huynh, KT; Clarke, A; Yoon, MN				Hoben, Matthias; Kent, Angelle; Kobagi, Nadia; Kha Tu Huynh; Clarke, Alix; Yoon, Minn N.			Effective strategies to motivate nursing home residents in oral care and to prevent or reduce responsive behaviors to oral care: A systematic review	PLOS ONE			English	Review							LONG-TERM-CARE; INSTITUTIONALIZED ELDERLY-PEOPLE; QUALITY-OF-LIFE; HEALTH-CARE; ALZHEIMERS-DISEASE; COMMUNICATION STRATEGIES; AGITATED BEHAVIOR; SEVERE DEMENTIA; SINGLE-SESSION; MORNING CARE	Background Poor oral health has been a persistent problem in nursing home residents for decades, with severe consequences for residents and the health care system. Two major barriers to providing appropriate oral care are residents' responsive behaviors to oral care and residents' lack of ability or motivation to perform oral care on their own. Objectives To evaluate the effectiveness of strategies that nursing home care providers can apply to either prevent/overcome residents' responsive behaviors to oral care, or enable/motivate residents to perform their own oral care. Materials and methods We searched the databases Medline, EMBASE, Evidence Based Reviews-Cochrane Central Register of Controlled Trials, CINAHL, and Web of Science for intervention studies assessing the effectiveness of eligible strategies. Two reviewers independently (a) screened titles, abstracts and retrieved full-texts; (b) searched key journal contents, key author publications, and reference lists of all included studies; and (c) assessed methodological quality of included studies. Discrepancies at any stage were resolved by consensus. We conducted a narrative synthesis of study results. Results We included three one-group pre-test, post-test studies, and one cross-sectional study. Methodological quality was low (n = 3) and low moderate (n = 1). Two studies assessed strategies to enable/motivate nursing home residents to perform their own oral care, and to studies assessed strategies to prevent or overcome responsive behaviors to oral care. All studies reported improvements of at least some of the outcomes measured, but interpretation is limited due to methodological problems. Conclusions Potentially promising strategies are available that nursing home care providers can apply to prevent/overcome residents' responsive behaviors to oral care or to enable/motivate residents to perform their own oral care. However, studies assessing these strategies have a high risk for bias. To overcome oral health problems in nursing homes, care providers will need practical strategies whose effectiveness was assessed in robust studies.	[Hoben, Matthias; Kent, Angelle; Kha Tu Huynh] Univ Alberta, Fac Nursing, Edmonton, AB, Canada; [Kobagi, Nadia; Clarke, Alix; Yoon, Minn N.] Univ Alberta, Sch Dent, Fac Med & Dent, Edmonton, AB, Canada	University of Alberta; University of Alberta	Hoben, M (corresponding author), Univ Alberta, Fac Nursing, Edmonton, AB, Canada.	mhoben@ualberta.ca		Hoben, Matthias/0000-0003-3465-315X; Yoon, Minn/0000-0002-1949-793X	School of Dentistry, University of Alberta; Faculty of Nursing, University of Alberta; Dr. Carole Estabrooks, Canada Research Chair (Tier 1) in Knowledge Translation, Faculty of Nursing, University of Alberta	School of Dentistry, University of Alberta; Faculty of Nursing, University of Alberta(University of Alberta); Dr. Carole Estabrooks, Canada Research Chair (Tier 1) in Knowledge Translation, Faculty of Nursing, University of Alberta	This research has been supported by intramural funds from the School of Dentistry, University of Alberta, and the Faculty of Nursing, University of Alberta; MH holds an Alberta Innovates Health Solutions (AIHS) Post Doctoral Fellowship. Additional funding was provided by Dr. Carole Estabrooks, Canada Research Chair (Tier 1) in Knowledge Translation, Faculty of Nursing, University of Alberta. None of the funders has played any role in developing the systematic review protocol.	Adegbembo Albert O, 2002, J Can Dent Assoc, V68, P412; Almomani F, 2009, J DENT RES, V88, P648, DOI 10.1177/0022034509338156; Alzheimer Society of Canada, 2010, RIS TID IMP DEM CAN; Alzheimer Society Ontario, WHAT AR RESP BEH; [Anonymous], 2015, WORLD ALZH REP 2015; Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x; Arpin S, 2008, J CAN DENT ASSOC, V74, P807; Awano S, 2008, J DENT RES, V87, P334, DOI 10.1177/154405910808700418; Azarpazhooh Amir, 2012, J Can Dent Assoc, V78, pc25; Ballard CG, 2002, J CLIN PSYCHIAT, V63, P553, DOI 10.4088/JCP.v63n0703; Bartfay E, 2013, INT J GERIATR PSYCH, V28, P1086, DOI 10.1002/gps.3934; Beerens HC, 2015, J ADV NURS, V71, P1435, DOI 10.1111/jan.12570; Berta W, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-25; Blinkhorn FA, 2012, HEALTH EDUC J, V71, P527, DOI 10.1177/0017896911412127; Brand VS, 2013, INT J DENT HYG, V11, P134, DOI 10.1111/idh.12012; Bureau of Labor Statistics, 2014, OCC EMPL STAT MAY 20; Burgio LD, 2002, GERONTOLOGIST, V42, P487, DOI 10.1093/geront/42.4.487; Canada Statistics, 2011, RES CAR FAC 2009 201; Canadian Healthcare Association, 2009, NEW DIR FAC BAS LONG; Cascaes AM, 2014, REV SAUDE PUBL, V48, P142, DOI 10.1590/S0034-8910.2014048004616; Chalmers J, 2005, J ADV NURS, V52, P410, DOI 10.1111/j.1365-2648.2005.03605.x; Chalmers Jane M, 2002, Gerodontology, V19, P30, DOI 10.1111/j.1741-2358.2002.00030.x; Chami K, 2012, J AM MED DIR ASSOC, V13, pE1, DOI 10.1016/j.jamda.2011.06.007; Chung J C, 2002, Cochrane Database Syst Rev, pCD003152; Clark M E, 1998, J Gerontol Nurs, V24, P10; Clarke M, 2001, COCHRANE REV HDB 4 1; Coker E, 2014, RES GERONTOL NURS, V7, P87, DOI 10.3928/19404921-20140110-01; Coleman P, 2006, J AM GERIATR SOC, V54, P138, DOI 10.1111/j.1532-5415.2005.00565.x; Commission European, 2012, LONG TERM CAR ELD PR; Congress of the United States - Congressional Budget Office, 2013, RIS DEM LONG TERM SE; Connell B., 2002, ALZHEIMERS CARE Q, V3, P19; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; de Lugt-Lustig KHME, 2014, COMMUNITY DENT ORAL, V42, P88, DOI 10.1111/cdoe.12063; De Vet H, 1997, PHYSIOTHERAPY, V83, P284, DOI DOI 10.1016/S0031-9406(05)66175-5; De Visschere LMJ, 2011, GERODONTOLOGY, V28, P307, DOI 10.1111/j.1741-2358.2010.00406.x; Dunn Joshua C, 2002, J Gerontol Nurs, V28, P6; Edberg A K, 1996, Clin Nurs Res, V5, P127, DOI 10.1177/105477389600500202; Emami E, 2013, INT J DENT, V2013, DOI 10.1155/2013/498305; Estabrooks CA, 2015, CAN J AGING, V34, P47, DOI 10.1017/S0714980814000506; Estabrooks CA, 2013, CAN J AGING, V32, P223, DOI 10.1017/S0714980813000287; Frenkel H, 2010, ORAL HEALTHCARE FRAI, P187; Ganss C, 2009, CLIN ORAL INVEST, V13, P203, DOI 10.1007/s00784-008-0230-8; Garland K, 2007, AM J GERIAT PSYCHIAT, V15, P514, DOI 10.1097/01.JGP.0000249388.37080.b4; Gerdner LA, 2000, INT PSYCHOGERIATR, V12, P49, DOI 10.1017/S1041610200006190; Godard A, 2011, J CLIN PERIODONTOL, V38, P1099, DOI 10.1111/j.1600-051X.2011.01782.x; Harrington C., 2015, NURSING FACILITIES S; Harris-Kojetin L., 2016, VITAL HLTH STAT, V3, DOI DOI 10.1111/J.1532-5415.2010.02875.X; Harrison RL, 2012, J DENT RES, V91, P1032, DOI 10.1177/0022034512459758; Harrison R, 2007, PEDIATR DENT, V29, P16; Haumschild MS, 2009, J AM MED DIR ASSOC, V10, P667, DOI 10.1016/j.jamda.2009.01.002; He W, 2016, P95161 US CENS BUR, VP95, P16; Hirdes JP, 2011, CAN J AGING, V30, P371, DOI 10.1017/S0714980811000304; Hoben M, 2014, INT J HLTH PROF, V1, P34, DOI DOI 10.2478/IJHP-2014-0002; Hoben M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011159; Hoffmann F, 2014, AGING CLIN EXP RES, V26, P555, DOI 10.1007/s40520-014-0210-6; Holmes C, 2002, INT J GERIATR PSYCH, V17, P305, DOI 10.1002/gps.593; Institute of Medicine of the National Academies, 2011, ADV OR HLTH AM; Ismail AI, 2011, COMMUNITY DENT ORAL, V39, P433, DOI 10.1111/j.1600-0528.2011.00613.x; Jablonski RA, 2011, SPEC CARE DENT, V31, P77, DOI 10.1111/j.1754-4505.2011.00190.x; Jablonski RA, 2011, RES THEOR NURS PRACT, V25, P163, DOI 10.1891/1541-6577.25.3.163; Jablonski RA, 2011, BMC ORAL HEALTH, V11, DOI 10.1186/1472-6831-11-30; Jablonski-Jaudon RA, 2016, J GERONTOL NURS, V42, P15, DOI 10.3928/00989134-20160212-05; Jansen I., 2009, RESIDENTIAL LONG TER; Johnson VB, 2012, J GERONTOL NURS, V38, P11, DOI 10.3928/00989134-20121003-02; Jonsson B, 2010, J CLIN PERIODONTOL, V37, P912, DOI 10.1111/j.1600-051X.2010.01590.x; Kajermo KN, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-32; Khan K. S., 2001, 4 CRD U YORK; Kmet LM, 2004, STANDARD QUALITY ASS, DOI DOI 10.7939/R37M04F16; Little SJ, 1997, J PERIODONTAL RES, V32, P315, DOI 10.1111/j.1600-0765.1997.tb00540.x; Locker D, 1993, J Can Dent Assoc, V59, P830; Lopez-Jornet P, 2014, GERODONTOLOGY, V31, P288, DOI 10.1111/ger.12037; Louropoulou A, 2014, J EVID-BASED DENT PR, V14, P60, DOI 10.1016/j.jebdp.2014.03.008; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; MacEntee MI, 2006, J CAN DENT ASSOC, V72, P421; MacEntee MI, 2011, J DENT, V39, pS34, DOI 10.1016/j.jdent.2011.10.017; Mancini M, 2010, CURR ALZHEIMER RES, V7, P368, DOI 10.2174/156720510791162359; Zuluaga DJM, 2012, GERODONTOLOGY, V29, pE420, DOI 10.1111/j.1741-2358.2011.00490.x; Matthews DC, 2012, J CAN DENT ASSOC, V78, P1; Maupome Gerardo, 2002, Spec Care Dentist, V22, P194, DOI 10.1111/j.1754-4505.2002.tb00270.x; McCallion P, 1999, GERONTOLOGIST, V39, P546, DOI 10.1093/geront/39.5.546; McGilton KS, 2009, WORLDV EVID-BASED NU, V6, P149, DOI 10.1111/j.1741-6787.2009.00155.x; McGrath C, 2009, GERODONTOLOGY, V26, P85, DOI 10.1111/j.1741-2358.2008.00232.x; McGregor MJ, 2011, RESIDENTIAL LONG TER; McNally ME, 2014, GERODONTOLOGY, V31, P123, DOI 10.1111/ger.12022; Miegel K, 2009, INT J OLDER PEOPLE N, V4, P97, DOI 10.1111/j.1748-3743.2008.00150.x; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; O'Connor DW, 2009, INT PSYCHOGERIATR, V21, P225, DOI 10.1017/S1041610208007588; O'Connor LJ, 2012, EVIDENCE BASED GERIA, P409; OECD, 2015, ADDR DEM OECD RESP O; Organisation for Economic Co-operation and Development, 2015, OECD HLTH STAT 2015; Patrick DL, 2010, COMMONWEALTHS HIGH R; Pearson Alan, 2004, JBI Libr Syst Rev, V2, P1; Preston AJ, 2006, BRIT DENT J, V201, P293, DOI 10.1038/sj.bdj.4813973; Raghoonandan P., 2011, CAN J DENT HYGIENE, V45, P217; Registered Nurses' Association of Ontario (RNAO), 2008, OR HLTH NURS ASS INT; Renz A, 2007, COCHRANE DB SYST REV, V2007; Shimazaki Y, 2004, J ORAL REHABIL, V31, P837, DOI 10.1111/j.1365-2842.2004.01320.x; Shippee TP, 2015, GERONTOLOGIST, V55, P643, DOI 10.1093/geront/gnt148; Slade GD, 1996, J DENT RES, V75, P1439, DOI 10.1177/00220345960750070301; Sloane P, 2012, ALZHEIMERS DEMENT, V8, pP251; Sloane PD, 2013, J AM GERIATR SOC, V61, P1158, DOI 10.1111/jgs.12317; Speziale J, 2009, GERONTOLOGIST, V49, P570, DOI 10.1093/geront/gnp069; Squires JE, 2015, NURS RES PRACT, V2015, DOI 10.1155/2015/157924; Squires JE, 2011, IMPLEMENT SCI, V6, DOI [10.1186/1748-5908-6-1, 10.1186/1748-5908-6-21]; Stenman J, 2012, J CLIN PERIODONTOL, V39, P947, DOI 10.1111/j.1600-051X.2012.01926.x; STEWART JE, 1991, J CLIN PERIODONTOL, V18, P219, DOI 10.1111/j.1600-051X.1991.tb00418.x; Stewart JE, 1996, PATIENT EDUC COUNS, V27, P269, DOI 10.1016/0738-3991(95)00843-8; Stewart R, 2014, AGE AGEING, V43, P562, DOI 10.1093/ageing/afu062; Taylor GW, 2000, J PUBLIC HEALTH DENT, V60, P313, DOI 10.1111/j.1752-7325.2000.tb03341.x; Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x; United States Department of Health and Human Services, 2000, HLTH PEOPL 2010, V2; van Weert JCM, 2006, J ADV NURS, V53, P656, DOI 10.1111/j.1365-2648.2006.03772.x; van Weert JCM, 2005, PATIENT EDUC COUNS, V58, P312, DOI 10.1016/j.pec.2004.07.013; Vanobbergen JN, 2005, COMMUNITY DENT HLTH, V22, P260; Vasse E, 2010, INT PSYCHOGERIATR, V22, P189, DOI 10.1017/S1041610209990615; Wardh Inger, 2012, Gerodontology, V29, pe787, DOI 10.1111/j.1741-2358.2011.00562.x; Weening-Verbree L, 2013, INT J NURS STUD, V50, P569, DOI 10.1016/j.ijnurstu.2012.12.004; Weinstein R, 1996, J CLIN PERIODONTOL, V23, P283, DOI 10.1111/j.1600-051X.1996.tb02090.x; Wells DL, 2000, J AM GERIATR SOC, V48, P442; Wilson R, 2013, J COMMUN DISORD, V46, P249, DOI 10.1016/j.jcomdis.2013.01.004; Wyatt Chris C L, 2002, J Can Dent Assoc, V68, P359; Yao CS, 2014, J CAN DENT ASSOC, V80; Young BC, 2008, BRIT DENT J, V205, DOI 10.1038/sj.bdj.2008.894; Zimmerman S, 2012, ALZHEIMERS DEMENT, V8, pP384; Zimmerman S, 2014, GERONTOLOGIST, V54, pS25, DOI 10.1093/geront/gnt145	126	19	19	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2017	12	6							e0178913	10.1371/journal.pone.0178913	http://dx.doi.org/10.1371/journal.pone.0178913			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX5IQ	28609476	gold, Green Published, Green Submitted			2023-01-03	WOS:000403274700017
J	Walker, J; Chaar, BB; Vera, N; Pillai, AS; Lim, JS; Bero, L; Moles, RJ				Walker, Josephine; Chaar, Betty B.; Vera, Numa; Pillai, Alvish S.; Lim, Jessy S.; Bero, Lisa; Moles, Rebekah J.			Medicine shortages in Fiji: A qualitative exploration of stakeholders' views	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; DRUGS; OUTCOMES; RECOMMENDATIONS; MANAGEMENT; LOGISTICS; ADHERENCE; CARE	Objectives Medicine access is a human right; yet, concerningly, there are international instances of shortages. Quantitative data has allowed WHO to propose global solutions; however, individualised understanding of specific regions is still required to work towards national solutions. Fiji has an established issue with medication supply and the aim of this study was to use qualitative methods to gain a fuller understanding of this context. Methods Semi-structured interviews were used to gain the perspective of key stakeholders involved in the Fijian medicine supply chain in regards to causes, impacts and possible solutions of medicine shortages. Thematic analysis was used to analyse the interview data. Results In total, 48 stakeholders participated and the information was synthesised into three main themes, causes, impacts and solutions and the sub-themes including; political, system and patient causes, adverse health effects on patients, professional dissatisfaction, monetary loss and loss of faith in the health system, workarounds, operation improvements, government intervention and education and training. Conclusions The situation in Fiji is not dissimilar to other instances of shortages around the world and hence international solutions like that proposed by WHO are feasible; however, they must be modified to be uniquely Fijian to work in this context.	[Walker, Josephine; Chaar, Betty B.; Lim, Jessy S.; Bero, Lisa; Moles, Rebekah J.] Univ Sydney, Fac Pharm, Sydney, NSW, Australia; [Vera, Numa; Pillai, Alvish S.] Fiji Natl Univ, Coll Med Nursing & Hlth Sci, Suva, Fiji; [Bero, Lisa] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia	University of Sydney; Fiji National University (FNU); University of Sydney	Walker, J (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW, Australia.	jwal7710@uni.sydney.edu.au	Lim, Jessy/GLU-0166-2022	Bero, Lisa/0000-0003-1893-6651				[Anonymous], 2016, WHO Drug Information, V30, P180; [Anonymous], 2013, SA PHARM J, V80, P45; Araszkiewicz A Aleksander, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P549, DOI 10.1586/14737167.8.6.549; Bailey M., 2004, AFFORDABILITY MEDICI; Banek K, 2015, HEALTH POLICY PLANN, V30, P451, DOI 10.1093/heapol/czu033; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Bateman C, 2013, SAMJ S AFR MED J, V103, P69, DOI [10.7196/samj.6663, 10.7196/SAMJ.6663]; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087576; Besancon L, 2013, REP INT SUMM MED SHO; Bhaskarabhatla A., 2016, HLTH POLICY PLAN; Bogaert P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125691; Bossert TJ, 2007, HEALTH POLICY PLANN, V22, P73, DOI 10.1093/heapol/czl041; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Chaar BB, 2014, AUSTRALAS MED J, V7, P161, DOI 10.4066/AMJ.2014.1943; Colquhoun S, 2016, GLOBAL HEART, V11, pe61, DOI DOI 10.1016/J.GHEART.2016.03.214; Comission FC, 2014, DET PRIC ESS PHARM P; Corrao G, 2014, EUR J INTERN MED, V25, P745, DOI 10.1016/j.ejim.2014.08.002; Corrao G, 2014, EUR J CLIN INVEST, V44, P933, DOI 10.1111/eci.12326; DeRoeck D, 2006, INT J HEALTH PLAN M, V21, P23, DOI 10.1002/hpm.822; Dowswell T, 1998, J ADV NURS, V28, P1326, DOI 10.1046/j.1365-2648.1998.00841.x; Dunne SS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0415-3; Duong M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143654; Evans D, 2002, J MED LIBR ASSOC, V90, P290; Fry G, 2015, NEW PACIFIC DIPLOMACY, P3; Gagne JJ, 2014, ANN INTERN MED, V161, P400, DOI 10.7326/M13-2942; Garuoliene K, 2011, EXPERT REV PHARM OUT, V11, P343, DOI [10.1586/ERP.11.24, 10.1586/erp.11.24]; Gijbels Harry, 2010, Nurse Educ Pract, V10, P64, DOI 10.1016/j.nepr.2009.03.011; Godman B, 2013, EXPERT REV PHARM OUT, V13, P469, DOI 10.1586/14737167.2013.820956; Graham Roberts FNU, 2011, FIJI ISLANDS HLTH SY, P19; Griffith MM, 2012, CLIN INFECT DIS; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Hassali MA, 2014, SAUDI PHARM J, V22, P491, DOI 10.1016/j.jsps.2013.12.017; Hogerzeil HV, 2006, B WORLD HEALTH ORGAN, V84, P371, DOI 10.2471/BLT.06.031153; Kessaram T, 2015, AUST NZ J PUBL HEAL, V39, P336, DOI 10.1111/1753-6405.12398; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Lopes GD, 2013, NAT REV CLIN ONCOL, V10, P314, DOI 10.1038/nrclinonc.2013.55; Lubinga SJ, 2014, IMPLEMENT SCI, V9, P1; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Ministry of Health and Medical Services F, 2015, FIJ FREE MED PROGR; Mohammed J, 2016, INT J HEALTH POLICY, V5, P173, DOI 10.15171/ijhpm.2015.199; MoHaMS Fiji, 2015, FIJI ESSENTIAL MED L; Mudaliar LA, 2017, EMIGRANTS EXPERIENCE; Pasquet A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013414; Paton C, 2006, BRIT J PSYCHIAT, V189, P184, DOI 10.1192/bjp.bp.105.017079; Pauwels K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119322; Qureshi NA, 2015, MEDITERRANEAN J MED, V2; Ravindra SS, ARXIV150703659; Rinaldi F, CANADIAN J CARDIOLOG; Scheyvens R, 2012, TOURISM GEOGR, V14, P1, DOI 10.1080/14616688.2011.593188; Statisics FBo, 2017, POP DEM FIJI BUR STA; Tan YX, 2016, INT J CLIN PHARM-NET, V38, P1133, DOI 10.1007/s11096-016-0342-1; Veronin MA, 2011, J PHARM HEALTH SERV, V2, P135, DOI 10.1111/j.1759-8893.2011.00059.x; Wertz FJ, 2011, 5 WAYS DOING QUALITA; Wu YCJ, 2013, COMPUT HUM BEHAV, V29, P323, DOI 10.1016/j.chb.2012.07.027	55	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2017	12	6							e0178429	10.1371/journal.pone.0178429	http://dx.doi.org/10.1371/journal.pone.0178429			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EW9KF	28582409	gold, Green Published, Green Submitted			2023-01-03	WOS:000402837600016
J	Maeoka, Y; Naito, T; Irifuku, T; Shimizu, Y; Ogawa, T; Masaki, T				Maeoka, Yujiro; Naito, Takayuki; Irifuku, Taisuke; Shimizu, Yuka; Ogawa, Takahiko; Masaki, Takao			Seasonal variation in hemodialysis initiation: A single-center retrospective analysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; RESPIRATORY SYNCYTIAL VIRUS; HEART-FAILURE; BLOOD-PRESSURE; UNITED-STATES; WEIGHT-GAIN; DIALYSIS; MORTALITY; HOSPITALIZATIONS	The number of new dialysis patients has been increasing worldwide, particularly among elderly individuals. However, information on seasonal variation in hemodialysis initiation in recent decades is lacking, and the seasonal distribution of patients' conditions immediately prior to starting dialysis remains unclear. Having this information could help in developing a modifiable approach to improving pre-dialysis care. We retrospectively investigated the records of 297 patients who initiated hemodialysis at Hiroshima Prefectural Hospital from January 1st, 2009 to December 31st, 2013. Seasonal differences were assessed by chi(2) or Kruskal-Wallis tests. Multiple comparison analysis was performed with the Steel test. The overall number of patients starting dialysis was greatest in winter (n = 85, 28.6%), followed by spring (n = 74, 24.9%), summer (n = 70, 23.6%), and autumn (n = 68, 22.9%), though the differences were not significant. However, there was a significant winter peak in dialysis initiation among patients aged >= 65 years, but not in those aged <65 years. Fluid overload assessed by clinicians was the most common uremic symptom among all patients, but a winter peak was only detected in patients aged >= 65 years. The body weight gain ratio showed a similar trend to fluid overload assessed by clinicians. Pulmonary edema was most pronounced in winter among patients aged >= 65 years compared with other seasons. The incidences of infection were modestly increased in summer and winter, but not statistically significant. Cardiac complications were similar in all seasons. This study demonstrated the existence of seasonal variation in dialysis initiation, with a winter peak among patients aged >= 65 years. The winter increment in dialysis initiation was mainly attributable to increased fluid overload. These findings suggest that elderly individuals should be monitored particularly closely during the winter.	[Maeoka, Yujiro; Irifuku, Taisuke; Masaki, Takao] Hiroshima Univ Hosp, Dept Nephrol, Hiroshima, Japan; [Naito, Takayuki; Shimizu, Yuka; Ogawa, Takahiko] Hiroshima Prefectural Hosp, Div Nephrol & Dialysis, Hiroshima, Japan; [Irifuku, Taisuke] Natl Hosp Org Higashihiroshima, Med Ctr, Dept Nephrol, Higashihiroshima, Japan	Hiroshima University	Naito, T (corresponding author), Hiroshima Prefectural Hosp, Div Nephrol & Dialysis, Hiroshima, Japan.	chonbori.chorori.chu@yahoo.co.jp	Barretti, Pasqual/K-4156-2012	Barretti, Pasqual/0000-0003-4979-4836; Maeoka, Yujiro/0000-0003-1808-2772				Afsar B, 2013, GEN HOSP PSYCHIAT, V35, P28, DOI 10.1016/j.genhosppsych.2012.08.007; Boulay F, 1999, CIRCULATION, V100, P280, DOI 10.1161/01.CIR.100.3.280; Cotter G, 2008, EUR J HEART FAIL, V10, P165, DOI 10.1016/j.ejheart.2008.01.007; DeFilippi CR, 2005, AM J KIDNEY DIS, V46, P35, DOI 10.1053/j.ajkd.2005.04.007; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; FAGIUS J, 1991, ACTA PHYSIOL SCAND, V142, P201, DOI 10.1111/j.1748-1716.1991.tb09148.x; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Foote C, 2012, NEPHROL DIAL TRANSPL, V27, P3581, DOI 10.1093/ndt/gfs096; Hajat S, 2004, EUR J EPIDEMIOL, V19, P959, DOI 10.1007/s10654-004-5731-4; HATA T, 1982, CLIN EXP HYPERTENS, V4, P341, DOI 10.3109/10641968209060747; Hirai M, 2015, CIRC J, V79, P129, DOI 10.1253/circj.CJ-14-0710; Iseki K, 1996, AM J NEPHROL, V16, P375, DOI 10.1159/000169028; IZZO JL, 1990, AM J HYPERTENS, V3, P405, DOI 10.1093/ajh/3.5.405; Kausz AT, 2000, J AM SOC NEPHROL, V11, P2351, DOI 10.1681/ASN.V11122351; Kessler M, 2003, AM J KIDNEY DIS, V42, P474, DOI 10.1016/S0272-6386(03)00805-9; Krishnan M, 2002, SEMIN DIALYSIS, V15, P79, DOI 10.1046/j.1525-139X.2002.00028.x; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Lewin J, 2005, EUR J HEART FAIL, V7, P953, DOI 10.1016/j.ejheart.2005.06.003; Martinez-Selles M, 2002, EUR J HEART FAIL, V4, P779, DOI 10.1016/S1388-9842(02)00116-2; Matsukawa T, 1998, AM J PHYSIOL-REG I, V275, pR1600, DOI 10.1152/ajpregu.1998.275.5.R1600; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Neumann J, 2004, KIDNEY INT, V65, P1568, DOI 10.1111/j.1523-1755.2004.00552.x; Obrador GT, 1999, KIDNEY INT, V56, P2227, DOI 10.1046/j.1523-1755.1999.00779.x; Shahar DR, 2001, EUR J EPIDEMIOL, V17, P129, DOI 10.1023/A:1017542928978; Spencer FA, 1998, J AM COLL CARDIOL, V31, P1226, DOI 10.1016/S0735-1097(98)00098-9; Sposito M, 2000, AM J KIDNEY DIS, V35, P812, DOI 10.1016/S0272-6386(00)70249-6; Stewart S, 2002, J AM COLL CARDIOL, V39, P760, DOI 10.1016/S0735-1097(02)01685-6; Usvyat LA, 2012, CLIN J AM SOC NEPHRO, V7, P108, DOI 10.2215/CJN.03880411; Yanovski JA, 2000, NEW ENGL J MED, V342, P861, DOI 10.1056/NEJM200003233421206	29	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178967	10.1371/journal.pone.0178967	http://dx.doi.org/10.1371/journal.pone.0178967			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6MJ	28575124	Green Submitted, Green Published, gold			2023-01-03	WOS:000402624300136
J	Steinberg, DI				Steinberg, Daniel I.			Review: Interventions improve hospital antibiotic prescribing and reduce hospital stay but do not affect mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Steinberg, Daniel I.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Steinberg, DI (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.	p.g.davey@dundee.ac.uk							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2017	166	10					JC59	JC59		10.7326/ACPJC-2017-166-10-059	http://dx.doi.org/10.7326/ACPJC-2017-166-10-059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU7UM	28505643				2023-01-03	WOS:000401240200011
J	Hammond, NE; Taylor, C; Finfer, S; Machado, FR; An, YZ; Billot, L; Bloos, F; Bozza, F; Cavalcanti, AB; Correa, M; Du, B; Hjortrup, PB; Li, Y; McIntryre, L; Saxena, M; Schortgen, F; Watts, NR; Myburgh, J				Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Machado, Flavia R.; An, YouZhong; Billot, Laurent; Bloos, Frank; Bozza, Fernando; Cavalcanti, Alexandre Biasi; Correa, Maryam; Du, Bin; Hjortrup, Peter B.; Li, Yang; McIntryre, Lauralyn; Saxena, Manoj; Schortgen, Frederique; Watts, Nicola R.; Myburgh, John		Fluid-TRIPS Fluidos Investigators; George Inst Global Hlth; ANZICS Clinical Trials Grp; BRICNet; REVA Res Network	Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; HYDROXYETHYL STARCH 130/0.4; CRITICALLY-ILL ADULTS; KIDNEY INJURY; ASSOCIATION; SEPSIS; SALINE; CHOICE; SCORE; SHOCK	Background In 2007, the Saline versus Albumin Fluid Evaluation D Translation of Research Into Practice Study (SAFE-TRIPS) reported that 0.9% sodium chloride (saline) and hydroxyethyl starch (HES) were the most commonly used resuscitation fluids in intensive care unit (ICU) patients. Evidence has emerged since 2007 that these fluids are associated with adverse patient-centred outcomes. Based on the published evidence since 2007, we sought to determine the current type of fluid resuscitation used in clinical practice and the predictors of fluid choice and determine whether these have changed between 2007 and 2014. Methods In 2014, an international, cross-sectional study was conducted (Fluid-TRIPS) to document current patterns of intravenous resuscitation fluid use and determine factors associated with fluid choice. We examined univariate and multivariate associations between patients and prescriber characteristics, geographical region and fluid type. Additionally, we report secular trends of resuscitation fluid use in a cohort of ICUs that participated in both the 2007 and 2014 studies. Regression analysis were conducted to determine changes in the administration of crystalloid or colloid between 2007 and 2014. Findings In 2014, a total of 426 ICUs in 27 countries participated. Over the 24 hour study day, 1456/ 6707 (21.7%) patients received resuscitation fluid during 2716 resuscitation episodes. Crystalloids were administered to 1227/1456 (84.3%) patients during 2208/2716 (81.3%) episodes and colloids to 394/1456 (27.1%) patients during 581/2716 (21.4%) episodes. In multivariate analyses, practice significantly varied between geographical regions. Additionally, patients with a traumatic brain injury were less likely to receive colloid when compared to patients with no trauma (adjusted OR 0.24; 95% CI 0.1 to 0.62; p = 0.003). Patients in the ICU for one or more days where more likely to receive colloid compared to patients in the ICU on their admission date (adjusted OR 1.75; 95% CI 1.27 to 2.41; p = < 0.001). For secular trends in fluid resuscitation, 84 ICUs in 17 countries contributed data. In 2007, 527/1663 (31.7%) patients received fluid resuscitation during 1167 episodes compared to 491/1763 (27.9%) patients during 960 episodes in 2014. The use of crystalloids increased from 498/1167 (42.7%) in 2007 to 694/960 (72.3%) in 2014 (odds ratio (OR) 3.75, 95% confidence interval (CI) 2.95 to 4.77; p = < 0.001), primarily due to a significant increase in the use of buffered salt solutions. The use of colloids decreased from 724/1167 (62.0%) in 2007 to 297/960 (30.9%) in 2014 (OR 0.29, 95% CI 0.19 to 0.43; p = < 0.001), primarily due to a decrease in the use of HES, but an overall increase in the use of albumin. Conclusions Clinical practices of intravenous fluid resuscitation have changed between 2007 and 2014. Geographical location remains a strong predictor of the type of fluid administered for fluid resuscitation. Overall, there is a preferential use of crystalloids, specifically buffered salt solutions, over colloids. There is now an imperative to conduct a trial determining the safety and efficacy of these fluids on patient-centred outcomes.	[Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Correa, Maryam; Li, Yang; Saxena, Manoj; Watts, Nicola R.; Myburgh, John] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia; [Hammond, Naomi E.; Finfer, Simon] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia; [Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Billot, Laurent] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Hammond, Naomi E.; Saxena, Manoj; Myburgh, John] Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia; [Machado, Flavia R.] Univ Fed Sao Paulo, Pain & Intens Care Dept, Anesthesiol, Sao Paulo, Brazil; Peking Univ, Peoples Hosp, Dept Crit Care Med, Beijing, Peoples R China; George Inst Global Hlth, Stat Div, Sydney, NSW, Australia; Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany; DOr Inst Res & Educ, Rio De Janeiro, Brazil; Hosp Coracao, Res Inst, Sao Paulo, Brazil; Peking Union Med Coll Hosp, Med Intens Care Unit, Beijing, Peoples R China; Copenhagen Univ Hosp, Rigshosp, Dept Intens Care, Copenhagen, Denmark; Ottawa Hosp, Res Inst, Dept Med Crit Care, Ottawa, ON, Canada; St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia; Reanimat Med Grp Hosp Henri Mondor, Assistance Publ Hop Paris, Creteil, France	George Institute for Global Health; University of Sydney; Royal North Shore Hospital; University of Sydney; University of New South Wales Sydney; Universidade Federal de Sao Paulo (UNIFESP); Peking University; George Institute for Global Health; University of Sydney; Friedrich Schiller University of Jena; IDOR - Instituto D'Or de Ensino e Pesquisa; Hospital do Coracao - HCor; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Rigshospitalet; University of Copenhagen; University of Ottawa; Ottawa Hospital Research Institute; St George Hospital; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Hammond, NE (corresponding author), George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia.	nhammond@georgeinstitute.org.au	Bozza, Fernando A/A-2618-2013; Christian, Michael/AAZ-4452-2020; Colombo, Riccardo/AAK-9081-2020; Christian, Mike/AAO-6338-2020; Biondi, Rodrigo S/H-5212-2016; Billot, Laurent/Y-1241-2019; Bloos, Frank/AAY-8265-2020; Cavalcanti, Alexandre/K-5529-2013; Du, Bin/K-4283-2013	Bozza, Fernando A/0000-0003-4878-0256; Christian, Michael/0000-0001-9644-9950; Colombo, Riccardo/0000-0002-9616-803X; Christian, Mike/0000-0001-9644-9950; Biondi, Rodrigo S/0000-0002-9242-6062; Billot, Laurent/0000-0002-4975-9793; Bloos, Frank/0000-0002-0767-7941; Schortgen, Frederique/0000-0003-1756-7508; Hammond, Naomi/0000-0002-6559-7747; da Costa Nunes Bosso, Carlos Eduardo/0000-0001-8216-4372; Micallef, Sharon/0000-0002-8496-2324; Cavalcanti, Alexandre/0000-0003-2798-6263; Deeb, Ahmad/0000-0002-3680-7338; Myburgh, John/0000-0003-4088-7016; Du, Bin/0000-0001-6237-2895; Finfer, Simon/0000-0002-2785-5864; Saxena, Manoj/0000-0002-0385-6731; Banner-Goodspeed, Valerie/0000-0002-7644-2521	Baxter Healthcare; CSL Behring; National Health and Medical Research Council of Australia [APP1039312]	Baxter Healthcare; CSL Behring; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was partially supported by unrestricted fluid grants from Baxter Healthcare and CSL Behring paid to The George Institute for Global Health. NH received a National Health and Medical Research Council of Australia Postgraduate Scholarship (2012-2014) that has supported part of this work [APP1039312]. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; or decision to submit the manuscript for publication.	Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; EMA, 2013, PRAC REC SUSP MARK A; FDA, 2013, HYDR STARCH SOL FDA; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Hammond NE, 2015, INTENS CARE MED, V41, P1611, DOI 10.1007/s00134-015-3878-y; Hammond Naomi, 2015, Rev. bras. ter. intensiva, V27, P309, DOI 10.5935/0103-507X.20150053; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MHRA, 2013, HYDR STARCH HES PROD; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Raghunathan K, 2015, ANESTHESIOLOGY, V123, P1385, DOI 10.1097/ALN.0000000000000861; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Team R. C, 2018, R LANG ENV STAT COMP; TGA, 2014, HYDR STRACH VOL VOL; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356	30	65	68	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2017	12	5							e0176292	10.1371/journal.pone.0176292	http://dx.doi.org/10.1371/journal.pone.0176292			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UR	28498856	Green Submitted, Green Published, gold			2023-01-03	WOS:000401314500003
J	Charvet, LE; Yang, J; Shaw, MT; Sherman, K; Haider, L; Xu, JJ; Krupp, LB				Charvet, Leigh E.; Yang, Jie; Shaw, Michael T.; Sherman, Kathleen; Haider, Lamia; Xu, Jianjin; Krupp, Lauren B.			Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial	PLOS ONE			English	Article							VERBAL MEMORY; REHABILITATION; SCHIZOPHRENIA; IMPAIRMENT; ADULTS; RISK	Cognitive impairment affects more than half of all individuals living with multiple sclerosis (MS). We hypothesized that training at home with an adaptive online cognitive training program would have greater cognitive benefit than ordinary computer games in cognitively-impaired adults with MS. This was a double-blind, randomized, active-placebo-controlled trial. Participants with MS were recruited through Stony Brook Medicine and randomly assigned to either the adaptive cognitive remediation (ACR) program or active control of ordinary computer games for 60 hours over 12 weeks. Training was remotely-supervised and delivered through a study-provided laptop computer. A computer generated, blocked stratification table prepared by statistician provided the randomization schedule and condition was assigned by a study technician. The primary outcome, administered by study psychometrician, was measured by change in a neuropsychological composite measure from baseline to study end. An intent-to-treat analysis was employed and missing primary outcome values were imputed via Markov Chain Monte Carlo method. Participants in the ACR (n = 74) vs. active control (n = 61) training program had significantly greater improvement in the primary outcome of cognitive functioning (mean change in composite z score +/- SD: 0.25 +/- 0.45 vs. 0.09 +/- 0.37, p = 0.03, estimated difference = 0.16 with 95% CI: 0.02-0.30), despite greater training time in the active control condition (mean +/- SD: 56.9 +/- 34.6 vs. 37.7 +/- 23.8 hours played, p = 0.006). This study provides Class I evidence that adaptive, computer-based cognitive remediation accessed from home can improve cognitive functioning in MS. This telerehabilitation approach allowed for rapid recruitment and high compliance, and can be readily applied to other neurological conditions associated with cognitive dysfunction.	[Charvet, Leigh E.; Shaw, Michael T.; Sherman, Kathleen; Krupp, Lauren B.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Yang, Jie] Stony Brook Med, Dept Family Populat & Prevent Med, New York, NY USA; [Haider, Lamia] Columbia Univ, Med Ctr, Taub Inst, New York, NY USA; [Xu, Jianjin] Stony Brook Med, Dept Appl Math & Stat, Stony Brook, NY USA	New York University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Charvet, LE (corresponding author), NYU, Sch Med, Dept Neurol, New York, NY 10016 USA.	leigh.charvet@nyumc.org		Shaw, Michael/0000-0003-4755-4484; krupp, lauren/0000-0001-7003-807X; Charvet, Leigh/0000-0003-4429-9713	National Multiple Sclerosis Society [RG4808A81]; Biostatistical Consulting Core at School of Medicine, Stony Brook University	National Multiple Sclerosis Society(National Multiple Sclerosis Society); Biostatistical Consulting Core at School of Medicine, Stony Brook University	This study was supported by the National Multiple Sclerosis Society, award number: RG4808A81.; We would like to thank Maria Amella, Wendy Fang, Ariana Frontario, Patricia Melville, William Scherl and Colleen Schwarz for their support of this study. We acknowledge the biostatistical consultation and support provided by the Biostatistical Consulting Core at School of Medicine, Stony Brook University.	Benedict RHB, 2011, NAT REV NEUROL, V7, P332, DOI 10.1038/nrneurol.2011.61; Benedict RH, 2007, BRIEF VISUOSPATIAL M; Brain HQ, 2015, POSIT SCI; Charvet LMS, 2015, MULTSCLER J EXP TRAN, V1, P1, DOI DOI 10.HTTP://DX.D0I.0RG/10.1177/2055217315609629; Chiaravalloti ND, 2013, NEUROLOGY, V81, P2066, DOI 10.1212/01.wnl.0000437295.97946.a8; Delis D. C., 2001, DELIS KAPLAN EXECUTI; Fisher M, 2015, SCHIZOPHRENIA BULL, V41, P250, DOI 10.1093/schbul/sbt232; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Gaming H., 2008, LLC; Hancock LM, 2015, J CLIN EXP NEUROPSYC, V37, P113, DOI 10.1080/13803395.2014.989818; Hartman David E, 2009, Appl Neuropsychol, V16, P85, DOI 10.1080/09084280802644466; Keefe RSE, 2012, J CLIN PSYCHIAT, V73, P1016, DOI 10.4088/JCP.11m07100; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; Little R. J. A., 1987, STAT ANAL MISSING DA; Loewy R, 2016, SCHIZOPHRENIA BULL, V42, pS118, DOI 10.1093/schbul/sbw009; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; McCabe JA, 2016, PSYCHOL SCI PUBL INT, V17, P187, DOI 10.1177/1529100616664716; Merzenich MM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00385; Mishra J, 2014, NEURON, V84, P1091, DOI 10.1016/j.neuron.2014.10.034; O'Brien AR, 2008, ARCH PHYS MED REHAB, V89, P761, DOI 10.1016/j.apmr.2007.10.019; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; Parmenter BA, 2007, J CLIN EXP NEUROPSYC, V29, P215, DOI 10.1080/13803390600672163; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Rocca M. A., 2015, LANCET NEUROLOGY; Rosti-Otajarvi EM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009131.pub2; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Scherl WF, 2004, PSYCHOL REP, V95, P593, DOI 10.2466/PR0.95.6.593-603; Smith A., 1982, SYMBOL DIGIT MODALIT; Stuifbergen AK, 2012, CLIN REHABIL, V26, P882, DOI 10.1177/0269215511434997; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; University V, 2016, REDCAP RES EL DAT CA; Vinogradov S, 2012, NEUROPSYCHOPHARMACOL, V37, P43, DOI 10.1038/npp.2011.251	32	66	66	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177177	10.1371/journal.pone.0177177	http://dx.doi.org/10.1371/journal.pone.0177177			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EU8UP	28493924	Green Submitted, Green Published, gold			2023-01-03	WOS:000401314300068
J	Lemani, C; Tang, JH; Kopp, D; Phiri, B; Kumvula, C; Chikosi, L; Mwale, M; Rosenberg, NE				Lemani, Clara; Tang, Jennifer H.; Kopp, Dawn; Phiri, Billy; Kumvula, Chrissy; Chikosi, Loyce; Mwale, Mwawi; Rosenberg, Nora E.			Contraceptive uptake after training community health workers in couples counseling: A cluster randomized trial	PLOS ONE			English	Article							YOUNG MARRIED-COUPLES; INTERVENTIONS; SERVICES; DELIVERY	Background Young women in Malawi face many challenges in accessing family planning (FP), including distance to the health facility and partner disapproval. Our primary objective was to assess if training HSAs in couples counseling would increase modern FP uptake among young women. Methods In this cluster randomized controlled trial, 30 HSAs from Lilongwe, Malawi received training in FP. The HSAs were then randomized 1: 1 to receive or not receive additional training in couples counseling. All HSAs were asked to provide FP counseling to women in their communities and record their contraceptive uptake over 6 months. Sexually-active women <30 years of age who had never used a modern FP method were included in this analysis. Generalized estimating equations with an exchangeable correlation matrix to account for clustering by HSA were used to estimate risk differences (RDs) and 95% confidence intervals (CIs). Results 430 (53%) young women were counseled by the 15 HSAs who received couples counseling training, and 378 (47%) were counseled by the 15 HSAs who did not. 115 (26%) from the couples counseling group had male partners present during their first visit, compared to only 6 (2%) from the other group (RD: 0.21, 95% CI: 0.09 to 0.33, p<0.01). Nearly all (99.5%) initiated a modern FP method, with no difference between groups (p = 0.09). Women in the couples counseling group were 8% more likely to receive male condoms (RD: 0.08, 95% CI: -7% to 23%, p = 0.28) and 8% more likely to receive dual methods (RD: 0.08, 95% CI: -0.065, 0.232, p = 0.274). Conclusion Training HSAs in FP led to high modern FP uptake among young women who had never used FP. Couples counseling training increased male involvement with a trend towards higher male condom uptake.	[Lemani, Clara; Tang, Jennifer H.; Kopp, Dawn; Phiri, Billy; Rosenberg, Nora E.] UNC Project Malawi, Lilongwe, Malawi; [Tang, Jennifer H.] Univ North Carolina Chapel Hill, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27514 USA; [Kumvula, Chrissy; Chikosi, Loyce] Hlth Ctr, Area 25, Lilongwe, Malawi; [Mwale, Mwawi] Lilongwe Dist Hlth Off, Lilongwe, Malawi; [Rosenberg, Nora E.] Univ North Carolina Chapel Hill, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Tang, JH (corresponding author), UNC Project Malawi, Lilongwe, Malawi.; Tang, JH (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27514 USA.	jennifer_tang@med.unc.edu			Bill and Melinda Gates Foundation [OPP1098307]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was supported by the Bill and Melinda Gates Foundation (OPP1098307). The funder had no role in study design, data collection and analysis, decision to publish, preparation of the manuscript.	Abt Associates, 2015, COUNS WOM COUPL FAM; Advancing Partners Communities, 2014, COUNTR PROF MAL COMM; Ankomah A, 2011, J CONTRACEPTION, P95; Becker S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1309; Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026; Daniel EE, 2008, INT FAM PLAN PERSPEC, V34, P189, DOI [10.1363/3418908, 10.1363/ifpp.34.189.08]; Darteh EKM, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-23; FHI 360, 2013, INCR MAL INV FAM PLA; FHI360, 2010, EV COMM BAS DISTR DM; Gueye A, 2015, INT PERSPECT SEX R H, V41, P191, DOI 10.1363/4119115; Haddad L, 2013, AIDS, V27, pS93, DOI 10.1097/QAD.0000000000000039; MacQuarrie KLD, 2014, UNMET NEED FAMILY PL; Megquier S., 2014, REPROD TRANSITIONS U; MicrosoftCorporation, 2010, MICR ACC; National Statistical Office (NSO) [Malawi] and ICF Macro, 2011, MAL DEM HLTH SURV; Nyirenda L., 2014, REPORT CONTEXT ANAL; Phillips JF, 2003, INT FAM PLAN PERSPEC, V29, P138, DOI 10.2307/3181080; Raj A, 2015, PLOS ONE, V11; Richardson F, 2009, COMMUNITY BASED DIST; Sarkar A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2352-7; Shattuck D, 2011, AM J PUBLIC HLTH, V101; Tilahun T, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2057-y	22	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2017	12	4							e175879	10.1371/journal.pone.0175879	http://dx.doi.org/10.1371/journal.pone.0175879			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ET6EL	28448502	Green Published, gold, Green Submitted			2023-01-03	WOS:000400383600029
J	Henderson, JT; Thompson, JH; Burda, BU; Cantor, A				Henderson, Jillian T.; Thompson, Jamie H.; Burda, Brittany U.; Cantor, Amy			Preeclampsia Screening Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							UTERINE ARTERY DOPPLER; PROTEIN-CREATININE RATIO; TOTAL PROTEIN/CREATININE RATIO; BLOOD-PRESSURE-MEASUREMENT; RISK PREDICTION MODELS; 24-HOUR URINE PROTEIN; LOW-DOSE ASPIRIN; MATERNAL CHARACTERISTICS; EXTERNAL VALIDITY; PAPP-A	IMPORTANCE Preeclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement. OBJECTIVE To systematically review the benefits and harms of preeclampsia screening and risk assessment for the US Preventive Services Task Force. DATA SOURCES MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials databases from 1990 through September 1, 2015. Surveillance for new evidence in targeted publications was conducted through October 5, 2016. STUDY SELECTION English-language trials and observational studies, including externally validated prediction models, of screening effectiveness, benefits, and harms from routine preeclampsia screening during pregnancy. DATA EXTRACTION AND SYNTHESIS Independent dual review of article abstracts and full texts against a priori inclusion criteria. Meta-analysis was not performed because of clinical and statistical heterogeneity of included studies. MAIN OUTCOMES AND MEASURES Maternal and infant health outcomes, including eclampsia, stroke, stillbirth, preterm birth, and low birthweight; screening and risk prediction test performance; harms of screening and risk assessment. RESULTS Twenty-one studies (13 982 participants) were included. No studies directly compared the effectiveness of preeclampsia screening in a screened population vs an unscreened population; 1 US trial (n = 2764) found no difference in benefits or harms with fewer prenatal visits but was underpowered for rare, serious outcomes. For harms, a before-after comparison cohort noninferiority study of urine protein screening for specific indications compared with routine screening (n = 1952) did not identify harms with fewer urine screening tests. Four studies (n = 7123) reported external validation performance of 16 risk prediction models, 5 of which had good or better discrimination (c statistic >0.80) for prediction of preeclampsia, and positive predictive values of 4% in the largest, most applicable validation cohorts. Calibration was not reported despite being a key model performance measure. There were no studies of urine screening test performance conducted in asymptomatic primary care populations; 14 studies of protein urine test performance among women being evaluated for suspected preeclampsia (n = 1888) had wide-ranging test accuracy (sensitivity, 22%-100%; specificity, 36%-100%) and high statistical and clinical heterogeneity in tests used, eligibility criteria, and proteinuria prevalence (8.7%-93.8%). CONCLUSIONS AND RELEVANCE Evidence to estimate benefits and harms of preeclampsia screening and the test performance of different screening approaches over the course of pregnancy was limited. Externally validated risk prediction models had limited applicability and lacked calibration and clinical implementation data needed to support routine use. Further research is needed to better inform risk-based screening approaches and improve screening strategies, given the complex pathophysiology and clinical unpredictability of preeclampsia.	[Henderson, Jillian T.; Thompson, Jamie H.; Burda, Brittany U.] Kaiser Permanente, Ctr Hlth Res, Kaiser Permanente Res Affiliates Evidence based P, 3800 N Interstate Ave, Portland, OR 97227 USA; [Cantor, Amy] Oregon Hlth & Sci Univ, Portland, OR USA	Kaiser Permanente; Oregon Health & Science University	Henderson, JT (corresponding author), Kaiser Permanente, Ctr Hlth Res, Kaiser Permanente Res Affiliates Evidence based P, 3800 N Interstate Ave, Portland, OR 97227 USA.	jillian.t.henderson@kpchr.org		Cantor, Amy/0000-0002-4467-8484	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA-290-2012-00151-I]	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services	This research was funded under contract HHSA-290-2012-00151-I, Task Order 4, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.	Akolekar R, 2013, FETAL DIAGN THER, V33, P8, DOI 10.1159/000341264; Al-Rubaie ZTA, 2016, BJOG-INT J OBSTET GY, V123, P1441, DOI 10.1111/1471-0528.14029; Ananth CV, 2013, BMJ-BRIT MED J, V347, pf6564; [Anonymous], 2015, Obstet Gynecol, V126, pe25, DOI 10.1097/AOG.0000000000001049; [Anonymous], 2002, OBSTET GYNECOL, V99, P159; [Anonymous], 2013, HYPERTENSION PREGNAN; Askie LM, 2007, LANCET, V369, P1791, DOI 10.1016/S0140-6736(07)60712-0; Bartsch E, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1753; Bartsch E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116296; Bhide A, 2015, ACTA OBSTET GYN SCAN, V94, P542, DOI 10.1111/aogs.12624; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Bramham K, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2301; Broekhuijsen K, 2015, LANCET, V385, P2492, DOI 10.1016/S0140-6736(14)61998-X; Brunelli VB, 2015, BJOG-INT J OBSTET GY, V122, P904, DOI 10.1111/1471-0528.13334; Bujold E, 2010, OBSTET GYNECOL, V116, P402, DOI 10.1097/AOG.0b013e3181e9322a; Caradeux J, 2013, PRENATAL DIAG, V33, P732, DOI 10.1002/pd.4113; Chappell LC, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6349; Cnossen JS, 2009, ACTA OBSTET GYN SCAN, V88, P758, DOI 10.1080/00016340903008953; Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402; Cote AM, 2008, BRIT MED J, V336, P1003, DOI 10.1136/bmj.39532.543947.BE; Debray TPA, 2015, J CLIN EPIDEMIOL, V68, P280, DOI 10.1016/j.jclinepi.2014.06.018; Deeks JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/bmj.329.7458.168; DiGiuseppi C, 1996, GUID CLIN PREV SERV, P419; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Duley L, 2007, BJOG-INT J OBSTET GY, V114, P300, DOI 10.1111/j.1471-0528.2006.01166.x; Duley L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001449.pub3; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000025.pub2; Duley L, 2007, BJOG-INT J OBSTET GY, V114, P289, DOI 10.1111/j.1471-0528.2006.01165.x; Durnwald C, 2003, AM J OBSTET GYNECOL, V189, P848, DOI 10.1067/S0002-9378(03)00849-4; Dwyer BK, 2008, J PERINATOL, V28, P461, DOI 10.1038/jp.2008.4; Farina A, 2011, PRENATAL DIAG, V31, P1147, DOI 10.1002/pd.2849; Ghulmiyyah L, 2012, SEMIN PERINATOL, V36, P56, DOI 10.1053/j.semperi.2011.09.011; Gillon TER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113715; Grady D, 2011, ARCH INTERN MED, V171, P1701, DOI 10.1001/archinternmed.2011.482; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Higgins JR, 2001, LANCET, V357, P131, DOI 10.1016/S0140-6736(00)03552-2; Huppertz B, 2008, HYPERTENSION, V51, P970, DOI 10.1161/HYPERTENSIONAHA.107.107607; Ioannidis JPA, 2010, JAMA-J AM MED ASSOC, V303, P1646, DOI 10.1001/jama.2010.503; Kleinrouweler CE, 2016, AM J OBSTET GYNECOL, V214, P79, DOI 10.1016/j.ajog.2015.06.013; Koopmans CM, 2009, LANCET, V374, P979, DOI 10.1016/S0140-6736(09)60736-4; Kyle PM, 2008, BJOG-INT J OBSTET GY, V115, P523, DOI 10.1111/j.1471-0528.2007.01621.x; Lamontagne A, 2014, J OBSTET GYNAECOL CA, V36, P303, DOI 10.1016/S1701-2163(15)30605-8; LeFevre ML, 2014, ANN INTERN MED, V161, P819, DOI 10.7326/M14-1884; Moura SBMEH, 2016, J MATERN-FETAL NEO M, V29, P897, DOI 10.3109/14767058.2015.1022865; McDuffie RS, 1996, JAMA-J AM MED ASSOC, V275, P847, DOI 10.1001/jama.275.11.847; MEYER NL, 1994, AM J OBSTET GYNECOL, V170, P137; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Moons KGM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001744; Moore GS, 2015, J PERINATOL, V35, P328, DOI 10.1038/jp.2014.214; Morris RK, 2012, BMJ-BRIT MED J, V345, pe4342; Odibo AO, 2011, PLACENTA, V32, P598, DOI 10.1016/j.placenta.2011.05.006; Oliveira N, 2014, ULTRASOUND OBST GYN, V44, P286, DOI 10.1002/uog.13433; Oliveira N, 2014, ULTRASOUND OBST GYN, V44, P279, DOI 10.1002/uog.13435; Onwudiwe N, 2008, ULTRASOUND OBST GYN, V32, P877, DOI 10.1002/uog.6124; Papanna R, 2008, OBSTET GYNECOL, V112, P135, DOI 10.1097/AOG.0b013e3181778cfc; Park F, 2015, ULTRASOUND OBST GYN, V46, P419, DOI 10.1002/uog.14819; Park FJ, 2013, AUST NZ J OBSTET GYN, V53, P532, DOI 10.1111/ajo.12126; Parra-Cordero M, 2013, ULTRASOUND OBST GYN, V41, P538, DOI 10.1002/uog.12264; Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6; Plasencia W, 2008, ULTRASOUND OBST GYN, V32, P138, DOI 10.1002/uog.5402; Plasencia W, 2007, ULTRASOUND OBST GYN, V30, P742, DOI 10.1002/uog.5157; Poon LCY, 2009, ULTRASOUND OBST GYN, V34, P497, DOI 10.1002/uog.7439; Poon LCY, 2010, J HUM HYPERTENS, V24, P104, DOI 10.1038/jhh.2009.45; Poon LCY, 2009, ULTRASOUND OBST GYN, V33, P23, DOI 10.1002/uog.6280; Poon LCY, 2010, PRENATAL DIAG, V30, P216, DOI 10.1002/pd.2440; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Rhode MA, 2007, J REPROD MED, V52, P214; Scazzocchio E, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.12.016; Sethuram R, 2011, J OBSTET GYNAECOL, V31, P128, DOI 10.3109/01443615.2010.538771; Simeone S, 2015, PRENATAL DIAG, V35, P60, DOI 10.1002/pd.4485; Siu AL, 2015, ANN INTERN MED, V163, P778, DOI 10.7326/M15-2223; Skrastad RB, 2014, BJOG, DOI [10.1111/1471-0528, DOI 10.1111/1471-0528]; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Stout MJ, 2013, J MATERN-FETAL NEO M, V26, P66, DOI 10.3109/14767058.2012.727048; Thangaratinam S, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-10; Too GT, 2013, SEMIN PERINATOL, V37, P280, DOI 10.1053/j.semperi.2013.04.007; Tun C, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.010; United Nations Development Program, 2014, HUM DEV REP 2014; US Preventive Services Task Force, 2014, PROC MAN; Valdes E, 2016, GYNECOL OBSTET INVES, V81, P78, DOI 10.1159/000381773; Verdonk K, 2014, BJOG-INT J OBSTET GY, V121, P1660, DOI 10.1111/1471-0528.12803; Waugh J, 2004, AM J OBSTET GYNECOL, V191, P1049, DOI 10.1016/j.ajog.2004.05.040; Waugh J, 2001, HYPERTENS PREGNANCY, V20, P205, DOI 10.1081/PRG-100106970; Waugh JJS, 2005, BJOG-INT J OBSTET GY, V112, P412, DOI 10.1111/j.1471-0528.2004.00455.x; Wells G, 2014, NEWCASTLE OTTAWA SCA; Wheeler TL, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.10.892; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Woelkers D., 2015, PREGNANCY HYPERTENSI, V5, P38, DOI DOI 10.1016/J.PREGHY.2014.10.075; Wright D, 2012, FETAL DIAGN THER, V32, P171, DOI 10.1159/000338470; Young RA, 1996, J FAM PRACTICE, V42, P385	90	74	86	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2017	317	16					1668	1683		10.1001/jama.2016.18315	http://dx.doi.org/10.1001/jama.2016.18315			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET1FW	28444285				2023-01-03	WOS:000400014000017
J	Clarke, G; Fistein, E; Holland, A; Barclay, M; Theimann, P; Barclay, S				Clarke, Gemma; Fistein, Elizabeth; Holland, Anthony; Barclay, Matthew; Theimann, Pia; Barclay, Stephen			Preferences for care towards the end of life when decision-making capacity may be impaired: A large scale cross-sectional survey of public attitudes in Great Britain and the United States	PLOS ONE			English	Article							PHYSICIAN-ASSISTED DEATH	Background There is continuing public debate about treatment preferences at the end of life, and the acceptability and legal status of treatments that sustain or end life. However, most surveys use binary yes/no measures, and little is known about preferences in neurological disease when decision-making capacity is lost, as most studies focus on cancer. This study investigates changes in public preferences for care towards the end of life, with a focus on measures to sustain or end life. Methods Large-scale international public opinion surveys using a six-stage patient vignette, respondents chose a level of intervention for each stage as health and decision-making capacity deteriorated. Cross-sectional representative samples of the general public in Great Britain and the USA (N = 2016). Primary outcome measure: changes in respondents' preferences for care, measured on a four-point scale designed before data collection. The scale ranged from: maintaining life at all costs; to intervention with agreement; to no intervention; to measures for ending life. Results There were no significant differences between GB and USA. Preference for measures to sustain life at all costs peaked at short-term memory loss (30.2%, n = 610). Respondents selecting 'measures to help me die peacefully' increased from 3.9% to 37.0% as the condition deteriorated, with the largest increase occurring when decision-making capacity was lost (10.3% to 23.0%). Predictors of choosing 'measures to help me die peacefully' at any stage were: previous personal experience (OR = 1.34, p<0.010), and older age (OR = 1.09 per decade, p<0.010). Negative predictors: living with children (OR = 0.72, p<0.010) and being of "black" race/ethnicity (OR = 0.45, p<0.001). Conclusions Public opinion was uniform between GB and USA, but markedly heterogeneous. Despite contemporaneous capacitous consent providing an essential legal safeguard in most jurisdictions, there was a high prevalence of preference for "measures to end my life peacefully" when decision-making capacity was compromised, which increased as dementia progressed. In contrast, a significant number chose preservation of life at all costs, even in end stage dementia. It is challenging to respect the longstanding values of people with dementia concerning either the inviolability of life or personal autonomy, whilst protecting those without decision-making capacity.	[Clarke, Gemma; Fistein, Elizabeth; Barclay, Matthew; Theimann, Pia; Barclay, Stephen] Univ Cambridge, Cambridge Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge Biomed Campus,Forvie Site,Robinson Way, Cambridge, England; [Holland, Anthony] Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Douglas House, Cambridge, England	University of Cambridge; University of Cambridge	Clarke, G (corresponding author), Univ Cambridge, Cambridge Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge Biomed Campus,Forvie Site,Robinson Way, Cambridge, England.	gcc29@medschl.cam.ac.uk	Barclay, Matthew Edward/Q-2626-2019	Barclay, Matthew Edward/0000-0003-1148-1922; Clarke, Gemma/0000-0001-8438-7131	Dunhill Medical Trust [R317/1113]; National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East of England at Cambridgeshire and Peterborough NHS Foundation Trust; Health Foundation; National Institute for Health Research (NIHR); National Institute for Health Research [NF-SI-0509-10211] Funding Source: researchfish	Dunhill Medical Trust(Dunhill Medical Trust); National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East of England at Cambridgeshire and Peterborough NHS Foundation Trust(National Institute for Health Research (NIHR)); Health Foundation; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by The Dunhill Medical Trust [grant number R317/1113]. AH and SB are supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East of England at Cambridgeshire and Peterborough NHS Foundation Trust. AH is also supported by the Health Foundation. The funders had no role in the design, undertaking or writing of this paper, and no part in the decision to submit for publication. This paper presents independent research partly funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.; All authors meet the criteria for authorship. GC, AH, SB designed the research, undertook analysis, and contributed to writing the paper. EF, MB, PT undertook analysis, and contributed to writing the paper. This paper presents independent research partly funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	AMA, 2009, H140952 AMA; Barter C, 1999, USES VIGNETTES QUALI; Beauchamp T. L., 2012, PRINCIPLES BIOMEDICA, VVII-a; BMA, 2016, END LIF CAR PHYS ASS; Burstein P, 2003, POLIT RES QUART, V56, P29, DOI 10.1177/106591290305600103; Clarke G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061475; Clarke G, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0034-8; Cohen-Almagor R, 2004, EUTHANASIA NETHERLAN; Cox K, 2013, BMJ SUPPORT PALLIAT, V3, P37, DOI 10.1136/bmjspcare-2012-000203; Davis J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4437; Dresser Rebecca, 1986, Ariz Law Rev, V28, P373; Dugan A, 2015, SUPPORT DOCTOR ASSIS; Fischer KE, 2012, HEALTH POLICY, V107, P218, DOI 10.1016/j.healthpol.2012.07.005; Godlee F, 2015, ASSISTED DYING D TIM, V09, P46; Hawkins O, 2015, CBP7186; IpsosMORI, 2015, PUBL ATT ASS DYING P; Lehnert T, 2011, MED CARE RES REV, V68, P387, DOI 10.1177/1077558711399580; Lewis-Black M, 2004, ENCY SOCIAL SCI RES; Magelssen M, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0107-3; McGuinness F, 2012, HOUSE LORDS STAT SN; McLean J., 2008, RISK PROTECTIVE FACT; Periyakoil VS, 2016, J PALLIAT MED, V19, P1060, DOI 10.1089/jpm.2016.0160; Prokopetz JJZ, 2012, NEW ENGL J MED, V367, P97, DOI 10.1056/NEJMp1205283; Quill TE, 2016, JAMA-J AM MED ASSOC, V315, P245, DOI 10.1001/jama.2015.16210; Shapiro RY, 2011, PUBLIC OPIN QUART, V75, P982, DOI 10.1093/poq/nfr053; Thulesius HO, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-13; WALTER T, 1991, SOCIOLOGY, V25, P293, DOI 10.1177/0038038591025002009; Yang YT, 2016, JAMA-J AM MED ASSOC, V315, P247, DOI 10.1001/jama.2015.16194; YouGov, 2014, MAJ PUBL WOULD PROB; YouGov, 2013, WESTM FAITH DEB YOUG; Zulman DM, 2014, J GEN INTERN MED, V29, P529, DOI 10.1007/s11606-013-2616-9	31	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0172104	10.1371/journal.pone.0172104	http://dx.doi.org/10.1371/journal.pone.0172104			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2JD	28379955	Green Published, Green Submitted, gold			2023-01-03	WOS:000399353500004
J	Huang, DTN; Lu, CY; Shao, PL; Chang, LY; Wang, JY; Chang, YH; Lai, MJ; Chi, YH; Huang, LM				Huang, Daniel Tsung-Ning; Lu, Chun-Yi; Shao, Pei-Lan; Chang, Luan-Yin; Wang, Jin-Yuan; Chang, Yi-Hsuan; Lai, Mei-Ju; Chi, Ya-Hui; Huang, Li-Min			In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery	PLOS ONE			English	Article							GENE; CELLS; MICE; H5N1; INFECTION; PROTEIN; MATRIX	Background Influenza virus infection is a major threat to human health. Small interfering RNA (siRNA) is a promising approach for the prevention and treatment of viral infections. In this study, we constructed a series of DNA vector-based short hairpin RNAs (shRNAs) that target various genes of the influenza A virus using the polymerase III U6-RNA promoter to prevent influenza virus infection in vitro and in a mouse model. Results Three sets of DNA vector-based shRNA, two targeting genes encoding the polymerase acidic protein (PA) and one targeting polymerase basic protein 2 (PB2), efficiently inhibited the replication of influenza virus A/WSN/33(H1 N1) in vitro. We also successfully prevented influenza virus A/WSN/33(H1N1) infection in a C57BU6 mouse model by intratracheal delivery of anti-PB2 shRNA. Conclusions Our findings suggest that the PB2-targeting shRNA plasmid showed potential for use as an RNAi-based therapeutic for influenza virus infection.	[Huang, Daniel Tsung-Ning; Wang, Jin-Yuan] Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan; [Huang, Daniel Tsung-Ning; Chang, Luan-Yin; Huang, Li-Min] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Lu, Chun-Yi; Shao, Pei-Lan; Chang, Luan-Yin; Chang, Yi-Hsuan; Lai, Mei-Ju; Huang, Li-Min] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Pediat, Taipei, Taiwan; [Chi, Ya-Hui] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan, Taiwan	Mackay Memorial Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan	Huang, DTN (corresponding author), Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan.; Huang, DTN; Huang, LM (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.; Huang, LM (corresponding author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Pediat, Taipei, Taiwan.	zoning12huang@gmail.com; lmhuang@ntu.edu.tw	Chi, Ya-Hui/ABE-8550-2020	Chi, Ya-Hui/0000-0002-9216-0938; LU, CHUN-YI/0000-0002-5240-2808; CHANG, LUAN-YIN/0000-0003-2632-1956; HUANG, LI-MIN/0000-0002-9291-260X; Huang, Daniel Tsung-Ning/0000-0001-6940-6701				Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005; Barik S, 2015, METHODS MOL BIOL, V1218, P251, DOI 10.1007/978-1-4939-1538-5_14; Betakova T, 2013, ACTA VIROL, V57, P97, DOI 10.4149/av_2013_02_97; Bresee J, 2013, NEW ENGL J MED, V368, P589, DOI 10.1056/NEJMp1300375; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fewell GD, 2006, DRUG DISCOV TODAY, V11, P975, DOI 10.1016/j.drudis.2006.09.008; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Hsieh Yu-Chia, 2005, Journal of Microbiology Immunology and Infection, V38, P238; Jeong JH, 2009, BIOCONJUGATE CHEM, V20, P5, DOI 10.1021/bc800278e; Kitphati R, 2009, CLIN VACCINE IMMUNOL, V16, P978, DOI 10.1128/CVI.00062-09; Li WY, 2011, ARCH VIROL, V156, P1979, DOI 10.1007/s00705-011-1087-8; Li YC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-603; Matskevich AA, 2009, J INNATE IMMUN, V1, P389, DOI 10.1159/000191408; Mauskopf Josephine, 2013, J Med Econ, V16, P264, DOI 10.3111/13696998.2012.752376; McMillen CM, 2016, VIROLOGY, V497, P171, DOI 10.1016/j.virol.2016.07.019; Poole E, 2004, VIROLOGY, V321, P120, DOI 10.1016/j.virol.2003.12.022; Rajput R, 2012, NUCLEIC ACID THER, V22, P414, DOI 10.1089/nat.2012.0359; Stiver G, 2003, CAN MED ASSOC J, V168, P49; Sui HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005671; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Wu YH, 2008, BIOCHEM BIOPH RES CO, V365, P369, DOI 10.1016/j.bbrc.2007.10.196; Zhang W, 2009, BIOCHEM BIOPH RES CO, V390, P421, DOI 10.1016/j.bbrc.2009.09.039; Zhou HB, 2007, ANTIVIR RES, V76, P186, DOI 10.1016/j.antiviral.2007.07.002; Zhou K, 2008, J BIOTECHNOL, V135, P140, DOI 10.1016/j.jbiotec.2008.03.007	24	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0174523	10.1371/journal.pone.0174523	http://dx.doi.org/10.1371/journal.pone.0174523			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28380007	Green Published, gold, Green Submitted			2023-01-03	WOS:000399353500051
J	Suswardany, DL; Sibbritt, DW; Supardi, S; Pardosi, JF; Chang, S; Adams, J				Suswardany, Dwi Linna; Sibbritt, David W.; Supardi, Sudibyo; Pardosi, Jerico F.; Chang, Sungwon; Adams, Jon			A cross-sectional analysis of traditional medicine use for malaria alongside free antimalarial drugs treatment amongst adults in high-risk malaria endemic provinces of Indonesia	PLOS ONE			English	Article							HEALTH-CARE-SEEKING; COMMUNITY PERCEPTIONS; JAVA; ELIMINATION; COUNTRIES; CHILDREN; DISEASE; PATIENT; ACCESS; SYSTEM	Background The level of traditional medicine use, particularly Jamu use, in Indonesia is substantial. Indonesians do not always seek timely treatment for malaria and may seek self-medication via traditional medicine. This paper reports findings from the first focused analyses of traditional medicine use for malaria in Indonesia and the first such analyses worldwide to draw upon a large sample of respondents across high-risk malaria endemic areas. Methods A sub-study of the Indonesia Basic Health Research/Riskesdas Study 2010 focused on 12,226 adults aged 15 years and above residing in high-risk malaria-endemic provinces. Logistic regression was undertaken to determine the significant associations for traditional medicine use for malaria symptoms. Findings Approximately one in five respondents use traditional medicine for malaria symptoms and the vast majority experiencing multiple episodes of malaria use traditional medicine alongside free antimalarial drug treatments. Respondents consuming traditional medicine for general health/common illness purposes every day (odds ratio: 3.75, 95% Confidence Interval: 2.93 4.79), those without a hospital in local vicinity (odds ratio: 1.31, 95% Confidence Interval: 1.10 1.57), and those living in poorer quality housing, were more likely to use traditional medicine for malaria symptoms. Conclusion A substantial percentage of those with malaria symptoms utilize traditional medicine for treating their malaria symptoms. In order to promote safe and effective malaria treatment, all providing malaria care in Indonesia need to enquire with their patients about possible traditional medicine use.	[Suswardany, Dwi Linna; Sibbritt, David W.; Chang, Sungwon; Adams, Jon] Univ Technol Sydney, Fac Hlth, ARCCIM, Sydney, NSW, Australia; [Suswardany, Dwi Linna] Univ Muhammadiyah Surakarta, Cent Java, Indonesia; [Supardi, Sudibyo; Pardosi, Jerico F.] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia; [Pardosi, Jerico F.] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	University of Technology Sydney; Universitas Muhammadiyah Surakarta; Ministry of Health - Indonesia; National Institute of Health Research & Development - Indonesia; University of New South Wales Sydney	Adams, J (corresponding author), Univ Technol Sydney, Fac Hlth, ARCCIM, Sydney, NSW, Australia.	Jon.Adams@uts.edu.au	Pardosi, Jerico/L-7873-2019; Chang, Sungwon/ABB-1454-2021; Sibbritt, David W/F-8070-2017; Suswardany, Dwi Linna/GQZ-4670-2022	Pardosi, Jerico/0000-0003-3753-5669; Sibbritt, David W/0000-0003-3561-9447; Suswardany, Dwi Linna/0000-0003-0793-9945; Adams, Jon/0000-0002-9901-5717; Chang, Sungwon/0000-0003-0723-3192	Ministry of Research, Technology, and Higher Education, Indonesia; Directorate General for Higher Education (DIKTI)	Ministry of Research, Technology, and Higher Education, Indonesia; Directorate General for Higher Education (DIKTI)	PhD scholarship for DLS was via the Ministry of Research, Technology, and Higher Education, Indonesia. Cost for publication is provided by Australian Research Centre in Complementary and Integrative Medicine (ARCCIM).; We would like to thank: the National Institute of Health Research and Development, Ministry of Health, Indonesia for approving and facilitating access to the data set; the Directorate General for Higher Education (DIKTI), Ministry of Research, Technology, and Higher Education, Indonesia for funding a PhD Scholarship for DLS; Universitas Muhammadiyah Surakarta for supporting DLS' study, and Ki Hariyadi for contributing via early correspondence on this topic.	Alkire S, 2014, WORLD DEV, V59, P251, DOI 10.1016/j.worlddev.2014.01.026; [Anonymous], 2015, GUIDELINES FOR THE T; Aqil A, 2009, HEALTH POLICY PLANN, V24, P217, DOI 10.1093/heapol/czp010; Asih PBS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-291; Badan Penelitian dan Pengembangan Kesehatan Kemenkes (National Health Research and Develop- ment Ministry of Health Indonesia), 2013, LAPORAN RISKESDAS; Badan Penelitian dan Pengembangan Kesehatan Kemenkes (National Health Research and Development Ministry of Health Indonesia), 2010, LAPORAN RISKESDAS; Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia (National Health Research and Development Ministry of Health Indonesia), 2010, PED PENG KEUS RISK 2; Badan Pusat Statistik (Statistics Indonesia), 2015, PERSENTASE PENDUDUK; Bruxvoort K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084555; Chaturvedi HK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-301; Das A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-39; Delima D, 2012, BULETIN PENELITIAN K, V40; Diaz T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-157; Douglas NM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001575; Elfahmi, 2014, J HERB MED, V4, P51, DOI 10.1016/j.hermed.2014.01.002; Elyazar IRF, 2011, ADV PARASIT, V74, P41, DOI 10.1016/B978-0-12-385897-9.00002-1; Gazali A. K, 2013, PERILAKU PENCARIAN P; Gyasi R.M., 2011, GLOBAL J HLTH SCI, V3, P2, DOI DOI 10.5539/gjhs.v3n2p40; Handayani L, 2011, BULETIN PENELITIAN S, V14; Harijanto PN, 2010, ACTA MED INDONES, V42, P11; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Kusriastuti Rita, 2012, Acta Med Indones, V44, P265; Limpakarnjanarat K., 2011, NATIONAL MALARIA CON; Linn TZ, 2005, J NAT PROD, V68, P706, DOI 10.1021/np0401720; Luthi B, 2015, TRAVEL MED INFECT DI, V13, P48, DOI 10.1016/j.tmaid.2014.04.014; Mahapatra P, 2007, LANCET, V370, P1653, DOI 10.1016/S0140-6736(07)61308-7; Mardiana M, 2004, MEDIA PENELITIAN DAN, V14; Meessen B, 2011, HEALTH POLICY PLANN, V26, pII16, DOI 10.1093/heapol/czr062; Morris MB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-5; Moszynski P, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5645; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; Mustofa, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P609; Nimpagaritse M, 2011, HEALTH POLICY PLANN, V26, pII63, DOI 10.1093/heapol/czr061; Nonaka D, 2009, ACTA TROP, V112, P283, DOI 10.1016/j.actatropica.2009.08.013; Orem JN, 2011, HEALTH POLICY PLANN, V26, pII41, DOI 10.1093/heapol/czr065; Pradono J, 2005, SURVEI KESEHATAN RUM; Ramadianto A. S., 2015, J AMSA, V4, P4; Ransford HE, 2010, J HEALTH CARE POOR U, V21, P862, DOI 10.1353/hpu.0.0348; Roosita K, 2008, J ETHNOPHARMACOL, V115, P72, DOI 10.1016/j.jep.2007.09.010; Russell S, 2004, AM J TROP MED HYG, V71, P147, DOI 10.4269/ajtmh.2004.71.147; Sanjana P, 2006, AM J TROP MED HYG, V75, P783, DOI 10.4269/ajtmh.2006.75.783; Shah GM, 2014, J ETHNOPHARMACOL, V155, P450, DOI 10.1016/j.jep.2014.05.047; Shinta S, 2005, JURNAL EKOLOGI KESEH, V4; Shirayama Yoshihisa, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P622; Sidik NA, 2013, TROP MED INT HEALTH, V18, P407, DOI 10.1111/tmi.12061; Srivastava D, 2015, SOC SCI MED, V133, P21, DOI 10.1016/j.socscimed.2015.03.021; Subeki S, 2012, J TEKNOLOGI DAN IND, V13; Sujarwo W, 2015, J ETHNOPHARMACOL, V169, P34, DOI 10.1016/j.jep.2015.03.079; Supardi S, 2011, HLTH SCI J INDONES, V2, P3; Supardi S, 2011, BULETIN PENELITIAN S, V13; Suswardany DL, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0593-7; Tangjang S, 2011, J ETHNOPHARMACOL, V134, P18, DOI 10.1016/j.jep.2010.11.053; Torri MC, 2016, J SMALL BUS MANAGE, V54, P341, DOI 10.1111/jsbm.12148; Tynan A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-204; Utarini A, 2003, SOC SCI MED, V56, P701, DOI 10.1016/S0277-9536(02)00066-7; Vijayakumar KN, 2009, ACTA TROP, V112, P137, DOI 10.1016/j.actatropica.2009.07.011; Wangroongsarb P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-117; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Widowati L, 2014, MEDIA PENELIT PENGEM, V24, P95; Witter S, 2011, HEALTH POLICY PLANN, V26, pII84, DOI 10.1093/heapol/czr066; Xu JW, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-417	61	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0173522	10.1371/journal.pone.0173522	http://dx.doi.org/10.1371/journal.pone.0173522			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER8SZ	28329019	Green Published, gold, Green Submitted			2023-01-03	WOS:000399094700023
J	Harris, PF				Harris, Patricia F.			Review: Palliative care improves quality of life and symptom burden but does not affect mortality at 1 to 3 months	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Harris, Patricia F.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Harris, PF (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.							El-Jawahri Areej, 2011, J Support Oncol, V9, P87; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698	2	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2017	166	6					JC31	JC31		10.7326/ACPJC-2017-166-6-031	http://dx.doi.org/10.7326/ACPJC-2017-166-6-031			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO9RM	28320005				2023-01-03	WOS:000397025800008
J	Son, SH; Choi, KH; Kim, SW				Son, Seok Hyun; Choi, Kyu Hye; Kim, Shin-Wook			Dosimetric comparison of simultaneous integrated boost with whole-breast irradiation for early breast cancer	PLOS ONE			English	Article							TUMOR BED; LOCAL-CONTROL; RADIOTHERAPY; SURVIVAL; ELECTRON; THERAPY	Purpose The purpose of this study was to identify a more suitable boost plan for simultaneously integrated boost scheme in patients with breast cancer by comparing among 3 types of whole-breast irradiation plus tumor bed boost plans. Methods Twenty patients who received radiotherapy following breast-conserving surgery for early breast cancer were enrolled in this study. We performed 1 type of electron plan (E1P plan) and 2 types of 3-dimensional conformal plans using a photon (P3P and P5P plans). The dosimetric parameters for the heart, total lung and the target volume between the 3 treatment types were compared. Results For the tumor bed, the difference in the mean dose between the 3 plans was maximally 0.1 Gy. For normal breast parenchyma, the difference in the mean dose between the 3 plans was maximally 1.1 Gy. In the dose range over the prescribed dose of 51 Gy, V-55 and V-60 in the E1P plan were lower than those in the P3P and P5P plans, which indicated that the E1P plan was more suitable than the P3P and P5P plans. In case of the heart and total lung, the values of clinically important parameters were slightly higher in the E1P plan than in the P3P and P5P plans. However, these differences were less than 2%. Conclusion We observed that a simple electron plan for tumor bed boost is preferable over multi-field photon plans in terms of the target volume coverage and normal tissue sparing.	[Son, Seok Hyun; Choi, Kyu Hye; Kim, Shin-Wook] Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Dept Radiat Oncol, Seoul, South Korea	Catholic University of Korea	Son, SH (corresponding author), Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Dept Radiat Oncol, Seoul, South Korea.	sonshyun@catholic.ac.kr		Son, Seok Hyun/0000-0002-2577-1915				Abe O, 2005, LANCET, V366, P2087; Aly MMOM, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0452-2; Bartelink H, 2007, J CLIN ONCOL, V25, P3259, DOI 10.1200/JCO.2007.11.4991; Chen GP, 2015, MED DOSIM, V40, P21, DOI 10.1016/j.meddos.2014.06.007; Chen XJ, 2014, INT J RADIAT ONCOL, V90, P1208, DOI 10.1016/j.ijrobp.2014.08.342; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Gagliardi G, 2010, INT J RADIAT ONCOL, V76, pS77, DOI 10.1016/j.ijrobp.2009.04.093; Ghoncheh Mahshid, 2016, Asian Pac J Cancer Prev, V17, P43; Guerrero M, 2004, INT J RADIAT ONCOL, V59, P1513, DOI 10.1016/j.ijrobp.2004.04.007; Marks LB, 2010, INT J RADIAT ONCOL, V76, pS70, DOI 10.1016/j.ijrobp.2009.06.091; Offersen BV, 2016, RADIOTHER ONCOL, V118, P205, DOI 10.1016/j.radonc.2015.12.027; Park K, 2015, RADIAT ONCOL J, V33, P242, DOI 10.3857/roj.2015.33.3.242; Park SH, 2013, J BREAST CANCER, V16, P300, DOI 10.4048/jbc.2013.16.3.300; Sautter-Bihl ML, 2006, STRAHLENTHER ONKOL, V182, P199, DOI 10.1007/s00066-006-6701-4; Toscas JI, 2010, RADIOTHER ONCOL, V96, P192, DOI 10.1016/j.radonc.2010.05.007; Van Parijs H, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-36; Wong P, 2011, INT J RADIAT ONCOL, V79, P39, DOI 10.1016/j.ijrobp.2009.10.023; Wu SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120811	18	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2017	12	3							e0173552	10.1371/journal.pone.0173552	http://dx.doi.org/10.1371/journal.pone.0173552			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5VL	28273157	gold, Green Published, Green Submitted			2023-01-03	WOS:000396073700017
J	Kumar, S				Kumar, Sanjay			SCIENTIFIC COMMUNITY Critics assail India's attempt to 'validate' folk remedy	SCIENCE			English	News Item																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2017	355	6328					898	898		10.1126/science.355.6328.898	http://dx.doi.org/10.1126/science.355.6328.898			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM2YM	28254894				2023-01-03	WOS:000395181700015
J	Saglimbene, V; Palmer, SC; Craig, JC; Ruospo, M; Nicolucci, A; Tonelli, M; Johnson, D; Lucisano, G; Williams, G; Valentini, M; D'Alonzo, D; Pellegrini, F; Strippoli, P; Salomone, M; Santoro, A; Maffei, S; Hegbrant, J; Tognoni, G; Strippoli, GFM				Saglimbene, Valeria; Palmer, Suetonia C.; Craig, Jonathan C.; Ruospo, Marinella; Nicolucci, Antonio; Tonelli, Marcello; Johnson, David; Lucisano, Giuseppe; Williams, Gabrielle; Valentini, Miriam; D'Alonzo, Daniela; Pellegrini, Fabio; Strippoli, Paolo; Salomone, Mario; Santoro, Antonio; Maffei, Stefano; Hegbrant, Joergen; Tognoni, Gianni; Strippoli, Giovanni F. M.		CE-DOSE Study Investigators	Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; STAGE RENAL-DISEASE; CARDIOVASCULAR EVENTS; EPOETIN-ALPHA; MORTALITY; ASSOCIATION; MORBIDITY; IMPACT	The increased risks of death and adverse events with erythropoiesis-stimulating agent (ESA) therapy targeting a higher hemoglobin level are established. It is uncertain whether the adverse effects of ESA therapy are related to dose and are mitigated when a fixed low ESA dose is used. We conducted a multicenter, prospective randomized open-label, blinded-endpoint (PROBE) trial to evaluate fixed low versus high dose ESA therapy on patient outcomes. We intended to recruit 2104 hemodialysis patients >18 years with anemia or receiving ESA treated at dialysis clinics in Italy. The intervention was fixed low (4000 IU epoetin alfa equivalent weekly) or high (18,000 IU epoetin alfa equivalent weekly) dose ESA for 12 months. Primary outcomes were serum transferrin, ferritin, albumin, C-reactive protein and ESA dose. Secondary outcomes were the composite of death or cardiovascular event, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, cardiovascular hospitalization, and quality of life. Study recruitment was terminated after inclusion of 656 participants with convergence of ESA dose between groups during follow up. Fixed low dose ESA had uncertain effects on serum ferritin (delta of delta (DD) 3.9 ng/ml, 95% CI -85.0 to 92.8), transferrin (9.2 mg/dl, -6.3 to 24.8), transferrin saturation (3.7%, -5.0 to 12.3), serum albumin (-0.03 g/dl, -0.2 to 0.1), or C-reactive protein (-0.6 mg/l, -3.3 to 2.1). In addition, fixed dose therapy had inconclusive effects on the composite endpoint of mortality and cardiovascular events (hazard ratio [HR] 0.95, 95% CI 0.66 to 1.37), death (0.98, 0.64 to 1.52), nonfatal myocardial infarction (0.52, 0.18 to 1.52), nonfatal stroke (no events), hospital admission for cardiovascular causes (0.93, 0.50 to 1.72) or health-related quality of life. A fixed low ESA dose in hemodialysis patients has uncertain effects on serum parameters, mortality, cardiovascular events, and quality of life. Hemoglobin targets may be so entrenched in nephrology practice that a trial of ESA dose is no longer possible.	[Saglimbene, Valeria; Craig, Jonathan C.; Williams, Gabrielle; Strippoli, Giovanni F. M.] Univ Sydney, Sydney Sch Publ Hlth, Edward Ford Bldg, Sydney, NSW, Australia; [Saglimbene, Valeria; Ruospo, Marinella; Hegbrant, Joergen; Strippoli, Giovanni F. M.] Diaverum Renal Serv Grp, Lund, Sweden; [Palmer, Suetonia C.] Univ Otago Christchurch, Dept Med, Christchurch, New Zealand; [Ruospo, Marinella] Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy; [Nicolucci, Antonio; Lucisano, Giuseppe] Ctr Outcomes Res & Clin Epidemiol CORESEARCH, Pescara, Italy; [Tonelli, Marcello] Univ Calgary, Cumming Sch Med, Hlth Sci Ctr, Foothills Campus, Calgary, AB, Canada; [Johnson, David] Univ Queensland, Princess Alexandra Hosp, Div Med, Dept Renal Med, Woolloongabba, Qld, Australia; [Johnson, David] Univ Queensland, Translat Res Inst, Woolloongabba, Qld, Australia; [Valentini, Miriam] Quintiles Srl, Milan, Italy; [D'Alonzo, Daniela] ASL Lanciano Vasto, Chieti, Italy; [Pellegrini, Fabio] Global Med Biogen Idec, Cambridge, MA USA; [Strippoli, Paolo] Osped A Perrino, Dept Nephrol & Dialysis, Brindisi, Italy; [Salomone, Mario; Maffei, Stefano] Osped Maggiore Chieri, Dept Nephrol & Dialysis, Chieri, Italy; [Santoro, Antonio] St Orsola Marcello Malpighi Hosp, Dept Nephrol & Dialysis, Bologna, Italy; [Tognoni, Gianni] Mario Negri Inst Pharmacol Res, Milan, Italy; [Strippoli, Giovanni F. M.] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy	University of Sydney; Diaverum; University of Otago; University of Eastern Piedmont Amedeo Avogadro; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Queensland; University of Queensland; IQVIA; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universita degli Studi di Bari Aldo Moro	Strippoli, GFM (corresponding author), Univ Sydney, Sydney Sch Publ Hlth, Edward Ford Bldg, Sydney, NSW, Australia.; Strippoli, GFM (corresponding author), Diaverum Renal Serv Grp, Lund, Sweden.; Strippoli, GFM (corresponding author), Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy.	gfmstrippoli@gmail.com	Craig, Jonathan/E-2813-2013; Tonelli, Marcello/B-3028-2009; Johnson, David/F-2897-2011	Craig, Jonathan/0000-0002-2548-4035; Tonelli, Marcello/0000-0002-0846-3187; Johnson, David/0000-0001-5491-3460	Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]) [FARM6X822T]	Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA])	The study received funding from the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]: grant number FARM6X822T). This trial was funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]). The funder required the inclusion of specified outcomes during trial conduct, but played no role in finalizing the study design, data analysis, data interpretation, or report writing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One or more of the authors are employed by a commercial company (Diaverum Renal Services Group: VS, MR, JH, GFMS, Quintiles srl: MV, Global Medical Biogen Idec: FP). These funding organizations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries. The funders provided support in the form of salaries for authors VS, MR, JH, GS, MV, FP but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; BAHLMANN J, 1991, CONTRIB NEPHROL, V88, P90; Bellinghieri G, 2015, J RENAL NUTR, V25, P164, DOI 10.1053/j.jrn.2014.10.012; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Clement FM, 2009, ARCH INTERN MED, V169, P1104, DOI 10.1001/archinternmed.2009.112; Collins A J, 1998, Am J Kidney Dis, V32, pS133, DOI 10.1016/S0272-6386(98)70176-3; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hays R, 1995, P7994 RAND, P7994; Inrig JK, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-67; Italian Medicines Agency (AIFA) Research & Development Working Group, 2009, EUR J CLIN INVEST, V40, P69; Johnson DW, 2015, AM J KIDNEY DIS, V65, P49, DOI 10.1053/j.ajkd.2014.06.020; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9; Singer J., 2003, APPL LONGITUDINAL DA; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Strippoli GFM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-70; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; US Food and Drug Administration, 2011, FDA DRUG SAF COMM MO; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x; Zhang Y, 2011, KIDNEY INT, V80, P663, DOI 10.1038/ki.2011.188; ZINS B, 1986, LANCET, V2, P1329	29	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0172735	10.1371/journal.pone.0172735	http://dx.doi.org/10.1371/journal.pone.0172735			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4NF	28249030	gold, Green Published, Green Submitted			2023-01-03	WOS:000395983500055
J	Murray, SA; Kendall, M; Mitchell, G; Moine, S; Amblas-Novellas, J; Boyd, K				Murray, Scott A.; Kendall, M.; Mitchell, G.; Moine, S.; Amblas-Novellas, J.; Boyd, K.			Palliative care from diagnosis to death	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CANCER; END; PEOPLE; LIFE; UNCERTAINTY; DISEASES; FAILURE; FRAILTY; TOOLS; NEEDS		[Murray, Scott A.; Kendall, M.; Boyd, K.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Primary Palliat Care Res Grp, Edinburgh, Midlothian, Scotland; [Mitchell, G.] Univ Queensland, Fac Med & Biomed Sci, Gen Practice & Palliat Care, Brisbane, Qld, Australia; [Moine, S.] Amiens Univ Hosp, Hlth Educ & Practices Lab, Amiens, France; [Amblas-Novellas, J.] Univ Vic, Geriatr & Palliat Care Dept, Barcelona, Spain	University of Edinburgh; University of Queensland; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Murray, SA (corresponding author), Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Primary Palliat Care Res Grp, Edinburgh, Midlothian, Scotland.	Scott.Murray@ed.ac.uk	Amblàs-Novellas, Jordi/AAB-4651-2019	Amblàs-Novellas, Jordi/0000-0002-2338-3054; Murray, Scott A/0000-0002-6649-9428; Boyd, Kirsty/0000-0002-5526-1078; MOINE, Sebastien/0000-0003-3960-9422				Amblas-Novellas J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012340; Back AL, 2005, CA-CANCER J CLIN, V55, P164, DOI 10.3322/canjclin.55.3.164; Bacon J., 2012, PALLIATIVE APPROACH; Beernaert K, 2016, EUR J CANCER CARE, V25, P534, DOI 10.1111/ecc.12522; British Medical Association, 2016, END OF LIF CAR PHYS, V3; Caprio AJ, 2016, CAN MED ASSOC J, V188, P711, DOI 10.1503/cmaj.160206; Cavers D, 2012, CAN MED ASSOC J, V184, pE373, DOI 10.1503/cmaj.111622; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Gamondi C., 2013, EUROPEAN J PALLIATIV, V20, P86; Gomez-Batiste X, 2016, J PAIN SYMPTOM MANAG; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Hui D, 2016, NAT REV CLIN ONCOL, V13, P159, DOI 10.1038/nrclinonc.2015.201; Jackson VA, 2013, J PALLIAT MED, V16, P894, DOI 10.1089/jpm.2012.0547; Kendall M, 2015, J PAIN SYMPTOM MANAG, V50, P216, DOI 10.1016/j.jpainsymman.2015.02.017; Kimbell B, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3802; Lloyd A, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0350-y; Maas EAT, 2013, BMJ SUPPORT PALLIAT, V3, P444, DOI 10.1136/bmjspcare-2013-000527; Mason B, 2016, BMJ SUPPORT PALLIAT, V6, P60, DOI 10.1136/bmjspcare-2013-000639; Masso M, 2015, PALLIATIVE MED, V29, P22, DOI 10.1177/0269216314551814; Mitchell G, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-24; Murray SA, 2008, BRIT MED J, V336, P958, DOI 10.1136/bmj.39535.491238.94; Murtagh FEM, 2014, PALLIATIVE MED, V28, P49, DOI 10.1177/0269216313489367; Parry R, 2014, BMJ SUPPORT PALLIAT, V4, P331, DOI 10.1136/bmjspcare-2014-000649; Rocker G, 2016, CAN MED ASSOC J, V188, pE493, DOI 10.1503/cmaj.151454; Smith AK, 2013, NEW ENGL J MED, V368, P2448, DOI 10.1056/NEJMp1303295; Tapsfield J, 2019, BMJ SUPPORT PALLIAT, V9, DOI 10.1136/bmjspcare-2015-001014; Tassinari D, 2016, REV RECENT CLIN TRIA, V11, P63, DOI 10.2174/1574887110666151014141650; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Temel JS, 2016, J CLIN ONCOL, V3; Walsh RI, 2015, J PALLIAT CARE, V31, P118, DOI 10.1177/082585971503100208; World Health Assembly, 2014, 134 SESS WORLD HLTH; Zimmermann C, 2016, CAN MED ASSOC J, V188, pE217, DOI 10.1503/cmaj.151171	32	99	99	2	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2017	356								j878	10.1136/bmj.j878	http://dx.doi.org/10.1136/bmj.j878			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM9JP	28242747	Green Submitted			2023-01-03	WOS:000395628000008
J	Perez-Sanchez, A; Borras-Linares, I; Barrajon-Catalan, E; Arraez-Roman, D; Gonzalez-Alvarez, I; Ibanez, E; Segura-Carretero, A; Bermejo, M; Micol, V				Perez-Sanchez, Almudena; Borras-Linares, Isabel; Barrajon-Catalan, Enrique; Arraez-Roman, David; Gonzalez-Alvarez, Isabel; Ibanez, Elena; Segura-Carretero, Antonio; Bermejo, Marival; Micol, Vicente			Evaluation of the intestinal permeability of rosemary (Rosmarinus officinalis L.) extract polyphenols and terpenoids in Caco-2 cell monolayers	PLOS ONE			English	Article							PHOSPHOLIPID MODEL MEMBRANES; DRUG-DELIVERY SYSTEMS; CANCER-CELLS; ANTIOXIDANT PROPERTIES; BIOAVAILABILITY; TRANSPORT; CLASSIFICATION; ABSORPTION; FLAVONOIDS; CARNOSOL	Rosemary (Rosmarinus officinalis) is grown throughout the world and is widely used as a medicinal herb and to season and preserve food. Rosemary polyphenols and terpenoids have attracted great interest due to their potential health benefits. However, complete information regarding their absorption and bioavailability in Caco-2 cell model is scarce. The permeation properties of the bioactive compounds (flavonoids, diterpenes, triterpenes and phenylpropanoids) of a rosemary extract (RE), obtained by supercritical fluid extraction, was studied in Caco-2 cell monolayer model, both in a free form or liposomed. Compounds were identified and quantitated by liquid chromatography coupled to quadrupole time-of-flight with electrospray ionization mass spectrometry analysis (HPLC-ESI-QTOF-MS), and the apparent permeability values (P-app) were determined, for the first time in the extract, for 24 compounds in both directions across cell monolayer. For some compounds, such as triterpenoids and some flavonoids, P-app values found were reported for the first time in Caco-2 cells. Our results indicate that most compounds are scarcely absorbed, and passive diffusion is suggested to be the primary mechanism of absorption. The use of liposomes to vehiculize the extract resulted in reduced permeability for most compounds. Finally, the biopharmaceutical classification (BCS) of all the compounds was achieved according to their permeability and solubility data for bioequivalence purposes. BCS study reveal that most of the RE compounds could be classified as classes III and IV (low permeability); therefore, RE itself should also be classified into this category.	[Perez-Sanchez, Almudena; Barrajon-Catalan, Enrique; Micol, Vicente] Miguel Hernandez Univ, Inst Mol & Cell Biol, Avda Univ S-N, Elche, Spain; [Borras-Linares, Isabel; Arraez-Roman, David; Segura-Carretero, Antonio] Univ Granada, Fac Sci, Dept Analyt Chem, Avda Fuentenueva S-N, Granada, Spain; [Borras-Linares, Isabel; Arraez-Roman, David; Segura-Carretero, Antonio] Res & Dev Funct Food Ctr CIDAF, Hlth Sci Technol Pk,Avda Conocimiento 37, Armilla, Spain; [Barrajon-Catalan, Enrique; Gonzalez-Alvarez, Isabel; Bermejo, Marival] Univ Miguel Hernandez, Dept Engn, Pharmacokinet & Pharmaceut Technol Area, Alicante, Spain; [Barrajon-Catalan, Enrique] INVTROTECNIA SL, Santiago Grisolia 2, Madrid, Spain; [Ibanez, Elena] CSIC UAM, Inst Food Sci Res CIAL, Lab Food, Nicolas Cabrera 9,Campus Cantoblanco, Madrid, Spain; [Micol, Vicente] Inst Salud Carlos III, CIBER, CIBERobn, Fisiopatol Obesidad & Nutr, Madrid, Spain	Universidad Miguel Hernandez de Elche; University of Granada; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UAM - Instituto de Investigacion en Ciencias de la Alimentacion (CIAL); CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Micol, V (corresponding author), Miguel Hernandez Univ, Inst Mol & Cell Biol, Avda Univ S-N, Elche, Spain.; Micol, V (corresponding author), Inst Salud Carlos III, CIBER, CIBERobn, Fisiopatol Obesidad & Nutr, Madrid, Spain.	vmicol@umh.es	Gonzalez-Alvarez, Isabel/AAD-5896-2019; Carretero, Antonio Segura/B-6867-2014; Bermejo, Marival/A-4163-2009; Barrajón-Catalán, Enrique/C-2884-2013; Borrás, Isabel/K-9154-2014; Arraez-Roman, David/M-8256-2014; GONZALEZ-ALVAREZ, ISABEL/N-3614-2013; Micol, Vicente/K-6841-2014; Ibanez, Elena/AAJ-2177-2020	Gonzalez-Alvarez, Isabel/0000-0002-1685-142X; Carretero, Antonio Segura/0000-0002-5564-5338; Bermejo, Marival/0000-0001-5022-0544; Barrajón-Catalán, Enrique/0000-0001-8113-0795; Borrás, Isabel/0000-0002-5227-9002; Arraez-Roman, David/0000-0003-1267-6676; GONZALEZ-ALVAREZ, ISABEL/0000-0002-1685-142X; Ibanez, Elena/0000-0003-2127-8303; Micol, Vicente/0000-0001-8089-0696	Spanish Ministry of Science and Innovation [AGL2011-29857-C03-02, AGL2011-29857-C03-03, AGL2015-67995-C3-1-R, AGL2015-67995-C3-2-R, AP2007-03246]; Spanish Ministry of Economy and Competitiveness (MINECO) [PTQ-13-06429, PTQ-14-07243]; Andalusian Regional Government Council of Innovation and Science [P11-CTS-7625]; Generalitat Valenciana [PROMETEO/2016/006, ACOMP/2013/093, ACIF/2013/064]; CIBER [CB12/03/30038]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Economy and Competitiveness (MINECO)(Spanish Government); Andalusian Regional Government Council of Innovation and Science; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); CIBER	This work was supported by projects AGL2011-29857-C03-02, AGL2011-29857-C03-03, AGL2015-67995-C3-1-R, and AGL2015-67995-C3-2-R, and FPU grant (AP2007-03246) from Spanish Ministry of Science and Innovation; Torres Quevedo grants PTQ-13-06429 and PTQ-14-07243 from the Spanish Ministry of Economy and Competitiveness (MINECO); grant P11-CTS-7625 from Andalusian Regional Government Council of Innovation and Science; PROMETEO/2016/006, ACOMP/2013/093 and ACIF/2013/064 from Generalitat Valenciana; CIBER (CB12/03/30038, Fisiopatologia de la Obesidad y la Nutricion, CIBERobn, Instituto de Salud Carlos III). The authors are also thankful to ChemAxon for providing a free academic license of Marvin for structure handling and other toolkits. The funder Invitrotecnia S. L. provided support in the form of salaries for author EBC.; This work was supported by projects AGL2011-29857-C03-02, AGL2011-29857-C03-03, AGL2015-67995-C3-1-R, and AGL2015-67995-C3-2-R, and FPU grant (AP2007-03246) from Spanish Ministry of Science and Innovation; Torres Quevedo grants PTQ-13-06429 and PTQ-14-07243 from the Spanish Ministry of Economy and Competitiveness (MINECO); grant P11-CTS-7625 from Andalusian Regional Government Council of Innovation and Science; PROMETEO/2016/006, ACOMP/2013/093 and ACIF/2013/064 from Generalitat Valenciana; CIBER (CB12/03/30038, Fisiopatologia de la Obesidad y la Nutricion, CIBERobn, Instituto de Salud Carlos III). The authors are also thankful to ChemAxon for providing a free academic license of Marvin for structure handling and other toolkits.	Altinier G, 2007, J AGR FOOD CHEM, V55, P1718, DOI 10.1021/jf062610+; Alves DS, 2004, BIOCHEM PHARMACOL, V68, P549, DOI 10.1016/j.bcp.2004.04.012; Ambrosini MV, 1997, PHYSIOL BEHAV, V62, P773, DOI 10.1016/S0031-9384(97)00196-0; AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288; Anabousi S, 2006, EUR J PHARM SCI, V29, P367, DOI 10.1016/j.ejps.2006.07.004; Anilkumar APP, 2008, ACTA NEUROPSYCHIATR, V20, P129, DOI 10.1111/j.1601-5215.2008.00280.x; Arranz E, 2015, J FUNCT FOODS, V13, P384, DOI 10.1016/j.jff.2015.01.015; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Artursson P, 2001, ADV DRUG DELIVER REV, V46, P27, DOI 10.1016/S0169-409X(00)00128-9; ARTURSSON P, 1990, J PHARM SCI-US, V79, P476, DOI 10.1002/jps.2600790604; Bakirel T, 2008, J ETHNOPHARMACOL, V116, P64, DOI 10.1016/j.jep.2007.10.039; Barrajon-Catalan E., 2016, CURCUMIN CLIN USES H, P99; Barrajon-Catalan E, 2010, CANCER LETT, V290, P192, DOI 10.1016/j.canlet.2009.09.010; Benet LZ, 2013, J PHARM SCI-US, V102, P34, DOI 10.1002/jps.23359; Borras-Linares I, 2015, INT J MOL SCI, V16, P18396, DOI 10.3390/ijms160818396; Borras-Linares I, 2015, FOOD CHEM TOXICOL, V80, P215, DOI 10.1016/j.fct.2015.03.013; Bozin B, 2007, J AGR FOOD CHEM, V55, P7879, DOI 10.1021/jf0715323; Catania A, 2013, BREAST CANCER RES TR, V141, P55, DOI 10.1007/s10549-013-2667-y; Caturla N, 2003, FREE RADICAL BIO MED, V34, P648, DOI 10.1016/S0891-5849(02)01366-7; Cristina SR, 2010, J AGR FOOD CHEM, V58, P1144, DOI [10.1021/jf9028087q, DOI 10.1021/JF9028087Q]; D'Antuono I, 2015, FOOD FUNCT, V6, P1268, DOI [10.1039/c5fo00137d, 10.1039/C5FO00137D]; Del Campo J, 2000, J FOOD PROTECT, V63, P1359, DOI 10.4315/0362-028X-63.10.1359; Doolaege EHA, 2011, PLANT FOOD HUM NUTR, V66, P196, DOI 10.1007/s11130-011-0233-5; Dorrie J, 2001, CANCER LETT, V170, P33, DOI 10.1016/S0304-3835(01)00549-3; Fale PL, 2013, FOOD FUNCT, V4, P426, DOI 10.1039/c2fo30318c; Funes L, 2010, CHEM PHYS LIPIDS, V163, P190, DOI 10.1016/j.chemphyslip.2009.11.004; Herrero M, 2010, J CHROMATOGR A, V1217, P2512, DOI 10.1016/j.chroma.2009.11.032; Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019; Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h; Kaur H, 2014, J PHARMACEUTICS, V2014, DOI 10.1155/2014/180845; Lian T, 2001, J PHARM SCI-US, V90, P667, DOI 10.1002/jps.1023; Lin HX, 2007, INT J PHARMACEUT, V330, P23, DOI 10.1016/j.ijpharm.2006.08.043; Lo AH, 2002, CARCINOGENESIS, V23, P983, DOI 10.1093/carcin/23.6.983; Mukkavilli R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108386; Perez-Fons L, 2006, ARCH BIOCHEM BIOPHYS, V453, P224, DOI 10.1016/j.abb.2006.07.004; Perez-Fons L, 2010, J AGR FOOD CHEM, V58, P161, DOI 10.1021/jf9026487; Qiang ZY, 2011, J ETHNOPHARMACOL, V137, P1107, DOI 10.1016/j.jep.2011.07.037; Vaquero MR, 2013, MOL NUTR FOOD RES, V57, P1834, DOI 10.1002/mnfr.201300052; Seiquer I, 2015, FOOD CHEM, V188, P496, DOI 10.1016/j.foodchem.2015.05.006; Serra H, 2008, BIOORGAN MED CHEM, V16, P4009, DOI 10.1016/j.bmc.2008.01.028; Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X; Sotelo-Felix JI, 2002, J ETHNOPHARMACOL, V81, P145, DOI 10.1016/S0378-8741(02)00090-9; Takagi T, 2006, MOL PHARMACEUT, V3, P631, DOI 10.1021/mp0600182; Tarko Tomasz, 2013, Rocz Panstw Zakl Hig, V64, P79; Tian XJ, 2009, INT J PHARMACEUT, V367, P58, DOI 10.1016/j.ijpharm.2008.09.023; Tsai TH, 2013, J MED FOOD, V16, P324, DOI 10.1089/jmf.2012.2577; Valdes A, 2014, ANAL CHEM, V86, P9807, DOI 10.1021/ac502401j; Valdes A, 2013, GENES NUTR, V8, P43, DOI 10.1007/s12263-012-0311-9; van Breemen Richard B, 2005, Expert Opin Drug Metab Toxicol, V1, P175, DOI 10.1517/17425255.1.2.175; Wang Y, 2011, BIOPHARM DRUG DISPOS, V32, P16, DOI 10.1002/bdd.735; Yang YY, 2014, TOXICOL IN VITRO, V28, P388, DOI 10.1016/j.tiv.2013.12.002; Yue-Chun L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039394	52	29	32	1	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0172063	10.1371/journal.pone.0172063	http://dx.doi.org/10.1371/journal.pone.0172063			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28234919	Green Published, Green Submitted, gold			2023-01-03	WOS:000394688200044
J	Palermo, E; Laut, J; Nov, O; Cappa, P; Porfiri, M				Palermo, Eduardo; Laut, Jeffrey; Nov, Oded; Cappa, Paolo; Porfiri, Maurizio			A natural user interface to integrate citizen science and physical exercise	PLOS ONE			English	Article							ROBOT-ASSISTED THERAPY; STROKE REHABILITATION; ECOLOGICAL RESEARCH; KINECT APPLICATIONS; MOTOR RECOVERY; ARM; SYSTEM; MOTION; SENSOR; TOOL	Citizen science enables volunteers to contribute to scientific projects, where massive data collection and analysis are often required. Volunteers participate in citizen science activities online from their homes or in the field and are motivated by both intrinsic and extrinsic factors. Here, we investigated the possibility of integrating citizen science tasks within physical exercises envisaged as part of a potential rehabilitation therapy session. The citizen science activity entailed environmental mapping of a polluted body of water using a miniature instrumented boat, which was remotely controlled by the participants through their physical gesture tracked by a low-cost markerless motion capture system. Our findings demonstrate that the natural user interface offers an engaging and effective means for performing environmental monitoring tasks. At the same time, the citizen science activity increases the commitment of the participants, leading to a better motion performance, quantified through an array of objective indices. The study constitutes a first and necessary step toward rehabilitative treatments of the upper limb through citizen science and low-cost markerless optical systems.	[Palermo, Eduardo; Laut, Jeffrey; Cappa, Paolo; Porfiri, Maurizio] NYU, Tandon Sch Engn, Dept Mech & Aerosp Engn, Brooklyn, NY 11201 USA; [Palermo, Eduardo; Cappa, Paolo] Sapienza Univ Rome, Dept Mech & Aerosp Engn, Rome, Italy; [Nov, Oded] NYU, Tandon Sch Engn, Dept Technol Management & Innovat, Brooklyn, NY USA	New York University; New York University Tandon School of Engineering; Sapienza University Rome; New York University; New York University Tandon School of Engineering	Porfiri, M (corresponding author), NYU, Tandon Sch Engn, Dept Mech & Aerosp Engn, Brooklyn, NY 11201 USA.	mporfiri@nyu.edu	Coish, Elizabeth/AAU-1245-2020; Palermo, Eduardo/AAX-8426-2021	Palermo, Eduardo/0000-0002-3213-8261; Porfiri, Maurizio/0000-0002-1480-3539	National Science Foundation [BCS-1 124795, CBET-1604355]; Directorate For Engineering [1604355] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Directorate For Engineering(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This research was supported by the National Science Foundation under Grant #s BCS-1 124795 and CBET-1604355, www.nsf.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acai M, 2010, GAIT POSTURE, V32, P641, DOI 10.1016/j.gaitpost.2010.09.008; ALLEN IE, 2007, QUAL PROG, V40, P64, DOI DOI 10.1111/J.1365-2929.2004.02012.X; ARMSTRONG RL, 1987, PERCEPT MOTOR SKILL, V64, P359, DOI 10.2466/pms.1987.64.2.359; Attygalle S, 2008, 2008 VIRTUAL REHABILITATION, P168, DOI 10.1109/ICVR.2008.4625155; Awad M., 2014, P IEEE SEGAH, P1; Bach-y-Rita Paul, 2002, Top Stroke Rehabil, V8, P1; Bamberg SJM, 2008, IEEE T INF TECHNOL B, V12, P413, DOI 10.1109/TITB.2007.899493; Becker M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081638; Bouzit M, 2002, IEEE-ASME T MECH, V7, P256, DOI 10.1109/TMECH.2002.1011262; Bowser A, 2014, P COMP PUBL 17 ACM C, P137, DOI DOI 10.1145/2556420.2556502; BURTON S, 1991, PUBLIC OPIN QUART, V55, P50, DOI 10.1086/269241; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Cappa F, 2016, J ENVIRON MANAGE, V182, P374, DOI 10.1016/j.jenvman.2016.07.092; Cappa P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083945; Casella G, 2002, STAT INFERENCE, V2; Celik O, 2010, IEEE T NEUR SYS REH, V18, P433, DOI 10.1109/TNSRE.2010.2047600; Chang CM, 2012, PATIENT PREFER ADHER, V6, P821, DOI 10.2147/PPA.S37190; Charles Jeanne, 2005, Neural Plasticity, V12, P245, DOI 10.1155/NP.2005.245; Connolly TM, 2012, COMPUT EDUC, V59, P661, DOI 10.1016/j.compedu.2012.03.004; Conrad CC, 2011, ENVIRON MONIT ASSESS, V176, P273, DOI 10.1007/s10661-010-1582-5; Cooper CB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106508; Coote S, 2008, CLIN REHABIL, V22, P395, DOI 10.1177/0269215507085060; Crowley D. N., 2012, P IEEE INT GAM INN C, P1, DOI DOI 10.1109/IGIC.2012.6329849; Da Gama A., 2012, 2012 IEEE Symposium on 3D User Interfaces (3DUI), P145, DOI 10.1109/3DUI.2012.6184203; Diaz I, 2011, J ROBOT, V2011, DOI 10.1155/2011/759764; Dickinson JL, 2012, FRONT ECOL ENVIRON, V10, P291, DOI 10.1890/110236; Dickinson JL, 2010, ANNU REV ECOL EVOL S, V41, P149, DOI 10.1146/annurev-ecolsys-102209-144636; Dipietro L, 2009, CORTEX, V45, P318, DOI 10.1016/j.cortex.2008.02.008; Dong SF, 2006, IEEE T NEUR SYS REH, V14, P55, DOI 10.1109/TNSRE.2005.863839; Duncan PW, 2002, STROKE, V33, P167, DOI 10.1161/hs0102.101014; Fern'ndez-Baena A., 2012, 2012 4th International Conference on Intelligent Networking and Collaborative Systems (INCoS 2012), P656, DOI 10.1109/iNCoS.2012.66; Flores E., 2008, P 2008 INT C ADV COM, P381, DOI [10.1145/1501750.1501839, DOI 10.1145/1501750.1501839]; Fortson L, 2011, ARXIV11045512; Foster-Smith J, 2003, BIOL CONSERV, V113, P199, DOI 10.1016/S0006-3207(02)00373-7; Gerling K., 2012, P 2012 ACM ANN C HUM, P1873, DOI [10.1145/2207676.2208324, DOI 10.1145/2207676.2208324]; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Gonzalez A, 2014, SENSORS-BASEL, V14, P16955, DOI 10.3390/s140916955; Gouveia C, 2004, J ENVIRON MANAGE, V71, P135, DOI 10.1016/j.jenvman.2004.01.009; Gregersen A., 2011, MEDIEKULTUR J MEDIA, V51, P94, DOI [DOI 10.7146/MEDIEKULTUR.V27I51.4084, 10.7146/mediekultur.v27i51.4084]; Gupta A, 2006, IEEE-ASME T MECH, V11, P280, DOI 10.1109/TMECH.2006.875558; Haklay M., 2013, CROWDSOURCING GEOGRA, P105, DOI [10.1007/978-94-007-4587-2_7, DOI 10.1007/978-94-007-4587-2_7]; Han JG, 2013, IEEE T CYBERNETICS, V43, P1318, DOI 10.1109/TCYB.2013.2265378; HIGHLAND TR, 1992, SPINE, V17, pS77, DOI 10.1097/00007632-199206001-00003; Holden MK, 2007, IEEE T NEUR SYS REH, V15, P36, DOI 10.1109/TNSRE.2007.891388; Johansson BB, 2011, ACTA NEUROL SCAND, V123, P147, DOI 10.1111/j.1600-0404.2010.01417.x; Johnson MJ, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-29; Kitsunezaki N, 2013, IEEE INT SYM MED MEA, P294, DOI 10.1109/MeMeA.2013.6549755; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Lange B, 2011, IEEE ENG MED BIO, P1831, DOI 10.1109/IEMBS.2011.6090521; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Laut J, J ASS INFORM SCI TEC; Laut J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117013; Laut J, 2014, IEEE-ASME T MECH, V19, P1541, DOI 10.1109/TMECH.2013.2287705; Laut J, 2014, IEEE CONTR SYST MAG, V34, P60, DOI 10.1109/MCS.2013.2287386; Liao WW, 2012, CLIN REHABIL, V26, P111, DOI 10.1177/0269215511416383; Lintott CJ, 2008, MON NOT R ASTRON SOC, V389, P1179, DOI 10.1111/j.1365-2966.2008.13689.x; Liu T, 2010, SENSORS-BASEL, V10, P10240, DOI 10.3390/s101110240; Liu T, 2009, IEEE SENS J, V9, P1103, DOI 10.1109/JSEN.2009.2026509; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lukowicz P, 2006, LECT NOTES COMPUT SC, V3968, P101; Malfait N, 2004, J NEUROSCI, V24, P8084, DOI 10.1523/JNEUROSCI.1742-04.2004; Masia L, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-28; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Microsoft, KIN SDK; Mitra S, 2007, IEEE T SYST MAN CY C, V37, P311, DOI 10.1109/TSMCC.2007.893280; Morrow K, 2006, 2006 INTERNATIONAL WORKSHOP ON VIRTUAL REHABILITATION, P6, DOI 10.1109/IWVR.2006.1707518; Nov O., 2010, PROC 19 INT C WORLD, P741, DOI [10.1145/1772690.1772766, DOI 10.1145/1772690.1772766]; Nov O, 2011, P 2011 ICONFERENCE, P68, DOI [DOI 10.1145/1940761.1940771, 10.1145/1940761.1940771]; Nov O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090375; NYU, BROOKL ATL; O'Luanaigh P, 2005, GAME DESIGN COMPLETE; Obdrzalek S, 2012, IEEE ENG MED BIO, P1188, DOI 10.1109/EMBC.2012.6346149; Pacilli A, 2014, APPL BIONICS BIOMECH, V11, P91, DOI [10.3233/ABB-140095, 10.1155/2014/251931]; Parker J. R., 2008, LOADING, V2, P2; Patane F, 2011, IEEE T NEUR SYS REH, V19, P157, DOI 10.1109/TNSRE.2010.2089535; Patritti BL, 2010, PM&R, V2, P71, DOI 10.1016/j.pmrj.2009.10.012; Patton JL, 2004, IEEE T BIO-MED ENG, V51, P636, DOI 10.1109/TBME.2003.821035; Pearsall H, 2013, URBAN STUD, V50, P2293, DOI 10.1177/0042098013478236; Pett M. A., 1997, NONPARAMETRIC STAT H; Phamduy P, 2015, IEEE T MULTIMEDIA, V17, P2328, DOI 10.1109/TMM.2015.2480226; Rastgaar M, 2014, TR AUGM HUM PERF, V2, P157, DOI 10.1007/978-94-017-8932-5__6; Rohrer B, 2002, J NEUROSCI, V22, P8297; Rossi S, 2014, P IEEE RAS-EMBS INT, P504, DOI 10.1109/BIOROB.2014.6913827; Saini S., 2012, 2012 Proceedings of International Conference on Computer & Information Science (ICCIS 2012), P55, DOI 10.1109/ICCISci.2012.6297212; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Scott D, 2009, GEOFORUM, V40, P373, DOI 10.1016/j.geoforum.2008.12.002; Silvertown J, 2009, TRENDS ECOL EVOL, V24, P467, DOI 10.1016/j.tree.2009.03.017; Stewart KC, 2006, J NEUROL SCI, V244, P89, DOI 10.1016/j.jns.2006.01.005; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Takahashi CD, 2001, J NEUROPHYSIOL, V86, P1047, DOI 10.1152/jn.2001.86.2.1047; Tao WJ, 2012, SENSORS-BASEL, V12, P2255, DOI 10.3390/s120202255; Taub E, 2013, STROKE, V44, P1383, DOI 10.1161/STROKEAHA.111.000559; Taub E, 2011, J CHILD NEUROL, V26, P1163, DOI 10.1177/0883073811408423; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Webster D, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-108; Wu G, 2005, J BIOMECH, V38, P981, DOI 10.1016/j.jbiomech.2004.05.042; Zhang WL, 2016, J DYN SYST-T ASME, V138, DOI 10.1115/1.4033949	97	14	14	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0172587	10.1371/journal.pone.0172587	http://dx.doi.org/10.1371/journal.pone.0172587			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL5SX	28231261	Green Published, gold			2023-01-03	WOS:000394682400057
J	Schoonees, A; Rohwer, A; Young, T				Schoonees, Anel; Rohwer, Anke; Young, Taryn			Evaluating evidence-based health care teaching and learning in the undergraduate human nutrition; occupational therapy; physiotherapy; and speech, language and hearing therapy programs at a sub-Saharan African academic institution	PLOS ONE			English	Article							EVIDENCE-BASED MEDICINE; STUDENTS; PERCEPTIONS; INFORMATION; KNOWLEDGE; ATTITUDES; EDUCATION	Background It is important that all undergraduate healthcare students are equipped with evidence-based health care (EBHC) knowledge and skills to encourage evidence-informed decision-making after graduation. We assessed EBHC teaching and learning in undergraduate human nutrition (HN); occupational therapy (OT); physiotherapy (PT); and speech, language and hearing therapy (SPLH) programs at a sub-Saharan African university. Methods We used methodological triangulation to obtain a comprehensive understanding of EBHC teaching and learning: (1) through a document review of module guides, we identified learning outcomes related to pre-specified EBHC competencies; we conducted (2) focus group discussions and interviews of lecturers to obtain their perspectives on EBHC and on EBHC teaching and learning; and we (3) invited final year students (2013) and 2012 graduates to complete an online survey on EBHC attitudes, self-perceived EBHC competence, and their experience of EBHC teaching and learning. Results We reviewed all module outlines (n = 89) from HN, PT and SLHT. The OT curriculum was being revised at that time and could not be included. Six lecturers each from HN and OT, and five lecturers each from PT and SLHT participated in the focus groups. Thirty percent (53/176) of invited students responded to the survey. EBHC competencies were addressed to varying degrees in the four programs, although EBHC teaching and learning mostly occurred implicitly. Learning outcomes referring to EBHC focused on enabling competencies (e.g., critical thinking, biostatistics, epidemiology) and were concentrated in theoretical modules. Key competencies (e.g., asking questions, searching databases, critical appraisal) were rarely addressed explicitly. Students felt that EBHC learning should be integrated throughout the four year study period to allow for repetition, consolidation and application of knowledge and skills. Lecturers highlighted several challenges to teaching and practising EBHC, including lack of evidence relevant to the African context and lack of time within curricula.	[Schoonees, Anel; Rohwer, Anke; Young, Taryn] Univ Stellenbosch, Ctr Evidence Based Hlth Care, Fac Med & Hlth Sci, Cape Town, South Africa	Stellenbosch University	Schoonees, A (corresponding author), Univ Stellenbosch, Ctr Evidence Based Hlth Care, Fac Med & Hlth Sci, Cape Town, South Africa.	anelschoonees@sun.ac.za		Young, Taryn/0000-0003-2406-081X; Schoonees, Anel/0000-0001-8989-6891	Stellenbosch University's Faculty of Medicine and Health Sciences strategic fund	Stellenbosch University's Faculty of Medicine and Health Sciences strategic fund	The authors declare no conflict of interest. The funder, Stellenbosch University's Faculty of Medicine and Health Sciences strategic fund, had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akobeng AK, 2005, ARCH DIS CHILD, V90, P837, DOI 10.1136/adc.2005.071761; [Anonymous], READ PAPER BASICS EV; Asokan G V, 2012, J Evid Based Med, V5, P226, DOI 10.1111/jebm.12000; Baum KD, 2003, MED ED ONLINE, V8, P4; Bennett S, 2011, J EVAL CLIN PRACT, V17, P635, DOI 10.1111/j.1365-2753.2010.01602.x; Birbeck GL, 2013, BMC MED, V11, DOI [10.1186/1741-7015-11-223, 10.1186/1741-7015-11-226]; Bloom Benjamin, 1956, HDB 1 COGNITIVE DOMA; Boruff JT, 2011, HEALTH INFO LIBR J, V28, P264, DOI [10.1111/J.1471-1842.2011.00953.x, 10.1111/j.1471-1842.2011.00953.x]; Bozzolan M, 2014, PHYSIOTHER THEOR PR, V30, P557, DOI 10.3109/09593985.2014.910285; Byham-Gray LD, 2005, J AM DIET ASSOC, V105, P1574, DOI 10.1016/j.jada.2005.07.007; Cameron Karen Ann V, 2005, Occup Ther Int, V12, P123, DOI 10.1002/oti.1; Chiu YW, 2012, ASIA PAC J CLIN NUTR, V21, P630; Dawes Martin, 2005, BMC Med Educ, V5, P1; Dizon JMR, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-147; Eraut M, 2000, BRIT J EDUC PSYCHOL, V70, P113, DOI 10.1348/000709900158001; Forland F, 2013, EVIDENCE BASED MED, V18; Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5; Glasziou P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1253; Gray M, 2012, AUST OCCUP THER J, V59, P445, DOI 10.1111/j.1440-1630.2012.01029.x; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Harden RM, 2001, MED TEACH, V23, P123, DOI 10.1080/01421590120036547; Kelly MP, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0063-3; Kendrick T, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1499; Khan Khalid S, 2006, BMC Med Educ, V6, P59, DOI 10.1186/1472-6920-6-59; Levels of Evidence Working Group Oxford Centre for Evidence-Based Medicine, 2015, OXFORD 2011 LEVELS E; Long K, 2011, INTERNET J ALLIED HE, V9; Maggio LA, 2013, ACAD MED, V88, P1022, DOI 10.1097/ACM.0b013e3182951959; Niemivirta M, 1999, INT J EDUC RES, V31, P499; Rindflesch A, 2013, WORK, V44, P265, DOI 10.3233/WOR-121503; Rohwer A, 2015, AFR J HLTH PROF ED, V7, P98; Rohwer A, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-236; Rohwer A, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-77; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Salbach NM, 2011, J EVAL CLIN PRACT, V17, P794, DOI 10.1111/j.1365-2753.2010.01478.x; Salls J, 2009, OCCUP THER HEALTH CA, V23, P134, DOI 10.1080/07380570902773305; Smith R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g371; Spek B, 2013, INT J LANG COMM DIS, V48, P444, DOI 10.1111/1460-6984.12020; Straus SE, 2000, CAN MED ASSOC J, V163, P837; Thomas DE, 2003, J HUM NUTR DIET, V16, P315, DOI 10.1046/j.1365-277X.2003.00462.x; Young T, 2015, S AFR FAM PRACT, V57, P354, DOI 10.1080/20786190.2015.1090689; Young T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086706	41	11	13	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2017	12	2							e0172199	10.1371/journal.pone.0172199	http://dx.doi.org/10.1371/journal.pone.0172199			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BG	28207842	Green Published, gold, Green Submitted			2023-01-03	WOS:000394424500096
J	Clemens, JD; Nair, GB; Ahmed, T; Qadri, F; Holmgren, J				Clemens, John D.; Nair, G. Balakrish; Ahmed, Tahmeed; Qadri, Firdausi; Holmgren, Jan			Cholera	LANCET			English	Review							SEVERELY MALNOURISHED CHILDREN; ORAL REHYDRATION SOLUTION; SINGLE-DOSE AZITHROMYCIN; VACCINE CVD 103-HGR; O139 SYNONYM BENGAL; EL-TOR CHOLERA; VIBRIO-CHOLERAE; RAPID DIAGNOSIS; FIELD TRIAL; BLOOD-GROUP	Cholera is an acute, watery diarrhoeal disease caused by Vibrio cholerae of the O1 or O139 serogroups. In the past two centuries, cholera has emerged and spread from the Ganges Delta six times and from Indonesia once to cause global pandemics. Rational approaches to the case management of cholera with oral and intravenous rehydration therapy have reduced the case fatality of cholera from more than 50% to much less than 1%. Despite improvements in water quality, sanitation, and hygiene, as well as in the clinical treatment of cholera, the disease is still estimated to cause about 100 000 deaths every year. Most deaths occur in cholera-endemic settings, and virtually all deaths occur in developing countries. Contemporary understanding of immune protection against cholera, which results from local intestinal immunity, has yielded safe and protective orally administered cholera vaccines that are now globally stockpiled for use in the control of both epidemic and endemic cholera.	[Clemens, John D.; Ahmed, Tahmeed; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, GPO Box 128, Dhaka, Bangladesh; [Clemens, John D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Clemens, John D.] Korea Univ, Sch Med, Seoul, South Korea; [Nair, G. Balakrish] WHO, Delhi, India; [Holmgren, Jan] Univ Goteborg, Gothenburg, Sweden	International Centre for Diarrhoeal Disease Research (ICDDR); University of California System; University of California Los Angeles; Korea University; Korea University Medicine (KU Medicine); World Health Organization; University of Gothenburg	Clemens, JD (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, GPO Box 128, Dhaka, Bangladesh.	jclemens@icddrb.org	Al, Mamun M./AAF-5850-2019; Qadri, Firdausi/AAF-4583-2019	Holmgren, Jan/0000-0003-1784-5918	Government of Bangladesh; Government of Canada; Government of Sweden; Government of UK	Government of Bangladesh; Government of Canada(CGIAR); Government of Sweden; Government of UK	This work was supported by core grants to the International Centre for Diarrhoeal Disease Research, Bangladesh. We thank the Governments of Bangladesh, Canada, Sweden, and the UK for providing core or unrestricted support. We thank Jocalyn Clark for superb editorial assistance.	Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Alam NH, 2003, J PEDIATR-US, V143, P614, DOI 10.1067/S0022-3476(03)00500-6; Alam Nure H, 2003, Paediatr Drugs, V5, P151, DOI 10.2165/00128072-200305030-00002; ALBERT MJ, 1993, LANCET, V342, P387, DOI 10.1016/0140-6736(93)92811-7; Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6; Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; Ali M, 2011, J INFECT DIS, V204, P912, DOI 10.1093/infdis/jir416; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P537; [Anonymous], 1971, BMJ-BRIT MED J, V3, P266; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P517; [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117; BAINE WB, 1974, LANCET, V2, P1370; BANWELL JG, 1970, J CLIN INVEST, V49, P183, DOI 10.1172/JCI106217; BENENSON A. S., 1964, BULL WORLD HEALTH ORGAN, V30, P827; BENENSON AS, 1968, B WORLD HEALTH ORGAN, V38, P347; BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1; Bhuiyan NA, 2003, J CLIN MICROBIOL, V41, P3939, DOI 10.1128/JCM.41.8.3939-3941.2003; Bhuiyan TR, 2016, CLIN VACCINE IMMUNOL, V23, P27, DOI 10.1128/CVI.00526-15; Bhuiyan TR, 2009, INFECT IMMUN, V77, P1888, DOI 10.1128/IAI.01101-08; Butler SM, 2005, NAT REV MICROBIOL, V3, P611, DOI 10.1038/nrmicro1207; CAMERON DN, 1994, J CLIN MICROBIOL, V32, P1685, DOI 10.1128/JCM.32.7.1685-1690.1994; CARPENTER CC, 1968, J CLIN INVEST, V47, P1210, DOI 10.1172/JCI105810; CASH RA, 1974, J INFECT DIS, V130, P325, DOI 10.1093/infdis/130.4.325; Centers for Disease Control and Prevention, 2016, LAB ID VIBR CHOL; Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145; Chin CS, 2011, NEW ENGL J MED, V364, P33, DOI 10.1056/NEJMoa1012928; Ciglenecki I, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002368; CLEMENS J, 1993, INT J EPIDEMIOL, V22, P724, DOI 10.1093/ije/22.4.724; Clemens J, 2013, VACCINES; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235; Clemens J, 2014, CURR TOP MICROBIOL, V379, P231, DOI 10.1007/82_2013_353; Clemens J, 2011, NAT REV GASTRO HEPAT, V8, P701, DOI 10.1038/nrgastro.2011.174; Cohen MB, 2002, INFECT IMMUN, V70, P1965, DOI 10.1128/IAI.70.4.1965-1970.2002; Colwell RR, 2003, P NATL ACAD SCI USA, V100, P1051, DOI 10.1073/pnas.0237386100; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; COSTER TS, 1995, LANCET, V345, P949, DOI 10.1016/S0140-6736(95)90698-3; Cutler D, 2005, DEMOGRAPHY, V42, P1, DOI 10.1353/dem.2005.0002; CVJETANOVIC B, 1972, NATURE, V239, P137, DOI 10.1038/239137a0; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; Devault AM, 2014, NEW ENGL J MED, V370, P334, DOI 10.1056/NEJMoa1308663; Evans CAW, 1997, T ROY SOC TROP MED H, V91, P681, DOI 10.1016/S0035-9203(97)90523-X; Faruque SM, 2014, CURR TOP MICROBIOL, V379, P165, DOI 10.1007/82_2013_358; Faruque SM, 2006, P NATL ACAD SCI USA, V103, P6350, DOI 10.1073/pnas.0601277103; FIELD M, 1972, J CLIN INVEST, V51, P796, DOI 10.1172/JCI106874; Flach CF, 2007, INFECT IMMUN, V75, P2343, DOI 10.1128/IAI.01900-06; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Garcia L, 2005, INFECT IMMUN, V73, P3018, DOI 10.1128/IAI.73.5.3018-3024.2005; George CM, 2014, TROP MED INT HEALTH, V19, P301, DOI 10.1111/tmi.12252; George CM, 2016, EMERG INFECT DIS, V22, P233, DOI [10.3201/eid2202.151175, 10.3201/eid2202.15117]; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GLASS RI, 1983, J INFECT DIS, V148, P998, DOI 10.1093/infdis/148.6.998; GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; GREENOUGH WB, 1964, LANCET, V1, P355; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; Harris JB, 2012, LANCET, V379, P2466, DOI 10.1016/S0140-6736(12)60436-X; Harris JB, 2010, LANCET, V376, P1961, DOI 10.1016/S0140-6736(10)62172-1; Harris JB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000221; Harris JB, 2005, INFECT IMMUN, V73, P7422, DOI 10.1128/IAI.73.11.7422-7427.2005; Hartley DM, 2006, PLOS MED, V3, P63, DOI 10.1371/journal.pmed.0030007; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; HOLMGREN J, 1983, PROG ALLERGY, V33, P106; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; HORNICK RB, 1971, B NEW YORK ACAD MED, V47, P1181; Hoshino K, 1998, FEMS IMMUNOL MED MIC, V20, P201, DOI 10.1111/j.1574-695X.1998.tb01128.x; Hsiao A, 2014, NATURE, V515, P423, DOI 10.1038/nature13738; JOHNSON JA, 1994, INFECT IMMUN, V62, P2108, DOI 10.1128/IAI.62.5.2108-2110.1994; Jonson G, 1996, INFECT IMMUN, V64, P3778, DOI 10.1128/IAI.64.9.3778-3785.1996; Joo I., 1974, CHOLERA, P333; Jutla AS, 2011, AM J TROP MED HYG, V85, P303, DOI 10.4269/ajtmh.2011.11-0181; Karlsson EK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006338; Kaushik JS, 2010, INDIAN PEDIATR, V47, P309, DOI 10.1007/s13312-010-0059-5; Kirn TJ, 2005, NATURE, V438, P863, DOI 10.1038/nature04249; KOCH R, 1883, DEUT MED WOCHENSCHR, V9, P743, DOI DOI 10.1055/S-0029-1197083; Koelle K, 2005, NATURE, V436, P696, DOI 10.1038/nature03820; KUSTNER HGV, 1981, S AFR MED J, V60, P87; LANGE S, 1978, ACTA PATH MICRO IM C, V86, P145; LaRocque RC, 2009, GENES IMMUN, V10, P267, DOI 10.1038/gene.2009.2; Leung DT, 2012, EXPERT REV ANTI-INFE, V10, P435, DOI [10.1586/eri.12.23, 10.1586/ERI.12.23]; Leung DT, 2011, CLIN VACCINE IMMUNOL, V18, P1317, DOI 10.1128/CVI.05124-11; LEVINE M M, 1988, Lancet, V2, P467; LEWIS DJM, 1994, AIDS, V8, P779, DOI 10.1097/00002030-199406000-00009; Liang WL, 2003, INFECT IMMUN, V71, P5498, DOI 10.1128/IAI.71.10.5498-5504.2003; LINDENBAUM J, 1967, B WORLD HEALTH ORGAN, V37, P529; Liu J, 2013, J CLIN MICROBIOL, V51, P472, DOI 10.1128/JCM.02658-12; Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336; LONNROTH I, 1973, J GEN MICROBIOL, V76, P417, DOI 10.1099/00221287-76-2-417; Lundgren O, 2002, PHARMACOL TOXICOL, V90, P109, DOI 10.1034/j.1600-0773.2002.900301.x; Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680; Mahalanabis D, 2009, VACCINE, V27, P4850, DOI 10.1016/j.vaccine.2009.05.065; Martin S, 2014, B WORLD HEALTH ORGAN, V92, P881, DOI 10.2471/BLT.14.139949; Meibom KL, 2005, SCIENCE, V310, P1824, DOI 10.1126/science.1120096; Morris JG, 2003, CLIN INFECT DIS, V37, P272, DOI 10.1086/375600; Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392; Nelson EJ, 2007, P NATL ACAD SCI USA, V104, P19091, DOI 10.1073/pnas.0706352104; O'Connor KA, 2011, EMERG INFECT DIS, V17, P2136, DOI 10.3201/eid1711.110810; Onis M. de, 2006, Acta Paediatrica, V95, P76; Ouchterlony O, NATURE; Ouchterlony O, 1978, 43 NOB S STOCKH AUG; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; POLLITZER R, 1959, CHOLERA; QADRI F, 1995, J CLIN MICROBIOL, V33, P732, DOI 10.1128/JCM.33.3.732-734.1995; Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330; Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0; RAHMAN M, 1987, J CLIN MICROBIOL, V25, P2204, DOI 10.1128/JCM.25.11.2204-2206.1987; Ramakrishna BS, 2000, NEW ENGL J MED, V342, P308, DOI 10.1056/NEJM200002033420502; Richie E, 2000, VACCINE, V18, P2399, DOI 10.1016/S0264-410X(00)00006-2; Rothenbacher FP, 2014, GUT MICROBES, V5, P120, DOI 10.4161/gmic.26944; Roy SK, 2008, BMJ-BRIT MED J, V336, P266, DOI 10.1136/bmj.39416.646250.AE; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Safa A, 2008, EMERG INFECT DIS, V14, P987, DOI 10.3201/eid1406.080129; Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493; Sanchez J, 2008, CELL MOL LIFE SCI, V65, P1347, DOI 10.1007/s00018-008-7496-5; Siddique AK, 2010, EPIDEMIOL INFECT, V138, P347, DOI 10.1017/S0950268809990550; Silva AJ, 2006, INFECT IMMUN, V74, P2072, DOI 10.1128/IAI.74.4.2072-2079.2006; Snow J., 1855, MODE COMMUNICATION C; SVENNERHOLM AM, 1984, J INFECT DIS, V149, P884, DOI 10.1093/infdis/149.6.884; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; TACKET CO, 1995, J INFECT DIS, V172, P883, DOI 10.1093/infdis/172.3.883; TANAMAL STW, 1959, AM J TROP MED HYG, V8, P72, DOI 10.4269/ajtmh.1959.8.72; Tariq M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007552; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Telesmanich N. R., 2009, Klinicheskaya Laboratornaya Diagnostika, P51; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Uddin T, 2011, CLIN VACCINE IMMUNOL, V18, P506, DOI 10.1128/CVI.00481-10; VanHeyningen WE, 1983, CHOLERA AM SCI EXPER; von Seidlein L, 2008, TROP MED INT HEALTH, V13, P683, DOI 10.1111/j.1365-3156.2008.02051.x; Waldor MK, 1996, J BACTERIOL, V178, P4157, DOI 10.1128/jb.178.14.4157-4165.1996; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Weil AA, 2014, AM J TROP MED HYG, V91, P738, DOI 10.4269/ajtmh.14-0095; WEIL O, 1992, REV EPIDEMIOL SANTE, V40, P145; Wernick NLB, 2010, TOXINS, V2, P310, DOI 10.3390/toxins2030310; WHO, 1999, WHO M GEN SWITZ 12 1; WHO, 2004, WHOFCHCAH047; World Health Organization, 2012, WHO TECHN WORK GROUP; World Health Organization, 2005, TREATM DIARRH MAN PH; World Health Organization, 2015, PROGR SAN DRINK WAT; World Health Organization, 2013, POCK BOOK HOSP CAR C; World Health Organization, 2013, GUID UPD MAN SEV AC	147	204	210	10	123	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 23	2017	390	10101					1539	1549		10.1016/S0140-6736(17)30559-7	http://dx.doi.org/10.1016/S0140-6736(17)30559-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH7BS	28302312				2023-01-03	WOS:000411337100028
J	Charo, RA				Charo, R. Alta			Alternative Science and Human Reproduction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Charo, R. Alta] Univ Wisconsin, Sch Law, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Charo, RA (corresponding author), Univ Wisconsin, Sch Law, Madison, WI 53706 USA.			Charo, Robin Alta/0000-0003-3710-1043				[Anonymous], 2013, FACTS ARE IMP FET PA; Biggs MA, 2017, JAMA PSYCHIAT, V74, P169, DOI 10.1001/jamapsychiatry.2016.3478; Cohen J., 2017, SCIENCE; Durand M, 2001, CONTRACEPTION, V64, P227, DOI 10.1016/S0010-7824(01)00250-5; [No title captured]	5	5	5	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2017	377	4					309	311		10.1056/NEJMp1707107	http://dx.doi.org/10.1056/NEJMp1707107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BB	28613992				2023-01-03	WOS:000406295000001
J	Chang, DG; Kertesz, SG				Chang, Douglas G.; Kertesz, Stefan G.			Yoga and Low Back Pain: No Fool's Tool	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Chang, Douglas G.] Univ Calif San Diego, San Diego, CA 92103 USA; [Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, 700 South 19th St,REAP Mail Stop 151, Birmingham, AL 35233 USA; [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Chang, Douglas G.] Univ Calif San Diego, Dept Orthopaed Surg, 350 Dickinson St,Suite 121, San Diego, CA 92103 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Diego	Kertesz, SG (corresponding author), Birmingham Vet Affairs Med Ctr, 700 South 19th St,REAP Mail Stop 151, Birmingham, AL 35233 USA.	skertesz@uabmc.edu						Carey TS, 2003, SPINE, V28, P390, DOI 10.1097/00007632-200302150-00016; Chang Douglas G, 2016, J Orthop Rheumatol, V3, P1; Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459; Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16-2458; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Saper RB, 2017, ANN INTERN MED, V167, P85, DOI 10.7326/M16-2579; Simons LE, 2014, NEUROSCI BIOBEHAV R, V39, P61, DOI 10.1016/j.neubiorev.2013.12.006; Stratford PW, 2016, PHYSIOTHER CAN, V68, P29, DOI 10.3138/ptc.2014-85; Tucker JA, 2006, ADDICTION, V101, P918, DOI 10.1111/j.1360-0443.2006.01396.x	10	2	2	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2017	167	2					129	+		10.7326/M17-1263	http://dx.doi.org/10.7326/M17-1263			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA6SD	28631002	Green Accepted			2023-01-03	WOS:000405573400021
J	Armstrong, DG; Boulton, AJM; Bus, SA				Armstrong, David G.; Boulton, Andrew J. M.; Bus, Sicco A.			Diabetic Foot Ulcers and Their Recurrence	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RISK-FACTORS; PLANTAR PRESSURE; OFFLOADING INTERVENTIONS; THERAPEUTIC FOOTWEAR; SECONDARY PREVENTION; NEUROPATHIC ULCERS; IWGDF GUIDANCE; ULCERATION; CARE; DISEASE		[Armstrong, David G.] Univ Arizona, Coll Med, Dept Surg, SALSA, 1501 N Campbell Ave, Tucson, AZ 85724 USA; [Armstrong, David G.; Boulton, Andrew J. M.] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Bus, Sicco A.] Univ Amsterdam, Acad Med Ctr, Dept Rehabil Med, Amsterdam, Netherlands; [Bus, Sicco A.] Amsterdam Movement Sci, Amsterdam, Netherlands	University of Arizona; University of Manchester; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Armstrong, DG (corresponding author), Univ Arizona, Coll Med, Dept Surg, SALSA, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	armstrong@usa.net		Bus, Sicco/0000-0002-8357-9163	Spiracur; Kinetic Concepts	Spiracur; Kinetic Concepts	Dr. Armstrong reports receiving grant support from Spiracur and consulting fees from Kinetic Concepts. No other potential conflict of interest relevant to this article was reported.	Abbott CA, 2002, DIABETIC MED, V19, P377, DOI 10.1046/j.1464-5491.2002.00698.x; Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; [Anonymous], 2015, BRUSS INT DIAB FED; APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong D G, 1998, J Foot Ankle Surg, V37, P460; Armstrong David G, 2007, Int Wound J, V4, P286; Armstrong DG, 2007, AM J MED, V120, P1042, DOI 10.1016/j.amjmed.2007.06.028; Armstrong DG, 2013, J AM PODIAT MED ASSN, V103, P161, DOI 10.7547/1030161; Armstrong DG, 2012, DIABETES-METAB RES, V28, P514, DOI 10.1002/dmrr.2299; Armstrong David G, 2012, Foot Ankle Spec, V5, P235, DOI 10.1177/1938640012449038; Armstrong David G, 2005, Int Wound J, V2, P166, DOI 10.1111/j.1742-4801.2005.00097.x; Armstrong DG, 2005, J AM PODIAT MED ASSN, V95, P353, DOI 10.7547/0950353; Armstrong DG, 2003, DIABETES CARE, V26, P3284, DOI 10.2337/diacare.26.12.3284; Barshes NR, 2013, DIABET FOOT ANKLE, V4, DOI 10.3402/dfa.v4i0.21847; Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966; Boulton AJM, 2012, DIABETES-METAB RES, V28, P3, DOI 10.1002/dmrr.2230; Boyko EJ, 2006, DIABETES CARE, V29, P1202, DOI 10.2337/dc05-2031; Bus SA, 2016, DIABETES-METAB RES, V32, P25, DOI 10.1002/dmrr.2697; Bus SA, 2016, DIABETES-METAB RES, V32, P16, DOI 10.1002/dmrr.2696; Bus SA, 2016, DIABETES-METAB RES, V32, P99, DOI 10.1002/dmrr.2702; Bus SA, 2016, PLAST RECONSTR SURG, V138, p179S, DOI 10.1097/PRS.0000000000002686; Bus SA, 2016, DIABETES-METAB RES, V32, P195, DOI 10.1002/dmrr.2738; Bus SA, 2013, DIABETES CARE, V36, P4109, DOI 10.2337/dc13-0996; Bus SA, 2012, DIABETES-METAB RES, V28, P54, DOI 10.1002/dmrr.2240; Bus SA, 2011, DIABETES CARE, V34, P1595, DOI 10.2337/dc10-2206; Busch K, 2003, DIABETIC MED, V20, P665, DOI 10.1046/j.1464-5491.2003.01003.x; Calle-Pascual AL, 2001, DIABETES CARE, V24, P405, DOI 10.2337/diacare.24.2.405; CHANTELAU E, 1994, DIABETIC MED, V11, P114, DOI 10.1111/j.1464-5491.1994.tb00240.x; Cisneros LL, 2010, BRAZ J PHYS THER, V14, P31, DOI 10.1590/S1413-35552010000100006; Crawford F, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19570; Dargis V, 1999, DIABETES CARE, V22, P1428, DOI 10.2337/diacare.22.9.1428; Driver VR, 2010, J VASC SURG, V52, p17S, DOI 10.1016/j.jvs.2010.06.003; Dubsky M, 2013, INT WOUND J, V10, P555, DOI 10.1111/j.1742-481X.2012.01022.x; Faglia E, 2012, J FOOT ANKLE SURG, V51, P593, DOI 10.1053/j.jfas.2012.05.015; Frykberg RG, 2017, DIABETES CARE; Ghanassia E, 2008, DIABETES CARE, V31, P1288, DOI 10.2337/dc07-2145; Hamonet J., 2010, Annals of Physical and Rehabilitation Medicine, V53, P306, DOI 10.1016/j.rehab.2010.04.001; HELM PA, 1991, ARCH PHYS MED REHAB, V72, P967; Hinchliffe RJ, 2016, DIABETES-METAB RES, V32, P136, DOI 10.1002/dmrr.2705; History of foot ulcer among persons with diabetes-United States, 2000, MMWR-MORBID MORTAL W, V52, P1098; Iversen MM, 2009, DIABETES CARE, V32, P2193, DOI 10.2337/dc09-0651; Kerr M, 2014, DIABETIC MED, V31, P1498, DOI 10.1111/dme.12545; Kloos C, 2009, DIABETES CARE, V32, P894, DOI 10.2337/dc08-0490; Lavery LA, 2004, DIABETES CARE, V27, P2642, DOI 10.2337/diacare.27.11.2642; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; Lavery LA, 2007, DIABETES CARE, V30, P14, DOI 10.2337/dc06-1600; Lavery LA, 2012, ADV SKIN WOUND CARE, V25, P519, DOI 10.1097/01.ASW.0000422625.17407.93; Lavery LA, 2010, DIABETES CARE, V33, P2365, DOI 10.2337/dc10-1213; Lavery LA, 2010, DIABETES CARE, V33, P1460, DOI 10.2337/dc10-0310; Lincoln NB, 2008, DIABETOLOGIA, V51, P1954, DOI 10.1007/s00125-008-1110-0; Lipsky BA, 2012, CLIN INFECT DIS, V54, P1679, DOI [10.1093/cid/cis460, 10.1093/cid/cis346]; Margolis DJ, 2011, INCIDENCE DIABETIC F; Mills JL, 2014, J VASC SURG, V59, P220, DOI 10.1016/j.jvs.2013.08.003; Monami M, 2008, J AM PODIAT MED ASSN, V98, P130, DOI 10.7547/0980130; Monteiro-Soares M, 2012, DIABETES-METAB RES, V28, P574, DOI 10.1002/dmrr.2319; Morbach S, 2016, DIABETES-METAB RES, V32, P318, DOI 10.1002/dmrr.2752; Morbach S, 2013, DIABETES CARE, V36, pE62, DOI 10.2337/dc12-2335; Mueller MJ, 2003, J BONE JOINT SURG AM, V85A, P1436, DOI 10.2106/00004623-200308000-00003; Peters EJG, 2007, DIABETES CARE, V30, P2077, DOI 10.2337/dc07-0445; Piaggesi A, 1998, DIABETIC MED, V15, P412, DOI 10.1002/(SICI)1096-9136(199805)15:5<412::AID-DIA584>3.3.CO;2-T; Pilhammar E, 2011, EUR DIABETES NURS, V8, P102; Plank J, 2003, DIABETES CARE, V26, P1691, DOI 10.2337/diacare.26.6.1691; Pound N, 2005, DIABETIC MED, V22, P1306, DOI 10.1111/j.1464-5491.2005.01640.x; Prompers L, 2008, DIABETOLOGIA, V51, P747, DOI 10.1007/s00125-008-0940-0; Prompers L, 2007, DIABETOLOGIA, V50, P18, DOI 10.1007/s00125-006-0491-1; Reiber GE, 2002, JAMA-J AM MED ASSOC, V287, P2552, DOI 10.1001/jama.287.19.2552; Reike H., 1997, DIABETES STOFFWECH H, V6, P107; Rizzo L, 2012, INT J LOW EXTR WOUND, V11, P59, DOI 10.1177/1534734612438729; Scottish Diabetes Survey Monitoring Group, SCOTT DIAB SURV 2014; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Skrepnek GH, 2017, HLTH CARE SERVICE OU; UCCIOLI L, 1995, DIABETES CARE, V18, P1376, DOI 10.2337/diacare.18.10.1376; Ulbrecht JS, 2014, DIABETES CARE, V37, P1982, DOI 10.2337/dc13-2956; van Netten JJ, 2016, DIABETES-METAB RES, V32, P84, DOI 10.1002/dmrr.2701; Vanlerberghe B, 2014, ANN CHIR PLAST ESTH, V59, P161, DOI 10.1016/j.anplas.2013.07.008; Verdin C, 2017, J PALLIAT MED, V20, P6, DOI 10.1089/jpm.2016.0384; Viswanathan V, 2005, DIABETES CARE, V28, P1019, DOI 10.2337/diacare.28.5.1019; Viswanathan V, 2004, DIABETES CARE, V27, P474, DOI 10.2337/diacare.27.2.474; Waaijman R, 2014, DIABETES CARE, V37, P1697, DOI 10.2337/dc13-2470; Walsh JW, 2016, DIABETIC MED, V33, P1493, DOI 10.1111/dme.13054; Ward R, 2017, ANN VASC SURG, V38, P84, DOI 10.1016/j.avsg.2016.08.005; Winkley K, 2007, J DIABETES COMPLICAT, V21, P341, DOI 10.1016/j.jdiacomp.2007.09.004; Zhang PZ, 2017, ANN MED, V49, P106, DOI 10.1080/07853890.2016.1231932	83	1169	1235	85	455	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	2017	376	24					2367	2375		10.1056/NEJMra1615439	http://dx.doi.org/10.1056/NEJMra1615439			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX4UQ	28614678				2023-01-03	WOS:000403230800010
J	Mkentane, K; van Wyk, JC; Sishi, N; Gumedze, F; Ngoepe, M; Davids, LM; Khumalo, NP				Mkentane, K.; van Wyk, J. C.; Sishi, N.; Gumedze, F.; Ngoepe, M.; Davids, L. M.; Khumalo, N. P.			Geometric classification of scalp hair for valid drug testing, 6 more reliable than 8 hair curl groups	PLOS ONE			English	Article							SHAPE; AGREEMENT; FORM; CORTISOL	Introduction Curly hair is reported to contain higher lipid content than straight hair, which may influence incorporation of lipid soluble drugs. The use of race to describe hair curl variation (Asian, Caucasian and African) is unscientific yet common in medical literature (including reports of drug levels in hair). This study investigated the reliability of a geometric classification of hair (based on 3 measurements: the curve diameter, curl index and number of waves). Materials and methods After ethical approval and informed consent, proximal virgin (6cm) hair sampled from the vertex of scalp in 48 healthy volunteers were evaluated. Three raters each scored hairs from 48 volunteers at two occasions each for the 8 and 6-group classifications. One rater applied the 6-group classification to 80 additional volunteers in order to further confirm the reliability of this system. The Kappa statistic was used to assess intra and inter rater agreement. Results Each rater classified 480 hairs on each occasion. No rater classified any volunteer's 10 hairs into the same group; the most frequently occurring group was used for analysis. The inter-rater agreement was poor for the 8-groups (k = 0.418) but improved for the 6-groups (k = 0.671). The intra-rater agreement also improved (k = 0.444 to 0.648 versus 0.599 to 0.836) for 6-groups; that for the one evaluator for all volunteers was good (k = 0.754). Conclusions Although small, this is the first study to test the reliability of a geometric classification. The 6-group method is more reliable. However, a digital classification system is likely to reduce operator error. A reliable objective classification of human hair curl is long overdue, particularly with the increasing use of hair as a testing substrate for treatment compliance in Medicine.	[Mkentane, K.; van Wyk, J. C.; Sishi, N.; Khumalo, N. P.] Groote Schuur Hosp, Div Dermatol, Hair & Skin Res Lab, Cape Town, South Africa; [Mkentane, K.; Davids, L. M.] Univ Cape Town, Dept Human Biol, Fac Hlth Sci, Cape Town, South Africa; [Gumedze, F.] Univ Cape Town, Stat Sci, Fac Sci, Cape Town, South Africa; [Ngoepe, M.] Univ Cape Town, Engn, Cape Town, South Africa	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town	Khumalo, NP (corresponding author), Groote Schuur Hosp, Div Dermatol, Hair & Skin Res Lab, Cape Town, South Africa.	n.khumalo@uct.ac.za	Khumalo, Nonhlanhla/AAA-8068-2020; Van Wyk, Jennifer/B-3179-2016; Van Wyk, Jennifer Caroline/AAA-3463-2022	Khumalo, Nonhlanhla/0000-0002-1686-1900; Van Wyk, Jennifer/0000-0002-6402-4488; Van Wyk, Jennifer Caroline/0000-0002-6402-4488; Gumedze, Freedom N/0000-0003-4387-8844; Ngoepe, Malebogo/0000-0002-3639-9063	The University of Cape Town	The University of Cape Town	This work received Seed Funding from The University of Cape Town.	[Anonymous], [No title captured]; Bailey Schliebe S., 1985, HUMAN HAIR, P147; Bartelink IH, 2013, J CLIN PHARMACOL, VXX, P1; Barton P.M.J., 2011, FORENSIC INVESTIGATI; Bigby M, 2006, J AM ACAD DERMATOL, V54, P1077, DOI 10.1016/j.jaad.2006.01.036; Bryant H, 2012, INT J DERMATOL, V51, P8, DOI 10.1111/j.1365-4632.2012.05555.x; Chi W, 2013, DEVELOPMENT, V140, P1676, DOI 10.1242/dev.090662; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cruz CF, 2013, INT J COSMETIC SCI, V35, P244, DOI 10.1111/ics.12035; Davis-Sivasothy A., 2011, SCI BLACK HAIR COMPR; de la Mettrie R, 2007, HUM BIOL, V79, P265, DOI 10.1353/hub.2007.0045; Gray J., 2001, HUMAN HAIR DIVERSITY; HRDY D, 1973, AM J PHYS ANTHROPOL, V39, P7, DOI 10.1002/ajpa.1330390103; Karlen J, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-12; Khumalo NP, 2007, J AM ACAD DERMATOL, V56, P709, DOI 10.1016/j.jaad.2006.10.016; Khumalo NP, 2011, INT J DERMATOL, V50, P1212, DOI 10.1111/j.1365-4632.2010.04655.x; Kirschbaum C, 2009, HAIR RETROSPECTIVE C, P32; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LINDELOF B, 1988, ARCH DERMATOL, V124, P1359, DOI 10.1001/archderm.124.9.1359; Loussouarn G, 2007, INT J DERMATOL, V46, P2, DOI 10.1111/j.1365-4632.2007.03453.x; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; OIMOMI M, 1988, JPN J MED, V27, P277, DOI 10.2169/internalmedicine1962.27.277; Porter CE, 2009, BEHAV HAIR DIFFERENT, V109, P97; Robbins C.R., 2012, CHEM PHYS BEHAV HUMA, V5, P537, DOI DOI 10.1007/978-3-642-25611-0_9; Robbins CR., 2012, CHEM PHYS BEHAV HAIR, P177; Robbins CR, 2012, CHEM COMPOSITON DIFF; Russell E, 2012, PSYCHONEUROENDOCRINO, V37, P589, DOI 10.1016/j.psyneuen.2011.09.009; Sauve B, 2007, CLIN INVEST MED, V30, pE183, DOI 10.25011/cim.v30i5.2894; Schlake T, 2007, SEMIN CELL DEV BIOL, V18, P267, DOI 10.1016/j.semcdb.2007.01.005; Thibaut S, 2005, BRIT J DERMATOL, V152, P632, DOI 10.1111/j.1365-2133.2005.06521.x; Valerie D.Callender, 2008, HAIR GROWTH DISORDER, P483; Viera AJ, 2005, FAM MED, V37, P360; WICKENHEISER RA, 1990, J FORENSIC SCI, V35, P1323	33	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2017	12	6							e0172834	10.1371/journal.pone.0172834	http://dx.doi.org/10.1371/journal.pone.0172834			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6HZ	28570555	Green Published, Green Submitted, gold			2023-01-03	WOS:000402611800001
J	Juneja, S; Gupta, A; Moon, S; Resch, S				Juneja, Sandeep; Gupta, Aastha; Moon, Suerie; Resch, Stephen			Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)	PLOS ONE			English	Article							ANTIRETROVIRAL MEDICINES; IMPROVE ACCESS	The Medicines Patent Pool (MPP) was established in 2010 to ensure timely access to lowcost generic versions of patented antiretroviral (ARV) medicines in low-and middle-income countries (LMICs) through the negotiation of voluntary licences with patent holders. While robust data on the savings generated by MPP and other major global public health initiatives is important, it is also difficult to quantify. In this study, we estimate the savings generated by licences negotiated by the MPP for ARV medicines to treat HIV/AIDS in LMICs for the period 2010-2028 and generate a cost-benefit ratio-based on people living with HIV (PLHIVs) in any new countries which gain access to an ARV due to MPP licences and the price differential between originator's tiered price and generics price, within the period where that ARV is patented. We found that the direct savings generated by the MPP are estimated to be USD 2.3 billion (net present value) by 2028, representing an estimated cost-benefit ratio of 1: 43, which means for every USD 1 spent on MPP, the global public health community saves USD 43. The saving of USD 2.3 billion is equivalent to more than 24 million PLHIV receiving first-line ART in LMICs for 1 year at average prices today.	[Juneja, Sandeep; Gupta, Aastha] Med Patent Pool, Geneva, Switzerland; [Moon, Suerie; Resch, Stephen] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health	Gupta, A (corresponding author), Med Patent Pool, Geneva, Switzerland.	agupta@medicinespatentpool.org	juneja, sandeep/AAP-3404-2020	Juneja, Sandeep/0000-0002-3735-3120; Moon, Suerie/0000-0001-8504-1212				Accenture, 2012, ACC DEV PARTN INV BA; AMIN T, 2007, VOLUNTARY LICENSING; Gupta A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164619; Joint United Nations Programme on HIV/AIDS, 2014, FAST TRACK END AIDS; Medecins Sans Frontieres, UNT WEB ANT PRIC RED; Medicines Patent Pool, MED PAT LIC DAT; Medicines Patent Pool, OR WORK MPP LIC AGR; Medicines Patent Pool, SUBL WORK MPP LIC AG; Medicines Patent Pool, IND ASS STAT KPMG; Medicines Patent Pool, PROGR ACH MED PAT PO; Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39; [MPP UNITAID], PAT LIC ANT SNAPSH; 't Hoen E, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-15; UNAIDS, 2015, UND FAST TRACK ACC A; UNAIDS (Joint United Nations Programme on HIV and AIDS), 2016, FAST TRACK COMM END; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; Waning B, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-9; [WIPO WTO WHO], 2013, PROM ACC MED TECHN I; WIPO, STUD PROM ACC MED TE; World Health Organization, GLOB PRIC REP MECH H; World Health Organization, 2007, VOL LIC PRACT PHARM; World Health Organization, CONS GUID US ANT DRU	22	13	13	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2017	12	5							e0177770	10.1371/journal.pone.0177770	http://dx.doi.org/10.1371/journal.pone.0177770			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VR	28542239	Green Published, gold			2023-01-03	WOS:000402062800025
J	Ren, LL; Li, X; Kang, LH; Brunson, K; Liu, HG; Dong, WM; Li, HM; Min, R; Liu, X; Dong, GH				Ren, Lele; Li, Xin; Kang, Lihong; Brunson, Katherine; Liu, Honggao; Dong, Weimiao; Li, Haiming; Min, Rui; Liu, Xu; Dong, Guanghui			Human paleodiet and animal utilization strategies during the Bronze Age in northwest Yunnan Province, southwest China	PLOS ONE			English	Article							STABLE-ISOTOPE ANALYSIS; WESTERN LOESS PLATEAU; BONE-COLLAGEN; FAUNAL REMAINS; TROPHIC LEVEL; HUMAN DIET; NITROGEN; AGRICULTURE; SUBSISTENCE; CARBON	Reconstructing ancient diets and the use of animals and plants augment our understanding of how humans adapted to different environments. Yunnan Province in southwest China is ecologically and environmentally diverse. During the Neolithic and Bronze Age periods, this region was occupied by a variety of local culture groups with diverse subsistence systems and material culture. In this paper, we obtained carbon (delta C-13) and nitrogen (delta N-15) isotopic ratios from human and faunal remains in order to reconstruct human paleodiets and strategies for animal exploitation at the Bronze Age site of Shilinggang (ca. 2500 Cal BP) in northwest Yunnan Province. The delta C-13 results for human samples from Shilinggang demonstrate that people's diets were mainly dominated by C-3-based foodstuffs, probably due to both direct consumption of C-3 food and as a result of C-3 foddering of consumed animals. Auxiliary C-4 food signals can also be detected. High delta N-15 values indicate that meat was an important component of the diet. Analysis of faunal samples indicates that people primarily fed pigs and dogs with human food waste, while sheep/goats and cattle were foddered with other food sources. We compare stable isotope and archaeobotanical data from Shilinggang with data from other Bronze Age sites in Yunnan to explore potential regional variation in subsistence strategies. Our work suggests that people adopted different animal utilization and subsistence strategies in different parts of Yunnan during the Bronze Age period, probably as local adaptations to the highly diversified and isolated environments in the region.	[Ren, Lele; Liu, Honggao; Li, Haiming; Dong, Guanghui] Lanzhou Univ, Coll Earth Environm Sci, MOE Key Lab Western Chinas Environm Syst, Lanzhou, Gansu, Peoples R China; [Li, Xin] Lanzhou Univ, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China; [Kang, Lihong; Min, Rui; Liu, Xu] Yunnan Prov Inst Cultural Rel & Archaeol, Kunming, Peoples R China; [Brunson, Katherine] Brown Univ, Joukowsky Inst Archaeol & Ancient World, Providence, RI 02912 USA; [Liu, Honggao] Yunnan Agr Univ, Coll Agron & Biotechnol, Kunming, Peoples R China; [Dong, Weimiao] Fudan Univ, Dept Cultural Heritage & Museol, Shanghai, Peoples R China	Lanzhou University; Lanzhou University; Brown University; Yunnan Agricultural University; Fudan University	Dong, GH (corresponding author), Lanzhou Univ, Coll Earth Environm Sci, MOE Key Lab Western Chinas Environm Syst, Lanzhou, Gansu, Peoples R China.	ghdong@lzu.edu.cn	Dong, Guanghui/C-5985-2013	Brunson, Katherine/0000-0001-9793-291X; Dong, Guanghui/0000-0001-8005-759X	National Natural Science Foundation of China [41671077, 41620104007, 41271218]; Fundamental Research Funds for the Central Universities [lzujbky-2015-k09, lzujbky-2016-251]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This research was funded by the National Natural Science Foundation of China (Grant Nos. 41671077, 41620104007 and 41271218), Fundamental Research Funds for the Central Universities (lzujbky-2015-k09 and lzujbky-2016-251).	Ambrose S.H., 1993, PREHISTORIC HUMAN BO, P1; AMBROSE SH, 1991, J ARCHAEOL SCI, V18, P293, DOI 10.1016/0305-4403(91)90067-Y; AMBROSE SH, 1987, NATURE, V325, P201, DOI 10.1038/325201a0; Ambrose SH, 1997, AM J PHYS ANTHROPOL, V104, P343; AMBROSE SH, 1990, J ARCHAEOL SCI, V17, P431, DOI 10.1016/0305-4403(90)90007-R; Atahan P, 2011, J ARCHAEOL SCI, V38, P1747, DOI 10.1016/j.jas.2011.03.006; Barton L, 2009, P NATL ACAD SCI USA, V106, P5523, DOI 10.1073/pnas.0809960106; Bocherens H, 2003, INT J OSTEOARCHAEOL, V13, P46, DOI 10.1002/oa.662; Bogaard A, 2007, J ARCHAEOL SCI, V34, P335, DOI 10.1016/j.jas.2006.04.009; Buikstra JE, 1996, HUM BIOL, V68, P155; Chen FH, 2015, SCIENCE, V347, P248, DOI 10.1126/science.1259172; Collard IF, 2002, EVOL ECOL RES, V4, P371; Cucchi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158523; DENIRO MJ, 1985, NATURE, V317, P806, DOI 10.1038/317806a0; Dong GH, 2016, QUAT INT; Dong GH, 2017, SCI CHINA EARTH SCI, V60, P1110, DOI 10.1007/s11430-016-9037-x; DRASS RR, 1990, PLAINS ANTHROPOL, V35, P175, DOI 10.1080/2052546.1990.11909567; Erickson CL, 2006, BIOCHEM J, V396, P117; Fan Y., 2007, SICHUAN CULTURAL REL, V2, P64; Fang T., 2007, DIETETIC CULTURE RES, V3, P37; Farley NW, 2015, INT J HUMANIT SOC SC, V5, P29; Fuller BT, 2006, AM J PHYS ANTHROPOL, V129, P279, DOI 10.1002/ajpa.20249; Fuller BT, 2005, RAPID COMMUN MASS SP, V19, P2497, DOI 10.1002/rcm.2090; Guedes JAD, 2015, P NATL ACAD SCI USA, V112, P5625, DOI 10.1073/pnas.1423708112; He XR, 1982, ZOOL RES, VS2, P349; Hedges REM, 2007, J ARCHAEOL SCI, V34, P1240, DOI 10.1016/j.jas.2006.10.015; HOBSON KA, 1993, CONDOR, V95, P388, DOI 10.2307/1369361; Hou LL, 2013, J ARCHAEOL SCI, V40, P2344, DOI 10.1016/j.jas.2013.01.005; Hu Y., 2008, CHINA SCI D, V38, P693; Hu YW, 2006, J ARCHAEOL SCI, V33, P1319, DOI 10.1016/j.jas.2006.01.007; Jia X, 2016, TRANSITION HUMAN SUB; Jia X, 2013, HOLOCENE, V23, P85, DOI 10.1177/0959683612450203; Jin H.T., 2014, JIANGHAN ARCHAEOLOGY, V3, P109; Jing Y, 2005, J ANTHROPOL ARCHAEOL, V24, P252, DOI 10.1016/j.jaa.2005.03.001; Kang LH, 2015, POPULAR ARCHAEOLOGY, V6, P12; Kohn MJ, 1999, SCIENCE, V283, P335, DOI 10.1126/science.283.5400.335; Layman CA, 2012, BIOL REV, V87, P545, DOI 10.1111/j.1469-185X.2011.00208.x; Li G., 2002, THESIS; Li HM, 2016, SCI CHINA EARTH SCI, V59, P1562, DOI 10.1007/s11430-016-5292-x; Li SM, 2013, RESEARCH ON THE EVOL, P54; Li XQ, 2009, HOLOCENE, V19, P1213, DOI 10.1177/0959683609345083; Liu L, 2011, J ARCHAEOL SCI, V38, P3524, DOI 10.1016/j.jas.2011.08.015; Ma M, 2015, INT J OSTEOARCHAEOL, V25, P923, DOI 10.1002/oa.2379; Ma MM, 2014, ARCHAEOMETRY, V56, P237, DOI 10.1111/arcm.12071; Ma MM, 2016, QUATERNARY SCI REV, V145, P57, DOI 10.1016/j.quascirev.2016.05.041; Mansur ME, 2009, ARCTIC ANTHROPOL, V82, P342; Mays SA, 2002, ANTIQUITY, V76, P654, DOI 10.1017/S0003598X00091067; McGovern PE, 2004, P NATL ACAD SCI USA, V101, P17593, DOI 10.1073/pnas.0407921102; [胡耀武 Hu Yaowu], 2010, [人类学学报, Acta Anthropologica Sinica], V29, P264; Nardoto GB, 2006, AM J PHYS ANTHROPOL, V131, P137, DOI 10.1002/ajpa.20409; National Meteorological Information Center (CMA Meteorological Data Center), 2005, DAT DAT MONTHL SURF; O'Connell TC, 2012, AM J PHYS ANTHROPOL, V149, P426, DOI 10.1002/ajpa.22140; OLEARY MH, 1981, PHYTOCHEMISTRY, V20, P553, DOI 10.1016/0031-9422(81)85134-5; Pearson JA, 2015, J ARCHAEOL SCI, V57, P69, DOI 10.1016/j.jas.2015.01.007; Pechenkina EA, 2005, J ARCHAEOL SCI, V32, P1176, DOI 10.1016/j.jas.2005.02.015; PRICE TD, 1992, J ARCHAEOL SCI, V19, P513, DOI 10.1016/0305-4403(92)90026-Y; Privat KL, 2002, J ARCHAEOL SCI, V29, P779, DOI 10.1006/jasc.2001.0785; Richards MP, 1999, J ARCHAEOL SCI, V26, P717, DOI 10.1006/jasc.1998.0387; Roberts P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157408; Sage R.F., 1999, C4 PLANT BIOL, P313; Schoeninger MJ, 1997, AM J PHYS ANTHROPOL, V103, P69, DOI 10.1002/(SICI)1096-8644(199705)103:1<69::AID-AJPA5>3.0.CO;2-8; Schoeninger MJ, 1999, AM J PRIMATOL, V49, P297, DOI 10.1002/(SICI)1098-2345(199912)49:4<297::AID-AJP2>3.0.CO;2-N; SCHOENINGER MJ, 1984, GEOCHIM COSMOCHIM AC, V48, P625, DOI 10.1016/0016-7037(84)90091-7; SCHWARCZ HP, 1991, YEARB PHYS ANTHROPOL, V34, P283; Shelach G., 1996, ASIAN PERSPECT, V35, P1; Shen J, 2006, HOLOCENE, V16, P265, DOI 10.1191/0959683606hl923rp; Smith AT., 2010, GUIDE ESTIMATES PRB; Somerville AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159982; Van Klinken GJ, 1999, J ARCHAEOL SCI, V26, P687, DOI 10.1006/jasc.1998.0385; VANDERMERWE NJ, 1978, NATURE, V276, P815, DOI 10.1038/276815a0; Wang C., 2001, B SOIL WATER CONSERV, V21, P20; Wang C, 2016, PLOS ONE; Wang Q., 2014, THESIS; Wang TT, 2015, INT J OSTEOARCHAEOL; Xue Y., 2010, THESIS; Yunnan Provincial Institute of Cultural Relics and Archaeology (YNICRA), 2010, SHIF IN GENGM; Yunnan Provincial Institute of Cultural Relics and Archaeology (YNICRA), 1998, ARCH PAP YUNN PROV; Zanden MJV, 1997, CAN J FISH AQUAT SCI; Zhang J., 2022, VESSEL PLUS, V6, P20, DOI [10.20517/2574-1209.2021.140, DOI 10.20517/2574-1209.2021.140]; Zhang QC, 2011, ARCHAEOLOGY, V1; Zhang XX, 2014, J ARCHAEOL SCI, V50, P414, DOI 10.1016/j.jas.2014.08.001; Zhao DY, 2015, ASIAN ARCHAEOLOGY, V3, P129; Zhao Y., 2011, THESIS; Zhao Z J, 2003, ACTA ARCHAEOL SIN, V2, P28; 胡耀武, 2007, [科学通报, Chinese science bulletin], V52, P85	85	11	13	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2017	12	5							e0177867	10.1371/journal.pone.0177867	http://dx.doi.org/10.1371/journal.pone.0177867			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	EV8UA	28531221	Green Submitted, gold, Green Published			2023-01-03	WOS:000402058400033
J	Lee, TC; Bonnici, AA; Tamblyn, R; McDonald, EG				Lee, Todd C.; Bonnici, Andre A.; Tamblyn, Robyn; McDonald, Emily G.			Inpatient Z-drug use commonly exceeds safe dosing recommendations	PLOS ONE			English	Article							INSOMNIA; MEDICATIONS; DISCHARGE; ADULTS	Importance In 2016 recommendations for safer prescribing practices were circulated to all doctors in one of Canada's largest provinces, by the college of physicians, following a coroner's inquest into a vehicular death related to Z-drug use. We sought to determine how frequently Z-drug prescriptions in our institution were not adhering to these recommendations. Design Retrospective cohort study. Setting McGill University Health Centre, an 832-bed tertiary care institution in Montreal, Canada. Participants All adult non-obstetrical patients admitted between April 1, 2015 and March 31, 2016. Exposure The receipt of at least one dose of Z-drug as determined by pharmacy records. Main outcomes and measures Adherence to four recommendations related to starting dose, maximal dose, concomitant drug administration, and duration of use were evaluated. Results 1,409 unique patients received a Z-drug during 1,783 admissions representing use in 9.3% of non-obstetrical patients. Standing orders were seen in 42% (745/1783) of admissions. Non-conformity with the coroner's recommendations was common. Overall, 672/1783 (38%) admissions involved a patient receiving more than the recommended daily maximum dose (643/999 older patients, 64%). Of 607 admissions which were longer than 10 days, 257 (39%) involved a prescription which exceeded 10 days. Conclusions and relevance A coroner's recommendation that doctors receive instructions about safe Z-drug prescribing is unprecedented, and was likely required given that use of Z-drugs occurs at doses and durations that often exceed best practice recommendations. Similar interventions may be required in other jurisdictions.	[Lee, Todd C.; Tamblyn, Robyn; McDonald, Emily G.] McGill Univ, Hlth Ctr, Dept Med, Montreal, PQ, Canada; [Lee, Todd C.; McDonald, Emily G.] McGill Univ, Hlth Ctr, Clin Practice Assessment Unit, Montreal, PQ, Canada; [Lee, Todd C.; Tamblyn, Robyn] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Bonnici, Andre A.] McGill Univ, Hlth Ctr, Pharm Dept, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	McDonald, EG (corresponding author), McGill Univ, Hlth Ctr, Dept Med, Montreal, PQ, Canada.; McDonald, EG (corresponding author), McGill Univ, Hlth Ctr, Clin Practice Assessment Unit, Montreal, PQ, Canada.	emily.mcdonald@mcgill.ca	McDonald, Emily/AAS-8905-2020	Lee, Todd/0000-0002-2267-4239				AGS Choosing Wisely Workgroup, 2013, J AM GERIATRICS SOC, V61, P622; Alessi-Severini Silvia, 2014, CMAJ Open, V2, pE208, DOI 10.9778/cmajo.20130076; College des medecins du Quebec, 2016, IM ZOP NOUV POS REC; Ford ES, 2014, SLEEP, V37, P1283, DOI 10.5665/sleep.3914; Glass J, 2005, BMJ-BRIT MED J, V331, P1169, DOI 10.1136/bmj.38623.768588.47; Grad R, 1999, J AM GERIATR SOC, V47, P184, DOI 10.1111/j.1532-5415.1999.tb04576.x; Health Canada, 2014, IMOVANE ZOP NEW DOS; Kapil V, 2014, BRIT J PSYCHIAT, V205, P407, DOI 10.1192/bjp.bp.114.149252; Lee TC, 2016, JAMA INTERNAL MED; McDonald EG, 2015, AM J MED, V128, P193, DOI 10.1016/j.amjmed.2014.10.016; Moloney ME, 2011, AM J PUBLIC HEALTH, V101, P1429, DOI 10.2105/AJPH.2010.300014; Overdyk FJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150214; Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175; Regie de l'assurance maladie du Quebec, LIST MED; Scales DC, 2016, J GEN INTERN MED, V31, P196, DOI 10.1007/s11606-015-3501-5; Tamblyn R, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-150; US Food and Drug Administration, 2014, FDA DRUG SAF COMM FD	17	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177645	10.1371/journal.pone.0177645	http://dx.doi.org/10.1371/journal.pone.0177645			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV1DC	28520804	Green Published, gold, Green Submitted			2023-01-03	WOS:000401485500051
J	Berhe, M; Medhaniye, AA; Kahsay, G; Birhane, E; Abay, M				Berhe, Megbey; Medhaniye, Araya Abraha; Kahsay, Gizienesh; Birhane, Ermyas; Abay, Mebrahtu			Essential neonatal care utilization and associated factors among mothers in public health facilities of Aksum Town, North Ethiopia, 2016	PLOS ONE			English	Article								Background Globally, neonatal death accounts about 44% of child death in 2013. Ethiopia is one of the ten countries with the highest number of neonatal death. Worldwide, more than 43% of deaths among under five year children is contributed by neonates. Half of the neonatal death occur in the first day of life. Recommendations about newborn care practices may conflict with local beliefs and practices. So, it is important to understand the existing newborn care practice and factors affecting it in order to take interventions so as to decrease neonatal death. Objective To assess magnitude of essential neonatal care utilization and associated factors among women visiting public health facilities in Aksum Town, Tigray, Northern Ethiopia, 2015. Methods Facility based cross sectional study was conducted from December 30, 2015 to January 31, 2016. The sampled population are 423 women who gave live births within the last 6 months prior to data collection. Systematic random sampling technique was employed. Data were entered, coded and cleaned using Epi info version 7, and SPSS Version 21 software was used for analysis. Both bivariable and multivariable logistic regression models were used to determine factors associated with essential neonatal care utilization. Variables with P-value <0.2 in the bivariable logistic regression model were included in to multivariable logistic regression model, and finally variables with P-value <0.05 were considered as independent factors. Odds ratio was used to measure strength of association at 95% confidence level. Result A total of 423 mothers included in the study. Prevalence of safe cord care, optimal breast feeding, thermal care and baby received Tetracycline eye ointment and vaccine at birth were 42.8%, 63.1%, 32.6% and 44.7% among the respondents respectively. Only 113 (26.7%) of the participants fulfilled essential new born care practice. Occupation, parity and counseling on essential new born care during delivery were significantly associated with utilization of essential new born care. Employed women (AOR = 7.08; 95% CI (2.21, 12.72), 2-3 number of deliveries (AOR = 1.84; 95% CI (1.04, 3.26) and received counseling about essential new born car during delivery (AOR = 3.36; 95% CI (1.86, 6.08) were more likely to practice essential neonatal care practice than their counterparts. Conclusion and recommendation Around three-fourth of mothers were not practicing Essential Newborn Care (ENC). Occupation, parity and essential new born care counseling during delivery were significantly associated with utilization of ENC. Promotion of information at community level, women empowerment and staff training is recommended.	[Berhe, Megbey; Kahsay, Gizienesh; Birhane, Ermyas; Abay, Mebrahtu] Aksum Univ, Dept Publ Hlth, Aksum, Ethiopia; [Medhaniye, Araya Abraha] Mekelle Univ, Sch Publ Hlth, Mekelle, Ethiopia	Mekelle University	Abay, M (corresponding author), Aksum Univ, Dept Publ Hlth, Aksum, Ethiopia.	gmebrahtuabay@gmail.com		Abay, Mebrahtu/0000-0002-3307-0588				[Anonymous], 2014, EXECUTIVE SUMMARY LA; [Anonymous], 2014, OPPORTUNITIES AFRICA; [Anonymous], 2012, ETHIOPIAN DEMOGRAPHI; [Anonymous], 2014, HLTH SECT DEV PLAN 4; [Anonymous], 2004, COMPONENTS ESSENTIAL; Callaghan-koru JA, 2013, NEWBORN CARE PRACTIC; Daba W., 2015, ASSESSMENT MAGNITUDE; Dickson KE, 2014, EVERY NEWBORN 4 HLTH, V6736, P1; Lawn JE, 2012, NEWBORN SURVIVAL MUL, P6; Maternal Newborn, 2013, MATERNAL NEWBORN CHI; Mohammadi Y, 2014, PROTOCOL NASBOD STUD, V17, P3; Patel A, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S10; Saaka M, 2014, PATTERNS DETERMINANT, P2014; Tegene T., 2015, CLINICS MOTHER CHILD, V12, P1, DOI [10.4172/2090-7214.1000172, DOI 10.4172/2090-7214.1000172]; Tura G, 2015, NEONATAL CARE PRACTI, P1; Wardlaw T, 2014, UNICEF REPORT ENORMO, P1; World Health Organization (WHO), 1996, MAT NEWB HLTH SAF MO; Zone G, 2015, COMMUNITY BASED ESSE, V01, P17	18	24	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2017	12	4							e0175902	10.1371/journal.pone.0175902	http://dx.doi.org/10.1371/journal.pone.0175902			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KK	28423043	gold, Green Submitted, Green Published			2023-01-03	WOS:000399875600060
J	Huang, HK; Lin, SM; Yang, CSH; Liang, CC; Cheng, HY				Huang, Huei Kai; Lin, Shu Man; Yang, Clement Shih Hsien; Liang, Chung Chao; Cheng, Hung Yu			Post-ischemic stroke rehabilitation is associated with a higher risk of fractures in older women: A population-based cohort study	PLOS ONE			English	Article							ISCHEMIC-STROKE; HIP FRACTURE; ELDERLY-WOMEN; MEDICAL COMPLICATIONS; FRAGILITY FRACTURES; FALLS PREVENTION; HOSPITAL-LEVEL; FOLLOW-UP; MORTALITY; INPATIENT	Background Rehabilitation can improve physical activity after stroke. However, patients may be more prone to falls and fractures because of balance and gait deficits. Few reports have studied the relationship between rehabilitation and subsequent fractures after ischemic stroke. Objective To investigate whether post-stroke rehabilitation affects fracture risk. Methods We conducted a population-based retrospective cohort study based on the Taiwan National Health Insurance Research Database. Patients with a newly diagnosed ischemic stroke between 2000 and 2012 were included. After propensity score matching, a total of 8,384 patients were enrolled. Half of the patients (4,192) received post-stroke rehabilitation within 1 month; the other half did not receive any post-stroke rehabilitation. Cox proportional hazards regression model was used to calculate hazard ratios (HRs) for fractures among patients with and without rehabilitation within 1 year after ischemic stroke. Patients were further stratified by sex and age (20-64 and >= 65 years). Results Patients receiving post-stroke rehabilitation had a higher incidence of fracture (6.2 per 100 person-years) than those who did not (4.1 per 100 person-years) after adjustment for socio-demographic and coexisting medical conditions [HR = 1.53, 95% confidence interval (CI) = 1.25-1.87, p < 0.001]. The analyses performed after stratifying for sex and age showed that only older women undergoing rehabilitation had a significantly higher risk of fracture (HR = 1.62, 95% CI = 1.21-2.17, p = 0.001). Conclusion Rehabilitation after ischemic stroke is associated with an increased fracture risk in older women.	[Huang, Huei Kai] Buddhist Tzu Chi Gen Hosp, Dept Family Med, Hualien, Taiwan; [Lin, Shu Man; Yang, Clement Shih Hsien; Liang, Chung Chao; Cheng, Hung Yu] Buddhist Tzu Chi Gen Hosp, Dept Phys Med & Rehabil, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital	Cheng, HY (corresponding author), Buddhist Tzu Chi Gen Hosp, Dept Phys Med & Rehabil, Hualien, Taiwan.	hycheng@tzuchi.com.tw	; Huang, Huei-Kai/J-9220-2019	Lin, Shu-Man/0000-0002-3257-0038; Huang, Huei-Kai/0000-0003-3612-653X				Alegre-Lopez J, 2005, OSTEOPOROSIS INT, V16, P729, DOI 10.1007/s00198-004-1740-0; Alexandru Daniela, 2012, Perm J, V16, P46; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112; Batchelor F, 2010, STROKE, V41, P1715, DOI 10.1161/STROKEAHA.109.570390; Batchelor FA, 2012, ARCH PHYS MED REHAB, V93, P1648, DOI 10.1016/j.apmr.2012.03.031; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bliuc D, 2015, J BONE MINER RES, V30, P637, DOI 10.1002/jbmr.2393; Bouza C, 2007, OSTEOPOROSIS INT, V18, P649, DOI 10.1007/s00198-006-0292-x; Callaly EL, 2015, AGE AGEING, V44, P882, DOI 10.1093/ageing/afv093; Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen HF, 2009, J WOMENS HEALTH, V18, P647, DOI 10.1089/jwh.2008.0918; Chen TT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003620; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cheng PT, 2001, ARCH PHYS MED REHAB, V82, P1650, DOI 10.1053/apmr.2001.26256; Chiu HF, 2011, AM J GASTROENTEROL, V106, P894, DOI 10.1038/ajg.2010.475; Chou YC, 2012, J REHABIL MED, V44, P319, DOI 10.2340/16501977-0935; Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621; Dionyssiotis Y, 2014, CLIN MED INSIGHTS-AR, V7, P33, DOI 10.4137/CMAMD.S14077; Diserens K, 2012, CLIN REHABIL, V26, P451, DOI 10.1177/0269215511425541; Empana JP, 2004, J AM GERIATR SOC, V52, P685, DOI 10.1111/j.1532-5415.2004.52203.x; Franzo A, 2005, EUR J EPIDEMIOL, V20, P985, DOI 10.1007/s10654-005-4280-9; Govan L, 2007, STROKE, V38, P2536, DOI 10.1161/STROKEAHA.106.478842; Green J, 2002, LANCET, V359, P199, DOI 10.1016/S0140-6736(02)07443-3; Harnod T, 2015, MEDICINE, V94, DOI [10.1097/MD.0000000000001506, 10.1097/MD.0000000000001571]; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; Jalayondeja C, 2014, GERIATR GERONTOL INT, V14, P778, DOI 10.1111/ggi.12164; Johansson J, 2016, J AM MED DIR ASSOC, V17, P535, DOI 10.1016/j.jamda.2016.02.009; Kanis J, 2001, STROKE, V32, P702, DOI 10.1161/01.STR.32.3.702; Kanis JA, 2004, OSTEOPOROSIS INT, V15, P108, DOI 10.1007/s00198-003-1516-y; Kapral MK, 2016, NEUROLOGY; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Kwok T, 2006, J CLIN NURS, V15, P581, DOI 10.1111/j.1365-2702.2006.01354.x; Langhorne P, 1999, CEREBROVASC DIS, V9, P2, DOI 10.1159/000047570; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Lee A. Y. J., 2007, SMJ Singapore Medical Journal, V48, P996; Lee HC, 2013, J CHIN MED ASSOC, V76, P703, DOI 10.1016/j.jcma.2013.08.003; Lee HC, 2010, AM J MANAG CARE, V16, pE67; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Lin HC, 2008, STROKE, V39, P2744, DOI 10.1161/STROKEAHA.108.519090; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Lofman O, 2007, ACTA ORTHOP, V78, P813, DOI 10.1080/17453670710014608; Marigold DS, 2005, J AM GERIATR SOC, V53, P416, DOI 10.1111/j.1532-5415.2005.53158.x; MAYO NE, 1994, ARCH PHYS MED REHAB, V75, P1302; McLean DE, 2004, ARCH PHYS MED REHAB, V85, P466, DOI 10.1016/S0003-9993(03)00484-2; Mittmann N, 2012, CAN J NEUROL SCI, V39, P793, DOI 10.1017/S0317167100015638; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Naves M, 2003, OSTEOPOROSIS INT, V14, P520, DOI 10.1007/s00198-003-1405-4; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; NYBERG L, 1995, STROKE, V26, P838, DOI 10.1161/01.STR.26.5.838; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; Palvanen M, 2000, OSTEOPOROSIS INT, V11, P822, DOI 10.1007/s001980070040; Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-105; Pfeifer M, 2004, J BONE MINER RES, V19, P1208, DOI 10.1359/JBMR.040507; Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171; Pouwels S, 2009, STROKE, V40, P3281, DOI 10.1161/STROKEAHA.109.554055; Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053; Ramnemark A, 2000, STROKE, V31, P1572, DOI 10.1161/01.STR.31.7.1572; Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169; Schmid AA, 2012, ARCH PHYS MED REHAB, V93, P1101, DOI 10.1016/j.apmr.2012.01.020; Simpson LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019431; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; Sung SF, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1769-8; Sung SF, 2015, J CLIN EPIDEMIOL, V68, P1292, DOI 10.1016/j.jclinepi.2015.01.009; Teng GG, 2008, CLIN EXP RHEUMATOL, V26, pS125; Tsan YT, 2012, J CLIN ONCOL, V30, P623, DOI 10.1200/JCO.2011.36.0917; Tung YC, 2015, INT J QUAL HEALTH C, V27, P260, DOI 10.1093/intqhc/mzv038; Verheyden GSAF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008728.pub2; von Koch L, 2001, CEREBROVASC DIS, V12, P131, DOI 10.1159/000047692; Wang WJ, 2014, J BONE MINER RES, V29, P676, DOI 10.1002/jbmr.2061; Weerdesteyn V, 2008, J REHABIL RES DEV, V45, P1195, DOI 10.1682/JRRD.2007.09.0145; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; Wu CH, 2011, ARCH PHYS MED REHAB, V92, P1987, DOI 10.1016/j.apmr.2011.06.028; Wu JC, 2012, NEUROSURGERY, V70, P594, DOI 10.1227/NEU.0b013e318232d4f2; Yang NP, 2010, INJURY, V41, P1266, DOI 10.1016/j.injury.2010.05.025	77	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2017	12	4							e0175825	10.1371/journal.pone.0175825	http://dx.doi.org/10.1371/journal.pone.0175825			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES9KD	28414796	Green Submitted, Green Published, gold			2023-01-03	WOS:000399874800060
J	Kaiser, J				Kaiser, Jocelyn			Personalized tumor vaccines keep cancer in check	SCIENCE			English	News Item																			0	13	13	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2017	356	6334					122	122		10.1126/science.356.6334.122	http://dx.doi.org/10.1126/science.356.6334.122			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER7SM	28408552				2023-01-03	WOS:000399013800011
J	Devarajooh, C; Chinna, K				Devarajooh, Cassidy; Chinna, Karuthan			Depression, distress and self-efficacy: The impact on diabetes self-care practices	PLOS ONE			English	Article							MANAGEMENT; ADULTS; HEALTH; BEHAVIOR; ADHERENCE; SYMPTOMS; SUPPORT; STRESS; PEOPLE; WOMEN	The prevalence of type 2 diabetes is increasing in Malaysia, and people with diabetes have been reported to suffer from depression and diabetes distress which influences their self efficacy in performing diabetes self-care practices. This interviewer administered, cross sectional study, conducted in the district of Hulu Selangor, Malaysia, involving 371 randomly selected patients with type 2 diabetes, recruited from 6 health clinics, aimed to examine a conceptual model regarding the association between depression, diabetes distress and self-efficacy with diabetes self-care practices using the partial least square approach of structural equation modeling. In this study, diabetes self-care practices were similar regardless of sex, age group, ethnicity, education level, diabetes complications or type of diabetes medication. This study found that self-efficacy had a direct effect on diabetes self-care practice (path coefficient = 0.438, p<0.001). Self-care was not directly affected by depression and diabetes distress, but indirectly by depression (path coefficient = -0.115, p<0.01) and diabetes distress (path coefficient = -0.122, p<0.001) via self-efficacy. In conclusion, to improve self-care practices, effort must be focused on enhancing self-efficacy levels, while not forgetting to deal with depression and diabetes distress, especially among those with poorer levels of self-efficacy.	[Devarajooh, Cassidy; Chinna, Karuthan] Univ Malaya, Fac Med, Dept Social & Prevent Med, Jalan Univ, Kuala Lumpur, Malaysia	Universiti Malaya	Devarajooh, C (corresponding author), Univ Malaya, Fac Med, Dept Social & Prevent Med, Jalan Univ, Kuala Lumpur, Malaysia.	cassdeva@hotmail.com						Adam J, 2014, JNP-J NURSE PRACT, V10, P42, DOI 10.1016/j.nurpra.2014.07.033; Adebayo SO, 2014, ONLINE J SOCIAL SCI, V3; Al Johani KA, 2015, E MEDITERR HEALTH J, V21, P621, DOI 10.26719/2015.21.9.621; Al-Khawaldeh OA, 2012, J DIABETES COMPLICAT, V26, P10, DOI 10.1016/j.jdiacomp.2011.11.002; Anita TF, 2013, J NURSING ED PRACTIC, V3, P61; Atak N, 2013, AUSTR J ADV NURSING, V26, P66; Bai YL, 2009, J CLIN NURS, V18, P3308, DOI 10.1111/j.1365-2702.2009.02992.x; Bandura A., 1994, SELF EFFICACY; Beckerle C. M., 2013, Diabetes Spectrum, V26, P172, DOI 10.2337/diaspect.26.3.172; Campbell MD, 2015, BMJ OPEN DIAB RES CA, V3, DOI [10.1136/bmjdrc-2015000085, 10.1136/bmjdrc-2015-000085]; Carper MM, 2014, J BEHAV MED, V37, P501, DOI 10.1007/s10865-013-9505-x; Chan HL, 2012, DIABETES RES CLIN PR, V98, pE4, DOI 10.1016/j.diabres.2012.06.003; Choi SE, 2009, DIABETES EDUCATOR, V35, P978, DOI 10.1177/0145721709349220; Clark DO, 1999, HEALTH EDUC BEHAV, V26, P535, DOI 10.1177/109019819902600410; Diane OR, 2010, SOUTHERN ONLINE JOUR, V10; Dunlop DD, 2003, AM J PUBLIC HEALTH, V93, P1945, DOI 10.2105/AJPH.93.11.1945; Engum A, 2005, DIABETES CARE, V28, P1904, DOI 10.2337/diacare.28.8.1904; Fisher L, 2009, DIABETIC MED, V26, P622, DOI 10.1111/j.1464-5491.2009.02730.x; Fisher L, 2008, ANN FAM MED, V6, P246, DOI 10.1370/afm.842; Fisher L, 2012, DIABETES CARE, V35, P259, DOI 10.2337/dc11-1572; Freitas SS, 2014, ACTA SCI-HEALTH SCI, V36, P73, DOI 10.4025/actascihealthsci.v36i1.16251; Gillani SW, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.1000252; Gonzalez JS, 2008, DIABETOLOGIA, V51, P1822, DOI 10.1007/s00125-008-1113-x; Gonzalez JS, 2011, PSYCHOLOGICAL CO-MORBIDITIES OF PHYSICAL ILLNESS: A BEHAVIORAL MEDICINE PERSPECTIVE, P73, DOI 10.1007/978-1-4419-0029-6_2; Gopichandran V, 2012, NATL MED J INDIA, V25, P14; Grewal K, 2010, HEART LUNG, V39, P180, DOI 10.1016/j.hrtlng.2009.06.016; Habtewold TD, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0809-6; Hair JF, 2011, J MARKET THEORY PRAC, V19, P139, DOI 10.2753/MTP1069-6679190202; Henseler Jr, 2009, USE PARTIAL LEAST SQ; Huang MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095138; Ikeda K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109323; Jalaludin My, 2012, Malays Fam Physician, V7, P10; Joseph Nitin, 2013, Indian J Endocrinol Metab, V17, P681, DOI 10.4103/2230-8210.113761; Kaur G, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-69; Koopman C, 2003, AM J HEALTH PROMOT, V17, P259, DOI 10.4278/0890-1171-17.4.259; Lin EHB, 2004, DIABETES CARE, V27, P2154, DOI 10.2337/diacare.27.9.2154; Ludman EJ, 2013, BEHAV MED, V39, P1, DOI 10.1080/08964289.2012.708682; Mohamed HJBJ, 2015, ASIA-PAC J PUBLIC HE, V27, P123, DOI 10.1177/1010539514562447; Mohammad AH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/302097; Nolen-Hoeksema S, 2001, CURR DIR PSYCHOL SCI, V10, P173, DOI 10.1111/1467-8721.00142; Nwasuruba C, 2009, J DIABETES COMPLICAT, V23, P112, DOI 10.1016/j.jdiacomp.2007.11.005; Nyunt SW, 2010, SE ASIAN J TROP MED, V41, P943; O'Reilly KB, 2011, TACTICS IMPROVE DRUG; Peyrot M, 2010, DIABETES CARE, V33, P240, DOI 10.2337/dc09-1348; Polonsky W.H., 2004, CLIN DIABETES, V22, P147, DOI DOI 10.2337/diaclin.22.3.147; Pouwer F, 2005, DIABETES RES CLIN PR, V70, P166, DOI 10.1016/j.diabres.2005.03.031; Pouwer F, 2013, DIABETIC MED, V30, pE25, DOI 10.1111/dme.12031; Primozic S, 2012, DIABETES RES CLIN PR, V95, P48, DOI 10.1016/j.diabres.2011.09.004; Rifkin DE, 2010, AM J KIDNEY DIS, V56, P439, DOI 10.1053/j.ajkd.2010.04.021; Robert RW, 2014, J DIABETES METABOLIS; Senecal C, 2000, HEALTH PSYCHOL, V19, P452, DOI 10.1037//0278-6133.19.5.452; Sharoni SKA, 2012, NURS HEALTH SCI, V14, P38, DOI 10.1111/j.1442-2018.2011.00658.x; Sherina M S, 2004, Asia Pac J Public Health, V16, P109, DOI 10.1177/101053950401600206; Sherina M S, 2012, Med J Malaysia, V67, P309; Song Y, 2012, DIABETES EDUCATOR, V38, P77, DOI 10.1177/0145721711432456; Tadele A, 2014, WORLD J MED MED SCI, V2; Taherdoost H., 2014, ADV APPL PURE MATH, V27, P375, DOI DOI 10.2139/SSRN.3205035; Tahmasebi R, 2015, ASIA-PAC J PUBLIC HE, V27, pNP524, DOI 10.1177/1010539513475652; Tan MY, 2008, PATIENT EDUC COUNS, V72, P252, DOI 10.1016/j.pec.2008.03.017; Tanenbaum ML, 2016, J DIABETES COMPLICAT, V30, P1060, DOI 10.1016/j.jdiacomp.2016.04.023; Thanakwang K, 2014, CLIN INTERV AGING, V9, P1353, DOI 10.2147/CIA.S67200; Venkataraman K, 2012, J COMMUN HEALTH, V37, P653, DOI 10.1007/s10900-011-9496-x; Wardian J, 2014, SOC WORK HEALTH CARE, V53, P364, DOI 10.1080/00981389.2014.884038; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; Whittemore R, 2005, J CLIN NURS, V14, P195, DOI 10.1111/j.1365-2702.2004.00937.x; Wyatt LC, 2015, J HEALTH CARE POOR U, V26, P191, DOI 10.1353/hpu.2015.0059; Yong A. G., 2013, TUTORIALS QUANTITATI, V9; Zgibor JC, 2002, DIABETES CARE, V25, P1772, DOI 10.2337/diacare.25.10.1772	68	58	64	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2017	12	3							e0175096	10.1371/journal.pone.0175096	http://dx.doi.org/10.1371/journal.pone.0175096			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER9VK	28362861	Green Published, Green Submitted, gold			2023-01-03	WOS:000399175000071
J	Valbusa, F; Bonapace, S; Agnoletti, D; Scala, L; Grillo, C; Arduini, P; Turcato, E; Mantovani, A; Zoppini, G; Arcaro, G; Byrne, C; Targher, G				Valbusa, Filippo; Bonapace, Stefano; Agnoletti, Davide; Scala, Luca; Grillo, Cristina; Arduini, Pietro; Turcato, Emanuela; Mantovani, Alessandro; Zoppini, Giacomo; Arcaro, Guido; Byrne, Christopher; Targher, Giovanni			Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure	PLOS ONE			English	Article							GAMMA-GLUTAMYL-TRANSFERASE; CARDIOVASCULAR-DISEASE; ATRIAL-FIBRILLATION; PREVALENCE; REHOSPITALIZATION; METAANALYSIS; ASSOCIATION; DYSFUNCTION; DIAGNOSIS; REGISTRY	Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for heart failure (HF). Although some progress has been made in improving survival among patients admitted for HF, the rates of hospital readmissions and the related costs continue to rise dramatically. We sought to examine whether NAFLD and its severity (diagnosed at hospital admission) was independently associated with a higher risk of 1-year all-cause and cardiac re-hospitalization in patients admitted for acute HF. We studied 212 elderly patients who were consecutively admitted with acute HF to the Hospital of Negrar (Verona) over a 1-year period. Diagnosis of NAFLD was based on ultrasonography, whereas the severity of advanced NAFLD fibrosis was based on the fibrosis (FIB)-4 score and other non-invasive fibrosis scores. Patients with acute myocardial infarction, severe valvular heart diseases, endstage renal disease, cancer, known liver diseases or decompensated cirrhosis were excluded. Cox regression was used to estimate hazard ratios (HR) for the associations between NAFLD and the outcome(s) of interest. The cumulative rate of 1-year all-cause re-hospitalizations was 46.7% (n = 99, mainly due to cardiac causes). Patients with NAFLD (n = 109; 51.4%) had remarkably higher 1-year all-cause and cardiac re-hospitalization rates compared with their counterparts without NAFLD. Both event rates were particularly increased in those with advanced NAFLD fibrosis. NAFLD was associated with a 5-fold increased risk of 1-year all-cause re-hospitalization (adjusted-hazard ratio 5.05, 95% confidence intervals 2.78-9.10, p<0.0001) after adjustment for established risk factors and potential confounders. Similar results were found for 1-year cardiac re-hospitalization (adjusted-hazard ratio 8.05, 95% confidence intervals 3.77-15.8, p<0.0001). In conclusion, NAFLD and its severity were strongly and independently associated with an increased risk of 1-year all-cause and cardiac re-hospitalization in elderly patients admitted with acute HF.	[Valbusa, Filippo; Agnoletti, Davide; Scala, Luca; Grillo, Cristina; Arcaro, Guido] Sacro Cuore Hosp, Div Gen Med, Verona, Italy; [Bonapace, Stefano] Sacro Cuore Hosp, Div Cardiol, Verona, Italy; [Arduini, Pietro; Turcato, Emanuela] Sacro Cuore Hosp, Div Geriatr, Verona, Italy; [Mantovani, Alessandro; Zoppini, Giacomo; Targher, Giovanni] Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy; [Mantovani, Alessandro; Zoppini, Giacomo; Targher, Giovanni] Azienda Osped Univ Integrata Verona, Verona, Italy; [Byrne, Christopher] Univ Southampton, Nutr & Metab, Fac Med, Southampton, Hants, England; [Byrne, Christopher] Southampton Univ Hosp, Southampton NIHR Biomed Res Ctr, Southampton, Hants, England	IRCCS Sacro Cuore Don Calabria; IRCCS Sacro Cuore Don Calabria; IRCCS Sacro Cuore Don Calabria; University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Southampton; University of Southampton	Targher, G (corresponding author), Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy.; Targher, G (corresponding author), Azienda Osped Univ Integrata Verona, Verona, Italy.	giovanni.targher@univr.it	Targher, Giovanni/AAB-9008-2019; zoppini, giacomo/AAA-9000-2022; Mantovani, Alessandro/AAB-9015-2019; Agnoletti, Davide/K-1441-2016	Targher, Giovanni/0000-0002-4325-3900; zoppini, giacomo/0000-0003-1085-554X; Mantovani, Alessandro/0000-0002-7271-6329; Agnoletti, Davide/0000-0001-8108-7133; Byrne, Christopher D/0000-0001-6322-7753; Bonapace, Stefano/0000-0001-9122-2642	Southampton National Institute for Health Research Biomedical Research Centre; University School of Medicine of Verona, Verona, Italy	Southampton National Institute for Health Research Biomedical Research Centre; University School of Medicine of Verona, Verona, Italy	The authors received no specific funding for this work. However, CDB is supported in part by the Southampton National Institute for Health Research Biomedical Research Centre. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy.	Alonso A, 2014, HEART, V100, P1511, DOI 10.1136/heartjnl-2014-305756; Alvarez AM, 2011, INT J ANGIOL, V20, P135, DOI 10.1055/s-0031-1284434; Ballestri S, 2015, EXPERT REV GASTROENT, V9, P603, DOI 10.1586/17474124.2015.1007955; Byrne CD, 2016, GASTROENTEROLOGY, V150, P7, DOI 10.1053/j.gastro.2015.11.016; Byrne CD, 2015, J HEPATOL, V62, pS47, DOI 10.1016/j.jhep.2014.12.012; Dhingra R, 2010, ARTERIOSCL THROM VAS, V30, P1855, DOI 10.1161/ATVBAHA.110.207340; EASL, 2016, DIABETOLOGIA, V59, P1121, DOI 10.1007/s00125-016-3902-y; Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038; Graner M, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.114.001979; Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452; Karajamaki AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142937; Kociol RD, 2011, CIRC-HEART FAIL, V4, P628, DOI 10.1161/CIRCHEARTFAILURE.111.962290; Lang RM, 2006, EUR J ECHOCARDIOGR, V7, P79, DOI 10.1016/j.euje.2005.12.014; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lonardo A, 2016, WORLD J GASTROENTERO, V22, P9674, DOI 10.3748/wjg.v22.i44.9674; Lonardo A, 2015, DIGEST LIVER DIS, V47, P997, DOI 10.1016/j.dld.2015.08.004; Mantovani A, 2016, DIGEST DIS SCI, V61, P1246, DOI 10.1007/s10620-016-4040-6; McMurray JJV, 2012, EUR J HEART FAIL, V14, P803, DOI 10.1093/eurjhf/hfs105; McPherson S., 2016, AM J GASTROENTEROL; Park CC, 2017, GASTROENTEROLOGY, V152, P598, DOI 10.1053/j.gastro.2016.10.026; Poelzl G, 2009, CIRC-HEART FAIL, V2, P294, DOI 10.1161/CIRCHEARTFAILURE.108.826735; Santaguida PL, 2014, HEART FAIL REV, V19, P453, DOI 10.1007/s10741-014-9442-y; Siegelman ES, 2001, SEMIN LIVER DIS, V21, P71, DOI 10.1055/s-2001-12930; Targher G, 2017, EUR J HEART FAIL, V19, P54, DOI 10.1002/ejhf.679; Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013; Targher G, 2016, INT J CARDIOL, V203, P587, DOI 10.1016/j.ijcard.2015.10.207; Targher G, 2013, CLIN SCI, V125, P301, DOI 10.1042/CS20130036; Targher G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057183; Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063; Valbusa F, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002760; van Riet EES, 2016, EUR J HEART FAIL, V18, P242, DOI 10.1002/ejhf.483; VanWagner LB, 2015, HEPATOLOGY, V62, P773, DOI 10.1002/hep.27869; Wang YJ, 2013, HEART, V99, P163, DOI 10.1136/heartjnl-2012-302972; Wannamethee SG, 2012, ARTERIOSCL THROM VAS, V32, P830, DOI 10.1161/ATVBAHA.111.240457	34	24	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2017	12	3							e0173398	10.1371/journal.pone.0173398	http://dx.doi.org/10.1371/journal.pone.0173398			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6CP	28288193	Green Accepted, gold, Green Submitted, Green Published			2023-01-03	WOS:000396092400015
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Why I'm changing my mind about resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Brazier M, 2011, MED PATIENTS LAW; Etheridge Z, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2640; Masters K, 2016, BMJ; Masters K, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1084; NHS End of Life Care Programme, 2012, DNACPR DEC WHO DEC; Oliver D, 2015, HLTH SERV J; Oliver D, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1494; Oliver D, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4846; Poole N, 2015, LEARNED FRIEND B MAR; Resuscitation Council (UK), 2016, RESPECT PROGR UPD; Smith J, 2016, BRIT GER SOC SPRING, P47; Sokol DK, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i26	12	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2017	356								j1143	10.1136/bmj.j1143	http://dx.doi.org/10.1136/bmj.j1143			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BP	28270417	Bronze, Green Published			2023-01-03	WOS:000396432900001
J	Imanishi, Y; Fukuma, S; Karaboyas, A; Robinson, BM; Pisoni, RL; Nomura, T; Akiba, T; Akizawa, T; Kurokawa, K; Saito, A; Fukuhara, S; Inaba, M				Imanishi, Yasuo; Fukuma, Shingo; Karaboyas, Angelo; Robinson, Bruce M.; Pisoni, Ronald L.; Nomura, Takanobu; Akiba, Takashi; Akizawa, Tadao; Kurokawa, Kiyoshi; Saito, Akira; Fukuhara, Shunichi; Inaba, Masaaki			Associations of employment status and educational levels with mortality and hospitalization in the dialysis outcomes and practice patterns study in Japan	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SOCIAL ADAPTABILITY INDEX; SOCIOECONOMIC-STATUS; HEMODIALYSIS-PATIENTS; INTERNATIONAL HEMODIALYSIS; MULTILEVEL ANALYSIS; ELDERLY POPULATION; INCOME INEQUALITY; HEALTH; DOPPS	Background Socioeconomic status (SES) factors such as employment, educational attainment, income, and marital status can affect the health and well-being of the general population and have been associated with the prevalence of chronic kidney disease (CKD). However, no studies to date in Japan have reported on the prognosis of patients with CKD with respect to SES. This study aimed to investigate the influences of employment and education level on mortality and hospitalization among maintenance hemodialysis (HD) patients in Japan. Methods Data on 7974 HD patients enrolled in Dialysis Outcomes and Practice Patterns Study phases 1-4 (1999-2011) in Japan were analysed. Employment status, education level, demographic data, and comorbidities were abstracted at entry into DOPPS from patient records. Mortality and hospitalization events were collected during follow-up. Patients on dialysis < 120 days at study entry were excluded from the analyses. Cox regression modelled the association between employment and both mortality and hospitalization among patients < 60 years old. The association between education and outcomes was also assessed. The association between patient characteristics and employment among patients < 60 years old was assessed using logistic regression. Results During a median follow-up of 24.9 months (interquartile range, 18.4-32.0), 10% of patients died and 43% of patients had an inpatient hospitalization. Unemployment was associated with mortality (hazard ratio [HR] = 1.57; 95% confidence interval [CI]: 1.05-2.36) and hospitalization (HR = 1.25; 95% CI: 1.08-1.44). Compared to patients who graduated from university, patients with less than a high school (HS) education and patients who graduated HS with some college tended to have elevated mortality (HR = 1.41; 95% CI, 1.04-1.92 and HR = 1.36; 95% CI: 1.02-1.82, respectively) but were not at risk for increased hospitalizations. Factors associated with unemployment included lower level of education, older age, female gender, longer vintage, and several comorbidities. Conclusions Employment and education status were inversely associated with mortality in patients on maintenance HD in Japan. Employment but not education was also inversely associated with hospitalizations. After adjustment for comorbidities, the associations with clinical outcomes tended to be stronger for employment than education status.	[Imanishi, Yasuo; Inaba, Masaaki] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka, Japan; [Fukuma, Shingo; Fukuhara, Shunichi] Kyoto Univ, Dept Healthcare Epidemiol, Sch Publ Hlth, Grad Sch Med, Kyoto, Japan; [Karaboyas, Angelo; Robinson, Bruce M.; Pisoni, Ronald L.] Arbor Res Collaborat Hlth, Ann Arbor, MI USA; [Robinson, Bruce M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Nomura, Takanobu] Kyowa Hakko Kirin Co Ltd, Med Affairs, Kyowa, Tokyo, Japan; [Akiba, Takashi] Tokyo Womens Med Univ, Dept Blood Purificat & Internal Med, Kidney Ctr, Tokyo, Japan; [Akizawa, Tadao] Showa Univ, Sch Med, Div Nephrol, Dept Med, Tokyo, Japan; [Kurokawa, Kiyoshi] Natl Grad Inst Policy Studies, Tokyo, Japan; [Saito, Akira] Shonantobu Gen Hosp, Div Nephrol, Kanagawa, Japan; [Saito, Akira] Shonantobu Gen Hosp, Dialysis Ctr, Kanagawa, Japan; [Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima, Japan	Osaka Metropolitan University; Kyoto University; Arbor Research Collaborative for Health; University of Michigan System; University of Michigan; Kyowa Kirin Ltd; Tokyo Women's Medical University; Showa University; National Graduate Institute for Policy Studies; Fukushima Medical University	Imanishi, Y (corresponding author), Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka, Japan.	imanishi@med.osaka-cu.ac.jp			Amgen; Kyowa Hakko Kirin; AbbVie; Sanofi Renal; Baxter Healthcare; Vifor Fresenius Medical Care Renal Pharma; Keryx Biopharmaceuticals; Merck Sharp Dohme; Proteon Therapeutics; Relypsa; F. Hoffmann-LaRoche; BHC Medical; Janssen; Takeda; Hexal; DGfN; Shire; WiNe Institute; Japanese Society for Peritoneal Dialysis (JSPD); Kyowa Hakko Kirin, Co.Ltd.	Amgen(Amgen); Kyowa Hakko Kirin(Kyowa Kirin Ltd); AbbVie(AbbVie); Sanofi Renal; Baxter Healthcare; Vifor Fresenius Medical Care Renal Pharma; Keryx Biopharmaceuticals; Merck Sharp Dohme(Merck & Company); Proteon Therapeutics; Relypsa; F. Hoffmann-LaRoche(Hoffmann-La Roche); BHC Medical; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Takeda(Takeda Pharmaceutical Company Ltd); Hexal; DGfN; Shire; WiNe Institute; Japanese Society for Peritoneal Dialysis (JSPD); Kyowa Hakko Kirin, Co.Ltd.(Kyowa Kirin Ltd)	The DOPPS Program is supported by Amgen, Kyowa Hakko Kirin, AbbVie, Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma. Additional support for specific projects and countries is provided by Keryx Biopharmaceuticals, Merck Sharp & Dohme, Proteon Therapeutics, Relypsa, and F. Hoffmann-LaRoche; in Canada by Amgen, BHC Medical, Janssen, Takeda, and the Kidney Foundation of Canada (for logistics support); in Germany by Hexal, DGfN, Shire, and the WiNe Institute; and for PDOPPS in Japan by the Japanese Society for Peritoneal Dialysis (JSPD). All support is provided without restrictions on publications. Kyowa Hakko Kirin, Co.Ltd. provided support in the form of salaries for authors T.N., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Drey N, 2003, AM J KIDNEY DIS, V42, P677, DOI 10.1016/S0272-6386(03)00916-8; Edwards M, 2009, PATIENT EDUC COUNS, V75, P37, DOI 10.1016/j.pec.2008.09.025; Fedewa SA, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-136; Fored CM, 2003, NEPHROL DIAL TRANSPL, V18, P82, DOI 10.1093/ndt/18.1.82; Fujino Y, 2005, PREV MED, V40, P444, DOI 10.1016/j.ypmed.2004.07.002; Fukuda Y, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-53; Fukuda Y, 2004, SOC SCI MED, V59, P2435, DOI 10.1016/j.socscimed.2004.04.012; Giskes K, 2002, PUBLIC HEALTH NUTR, V5, P663, DOI 10.1079/PHN2002339; Goldfarb-Rumyantzev AS, 2010, NEPHROL DIAL TRANSPL, V25, P3672, DOI 10.1093/ndt/gfq177; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Gray L, 2009, PUBLIC HEALTH NUTR, V12, P1351, DOI 10.1017/S1368980008004047; Ishikawa Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040664; Kagamimori S, 2009, SOC SCI MED, V68, P2152, DOI 10.1016/j.socscimed.2009.03.030; Keita AD, 2009, J AM DIET ASSOC, V109, P1612, DOI 10.1016/j.jada.2009.06.373; Lopes AA, 2007, NEPHROL DIAL TRANSPL, V22, P3538, DOI 10.1093/ndt/gfm453; Lopes AA, 2010, J RENAL NUTR, V20, P224, DOI 10.1053/j.jrn.2009.10.002; Marinovich S, 2012, NEFROLOGIA, V32, P79, DOI 10.3265/Nefrologia.pre2011.Nov.11110; Marmot M, 2001, NEW ENGL J MED, V345, P134, DOI 10.1056/NEJM200107123450210; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; McClellan WM, 2010, AM J NEPHROL, V32, P38, DOI 10.1159/000313883; Merkin SS, 2007, SOC SCI MED, V65, P809, DOI 10.1016/j.socscimed.2007.04.011; Merkin SS, 2005, AM J KIDNEY DIS, V46, P203, DOI 10.1053/j.ajkd.2005.04.033; Pickett KE, 2015, PEDIATRICS, V135, pS39, DOI 10.1542/peds.2014-3549E; Pifer TB, 2002, KIDNEY INT, V62, P2238, DOI 10.1046/j.1523-1755.2002.00658.x; Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Robinson BM, 2009, CLIN J AM SOC NEPHRO, V4, pS12, DOI 10.2215/CJN.04720709; Sandhu GS, 2011, NEPHROL DIAL TRANSPL, V26, P2667, DOI 10.1093/ndt/gfq789; Wilkinson RG, 2006, SOC SCI MED, V62, P1768, DOI 10.1016/j.socscimed.2005.08.036; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x	30	15	15	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2017	12	3							e0170731	10.1371/journal.pone.0170731	http://dx.doi.org/10.1371/journal.pone.0170731			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN5OE	28264035	gold, Green Published, Green Submitted			2023-01-03	WOS:000396054300003
J	Kotreka, UK; Davis, VL; Adeyeye, MC				Kotreka, Udaya K.; Davis, Vicki L.; Adeyeye, Moji C.			Development of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts	PLOS ONE			English	Article							LENS EPITHELIAL-CELLS; OCULAR DRUG-DELIVERY; BLUE MOUNTAINS EYE; ESTROGEN-RECEPTOR; PHYSIOLOGICAL CONDITIONS; 17-BETA-ESTRADIOL; HYDROGELS; TIMOLOL; VITRO; BETA	The goal of this study was to develop and characterize an ion-activated in situ gel-forming estradiol (E-2) solution eye drops intended for the prevention of age-related cataracts. Accordingly, in situ gelling eye drops were made using gellan gum as an ion-activated gel-forming polymer, polysorbate-80 as drug solubilizing agent, mannitol as tonicity agent, and combination of potassium sorbate and edetate disodium dihydrate (EDTA) as preservatives. The formulations were tested for the following characteristics: pH, clarity, osmolality, antimicrobial efficacy, rheological behavior, and in vitro drug release. Stability of the formulation was also monitored for 6 months at multiple storage conditions per ICH Q1A (R2) guidelines. The solution eye drops resulted in an in-situ phase change to gel-state when mixed with simulated tear fluid (STF). The gel structure formation was confirmed by viscoelastic measurements. Drug release from the gel followed non-fickian mechanism with 80% of drug released in 8 hr. The formulations were found to be clear, isotonic with suitable pH and viscoelastic behavior and stable at accelerated and long-term storage conditions for 6 months. In vitro results suggest that the developed formulation is suitable for further investigation in animal models to elucidate the ability of estrogen to prevent and delay cataracts.	[Kotreka, Udaya K.; Davis, Vicki L.; Adeyeye, Moji C.] Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15219 USA; [Kotreka, Udaya K.] Vanda Pharmaceut Inc, Washington, DC USA; [Adeyeye, Moji C.] Roosevelt Univ, Coll Pharm, Schaumburg, IL 60173 USA	Duquesne University	Adeyeye, MC (corresponding author), Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15219 USA.; Adeyeye, MC (corresponding author), Roosevelt Univ, Coll Pharm, Schaumburg, IL 60173 USA.	madeyeye@roosevelt.edu			CURE Grant, Pennsylvania Department of Health	CURE Grant, Pennsylvania Department of Health	This work was supported by the CURE Grant, Pennsylvania Department of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeyeye CM, 2002, AAPS PHARMSCITECH, V3, pE8, DOI [10.1208/pt030208, DOI 10.1208/PT030208]; Adeyeye MC, 2011, US Patent Publication, Patent No. [0082128 A1, 0082128]; Al-Ghananeem A, 2002, AAPS PHARMSCITECH, V3, P40; [Anonymous], 1996, GUID IND Q2 R1 ICH H; [Anonymous], 1996, Santee Pharmaceutical Co, Ltd, Patent No. [US5559157, 5559157]; Bachmann GA, 1998, AM J OBSTET GYNECOL, V178, pS257, DOI 10.1016/S0002-9378(98)70558-7; Balasubramaniam Jagdish, 2003, Acta Pharmaceutica (Zagreb), V53, P251; Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328; Cammarata PR, 2004, EXP EYE RES, V78, P861, DOI 10.1016/j.exer.2003.09.027; Carlfors J, 1998, EUR J PHARM SCI, V6, P113, DOI 10.1016/S0928-0987(97)00074-2; Centers for Disease Control and Prevention, 2011, STAT VIS AG PUBL HLT; Centers for Disease Control and Prevention, 1983, CAT MAJ BLIND DIS; Colitz CMH, 2009, MOL VIS, V15, P2259; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487; Cumming RG, 1997, AM J EPIDEMIOL, V145, P242; Davies NM, 2000, CLIN EXP PHARMACOL P, V27, P558, DOI 10.1046/j.1440-1681.2000.03288.x; Davis VL, 2002, P NATL ACAD SCI USA, V99, P9427, DOI 10.1073/pnas.132247999; delCastillo JMB, 1997, OPHTHALMOLOGY, V104, P970; Dikstein S, 1992, US Patent, Patent No. 5106615; Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804; *FDA, 1995, GUID IND IMM REL SOL; Food and Drug Administration, 2003, GUID IND Q1AR2 STAB; Gongdon N, 2001, INVEST OPHTH VIS SCI, V42, P2478; Hagerstrom H, 2000, EUR J PHARM SCI, V9, P301, DOI 10.1016/S0928-0987(99)00070-6; Hales AM, 1997, J EXP MED, V185, P273, DOI 10.1084/jem.185.2.273; Hariharan S, 2006, PHARM RES-DORDR, V23, P184, DOI 10.1007/s11095-005-8418-y; Kalam MA, 2008, J DISPER SCI TECHNOL, V29, P89, DOI 10.1080/01932690701688482; Kanthan GL, 2008, OPHTHALMOLOGY, V115, P808, DOI 10.1016/j.ophtha.2007.07.008; Kirker MR, 2013, EXP EYE RES, V112, P1, DOI 10.1016/j.exer.2013.04.002; Kitano M, 1998, INT J PHARM, V174, P19, DOI 10.1016/S0378-5173(98)00234-8; Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024; Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8; KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9; Kotreka UK, 2011, THESIS; Lai KR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078647; Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5; Lindblad BE, 2010, OPHTHALMOLOGY, V117, P424, DOI 10.1016/j.ophtha.2009.07.046; LIVINGSTON PM, 1994, DEV OPHTHALMOL, V26, P1; LOFTSSON T, 1989, ACTA PHARM NORDICA, V1, P185; Lokind KB, 1996, INT J PHARM, V127, P155, DOI 10.1016/0378-5173(95)04118-4; Martens-Lobenhoffer J, 2002, CLIN PHARMACOKINET, V41, P197, DOI 10.2165/00003088-200241030-00004; MESEGUER G, 1994, J DRUG TARGET, V2, P269, DOI 10.3109/10611869409015908; Moore J. W., 1996, PHARM TECH, V20, P64; Morishima K, 2007, US Patent, Patent No. [0248697A1, 0248697]; Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877; Mundada AS, 2009, CRIT REV THER DRUG, V26, P85, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i1.30; Nagarwal RC, 2009, AAPS PHARMSCITECH, V10, P977, DOI 10.1208/s12249-009-9285-3; Nanjawade BK, 2007, J CONTROL RELEASE, V122, P119, DOI 10.1016/j.jconrel.2007.07.009; Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906; Oliveira Regina de Souza Carvalho de Salles, 2005, Clinics, V60, P455, DOI 10.1590/S1807-59322005000600005; Paulsson M, 1999, EUR J PHARM SCI, V9, P99, DOI 10.1016/S0928-0987(99)00051-2; Qian Y, 2010, DRUG DEV IND PHARM, V36, P1340, DOI 10.3109/03639041003801893; ROZIER A, 1989, INT J PHARM, V57, P163, DOI 10.1016/0378-5173(89)90305-0; RUCKER C W, 1965, Invest Ophthalmol, V4, P377; Rupenthal ID, 2011, INT J PHARMACEUT, V411, P69, DOI 10.1016/j.ijpharm.2011.03.042; Schenker HI, 2000, AM J OPHTHALMOL, V130, P145, DOI 10.1016/S0002-9394(00)00458-X; Shedden A, 2001, CLIN THER, V23, P440, DOI 10.1016/S0149-2918(01)80048-5; Singh BN, 2004, PHARM DEV TECHNOL, V9, P399, DOI 10.1081/PDT-200035793; Sultana Y, 2006, DRUG DELIV, V13, P215, DOI 10.1080/10717540500309164; Sunil T, 2012, J PHARM BIOALLIED SC, V4, pS6, DOI 10.4103/0975-7406.94117; Tsuji M, 2004, US Patent, Patent No. [0034042 A1, 0034042]; Variankaval NE, 2002, J MATER SCI-MATER M, V13, P271, DOI 10.1023/A:1014058817352; World Health Organization, 2012, GLOBAL DATA VISUAL I; World Health Organization, 2013, UN EYE HLTH GLOB ACT; Worzala K, 2001, ARCH INTERN MED, V161, P1448, DOI 10.1001/archinte.161.11.1448; Zhang XH, 2003, J CATARACT REFR SURG, V29, P71, DOI 10.1016/S0886-3350(02)01436-0; ZIGNANI M, 1995, ADV DRUG DELIVER REV, V16, P51, DOI 10.1016/0169-409X(95)00015-Y	67	37	38	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2017	12	2							e0172306	10.1371/journal.pone.0172306	http://dx.doi.org/10.1371/journal.pone.0172306			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5QV	28222100	Green Submitted, Green Published, gold			2023-01-03	WOS:000394676800047
J	Yurugi, H; Marini, F; Weber, C; David, K; Zhao, Q; Binder, H; Desaubry, L; Rajalingam, K				Yurugi, H.; Marini, F.; Weber, C.; David, K.; Zhao, Q.; Binder, H.; Desaubry, L.; Rajalingam, K.			Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours	ONCOGENE			English	Article							CELL-PROLIFERATION; SIGNALING PATHWAYS; RAS; ACTIVATION; CRAF; DIMERIZATION; MUTATIONS; BRAF	KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a direct RAS effector protein, is required for KRAS-mediated tumourigenesis. Thus, the molecular mechanisms driving the activation of CRAF are intensively studied. Prohibitin 1 (PHB1) is an evolutionarily conserved adaptor protein and interaction of CRAF with PHB1 at the plasma membrane is essential for CRAF activation. Here, we demonstrate that PHB1 is highly expressed in NSCLC patients and correlates with poor survival. Targeting of PHB1 with two chemical ligands (rocaglamide and fluorizoline) inhibits epidermal growth factor (EGF)/RAS-induced CRAF activation. Consistently, treatment with rocaglamide inhibited proliferation, migration and anchorage-independent growth of KRAS-mutated lung carcinoma cell lines. Surprisingly, rocaglamide treatment inhibited Ras-GTP loading in KRAS-mutated cells as well as in EGF-stimulated cells. Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models. Our results suggest rocaglamide as a RAS inhibitor and that targeting plasma membrane-associated PHB1 with chemical ligands would be a viable therapeutic strategy to combat KRAS-mediated NSCLCs.	[Yurugi, H.; Rajalingam, K.] Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Mainz, Germany; [Marini, F.; Binder, H.] Univ Med Ctr Mainz, Inst Med Biostat Epidemiol & Informat, Mainz, Germany; [Weber, C.; David, K.] Indivumed GmbH, Hamburg, Germany; [Zhao, Q.; Desaubry, L.] Univ Strasbourg, Therapeut Innovat Lab, CNRS, UMR7200, Strasbourg, France; [Desaubry, L.] Tianjin Univ Sci & Technol, Coll Biotechnol, Sinofrench Joint Lab Food Nutr Safety & Med Chem, Tianjin, Peoples R China; [Rajalingam, K.] German Canc Consortium DKTK, DKFZ, Partner Site Frankfurt Mainz, UCT, Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tianjin University Science & Technology; Helmholtz Association; German Cancer Research Center (DKFZ)	Rajalingam, K (corresponding author), JGU Mainz, Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Langebeck St 1, D-55131 Mainz, Germany.	Krishna@uni-mainz.de; Krishna@uni-mainz.de	Marini, Federico/AAQ-2427-2020; Desaubry, Laurent G/R-5446-2017; Binder, Harald/C-7413-2009	Marini, Federico/0000-0003-3252-7758; Desaubry, Laurent G/0000-0002-1192-2970; Binder, Harald/0000-0002-5666-8662	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing; Association pour la Recherche sur le Cancer; 'Association Nationale de la Recherche et de la Technologie' (ANRT)	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing(Boehringer Ingelheim); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); 'Association Nationale de la Recherche et de la Technologie' (ANRT)	We thank Alexandra Dimitrijevic for the excellent technical assistance, and Dr Melzer for her help and advice with the animal experiments. We thank Professors Tyler Jacks, Susan Horwitz, Scott Randell, Channing Der and Ulf Rapp for contributing several constructs and cell lines that are employed in this study. We thank Professor Hartmut Juhl and Dr Bernd Gromoll (Indivumed GmbH) for assistance with the analyses of the NSCLC tissue microarrays. This work is supported through a BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing to KR. KR is a Heisenberg Professor of the DFG (RA1739/4-1) and a GFK fellow. A generous financial support for this work was provided by the 'Association pour la Recherche sur le Cancer' to LD. We are also grateful to AAREC Filia Research and the 'Association Nationale de la Recherche et de la Technologie' (ANRT) for fellowships to QZ.	Ande SR, 2010, BIOCHEM CELL BIOL, V88, P553, DOI [10.1139/o09-177, 10.1139/O09-177]; Becker MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.528; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Chiu CF, 2013, ONCOGENE, V32, P777, DOI 10.1038/onc.2012.86; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Doudican NA, 2017, ONCOGENE, V36, P423, DOI 10.1038/onc.2016.214; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 2011, NAT MED, V17, P286, DOI 10.1038/nm0311-286; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Luan Z, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-38; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Merkwirth C, 2008, GENE DEV, V22, P476, DOI 10.1101/gad.460708; Merkwirth C, 2009, BBA-MOL CELL RES, V1793, P27, DOI 10.1016/j.bbamcr.2008.05.013; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Perez-Perarnau A, 2014, ANGEW CHEM INT EDIT, V53, P10150, DOI 10.1002/anie.201405758; Polier G, 2012, CHEM BIOL, V19, P1093, DOI 10.1016/j.chembiol.2012.07.012; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Yurugi H, 2013, BIOCHEM BIOPH RES CO, V434, P376, DOI 10.1016/j.bbrc.2013.03.085; Yurugi H, 2012, BIOCHEM BIOPH RES CO, V420, P275, DOI 10.1016/j.bbrc.2012.02.149	37	19	23	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4778	4789		10.1038/onc.2017.93	http://dx.doi.org/10.1038/onc.2017.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414306				2023-01-03	WOS:000407702400010
J	Piechotta, A; Parthier, C; Kleinschmidt, M; Gnoth, K; Pillot, T; Lues, I; Demuth, HU; Schilling, S; Rahfeld, JU; Stubbs, MT				Piechotta, Anke; Parthier, Christoph; Kleinschmidt, Martin; Gnoth, Kathrin; Pillot, Thierry; Lues, Inge; Demuth, Hans-Ulrich; Schilling, Stephan; Rahfeld, Jens-Ulrich; Stubbs, Milton T.			Structural and functional analyses of pyroglutamate-amyloid--specific antibodies as a basis for Alzheimer immunotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Alzheimer disease; amyloid-beta (A); crystal structure; drug development; monoclonal antibody; thermodynamics; ligand binding	A-BETA OLIGOMERS; STRUCTURE REVEALS; DISEASE; PEPTIDE; PROTEIN; MOUSE; BAPINEUZUMAB; DEPOSITION; PLAQUES; MODEL	Alzheimer disease is associated with deposition of the amyloidogenic peptide A in the brain. Passive immunization using A-specific antibodies has been demonstrated to reduce amyloid deposition both in vitro and in vivo. Because N-terminally truncated pyroglutamate (pE)-modified A species (A(pE3)) exhibit enhanced aggregation potential and propensity to form toxic oligomers, they represent particularly attractive targets for antibody therapy. Here we present three separate monoclonal antibodies that specifically recognize A(pE3) with affinities of 1-10 nm and inhibit A(pE3) fibril formation in vitro. In vivo application of one of these resulted in improved memory in A(pE3) oligomer-treated mice. Crystal structures of F-ab-A(pE3) complexes revealed two distinct binding modes for the peptide. Juxtaposition of pyroglutamate pE3 and the F4 side chain (the pEF head) confers a pronounced bulky hydrophobic nature to the A(pE3) N terminus that might explain the enhanced aggregation properties of the modified peptide. The deep burial of the pEF head by two of the antibodies explains their high target specificity and low cross-reactivity, making them promising candidates for the development of clinical antibodies.	[Piechotta, Anke; Kleinschmidt, Martin; Gnoth, Kathrin; Lues, Inge; Demuth, Hans-Ulrich; Schilling, Stephan; Rahfeld, Jens-Ulrich] Probiodrug AG, Weinbergweg 22, D-06120 Halle, Saale, Germany; [Piechotta, Anke; Parthier, Christoph; Stubbs, Milton T.] Martin Luther Univ Halle Wittenberg, Inst Biotechnol, D-06108 Halle, Germany; [Piechotta, Anke; Kleinschmidt, Martin; Gnoth, Kathrin; Demuth, Hans-Ulrich; Schilling, Stephan; Rahfeld, Jens-Ulrich] Fraunhofer Inst Cell Therapy & Immunol, Dept Mol Drug Biochem & Therapy, Weinbergweg 22, D-06120 Halle, Germany; [Pillot, Thierry] SynAging SAS, F-54518 Vandoeuvre Les Nancy, France	Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; Fraunhofer Gesellschaft	Rahfeld, JU (corresponding author), Probiodrug AG, Weinbergweg 22, D-06120 Halle, Saale, Germany.; Stubbs, MT (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.	jens-ulrich.rahfeld@probiodrug.de; stubbs@biochemtech.uni-halle.de	Stubbs, Milton/ABC-7585-2020	Stubbs, Milton/0000-0003-1278-9013	Deutsche Forschungsgemeinschaft [GRK1026]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by funds from the Deutsche Forschungsgemeinschaft GRK1026 Conformational Transitions in Macromolecular Interactions (to M. T. S.). M. K., H.-U. D., S. S., and J.-U. R. are consultants and former employees of Probiodrug. I. L. and H.-U. D. are shareholders and I. L. is chief development officer of Probiodrug.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Antonyuk SV, 2011, P NATL ACAD SCI USA, V108, P15780, DOI 10.1073/pnas.1109051108; Basi GS, 2010, J BIOL CHEM, V285, P3417, DOI 10.1074/jbc.M109.045187; Bibl M, 2012, PROTEOM CLIN APPL, V6, P163, DOI 10.1002/prca.201100082; Bohrmann B, 2012, J ALZHEIMERS DIS, V28, P49, DOI 10.3233/JAD-2011-110977; Bouter Y, 2015, ACTA NEUROPATHOL, V130, P713, DOI 10.1007/s00401-015-1489-x; Bouter Y, 2013, ACTA NEUROPATHOL, V126, P189, DOI 10.1007/s00401-013-1129-2; Bussiere T., 2014, Patent, Patent No. [WO2014089500, 2014089500]; Dammers C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139710; DeMattos RB, 2012, NEURON, V76, P908, DOI 10.1016/j.neuron.2012.10.029; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; ELMORE MA, 1990, NEUROPEPTIDES, V15, P31, DOI 10.1016/0143-4179(90)90157-T; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Feinberg H, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt261; Frost JL, 2015, NEUROBIOL AGING, V36, P3187, DOI 10.1016/j.neurobiolaging.2015.08.021; Frost JL, 2012, NEURODEGENER DIS, V10, P265, DOI 10.1159/000335913; Garcia P, 2010, J NEUROSCI, V30, P7516, DOI 10.1523/JNEUROSCI.4182-09.2010; Gardberg AS, 2007, P NATL ACAD SCI USA, V104, P15659, DOI 10.1073/pnas.0705888104; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kumar DKV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1059; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Lannfelt L, 2014, J INTERN MED, V275, P284, DOI 10.1111/joim.12168; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Lemere CA, 2010, NAT REV NEUROL, V6, P108, DOI 10.1038/nrneurol.2009.219; Lu JX, 2013, CELL, V154, P1257, DOI 10.1016/j.cell.2013.08.035; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Miles LA, 2008, J MOL BIOL, V377, P181, DOI 10.1016/j.jmb.2007.12.036; Miles LA, 2013, SCI REP-UK, V3, DOI 10.1038/srep01302; Miravalle L, 2005, BIOCHEMISTRY-US, V44, P10810, DOI 10.1021/bi0508237; MORI H, 1992, J BIOL CHEM, V267, P17082; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nussbaum JM, 2012, NATURE, V485, P651, DOI 10.1038/nature11060; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Puzzo D, 2013, J ALZHEIMERS DIS, V33, pS111, DOI 10.3233/JAD-2012-129033; Puzzo D, 2011, ANN NEUROL, V69, P819, DOI 10.1002/ana.22313; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Schilling S, 2008, NAT MED, V14, P1106, DOI 10.1038/nm.1872; Schilling S, 2006, BIOCHEMISTRY-US, V45, P12393, DOI 10.1021/bi0612667; Schlenzig D, 2012, J NEUROCHEM, V121, P774, DOI 10.1111/j.1471-4159.2012.07707.x; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Sergeant N, 2003, J NEUROCHEM, V85, P1581, DOI 10.1046/j.1471-4159.2003.01818.x; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Sun N, 2012, J PEPT SCI, V18, P691, DOI 10.1002/psc.2456; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Williams LK, 2012, J MED CHEM, V55, P10177, DOI 10.1021/jm301273u; Wirths O, 2010, J BIOL CHEM, V285, P41517, DOI 10.1074/jbc.M110.178707; Wirths O, 2010, J NEURAL TRANSM, V117, P85, DOI 10.1007/s00702-009-0314-x; Wu GX, 2014, NEURODEGENER DIS, V14, P53, DOI 10.1159/000353634; Youssef I, 2008, NEUROBIOL AGING, V29, P1319, DOI 10.1016/j.neurobiolaging.2007.03.005	58	21	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2017	292	30					12713	12724		10.1074/jbc.M117.777839	http://dx.doi.org/10.1074/jbc.M117.777839			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC1ZM	28623233	hybrid, Green Published			2023-01-03	WOS:000406636900034
J	Fizazi, K; Tran, N; Fein, L; Matsubara, N; Rodriguez-Antolin, A; Alekseev, BY; Ozguroglu, M; Ye, DW; Feyerabend, S; Protheroe, A; De Porre, P; Kheoh, T; Park, YC; Todd, MB; Chi, KN				Fizazi, Karim; NamPhuong Tran; Fein, Luis; Matsubara, Nobuaki; Rodriguez-Antolin, Alfredo; Alekseev, Boris Y.; Ozguroglu, Mustafa; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; De Porre, Peter; Kheoh, Thian; Park, Youn C.; Todd, Mary B.; Chi, Kim N.		LATITUDE Investigators	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN-DEPRIVATION THERAPY; PLACEBO-CONTROLLED PHASE-3; LEUPROLIDE ACETATE; SURVIVAL ANALYSIS; CLINICAL-TRIALS; DOUBLE-BLIND; CHEMOTHERAPY; DOCETAXEL; RECOMMENDATIONS; NEOADJUVANT	BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival. RESULTS After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median overall survival was significantly longer in the abiraterone group than in the placebo group (not reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P<0.001). The median length of radiographic progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). Significantly better outcomes in all secondary end points were observed in the abiraterone group, including the time until pain progression, next subsequent therapy for prostate cancer, initiation of chemotherapy, and prostate-specific antigen progression (P<0.001 for all comparisons), along with next symptomatic skeletal events (P=0.009). These findings led to the unanimous recommendation by the independent data and safety monitoring committee that the trial be unblinded and crossover be allowed for patients in the placebo group to receive abiraterone. Rates of grade 3 hypertension and hypokalemia were higher in the abiraterone group. CONCLUSIONS The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, metastatic, castration-sensitive prostate cancer.	[Fizazi, Karim] Univ Paris Sud, Gustave Roussy, Villejuif, France; [NamPhuong Tran] Janssen Res & Dev, Los Angeles, CA USA; [De Porre, Peter] Janssen Res & Dev, Beerse, Belgium; [Kheoh, Thian] Janssen Res & Dev, San Diego, CA USA; [Park, Youn C.] Janssen Res & Dev, Raritan, NJ USA; [Fein, Luis] Inst Oncol Rosario, Rosario, Santa Fe, Argentina; [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Chiba, Japan; [Rodriguez-Antolin, Alfredo] 12 Octubre Univ Hosp, Madrid, Spain; [Alekseev, Boris Y.] PA Hertsen Moscow Canc Res Inst, Moscow, Russia; [Ozguroglu, Mustafa] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey; [Ye, Dingwei] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Feyerabend, Susan] Studienpraxis Urol, Nurtingen, Germany; [Protheroe, Andrew] Oxford Univ Hosp Fdn NHS Trust, Oxford, England; [Todd, Mary B.] Janssen Global Serv, Raritan, NJ USA; [Chi, Kim N.] BC Canc Agcy, Vancouver, BC, Canada	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; National Cancer Center - Japan; Hospital Universitario 12 de Octubre; Istanbul University; Istanbul University - Cerrahpasa; Fudan University; Oxford University Hospitals NHS Foundation Trust; British Columbia Cancer Agency	Fizazi, K (corresponding author), Univ Paris Sud, Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94800 Villejuif, France.	karim.fizazi@gustaveroussy.fr	Pavlik, Ivan/O-5730-2017; Alekseev, Boris/O-1008-2017; Facchini, Gaetano/P-4491-2015; MUSTAFA, ÖZGÜROĞLU/A-8234-2016; Basso, Umberto/F-4229-2014; VILLERS, Arnauld/K-6629-2016; Vaarala, Markku/B-4116-2013; Volovat, Constantin/N-6580-2013	Pavlik, Ivan/0000-0001-5506-9783; Alekseev, Boris/0000-0002-3398-4128; Facchini, Gaetano/0000-0002-7430-001X; MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628; Basso, Umberto/0000-0002-5075-2177; VILLERS, Arnauld/0000-0002-6298-7758; Vaarala, Markku/0000-0003-4735-815X; Volovat, Constantin/0000-0003-1582-0135; Fradet, Yves/0000-0002-7581-2500	Janssen Research and Development	Janssen Research and Development	Funded by Janssen Research and Development; LATITUDE ClinicalTrials.gov number, NCT01715285.	Amit O, 2011, EUR J CANCER, V47, P1772, DOI 10.1016/j.ejca.2011.02.013; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960-0760(94)90131-7; Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002; Dalesio O, 2000, LANCET, V355, P1491; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Efstathiou E, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.5005; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Fizazi K, 2015, ANN ONCOL, V26, P1660, DOI 10.1093/annonc/mdv245; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257; Glass TR, 2003, J UROLOGY, V169, P164, DOI 10.1016/S0022-5347(05)64059-1; Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005; Gravis G, 2015, EUR UROL, V68, P196, DOI 10.1016/j.eururo.2014.09.022; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032; Li ZF, 2015, NATURE, V523, P347, DOI 10.1038/nature14406; Millikan RE, 2008, J CLIN ONCOL, V26, P5936, DOI 10.1200/JCO.2007.15.9830; O'Donnell A, 2004, BRIT J CANCER, V90, P2317, DOI 10.1038/sj.bjc.6601879; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Rathkopf DE, 2014, EUR UROL, V66, P815, DOI 10.1016/j.eururo.2014.02.056; Reese DM, 2000, LANCET, V355, P1474, DOI 10.1016/S0140-6736(00)02155-3; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scosyrev E, 2012, CANCER-AM CANCER SOC, V118, P3062, DOI 10.1002/cncr.26392; Sweeney C., 2016, ANN ONCOL S, V27, pvi243; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tangen Catherine M, 2003, Clin Prostate Cancer, V2, P41, DOI 10.3816/CGC.2003.n.011; Taplin ME, 2014, J CLIN ONCOL, V32, P3705, DOI 10.1200/JCO.2013.53.4578; Weiner AB, 2016, PROSTATE CANCER P D, V19, P395, DOI 10.1038/pcan.2016.30; Yamaoka M, 2010, CLIN CANCER RES, V16, P4319, DOI 10.1158/1078-0432.CCR-10-0255	34	1158	1177	2	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2017	377	4					352	360		10.1056/NEJMoa1704174	http://dx.doi.org/10.1056/NEJMoa1704174			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BB	28578607	Bronze, Green Published			2023-01-03	WOS:000406295000007
J	Volkow, ND; Collins, FS				Volkow, Nora D.; Collins, Francis S.			The Role of Science in Addressing the Opioid Crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									[Volkow, Nora D.] NIDA, Bethesda, MD 20892 USA; [Collins, Francis S.] NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA	Volkow, ND (corresponding author), NIDA, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; Eon V, 2015, FASEB J S6, V29, P415; Guedon JMG, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0018-1; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Kwilasz AJ, 2015, NEUROPHARMACOLOGY, V96, P55, DOI 10.1016/j.neuropharm.2014.10.020; Mulcahy JV, 2016, DEV SELECTIVE INHIBI; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Tomassoni AJ, 2017, MMWR-MORBID MORTAL W, V66, P107, DOI 10.15585/mm6604a4; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780	10	317	321	2	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2017	377	4					391	394		10.1056/NEJMsr1706626	http://dx.doi.org/10.1056/NEJMsr1706626			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BB	28564549	Bronze			2023-01-03	WOS:000406295000015
J	Lee, MJ; Park, JT; Han, SH; Kim, YL; Kim, YS; Yang, CW; Kim, NH; Kang, SW; Kim, HJ; Yoo, TH				Lee, Mi Jung; Park, Jung Tak; Han, Seung Hyeok; Kim, Yong-Lim; Kim, Yon Su; Yang, Chul Woo; Kim, Nam-Ho; Kang, Shin-Wook; Kim, Hyung Jong; Yoo, Tae-Hyun			The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea	PLOS ONE			English	Article							HIGH-DENSITY-LIPOPROTEIN; STAGE RENAL-DISEASE; CHOLESTEROL RATIO; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR EVENTS; PERITONEAL-DIALYSIS; MAINTENANCE HEMODIALYSIS; MYOCARDIAL-INFARCTION; HDL-CHOLESTEROL; ASSOCIATION	Background The atherogenic index of plasma (AIP), which is the logarithmic ratio of triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C), had a linear relationship with clinical outcomes in the general population. However, the association of each lipid profile, TG and HDL-C, with survival was not straightforward in dialysis patients. This non-linear association led us to further investigate the prognostic impact of the AIP in these patients. Methods From a nationwide prospective cohort, 1,174 incident dialysis patients were included. Patients were categorized into quintiles according to the AIP. An independent association of the AIP with all-cause and cardiovascular mortality was determined. Results During a mean follow-up duration of 33.2 months, 170 patients (14.5%) died, and cardiovascular death was observed in 55 patients (4.7%). Multivariate Cox analyses revealed that the lowest (quintile 1, hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.02-3.03) and the highest (quintile 5, HR = 2.15, 95% CI = 1.26-3.65) AIP groups were significantly associated with higher all-cause mortality compared to patients in quintile 3 (reference group). In terms of cardiovascular mortality, only the highest AIP group (quintile 5, HR = 2.59, 95% CI = 1.06-6.34) was significantly associated with increased risk of mortality. Sensitivity analyses showed that a U-shaped association between the AIP and all-cause mortality remained significant in non-diabetic and underweight to normal body mass index patients. Conclusions Both the highest and the lowest AIP groups were independently associated with all-cause mortality, showing a U-shaped association. It suggested further studies are needed to identify targets and subgroups that can benefit from intervention of the AIP in incident dialysis patients.	[Lee, Mi Jung; Kim, Hyung Jong] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Seongnam, South Korea; [Park, Jung Tak; Han, Seung Hyeok; Kang, Shin-Wook; Yoo, Tae-Hyun] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Kim, Yong-Lim; Kim, Yon Su; Yang, Chul Woo; Kim, Nam-Ho; Kang, Shin-Wook] Clin Res Ctr End Stage Renal Dis, Daegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Med Sch, Dept Internal Med, Gwangju, South Korea	Pochon Cha University; Yonsei University; Yonsei University Health System; Kyungpook National University; Seoul National University (SNU); Catholic University of Korea; Chonnam National University	Kim, HJ (corresponding author), CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Seongnam, South Korea.; Yoo, TH (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	khj04@cha.ac.kr; yoosy0316@yush.ac	Han, Seung Hyeok/K-4559-2018; Han, Seung Hyeok/W-8825-2019	Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; Yoo, Tae-Hyun/0000-0002-9183-4507; Kang, Shin-Wook/0000-0002-5677-4756; Park, Jung Tak/0000-0002-2325-8982; Lee, Mi Jung/0000-0001-8888-029X	Brain Korea 21 PLUS Project for Medical Science, Yonsei University; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [NRF-2011-0030711]; Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HC15C1129]	Brain Korea 21 PLUS Project for Medical Science, Yonsei University; National Research Foundation of Korea (NRF) grant - Korea government (MEST); Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This work was supported by the Brain Korea 21 PLUS Project for Medical Science, Yonsei University, by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. NRF-2011-0030711), and by a grant of the Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HC15C1129). Clinical research center for end stage renal disease received the funding, and the leader of the center is YLK. The "Ministry of Health and Welfare URL is: http://www.mw.go.kr/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Bittner V, 2009, AM HEART J, V157, P548, DOI 10.1016/j.ahj.2008.11.014; Chen HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000619; Dobiasova M, 2001, CLIN BIOCHEM, V34, P583, DOI 10.1016/S0009-9120(01)00263-6; Eeg-Olofsson K, 2014, DIABETES RES CLIN PR, V106, P136, DOI 10.1016/j.diabres.2014.07.010; Erdur MF, 2013, RENAL FAILURE, V35, P1193, DOI 10.3109/0886022X.2013.823826; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; Habib AN, 2006, NEPHROL DIAL TRANSPL, V21, P2881, DOI 10.1093/ndt/gfl272; Hermans MP, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-132; Hermans MP, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-88; Honda H, 2012, ATHEROSCLEROSIS, V220, P493, DOI 10.1016/j.atherosclerosis.2011.10.038; Jin DC, 2015, KIDNEY RES CLIN PRAC, V34, P132, DOI 10.1016/j.krcp.2015.08.004; Kilpatrick RD, 2007, J AM SOC NEPHROL, V18, P293, DOI 10.1681/ASN.2006070795; McLaughlin T, 2005, AM J CARDIOL, V96, P399, DOI 10.1016/j.amjcard.2005.03.085; Moradi H, 2014, NEPHROL DIAL TRANSPL, V29, P1554, DOI 10.1093/ndt/gfu022; Moradi H, 2013, J RENAL NUTR, V23, P203, DOI 10.1053/j.jrn.2013.01.022; Onat A, 2010, J CLIN LIPIDOL, V4, P89, DOI 10.1016/j.jacl.2010.02.005; Postorino M, 2011, KIDNEY INT, V79, P765, DOI 10.1038/ki.2010.493; Silbernagel G, 2015, J AM SOC NEPHROL, V26, P484, DOI 10.1681/ASN.2013080816; Sirimarco G, 2014, STROKE, V45, P1429, DOI 10.1161/STROKEAHA.113.004229; Turak O, 2016, J CLIN HYPERTENS, V18, P772, DOI 10.1111/jch.12758; Vaziri ND, 2009, KIDNEY INT, V76, P437, DOI 10.1038/ki.2009.177; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Weichhart T, 2012, J AM SOC NEPHROL, V23, P934, DOI 10.1681/ASN.2011070668; Wu H, 2015, NUTR METAB CARDIOVAS, V25, P749, DOI 10.1016/j.numecd.2015.05.006; Yamamoto S, 2012, J AM COLL CARDIOL, V60, P2372, DOI 10.1016/j.jacc.2012.09.013; Yildiz G, 2013, HEMODIAL INT, V17, P397, DOI 10.1111/hdi.12041; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	30	32	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2017	12	5							e0177499	10.1371/journal.pone.0177499	http://dx.doi.org/10.1371/journal.pone.0177499			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VT	28549070	Green Published, gold, Green Submitted			2023-01-03	WOS:000402063000007
J	Steinberg, D; Bennett, GG; Svetkey, L				Steinberg, Dori; Bennett, Gary G.; Svetkey, Laura			The DASH Diet, 20 Years Later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BLOOD-PRESSURE; HEART-DISEASE; HYPERTENSION; TRIAL		[Steinberg, Dori; Bennett, Gary G.] Duke Univ, Duke Global Hlth Inst, Duke Global Digital Hlth Sci Ctr, 310 Trent Dr,POB 90519, Durham, NC 27708 USA; [Bennett, Gary G.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA; [Svetkey, Laura] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Steinberg, D (corresponding author), Duke Univ, Duke Global Hlth Inst, Duke Global Digital Hlth Sci Ctr, 310 Trent Dr,POB 90519, Durham, NC 27708 USA.	dori.steinberg@duke.edu		Steinberg, Dori/0000-0001-7588-4216	National Institutes of Health [K12HD043446]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043446] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Dr Steinberg was supported by the Building Interdisciplinary Research Careers in Women's Health Career Development Award K12HD043446 from the National Institutes of Health.	Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Bell RA, 2008, PATIENT EDUC COUNS, V72, P115, DOI 10.1016/j.pec.2008.01.021; Burke LE, 2012, AM J PREV MED, V43, P20, DOI 10.1016/j.amepre.2012.03.016; Erlinger TP, 2003, PREV MED, V37, P327, DOI 10.1016/S0091-7435(03)00140-3; James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Kim Hyun, 2016, Prev Med Rep, V4, P525; Mellen PB, 2008, ARCH INTERN MED, V168, P308, DOI 10.1001/archinternmed.2007.119; Mozaffarian D, 2016, CIRCULATION, V133, P447, DOI 10.1161/CIR.0000000000000366; Pew Research Center, MOB FACT SHEET; Young CM, 2008, J CLIN HYPERTENS, V10, P603, DOI 10.1111/j.1751-7176.2008.08199.x	10	53	55	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2017	317	15					1529	1530		10.1001/jama.2017.1628	http://dx.doi.org/10.1001/jama.2017.1628			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ES2YN	28278326	Green Accepted			2023-01-03	WOS:000399393900010
J	Tessema, RA				Tessema, Roba Argaw			Assessment of the implementation of community-led total sanitation, hygiene, and associated factors in Diretiyara district, Eastern Ethiopia	PLOS ONE			English	Article								Based on the sustainable development goals, the United Nations plans to achieve equitable sanitation and hygiene for all and to end open defecation by 2030. In Ethiopia, 60% to 80% of health problems are due to communicable diseases attributable to unsafe water supply, unhygienic and unsanitary waste management, which are directly linked to the practice of open defecation. This study has aimed at assessing the implementation of community-led total sanitation and hygiene (CLTSH) and associated factors. A community-based cross-sectional study design involving 420 of the 7,225 households found in Diretiyara district was conducted in June 2014. Both quantitative and qualitative data were collected. Using Logistic Regressions, bivariate and multivariate analyses were computed. This study showed that 66% of the respondents have knowledge of CLTSH. Eighty-nine percent of the respondents have latrine, of which 78% were constructed after the introduction of CLTSH. Eleven percent of the respondents reported to have defected in the open field and 15% of them reported that they had been recently exposed to diarrhea diseases. The occurrence of diarrheal disease was significantly associated with the extent of latrine ownership [AOR = 2.48; 95% CI 1.00, 6.12]. Attitude and perception parameters were significantly associated with consistent latrine utilization. Respondents who agreed that "Open defecation is preferred due to the unpleasant smell and heat from the Latrine'' [COR = 0.58; 95% CI 0.34, 0.99] were 58% less likely to use the latrine consistently. In conclusion, CLTSH has increased the extent of latrine ownership and decreased practice of open defecation, and yet, intermittent latrine use and poor hygienic practice were reported. Although some fundamental misconceptions were reported, the majority of the respondents have accepted CLTSH approach as a means to ending open defecation in their village. Health extension workers and local authorities should give emphasis to achieving sustainable behavioral change on improved sanitation and good hygiene practices.	[Tessema, Roba Argaw] Haramaya Univ, Dept Environm Hlth Sci, Coll Hlth & Med Sci, Dire Dawa, Ethiopia	Haramaya University	Tessema, RA (corresponding author), Haramaya Univ, Dept Environm Hlth Sci, Coll Hlth & Med Sci, Dire Dawa, Ethiopia.	robaargaw@gmail.com	Te, Roba A/I-3383-2019	Te, Roba A/0000-0001-8734-4030	HARAMAYA UNIVERSITY	HARAMAYA UNIVERSITY	This work was supported by HARAMAYA UNIVERSITY, email:haramaya.univ@ethio.net.	Araya M, 2016, UNICEF ETHIOPIA LEAD; Ayalew D, 2008, TROP MED INT HEALTH, V13, P472, DOI 10.1111/j.1365-3156.2008.02024.x; Azage M, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0090-z; Bongartz P, 2016, SUSTAINABLE SANITATI; David D, 2015, UN SUMMIT ADOPTION P; Department for International Development, 2013, WAT SAN HYG; Department for International Development, POL PAP 2010 2015 GO; Eshete N, 2015, SCI J PUBLIC HLTH, V3, P669, DOI DOI 10.11648/j.sjph.20150305.22; Federal Democratic Republic of Ethiopia Ministry of Health (FDREMOH), 2011, NAT DRINK WAT QUAL M; Federal Ministry of Health (FMOH), 2014, HLTH HLTH REL IND VE, p14p; FMoH, 2011, HLTH HLTH REL IND; Gonzalez AH, 2013, PATHWAYS SUSTAINABIL; Harari Regional Health Bureau, 2011, ANN REPORT; Kedir AA, 2015, ABC RES ALERT 2015, V3, P2; Leonie K., 2011, OPPORTUNITIES CONSTR; Maria LA, 2015, FINAL REPORT IMPACT; Nucleus Research P.L.C. African Medical and Research Foundation in Ethiopia, 2011, AFR MED RES FDN ETH; Plan UNC Water Institute, 2015, TEST CLTS APPR SCAL; Pruss-Ustun A., 2008, SAFER WATER BETTER H; Robert Ch, 2009, GOING SCALE COMMUNIT; Sah S., 2009, DESALINATION, P1; Samuel G, 2016, UNICEF ETHIOPIA BABY; Thewodros B., 2016, INT J ENV AGRI BIOTE, V1, P1; UNICEF; WHO, 2015, WHO 25 YEARS PROGR S; Woldu W, 2016, TROP MED HEALTH, V44, DOI 10.1186/s41182-016-0040-7	25	20	21	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2017	12	4							e0175233	10.1371/journal.pone.0175233	http://dx.doi.org/10.1371/journal.pone.0175233			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MB	28407003	Green Published, Green Submitted, gold			2023-01-03	WOS:000399955400035
J	Curbelo, J; Bueno, SL; Galvan-Roman, JM; Ortega-Gomez, M; Rajas, O; Fernandez-Jimenez, G; Vega-Piris, L; Rodriguez-Salvanes, F; Arnalich, B; Diaz, A; Costa, R; de la Fuente, H; Lancho, A; Suarez, C; Ancochea, J; Aspa, J				Curbelo, Jose; Luquero Bueno, Sergio; Maria Galvan-Roman, Jose; Ortega-Gomez, Mara; Rajas, Olga; Fernandez-Jimenez, Guillermo; Vega-Piris, Lorena; Rodriguez-Salvanes, Francisco; Arnalich, Belen; Diaz, Ana; Costa, Ramon; de la Fuente, Hortensia; Lancho, Angel; Suarez, Carmen; Ancochea, Julio; Aspa, Javier			Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio	PLOS ONE			English	Article							LONG-TERM MORTALITY; PRO-ADRENOMEDULLIN; SEVERITY; PROADRENOMEDULLIN; SURVIVAL; HOSPITALIZATION; METAANALYSIS; ASSOCIATION; RESECTION; OUTCOMES	Introduction The increase and persistence of inflammation in community-acquired pneumonia (CAP) patients can lead to higher mortality. Biomarkers capable of measuring this inadequate inflammatory response are likely candidates to be related with a bad outcome. We investigated the association between concentrations of several inflammatory markers and mortality of CAP patients. Material and methods This was a prospective study of hospitalised CAP patients in a Spanish university hospital. Blood tests upon admittance and in the early-stage evolution (72-120 hours) were carried out, where C-reactive protein, procalcitonin, proadrenomedullin, copeptin, white blood cell, Lymphocyte Count Percentage (LCP), Neutrophil Count Percentage (NCP) and Neutrophil/Lymphocyte Ratio (NLR) were measured. The outcome variable was mortality at 30 and 90 days. Statistical analysis included logistic regression, ROC analysis and area-under-curve test. Results 154 hospitalised CAP patients were included. Patients who died during follow-up had higher levels of procalcitonin, copeptin, proadrenomedullin, lower levels of LCP, and higher of NCP and NLR. Remarkably, multivariate analysis showed a relationship between NCP and mortality, regardless of age, severity of CAP and comorbidities. AUC analysis showed that NLR and NCP at admittance and during early-stage evolution achieved a good diagnostic power. ROC test for NCP and NLR were similar to those of the novel serum biomarkers analysed. Conclusions NLR and NCP, are promising candidate predictors of mortality for hospitalised CAP patients, and both are cheaper, easier to perform, and at least as reliable as the new serum biomarkers. Future implementation of new biomarkers would require comparison not only with classic inflammatory parameters like White Blood Cell count but also with NLR and NCP.	[Curbelo, Jose; Costa, Ramon; Suarez, Carmen] Hosp Univ La Princesa, Inst Invest Sanitaria, Dept Internal Med, Madrid, Spain; [Luquero Bueno, Sergio; Ortega-Gomez, Mara] Hosp Univ La Princesa, Inst Invest Sanitaria, Biobank, Madrid, Spain; [Maria Galvan-Roman, Jose; de la Fuente, Hortensia; Lancho, Angel] Hosp Univ La Princesa, Inst Invest Sanitaria, Dept Immunol, Madrid, Spain; [Rajas, Olga; Ancochea, Julio; Aspa, Javier] Hosp Univ La Princesa, Inst Invest Sanitaria, Dept Pneumol, Madrid, Spain; [Fernandez-Jimenez, Guillermo] Hosp Univ La Princesa, Inst Invest Sanitaria, Clin Informat Unit, Madrid, Spain; [Vega-Piris, Lorena; Rodriguez-Salvanes, Francisco] Hosp Univ La Princesa, Inst Invest Sanitaria, Methodol Unit, Madrid, Spain; [Arnalich, Belen] Hosp Henares, Dept Pneumol, Madrid, Spain; [Diaz, Ana] Hosp Univ La Princesa, Inst Invest Sanitaria, Dept Clin Anal, Madrid, Spain		Aspa, J (corresponding author), Hosp Univ La Princesa, Inst Invest Sanitaria, Dept Pneumol, Madrid, Spain.	jaspa@separ.es	de la Fuente, Hortensia/J-9890-2014; Lancho Sanchez, Angel/AFT-9963-2022	de la Fuente, Hortensia/0000-0001-8708-753X; Lancho Sanchez, Angel/0000-0001-7962-6038; Curbelo, Jose/0000-0002-0809-9944; Galvan Roman, Jose Maria/0000-0001-9260-8141; Ancochea, julio/0000-0001-7451-4133; Ortega, Mara/0000-0003-3059-0147; Luquero-Bueno, Sergio/0000-0003-4517-4082	Institute de Salud Carlos III (ES) - European Regional Development Fund [PI 12/01142, PI 15/01231]; Spanish Respiratory Society - SEPAR	Institute de Salud Carlos III (ES) - European Regional Development Fund; Spanish Respiratory Society - SEPAR	This work was funded by the Institute de Salud Carlos III (ES) - European Regional Development Fund - PI 12/01142 and PI 15/01231; and Spanish Respiratory Society - SEPAR 2013.	Adamuz J, 2014, J INFECTION, V68, P534, DOI 10.1016/j.jinf.2014.02.006; Albrich WC, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-112; Bello S, 2015, RESP MED, V109, P1193, DOI 10.1016/j.rmed.2015.07.003; Bozbay M, 2015, J CRIT CARE, V30, P822, DOI 10.1016/j.jcrc.2015.04.115; BRANCATI FL, 1993, LANCET, V342, P30, DOI 10.1016/0140-6736(93)91887-R; Cavallazzi R, 2014, RESP MED, V108, P1569, DOI 10.1016/j.rmed.2014.09.018; Chalmers JD, 2010, THORAX, V65, P878, DOI 10.1136/thx.2009.133280; Christ-Crain M, 2006, CRIT CARE, V10, DOI 10.1186/cc4955; Courtais C, 2013, AM J EMERG MED, V31, P215, DOI 10.1016/j.ajem.2012.07.017; de Jager CPC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046561; Espana PP, 2015, J INFECTION, V70, P457, DOI 10.1016/j.jinf.2014.12.003; Yandiola PPE, 2009, CHEST, V135, P1572, DOI 10.1378/chest.08-2179; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Halazun KJ, 2008, EJSO-EUR J SURG ONC, V34, P55, DOI 10.1016/j.ejso.2007.02.014; Han Song Yi, 2016, Korean J Pediatr, V59, P139, DOI 10.3345/kjp.2016.59.3.139; Huang DT, 2009, CHEST, V136, P823, DOI 10.1378/chest.08-1981; Kolditz M, 2012, RESP MED, V106, P1320, DOI 10.1016/j.rmed.2012.06.008; Kruger S, 2010, AM J RESP CRIT CARE, V182, P1426, DOI 10.1164/rccm.201003-0415OC; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; National Institute for Health and Care Excellence (NICE), 2015, GUID GUID; Rajas O, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-197; Sarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046; Schuetz P, 2011, EUR RESPIR J, V37, P384, DOI 10.1183/09031936.00035610; SOLOMON CG, 2014, NEW ENGL J MED, V370, P543; Viasus D, 2016, J INFECTION, V72, P273, DOI 10.1016/j.jinf.2016.01.002; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x; Zhydkov A, 2015, CLIN CHEM LAB MED CC, V53	28	78	83	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173947	10.1371/journal.pone.0173947	http://dx.doi.org/10.1371/journal.pone.0173947			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301543	Green Published, Green Submitted, gold			2023-01-03	WOS:000396318300100
J	Gan, S; Zakaria, S; Chia, CH; Chen, RS; Ellis, AV; Kaco, H				Gan, Sinyee; Zakaria, Sarani; Chia, Chin Hua; Chen, Ruey Shan; Ellis, Amanda V.; Kaco, Hatika			Highly porous regenerated cellulose hydrogel and aerogel prepared from hydrothermal synthesized cellulose carbamate	PLOS ONE			English	Article								Here, a stable derivative of cellulose, called cellulose carbamate (CC), was produced from Kenaf (Hibiscus cannabinus) core pulp (KCP) and urea with the aid of a hydrothermal method. Further investigation was carried out for the amount of nitrogen yielded in CC as different urea concentrations were applied to react with cellulose. The effect of nitrogen concentration of CC on its solubility in a urea-alkaline system was also studied. Regenerated cellulose products (hydrogels and aerogels) were fabricated through the rapid dissolution of CC in a urea-alkaline system. The morphology of the regenerated cellulose products was viewed under Field emission scanning electron microscope (FESEM). The transformation of allomorphs in regenerated cellulose products was examined by X-ray diffraction (XRD). The transparency of regenerated cellulose products was determined by Ultraviolet-visible (UV-Vis) spectrophotometer. The degree of swelling (DS) of regenerated cellulose products was also evaluated. This investigation provides a simple and efficient procedure of CC determination which is useful in producing regenerated CC products.	[Gan, Sinyee; Zakaria, Sarani; Chia, Chin Hua; Chen, Ruey Shan; Kaco, Hatika] Univ Kebangsaan Malaysia, Sch Appl Phys, Fac Sci & Technol, Bangi, Selangor, Malaysia; [Ellis, Amanda V.] Univ Melbourne, Dept Chem Engn, Parkville, Vic, Australia	Universiti Kebangsaan Malaysia; University of Melbourne	Gan, S; Zakaria, S (corresponding author), Univ Kebangsaan Malaysia, Sch Appl Phys, Fac Sci & Technol, Bangi, Selangor, Malaysia.	gansinyee@ukm.edu.my; szakaria@ukm.edu.my	Chia, Chin-hua/I-7261-2013; YEE, GAN SIN/Q-6347-2018; Ellis, Amanda V/AAD-3450-2019; zakaria, sarani/D-6099-2018; Chen, Ruey Shan/C-7376-2017	Chia, Chin-hua/0000-0002-5269-4070; YEE, GAN SIN/0000-0003-2411-4611; Ellis, Amanda V/0000-0002-0053-5641; Chen, Ruey Shan/0000-0002-2713-942X; Zakaria, Sarani/0000-0002-5981-0986	Universiti Kebangsaan Malaysia (UKM) [AP-2015-005, DIP-2016-004, LRGS/TD/2012/USM-UKM/PT/04]; Ministry of Higher Education Malaysia	Universiti Kebangsaan Malaysia (UKM); Ministry of Higher Education Malaysia(Ministry of Education, Malaysia)	The authors thank Universiti Kebangsaan Malaysia (UKM) for the financial support via the research Project Grants AP-2015-005, DIP-2016-004, LRGS/TD/2012/USM-UKM/PT/04 and the Ministry of Higher Education Malaysia for MyBrain15-MyMaster Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Universiti Kebangsaan Malaysia (UKM) for the financial support via the research Project Grants AP-2015-005, DIP-2016-004, LRGS/TD/2012/USM-UKM/PT/04 and the Ministry of Higher Education Malaysia for MyBrainl5-MyMaster Scholarship. The authors are also thankful to the Centre for Research and Instrumentation Management (CRIM) at UKM for providing the XRD and FESEM testing.	Ahmed EM., 2013, J ADV RES, P17; Cai J, 2008, CHEMSUSCHEM, V1, P149, DOI 10.1002/cssc.200700039; Chang CY, 2011, CARBOHYD POLYM, V84, P40, DOI 10.1016/j.carbpol.2010.12.023; Chang CY, 2009, POLYMER, V50, P5467, DOI 10.1016/j.polymer.2009.06.001; Ding ZD, 2012, CARBOHYD POLYM, V89, P7, DOI 10.1016/j.carbpol.2012.01.080; Dong H, 2013, CARBOHYD POLYM, V95, P760, DOI 10.1016/j.carbpol.2013.03.041; Eichhorn SJ, 2001, J MATER SCI, V36, P2107, DOI 10.1023/A:1017512029696; Fu FY, 2015, ACS SUSTAIN CHEM ENG, V3, P1510, DOI 10.1021/acssuschemeng.5b00219; Fu YJ, 2017, BIORESOURCES, V12, P992, DOI 10.15376/biores.12.1.992-1006; Gan S, 2016, BIORESOURCES, V11, P126; Gan S, 2015, CELLULOSE, V22, P3851, DOI 10.1007/s10570-015-0749-1; Gan S, 2015, BIORESOURCES, V10, P2244, DOI 10.15376/biores.10.2.2244-2255; Gan S, 2014, CARBOHYD POLYM, V106, P160, DOI 10.1016/j.carbpol.2014.01.076; Ganji F, 2010, IRAN POLYM J, V19, P375; Glasser W. G., 2008, TOP CURR CHEM, V1473; Guo Y, 2010, CELLULOSE, V17, P1115, DOI 10.1007/s10570-010-9446-2; Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587; Klemm D., 2005, CELLULOSE BIOPOLYMER; Kotek R., 2006, HDB FIBER CHEM, P668; Ma AAMA, 2000, POLYM DEGRAD STABIL, V70, P347; OLSSON C, 2013, CELLULOSE FUNDAMENTA; Padzil FNM, 2015, CARBOHYD POLYM, V124, P164, DOI 10.1016/j.carbpol.2015.02.013; Paunonen S., 2013, STRENGTH BARRIER ENH; Pinnow M, 2008, MACROMOL SYMP, V262, P129, DOI 10.1002/masy.200850213; Qiu XY, 2013, MATERIALS, V6, P738, DOI 10.3390/ma6030738; Shen XD, 2005, POLYM BULL, V55, P317, DOI 10.1007/s00289-005-0442-x; Vo LTT, 2010, CARBOHYD POLYM, V82, P1191, DOI 10.1016/j.carbpol.2010.06.052; Wang Y, 2008, CELLULOSE FIBER DISS; Wong SS, 2009, CARBOHYD POLYM, V77, P280, DOI 10.1016/j.carbpol.2008.12.038; Yin CY, 2007, EUR POLYM J, V43, P2111, DOI 10.1016/j.eurpolymj.2007.01.041; Yin CY, 2007, CARBOHYD POLYM, V67, P147, DOI 10.1016/j.carbpol.2006.05.010; Zhang JX, 2010, CARBOHYD POLYM, V79, P164, DOI 10.1016/j.carbpol.2009.07.038	32	32	33	6	76	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2017	12	3							e0173743	10.1371/journal.pone.0173743	http://dx.doi.org/10.1371/journal.pone.0173743			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9HQ	28296977	gold, Green Published			2023-01-03	WOS:000396311700054
J	Hu, ZZ; Zhu, FM; Zhang, N; Zhang, CX; Pei, GC; Wang, PG; Yang, J; Guo, YJ; Wang, M; Wang, YX; Yang, Q; Zhu, H; Liao, WH; Zhang, ZG; Yao, Y; Zeng, R; Xu, G				Hu, Zhizhi; Zhu, Fengmin; Zhang, Nan; Zhang, Chunxiu; Pei, Guangchang; Wang, Pengge; Yang, Juan; Guo, Yujiao; Wang, Meng; Wang, Yuxi; Yang, Qian; Zhu, Han; Liao, Wenhui; Zhang, Zhiguo; Yao, Ying; Zeng, Rui; Xu, Gang			Impact of arteriovenous fistula blood flow on serum il-6, cardiovascular events and death: An ambispective cohort analysis of 64 Chinese hemodialysis patients	PLOS ONE			English	Article							C-REACTIVE PROTEIN; INTERLEUKIN-6 LEVELS; MICROINFLAMMATORY STATE; VASCULAR ACCESS; RENAL-DISEASE; MORTALITY; MALNUTRITION; PREDICTOR; INFLAMMATION; ALBUMIN	Flows (Qa) of arteriovenous fistula (AVF) impact the dialysis adequacy in hemodialysis (HD) patients. However, data for different access flow levels on outcomes related to long-term dialysis patients, especially in Chinese patients, are limited. Herein, we performed an ambispective, mono-centric cohort study investigating the association between the AVF flows and inflammation, cardiovascular events and deaths in Chinese hemodialysis patients bearing a radio-cephalic fistula (AVF) from 2009 to 2015. Twenty-three patients (35.9%) developed at least one episode of cardiovascular disease (CVD) in two years after AVF creation. AVF Qa, IL-6 and hsCRP were significantly higher in patients with CVD than in patients without CVD. Multi-factorial binary logistic regression analysis found that the independent and strongest risk factor for CVD in HD patients was serum IL-6, which showed a positive association with AVF Qa levels in patients. Therefore, the linkage between AVF Qa tertiles and adverse clinical outcomes (cardiovascular events and mortality) was examined over a median follow-up of five years. IL-6 was significantly increased in the high AVF Qa (>1027.13 ml/min) group. Patients with median AVF Qa showed the lowest morbidity and mortality of CVD according to the AVF Qa tertiles, whereas higher Qa was associated with a higher risk of CVD, and lower AVF Qa (600 ml/min <= AVF Qa <821.12 ml/min) had a higher risk of non-CVD death. Therefore, keeping the AVF Qa at an optimal level (821.12 to 1027.13 ml/min) would benefit HD patients, improve long-term clinical outcomes and lower AVF-induced inflammation.	[Hu, Zhizhi; Zhu, Fengmin; Zhang, Nan; Zhang, Chunxiu; Pei, Guangchang; Wang, Pengge; Yang, Juan; Guo, Yujiao; Wang, Meng; Wang, Yuxi; Yang, Qian; Zhu, Han; Yao, Ying; Zeng, Rui; Xu, Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Div Nephrol, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Zhang, Nan] Jining Med Univ, Affiliated Hosp, Dept Nephrol, Jining, Shandong, Peoples R China; [Liao, Wenhui] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Geriatr, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Zhang, Zhiguo] Huazhong Univ Sci & Technol, Sch Med & Hlth Management, Tongji Med Coll, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology; Jining Medical University; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zeng, R; Xu, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Div Nephrol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.	zengrui@tjh.tjmu.edu.cn; xugang@tjh.tjmu.edu.cn	Zeng, RUI/AAF-7238-2019; Yang, Juan/ABF-4433-2021; Zeng, Rui/GRY-0646-2022	Zeng, Rui/0000-0003-1188-3198	National Natural Science Foundation of China [81270770, 81470948, 81270771, 81370798, 81170686]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (Grants 81270770, 81470948, 81270771, 81370798 and 81170686).	[Anonymous], 2001, AMERICAN JOURNAL OF, V37, pS137; Basile C, 2008, NEPHROL DIAL TRANSPL, V23, P282, DOI 10.1093/ndt/gfm549; BATAILLE R, 1992, ARTHRITIS RHEUM-US, V35, P982, DOI 10.1002/art.1780350824; Begin V, 2002, AM J KIDNEY DIS, V40, P1277, DOI 10.1053/ajkd.2002.36898; Bode AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034491; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Hoshi T, 2005, STROKE, V36, P768, DOI 10.1161/01.STR.0000158915.28329.51; Hua Jincheng, 2015, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V27, P354, DOI 10.3760/cma.j.issn.2095-4352.2015.05.007; Kaizu Y, 1998, AM J KIDNEY DIS, V31, P93, DOI 10.1053/ajkd.1998.v31.pm9428458; Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549, DOI 10.1681/ASN.V1271549; Kobayashi S, 2003, BIOCHEM BIOPH RES CO, V308, P306, DOI 10.1016/S0006-291X(03)01362-7; Korsheed S, 2009, HEMODIAL INT, V13, P505, DOI 10.1111/j.1542-4758.2009.00384.x; Lameire N, 2012, NEPHROL DIAL TRANSPL, V27, P3758, DOI 10.1093/ndt/gfs275; Langer S, 2011, MAGN RESON IMAGING, V29, P57, DOI 10.1016/j.mri.2010.07.010; Memoli B, 2002, AM J KIDNEY DIS, V39, P266, DOI 10.1053/ajkd.2002.30545; Neyra NR, 1998, KIDNEY INT, V54, P1714, DOI 10.1046/j.1523-1755.1998.00145.x; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; Panichi V, 2004, NEPHROL DIAL TRANSPL, V19, P1154, DOI 10.1093/ndt/gfh052; Pecoits-Filho R, 2002, NEPHROL DIAL TRANSPL, V17, P1684, DOI 10.1093/ndt/17.9.1684; Qureshi AR, 2002, J AM SOC NEPHROL, V13, pS28; Rao M, 2005, AM J KIDNEY DIS, V45, P324, DOI 10.1053/j.ajkd.2004.09.018; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Schomig M, 2000, BLOOD PURIFICAT, V18, P327, DOI 10.1159/000014457; Stenvinkel P, 2002, AM J KIDNEY DIS, V39, P274, DOI 10.1053/ajkd.2002.30546; Wollert K C, 2001, Heart Fail Rev, V6, P95; Yao Q, 2004, ASAIO J, V50, pLII, DOI 10.1097/01.MAT.0000147958.87989.EB; Yun KA, 2004, SCAND J CLIN LAB INV, V64, P223, DOI 10.1080/00365510410005749	29	5	6	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2017	12	3							e0172490	10.1371/journal.pone.0172490	http://dx.doi.org/10.1371/journal.pone.0172490			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5QM	28267753	gold, Green Published, Green Submitted			2023-01-03	WOS:000396060600052
J	Martinez-Gonzalez, MA; Estruch, R; Corella, D; Ros, E; Fito, M; Schwingshackl, L; Salas-Salvado, J				Martinez-Gonzalez, Miguel A.; Estruch, Ramon; Corella, Dolores; Ros, Emilio; Fito, Montse; Schwingshackl, Lukas; Salas-Salvado, Jordi			Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake	ANNALS OF INTERNAL MEDICINE			English	Letter									[Martinez-Gonzalez, Miguel A.] Univ Navarra, Pamplona, Spain; [Estruch, Ramon] Hosp Clin Barcelona, Barcelona, Spain; [Corella, Dolores] Univ Valencia, Valencia, Spain; [Ros, Emilio] Ctr Invest Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Fito, Montse] Inst Municipal Invest Med, Barcelona, Spain; [Schwingshackl, Lukas] German Inst Human Nutr, Potsdam, Germany; [Salas-Salvado, Jordi] Univ Rovira Virgili, Reus, Tarragona, Spain	University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; University of Valencia; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Universitat Rovira i Virgili	Martinez-Gonzalez, MA (corresponding author), Univ Navarra, Pamplona, Spain.		Estruch, Ramon/AAZ-3723-2020; Schwingshackl, Lukas/AAC-4119-2019; Salas-Salvado, Jordi/C-7229-2017; Martinez-Gonzalez, Miguel A./AAE-7669-2019	Schwingshackl, Lukas/0000-0003-3407-7594; Salas-Salvado, Jordi/0000-0003-2700-7459; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808				Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Martinez-Gonzalez MA, 2016, CURR OPIN CLIN NUTR, V19, P401, DOI 10.1097/MCO.0000000000000316; Schwingshackl L, 2015, J ACAD NUTR DIET, V115, P780, DOI 10.1016/j.jand.2014.12.009; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169	5	2	2	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					378	378		10.7326/L16-0589	http://dx.doi.org/10.7326/L16-0589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265657				2023-01-03	WOS:000396432800018
J	Cole, KP; Groh, JM; Johnson, MD; Burcham, CL; Campbell, BM; Diseroad, WD; Heller, MR; Howell, JR; Kallman, NJ; Koenig, TM; May, SA; Miller, RD; Mitchell, D; Myers, DP; Myers, SS; Phillips, JL; Polster, CS; White, TD; Cashman, J; Hurley, D; Moylan, R; Sheehan, P; Spencer, RD; Desmond, K; Desmond, P; Gowran, O				Cole, Kevin P.; Groh, Jennifer McClary; Johnson, Martin D.; Burcham, Christopher L.; Campbell, Bradley M.; Diseroad, William D.; Heller, Michael R.; Howell, John R.; Kallman, Neil J.; Koenig, Thomas M.; May, Scott A.; Miller, Richard D.; Mitchell, David; Myers, David P.; Myers, Steven S.; Phillips, Joseph L.; Polster, Christopher S.; White, Timothy D.; Cashman, Jim; Hurley, Declan; Moylan, Robert; Sheehan, Paul; Spencer, Richard D.; Desmond, Kenneth; Desmond, Paul; Gowran, Olivia			Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow CGMP conditions	SCIENCE			English	Article							PHARMACEUTICALS; PURIFICATION	Advances in drug potency and tailored therapeutics are promoting pharmaceutical manufacturing to transition from a traditional batch paradigm to more flexible continuous processing. Here we report the development of a multistep continuous-flow CGMP (current good manufacturing practices) process that produced 24 kilograms of prexasertib monolactate monohydrate suitable for use in human clinical trials. Eight continuous unit operations were conducted to produce the target at roughly 3 kilograms per day using small continuous reactors, extractors, evaporators, crystallizers, and filters in laboratory fume hoods. Success was enabled by advances in chemistry, engineering, analytical science, process modeling, and equipment design. Substantial technical and business drivers were identified, which merited the continuous process. The continuous process afforded improved performance and safety relative to batch processes and also improved containment of a highly potent compound.	[Cole, Kevin P.; Groh, Jennifer McClary; Johnson, Martin D.; Burcham, Christopher L.; Campbell, Bradley M.; Heller, Michael R.; Howell, John R.; Kallman, Neil J.; May, Scott A.; Miller, Richard D.; Mitchell, David; Myers, David P.; Myers, Steven S.; Phillips, Joseph L.; Polster, Christopher S.; White, Timothy D.] Eli Lilly & Co, Lilly Res Labs, Small Mol Design & Dev, Indianapolis, IN 46285 USA; [Diseroad, William D.] Eli Lilly & Co, Tech Serv Mfg Sci, Indianapolis, IN 46285 USA; [Koenig, Thomas M.] Eli Lilly & Co, Tech Serv Mfg Sci, Greenfield, IN 46140 USA; [Cashman, Jim] Eli Lilly & Co, Qual Assurance, Kinsale, Cork, Ireland; [Hurley, Declan; Moylan, Robert; Sheehan, Paul] Eli Lilly & Co, Tech Serv Mfg Sci, Kinsale, Cork, Ireland; [Spencer, Richard D.] Eli Lilly & Co, Proc Engn, Kinsale, Cork, Ireland; [Desmond, Kenneth; Desmond, Paul; Gowran, Olivia] Eli Lilly & Co, Qual Control, Kinsale, Cork, Ireland	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Cole, KP (corresponding author), Eli Lilly & Co, Lilly Res Labs, Small Mol Design & Dev, Indianapolis, IN 46285 USA.	k_cole@lilly.com	Burcham, Chris/AAX-6635-2020	Burcham, Chris/0000-0002-1251-4725; Polster, Christopher/0000-0003-3376-8561				Adamo A, 2016, SCIENCE, V352, P61, DOI 10.1126/science.aaf1337; [Anonymous], 2006, GUID IND QUAL SYST A; [Anonymous], 2016, IRISH TIMES; [Anonymous], 2015, NIACIN NIACINAMIDE C; Bogdan AR, 2009, ANGEW CHEM INT EDIT, V48, P8547, DOI 10.1002/anie.200903055; Cole KP, 2016, ORG PROCESS RES DEV, V20, P820, DOI 10.1021/acs.oprd.6b00030; Faanes A, 2003, IND ENG CHEM RES, V42, P2198, DOI 10.1021/ie020525v; Farouz F. S., 2011, U.S. Patent, Patent No. [20110144126 A1, 20110144126]; Farouz F. S., 2010, WO Patent, Patent No. [2010077758 A1, 2010077758]; Frederick MO, 2015, ORG PROCESS RES DEV, V19, P1411, DOI 10.1021/acs.oprd.5b00240; Gautam A, 2016, DRUG DISCOV TODAY, V21, P379, DOI 10.1016/j.drudis.2015.10.002; Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318; Hong D, 2016, J CLIN ONCOL, V34, P1764, DOI 10.1200/JCO.2015.64.5788; Johnson MD, 2012, ORG PROCESS RES DEV, V16, P1017, DOI 10.1021/op200362h; King C, 2015, MOL CANCER THER, V14, P2004, DOI 10.1158/1535-7163.MCT-14-1037; Lau SH, 2015, ORG LETT, V17, P3218, DOI 10.1021/acs.orglett.5b01307; Lee J. M., 2016, ANN ONCOL          S, V27, P8550; Lee SL, 2015, J PHARM INNOV, V10, P191, DOI 10.1007/s12247-015-9215-8; Mascia S, 2013, ANGEW CHEM INT EDIT, V52, P12359, DOI 10.1002/anie.201305429; May SA, 2016, ORG PROCESS RES DEV, V20, P1870, DOI 10.1021/acs.oprd.6b00148; May SA, 2012, ORG PROCESS RES DEV, V16, P982, DOI 10.1021/op200351g; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; PALAMIDESSI G, 1974, J HETEROCYCLIC CHEM, V11, P607, DOI 10.1002/jhet.5570110428; Palmer E., 2016, FIERCEPHARMA    0414; Palmer E., 2015, FIERCEPHARMA    0629; Quon JL, 2012, CRYST GROWTH DES, V12, P3036, DOI 10.1021/cg300253a; Richon VM, 2013, HEMATOL-AM SOC HEMAT, P19, DOI 10.1182/asheducation-2013.1.19; Roberge DM, 2008, ORG PROCESS RES DEV, V12, P905, DOI 10.1021/op8001273; Snead DR, 2015, ANGEW CHEM INT EDIT, V54, P983, DOI 10.1002/anie.201409093; Srai JS, 2015, J PHARM SCI-US, V104, P840, DOI 10.1002/jps.24343; Tsubogo T, 2015, NATURE, V520, P329, DOI 10.1038/nature14343; U.S. Food and Drug Administration (FDA), 2013, IFPAC ANN M BALT MD; White TD, 2012, ORG PROCESS RES DEV, V16, P939, DOI 10.1021/op200344a; Wollowitz S, 2010, DRUG DEVELOP RES, V71, P420, DOI 10.1002/ddr.20385; Yu LX, 2014, AAPS J, V16, P771, DOI 10.1208/s12248-014-9598-3	35	174	175	7	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	2017	356	6343					1144	1150		10.1126/science.aan0745	http://dx.doi.org/10.1126/science.aan0745			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX6BO	28619938				2023-01-03	WOS:000403327400030
J	Lee, RP; Bamford, C; Poole, M; McLellan, E; Exley, C; Robinson, L				Lee, Richard Philip; Bamford, Claire; Poole, Marie; McLellan, Emma; Exley, Catherine; Robinson, Louise			End of life care for people with dementia: The views of health professionals, social care service managers and frontline staff on key requirements for good practice	PLOS ONE			English	Article							NURSING-HOME RESIDENTS; 5 EUROPEAN COUNTRIES; OLDER-PEOPLE; PALLIATIVE CARE; STAGE DEMENTIA; QUALITY; EXPERIENCE; COMMUNITY; WELL	Background Evidence consistently shows that people with advanced dementia experience suboptimal end of life care compared to those with cancer; with increased hospitalisation, inadequate pain control and fewer palliative care interventions. Understanding the views of those service managers and frontline staff who organise and provide care is crucial in order to develop better end of life care for people with dementia. Methods and findings Qualitative interviews and focus groups were conducted from 2013 to 2015 with 33 service managers and 54 staff involved in frontline care, including doctors, nurses, nursing and care home managers, service development leads, senior managers/directors, care assistants and senior care assistants/team leads. All were audio recorded and transcribed verbatim. Participants represented a diverse range of service types and occupation. Transcripts were subject to coding and thematic analysis in data meetings. Analysis of the data led to the development of seven key themes: Recognising end of life (EOL) and tools to support end of life care (EOLC), Communicating with families about EOL, Collaborative working, Continuity of care, Ensuring comfort at EOL, Supporting families, Developing and supporting staff. Each is discussed in detail and comprise individual and collective views on approaches to good end of life care for people with dementia. Conclusions The significant challenges of providing good end of life care for people with dementia requires that different forms of expertise should be recognised and used; including the skills and knowledge of care assistants. Successfully engaging with people with dementia and family members and helping them to recognise the dying trajectory requires a supportive integration of emotional and technical expertise. The study strengthens the existing evidence base in this area and will be used with a related set of studies (on the views of other stakeholders and observations and interviews conducted in four services) to develop an evidence-based intervention.	[Lee, Richard Philip; Bamford, Claire; Poole, Marie; McLellan, Emma; Robinson, Louise] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Exley, Catherine] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Northumbria University	Lee, RP (corresponding author), Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England.	Richard.lee@newcastle.ac.uk		Lee, Richard/0000-0003-3854-601X; Exley, Catherine/0000-0002-3570-7503	National Institute for Health Research (Programme Grants for Applied Research, Supporting Excellence in End of Life Care in Dementia) [RP-PG-0611-20005]; National Institute for Health Research [RP-PG-0611-20005, NIHR-RP-011-043] Funding Source: researchfish	National Institute for Health Research (Programme Grants for Applied Research, Supporting Excellence in End of Life Care in Dementia); National Institute for Health Research(National Institute for Health Research (NIHR))	This paper is independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Supporting Excellence in End of Life Care in Dementia, RP-PG-0611-20005). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.	Albinsson L, 2002, HEALTH SOC CARE COMM, V10, P313, DOI 10.1046/j.1365-2524.2002.00364.x; Alzheimer's Disease International, 2016, WORLD ALZH REP 2016; Aminoff Bechor Zvi, 2004, Am J Alzheimers Dis Other Demen, V19, P243, DOI 10.1177/153331750401900402; [Anonymous], 2011, QUAL RES; [Anonymous], 2010, WORLD ALZHEIMER REPO; Bailey S, 2015, AGEING SOC, V35, P246, DOI 10.1017/S0144686X13000573; Ballard C, 2001, BRIT MED J, V323, P426, DOI 10.1136/bmj.323.7310.426; Bassal C, 2016, RES AGING, V38, P477, DOI 10.1177/0164027515591629; Bekelman DB, 2005, J PAIN SYMPTOM MANAG, V30, P208, DOI 10.1016/j.jpainsymman.2005.04.003; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Bunn F, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0192-4; Burton LC, 2001, J AM GERIATR SOC, V49, P142, DOI 10.1046/j.1532-5415.2001.49034.x; Chester H, 2014, AGEING SOC, V34, P930, DOI 10.1017/S0144686X12001249; Craig P, 2006, DEV EVALUATING COMPL; Davies N, 2016, PALLIATIVE MED; Davies N, 2014, PALLIATIVE MED, V28, P919, DOI 10.1177/0269216314526766; Davies N, 2014, AGING MENT HEALTH, V18, P400, DOI 10.1080/13607863.2013.843157; Department of Health, 2009, LIV WELL DEM NATL ST; Evers MM, 2002, PSYCHIAT SERV, V53, P609, DOI 10.1176/appi.ps.53.5.609; Froggatt K, 2011, HEALTH PLACE, V17, P263, DOI 10.1016/j.healthplace.2010.11.001; Goodman C, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0040-0; Goodman C, 2010, INT J GERIATR PSYCH, V25, P329, DOI 10.1002/gps.2343; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; Haydar ZR, 2004, J AM GERIATR SOC, V52, P736, DOI 10.1111/j.1532-5415.2004.52210.x; Hirakawa Y, 2006, ARCH GERONTOL GERIAT, V42, P233, DOI 10.1016/j.archger.2005.07.006; Hirakawa Y, 2006, PSYCHOGERIATRICS, V6, P60; Houttekier D, 2010, J AM GERIATR SOC, V58, P751, DOI 10.1111/j.1532-5415.2010.02771.x; Hughes, 2011, THINKING DEMENTIA; Humphries R., 2016, SOCIAL CARE OLDER PE; Independent Review of the Liverpool Care Pathway, 2013, MORE CARE LESS PATHW; Kovach CR, 1999, J PAIN SYMPTOM MANAG, V18, P412, DOI 10.1016/S0885-3924(99)00094-9; Kovach CR, 1996, AM J ALZHEIMERS DIS, V11, P7, DOI DOI 10.1177/153331759601100402; Lamberg JL, 2005, J AM GERIATR SOC, V53, P1396, DOI 10.1111/j.1532-5415.2005.53426.x; Lawrence V, 2011, BRIT J PSYCHIAT, V199, P417, DOI 10.1192/bjp.bp.111.093989; Leadership Alliance for the Care of Dying People, 2014, ONE CHANC GET RIGHT; Lee RP, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0028-9; Livingston G, 2012, INT J GERIATR PSYCH, V27, P643, DOI 10.1002/gps.2772; Mannion R, 2011, BRIT MED BULL, V97, P7, DOI 10.1093/bmb/ldq042; Mayrhofer A, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0081-z; McCarthy M, 1997, INT J GERIATR PSYCH, V12, P404; McCormick WC, 2001, J AM GERIATR SOC, V49, P1156, DOI 10.1046/j.1532-5415.2001.49231.x; Mitchell SL, 2004, ARCH INTERN MED, V164, P321, DOI 10.1001/archinte.164.3.321; National Institute for Health and Care Excellence, CAR DYING LAST DAYS; National Institute for Health and Care Excellence, DEM CAR COMM GUID; National Institute for Health and Care Excellence (NICE), 2006, DEMSUPP PEOPL DEM TH, V42; Office for National Statistics, 2016, STAT B DEATHS REG EN; Prince M., 2015, ALZHEIMERS DIS INT W; Public Health England, 2016, DYING DEM; Robinson L, 2013, PALLIATIVE MED, V27, P401, DOI 10.1177/0269216312465651; Robinson L, 2005, REV CLIN GERONTOL, V15, P135, DOI 10.1017/S0959259806001833; Sachs GA, 2004, J GEN INTERN MED, V19, P1057, DOI 10.1111/j.1525-1497.2004.30329.x; Sampson EL, 2006, AGE AGEING, V35, P187, DOI 10.1093/ageing/afj025; Scherder E, 2005, BMJ-BRIT MED J, V330, P461, DOI 10.1136/bmj.330.7489.461; Scott S., 2009, DEMENTIA, V8, P435, DOI DOI 10.1177/14713012090080030705; Seymour JE, 2011, PALLIATIVE MED, V25, P125, DOI 10.1177/0269216310387964; Shaw KL, 2010, PALLIATIVE MED, V24, P317, DOI 10.1177/0269216310362005; The AM, 2002, BRIT MED J, V325, P1326, DOI 10.1136/bmj.325.7376.1326; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; Wilson E, 2015, PALLIATIVE MED, V29, P60, DOI 10.1177/0269216314543042; World Health Organisation Regional office for Europe, 2011, PALLIATIVE CARE OLDE	60	25	25	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2017	12	6							e0179355	10.1371/journal.pone.0179355	http://dx.doi.org/10.1371/journal.pone.0179355			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX8NF	28622379	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000403506300026
J	Yi, J; Lei, YJ; Xu, SY; Si, YY; Li, SY; Xia, ZY; Shi, YS; Gu, XP; Yu, JS; Xu, GH; Gu, EW; Yu, YH; Chen, YQ; Jia, HQ; Wang, YL; Wang, XL; Chai, XQ; Jin, XJ; Chen, JP; Xu, MY; Xiong, JY; Wang, GN; Lu, KZ; Yu, WL; Lei, WF; Qin, ZS; Xiang, JG; Li, LY; Xiang, ZY; Pan, S; Zhan, LJ; Qiu, K; Yao, M; Huang, YG				Yi, Jie; Lei, Yongjing; Xu, Shiyuan; Si, Yongyu; Li, Shiyang; Xia, Zhongyuan; Shi, Yisa; Gu, Xiaoping; Yu, Jianshe; Xu, Guohai; Gu, Erwei; Yu, Yonghao; Chen, Yanqing; Jia, Hequn; Wang, Yinglin; Wang, Xiuli; Chai, Xiaoqing; Jin, Xiaoju; Chen, Junping; Xu, Meiying; Xiong, Junyu; Wang, Guonian; Lu, Kaizhi; Yu, Wenli; Lei, Weifu; Qin, Zaisheng; Xiang, Jingguo; Li, Longyun; Xiang, Ziyong; Pan, Shuang; Zhan, Lujing; Qiu, Kai; Yao, Min; Huang, Yuguang			Intraoperative hypothermia and its clinical outcomes in patients undergoing general anesthesia: National study in China	PLOS ONE			English	Article							WOUND-INFECTION; BLOOD-LOSS; MILD; INCREASES; NORMOTHERMIA; DURATION	Background/Objective Inadvertent intraoperative hypothermia (core temperature <36 degrees C) is a frequently preventable complication with several adverse consequences. Our study aimed to determine the overall incidence of inadvertent intraoperative hypothermia and its risk factors associated with clinical outcomes in this national survey in China. Methods We conducted a national cross-sectional study with 30 days postoperative follow-up from November 2014 through August 2015. A total of 3132 eligible patients underwent general anesthesia were randomly selected from 28 hospitals in the nationwide of China. Results The overall incidence of intraoperative hypothermia was as high as 44.3%, in which cumulative incidence rates of hypothermia being 17.8%, 36.2%, 42.5% and 44.1% within 1 h, 2 h, 3 h and 4 h respectively following induction of anesthesia. All patients were warmed passively by covering of surgical draping, sheets or cotton blankets, whereas only 14.2% of patients received active warming with space heaters or electric heater or electronic blankets. Compared to normothermic patients, patients with hypothermia is associated with more postoperative ICU admit, longer PACU and more postoperative hospital days, but no difference in surgical site infection (SSI) rates or 30-day mortality. Several factors were shown to be associated with decreased risk of hypothermia. They are active warming (OR = 0.46, 95% CI 0.26-0.81), BMI >= 25 (OR = 0.54, 95% CI 0.45-0.65), higher baseline core temperature (OR = 0.04, 95% CI 0.03-0.06), and higher ambient temperature (OR = 0.83, 95% CI 0.78-0.88). Risk factors associated with an increased risk of hypothermia included major-plus surgery (OR = 1.49, 95% CI 1.23-1.79), and long anesthesia (>2 h) (OR = 2.60, 95% CI 2.09-3.24). Conclusions The incidence of intraoperative hypothermia in China is high, and the rate of active warming of patients during operation is low. Hypothermia is associated with more postoperative shivering, increased ICU admissions, and longer postoperative hospital days.	[Yi, Jie; Huang, Yuguang] Chinese Acad Med Sci, Dept Anesthesiol, Beijing, Peoples R China; [Yi, Jie; Huang, Yuguang] Peking Union Med Coll Hosp, Beijing, Peoples R China; [Lei, Yongjing] Second Peoples Hosp Wuhu, Dept Anesthesiol, Wuhu, Anhui, Peoples R China; [Xu, Shiyuan] Southern Med Univ, Zhujiang Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Si, Yongyu] Kunming Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Kunming, Yunnan, Peoples R China; [Li, Shiyang] Quanzhou Womens & Childrens Hosp, Dept Anesthesiol, Fujian, Peoples R China; [Xia, Zhongyuan] Wuhan Univ, Renmin Hosp, Dept Anesthesiol, Wuhan, Hubei, Peoples R China; [Shi, Yisa] Lanzhou Univ Second Hosp, Dept Anesthesiol, Lanzhou, Ganshu, Peoples R China; [Gu, Xiaoping] Nanjing Univ, Med Sch, Dept Anesthesiol, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Yu, Jianshe] Inner Mongolia Med Univ, Affiliated Hosp, Dept Anesthesiol, Hohhot, Inner Mongolia, Peoples R China; [Xu, Guohai] Nanchang Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanchang, Jiangxi, Peoples R China; [Gu, Erwei] Anhui Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Hefei, Anhui, Peoples R China; [Yu, Yonghao] Tianjin Med Univ Gen Hosp, Dept Anesthesiol, Tianjin, Peoples R China; [Chen, Yanqing] Fujian Prov Hosp, Dept Anesthesiol, Fuzhou, Fujian, Peoples R China; [Jia, Hequn] Fourth Hosp Hebei Med Univ, Dept Anesthesiol, Shijiazhuang, Hebei, Peoples R China; [Wang, Yinglin] Haikou Peoples Hosp, Dept Anesthesiol, Haikou, Hainan, Peoples R China; [Wang, Xiuli] Third Hosp Hebei Med Univ, Dept Anesthesiol, Shijiazhuang, Hebei, Peoples R China; [Chai, Xiaoqing] Anhui Prov Hosp, Dept Anesthesiol, Hefei, Anhui, Peoples R China; [Jin, Xiaoju] Wannan Med Coll, Affiliated Hosp 1, Dept Anesthesiol, Wuhu, Anhui, Peoples R China; [Chen, Junping] Ningbo 2 Hosp, Dept Anesthesiol, Ningbo, Zhejiang, Peoples R China; [Xu, Meiying] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, Shanghai, Peoples R China; [Xiong, Junyu] Second Hosp Dalian Med Univ, Dept Anesthesiol, Dalian, Liaoning, Peoples R China; [Wang, Guonian] Harbin Med Univ, Canc Hosp, Dept Anesthesiol, Harbin, Heilongjiang, Peoples R China; [Lu, Kaizhi] Chongqing Third Mil Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Chongqing, Peoples R China; [Yu, Wenli] Tianjin First Cent Hosp, Dept Anesthesiol, Tianjin, Peoples R China; [Lei, Weifu] Shandong Univ, Qilu Hosp, Dept Anesthesiol, Jinan, Shandong, Peoples R China; [Qin, Zaisheng] Nanfang Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Xiang, Jingguo] Peoples Hosp Sanya, Dept Anesthesiol, Sanya, Hainan, Peoples R China; [Li, Longyun] Jilin Univ, Sino Japanese Union Hosp, Dept Anesthesiol, Changchun, Jilin, Peoples R China; [Xiang, Ziyong; Pan, Shuang; Zhan, Lujing; Qiu, Kai; Yao, Min] 3M R&D Ctr, Shanghai, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Southern Medical University - China; Kunming Medical University; Wuhan University; Nanjing University; Inner Mongolia Medical University; Nanchang University; Anhui Medical University; Tianjin Medical University; Fujian Provincial Hospital; Hebei Medical University; Wannan Medical College; Shanghai Jiao Tong University; Dalian Medical University; Harbin Medical University; Tianjin Medical University; Shandong University; Southern Medical University - China; Jilin University	Huang, YG (corresponding author), Chinese Acad Med Sci, Dept Anesthesiol, Beijing, Peoples R China.; Huang, YG (corresponding author), Peking Union Med Coll Hosp, Beijing, Peoples R China.	huangyg@pumch.cn		xia, zhongyuan/0000-0002-5807-9554	China National Health and Planned Parenthood Committee Health Quality Improvement Award [201402017]; China National Nature Science Foundation [31070930]; unrestricted research grant from 3M China [MDI0091]	China National Health and Planned Parenthood Committee Health Quality Improvement Award; China National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); unrestricted research grant from 3M China	This study was funded by three separate grants: China National Health and Planned Parenthood Committee Health Quality Improvement Award (ID# 201402017, principle investigator Yuguang Huang, MD), China National Nature Science Foundation (Grant # 31070930, principle investigator Yuguang Huang, MD), and an unrestricted research grant (MDI0091, principal investigator Yuguang Huang, MD) from 3M China. However, none of these grants provided salary support to any of the investigators. These grants were for IRB review, investigator meeting and CRO (study monitoring, data management, statistical analysis and report etc.), travel, national or international conference and publication.	Aasen Ansgar O, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS1, DOI 10.1089/sur.2002.3.s1-1; Aasen Ansgar O, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS99, DOI 10.1089/sur.2002.3.s1-99; Barie Philip S, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS9, DOI 10.1089/sur.2002.3.s1-9; Bock M, 1998, BRIT J ANAESTH, V80, P159, DOI 10.1093/bja/80.2.159; Burger Leona, 2009, Br J Nurs, V18, P1116; Burns SM, 2010, J PERIANESTH NURS, V25, P286, DOI 10.1016/j.jopan.2010.07.001; Forbes SS, 2009, J AM COLL SURGEONS, V209, P492, DOI 10.1016/j.jamcollsurg.2009.07.002; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; Hedrick TL, 2007, J AM COLL SURGEONS, V205, P432, DOI 10.1016/j.jamcollsurg.2007.04.042; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; Jeran L, 2001, J Perianesth Nurs, V16, P303, DOI 10.1053/jpan.2001.28452; Kongsayreepong S, 2003, ANESTH ANALG, V96, P826, DOI 10.1213/01.ANE.0000048822.27698.28; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lenhardt R, 1997, ANESTHESIOLOGY, V87, P1318, DOI 10.1097/00000542-199712000-00009; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Long KC, 2013, GYNECOL ONCOL, V131, P525, DOI 10.1016/j.ygyno.2013.08.034; Mahoney C B, 1999, AANA J, V67, P155; NICE, 2003, PREOP TESTS US PREOP; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Scott AV, 2015, ANESTHESIOLOGY, V123, P116, DOI 10.1097/ALN.0000000000000681; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; SLOTMAN GJ, 1985, AM J SURG, V149, P495, DOI 10.1016/S0002-9610(85)80046-5; Tappen R M, 1996, AORN J, V63, P639, DOI 10.1016/S0001-2092(06)63411-X; Wong PF, 2007, BRIT J SURG, V94, P421, DOI 10.1002/bjs.5631; Yi J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136136	27	54	73	4	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e0177221	10.1371/journal.pone.0177221	http://dx.doi.org/10.1371/journal.pone.0177221			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0PL	28594825	Green Published, gold, Green Submitted			2023-01-03	WOS:000402923200009
J	Lu, M; Ueno, S				Lu, Mai; Ueno, Shoogo			Comparison of the induced fields using different coil configurations during deep transcranial magnetic stimulation	PLOS ONE			English	Article							DOUBLE-CONE COIL; DIELECTRIC-PROPERTIES; PARKINSONS-DISEASE; BIOLOGICAL TISSUES; ELECTRIC-FIELD; HUMAN HEAD; H-COIL; ADD-ON; BRAIN; DEPRESSION	Stimulation of deeper brain structures by transcranial magnetic stimulation (TMS) plays a role in the study of reward and motivation mechanisms, which may be beneficial in the treatment of several neurological and psychiatric disorders. However, electric field distributions induced in the brain by deep transcranial magnetic stimulation (dTMS) are still unknown. In this paper, the double cone coil, H-coil and Halo-circular assembly (HCA) coil which have been proposed for dTMS have been numerically designed. The distributions of magnetic flux density, induced electric field in an anatomically based realistic head model by applying the dTMS coils were numerically calculated by the impedance method. Results were compared with that of standard figure-of-eight (Fo8) coil. Simulation results show that double cone, H-and HCA coils have significantly deep field penetration compared to the conventional Fo8 coil, at the expense of induced higher and wider spread electrical fields in superficial cortical regions. Double cone and HCA coils have better ability to stimulate deep brain subregions compared to that of the H-coil. In the mean time, both double cone and HCA coils increase risk for optical nerve excitation. Our results suggest although the dTMS coils offer new tool with potential for both research and clinical applications for psychiatric and neurological disorders associated with dysfunctions of deep brain regions, the selection of the most suitable coil settings for a specific clinical application should be based on a balanced evaluation between stimulation depth and focality.	[Lu, Mai] Lanzhou Jiaotong Univ, Minist Educ, Key Lab Optelect Technol & Intelligent Control, Lanzhou 730070, Gansu, Peoples R China; [Ueno, Shoogo] Kyushu Univ, Dept Appl Quantum Phys, Grad Sch Engn, Fukuoka 8128581, Japan	Lanzhou Jiaotong University; Kyushu University	Lu, M (corresponding author), Lanzhou Jiaotong Univ, Minist Educ, Key Lab Optelect Technol & Intelligent Control, Lanzhou 730070, Gansu, Peoples R China.	mai.lu@hotmail.com			National Nature Science Foundation of China [51267010, 51567015]; Gansu Science Fund for Distinguished Young Scholars [1308RJDA013]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Gansu Science Fund for Distinguished Young Scholars	This work is supported in part by the National Nature Science Foundation of China (No. 51267010, 51567015), and in part by the Gansu Science Fund for Distinguished Young Scholars (No. 1308RJDA013). There was no additional external funding received for this study.; This work is supported in part by the National Nature Science Foundation of China (No. 51267010, 51567015), and in part by the Gansu Science Fund for Distinguished Young Scholars (No. 1308RJDA013). There was no additional external funding received for this study.	BARKER AT, 1985, LANCET, V1, P1106; Breiter HC, 1999, ANN NY ACAD SCI, V877, P523, DOI 10.1111/j.1749-6632.1999.tb09287.x; Christ A, 2010, PHYS MED BIOL, V55, pN23, DOI 10.1088/0031-9155/55/2/N01; Cole KS, 1941, J CHEM PHYS, V9, P341, DOI 10.1063/1.1750906; Crowther LJ, 2012, J APPL PHYS, V111, DOI 10.1063/1.3676623; Crowther LJ, 2011, J APPL PHYS, V109, DOI 10.1063/1.3563076; De Geeter N, 2011, IEEE T BIO-MED ENG, V58, P310, DOI 10.1109/TBME.2010.2087758; Deng ZD, 2014, CLIN NEUROPHYSIOL, V125, P1202, DOI 10.1016/j.clinph.2013.11.038; Deng ZD, 2013, BRAIN STIMUL, V6, P1, DOI 10.1016/j.brs.2012.02.005; Ferreri F, 2003, ANN NEUROL, V53, P102, DOI 10.1002/ana.10416; Fregni F, 2005, J NEUROL NEUROSUR PS, V76, P1614, DOI 10.1136/jnnp.2005.069849; Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001; Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002; Gabriel S, 1996, PHYS MED BIOL, V41, P2271, DOI 10.1088/0031-9155/41/11/003; George MS, 2007, TRANSCRANIAL MAGNETI; Harel EV, 2011, WORLD J BIOL PSYCHIA, V12, P119, DOI 10.3109/15622975.2010.510893; Holtzheimer PE., 2014, CLIN GUIDE TRANSCRAN; Huang YZ, 2009, BRAIN STIMUL, V2, P2, DOI 10.1016/j.brs.2008.09.007; Kakuda W, 2013, ACTA NEUROL SCAND, V128, P100, DOI 10.1111/ane.12085; Kreuzer PM, 2015, BRAIN STIMUL, V8, P240, DOI 10.1016/j.brs.2014.11.014; Li XB, 2013, BIOL PSYCHIAT, V73, P714, DOI 10.1016/j.biopsych.2013.01.003; Lontis ER, 2006, J CLIN NEUROPHYSIOL, V23, P462; Lu M, 2014, IFMBE P, V41, P1663; Lu M, 2015, IEEE T BIO-MED ENG, V62, P2911, DOI 10.1109/TBME.2015.2452261; Lu M, 2011, IEEE T MAGN, V47, P3841, DOI 10.1109/TMAG.2011.2157086; Lu M, 2009, IEEE T MAGN, V45, P1662, DOI 10.1109/TMAG.2009.2012770; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; McNamara B, 2001, PSYCHOL MED, V31, P1141, DOI 10.1017/S0033291701004378; Meng Y, 2015, J APPL PHYS, V117, DOI 10.1063/1.4913937; Nadeem M, 2003, IEEE T BIO-MED ENG, V50, P900, DOI 10.1109/TBME.2003.813548; Nemeroff Charles B, 2002, Psychopharmacol Bull, V36 Suppl 2, P6; ORCUTT N, 1988, IEEE T BIO-MED ENG, V35, P577, DOI 10.1109/10.4590; Politi E, 2008, AM J ADDICTION, V17, P345, DOI 10.1080/10550490802139283; Prikryl R, 2013, SCHIZOPHR RES, V149, P167, DOI 10.1016/j.schres.2013.06.015; Roth Y, 2002, J CLIN NEUROPHYSIOL, V19, P361, DOI 10.1097/00004691-200208000-00008; Shen Y, 2017, BIOL PSYCHIAT, V81, pE49, DOI 10.1016/j.biopsych.2016.06.013; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Spagnolo F, 2014, BRAIN STIMUL, V7, P297, DOI 10.1016/j.brs.2013.10.007; Trebbastoni A, 2013, BRAIN STIMUL, V6, P545, DOI 10.1016/j.brs.2012.09.014; UENO S, 1988, J APPL PHYS, V64, P5862, DOI 10.1063/1.342181; Vanneste S, 2014, NEUROCASE, V20, P61, DOI 10.1080/13554794.2012.732086; Walsh V, 2003, BRADFORD BOOKS, P1; Yoth Y, 2007, J CLIN NEUROPHYSIOL, V24, P31	44	64	67	4	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2017	12	6							e0178422	10.1371/journal.pone.0178422	http://dx.doi.org/10.1371/journal.pone.0178422			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW9YQ	28586349	Green Published, gold, Green Submitted			2023-01-03	WOS:000402875700011
J	Williamson, A				Williamson, Arthur			Robert C Gray OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 2	2017	357								j2702	10.1136/bmj.j2702	http://dx.doi.org/10.1136/bmj.j2702			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW6NF	28576930				2023-01-03	WOS:000402626600009
J	Krischel, M; Hansson, N				Krischel, Matthis; Hansson, Nils			Rejuvenation study stirs old memories	NATURE			English	Letter									[Krischel, Matthis; Hansson, Nils] Heinrich Heine Univ, Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Hansson, N (corresponding author), Heinrich Heine Univ, Dusseldorf, Germany.	nils.hansson@hhu.de						Castellano JM, 2017, NATURE, V544, P488, DOI 10.1038/nature22067	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 1	2017	546	7656					33	33		10.1038/546033e	http://dx.doi.org/10.1038/546033e			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW3CR	28569802	Bronze			2023-01-03	WOS:000402372800020
J	Lewith, H; Moore, M; Little, P				Lewith, Henry; Moore, Michael; Little, Paul			George Lewith OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																		LEWITH G, PUBLICATION LIST, P94477	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	2017	357								j2656	10.1136/bmj.j2656	http://dx.doi.org/10.1136/bmj.j2656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW6NB	28572080				2023-01-03	WOS:000402626200012
J	Moriki, T; Nakamura, T; Kamijo, Y; Nishimura, Y; Banno, M; Kinoshita, T; Uenishi, H; Tajima, F				Moriki, Takashi; Nakamura, Takeshi; Kamijo, Yoshi-ichiro; Nishimura, Yukihide; Banno, Motohiko; Kinoshita, Tokio; Uenishi, Hiroyasu; Tajima, Fumihiro			Noninvasive positive pressure ventilation enhances the effects of aerobic training on cardiopulmonary function	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; END-EXPIRATORY PRESSURE; MAXIMAL OXYGEN INTAKE; CARDIORESPIRATORY FITNESS; DIASTOLIC VOLUMES; PHYSICAL-ACTIVITY; HEALTHY-MEN; BED REST; EXERCISE; PREDICTION	Purpose The purpose of this study was to determine the effect of aerobic training under noninvasive positive pressure ventilation (NPPV) on maximal oxygen uptake (VO2max). Methods Ten healthy young male volunteers participated in the study. Before the training, stroke volume (SV) and cardiac output (CO) were measured in all subjects under 0, 4, 8, and 12 cmH(2)O NPPV at rest. Then, the subjects exercised on a cycle ergometer at 60% of pretraining VO2max for 30 min daily for 5 consecutive days with/without NPPV. The 5-day exercise protocol was repeated after a three-week washout period without/with NPPV. The primary endpoint was changes in VO2max. The secondary endpoints were changes in SV, CO, maximum heart rate (HRmax), maximum respiratory rate (RRmax), maximum expiratory minute volume (VEmax) and the percent change in plasma volume (PV). Results NPPV at 12 cmH(2)O significantly reduced SV and CO at rest. VO2max significantly increased after 5 days training with and without NPPV, but the magnitude of increase in VO2max after training under 12 cmH(2)O NPPV was significantly higher than after training without NPPV. VEmax significantly increased after training under NPPV, but not after training without NPPV. HRmax and RRmax did not change during training irrespective of NPPV. The percent change in PV was similar between training with and without NPPV. The 5-day training program with NPPV resulted in greater improvement in VO2max than without NPPV. Conclusions Aerobic training under NPPV has add-on effects on VO2max and exercise-related health benefits in healthy young men.	[Moriki, Takashi; Kamijo, Yoshi-ichiro; Nishimura, Yukihide; Banno, Motohiko; Kinoshita, Tokio; Uenishi, Hiroyasu; Tajima, Fumihiro] Wakayama Med Univ, Dept Rehabil Med, Wakayama, Wakayama, Japan; [Nakamura, Takeshi] Yokohama City Univ, Sch Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan	Wakayama Medical University; Yokohama City University	Nakamura, T (corresponding author), Yokohama City Univ, Sch Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan.	take_n@yokohama-cu.ac.jp	Kamijo, Yoshi-ichiro/AAH-2810-2020	Nishimura, Yukihide/0000-0002-5365-1347	MEXT KAKENHI Grant [JP15K01382]; Ministry of Education, Culture, Sports, Science and Technology (MEXT)	MEXT KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by MEXT KAKENHI Grant Number JP15K01382. The URLs of Ministry of Education, Culture, Sports, Science and Technology (MEXT) is http://www.mext.go.jp/en/index.htm. Author who received funding is TN. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham KA, 2002, J PHYSIOL-LONDON, V541, P653, DOI 10.1113/jphysiol.2001.013462; ASTRAND PO, 1956, PHYSIOL REV, V36, P307; Baisch F, 2000, EUR J CLIN INVEST, V30, P1055, DOI 10.1046/j.1365-2362.2000.00750.x; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; Buchan DS, 2012, J PUBLIC HEALTH RES, V1, P59, DOI 10.4081/jphr.2012.e11; COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201; CURETON KJ, 1995, MED SCI SPORT EXER, V27, P445; DORINSKY PM, 1983, CHEST, V84, P210, DOI 10.1378/chest.84.2.210; Fernhall Bo, 2008, J Health Hum Serv Adm, V30, P468; FEWELL JE, 1980, CIRC RES, V47, P467, DOI 10.1161/01.RES.47.3.467; FEWELL JE, 1980, CIRC RES, V46, P125, DOI 10.1161/01.RES.46.1.125; Goodman JM, 2005, J APPL PHYSIOL, V98, P454, DOI 10.1152/japplphysiol.00258.2004; Gordon D, 2014, EUR J APPL PHYSIOL, V114, P21, DOI 10.1007/s00421-013-2743-3; Haller JM, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.124; HENKE KG, 1988, J APPL PHYSIOL, V64, P135, DOI 10.1152/jappl.1988.64.1.135; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Holm Paige, 2004, BMC Physiol, V4, P9, DOI 10.1186/1472-6793-4-9; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; Jones AM, 2000, SPORTS MED, V29, P373, DOI 10.2165/00007256-200029060-00001; JONES NL, 1979, B EUR PHYSIOPATH RES, V15, P321; Kilmer David D, 2005, Phys Med Rehabil Clin N Am, V16, P1053, DOI 10.1016/j.pmr.2005.08.014; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Lee DC, 2011, BRIT J SPORT MED, V45, P504, DOI 10.1136/bjsm.2009.066209; Levine BD, 2008, J PHYSIOL-LONDON, V586, P25, DOI 10.1113/jphysiol.2007.147629; Luecke T, 2005, CRIT CARE, V9, P607, DOI 10.1186/cc3877; Perhonen MA, 2001, J APPL PHYSIOL, V91, P645, DOI 10.1152/jappl.2001.91.2.645; Puente-Maestu Luis, 2006, Int J Chron Obstruct Pulmon Dis, V1, P381, DOI 10.2147/copd.2006.1.4.381; Saltin B., 1968, CIRCULATION, V38, P1, DOI 10.1161/01.CIR.38.1.1; Shibasaki M, 2009, AM J PHYSIOL-REG I, V297, pR1706, DOI 10.1152/ajpregu.00242.2009; STORER TW, 1990, MED SCI SPORT EXER, V22, P704, DOI 10.1249/00005768-199010000-00024; STROHL KP, 1981, J APPL PHYSIOL, V51, P1471, DOI 10.1152/jappl.1981.51.6.1471; Sugiura H, 2013, J PHYS THER SCI, V25, P1491, DOI 10.1589/jpts.25.1491; Swain DP, 2002, MED SCI SPORT EXER, V34, P152, DOI 10.1097/00005768-200201000-00023; VANDERSCHANS GP, 1994, CHEST, V105, P782, DOI 10.1378/chest.105.3.782; VIQUERAT CE, 1983, CHEST, V83, P509, DOI 10.1378/chest.83.3.509; Wasserman K, 1997, CHEST, V112, P1091, DOI 10.1378/chest.112.4.1091; Watenpaugh DE, 2000, J APPL PHYSIOL, V89, P218, DOI 10.1152/jappl.2000.89.1.218; Wibmer T, 2014, RESP CARE, V59, P699, DOI 10.4187/respcare.02668	40	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2017	12	5							e0178003	10.1371/journal.pone.0178003	http://dx.doi.org/10.1371/journal.pone.0178003			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UA	28531211	Green Published, gold, Green Submitted			2023-01-03	WOS:000402058400048
J	Millstine, D; Chen, CY; Bauer, B				Millstine, Denise; Chen, Christina Y.; Bauer, Brent			Complementary and integrative medicine in the management of headache	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TENSION-TYPE HEADACHE; DOUBLE-BLIND; ALTERNATIVE MEDICINE; MANUAL THERAPY; MIGRAINE PROPHYLAXIS; PETASITES-HYBRIDUS; CONTROLLED-TRIAL; EAR ACUPUNCTURE; FATTY-ACIDS; EFFICACY	Headaches, including primary headaches such as migraine and tension-type headache, are a common clinical problem. Complementary and integrative medicine (CIM), formerly known as complementary and alternative medicine (CAM), uses evidence informed modalities to assist in the health and healing of patients. CIM commonly includes the use of nutrition, movement practices, manual therapy, traditional Chinese medicine, and mind-body strategies. This review summarizes the literature on the use of CIM for primary headache and is based on five meta-analyses, seven systematic reviews, and 34 randomized controlled trials (RCTs). The overall quality of the evidence for CIM in headache management is generally low and occasionally moderate. Available evidence suggests that traditional Chinese medicine including acupuncture, massage, yoga, biofeedback, and meditation have a positive effect on migraine and tension headaches. Spinal manipulation, chiropractic care, some supplements and botanicals, diet alteration, and hydrotherapy may also be beneficial in migraine headache. CIM has not been studied or it is not effective for cluster headache. Further research is needed to determine the most effective role for CIM in patients with headache.	[Millstine, Denise] Mayo Clin, Womens Hlth Internal Med, Dept Gen Internal Med, Integrat Med Sect, Scottsdale, AZ 85260 USA; [Chen, Christina Y.] Mayo Clin, Div Geriatr, Primary Care Internal Med, Rochester, MN 55905 USA; [Bauer, Brent] Mayo Clin, Div Gen Internal Med, Integrat Med Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic	Millstine, D (corresponding author), Mayo Clin, Womens Hlth Internal Med, Dept Gen Internal Med, Integrat Med Sect, Scottsdale, AZ 85260 USA.	Millstine.Denise@mayo.edu						Abdoli S, 2012, SCAND J CARING SCI, V26, P254, DOI 10.1111/j.1471-6712.2011.00926.x; Adams J, 2013, HEADACHE, V53, P459, DOI 10.1111/j.1526-4610.2012.02271.x; Ahn CB, 2011, J ACUPUNCT MERIDIAN, V4, P29, DOI 10.1016/S2005-2901(11)60005-8; Allais G, 2011, NEUROL SCI, V32, pS173, DOI 10.1007/s10072-011-0525-4; Bennett MH, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005219.pub3; Bhatia R, 2007, Indian J Physiol Pharmacol, V51, P333; Bond DS, 2013, CONTEMP CLIN TRIALS, V35, P133, DOI 10.1016/j.cct.2013.03.004; Bougea AM, 2013, EXPLORE-NY, V9, P91, DOI 10.1016/j.explore.2012.12.005; Bronfort G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001878.PUB2; Bryans R, 2011, J MANIP PHYSIOL THER, V34, P274, DOI 10.1016/j.jmpt.2011.04.008; Bussing A, 2012, J PAIN, V13, P1, DOI 10.1016/j.jpain.2011.10.001; Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482; Cady RK, 2011, HEADACHE, V51, P1078, DOI 10.1111/j.1526-4610.2011.01910.x; Castien RF, 2011, CEPHALALGIA, V31, P133, DOI 10.1177/0333102410377362; Cathcart S, 2014, BEHAV COGN PSYCHOTH, V42, P1, DOI 10.1017/S1352465813000234; Ceccherelli F, 2012, ACUPUNCTURE ELECTRO, V37, P277; Cerritelli F, 2015, COMPLEMENT THER MED, V23, P149, DOI 10.1016/j.ctim.2015.01.011; Chai NC, 2014, HEADACHE, V54, P219, DOI 10.1111/head.12296; Chaibi A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008095; Chaibi A, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-67; Chaibi A, 2011, J HEADACHE PAIN, V12, P127, DOI 10.1007/s10194-011-0296-6; Chatchawan U, 2014, J ALTERN COMPLEM MED, V20, P486, DOI 10.1089/acm.2013.0176; Church D., 2013, PSYCHOLOGY, V04, P645, DOI [10.4236/psych.2013.48092, DOI 10.4236/PSYCH.2013.48092]; Conboy L, 2005, J ALTERN COMPLEM MED, V11, P977, DOI 10.1089/acm.2005.11.977; Cowan RP, 2014, HEADACHE, V54, P1097, DOI 10.1111/head.12364; Day MA, 2014, CLIN J PAIN, V30, P152, DOI 10.1097/AJP.0b013e318287a1dc; Di Lorenzo C, 2015, EUR J NEUROL, V22, P170, DOI 10.1111/ene.12550; Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9; Diener HC, 2004, EUR NEUROL, V51, P89, DOI 10.1159/000076535; Espi-Lopez GV, 2014, EUR J PHYS REHAB MED, V50, P641; Espi-Lopez GV, 2014, J BODYW MOV THER, V18, P576, DOI 10.1016/j.jbmt.2014.01.001; Gaul C, 2009, CEPHALALGIA, V29, P1069, DOI 10.1111/j.1468-2982.2009.01841.x; Gaul C, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0516-6; Ghanbari A, 2015, NEUROREHABILITATION, V37, P157, DOI 10.3233/NRE-151248; Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106; Gouveia LO, 2009, SPINE, V34, pE405, DOI 10.1097/BRS.0b013e3181a16d63; Grossmann M, 2000, INT J CLIN PHARM TH, V38, P430; Hall A, 2017, PHYS THER, V97, P227, DOI 10.2522/ptj.20160246; Holland S, 2012, NEUROLOGY, V78, P1346, DOI 10.1212/WNL.0b013e3182535d0c; Jafarpour M, 2016, J ETHNOPHARMACOL, V179, P170, DOI 10.1016/j.jep.2015.12.040; Jensen R, 2008, LANCET NEUROL, V7, P354, DOI 10.1016/S1474-4422(08)70062-0; John PJ, 2007, HEADACHE, V47, P654, DOI 10.1111/j.1526-4610.2007.00789.x; Jonas WB, 2016, MED ACUPUNCT, V28, P113, DOI 10.1089/acu.2016.1183; Kabat-Zinn J., 1986, CLIN J PAIN, V2, P159, DOI DOI 10.1097/00002508-198602030-00004; Kisan Ravikiran, 2014, Int J Yoga, V7, P126, DOI 10.4103/0973-6131.133891; Li Y, 2009, HEADACHE, V49, P805, DOI 10.1111/j.1526-4610.2009.01424.x; Linde K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001218.pub3; Linde K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007587.pub2; Lipton RB, 2004, NEUROLOGY, V63, P2240, DOI 10.1212/01.WNL.0000147290.68260.11; Liu YL, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-015-0535-7; Maizes V, 2009, EXPLORE-NY, V5, P277, DOI 10.1016/j.explore.2009.06.008; Mayo Clinic, MINDF EX; Menon S, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0652-7; Mesa-Jimenez JA, 2015, CEPHALALGIA, V35, P1323, DOI 10.1177/0333102415576226; Nestoriuc Y, 2008, APPL PSYCHOPHYS BIOF, V33, P125, DOI 10.1007/s10484-008-9060-3; Nestoriuc Y, 2008, J CONSULT CLIN PSYCH, V76, P379, DOI 10.1037/0022-006X.76.3.379; Neuman MG, 2015, J PHARM PHARM SCI, V18, P825, DOI 10.18433/J3BG7J; Odawara M, 2015, INT J BEHAV MED, V22, P748, DOI 10.1007/s12529-015-9469-z; Orr SL, 2016, CEPHALALGIA, V36, P1112, DOI 10.1177/0333102415590239; Peikert A, 1996, CEPHALALGIA, V16, P257, DOI 10.1046/j.1468-2982.1996.1604257.x; Peng PWH, 2012, REGION ANESTH PAIN M, V37, P372, DOI 10.1097/AAP.0b013e31824f6629; Pfaffenrath V, 1996, CEPHALALGIA, V16, P436, DOI 10.1046/j.1468-2982.1996.1606436.x; Pintov S, 1997, PEDIATR NEUROL, V17, P129, DOI 10.1016/S0887-8994(97)00086-6; Powers Thomas L, 2003, J Hosp Mark Public Relations, V15, P45; Pradalier A, 2001, CEPHALALGIA, V21, P818, DOI 10.1046/j.1468-2982.2001.00240.x; Rajapakse T, 2016, HEADACHE, V56, P808, DOI 10.1111/head.12789; Ramsden CE, 2013, PAIN, V154, P2441, DOI 10.1016/j.pain.2013.07.028; Robbins MS, 2016, HEADACHE, V56, P1093, DOI 10.1111/head.12866; Sadeghi Omid, 2015, Iran J Nurs Midwifery Res, V20, P334; Sandor PS, 2005, NEUROLOGY, V64, P713, DOI 10.1212/01.WNL.0000151975.03598.ED; Sasannejad P, 2012, EUR NEUROL, V67, P288, DOI 10.1159/000335249; Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466; Soderberg EI, 2011, CLIN J PAIN, V27, P448, DOI 10.1097/AJP.0b013e318208c8fe; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; Steiner TJ, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-31; Sujan MU, 2016, J NEUROSCI RURAL PRA, V7, P109, DOI 10.4103/0976-3147.165389; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; Toro-Velasco C, 2009, J MANIP PHYSIOL THER, V32, P527, DOI 10.1016/j.jmpt.2009.08.011; Walach H, 2003, J ALTERN COMPLEM MED, V9, P837, DOI 10.1089/107555303771952181; Wang LP, 2012, PAIN MED, V13, P623, DOI 10.1111/j.1526-4637.2012.01376.x; Wells RE, 2014, HEADACHE, V54, P1484, DOI 10.1111/head.12420; Wells RE, 2011, HEADACHE, V51, P1087, DOI 10.1111/j.1526-4610.2011.01917.x; Wider B, 2015, COCHRANE DB SYST REV, V4; Yang CP, 2011, CEPHALALGIA, V31, P1510, DOI 10.1177/0333102411420585; Yang CP, 2013, CLIN J PAIN, V29, P982, DOI 10.1097/AJP.0b013e31827eb511; Yang Y, 2016, ACUPUNCT MED, V34, P76, DOI 10.1136/acupmed-2015-010903; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; Zheng H, 2015, ACUPUNCT MED, V33, P121, DOI 10.1136/acupmed-2014-010679	88	46	48	5	64	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	2017	357								j1805	10.1136/bmj.j1805	http://dx.doi.org/10.1136/bmj.j1805			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV6RJ	28512119				2023-01-03	WOS:000401898900002
J	Renton, T; Tibbles, A; Topolovec-Vranic, J				Renton, Tian; Tibbles, Alana; Topolovec-Vranic, Jane			Neurofeedback as a form of cognitive rehabilitation therapy following stroke: A systematic review	PLOS ONE			English	Review							RECOVERY; BRAIN; NEUROTHERAPY; PRINCIPLES; HEALTH	Neurofeedback therapy (NFT) has been used within a number of populations however it has not been applied or thoroughly examined as a form of cognitive rehabilitation within a stroke population. Objectives for this systematic review included: i) identifying how NFT is utilized to treat cognitive deficits following stroke, ii) examining the strength and quality of evidence to support the use of NFT as a form of cognitive rehabilitation therapy (CRT) and iii) providing recommendations for future investigations. Searches were conducted using OVID (Medline, Health Star, Embase + Embase Classic) and PubMed databases. Additional searches were completed using the Cochrane Reviews library database, Google Scholar, the University of Toronto online library catalogue, ClinicalTrials.gov website and select journals. Searches were completed Feb/March 2015 and updated in June/July/Aug 2015. Eight studies were eligible for inclusion in this review. Studies were eligible for inclusion if they: i) were specific to a stroke population, ii) delivered CRT via a NFT protocol, iii) included participants who were affected by a cognitive deficit(s) following stroke (i.e. memory loss, loss of executive function, speech impairment etc.). NFT protocols were highly specific and varied within each study. The majority of studies identified improvements in participant cognitive deficits following the initiation of therapy. Reviewers assessed study quality using the Downs and Black Checklist for Measuring Study Quality tool; limited study quality and strength of evidence restricted generalizability of conclusions regarding the use of this therapy to the greater stroke population. Progression in this field requires further inquiry to strengthen methodology quality and study design. Future investigations should aim to standardize NFT protocols in an effort to understand the dose-response relationship between NFT and improvements in functional outcome. Future investigations should also place a large emphasis on long-term participant follow-up.	[Renton, Tian; Tibbles, Alana; Topolovec-Vranic, Jane] Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON, Canada; [Renton, Tian; Topolovec-Vranic, Jane] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON, Canada; [Topolovec-Vranic, Jane] Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Renton, T (corresponding author), Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON, Canada.; Renton, T (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON, Canada.	tian.renton@mail.utoronto.ca	Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Renton, Tian/0000-0002-9772-0551				Ammann BC, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0167-2; [Anonymous], 2009, SYSTEMATIC REV; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P1; Bearden TS, 2003, APPL PSYCHOPHYS BIOF, V28, P241, DOI 10.1023/A:1024689315563; Breteler MHM, 2010, APPL PSYCHOPHYS BIOF, V35, P5, DOI 10.1007/s10484-009-9105-2; Brosseau L, 2006, TOP STROKE REHABIL, V13, P1, DOI 10.1310/3TKX-7XEC-2DTG-XQKH; Cannon KB., 2010, J NEUROTHER, V14, P107, DOI [10.1080/10874201003772155, DOI 10.1080/10874201003772155]; Cho HY, 2015, J PHYS THER SCI, V27, P673, DOI 10.1589/jpts.27.673; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coben R, 2010, APPL PSYCHOPHYS BIOF, V35, P83, DOI 10.1007/s10484-009-9117-y; Corydon Hammond D., 2011, J NEUROTHERAPY, V15, P54, DOI [10.1080/10874208.2010.545760, DOI 10.1080/10874208.2010.545760]; Deeks J J, 2003, Health Technol Assess, V7, piii; Dehghani-Arani F, 2013, APPL PSYCHOPHYS BIOF, V38, P133, DOI 10.1007/s10484-013-9218-5; Doppeimayr M., 2007, BIOFEEDBACK, V35, P126; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4; Glasziou P.P., 2001, SYSTEMATIC REV HLTH, DOI DOI 10.1017/CBO9780511543500; Hammond D.C., 2008, J NEUROTHER, V12, P79, DOI [10.1080/10874200802219947, DOI 10.1080/10874200802219947]; Hammond DC, 2007, J NEUROTHER, V10, P25, DOI DOI 10.1300/J184V10N04; Hasbani MJ, 2000, NEUROSCIENTIST, V6, P110, DOI 10.1177/107385840000600208; HIER DB, 1983, NEUROLOGY, V33, P345, DOI 10.1212/WNL.33.3.345; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; Kayiran S, 2010, APPL PSYCHOPHYS BIOF, V35, P293, DOI [10.1007/s10484.010.9135.9, 10.1007/s10484-010-9135-9]; Khan KS, 2003, J ROY SOC MED, V96, P118, DOI 10.1258/jrsm.96.3.118; Kiran Swathi, 2012, ISRN Neurol, V2012, P786872, DOI 10.5402/2012/786872; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P21; Liu YW., 2007, CHINA J INFORM SYSTE, V1, P16, DOI DOI 10.1089/SCD.2006.0118; MacLehose R R, 2000, Health Technol Assess, V4, P1; Matthews T. V., 2008, J NEUROTHER, V11, P63, DOI [10.1080/10874200802126290, DOI 10.1080/10874200802126290]; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mroczkowska D, 2014, POSTEP PSYCHIATR NEU, V23, P190, DOI 10.1016/j.pin.2014.09.002; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; National Collaborating Centre for Methods and Tools, 2008, QUAL CHECKL HLTH CAR; National Institute of Neurological Disorders and Stroke, 2011, POSTSTR REH FACT SHE; National Stroke Association, POSTSTR COND; Nelson LA, 2007, TOP STROKE REHABIL, V14, P59, DOI 10.1310/tsr1404-59; NeurOptimal, 2017, ADV BRAIN TRAIN SYST; Othmer S., ASS APPL PSYCH BIOF; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; Phillips B, 2009, OXFORD CTR EVIDENCE; Putnam JA, 2001, J NEUROTHERAPY, V5, P27; Research ISfN, COD ETH PRINC PROF C; Rickhag M, 2006, J NEUROCHEM, V96, P14, DOI 10.1111/j.1471-4159.2005.03508.x; ROZELLE GR, 1995, BIOFEEDBACK SELF-REG, V20, P211, DOI 10.1007/BF01474514; Simons M, 2011, GUIDELINES WRITING S; Staines WR, CURRENT ISSUES CARDI; Statistics Canada, 2011, 10 LEAD CAUS DEATH; STERMAN MB, 1978, EPILEPSIA, V19, P207, DOI 10.1111/j.1528-1157.1978.tb04483.x; Teasell Robert, 2005, Top Stroke Rehabil, V12, P11; The Heart and Stroke Foundation, 2014, STROK REP 2014 TOG R; Thompson L, 2010, APPL PSYCHOPHYS BIOF, V35, P63, DOI 10.1007/s10484-009-9120-3; Toppi J, 2014, IEEE ENG MED BIO, P6786, DOI 10.1109/EMBC.2014.6945186	54	38	42	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177290	10.1371/journal.pone.0177290	http://dx.doi.org/10.1371/journal.pone.0177290			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DC	28510578	gold, Green Published, Green Submitted			2023-01-03	WOS:000401485500021
J	Yamazaki, H; Lai, YC; Tateno, M; Setoguchi, A; Goto-Koshino, Y; Endo, Y; Nakaichi, M; Tsujimoto, H; Miura, N				Yamazaki, Hiroki; Lai, Yu-Chang; Tateno, Morihiro; Setoguchi, Asuka; Goto-Koshino, Yuko; Endo, Yasuyuki; Nakaichi, Munekazu; Tsujimoto, Hajime; Miura, Naoki			Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SOFT-TISSUE SARCOMA; INDUCIBLE FACTOR-1-ALPHA; PHASE-I; MULTIDRUG-RESISTANCE; MALIGNANT-LYMPHOMA; EXPRESSION; CANCER; LINE; LEUKEMIA	We tested the hypotheses that hypoxic stimulation enhances growth potentials of canine lymphoma cells by activating hypoxia-inducible factor 1 alpha (HIF-1 alpha), and that the hypoxia-activated prodrug (TH-302) inhibits growth potentials in the cells. We investigated how hypoxic culture affects the growth rate, chemoresistance, and invasiveness of canine lymphoma cells and doxorubicin (DOX)-resistant lymphoma cells, and influences of TH-302 on survival rate of the cells under hypoxic conditions. Our results demonstrated that hypoxic culture upregulated the expression of HIF-1a and its target genes, including ATP-binding cassette transporter B1 (ABCB1), ATP-binding cassette transporter G2 (ABCG2), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and survivin, and enhanced the growth rate, DOX resistance, and invasiveness of the cells. Additionally, TH-302 decreased the survival rate of the cells under hypoxic condition. Our studies suggest that hypoxic stimulation may advance the tumorigenicity of canine lymphoma cells, favoring malignant transformation. Therefore, the data presented may contribute to the development of TH-302-based hypoxia-targeting therapies for canine lymphoma.	[Yamazaki, Hiroki; Lai, Yu-Chang; Miura, Naoki] Kagoshima Univ, Vet Teaching Hosp, Joint Fac Vet Med, Korimoto, Kagoshima, Japan; [Tateno, Morihiro; Endo, Yasuyuki] Kagoshima Univ, Joint Fac Vet Med, Lab Vet Internal Med, Korimoto, Kagoshima, Japan; [Setoguchi, Asuka] Bayside Anim Clin, Yokohama, Kanagawa, Japan; [Goto-Koshino, Yuko; Tsujimoto, Hajime] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Internal Med, Bunkyo Ku, Tokyo, Japan; [Nakaichi, Munekazu] Yamaguchi Univ, Joint Fac Vet Med, Dept Vet Med, Lab Vet Radiol, Yoshida, Yamaguchi, Japan; [Yamazaki, Hiroki] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Vet Med Ctr, Izumisano, Osaka, Japan	Kagoshima University; Kagoshima University; University of Tokyo; Yamaguchi University; Osaka Metropolitan University	Miura, N (corresponding author), Kagoshima Univ, Vet Teaching Hosp, Joint Fac Vet Med, Korimoto, Kagoshima, Japan.	k9236024@kadai.jp	Miura, Naoki/A-5734-2010; Miura, Naoki/O-6997-2016	Miura, Naoki/0000-0002-4625-5231; Miura, Naoki/0000-0002-4625-5231; Goto-Koshino, Yuko/0000-0002-5228-7125; Tsujimoto, Hajime/0000-0002-3771-6235	Japan Society for the Promotion of Science (JSPS) KAKENHI [25292180, 15K14872, 17H03926]; Grants-in-Aid for Scientific Research [16H05845, 17H03926] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (grant numbers 25292180, 15K14872, and 17H03926). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appiah-Kubi K, 2016, TUMOUR BIOL; Arico A, 2014, J COMP PATHOL, V151, P322, DOI 10.1016/j.jcpa.2014.07.001; Badar T, 2016, AM J HEMATOL, V91, P800, DOI 10.1002/ajh.24415; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Chawla SP, 2014, J CLIN ONCOL, V32, P3299, DOI 10.1200/JCO.2013.54.3660; Chen YQ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-29; Comerford KM, 2002, CANCER RES, V62, P3387; Evens AM, 2010, J CLIN ONCOL, V28, P1017, DOI 10.1200/JCO.2009.24.1893; Ganjoo KN, 2011, ONCOLOGY-BASEL, V80, P50, DOI 10.1159/000327739; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hendifar AE, 2015, ANN CANC RES, V2, P5; Hernandez-Luna MA, 2013, LEUKEMIA LYMPHOMA, V54, P1048, DOI 10.3109/10428194.2012.733874; Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood-2010-02-269126; Ito D, 2014, VET IMMUNOL IMMUNOP, V159, P192, DOI 10.1016/j.vetimm.2014.02.016; Izaki S, 2007, INT J HEMATOL, V86, P253, DOI 10.1007/BF03006930; Kambayashi S, 2015, J VET MED SCI, V77, P1405, DOI 10.1292/jvms.15-0258; Marconato L, 2009, VET COMP ONCOL, V7, P236, DOI 10.1111/j.1476-5829.2009.00196.x; Momoi Y, 1997, VET IMMUNOL IMMUNOP, V59, P11, DOI 10.1016/S0165-2427(97)00053-6; Nakaichi M, 1996, J VET MED SCI, V58, P469, DOI 10.1292/jvms.58.469; Pang YY, 2015, LEUKEMIA LYMPHOMA, V56, P1821, DOI 10.3109/10428194.2014.963575; Perry AM, 2016, HAEMATOLOGICA, V101, P1244, DOI 10.3324/haematol.2016.148809; Phillips RM, 2016, CANCER CHEMOTH PHARM, V77, P441, DOI 10.1007/s00280-015-2920-7; Powell JR, 2013, LEUKEMIA LYMPHOMA, V54, P959, DOI 10.3109/10428194.2012.733875; Sharif H, 2012, VET J, V194, P40, DOI 10.1016/j.tvjl.2012.03.006; Shoeneman JK, 2016, VET COMP ONCOL, V14, pE45, DOI 10.1111/vco.12104; Sia D, 2014, CURR PHARM DESIGN, V20, P2834, DOI 10.2174/13816128113199990590; Takahashi M, 2014, J VET MED SCI, V76, P895, DOI 10.1292/jvms.13-0345; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tuomela J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-596; Weiss GJ, 2011, CLIN CANCER RES, V17, P2997, DOI 10.1158/1078-0432.CCR-10-3425; Wolfesberger B, 2007, J COMP PATHOL, V137, P30, DOI 10.1016/j.jcpa.2007.03.003; Xia Y, 2012, EUR J MED CHEM, V49, P24, DOI 10.1016/j.ejmech.2012.01.033; Zandvliet M, 2016, VET QUART, V36, P76, DOI 10.1080/01652176.2016.1152633; Zandvliet M, 2015, VET J, V205, P263, DOI 10.1016/j.tvjl.2014.11.002; Zandvliet M, 2014, TOXICOL IN VITRO, V28, P1498, DOI 10.1016/j.tiv.2014.06.004	36	4	4	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2017	12	5							e0177305	10.1371/journal.pone.0177305	http://dx.doi.org/10.1371/journal.pone.0177305			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UN	28489881	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314100058
J	Steinbrook, R				Steinbrook, Robert			Physicians, Industry Payments for Food and Beverages, and Drug Prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHARMACEUTICAL-INDUSTRY		[Steinbrook, Robert] Yale Sch Med, Dept Internal Med, 333 Cedar St,I-456 SHM,POB 208008, New Haven, CT 06520 USA	Yale University	Steinbrook, R (corresponding author), Yale Sch Med, Dept Internal Med, 333 Cedar St,I-456 SHM,POB 208008, New Haven, CT 06520 USA.	robert.steinbrook@yale.edu						American Medical Association, 2016, COD MED ETH; [Anonymous], OP PAYM; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; DeJong C, 2016, JAMA INTERN MED, V176, P1114, DOI 10.1001/jamainternmed.2016.2765; Goschowski Jones R, 2016, MATCHING IND PAYMENT; Ornstein Charles, 2016, NOW THERES PROOF DOC; Steinbrook R, 2016, JAMA INTERN MED, V176, P1123, DOI 10.1001/jamainternmed.2016.2959; Steinbrook R, 2009, NEW ENGL J MED, V360, P557, DOI 10.1056/NEJMp0900143; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Winter A, 2016, PAYMENTS DRUG DEVICE	10	19	20	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2017	317	17					1753	1754		10.1001/jama.2017.2477	http://dx.doi.org/10.1001/jama.2017.2477			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET6YU	28464155				2023-01-03	WOS:000400440700026
J	Qin, JS; Mai, YX; Li, Y; Jiang, ZS; Gao, Y				Qin, Jiasheng; Mai, Yanxing; Li, Yang; Jiang, Zesheng; Gao, Yi			Effect of mild hypothermia preconditioning against low temperature (4 degrees C) induced rat liver cell injury in vitro	PLOS ONE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE STRESS; MODERATE HYPOTHERMIA; BIOARTIFICIAL LIVER; RECOMBINANT HEPG2; APOPTOSIS; PROTECTS; HEPATOCYTES; ACTIVATION; INHIBITION	Bioartificial liver holds special position in the field of regenerative medicine, and cold environment at 4 degrees C is widely used for the short storage of both organ and liver cell for later application. However, the disadvantages of such cold storage could influence cell viability and lead to cell apoptosis in different degrees. In this study, we mainly explore the pre-protective effect of mild hypothermia against low temperature (4 degrees C) -induced rat liver cell injury in vitro. Our results indicated that the precondition with mild hypothermia could increase cell viability, such as cell proliferation, LDH regulation and glycogen synthesis ability of liver cell. The precondition also decreased the ROS production and relieved cell apoptosis in liver cells. Compared with the model group, the mitochondrial membrane potential was restored in the mild hypothermia group, as well as the mitochondrial membrane permeability transition pore opening, indicating that the therapeutic mechanism was related to mitochondrial protection. Further analysis showed that PI3K-Akt-GSK3 beta signal pathway might be associated with the pre-protective effect of mild hypothermia. Thus, our study suggested that the precondition with mild hypothermia hold the protective effect for liver cell in cold environment, and further developed a novel strategy for the storage of liver seed cells, even bioartificial liver.	[Qin, Jiasheng; Li, Yang; Jiang, Zesheng; Gao, Yi] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Guangzhou, Guangdong, Peoples R China; [Qin, Jiasheng; Li, Yang; Jiang, Zesheng; Gao, Yi] Southern Med Univ, Inst Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Mai, Yanxing] Southern Med Univ, Zhujiang Hosp, Dept Geriatr, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Gao, Y (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Guangzhou, Guangdong, Peoples R China.; Gao, Y (corresponding author), Southern Med Univ, Inst Regenerat Med, Guangzhou, Guangdong, Peoples R China.	gaoyi6146@163.com			National High Technology Research and Development Program of China ("863" Program) [2012AA020505]; National Natural Science Foundation of China [81470875]; Science and Technology Planning Project of Guangdong Province [201413020227002, 201513020229002, 20156090903069]; Natural Science Foundation of Guangdong Province [2014A030312013]; Educational Commission of Guangdong Province [C10319040]	National High Technology Research and Development Program of China ("863" Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Educational Commission of Guangdong Province	This study was supported by the grants from the National High Technology Research and Development Program of China ("863" Program 2012AA020505); National Natural Science Foundation of China (81470875); Science and Technology Planning Project of Guangdong Province (201413020227002,201513020229002,20156090903069); Natural Science Foundation of Guangdong Province (2014A030312013); Educational Commission of Guangdong Province (C10319040).	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Baines CP, 2009, BASIC RES CARDIOL, V104, P181, DOI 10.1007/s00395-009-0004-8; Blei A, 2000, LIVER TRANSPLANT, V6, P245, DOI 10.1002/lt.500060206; Cai Jinglei, 2013, Cell Regen, V2, P6, DOI 10.1186/2045-9769-2-6; Chen WN, 2015, AM J PATHOL, V185, P1033, DOI 10.1016/j.ajpath.2014.12.020; Dai HB, 2016, MOL NEUROBIOL, V53, P4865, DOI 10.1007/s12035-015-9391-z; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Enosawa S, 2001, CELL TRANSPLANT, V10, P429; Enosawa S, 2006, CELL TRANSPLANT, V15, P873, DOI 10.3727/000000006783981350; Ferrigno A, 2011, CRYOBIOLOGY, V62, P152, DOI 10.1016/j.cryobiol.2011.02.004; Fu T, 2004, CELL TRANSPLANT, V13, P667, DOI 10.3727/000000004783983495; Gao XY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07091; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gong P, 2013, J CEREBR BLOOD F MET, V33, P928, DOI 10.1038/jcbfm.2013.33; Guo XL, 2016, EUR J PHARMACOL, V791, P578, DOI 10.1016/j.ejphar.2016.09.031; Hong MF, 2005, CURR OPIN CARDIOL, V20, P1; Hosseini MJ, 2016, ENVIRON TOXICOL, V31, P979, DOI 10.1002/tox.22107; Huang K, 2014, SCI CHINA LIFE SCI, V57, P162, DOI 10.1007/s11427-013-4598-6; Iqbal J, 2013, J BIOL CHEM, V288, P36994, DOI 10.1074/jbc.M113.492314; Jacobs S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127368; Jacobs Susan E, 2005, J Pediatr, V147, P122, DOI 10.1016/j.jpeds.2005.04.047; Khaliulin I, 2007, J PHYSIOL-LONDON, V581, P1147, DOI 10.1113/jphysiol.2007.130369; Kim HJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/306421; Lai SS, 2016, J HEPATOL, V64, P352, DOI 10.1016/j.jhep.2015.09.025; Lakshmanan J, 2015, J CELL BIOCHEM, V116, P133, DOI 10.1002/jcb.24951; Lian F, 2015, MOL MED REP, V12, P5821, DOI 10.3892/mmr.2015.4159; Liu PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097123; Liu PF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069617; Liu PF, 2013, LIFE SCI, V92, P829, DOI 10.1016/j.lfs.2013.02.016; Mochizuki T, 2012, RESUSCITATION, V83, P238, DOI 10.1016/j.resuscitation.2011.08.013; Pan CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039151; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Puts CF, 2015, CRYOBIOLOGY, V71, P125, DOI 10.1016/j.cryobiol.2015.04.010; Qadir XV, 2015, AM J PATHOL, V185, P3141, DOI 10.1016/j.ajpath.2015.08.020; Sabir H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109845; Sakurai T, 2006, BBA-MOL CELL RES, V1763, P290, DOI 10.1016/j.bbamcr.2006.02.007; Sakurai T, 2013, DIGEST DIS, V31, P440, DOI 10.1159/000355242; Sakurai T, 2013, CANCER RES, V73, P215, DOI 10.1158/0008-5472.CAN-12-1602; Selden C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082312; Takahara I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170591; Tanoi T, 2016, HEPATOL RES, V46, P697, DOI 10.1111/hepr.12607; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Xiao J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/607271; Xiong W, 2016, J SURG RES, V200, P250, DOI 10.1016/j.jss.2015.06.068; Yu YH, 2015, MOL CELL BIOCHEM, V403, P287, DOI 10.1007/s11010-015-2358-6; Zhang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113107; Zheng T, 2015, BRIT J PHARMACOL, V172, P3284, DOI 10.1111/bph.13120; Zuo DY, 2016, COLLOID SURFACE B, V145, P232, DOI 10.1016/j.colsurfb.2016.05.006	48	11	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2017	12	4							e0176652	10.1371/journal.pone.0176652	http://dx.doi.org/10.1371/journal.pone.0176652			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EO	28453529	Green Submitted, Green Published, gold			2023-01-03	WOS:000400383900040
J	Shukla, S; Abel, B; Chufan, EE; Ambudkar, SV				Shukla, Suneet; Abel, Biebele; Chufan, Eduardo E.; Ambudkar, Suresh V.			Effects of a detergent micelle environment on P-glycoprotein (ABCB1)-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; MULTIDRUG TRANSPORTER; ATP-BINDING; ELECTRON-MICROSCOPY; CATALYTIC CYCLE; DRUG-BINDING; RESISTANCE; ABCB1; INHIBITION; MECHANISM	P-glycoprotein (P-gp) is a multidrug transporter that uses energy from ATP hydrolysis to export many structurally dissimilar hydrophobic and amphipathic compounds, including anticancer drugs from cells. Several structural studies on purified P-gp have been reported, but only limited and sometimes conflicting information is available on ligand interactions with the isolated transporter in a dodecyl-maltoside detergent environment. In this report we compared the biochemical properties of P-gp in native membranes, detergent micelles, and when reconstituted in artificial membranes. We found that the modulators zosuquidar, tariquidar, and elacridar stimulated the ATPase activity of purified human or mouse P-gp in a detergent micelle environment. In contrast, these drugs inhibited ATPase activity in native membranes or in proteoliposomes, with IC50 values in the 10-40 nM range. Similarly, a 30-150-fold decrease in the apparent affinity for verapamil and cyclic peptide inhibitor QZ59-SSS was observed in detergent micelles compared with native or artificial membranes. Together, these findings demonstrate that the high-affinity site is inaccessible because of either a conformational change or binding of detergent at the binding site in a detergent micelle environment. The ligands bind to a low-affinity site, resulting in altered modulation of P-gp ATPase activity. We, therefore, recommend studying structural and functional aspects of ligand interactions with purified P-gp and other ATP-binding cassette transporters that transport amphipathic or hydrophobic substrates in a detergent-free native or artificial membrane environment.	[Shukla, Suneet; Abel, Biebele; Chufan, Eduardo E.; Ambudkar, Suresh V.] NCI, Lab Cell Biol, Ctr Canc Res, NIH, 37 Convent Dr,Rm 2120, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Lab Cell Biol, Ctr Canc Res, NIH, 37 Convent Dr,Rm 2120, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/L-1317-2016		Intramural Research Program of the National Institutes of Health, NCI, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010030] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, NCI, Center for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the Intramural Research Program of the National Institutes of Health, NCI, Center for Cancer Research. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P504; Beck A, 2013, BIOCHEMISTRY-US, V52, P3297, DOI 10.1021/bi400203d; Blatter XL, 2010, BIOPHYS J, V99, P3589, DOI 10.1016/j.bpj.2010.10.033; Choudhury HG, 2014, P NATL ACAD SCI USA, V111, P9145, DOI 10.1073/pnas.1320506111; Chufan EE, 2016, BIOCHEM PHARMACOL, V101, P40, DOI 10.1016/j.bcp.2015.12.007; Chufan EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082463; Denisov IG, 2016, NAT STRUCT MOL BIOL, V23, P481, DOI 10.1038/nsmb.3195; Esser L, 2017, J BIOL CHEM, V292, P446, DOI 10.1074/jbc.M116.755884; Frank GA, 2016, MOL PHARMACOL, V90, P35, DOI 10.1124/mol.116.104190; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Jin MS, 2012, NATURE, V490, P566, DOI 10.1038/nature11448; Kapoor K., 2013, MOL MECH TUMOR CELL, P1; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Lee JY, 2008, J BIOL CHEM, V283, P5769, DOI 10.1074/jbc.M707028200; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Li JZ, 2014, PROTEIN SCI, V23, P34, DOI 10.1002/pro.2387; Loo TW, 2016, BIOCHEM BIOPH RES CO, V472, P379, DOI 10.1016/j.bbrc.2016.02.124; Loo TW, 2015, J BIOL CHEM, V290, P29389, DOI 10.1074/jbc.M115.695171; Loo TW, 2012, J BIOL CHEM, V287, P26806, DOI 10.1074/jbc.M112.376202; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Maki N, 2003, J BIOL CHEM, V278, P18132, DOI 10.1074/jbc.M210413200; Marcoux J, 2013, P NATL ACAD SCI USA, V110, P9704, DOI 10.1073/pnas.1303888110; Moeller A, 2015, STRUCTURE, V23, P450, DOI 10.1016/j.str.2014.12.013; Orlowski S, 1998, Cancer Biochem Biophys, V16, P85; Pluchino KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136396; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Ritchie TK, 2011, J BIOL CHEM, V286, P39489, DOI 10.1074/jbc.M111.284554; Rybczynska M, 2001, BRIT J CANCER, V84, P1405, DOI 10.1054/bjoc.2001.1776; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2006, J BIOL CHEM, V281, P26501, DOI 10.1074/jbc.M601917200; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Shintre CA, 2013, P NATL ACAD SCI USA, V110, P9710, DOI 10.1073/pnas.1217042110; Singh S, 2014, CHEMBIOCHEM, V15, P157, DOI 10.1002/cbic.201300565; Szewczyk P, 2015, ACTA CRYSTALLOGR D, V71, P732, DOI 10.1107/S1399004715000978; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Ward AB, 2013, P NATL ACAD SCI USA, V110, P13386, DOI 10.1073/pnas.1309275110; Zoghbi ME, 2016, J BIOL CHEM, V291, P4453, DOI 10.1074/jbc.M115.698498	43	32	32	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2017	292	17					7066	7076		10.1074/jbc.M116.771634	http://dx.doi.org/10.1074/jbc.M116.771634			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET7LP	28283574	Green Published, hybrid			2023-01-03	WOS:000400478300017
J	Zhou, Q; Sun, Y; Tan, WX; Liu, X; Qian, YC; Ma, XH; Wang, T; Wang, XY; Gao, XM				Zhou, Qian; Sun, Yan; Tan, Wangxiao; Liu, Xiao; Qian, Yuchen; Ma, Xianghui; Wang, Ting; Wang, Xiaoying; Gao, Xiumei			Effect of Shenmai injection on preventing the development of nitroglycerin-induced tolerance in rats	PLOS ONE			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; INDUCED ENDOTHELIAL DYSFUNCTION; SERINE 239 PHOSPHORYLATION; DEPENDENT PROTEIN-KINASE; SOLUBLE GUANYLYL CYCLASE; HUMAN BLOOD-VESSELS; NITRATE TOLERANCE; NITRIC-OXIDE; CORONARY-ARTERIES	Long-term nitroglycerin (NTG) therapy causes tolerance to its effects attributing to increased oxidative stress and endothelial dysfunction. Shenmai injection (SMI), which is clinically used to treat cardiovascular diseases, consists of two herbal medicines, Ginseng Rubra and Ophiopogonjaponicas, and is reported to have antioxidant effects. The present study was designed to investigate the potential preventive effects of Shenmai injection on development of nitroglycerin- induced tolerance. The present study involves both in vivo and in vitro experiments to investigate nitroglycerin-induced tolerance. We examined the effect of Shenmai injection on the cardiovascular oxidative stress by measuring the serum levels of malondialdehyde (MDA) and superoxide dismutase (SOD). Endothelial dysfunction was determined by an endothelium-dependent vasorelaxation method in aortic rings and NOS activity. Inhibition of the cGMP/cGK-I signalling pathway was determined from released serum levels of cGMP and the protein expression levels of sGC, cGK-I, PDE1A and P-VASP by western blot. Here, we showed that SMI ameliorated the decrease in AV Peak Vel, the attenuation in the vasodilation response to nitroglycerin and endothelial dysfunction. SMI also reduced the cardiovascular oxidative stress by reducing the release of MDA and increasing the activity of SOD. Shenmai injection further ameliorated inhibition of the cGMP/ cGK-I signalling pathway triggered by nitroglycerin- induced tolerance through up-regulating the protein expression of sGC, cGK-I, and P-VASP and down-regulating the proteins expression of PDE1A. In vitro studies showed that Shenmai injection could recover the attenuated vasodilation response to nitroglycerin following incubation (of aortic rings) with nitroglycerin via activating the enzymes of sGC and cGK-I. Therefore, we conclude that Shenmai injection could prevent NTG nitroglycerin- induced tolerance at least in part by decreasing the cardiovascular oxidative stress, meliorating the endothelial dysfunction and ameliorating the inhibition of the cGMP/cGK-I signalling pathway. These findings indicate the potential of Shenmai injection (SMI) as a promising medicine for preventing the development of nitroglycerin- induced tolerance.	[Zhou, Qian; Sun, Yan; Tan, Wangxiao; Liu, Xiao; Qian, Yuchen; Ma, Xianghui; Wang, Ting; Wang, Xiaoying; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [Wang, Xiaoying] Tianjin Univ Tradit Chinese Med, Coll Tradit Chinese Med, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Wang, XY (corresponding author), Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin, Peoples R China.; Wang, XY (corresponding author), Tianjin Univ Tradit Chinese Med, Coll Tradit Chinese Med, Tianjin, Peoples R China.	wxy@tjutcm.edu.cn			National Program for Key Basic Research Projects [2012CB518404]; NSFC [81673708, 81630106]; Ministry of Education of PRC "Program for Innovative Research Team in University" [IRT1276, IRT_16R54, IRT_14R41]	National Program for Key Basic Research Projects; NSFC(National Natural Science Foundation of China (NSFC)); Ministry of Education of PRC "Program for Innovative Research Team in University"	This work was supported by the National Program for Key Basic Research Projects (2012CB518404), the NSFC (81673708 and 81630106), the Ministry of Education of PRC "Program for Innovative Research Team in University" (NO. IRT1276).; This work was supported by the National Program for Key Basic Research Projects (2012CB518404), the NSFC (81673708 and 81630106), the Ministry of Education of PRC "Program for Innovative Research Team in University" (NO. IRT_16R54 and IRT_14R41).	Abou-Mohamed G, 2004, J PHARMACOL EXP THER, V308, P289, DOI 10.1124/jpet.103.056119; Azarmi Y, 2014, J CARDIOVASC PHARM, V63, P113, DOI 10.1097/FJC.0000000000000029; Chen YR, 2007, EUR J PHARMACOL, V571, P44, DOI 10.1016/j.ejphar.2007.05.042; Colussi C, 2012, ARTERIOSCL THROM VAS, V32, P2435, DOI 10.1161/ATVBAHA.112.254011; Daiber A, 2015, ANTIOXID REDOX SIGN, V23, P899, DOI 10.1089/ars.2015.6376; Dudek M, 2010, FUND CLIN PHARMACOL, V24, P47, DOI 10.1111/j.1472-8206.2009.00728.x; El-Demerdash E, 2006, PHARMACOL RES, V53, P380, DOI 10.1016/j.phrs.2006.01.007; Fekete V, 2013, J CARDIOVASC PHARM, V62, P298, DOI 10.1097/FJC.0b013e3182993ae0; Garcia-Bou R, 2012, BBA-BIOENERGETICS, V1817, P828, DOI 10.1016/j.bbabio.2012.02.013; Hink U, 2007, J AM COLL CARDIOL, V50, P2226, DOI 10.1016/j.jacc.2007.08.031; Hu R, 2014, TRENDS PHARMACOL SCI, V35, P369, DOI 10.1016/j.tips.2014.06.001; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jabs A, 2015, VASC PHARMACOL, V71, P181, DOI 10.1016/j.vph.2015.03.007; Jiao Hong, 2014, Zhongguo Zhong Yao Za Zhi, V39, P2956; Kim D, 2001, CIRCULATION, V104, P2338, DOI 10.1161/hc4401.098432; Knorr M, 2011, ARTERIOSCL THROM VAS, V31, P2223, DOI 10.1161/ATVBAHA.111.232058; Kosmicki MA, 2009, CURR CLIN PHARMACOL, V4, P132, DOI 10.2174/157488409788185016; Lei S., 2013, OXIDATIVE MED CELLUL, V2013; Levine GN, 2016, J AM COLL CARDIOLOGY; Li YJ, 2003, MED HYPOTHESES, V60, P693, DOI 10.1016/S0306-9877(03)00024-0; Lin Lina, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1155; Liuni A, 2011, J AM COLL CARDIOL, V57, P93, DOI 10.1016/j.jacc.2010.07.037; Major TC, 2013, BIOMATERIALS, V34, P8086, DOI 10.1016/j.biomaterials.2013.07.041; Matsuzaki T, 2002, CLIN EXP PHARMACOL P, V29, P1091, DOI 10.1046/j.1440-1681.2002.03776.x; Mink SN, 2005, J MOL CELL CARDIOL, V39, P615, DOI 10.1016/j.yjmcc.2005.06.009; Mulsch A, 2001, CIRCULATION, V103, P2188; Munzel T, 2005, ARTERIOSCL THROM VAS, V25, P1551, DOI 10.1161/01.ATV.0000168896.64927.bb; Nossaman BD, 2013, OCHSNER J, V13, P147; PACKER M, 1990, J AM COLL CARDIOL, V16, P932, DOI 10.1016/S0735-1097(10)80343-2; Sage PR, 2000, CIRCULATION, V102, P2810; Schulz E, 2002, CIRCULATION, V105, P1170, DOI 10.1161/hc1002.105186; Shi LW, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0939-2; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; Szocs K, 2007, J MOL CELL CARDIOL, V42, P1111, DOI 10.1016/j.yjmcc.2007.03.904; Tan T, 2010, CARDIOVASC DRUG THER, V24, P95, DOI 10.1007/s10557-010-6229-9; Tawa M, 2014, J PHARMACOL SCI, V125, P169, DOI 10.1254/jphs.14046FP; Tsou PS, 2009, J PHARMACOL EXP THER, V329, P649, DOI 10.1124/jpet.108.149997; Van Hove CE, 2009, BRIT J PHARMACOL, V158, P920, DOI 10.1111/j.1476-5381.2009.00396.x; Wang XY, 2015, PHYTOMEDICINE, V22, P875, DOI 10.1016/j.phymed.2015.06.010; [吴茵 Wu Yin], 2014, [中草药, Chinese Traditional and Herbal Drugs], V45, P2625; Yu J, 2014, J ETHNOPHARMACOL, V154, P391, DOI 10.1016/j.jep.2014.04.014; Yu K, 2007, J PHARMACEUT BIOMED, V44, P532, DOI 10.1016/j.jpba.2007.01.032; Zhang GG, 2008, LIFE SCI, V82, P699, DOI 10.1016/j.lfs.2008.01.002; Zhao Xiyue, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2153; Zheng Xiaojun, 2011, Zhongguo Zhong Yao Za Zhi, V36, P3023; Zhu JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078026	47	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2017	12	4							e0176777	10.1371/journal.pone.0176777	http://dx.doi.org/10.1371/journal.pone.0176777			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EO	28453571	Green Submitted, Green Published, gold			2023-01-03	WOS:000400383900054
J	Tadakamadla, J; Kumar, S; Lalloo, R; Johnson, NW				Tadakamadla, Jyothi; Kumar, Santhosh; Lalloo, Ratilal; Johnson, Newell W.			Qualitative analysis of the impact of Oral Potentially Malignant Disorders on daily life activities	PLOS ONE			English	Article							REPORTED OUTCOME MEASURES; OF-LIFE; SUBMUCOUS FIBROSIS; MUCOSAL DISEASE; CLASSIFICATION; INTERVENTIONS; QUESTIONNAIRE; INTERVIEWS; VALIDITY; SYSTEM	Objective To evaluate the impact of Oral Potentially Malignant Disorders (OPMD) on daily life activities. Materials and methods Patients diagnosed with Oral Leukoplakia, Oral submucous fibrosis and Oral Lichen Planus attending the Oral Medicine clinic of Panineeya Institute of Dental Sciences & Research Centre, Hyderabad, India were invited to participate. Eighteen interviews and three focus groups were conducted in a non-clinical setting. Voice recordings were transcribed and translated from Telugu to English. Data coding was performed using the NVivo software. Results Sample size for this qualitative study comprised 32 patients. Four main themes emerged: (1) difficulties with diagnosis and knowledge about the condition, (2) physical impairment and functional limitations, (3) psychological and social wellbeing and (4) effects of treatment on daily life. In a majority of the patients, most of the interview time was spent discussing physical impairment and functional limitations. Patients also reported their mouth condition having a debilitating effect on their psychological well-being and social interactions. Conclusions 'Physical impairment and functional limitations' was the most important theme for many of the patients. However, the impacts of OPMD also extended beyond physical impairment and functional limitations to aspects of daily living, notably psychological and social wellbeing.	[Tadakamadla, Jyothi; Kumar, Santhosh; Johnson, Newell W.] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Tadakamadla, Jyothi; Kumar, Santhosh] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia; [Lalloo, Ratilal] Univ Queensland, Sch Dent, Brisbane, Qld, Australia	Griffith University; Menzies Health Institute Queensland; Griffith University; University of Queensland	Tadakamadla, J (corresponding author), Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia.; Tadakamadla, J (corresponding author), Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia.	jyothi.tadakamadla@griffithuni.edu.au	Tadakamadla, santosh kumar/Y-8446-2019; Johnson, Newell W/D-8152-2019; Lalloo, Ratilal/O-5624-2014	Tadakamadla, santosh kumar/0000-0003-2775-2897; Johnson, Newell W/0000-0001-5866-262X; Lalloo, Ratilal/0000-0001-5822-1269				Adulyanon S., 1997, MEASURING ORAL HLTH, P151; Al-Busaidi Zakiya Q, 2008, Sultan Qaboos Univ Med J, V8, P11; Ali MIR Shahid, 2014, INDIAN J HLTH WELLBE, V5, P681; Antunes B, 2014, PALLIATIVE MED, V28, P158, DOI 10.1177/0269216313491619; Bredart A, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-15; Chandu A, 2006, J ORAL MAXIL SURG, V64, P495, DOI 10.1016/j.joms.2005.11.028; Dinshaw K. A., 2005, HLTH ADM, V7, P10; Escudier M, 2007, BRIT J DERMATOL, V157, P765, DOI 10.1111/j.1365-2133.2007.08106.x; Fedorowicz Z, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007156.pub2; Gill P, 2008, BRIT DENT J, V204, P291, DOI 10.1038/bdj.2008.192; Ishak N. M., 2012, ED RES J, V2, P94; Keles H, 2007, INTERN MED J, V37, P6, DOI 10.1111/j.1445-5994.2006.01215.x; Kerr AR, 2011, ORAL DIS, V17, P42, DOI 10.1111/j.1601-0825.2011.01791.x; Kerr C, 2010, EXPERT REV PHARM OUT, V10, P269, DOI [10.1586/erp.10.30, 10.1586/ERP.10.30]; Kulkarni Ravikumar S, 2015, J Nat Sci Biol Med, V6, P116, DOI 10.4103/0976-9668.149104; LAI DR, 1995, J ORAL PATHOL MED, V24, P402, DOI 10.1111/j.1600-0714.1995.tb01209.x; Lodi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001829.pub3; LODI G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001829.PUB2; MAHER R, 1994, J ORAL PATHOL MED, V23, P65, DOI 10.1111/j.1600-0714.1994.tb00258.x; McKenna SP, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-86; Morgan D., 1997, FOCUS GROUPS QUALITA, DOI [10.4135/9781412984287, DOI 10.4135/9781412984287]; Mortazavi Hamed, 2014, J Dent Res Dent Clin Dent Prospects, V8, P6, DOI 10.5681/joddd.2014.002; Nelson EC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7818; Nikander P., 2008, QUAL RES PSYCHOL, V5, P225, DOI DOI 10.1080/14780880802314346; Patrick DL, 2011, VALUE HEALTH, V14, P967, DOI 10.1016/j.jval.2011.06.014; Riordain RN, 2011, ORAL DIS, V17, P265, DOI 10.1111/j.1601-0825.2010.01734.x; Riordain RN, 2011, J ORAL PATHOL MED, V40, P604, DOI 10.1111/j.1600-0714.2011.01021.x; Rogers SN, 1999, INT J ORAL MAX SURG, V28, P99, DOI 10.1016/S0901-5027(99)80201-X; Sarode SC, 2012, ORAL ONCOL, V48, P759, DOI 10.1016/j.oraloncology.2012.02.025; Sarode SC, 2011, ORAL ONCOL, V47, P920, DOI 10.1016/j.oraloncology.2011.06.005; Satheeshkumar PS, 2014, ORAL ONCOL, V50, pE51, DOI 10.1016/j.oraloncology.2014.07.006; Shah AA, 2011, ORAL ONCOL, V47, P920; Shah AA, 2012, ORAL ONCOL, V48, pE26, DOI 10.1016/j.oraloncology.2012.05.003; Streiner DL, 2003, HLTH MEASUREMENT SCA, P15; Tadakamadla J, 2017, OR SURG OR MED OR PA, V123, P338, DOI 10.1016/j.oooo.2016.10.025; Tadakamadla J, 2015, OR SURG OR MED OR PA, V119, P644, DOI 10.1016/j.oooo.2015.01.025; Thongprasom K, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001168, 10.1002/14651858.CD001168.pub2]; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Torres-Pereira Cassius, 2010, Braz. oral res., V24, P37, DOI 10.1590/S1806-83242010000500007; van der Waal I, 2000, ORAL ONCOL, V36, P264, DOI 10.1016/S1368-8375(99)00092-5; van der Waal I, 2009, ORAL ONCOL, V45, P317, DOI 10.1016/j.oraloncology.2008.05.016; Villa A, 2011, AUST DENT J, V56, P253, DOI 10.1111/j.1834-7819.2011.01337.x; Walsh T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010173.pub2; Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x; Zide MF, 2008, J ORAL MAXIL SURG, V66, P1162, DOI 10.1016/j.joms.2008.01.047	45	9	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2017	12	4							e0175531	10.1371/journal.pone.0175531	http://dx.doi.org/10.1371/journal.pone.0175531			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MD	28410381	Green Submitted, gold, Green Published			2023-01-03	WOS:000399955600023
J	Kass, L; Rosanoff, A; Tanner, A; Sullivan, K; McAuley, W; Plesset, M				Kass, Lindsy; Rosanoff, Andrea; Tanner, Amy; Sullivan, Keith; McAuley, William; Plesset, Michael			Effect of transdermal magnesium cream on serum and urinary magnesium levels in humans: A pilot study	PLOS ONE			English	Article							BLOOD-PRESSURE; DIETARY MAGNESIUM; SUPPLEMENTATION; RISK; METAANALYSIS; EXERCISE; DISEASE	Background Oral magnesium supplementation is commonly used to support a low magnesium diet. This investigation set out to determine whether magnesium in a cream could be absorbed transdermally in humans to improve magnesium status. Methods and findings In this single blind, parallel designed pilot study, n = 25 participants (aged 34.3+/-14.8y, height 171.5+/-11cm, weight 75.9 +/- 14 Kg) were randomly assigned to either a 56mg/day magnesium cream or placebo cream group for two weeks. Magnesium serum and 24hour urinary excretion were measured at baseline and at 14 days intervention. Food diaries were recorded for 8 days during this period. Mg test and placebo groups' serum and urinary Mg did not differ at baseline. After the Mg2+ cream intervention there was a clinically relevant increase in serum magnesium (0.82 to 0.89 mmol/l,p = 0.29) that was not seen in the placebo group (0.77 to 0.79 mmol/L), but was only statistically significant (p = 0.02)) in a subgroup of non-athletes. Magnesium urinary excretion increased from baseline slightly in the Mg2+ group but with no statistical significance (p = 0.48). The Mg2+ group showed an 8.54% increase in serum Mg2+ and a 9.1% increase in urinary Mg2+ while these figures for the placebo group were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the placebo group, both serum and urine concentrations showed no statistically significant change after the application of the placebo cream. Conclusion No previous studies have looked at transdermal absorbency of Mg2+ in human subjects. In this pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commercial transdermal Mg2+ products available) showed a larger percentage rise in both serum and urinary markers from pre to post intervention compared with subjects using the placebo cream, but statistical significance was achieved only for serum Mg2+ in a subgroup of nonathletes. Future studies should look at higher dosage of magnesium cream for longer durations.	[Kass, Lindsy; Tanner, Amy; Sullivan, Keith; McAuley, William] Univ Hertfordshire, Hatfield, Herts, England; [Rosanoff, Andrea; Plesset, Michael] Ctr Magnesium Educ & Res, Pahoa, HI USA	University of Hertfordshire	Kass, L (corresponding author), Univ Hertfordshire, Hatfield, Herts, England.	l.s.kass@herts.ac.uk	Rosanoff, Andrea/L-6869-2019	McAuley, William/0000-0003-3065-4649				Bain LKM, 2015, INT J CARDIOL, V196, P108, DOI 10.1016/j.ijcard.2015.05.166; Chen K, 2016, ADV MATER INTERFACES, V3, DOI 10.1002/admi.201600115; Cunha AR, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/754250; Del Gobbo LC, 2013, AM J CLIN NUTR, V98, P160, DOI 10.3945/ajcn.112.053132; DJURHUUS MS, 1995, SCAND J CLIN LAB INV, V55, P549, DOI 10.3109/00365519509075394; Elin RJ, 2010, MAGNESIUM RES, V23, pS194, DOI 10.1684/mrh.2010.0213; Guerrero-Romero F, 2002, ACTA DIABETOL, V39, P209, DOI 10.1007/s005920200036; Hostynek JJ, 2003, FOOD CHEM TOXICOL, V41, P327, DOI 10.1016/S0278-6915(02)00257-0; Jahnen-Dechent W, 2012, CLIN KIDNEY J, V5, P3, DOI 10.1093/ndtplus/sfr163; Kass L, 2012, EUR J CLIN NUTR, V66, P411, DOI 10.1038/ejcn.2012.4; Laires MJ, 2008, MAGNESIUM RES, V21, P92; Larsson SC, 2013, AM J CLIN NUTR, V97, P1159, DOI 10.3945/ajcn.113.063354; Laurant P, 2000, J HYPERTENS, V18, P1177, DOI 10.1097/00004872-200018090-00003; LUKASKI HC, 1995, INT J SPORT NUTR, V5, pS74, DOI 10.1123/ijsn.5.s1.s74; Lutsey PL, 2014, AM J CLIN NUTR, V100, P756, DOI 10.3945/ajcn.114.085167; Newhouse IJ, 2000, CLIN J SPORT MED, V10, P195, DOI 10.1097/00042752-200007000-00008; Nielsen FH, 2006, MAGNESIUM RES, V19, P180; Royal College of Physicians and surgeons C, 2015, CLIN LAB TESTS REF V; Staff K, 2011, TOXICOL LETT, V202, P155, DOI 10.1016/j.toxlet.2011.01.017; Trauninger A, 2002, HEADACHE, V42, P114, DOI 10.1046/j.1526-4610.2002.02026.x; Zhang X, 2016, HYPERTENSION, V68, P324, DOI 10.1161/HYPERTENSIONAHA.116.07664	21	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2017	12	4							e0174817	10.1371/journal.pone.0174817	http://dx.doi.org/10.1371/journal.pone.0174817			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0LZ	28403154	Green Published, Green Submitted, gold			2023-01-03	WOS:000399955200023
J	Saberi, S; Wheeler, M; Bragg-Gresham, J; Hornsby, W; Agarwal, PP; Attili, A; Concannon, M; Dries, AM; Shmargad, Y; Salisbury, H; Kumar, S; Herrera, J; Myers, J; Helms, AS; Ashley, EA; Day, SM				Saberi, Sara; Wheeler, Matthew; Bragg-Gresham, Jennifer; Hornsby, Whitney; Agarwal, Prachi P.; Attili, Anil; Concannon, Maryann; Dries, Annika M.; Shmargad, Yael; Salisbury, Heidi; Kumar, Suwen; Herrera, Jonathan; Myers, Jonathan; Helms, Adam S.; Ashley, Euan A.; Day, Sharlene M.			Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC HEART-FAILURE; BLOOD-PRESSURE RESPONSE; COLLEGE-OF-CARDIOLOGY; PHYSICAL-ACTIVITY; SPORTS PARTICIPATION; SCIENTIFIC STATEMENT; SYMPTOMATIC PATIENTS; PROGNOSTIC VALUE; LEISURE-TIME; TASK-FORCE	IMPORTANCE Formulating exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of concern about triggering ventricular arrhythmias and because a clinical benefit has not been previously established in this population. OBJECTIVE To determine whether moderate-intensity exercise training improves exercise capacity in adults with hypertrophic cardiomyopathy. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April 2010 and October 2015 at 2 academic medical centers in the United States (University of Michigan Health System and Stanford University Medical Center). Date of last follow-up was November 2016. INTERVENTIONS Participants were randomly assigned to 16 weeks of moderate-intensity exercise training (n = 67) or usual activity (n = 69). MAIN OUTCOMES AND MEASURES The primary outcome measure was change in peak oxygen consumption from baseline to 16 weeks. RESULTS Among the 136 randomized participants (mean age, 50.4 [SD, 13.3] years; 42% women), 113 (83%) completed the study. At 16 weeks, the change in mean peak oxygen consumption was + 1.35 (95% CI, 0.50 to 2.21) mL/kg/min among participants in the exercise training group and + 0.08 (95% CI, -0.62 to 0.79) mL/kg/min among participants in the usual-activity group (between-group difference, 1.27 [95% CI, 0.17 to 2.37]; P = .02). There were no occurrences of sustained ventricular arrhythmia, sudden cardiac arrest, appropriate defibrillator shock, or death in either group. CONCLUSIONS AND RELEVANCE In this preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise compared with usual activity resulted in a statistically significant but small increase in exercise capacity at 16 weeks. Further research is needed to understand the clinical importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term safety of exercise at moderate and higher levels of intensity.	[Saberi, Sara; Bragg-Gresham, Jennifer; Hornsby, Whitney; Agarwal, Prachi P.; Attili, Anil; Concannon, Maryann; Kumar, Suwen; Herrera, Jonathan; Helms, Adam S.; Day, Sharlene M.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Wheeler, Matthew; Dries, Annika M.; Shmargad, Yael; Salisbury, Heidi; Ashley, Euan A.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Myers, Jonathan] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA	University of Michigan System; University of Michigan; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Saberi, S (corresponding author), Univ Michigan, Sch Med, Frankel Cardiovasc Ctr, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	saberis@med.umich.edu		Wheeler, Matthew/0000-0001-8721-3022; Helms, Adam/0000-0002-0234-6430	Michigan Institute for Clinical & Health Research [UL1TR000433]; University of Michigan Frankel Cardiovascular Center McKay Research Grant; University of Michigan Frankel Cardiovascular Center Inaugural Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; Veterans Affairs [IK6RX002477] Funding Source: NIH RePORTER	Michigan Institute for Clinical & Health Research; University of Michigan Frankel Cardiovascular Center McKay Research Grant; University of Michigan Frankel Cardiovascular Center Inaugural Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by research grant UL1TR000433 from the Michigan Institute for Clinical & Health Research, the University of Michigan Frankel Cardiovascular Center McKay Research Grant, the University of Michigan Frankel Cardiovascular Center Inaugural Grant, and an anonymous donor. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Alcalai R, 2008, J CARDIOVASC ELECTR, V19, P104, DOI 10.1111/j.1540-8167.2007.00965.x; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRAUNWALD E, 1964, CIRCULATION, V30, P3; Chan RH, 2014, CIRCULATION, V130, P484, DOI 10.1161/CIRCULATIONAHA.113.007094; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; Coats CJ, 2015, CIRC-HEART FAIL, V8, P1022, DOI 10.1161/CIRCHEARTFAILURE.114.002248; Finocchiaro G, 2015, JACC-HEART FAIL, V3, P408, DOI 10.1016/j.jchf.2014.11.011; Fletcher GF, 2013, CIRCULATION, V128, P873, DOI 10.1161/CIR.0b013e31829b5b44; Gersh BJ, 2011, CIRCULATION, V124, P2761, DOI 10.1161/CIR.0b013e318223e230; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Huff CM, 2013, QUAL LIFE RES, V22, P647, DOI 10.1007/s11136-012-0182-y; Klempfner R, 2015, EUR J PREV CARDIOL, V22, P13, DOI 10.1177/2047487313501277; Kokkinos P, 2008, CIRCULATION, V117, P614, DOI 10.1161/CIRCULATIONAHA.107.734764; Le VV, 2009, AM HEART J, V158, pE27, DOI 10.1016/j.ahj.2009.06.006; Maron BJ, 2015, CIRCULATION, V132, pE273, DOI 10.1161/CIR.0000000000000239; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; Maron BJ, 2004, CIRCULATION, V109, P2807, DOI 10.1161/01.CIR.0000128363.85581.E1; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Olivotto I, 1999, J AM COLL CARDIOL, V33, P2044, DOI 10.1016/S0735-1097(99)00094-7; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; Pandey A, 2015, CIRC-HEART FAIL, V8, P33, DOI 10.1161/CIRCHEARTFAILURE.114.001615; Pelliccia A, 2006, EUR J CARDIOV PREV R, V13, P876, DOI 10.1097/01.hjr.0000238393.96975.32; Reineck E, 2013, AM J CARDIOL, V111, P1034, DOI 10.1016/j.amjcard.2012.12.018; Sadoul N, 1997, CIRCULATION, V96, P2987, DOI 10.1161/01.CIR.96.9.2987; Sattelmair J, 2011, CIRCULATION, V124, P789, DOI 10.1161/CIRCULATIONAHA.110.010710; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Semsarian C, 2015, J AM COLL CARDIOL, V65, P1249, DOI 10.1016/j.jacc.2015.01.019; Sharma S, 2001, Cardiol Rev, V9, P70, DOI 10.1097/00045415-200103000-00005; Sofi F, 2008, EUR J CARDIOV PREV R, V15, P247, DOI 10.1097/HJR.0b013e3282f232ac; Sorajja P, 2012, AM J CARDIOL, V109, P1494, DOI 10.1016/j.amjcard.2012.01.363; Swank AM, 2012, CIRC-HEART FAIL, V5, P579, DOI 10.1161/CIRCHEARTFAILURE.111.965186; Sweeting J, 2015, CIRC-CARDIOVASC GENE, V8, P178, DOI 10.1161/CIRCGENETICS.114.000784; Vromen T, 2016, INT J CARDIOL, V208, P120, DOI 10.1016/j.ijcard.2016.01.207; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6	36	111	116	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2017	317	13					1349	1357		10.1001/jama.2017.2503	http://dx.doi.org/10.1001/jama.2017.2503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ9VR	28306757	Green Published			2023-01-03	WOS:000398434200019
J	Garber, K				Garber, Ken			Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy	NATURE BIOTECHNOLOGY			English	News Item																		2015, NAT BIOTECHNOL, V33, P1217; 2008, CANC RES, V68, P889; 1993, CELL, V75, P2515; 2015, N ENGL J MED, V372, P2509; 2012, N ENGL J MED, V366, P2443; 2016, CLIN ADV HEMATOL ONC, V14, P476	6	9	11	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2017	35	4					297	298		10.1038/nbt0417-297a	http://dx.doi.org/10.1038/nbt0417-297a			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ER4OT	28398313				2023-01-03	WOS:000398780600006
J	Nijssen, EC; Rennenberg, RJ; Nelemans, PJ; Essers, BA; Janssen, MM; Vermeeren, MA; van Ommen, V; Wildberger, JE				Nijssen, Estelle C.; Rennenberg, Roger J.; Nelemans, Patty J.; Essers, Brigitte A.; Janssen, Marga M.; Vermeeren, Marja A.; van Ommen, Vincent; Wildberger, Joachim E.			Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial	LANCET			English	Article							ACUTE KIDNEY INJURY; INDUCED NEPHROTOXICITY; CORONARY-ANGIOGRAPHY; MEDIA; OUTCOMES; DISEASE	Background Intravenous saline is recommended in clinical practice guidelines as the cornerstone for preventing contrast-induced nephropathy in patients with compromised renal function. However, clinical-effectiveness and cost-effectiveness of this prophylactic hydration treatment in protecting renal function has not been adequately studied in the population targeted by the guidelines, against a group receiving no prophylaxis. This was the aim of the AMACING trial. Methods AMACING is a prospective, randomised, phase 3, parallel-group, open-label, non-inferiority trial of patients at risk of contrast-induced nephropathy according to current guidelines. High-risk patients (with an estimated glomerular filtration rate [eGFR] of 30-59 mL per min/1.73 m(2)) aged 18 years and older, undergoing an elective procedure requiring iodinated contrast material administration at Maastricht University Medical Centre, the Netherlands, were randomly assigned (1:1) to receive intravenous 0.9% NaCl or no prophylaxis. We excluded patients with eGFR lower than 30 mL per min/1.73 m(2), previous dialysis, or no referral for intravenous hydration. Randomisation was stratified by predefined risk factors. The primary outcome was incidence of contrast-induced nephropathy, defined as an increase in serum creatinine from baseline of more than 25% or 44 mu mol/L within 2-6 days of contrast exposure, and cost-effectiveness of no prophylaxis compared with intravenous hydration in the prevention of contrast-induced nephropathy. We measured serum creatinine immediately before, 2-6 days, and 26-35 days after contrast-material exposure. Laboratory personnel were masked to treatment allocation. Adverse events and use of resources were systematically recorded. The non-inferiority margin was set at 2.1%. Both intention-to-treat and per-protocol analyses were done. This trial is registered with ClinicalTrials.gov, number NCT02106234. Findings Between June 17, 2014, and July 17, 2016, 660 consecutive patients were randomly assigned to receive no prophylaxis (n = 332) or intravenous hydration (n = 328). 2-6 day serum creatinine was available for 307 (92%) of 332 patients in the no prophylaxis group and 296 (90%) of 328 patients in the intravenous hydration group. Contrast-induced nephropathy was recorded in eight (2.6%) of 307 non-hydrated patients and in eight (2.7%) of 296 hydrated patients. The absolute difference (no hydration vs hydration) was -0.10% (one-sided 95% CI -2.25 to 2.06; one-tailed p = 0.4710). No hydration was cost-saving relative to hydration. No haemodialysis or related deaths occurred within 35 days. 18 (5.5%) of 328 patients had complications associated with intravenous hydration. Interpretation We found no prophylaxis to be non-inferior and cost-saving in preventing contrast-induced nephropathy compared with intravenous hydration according to current clinical practice guidelines.	[Nijssen, Estelle C.; Janssen, Marga M.; Wildberger, Joachim E.] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, NL-6202 AZ Maastricht, Netherlands; [Rennenberg, Roger J.] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands; [Nelemans, Patty J.] Maastricht Univ, Med Ctr, Dept Epidemiol, Maastricht, Netherlands; [Essers, Brigitte A.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [Vermeeren, Marja A.; van Ommen, Vincent] Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University; Maastricht University	Nijssen, EC (corresponding author), Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, NL-6202 AZ Maastricht, Netherlands.	estelle.nijssen@mumc.nl	Rennenberg, Roger/L-6552-2019	Wildberger, Joachim/0000-0002-4810-6854	Stichting de Weijerhorst	Stichting de Weijerhorst	Stichting de Weijerhorst.	Balemans CEA, 2012, RADIOLOGY, V263, P706, DOI 10.1148/radiol.12111667; BARTELS ED, 1954, ACTA MED SCAND, V150, P297; Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2; Bruck K, 2016, J AM SOC NEPHROL, V27, P2135, DOI 10.1681/ASN.2015050542; Christiansen C, 2005, TOXICOLOGY, V209, P185, DOI 10.1016/j.tox.2004.12.020; European Society of Urogenital Radiology, 2014, ESUR GUID CONTR MED; Hakkaart-van Roijen L, 2015, OPDRACHT ZORGINSTITU, P12; Hilton AK, 2008, MED J AUSTRALIA, V189, P509, DOI 10.5694/j.1326-5377.2008.tb02147.x; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; James MT, 2013, CIRC-CARDIOVASC INTE, V6, P37, DOI 10.1161/CIRCINTERVENTIONS.112.974493; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Jurado-Roman A, 2015, AM J CARDIOL, V115, P1174, DOI 10.1016/j.amjcard.2015.02.004; Katzberg RW, 2010, RADIOLOGY, V256, P21, DOI 10.1148/radiol.10092000; Kooiman J, 2014, J THROMB HAEMOST, V12, P1658, DOI 10.1111/jth.12701; LaBounty TM, 2012, AM J CARDIOL, V109, P1594, DOI 10.1016/j.amjcard.2012.01.380; Luo Y, 2014, INTERNAL MED, V53, P2265, DOI 10.2169/internalmedicine.53.1853; McCullough PA, 2008, J AM COLL CARDIOL, V51, P1419, DOI 10.1016/j.jacc.2007.12.035; Morcos SK, 1999, EUR RADIOL, V9, P1602, DOI 10.1007/s003300050894; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; NICE, 2013, GUID 2 AC KIDN INJ P; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; PORTER GA, 1990, AM J CARDIOL, V66, pF18, DOI 10.1016/0002-9149(90)90636-F; Prowle JR, 2010, NAT REV NEPHROL, V6, P107, DOI 10.1038/nrneph.2009.213; Rudnick MR, 2008, CLIN J AM SOC NEPHRO, V3, P261, DOI 10.2215/CJN.04951107; Stacul F, 2011, EUR RADIOL, V21, P2527, DOI 10.1007/s00330-011-2225-0; Thomsen HS, 2008, ACTA RADIOL, V49, P646, DOI 10.1080/02841850801995413; Veligheids Management Systeem, 2009, VMS VEIL VOORK NIER	27	259	270	4	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2017	389	10076					1312	1322		10.1016/S0140-6736(17)30057-0	http://dx.doi.org/10.1016/S0140-6736(17)30057-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ2OF	28233565				2023-01-03	WOS:000397908700024
J	Beni, MS; Ng, CYP; Krstic, D; Nikezic, D; Yu, KN				Beni, Mehrdad Shahmohammadi; Ng, C. Y. P.; Krstic, D.; Nikezic, D.; Yu, K. N.			Conversion coefficients for determination of dispersed photon dose during radiotherapy: NRUrad input code for MCNP	PLOS ONE			English	Article							RADIATION-THERAPY; MONTE-CARLO; LINEAR ACCELERATORS; 6 MV; BEAM; SIMULATION; ORGANS; IMRT; RISK; ROOM	Radiotherapy is a common cancer treatment module, where a certain amount of dose will be delivered to the targeted organ. This is achieved usually by photons generated by linear accelerator units. However, radiation scattering within the patient's body and the surrounding environment will lead to dose dispersion to healthy tissues which are not targets of the primary radiation. Determination of the dispersed dose would be important for assessing the risk and biological consequences in different organs or tissues. In the present work, the concept of conversion coefficient (F) of the dispersed dose was developed, in which F = (D-d/D-t), where D-d was the dispersed dose in a non-targeted tissue and D-t is the absorbed dose in the targeted tissue. To quantify D-d and D-t, a comprehensive model was developed using the Monte Carlo N-Particle (MCNP) package to simulate the linear accelerator head, the human phantom, the treatment couch and the radiotherapy treatment room. The present work also demonstrated the feasibility and power of parallel computing through the use of the Message Passing Interface (MPI) version of MCNP5.	[Beni, Mehrdad Shahmohammadi; Ng, C. Y. P.; Nikezic, D.; Yu, K. N.] City Univ Hong Kong, Dept Phys & Mat Sci, Tat Chee Ave, Kowloon Tong, Hong Kong, Peoples R China; [Krstic, D.; Nikezic, D.] Univ Kragujevac, Fac Sci, Kragujevac, Serbia	City University of Hong Kong; University of Kragujevac	Yu, KN (corresponding author), City Univ Hong Kong, Dept Phys & Mat Sci, Tat Chee Ave, Kowloon Tong, Hong Kong, Peoples R China.	peter.yu@cityu.edu.hk	Nikezic, Dragoslav R/B-9343-2009; Beni, Mehrdad Shahmohammadi/ABA-8764-2020; Yu, Peter K.N./C-7051-2013	Yu, Peter K.N./0000-0003-1669-5348; Nikezic, Dragoslav/0000-0002-3236-4912; Krstic, Dragana/0000-0002-3517-9210	Department of Physics and Materials Science, City University of Hong Kong	Department of Physics and Materials Science, City University of Hong Kong	We acknowledge the support of the Neutron computer cluster from the Department of Physics and Materials Science, City University of Hong Kong, for the computational work involved in this paper.	[Anonymous], 1991, ANN ICRP, V21, P1; Becker J, 2007, PHYS MED BIOL, V52, P6375, DOI 10.1088/0031-9155/52/21/002; Bednarz B, 2009, PHYS MED BIOL, V54, pN43, DOI 10.1088/0031-9155/54/4/N01; Bencheikh M, 2016, MOROC J CHEM, V4, P722; Beni MS, 2016, J RADIAT RES, V57, P492, DOI 10.1093/jrr/rrw063; FRANCOIS P, 1988, MED PHYS, V15, P879, DOI 10.1118/1.596170; Garnica-Garza HM, 2005, PHYS MED BIOL, V50, P531, DOI 10.1088/0031-9155/50/3/010; Ghiasi H, 2010, IRAN J RADIAT RES, V8, P187; Goorley T., MCNP MED PHYS GEOMET; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Howell RM, 2006, MED PHYS, V33, P360, DOI 10.1118/1.2140119; Krstic D, 2007, COMPUT PHYS COMMUN, V176, P33, DOI 10.1016/j.cpc.2006.06.016; Kry SF, 2005, INT J RADIAT ONCOL, V62, P1204, DOI 10.1016/j.ijrobp.2004.12.091; Lewis RD, 1999, PHYS MED BIOL, V44, P1219, DOI 10.1088/0031-9155/44/5/010; Maarouf M, 2005, STRAHLENTHER ONKOL, V181, P463, DOI 10.1007/s00066-005-1391-x; Mesbahi A, 2010, RADIAT PROT DOSIM, V140, P242, DOI 10.1093/rpd/ncp303; Mesbahi A, 2010, JPN J RADIOL, V28, P398, DOI 10.1007/s11604-010-0432-2; National Institute for Health and Clinical Excellence, 2005, REF SUSP CANC; NCRP, 1993, 116 NCRP; Rafi Uddin M, 2003, BANGLADESH J MED PHY, V2, P41; Reis JP, 2014, PROG NUCL ENERG, V70, P64, DOI 10.1016/j.pnucene.2013.07.013; Scottish Intercollegiate Guidelines Network, 2005, MAN PAT LUNG CANC; Seco J., 2013, MONTE CARLO TECHNIQU; Taylor ML, 2011, J MED PHYS, V36, P59, DOI 10.4103/0971-6203.79686; Van Dyk J, 1986, PHYS ASPECT TOTAL HA; vanderGiessen PH, 1996, INT J RADIAT ONCOL, V35, P399, DOI 10.1016/0360-3016(96)00083-1; Verhaegen F, 2003, PHYS MED BIOL, V48, pR107, DOI 10.1088/0031-9155/48/21/R01; X-5 Monte Carlo Team, 2000, LAUR031987, VI, P3; Xu XG, 2008, PHYS MED BIOL, V53, pR193, DOI 10.1088/0031-9155/53/13/R01; Zabihinpoor S., 2011, ADV STUDIES THEOR PH, V5, P421	30	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2017	12	3							e0174836	10.1371/journal.pone.0174836	http://dx.doi.org/10.1371/journal.pone.0174836			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9VK	28362837	Green Published, Green Submitted, gold			2023-01-03	WOS:000399175000041
J	Huang, WY; Ho, CL; Lee, CC; Hsiao, CW; Wu, CC; Jao, SW; Yang, JF; Lo, CH; Chen, JH				Huang, Wen-Yen; Ho, Ching-Liang; Lee, Chia-Cheng; Hsiao, Cheng-Wen; Wu, Chang-Chieh; Jao, Shu-Wen; Yang, Jen-Fu; Lo, Cheng-Hsiang; Chen, Jia-Hong			Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer	PLOS ONE			English	Article							METASTATIC COLORECTAL-CANCER; ADVANCED HEPATOCELLULAR-CARCINOMA; RECURRENT MALIGNANT GLIOMA; RENAL-CELL CARCINOMA; PHASE-II; ADJUVANT TREATMENT; PROSTATE-CANCER; OVARIAN-CANCER; CHEMOTHERAPY; TRIAL	The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage I I I colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage I I I colon carcinomas treated with radical RO resection were reviewed. One hundred thirty two patients were treated with a FOLFOX regimen (comparison group), and 113 patients were treated with the same regimen followed by additional oral UFUR (UFUR group). The clinical characteristics and mean age of the comparison and UFUR groups were similar. Furthermore, for all study patients, DFS was not significantly different between the two groups. However, 5-year OS rates were 86.8% and 68.5% in the UFUR and comparison groups, respectively (p = 0.0107). Adding UFUR to a FOLFOX regimen was found to significantly improve the OS in patients with stage III colon cancer. UFUR as a maintenance therapy following FOLFOX regimen as an alternative therapeutic option for the treatment of stage I I I colon cancer patients.	[Huang, Wen-Yen; Yang, Jen-Fu; Lo, Cheng-Hsiang] Natl Def Med Ctr, Triserv Gen Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Huang, Wen-Yen] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan; [Ho, Ching-Liang; Chen, Jia-Hong] Natl Def Med Ctr, Triserv Gen Hosp, Div Hematol Oncol, Dept Med, Taipei, Taiwan; [Lee, Chia-Cheng; Hsiao, Cheng-Wen; Wu, Chang-Chieh; Jao, Shu-Wen] Natl Def Med Ctr, Triserv Gen Hosp, Div Colon & Rectal Surg, Taipei, Taiwan; [Chen, Jia-Hong] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Yang Ming Chiao Tung University; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University	Chen, JH (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Div Hematol Oncol, Dept Med, Taipei, Taiwan.; Chen, JH (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.	ndmc_tw.tw@yahoo.com.tw	huang, wen/GXW-0661-2022	Lo, Cheng-Hsiang/0000-0001-5002-587X	 [TSGH-C104-053];  [TSGH-C105-049]	; 	The study was supported in part by the study projects of TSGH-C104-053 & TSGH-C105-049. The funders had no role study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Bellmunt J, 2010, LANCET ONCOL, V11, P350, DOI 10.1016/S1470-2045(09)70383-3; Bosetti C, 2011, INT J CANCER, V129, P180, DOI 10.1002/ijc.25653; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Carmichael J, 2002, J CLIN ONCOL, V20, P3617, DOI 10.1200/JCO.2002.10.129; Chan TS, 2016, J EXP MED, V213, P2967, DOI 10.1084/jem.20151665; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Fontana A, 2009, CLIN CANCER RES, V15, P4954, DOI 10.1158/1078-0432.CCR-08-3317; Garcia AA, 2008, J CLIN ONCOL, V26, P76, DOI 10.1200/JCO.2007.12.1939; GonzalezBaron M, 1995, EUR J CANCER, V31A, P2215, DOI 10.1016/0959-8049(95)00487-4; Hsu CH, 2010, J HEPATOL, V53, P126, DOI 10.1016/j.jhep.2010.01.035; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Lin PC, 2007, CANCER CHEMOTH PHARM, V60, P351, DOI 10.1007/s00280-006-0377-4; Lord R, 2007, J UROLOGY, V177, P2136, DOI 10.1016/j.juro.2007.01.143; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Ogata Y, 2007, ANTICANCER RES, V27, P2605; Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82; PAZDUR R, 1994, J CLIN ONCOL, V12, P2296, DOI 10.1200/JCO.1994.12.11.2296; Perry JR, 2010, J CLIN ONCOL, V28, P2051, DOI 10.1200/JCO.2009.26.5520; Reardon DA, 2009, BRIT J CANCER, V101, P1986, DOI 10.1038/sj.bjc.6605412; Rosati G, 2005, ONCOLOGY-BASEL, V69, P122, DOI 10.1159/000087814; Sadahiro S, 2015, ANN ONCOL, V26, P2274, DOI 10.1093/annonc/mdv358; Shaked Y, 2016, CANCER RES, V76, P5983, DOI 10.1158/0008-5472.CAN-16-0136; Shao YY, 2012, ONCOLOGY-BASEL, V82, P59, DOI 10.1159/000336126; Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Watanabe T, 2009, J CLIN ONCOL, V27, P1368, DOI 10.1200/JCO.2008.18.3939	29	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0174280	10.1371/journal.pone.0174280	http://dx.doi.org/10.1371/journal.pone.0174280			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8SZ	28328969	Green Published, gold, Green Submitted			2023-01-03	WOS:000399094700078
J	Garcia-Garcia, ML; Calvo, C; Rey, C; Diaz, B; Molinero, MD; Pozo, F; Casas, I				Luz Garcia-Garcia, Maria; Calvo, Cristina; Rey, Cristina; Diaz, Beatriz; del Mar Molinero, Maria; Pozo, Francisco; Casas, Inmaculada			Human metapnuemovirus infections in hospitalized children and comparison with other respiratory viruses. 2005-2014 prospective study	PLOS ONE			English	Article							HUMAN METAPNEUMOVIRUS INFECTION; SYNCYTIAL-VIRUS; DISEASE	Background Human metapneumovirus (HMPV) has an important etiological role in acute lower respiratory infections in children under five years. Our objectives were to estimate the relative contribution of HMPV to hospitalization in children with acute respiratory infection, to define the clinical and epidemiological features of HMPV single and multiple infections, and to compare HMPV infections with respiratory syncytial virus (HRSV), rhinovirus (HRV), adenovirus and human bocavirus infections in the same population. Methods and findings A prospective study performed on all children less than 14 years of age with a respiratory tract disease admitted to a secondary hospital between September 2005-June 2014. Clinical characteristics of patients were analyzed. Nasopharyngeal aspirate was taken at admission for viral study with polymerase chain reaction for 16 respiratory viruses. A total of 3,906 children were included. At least one respiratory virus was detected in 75.2% of them. The most common identified virus was HRSV, followed by HRV. HMPV was detected in 214 cases (5.5%); 133 (62%) were single infections and the remaining were detected in coinfection with other viruses. 90.7% cases were detected between February and May. Children's mean age was 13.83 +/- 18 months. Fever was frequent (69%), and bronchiolitis (27%), and recurrent wheezing (63%) were the main clinical diagnosis. Hypoxia was present in 65% of the patients and 47% of them had an infiltrate in X-ray. Only 6 (2.8%) children were admitted to the intensive care unit. Only the duration of the hospitalization was different, being longer in the coinfections group (p < 0.05). There were many differences in seasonality and clinical characteristics between HMPV and other respiratory viruses being more similar to HRSV. Conclusions HMPV infections accounted for 5.5% of total viral infections in hospitalized children. The clinical characteristics were similar to HRSV infections, but seasonality and clinical data were different from other viral infections.	[Luz Garcia-Garcia, Maria; Calvo, Cristina] Severo Ochoa Hosp, Dept Pediat, Madrid, Spain; [Luz Garcia-Garcia, Maria; Calvo, Cristina; Rey, Cristina; Diaz, Beatriz] Univ Alfonson X el Sabio, Madrid, Spain; [Luz Garcia-Garcia, Maria; Calvo, Cristina; Pozo, Francisco; Casas, Inmaculada] Traslat Res Network Pediat Infectious Diseases RI, Madrid, Spain; [Luz Garcia-Garcia, Maria; Calvo, Cristina; Rey, Cristina; Diaz, Beatriz] European Network Excellence, Pediat Clin Res, Bari, Italy; [del Mar Molinero, Maria; Pozo, Francisco; Casas, Inmaculada] Natl Microbiol Ctr ISCIII, Respiratory Viruses & Influenza Unit, Madrid, Spain	Severo Ochoa University Hospital	Calvo, C (corresponding author), European Network Excellence, Pediat Clin Res, Bari, Italy.	ccalvorey@ono.com	Casas, Inmaculada/H-9442-2015; Calvo, Cristina/T-5028-2018; Casas, Inmaculada/X-7579-2019; Pozo, Francisco/F-4426-2012	Casas, Inmaculada/0000-0003-1840-1198; Calvo, Cristina/0000-0002-6503-3423; Casas, Inmaculada/0000-0003-1840-1198; Pozo, Francisco/0000-0003-1828-733X; GARCIA-GARCIA, MARIA LUZ/0000-0003-4906-4227	FIS (Fondo de Investigaciones Sanitarias - Spanish Health Research Fund) [PI06/0532, PI09/0246, PI12/0129]	FIS (Fondo de Investigaciones Sanitarias - Spanish Health Research Fund)	This study has been supported by FIS (Fondo de Investigaciones Sanitarias - Spanish Health Research Fund) grants no: PI06/0532, PI09/0246, and PI12/0129.	Afonso CL, 2016, ARCH VIROL, V161, P2351, DOI 10.1007/s00705-016-2880-1; Anderson Evan J, 2012, J Pediatric Infect Dis Soc, V1, P212, DOI 10.1093/jpids/pis069; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008; Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255; Edwards KM, 2013, NEW ENGL J MED, V368, P633, DOI 10.1056/NEJMoa1204630; Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024; Garcia-Garcia ML, 2010, PEDIATR PULM, V45, P585, DOI 10.1002/ppul.21225; Hahn A, 2013, EPIDEMIOL INFECT, V141, P2213, DOI 10.1017/S0950268812002920; Lopez-Huertas MR, 2005, J VIROL METHODS, V129, P1, DOI 10.1016/j.jviromet.2005.05.004; Marcone DN, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1213-4; MCCONNOCHIE KM, 1983, AM J DIS CHILD, V137, P11, DOI 10.1001/archpedi.1983.02140270007003; McCracken JP, 2014, INFLUENZA OTHER RESP, V8, P414, DOI 10.1111/irv.12251; Othman HT, 2016, J INFECT DEV COUNTR, V10, P283, DOI 10.3855/jidc.7087; Pancham K, 2016, PEDIATR NEONATOL, V57, P27, DOI 10.1016/j.pedneo.2015.03.008; Papenburg J, 2012, J INFECT DIS, V206, P178, DOI 10.1093/infdis/jis333; Reiche J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088342; Schuster JE, 2015, PEDIATR INFECT DIS J, V34, P1335, DOI 10.1097/INF.0000000000000892; Semple MG, 2005, J INFECT DIS, V191, P382, DOI 10.1086/426457; Shi T, 2015, J GLOB HEALTH, V5, P122, DOI 10.7189/jogh.05.010408; van den Hoogen BG, 2002, VIROLOGY, V295, P119, DOI 10.1006/viro.2001.1355; van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098	23	24	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173504	10.1371/journal.pone.0173504	http://dx.doi.org/10.1371/journal.pone.0173504			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301570	Green Published, Green Submitted, gold			2023-01-03	WOS:000396318300046
J	Pearson, LJ; Klaharn, IY; Thongsawang, B; Manuprasert, W; Saejew, T; Somparn, P; Chuengsaman, P; Kanjanabuch, T; Pisitkun, T				Pearson, Lachlan James; Klaharn, I-Yanut; Thongsawang, Bussakorn; Manuprasert, Wasin; Saejew, Thunvarat; Somparn, Poorichaya; Chuengsaman, Piyatida; Kanjanabuch, Talerngsak; Pisitkun, Trairak			Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers	PLOS ONE			English	Article							PROTEOMIC ANALYSIS; APOPTOTIC BODIES; MESOTHELIAL CELL; EXOSOMES; MICROVESICLES; FLUID; MEMBRANE; IDENTIFICATION; TRANSITION; PROTEIN	Peritoneal dialysis inevitability results in activation of inflammatory processes and its efficiency is highly variable between patients. An improved method to isolate biomarkers and study pathophysiological mechanisms in peritoneal dialysis effluent (PDE) is expected to be of much benefit for the development of this treatment approach and help with patient management. Extracellular vesicles (EVs) are released as part of normal cellular processes. Their proteome is expected to reflect both type and health of their cell of origin. Although there is a significant interest in using EVs for "liquid biopsies", little is reported of their presence or composition in plentiful dialysis waste fluids, including peritoneal dialysis effluent (PDE). Here we determined the presence of EVs in PDE and subsequently characterized their proteome. EVs were first isolated from PDE using differential centrifugation, then a further enrichment using size exclusion chromatography (SEC) was performed. The presence of EVs was demonstrated using transmission electron microscopy, and their particle counts were investigated using nanoparticle tracking analysis and dynamic light scattering. Using tandem mass spectrometry, marker proteins from three types of EVs i.e. apoptotic bodies, ectosomes, and exosomes were identified. The proteomic results demonstrated that the isolation of EVs by differential centrifugation helped enrich for over 2,000 proteins normally masked by abundant proteins in PDE such as albumin and SEC markedly further improved the isolation of low abundant proteins. Gene ontology analysis of all identified proteins showed the marked enrichment of exosome and membrane-associated proteins. Over 3,700 proteins were identified in total, including many proteins with known roles in peritoneal pathophysiology. This study demonstrated the prominence of EVs in PDE and their potential value as a source of biomarkers for peritoneal dialysis patients.	[Pearson, Lachlan James; Klaharn, I-Yanut; Somparn, Poorichaya; Pisitkun, Trairak] Chulalongkorn Univ, Syst Biol Ctr, Res Affairs, Fac Med, Bangkok, Thailand; [Thongsawang, Bussakorn; Manuprasert, Wasin; Kanjanabuch, Talerngsak] Chulalongkorn Univ, Kidney & Metab Res Unit, Fac Med, Bangkok, Thailand; [Saejew, Thunvarat; Kanjanabuch, Talerngsak] King Chulalongkorn Mem Hosp, Peritoneal Dialysis Excellence Ctr, Bangkok, Thailand; [Chuengsaman, Piyatida] Bamphaeo Hosp, Prommitr Branch, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Pisitkun, T (corresponding author), Chulalongkorn Univ, Syst Biol Ctr, Res Affairs, Fac Med, Bangkok, Thailand.; Kanjanabuch, T (corresponding author), Chulalongkorn Univ, Kidney & Metab Res Unit, Fac Med, Bangkok, Thailand.; Kanjanabuch, T (corresponding author), King Chulalongkorn Mem Hosp, Peritoneal Dialysis Excellence Ctr, Bangkok, Thailand.	golfnephro@hotmail.com; Trairak.P@chula.ac.th		Kanjanabuch, Talerngsak/0000-0002-2996-8934	Rachadapisek Sompot Fund; Chulalongkorn University; National Research Council of Thailand [2558-113]; Grant for International Research Integration: Chula Research Scholar, and Rachadaphiseksompot Endowment Fund	Rachadapisek Sompot Fund; Chulalongkorn University(Chulalongkorn University); National Research Council of Thailand(National Research Council of Thailand (NRCT)); Grant for International Research Integration: Chula Research Scholar, and Rachadaphiseksompot Endowment Fund	This research is supported by Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University, National Research Council of Thailand (2558-113), Grant for International Research Integration: Chula Research Scholar, and Rachadaphiseksompot Endowment Fund (GCURS_59_12_30_03 and Part of the "Research Grant for New Scholar CU Researcher's Project").	Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Brewis IA, 2010, NEPHROL DIAL TRANSPL, V25, P1749, DOI 10.1093/ndt/gfq145; Cheema H, 2013, PERITON DIALYSIS INT, V33, P349, DOI 10.3747/pdi.2012.00320; Cuccurullo M, 2011, NEPHROL DIAL TRANSPL, V26, P1990, DOI 10.1093/ndt/gfq670; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; Erdbrugger U, 2016, CYTOM PART A, V89A, P123, DOI 10.1002/cyto.a.22795; Finkelstein FO, 2014, NAT REV NEPHROL, V10, P618, DOI 10.1038/nrneph.2014.176; Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Kawanishi H, 2005, NEPHROLOGY, V10, P249, DOI 10.1111/j.1440-1797.2005.00413.x; Keerthikumar S, 2015, ONCOTARGET, V6, P15375, DOI 10.18632/oncotarget.3801; Kim YL, 2009, PERITON DIALYSIS INT, V29, pS123; Korabecna M, 2013, J NEPHROL, V26, P1001, DOI 10.5301/jn.5000301; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Liu Y, 2015, PERITON DIALYSIS INT, V35, P14, DOI 10.3747/pdi.2014.00188; Lobb RJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27031; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Oh HJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001636; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Raaijmakers R, 2008, NEPHROL DIAL TRANSPL, V23, P2402, DOI 10.1093/ndt/gfn212; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Schiller M, 2008, CELL DEATH DIFFER, V15, P183, DOI 10.1038/sj.cdd.4402239; Sole C, 2015, NEPHROL DIAL TRANSPL, V30, P1488, DOI 10.1093/ndt/gfv128; Sritippayawain S, 2007, J PROTEOME RES, V6, P4356, DOI 10.1021/pr0702969; Stanley M, 2010, NEPHROLOGY, V15, pS24, DOI 10.1111/j.1440-1797.2010.01228.x; Struijk DG, 2008, NDT PLUS, V1, piv29; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thomas CJ, 2002, FEBS LETT, V531, P184, DOI 10.1016/S0014-5793(02)03499-3; Torr EE, 2012, CELL DEATH DIFFER, V19, P671, DOI 10.1038/cdd.2011.167; Turiak L, 2011, J PROTEOMICS, V74, P2025, DOI 10.1016/j.jprot.2011.05.023; Tyan YC, 2013, CLIN CHIM ACTA, V420, P34, DOI 10.1016/j.cca.2012.10.010; Vaksman O, 2014, CARCINOGENESIS, V35, P2113, DOI 10.1093/carcin/bgu130; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Wang HY, 2012, J PROTEOMICS, V75, P2053, DOI 10.1016/j.jprot.2012.01.011; Wang HY, 2010, NEPHROL DIAL TRANSPL, V25, P1955, DOI 10.1093/ndt/gfp696; Westman J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005319; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Windgassen EB, 2011, POSTGRAD MED, V123, P114, DOI 10.3810/pgm.2011.01.2252; Yoshioka Y, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20424; Yuana Y., 2014, J EXTRACELL VESICLES, V3	44	17	19	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e0178601	10.1371/journal.pone.0178601	http://dx.doi.org/10.1371/journal.pone.0178601			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0PL	28594924	Green Published, gold, Green Submitted			2023-01-03	WOS:000402923200041
J	Kopp, M; Rotan, O; Papadopoulos, C; Schulze, N; Meyer, H; Epple, M				Kopp, Mathis; Rotan, Olga; Papadopoulos, Chrisovalantis; Schulze, Nina; Meyer, Hemmo; Epple, Matthias			Delivery of the autofluorescent protein R-phycoerythrin by calcium phosphate nanoparticles into four different eukaryotic cell lines ( HeLa, HEK293T, MG-63, MC3T3): Highly efficient, but leading to endolysosomal proteolysis in HeLa and MC3T3 cells	PLOS ONE			English	Article							GENE DELIVERY; BIODEGRADABLE NANOPARTICLES; INORGANIC NANOPARTICLES; INTRACELLULAR DELIVERY; GOLD NANOPARTICLES; NONVIRAL VECTOR; DRUG-DELIVERY; NUCLEIC-ACIDS; PLASMID DNA; TRANSFECTION	Nanoparticles can be used as carriers to transport biomolecules like proteins and synthetic molecules across the cell membrane because many molecules are not able to cross the cell membrane on their own. The uptake of nanoparticles together with their cargo typically occurs via endocytosis, raising concerns about the possible degradation of the cargo in the endolysosomal system. As the tracking of a dye-labelled protein during cellular uptake and processing is not indicative of the presence of the protein itself but only for the fluorescent label, a label-free tracking was performed with the red-fluorescing model protein R-phycoerythrin (R-PE). Four different eukaryotic cell lines were investigated: HeLa, HEK293T, MG-63, and MC3T3. Alone, the protein was not taken up by any cell line; only with the help of calcium phosphate nanoparticles, an efficient uptake occurred. After the uptake into HeLa cells, the protein was found in early endosomes (shown by the marker EEA1) and lysosomes (shown by the marker Lamp1). There, it was still intact and functional (i.e. properly folded) as its red fluorescence was detected. However, a few hours after the uptake, proteolysis started as indicated by the decreasing red fluorescence intensity in the case of HeLa and MC3T3 cells. 12 h after the uptake, the protein was almost completely degraded in HeLa cells and MC3T3 cells. In HEK293T cells and MG-63 cells, no degradation of the protein was observed. In the presence of Bafilomycin A1, an inhibitor of acidification and protein degradation in lysosomes, the fluorescence of R-PE remained intact over the whole observation period in the four cell lines. These results indicate that despite an efficient nanoparticle-mediated uptake of proteins by cells, a rapid endolysosomal degradation may prevent the desired (e.g. therapeutic) effect of a protein inside a cell.	[Kopp, Mathis; Rotan, Olga; Epple, Matthias] Univ Duisburg Essen, Inorgan Chem, Essen, Germany; [Kopp, Mathis; Rotan, Olga; Epple, Matthias] Univ Duisburg Essen, Ctr Nanointegrat Duisburg Essen CeNIDE, Essen, Germany; [Papadopoulos, Chrisovalantis; Meyer, Hemmo] Univ Duisburg Essen, Ctr Med Biotechnol, Fac Biol, Essen, Germany; [Schulze, Nina] Univ Duisburg Essen, ICCE, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Epple, M (corresponding author), Univ Duisburg Essen, Inorgan Chem, Essen, Germany.; Epple, M (corresponding author), Univ Duisburg Essen, Ctr Nanointegrat Duisburg Essen CeNIDE, Essen, Germany.	matthias.epple@uni-due.de	Epple, Matthias/AAX-9694-2020; Meyer, Hemmo/GNH-5784-2022	Epple, Matthias/0000-0002-1641-7068; Meyer, Hemmo/0000-0003-1883-1796	Deutsche Forschungsgemeinschaft (DFG), within the collaborative research centre [SFB 1093]	Deutsche Forschungsgemeinschaft (DFG), within the collaborative research centre(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (DFG), within the collaborative research centre SFB 1093: Supramolecular chemistry on proteins to ME and HM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Deutsche Forschungsgemeinschaft (DFG), within the collaborative research centre SFB 1093: Supramolecular chemistry on proteins to ME and HM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696; Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432; Beddoes CM, 2015, ADV COLLOID INTERFAC, V218, P48, DOI 10.1016/j.cis.2015.01.007; Cai YR, 2008, J MATER CHEM, V18, P3775, DOI 10.1039/b805407j; Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b; Cao X, 2011, INT J NANOMED, V6, P3335, DOI 10.2147/IJN.S27370; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chernousova S, 2017, GENE THER IN PRESS; Creusat G, 2010, BIOCONJUGATE CHEM, V21, P994, DOI 10.1021/bc100010k; CSATORDAY K, 1987, PHOTOCHEM PHOTOBIOL, V45, P845, DOI 10.1111/j.1751-1097.1987.tb07893.x; CSATORDAY K, 1988, PHOTOCHEM PHOTOBIOL, V47, P285, DOI 10.1111/j.1751-1097.1988.tb02728.x; Dautova Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097565; Domey J, 2016, NANOTOXICOLOGY, V10, P20, DOI 10.3109/17435390.2014.1000413; Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h; Ewence AE, 2008, CIRC RES, V103, pE28, DOI 10.1161/CIRCRESAHA.108.181305; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; FICNER R, 1993, EUR J BIOCHEM, V218, P103, DOI 10.1111/j.1432-1033.1993.tb18356.x; Fu AL, 2014, BIOCONJUGATE CHEM, V25, P1602, DOI 10.1021/bc500320j; Gemeinhart RA, 2005, BIOTECHNOL PROGR, V21, P532, DOI 10.1021/bp049648w; Ghosh P, 2010, J AM CHEM SOC, V132, P2642, DOI 10.1021/ja907887z; Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359; Gilmore Ian R., 2006, Current Drug Delivery, V3, P147, DOI 10.2174/156720106776359159; Giner-Casares JJ, 2016, MATER TODAY, V19, P19, DOI 10.1016/j.mattod.2015.07.004; GLAZER AN, 1975, J BIOL CHEM, V250, P5487; Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Guo X, 2012, ACCOUNTS CHEM RES, V45, P971, DOI 10.1021/ar200151m; Habraken W, 2016, MATER TODAY, V19, P69, DOI 10.1016/j.mattod.2015.10.008; Hadjicharalambous C, 2015, J BIOMED MATER RES A, V103, P3834, DOI 10.1002/jbm.a.35527; Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z; HUANG C, 1987, BIOCHEMISTRY-US, V26, P243, DOI 10.1021/bi00375a033; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Ito T, 2014, J PHARM SCI-US, V103, P179, DOI 10.1002/jps.23768; Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003; Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99; Karim AA, 2016, CHEM-ASIAN J, V11, P1300, DOI 10.1002/asia.201501434; Kastl L, 2013, ACS NANO, V7, P6605, DOI 10.1021/nn306032k; Kesharwani P, 2012, BIOMATERIALS, V33, P7138, DOI 10.1016/j.biomaterials.2012.06.068; Knuschke T, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0258-9; Kozlova D, 2013, BIONANOMAT, V14, P161; Kuhn DA, 2014, BEILSTEIN J NANOTECH, V5, P1625, DOI 10.3762/bjnano.5.174; Kurreck J, 2009, ANGEW CHEM INT EDIT, V48, P1378, DOI 10.1002/anie.200802092; Lee K, 2013, INT J PHARMACEUT, V445, P196, DOI 10.1016/j.ijpharm.2013.01.014; Lee MS, 2014, J CONTROL RELEASE, V192, P122, DOI 10.1016/j.jconrel.2014.06.049; Liu LN, 2009, BBA-BIOENERGETICS, V1787, P939, DOI 10.1016/j.bbabio.2009.02.018; Liu YC, 2011, INT J NANOMED, V6, P721, DOI 10.2147/IJN.S17096; MACCOLL R, 1990, BIOCHEMISTRY-US, V29, P430, DOI 10.1021/bi00454a018; Maitra A, 2005, EXPERT REV MOL DIAGN, V5, P893, DOI 10.1586/14737159.5.6.893; Mathaes R, 2015, EXPERT OPIN DRUG DEL, V12, P481, DOI 10.1517/17425247.2015.963055; Messerschmidt C, 2016, BEILSTEIN J NANOTECH, V7, P1296, DOI 10.3762/bjnano.7.121; Midoux P, 2009, BRIT J PHARMACOL, V157, P166, DOI 10.1111/j.1476-5381.2009.00288.x; Min KH, 2012, BIOMATERIALS, V33, P5788, DOI 10.1016/j.biomaterials.2012.04.057; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Moore NM, 2009, ACTA BIOMATER, V5, P854, DOI 10.1016/j.actbio.2008.09.009; Muller KH, 2014, BIOMATERIALS, V35, P1074, DOI 10.1016/j.biomaterials.2013.10.041; Neuhaus B, 2016, RSC ADV, V6, P18102, DOI 10.1039/c5ra25333k; Neumann S, 2009, BIOMATERIALS, V30, P6794, DOI 10.1016/j.biomaterials.2009.08.043; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Perez-Martinez FC, 2011, PHARM RES-DORDR, V28, P1843, DOI 10.1007/s11095-010-0364-7; Pichon C, 2010, CURR OPIN BIOTECH, V21, P640, DOI 10.1016/j.copbio.2010.07.003; Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585; Rotan O, 2013, MATERIALWISS WERKST, V44, P176, DOI 10.1002/mawe.201300085; Rotan O, 2017, BEILSTEIN J NANOTECH, V8, P381, DOI 10.3762/bjnano.8.40; Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036; Sahdev P, 2013, J BIOMED NANOTECHNOL, V9, P132, DOI 10.1166/jbn.2013.1545; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shang L, 2014, BEILSTEIN J NANOTECH, V5, P2388, DOI 10.3762/bjnano.5.248; Silva JM, 2013, J CONTROL RELEASE, V168, P179, DOI 10.1016/j.jconrel.2013.03.010; Sokolova V, 2011, ACTA BIOMATER, V7, P4029, DOI 10.1016/j.actbio.2011.07.010; Sokolova V, 2008, ANGEW CHEM INT EDIT, V47, P1382, DOI 10.1002/anie.200703039; Sokolova V, 2015, J MATER CHEM B, V3, P4767, DOI 10.1039/c5tb00618j; Sokolova V, 2013, ACTA BIOMATER, V9, P7527, DOI 10.1016/j.actbio.2013.02.034; Sokolova V, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0910-9; Sokolova V, 2011, NANOSCALE, V3, P1957, DOI 10.1039/c1nr00002k; Sun TM, 2014, ANGEW CHEM INT EDIT, V53, P12320, DOI 10.1002/anie.201403036; Tabakovic A, 2012, WIRES NANOMED NANOBI, V4, P96, DOI 10.1002/wnan.163; Tan HX, 2016, MAR DRUGS, V14, DOI 10.3390/md14090166; Tang J, 2012, INT J PHARMACEUT, V431, P210, DOI 10.1016/j.ijpharm.2012.04.046; Tang R, 2013, ACS NANO, V7, P6667, DOI 10.1021/nn402753y; Tenkumo T, 2016, GENES CELLS, V21, P682, DOI 10.1111/gtc.12374; Urch H, 2009, J MATER CHEM, V19, P2166, DOI 10.1039/b810026h; Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746; Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004; Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003; Vercauteren D, 2012, J CONTROL RELEASE, V161, P566, DOI 10.1016/j.jconrel.2012.05.020; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Xiao L, 2011, ACS NANO, V5, P6315, DOI 10.1021/nn201348s; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	88	15	15	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2017	12	6							e0178260	10.1371/journal.pone.0178260	http://dx.doi.org/10.1371/journal.pone.0178260			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW9YQ	28586345	Green Published, gold, Green Submitted			2023-01-03	WOS:000402875700010
J	Hsu, WY; Zanto, TP; van Schouwenburg, MR; Gazzaley, A				Hsu, Wan-Yu; Zanto, Theodore P.; van Schouwenburg, Martine R.; Gazzaley, Adam			Enhancement of multitasking performance and neural oscillations by transcranial alternating current stimulation	PLOS ONE			English	Article							BETA-BAND OSCILLATIONS; DORSOLATERAL PREFRONTAL CORTEX; WORKING-MEMORY; ELECTRICAL-STIMULATION; THETA-OSCILLATIONS; FLUID INTELLIGENCE; BRAIN-STIMULATION; COGNITIVE CONTROL; MOTOR SYSTEM; OLDER-ADULTS	Multitasking is associated with the generation of stimulus-locked theta (4-7 Hz) oscillations arising from prefrontal cortex (PFC). Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation technique that influences endogenous brain oscillations. Here, we investigate whether applying alternating current stimulation within the theta frequency band would affect multitasking performance, and explore tACS effects on neurophysiological measures. Brief runs of bilateral PFC theta-tACS were applied while participants were engaged in a multitasking paradigm accompanied by electroencephalography (EEG) data collection. Unlike an active control group, a tACS stimulation group showed enhancement of multitasking performance after a 90-minute session (F-1,F-35 = 6.63, p = 0.01, eta p(2) = 0.16; effect size = 0.96), coupled with significant modulation of posterior beta (13-30 Hz) activities (F-1,F-32 =7.66, p = 0.009, eta p(2) = 0.19; effect size = 0.96). Across participant regression analyses indicated that those participants with greater increases in frontal theta, alpha and beta oscillations exhibited greater multitasking performance improvements. These results indicate frontal theta-tACS generates benefits on multitasking performance accompanied by widespread neuronal oscillatory changes, and suggests that future tACS studies with extended treatments are worth exploring as promising tools for cognitive enhancement.	[Hsu, Wan-Yu; Zanto, Theodore P.; van Schouwenburg, Martine R.; Gazzaley, Adam] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Hsu, Wan-Yu; Zanto, Theodore P.; Gazzaley, Adam] Univ Calif San Francisco, Neuroscape, San Francisco, CA 94143 USA; [Gazzaley, Adam] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Gazzaley, Adam] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Zanto, TP; Gazzaley, A (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Zanto, TP; Gazzaley, A (corresponding author), Univ Calif San Francisco, Neuroscape, San Francisco, CA 94143 USA.; Gazzaley, A (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Gazzaley, A (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.	theodore.zanto@ucsf.edu; adam.gazzaley@ucsf.edu			NIH Grant [R01MH096861]; Hart Center for Deep Rhythm	NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hart Center for Deep Rhythm	This work was supported by the NIH Grant R01MH096861 and Hart Center for Deep Rhythm. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alekseichuk I, 2016, CURR BIOL, V26, P1513, DOI 10.1016/j.cub.2016.04.035; Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Anguera JA, 2013, NATURE, V501, P97, DOI 10.1038/nature12486; Antal A, 2012, CLIN EEG NEUROSCI, V43, P175, DOI 10.1177/1550059412448030; Basile LFH, 2007, INT J PSYCHOPHYSIOL, V65, P238, DOI 10.1016/j.ijpsycho.2007.05.001; Brinkman L, 2016, J NEUROSCI, V36, P8726, DOI 10.1523/JNEUROSCI.0868-16.2016; Brittain JS, 2013, CURR BIOL, V23, P436, DOI 10.1016/j.cub.2013.01.068; Chander BS, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00120; Clapp WC, 2011, P NATL ACAD SCI USA, V108, P7212, DOI 10.1073/pnas.1015297108; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Feurra M, 2013, J NEUROSCI, V33, P17483, DOI 10.1523/JNEUROSCI.1414-13.2013; Feurra M, 2011, J NEUROSCI, V31, P12165, DOI 10.1523/JNEUROSCI.0978-11.2011; Feurra M, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00013; Filmer HL, 2013, CORTEX, V49, P2845, DOI 10.1016/j.cortex.2013.08.015; Forkel SJ, 2014, CORTEX, V56, P73, DOI 10.1016/j.cortex.2012.09.005; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Helfrich RF, 2014, CURR BIOL, V24, P333, DOI 10.1016/j.cub.2013.12.041; Histed MH, 2009, NEURON, V63, P508, DOI 10.1016/j.neuron.2009.07.016; Hoppenbrouwers SS, 2013, CORTEX, V49, P1377, DOI 10.1016/j.cortex.2012.06.003; Hsu WY, 2015, CORTEX, V69, P175, DOI 10.1016/j.cortex.2015.05.014; Hsu WY, 2015, NEUROBIOL AGING, V36, P2348, DOI 10.1016/j.neurobiolaging.2015.04.016; Hyafil A, 2009, J NEUROSCI, V29, P5135, DOI 10.1523/JNEUROSCI.2828-08.2009; Ishii R, 1999, NEUROREPORT, V10, P675, DOI 10.1097/00001756-199903170-00003; Jausovec N, 2014, ACTA PSYCHOL, V146, P1, DOI 10.1016/j.actpsy.2013.11.011; Jausovec N, 2014, BIOL PSYCHOL, V96, P42, DOI 10.1016/j.biopsycho.2013.11.006; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689, DOI 10.1152/physrev.1995.75.4.689; Joundi RA, 2012, CURR BIOL, V22, P403, DOI 10.1016/j.cub.2012.01.024; Kaminski J, 2012, INT J PSYCHOPHYSIOL, V85, P125, DOI 10.1016/j.ijpsycho.2011.11.006; Kanai R, 2008, CURR BIOL, V18, P1839, DOI 10.1016/j.cub.2008.10.027; Kirov R, 2009, P NATL ACAD SCI USA, V106, P15460, DOI 10.1073/pnas.0904438106; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2012, TRENDS COGN SCI, V16, P606, DOI 10.1016/j.tics.2012.10.007; Knapp T. R., 2009, PRACTICAL ASSESSMENT, V14; Kuo MF, 2012, CLIN EEG NEUROSCI, V43, P192, DOI 10.1177/1550059412444975; Lin CT, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-11; Marois R, 2005, TRENDS COGN SCI, V9, P296, DOI 10.1016/j.tics.2005.04.010; Marshall L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016905; Meiron O, 2014, CLIN NEUROPHYSIOL, V125, P77, DOI 10.1016/j.clinph.2013.06.013; Merlet I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057330; Neuling T, 2012, NEUROIMAGE, V63, P771, DOI 10.1016/j.neuroimage.2012.07.024; Neuling T, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00161; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Ortuno F, 2002, NEUROIMAGE, V17, P411, DOI 10.1006/nimg.2002.1168; Ozen S, 2010, J NEUROSCI, V30, P11476, DOI 10.1523/JNEUROSCI.5252-09.2010; Pahor A, 2014, INT J PSYCHOPHYSIOL, V93, P322, DOI 10.1016/j.ijpsycho.2014.06.015; Pogosyan A, 2009, CURR BIOL, V19, P1637, DOI 10.1016/j.cub.2009.07.074; Raco V, 2014, BRAIN STIMUL, V7, P823, DOI 10.1016/j.brs.2014.08.005; Raghavachari S, 2006, J NEUROPHYSIOL, V95, P1630, DOI 10.1152/jn.00409.2005; Reato D, 2010, J NEUROSCI, V30, P15067, DOI 10.1523/JNEUROSCI.2059-10.2010; Santarnecchi E, 2013, CURR BIOL, V23, P1449, DOI 10.1016/j.cub.2013.06.022; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Thut G, 2011, CURR BIOL, V21, P1176, DOI 10.1016/j.cub.2011.05.049; Thut G, 2009, TRENDS COGN SCI, V13, P182, DOI 10.1016/j.tics.2009.01.004; Turi Z, 2013, RESTOR NEUROL NEUROS, V31, P275, DOI 10.3233/RNN-120297; van Schouwenburg MR, 2017, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00658; Vanderhasselt MA, 2006, EXP BRAIN RES, V169, P279, DOI 10.1007/s00221-005-0344-z; Voss U, 2014, NAT NEUROSCI, V17, P810, DOI 10.1038/nn.3719; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004; Zaehle T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013766; Zanto TP, 2011, NAT NEUROSCI, V14, P656, DOI 10.1038/nn.2773	62	24	24	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2017	12	5							e0178579	10.1371/journal.pone.0178579	http://dx.doi.org/10.1371/journal.pone.0178579			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6GY	28562642	Green Published, gold			2023-01-03	WOS:000402608700076
J	van Wijngaarden, E; Klink, A; Leget, C; The, AM				van Wijngaarden, Els; Klink, Ab; Leget, Carlo; The, Anne-Mei			Assisted dying for healthy older people: a step too far?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[van Wijngaarden, Els; Leget, Carlo] Univ Humanist Studies, Utrecht, Netherlands; [Klink, Ab] Vrije Univ Amsterdam, Amsterdam, Netherlands; [The, Anne-Mei] Univ Amsterdam, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam	van Wijngaarden, E (corresponding author), Univ Humanist Studies, Utrecht, Netherlands.	e.vanwijngaarden@uvh.nl	The, Anne-Mei/AAE-3468-2020; van Wijngaarden, Els/AAH-3414-2021	van Wijngaarden, Els/0000-0002-2940-9163; Leget, Carlo/0000-0002-6647-8141				BAM, 2002, PALL CAR COMM EXP CL; BAM, 2007, NAAST STERV PAT BESL; BAM, 2009, VERL NAAST GOD DOKT; BAM, 2006, TUSS HOOP VREES PALL; Beekman W, 2011, SELF CHOSEN DEATH EL; Bolt EE, 2015, J MED ETHICS, V41, P592, DOI 10.1136/medethics-2014-102150; Buiting HM, 2012, J MED ETHICS, V38, P267, DOI 10.1136/medethics-2011-100066; Cohen-Almagor R, 2004, EUTHANASIA NETHERLAN; de Lange J, 2017, ERVARING VOLTOOID LE; de Vries Ubaldus, 2004, Ann Health Law, V13, P365; Department of Health, 2016, KAB VIS VOLT LEV; Dutch Ministry of Security and Justice, 2014, TERM LIF REQ ASS SUI; Heman RACL, 2017, OVERWEGINGEN ARTSENF; Huxtable R, 2007, BIOETHICS, V21, P117, DOI 10.1111/j.1467-8519.2007.00535.x; Jackson E, 2011, DEBATING EUTHANASIA; Kennedy J, 2002, WELOVERWOGEN DOOD EU; Keown J, 2002, EUTHANASIA ETHICS PU, DOI [10.1017/CBO9780511495335, DOI 10.1017/CBO9780511495335]; Legemaate J, 2003, LEV HAND DOOR ARTS V, P216; Rietjens JAC, 2005, SOC SCI MED, V61, P1723, DOI 10.1016/j.socscimed.2005.03.024; Schnabel P, 2016, VOLTOOID LEVEN HULP, P243; Sheldon Tony, 2003, BMJ, V326, P71; Sheldon T, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1045; van de Laar M, 2016, HULP OUDEREN MET LAN; van der Heide A, 2014, KENNISSYNTHESE OUDER; van der Heide A, 2012, TWEEDE EVALUATIE WET; van Wijngaarden EJ, 2016, READY GIVE LIFE STUD; van Wijngaarden E, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009895; van Wijngaarden E, 2015, SOC SCI MED, V138, P257, DOI 10.1016/j.socscimed.2015.05.015; van Wijngaarden E, 2014, OMEGA-J DEATH DYING, V69, P191, DOI 10.2190/OM.69.2.f; van Wijngaarden EJ, 2016, GERONTOLOGIST, V56, P1062, DOI 10.1093/geront/gnv060; Yuill KL, 2015, ASSISTED SUICIDE LIB	31	7	7	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2017	357								j2298	10.1136/bmj.j2298	http://dx.doi.org/10.1136/bmj.j2298			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV6RR	28526705				2023-01-03	WOS:000401900300001
J	Crowley, R; Kirschner, N; Dunn, AS; Bornstein, SS				Crowley, Ryan; Kirschner, Neil; Dunn, Andrew S.; Bornstein, Sue S.		Hlth Public Policy Comm; Amer Coll Phys	Health and Public Policy to Facilitate Effective Prevention and Treatment of Substance Use Disorders Involving Illicit and Prescription Drugs: An American College of Physicians Position Paper	ANNALS OF INTERNAL MEDICINE			English	Review							MEDICATION-ASSISTED TREATMENT; UNITED-STATES; MENTAL-HEALTH; INJECT DRUGS; MARIJUANA LEGALIZATION; MONITORING PROGRAMS; FEDERAL PARITY; BRAIN DISEASE; ADDICTION; BARRIERS	Substance use disorders involving illicit and prescription drugs are a serious public health issue. In the United States, millions of individuals need treatment for substance use disorders but few receive it. The rising number of drug overdose deaths and the changing legal status of marijuana pose new challenges. In this position paper, the American College of Physicians maintains that substance use disorder is a treatable chronic medical condition and offers recommendations on expanding treatment options, the legal status of marijuana, addressing the opioid epidemic, insurance coverage of substance use disorders treatment, education and workforce, and public health interventions.	[Crowley, Ryan; Kirschner, Neil] Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA; [Dunn, Andrew S.] Mt Sinai Med Ctr, Box 1086,1470 Madison Ave, New York, NY 10029 USA; [Bornstein, Sue S.] 3111 Beverly Dr, Dallas, TX 75205 USA	American College of Physicians; Icahn School of Medicine at Mount Sinai	Crowley, R (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	RCrowley@mail.acponline.org		Lenchus, Joshua/0000-0003-1220-0803	ACP operating budget	ACP operating budget	Financial support for the development of this guideline comes exclusively from the ACP operating budget.	Advocates for Human Potential, 2014, AD BEH HLTH WORKF ME; Alford DP, 2016, PAIN MED, V17, P52, DOI 10.1111/pme.12878; American Academy of Addiction Medicine, 2013, TERM REL SPECTR UNH; American College of Physicians-American Society of Internal Medicine, 1998, ILL DRUG AB NAT DRUG; American Psychiatric Association, 2013, SUBST REL ADD DIS; American Society of Addiction Medicine, 2011, QUAL PRACT DEF ADD; [Anonymous], 2012, PRINC DRUG ADD TREAT; [Anonymous], 2015, MENTAL HLTH BENEFITS; [Anonymous], 2016, JAMA PEDIAT; [Anonymous], IMP OP CRIS HEALTHC; Appuzo Matt, 2014, NY TIMES; Aspinall EJ, 2014, INT J EPIDEMIOL, V43, P235, DOI 10.1093/ije/dyt243; Associated Press-NORC Center for Public Affairs Research, 2016, AM ATT SUBST US US S; Bao YH, 2016, HEALTH AFFAIR, V35, P1045, DOI 10.1377/hlthaff.2015.1673; Barry CL, 2014, PSYCHIAT SERV, V65, P1269, DOI 10.1176/appi.ps.201400140; Beletsky L, 2008, AM J PUBLIC HEALTH, V98, P231, DOI 10.2105/AJPH.2006.103747; Berry KN, 2015, PSYCHIAT SERV, V66, P565, DOI 10.1176/appi.ps.201400582; Bettinardi-Angres K, 2010, J NURS REGUL, V1, P31, DOI 10.1016/S2155-8256(15)30348-3; Bradford AC, 2016, HEALTH AFFAIR, V35, P1230, DOI 10.1377/hlthaff.2015.1661; Bramson H, 2015, J PUBLIC HEALTH POL, V36, P212, DOI 10.1057/jphp.2014.54; Branch MN, 2011, J EXP ANAL BEHAV, V95, P263, DOI 10.1901/jeab.2011.95-263; BUPPractice, 2017, DSM 5 CRIT SUSBST US; Busch SH, 2014, AM J MANAG CARE, V20, P76; CASA Columbia University, 2000, MISS OPP NAT SURV PR; Caulkins J.P, 2015, OPTIONS ISSUES REGAR; Centers for Disease Control and Prevention, 2017, HIV INJ DRUG US US; Centers for Disease Control and Prevention, 2015, INJ PREV CONTR OP OV; Centers for Disease Control and Prevention and National Center for Injury Prevention and Control, 2020, OPIOID OVERDOSE DRUG; Chaiyachati K, 2016, HLTH AFFAIRS BLOG; Clark RE, 2011, HEALTH AFFAIR, V30, P1425, DOI 10.1377/hlthaff.2010.0532; Colorado Department of Public Health & Environment, 2015, HLTH KIDS COL SURV; Compton WM, 2016, LANCET PSYCHIAT, V3, P954, DOI 10.1016/S2215-0366(16)30208-5; Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3; Crowley RA, 2015, ANN INTERN MED, V163, P298, DOI 10.7326/M15-0510; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; Des Jarlais DC, 2015, MMWR-MORBID MORTAL W, V64, P1337, DOI 10.15585/mmwr.mm6448a3; Jarlais DC, 2009, ADDICTION, V104, P1441, DOI 10.1111/j.1360-0443.2008.02465.x; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; DuPont RL, 2012, WHITE PAPER STATE LE; Dutra L, 2008, NEW ENGL J MED, V165, p[179, 357]; Eilperin J, 2016, WASHINGTON POST; Faggiano F, 2009, COCHRANE LIB, V4, P1; Federation of State Medical Boards, CONT MED ED BOARD BY; Food and Drug Administration, 2016, FED REG; Friedmann PD, 2012, SUBST ABUS, V33, P9, DOI 10.1080/08897077.2011.611460; Gloucester Police Department, 2017, ADD THEIR FRIENDS FA; Goodnough A., 2015, NY TIMES; Governing, 2015, STAT MAR LAWS MAP; Grill C, 2013, B AM COLL SURG; Gupta R, 2016, NEW ENGL J MED, V375, P2213, DOI 10.1056/NEJMp1609578; Hammer Rachel, 2013, AJOB Neurosci, V4, P27; Han B, 2015, NSDUH DATA REV; Health Resources and Services Administration, SHORT DES HLTH PROF; Heisler E. J., 2015, MENTAL HLTH WORKFORC; Henchman J, 2016, MARIJUANA LEGALIZATI; Hendriksson M, 2016, WORDS MATTER; Hutchinson E, 2014, ANN FAM MED, V12, P128, DOI 10.1370/afm.1595; Hyde PS, 2013, C NAT SUSBT AB MENT; Illinois State Medical Society, 2015, REC DET IMPR US OP R; Indiana University School of Public Health, 2015, SYR EXCH IND NEED SU; Kann L, 2016, MMWR-MORBID MORTAL W, V65, P106, DOI 10.15585/mmwr.mm6505a2; Kilmer Beau, 2016, BACK NATL SPOTLIGHT; Kinnard EN, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-29; Klepper D, 2016, ONCE UNTHINKABLE US; Komaromy M, 2016, SUBST ABUS, V37, P20, DOI 10.1080/08897077.2015.1129388; Kovaleski S., 2014, NY TIMES; Kraus ML, 2011, J ADDICT MED, V5, P254, DOI 10.1097/ADM.0b013e3182312983; Lavitt J, 2015, THE FIX         0828; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Leshner AI, 2001, ADDICTION IS BRAIN D; Livingston JD, 2012, ADDICTION, V107, P39, DOI 10.1111/j.1360-0443.2011.03601.x; Masters B, 2016, RECOVERY REACH MEDIC; Matusow H, 2013, J SUBST ABUSE TREAT, V44, P473, DOI 10.1016/j.jsat.2012.10.004; Meltzer EC, 2013, SUBST ABUS, V34, P356, DOI 10.1080/08897077.2013.815143; Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007; Monte AA, 2015, JAMA-J AM MED ASSOC, V313, P241, DOI 10.1001/jama.2014.17057; Mumola C., 2007, DRUG USE DEPENDENCE; Namey B, 2016, LIFE SAVING OVERDOSE; National Academies of Sciences Engineering and Medicine, 2016, END DICR PEOPL MENT; National Center on Addiction and Substance Abuse, 2016, UNC COV GAPS REV ADD; National Center on Addiction and Substance Abuse at Columbia University, 2010, BARS 2 SUBST AB AM P; National Conference of State Legislatures, 2017, DEEP DIV MAR; National Conference of State Legislatures, 2014, PRESCR DURG OV STRAT; National Conference of State Legislatures, 2016, DRUG OV IMM GOOD SEM; National Institute of Justice, 2016, DRUG COURTS; National Institute on Drug Abuse, 2012, EV BAS APPR DRUG ADD; National Institute on Drug Abuse, 2008, DRUGS BRAINS BEH SCI; Nessoulli A., 2016, UPSTATE NY MAYOR PRO; NORMAND J, 1995, PREVENTING HIV TRANS; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; O'Connor PG, 2013, JAMA-J AM MED ASSOC, V310, P1132, DOI 10.1001/jama.2013.277610; Office of the Surgeon General, 2016, FAC ADD AM SURG GEN; Oregon Department of Revenue, 2017, MAR TAX; Patrick SW, 2016, HEALTH AFFAIR, V35, P1324, DOI 10.1377/hlthaff.2015.1496; Pearson MR, 2015, STIGMA SUBSTANCE USE; Pew Research Center, 2014, AM NEW DRUG POL LAND; Polydorou Soteri, 2008, Curr Psychiatry Rep, V10, P399, DOI 10.1007/s11920-008-0064-8; Qaseem Amir, 2017, Ann Intern Med, V166, P514, DOI 10.7326/M16-2367; Reddon H, 2011, AIDS EDUC PREV, V23, P412, DOI 10.1521/aeap.2011.23.5.412; Reuter P, 2013, CRIME JUSTICE, V42, P75, DOI 10.1086/670818; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Rossman SB, 2011, MULTISTATE ADULT DRU; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Ryan O, 2012, VITAL SIGNS TAKING P; Rydell CP, 1994, CONTROLLING COCAINE; Salinas Gregory D, 2012, J Pain Res, V5, P363, DOI 10.2147/JPR.S35798; Satel S, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00141; Schiff DM, 2016, NEW ENGL J MED, V375, P2505; Silverman E, 2016, SENATORS ASK DRUG MA; Sipe TA, 2015, AM J PREV MED, V48, P755, DOI 10.1016/j.amepre.2015.01.022; Snyder L, 2012, ANN INTERN MED, V156, DOI 10.7326/0003-4819-156-1-201201031-00001; Strang J, 2012, LANCET, V379, P71, DOI 10.1016/S0140-6736(11)61674-7; Substance abuse and mental health services administration, 2016, HHS PUBL; Substance Abuse and Mental Health Services Administration, 2017, BUPR WAIV MAN; Substance Abuse and Mental Health Services Administration, 2015, BEH HLTH TRENDS US R; Substance Abuse and Mental Health Services Administration, 2015, SUBST US DIS; Substance Abuse and Mental Health Services Administration, 2016, PHYS PROGR DAT; Substance Abuse and Mental Health Services Administration, 2015, REC SERV BEH HLTH PR; The Police Assisted Addiction and Recovery Initiative, 2017, US; U.S. Department of Health and Human Services, 2016, PAR TASK FORC SUMM 2; U.S. Department of Health and Human Services, 2016, MENT HLTH SUBST US D; U.S. Department of Justice National Drug Intelligence Center, 2011, NAT DRUG THREAT ASS; U.S. Food and Drug Administration, 2016, FACT SHEET FDA OP AC; U.S. States Congress Office of Technology Assessment, 2004, BIOL COMP SUBST AB A; Ungar L, 2016, US TODAY; United Nations Office on Drugs and Crime, 2017, WORLD DRUG REP 2015; Vestal C, 2016, HEALTH AFFAIR, V35, P1052, DOI 10.1377/hlthaff.2016.0504; Volkow ND, 2016, JAMA PSYCHIAT, V73, P292, DOI 10.1001/jamapsychiatry.2015.3278; Wall MM, 2011, ANN EPIDEMIOL, V21, P714, DOI 10.1016/j.annepidem.2011.06.001; Weinmeyer Richard, 2016, AMA J Ethics, V18, P252, DOI 10.1001/journalofethics.2016.18.3.hlaw1-1603; Wen HF, 2013, JAMA PSYCHIAT, V70, P1355, DOI 10.1001/jamapsychiatry.2013.2169; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Wilkinson ST, 2016, ANNU REV MED, V67, P453, DOI 10.1146/annurev-med-050214-013454; Wolfe R, DOING LOT LITTLE STA; Wong K, 2016, LEGALIZATION MARIJUA; Wynn M, 2015, LOUISVILLE COURIER J	136	43	43	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2017	166	10					733	+		10.7326/M16-2953	http://dx.doi.org/10.7326/M16-2953			21	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU7UM	28346947				2023-01-03	WOS:000401240200017
J	Medland, NA; Chow, EPF; McMahon, JH; Elliott, JH; Hoy, JF; Fairley, CK				Medland, Nicholas A.; Chow, Eric P. F.; McMahon, James H.; Elliott, Julian H.; Hoy, Jennifer F.; Fairley, Christopher K.			Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015	PLOS ONE			English	Article							PREVENTION; CARE	Introduction The HIV care cascade is increasingly used to evaluate HIV treatment programs at the population level. However, the cascade indicators lack the ability to show changes over time, which reduces their utility to guide health policy. Alternatives have been proposed but are complex or result in a delay in results. We propose a new indicator of ART uptake, the time from HIV diagnosis to commencement of ART, and compare it to the existing cascade indicator of proportion of patients on treatment and the WHO proposed cohort cascade indicator of proportion of patients on treatment within one year of diagnosis. Methods and materials Records from patients from the two largest HIV treatment centres in the state of Victoria, Australia (Melbourne Sexual Health Centre and The Alfred Hospital Department of Infectious Diseases) from 2011 to 2015 were extracted. The intervals between date of diagnosis, entry into care and initiation of ART were compared. Results and discussion From 2011 to 2015 the proportion of in-care patients who were on ART rose from 87% to 93% (p<0.0001). From 2011 to 2014, the proportion of patients in care and on ART within one year of diagnosis increased from 43.4% to 78.9% (p = 0.001). The median time from diagnosis to ART fell from 418 days (IQR: 91-1176) to 77 days (IQR: 39-290)(p< 0.001) by calendar year in which ART was commenced. Conclusions From 2011 to 2015 there were substantial and clinically important falls in the median time from diagnosis to commencing ART in those that commenced ART. The size of this dramatic change was not apparent when only reporting the proportion of patients on ART. Time to ART is a useful indicator and can be used to supplement existing cascade indicators in measuring progress toward universal ART coverage.	[Medland, Nicholas A.; Chow, Eric P. F.; Fairley, Christopher K.] Monash Univ, Cent Clin Sch, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia; [McMahon, James H.; Elliott, Julian H.; Hoy, Jennifer F.] Monash Univ, Cent Clin Sch, Alfred Hosp, Melbourne, Vic, Australia	Monash University; Florey Institute of Neuroscience & Mental Health; Monash University	Medland, NA (corresponding author), Monash Univ, Cent Clin Sch, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.	nmedland@mshc.org.au	Hoy, Jennifer/AAK-7968-2020; Chow, Eric P.F./W-6684-2019	Chow, Eric P.F./0000-0003-1766-0657; McMahon, James/0000-0003-1460-5572; Medland, Nicholas Andrew/0000-0003-0403-8930; Christopher, Fairley/0000-0001-9081-1664; Hoy, Jennifer/0000-0002-6948-7086	Australian National Health and Medical Research Council [GNT1094518, 1091226, 1111099]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	` This work was supported by the Australian National Health and Medical Research Council to NAM (Postgraduate Scholarship Number GNT1094518), and to EPF Cand JHM (Early Career Fellowships numbers 1091226 and 1111099). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	[Anonymous], 2015, GUID US ANT AG HIV 1; Australasian Society of HIV Medicine, 2015, ANT GUID US DHSS GUI; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Grulich AE, 2016, C RETR OPP INF BOSTO; Lesko CR, 2016, AIDS, V30, P2227, DOI 10.1097/QAD.0000000000001183; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Mao LM, 2015, MED J AUSTRALIA, V202, P258, DOI 10.5694/mja14.00443; McMahon JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127726; Medland NA, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20634; NSW Health, 2014, NSW HIV STRAT 2012 1; Obama B, 2013, EXECUTIVE ORDER HIV; [Pharmaceutical Benefits Advisory Committee Department of Health], 2013, 1 LIN ANT THER ART P; Rodger A, 2016, C RETR OPP INF BOST2; Tanser F, 2013, SCIENCE, V339, P966, DOI 10.1126/science.1228160; TEMPRANO Study Group, 2015, NEW ENGLAND J MED; The Kirby Institute, 2014, VIRAL HEPTATITIS AND; The Kirby Institute, 2015, HIV VIR HEP SEX TRAN; Toren KG, 2016, SEX TRANSM DIS, V43, P34, DOI 10.1097/OLQ.0000000000000376; World Health Organization, 2015, CONS STRAT INF GUID	20	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2017	12	5							e0177634	10.1371/journal.pone.0177634	http://dx.doi.org/10.1371/journal.pone.0177634			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DC	28520807	gold, Green Submitted, Green Published			2023-01-03	WOS:000401485500049
J	Jerez-Roig, J; Ferreira, LMDM; de Araujo, JRT; Lima, KC				Jerez-Roig, Javier; de Brito Macedo Ferreira, Lidiane Maria; Torres de Araujo, Jose Rodolfo; Lima, Kenio Costa			Functional decline in nursing home residents: A prognostic study	PLOS ONE			English	Article							DAILY LIVING ADL; CULTURAL-ADAPTATION; IMPAIRMENT; VALIDATION; DISABILITY; CAPACITY; PEOPLE; RISK	Aim To verify the probability of maintaining functional capacity in basic activities of daily living and identify the prognostic factors of functional decline in institutionalized older adults. Methods A longitudinal study is presented herein, with 5 waves every 6 months, throughout 2 years (2013-2015), conducted with individuals >= 60 years old in 10 nursing homes in the city of Natal-RN (Brazil). Functional capacity was assessed by the items 'eating', 'personal hygiene', 'dressing', 'bathing', 'transferring', 'toileting' and 'walking', through a 5-item Likert scale. Sociodemographic, institution-related and health-related variables were considered to establish the baseline. Time dependent variables included continence decline, cognitive decline, increase in the number of medication, and incidences of falls, hospitalizations and fractures. The actuarial method, the log-rank test and Cox's regression were applied as statistical methods. Results The cumulative probability of functional maintenance was 78.2% (CI 95%: 72.8 - 82.7%), 65.1% (CI 95%: 58.9 - 70.5%), 53.5% (CI 95%: 47.2 - 59.5%) and 44.0% (CI 95%: 37.7 - 50.2%) at 6, 12, 18 and 24 months, respectively. Predicting factors for functional decline were: severe cognitive impairment (HR = 1.96; p = 0.001), continence decline (HR = 1.85; p = 0.002) and incidence of hospitalizations (HR = 1.62; p = 0.020), adjusted by the incidence of depression, age, education level, presence of chronic diseases and low weight. Conclusions The cumulative probability of maintaining functional capacity in institutionalized older adults was only 44% at the 2-year follow-up. Prognostic factors for functional decline included severe cognitive impairment, continence decline and incidence of hospitalizations.	[Jerez-Roig, Javier; de Brito Macedo Ferreira, Lidiane Maria; Lima, Kenio Costa] Fed Univ Rio Grande do Norte UFRN, Odontol Dept, Postgrad Program Collect Hlth, Ave Salgado Filho 1787, Natal, RN, Brazil; [Jerez-Roig, Javier] Can Misses Hosp, Ibiza, Spain; [Torres de Araujo, Jose Rodolfo] Fed Univ Rio Grande do Norte UFRN, Ctr Hlth Sci, Postgrad Program Hlth Sci, Av Gustavo Cordeiro de Farias S-N, Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Hospital Can Misses; Universidade Federal do Rio Grande do Norte	Jerez-Roig, J (corresponding author), Fed Univ Rio Grande do Norte UFRN, Odontol Dept, Postgrad Program Collect Hlth, Ave Salgado Filho 1787, Natal, RN, Brazil.; Jerez-Roig, J (corresponding author), Can Misses Hosp, Ibiza, Spain.	javijerez81@hotmail.com	Jerez-Roig, Javier/V-6119-2018	Jerez-Roig, Javier/0000-0002-1968-4452; Lima, Kenio Costa/0000-0002-5668-4398; Torres de Araujo, Jose Rodolfo/0000-0002-4257-6927				Banaszak-Holl J, 2011, J AGING HEALTH, V23, P862, DOI 10.1177/0898264311399759; Burge E, 2013, ARCH GERONTOL GERIAT, V56, P250, DOI 10.1016/j.archger.2012.09.001; Carpenter G Iain, 2006, BMC Geriatr, V6, P7, DOI 10.1186/1471-2318-6-7; Chen LY, 2013, J AM MED DIR ASSOC, V14, DOI 10.1016/j.jamda.2013.01.017; Cincura C, 2009, CEREBROVASC DIS, V27, P119, DOI 10.1159/000177918; Coll-Planas L, 2008, Z GERONTOL GERIATR, V41, P283, DOI 10.1007/s00391-008-0563-6; Courtney MD, 2012, J EVAL CLIN PRACT, V18, P128, DOI 10.1111/j.1365-2753.2010.01547.x; de la Iglesia JM, 2001, MED CLIN-BARCELONA, V117, P129; Finlayson M, 2005, J CLIN EPIDEMIOL, V58, P338, DOI 10.1016/j.jclinepi.2004.10.008; Guigoz Y, 1994, FACTS RES GERONTOL, V2, P15, DOI DOI 10.1016/S0899-9007(98)00171-3; Instituto de Pesquisa Econo A mica Aplicada (IPEA), 2011, COND FUNC INFR I LON, V2014; Javier Jerez-Roig, 2016, J GERIATR PHYS THER; Javier Jerez-Roig, 2017, DISABIL HLTH J, V10, P279; Jerez-Roig J, 2014, NEUROUROL URODYNAM; LIPSCHITZ DA, 1994, PRIMARY CARE, V21, P55; Lisboa CR, 2012, REV BRAS ENFERM, V65, P482, DOI 10.1590/S0034-71672012000300013; McConnell ES, 2002, J GERONTOL A-BIOL, V57, pM778, DOI 10.1093/gerona/57.12.M778; Raiche M, 2012, ARCH GERONTOL GERIAT, V55, P399, DOI 10.1016/j.archger.2011.12.007; Reis LA, 2011, REV BRAS ENFERM, V64, P274, DOI 10.1590/S0034-71672011000200009; Rosset I, 2011, REV ESC ENFERM USP, V45, P258; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Goncalves LHT, 2010, CAD SAUDE PUBLICA, V26, P1738, DOI 10.1590/S0102-311X2010000900007; Wang J, 2009, J GERONTOL A-BIOL, V64, P473, DOI 10.1093/gerona/gln040; Wang SY, 2013, ARCH GERONTOL GERIAT, V57, P16, DOI 10.1016/j.archger.2013.03.007; WHO Collaborating Centre for Drug Statistics Methodology, 2012, GUID ATC CLASS DDD A; World Health Organization, 1984, US EP STUD ELD	26	31	34	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177353	10.1371/journal.pone.0177353	http://dx.doi.org/10.1371/journal.pone.0177353			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EU8UP	28493946	Green Published, gold, Green Submitted			2023-01-03	WOS:000401314300092
J	Larkin, I; Ang, D; Steinhart, J; Chao, M; Patterson, M; Sah, S; Wu, TN; Schoenbaum, M; Hutchins, D; Brennan, T; Loewenstein, G				Larkin, Ian; Ang, Desmond; Steinhart, Jonathan; Chao, Matthew; Patterson, Mark; Sah, Sunita; Wu, Tina; Schoenbaum, Michael; Hutchins, David; Brennan, Troyen; Loewenstein, George			Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-INTEREST-POLICIES; DIFFERENCE	IMPORTANCE In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. OBJECTIVE To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. DESIGN, SETTING, AND PARTICIPANTS The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. EXPOSURES Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. MAIN OUTCOMES AND MEASURES The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. RESULTS The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policywas associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P<.001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P<.001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas. CONCLUSIONS AND RELEVANCE Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies.	[Larkin, Ian] Univ Calif Los Angeles, Los Angeles, CA USA; [Ang, Desmond] Univ Calif San Diego, San Diego, CA 92103 USA; [Steinhart, Jonathan] Austrian Inst Technol, Seibersdorf, Austria; [Steinhart, Jonathan] Johannes Kepler Univ Linz, Linz, Austria; [Chao, Matthew] Williams Coll, Williamstown, MA 01267 USA; [Patterson, Mark; Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; [Sah, Sunita] Cornell Univ, Ithaca, NY USA; [Wu, Tina] NYU, Langone Sch Med, New York, NY USA; [Schoenbaum, Michael] NIMH, Bethesda, MD 20892 USA; [Hutchins, David; Brennan, Troyen] CVS Caremark, Woonsocket, RI USA	University of California System; University of California Los Angeles; University of California System; University of California San Diego; Austrian Institute of Technology (AIT); Johannes Kepler University Linz; Williams College; Carnegie Mellon University; Cornell University; New York University; NYU Langone Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Larkin, I (corresponding author), Univ Calif Los Angeles, Anderson Sch Management, 110 Westwood Plaza, Los Angeles, CA 90095 USA.	ian.larkin@anderson.ucla.edu	Schoenbaum, Michael/GRR-3988-2022; Loewenstein, George/G-7616-2014; Sah, Sunita/J-4613-2014	Loewenstein, George/0000-0003-2790-0474; Wu, Tina/0000-0003-4902-2916; Sah, Sunita/0000-0003-1671-4414; Chao, Matthew/0000-0002-4757-2001	Division of Research and Faculty Development at Harvard Business School; National Science Foundation; National Institute of Mental Health	Division of Research and Faculty Development at Harvard Business School; National Science Foundation(National Science Foundation (NSF)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Licenses for some of the data used in the study were purchased by Dr Larkin with support from the Division of Research and Faculty Development at Harvard Business School. Mr Ang and Dr Chao were supported by the National Science Foundation. This study was supported by a contract from the National Institute of Mental Health awarded to Dr Loewenstein and by the provision of data and assistance from CVS Caremark.	American Board of Medical Specialties, ACCR MED SCH US CAN; American Medical Student Association, AM MED STUD ASS SCOR; Anderson TS, 2015, MED CARE, V53, P338, DOI 10.1097/MLR.0000000000000329; [Anonymous], OR BOOK DAT FIL; Chressanthis GA, 2012, J CLIN HYPERTENS, V14, P435, DOI 10.1111/j.1751-7176.2012.00651.x; DeJong C, 2016, JAMA INTERN MED, V176, P1114, DOI 10.1001/jamainternmed.2016.2765; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; Drugs.com, TOP 200 DRUGS 2010 S; Epstein AJ, 2013, MED CARE, V51, P199, DOI 10.1097/MLR.0b013e318277eb19; Essick C, 2013, BMJ-BRIT MED J, V346, pf264; Generic Pharmaceutical Association, 2011, EC AN GEN DRUG US US; Henry J. Kaiser Family Foundation, TOTAL NUMBER RETAIL; Institute on Medicine as a Profession, CONFL INT POL DAT; Larkin I, 2014, HEALTH AFFAIR, V33, P1014, DOI 10.1377/hlthaff.2013.0939; Perlis RH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155474; PhRMA, 2002, 2002 PHRMA COD INT H; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Steinbrook R, 2006, NEW ENGL J MED, V354, P2745, DOI 10.1056/NEJMp068125; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; Yeh JS, 2016, JAMA INTERN MED, V176, P763, DOI 10.1001/jamainternmed.2016.1709	21	53	53	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2017	317	17					1785	1795		10.1001/jama.2017.4039	http://dx.doi.org/10.1001/jama.2017.4039			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET6YU	28464141	Green Published			2023-01-03	WOS:000400440700036
J	Assir, MZK				Assir, Muhammad Zaman Khan			Time to stop prophylactic platelet transfusion for adult dengue	LANCET			English	Editorial Material							HEMORRHAGE		[Assir, Muhammad Zaman Khan] Allama Iqbal Med Coll, Dept Med, Lahore 54550, Pakistan; [Assir, Muhammad Zaman Khan] Jinnah Hosp, Lahore 54550, Pakistan		Assir, MZK (corresponding author), Allama Iqbal Med Coll, Dept Med, Lahore 54550, Pakistan.; Assir, MZK (corresponding author), Jinnah Hosp, Lahore 54550, Pakistan.	dr.zamankhan@yahoo.com		Assir, Muhammad/0000-0002-8940-9747	NUS	NUS(National University of Singapore)	I presented my research work at the National University of Singapore (NUS) to David C Lye and his colleagues in 2012, with travel and accommodation sponsored by NUS.	Assir MZK, 2013, TRANSFUS MED HEMOTH, V40, P362, DOI 10.1159/000354837; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842; GAYDOS LA, 1962, NEW ENGL J MED, V266, P905, DOI 10.1056/NEJM196205032661802; Lee TH, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004576; Lye DC, 2009, CLIN INFECT DIS, V48, P1262, DOI 10.1086/597773; Lye DC, 2017, LANCET; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Whitehorn J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001716; Wong JGX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148579	11	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2017	389	10079					1583	1584		10.1016/S0140-6736(17)30545-7	http://dx.doi.org/10.1016/S0140-6736(17)30545-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ES5EK	28283287				2023-01-03	WOS:000399560000004
J	Dasch, B; Kalies, H; Feddersen, B; Ruderer, C; Hiddemann, W; Bausewein, C				Dasch, Burkhard; Kalies, Helen; Feddersen, Berend; Ruderer, Caecilie; Hiddemann, Wolfgang; Bausewein, Claudia			Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; SINGLE-CENTER ANALYSIS; OF-LIFE; CHEMOTHERAPY USE; CARDIOPULMONARY-RESUSCITATION; MEDICINE CONSULTATION; QUALITY; ONCOLOGY	Background Cancer care including aggressive treatment procedures during the last phase of life in patients with incurable cancer has increasingly come under scrutiny, while integrating specialist palliative care at an early stage is regarded as indication for high quality end-of-life patient care. Aim To describe the demographic and clinical characteristics and the medical care provided at the end of life of cancer patients who died in a German university hospital. Methods Retrospective cross-sectional study on the basis of anonymized hospital data for cancer patients who died in the Munich University Hospital in 2014. Descriptive analysis and multivariate logistic regression analyses for factors influencing the administration of aggressive treatment procedures at the end of life. Results Overall, 532 cancer patients died. Mean age was 66.8 years, 58.5% were men. 110/532 (20.7%) decedents had hematologic malignancies and 422/532 (79.3%) a solid tumor. Patients underwent the following medical interventions in the last 7/30 days: chemotherapy (7.7%/38.3%), radiotherapy (2.6%/6.4%), resuscitation (8.5%/10.5%), surgery (15.2%/31.0%), renal replacement therapy (12.0%/16.9%), blood transfusions (21.2%/39.5%), CT scan (33.8%/60.9%). In comparison to patients with solid tumors, patients with hematologic malignancies were more likely to die in intensive care (25.4% vs. 49.1%; p = 0.001), and were also more likely to receive blood transfusions (OR 2.21; 95% CI, 1.36 to 3.58; p = 0.001) and renal replacement therapy (OR 2.65; 95% CI, 1.49 to 4.70; p = 0.001) in the last 7 days of life. Contact with the hospital palliative care team had been initiated in 161/532 patients (30.3%). In 87/161 cases (54.0%), the contact was initiated within the last week of the patient's life. Conclusions Overambitious treatments are still reality at the end of life in cancer patients in hospital but patients with solid tumors and hematologic malignancies have to be differentiated. More efforts are necessary for the timely inclusion of specialist palliative care.	[Dasch, Burkhard; Kalies, Helen; Feddersen, Berend; Bausewein, Claudia] Ludwig Maximilian Univ Munich, Munich Univ Hosp, Dept Palliat Med, Munich, Germany; [Ruderer, Caecilie] Specialized Palliat Home Care, Dist Of Berchtesgaden, Germany; [Ruderer, Caecilie] Specialized Palliat Home Care, Dist Of Traunstein, Germany; [Hiddemann, Wolfgang] Ludwig Maximilian Univ Munich, Munich Univ Hosp, Dept Internal Med 3, Munich, Germany	University of Munich; University of Munich	Dasch, B (corresponding author), Ludwig Maximilian Univ Munich, Munich Univ Hosp, Dept Palliat Med, Munich, Germany.	burkharddasch@web.de		Bausewein, Claudia/0000-0002-0958-3041				Adam H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-26; American Society of Clinical Oncology (ASCO), INT PALL CAR STAND O; Assi T, 2016, SUPPORT CARE CANCER, V24, P1603, DOI 10.1007/s00520-015-2959-3; Bailey FA, 2012, J PALLIAT MED, V15, P751, DOI 10.1089/jpm.2011.0321; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Bausewein C, 2016, PALLIATIVE MED, V30, P6, DOI 10.1177/0269216315589898; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Billingham MJ, 2013, BMJ SUPPORT PALLIAT, V3, P144, DOI 10.1136/bmjspcare-2012-000292; Bird GT, 2012, BRIT J ANAESTH, V108, P452, DOI 10.1093/bja/aer449; Boyaci N, 2014, HEMATOLOGY, V19, P338, DOI 10.1179/1607845413Y.0000000130; Braga S, 2007, PSYCHO-ONCOL, V16, P863, DOI 10.1002/pon.1140; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Chen JS, 2009, RESUSCITATION, V80, P1388, DOI 10.1016/j.resuscitation.2009.08.015; Cherny N, 2010, ANN ONCOL, V21, P362, DOI 10.1093/annonc/mdp318; Chu DT, 2009, LUNG CANCER, V66, P250, DOI 10.1016/j.lungcan.2009.01.022; Cohen J, 2015, BRIT J CANCER, V113, P1397, DOI 10.1038/bjc.2015.312; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; Dalgaard KM, 2014, PALLIAT SUPPORT CARE, V12, P495, DOI 10.1017/S1478951513001338; Davis MP, 2015, ANN PALLIAT MED, V4, P99, DOI 10.3978/j.issn.2224-5820.2015.04.04; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fadul N, 2009, CANCER-AM CANCER SOC, V115, P2013, DOI 10.1002/cncr.24206; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Gaertner J, 2015, ANN PALLIAT MED, V4, P156, DOI 10.3978/j.issn.2224-5820.2015.07.02; Gaertner J, 2011, SUPPORT CARE CANCER, V19, P1037, DOI 10.1007/s00520-011-1131-y; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Howell Debra A, 2010, BMC Palliat Care, V9, P9, DOI 10.1186/1472-684X-9-9; Hui D, 2015, ANN PALLIAT MED, V4, P89, DOI 10.3978/j.issn.2224-5820.2015.04.01; Hui D, 2014, CANCER-AM CANCER SOC, V120, P1572, DOI 10.1002/cncr.28614; Kao S, 2009, ANN ONCOL, V20, P1555, DOI 10.1093/annonc/mdp027; Klinger CA, 2014, PALLIATIVE MED, V28, P111, DOI 10.1177/0269216313493342; Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF), 2015, PALL PAT NICHT HEILB; Lordick F, 2012, FORUM, V27, P367; Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; Magarotto R, 2011, TUMORI J, V97, P573, DOI 10.1700/989.10714; Martoni AA, 2007, TUMORI J, V93, P417; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; Murillo JR, 2006, ONCOLOGIST, V11, P1095, DOI 10.1634/theoncologist.11-10-1095; Nappa U, 2011, ANN ONCOL, V22, P2375, DOI 10.1093/annonc/mdq778; Pacetti P, 2015, SUPPORT CARE CANCER, V23, P3277, DOI 10.1007/s00520-015-2733-6; Pantilat SZ, 2010, ARCH INTERN MED, V170, P2038, DOI 10.1001/archinternmed.2010.460; Prigerson HG, 2015, JAMA ONCOL, V1, P778, DOI 10.1001/jamaoncol.2015.2378; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Radbruch L, 2015, ANAL SELECTED TREATM; Reisfield GM, 2006, RESUSCITATION, V71, P152, DOI 10.1016/j.resuscitation.2006.02.022; Saito AM, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-14; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Starks H, 2013, J PALLIAT MED, V16, P1215, DOI 10.1089/jpm.2013.0163; Swetz KM, 2010, CANCER J, V16, P467, DOI 10.1097/PPO.0b013e3181f28ab3; Taberner Bonastre Pilar, 2016, Farm Hosp., V40, P14, DOI 10.7399/fh.2016.40.1.8918; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Yun YH, 2007, ONCOLOGY-BASEL, V72, P164, DOI 10.1159/000112802; Zhi WI, 2015, ANN PALLIAT MED, V4, P122, DOI 10.3978/j.issn.2224-5820.2015.07.03; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	65	32	32	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e0175124	10.1371/journal.pone.0175124	http://dx.doi.org/10.1371/journal.pone.0175124			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2QB	28384214	Green Published, Green Submitted, gold			2023-01-03	WOS:000399371900093
J	Bennell, KL; Nelligan, R; Dobson, F; Rini, C; Keefe, F; Kasza, J; French, S; Bryant, C; Dalwood, A; Abbott, JH; Hinman, RS				Bennell, Kim L.; Nelligan, Rachel; Dobson, Fiona; Rini, Christine; Keefe, Francis; Kasza, Jessica; French, Simon; Bryant, Christina; Dalwood, Andrew; Abbott, J. Haxby; Hinman, Rana S.			Effectiveness of an Internet-Delivered Exercise and Pain-Coping Skills Training Intervention for Persons With Chronic Knee Pain A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							IN-HOME TELEREHABILITATION; PHYSICAL-ACTIVITY PROGRAM; HIP OSTEOARTHRITIS; SELF-MANAGEMENT; HEALTH-CARE; ARTHRITIS; PEOPLE; ARTHROPLASTY; ADULTS; IMPACT	Background: Effective, accessible biopsychosocial treatments are needed to manage chronic knee pain on a population level. Objective: To evaluate the effectiveness of Internet-delivered, physiotherapist-prescribed home exercise and pain-coping skills training (PCST). Design: Pragmatic parallel-group randomized, controlled trial. (Australian New Zealand Clinical Trials Registry: ACTRN12614000243617) Setting: Community (Australia). Patients: 148 persons aged 50 years or older with chronic knee pain. Intervention: The intervention was delivered via the Internet and included educational material, 7 videoconferencing (Skype [Microsoft]) sessions with a physiotherapist for home exercise, and a PCST program over 3 months. The control was Internetbased educational material. Measurements: Primary outcomes were pain during walking (11-point numerical rating scale) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index) at 3 months. Secondary outcomes were knee pain, quality of life, global change (overall, pain, and functional status), arthritis selfefficacy, coping, and pain catastrophizing. Outcomes were also measured at 9 months. Results: Of participants enrolled, 139 (94%) completed primary outcome measures at 3 months and 133 (90%) completed secondary outcome measures at 9 months; multiple imputation was used for missing data. The intervention group reported significantly more improvement in pain (mean difference, 1.6 units [95% CI, 0.9 to 2.3 units]) and physical function (mean difference, 9.3 units [CI, 5.9 to 12.7 units]) than the control group at 3 months, and improvements were sustained at 9 months (mean differences, 1.1 units [CI, 0.4 to 1.8 units] and 7.0 units [CI, 3.4 to 10.5 units], respectively). Intervention participants showed significantly more improvement in most secondary outcomes than control participants. At both time points, significantly more intervention participants reported global improvements. Limitation: Participants were unblinded. Conclusion: For persons with chronic knee pain, Internetdelivered, physiotherapist-prescribed exercise and PCST provide clinically meaningful improvements in pain and function that are sustained for at least 6 months.	[Bennell, Kim L.; Nelligan, Rachel; Dobson, Fiona; Hinman, Rana S.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Level 7,Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3010, Australia; [Kasza, Jessica] Monash Univ, Alfred Ctr, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia; Royal Womens Hosp, Melbourne, Vic, Australia; Physioworks Hlth Grp, Melbourne, Vic, Australia; UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; Duke Univ, Durham, NC USA; [French, Simon] Queens Univ, Sch Rehabil Therapy, Fac Hlth Sci, Louise D Acton Bldg,31 George St, Kingston, ON K7L 3N6, Canada; [Abbott, J. Haxby] Univ Otago, Dunedin Sch Med, Dept Surg Sci, Ctr Musculoskeletal Outcomes Res,Orthopaed Surg S, POB 913, Dunedin 9054, New Zealand; [Rini, Christine] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Campus Box 7440,319C Rosenau Hall, Chapel Hill, NC 27599 USA; [Keefe, Francis] Duke Pain Prevent & Treatment Res Program, Suite 340,2200 West Main St, Durham, NC 27705 USA; [Bryant, Christina] Chelsea House,Suite 225,55 Flemington Rd, North Melbourne, Vic 3051, Australia; [Dalwood, Andrew] Waverley Pk Physiotherapy Ctr, 439 Police Rd, Mulgrave, Vic 3170, Australia	University of Melbourne; Monash University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Queens University - Canada; University of Otago; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Bennell, KL (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Level 7,Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3010, Australia.	k.bennell@unimelb.edu.au; jessica.kasza@monash.edu	/AAB-3060-2019; Abbott, J. Haxby/AAK-4346-2020; ABBOTT, J. Haxby/AAH-3262-2019; Bennell, Kim/C-7022-2014	Abbott, J. Haxby/0000-0001-6468-7284; Hinman, Rana/0000-0001-6368-9456; Bryant, Christina/0000-0003-4728-981X; French, Simon/0000-0002-7061-7706; Bennell, Kim/0000-0003-4982-5639; Rini, Christine/0000-0002-3169-3626; Nelligan, Rachel/0000-0002-8689-6594	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	National Health and Medical Research Council.	Ackerman IN, 2012, BEST PRACT RES CL RH, V26, P561, DOI 10.1016/j.berh.2012.08.002; Beatty L, 2013, CLIN PSYCHOL REV, V33, P609, DOI 10.1016/j.cpr.2013.03.004; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; BELLAMY N, 1992, J RHEUMATOL, V19, P444; Bennell KL, 2017, ARTHRIT CARE RES, V69, P84, DOI 10.1002/acr.22915; Bennell KL, 2016, ARTHRIT CARE RES, V68, P590, DOI 10.1002/acr.22744; Bennell KL, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-246; Bini SA, 2017, J TELEMED TELECARE, V23, P239, DOI 10.1177/1357633X16634518; Bossen D, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2662; Brand CA, 2014, ARTHRIT CARE RES, V66, P551, DOI 10.1002/acr.22197; Carpenter J. R., 2013, MULTIPLE IMPUTATION; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Day ML, 2004, J STRENGTH COND RES, V18, P353, DOI 10.1519/00124278-200405000-00027; Dixon KE, 2007, HEALTH PSYCHOL, V26, P241, DOI 10.1037/0278-6133.26.3.241; Dobson F, 2016, AM J PHYS MED REHAB, V95, P372, DOI 10.1097/PHM.0000000000000448; Dobson Fiona, 2014, BMC Musculoskelet Disord, V15, P279, DOI 10.1186/1471-2474-15-279; Fransen M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-095424; Gierisch JM, 2014, ANN INTERN MED, V160, P836, DOI 10.7326/M14-0318; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hunter DJ, 2014, NAT REV RHEUMATOL, V10, P437, DOI 10.1038/nrrheum.2014.44; Jinks C, 2004, RHEUMATOLOGY, V43, P55, DOI 10.1093/rheumatology/keg438; Juhl C, 2014, ARTHRITIS RHEUMATOL, V66, P622, DOI 10.1002/art.38290; Kairy D, 2013, INT J ENV RES PUB HE, V10, P3998, DOI 10.3390/ijerph10093998; KEEFE FJ, 1987, J CONSULT CLIN PSYCH, V55, P208, DOI 10.1037/0022-006X.55.2.208; Kelders SM, 2012, J MED INTERNET RES, V14, P17, DOI 10.2196/jmir.2104; Kroon FPB, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008963.pub2; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005; Moffet H, 2015, J BONE JOINT SURG AM, V97A, P1129, DOI 10.2106/JBJS.N.01066; Muller CJ, 2014, INT J EPIDEMIOL, V43, P962, DOI 10.1093/ije/dyu029; Murphy LB, 2012, ARTHRIT CARE RES, V64, P968, DOI 10.1002/acr.21685; National Clinical Guideline Centre, 2014, OST CAR MAN AD NICE; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Odole AC, 2014, INT J TELEMED APPL, V2014, DOI 10.1155/2014/903816; Odole AC, 2013, INT J TELEREHABILITA, V5, P11, DOI 10.5195/ijt.2013.6125; Osborne RH, 2003, J CLIN EPIDEMIOL, V56, P138, DOI 10.1016/S0895-4356(02)00601-7; Osman A, 2000, J BEHAV MED, V23, P351, DOI 10.1023/A:1005548801037; Pereira D, 2011, OSTEOARTHR CARTILAGE, V19, P1270, DOI 10.1016/j.joca.2011.08.009; Pietrzak E, 2013, TELEMED E-HEALTH, V19, P800, DOI 10.1089/tmj.2012.0288; Piqueras M, 2013, J REHABIL MED, V45, P392, DOI 10.2340/16501977-1119; Rini C, 2015, PAIN, V156, P837, DOI 10.1097/j.pain.0000000000000121; Rini Christine, 2014, J Med Internet Res, V16, pe245, DOI 10.2196/jmir.3374; Rini C, 2012, TRANSL BEHAV MED, V2, P82, DOI 10.1007/s13142-011-0107-2; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Russell TG, 2011, J BONE JOINT SURG AM, V93A, P113, DOI 10.2106/JBJS.I.01375; Shukla H, 2017, J TELEMED TELECARE, V23, P339, DOI 10.1177/1357633X16628996; Tousignant M, 2011, TELEMED E-HEALTH, V17, P376, DOI 10.1089/tmj.2010.0198; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Turkiewicz A, 2014, OSTEOARTHR CARTILAGE, V22, P1826, DOI 10.1016/j.joca.2014.07.015; White IR, 2011, STAT MED, V30, P3192, DOI 10.1002/sim.4360; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Wong YK, 2005, J TELEMED TELECARE, V11, P310, DOI 10.1258/1357633054893346; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013; Zickuhr K, 2012, PEW INTERNET AM LIFE; Ziebland S, 2015, BRIT J PAIN, V9, P62, DOI 10.1177/2049463714555438; Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387	57	125	126	4	65	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2017	166	7					453	+		10.7326/M16-1714	http://dx.doi.org/10.7326/M16-1714			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EQ4PT	28241215				2023-01-03	WOS:000398061100007
J	Clouthier, DL; Ohashi, PS				Clouthier, Derek L.; Ohashi, Pamela S.			Costimulation, a surprising connection for immunotherapy	SCIENCE			English	Editorial Material							NIVOLUMAB PLUS IPILIMUMAB; CD8 T-CELLS; IMMUNITY; MELANOMA; PD-1		[Clouthier, Derek L.; Ohashi, Pamela S.] Princess Margaret Canc Ctr, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Ohashi, Pamela S.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Ohashi, Pamela S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Ohashi, PS (corresponding author), Princess Margaret Canc Ctr, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada.; Ohashi, PS (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.; Ohashi, PS (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.	pohashi@uhnresearch.ca		Ohashi, Pamela S./0000-0003-2915-9317				Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Goldberg MV, 2007, BLOOD, V110, P186, DOI 10.1182/blood-2006-12-062422; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Iwai YH, 2003, J EXP MED, V198, P39, DOI 10.1084/jem.20022235; Kamphorst AO, 2017, SCIENCE, V355, P1423, DOI 10.1126/science.aaf0683; LAFFERTY KJ, 1977, IMMUNOL REV, V35, P231, DOI 10.1111/j.1600-065X.1977.tb00241.x; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	15	7	8	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2017	355	6332					1373	1374		10.1126/science.aan1467	http://dx.doi.org/10.1126/science.aan1467			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EQ1DL	28360282				2023-01-03	WOS:000397809500020
J	Homma, Y; Yamauchi, S; Mizobe, M; Nakashima, Y; Takahashi, J; Funakoshi, H; Urayama, KY; Ohde, S; Takahashi, O; Shiga, T				Homma, Yosuke; Yamauchi, Sunao; Mizobe, Michiko; Nakashima, Yoshiyuki; Takahashi, Jin; Funakoshi, Hiraku; Urayama, Kevin Y.; Ohde, Sachiko; Takahashi, Osamu; Shiga, Takashi			Emergency department outpatient treatment of alcohol-intoxicated bicyclists increases the cost of medical care in Japan	PLOS ONE			English	Article							INJURY SEVERITY; RISK; CYCLISTS; TRAUMA; HEAD	Riding a bicycle under the influence of alcohol is illegal in Japan. Nevertheless, intoxicated bicyclists are frequently treated at hospital emergency departments for bicycle-related injuries. This patient population usually requires more hospital resources, even for relatively minor injuries. Therefore, we hypothesized that bicycle-related crashes involving bicyclists under the influence of alcohol cost more to treat than those that do not involve alcohol intoxication. The aim of the present study was to examine the costs associated with bicycle-related minor injuries and alcohol intoxication of the bicyclist. The study was conducted at the Tokyo Bay Urayasu Ichikawa Medical Center Emergency Department, Japan. All minor bicycle crashes involving 217 individuals aged >= 20 years treated from September 1, 2012 to August 31, 2013 were included in the analysis of data obtained from medical records. Variables included alcohol intoxication, sex, age, collision with a motor vehicle, Glasgow Coma Scale, injury severity score (ISS), laboratory tests, treatment of wounds, number of X-ray images, number of computed tomography scans, and medical costs. Multiple linear regression analysis was performed to evaluate the association between alcohol intoxication and medical costs. Seventy (32%) patients consumed alcohol, and the median medical cost was 253 USD (interquartile range [IQR], 164-330). Multivariable analysis showed that alcohol intoxication was independently associated with higher medical costs (p = 0.030, adjusted R-square value = 0.55). These findings support our hypothesis and should encourage authorities to implement comprehensive measures to prohibit bicycling under the influence of alcohol to prevent injuries and to reduce medical costs.	[Homma, Yosuke; Mizobe, Michiko; Nakashima, Yoshiyuki; Takahashi, Jin; Funakoshi, Hiraku; Shiga, Takashi] Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency Med & Crit Care, Chiba, Japan; [Yamauchi, Sunao] Univ Iowa Hosp & Clin, Dept Emergency Med, Iowa City, IA 52242 USA; [Urayama, Kevin Y.; Ohde, Sachiko; Takahashi, Osamu] St Lukes Int Univ, Ctr Clin Epidemiol, Tokyo, Japan	University of Iowa; St. Luke's International Hospital	Homma, Y (corresponding author), Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency Med & Crit Care, Chiba, Japan.	jazz.dr.homma@gmail.com	Ohde, Sachiko/AAC-6496-2019; Funakoshi, Hiraku/R-4400-2019	Ohde, Sachiko/0000-0001-9137-0047; Homma, Yosuke/0000-0002-0473-9617; Takahashi, Jin/0000-0001-5396-0054				Asbridge M, 2014, PREV MED, V66, P80, DOI 10.1016/j.ypmed.2014.06.006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brick J, 2009, ALCOHOL CLIN EXP RES, V33, P1489, DOI 10.1111/j.1530-0277.2009.00979.x; Chen WS, 2013, ACAD EMERG MED, V20, P570, DOI 10.1111/acem.12146; Crocker P, 2010, AM J EMERG MED, V28, P68, DOI 10.1016/j.ajem.2008.09.011; Hakucho Ayako, 2014, Nihon Arukoru Yakubutsu Igakkai Zasshi, V49, P177; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; Martinez-Ruiz V, 2013, ACCIDENT ANAL PREV, V51, P228, DOI 10.1016/j.aap.2012.11.023; Morgan AS, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-699; Olson KN, 2013, ALCOHOL ALCOHOLISM, V48, P386, DOI 10.1093/alcalc/agt042; Scholten AC, 2015, ACCIDENT ANAL PREV, V81, P51, DOI 10.1016/j.aap.2015.04.022; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; Twisk DAM, 2013, ACCIDENT ANAL PREV, V60, P134, DOI 10.1016/j.aap.2013.08.015	15	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0174408	10.1371/journal.pone.0174408	http://dx.doi.org/10.1371/journal.pone.0174408			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER8SZ	28329002	Green Published, Green Submitted, gold			2023-01-03	WOS:000399094700089
J	Guan, JZ; Yuan, SF; Wu, HQMG; Na, RS; Wu, XQ; Wang, X; Bao, S				Guan, Jingzhi; Yuan, Shaofei; Wu, Hanqimuge; Na, Risu; Wu, Xueqin; Wang, Xin; Bao, Shan			Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review								Background and objective To systematically evaluate the clinical effects and safety of traditional Chinese medical bath therapy (TCMBT) combined with ultraviolet irradiation in the treatment of psoriasis. Methods Electronic database retrieval was utilized. The foreign retrieval databases consulted included those of the Cochrane Library, PubMed and EMBASE; the domestic retrieval databases included the Chinese Biomedical Literature Database (Sino-Med), the China National Knowledge Infrastructure (CNKI), VIP and the WangFang Database. Clinical randomized controlled trials were conducted to evaluate the effects of TCMBT combined with ultraviolet irradiation in the treatment of psoriasis; the language of the retrieved articles was Chinese or English. Each database was searched from its inception to August 1, 2015. Two researchers independently collected the data and analyzed the methodology of the documented literature. The researchers conducted a meta-analysis with RevMan 5.2.3 software. Results According to the available literature, 25 RCTs (randomized controlled trials) of low research quality were conducted. According to the meta-analysis, the total effective rate of TCMBT combined with ultraviolet irradiation was relatively higher than that of ultraviolet irradiation alone. The recurrence rate, incidence of adverse reactions and Psoriasis Area and Severity Index (PASI) for the combined therapy was lower than that of ultraviolet irradiation (P<0.05). Conclusion For the treatment of psoriasis, the clinical effects and safety of TCMBT combined with ultraviolet irradiation are generally better than those of ultraviolet irradiation alone. However, the original literature was written in Chinese, and the quality of the studies was not high. Thus, it is difficult to confirm the clinical effects and safety of TCMBT combined with ultraviolet irradiation. It is necessary to conduct a scientific, normalized and high-quality RCT with multiple large samples and centers.	[Guan, Jingzhi; Wu, Xueqin; Wang, Xin; Bao, Shan] Inner Mongolia Int Mongolian Hosp, Dept Pharmaceut, Hohhot, Inner Mongolia, Peoples R China; [Yuan, Shaofei] Baotou Med Coll, Dept Pharmaceut, Affiliated Hosp 2, Baotou, Inner Mongolia, Peoples R China; [Wu, Hanqimuge] Inner Mongolia Int Mongolian Hosp, Pharmaceut Lab, Hohhot, Inner Mongolia, Peoples R China; [Na, Risu] Inner Mongolia Int Mongolian Hosp, Dept Psychosomat Med, Hohhot, Inner Mongolia, Peoples R China	Baotou Medical College	Bao, S (corresponding author), Inner Mongolia Int Mongolian Hosp, Dept Pharmaceut, Hohhot, Inner Mongolia, Peoples R China.	shanbao_IMIMH@163.com		bao, shan/0000-0002-1996-2280				Bandow GD, 2004, INT J DERMATOL, V43, P555, DOI 10.1111/j.1365-4632.2004.02032.x; Cui Bing-Nan, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P355; Declercq SD, 2013, SCI WORLD J, DOI 10.1155/2013/980419; Dong X, 2016, CONTINUING MED ED, V2, P115; Duan X, 2013, CHINESE J DERMATOVEN, V27, P192; Feng XG, 2009, MODERN J INTEGRATED, V8, P932; Han L., 2013, J GUIYANG U CHIN MED, V35, P149; Hu SJ, 2006, CHINA J LEPROSY SKIN, V9, P779; Kang DY, 2003, J EVIDENCE BASED MED, V1, P46; Kimball AB, 2014, BRIT J DERMATOL, V170, P366, DOI 10.1111/bjd.12744; Lan HR, 2015, JIANGXI J TRADITIONA, V10, P7; Li LZ, 2016, MODERN J INTEGRATED, V1, P680; Li N., 2014, CHINA HLTH IND, P190; Lin GS, 2010, ACTA U MED ANHUI, V3, P404; Liu B, 2005, J CLIN DERMATOLOGY, V8, P552; Liu HQ, 2005, N J TRADIT CHIN MED, V2, P53; Liu HX, 2008, OBSERVED CLIN CURATI; LIU XW, 2010, J DALIAN MED U, V32, P551; Luo GP, 2014, HUBEI J TRADITIONAL, V8, P12; Luo SM, 2010, CHINESE J DERMATOLOG, V4, P284; Mehta D, 2016, AM J CLIN DERMATOL, V17, P125, DOI 10.1007/s40257-016-0176-6; MU Z, 2009, CHINA MED ABSTRACT D, V3, P156; Peter Juni, 2001, CHINESE J EVIDENCE B, V4, P250; Qu YY, 2011, XINJIANG MED J, V4, P28; Racz E, 2015, DERMATOL CLIN, V33, P79, DOI 10.1016/j.det.2014.09.007; Re YEHGL WXE, 2012, SHAANXI J TRADITIONA, V7, P860; [师秀利 Shi Xiuli], 2011, [中国激光医学杂志, Chinese Journal of Laser Medicine and Surgery], V20, P314; Skobowiat C, 2013, BRIT J DERMATOL, V168, P595, DOI 10.1111/bjd.12096; Skobowiat C., 2016, PHOTOCHEM PHOTOBIOL; Skobowiat C, 2016, EXP DERMATOL, V25, P120, DOI 10.1111/exd.12890; Skobowiat C, 2015, J INVEST DERMATOL, V135, P1638, DOI 10.1038/jid.2014.450; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Slominski A., 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2015, STEROIDS, V103, P72, DOI 10.1016/j.steroids.2015.04.006; Slominski AT, 2015, PHOTODERMATOL PHOTO, V31, P121, DOI 10.1111/phpp.12165; Song LJ, 2011, CHINESE J DERMATOLOG, V44, P60; SUN ZJ, 2010, CONT MED, V30, P152; Tan YQ, 2011, CHIN J INTEGR MED, V17, P150, DOI 10.1007/s11655-011-0645-y; The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184.CH9; Wang FE, 2013, CLIN MED, V9, P112; Wang GC, 2002, DERMATOLOGY VENEREAL, P538; Wang LX, 2012, NEI MONGOL J TRADITI, V7, P115; Wang XG, 2015, CLIN J MED OFFICERS, V3, P300; Wang XN, 2015, PHARM BIOTECHNOLOGY, V3, P259; Wang XS, 2005, YANG GUOLIANG DERMAT, P508; Wang YQ, 2013, MED J NATL DEFENDING, V3, P260; Wang YS, 2014, WIT TRANS ENG SCI, V84, P85, DOI 10.2495/MEEE20130121; Wang ZX, 2011, HENAN XUE XUE BAO, V30, P226; Wu ZH, 2004, MODERN DERMATOLOGY, P450; Xuan ML, 2015, CHIN J INTEGR MED, V21, P108, DOI 10.1007/s11655-014-1792-0; Yan YH, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/719641; YE CG, 2009, CHINA TROPICAL MED, V4, P636; Yu JJ, 2013, TOPICA CHINESE HERBA; YUAN LL, 2014, CHINA J LEPROSY SKIN, V8, P473; Zhang CS, 2016, COMPLEMENT THER MED, V25, P55, DOI 10.1016/j.ctim.2015.12.014; Zhang Y, 2014, HUNAN CHINESE MED J, V30, P184; Zhang YH, 2014, J HUBEI U CHINESE ME, V2, P95; Zhang YS, 2010, ZHONG GUO MA FENG PI, V26, P815; Zhao B, 2009, CHINA CLIN DERMATOLO, P1011; Zhao D, 2015, CLIN J TRADITIONAL C, V5, P695; Zhao XN, 2002, CLIN DERMATOL, P1034; Zhou M, 2005, LIAONING J TRADITION, V10, P1025; Zhou ML, 2014, MED INFORM, V4, P166; Zhou XY, 2002, J EVIDENCE BASED MED, V4, P216	64	8	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2017	12	3							e0173276	10.1371/journal.pone.0173276	http://dx.doi.org/10.1371/journal.pone.0173276			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8RG	28323822	Green Published, gold, Green Submitted			2023-01-03	WOS:000399089000016
J	Chu, YW; Wu, WS; Hsu, CF; Wang, JJ; Weng, SF; Chien, CC				Chu, Yeh-Wen; Wu, Wen-Shiann; Hsu, Chen-Fang; Wang, Jhi-Joung; Weng, Shih-Feng; Chien, Chih-Chiang			Bidirectional association between ESRD dialysis and diabetes: National cohort study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; GLUCOSE-INTOLERANCE; INSULIN-RESISTANCE; MORTALITY; TAIWAN; HEMODIALYSIS; MELLITUS; IMPACT	Background Diabetes is associated with development of end-stage renal disease (ESRD) dialysis, but it is not clear whether ESRD dialysis is a risk factor for new-onset diabetes (NODM). Methods Using the Taiwan National Health Insurance Research Database, we designed two cohort studies to determine the association between dialysis and diabetes. Analysis 1 estimated the hazard ratios (HR) of ESRD dialysis in 20,585 patients with type 2 diabetes (T2DM) and 82,340 gender- and age-matched controls without diabetes. Analysis 2 estimated the HRs of NODM in 18,489 ESRD patients undergoing dialysis and 73,956 gender- and age matched controls without ESRD dialysis. The follow-up period was from 2000 to date of endpoint, the date of death, or December 31, 2008. Cox proportional models were used to estimate the relative hazards. Results In analysis 1, the incidence of ESRD dialysis was higher in the T2DM cohort than in the non diabetes cohort (6.78 vs. 0.61 per 1,000 person-years; HR: 7.97; 95%X1: 7.05-8.00). In analysis 2, the incidence of NODM was higher in the ESRD dialysis cohort than in the without-ESRD dialysis cohort (22.84 vs. 13.99 per 1,000 person-years; HR: 1.40; 95% CI: 1.34-1.47). Conclusions ESRD dialysis and diabetes were bidirectionally associated. The relationship between T2DM and incident ESRD dialysis was much stronger than between ESRD dialysis and NODM. Further studies are needed to determine the mechanism of ESRD dialysis-related NODM.	[Chu, Yeh-Wen; Chien, Chih-Chiang] Chi Mei Med Ctr, Dept Nephrol, Tainan, Taiwan; [Wu, Wen-Shiann] Chi Mei Med Ctr, Dept Cardiol, Tainan, Taiwan; [Wu, Wen-Shiann] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan; [Hsu, Chen-Fang] Chi Mei Med Ctr, Dept Pediat, Tainan, Taiwan; [Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Weng, Shih-Feng] Kaohsiung Med Univ, Dept Healthcare Adm & Med Informat, Kaohsiung, Taiwan	Chi Mei Hospital; Chi Mei Hospital; Chia Nan University of Pharmacy & Science; Chi Mei Hospital; Chi Mei Hospital; Kaohsiung Medical University	Chien, CC (corresponding author), Chi Mei Med Ctr, Dept Nephrol, Tainan, Taiwan.	ccchien58@yahoo.com.tw		Weng, Shih-Feng/0000-0001-8684-3487	Chi-Mei Medical Center [CMFHR10242]; National Health Research Institutes in Taiwan [NHRI-NHIRD-99182, NHRI-NHIRD-100057]	Chi-Mei Medical Center; National Health Research Institutes in Taiwan(National Health Research Institutes - Taiwan)	The study was supported by grant CMFHR10242 from Chi-Mei Medical Center and grant NHRI-NHIRD-99182 and NHRI-NHIRD-100057 from the National Health Research Institutes in Taiwan. All the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	CHEN M, 1985, J CLIN ENDOCR METAB, V60, P13, DOI 10.1210/jcem-60-1-13; Chien CC, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-43; Chou MT, 2013, INT J CARDIOL, V167, P2719, DOI 10.1016/j.ijcard.2012.06.108; DEFRONZO RA, 1981, DIABETES CARE, V4, P493, DOI 10.2337/diacare.4.4.493; DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095; Hoffmann F, 2011, NEPHROL DIAL TRANSPL, V26, P1634, DOI 10.1093/ndt/gfq609; Hsu CY, 2009, ARCH INTERN MED, V169, P342, DOI 10.1001/archinternmed.2008.605; Jiang Y., 2009, Plant Biology (Rockville), V2009, P111; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; Kan WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068748; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Kuo HW, 2007, AM J KIDNEY DIS, V49, P46, DOI 10.1053/j.ajkd.2006.10.007; Lin-Tan DT, 2007, J AM SOC NEPHROL, V18, P2385, DOI 10.1681/ASN.2006121409; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; MANTTARI M, 1995, HYPERTENSION, V26, P670, DOI 10.1161/01.HYP.26.4.670; Mari A, 2010, DIABETOLOGIA, V53, P749, DOI 10.1007/s00125-009-1647-6; Pavkov ME, 2006, JAMA-J AM MED ASSOC, V296, P421, DOI 10.1001/jama.296.4.421; Pecoits R, 2003, KIDNEY INT, V63, pS162, DOI 10.1046/j.1523-1755.63.s84.39.x; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; Pupim LB, 2004, KIDNEY INT, V66, P2054, DOI 10.1111/j.1523-1755.2004.00978.x; Sabe MA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002850; Salifu MO, 2010, AM J NEPHROL, V31, P239, DOI 10.1159/000276542; Szeto CC, 2007, AM J KIDNEY DIS, V49, P524, DOI 10.1053/j.ajkd.2007.01.018; Tien KJ, 2013, DIABETES CARE, V36, P3027, DOI 10.2337/dc12-2148; United States Renal Data System, 2011, EXC USRDS 2009 ANN R; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Woodward RS, 2003, AM J TRANSPLANT, V3, P590, DOI 10.1034/j.1600-6143.2003.00082.x; Wu CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158533; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	29	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2017	12	3							e0173785	10.1371/journal.pone.0173785	http://dx.doi.org/10.1371/journal.pone.0173785			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9HQ	28296932	Green Published, Green Submitted, gold			2023-01-03	WOS:000396311700064
J	Coombes, R				Coombes, Rebecca			We need to talk about resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmj.com							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2017	356								j1216	10.1136/bmj.j1216	http://dx.doi.org/10.1136/bmj.j1216			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BU	28279959	Green Published, Bronze			2023-01-03	WOS:000396433400005
J	Rohr, R				Rohr, Richard			Why Physician Leaders of Health Care Organizations Should Participate in Direct Patient Care	ANNALS OF INTERNAL MEDICINE			English	Letter																		Detsky AS, 2016, ANN INTERN MED, V165, P519, DOI 10.7326/M16-0820	1	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					376	376		10.7326/L16-0626	http://dx.doi.org/10.7326/L16-0626			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265662				2023-01-03	WOS:000396432800015
J	Khvorova, A; Watts, JK				Khvorova, Anastasia; Watts, Jonathan K.			The chemical evolution of oligonucleotide therapies of clinical utility	NATURE BIOTECHNOLOGY			English	Review							ALLELE-SELECTIVE INHIBITION; TARGETING HUMAN LIPOPROTEIN; LOCKED NUCLEIC-ACIDS; ANTISENSE OLIGONUCLEOTIDES; IN-VIVO; MUTANT HUNTINGTIN; MESSENGER-RNA; STRUCTURAL BASIS; THERMODYNAMIC STABILITY; NUCLEOSIDE ANALOGS	After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clinical productivity. One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chemical structure of the oligonucleotide whereas their target is defined by the base sequence. Thus, as oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue. To achieve clinical productivity, the chemical architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3'-and 5'-terminal modifications. A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chemical changes often translating into major improvements in clinical efficacy. One outstanding challenge in oligonucleotide chemical development is the optimization of chemical architectures to ensure long-term safety. There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop designs that enable robust clinical efficacy in additional tissues.	[Khvorova, Anastasia; Watts, Jonathan K.] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01605 USA; [Khvorova, Anastasia] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; [Watts, Jonathan K.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Khvorova, A; Watts, JK (corresponding author), Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01605 USA.; Khvorova, A (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.; Watts, JK (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	anastasia.khvorova@umassmed.edu; jonathan.watts@umassmed.edu			RNA Therapeutics Institute of University of Massachusetts Medical School; CHDI Foundation; US National Institutes of Health [R01GM1088030181, R01HD086111, UH3TR000888]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD086111] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108803] Funding Source: NIH RePORTER	RNA Therapeutics Institute of University of Massachusetts Medical School; CHDI Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Osborn for the oligonucleotide image in Figure 1. We would like to acknowledge the oligonucleotide research community who contributed to the evolution of this field, including those whose excellent work we could not mention for lack of space. We thank D. Conte for significant help with manuscript preparation. This work was supported by the RNA Therapeutics Institute of University of Massachusetts Medical School, the CHDI Foundation, and US National Institutes of Health grants R01GM1088030181, R01HD086111, and UH3TR000888 to A.K.	Addepalli H, 2010, NUCLEIC ACIDS RES, V38, P7320, DOI 10.1093/nar/gkq568; Allerson CR, 2005, J MED CHEM, V48, P901, DOI 10.1021/jm049167j; Alterman JF, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.38; [Anonymous], 1995, HELV CHIM ACTA, DOI DOI 10.1002/HLCA.19950780219; Bartlett DW, 2007, BIOTECHNOL BIOENG, V97, P909, DOI 10.1002/bit.21285; Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654; Bhagat L, 2011, J MED CHEM, V54, P3027, DOI 10.1021/jm200113t; Boczkowska M, 2002, BIOCHEMISTRY-US, V41, P12483, DOI 10.1021/bi026225z; Burel SA, 2016, NUCLEIC ACIDS RES, V44, P2093, DOI 10.1093/nar/gkv1210; Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008; Byrne M, 2013, J OCUL PHARMACOL TH, V29, P855, DOI 10.1089/jop.2013.0148; Chen PY, 2008, RNA, V14, P263, DOI 10.1261/rna.789808; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; Choung S, 2006, BIOCHEM BIOPH RES CO, V342, P919, DOI 10.1016/j.bbrc.2006.02.049; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Cohen J S, 1991, Antisense Res Dev, V1, P191; Corey DR, 2007, NAT CHEM BIOL, V3, P8, DOI 10.1038/nchembio0107-8; Cuellar TL, 2015, NUCLEIC ACIDS RES, V43, P1189, DOI 10.1093/nar/gku1362; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Damha MJ, 1998, J AM CHEM SOC, V120, P12976, DOI 10.1021/ja982325+; Dar SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep20031; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Deleavey G. F., 2009, CURR PROTOC NUCL ACI, V16; Deleavey GF, 2012, CHEM BIOL, V19, P937, DOI 10.1016/j.chembiol.2012.07.011; Deleavey GF, 2010, NUCLEIC ACIDS RES, V38, P4547, DOI 10.1093/nar/gkq181; DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107; Eckstein F, 2014, NUCLEIC ACID THER, V24, P374, DOI 10.1089/nat.2014.0506; Egli M, 2005, BIOCHEMISTRY-US, V44, P9045, DOI 10.1021/bi050574m; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fitzgerald K, 2017, NEW ENGL J MED, V376, P41, DOI 10.1056/NEJMoa1609243; Fluiter K., 2009, CHEMMEDCHEM, V4, P879; Frank F, 2010, NATURE, V465, P818, DOI 10.1038/nature09039; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; Gagnon KT, 2014, NUCLEIC ACID THER, V24, P428, DOI 10.1089/nat.2014.1502; Gagnon KT, 2010, BIOCHEMISTRY-US, V49, P10166, DOI 10.1021/bi101208k; Garber K, 2016, NAT BIOTECHNOL, V34, P1002, DOI 10.1038/nbt1016-1002; Geary RS, 2015, ADV DRUG DELIVER REV, V87, P46, DOI 10.1016/j.addr.2015.01.008; Gebert LFR, 2014, NUCLEIC ACIDS RES, V42, P609, DOI 10.1093/nar/gkt852; Goyenvalle A, 2015, NAT MED, V21, P270, DOI 10.1038/nm.3765; Ito K. R., COMPREHENSI IN PRESS; Ittig D, 2004, NUCLEIC ACIDS RES, V32, P346, DOI 10.1093/nar/gkh187; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Janas M. M., 2016, NUCL ACID THER; Jaschinski F., 2013, 9 ANN M OL THER SOC; Jiang K., SPOONFUL OF MED; Juliano RL, 2016, NUCLEIC ACIDS RES, V44, P6518, DOI 10.1093/nar/gkw236; Kamola PJ, 2015, NUCLEIC ACIDS RES, V43, P8638, DOI 10.1093/nar/gkv857; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kasuya T, 2016, SCI REP-UK, V6, DOI 10.1038/srep30377; Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141; Kel'in AV, 2016, J ORG CHEM, V81, P2261, DOI 10.1021/acs.joc.5b02375; Kenski DM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.4; Khorkova O, 2017, NAT BIOTECHNOL, V35, P249, DOI 10.1038/nbt.3784; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Khvorova A, 2017, NEW ENGL J MED, V376, P4, DOI 10.1056/NEJMp1614154; Koch T, 2014, NUCLEIC ACID THER, V24, P139, DOI 10.1089/nat.2013.0465; Koller E, 2011, NUCLEIC ACIDS RES, V39, P4795, DOI 10.1093/nar/gkr089; Kool ET, 1997, CHEM REV, V97, P1473, DOI 10.1021/cr9603791; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; Koziolkiewicz M, 1995, NUCLEIC ACIDS RES, V23, P5000, DOI 10.1093/nar/23.24.5000; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lennox KA, 2016, NUCLEIC ACIDS RES, V44, P863, DOI 10.1093/nar/gkv1206; Lennox KA, 2010, PHARM RES-DORDR, V27, P1788, DOI 10.1007/s11095-010-0156-0; Li LD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10606; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liang XH, 2016, NAT BIOTECHNOL, V34, P875, DOI 10.1038/nbt.3589; Lima WF, 2012, CELL, V150, P883, DOI 10.1016/j.cell.2012.08.014; Lindow M, 2012, J CELL BIOL, V199, P407, DOI 10.1083/jcb.201208082; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Makila J, 2014, BIOORGAN MED CHEM, V22, P6806, DOI 10.1016/j.bmc.2014.10.034; Mangos Maria M., 2002, Current Topics in Medicinal Chemistry, V2, P1147, DOI 10.2174/1568026023393110; Mangos MM, 2003, J AM CHEM SOC, V125, P654, DOI 10.1021/ja025557o; Manoharan M, 1999, BBA-GENE STRUCT EXPR, V1489, P117, DOI 10.1016/S0167-4781(99)00138-4; Manoharan M, 2011, ANGEW CHEM INT EDIT, V50, P2284, DOI 10.1002/anie.201006519; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Matsuda S, 2015, ACS CHEM BIOL, V10, P1181, DOI 10.1021/cb501028c; Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982; Min KL, 2002, BIOORG MED CHEM LETT, V12, P2651, DOI 10.1016/S0960-894X(02)00439-0; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Monia BP, 1996, J BIOL CHEM, V271, P14533, DOI 10.1074/jbc.271.24.14533; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Nikan M, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.50; Nomakuchi TT, 2016, NAT BIOTECHNOL, V34, P164, DOI 10.1038/nbt.3427; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Ostergaard ME, 2015, NUCLEIC ACID THER, V25, P266, DOI 10.1089/nat.2015.0547; Ostergaard ME, 2013, NUCLEIC ACIDS RES, V41, P9634, DOI 10.1093/nar/gkt725; Owczarzy R, 2011, BIOCHEMISTRY-US, V50, P9352, DOI 10.1021/bi200904e; Parmar R, 2016, CHEMBIOCHEM, V17, P985, DOI 10.1002/cbic.201600130; Pedersen L, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.72; Pei Y, 2010, RNA, V16, P2553, DOI 10.1261/rna.2255810; Prakash TP, 2016, BIOORG MED CHEM LETT, V26, P2817, DOI 10.1016/j.bmcl.2016.04.063; Prakash TP, 2015, NUCLEIC ACIDS RES, V43, P2993, DOI 10.1093/nar/gkv162; Prakash TP, 2014, NUCLEIC ACIDS RES, V42, P8796, DOI 10.1093/nar/gku531; Prakash TP, 2011, CHEM BIODIVERS, V8, P1616, DOI 10.1002/cbdv.201100081; Prakash TP, 2005, J MED CHEM, V48, P4247, DOI 10.1021/jm050044o; Rajeev K. G., 2016, US patent, Patent No. [9,399,775, 9399775]; Rajeev KG, 2015, CHEMBIOCHEM, V16, P903, DOI 10.1002/cbic.201500023; Robbins M, 2007, MOL THER, V15, P1663, DOI 10.1038/sj.mt.6300240; Salomon WE, 2015, CELL, V162, P84, DOI 10.1016/j.cell.2015.06.029; Schirle NT, 2016, J AM CHEM SOC, V138, P8694, DOI 10.1021/jacs.6b04454; Schirle NT, 2014, SCIENCE, V346, P608, DOI 10.1126/science.1258040; Schwartz JC, 2008, NAT STRUCT MOL BIOL, V15, P842, DOI 10.1038/nsmb.1444; Sehgal A, 2015, NAT MED, V21, P492, DOI 10.1038/nm.3847; Seth PP, 2009, J MED CHEM, V52, P10, DOI 10.1021/jm801294h; Sharma VK, 2015, FUTURE MED CHEM, V7, P2221, DOI 10.4155/fmc.15.144; Shen W, 2015, NUCLEIC ACIDS RES, V43, P4569, DOI 10.1093/nar/gkv298; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; Snead NM, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.36; Southwell AL, 2014, MOL THER, V22, P2093, DOI 10.1038/mt.2014.153; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Stalder L, 2013, EMBO J, V32, P1115, DOI 10.1038/emboj.2013.52; Stec WJ, 1997, ANTISENSE NUCLEIC A, V7, P567, DOI 10.1089/oli.1.1997.7.567; Stein CA, 2009, CLIN CANCER RES, V15, P2797, DOI 10.1158/1078-0432.CCR-08-2610; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Straarup EM, 2010, NUCLEIC ACIDS RES, V38, P7100, DOI 10.1093/nar/gkq457; Subramanian RR, 2015, NUCLEIC ACIDS RES, V43, P9123, DOI 10.1093/nar/gkv992; Sullenger BA, 2016, SCIENCE, V352, P1417, DOI 10.1126/science.aad8709; Swayze EE, 2007, NUCLEIC ACIDS RES, V35, P687, DOI 10.1093/nar/gkl1071; Thompson JD, 2012, NUCLEIC ACID THER, V22, P255, DOI 10.1089/nat.2012.0371; Wan WB, 2016, J MED CHEM, V59, P9645, DOI 10.1021/acs.jmedchem.6b00551; Watts JK, 2008, DRUG DISCOV TODAY, V13, P842, DOI 10.1016/j.drudis.2008.05.007; Watts JK, 2008, CAN J CHEM, V86, P641, DOI 10.1139/V08-049; Watts JK, 2013, CHEM COMMUN, V49, P5618, DOI 10.1039/c3cc40340h; Weitzer S, 2007, NATURE, V447, P222, DOI 10.1038/nature05777; Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339; Woo C., 2015, HARV EP S BOST MA OC; World Health Organzation, 2016, WHO DRUG INFORM, V30, P477; Yamamoto T, 2011, FUTURE MED CHEM, V3, P339, DOI [10.4155/FMC.11.2, 10.4155/fmc.11.2]; Yu DB, 2012, CELL, V150, P895, DOI 10.1016/j.cell.2012.08.002; Yu RZ, 2016, NUCLEIC ACID THER, V26, P372, DOI 10.1089/nat.2016.0623; Yu RZ, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.26; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zanardi TA, 2012, J PHARMACOL EXP THER, V343, P489, DOI 10.1124/jpet.112.197426	138	565	580	13	284	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2017	35	3					238	248		10.1038/nbt.3765	http://dx.doi.org/10.1038/nbt.3765			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	EN3RC	28244990	Green Accepted			2023-01-03	WOS:000395924600023
J	Saper, RB; Lemaster, C; Delitto, A; Sherman, KJ; Herman, PM; Sadikova, E; Stevans, J; Keosaian, JE; Cerrada, CJ; Femia, AL; Roseen, EJ; Gardiner, P; Barnett, KG; Faulkner, C; Weinberg, J				Saper, Robert B.; Lemaster, Chelsey; Delitto, Anthony; Sherman, Karen J.; Herman, Patricia M.; Sadikova, Ekaterina; Stevans, Joel; Keosaian, Julia E.; Cerrada, Christian J.; Femia, Alexandra L.; Roseen, Eric J.; Gardiner, Paula; Barnett, Katherine Gergen; Faulkner, Carol; Weinberg, Janice			Yoga, Physical Therapy, or Education for Chronic Low Back Pain A Randomized Noninferiority Trial	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICALLY IMPORTANT DIFFERENCE; FEAR-AVOIDANCE BELIEFS; SELF-CARE BOOK; SUBGROUPING PATIENTS; COMPARING YOGA; EXERCISE; PREVALENCE; DISABILITY; INTERVENTION; METAANALYSIS	Background: Yoga is effective for mild to moderate chronic low back pain (cLBP), but its comparative effectiveness with physical therapy (PT) is unknown. Moreover, little is known about yoga's effectiveness in underserved patients with more severe functional disability and pain. Objective: To determine whether yoga is noninferior to PT for cLBP. Design: 12-week, single-blind, 3-group randomized noninferiority trial and subsequent 40-week maintenance phase. (Clinical Trials.gov: NCT01343927) Setting: Academic safety-net hospital and 7 affiliated community health centers. Participants: 320 predominantly low-income, racially diverse adults with nonspecific cLBP. Intervention: Participants received 12 weekly yoga classes, 15 PT visits, or an educational book and newsletters. The maintenance phase compared yoga drop-in classes versus home practice and PT booster sessions versus home practice. Measurements: Primary outcomes were back-related function, measured by the Roland Morris Disability Questionnaire (RMDQ), and pain, measured by an 11-point scale, at 12 weeks. Prespecified noninferiority margins were 1.5 (RMDQ) and 1.0 (pain). Secondary outcomes included pain medication use, global improvement, satisfaction with intervention, and healthrelated quality of life. Results: One-sided 95% lower confidence limits were 0.83 (RMDQ) and 0.97 (pain), demonstrating noninferiority of yoga to PT. However, yoga was not superior to education for either outcome. Yoga and PT were similar for most secondary outcomes. Yoga and PT participants were 21 and 22 percentage points less likely, respectively, than education participants to use pain medication at 12 weeks. Improvements in yoga and PT groups were maintained at 1 year with no differences between maintenance strategies. Frequency of adverse events, mostly mild self-limited joint and back pain, did not differ between the yoga and PT groups. Limitations: Participants were not blinded to treatment assignment. The PT group had disproportionate loss to follow-up. Conclusion: A manualized yoga program for nonspecific cLBP was noninferior to PT for function and pain.	Boston Univ, Sch Med, Boston, MA USA; [Saper, Robert B.; Lemaster, Chelsey; Femia, Alexandra L.; Roseen, Eric J.; Gardiner, Paula; Barnett, Katherine Gergen; Faulkner, Carol] Boston Med Ctr, Dept Family Med, 1 Boston Med Ct Pl,Dowling 5 South, Boston, MA 02118 USA; [Keosaian, Julia E.] Boston Med Ctr, Sect Gen Internal Med, Crosstown Ctr, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA; [Sadikova, Ekaterina] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Weinberg, Janice] Boston Univ, Sch Publ Hlth, Dept Biostat, Crosstown Ctr, 801 Massachusetts Ave,3nd Floor, Boston, MA 02118 USA; [Delitto, Anthony; Stevans, Joel] Univ Pittsburgh, Sch Hlth & Rehabil Sci, 4029 Forbes Tower, Pittsburgh, PA 15260 USA; Grp Hlth Res Inst, Seattle, WA USA; Univ Washington, Seattle, WA 98195 USA; [Herman, Patricia M.] RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA; [Sherman, Karen J.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA; [Cerrada, Christian J.] Soto St Bldg,SSB 1,2001 North Soto, Los Angeles, CA 90032 USA	Boston University; Boston Medical Center; Boston Medical Center; Harvard University; Harvard Medical School; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; RAND Corporation; Group Health Cooperative	Saper, RB (corresponding author), Boston Med Ctr, Dept Family Med, 1 Boston Med Ct Pl,Dowling 5 South, Boston, MA 02118 USA.	robert.saper@bmc.org	Saper, Robert B/Y-4598-2018; Stevans, Joel/M-2058-2018	Saper, Robert B/0000-0002-0992-6198; Stevans, Joel/0000-0001-8642-9446; Weinberg, Janice/0000-0002-3503-0061	National Center for Complementary and Integrative Health of the National Institutes of Health; National Center for Complementary & Integrative Health [R01AT005956] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health of the National Institutes of Health; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	National Center for Complementary and Integrative Health of the National Institutes of Health.	American Physical Therapy Association, FAIR PHYS THER COP; Beinart NA, 2013, SPINE J, V13, P1940, DOI 10.1016/j.spinee.2013.08.027; Bombardier C, 2001, J RHEUMATOL, V28, P431; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Chibnall JT, 2005, PAIN, V114, P462, DOI 10.1016/j.pain.2005.01.011; Chou R, 2016, AHRQ PUBLICATION; Clarke Tainya C, 2015, Natl Health Stat Report, P1; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Freburger Janet K, 2005, Spine J, V5, P530, DOI 10.1016/j.spinee.2005.03.008; Freburger JK, 2003, ARCH PHYS MED REHAB, V84, P1839, DOI 10.1016/S0003-9993(03)00375-7; Fritz JM, 2006, SPINE, V31, P77, DOI 10.1097/01.brs.0000193898.14803.8a; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Fritz JM, 2007, J ORTHOP SPORT PHYS, V37, P290, DOI 10.2519/jospt.2007.2498; Hausmann LRM, 2013, PAIN, V154, P46, DOI 10.1016/j.pain.2012.07.034; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Heapy AA, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0924-z; Hudak PL, 2000, SPINE, V25, P3167, DOI 10.1097/00007632-200012150-00012; Institute of Medicine Committee on Advancing Pain Research Care and Education, 2011, REL PAIN AM BLUEPR T; Jordan K, 2006, J CLIN EPIDEMIOL, V59, P45, DOI 10.1016/j.jclinepi.2005.03.018; Keosaian JE, 2016, COMPLEMENT THER MED, V24, P34, DOI 10.1016/j.ctim.2015.11.007; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Meng XG, 2015, AM J PHYS MED REHAB, V94, P358, DOI 10.1097/PHM.0000000000000188; MOORE JEL, 1999, BACK PAIN HELPBOOK; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Patrick N, 2016, MED CLIN N AM, V100, P173, DOI 10.1016/j.mcna.2015.08.015; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Roland M, 1996, THE BACK BOOK; Saper Robert, 2016, Glob Adv Health Med, V5, P5, DOI 10.7453/gahmj.2015.133; Saper RB, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-67; Saper RB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/658030; Saper RB, 2009, ALTERN THER HEALTH M, V15, P18; Schumi J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-106; Sherman KJ, 2011, ARCH INTERN MED, V171, P2019, DOI 10.1001/archinternmed.2011.524; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Tilbrook HE, 2011, ANN INTERN MED, V155, P569, DOI 10.7326/0003-4819-155-9-201111010-00003; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Werneke MW, 2009, ARCH PHYS MED REHAB, V90, P768, DOI 10.1016/j.apmr.2008.11.008; Wieland LS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010671.pub2; Wiens BL, 2002, CONTROL CLIN TRIALS, V23, P2, DOI 10.1016/S0197-2456(01)00196-9	44	84	87	14	61	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2017	167	2					85	94		10.7326/M16-2579	http://dx.doi.org/10.7326/M16-2579			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA6SD	28631003	Green Accepted			2023-01-03	WOS:000405573400014
J	Gurwitz, JH; Bonner, A; Berwick, DM				Gurwitz, Jerry H.; Bonner, Alice; Berwick, Donald M.			Reducing Excessive Use of Antipsychotic Agents in Nursing Homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG-USE		[Gurwitz, Jerry H.] Meyers Primary Care Inst, 630 Plantat St, Worcester, MA 01605 USA; [Gurwitz, Jerry H.] Univ Massachusetts, Sch Med, Div Geriatr Med, Worcester, MA USA; [Bonner, Alice] Massachusetts Execut Off Elder Affairs, Boston, MA USA; [Berwick, Donald M.] Inst Healthcare Improvement, Cambridge, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Institute for Healthcare Improvement	Gurwitz, JH (corresponding author), Meyers Primary Care Inst, 630 Plantat St, Worcester, MA 01605 USA.	jgurwitz@meyersprimary.org			NIA NIH HHS [R24 AG045050] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R24AG045050] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Centers for Medicare and Medicaid Services, NAT PARTN IMPR DEM C; Centers for Medicare and Medicaid Services, 2022, NAT PARTN IMPR DEM C; Harris-Kojetin L., 2016, VITAL HLTH STAT, V3, DOI DOI 10.1111/J.1532-5415.2010.02875.X; Levinson DR, OVERPRESCRIBED HUMAN; Levinson DR, MEDICARE ATYPICAL AN; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358	7	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2017	318	2					118	119		10.1001/jama.2017.7032	http://dx.doi.org/10.1001/jama.2017.7032			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA1HS	28617907				2023-01-03	WOS:000405190800008
J	Bai, AP; Mao, CG; Jenkins, RW; Szulc, ZM; Bielawska, A; Hannun, YA				Bai, Aiping; Mao, Cungui; Jenkins, Russell W.; Szulc, Zdzislaw M.; Bielawska, Alicja; Hannun, Yusuf A.			Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase	PLOS ONE			English	Article							TUMOR-GROWTH; CELL-DEATH; CANCER; ANALOGS; B13; EXPRESSION; RESISTANCE; APOPTOSIS; SPHINGOLIPIDS; SPHINGOSINE	Acid ceramidase, which catalyzes ceramide hydrolysis to sphingosine and free fatty acid mainly in the lysosome, is being recognized as a potential therapeutic target for cancer. B13 is an effective and selective acid ceramidase inhibitor in vitro, but not as effective in cells due to poor access to the lysosomal compartment. In order to achieve targeting of B13 to the lysosome, we designed lysosomotropic N, N-dimethyl glycine (DMG)-conjugated B13 prodrug LCL521 (1,3-di-DMG-B13). Our previous results indicated the efficient delivery of B13 to the lysosome resulted in augmented effects of LCL521 on cellular acid ceramidase as evaluated by effects on substrate/product levels. Our current studies indicate that functionally, this translated into enhanced inhibition of cell proliferation. Moreover, there were greater synergistic effects of LCL521 with either ionizing radiation or Tamoxifen. Taken together, these results clearly indicate that compartmental targeting for the inhibition of acid ceramidase is an efficient and valuable therapeutic strategy.	[Bai, Aiping; Jenkins, Russell W.; Szulc, Zdzislaw M.; Bielawska, Alicja] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Bai, Aiping; Jenkins, Russell W.; Szulc, Zdzislaw M.; Bielawska, Alicja] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Mao, Cungui; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Mao, Cungui; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Jenkins, Russell W.] Dana Farber Canc Inst, Internal Med, Boston, MA 02115 USA	Medical University of South Carolina; Medical University of South Carolina; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Dana-Farber Cancer Institute	Bai, AP (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Bai, AP (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	baia@musc.edu		, Aiping/0000-0002-7762-7835	National Cancer Institute (NCI) [P01 CA097132]; National Institute of General Medical Sciences (NIGMS) [P30 GM103339]; South Carolina Clinical & Translational Research (SCTR) Institute; MUSC/HCC Cancer Center Support Grant [P30 GM103339]; NCI [P01-CA097132]; NIH/NCATS [UL1TR000062]; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103339] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); South Carolina Clinical & Translational Research (SCTR) Institute; MUSC/HCC Cancer Center Support Grant; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The work was supported by the following: 1. National Cancer Institute (NCI) Grant P01 CA097132 (YAH), http//www.cancer.gov/. 2. National Institute of General Medical Sciences (NIGMS) Grant P30 GM103339 (AB), https://www. nigms.nih.gov/. 3. South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina CTSA, NIH/NCATS grant number UL1TR000062, http://academicdepartments.musc. edu/sctr/index.htm.; We acknowledge MUSC Flow Cytometry and cell sorting facility for cell cycle analysis, and Lipidomics Shared Resources for sphingolipids analysis (MUSC/HCC Cancer Center Support Grant P30 GM103339); Special acknowledgement goes to Dr. Jacek Bielawski at the Lipidomics Shared Resources MUSC for the excellent lipid analysis. Financial support was provided by NCI Grant #P01-CA097132 (YH). We also thank NIH/NCATS grant # UL1TR000062 Voucher Pilot Program for several key reagents purchase (APB).	Bai AP, 2014, BIOORGAN MED CHEM, V22, P6933, DOI 10.1016/j.bmc.2014.10.025; Bai AP, 2009, BIOORGAN MED CHEM, V17, P1840, DOI 10.1016/j.bmc.2009.01.057; Bedia C, 2011, J BIOL CHEM, V286, P28200, DOI 10.1074/jbc.M110.216382; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Bielawski J, 2010, ADV EXP MED BIOL, V688, P46; Canals D, 2010, J BIOL CHEM, V285, P32476, DOI 10.1074/jbc.M110.141028; Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791; Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004; Eliyahu E, 2011, J BIOL CHEM, V286, P35624, DOI 10.1074/jbc.M111.260372; Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; HOFFMAN RM, 1991, J CLIN LAB ANAL, V5, P133, DOI 10.1002/jcla.1860050211; Hu XL, 2011, CANCER RES, V71, P2882, DOI 10.1158/0008-5472.CAN-10-2493; Kitatani K, 2015, MOL CELLS, V38, P482, DOI 10.14348/molcells.2015.0118; Liu FY, 2016, ONCOTARGET, V7, P83907, DOI 10.18632/oncotarget.13438; Morales A, 2007, ONCOGENE, V26, P905, DOI 10.1038/sj.onc.1209834; Nahas Z, 2009, BEHAV BRAIN RES, V197, P41, DOI 10.1016/j.bbr.2008.07.040; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Roh JL, 2016, EUR J CANCER, V52, P163, DOI 10.1016/j.ejca.2015.10.056; Samsel L, 2004, PROSTATE, V58, P382, DOI 10.1002/pros.10350; Selzner M, 2001, CANCER RES, V61, P1233; Separovic D, 2011, BIOCHEM BIOPH RES CO, V409, P372, DOI 10.1016/j.bbrc.2011.04.091; Szulc ZM, 2008, BIOORGAN MED CHEM, V16, P1015, DOI 10.1016/j.bmc.2007.08.033; Takabe K, 2014, J LIPID RES, V55, P1839, DOI 10.1194/jlr.R046656; Xu RJ, 2010, FASEB J, V24, P2507, DOI 10.1096/fj.09-153635	28	18	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							0177805	10.1371/journal.pone.0177805	http://dx.doi.org/10.1371/journal.pone.0177805			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX5KN	28614356	Green Submitted, gold, Green Published			2023-01-03	WOS:000403280900007
J	Li, YM; Wang, L; Jia, M; Guo, JH; Wang, HJ; Wang, MW				Li, Yanmin; Wang, Lin; Jia, Meng; Guo, Jihong; Wang, Huijun; Wang, Mingwei			The effects of high-frequency rTMS over the left DLPFC on cognitive control in young healthy participants	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; STROOP TASK-PERFORMANCE; EVENT-RELATED POTENTIALS; MAJOR DEPRESSION; RESPONSE CONFLICT; HF-RTMS; CORTICAL EXCITABILITY; BRAIN-STIMULATION	A large body of evidence suggests that repetitive transcranial magnetic stimulation (rTMS) is clinically effective in treating neuropsychiatric disorders and multiple sessions are commonly used. However, it is unknown whether multiple sessions of rTMS improve cognitive control, which is a function of the neural circuitry of the left dorsolateral prefrontal cortex (DLPFC)-cingulate cortex in healthy individuals. In addition, it is still unclear which stages of neural processing are altered by rTMS. In this study, we investigated the effects of high-frequency rTMS on cognitive control and explored the time course changes of cognitive processing after rTMS using event-related potentials (ERPs). For seven consecutive days, 25 young healthy participants underwent one 10-Hz rTMS session per day in which stimulation was applied over the left DLPFC, and a homogeneous participant group of 25 individuals received a sham rTMS treatment. A Stroop task was performed, and an electroencephalogram (EEG) was recorded. The results revealed that multiple sessions of rTMS can decrease reaction time (RTs) under both congruent and incongruent conditions and also increased the amplitudes of both N2 and N450 compared with sham rTMS. The negative correlations between the mean amplitudes of both N2 and N450 and the RTs were found, however, the latter correlation were restricted to incongruent trials and the correlation was enhanced significantly by rTMS. This observation supports the view that high-frequency rTMS over the left DLPFC can not only recruit more neural resources from the prefrontal cortex by inducing an electrophysiologically excitatory effect but also enhance efficiency of resources to deploy for conflict resolution during multiple stages of cognitive control processing in healthy young people.	[Li, Yanmin; Wang, Lin; Jia, Meng; Wang, Mingwei] Hebei Med Univ, Dept Neurol, Hosp 1, Shijiazhuang, Hebei Province, Peoples R China; [Li, Yanmin; Wang, Mingwei] Brain Aging & Cognit Neurosci Lab Hebei Prov, Shijiazhuang, Hebei Province, Peoples R China; [Guo, Jihong; Wang, Huijun] Hebei Med Univ, Hosp 1, Dept Neural Electrophysiol, Shijiazhuang, Hebei Province, Peoples R China	Hebei Medical University; Hebei Medical University	Wang, MW (corresponding author), Hebei Med Univ, Dept Neurol, Hosp 1, Shijiazhuang, Hebei Province, Peoples R China.; Wang, MW (corresponding author), Brain Aging & Cognit Neurosci Lab Hebei Prov, Shijiazhuang, Hebei Province, Peoples R China.	mwwang2015@163.com	wang, hui/GRS-4730-2022; wang, huimin/HDM-8421-2022		National Basic Research Program of China [2010CB535005]; Key medical Program of Hebei Province [zd2013079]; Hebei Medical University [XH201705]	National Basic Research Program of China(National Basic Research Program of China); Key medical Program of Hebei Province; Hebei Medical University	This work was supported by the Project of Special Foundation for National Basic Research Program of China (2010CB535005), Key medical Program of Hebei Province (zd2013079) and Spark Program for Young Scholar of The First Hospital of Hebei Medical University (XH201705). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Project of Special Foundation for National Basic Research Program of China (2010CB535005), Key medical Program of Hebei Province (zd2013079) and Spark Program for Young Scholar of The First Hospital of Hebei Medical University (XH201705). The authors wish to thank doctor J Shi in the First Hospital of Hebei Medical University for the assistance throughout the experiment.	Ahmed MA, 2012, J NEUROL, V259, P83, DOI 10.1007/s00415-011-6128-4; Anand S, 2002, BRAIN COGNITION, V50, P366, DOI 10.1016/S0278-2626(02)00512-2; Baeken C, 2010, PROG NEURO-PSYCHOPH, V34, P684, DOI 10.1016/j.pnpbp.2010.03.021; Baeken C, 2015, BRAIN STIMUL, V8, P808, DOI 10.1016/j.brs.2015.01.415; BARKER AT, 1991, J CLIN NEUROPHYSIOL, V8, P26, DOI 10.1097/00004691-199101000-00005; Bartholow BD, 2005, PSYCHOPHYSIOLOGY, V42, P33, DOI 10.1111/j.1469-8986.2005.00258.x; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chouiter L, 2014, BRAIN TOPOGR, V27, P279, DOI 10.1007/s10548-013-0303-0; Cotelli M, 2011, J NEUROL NEUROSUR PS, V82, P794, DOI 10.1136/jnnp.2009.197848; Dall'Agnol L, 2014, J PAIN, V15, P845, DOI 10.1016/j.jpain.2014.05.001; DALRYMPLEALFORD EC, 1966, PERCEPT MOTOR SKILL, V23, P1211, DOI 10.2466/pms.1966.23.3f.1211; De Raedt R, 2010, BIOL PSYCHOL, V85, P487, DOI 10.1016/j.biopsycho.2010.09.015; Eisenegger C, 2008, NEUROIMAGE, V42, P379, DOI 10.1016/j.neuroimage.2008.04.172; Eliasova I, 2014, J NEUROL SCI, V346, P318, DOI 10.1016/j.jns.2014.08.036; Esslinger C, 2014, HUM BRAIN MAPP, V35, P140, DOI 10.1002/hbm.22165; Evers S, 2001, NEUROREPORT, V12, P2915, DOI 10.1097/00001756-200109170-00032; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox P, 1997, NEUROREPORT, V8, P2787, DOI 10.1097/00001756-199708180-00027; Gajewski PD, 2015, BRAIN COGNITION, V98, P87, DOI 10.1016/j.bandc.2015.06.004; Goldfarb L, 2007, J EXP PSYCHOL HUMAN, V33, P1170, DOI 10.1037/0096-1523.33.5.1170; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; Guse B, 2010, J NEURAL TRANSM, V117, P105, DOI 10.1007/s00702-009-0333-7; Haghighi M, 2015, J PSYCHIATR RES, V68, P238, DOI 10.1016/j.jpsychires.2015.06.020; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Haraldsson HM, 2004, SCHIZOPHR RES, V71, P1, DOI 10.1016/j.schres.2003.10.006; Harrison BJ, 2005, NEUROIMAGE, V24, P181, DOI 10.1016/j.neuroimage.2004.08.033; Hoeppner J, 2010, EUR ARCH PSY CLIN N, V260, P197, DOI 10.1007/s00406-009-0039-8; Holmes AJ, 2008, NEUROPSYCHOLOGIA, V46, P2904, DOI 10.1016/j.neuropsychologia.2008.05.028; Huang CC, 2004, J PSYCHIATR RES, V38, P513, DOI 10.1016/j.jpsychires.2004.01.006; Hwang JH, 2010, BRAIN RES, V1329, P152, DOI 10.1016/j.brainres.2010.03.013; Kerns JG, 2006, NEUROIMAGE, V33, P399, DOI 10.1016/j.neuroimage.2006.06.012; Kim SH, 2012, NEUROSCI RES, V74, P256, DOI 10.1016/j.neures.2012.08.008; Krompinger JW, 2011, BIOL PSYCHOL, V86, P239, DOI 10.1016/j.biopsycho.2010.12.004; Larson MJ, 2014, INT J PSYCHOPHYSIOL, V93, P283, DOI 10.1016/j.ijpsycho.2014.06.007; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; Little JT, 2000, NEUROPSY NEUROPSY BE, V13, P119; Lucci G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056566; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Markela-Lerenc J, 2004, COGNITIVE BRAIN RES, V18, P278, DOI 10.1016/j.cogbrainres.2003.10.013; Martis B, 2003, CLIN NEUROPHYSIOL, V114, P1125, DOI 10.1016/S1388-2457(03)00046-4; Millner AJ, 2012, NEUROIMAGE, V63, P742, DOI 10.1016/j.neuroimage.2012.07.032; Minzenberg MJ, 2014, PSYCHIAT RES-NEUROIM, V221, P114, DOI 10.1016/j.pscychresns.2013.11.003; Mir-Moghtadaei A, 2015, BRAIN STIMUL, V8, P965, DOI 10.1016/j.brs.2015.05.008; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nieuwenhuis S, 2004, PSYCHOPHYSIOLOGY, V41, P157, DOI 10.1046/j.1469-8986.2003.00128.x; Padberg F, 1999, PSYCHIAT RES, V88, P163, DOI 10.1016/S0165-1781(99)00092-X; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Pliszka SR, 2000, BIOL PSYCHIAT, V48, P238, DOI 10.1016/S0006-3223(00)00890-8; Rektor I, 2010, NEURODEGENER DIS, V7, P160, DOI 10.1159/000289228; Rektorova I, 2005, J NEUROL SCI, V229, P157, DOI 10.1016/j.jns.2004.11.021; REN CY, 1995, IEEE T BIO-MED ENG, V42, P918, DOI 10.1109/10.412658; Rollnik JD, 2004, CLIN NEUROPHYSIOL, V115, P145, DOI 10.1016/j.clinph.2003.05.001; Rossi S, 2004, TRENDS COGN SCI, V8, P273, DOI 10.1016/j.tics.2004.04.012; Rounis E, 2006, J NEUROSCI, V26, P9629, DOI 10.1523/JNEUROSCI.2657-06.2006; Scherr M, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2014-011612; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Sole-Padulles C, 2006, CEREB CORTEX, V16, P1487, DOI 10.1093/cercor/bhj083; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Takahashi S, 2015, NEUROCASE, V21, P339, DOI 10.1080/13554794.2014.893000; Van den Eynde F, 2011, EAT WEIGHT DISORD-ST, V16, pE45; van den Heuvel OA, 2013, HUM BRAIN MAPP, V34, P347, DOI 10.1002/hbm.21443; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vanderhasselt MA, 2006, EXP BRAIN RES, V169, P279, DOI 10.1007/s00221-005-0344-z; Vanderhasselt MA, 2007, BRAIN RES, V1137, P111, DOI 10.1016/j.brainres.2006.12.050; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2004, J COGNITIVE NEUROSCI, V16, P103, DOI 10.1162/089892904322755593; Yang HY, 2015, BEHAV BRAIN RES, V281, P149, DOI 10.1016/j.bbr.2014.12.037; Yeung N, 2009, J NEUROSCI, V29, P14506, DOI 10.1523/JNEUROSCI.3615-09.2009	74	22	25	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							e0179430	10.1371/journal.pone.0179430	http://dx.doi.org/10.1371/journal.pone.0179430			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX5KN	28614399	Green Submitted, gold, Green Published			2023-01-03	WOS:000403280900052
J	Oliver, D				Oliver, David			David Oliver: Reducing acute admissions-a timely reality check	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Bardsley M, 2013, EVALUATING INTEGRATE; Castle-Clarke S, 2017, THE NUFFIELD TRUST; Ham C, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1678; King's Fund, 2017, SUST TRANSF PLANS; NHS England, 2017, NEW PAT CAR TEST HOS; Purdy S, 2012, INTERVENTIONS REDUCE; Royal College of Physicians, 2016, BACKGR SUST TRANSF P	7	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 9	2017	357								j2082	10.1136/bmj.j2082	http://dx.doi.org/10.1136/bmj.j2082			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU6UA	28487315	Bronze, Green Published			2023-01-03	WOS:000401169100004
J	Lebwohl, B; Cao, Y; Zong, G; Hu, FB; Green, PHR; Neugut, AI; Rimm, EB; Sampson, L; Dougherty, LW; Giovannucci, E; Willett, WC; Sun, Q; Chan, AT				Lebwohl, Benjamin; Cao, Yin; Zong, Geng; Hu, Frank B.; Green, Peter H. R.; Neugut, Alfred I.; Rimm, Eric B.; Sampson, Laura; Dougherty, Lauren W.; Giovannucci, Edward; Willett, Walter C.; Sun, Qi; Chan, Andrew T.			Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FREE DIET; DOUBLE-BLIND; FOOD; REPRODUCIBILITY; VALIDITY; QUESTIONNAIRE; AVAILABILITY; SENSITIVITY; SYMPTOMS; HEALTH	OBJECTIVE To examine the association of long term intake of gluten with the development of incident coronary heart disease. DESIGN Prospective cohort study. SETTING AND PARTICIPANTS 64 714 women in the Nurses' Health Study and 45 303 men in the Health Professionals Follow-up Study without a history of coronary heart disease who completed a 131 item semiquantitative food frequency questionnaire in 1986 that was updated every four years through 2010. EXPOSURE Consumption of gluten, estimated from food frequency questionnaires. MAIN OUTCOME MEASURE Development of coronary heart disease (fatal or non-fatal myocardial infarction). RESULTS During 26 years of follow-up encompassing 2 273 931 person years, 2431 women and 4098 men developed coronary heart disease. Compared with participants in the lowest fifth of gluten intake, who had a coronary heart disease incidence rate of 352 per 100 000 person years, those in the highest fifth had a rate of 277 events per 100 000 person years, leading to an unadjusted rate difference of 75 (95% confidence interval 51 to 98) fewer cases of coronary heart disease per 100 000 person years. After adjustment for known risk factors, participants in the highest fifth of estimated gluten intake had a multivariable hazard ratio for coronary heart disease of 0.95 (95% confidence interval 0.88 to 1.02; P for trend = 0.29). After additional adjustment for intake of whole grains (leaving the remaining variance of gluten corresponding to refined grains), the multivariate hazard ratio was 1.00 (0.92 to 1.09; P for trend = 0.77). In contrast, after additional adjustment for intake of refined grains (leaving the variance of gluten intake correlating with whole grain intake), estimated gluten consumption was associated with a lower risk of coronary heart disease (multivariate hazard ratio 0.85, 0.77 to 0.93; P for trend = 0.002). CONCLUSION Long term dietary intake of gluten was not associated with risk of coronary heart disease. However, the avoidance of gluten may result in reduced consumption of beneficial whole grains, which may affect cardiovascular risk. The promotion of gluten-free diets among people without celiac disease should not be encouraged.	[Lebwohl, Benjamin; Green, Peter H. R.; Neugut, Alfred I.] Columbia Univ Coll Phys & Surg, Dept Med, Celiac Dis Ctr, New York, NY USA; [Lebwohl, Benjamin; Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA; [Cao, Yin; Hu, Frank B.; Chan, Andrew T.] Harvard Med Sch, Boston, MA 02115 USA; [Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Cao, Yin; Zong, Geng; Rimm, Eric B.; Sampson, Laura; Dougherty, Lauren W.; Giovannucci, Edward; Willett, Walter C.; Sun, Qi] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Hu, Frank B.; Rimm, Eric B.; Giovannucci, Edward; Willett, Walter C.; Sun, Qi; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Rimm, Eric B.; Giovannucci, Edward; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Columbia University; Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Chan, AT (corresponding author), Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.; Chan, AT (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Chan, AT (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.; Chan, AT (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.	ACHAN@mgh.harvard.edu	Cao, Yin/ABE-2332-2021; Zong, Geng/ABG-6946-2021	Cao, Yin/0000-0001-9835-7662; 	American Gastroenterological Association; Massachusetts General Hospital; National Institutes of Health (NIH) [K24 DK098311, UM1 CA186107, UM1 CA167552]; NIH [UM1 CA167552, R01 HL035464, R01 HL060712, R01 HL034594]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	American Gastroenterological Association; Massachusetts General Hospital(General Electric); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	BL is supported by the American Gastroenterological Association's foundation research scholar award. ATC is supported by the Massachusetts General Hospital research scholars award and National Institutes of Health (NIH) grants K24 DK098311 and UM1 CA186107. WCW is supported by NIH grant UM1 CA167552, EBR by grant R01 HL035464, QS by grant R01 HL035464, and FBH by grants R01 HL060712 and R01 HL034594.	Aronsson CA, 2016, CLIN GASTROENTEROL H, V14, P403, DOI 10.1016/j.cgh.2015.09.030; Aune D, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2716; Bernstein AM, 2011, EUR J EPIDEMIOL, V26, P877, DOI 10.1007/s10654-011-9626-x; Biesiekierski JR, 2013, GASTROENTEROLOGY, V145, P320, DOI 10.1053/j.gastro.2013.04.051; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P508, DOI 10.1038/ajg.2010.487; Burden M, 2015, POSTGRAD MED J, V91, P622, DOI 10.1136/postgradmedj-2015-133395; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Davis W., 2011, WHEAT BELLY LOSE WHE; Eaton WW, 2015, AM J PSYCHIAT, V172, P219, DOI 10.1176/appi.ajp.2014.14040550; Elkan AC, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2388; Emilsson L, 2013, ALIMENT PHARM THER, V37, P905, DOI 10.1111/apt.12271; Estevez V, 2016, EUR J CLIN NUTR, V70, P1215, DOI 10.1038/ejcn.2016.139; Fasano A, 2015, GASTROENTEROLOGY, V148, P1195, DOI 10.1053/j.gastro.2014.12.049; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Harvard TH, NUTRIENT TABLES; Jamnik J, 2015, J NUTR, V145, P1256, DOI 10.3945/jn.115.212829; Johnson KB, 2012, AM J PHYSIOL-HEART C, V302, pH1355, DOI 10.1152/ajpheart.00918.2011; Kasarda DD, 2013, J AGR FOOD CHEM, V61, P1155, DOI 10.1021/jf305122s; Kim HS, 2016, JAMA INTERN MED, V176, P1716, DOI 10.1001/jamainternmed.2016.5254; Larsen J, 2014, EUR J IMMUNOL, V44, P3056, DOI 10.1002/eji.201344264; Lee AR, 2007, J HUM NUTR DIET, V20, P423, DOI 10.1111/j.1365-277X.2007.00763.x; Li YP, 2015, J AM COLL CARDIOL, V66, P1538, DOI 10.1016/j.jacc.2015.07.055; Ludvigsson JF, 2011, CIRCULATION, V123, P483, DOI 10.1161/CIRCULATIONAHA.110.965624; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Marietta EV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078687; Miller D, 2016, JAMA INTERN MED, V176, P1717, DOI 10.1001/jamainternmed.2016.5271; NPD Group, 2013, PERC US AD TRYING CU; Perlmutter D., 2013, GRAIN BRAIN SURPRISI; Peters SL, 2014, ALIMENT PHARM THER, V39, P1104, DOI 10.1111/apt.12730; Soares FLP, 2013, J NUTR BIOCHEM, V24, P1105, DOI 10.1016/j.jnutbio.2012.08.009; Qi Jun-cong, 2005, J Zhejiang Univ Sci B, V6, P1069, DOI 10.1631/jzus.2005.B1069; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Schiltz B, 2009, METAB SYNDR RELAT D, V7, P187, DOI 10.1089/met.2008.0051; See JA, 2015, NAT REV GASTRO HEPAT, V12, P580, DOI 10.1038/nrgastro.2015.156; Steppan J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000599; Vanga R, 2013, GASTROENTEROLOGY, V145, P276, DOI 10.1053/j.gastro.2013.06.027; vanOverbeek FM, 1997, EUR J GASTROEN HEPAT, V9, P1097, DOI 10.1097/00042737-199711000-00013; West J, 2004, ALIMENT PHARM THERAP, V20, P73, DOI 10.1111/j.1365-2036.2004.02008.x; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wu HY, 2015, JAMA INTERN MED, V175, P373, DOI 10.1001/jamainternmed.2014.6283; Yuan C, 2017, AM J EPIDEMIOL, P1	45	98	103	1	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	2017	357								j1892	10.1136/bmj.j1892	http://dx.doi.org/10.1136/bmj.j1892			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU2WB	28465308	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000400889500002
J	Sordo, L; Barrio, G; Bravo, MJ; Indave, BI; Degenhardt, L; Wiessing, L; Ferri, M; Pastor-Barriuso, R				Sordo, Luis; Barrio, Gregorio; Bravo, Maria J.; Iciar Indave, B.; Degenhardt, Louisa; Wiessing, Lucas; Ferri, Marica; Pastor-Barriuso, Roberto			Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							METHADONE-MAINTENANCE TREATMENT; PRIMARY-CARE; RECEIVING METHADONE; OVERDOSE MORTALITY; HEROIN DEPENDENCE; DRUG-TREATMENT; ADDICTS RISK; BUPRENORPHINE; THERAPY; DEATHS	OBJECTIVE To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, Embase, PsycINFO, and LILACS to September 2016. STUDY SELECTION Prospective or retrospective cohort studies in people with opioid dependence that reported deaths from all causes or overdose during follow-up periods in and out of opioid substitution treatment with methadone or buprenorphine. DATA EXTRACTION AND SYNTHESIS Two independent reviewers performed data extraction and assessed study quality. Mortality rates in and out of treatment were jointly combined across methadone or buprenorphine cohorts by using multivariate random effects meta-analysis. RESULTS There were 19 eligible cohorts, following 122 885 people treated with methadone over 1.3-13.9 years and 15 831 people treated with buprenorphine over 1.1-4.5 years. Pooled all cause mortality rates were 11.3 and 36.1 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 3.20, 95% confidence interval 2.65 to 3.86) and reduced to 4.3 and 9.5 in and out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment. CONCLUSIONS Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids. The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.	[Sordo, Luis; Bravo, Maria J.; Iciar Indave, B.; Pastor-Barriuso, Roberto] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain; [Sordo, Luis; Bravo, Maria J.; Iciar Indave, B.; Pastor-Barriuso, Roberto] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain; [Sordo, Luis] Univ Complutense Madrid, Fac Med, Dept Prevent Med & Publ Hlth, Madrid, Spain; [Barrio, Gregorio] Carlos III Inst Hlth, Natl Sch Publ Hlth, Madrid 28029, Spain; [Degenhardt, Louisa] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Degenhardt, Louisa] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Wiessing, Lucas; Ferri, Marica] EMCDDA, Sect Best Practices Knowledge Exchange & Econ Is, Lisbon, Portugal	Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Complutense University of Madrid; Instituto de Salud Carlos III; University of New South Wales Sydney; University of Melbourne	Barrio, G (corresponding author), Carlos III Inst Hlth, Natl Sch Publ Hlth, Madrid 28029, Spain.	gbarrio@isciii.es	Pastor-Barriuso, Roberto/AAA-6746-2019; Degenhardt, Louisa J/D-4515-2012; Ferri, Marica/AAJ-4612-2020	Pastor-Barriuso, Roberto/0000-0002-7325-3960; Degenhardt, Louisa J/0000-0002-8513-2218; sordo, Luis/0000-0003-1760-9472; BARRIO, GREGORIO/0000-0002-6257-3213	ISCIII Network on Addictive Disorders (Networks for Cooperative Research in Health from the Carlos III Institute of Health) [RD16/0017/0013, RD12/0028/0018]; EMCDDA	ISCIII Network on Addictive Disorders (Networks for Cooperative Research in Health from the Carlos III Institute of Health); EMCDDA	This work was partially supported by the ISCIII Network on Addictive Disorders (Networks for Cooperative Research in Health from the Carlos III Institute of Health) (grant No RD16/0017/0013 and RD12/0028/0018) and by the EMCDDA in the context of the activities related to identification, promotion, and monitor of best practices.	Auriacombe M, 2001, JAMA-J AM MED ASSOC, V285, P45, DOI 10.1001/jama.285.1.45; Bell J, 2006, DRUG ALCOHOL DEPEN, V81, P55, DOI 10.1016/j.drugalcdep.2005.05.010; Bell J, 2009, ADDICTION, V104, P1193, DOI 10.1111/j.1360-0443.2009.02627.x; Bell JR, 2009, DRUG ALCOHOL DEPEN, V104, P73, DOI 10.1016/j.drugalcdep.2009.03.020; Berkey CS, 1998, STAT MED, V17, P2537, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2537::AID-SIM953>3.0.CO;2-C; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Brogly SB, 2014, AM J EPIDEMIOL, V180, P673, DOI 10.1093/aje/kwu190; Brugal MT, 2005, ADDICTION, V100, P981, DOI 10.1111/j.1360-0443.2005.01089.x; Buster MCA, 2002, ADDICTION, V97, P993, DOI 10.1046/j.1360-0443.2002.00179.x; Caplehorn JRM, 1996, SUBST USE MISUSE, V31, P177, DOI 10.3109/10826089609045806; CAPLEHORN JRM, 1994, ADDICTION, V89, P203, DOI 10.1111/j.1360-0443.1994.tb00879.x; Clausen T, 2008, DRUG ALCOHOL DEPEN, V94, P151, DOI 10.1016/j.drugalcdep.2007.11.003; Cornish Rosie, 2010, BMJ, V341, pc5475, DOI 10.1136/bmj.c5475; Cousins G, 2016, ADDICTION, V111, P73, DOI 10.1111/add.13087; Cousins G, 2011, J SUBST ABUSE TREAT, V41, P252, DOI 10.1016/j.jsat.2011.05.001; CUSHMAN P, 1977, AM J DRUG ALCOHOL AB, V4, P543, DOI 10.3109/00952997709007010; Davoli M, 2007, ADDICTION, V102, P1954, DOI 10.1111/j.1360-0443.2007.02025.x; Degenhardt L., 2009, 13 U NSW NAT DRUG AL; Degenhardt L, 2014, ADDICTION, V109, P1320, DOI 10.1111/add.12551; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Degenhardt L, 2009, DRUG ALCOHOL DEPEN, V105, P9, DOI 10.1016/j.drugalcdep.2009.05.021; Eap CB, 2002, CLIN PHARMACOKINET, V41, P1153, DOI 10.2165/00003088-200241140-00003; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EMCDDA, 2015, PREV OV DEATHS EUR; European Monitoring Centre for Drugs and Drug Addiction, 2019, EU DRUG MARK REP 201; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2011, MORT REALT DRUG US E; Evans E, 2015, ADDICTION, V110, P996, DOI 10.1111/add.12863; Fugelstad A, 2007, ADDICTION, V102, P406, DOI 10.1111/j.1360-0443.2006.01714.x; Fugelstad A, 1998, SUBST USE MISUSE, V33, P2803, DOI 10.3109/10826089809059352; FUGELSTAD A, 1995, ADDICTION, V90, P711, DOI 10.1111/j.1360-0443.1995.tb02209.x; Gasparrini A, 2012, STAT MED, V31, P3821, DOI 10.1002/sim.5471; GEARING FR, 1974, AM J EPIDEMIOL, V100, P101, DOI 10.1093/oxfordjournals.aje.a112012; Gossop M, 2002, ADDICTION, V97, P39, DOI 10.1046/j.1360-0443.2002.00079.x; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; Hickman M, 2016, ADDICTION, V111, P83, DOI 10.1111/add.13185; Hser YI, 2015, HARVARD REV PSYCHIAT, V23, P76, DOI 10.1097/HRP.0000000000000052; Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453; Jackson D, 2011, STAT MED, V30, P2481, DOI 10.1002/sim.4172; Jolley CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140995; Kakko J, 2007, AM J PSYCHIAT, V164, P797, DOI 10.1176/appi.ajp.164.5.797; Kimber J, 2015, LANCET PSYCHIAT, V2, P901, DOI 10.1016/S2215-0366(15)00366-1; Kleber Herbert D, 2007, Dialogues Clin Neurosci, V9, P455; Lawrinson P, 2008, ADDICTION, V103, P1484, DOI 10.1111/j.1360-0443.2008.02249.x; Manhapra A, 2016, DRUG ALCOHOL DEPEN, V160, P82, DOI 10.1016/j.drugalcdep.2015.12.035; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McCowan C, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2225; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Merralll ELC, 2013, ADDICTION, V108, P377, DOI 10.1111/j.1360-0443.2012.04066.x; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nordt C, 2015, J CLIN EPIDEMIOL, V68, P1346, DOI 10.1016/j.jclinepi.2015.05.002; Nosyk B, 2015, CLIN INFECT DIS, V61, P1157, DOI 10.1093/cid/civ476; Peles E, 2010, DRUG ALCOHOL DEPEN, V107, P141, DOI 10.1016/j.drugalcdep.2009.09.013; Pirnay S, 2004, ADDICTION, V99, P978, DOI 10.1111/j.1360-0443.2004.00790.x; Reece AS, 2010, J ADDICT DIS, V29, P30, DOI 10.1080/10550880903435988; Rhodes T, 2016, STRATEGIES PREVENT D; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Scherbaum N, 2002, FORTSCHR NEUROL PSYC, V70, P455, DOI 10.1055/s-2002-33758; Scottish Intercollegiate Guidelines Network, 2014, SIGN 50 GUID DEV HDB; Soyka M, 2006, J CLIN PSYCHOPHARM, V26, P657, DOI 10.1097/01.jcp.0000245561.99036.49; Teesson M, 2015, ADDICTION, V110, P986, DOI 10.1111/add.12860; Thomas CP, 2014, PSYCHIAT SERV, V65, P158, DOI 10.1176/appi.ps.201300256; United Nations Office on Drugs and Crime, 2015, WORLD DRUG REP 2015; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2; Wells G, 2013, 3 S SYST REV BAS IMP; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Yokell Michael A, 2011, Curr Drug Abuse Rev, V4, P28; Zador D, 2000, ADDICTION, V95, P77, DOI 10.1046/j.1360-0443.2000.951778.x	72	836	837	5	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2017	357								j1550	10.1136/bmj.j1550	http://dx.doi.org/10.1136/bmj.j1550			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET6XX	28446428	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000400438000001
J	Privett, AJ; Teixeira, ES; Stopera, C; Morales, JA				Privett, Austin J.; Teixeira, Erico S.; Stopera, Christopher; Morales, Jorge A.			Exploring water radiolysis in proton cancer therapy: Time-dependent, non-adiabatic simulations of H+ + (H2O) 1-6	PLOS ONE			English	Article							ELECTRON-NUCLEAR DYNAMICS; RELATIVE ENERGIES; CROSS-SECTIONS; DNA-DAMAGE; RADIATION; CLUSTERS; IONIZATION; COLLISIONS; HEXAMER; CAPTURE	To elucidate microscopic details of proton cancer therapy (PCT), we apply the simplest-level electron nuclear dynamics (SLEND) method to H+ + (H2O) 1-6 at E-Lab = 100 keV. These systems are computationally tractable prototypes to simulate water radiolysis reactions D i.e. the PCT processes that generate the DNA-damaging species against cancerous cells. To capture incipient bulk-water effects, ten (H2O)(1-6) isomers are considered, ranging from quasi-planar/ multiplanar (H2O) 1-6 to "smallest-drop" prism and cage (H2O)(6) structures. SLEND is a time-dependent, variational, non-adiabatic and direct method that adopts a nuclear classicalmechanics description and an electronic single-determinantal wavefunction in the Thouless representation. Short-time SLEND/6-31G* (n = 1-6) and /6-31G** (n = 1-5) simulations render cluster-to-projectile 1-electron-transfer (1-ET) total integral cross sections (ICSs) and 1ET probabilities. In absolute quantitative terms, SLEND/6-31G* 1-ET ICS compares satisfactorily with alternative experimental and theoretical results only available for n = 1 and exhibits almost the same accuracy of the best alternative theoretical result. SLEND/6-31G** overestimates 1-ET ICS for n = 1, but a comparable overestimation is also observed with another theoretical method. An investigation on H+ + H indicates that electron direct ionization (DI) becomes significant with the large virtual-space quasi-continuum in large basis sets; thus, SLEND/6-31G** 1-ET ICS is overestimated by DI contributions. The solution to this problem is discussed. In relative quantitative terms, both SLEND/6-31* and /6-31G** 1-ET ICSs precisely fit into physically justified scaling formulae as a function of the cluster size; this indicates SLEND's suitability for predicting properties of water clusters with varying size. Longtime SLEND/6-31G* (n = 1-4) simulations predict the formation of the DNA-damaging radicals H, OH, O and H3O. While "smallest-drop" isomers are included, no early manifestations of bulk water PCT properties are observed and simulations with larger water clusters will be needed to capture those effects. This study is the largest SLEND investigation on water radiolysis to date.	[Privett, Austin J.; Teixeira, Erico S.; Stopera, Christopher; Morales, Jorge A.] Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA; [Privett, Austin J.] Lipscomb Univ, Dept Chem & Biochem, Nashville, TN USA; [Stopera, Christopher] Univ North Alabama, Dept Chem & Ind Hyg, Florence, AL, Italy	Texas Tech University System; Texas Tech University	Morales, JA (corresponding author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.	jorge.morales@ttu.edu	Teixeira, Erico Souza/AAS-9520-2020	Teixeira, Erico Souza/0000-0003-0520-5075	Science without Borders Fellowship Program of the National Council for Scientific and Technological Development of Brazil; Cancer Prevention and Research Institute of Texas [RP140478]	Science without Borders Fellowship Program of the National Council for Scientific and Technological Development of Brazil; Cancer Prevention and Research Institute of Texas	This work was supported by 1) Science without Borders Fellowship Program of the National Council for Scientific and Technological Development of Brazil, to EST, http://www.cienciasemfronteiras.gov.br/web/csf-eng/faq: 2) Cancer Prevention and Research Institute of Texas to JAM, grant: RP140478 http://www.cprit.state.tx.us/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8; Baccarelli I, 2007, ADV QUANTUM CHEM, V52, P189, DOI 10.1016/S0065-3276(06)52009-X; Bates DM, 2009, J PHYS CHEM A, V113, P3555, DOI 10.1021/jp8105919; Cabrera-Trujillo R, 2005, ADV QUANTUM CHEM, V48, P47, DOI 10.1016/S0065-3276(05)48005-3; Cabrera-Trujillo R, 2000, NUCL INSTRUM METH B, V168, P484, DOI 10.1016/S0168-583X(00)00064-1; Cabrera-Trujillo R, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.032719; Cabrera-Trujillo R, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.052714; Champion C, 2015, PHYS MED BIOL, V60, P7805, DOI 10.1088/0031-9155/60/20/7805; Champion C, 2012, PHYS MED BIOL, V57, P3039, DOI 10.1088/0031-9155/57/10/3039; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Child M. S., 1974, MOL COLLISION THEORY; Coutinho-Neto M, 2002, J CHEM PHYS, V116, P2794, DOI 10.1063/1.1434991; Dahlke EE, 2008, J PHYS CHEM A, V112, P3976, DOI 10.1021/jp077376k; DELOS JB, 1981, REV MOD PHYS, V53, P287, DOI 10.1103/RevModPhys.53.287; DEUMENS E, 1994, REV MOD PHYS, V66, P917, DOI 10.1103/RevModPhys.66.917; Dinesh Mayani Devanshi, 2011, J Oncol Pharm Pract, V17, P186, DOI 10.1177/1078155210375858; Fasso A, 2009, RADIAT PROT DOSIM, V137, P118, DOI 10.1093/rpd/ncp190; Flocke N, 2008, J COMPUT CHEM, V29, P2722, DOI 10.1002/jcc.21018; Friedland W, 2003, RADIAT RES, V159, P401, DOI 10.1667/0033-7587(2003)159[0401:SODDAP]2.0.CO;2; Garcia-Molina R, 2009, NUCL INSTRUM METH B, V267, P2647, DOI 10.1016/j.nimb.2009.05.038; Gillan MJ, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4944633; Girdhani S, 2013, RADIAT RES, V179, P257, DOI 10.1667/RR2839.1; Gobet F, 2006, CHEM PHYS LETT, V421, P68, DOI 10.1016/j.cplett.2006.01.016; Gobet F, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.062716; Gobet F, 2001, PHYS REV LETT, V86, P3751, DOI 10.1103/PhysRevLett.86.3751; Hagelberg F, 2014, ELECT DYNAMICS MOL I; Hedstrom M, 1997, CHEM PHYS LETT, V279, P241, DOI 10.1016/S0009-2614(97)01010-5; Hincapie G, 2010, J PHYS CHEM A, V114, P7809, DOI 10.1021/jp103683m; Illescas C, 2012, J PHYS CONF SER, V388, DOI 10.1088/1742-6596/388/10/102007; Incerti S, 2010, MED PHYS, V37, P4692, DOI 10.1118/1.3476457; Jacquemin D, 1997, J CHEM PHYS, V107, P6146, DOI 10.1063/1.474343; Jakel O, 2009, RADIAT PROT DOSIM, V137, P156, DOI 10.1093/rpd/ncp192; Jungwirth P, 2000, J PHYS CHEM A, V104, P145, DOI 10.1021/jp993010z; Keutsch FN, 2003, CHEM REV, V103, P2533, DOI 10.1021/cr980125a; Keutsch FN, 2001, P NATL ACAD SCI USA, V98, P10533, DOI 10.1073/pnas.191266498; Lee HM, 2000, J CHEM PHYS, V112, P9759, DOI 10.1063/1.481613; Levin WP, 2005, BRIT J CANCER, V93, P849, DOI 10.1038/sj.bjc.6602754; Liu XJ, 2011, CHEM PHYS LETT, V508, P270, DOI 10.1016/j.cplett.2011.04.055; LONGO R, 1994, CHEM PHYS LETT, V220, P305, DOI 10.1016/0009-2614(94)00171-5; LONGO R, 1993, J CHEM PHYS, V99, P4554, DOI 10.1063/1.466055; Losada M, 2002, J CHEM PHYS, V117, P2003, DOI 10.1063/1.1487371; Lotrich V, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2920482; Luna H, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.042711; Maiti B, 2007, CHEM PHYS, V340, P105, DOI 10.1016/j.chemphys.2007.07.033; Mamone S, 2010, SYMMETRY-BASEL, V2, P1423, DOI 10.3390/sym2031423; Mclaurin PM, 2015, MOL PHYS, V113, P297, DOI 10.1080/00268976.2014.938709; McLaurin PM, 2011, THESIS; MORALES J, 1995, J CHEM PHYS, V103, P9968, DOI 10.1063/1.469886; Murakami M, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.052704; Nikjoo H, 2006, RADIAT MEAS, V41, P1052, DOI 10.1016/j.radmeas.2006.02.001; Oi T, 2002, J NUCL SCI TECHNOL, V39, P419, DOI 10.3327/jnst.39.419; Perera SA, 2010, CHEM PHYS LETT, V496, P188, DOI 10.1016/j.cplett.2010.07.034; Perez C, 2012, SCIENCE, V336, P897, DOI 10.1126/science.1220574; Pichl L, 2004, IEEE T NUCL SCI, V51, P1407, DOI 10.1109/TNS.2004.832311; Privett AJ, 2014, CHEM PHYS LETT, V603, P82, DOI 10.1016/j.cplett.2014.04.018; Quinet O, 2009, INT J QUANTUM CHEM, V109, P259, DOI 10.1002/qua.21771; RUDD ME, 1985, PHYS REV A, V31, P492, DOI 10.1103/PhysRevA.31.492; Saykally RJ, 2012, SCIENCE, V336, P814, DOI 10.1126/science.1222007; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; SHAH MB, 1987, J PHYS B-AT MOL OPT, V20, P2481, DOI 10.1088/0022-3700/20/11/016; Shields RM, 2010, J PHYS CHEM A, V114, P11725, DOI 10.1021/jp104865w; Shikazono N, 2009, J RADIAT RES, V50, P27, DOI 10.1269/jrr.08086; Solov'yov AV, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011909; Stopera C, 2013, ADV QUANTUM CHEM, V66, P113, DOI 10.1016/B978-0-12-408099-7.00003-9; Surdutovich E, 2010, EUR PHYS J D, V60, P101, DOI 10.1140/epjd/e2010-00232-3; Surdutovich E, 2014, EUR PHYS J D, V68, DOI 10.1140/epjd/e2014-50004-0; Surdutovich E, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.051915; Szabo A., 1989, MODERN QUANTUM CHEM; Tabet J, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.022703; Tainter CJ, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4746157; THOULESS DJ, 1960, NUCL PHYS, V21, P225, DOI 10.1016/0029-5582(60)90048-1; TURNER JE, 1988, RADIAT PHYS CHEM, V32, P503; Valiev M, 2010, COMPUT PHYS COMMUN, V181, P1477, DOI 10.1016/j.cpc.2010.04.018; Wang YM, 2012, J AM CHEM SOC, V134, P11116, DOI 10.1021/ja304528m; Watanabe R, 2002, RADIAT ENVIRON BIOPH, V41, P207, DOI 10.1007/s00411-002-0161-8; WERNER U, 1995, PHYS REV LETT, V74, P1962, DOI 10.1103/PhysRevLett.74.1962; XANTHEAS SS, 1993, J CHEM PHYS, V99, P8774, DOI 10.1063/1.465599; Yoshikawa A, 2004, J MOL STRUC-THEOCHEM, V681, P27, DOI 10.1016/j.theochem.2004.04.047; Zare R. N., 1988, ANGULAR MOMENTUM UND	80	11	11	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2017	12	4							e0174456	10.1371/journal.pone.0174456	http://dx.doi.org/10.1371/journal.pone.0174456			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2IO	28376128	Green Published, Green Submitted, gold			2023-01-03	WOS:000399352000008
J	Woods, B; Manca, A; Weatherly, H; Saramago, P; Sideris, E; Giannopoulou, C; Rice, S; Corbett, M; Vickers, A; Bowes, M; MacPherson, H; Sculpher, M				Woods, Beth; Manca, Andrea; Weatherly, Helen; Saramago, Pedro; Sideris, Eleftherios; Giannopoulou, Christina; Rice, Stephen; Corbett, Mark; Vickers, Andrew; Bowes, Matthew; MacPherson, Hugh; Sculpher, Mark			Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee	PLOS ONE			English	Article							INDIVIDUAL-PATIENT-DATA; EQ-5D UTILITY VALUES; EULAR RECOMMENDATIONS; NETWORK METAANALYSIS; TASK-FORCE; ACUPUNCTURE; MANAGEMENT; PAIN; RESPONSES; TRIALS	Background There is limited information on the costs and benefits of alternative adjunct non pharmacological treatments for knee osteoarthritis and little guidance on which should be prioritised for commissioning within the NHS. This study estimates the costs and benefits of acupuncture, braces, heat treatment, insoles, interferential therapy, laser/light therapy, manual therapy, neuromuscular electrical stimulation, pulsed electrical stimulation, pulsed electromagnetic fields, static magnets and transcutaneous electrical nerve Stimulation (TENS), based on all relevant data, to facilitate a more complete assessment of value. Methods Data from 88 randomised controlled trials including 7,507 patients were obtained from a systematic review. The studies reported a wide range of outcomes. These were converted into EQ-5D index values using prediction models, and synthesised using network meta-analysis. Analyses were conducted including firstly all trials and secondly only trials with low risk of selection bias. Resource use was estimated from trials, expert opinion and the literature. A decision analytic model synthesised all evidence to assess interventions over a typical treatment period (constant benefit over eight weeks or linear increase in effect over weeks zero to eight and dissipation over weeks eight to 16). Results When all trials are considered, TENS is cost-effective at thresholds of 20-30,000 pound per QALY with an incremental cost-effectiveness ratio of 2,690 pound per QALY vs. usual care. When trials with a low risk of selection bias are considered, acupuncture is cost-effective with an incremental cost-effectiveness ratio of 13,502 pound per QALY vs. TENS. The results of the analysis were sensitive to varying the intensity, with which interventions were delivered, and the magnitude and duration of intervention effects on EQ-5D. Conclusions Using the 20,000 per QALY NICE threshold results in TENS being cost-effective if all trials are considered. If only higher quality trials are considered, acupuncture is cost-effective at this threshold, and thresholds down to 14,000 per QALY.	[Woods, Beth; Manca, Andrea; Weatherly, Helen; Saramago, Pedro; Sideris, Eleftherios; Giannopoulou, Christina; Sculpher, Mark] Univ York, Ctr Hlth Econ, York, N Yorkshire, England; [Rice, Stephen; Corbett, Mark] Univ York, Ctr Reviews & Disseminat, York, N Yorkshire, England; [Vickers, Andrew] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Bowes, Matthew] York Teaching Hosp NHS Fdn Trust, York, N Yorkshire, England; [MacPherson, Hugh] Univ York, Dept Hlth Sci, York, N Yorkshire, England	University of York - UK; University of York - UK; Memorial Sloan Kettering Cancer Center; University of York - UK	Woods, B (corresponding author), Univ York, Ctr Hlth Econ, York, N Yorkshire, England.	Beth.woods@york.ac.uk		Sculpher, Mark/0000-0003-3746-9913; Woods, Bethan Sarah/0000-0002-7669-9415	National Institute for Health Research (NIHR) [RP-PG-0707-10186]; R21 from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) [AT0041891]; Samueli Institute; NIHR [CDF-2009-02-21]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006794] Funding Source: NIH RePORTER; National Institute for Health Research [CDF-2009-02-21, RP-PG-0707-10186] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); R21 from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH); Samueli Institute; NIHR(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by the National Institute for Health Research (NIHR) under Programme Grants for Applied Research [Grant number: RP-PG-0707-10186]. The views expressed in this presentation are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Acupuncture Trialists' Collaboration (ATC) is funded by an R21 [Grant number: AT0041891] from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) to Dr Vickers and by a grant from the Samueli Institute. AM contribution was made under the terms of a Career Development research training fellowship issued by the NIHR [Grant number: CDF-2009-02-21]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adedoyin RA, 2002, PHYSIOTHERAPY, V88, P493, DOI [10.1016/S0031-9406(05)60851-6, DOI 10.1016/S0031-9406(05)60851-6]; [Anonymous], METHODS ESTIMATION N; Barton GR, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-51; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Burch FX, 2008, OSTEOARTHR CARTILAGE, V16, P865, DOI 10.1016/j.joca.2007.11.013; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Claxton K, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16460; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Corbett MS, 2013, OSTEOARTHR CARTILAGE, V21, P1290, DOI 10.1016/j.joca.2013.05.007; Corbett MS, 2012, 40 CTR REV DISS; Curtis L, 2013, UNIT COSTS HLTH SOCI; Dakin H, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-151; Dias S, 2013, MED DECIS MAKING, V33, P618, DOI 10.1177/0272989X13485157; Drummond MF, 2015, METHODS EC EVALUATIO, V4th; Fernandes L, 2013, ANN RHEUM DIS, V72, P1125, DOI 10.1136/annrheumdis-2012-202745; Gray AM, 2006, MED DECIS MAKING, V26, P18, DOI 10.1177/0272989X05284108; Gu NY, 2012, PATIENT, V5, P185, DOI 10.2165/11630970-000000000-00000; Gundog M, 2012, AM J PHYS MED REHAB, V91, P107, DOI 10.1097/PHM.0b013e3182328687; healthandcare. co. uk, 2014, BAUERF GEN TRAIN KNE; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jansen JP, 2011, VALUE HEALTH, V14, P417, DOI 10.1016/j.jval.2011.04.002; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Longworth L, 2013, VALUE HEALTH, V16, P202, DOI 10.1016/j.jval.2012.10.010; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; MacPherson H, 2016, PAIN; MacPherson H, PROGRAMME G IN PRESS; MacPherson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093739; Maund E, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16110; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; National Institute for Health and Care Excellence, 2014, OST CAR MAN AD; Nuesch E, 2009, ARTHRIT RHEUM-ARTHR, V61, P1633, DOI 10.1002/art.24894; Penninsula Community Health, POD DISCH LETT; Rowen D, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-27; Saramago P, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0224-1; Underwood M, 2008, HLTH TECHNOLOGY ASSE, V12, P22; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654	37	36	36	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2017	12	3							e0172749	10.1371/journal.pone.0172749	http://dx.doi.org/10.1371/journal.pone.0172749			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5QM	28267751	Green Accepted, Green Submitted, gold, Green Published			2023-01-03	WOS:000396060600002
J	Schnichels, S; Schneider, N; Hohenadl, C; Hurst, J; Schatz, A; Januschowski, K; Spitzer, MS				Schnichels, Sven; Schneider, Nele; Hohenadl, Christine; Hurst, Jose; Schatz, Andreas; Januschowski, Kai; Spitzer, Martin S.			Efficacy of two different thiol-modified crosslinked hyaluronate formulations as vitreous replacement compared to silicone oil in a model of retinal detachment	PLOS ONE			English	Article							ACID; SUBSTITUTES; VITRECTOMY	The efficacy of two novel artificial vitreous body substitutes (VBS) consisting of highly bio-compatible thiolated cross-linked hyaluronic acid (HA)-based hydrogels in comparison to silicone oil in a model of retinal detachment was investigated. Pars plana vitrectomy (23G) was performed in the right eye of 24 pigmented rabbits. Retinal detachment of two quadrants was induced by creating a small retinotomy near the vascular arcade and injecting balanced salt solution (BSS) subretinally. The retina was reattached by injecting air, which was followed by increasing the infusion pressure, and the retinal tear was treated by endolaser photocoagulation. At the end of the procedure, the eye was filled either with 5000-cs silicone oil (after fluid air exchange) or the respective hydrogel (with two different viscosities). Follow- up examination included slit lamp examination, funduscopy, intraocular pressure measurements (IOP), optical coherence tomography (OCT) and electroretinogram (ERG) measurements. After a maximum follow-up of four weeks both eyes were removed, examined macroscopically, photographed, and prepared for histology. Of the eight rabbits that received silicone oil, seven (87.5%) developed a recurrent retinal detachment with pronounced proliferative vitreoretinopathy within the first two weeks after surgery. In contrast, in the hydrogel treated eyes, the retina stayed attached in the majority of the cases (73.3%). IOP and retinal morphology were normal as long as the retina remained re-attached. In conclusions, this model of retinal detachment, both thiolated crosslinked hyaluronate hydrogels showed superior efficacy when compared to silicone oil. These hydrogels have a promising potential as novel vitreous body substitutes.	[Schnichels, Sven; Schneider, Nele; Hurst, Jose; Schatz, Andreas; Januschowski, Kai; Spitzer, Martin S.] Univ Eye Hosp Tubingen, Ctr Ophthalmol, Tubingen, Germany; [Hohenadl, Christine] Croma Pharma GmbH, Leobendorf, Austria; [Spitzer, Martin S.] Univ Med Ctr Hamburg Eppendorf UKE, Dept Ophthalmol, Martinistr 52, Hamburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf	Spitzer, MS (corresponding author), Univ Eye Hosp Tubingen, Ctr Ophthalmol, Tubingen, Germany.; Spitzer, MS (corresponding author), Univ Med Ctr Hamburg Eppendorf UKE, Dept Ophthalmol, Martinistr 52, Hamburg, Germany.	mspitzer@uke.de		Schnichels, Sven/0000-0002-2385-5517; Hurst, Jose/0000-0002-8697-2569	Croma Pharma, Leobendorf, Austria	Croma Pharma, Leobendorf, Austria	The study was supported by Croma Pharma, Leobendorf, Austria that provided the hydrogels and paid for some of the animal experiments. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antoun J, 2016, RETINA; Azarmina Mohsen, 2011, J Ophthalmic Vis Res, V6, P109; Barth H, 2016, GRAEF ARCH CLIN EXP, V254, P697, DOI 10.1007/s00417-015-3256-z; Gjorloff K, 2004, DOC OPHTHALMOL, V109, P163, DOI 10.1007/s10633-004-3924-5; Hotta K, 2005, RETINA-J RET VIT DIS, V25, P167, DOI 10.1097/00006982-200502000-00009; Joussen AM, 2011, ACTA OPHTHALMOL, V89, pE483, DOI 10.1111/j.1755-3768.2011.02139.x; Kleinberg TT, 2011, SURV OPHTHALMOL, V56, P300, DOI 10.1016/j.survophthal.2010.09.001; Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21; LEE B, 1992, BIORHEOLOGY, V29, P521; Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4; MEREDITH TA, 1985, BRIT J OPHTHALMOL, V69, P254, DOI 10.1136/bjo.69.4.254; Nakagawa M, 1997, OPHTHALMIC RES, V29, P409, DOI 10.1159/000268042; PRUETT RC, 1979, ARCH OPHTHALMOL-CHIC, V97, P2325, DOI 10.1001/archopht.1979.01020020541006; Schramm C, 2012, INVEST OPHTH VIS SCI, V53, P613, DOI 10.1167/iovs.11-7322; Schultheiss M, 2012, RETINA-J RET VIT DIS, V32, P1343, DOI 10.1097/IAE.0b013e318232c37c; Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7; Szurman P, 2009, KLIN MONATSBL AUGENH, V226, P718, DOI 10.1055/s-0028-1109653; THALER A, 1986, DOC OPHTHALMOL, V62, P41, DOI 10.1007/BF00140545	18	27	27	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2017	12	3							e0172895	10.1371/journal.pone.0172895	http://dx.doi.org/10.1371/journal.pone.0172895			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4NF	28248989	gold, Green Submitted, Green Published			2023-01-03	WOS:000395983500061
J	Herbert, A; Gilbert, R; Cottrell, D; Li, L				Herbert, Annie; Gilbert, Ruth; Cottrell, David; Li, Leah			Causes of death up to 10 years after admissions to hospitals for self-inflicted, drug-related or alcohol-related, or violent injury during adolescence: a retrospective, nationwide, cohort study	LANCET			English	Article							EMERGENCY-DEPARTMENT; HARM; IDENTIFICATION; HOSPITALIZATIONS; YOUTH	Background Emergency hospital admission with adversity-related injury (ie, self-inflicted, drug-related or alcohol-related, or violent injury) affects 4% of 10-19-year-olds. Their risk of death in the decade after hospital discharge is twice as high as that of adolescents admitted to hospitals for accident-related injury. We established how cause of death varied between these groups. Methods We did a retrospective, nationwide, cohort study comparing risks of death in five causal groups (suicide, drugrelated or alcohol-related, homicide, accidental, and other causes of death) up to 10 years after hospital discharge following adversity-related (self-inflicted, drug-related or alcohol-related, or violent injury) or accident-related (for which there was no recorded adversity) injury. We included adolescents (aged 10-19 years) who were admitted as an emergency for adversity-related or accident-related injury between April 1, 1997, and March 31, 2012. We excluded adolescents who did not have their sex recorded, died during the index admission, had no valid discharge date, or were admitted with injury related to neither adversity nor accidents. We identified admissions for adversity-related or accident-related injury to the National Health Service in England with the International Classification of Diseases-10 codes in Hospital Episode Statistics data, linked to the Office for National Statistics mortality data for England, to establish cause-specific risks of death between the first day and 10 years after discharge, and to compare risks between adversity-related and accidentrelated index injury after adjustment for age group, socioeconomic status, and chronic conditions. Findings We identified 1 080 368 adolescents (388 937 [36.0%] girls, 690 546 [63.9%] boys, and 885 [0.1%] adolescents who did not have their sex recorded). Of these adolescents, we excluded 40 549 (10.4%) girls, 56 107 (8.1%) boys, and all 885 without their sex recorded. Of the 333 009 (30.8%) adolescents admitted with adversity-related injury (181 926 [54.6%] girls and 151 083 [45.4%] boys) and 649 818 (60.2%) admitted with accident-related injury (166 462 [25.6%] girls and 483 356 [74.4%] boys), 4782 (0.5%) died in the 10 years after discharge (1312 [27.4%] girls and 3470 [72.6%] boys). Adolescents discharged after adversity-related injury had higher risks of suicide (adjusted subhazard ratio 4.54 [95% CI 3.25-6.36] for girls, and 3.15 [2.73-3.63] for boys) and of drug-related or alcohol-related death (4.71 [3.28-6.76] for girls, and 3.53 [3.04-4.09] for boys) in the next decade than they did after accident-related injury. Although we included homicides in our estimates of 10-year risks of adversity-related deaths, we did not explicitly present these risks because of small numbers and risks of statistical disclosure. There was insufficient evidence that girls discharged after adversityrelated injury had increased risks of accidental deaths compared with those discharged after accident-related injury (adjusted subhazard ratio 1.21 [95% CI 0.90-1.63]), but there was evidence that this risk was increased for boys (1.26 [1.09-1.47]). There was evidence of decreased risks of other causes of death in girls (0.64 [0.53-0.77]), but not in boys (0.99 [0.84-1.17]). Risks of suicide were increased following self-inflicted injury (adjusted subhazard ratio 5.11 [95% CI 3.61-7.23] for girls, and 6.20 [5.27-7.30] for boys), drug-related or alcohol-related injury (4.55 [3.23-6.39] for girls, and 4.51 [3.89-5.24] for boys), and violent injury in boys (1.43 [1.15-1.78]) versus accident-related injury. However, the increased risk of suicide in girls following violent injury versus accident-related injury was not significantly increased (adjusted subhazard ratio 1.48 [95% CI 0.73-2.98]). Following each type of index injury, risks of suicide and risks of drugrelated or alcohol-related death were increased by similar magnitudes. Interpretation Risks of suicide were significantly increased after all types of adversity-related injury except for girls who had violent injury. Risks of drug-related or alcohol-related death increased by a similar magnitude. Current practice to reduce risks of harm after self-inflicted injury should be extended to drug-related or alcohol-related and violent injury in adolescence. Prevention should address the substantial risks of drug-related or alcohol-related death alongside risks of suicide.	[Herbert, Annie; Gilbert, Ruth; Li, Leah] UCL, UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice Programme, London, England; [Herbert, Annie] UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London WC1E 7HB, England; [Cottrell, David] Univ Leeds, Fac Med & Hlth, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England	University of London; University College London; University of London; University College London; University of Leeds	Herbert, A (corresponding author), UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London WC1E 7HB, England.	annie.herbert@ucl.ac.uk	Cottrell, David J/A-1211-2013; Herbert, Annie/AAA-4635-2019; Herbert, Annie/I-2337-2014	Cottrell, David J/0000-0001-8674-0955; Gilbert, Ruth/0000-0001-9347-2709; Herbert, Annie/0000-0002-5570-1408	UK Department of Health; Medical Research Council [MR/K006584/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0616-10097] Funding Source: researchfish	UK Department of Health; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	UK Department of Health.	[Anonymous], 2010, INP HES DAT DICT; Bekkering GE, 2014, J CHILD PSYCHOL PSYC, V55, P3, DOI 10.1111/jcpp.12145; Hagger-Johnson G, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008118; Hardelid P, 2013, OVERVIEW CHILD DEATH; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K., 2015, COCHRANE DB SYST REV, V12; Hawton K, 2007, J CLIN PSYCHIAT, V68, P1574, DOI 10.4088/JCP.v68n1017; Herbert A, 2017, INT J EPIDEMIOL, V46, P1093, DOI 10.1093/ije/dyx015; Herbert A, 2017, J PUBLIC HEALTH-UK, V39, P65, DOI 10.1093/pubmed/fdw020; Herbert A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001931; Herbert A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006079; Mars B, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5954; McKenzie K, 2010, AUST NZ J PUBL HEAL, V34, P146, DOI 10.1111/j.1753-6405.2010.00499.x; Medical Research Council and NHS Health Research Authority, 2015, DO I NEED NHS REC AP; Moran P, 2015, ACTA PSYCHIAT SCAND, V131, P61, DOI 10.1111/acps.12306; National Audit Office, 2012, HEALTHC UK COMP NHS; National Institute for Health and Clinical Excellence (NICE), 2004, SELF HARM 8S SHORT T; Newton AS, 2013, PEDIATR EMERG CARE, V29, P673, DOI 10.1097/PEC.0b013e31828ed325; NICE, 2011, SELF HARM LONGER TER; Office for National Statistics, 2010, ONS POL PROT CONF BI; Office for National Statistics, 2015, MORT MET; Office for National Statistics, 1997, DEATHS SPEC GROUP CA; Patrick AR, 2010, PHARMACOEPIDEM DR S, V19, P1263, DOI 10.1002/pds.2037; Snider C, 2009, CAN J EMERG MED, V11, P161; Swanepoel A, 2016, ARCH DIS CHILDHOOD-E, V101, P287, DOI 10.1136/archdischild-2016-310782; Viner RM, 2012, LANCET, V379, P1641, DOI 10.1016/S0140-6736(12)60149-4; Wang RH, 2010, J ADV NURS, V66, P313, DOI 10.1111/j.1365-2648.2009.05159.x; Wood DM, 2011, EMERG MED J, V28, P387, DOI 10.1136/emj.2009.088344	28	36	37	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2017	390	10094					577	587		10.1016/S0140-6736(17)31045-0	http://dx.doi.org/10.1016/S0140-6736(17)31045-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC5BM	28552365	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000406855800022
J	Venook, AP; Niedzwiecki, D; Lenz, HJ; Innocenti, F; Fruth, B; Meyerhardt, JA; Schrag, D; Greene, C; O'Neil, BH; Atkins, JN; Berry, S; Polite, BN; O'Reilly, EM; Goldberg, RM; Hochster, HS; Schilsky, RL; Bertagnolli, MM; El-Khoueiry, AB; Watson, P; Benson, A; Mulkerin, DL; Mayer, RJ; Blanke, C				Venook, Alan P.; Niedzwiecki, Donna; Lenz, Heinz-Josef; Innocenti, Federico; Fruth, Briant; Meyerhardt, Jeffrey A.; Schrag, Deborah; Greene, Claire; O'Neil, Bert H.; Atkins, James Norman; Berry, Scott; Polite, Blase N.; O'Reilly, Eileen M.; Goldberg, Richard M.; Hochster, Howard S.; Schilsky, Richard L.; Bertagnolli, Monica M.; El-Khoueiry, Anthony B.; Watson, Peter; Benson, Al B., III; Mulkerin, Daniel L.; Mayer, Robert J.; Blanke, Charles			Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLFIRI PLUS CETUXIMAB; PHASE-II; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; PROGRESSION; THERAPY; FIRE-3; TUMORS	IMPORTANCE Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. OBJECTIVE To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS Patients (>= 18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. INTERVENTIONS Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. MAIN OUTCOMES AND MEASURES The primary end pointwas overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. RESULTS Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P =.08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P =.45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P =.13). CONCLUSIONS AND RELEVANCE Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment.	[Venook, Alan P.; Greene, Claire] Univ Calif San Francisco, 1450 Third St,HD 376, San Francisco, CA 94158 USA; [Niedzwiecki, Donna] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Niedzwiecki, Donna] Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC USA; [Lenz, Heinz-Josef; El-Khoueiry, Anthony B.] Univ Southern Calif, Los Angeles, CA USA; [Innocenti, Federico] Univ N Carolina, Chapel Hill, NC USA; [Fruth, Briant] Mayo Clin, Ctr Canc, Alliance Stat & Data Ctr, Rochester, MN USA; [Meyerhardt, Jeffrey A.; Schrag, Deborah; Mayer, Robert J.] Dana Farber Partners CancerCare, Boston, MA USA; [O'Neil, Bert H.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA; [Atkins, James Norman] Natl Surg Adjuvant Breast & Bowel Project NRG Onc, Goldsboro, NC USA; [Atkins, James Norman] Southeastern Med Oncol Ctr, Goldsboro, NC USA; [Berry, Scott] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada; [Polite, Blase N.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA; [O'Reilly, Eileen M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Goldberg, Richard M.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Hochster, Howard S.] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA; [Schilsky, Richard L.] Amer Soc Clin Oncol, Alexandria, VA USA; [Bertagnolli, Monica M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Watson, Peter] Kinston Med Specialists PA, Lenoir Mem Hosp, Kinston, NC USA; [Benson, Al B., III] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Mulkerin, Daniel L.] Univ Wisconsin, Madison, WI 53706 USA; [Blanke, Charles] Oregon Hlth & Sci Univ, Southwest Oncol Grp Chairs Off, Portland, OR 97201 USA; [Blanke, Charles] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA	University of California System; University of California San Francisco; Duke University; Duke University; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic; Harvard University; Dana-Farber Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Robert H. Lurie Comprehensive Cancer Center; University of Chicago; Memorial Sloan Kettering Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Yale University; American Society of Clinical Oncology; Harvard University; Brigham & Women's Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University; Southwest Oncology Group; Oregon Health & Science University	Venook, AP (corresponding author), Univ Calif San Francisco, 1450 Third St,HD 376, San Francisco, CA 94158 USA.	alan.venook@ucsf.edu	Goldberg, Richard/O-1871-2017; Innocenti, Federico/G-3206-2018	Goldberg, Richard/0000-0003-3713-6895; O'Reilly, Eileen M./0000-0002-8076-9199; Niedzwiecki, Donna/0000-0002-3566-0450	National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, U10CA180790, U10CA180791, U10CA180795, U10CA180799, U10CA180830, U10CA180836, U10CA180838, U10CA180850, U10CA180867, U10CA180888]; Eli Lilly and Company; Genentech; Pfizer Inc; Sanofi; NATIONAL CANCER INSTITUTE [U10CA180820, U10CA180790, U10CA180850, U10CA180867, U10CA180836, R01CA149222, U10CA180795, U10CA180799, U10CA180882, K05CA169384, U10CA180838, U10CA180888, U10CA180830, U10CA180791, U10CA180821] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eli Lilly and Company(Eli Lilly); Genentech(Roche HoldingGenentech); Pfizer Inc(Pfizer); Sanofi(Sanofi-Aventis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health by grants U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA180790 (Mayo Clinic), U10CA180791 (Memorial Sloan-Kettering), U10CA180795 (Indiana University), U10CA180799 (University of Wisconsin), U10CA180830 (USC Norris Cancer Hospital), U10CA180836 (University of Chicago), U10CA180838 (University of North Carolina), U10CA180850 (Ohio State University), U10CA180867 (Dana-Farber Cancer Institute), and U10CA180888 (Southwest Oncology Group). The trial was also supported in part by Eli Lilly and Company, Genentech, Pfizer Inc, and Sanofi.	Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135; Heinemann V, OUTCOMES FOLFIRI PLU; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Modest DP, 2015, J CLIN ONCOL, V33, P3718, DOI 10.1200/JCO.2015.61.2887; O'Neil BH, 2015, J CLIN ONCOL, V33, P3686, DOI 10.1200/JCO.2015.62.8495; ODWYER PJ, 1990, J CLIN ONCOL, V8, P1497, DOI 10.1200/JCO.1990.8.9.1497; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473; Shi Q, 2015, J CLIN ONCOL, V33, P22, DOI 10.1200/JCO.2014.56.5887; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Venook AP, IMPACT PRIMARY 1 TUM	24	510	520	4	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2017	317	23					2392	2401		10.1001/jama.2017.7105	http://dx.doi.org/10.1001/jama.2017.7105			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY0NJ	28632865	Bronze, Green Accepted			2023-01-03	WOS:000403654600013
J	[Anonymous]				[Anonymous]			Breast cancer targeted therapy: successes and challenges	LANCET			English	Editorial Material																			0	33	33	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2017	389	10087					2350	2350		10.1016/S0140-6736(17)31662-8	http://dx.doi.org/10.1016/S0140-6736(17)31662-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX6ED	28635596	Bronze			2023-01-03	WOS:000403334400005
J	Castan, C; Munch, A; Mahling, M; Haffner, L; Griewatz, J; Hermann-Werner, A; Riessen, R; Reutershan, J; Celebi, N				Castan, Christoph; Munch, Alexander; Mahling, Moritz; Haffner, Leopold; Griewatz, Jan; Hermann-Werner, Anne; Riessen, Reimer; Reutershan, Jorg; Celebi, Nora			Factors associated with delayed defibrillation in cardiopulmonary resuscitation: A prospective simulation study	PLOS ONE			English	Article							COUNCIL GUIDELINES; CARDIAC ARRESTS; LIFE-SUPPORT; RETENTION; CARE	Introduction Early defibrillation is an important factor of survival in cardiac arrest. However, novice resuscitators often struggle with cardiac arrest patients. We investigated factors leading to delayed defibrillation performed by final-year medical students within a simulated bystander cardiac arrest situation. Methods Final-year medical students received a refresher lecture and basic life support training before being confronted with a simulated cardiac arrest situation in a simulation ambulance. The scenario was analyzed for factors leading to delayed defibrillation. We compared the time intervals the participants needed for various measures with a benchmark set by experienced resuscitators. After training, the participants were interviewed regarding challenges and thoughts during the scenario. Results The median time needed for defibrillation was 158 s (n = 49, interquartile range: 107-270 s), more than six-fold of the benchmark time. The major part of total defibrillation time (49%; median, n = 49) was between onset of ventricular fibrillation and beginning to prepare the defibrillator, more specifically the time between end of preparation of the defibrillator and actual delivery of the shock, with a mean proportion of 26% (n = 49, SD = 17%) of the overall time needed for defibrillation (maximum 67%). Self-reported reasons for this delay included uncertainty about the next step to take, as reported by 73% of the participants. A total of 35% were unsure about which algorithm to follow. Diagnosing the patient was subjectively difficult for 35% of the participants. Overall, 53% of the participants felt generally confused. Conclusions Our study shows that novice resuscitators rarely achieve guideline-recommended defibrillation times. The most relative delays were observed when participants had to choose what to do next or which algorithm to follow, and thus i.e. performed extensive airway management before a life-saving defibrillation. Our data provides a first insight in the process of defibrillation delay and can be used to generate new hypotheses on how to provide a timely defibrillation.	[Castan, Christoph; Haffner, Leopold] Univ Tubingen, Fac Med, Sch Med, Tubingen, Germany; [Munch, Alexander] Univ Tubingen, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; [Mahling, Moritz] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Tubingen, Germany; [Griewatz, Jan] Univ Tubingen, Fac Med, Competence Ctr Univ Teaching Med, Tubingen, Germany; [Hermann-Werner, Anne] Univ Tubingen, Fac Med, DocLab, Tubingen, Germany; [Hermann-Werner, Anne] Univ Tubingen, Dept Internal Med Psychosomat Med & Psychotherapy, Tubingen, Germany; [Riessen, Reimer] Univ Tubingen, Med Intens Care Unit, Dept Internal Med, Tubingen, Germany; [Reutershan, Jorg] Bayreuth Hosp, Dept Anesthesiol & Intens Care Med, Preuschwitzer Str 101, Bayreuth, Germany; [Celebi, Nora] PHV Dialysezentrum Waiblingen, Beinsteiner Str 8-3, Waiblingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Klinikum Bayreuth	Mahling, M (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Tubingen, Germany.	moritz.mahling@med.uni-tuebingen.de	Riessen, Reimer/AFR-0686-2022	Griewatz, Jan/0000-0002-9731-3171	"PROFIL" program, Faculty of Medicine, University of Tubingen	"PROFIL" program, Faculty of Medicine, University of Tubingen	This study was funded by the "PROFIL" program, Faculty of Medicine, University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Dreyfus S, 2004, B SCI TECHNOL SOC, V24, P177, DOI DOI 10.1177/0270467604264992; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Hunt EA, 2009, RESUSCITATION, V80, P819, DOI 10.1016/j.resuscitation.2009.03.020; Marsch SCU, 2005, CRIT CARE MED, V33, P963, DOI 10.1097/01.CCM.0000157750.43459.07; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Soar J, 2015, ADULT ADV LIFE SUPPO; Spearpoint KG, 2000, RESUSCITATION, V44, P165, DOI 10.1016/S0300-9572(00)00158-1; Sullivan NJ, 2015, RESUSCITATION, V86, P6, DOI 10.1016/j.resuscitation.2014.10.021; Yang CW, 2012, RESUSCITATION, V83, P1055, DOI 10.1016/j.resuscitation.2012.02.027	13	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e0178794	10.1371/journal.pone.0178794	http://dx.doi.org/10.1371/journal.pone.0178794			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX0PL	28594858	Green Published, Green Submitted, gold			2023-01-03	WOS:000402923200052
J	Killick-Cole, CL; Singleton, WGB; Bienemann, AS; Asby, DJ; Wyatt, MJ; Boulter, LJ; Barua, NU; Gill, SS				Killick-Cole, Clare L.; Singleton, William G. B.; Bienemann, Alison S.; Asby, Daniel J.; Wyatt, Marcella J.; Boulter, Lisa J.; Barua, Neil U.; Gill, Steven S.			Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma	PLOS ONE			English	Article							CONVECTION-ENHANCED DELIVERY; HISTONE DEACETYLASE INHIBITOR; ACTIVATING ACVR1 MUTATIONS; BRAIN-STEM GLIOMA; LEUKEMIA-CELLS; PHASE-I; ACID; GLIOBLASTOMA; CARBOPLATIN; EXPRESSION	Targeting epigenetic changes in diffuse intrinsic pontine glioma (DIPG) may provide a novel treatment option for patients. This report demonstrates that sodium valproate, a histone deacetylase inhibitor (HDACi), can increase the cytotoxicity of carboplatin in an additive and synergistic manner in DIPG cells in vitro. Sodium valproate causes a dose-dependent decrease in DIPG cell viability in three independent ex vivo cell lines. Furthermore, sodium valproate caused an increase in acetylation of histone H3. Changes in cell viability were consistent with an induction of apoptosis in DIPG cells in vitro, determined by flow cytometric analysis of Annexin V staining and assessment of apoptotic markers by western blotting. Subsequently, immunofluorescent staining of neuronal and glial markers was used to determine toxicity in normal rat hippocampal cells. Pre-treatment of cells with sodium valproate enhanced the cytotoxic effects of carboplatin, in three DIPG cell lines tested. These results demonstrate that sodium valproate causes increased histone H3 acetylation indicative of HDAC inhibition, which is inversely correlated with a reduction in cell viability. Cell viability is reduced through an induction of apoptosis in DIPG cells. Sodium valproate potentiates carboplatin cytotoxicity and prompts further work to define the mechanism responsible for the synergy between these two drugs and determine in vivo efficacy. These findings support the use of sodium valproate as an adjuvant treatment for DIPG.	[Killick-Cole, Clare L.; Singleton, William G. B.; Bienemann, Alison S.; Asby, Daniel J.; Wyatt, Marcella J.; Boulter, Lisa J.; Barua, Neil U.; Gill, Steven S.] Univ Bristol, Sch Clin Sci, Funct Neurosurg Res Grp, Southmead Hosp, Learning & Res Bldg, Bristol, Avon, England; [Singleton, William G. B.; Barua, Neil U.; Gill, Steven S.] North Bristol NHS Trust, Dept Neurosurg, Bristol, Avon, England	Southmead Hospital; University of Bristol; North Bristol NHS Trust	Killick-Cole, CL; Gill, SS (corresponding author), Univ Bristol, Sch Clin Sci, Funct Neurosurg Res Grp, Southmead Hosp, Learning & Res Bldg, Bristol, Avon, England.; Gill, SS (corresponding author), North Bristol NHS Trust, Dept Neurosurg, Bristol, Avon, England.	clare.killick-cole@bristol.ac.uk; steven.gill@nbt.nhs.uk		Asby, Daniel/0000-0002-1219-8347; Singleton, William/0000-0001-8836-7613	Functional Neurosurgery Research Fund; MRC [MR/J005134/1, G0601745, MR/N001370/1] Funding Source: UKRI; Medical Research Council [G0601745, MR/J005134/1, MR/N001370/1] Funding Source: researchfish	Functional Neurosurgery Research Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the Functional Neurosurgery Research Fund, held by Southmead Hospital Charities. SG and NB are advisers to Renishaw PLC. Neither Functional Neurosurgery Research Fund nor Renishaw had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arshad A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132266; Arvidsson Y, 2016, NEUROENDOCRINOLOGY, V103, P578, DOI 10.1159/000441849; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Barua NU, 2013, ACTA NEUROCHIR, V155, P1459, DOI 10.1007/s00701-013-1700-6; Barua NU, 2016, DRUG DELIV, V23, P167, DOI 10.3109/10717544.2014.908248; Barua NU, 2014, BRAIN PATHOL, V24, P117, DOI 10.1111/bpa.12082; Bokelmann I, 2008, MOL MED, V14, P20, DOI 10.2119/2007-00084.Bokelmann; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Castel D, 2015, ACTA NEUROPATHOL, V130, P815, DOI 10.1007/s00401-015-1478-0; Catalano MG, 2004, J CLIN ENDOCRINOLOGY, V90, P1383; Felix FHC, 2011, PEDIATR HEMAT ONCOL, V28, P556, DOI 10.3109/08880018.2011.563774; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cinatl J, 1997, ANTI-CANCER DRUG, V8, P958, DOI 10.1097/00001813-199711000-00007; Das CM, 2007, J NEURO-ONCOL, V85, P159, DOI 10.1007/s11060-007-9402-7; Donaldson SS, 2006, J CLIN ONCOL, V24, P1266, DOI 10.1200/JCO.2005.04.6599; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Falchook GS, 2013, INVEST NEW DRUG, V31, P1192, DOI 10.1007/s10637-013-0003-3; Felisbino MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029144; Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Halvorson KG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118926; Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716; Hashizume R, 2012, J NEURO-ONCOL, V110, P305, DOI 10.1007/s11060-012-0973-6; Hennika T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169485; Kawagoe R, 2002, LEUKEMIA RES, V26, P495, DOI 10.1016/S0145-2126(01)00151-5; Li YF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00058; Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478; Paugh BS, 2013, CANCER RES, V73, P6219, DOI 10.1158/0008-5472.CAN-13-1491; Pilatrino C, 2005, CANCER-AM CANCER SOC, V104, P101, DOI 10.1002/cncr.21132; Puget S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030313; Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162; Redjal N, 2016, J NEURO-ONCOL, V127, P505, DOI 10.1007/s11060-016-2054-8; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sawai H, 2011, BIOCHEM BIOPH RES CO, V411, P569, DOI 10.1016/j.bbrc.2011.06.186; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Singleton WGB, 2016, NEURO-ONCOLOGY, V18, P131; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; van Zanten SEMV, 2015, EXPERT REV ANTICANC, V15, P157, DOI 10.1586/14737140.2015.974563; Wagner S, 2009, TURK J CANC, V39, P104; WIESER HG, 1991, EPILEPSY RES, V9, P154, DOI 10.1016/0920-1211(91)90028-E; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Yeow WS, 2006, BRIT J CANCER, V94, P1436, DOI 10.1038/sj.bjc.6603132	45	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2017	12	5							e0176855	10.1371/journal.pone.0176855	http://dx.doi.org/10.1371/journal.pone.0176855			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VR	28542253	gold, Green Published, Green Submitted			2023-01-03	WOS:000402062800005
J	Schulze, J; Kaiser, O; Paasche, G; Lamm, H; Pich, A; Hoffmann, A; Lenarz, T; Warnecke, A				Schulze, Jennifer; Kaiser, Odett; Paasche, Gerrit; Lamm, Hans; Pich, Andreas; Hoffmann, Andrea; Lenarz, Thomas; Warnecke, Athanasia			Effect of hyperbaric oxygen on BDNF-release and neuroprotection: Investigations with human mesenchymal stem cells and genetically modified NIH3T3 fibroblasts as putative cell therapeutics	PLOS ONE			English	Article							SPIRAL-GANGLION NEURONS; MARROW STROMAL CELLS; NEUROTROPHIC FACTOR; IN-VITRO; AUDITORY NEURONS; HAIR-CELLS; NEURITE OUTGROWTH; NITRIC-OXIDE; EXPRESSION; SURVIVAL	Hyperbaric oxygen therapy (HBOT) is a noninvasive widely applied treatment that increases the oxygen pressure in tissues. In cochlear implant (CI) research, intracochlear application of neurotrophic factors (NTFs) is able to improve survival of spiral ganglion neurons (SGN) after deafness. Cell-based delivery of NTFs such as brain-derived neurotrophic factor (BDNF) may be realized by cell-coating of the surface of the CI electrode. Human mesenchymal stem cells (MSC) secrete a variety of different neurotrophic factors and may be used for the development of a biohybrid electrode in order to release endogenously-derived neuroprotective factors for the protection of residual SGN and for a guided outgrowth of dendrites in the direction of the CI electrode. HBOT could be used to influence cell behaviour after transplantation to the inner ear. The aim of this study was to investigate the effect of HBOT on the proliferation, BDNF-release and secretion of neuroprotective factors. Thus, model cells (an immortalized fibroblast cell line (NIH3T3)-native and genetically modified) and MSCs were repeatedly (3 x - 10 x) exposed to 100% oxygen at different pressures. The effects of HBO on cell proliferation were investigated in relation to normoxic and normobaric conditions (NOR). Moreover, the neuroprotective and neuroregenerative effects of HBO-treated cells were analysed by cultivation of SGN in conditioned medium. Both, the genetically modified NIH3T3/BDNF and native NIH3T3 fibroblasts, showed a highly significant increased proliferation after five days of HBOT in comparison to normoxic controls. By contrast, the number of MSCs was decreased in MSCs treated with 2.0 bar of HBO. Treating SGN cultures with supernatants of fibroblasts and MSCs significantly increased the survival rate of SGN. HBO treatment did not influence (increase / reduce) this effect. Secretome analysis showed that HBO treatment altered the protein expression pattern in MSCs.	[Schulze, Jennifer; Kaiser, Odett; Paasche, Gerrit; Lamm, Hans; Lenarz, Thomas; Warnecke, Athanasia] Hannover Med Sch, Dept Otorhinolaryngol Head & Neck Surg, Hannover, Germany; [Schulze, Jennifer; Kaiser, Odett; Paasche, Gerrit; Lenarz, Thomas; Warnecke, Athanasia] Cluster Excellence Hearing4all, Hannover, Germany; [Pich, Andreas] Hannover Med Sch, Core Facil Prote, Hannover, Germany; [Hoffmann, Andrea] Hannover Med Sch, Dept Orthopaed Surg, Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Schulze, J (corresponding author), Hannover Med Sch, Dept Otorhinolaryngol Head & Neck Surg, Hannover, Germany.; Schulze, J (corresponding author), Cluster Excellence Hearing4all, Hannover, Germany.	Schulze.Jennifer.HNO@mh-hannover.de	Warnecke, Athanasia/HHC-6174-2022; Hoffmann, Andrea/AAG-4488-2020	Hoffmann, Andrea/0000-0003-2318-8985	DFG Cluster of Excellence [EXC 1077/1]	DFG Cluster of Excellence(German Research Foundation (DFG))	This work was supported by DFG Cluster of Excellence EXC 1077/1 "Hearing4all", http:// hearing4all.eu/, JS, OK.	ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Bae KS, 2011, YONSEI MED J, V52, P401, DOI 10.3349/ymj.2011.52.3.401; Bailey EM, 2014, J NEUROSCI, V34, P13110, DOI 10.1523/JNEUROSCI.1014-14.2014; Budenz CL, 2015, SCI REP, V5, P1; Chikar JA, 2012, BIOMATERIALS, V33, P1982, DOI 10.1016/j.biomaterials.2011.11.052; Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006-3495(01)75733-5; Colombari GC, 2011, EUR ARCH OTO-RHINO-L, V268, P49, DOI 10.1007/s00405-010-1338-4; Conconi MT, 2003, J INVEST MED, V51, P227, DOI 10.1136/jim-51-04-24; Dimitrijevich SD, 1999, WOUND REPAIR REGEN, V7, P53; Fernandez KA, 2015, J NEUROSCI, V35, P7509, DOI 10.1523/JNEUROSCI.5138-14.2015; Flores-Otero J, 2011, J COMP NEUROL, V519, P1455, DOI 10.1002/cne.22576; Geng CK, 2015, ASIAN PAC J TROP MED, V8, P469, DOI [10.1016/j.apjtm.2015.05.001, 10.1016/S1995-7645(14)60362-X]; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Gillespie LN, 2001, NEUROREPORT, V12, P275, DOI 10.1097/00001756-200102120-00019; Gillespie LN, 2003, J NEUROSCI RES, V71, P785, DOI 10.1002/jnr.10542; Huang T, 2000, INT J DEV NEUROSCI, V18, P259, DOI 10.1016/S0736-5748(99)00094-5; Jin YL, 2013, CELL TISSUE RES, V351, P15, DOI 10.1007/s00441-012-1526-1; Jochim N, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-48; Kang Thomas S, 2004, Arch Facial Plast Surg, V6, P31, DOI 10.1001/archfaci.6.1.31; Kishino A, 2001, NEUROREPORT, V12, P1067, DOI 10.1097/00001756-200104170-00040; Kitaoka Y, 2016, EXP EYE RES, V152, P71, DOI 10.1016/j.exer.2016.09.007; Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102; Kunnavatana SS, 2005, ARCH OTOLARYNGOL, V131, P809, DOI 10.1001/archotol.131.9.809; Lagarde MMM, 2013, J NEUROSCI, V33, P1564, DOI 10.1523/JNEUROSCI.3088-12.2013; Lai R. C., 2012, INT J PROTEOMICS, V2012, P1; Lamm K, 1998, ADV OTO-RHINO-LARYNG, V54, P59; Lee CC, 2006, J BIOMED SCI, V13, P143, DOI 10.1007/s11373-005-9037-7; LEFEBVRE PP, 1994, NEUROREPORT, V5, P865, DOI 10.1097/00001756-199404000-00003; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lin SS, 2014, STEM CELL RES, V12, P260, DOI 10.1016/j.scr.2013.10.007; Matsuoka AJ, 2006, LARYNGOSCOPE, V116, P1363, DOI 10.1097/01.mlg.0000225986.18790.75; May LA, 2013, J CLIN INVEST, V123, P3577, DOI 10.1172/JCI68480; McGuinness SL, 2005, OTOL NEUROTOL, V26, P1064, DOI 10.1097/01.mao.0000185063.20081.50; Miller JM, 2007, J NEUROSCI RES, V85, P1959, DOI 10.1002/jnr.21320; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Monzack EL, 2013, HEARING RES, V303, P20, DOI 10.1016/j.heares.2013.01.008; Nakaizumi T, 2004, AUDIOL NEURO-OTOL, V9, P135, DOI 10.1159/000077264; Perez P, 2011, AGING DIS, V2, P231; Pirvola U, 1997, J NEUROBIOL, V33, P1019, DOI 10.1002/(SICI)1097-4695(199712)33:7<1019::AID-NEU11>3.0.CO;2-A; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; ROBERTS GP, 1994, BRIT J DERMATOL, V131, P630, DOI 10.1111/j.1365-2133.1994.tb04973.x; Roemer A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0408-y; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Schack LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065943; Schack LM, 2013, STEM CELLS DEV, V22, P3226, DOI 10.1089/scd.2013.0290; Schimmang T, 2014, NEUROSCIENCE, V283, P26, DOI 10.1016/j.neuroscience.2014.07.025; Schwieger J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133680; Seo JH, 2012, YONSEI MED J, V53, P1059, DOI 10.3349/ymj.2012.53.6.1059; Shyu KG, 2008, LIFE SCI, V83, P65, DOI 10.1016/j.lfs.2008.05.005; Stover T, 2007, LARYNGO RHINO OTOL, V86, P352, DOI 10.1055/s-2006-945005; Teixeira FG, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0124-z; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; Tompach PC, 1997, INT J ORAL MAX SURG, V26, P82, DOI 10.1016/S0901-5027(05)80632-0; Venetsanou K, 2012, EUR J APPL PHYSIOL, V112, P677, DOI 10.1007/s00421-011-2027-8; Villalobo A, 2006, FEBS J, V273, P2329, DOI 10.1111/j.1742-4658.2006.05250.x; Wan GQ, 2014, ELIFE, V3, DOI 10.7554/eLife.03564; Wang XL, 2007, NEUROREPORT, V18, P1753, DOI 10.1097/WNR.0b013e3282f0ec09; Warnecke A, 2007, NEUROREPORT, V18, P1683, DOI 10.1097/WNR.0b013e3282f0b5d7; Warnecke A, 2012, HEARING RES, V289, P86, DOI 10.1016/j.heares.2012.04.007; Wefstaedt P, 2005, NEUROREPORT, V16, P2011, DOI 10.1097/00001756-200512190-00008; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Wise AK, 2010, MOL THER, V18, P1111, DOI 10.1038/mt.2010.28; Yang HJ, 2016, J MOL NEUROSCI J MOL	66	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2017	12	5							e0178182	10.1371/journal.pone.0178182	http://dx.doi.org/10.1371/journal.pone.0178182			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8UE	28542481	Green Published, gold, Green Submitted			2023-01-03	WOS:000402058800045
J	Marino, N; Illingworth, S; Kodialbail, P; Patel, A; Calderon, H; Lear, R; Fisher, KD; Champion, BR; Brown, ACN				Marino, Nalini; Illingworth, Sam; Kodialbail, Prithvi; Patel, Ashvin; Calderon, Hugo; Lear, Rochelle; Fisher, Kerry D.; Champion, Brian R.; Brown, Alice C. N.			Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes	PLOS ONE			English	Article							ADVERSE EVENTS; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ONCOLOGY	Oncolytic viruses which infect and kill tumour cells can also be genetically modified to express therapeutic genes that augment their anti-cancer activities. Modifying oncolytic viruses to produce effective cancer therapies is challenging as encoding transgenes often attenuates virus activity or prevents systemic delivery in patients due to the risk of off-target expression of transgenes in healthy tissues. To overcome these issues we aimed to generate a readily modifiable virus platform using the oncolytic adenovirus, enadenotucirev. Enadenotucirev replicates in human tumour cells but not cells from healthy tissues and can be delivered intravenously because it is stable in human blood. Here, the enadenotucirev genome was used to generate plasmids into which synthesised transgene cassettes could be directly cloned in a single step reaction. The platform enabled generation of panels of reporter viruses to identify cloning sites and transgene cassette designs where transgene expression could be linked to the virus life cycle. It was demonstrated using these viruses that encoded transgene proteins could be successfully expressed in tumour cells in vitro and tumours in vivo. The expression of transgenes did not impact either the oncolytic activity or selective properties of the virus. The effectiveness of this approach as a drug delivery platform for complex therapeutics was demonstrated by inserting multiple genes in the virus genome to encode full length anti-VEGF antibodies. Functional antibody could be synthesised and secreted from infected tumour cells without impacting the activity of the virus particle in terms of oncolytic potency, manufacturing yields or selectivity for tumour cells. In vivo, viral particles could be efficaciously delivered intravenously to disseminated orthotopic tumours.	[Marino, Nalini; Illingworth, Sam; Kodialbail, Prithvi; Patel, Ashvin; Calderon, Hugo; Lear, Rochelle; Fisher, Kerry D.; Champion, Brian R.; Brown, Alice C. N.] PsiOxus Therapeut Ltd, 154B Brook Dr,Milton Pk, Abingdon, Oxon, England		Brown, ACN (corresponding author), PsiOxus Therapeut Ltd, 154B Brook Dr,Milton Pk, Abingdon, Oxon, England.	alice.brown@psioxus.com	Calderon, Hugo/AAB-2006-2019	Calderon, Hugo/0000-0002-8902-4302	PsiOxus Therapeutics Ltd; Cancer Research UK [17720] Funding Source: researchfish	PsiOxus Therapeutics Ltd; Cancer Research UK(Cancer Research UK)	The work is funded by the investors of PsiOxus Therapeutics Ltd, a private company. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcoser SY, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-124; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; Bird SW, 2015, VIROLOGY, V479, P444, DOI 10.1016/j.virol.2015.03.044; Buchbinder EI, 2016, NAT REV CLIN ONCOL, V13, P77, DOI 10.1038/nrclinonc.2015.237; Burns MC, 2016, EXPERT OPIN ORPHAN D, V4, P867, DOI 10.1080/21678707.2016.1191348; Calvo E, 2014, ANN ONCOL, V25, DOI 10.1093/annonc/mdu342.17; Calvo E, 2014, J CLIN ONCOL, V32, p5s; Cawood R, 2012, TRENDS MOL MED, V18, P564, DOI 10.1016/j.molmed.2012.07.007; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Di Y, 2014, GENE THER, V21, P440, DOI 10.1038/gt.2014.2; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fisher K, 2006, CURR OPIN MOL THER, V8, P301; Greig SL, 2016, DRUGS, V76, P147, DOI 10.1007/s40265-015-0522-7; Heo J, 2013, NAT MED, V19, P329, DOI 10.1038/nm.3089; Hodi FS, 2016, LANCET ONCOL; Hoos A, 2016, NAT REV DRUG DISCOV, V15, P235, DOI 10.1038/nrd.2015.35; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Jin F, 2005, MOL THER, V12, P1052, DOI 10.1016/j.ymthe.2005.07.696; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Keller BA, 2016, J MOL MED; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Knipe D.M.H., 2013, PETER FIELDS VIROLOG, V6th; Kuhn I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002409; Lawler S. E., 2016, JAMA ONCOL; Lichty BD, 2014, NAT REV CANCER, V14, P559, DOI 10.1038/nrc3770; Marquez-Rodas I, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.10.27; Marrone KA, 2016, CLIN PHARMACOL THER, V100, P242, DOI 10.1002/cpt.394; McNeish IA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps5611; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Pol J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1117740; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Tahtinen S, 2015, CANCER IMMUNOL RES, V3, P915, DOI 10.1158/2326-6066.CIR-14-0220-T; Tartari F, 2016, CANCER TREAT REV, V48, P20, DOI 10.1016/j.ctrv.2016.06.002; Tollefson A.E., 2007, METHODS MOL MED, V130, P223; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wang S, 2016, CLIN CANC RES; Workenhe ST, 2014, MOL THER, V22, P123, DOI 10.1038/mt.2013.238; Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095	41	23	25	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2017	12	5							e0177810	10.1371/journal.pone.0177810	http://dx.doi.org/10.1371/journal.pone.0177810			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV3PV	28542292	Green Submitted, Green Published, gold			2023-01-03	WOS:000401672400088
J	Aggarwal, R; Chen, Q; Goel, A; Seguy, N; Pendse, R; Ayer, T; Chhatwal, J				Aggarwal, Rakesh; Chen, Qiushi; Goel, Amit; Seguy, Nicole; Pendse, Razia; Ayer, Turgay; Chhatwal, Jagpreet			Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India	PLOS ONE			English	Article							GENOTYPE 1 INFECTION; QUALITY-OF-LIFE; UNITED-STATES; ALL-CAUSE; VIRUS; SOFOSBUVIR; LEDIPASVIR; FIBROSIS; INTERFERON-ALPHA-2B; PEGINTERFERON	Background & aims Availability of directly-acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has restricted their use in several countries. However, in some countries such as India, generic DAAs are available at much cheaper price. This study examined whether generic DAAs could be cost-saving and how long it would take for the treatment to become cost-saving/effective. Methods A previously-validated, mathematical model was adapted to the HCV-infected population in India to compare the outcomes of no treatment versus treatment with DAAs. Model parameters were estimated from published studies. Cost-effectiveness of HCV treatment using available DAAs was calculated, using a payer's perspective. We estimated quality-adjusted life years (QALYs), disability-adjusted life years (DALYs), total costs, and incremental cost-effectiveness ratio of DAAs versus no treatment. One-way and probabilistic sensitivity analyses were conducted. Results Compared with no treatment, the use of generic DAAs in Indian HCV patients would increase the life expectancy by 8.02 years, increase QALYs by 3.89, avert 19.07 DALYs, and reduce the lifetime healthcare costs by $1,309 per-person treated. Treatment became cost-effective within 2 years, and cost-saving within 10 years of its initiation overall and within 5 years in persons with cirrhosis. Treating 10,000 HCV-infected persons could prevent 3400-3850 decompensated cirrhosis, 1800-2500 HCC, and 4000-4550 liver-related deaths. The results were sensitive to the costs of DAAs, pre- and post-treatment diagnostic tests and management of cirrhosis, and quality of life after sustained virologic response. Conclusions Treatment with generic DAAs available in India will improve patient outcomes, provide a good value for money within 2 years, and be ultimately cost-saving. Therefore, in this and similar settings, HCV treatment should be a priority from a public health as well an economic perspective.	[Aggarwal, Rakesh; Goel, Amit] Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow, Uttar Pradesh, India; [Chen, Qiushi; Chhatwal, Jagpreet] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA; [Chen, Qiushi; Chhatwal, Jagpreet] Harvard Med Sch, Boston, MA 02115 USA; [Seguy, Nicole] WHO, India Country Off, New Delhi, India; [Pendse, Razia] WHO, Reg Off South East Asia, Communicable Dis Dept, New Delhi, India; [Ayer, Turgay] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA	Sanjay Gandhi Postgraduate Institute of Medical Sciences; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; World Health Organization; National Centre for Disease Control (NCDC); World Health Organization; University System of Georgia; Georgia Institute of Technology	Chhatwal, J (corresponding author), Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.; Chhatwal, J (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	JagChhatwal@mgh.harvard.edu	Chen, Qiushi/AAE-5002-2020; Aggarwal, Rakesh/D-1583-2009; Goel, Amit/H-2822-2019	Aggarwal, Rakesh/0000-0001-9689-494X; Chhatwal, Jagpreet/0000-0001-8741-4430; Goel, Amit/0000-0003-3525-9381	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Blach S, LANCET GAST IN PRESS; Cardoso AC, 2010, J HEPATOL, V52, P652, DOI 10.1016/j.jhep.2009.12.028; Chhatwal J, 2016, CLIN GASTROENTEROL H; Chhatwal J, 2016, PHARMACOECONOMICS, V34, P551, DOI 10.1007/s40273-015-0373-9; Chhatwal J, 2015, ANN INTERN MED, V162, P397, DOI 10.7326/M14-1336; Chhatwal J, 2013, VALUE HEALTH, V16, P973, DOI 10.1016/j.jval.2013.07.006; Chong CAKY, 2003, AM J GASTROENTEROL, V98, P630, DOI 10.1111/j.1572-0241.2003.07332.x; Davis KL, 2011, J CLIN GASTROENTEROL, V45, pE17, DOI 10.1097/MCG.0b013e3181e12c09; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Gimeno-Ballester V, 2015, EXPERT REV PHARM OUT, P1; Hanmer J, 2006, MED DECIS MAKING, V26, P391, DOI 10.1177/0272989X06290497; Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032; Kohli A, 2015, LANCET INFECT DIS, V15, P1049, DOI 10.1016/S1473-3099(15)00157-7; Linas BP, 2015, ANN INTERN MED, V162, P619, DOI 10.7326/M14-1313; McAdam-Marx C, 2011, J MANAGE CARE PHARM, V17, P531, DOI 10.18553/jmcp.2011.17.7.531; Najafzadeh M, 2015, ANN INTERN MED, V162, P407, DOI 10.7326/M14-1152; Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726; Planas R, 2004, J HEPATOL, V40, P823, DOI 10.1016/j.jhep.2004.01.005; Raghavan P, 2016, EC TIMES        0401; Razavi H, 2013, HEPATOLOGY, V57, P2164, DOI 10.1002/hep.26218; Shah N, 2013, EXPERT OPIN INV DRUG, V22, P1107, DOI 10.1517/13543784.2013.806482; Siebert U, 2003, GUT, V52, P425, DOI 10.1136/gut.52.3.425; Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7; Thein HH, 2008, HEPATOLOGY, V48, P418, DOI 10.1002/hep.22375; van der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878; Welzel TM, 2016, GUT; Westerhout K, 2015, J MED ECON, P1; WHO, 2016, WHO GUIDELINES SCREE; WHO, 2013, WHO METHODS DATA SOU; Wilson J, 2007, HEALTH TECHNOL ASSES, V11, P1; Wolfe RA, 2010, AM J TRANSPLANT, V10, P961, DOI 10.1111/j.1600-6143.2010.03021.x; World Health Organization, 2016, GLOB HLTH SECT STRAT; World Health Organization, 2016, VIT HEP STRAT INF MO	36	66	66	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2017	12	5							e0176503	10.1371/journal.pone.0176503	http://dx.doi.org/10.1371/journal.pone.0176503			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV1DX	28520728	Green Published, gold, Green Submitted			2023-01-03	WOS:000401487700019
J	Walker, J; Mertens, UK; Schmidt, CO; Chenot, JF				Walker, Jochen; Mertens, Ulf Kai; Schmidt, Carsten Oliver; Chenot, Jean-Francois			Effect on healthcare utilization and costs of spinal manual therapy for acute low back pain in routine care: A propensity score matched cohort study	PLOS ONE			English	Article							CLINICAL-PREDICTION RULE; PHYSICAL-THERAPY; MANIPULATION; GUIDELINES; MANAGEMENT; EXERCISE; UPDATE	Spinal manual therapy (SMT) is a popular treatment option for low back pain (LBP). The aim of our analysis was to evaluate the effects of manual therapy delivered by general practitioners and ambulatory orthopedic surgeons in routine care on follow up consultations, sick leave, health service utilization and costs for acute LBP compared to matched patients not receiving manual therapy. This is a propensity score matched cohort study based on health claims data. We identified a total of 113.652 adult patients with acute LBP and no coded red flags of whom 21.021 (18%) received SMT by physicians. In the final analysis 17.965 patients in each group could be matched. Balance on patients' coded characteristics, comorbidity and prior health service utilization was achieved. The provision of SMT for acute LBP had no relevant impact on follow up visits and days of sick leave for LBP in the index billing period and the following year. SMT was associated with a higher proportion of imaging studies for LBP (30.6% vs. 23%, SMD: 0.164 [95% CI 0.143-0.185]). SMT did not lead to meaningful savings by replacing other health services for LBP. SMT for acute non-specific LBP in routine care was not clinically meaningful effective to reduce sick leave and reconsultation rates compared to no SMT and did not lead to meaningful savings by replacing other health services from the perspective of health insurance. This does not imply that SMT is ineffective but might reflect a problem with selection of suitable patients and the quality and quantity of SMT in routine care. National Manual Medicine societies should state clearly that imaging is not routinely needed prior to SMT in patients with low suspicion of presence of red flags and monitor the quality of provided services.	[Walker, Jochen] Elsevier Hlth Analyt, Berlin, Germany; [Mertens, Ulf Kai] Heidelberg Univ, Inst Psychol, Dept Quantitat Res Methods, Heidelberg, Germany; [Schmidt, Carsten Oliver] Univ Med Greifswald, Inst Community Med, SHIP KEF, Greifswald, Germany; [Chenot, Jean-Francois] Univ Med Greifswald, Inst Community Med, Dept Gen Practice, Greifswald, Germany; [Walker, Jochen] Ingef Inst Angew Gesundheitsforsch, Berlin, Germany	Reed Elsevier; Elsevier; Ruprecht Karls University Heidelberg; Greifswald Medical School; Greifswald Medical School	Chenot, JF (corresponding author), Univ Med Greifswald, Inst Community Med, Dept Gen Practice, Greifswald, Germany.	jchenot@uni-greifswald.de	Schmidt, Carsten Oliver/AAH-2778-2019; Chenot, Jean-Francois/F-8241-2011	Schmidt, Carsten Oliver/0000-0001-5266-9396; Chenot, Jean-Francois/0000-0001-8877-2950	Elsevier Health Analytics	Elsevier Health Analytics	JW was employed by Elsevier Health Analytics at the time of the study. UKM did a student clerkship and received a stipend from Elsevier Health Analytics. Elsevier Health Analytics provided support in the form of salaries for JW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham I, 2002, ARCH INTERN MED, V162, P1442, DOI 10.1001/archinte.162.13.1442; Andersohn F, 2016, PHARMACOEPIDEM DR S, V25, P106, DOI 10.1002/pds.3895; [Anonymous], 2011, NATL VERSORGUNGSLEIT; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Chento J-F, 2014, VERSORGUNGS REPORT 2, P155; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0; Chu E, 2005, WHO GUIDELINES BASIC; Cleland JA, 2009, SPINE, V34, P2720, DOI 10.1097/BRS.0b013e3181b48809; Eisenberg DM, 2007, SPINE, V32, P151, DOI 10.1097/01.brs.0000252697.07214.65; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Fritz JM, 2015, JAMA-J AM MED ASSOC, V314, P1459, DOI 10.1001/jama.2015.11648; Hayden JA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000335.pub2; Hidalgo B, 2014, J MAN MANIP THER, V22, P59, DOI 10.1179/2042618613Y.0000000041; Ho DE, 2001, J STAT SOFTW, V42, P1; Hoiriis KT, 2004, J MANIP PHYSIOL THER, V27, P388, DOI 10.1016/j.jmpt.2004.05.003; Kendrick D, 2005, BMJ-BRIT MED J, V322, P400; Kent P, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-22; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Maigne J. -Y., 2007, Annales de Readaptation et de Medecine Physique, V50, P111, DOI 10.1016/j.annrmp.2006.08.004; Michaleff ZA, 2012, J ELECTROMYOGR KINES, V22, P655, DOI 10.1016/j.jelekin.2012.02.011; National Collaborating Centre for Primary Care, 2009, LOW BACK PAIN EARL M; Oliphant D, 2004, J MANIP PHYSIOL THER, V27, P197, DOI 10.1016/j.jmpt.2003.12.023; Peat G, 2008, PAIN, V139, P483, DOI 10.1016/j.pain.2008.09.002; Pillastrini P, 2012, JOINT BONE SPINE, V79, P176, DOI 10.1016/j.jbspin.2011.03.019; Rubinstein SM, 2013, SPINE, V38, pE158, DOI 10.1097/BRS.0b013e31827dd89d; Stanton TR, 2010, EUR SPINE J, V19, P533, DOI 10.1007/s00586-009-1214-3; Team RC, 2014, R LANG ENV STAT COMP; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; VONKORFF M, 1994, SPINE, V19, pS2041	31	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2017	12	5							e0177255	10.1371/journal.pone.0177255	http://dx.doi.org/10.1371/journal.pone.0177255			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV0YN	28505161	Green Published, Green Submitted, gold			2023-01-03	WOS:000401473500016
J	de Lannoy, L; Clarke, J; Stotz, PJ; Ross, R				de lannoy, Louise; Clarke, John; Stotz, Paula J.; Ross, Robert			Effects of intensity and amount of exercise on measures of insulin and glucose: Analysis of inter-individual variability	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; ABDOMINAL OBESITY; TOLERANCE; RESISTANCE; REDUCTION	Aim To determine the separate effects of exercise amount and intensity on the rate of response for glucose and insulin variables, where rate of response was defined as the number of individuals with improvement in glucose and insulin values that was beyond the day-to-day variability of measurement. Methods Participants were 171 sedentary, middle-aged abdominally obese adults who completed a 24-week intervention. Participants were randomly assigned to (1) no-exercise control (n = 51), (2) low-amount, low-intensity exercise (LALI, n = 38), (3) high-amount, low-intensity exercise (HALI, n = 52), or (4) high-amount, high-intensity exercise (HAHI, n = 30). Two-hour glucose, insulin area under the curve (AUC), and fasting insulin were measured during a 2-hour, 75g oral glucose challenge. The day-to-day variability for these measures was calculated to be +/- 2.2 mmol/L, +/- 940.2 pmol/L, and +/- 38.9 pmol/L, respectively. Results At 24 weeks, the number of nonresponders for 2-hr glucose was 98.0%, 86.8%, 94.2%, 86.7% in the control, LALI, HALI, and HAHI groups, respectively. The number of nonresponders for insulin AUC was 88.0%, 75.7%, 75.0%, 80.0% in the control, LALI, HALI, and HAHI groups, respectively. The number of nonresponders for fasting insulin was 88.2%, 84.2%, 84.6%, 93.3% in the control, LALI, HALI, and HAHI groups, respectively. The rate of response was not different between control and any of the exercise groups for any measure (p>0.05). Conclusion The improvement in glucose and insulin measures did not exceed the day-to-day variability of measurement for approximately 80% of the participants independent of exercise amount or intensity.	[de lannoy, Louise; Clarke, John; Stotz, Paula J.; Ross, Robert] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada; [Ross, Robert] Queens Univ, Sch Med, Div Endocrinol & Metab, Kingston, ON, Canada	Queens University - Canada; Queens University - Canada	Ross, R (corresponding author), Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada.; Ross, R (corresponding author), Queens Univ, Sch Med, Div Endocrinol & Metab, Kingston, ON, Canada.	rossr@queensu.ca	Gonzalez, Javier T/K-6910-2014	Gonzalez, Javier T/0000-0002-9939-0074; Ross, Robert/0000-0001-6875-785X	Canadian Institutes of Health Research [OHN-63277]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by the Canadian Institutes of Health Research [grant OHN-63277; http://www.cihr-irsc.gc.ca]. RR received this funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agresti ACB, 2007, AM STAT, V52, P119; [Anonymous], 2015, DIABETES CARE, V38, pS20, DOI 10.2337/dc15-S007; [Anonymous], 2008, SERV UDOHAH; [Anonymous], 2014, NAT HLTH NUTR EXAM S; Bouchard C, 1998, MED SCI SPORT EXER, V30, P252, DOI 10.1097/00005768-199802000-00013; Bouchard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037887; Boule NG, 2005, DIABETES CARE, V28, P108, DOI 10.2337/diacare.28.1.108; Clarke J, 2016, MED SCI SPORTS EXERC; Dallman MF, 1995, ANN NY ACAD SCI, V771, P730, DOI 10.1111/j.1749-6632.1995.tb44724.x; Donga E, 2010, J CLIN ENDOCR METAB, V95, P2963, DOI 10.1210/jc.2009-2430; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Gurd BJ, 2016, APPL PHYSIOL NUTR ME, V41, P229, DOI 10.1139/apnm-2015-0449; Hecksteden A, 1985, J APPL PHYSL 1985, V118, P1450, DOI DOI 10.1152/JAPPLPHYSI0L.00714.2014; Hirsch S, 2013, NUTR HOSP, V28, P541, DOI 10.3305/nh.2013.28.2.6161; Hong YL, 1998, J CLIN ENDOCR METAB, V83, P4239, DOI 10.1210/jc.83.12.4239; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; Ranawana V, 2010, NUTR RES, V30, P246, DOI 10.1016/j.nutres.2010.02.004; Rankinen T, 2015, CIRC RES, V116, P909, DOI 10.1161/CIRCRESAHA.116.302888; Ross R, 2004, OBES RES, V12, P789, DOI 10.1038/oby.2004.95; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Ross R, 2015, MAYO CLIN PROC, V90, P1506, DOI 10.1016/j.mayocp.2015.07.024; Ross R, 2015, ANN INTERN MED, V162, P325, DOI 10.7326/M14-1189; Ross R, 2013, CONTEMP CLIN TRIALS, V34, P155, DOI 10.1016/j.cct.2012.10.010; Utzschneider KM, 2007, DIABETOLOGIA, V50, P2516, DOI 10.1007/s00125-007-0819-5; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; Vega-Lopez S, 2007, DIABETES CARE, V30, P1412, DOI 10.2337/dc06-1598	26	30	30	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2017	12	5							e0177095	10.1371/journal.pone.0177095	http://dx.doi.org/10.1371/journal.pone.0177095			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU8UP	28493912	Green Submitted, gold, Green Published			2023-01-03	WOS:000401314300059
J	Owen, LS; Manley, BJ; Davis, PG; Doyle, LW				Owen, Louise S.; Manley, Brett J.; Davis, Peter G.; Doyle, Lex W.			Neonatal intensive care 2 The evolution of modern respiratory care for preterm infants	LANCET			English	Article							LOW-BIRTH-WEIGHT; OXYGEN-SATURATION TARGETS; MESENCHYMAL STEM-CELLS; BRONCHOPULMONARY DYSPLASIA; DISTRESS-SYNDROME; CONTROLLED-TRIAL; PULSE OXIMETRY; HYDROCORTISONE THERAPY; DEXAMETHASONE THERAPY; GESTATIONAL-AGE	Preterm birth rates are rising, and many preterm infants have breathing difficulty after birth. Treatments for infants with prolonged breathing difficulty include oxygen therapy, exogenous surfactant, various modes of respiratory support, and postnatal corticosteroids. In this Series paper, we review the history of neonatal respiratory care and its effect on long-term outcomes, and we outline the future direction of the research field. The delivery and monitoring of oxygen therapy remains controversial, despite being in use for more than 50 years. Exogenous surfactant replacement has been used for 25 years and has dramatically reduced mortality and morbidity, but more research on when and how it is administered is needed. Methods and techniques of neonatal respiratory support are evolving. Clinicians are moving away from routine intubation and ventilation, and new modes of non-invasive support are being investigated. Postnatal corticosteroids have a limited role in infants with evolving bronchopulmonary dysplasia, but more research is needed to identify the best timing, type, dose, and method of administration. Despite advances in neonatal care in the past 50 years, bronchopulmonary dysplasia, with all its adverse short-term and long-term consequences, is still a serious problem in neonatal care. The challenge remains to support breathing in preterm infants, with special attention to risk factors in the subpopulation of infants that are at highest risk of bronchopulmonary dysplasia, without damaging their lungs or adversely affecting their long-term health.	[Owen, Louise S.; Manley, Brett J.; Davis, Peter G.] Royal Womens Hosp, Neonatal Serv, Melbourne, Vic, Australia; [Owen, Louise S.; Manley, Brett J.; Davis, Peter G.; Doyle, Lex W.] Royal Womens Hosp, Newborn Res Ctr, Melbourne, Vic 3052, Australia; [Owen, Louise S.; Manley, Brett J.; Davis, Peter G.; Doyle, Lex W.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Owen, Louise S.; Davis, Peter G.; Doyle, Lex W.] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic, Australia	University of Melbourne; Murdoch Children's Research Institute	Owen, LS (corresponding author), Royal Womens Hosp, Newborn Res Ctr, Melbourne, Vic 3052, Australia.	louise.owen@thewomens.org.au	Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312; Manley, Brett/0000-0003-0212-7956	Centre for Research Excellence grant [1060733]; NHMRC, Australia [606789, 1090678, 1088279]; NHMRC [1059111]; Victorian Government	Centre for Research Excellence grant; NHMRC, Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government	LWD and PGD are recipients of a Centre for Research Excellence grant (Grant no. 1060733) and a Program Grant (Grant no. 606789), from the NHMRC, Australia. LSO and BJM are recipients of Early Career Fellowships from the NHMRC, Australia (Grant numbers 1090678 and 1088279 respectively). PGD holds an NHMRC Practitioner Fellowship (Grant no. 1059111). LWD thanks the Victorian Government's Operational Infrastructure Support Program. These funding sources had no input into the design or preparation of this manuscript.	AAP Committee on Fetus and Newborn, 2012, GUID PER CAR, V7th; Ardell S, 2015, COCHRANE DB SYST REV, V5; Askie LM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-6; Askie LM, 2003, NEW ENGL J MED, V349, P959, DOI 10.1056/NEJMoa023080; AVERY ME, 1987, PEDIATRICS, V79, P26; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BADEN M, 1972, PEDIATRICS, V50, P526; Bassler D, 2015, NEW ENGL J MED, V373, P1497, DOI 10.1056/NEJMoa1501917; Baud O, 2016, LANCET, V387, P1827, DOI 10.1016/S0140-6736(16)00202-6; Bell EF, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000503.pub3; Bhuta T., 2000, COCHRANE DB SYST REV, V2; Blackmon LR, 2002, PEDIATRICS, V109, P330; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Chang YS, 2014, J PEDIATR-US, V164, P966, DOI 10.1016/j.jpeds.2013.12.011; Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189; ClinicalTrials. gov, 2015, EFF SAF EV PNEUM VER; Cools F., 2015, COCHRANE DB SYST REV, V3; Darlow BA, 2014, J PEDIATR-US, V165, P30, DOI 10.1016/j.jpeds.2014.01.017; Davis PG, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000143; De Luca D, 2016, ARCH DIS CHILD-FETAL, V101, pF565, DOI 10.1136/archdischild-2016-310664; De Paoli AG, 2008, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002977.PUB2; Doyle LW, 2006, PEDIATRICS, V118, P108, DOI 10.1542/peds.2005-2522; Doyle LW, 2014, J PEDIATR-US, V165, P1258, DOI 10.1016/j.jpeds.2014.07.049; Doyle LW, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001146.pub4; Doyle LW, 2010, NEONATOLOGY, V98, P111, DOI 10.1159/000279992; Doyle LW, 2009, SEMIN FETAL NEONAT M, V14, P391, DOI 10.1016/j.siny.2009.08.004; Doyle LW, 2006, PEDIATRICS, V117, P75, DOI 10.1542/peds.2004-2843; Ehrenkranz RA, 2005, PEDIATRICS, V116, P1353, DOI 10.1542/peds.2005-0249; EWERBECK H, 1972, PEDIATRICS, V49, P467; FITZHARDINGE PM, 1974, PEDIATRICS, V53, P877; FUJIWARA T, 1980, LANCET, V1, P55; Gibson AM, 2014, SEMIN FETAL NEONAT M, V19, P105, DOI 10.1016/j.siny.2013.10.006; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; Greenough A, 2008, COCHRANE DB SYST REV, V1; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; Gultom E, 1997, AUST NZ J OBSTET GYN, V37, P56, DOI 10.1111/j.1479-828X.1997.tb02218.x; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Halliday HL, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001145.pub2, 10.1002/14651858.CD001146.pub2]; Halliday HL, 2001, PRENAT NEONAT MED, V6, P371; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Hummler H, 2014, KLIN PADIATR, V226, P204, DOI 10.1055/s-0034-1375617; JACOBSEN T, 1993, ACTA PAEDIATR, V82, P934, DOI 10.1111/j.1651-2227.1993.tb12603.x; Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00001; Kajantie E, 2014, SEMIN FETAL NEONAT M, V19, P112, DOI 10.1016/j.siny.2013.11.006; Kanmaz HG, 2013, PEDIATRICS, V131, pE502, DOI 10.1542/peds.2012-0603; Kattwinkel John, 2004, J Perinatol, V24, P360, DOI 10.1038/sj.jp.7211103; KITCHEN WH, 1982, SEMIN PERINATOL, V6, P373; KLAUS MH, 1961, P NATL ACAD SCI USA, V47, P1858, DOI 10.1073/pnas.47.11.1858; Klingenberg C, 2011, ARCH DIS CHILD-FETAL, V96, pF146, DOI 10.1136/adc.2009.181081; Kotecha SJ, 2013, THORAX, V68, P760, DOI 10.1136/thoraxjnl-2012-203079; Lemyre B, 2014, COCHRANE DB SYST REV, V9; LIGGINS GC, 1972, PEDIATRICS, V50, P515; MAMMEL MC, 1983, LANCET, V1, P1356; Manley BJ, 2016, SEMIN FETAL NEONAT M, V21, P139, DOI 10.1016/j.siny.2016.01.002; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Mourani PM, 2013, CURR OPIN PEDIATR, V25, P329, DOI 10.1097/MOP.0b013e328360a3f6; Onland W, 2012, COCHRANE DB SYST REV, V4; Onland W, 2009, PEDIATRICS, V123, P367, DOI 10.1542/peds.2008-0016; Parad RB, 2015, NEONATOLOGY, V107, P241, DOI 10.1159/000369878; Pfister RH, 2007, COCHRANE DB SYST REV, V4; Phelps DL, 2000, PEDIATRICS, V105, P295; Pinheiro JMB, 2016, J PERINATOL, V36, P196, DOI 10.1038/jp.2015.177; Poindexter BB, 2015, ANN AM THORAC SOC, V12, P1822, DOI 10.1513/AnnalsATS.201504-218OC; RICHARD D, 1993, J PEDIATR-US, V123, P963, DOI 10.1016/S0022-3476(05)80395-6; Roberts CT, 2013, NEONATOLOGY, V104, P203, DOI 10.1159/000353448; Roberts CT, 2016, NEW ENGL J MED, V375, P1142, DOI 10.1056/NEJMoa1603694; Roberts G, 2014, SEMIN FETAL NEONAT M, V19, P118, DOI 10.1016/j.siny.2013.11.003; ROBERTSON B, 1988, PEDIATRICS, V82, P683; ROBILLARD E, 1964, CAN MED ASSOC J, V90, P55; Rojas-Reyes MX, 2015, COCHRANE DB SYST REV, V10; Schmidt B, 2006, NEW ENGL J MED, V354, P2112, DOI 10.1056/NEJMoa054065; Schmidt B, 2013, JAMA-J AM MED ASSOC, V309, P2111, DOI 10.1001/jama.2013.5555; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Second working group of the British Association of Perinatal Medicine, 1999, GUID GOOD PRACT MAN; Seger N, 2009, COCHRANE DB SYST REV, V2; Shah SS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002058.pub2; Shah SS, 2012, COCHRANE DB SYST REV, V5; Shah VS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001969.pub3; Singh N, 2015, COCHRANE DB SYST REV, V12; Soll R., 1998, COCHRANE DB SYST REV, V1998, DOI [10.1002/14651858.CD001149, DOI 10.1002/14651858.CD001149]; Soll RF, 1998, COCHRANE DB SYST REV, V2; Soll RF, 1997, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000511; Sood BG, 2015, SEMIN FETAL NEONAT M, V20, P164, DOI 10.1016/j.siny.2015.03.008; Sood BG, AEROSOLIZED SURFACTA; Stein H, 2013, J PERINATOL, V33, P452, DOI 10.1038/jp.2012.136; Stenson BJ, 2016, NEONATOLOGY, V109, P352, DOI 10.1159/000444913; Stenson BJ, 2013, NEW ENGL J MED, V368, P2094, DOI 10.1056/NEJMoa1302298; Stevens TP, 2007, COCHRANE DB SYST REV, V4; Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244; Sweet DG, 2013, NEONATOLOGY, V103, P353, DOI 10.1159/000349928; TAEUSCH HW, 1973, PEDIATRICS, V52, P850; Tang SF, 2013, INDIAN PEDIATR, V50, P371, DOI 10.1007/s13312-013-0122-0; Tarnow-Mordi W, 2016, NEW ENGL J MED, V374, P749, DOI 10.1056/NEJMoa1514212; Taylor S, 2016, BRONCHOPULMONARY DYS, P325; Thibeault DW, 2004, BIOL NEONATE, V85, P273, DOI 10.1159/000076388; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; van Zanten HA, 2015, EUR J PEDIATR, V174, P1561, DOI 10.1007/s00431-015-2643-0; Vaucher YE, 2012, NEW ENGL J MED, V367, P2495, DOI 10.1056/NEJMoa1208506; Walsh MC, 2006, PEDIATRICS, V118, pE1328, DOI 10.1542/peds.2006-0359; Watkin SL, 1999, J CLIN MONITOR COMP, V15, P441, DOI 10.1023/A:1009938225495; Wheeler K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003666.pub3; Wilkinson D, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006405.pub3; WILSON MG, 1960, AMA J DIS CHILD, V99, P489, DOI 10.1001/archpedi.1960.02070030491011; Rojas-Reyes MX, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000510.pub2; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Yeh TF, 2016, AM J RESP CRIT CARE, V193, P86, DOI 10.1164/rccm.201505-0861OC; Yoder BA, 2009, PEDIATRICS, V124, P673, DOI 10.1542/peds.2008-2793	108	72	73	1	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2017	389	10079					1649	1659		10.1016/S0140-6736(17)30312-4	http://dx.doi.org/10.1016/S0140-6736(17)30312-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ES5EK	28443559				2023-01-03	WOS:000399560000032
J	Chen, L; Li, CX; Guo, J; Luo, N; Qu, XY; Kang, L; Liu, MM; Cheng, ZP				Chen, Li; Li, Caixia; Guo, Jing; Luo, Ning; Qu, Xiaoyan; Kang, Le; Liu, Mingmin; Cheng, Zhongping			Eutopic/ectopic endometrial apoptosis initiated by bilateral uterine artery occlusion: A new therapeutic mechanism for uterus-sparing surgery in adenomyosis	PLOS ONE			English	Article							LAPAROSCOPIC BIPOLAR COAGULATION; ENDOPLASMIC-RETICULUM STRESS; SYMPTOMATIC ADENOMYOSIS; PARTIAL RESECTION; CELLS; MYOMECTOMY; EMBOLIZATION; VESSELS	The objective of the present study was to investigate differences in the expression of apoptosis-related factors in the eutopic and ectopic endometrium (EuE/EE) in women with adenomyosis before and after laparoscopic bilateral uterine artery occlusion (LUAO). Ten patients with uterine adenomyosis who received LUAO were selected as the research subjects, from whom EuE and EE tissues were obtained before and after LUAO and detected for the expression of apoptosis-related molecules in EuE and EE by PT-PCR and Western blot, and changes in the mitochondrial structure by electron microscopy. Normal endometrial stromal cells (NESC), and EuE/EE stromal cells in women with adenomyosis were cultured in a 1% O2, 5% CO2 incubator to establish a physical anoxia state in an in vitro stromal cell model. The expression of apoptosis-related molecules was observed at 0, 6, 12, 24 and 48h of hypoxic. The results showed that the expression of apoptosis-related factors in EuE and EE were increased significantly after LUAO and under hypoxic conditions in vitro, suggesting that transient ischemia and hypoxia were involved in the apoptosis of adenomysis lesions, and that uterine artery occlusion could remove adenomyosis lesions on tissue/cell level by cytoreduction, thus reaching the goal of treating adenomyosis effectively.	[Chen, Li; Li, Caixia; Guo, Jing; Luo, Ning; Qu, Xiaoyan; Kang, Le; Liu, Mingmin; Cheng, Zhongping] Tongji Univ, Yangpu Hosp, Dept Obstet & Gynaecol, Sch Med, Shanghai, Peoples R China; [Chen, Li; Li, Caixia; Guo, Jing; Luo, Ning; Qu, Xiaoyan; Kang, Le; Liu, Mingmin; Cheng, Zhongping] Tongji Univ, Sch Med, Inst Gynaecol Minimally Invas Med, Shanghai, Peoples R China	Tongji University; Tongji University	Cheng, ZP (corresponding author), Tongji Univ, Yangpu Hosp, Dept Obstet & Gynaecol, Sch Med, Shanghai, Peoples R China.; Cheng, ZP (corresponding author), Tongji Univ, Sch Med, Inst Gynaecol Minimally Invas Med, Shanghai, Peoples R China.	mdcheng18@263.net						Benagiano G, 2006, BEST PRACT RES CL OB, V20, P449, DOI 10.1016/j.bpobgyn.2006.01.007; Brozzi F, 2015, DIABETOLOGIA, V58, P2307, DOI 10.1007/s00125-015-3669-6; Cheng ZP, 2009, EUR J OBSTET GYN R B, V145, P113, DOI 10.1016/j.ejogrb.2009.03.027; Cheng ZP, 2008, J MINIM INVAS GYN, V15, P346, DOI 10.1016/j.jmig.2008.01.005; Dubuisson J, 2015, ARCH GYNECOL OBSTET, V291, P737, DOI 10.1007/s00404-014-3546-4; Exacoustos C, 2014, BEST PRACT RES CL OB, V28, P655, DOI 10.1016/j.bpobgyn.2014.04.010; Garcia L, 2011, J MINIM INVAS GYN, V18, P428, DOI 10.1016/j.jmig.2011.04.004; Grimbizis GF, 2014, FERTIL STERIL, V101, P472, DOI 10.1016/j.fertnstert.2013.10.025; Guo J, 2016, SCI REP-UK, V6, DOI 10.1038/srep21416; Jonas EA, 2009, EXP NEUROL, V218, P203, DOI 10.1016/j.expneurol.2009.03.025; Kang L, 2009, J MINIM INVAS GYN, V16, P169, DOI 10.1016/j.jmig.2008.12.003; Liu MM, 2014, EUR J OBSTET GYN R B, V176, P20, DOI 10.1016/j.ejogrb.2013.11.014; Liu WM, 2000, J AM ASSOC GYN LAP, V7, P125, DOI 10.1016/S1074-3804(00)80022-5; Liu WM, 2001, FERTIL STERIL, V75, P417, DOI 10.1016/S0015-0282(00)01724-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nijenhuis RJ, 2015, CARDIOVASC INTER RAD, V38, P65, DOI 10.1007/s00270-014-0878-1; Popovic M, 2011, J VASC INTERV RADIOL, V22, P901, DOI 10.1016/j.jvir.2011.03.013; Qu XY, 2010, J MINIM INVAS GYN, V17, P47, DOI 10.1016/j.jmig.2009.10.001; Shveiky D, 2009, FERTIL STERIL, V91, P575, DOI 10.1016/j.fertnstert.2007.12.001; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Xie Y, 2014, ARCH GYNECOL OBSTET, V289, P1039, DOI 10.1007/s00404-013-3100-9; Yang W, 2016, EUR J OBSTET GYN R B, V204, P9, DOI 10.1016/j.ejogrb.2016.05.033; Yang WH, 2014, EUR J OBSTET GYN R B, V174, P123, DOI 10.1016/j.ejogrb.2013.12.013; Zhang Y., 2014, ENV HLTH, V13, P13, DOI DOI 10.1109/TRUSTC0M.2014.42	24	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2017	12	4							e0175511	10.1371/journal.pone.0175511	http://dx.doi.org/10.1371/journal.pone.0175511			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0MB	28406930	Green Submitted, Green Published, gold			2023-01-03	WOS:000399955400064
J	Ahn, BS; Park, SY; Park, JM; Choi, CH; Chun, M; Kim, JI				Ahn, Beom Seok; Park, So-Yeon; Park, Jong Min; Choi, Chang Heon; Chun, Minsoo; Kim, Jung-in			Dosimetric effects of sectional adjustments of collimator angles on volumetric modulated arc therapy for irregularly-shaped targets	PLOS ONE			English	Article							PROSTATE-CANCER; TREATMENT PLANS; RADIOTHERAPY; IMRT; RAPIDARC; VMAT	Purpose To calculate an optimal collimator angle at each of sectional arcs in a full-arc volumetric modulated arc therapy (VMAT) plan and evaluate dosimetric quality of these VMAT plans comparing full-arc VMAT plans with a fixed collimator angle. Methods Seventeen patients who had irregularly-shaped target in abdominal, head and neck, and chest cases were selected retrospectively. To calculate an optimal collimator angle at each of sectional arcs in VMAT, integrated MLC apertures which could cover all shapes of target determined by beam's-eye view (BEV) within angular sections were obtained for each VMAT plan. The angular sections were 40 degrees, 60 degrees, 90 degrees and 120 degrees. When the collimator settings were rotated at intervals of 2 degrees, we obtained the optimal collimator angle to minimize area size difference between the integrated MLC aperture and collimator settings with 5 mm-margins to the integrated MLC aperture. The VMAT plans with the optimal collimator angles (Colli-VMAT) were generated in the Eclipse (TM). For comparison purposes, one full-arc VMAT plans with a fixed collimator angles (Std-VMAT) were generated. The dose-volumetric parameters and total MUs were evaluated. Results The mean dose-volumetric parameters for target volume of Colli-VMAT were comparable to Std-VMAT. Colli-VMAT improved sparing of most normal organs but for brain stem, compared to Std-VMAT for all cases. There were decreasing tendencies in mean total MUs with decreasing angular section. The mean total MUs for Colli-VMAT with the angular section of 40 degrees (434 +/- 95 MU, 317 +/- 81 MU, and 371 +/- 43 MU for abdominal, head and neck, and chest cases, respectively) were lower than those for Std-VMAT (654 +/- 182 MU, 517 +/- 116 MU, and 533 +/- 25 MU, respectively). Conclusions For an irregularly-shaped target, Colli-VMAT with the angular section of 40 degrees reduced total MUs and improved sparing of normal organs, compared to Std-VMAT.	[Ahn, Beom Seok; Park, So-Yeon; Park, Jong Min; Choi, Chang Heon; Chun, Minsoo; Kim, Jung-in] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; [Park, So-Yeon; Park, Jong Min; Choi, Chang Heon; Chun, Minsoo; Kim, Jung-in] Seoul Natl Univ, Biomed Res Inst, Coll Med, Seoul, South Korea; [Park, So-Yeon; Park, Jong Min; Choi, Chang Heon; Chun, Minsoo; Kim, Jung-in] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea; [Park, Jong Min] Adv Inst Convergence Technol, Ctr Convergence Res Robot, Suwon, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Kim, JI (corresponding author), Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea.	madangin@gmail.com	Chun, Minsoo/C-4493-2014	Chun, Minsoo/0000-0001-8578-9976	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2015R1C1A1A02036331]; National Research Foundation of Korea (NRF); Korean government (MEST) [2016M2A2A7952290]	National Research Foundation of Korea (NRF) - Korea government (MSIP)(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (no. 2015R1C1A1A02036331) and by a grant from the National Research Foundation of Korea (NRF), which is funded by the Korean government (MEST, grant no. 2016M2A2A7952290). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allisy A., 1993, J INT COMMISSION RAD, V26, DOI 10.1093/jicru/ndq001; Bortfeld T, 2009, PHYS MED BIOL, V54, pN9, DOI 10.1088/0031-9155/54/1/N02; Cozzi L, 2008, RADIOTHER ONCOL, V89, P180, DOI 10.1016/j.radonc.2008.06.013; de Boer J, 2015, INT J RADIAT ONCOL, V91, P1009, DOI 10.1016/j.ijrobp.2014.11.020; Fogliata A, 2008, RADIOTHER ONCOL, V89, P254, DOI 10.1016/j.radonc.2008.07.021; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Holtzer N, 2012, INT J RADIAT ONCOL, V84, pS28, DOI 10.1016/j.ijrobp.2012.07.079; Kim H, 2014, RADIAT ONCOL J, V32, P187, DOI 10.3857/roj.2014.32.3.187; Kim YS, 2016, RADIAT ONCOL J, V34, P18, DOI 10.3857/roj.2016.34.1.18; Kjaer-Kristoffersen F, 2009, ACTA ONCOL, V48, P227, DOI 10.1080/02841860802266748; Mattes MD, 2016, RADIAT ONCOL J, V34, P145, DOI 10.3857/roj.2015.01592; Ostheimer C, 2016, RADIAT ONCOL J, V34, P313, DOI 10.3857/roj.2016.01935; Otto K, 2008, MED PHYS, V35, P310, DOI 10.1118/1.2818738; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Paik EK, 2015, RADIAT ONCOL J, V33, P233, DOI 10.3857/roj.2015.33.3.233; Park JM, 2012, BRIT J RADIOL, V85, pE323, DOI 10.1259/bjr/19088580; Park JM, 2014, BRIT J RADIOL, P87; Park JM, 2012, MED PHYS, V39, P1265, DOI 10.1118/1.3682172; Park JM, 2011, J APPL CLIN MED PHYS, V12, P147, DOI 10.1120/jacmp.v12i4.3563; Schneider U, 2005, INT J RADIAT ONCOL, V61, P1510, DOI 10.1016/j.ijrobp.2004.12.040; 김동욱, 2013, [PROGRESS in MEDICAL PHYSICS, 의학물리], V24, P295, DOI 10.14316/pmp.2013.24.4.295; Treutwein M, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-108; Varian Medical Systems, 2015, ECL PHOT EL INST USE; Yoon M, 2010, INT J RADIAT ONCOL, V77, P1477, DOI 10.1016/j.ijrobp.2009.07.011; Zhang PP, 2010, INT J RADIAT ONCOL, V77, P591, DOI 10.1016/j.ijrobp.2009.08.056	25	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e0174924	10.1371/journal.pone.0174924	http://dx.doi.org/10.1371/journal.pone.0174924			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2QB	28384262	Green Published, Green Submitted, gold			2023-01-03	WOS:000399371900054
J	Twigg, MJ; Wright, D; Kirkdale, CL; Desborough, JA; Thornley, T				Twigg, Michael J.; Wright, David; Kirkdale, Charlotte L.; Desborough, James A.; Thornley, Tracey			The UK Pharmacy Care Plan service: Description, recruitment and initial views on a new community pharmacy intervention	PLOS ONE			English	Article							MEDICINES USE REVIEWS; PATIENT-CENTEREDNESS; MEDICATION; PERCEPTIONS; FRAMEWORK; SUPPORT	Introduction The UK government advocates person-centred healthcare which is ideal for supporting patients to make appropriate lifestyle choices and to address non-adherence. The Community Pharmacy Future group, a collaboration between community pharmacy companies and independents in the UK, introduced a person-centred service for patients with multiple long-term conditions in 50 pharmacies in Northern England. Objective Describe the initial findings from the set up and delivery of a novel community pharmacy-based person-centred service. Method Patients over fifty years of age prescribed more than one medicine including at least one for cardiovascular disease or diabetes were enrolled. Medication review and person-centred consultation resulted in agreed health goals and steps towards achieving them. Data were collated and analysed to determine appropriateness of patient recruitment process and quality of outcome data collection. A focus group of seven pharmacists was used to ascertain initial views on the service. Results Within 3 months of service initiation, 683 patients had baseline clinical data recorded, of which 86.9% were overweight or obese, 53.7% had hypertension and 80.8% had high cardiovascular risk. 544 (77.2%) patients set at least one goal during the first consultation with 120 (22.1%) setting multiple goals. A majority of patients identified their goals as improvement in condition, activity or quality of life. Pharmacists could see the potential patient benefit and the extended role opportunities the service provided. Allowing patients to set their own goals occasionally identified gaps to be addressed in pharmacist knowledge. Conclusion Pharmacists successfully recruited a large number of patients who were appropriate for such a service. Patients were willing to identify goals with the pharmacist, the majority of which, if met, may result in improvements in quality of life. While challenges in delivery were acknowledged, allowing patients to identify their own personalised goals was seen as a positive approach to providing patient services.	[Twigg, Michael J.; Wright, David; Desborough, James A.] Univ East Anglia, Sch Pharm, Norwich, Norfolk, England; [Kirkdale, Charlotte L.; Thornley, Tracey] Boots UK, Nottingham, England; [Thornley, Tracey] Univ Nottingham, Sch Pharm, Nottingham, England	University of East Anglia; University of Nottingham	Twigg, MJ (corresponding author), Univ East Anglia, Sch Pharm, Norwich, Norfolk, England.	m.twigg@uea.ac.uk	Desborough, James/ABF-5389-2020	Thornley, Tracey/0000-0002-9276-052X; Twigg, Michael/0000-0003-0910-3850; Desborough, James/0000-0001-5807-1731	Community Pharmacy Future (CPF) group; UEA	Community Pharmacy Future (CPF) group; UEA	The study design and implementation was funded by the Community Pharmacy Future (CPF) group. The CPF group designed and implemented the service and had sight and approved the submission to the journal. The CPF research team (CLK and TT) are both employees receiving salaries from Boots UK, and were part of the evaluation team who were involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. The CPF group also paid a consultancy fee to the team at UEA (MT, DW, JD) to provide advice on service design, to support training and to undertake the evaluation for this service. The specific roles of these authors are articulated in the 'author contributions' section.	Barber N, 2004, QUAL SAF HEALTH CARE, V13, P172, DOI 10.1136/qshc.2003.005926; BROWN JB, 1989, CAN FAM PHYSICIAN, V35, P153; Bryant LJM, 2009, RES SOC ADMIN PHARM, V5, P347, DOI 10.1016/j.sapharm.2009.01.002; Campion P, 2002, BRIT MED J, V325, P691, DOI 10.1136/bmj.325.7366.691; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Celino G, 2007, INT J PHARM PRACT, V15, pB20; Centre for Postgraduate Pharmacy Education, 2014, CONS SKILLS PHARM PR; Collins GS, 2012, BMJ, V344; Cramer JA, 2008, INT J CLIN PRACT, V62, P76, DOI 10.1111/j.1742-1241.2007.01630.x; Davey R, 2010, CONTEMP CLIN TRIALS, V31, P345, DOI 10.1016/j.cct.2010.04.002; Department of Health, 2010, EQ EXC LIB NHS; Elvey Rebecca, 2013, Int J Pharm Pract, V21, P322, DOI 10.1111/ijpp.12019; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; Harding G, 2010, PHARM WORLD SCI, V32, P381, DOI 10.1007/s11096-010-9381-1; Health and Social Care Information Centre, 2013, NAT DIAB AUD 2011 20; Health and Social Care Information Centre, 2014, QUAL OUTC FRAM QOF 2; Health Foundation, 2014, PERS CTR CAR MAD SIM; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hibbard JH, 2005, HEALTH SERV RES, V40, P1918, DOI 10.1111/j.1475-6773.2005.00438.x; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Krousel-Wood M, 2009, AM J MANAG CARE, V15, P59; Latif A, 2008, PHARM WORLD SCI, V30, P536, DOI 10.1007/s11096-008-9203-x; McDonald R, 2010, SOC SCI MED, V71, P451, DOI 10.1016/j.socscimed.2010.04.021; Mead N, 2002, SOC SCI MED, V55, P283, DOI 10.1016/S0277-9536(01)00171-X; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Morisky DE, 2011, J CLIN EPIDEMIOL, V64, P255, DOI 10.1016/j.jclinepi.2010.09.002; National Collaborating Centre for Primary Care National Institute for Health and Clinical Excellence, 2009, MED ADH INV PAT DEC; National Institute for Health and Clinical Excellence, 2011, HYP CLIN MAN PRIM HY; NICE, 2009, TYP 2 DIAB MAN TYP 2; NICE, 2014, LIP MOD CARD RISK AS; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; Pharmaceutical Services Negotiating Committee, 2013, PHARMOUTCOMES DEL EV; The King's Fund, 2012, VIS ACT MAK PAT CTR; Twigg MJ, 2015, INT J PHARM PRACT, V23, P407, DOI 10.1111/ijpp.12196; WESTON WW, 1989, CAN FAM PHYSICIAN, V35, P147; Wilcock M., 2007, PHARM J, V279, P501, DOI 10.1211/PJ.2009.10967873; Wright David, 2015, Int J Pharm Pract, V23, P36, DOI 10.1111/ijpp.12165	38	22	22	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2017	12	4							e0174500	10.1371/journal.pone.0174500	http://dx.doi.org/10.1371/journal.pone.0174500			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2IH	28369064	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000399351000018
J	Tan, SY; Baig, N; Hansapinyo, L; Jhanji, V; Wei, SH; Tham, CC				Tan, Shaoying; Baig, Nafees; Hansapinyo, Linda; Jhanji, Vishal; Wei, Shihui; Tham, Clement C.			Comparison of self-measured diurnal intraocular pressure profiles using rebound tonometry between primary angle closure glaucoma and primary open angle glaucoma patients	PLOS ONE			English	Article							GOLDMANN APPLANATION TONOMETER; VISUAL-FIELD PROGRESSION; RISK-FACTOR; MANAGEMENT; CHILDREN; INTERVENTION; FLUCTUATION; PERIMETRY; EYES	Purpose To document the diurnal intraocular pressure (IOP) profile with rebound tonometry performed by primary glaucoma patients in non-clinic environment. Patients and methods Fifty-three medically-treated eyes of 31 primary angle closure glaucoma (PACG) and 22 primary open angle glaucoma (POAG) patients with no previous eye surgery were recruited. Diurnal IOP was measured 5 times per day at four-hourly intervals from 08: 00 to 24: 00 for 1 week in patients' study eye using rebound tonometry in a non-clinic environment. The diurnal IOP profiles were compared between PACG and POAG eyes. Results For both PACG and POAG eyes, mean patient-measured IOP was highest in the morning, gradually decreased over the course of a day, and was lowest by midnight (p < 0.001). The diurnal IOP fluctuation +/- 1 standard deviation (SD), as documented by SD in daily IOP values, was lower in PACG group (1.6 +/- 1.1 mmHg) than in POAG group (2.0 +/- 1.2 mmHg; p = 0.049). The mean trough IOP +/- 1 SD was higher in PACG group (12.9 +/- 2.8 mmHg), compared to POAG group (11.5 +/- 3.8 mmHg; p = 0.041). The mean IOP level at midnight +/- 1 SD in PACG group (14.0 +/- 3.2 mmHg) was higher than that in POAG group (12.1 +/- 3.7 mmHg; p = 0.013). Conclusions IOP in primary glaucoma patients was highest in the morning, and decreased over the course of a day in non-clinic environment. Treated diurnal IOP fluctuation seemed to be greater in POAG than PACG eyes.	[Tan, Shaoying; Baig, Nafees; Hansapinyo, Linda; Jhanji, Vishal; Tham, Clement C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China; [Tan, Shaoying; Wei, Shihui] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China; [Baig, Nafees; Hansapinyo, Linda; Jhanji, Vishal; Tham, Clement C.] Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China; [Hansapinyo, Linda] Chiang Mai Univ, Dept Ophthalmol, Fac Med, Chiang Mai, Thailand; [Jhanji, Vishal; Tham, Clement C.] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese People's Liberation Army General Hospital; Chiang Mai University; Chinese University of Hong Kong; Prince of Wales Hospital	Tham, CC (corresponding author), Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.; Tham, CC (corresponding author), Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.; Tham, CC (corresponding author), Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.	clemtham@cuhk.edu.hk	Tan, Shaoying/T-6816-2019; Tham, Chee Yung Clement/AAD-6528-2020	Tham, Chee Yung Clement/0000-0003-4407-6907; Hansapinyo, Linda/0000-0002-4718-798X; Tan, Shaoying/0000-0001-9997-7396	Chinese University of Hong Kong	Chinese University of Hong Kong(Chinese University of Hong Kong)	This project is supported by Direct Grant for Research from the Chinese University of Hong Kong 2011-2012. The funding organization had no role in the design or conduct of this research	Anderson DR, 2000, AM J OPHTHALMOL, V130, P827, DOI 10.1016/S0002-9394(00)00665-6; Asrani S, 2000, J GLAUCOMA, V9, P134; Asrani S, 2011, J GLAUCOMA, V20, P74, DOI 10.1097/IJG.0b013e3181d78811; Baskaran M, 2009, OPHTHALMOLOGY, V116, P2300, DOI 10.1016/j.ophtha.2009.06.010; Caprioli J, 2008, OPHTHALMOLOGY, V115, P1123, DOI 10.1016/j.ophtha.2007.10.031; Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x; Choudhari NS, 2009, OPHTHALMOLOGY, V116, P3, DOI 10.1016/j.ophtha.2008.06.020; Coleman AL, 2008, SURV OPHTHALMOL, V53, pS3, DOI 10.1016/j.survophthal.2008.08.006; Dabasia PL, 2016, BRIT J OPHTHALMOL, V100, P1139, DOI 10.1136/bjophthalmol-2015-307674; DAVID R, 1992, BRIT J OPHTHALMOL, V76, P280, DOI 10.1136/bjo.76.5.280; DRANCE SM, 1963, ARCH OPHTHALMOL-CHIC, V70, P302, DOI 10.1001/archopht.1963.00960050304004; ELLIS CJK, 1981, BRIT J OPHTHALMOL, V65, P754, DOI 10.1136/bjo.65.11.754; Fischer N, 2013, OPHTHALMOLOGE, V110, P755, DOI 10.1007/s00347-012-2774-x; Flemmons MS, 2011, AM J OPHTHALMOL, V152, P470, DOI 10.1016/j.ajo.2011.03.001; Gandhi NG, 2012, AM J OPHTHALMOL, V154, P843, DOI 10.1016/j.ajo.2012.05.003; Grigorian F, 2012, J AAPOS, V16, P508, DOI 10.1016/j.jaapos.2012.07.004; Halkiadakis I, 2012, GRAEF ARCH CLIN EXP, V250, P1207, DOI 10.1007/s00417-011-1875-6; Heijl A, 2011, ACTA OPHTHALMOL, V89, P309, DOI 10.1111/j.1755-3768.2011.02169.x; Hsiao YC, 2012, J AAPOS, V16, P58, DOI 10.1016/j.jaapos.2011.10.005; Hughes E, 2003, J GLAUCOMA, V12, P232, DOI 10.1097/00061198-200306000-00009; Katavisto M, 1964, ACTA OPHTHALMOL S78, P71; Kim KN, 2013, ACTA OPHTHALMOL, V91, pE392, DOI 10.1111/aos.12109; KITAZAWA Y, 1975, AM J OPHTHALMOL, V79, P557, DOI 10.1016/0002-9394(75)90792-8; Kontiola AI, 2000, ACTA OPHTHALMOL SCAN, V78, P142, DOI 10.1034/j.1600-0420.2000.078002142.x; Lazzaro EC, 2013, J GLAUCOMA; Liu JHK, 2003, INVEST OPHTH VIS SCI, V44, P1586, DOI 10.1167/iovs.02-0666; NEWELL FW, 1965, AM J OPHTHALMOL, V59, P840, DOI 10.1016/0002-9394(65)93016-3; Nouri-Mahdavi K, 2004, OPHTHALMOLOGY, V111, P1627, DOI 10.1016/j.ophtha.2004.02.017; Poostchi A, 2009, CLIN EXP OPHTHALMOL, V37, P687, DOI 10.1111/j.1442-9071.2009.02109.x; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Sigle KJ, 2011, VET OPHTHALMOL, V14, P48, DOI 10.1111/j.1463-5224.2011.00913.x; Sihota R., 2005, Indian Journal of Ophthalmology, V53, P243; SMITH J, 1985, OPHTHALMOLOGY, V92, P858; Tan SY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42067; Tan SY, 2015, INVEST OPHTH VIS SCI, V56, P4994, DOI 10.1167/iovs.15-17245; Wilensky Jacob T, 2004, Curr Opin Ophthalmol, V15, P90, DOI 10.1097/00055735-200404000-00005; WILENSKY JT, 1993, OPHTHALMOLOGY, V100, P940; YAMAGAMI J, 1993, OPHTHALMOLOGY, V100, P643; ZARETSKAYA RB, 1948, AM J OPHTHALMOL, V31, P721, DOI 10.1016/S0002-9394(48)91920-5	39	10	10	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2017	12	3							e0173905	10.1371/journal.pone.0173905	http://dx.doi.org/10.1371/journal.pone.0173905			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8VS	28333942	Green Published, gold			2023-01-03	WOS:000399102200028
J	Bloomfield, HE; Greer, N; Kane, R; Wilt, TJ				Bloomfield, Hanna E.; Greer, Nancy; Kane, Robert; Wilt, Timothy J.			Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Bloomfield, Hanna E.; Greer, Nancy; Wilt, Timothy J.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Kane, Robert] Univ Minnesota, Minneapolis, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Bloomfield, HE (corresponding author), Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA.							Fung TT, 2008, ARCH INTERN MED, V168, P713, DOI 10.1001/archinte.168.7.713; Rees K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub2	2	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					378	379		10.7326/L16-0617	http://dx.doi.org/10.7326/L16-0617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265659				2023-01-03	WOS:000396432800019
J	Vallejo-Cardona, AA; Martinez-Palou, R; Chavez-Gomez, B; Garcia-Caloca, G; Guerra-Camacho, J; Ceron-Camacho, R; Reyes-Avila, J; Karamath, JR; Aburto, J				Adriana Vallejo-Cardona, Alba; Martinez-Palou, Rafael; Chavez-Gomez, Benjamin; Garcia-Caloca, Graciela; Guerra-Camacho, Jairo; Ceron-Camacho, Ricardo; Reyes-Avila, Jesus; Robert Karamath, James; Aburto, Jorge			Demulsification of crude oil-in-water emulsions by means of fungal spores	PLOS ONE			English	Article							DEMULSIFYING EFFICIENCY; SEQUENCE ALIGNMENT; DE-EMULSIFICATION; ENHANCEMENT; INTERFACE; BREAKING; BACTERIA	The present feature describes for the first time the application of spores from Aspergillus sp. IMPMS7 to break out crude oil-in-water emulsions (O/W). The fungal spores were isolated from marine sediments polluted with petroleum hydrocarbons. The spores exhibited the ability to destabilize different O/W emulsions prepared with medium, heavy or extra-heavy Mexican crude oils with specific gravities between 10.1 and 21.2 degrees API. The isolated fungal spores showed a high hydrophobic power of 89.3 +/- 1.9% and with 2 g of spores per liter of emulsion, the half-life for emulsion destabilization was roughly 3.5 and 0.7 h for extra-heavy and medium crude oil, respectively. Then, the kinetics of water separation and the breaking of the O/W emulsion prepared with heavy oil through a spectrofluorometric technique were studied. A decrease in the fluorescence ratio at 339 and 326 nm (I339/I326) was observed in emulsions treated with spores, which is similar to previously reported results using chemical demulsifiers.	[Adriana Vallejo-Cardona, Alba] CONACYT Ctr Invest & Asistencia Tecnol & Diseno E, Ave Normalistas 800, Guadalajara, Jalisco, Mexico; [Martinez-Palou, Rafael; Chavez-Gomez, Benjamin; Garcia-Caloca, Graciela; Guerra-Camacho, Jairo; Ceron-Camacho, Ricardo; Reyes-Avila, Jesus; Robert Karamath, James; Aburto, Jorge] Inst Mexicano Petr, Direcc Invest Transformac Hidrocarburos, Gerencia Transformac Biomasa, Eje Cent Lazaro Cardenas Norte 152, Mexico City, DF, Mexico	Instituto Mexicano del Petroleo	Aburto, J (corresponding author), Inst Mexicano Petr, Direcc Invest Transformac Hidrocarburos, Gerencia Transformac Biomasa, Eje Cent Lazaro Cardenas Norte 152, Mexico City, DF, Mexico.	jaburto@imp.mx	Aburto, Jorge/B-4600-2009; Aburto, Jorge/AAR-7902-2021; Cerón-Camacho, Ricardo/I-4167-2017; Cerón-Camacho, Ricardo/P-1868-2019; Cardona, Alba Adriana Vallejo/G-8039-2019; Martinez-Palou, Rafael/O-1737-2019	Aburto, Jorge/0000-0002-8282-6046; Cerón-Camacho, Ricardo/0000-0003-2757-4963; Cerón-Camacho, Ricardo/0000-0003-2757-4963; Cardona, Alba Adriana Vallejo/0000-0002-4568-3787; Martinez-Palou, Rafael/0000-0003-3598-7207	Instituto Mexicano del Petroleo [D.60016]; IMP [D.60016 (D.01225)]	Instituto Mexicano del Petroleo; IMP	The authors thank Instituto Mexicano del Petroleo for the financial support provided through the project D.60016.; The Authors thank financial support from IMP through project D.60016 (D.01225).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; American Public Health Association, 2012, INDIAN J ENV SCI, V22nd; Bai N, ENV SCI POLLUT RES; Coutinho JOPA, 2013, BIORESOURCE TECHNOL, V128, P646, DOI 10.1016/j.biortech.2012.09.137; Dalmazzone C, 2009, OIL GAS SCI TECHNOL, V64, P543, DOI 10.2516/ogst:2008041; Das M, 2001, BIORESOURCE TECHNOL, V79, P15, DOI 10.1016/S0960-8524(01)00039-6; Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259; Henderson SB, 1999, MAR POLLUT BULL, V38, P1141, DOI 10.1016/S0025-326X(99)00144-7; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Hou N, 2014, ENVIRON SCI POLLUT R, V21, P10386, DOI 10.1007/s11356-014-2931-7; Huang XF, 2009, BIORESOURCE TECHNOL, V100, P1358, DOI 10.1016/j.biortech.2008.08.004; Imhof A, 1999, J PHYS CHEM B, V103, P1408, DOI 10.1021/jp983241q; JANIYANI KL, 1994, WORLD J MICROB BIOT, V10, P452, DOI 10.1007/BF00144471; Larone DH, 2012, MED IMPORTANT FUNGI; Li X, 2012, PROCESS BIOCHEM, V47, P626, DOI 10.1016/j.procbio.2012.01.004; Martinez-Palou R, 2011, J PETROL SCI ENG, V75, P274; Martinez-Palou R, 2015, IONIC LIQUIDS - CURRENT STATE OF THE ART, P305, DOI 10.5772/59094; Martinez-Palou R, 2015, CHEM ENG PROCESS, V98, P112, DOI 10.1016/j.cep.2015.09.014; Martinez-Palou R, 2013, FUEL, V113, P407, DOI 10.1016/j.fuel.2013.05.094; Mohebali G, 2012, COLLOID SURFACE B, V98, P120, DOI 10.1016/j.colsurfb.2012.04.037; Mullins OC, 2008, SPE J, V13, P48, DOI 10.2118/95801-PA; Murillo-Hernandez JA, 2009, ENERG FUEL, V23, P4584, DOI 10.1021/ef9004175; Nadarajah N, 2002, WORLD J MICROB BIOT, V18, P435, DOI 10.1023/A:1015517308905; Park SH, 2000, BIOTECHNOL LETT, V22, P1389, DOI 10.1023/A:1005660901558; ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1016/0378-1097(80)90106-8; Soca-Chafre G, 2011, FUNGAL BIOL-UK, V115, P143, DOI 10.1016/j.funbio.2010.11.004; Steffens J, 2011, J FLUORESC, V21, P859, DOI 10.1007/s10895-009-0586-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres E, 2005, ARCH BIOCHEM BIOPHYS, V437, P224, DOI 10.1016/j.abb.2005.03.006	29	9	9	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0170985	10.1371/journal.pone.0170985	http://dx.doi.org/10.1371/journal.pone.0170985			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28234917	Green Published, gold, Green Submitted			2023-01-03	WOS:000394688200015
J	Kimaro, GD; Mfinanga, S; Simms, V; Kivuyo, S; Bottomley, C; Hawkins, N; Harrison, TS; Jaffar, S; Guinness, L				Kimaro, Godfather Dickson; Mfinanga, Sayoki; Simms, Victoria; Kivuyo, Sokoine; Bottomley, Christian; Hawkins, Neil; Harrison, Thomas S.; Jaffar, Shabbar; Guinness, Lorna		REMSTART Trial Team	The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies	PLOS ONE			English	Article							SOUTH-AFRICA; MORTALITY; DELIVERY; PROGRAM; DURBAN	Background Understanding the costs associated with health care delivery strategies is essential for planning. There are few data on health service resources used by patients and their associated costs within antiretroviral (ART) programmes in Africa. Material and methods The study was nested within a large trial, which evaluated screening for cryptococcal meningitis and tuberculosis and a short initial period of home-based adherence support for patients initiating ART with advanced HIV disease in Tanzania and Zambia. The economic evaluation was done in Tanzania alone. We estimated costs of providing routine ART services from the health service provider's perspective using a micro-costing approach. Incremental costs for the different novel components of service delivery were also estimated. All costs were converted into US dollars (US$) and based on 2012 prices. Results Of 870 individuals enrolled in Tanzania, 434 were enrolled in the intervention arm and 436 in the standard care/control arm. Overall, the median (IQR) age and CD4 cell count at enrolment were 38 [31, 44] years and 52 [20, 89] cells/mm3, respectively. The mean per patient costs over the first three months and over a one year period of follow up following ART initiation in the standard care arm were US$ 107 (95%CI 101-112) and US$ 265 (95%CI 254-275) respectively. ART drugs, clinic visits and hospital admission constituted 50%, 19%, and 19% of the total cost per patient year, while diagnostic tests and non-ART drugs (co-tri-moxazole) accounted for 10% and 2% of total per patient year costs. The incremental costs of the intervention to the health service over the first three months was US$ 59 (p<0.001; 95%CI 52-67) and over a one year period was US$ 67(p<0.001; 95%CI 50-83). This is equivalent to an increase of 55% (95%CI 51%-59%) in the mean cost of care over the first three months, and 25% (95%CI 20%-30%) increase over one year of follow up.	[Kimaro, Godfather Dickson; Mfinanga, Sayoki; Kivuyo, Sokoine] Natl Inst Med Res, Muhimbili Med Res Ctr, Dar Es Salaam, Tanzania; [Kimaro, Godfather Dickson; Simms, Victoria; Bottomley, Christian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Hawkins, Neil; Guinness, Lorna] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England; [Harrison, Thomas S.] St Georges Univ London, Inst Infect & Immun, London, England; [Jaffar, Shabbar] Univ Liverpool Liverpool Sch Trop Med, Dept Int Publ Hlth, Liverpool, Merseyside, England	National Institute of Medical Research; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; St Georges University London; Liverpool School of Tropical Medicine	Kimaro, GD (corresponding author), Natl Inst Med Res, Muhimbili Med Res Ctr, Dar Es Salaam, Tanzania.; Kimaro, GD (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.	fatherdk@yahoo.com	Simms, Victoria/AAU-4134-2021; Guinness, Lorna/AAN-3875-2020; Simms, Victoria/C-3278-2009	Simms, Victoria/0000-0002-4897-458X; Harrison, Thomas/0000-0003-3619-4348; Guinness, Lorna/0000-0002-1013-4200; Bottomley, Christian/0000-0002-5241-8412; Kivuyo, Sokoine Lesikari/0000-0003-2257-5254; Hawkins, Neil/0000-0003-3199-221X; Jaffar, Shabbar/0000-0002-9615-1588	European and Developing Countries Clinical Trials Partnership [IP.2009.33011.003]; HIV Research Trust Scholarship [HIVRT15-008]; Medical Research Council [MR/K012126/1] Funding Source: researchfish	European and Developing Countries Clinical Trials Partnership; HIV Research Trust Scholarship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was nested within the REMSTART trial which was funded by the European and Developing Countries Clinical Trials Partnership (IP.2009.33011.003). GDK received a scholarship from HIV Research Trust Scholarship (HIVRT15-008) for his course on economic evaluation and attachment with experienced researchers at London School of Hygiene and Tropical Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliyu HB, 2012, JAIDS-J ACQ IMM DEF, V61, P221, DOI 10.1097/QAI.0b013e3182683b04; Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Bank of Tanzania, 2012, EXCH RAT; Bank of Tanzania, 2012, THE TREAS BOND; Bassett IV, 2010, AIDS, V24, pS37, DOI 10.1097/01.aids.0000366081.91192.1c; Beck EJ, 2010, CURR OPIN HIV AIDS, V5, P215, DOI 10.1097/COH.0b013e32833860e9; Bratt JH, 2011, TROP MED INT HEALTH, V16, P110, DOI 10.1111/j.1365-3156.2010.02640.x; Cianci F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100107; Frick KD, 2009, MED CARE, V47, pS76, DOI 10.1097/MLR.0b013e31819bc064; Frontieres MS, 2013, UNTANGLING WEB ANTIR; Galarraga O, 2011, PHARMACOECONOMICS, V29, P579, DOI 10.2165/11586120-000000000-00000; Gray A., 2011, APPL METHODS COST EF; Ingle SM, 2010, AIDS, V24, P2717, DOI 10.1097/QAD.0b013e32833fb71f; Ingle SM, 2010, SAMJ S AFR MED J, V100, P675, DOI 10.7196/SAMJ.3952; Institute for Quality and Efficiency in Health Care, 2009, WORK PAP COST EST; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; James C, 2013, COSTS DELIVERING HLT; Kirkwood Betty R, 2003, ESSENTIAL MED STAT; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Larson BA, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18026; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Long L, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001055; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Loubiere S, 2008, ANTIVIR THER, V13, P241; Marseille E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051993; Menzies NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048726; Mfinanga S, 2015, LANCET, V6736, P1; National Bureau of Statistics, 2013, UN REP TANZ POP DIST; National Bureau of Statistics, 2013, HIV AIDS MAL IND SUR; Rosen S, 2008, TROP MED INT HEALTH, V13, P1005, DOI 10.1111/j.1365-3156.2008.02114.x; Scott CA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-296; Siapka M, 2014, B WORLD HEALTH ORGAN, V92, P499, DOI 10.2471/BLT.13.127639; The United Republic of Tanzania, 2012, REPORT LAW MARRIAGE; UNAIDS, 2011, WORKB COLL COST INF; UNAIDS, 2016, GLOB REP GLOB AIDS E; Vassall A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001120; World Bank, GDP DEFL; World Health Organisation, 2013, WHO CONS GUID US ANT	38	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0171917	10.1371/journal.pone.0171917	http://dx.doi.org/10.1371/journal.pone.0171917			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28234969	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000394688200038
J	Santos, JA; Piccinelli, AC; Formagio, MD; Oliveira, CS; dos Santos, EP; Stefanello, MEA; Lanza, U; Oliveira, RJ; Sugizaki, MM; Kassuya, CAL				Santos, Joyce Alencar; Piccinelli, Ana Claudia; Formagio, Maira Dante; Oliveira, Cristhian Santos; dos Santos, Elide Pereira; Alves Stefanello, Maria Elida; Lanza Junior, Ubirajara; Oliveira, Rodrigo Juliano; Sugizaki, Mario Mateus; Kassuya, Caandida Aparecida Leite			Antidepressive and antinociceptive effects of ethanolic extract and fruticuline A from Salvia lachnostachys Benth leaves on rodents	PLOS ONE			English	Article							NEUROPATHIC PAIN; MICE; MODEL	Objectives This study investigated the antidepressant and antinociceptive effects of ethanolic extract (SLEE) and pure fruticuline A obtained from Salvia lachnostachys leaves on rats and mice. Methods In this study, SLEE (100 mg/kg, p. o. route) was evaluated for its effects on spared nerve injury (SNI) in rats. The animals were submitted to mechanical sensitivity, forced swim (FST) and cold sensitivity tests 10 and 15 days after surgery. SLEE (100 mg/kg, p. o.) and fruticuline A (3 mg/kg, p. o.) were also evaluated with respect to nociceptive behavior induced by formalin. In addition, clonidine-induced depressive-like behavior was also analyzed. Results The oral administration of SLEE for up to 15 days and the subcutaneous injection of 10 mg/ kg of ketamine (positive control) significantly inhibited SNI-induced mechanical hyperalgesia and decreased immobility in the FST. On the 15th day of oral treatment, SLEE prevented the SNI-induced increase in cold sensitivity. In the formalin test, SLEE and fruticuline A significantly reduced the frequency of paw licking during the first and second phases and decreased the formation of edema. In locomotor analysis (open field test without clonidine treatment), SLEE and fruticuline A did not alter the response. SLEE and fruticuline A significantly attenuated clonidine-induced suppression of spontaneous locomotor activity (squares invaded and licking) and emotionality (grooming and freezing) compared with controls, similar to the naive group. Conclusion SLEE exhibits antihyperalgesic, antidepressant, and antinociceptive effects, and fruticuline A appears to be at least partly responsible for the effects of SLEE. Together, these results demonstrate the antidepressive effects of SLEE and fruticuline A and indicate that both derivatives obtained from S. lachnostachys act against spontaneous neuropathic pain.	[Santos, Joyce Alencar] Fed Univ Grande Dourados, Coll Exact Sci & Technol, Dourados, MS, Brazil; [Piccinelli, Ana Claudia; Formagio, Maira Dante; Lanza Junior, Ubirajara; Kassuya, Caandida Aparecida Leite] Fed Univ Grande Dourados, Coll Hlth Sci, Dourados, MS, Brazil; [Oliveira, Cristhian Santos; Alves Stefanello, Maria Elida] Univ Fed Parana, Dept Chem, Curitiba, PR, Brazil; [dos Santos, Elide Pereira] Univ Fed Parana, Dept Bot, Curitiba, PR, Brazil; [Oliveira, Rodrigo Juliano] Univ Fed Mato Grosso do Sul, Coll Hlth Sci, Campo Grande, MS, Brazil; [Sugizaki, Mario Mateus] Univ Fed Mato Grosso, Coll Hlth Sci, Sinop, MT, Brazil	Universidade Federal da Grande Dourados; Universidade Federal da Grande Dourados; Universidade Federal do Parana; Universidade Federal do Parana; Universidade Federal de Mato Grosso do Sul; Universidade Federal de Mato Grosso	Santos, JA (corresponding author), Fed Univ Grande Dourados, Coll Exact Sci & Technol, Dourados, MS, Brazil.	joycealencarr@hotmail.com	Oliveira, Cristhian/AAU-9118-2020; Kassuya, Candida A. L./G-8329-2011; Oliveira, Rodrigo Juliano/M-3151-2018; Radai, Joyce Alencar Santos/AAF-2906-2019; LANZA, Ubirajara Lanza Jr ULJ/D-3691-2017; Oliveira, Rodrigo Juliano/AGQ-6655-2022; Oliveira, Rodrigo/D-9982-2013; sugizaki, mario/AAM-9904-2020; Santos, Elide/C-5841-2013	Oliveira, Rodrigo Juliano/0000-0003-3514-3346; LANZA, Ubirajara Lanza Jr ULJ/0000-0001-5461-3177; Oliveira, Rodrigo Juliano/0000-0003-3514-3346; Santos, Elide/0000-0002-8600-3039; Kassuya, Candida/0000-0002-8998-9219; Oliveira, Cristhian/0000-0001-5620-393X; Dante Formagio, Maira/0000-0003-0616-3305	Fundacao de Amparo a Pesquisa do Estado do Mato Grosso do Sul (FUNDECT) [45/2014, 23/200.622/2014]	Fundacao de Amparo a Pesquisa do Estado do Mato Grosso do Sul (FUNDECT)	The authors thank the Fundacao de Amparo a Pesquisa do Estado do Mato Grosso do Sul (FUNDECT) for financial support, through the projects FUNDECT/CAPES no 45/2014 - PAPOS REDE PRO-CENTRO-OESTE EASE II - No 23/200.622/2014 and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Rodrigues MRA, 2012, J ETHNOPHARMACOL, V139, P519, DOI 10.1016/j.jep.2011.11.042; Barauna SC, 2006, PHARMACOL BIOCHEM BE, V85, P160, DOI 10.1016/j.pbb.2006.07.030; Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5; Bisio A, 2008, J AGR FOOD CHEM, V56, P10468, DOI 10.1021/jf802200x; Bongiorno P, 2010, NAT MED J, V2, P3; Bourquin AF, 2006, PAIN, V122, P14, DOI 10.1016/j.pain.2005.10.036; Boyce-Rustay JM, 2010, METHODS MOL BIOL, V617, P41, DOI 10.1007/978-1-60327-323-7_4; Braida D, 2009, BRIT J PHARMACOL, V157, P844, DOI 10.1111/j.1476-5381.2009.00230.x; de Almeida AAC, 2014, PHARMACOL BIOCHEM BE, V118, P69, DOI 10.1016/j.pbb.2014.01.006; Chang CY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/159015; Colla ARS, 2014, PHARMACOL BIOCHEM BE, V124, P108, DOI 10.1016/j.pbb.2014.05.015; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Erbano M, 2012, MICROSC RES TECHNIQ, V75, P1737, DOI 10.1002/jemt.22125; Gonzalez-Cortazar M, 2013, MOLECULES, V18, P13260, DOI 10.3390/molecules181113260; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; Ito S, 2001, NEUROSCI RES, V41, P299, DOI 10.1016/S0168-0102(01)00289-9; Jung HJ, 2009, J ETHNOPHARMACOL, V126, P355, DOI 10.1016/j.jep.2009.08.031; Kassuya CAL, 2009, J ETHNOPHARMACOL, V124, P369, DOI 10.1016/j.jep.2009.06.003; Maletic V, 2009, FRONT BIOSCI-LANDMRK, V14, P5291, DOI 10.2741/3598; Marcus DJ, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0031-4; Oliveira CS, 2016, PHYTOCHEM LETT, V17, P140, DOI 10.1016/j.phytol.2016.07.005; Piccinelli AC, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/835914; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Reuben SS, 1998, ANESTHESIOLOGY, V89, P527, DOI 10.1097/00000542-199808000-00034; Sagheddu C, 2015, NEUROPHARMACOLOGY, V97, P383, DOI 10.1016/j.neuropharm.2015.06.003; Snedecor SJ, 2013, J PAIN RES, V6, P539, DOI 10.2147/JPR.S45966; Walker JB, 2007, ANN BOT-LONDON, V100, P375, DOI 10.1093/aob/mcl176; Wang J, 2011, ANESTHESIOLOGY, V115, P812, DOI 10.1097/ALN.0b013e31822f16ae; Xu B, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-15; Yang LM, 2014, BRAIN RES BULL, V100, P22, DOI 10.1016/j.brainresbull.2013.10.007; Zaki H. F., 2013, African Journal of Pharmacy and Pharmacology, V7, P2960	31	13	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2017	12	2							e72151	10.1371/journal.pone.0172151	http://dx.doi.org/10.1371/journal.pone.0172151			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5QV	28222143	gold, Green Submitted, Green Published			2023-01-03	WOS:000394676800035
J	Collins, FS; Fleming, R				Collins, Francis S.; Fleming, Renee			Sound Health An NIH-Kennedy Center Initiative to Explore Music and the Mind	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERFORMANCE; HYPOTHESIS; SPEECH		[Collins, Francis S.] NIH, Bldg 10, Bethesda, MD 20892 USA; [Fleming, Renee] John F Kennedy Ctr Performing Arts, Washington, DC USA	National Institutes of Health (NIH) - USA	Collins, FS (corresponding author), NIH, Off Director, One Ctr Dr, Bethesda, MD 20892 USA.	collinsf@mail.nih.gov						[Anonymous], 2011, ARTS HUM DEV LEARN L; Bailey JA, 2014, J COGNITIVE NEUROSCI, V26, P755, DOI 10.1162/jocn_a_00527; Hallam S, 2010, INT J MUSIC EDUC, V28, P269, DOI 10.1177/0255761410370658; Limb CJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001679; Moreno S, 2011, PSYCHOL SCI, V22, P1425, DOI 10.1177/0956797611416999; Norman-Haignere S, 2015, NEURON, V88, P1281, DOI 10.1016/j.neuron.2015.11.035; Patel AD, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00142; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; Schlaug G, 2015, PROG BRAIN RES, V217, P37, DOI 10.1016/bs.pbr.2014.11.020	9	13	13	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2017	317	24					2470	2471		10.1001/jama.2017.7423	http://dx.doi.org/10.1001/jama.2017.7423			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	EY6PV	28586832	Green Published			2023-01-03	WOS:000404106600001
J	Bennett, AS; Golub, A; Elliott, L				Bennett, Alex S.; Golub, Andrew; Elliott, Luther			A behavioral typology of opioid overdose risk behaviors among recent veterans in New York City	PLOS ONE			English	Article							LATENT CLASS ANALYSIS; CENTERED MEDICAL HOME; HEROIN OVERDOSE; SUBSTANCE USE; HEALTH-CARE; DRUG-USE; NONFATAL OVERDOSE; PEER SUPPORT; ABUSE; VALIDATION	Objective To identify meaningful classes of opioid-using military veterans in terms of self-reported opioid overdose risk behaviors. Method The study recruited a sample of 218 military veterans in the NYC area who were discharged from active duty service after September 11, 2001 and reported past-month opioid use. Survey data including measures of mental health, social stressors, substance use, and opioid-related overdose risk behaviors were analyzed using Latent Class Analysis (LCA). Results A five group solution had excellent fit scores and interpretability. Factor analysis confirmed the existence of two major dimensions of variation: non-adherence and heroin use. The five groups included lower-risk prescription opioid users, non-adherent prescription opioid users and heroin users. The non-adherent prescription opioid users and heroin user classes were both further subdivided into "occasional" and "regular" use categories. In addition to endorsing a greater number of overdose risk behaviors, users in the regular use classes were more likely to screen positive for alcohol and substance use disorders, reported greater self-medicating opioid use to relieve anxiety, reported greater problems with physical pain, were more likely to have had mental health, alcohol and drug treatment, and were less likely to be employed or in school. Heroin users also were less likely to report stable housing. Conclusions Findings indicate that opioid overdose risk classes are grounded in contextual factors related to experiences of psychological, physiological, and social adjustment pain and distress which should be addressed in tailored interventions targeting opioid users' unique constellations of risk behaviors and comorbid conditions.	[Bennett, Alex S.; Golub, Andrew; Elliott, Luther] Natl Dev & Res Inst Inc, New York, NY 10013 USA; [Bennett, Alex S.; Elliott, Luther] NYU, Rory Meyers Coll Nursing, Ctr Drug Use & HIV HCV Res, New York, NY 10003 USA	National Development & Research Institutes, Inc; New York University	Bennett, AS (corresponding author), Natl Dev & Res Inst Inc, New York, NY 10013 USA.; Bennett, AS (corresponding author), NYU, Rory Meyers Coll Nursing, Ctr Drug Use & HIV HCV Res, New York, NY 10003 USA.	Bennett@ndri.org			National Institutes of Health, National Institute on Drug Abuse [NIH R01 DA 036754]	National Institutes of Health, National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	Dr. Bennett's current project is a 4-year study of Opioid Use/Misuse and Overdose Risk among veterans (R01DA036754) that will help determine ecological, structural, and psychosocial aspects of opioid use and overdose risk. Funding for this project is provided by the National Institutes of Health, National Institute on Drug Abuse, awarded to Dr. Alex S. Bennett - (NIH R01 DA 036754). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2007, ADDICTION, V102, P94, DOI 10.1111/j.1360-0443.2006.01630.x; [Anonymous], 2002, ADDICT DISORD TREAT; Army US. Army, 2020, ARM 2020 GEN HLTH DI; Ashbury FD, 1998, PATIENT EDUC COUNS, V35, P89, DOI 10.1016/S0738-3991(98)00035-4; Barber JA, 2008, COMMUNITY MENT HLT J, V44, P433, DOI 10.1007/s10597-008-9146-7; Bennett AS, 2013, SUBST USE MISUSE, V48, P894, DOI 10.3109/10826084.2013.796991; Bergen-Cico DK., 2011, WAR DRUGS ROLE MILIT; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Bohnert ASB, 2012, AM J PSYCHIAT, V169, P64, DOI 10.1176/appi.ajp.2011.10101476; Britton PC, 2010, DRUG ALCOHOL DEPEN, V107, P51, DOI 10.1016/j.drugalcdep.2009.09.005; Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; Butler SF, 2010, CLIN J PAIN, V26, P770, DOI 10.1097/AJP.0b013e3181f195ba; Carlson RG, 2005, DRUG ALCOHOL DEPEN, V79, P167, DOI 10.1016/j.drugalcdep.2005.01.011; Cleeland C. S., 2009, BRIEF PAIN INVENTORY; Connell CM, 2009, J STUD ALCOHOL DRUGS, V70, P943, DOI 10.15288/jsad.2009.70.943; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Darke S, 2005, DRUG ALCOHOL REV, V24, P425, DOI 10.1080/09595230500286005; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Ferrante JM, 2010, ANN FAM MED, V8, P108, DOI 10.1370/afm.1080; Frank D, 2015, INT J DRUG POLICY, V26, P84, DOI 10.1016/j.drugpo.2014.07.013; Green TC, 2010, DRUG ALCOHOL DEPEN, V110, P208, DOI 10.1016/j.drugalcdep.2010.02.020; Gugelmann HM, 2011, JAMA-J AM MED ASSOC, V306, P2258, DOI 10.1001/jama.2011.1712; Hakkinen M, 2012, EUR J CLIN PHARMACOL, V68, P301, DOI 10.1007/s00228-011-1122-4; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hamilton CM, 2011, AM J EPIDEMIOL, V174, P253, DOI 10.1093/aje/kwr193; Institute of Medicine, 2012, SUBST US DIS US ARM; Jackson GL, 2013, ANN INTERN MED, V158, P169, DOI 10.7326/0003-4819-158-3-201302050-00579; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Jones JD, 2012, DRUG ALCOHOL DEPEN, V125, P8, DOI 10.1016/j.drugalcdep.2012.07.004; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Lanza S.T., 2015, LCA STATA PLUGIN USE; Lee EH, 2012, ASIAN NURS RES, V6, P121, DOI 10.1016/j.anr.2012.08.004; Li-Hui Chen HH, 2015, QUICKSTATS RATES DEA, P1999; Meyer JP, 2011, J WOMENS HEALTH, V20, P991, DOI 10.1089/jwh.2010.2328; Monga N, 2007, DRUG ALCOHOL DEPEN, V88, P1, DOI 10.1016/j.drugalcdep.2006.08.029; Nelson LS, 2012, JAMA-J AM MED ASSOC, V308, P457, DOI 10.1001/jama.2012.8165; New York City Department of Health and Mental Hygiene, 2015, UN DRUG POS OV DEATH, P2000; Norris SL, 2006, DIABETIC MED, V23, P544, DOI 10.1111/j.1464-5491.2006.01845.x; Nutting PA, 2009, ANN FAM MED, V7, P254, DOI 10.1370/afm.1002; O'Toole TP, 2003, J GEN INTERN MED, V18, P929, DOI 10.1046/j.1525-1497.2003.21209.x; Oliva EM, REPORT OPIOID OVERDO; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pedersen W, 1999, ADDICTION, V94, P1695, DOI 10.1046/j.1360-0443.1999.941116957.x; Perlin JB, 2004, AM J MANAG CARE, V10, P828; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Pouget ER, 2015, ABSTRACTS DRUG ALCOH, V156, pe180; Pouget ER, 2016, UNDERSTANDING HIV AI, P195; Quinones S., 2015, HEALTH AFFAIR, V34, P9; Rivers JE, 1998, AM BEHAV SCI, V41, P1136, DOI 10.1177/0002764298041008009; Robins LN, 2010, AM J ADDICTION, V19, P203, DOI 10.1111/j.1521-0391.2010.00046.x; ROBINS LN, 1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Rosland A-M, 2013, AM J MANAGED CARE, V19; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Seal KH, 2001, AM J PUBLIC HEALTH, V91, P1842, DOI 10.2105/AJPH.91.11.1842; Shin SH, 2010, DRUG ALCOHOL DEPEN, V109, P226, DOI 10.1016/j.drugalcdep.2010.01.013; Singer, 2016, FREE INQUIRY CREATIV, V28, P13; Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423; Singer MC, 2006, SOC SCI MED, V63, P2010, DOI 10.1016/j.socscimed.2006.05.012; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013, RES 2012 NAT SURV DR; U.S. Army, 2010, ARM HLTH PROM RISK R; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x	64	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2017	12	6							e179054	10.1371/journal.pone.0179054	http://dx.doi.org/10.1371/journal.pone.0179054			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX0PL	28594892	Green Published, gold, Green Submitted			2023-01-03	WOS:000402923200082
J	Chesnaye, NC; Schaefer, F; Bonthuis, M; Holman, R; Baiko, S; Baskin, E; Bjerre, A; Cloarec, S; Cornelissen, EAM; Espinosa, L; Heaf, J; Stone, R; Shtiza, D; Zagozdzon, I; Harambat, J; Jager, KJ; Groothoff, JW; van Stralen, KJ				Chesnaye, Nicholas C.; Schaefer, Franz; Bonthuis, Marjolein; Holman, Rebecca; Baiko, Sergey; Baskin, Esra; Bjerre, Anna; Cloarec, Sylvie; Cornelissen, Elisabeth A. M.; Espinosa, Laura; Heaf, James; Stone, Rosario; Shtiza, Diamant; Zagozdzon, Ilona; Harambat, Jerome; Jager, Kitty J.; Groothoff, Jaap W.; van Stralen, Karlijn J.		ESPN ERA-EDTA Registry Committee	Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis	LANCET			English	Article							BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MULTILEVEL ANALYSIS; SURVIVAL; DIALYSIS	Background We explored the variation in country mortality rates in the paediatric population receiving renal replacement therapy across Europe, and estimated how much of this variation could be explained by patient-level and country-level factors. Methods In this registry analysis, we extracted patient data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry for 32 European countries. We included incident patients younger than 19 years receiving renal replacement therapy. Adjusted hazard ratios (aHR) and the explained variation were modelled for patient-level and country-level factors with multilevel Cox regression. The primary outcome studied was all-cause mortality while on renal replacement therapy. Findings Between Jan 1, 2000, and Dec 31, 2013, the overall 5 year renal replacement therapy mortality rate was 15.8 deaths per 1000 patient-years (IQR 6.4-16.4). France had a mortality rate (9.2) of more than 3 SDs better, and Russia (35.2), Poland (39.9), Romania (47.4), and Bulgaria (68.6) had mortality rates more than 3 SDs worse than the European average. Public health expenditure was inversely associated with mortality risk (per SD increase, aHR 0.69, 95% CI 0.52-0.91) and explained 67% of the variation in renal replacement therapy mortality rates between countries. Child mortality rates showed a significant association with renal replacement therapy mortality, albeit mediated by macroeconomics (eg, neonatal mortality reduced from 1.31 [95% CI 1.13-1.53], p=0.0005, to 1.21 [0.97-1.51], p=0.10). After accounting for country distributions of patient age, the variation in renal replacement therapy mortality rates between countries increased by 21%. Interpretation Substantial international variation exists in paediatric renal replacement therapy mortality rates across Europe, most of which was explained by disparities in public health expenditure, which seems to limit the availability and quality of paediatric renal care. Differences between countries in their ability to accept and treat the youngest patients, who are the most complex and costly to treat, form an important source of disparity within this population. Our findings can be used by policy makers and health-care providers to explore potential strategies to help reduce these health disparities. Funding ERA-EDTA and ESPN.	[Chesnaye, Nicholas C.; Bonthuis, Marjolein; Jager, Kitty J.; van Stralen, Karlijn J.] ESPN ERA EDTA Registry, Amsterdam, Netherlands; [Jager, Kitty J.] ERA EDTA Registry, Amsterdam, Netherlands; [Schaefer, Franz] Heidelberg Univ, Ctr Paediat & Adolescent Med, Div Paediat Nephrol, Heidelberg, Germany; [Holman, Rebecca] Acad Med Ctr, Dept Med Informat, Amsterdam, Netherlands; [Holman, Rebecca] Acad Med Ctr, Clin Res Unit, Amsterdam, Netherlands; [Baiko, Sergey] Belarusian State Med Univ, Dept Paediat, Minsk, BELARUS; [Baskin, Esra] Baskent Univ, Dept Paediat Nephrol, Ankara, Turkey; [Bjerre, Anna] Natl Hosp Norway, Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Cloarec, Sylvie] Hop Clocheville, CHU Tours, Serv Nephrol Pediat, Tours, France; [Cornelissen, Elisabeth A. M.] Radboud Univ Nijmegen, Med Ctr, Dept Paediat Nephrol, Nijmegen, Netherlands; [Espinosa, Laura] Univ Hosp La Paz, Paediat Nephrol, Madrid, Spain; [Heaf, James] Zealand Univ Hosp, Dept Med, Roskilde, Denmark; [Stone, Rosario] Hosp Sta Maria, Unidade Nefrol & Transplantacao Renal, Dept Pediat, Ctr Acad Med Lisboa, Lisbon, Portugal; [Shtiza, Diamant] Univ Hosp Ctr Mother Tereza, Dept Paediat, Nephrol Unit, Tirana, Albania; [Zagozdzon, Ilona] Med Univ Gdansk, Dept Paediat Nephrol & Hypertens, Gdansk, Poland; [Harambat, Jerome] Bordeaux Univ Hosp, Dept Paediat, Bordeaux, France; [Groothoff, Jaap W.] Emma Childrens Hosp, Acad Med Ctr, Dept Paediat Nephrol, Amsterdam, Netherlands	Ruprecht Karls University Heidelberg; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Belarusian State Medical University; Baskent University; University of Oslo; National Hospital Norway; CHU Tours; Radboud University Nijmegen; Hospital Universitario La Paz; Universidade de Lisboa; Hospital Santa Maria; Fahrenheit Universities; Medical University Gdansk; CHU Bordeaux; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Jager, KJ (corresponding author), Acad Med Ctr, Dept Med Informat, NL-1100 DE Amsterdam, Netherlands.	k.j.jager@amc.uva.nl	Cornelissen, Elisabeth AM/F-3618-2015; Harambat, Jérôme/A-3359-2016; Chesnaye, Nicholas/G-5707-2013; Harambat, Jérôme/T-1371-2019; Baskin, Esra/B-5785-2018; Baiko, Sergey/CAJ-5056-2022	Cornelissen, Elisabeth AM/0000-0002-1156-5264; Chesnaye, Nicholas/0000-0003-4883-9174; Baskin, Esra/0000-0003-4361-8508; van Stralen, Karlijn/0000-0002-3243-2970; Stone, Rosario/0000-0002-7939-836X; Jager, Kitty/0000-0003-0444-8569	ERA-EDTA; ESPN	ERA-EDTA; ESPN	ERA-EDTA and ESPN.	Aelvoet W, 2016, INT J QUAL HEALTH C, V28, P22, DOI 10.1093/intqhc/mzv092; Buchan J, HLTH WORKER MIGRATIO; Buchan J., 2006, MIGRATION HLTH WORKE; Chesnaye NC, 2015, NEPHROL DIAL TRANSPL, P1; Chesnaye N, 2014, PEDIATR NEPHROL, V29, P2403, DOI 10.1007/s00467-014-2884-6; Covic A, 2010, CLIN NEPHROL, V74, pS23; Dussault G, MIGRATION HLTH PERSO; Ehrich JHH, 2005, NEPHROL DIAL TRANSPL, V20, P297, DOI 10.1093/ndt/gfh299; ERA-EDTA Registry, 2013, ERA EDTA REG ANN REP; Jager KJ, 2008, KIDNEY INT, V73, P256, DOI 10.1038/sj.ki.5002650; Kramer A, 2012, CLIN J AM SOC NEPHRO, V7, P1655, DOI 10.2215/CJN.10461011; Legrand C, 2006, CLIN TRIALS, V3, P10, DOI 10.1191/1740774506cn132oa; McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; Neuhaus T J, 1998, Praxis (Bern 1994), V87, P1593; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Rutkowski B, 2006, NEPHROL DIAL TRANSPL, V21, P4, DOI 10.1093/ndt/gfi251; Schaefer F, 2012, PERITON DIALYSIS INT, V32, P399, DOI 10.3747/pdi.2012.00126; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; Suicide, 2012, HLTH GLANC EUR 2012, P28; van Dijk PCW, 2007, KIDNEY INT, V71, P53, DOI 10.1038/sj.ki.5002008	22	29	29	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2017	389	10084					2128	2137		10.1016/S0140-6736(17)30063-6	http://dx.doi.org/10.1016/S0140-6736(17)30063-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV7QE	28336050				2023-01-03	WOS:000401973300031
J	Khatua, S; Dutta, AK; Chandra, S; Paloi, S; Das, K; Acharya, K				Khatua, Somanjana; Dutta, Arun Kumar; Chandra, Swarnendu; Paloi, Soumitra; Das, Kanad; Acharya, Krishnendu			Introducing a novel mushroom from mycophagy community with emphasis on biomedical potency	PLOS ONE			English	Article							WATER-SOLUBLE POLYSACCHARIDES; CHEMICAL-CHARACTERIZATION; IMMUNOMODULATING ACTIVITY; ANTIOXIDATIVE ACTIVITIES; ANTIMICROBIAL ACTIVITY; PLEUROTUS-OSTREATUS; EASTERN HIMALAYA; EXTRACTION; RUSSULA; PURIFICATION	Mushrooms have been prized by humankind as medicine and culinary wonder since antiquity. Though several species are ethnically valued; many prospective species are still being discovered. One such wild macrofungus has recently been discovered during subsequent field surveys in West Bengal, India which in turn exposed as a traditionally consumed popular myco-food. The collected taxon was found to be unique with regard to its morphological as well as genetical features. After detailed characterizations, the fungus was identified as a novel taxon belonging to the genus Russula (Russulaceae, Basidiomycota). Besides, the investigation was further extended in search of new functional ingredients and in this context, a water soluble crude polysaccharide rich extract (Rusalan) was isolated from dried basidiocarps. Accumulating evidences from GC-MS, HPTLC, FT-IR along with several spectrophotometric methods postulated that the fraction consisted mainly of carbohydrate in triple helical conformation, where glucose was the major monosaccharide mostly with ss-type glycosidic linkage. Conversely, Rusalan showed pronounced antioxidant activity in six in vitro assay systems with EC50 value ranging from 190-1328 mu g/ml concentration. The crude polysaccharide was also evaluated against six bacterial strains using microdilution method and the growth of Staphylococcus aureus and Bacillus subtilis were found to be inhibited effectively. In addition, immune-stimulatory assays demonstrated that Rusalan could evidently promote proliferation, induce phagocytosis, release NO, produce intracellular ROS and upregulate mRNA expression of iNOS, TNF-alpha, COX-2, as well as IL-6 genes in in mouse macrophage cells. Therefore, aim of the present study was not only to describe a new taxon to the world mycoflora but also to introduce a potent therapeutic agent that could be explored for food and pharmaceutical purposes. However, isolation of active component and in vivo studies need to be designed further.	[Khatua, Somanjana; Dutta, Arun Kumar; Chandra, Swarnendu; Paloi, Soumitra; Acharya, Krishnendu] Univ Calcutta, Ctr Adv Study, Dept Bot, Mol & Appl Mycol & Plant Pathol Lab, Kolkata, W Bengal, India; [Das, Kanad] Bot Survey India, Cryptogam Unit, Howrah, India	University of Calcutta; Botanical Survey of India (BSI)	Acharya, K (corresponding author), Univ Calcutta, Ctr Adv Study, Dept Bot, Mol & Appl Mycol & Plant Pathol Lab, Kolkata, W Bengal, India.	krish_paper@yahoo.com	Dutta, Arun Kumar/AAH-2797-2020; Acharya, Krishnendu/G-2317-2012; Khatua, Somanjana/AAR-9068-2021; Paloi, Soumitra/R-1519-2019	Dutta, Arun Kumar/0000-0001-5234-3441; Acharya, Krishnendu/0000-0003-1193-1823; Khatua, Somanjana/0000-0003-1752-5754; PALOI, SOUMITRA/0000-0003-3980-9168				Alves MJ, 2012, J APPL MICROBIOL, V113, P466, DOI 10.1111/j.1365-2672.2012.05347.x; Alves MJ, 2012, PLANTA MED, V78, P1707, DOI 10.1055/s-0032-1315370; [Anonymous], 2007, MEDICINA, V43, P597; Ayres DL, 2012, SYST BIOL, V61, P170, DOI [10.1093/sysbio/syr100, 10.1093/sysbio/sys029]; Bayar N, 2016, INT J BIOL MACROMOL, V92, P441, DOI 10.1016/j.ijbiomac.2016.07.042; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buyck B, 2008, FUNGAL DIVERS, V28, P15; Buyck B., 1989, BULL SOC MYCOL FR, V105, P1; Carocho M, 2013, FOOD CHEM TOXICOL, V51, P15, DOI 10.1016/j.fct.2012.09.021; Chatterjee A, 2013, GLYCOCONJUGATE J, V30, P759, DOI 10.1007/s10719-013-9479-5; Das K., 2005, RUSSULACEAE KUMAON H; DINIS TCP, 1994, ARCH BIOCHEM BIOPHYS, V315, P161, DOI 10.1006/abbi.1994.1485; Dong HM, 2016, INT J BIOL MACROMOL, V93, P179, DOI 10.1016/j.ijbiomac.2016.08.074; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; Dutta AK, 2015, TURK J BOT, V39, P850, DOI 10.3906/bot-1407-1; Ekanayake PM, 2005, J FOOD LIPIDS, V12, P34, DOI 10.1111/j.1745-4522.2005.00004.x; El Enshasy HA, 2013, TRENDS BIOTECHNOL, V31, P668, DOI 10.1016/j.tibtech.2013.09.003; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; GEYER CJ, 1991, COMPUTING SCIENCE AND STATISTICS, P156; Guan Di, 2011, International Journal of Biology, V3, P3; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; He JZ, 2012, MOLECULES, V17, P4373, DOI 10.3390/molecules17044373; He JZ, 2010, CHINESE J ANAL CHEM, V38, P372, DOI 10.3724/SP.J.1096.2010.00372; Hou Y, 2013, INDIAN J PHARM SCI, V75, P393, DOI 10.4103/0250-474X.119809; Hrudayanath Thatoi, 2014, African Journal of Biotechnology, V13, P523; Hsieh PW, 2013, BIOMEDICINE-TAIWAN, V3, P106, DOI 10.1016/j.biomed.2013.01.002; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Jayakumar T, 2011, FOOD RES INT, V44, P851, DOI 10.1016/j.foodres.2011.03.015; Khatua S., 2013, RES J PHARM TECHNOLO, V6, P496; Khatua S, 2016, J FOOD SCI TECH MYS, V53, P1878, DOI 10.1007/s13197-015-2145-0; Kim EJ, 2015, KOREAN J PHYSIOL PHA, V19, P211, DOI 10.4196/kjpp.2015.19.3.211; Klaus A, 2011, LWT-FOOD SCI TECHNOL, V44, P2005, DOI 10.1016/j.lwt.2011.05.010; KORNERUP A., 1967, Methuen handbook of colour.; Kozarski M, 2012, J FOOD COMPOS ANAL, V26, P144, DOI 10.1016/j.jfca.2012.02.004; Lee JS, 2013, INT IMMUNOPHARMACOL, V17, P858, DOI 10.1016/j.intimp.2013.09.019; Lima CUJO, 2016, REV BRAS FARMACOGN, V26, P780, DOI 10.1016/j.bjp.2016.05.013; Martinez CA, 2001, PLANT SCI, V160, P505, DOI 10.1016/S0168-9452(00)00418-0; Menaga D, 2012, INT J CHEM PHARM SCI, V3, P1; Mitra P., 2013, ASIAN J PHARM CLIN R, V6, P67; Nandi AK, 2014, CARBOHYD POLYM, V99, P774, DOI 10.1016/j.carbpol.2013.09.016; OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307; Palacios I, 2012, CARBOHYD RES, V358, P72, DOI 10.1016/j.carres.2012.06.016; Paloi S, 2016, PHYTOTAXA, V252, P123, DOI 10.11646/phytotaxa.252.2.4; Paloi S, 2015, PHYTOTAXA, V234, P255, DOI 10.11646/phytotaxa.234.3.6; Paterson R Russell M, 2014, Biomed J, V37, P357, DOI 10.4103/2319-4170.143502; Preethi S, 2016, INT J BIOL MACROMOL, V92, P347, DOI 10.1016/j.ijbiomac.2016.07.036; Prieto P, 1999, ANAL BIOCHEM, V269, P337, DOI 10.1006/abio.1999.4019; Qiu T, 2013, CARBOHYD POLYM, V98, P922, DOI 10.1016/j.carbpol.2013.07.014; Razali FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108988; Romagnesi H., 1967, LES RUSSULES DEUROPE; Ruthes AC, 2015, CARBOHYD POLYM, V117, P753, DOI 10.1016/j.carbpol.2014.10.051; Saini SS, 1989, INDIAN J MYCOL PL PA, V19, P44; Sarnari M., 1994, BOLLETTINO DELLASSOC, V33, P3; Sarnari M, 1998, MONOGRAFIA ILLUSTRAT; Sarnari M, 2005, MONOGRAFI ILLUSTRATA, V2; Shi JJ, 2016, INT J BIOL MACROMOL, V91, P23, DOI 10.1016/j.ijbiomac.2016.05.082; Stojkovic D, 2013, FOOD RES INT, V53, P56, DOI 10.1016/j.foodres.2013.03.046; Subarna Saha, 2013, International Journal of Green Pharmacy, V7, P182; Sun H, 2017, RES VET SCI, V110, P22, DOI 10.1016/j.rvsc.2016.10.015; Sun ZW, 2010, FOOD CHEM, V118, P675, DOI 10.1016/j.foodchem.2009.05.036; Synytsya A, 2009, CARBOHYD POLYM, V76, P548, DOI 10.1016/j.carbpol.2008.11.021; Tabarsa M, 2013, INT J BIOL MACROMOL, V59, P1, DOI 10.1016/j.ijbiomac.2013.04.022; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Venter G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096786; Vlatka P, 2010, CONSPEC SCI, V75, P149; Wang JQ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5692852; Wang M, 2017, CARBOHYD POLYM, V156, P390, DOI 10.1016/j.carbpol.2016.09.033; White T.J., 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; Yayeh T, 2012, J NAT MED-TOKYO, V66, P49, DOI 10.1007/s11418-011-0552-8; Zhang QH, 2016, INT J BIOL MACROMOL, V93, P459, DOI 10.1016/j.ijbiomac.2016.08.052	72	23	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2017	12	5							e0178050	10.1371/journal.pone.0178050	http://dx.doi.org/10.1371/journal.pone.0178050			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV8VT	28552988	gold, Green Published, Green Submitted			2023-01-03	WOS:000402063000019
J	Cabrera, AR; Shirk, PD; Teal, PEA				Cabrera, Ana R.; Shirk, Paul D.; Teal, Peter E. A.			A feeding protocol for delivery of agents to assess development in Varroa mites	PLOS ONE			English	Article							APIS-MELLIFERA L; DEFORMED WING VIRUS; HONEY-BEE; JACOBSONI OUD; DESTRUCTOR ANDERSON; ECTOPARASITIC MITE; DRONE BROOD; HOST; WORKER; VITELLOGENESIS	A novel feeding protocol for delivery of bio-active agents to Varroa mites was developed by providing mites with honey bee larva hemolymph supplemented with cultured insect cells and selected materials delivered on a fibrous cotton substrate. Mites were starved, fed on treated hemolymph to deliver selected agents and then returned to bee larvae. Transcript levels of two reference genes, actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as well as for nine selected genes involved in reproductive processes showed that the starvation and feeding protocol periods did not pose a high level of stress to the mites as transcript levels remained comparable between phoretic mites and those completing the protocol. The feeding protocol was used to deliver molecules such as hormone analogs or plasmids. Mites fed with Tebufenozide, an ecdysone analog, had higher transcript levels of shade than untreated or solvent treated mites. In order to extend this feeding protocol, cultured insect cells were incorporated to a final ratio of 1 part cells and 2 parts hemolymph. Although supplementation with Bombyx mori Bm5 cells increased the amount of hemolymph consumed per mite, there was a significant decrease in the percentage of mites that fed and survived. On the other hand, Drosophila melanogaster S2 cells reduced significantly the percentage of mites that fed and survived as well as the amount of hemolymph consumed. The feeding protocol provides a dynamic platform with which to challenge the Varroa mite to establish efficacy of control agents for this devastating honey bee pest.	[Cabrera, Ana R.] Univ Florida, Dept Entomol & Nematol, Gainesville, FL 32611 USA; [Shirk, Paul D.; Teal, Peter E. A.] USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA; [Cabrera, Ana R.] Bayer CropSci, Res Triangle Pk, NC USA	State University System of Florida; University of Florida; United States Department of Agriculture (USDA); Bayer AG; Bayer CropScience	Shirk, PD (corresponding author), USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA.	paul.shirk@ars.usda.gov			USDA, ARS, Insect Behavior and Biocontrol Research Unit, Center for Medical Agricultural and Veterinary Entomology, Gainesville, FL; USDA, ARS, Chemistry Research Unit, Center for Medical Agricultural and Veterinary Entomology, Gainesville, FL	USDA, ARS, Insect Behavior and Biocontrol Research Unit, Center for Medical Agricultural and Veterinary Entomology, Gainesville, FL; USDA, ARS, Chemistry Research Unit, Center for Medical Agricultural and Veterinary Entomology, Gainesville, FL	Funding for this project came from the USDA, ARS, Insect Behavior and Biocontrol Research Unit and Chemistry Research Unit, Center for Medical Agricultural and Veterinary Entomology, Gainesville, FL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Annoscia D, 2012, J INSECT PHYSIOL, V58, P1548, DOI 10.1016/j.jinsphys.2012.09.008; [Anonymous], 2015, COLONY LOSS 2014 201; BOOT WJ, 1995, APIDOLOGIE, V26, P109, DOI 10.1051/apido:19950204; BOOT WJ, 1994, EXP APPL ACAROL, V18, P371, DOI 10.1007/BF00116318; BOOT WJ, 1992, EXP APPL ACAROL, V16, P295, DOI 10.1007/BF01218571; Bossin H, 2007, INSECT MOL BIOL, V16, P37, DOI 10.1111/j.1365-2583.2006.00693.x; Bowen-Walker PL, 1999, J INVERTEBR PATHOL, V73, P101, DOI 10.1006/jipa.1998.4807; Bowen-Walker PL, 2001, ENTOMOL EXP APPL, V101, P207, DOI 10.1023/A:1019254727879; Brown MR, 2009, ANNU REV ENTOMOL, V54, P105, DOI 10.1146/annurev.ento.53.103106.093334; BRUCE WA, 1988, APIDOLOGIE, V19, P209, DOI 10.1051/apido:19880209; BRUCE WA, 1991, APIDOLOGIE, V22, P503, DOI 10.1051/apido:19910503; Cabrera AR, 2015, INSECT MOL BIOL, V24, P277, DOI 10.1111/imb.12155; Cabrera AR, 2013, INSECT MOL BIOL, V22, P505, DOI 10.1111/imb.12040; Cabrera AR, 2014, ARCH INSECT BIOCHEM, V85, P61, DOI 10.1002/arch.21143; Campbell EM, 2016, INSECT BIOCHEM MOLEC, V70, P116, DOI 10.1016/j.ibmb.2015.12.007; Campbell EM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-73; Carlson G.R., 2000, ACS SYM SER, P8, DOI [10.1021/bk-2000-0767.ch002, DOI 10.1021/BK-2000-0767.CH002]; Cordon ARC, 2013, INSECT MOL BIOL, V22, P88, DOI 10.1111/imb.12006; Cornman RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043562; DEGUZMAN LI, 1993, EXP APPL ACAROL, V17, P283, DOI 10.1007/BF02337278; Di Prisco G, 2016, P NATL ACAD SCI USA, V113, P3203, DOI 10.1073/pnas.1523515113; Dietemann V, 2012, J APICULT RES, V51, P125, DOI 10.3896/IBRA.1.51.1.15; Evans JD, 2011, TRENDS MICROBIOL, V19, P614, DOI 10.1016/j.tim.2011.09.003; Francis RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057540; Garedew A, 2004, APIDOLOGIE, V35, P419, DOI 10.1051/apido:2004032; Garrido C, 2000, APIDOLOGIE, V31, P559, DOI 10.1051/apido:2000146; Garrido C, 2003, EXP APPL ACAROL, V31, P269, DOI 10.1023/B:APPA.0000010386.10686.9f; Goblirsch M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058165, 10.1371/journal.pone.0069831]; Gromyko G., 1982, PCHELEVODSTVO, V5, P16; Hami M., 2005, Communications in Agricultural and Applied Biological Sciences, V70, P767; Hartwig A, 1987, P 31 INT C AP; Hunter WB, 2010, IN VITRO CELL DEV-AN, V46, P83, DOI 10.1007/s11626-009-9246-x; IFANTIDIS MD, 1983, J APICULT RES, V22, P200, DOI 10.1080/00218839.1983.11100588; KRAUS B, 1986, APIDOLOGIE, V17, P257, DOI 10.1051/apido:19860307; KRAUS B, 1993, J APICULT RES, V32, P57, DOI 10.1080/00218839.1993.11101288; Kuenen LPS, 1997, J INSECT BEHAV, V10, P213, DOI 10.1007/BF02765554; Le Conte Y, 2010, APIDOLOGIE, V41, P353, DOI 10.1051/apido/2010017; Lee KV, 2015, APIDOLOGIE, V46, P292, DOI 10.1007/s13592-015-0356-z; Macedo PA, 2002, J APICULT RES, V41, P3, DOI 10.1080/00218839.2002.11101062; Martin S, 1998, ECOL MODEL, V109, P267, DOI 10.1016/S0304-3800(98)00059-3; MARTIN SJ, 1994, EXP APPL ACAROL, V18, P87, DOI 10.1007/BF00055033; Martin SJ, 2001, J APPL ECOL, V38, P1082, DOI 10.1046/j.1365-2664.2001.00662.x; MARTIN SJ, 1995, EXP APPL ACAROL, V19, P199, DOI 10.1007/BF00130823; Martin SJ, 2013, J APICULT RES, V52; Martin SJ, 2012, SCIENCE, V336, P1304, DOI 10.1126/science.1220941; Nazzi F, 2016, ANNU REV ENTOMOL, V61, P417, DOI 10.1146/annurev-ento-010715-023731; Ogihara K, 2007, GEN COMP ENDOCR, V150, P371, DOI 10.1016/j.ygcen.2006.09.007; Ogihara MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124953; Rees HH, 2004, PARASITOLOGY, V129, pS127, DOI 10.1017/S003118200400530X; REHM SM, 1989, APIDOLOGIE, V20, P339, DOI 10.1051/apido:19890406; Rewitz KF, 2007, INSECT BIOCHEM MOLEC, V37, P741, DOI 10.1016/j.ibmb.2007.02.012; Rosenkranz P, 2010, J INVERTEBR PATHOL, V103, pS96, DOI 10.1016/j.jip.2009.07.016; Ryabov EV, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004230; Sammataro D, 2000, ANNU REV ENTOMOL, V45, P519, DOI 10.1146/annurev.ento.45.1.519; Sanchez-Bayo F, 2016, ENVIRON INT, V89-90, P7, DOI 10.1016/j.envint.2016.01.009; Schafer MO, 2010, J ECON ENTOMOL, V103, P10, DOI 10.1603/EC09233; Shirk PD, 2007, INSECT MOL BIOL, V16, P623, DOI 10.1111/j.1365-2583.2007.00759.x; SHIRK PD, 1990, ARCH INSECT BIOCHEM, V15, P183, DOI 10.1002/arch.940150306; Singh NK, 2016, INSECT MOL BIOL, V25, P181, DOI 10.1111/imb.12212; SMAGGHE G, 1994, PESTIC SCI, V42, P85, DOI 10.1002/ps.2780420204; STEINER J, 1995, EXP APPL ACAROL, V19, P411, DOI 10.1007/BF00145158; STEINER J, 1994, INVERTEBR REPROD DEV, V25, P175, DOI 10.1080/07924259.1994.9672384; Tabart J, 2013, EXP APPL ACAROL, V61, P107, DOI 10.1007/s10493-013-9675-9; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; vanEngelsdorp D, 2010, J INVERTEBR PATHOL, V103, pS80, DOI 10.1016/j.jip.2009.06.011; vanEngelsdorp D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006481; WEINBERG KP, 1985, APIDOLOGIE, V16, P421, DOI 10.1051/apido:19850407; Wilfert L, 2016, SCIENCE, V351, P594, DOI 10.1126/science.aac9976; Yang X, 2007, PARASITOLOGY, V134, P405, DOI 10.1017/S0031182006000710; Yang XL, 2005, P NATL ACAD SCI USA, V102, P7470, DOI 10.1073/pnas.0501860102	70	7	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2017	12	4							e0176097	10.1371/journal.pone.0176097	http://dx.doi.org/10.1371/journal.pone.0176097			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EL	28448606	gold, Green Published, Green Submitted			2023-01-03	WOS:000400383600038
J	Manley, BJ; Owen, LS; Hooper, SB; Jacobs, SE; Cheong, JLY; Doyle, LW; Davis, PG				Manley, Brett J.; Owen, Louise S.; Hooper, Stuart B.; Jacobs, Susan E.; Cheong, Jeanie L. Y.; Doyle, Lex W.; Davis, Peter G.			Neonatal intensive care 1 Towards evidence-based resuscitation of the newborn infant	LANCET			English	Article							UMBILICAL-CORD MILKING; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; BIRTH-WEIGHT INFANTS; MANUAL VENTILATION DEVICES; SUSTAINED LUNG-INFLATION; PRETERM INFANTS; CARDIOPULMONARY-RESUSCITATION; HEART-RATE; MASK VENTILATION; DELIVERY ROOM	Effective resuscitation of the newborn infant has the potential to save many lives around the world and reduce disabilities in children who survive peripartum asphyxia. In this Series paper, we highlight some of the important advances in the understanding of how best to resuscitate newborn infants, which includes monitoring techniques to guide resuscitative efforts, increasing awareness of the adverse effects of hyperoxia, delayed umbilical cord clamping, the avoidance of routine endotracheal intubation for extremely preterm infants, and therapeutic hypothermia for hypoxic-ischaemic encephalopathy. Despite the challenges of performing high-quality clinical research in the delivery room, researchers continue to refine and advance our knowledge of effective resuscitation of newborn infants through scientific experiments and clinical trials.	[Manley, Brett J.; Owen, Louise S.; Jacobs, Susan E.; Cheong, Jeanie L. Y.; Davis, Peter G.] Royal Womens Hosp, Neonatal Serv, Melbourne, Vic, Australia; [Manley, Brett J.; Owen, Louise S.; Jacobs, Susan E.; Cheong, Jeanie L. Y.; Doyle, Lex W.; Davis, Peter G.] Royal Womens Hosp, Newborn Res Ctr, Melbourne, Vic, Australia; [Manley, Brett J.; Jacobs, Susan E.; Cheong, Jeanie L. Y.; Doyle, Lex W.; Davis, Peter G.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Owen, Louise S.; Jacobs, Susan E.; Cheong, Jeanie L. Y.; Doyle, Lex W.; Davis, Peter G.] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic, Australia; [Hooper, Stuart B.] Ritchie Ctr, Hudson Inst Med Res, Melbourne, Vic, Australia; [Hooper, Stuart B.] Monash Univ, Dept Obstet & Gynaecol, Melbourne, Vic, Australia	University of Melbourne; Murdoch Children's Research Institute; Hudson Institute of Medical Research; Monash University	Manley, BJ (corresponding author), Royal Womens Hosp, Newborn Res Ctr, Parkville, Vic 3052, Australia.	brett.manley@thewomens.org.au	Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312; Hooper, Stuart/0000-0003-1676-4825; Manley, Brett/0000-0003-0212-7956	Centre for Research Excellence grant [1060733]; NHMRC, Australia [606789, 1088279, 1090678, 1073103, 1053787, 1058537, 1059111]; Victorian Government	Centre for Research Excellence grant; NHMRC, Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government	SEJ, JLYC, LWD, and PGD are recipients of a Centre for Research Excellence grant (grant number 1060733), and SBH, LWD, and PGD are recipients of a Program Grant (grant numberr 606789) from the NHMRC, Australia. BJM, LSO, SEJ, and JLYC are recipients of Early Career Fellowships from the NHMRC, Australia (grant numbers 1088279, 1090678, 1073103, and 1053787, respectively). SBH is the recipient of a Principal Research Fellowship from the NHMRC, Australia (grant number 1058537). PGD is the recipient of a Practitioner Fellowship from the NHMRC, Australia (grant number 1059111). SBH and LWD acknowledge the Victorian Government's Operational Infrastructure Support Program. These funding sources had no input into the preparation of this paper.	Al-Wassia H, 2015, JAMA PEDIATR, V169, P18, DOI 10.1001/jamapediatrics.2014.1906; Aladangady N, 2006, PEDIATRICS, V117, P93, DOI 10.1542/peds.2004-1773; Albert SM, 1997, NEUROLOGY, V49, P38, DOI 10.1212/WNL.49.1.38; Anotayanonth S, 2004, COCHRANE DB SYST REV, V4; APGAR V, 1953, Curr Res Anesth Analg, V32, P260; Austin T, 2013, ARCH DIS CHILD-FETAL, V98, pF451, DOI 10.1136/archdischild-2012-302069; AVERY ME, 1987, PEDIATRICS, V79, P26; Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Barber CA, 2006, PEDIATRICS, V118, P1028, DOI 10.1542/peds.2006-0416; Bhatt S, 2013, J PHYSIOL-LONDON, V591, P2113, DOI 10.1113/jphysiol.2012.250084; Boere I, 2015, ARCH DIS CHILD-FETAL, V100, pF121, DOI 10.1136/archdischild-2014-307144; Boland RA, 2015, AUST NZ J OBSTET GYN, V55, P163, DOI 10.1111/ajo.12313; Bora R, 2015, J PERINATOL, V35, P832, DOI 10.1038/jp.2015.92; Casey BM, 2001, NEW ENGL J MED, V344, P467, DOI 10.1056/NEJM200102153440701; Chettri S, 2015, J PEDIAT, V166, pe1; Chettri S, 2015, J PEDIATR-US, V166, P1208, DOI 10.1016/j.jpeds.2014.12.076; Dang D, 2015, J OBSTET GYNAECOL RE, V41, P890, DOI 10.1111/jog.12657; Dawson JA, 2010, ARCH DIS CHILD-FETAL, V95, pF177, DOI 10.1136/adc.2009.169102; Dawson JA, 2009, ARCH DIS CHILD-FETAL, V94, pF87, DOI 10.1136/adc.2008.141341; Dawson JA, 2010, PEDIATRICS, V125, pE1340, DOI 10.1542/peds.2009-1510; Doyle LW, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004661.pub3; Ersdal HL, 2012, RESUSCITATION, V83, P869, DOI 10.1016/j.resuscitation.2011.12.011; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Finer NN, 2001, RESUSCITATION, V49, P299, DOI 10.1016/S0300-9572(01)00311-2; Flenady V, 2014, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD002255.PUB2; Foglia EE, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0601-9; Halliday H.L., 2001, COCHRANE DB SYST REV, V2001, DOI [10.1002/14651858.CD000500, DOI 10.1002/14651858.CD000500]; HARDING R, 1986, J APPL PHYSIOL, V61, P68, DOI 10.1152/jappl.1986.61.1.68; Hooper SB, 2016, ARCH DIS CHILD-FETAL, V101, pF266, DOI 10.1136/archdischild-2013-305704; Hooper SB, 2015, PEDIATR RES, V77, P608, DOI 10.1038/pr.2015.21; Hussey SG, 2004, ARCH DIS CHILD-FETAL, V89, pF490, DOI 10.1136/adc.2003.047712; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; Jobe AH, 1998, EARLY HUM DEV, V53, P81, DOI 10.1016/S0378-3782(98)00045-0; Kamlin COF, 2008, J PEDIATR, V152, P756, DOI 10.1016/j.jpeds.2008.01.002; Kamlin COF, 2006, RESUSCITATION, V71, P319, DOI 10.1016/j.resuscitation.2006.04.015; Kamlin COF, 2013, PEDIATRICS, V132, pE381, DOI 10.1542/peds.2013-0361; Katheria AC, 2015, PEDIATRICS, V136, P61, DOI 10.1542/peds.2015-0368; Kattwinkel J, 2010, CIRCULATION, V122, pS909, DOI 10.1161/CIRCULATIONAHA.110.971119; Kelm M, 2012, J PERINAT MED, V40, P583, DOI 10.1515/jpm-2012-0023; Kenyon S, 2013, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD001058.PUB3; Kluckow M, 2015, SEMIN FETAL NEONAT M, V20, P225, DOI 10.1016/j.siny.2015.03.002; Kumar B, 2015, INDIAN PEDIATR, V52, P753, DOI 10.1007/s13312-015-0711-1; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 2007, PEDIATRICS, V119, pE643, DOI 10.1542/peds.2006-0943; Leone TA, 2006, PEDIATRICS, V118, pE202, DOI 10.1542/peds.2005-2493; Lista G, 2015, PEDIATRICS, V135, pE457, DOI 10.1542/peds.2014-1692; Lyu YY, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.0277; Mariani G, 2007, J PEDIATR-US, V150, P418, DOI 10.1016/j.jpeds.2006.12.015; McCall EM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004210.pub4; McCall KE, 2016, ARCH DIS CHILD-FETAL, V101, pF175, DOI 10.1136/archdischild-2015-309611; McCarthy LK, 2013, PEDIATRICS, V132, pE135, DOI 10.1542/peds.2013-0279; McDonald Susan J, 2013, Cochrane Database Syst Rev, pCD004074, DOI 10.1002/14651858.CD004074.pub3; Mercer JS, 2016, J PEDIAT, V168, pe1; Mercer JS, 2016, J PEDIATR-US, V168, P50, DOI 10.1016/j.jpeds.2015.09.068; Meyer MP, 2015, J PEDIATR-US, V166, P245, DOI 10.1016/j.jpeds.2014.09.049; Meyer MP, 2015, J PEDIAT, V166, pe1; Nangia S, 2016, RESUSCITATION, V105, P79, DOI 10.1016/j.resuscitation.2016.05.015; Natarajan G, 2012, PEDIATR RES, V72, P414, DOI 10.1038/pr.2012.103; Newton O, 2006, T ROY SOC TROP MED H, V100, P899, DOI 10.1016/j.trstmh.2006.02.012; O'Donnell CPF, 2007, ARCH DIS CHILD-FETAL, V92, P465, DOI 10.1136/adc.2007.120634; O'Donnell CPF, 2006, J PEDIATR-US, V149, P486, DOI 10.1016/j.jpeds.2006.05.040; O'Donnell CPF, 2005, ARCH DIS CHILD-FETAL, V90, pF392, DOI 10.1136/adc.2004.064691; O'Shea JE, 2015, PEDIATRICS, V136, P912, DOI 10.1542/peds.2015-1028; Oei JL, 2017, ARCH DIS CHILD-FETAL, V102, pF24, DOI 10.1136/archdischild-2016-310435; Oei JL, 2016, ACTA PAEDIATR, V105, P1061, DOI 10.1111/apa.13485; Owen LS, 2017, LANCET, V389, P1649, DOI 10.1016/S0140-6736(17)30312-4; Perlman JM, 2015, PEDIATRICS, V136, pS120, DOI 10.1542/peds.2015-3373D; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; PERLMAN JM, 1995, ARCH PEDIAT ADOL MED, V149, P20, DOI 10.1001/archpedi.1995.02170130022005; Poulton DA, 2011, RESUSCITATION, V82, P175, DOI 10.1016/j.resuscitation.2010.10.012; Rabe H, 2016, NEONATOLOGY, V109, P113, DOI 10.1159/000441891; Rabe H, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003248.pub3, 10.1002/14651858.CD003248.pub4]; Regier DA, 2010, VALUE HEALTH, V13, P695, DOI 10.1111/j.1524-4733.2010.00731.x; Rich W, 2012, PEDIATRICS, V129, P480, DOI 10.1542/peds.2011-2121; Rich WD, 2010, PEDIATRICS, V126, pE215, DOI 10.1542/peds.2009-3353; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Robertson NJ, 2012, J PEDIATR-US, V160, P544, DOI 10.1016/j.jpeds.2011.12.052; Roehr CC, 2010, AM J PERINAT, V27, P753, DOI 10.1055/s-0030-1254236; Roehr CC, 2010, RESUSCITATION, V81, P202, DOI 10.1016/j.resuscitation.2009.10.008; RUDOLPH AM, 1985, CIRC RES, V57, P811, DOI 10.1161/01.RES.57.6.811; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Saugstad OD, 2008, NEONATOLOGY, V94, P176, DOI 10.1159/000143397; Saugstad OD, 2014, ACTA PAEDIATR, V103, P744, DOI 10.1111/apa.12656; Schmidt B, 1999, J PEDIATR-US, V134, P151, DOI 10.1016/S0022-3476(99)70428-2; Schmolzer GM, 2015, ARCH DIS CHILD-FETAL, V100, pF361, DOI 10.1136/archdischild-2014-306836; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Schmolzer GM, 2011, ARCH DIS CHILD-FETAL, V96, pF254, DOI 10.1136/adc.2010.191171; Schmolzer GM, 2010, ARCH DIS CHILD-FETAL, V95, pF393, DOI 10.1136/adc.2009.174003; Schreiner MS, 2014, PEDIATRICS, V134, P1006, DOI 10.1542/peds.2014-0207; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Sobotka KS, 2011, PEDIATR RES, V70, P56, DOI 10.1203/PDR.0b013e31821d06a1; Strohm B, 2011, PEDIATRICS, V128, pE450, DOI 10.1542/peds.2010-3508; te Pas AB, 2009, PEDIATR RES, V66, P295, DOI 10.1203/PDR.0b013e3181b1bca4; Thoresen M, 2008, CLIN PERINATOL, V35, P749, DOI 10.1016/j.clp.2008.07.018; Tweed EJ, 2016, ARCH DIS CHILD-FETAL, V101, pF121, DOI 10.1136/archdischild-2015-308483; Vain NE, 2004, LANCET, V364, P597, DOI 10.1016/S0140-6736(04)16852-9; van Vonderen JJ, 2015, J PEDIATR-US, V166, P49, DOI 10.1016/j.jpeds.2014.09.015; van Vonderen JJ, 2014, J PEDIATR-US, V165, P903, DOI 10.1016/j.jpeds.2014.06.007; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2009, PEDIATRICS, V124, pE439, DOI 10.1542/peds.2009-0434; Walsh MC, 2005, J PEDIATR-US, V146, P798, DOI 10.1016/j.jpeds.2005.01.047; Wang CL, 2008, PEDIATRICS, V121, P1083, DOI 10.1542/peds.2007-1460; Wood FE, 2008, ARCH DIS CHILD-FETAL, V93, pF230, DOI 10.1136/adc.2007.117788; Zanelli S, 2011, J PERINATOL, V31, P377, DOI 10.1038/jp.2010.146	106	38	41	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2017	389	10079					1639	1648		10.1016/S0140-6736(17)30547-0	http://dx.doi.org/10.1016/S0140-6736(17)30547-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ES5EK	28443558				2023-01-03	WOS:000399560000031
J	Villa-Bellosta, R; Rodriguez-Osorio, L; Mas, S; Abadi, Y; Rubert, M; de la Piedra, C; Gracia-Iguacel, C; Mahillo, I; Ortiz, A; Egido, J; Gonzalez-Parra, E				Villa-Bellosta, Ricardo; Rodriguez-Osorio, Laura; Mas, Sebastian; Abadi, Younes; Rubert, Mercedes; de la Piedra, Concepcion; Gracia-Iguacel, Carolina; Mahillo, Ignacio; Ortiz, Alberto; Egido, Jesus; Gonzalez-Parra, Emilio			A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SECONDARY HYPERPARATHYROIDISM; SURVIVAL PREDICTABILITY; MINERAL METABOLISM; DIALYSIS PATIENTS; VITAMIN-D; CALCIUM; PHOSPHORUS; PHOSPHATE; MEN	Background The mortality of dialysis patients is 10- to 100-fold higher than in the general population. Baseline serum PTH levels, and more recently, changes in serum PTH levels (Delta PTH) over time, have been associated to mortality in dialysis patients. Methods We explored the relationship between.PTH over 1 year with mortality over the next year in a prospective cohort of 115 prevalent hemodialysis patients from a single center that had median baseline iPTH levels within guideline recommendations. Results Median baseline iPTH levels were 205 (116.5, 400) pg/ml. Delta iPTH between baseline and 1 year was 85.2 +/- 57.1 pg/ml. During the second year of follow-up, 27 patients died. Delta iPTH was significantly higher in patients who survived (+ 157.30 +/- 25.82 pg/ml) than in those who died (+39.03 +/- 60.95 pg/ml), while baseline iPTH values were not significantly different. The highest mortality (48%) was observed in patients with a decrease in Delta iPTH (Delta iPTH quartile 1, negative Delta iPTH) and the lowest (12%) mortality in quartile 3 Delta iPTH (Delta iPTH increase 101-300 pg/ml). In a logistic regression model,Delta iPTH was associated with mortality with an odds ratio (OR) of 0.998 (95% CI 0.996-0999, p = 0.038). In multivariable analysis, mortality risk was 73% and 88% lower for patients with Delta iPTH 0-100 pg/ml and 101-300 pg/ml, respectively, than for those with a decrease in Delta iPTH. In patients with a decrease in Delta iPTH, the OR for death was 4.131 (1.515-11.27)(p = 0.006). Conclusions In prevalent hemodialysis patients with median baseline iPTH values within the guideline recommended range, a decrease in Delta iPTH was associated with higher mortality. Further studies are required to understand the mechanisms and therapeutic implications of this observation that challenges current clinical practice.	[Villa-Bellosta, Ricardo; Rodriguez-Osorio, Laura; Mas, Sebastian; Abadi, Younes; Gracia-Iguacel, Carolina; Ortiz, Alberto; Egido, Jesus; Gonzalez-Parra, Emilio] Fdn Jimenez Diaz, Serv Nefrol, Madrid, Spain; [Villa-Bellosta, Ricardo; Rodriguez-Osorio, Laura; Mas, Sebastian; Gracia-Iguacel, Carolina; Mahillo, Ignacio; Ortiz, Alberto; Egido, Jesus; Gonzalez-Parra, Emilio] Fdn Jimenez Diaz IIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain; [Villa-Bellosta, Ricardo; Mas, Sebastian; Egido, Jesus] Spanish Biomed Res Network Diabet & Associated Me, Madrid, Spain; [Rodriguez-Osorio, Laura; Ortiz, Alberto; Gonzalez-Parra, Emilio] Spanish Kidney Res Network REDINREN, Madrid, Spain; [Rubert, Mercedes; de la Piedra, Concepcion] Fdn Jimenez Diaz, Serv Lab Bioquim, Madrid, Spain; [Ortiz, Alberto; Egido, Jesus; Gonzalez-Parra, Emilio] Univ Autonoma Madrid, Madrid, Spain	Fundacion Jimenez Diaz; Autonomous University of Madrid	Villa-Bellosta, R; Gonzalez-Parra, E (corresponding author), Fdn Jimenez Diaz, Serv Nefrol, Madrid, Spain.; Villa-Bellosta, R; Gonzalez-Parra, E (corresponding author), Fdn Jimenez Diaz IIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain.; Villa-Bellosta, R (corresponding author), Spanish Biomed Res Network Diabet & Associated Me, Madrid, Spain.; Gonzalez-Parra, E (corresponding author), Spanish Kidney Res Network REDINREN, Madrid, Spain.; Gonzalez-Parra, E (corresponding author), Univ Autonoma Madrid, Madrid, Spain.	ricardo.villa@fjd.es; egparra@fjd.es	Mas, S/T-1489-2018; ortiz, alberto/Y-7582-2018; Mahillo-Fernandez, Ignacio/T-2042-2018	Mas, S/0000-0001-6604-3327; ortiz, alberto/0000-0002-9805-9523; Villa-Bellosta, Ricardo/0000-0002-1680-552X; Mahillo-Fernandez, Ignacio/0000-0003-0558-6541	FIS [PI16/01298, PI13/00047, PI16/02057]; FEDER funds ISCIII-RETIC REDinREN [RD12/0021, RD16/0009]; FRIAT; Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CM); Spanish Ministerio de Economia y Competitividad [SAF-2014-60699-JIN]; Institute de Salud Carlos III [CD14/00198]	FIS(Instituto de Salud Carlos III); FEDER funds ISCIII-RETIC REDinREN; FRIAT; Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CM)(Instituto de Salud Carlos III); Spanish Ministerio de Economia y Competitividad(Spanish Government); Institute de Salud Carlos III(Instituto de Salud Carlos III)	This work was supported by FIS PI16/01298, PI13/00047, PI16/02057, FEDER funds ISCIII-RETIC REDinREN RD12/0021, RD16/0009, FRIAT and Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CM) to A.O. The Spanish Ministerio de Economia y Competitividad (SAF-2014-60699-JIN) and Institute de Salud Carlos III ("Sara borrell" CD14/00198 postdoctoral contract) supports R.V-B.	Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, P3588, DOI 10.1093/ndt/gfs108; de La Piedra C, 2008, NEFROLOGIA, V28, P123; Drechsler C, 2011, NEPHROL DIAL TRANSPL, V26, P1340, DOI 10.1093/ndt/gfq541; Drechsler C, 2009, NEPHROL DIAL TRANSPL, V24, P3151, DOI 10.1093/ndt/gfp260; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kovesdy CP, 2008, KIDNEY INT, V73, P1296, DOI 10.1038/ki.2008.64; Kovesdy CP, 2007, CLIN J AM SOC NEPHRO, V2, P1024, DOI 10.2215/CJN.01970507; Lertdumrongluk P, 2013, NEPHROL DIAL TRANSPL, V28, P2535, DOI 10.1093/ndt/gft290; Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009; Fernandez-Martin JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099; Merle E, 2016, KIDNEY INT, V89, P666, DOI 10.1016/j.kint.2015.12.001; Messa P, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0006-8; Moradi H, 2013, AM J NEPHROL, V38, P136, DOI 10.1159/000351758; Natoli JL, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-88; Neves KR, 2007, KIDNEY INT, V71, P1262, DOI 10.1038/sj.ki.5002241; Palmer SC, 2015, AM J KIDNEY DIS, V66, P962, DOI 10.1053/j.ajkd.2015.03.036; Parra EG, 2008, NEFROLOGIA, V28, P1; Snijder MB, 2005, J CLIN ENDOCR METAB, V90, P4119, DOI 10.1210/jc.2005-0216; Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F; Streja E, 2014, BONE, V61, P201, DOI 10.1016/j.bone.2014.01.016	25	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2017	12	3							e0173831	10.1371/journal.pone.0173831	http://dx.doi.org/10.1371/journal.pone.0173831			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER9AZ	28339474	gold, Green Submitted, Green Published			2023-01-03	WOS:000399116700014
J	Sgandurra, G; Lorentzen, J; Inguaggiato, E; Bartalena, L; Beani, E; Cecchi, F; Dario, P; Giampietri, M; Greisen, G; Herskind, A; Nielsen, JB; Rossi, G; Cioni, G				Sgandurra, Giuseppina; Lorentzen, Jakob; Inguaggiato, Emanuela; Bartalena, Laura; Beani, Elena; Cecchi, Francesca; Dario, Paolo; Giampietri, Matteo; Greisen, Gorm; Herskind, Anna; Nielsen, Jens Bo; Rossi, Giuseppe; Cioni, Giovanni		CareToy Consortium	A randomized clinical trial in preterm infants on the effects of a home-based early intervention with the 'CareToy System'	PLOS ONE			English	Article							BIRTH-WEIGHT CHILDREN; MOTOR DEVELOPMENT; CEREBRAL-PALSY; RISK; RELIABILITY; PLASTICITY; RECOVERY; VALIDITY; OUTCOMES; PROFILE	CareToy system is an innovative tele-rehabilitative tool, useful in providing intensive, individualized, home-based, family-centred Early Intervention (EI) in infants. Our aim was to evaluate, through a Randomized Clinical Trial (RCT) study, the effects of CareToy intervention on early motor and visual development in preterm infants. 41 preterm infants (range age: 3.0-5.9 months of corrected age) were enrolled and randomized into two groups, CareToy and Standard Care. 19 infants randomized in CareToy group performed a 4-week CareToy program, while 22 allocated to control group completed 4 weeks of Standard Care. Infant Motor Profile (IMP) was primary outcome measure, Alberta Infant Motor Scale (AIMS) and Teller Acuity Cards were secondary ones. Assessments were carried out at baseline (T0) and at the end of CareToy training or Standard Care period (T1). T1 was the primary endpoint. After RCT phase, 17 infants from control group carried out a 4-week CareToy program, while 18 infants from the CareToy group continued with Standard Care. At the end of this phase, infants were re-assessed at T2. In RCT phase, delta IMP total score and variation and performance sub-domains were significantly higher (P<0.050) in CareToy group if compared to Standard Care group. Similar results were found for Teller Acuity Cards, while no differences between groups were found for AIMS. No differences were found in any outcome measure results (T2-T0), between infants who started CareToy training before or after one month of standard care. This RCT study confirms the results of a previous pilot study, indicating that CareToy system can provide effective home-based EI.	[Sgandurra, Giuseppina; Inguaggiato, Emanuela; Beani, Elena; Cioni, Giovanni] IRCCS Fdn Stella Maris, Dept Dev Neurosci, Pisa, Italy; [Sgandurra, Giuseppina; Cioni, Giovanni] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy; [Lorentzen, Jakob; Herskind, Anna] Helene Elsass Ctr, Charlottenlund, Denmark; [Lorentzen, Jakob; Nielsen, Jens Bo] Univ Copenhagen, Dept Nutr Exercise & Sport, Copenhagen, Denmark; [Inguaggiato, Emanuela] Inst Life Sci, Scuola Super St Anna, Pisa, Italy; [Bartalena, Laura; Giampietri, Matteo] Pisa Univ Hosp Santa Chiara, Neonatal Intens Care Unit, Pisa, Italy; [Cecchi, Francesca; Dario, Paolo] BioRobot Inst, Polo St Anna Valdera, Pisa, Italy; [Greisen, Gorm; Herskind, Anna] Copenhagen Univ Hosp, Rigshosp, Dept Neonatol, Copenhagen, Denmark; [Herskind, Anna; Nielsen, Jens Bo] Univ Copenhagen, Dept Neurosci & Pharmacol, Copenhagen, Denmark; [Rossi, Giuseppe] CNR, Inst Clin Physiol, Unit Epidemiol & Biostat, Pisa, Italy	IRCCS Fondazione Stella Maris; University of Pisa; University of Copenhagen; Scuola Superiore Sant'Anna; Rigshospitalet; University of Copenhagen; University of Copenhagen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Sgandurra, G (corresponding author), IRCCS Fdn Stella Maris, Dept Dev Neurosci, Pisa, Italy.; Sgandurra, G (corresponding author), Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.	gsgandurra@fsm.unipi.it	Inguaggiato, Emanuela/K-3617-2018; Nielsen, Jens Bo/C-7632-2015; Inguaggiato, Emanuela/AAL-7004-2021; Sgandurra, Giuseppina/B-9961-2018; Beani, Elena/K-3121-2018; Beani, Elena/AAJ-6740-2021; Cioni, Giovanni/A-4178-2015; Greisen, Gorm/AAA-6463-2022; Giampietri, Matteo/K-8862-2016	Inguaggiato, Emanuela/0000-0002-0224-0628; Nielsen, Jens Bo/0000-0001-5568-2916; Inguaggiato, Emanuela/0000-0002-0224-0628; Sgandurra, Giuseppina/0000-0003-1081-1766; Beani, Elena/0000-0001-6931-7813; Beani, Elena/0000-0001-6931-7813; Cioni, Giovanni/0000-0002-6526-5566; Greisen, Gorm/0000-0001-8042-3262; CECCHI, FRANCESCA/0000-0001-5483-6354; Lorentzen, Jakob/0000-0002-7634-0218; Giampietri, Matteo/0000-0003-1878-7668	European Union under the Seventh Framework Program; theme Information and Communications Technology "Personal Health Systems (PHS)" [(ICT)-2011.5.1, ICT-2011.5.1-287932]	European Union under the Seventh Framework Program; theme Information and Communications Technology "Personal Health Systems (PHS)"	CareToy (http://www.caretoy.eu) was funded by the European Union under the Seventh Framework Program (https://ec.europa.eu/ research/fp7/index en.cfm), theme Information and Communications Technology (ICT)-2011.5.1 "Personal Health Systems (PHS)", Grant ICT-2011.5.1-287932 to PD, GC and JBN. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blauw-Hospers CH, 2005, DEV MED CHILD NEUROL, V47, P421, DOI 10.1017/S0012162205000824; Byblow W, 2016, ANN NEUROL, V80, P339, DOI 10.1002/ana.24735; Campbell SK, 2012, J PEDIATR REHAB MED, V5, P15, DOI 10.3233/PRM-2011-0185; Cecchi F, IEEE ROBOTI IN PRESS; Chakrabarty S, 2009, J NEUROPHYSIOL, V101, P1283, DOI 10.1152/jn.91026.2008; Cioni G, 2016, DEV MED CHILD NEUROL, V58, P61, DOI 10.1111/dmcn.13050; Cioni G, 2013, HAND CLINIC, V111, P3, DOI 10.1016/B978-0-444-52891-9.00001-4; Cohen J., 2013, STAT POWER ANAL BEHA; Darrah J, 1998, DEV MED CHILD NEUROL, V40, P485; de Kieviet JF, 2009, JAMA-J AM MED ASSOC, V302, P2235, DOI 10.1001/jama.2009.1708; Eyre JA, 2001, NEUROLOGY, V57, P1543, DOI 10.1212/WNL.57.9.1543; Geldof CJA, 2012, RES DEV DISABIL, V33, P726, DOI 10.1016/j.ridd.2011.08.025; Guzzetta A, 2009, J NEUROSCI, V29, P6042, DOI 10.1523/JNEUROSCI.5548-08.2009; Hadders-Algra M, 2010, PHYS THER, V90, P1823, DOI 10.2522/ptj.20100006; Hecker E, 2016, PEDIATR PHYS THER, V28, P217, DOI 10.1097/PEP.0000000000000244; Heineman KR, 2008, DEV MED CHILD NEUROL, V50, P275, DOI 10.1111/j.1469-8749.2008.02035.x; Heineman KR, 2013, DEV MED CHILD NEUROL, V55, P539, DOI 10.1111/dmcn.12100; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; Lang CE, 2016, ANN NEUROL, V80, P342, DOI 10.1002/ana.24734; Madan A, 2005, DEV MED CHILD NEUROL, V47, P276, DOI 10.1017/S0012162205000514; Manetti S, 2015, VALUE HEALTH, V18, pA358, DOI 10.1016/j.jval.2015.09.683; Martin JH, 2012, CLIN NEUROL NEUROSUR, V114, P515, DOI 10.1016/j.clineuro.2012.01.011; MCDONALD M, 1985, INVEST OPHTH VIS SCI, V26, P1158; Mitchell DE, 2009, PHILOS T R SOC B, V364, P383, DOI 10.1098/rstb.2008.0192; Morgan C, 2016, DEV MED CHILD NEUROL, V58, P900, DOI 10.1111/dmcn.13105; Morgan C, 2013, PEDIATRICS, V132, pE735, DOI 10.1542/peds.2012-3985; Orton J, 2009, DEV MED CHILD NEUROL, V51, P851, DOI 10.1111/j.1469-8749.2009.03414.x; Piper M.C., 1994, MOTOR ASSESSMENT DEV; Pratesi A, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0076-7; Purpura G, 2014, EARLY HUM DEV, V90, P809, DOI 10.1016/j.earlhumdev.2014.08.016; Rihar A, 2016, ANN BIOMED ENG; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Sgandurra G, 2016, RES DEV DISABIL, V53-54, P32, DOI 10.1016/j.ridd.2016.01.013; Sgandurra G, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-268; Spittle A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005495.pub3; Squires J., 2009, AGES STAGES QUESTION, V3rd ed, DOI DOI 10.1146/ANNUREV-BIOENG-071910-124654; van Hof-van Duin J, 1998, DEV MED CHILD NEUROL, V40, P302; Weller C, 2010, J WOUND CARE, V19, P347, DOI 10.12968/jowc.2010.19.8.77713	38	40	44	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0173521	10.1371/journal.pone.0173521	http://dx.doi.org/10.1371/journal.pone.0173521			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER8SZ	28328946	Green Published, Green Submitted, gold			2023-01-03	WOS:000399094700022
J	Zhou, LF; Zhang, MX; Kong, LQ; Liu, JJ; Feng, QM; Lu, W; Wei, B; Zhao, LP				Zhou, Li-fang; Zhang, Mao-xin; Kong, Ling-qian; Liu, Jun-jun; Feng, Qi-ming; Lu, Wei; Wei, Bo; Zhao, Lue Ping			Assessment of potential factors associating with costs of hospitalizing cardiovascular diseases in 141 hospitals in Guangxi, China	PLOS ONE			English	Article							HEALTH-INSURANCE; HEART-FAILURE; TRENDS	Background The rising cost of healthcare is of great concern in China, as evidenced by the media features negative reports almost daily. However there are only a few studies from well-developed cities, like Beijing or Shanghai, and little is known about healthcare costs in rest of the country. In this study, we use hospitalization summary reports (HSRs) from admitted cardiovascular diseases patients in Guangxi hospitals during 2013 - 2016, and we investigate temporal trends of healthcare costs and associated factors. Methods By generalized additive model, we compute temporal trends of cost per stay (CPS), cost per day (CPD) and others. We then use generalized linear models to assess which factors associate with CPS and CPD. Findings Using a total of 760,000 HSRs, we find that CPS appears to be stabilized around $ 1040 until the middle of year 2015, before exhibiting a downward trend. Similarly, CPD exhibits similar stable pattern. Meanwhile, surgery-specific CPS showed an increase in year 2013 - 2014, and then stabilized. Drug costs account for over 1/3 of CPS, but they are gradually declining. Costs associated with physicians' and nurses' services represent less than 5% of CPS. We found that age, sex, marital status, occupation and payment methods are significantly associated with CPS or CPD. Interestingly, we found no association between patient ethnicity and these costs. However, we did find that minority patients use more secondary hospitals than Han patients. Interpretations Healthcare costs in Guangxi are stable, contrary to the rise portrayed by Chinese mass media. Several factors can be associated with healthcare costs, and these may be useful for developing evidence-based policies. In particular, there is a need to encourage more Han patients to seek care in primary and secondary hospitals.	[Zhou, Li-fang; Zhang, Mao-xin; Liu, Jun-jun; Feng, Qi-ming; Wei, Bo] Guangxi Med Univ, Nanning, Peoples R China; [Zhou, Li-fang] Guangxi Med Univ, Fourth Affiliated Hosp, Liuzhou, Peoples R China; [Zhou, Li-fang; Zhao, Lue Ping] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Kong, Ling-qian; Lu, Wei] Hlth & Family Planning Commiss Guangxi, Nanning, Peoples R China	Guangxi Medical University; Guangxi Medical University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Wei, B (corresponding author), Guangxi Med Univ, Nanning, Peoples R China.; Zhao, LP (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.	weibogx@163.com; lzhao@fredhutch.org			Guangxi Education Department [YCBZ2015034]	Guangxi Education Department	This work is supported by Guangxi Education Department Grant (YCBZ2015034) entitled "Innovation Project of Guangxi Graduate Education" (LFZ). Other investigators are supported by their respective institutional supports.	Berry C, 2001, EUR J HEART FAIL, V3, P283, DOI 10.1016/S1388-9842(01)00123-4; Burner S T, 1992, Health Care Financ Rev, V14, P1; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; CHEN WWG, 2014, CHINESE CIRCULATION, V30, P617; Gao Sulan LW, 2013, CHINA MED ENG, V21, P133; Gu DF, 2005, CIRCULATION, V112, P658, DOI 10.1161/CIRCULATIONAHA.104.515072; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hongyu YGLSZ, 2013, J CHONGQING MED U, V38, P1378; Jia GS, 2013, J PEIKING U, V45, P382; Klenk J, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0089-x; Li C, 2011, SOC SCI MED, V73, P359, DOI 10.1016/j.socscimed.2011.06.002; Luengo-Fernandez R, 2006, HEART, V92, P1384, DOI 10.1136/hrt.2005.072173; McCullagh P, 1989, GEN LINEAR MODEL; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Sekhri N, 2005, B WORLD HEALTH ORGAN, V83, P127; Sun Xinxin YZ, 2013, MODERN BUSINESS TRAD, P132; Wood S.N, 2017, GEN ADDITIVE MODELS; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; Wu ZS, 2001, CIRCULATION, V103, P462; Xu Ling MQ, 2014, CHINESE J HLTH INFOR, P193; Xu Lixin LD, 2015, MOD HOSP, V15, P121; Yang Yuting, 2015, SHANGHAI CHIN J HOSP, V31, P271; Yao X, 2015, CHINESE HLTH EC, V34, P31; Zhang Qian ZD, 2016, J CARDIOVASCULAR PUL, V35, P75; Zhao LP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072166; Zhengjie LBZZF, 2006, CHINA TROPICAL MED, V6, P1513; 辛然, 2014, [中国老年学杂志, Chinese Journal of Gerontology], V34, P4308	27	1	1	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173451	10.1371/journal.pone.0173451	http://dx.doi.org/10.1371/journal.pone.0173451			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301501	Green Published, gold, Green Submitted			2023-01-03	WOS:000396318300041
J	Papadaki, A; Martinez, JA				Papadaki, Angeliki; Martinez, J. Alfredo			Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake	ANNALS OF INTERNAL MEDICINE			English	Letter							ADHERENCE		[Papadaki, Angeliki] Univ Bristol, Bristol, Avon, England; [Martinez, J. Alfredo] Univ Navarra, CIBERobn Nutr, Pamplona, Spain	University of Bristol; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; University of Navarra	Papadaki, A (corresponding author), Univ Bristol, Bristol, Avon, England.		Martinez-Gonzalez, Miguel A./AAE-7669-2019	Papadaki, Angeliki/0000-0002-5728-3975				Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Fung TT, 2008, ARCH INTERN MED, V168, P713, DOI 10.1001/archinte.168.7.713; Papadaki A, 2009, NUTR DIET RES PROG, P285; Sayon-Orea C, 2015, MENOPAUSE, V22, P750, DOI 10.1097/GME.0000000000000378; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169	5	1	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					377	378		10.7326/L16-0590	http://dx.doi.org/10.7326/L16-0590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28265658				2023-01-03	WOS:000396432800017
J	Belknap, SM				Belknap, Steven M.			Current vs past use of NSAIDs was linked to increased risk for first HF hospitalization; risk varied by drug	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Belknap, Steven M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Belknap, SM (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.			Belknap, Steven/0000-0002-3670-7409				Centers for Disease Control and Prevention, THER DRUG US; Lederle FA, 2016, ANN INTERN MED, V165, P663, DOI 10.7326/M16-1208; Shah NH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124653	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2017	166	4					JC23	JC23		10.7326/ACPJC-2017-166-4-023	http://dx.doi.org/10.7326/ACPJC-2017-166-4-023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL7FO	28241296				2023-01-03	WOS:000394786700011
J	de Queiroz, KB; Honorato-Sampaio, K; Rossoni, JV; Leal, DA; Pinto, ABG; Kappes-Becker, L; Evangelista, EA; Guerra-Sa, R				de Queiroz, Karina Barbosa; Honorato-Sampaio, Kinulpe; Rossoni Junior, Joamyr Victor; Leal, Diego Andrade; Pinto, Angelica Barbosa G.; Kappes-Becker, Lenice; Evangelista, Elisio Alberto; Guerra-Sa, Renata			Physical activity prevents alterations in mitochondrial ultrastructure and glucometabolic parameters in a high-sugar diet model	PLOS ONE			English	Article							TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; ACTIVATED PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; OXIDATIVE STRESS; GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; UP-REGULATION; EXERCISE	Endurance exercise is a remarkable intervention for the treatment of many diseases. Mitochondria) changes on skeletal muscle are likely important for many of the benefits provided by exercise. In this study, we aimed to evaluate the effects that a regular physical activity (swimming withoutworkload) has on mitochondrial morphological alterations and glucometabolic parameters induced by a high-sugar diet (HSD). Weaned male Wistar rats fed with a standard diet or a HSD (68% carbohydrate) were subjected to 60 minutes of regular physical activity by swimming (without workload) for four- (20 sessions) or eight-week (40 sessions) periods. After training, animals were euthanized and the sera, adipose tissues, and skeletal muscles were collected for further analysis. The HSD increased body weight after an 8 week period; it also increased the fat pads and the adipose index, resulting in glucose intolerance and insulin resistance (IR). Transmission electron microscopy showed an increase in alterations of mitochondrial ultrastructure in the gastrocnemius muscle, as well as a decrease in superoxide dismutase (SOD) activity, and an increase in protein carbonylation. Regular physical activity partially reverted these alterations in rats fed a HSD, preventing mitochondrial morphological alterations and IR. Moreover, we observed a decrease in Pgcla expression (qPCR analysis) in STD-EXE group and a less pronounced reduction in HSD-EXE group after an 8-week period. Thus, regular physical activity (swimming without workload) in rats fed a HSD can prevent mitochondrial dysfunction and IR, highlighting the crucial role for physical activity on metabolic homeostasis.	[de Queiroz, Karina Barbosa; Leal, Diego Andrade; Evangelista, Elisio Alberto; Guerra-Sa, Renata] Univ Fed Ouro Preto, Nucleo Pesquisas Ciencias Biol, Lab Bioquim & Biol Mol, Ouro Preto, MG, Brazil; [Honorato-Sampaio, Kinulpe] Univ Fed Vales Jequitinhonha & Mucuri, Fac Med, Campus JK, Diamantina, MG, Brazil; [Rossoni Junior, Joamyr Victor] Univ Fed Ouro Preto, Nucleo Pesquisas Ciencias Biol, Lab Bioquim Metab, Ouro Preto, MG, Brazil; [Pinto, Angelica Barbosa G.; Kappes-Becker, Lenice] Univ Fed Ouro Preto, Ctr Esportes, Ouro Preto, MG, Brazil	Universidade Federal de Ouro Preto; Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal de Ouro Preto; Universidade Federal de Ouro Preto	de Queiroz, KB (corresponding author), Univ Fed Ouro Preto, Nucleo Pesquisas Ciencias Biol, Lab Bioquim & Biol Mol, Ouro Preto, MG, Brazil.	karinabq@gmail.com	de Queiroz, Karina Barbosa/S-9628-2017; Honorato-Sampaio, Kinulpe/AAX-3742-2021	de Queiroz, Karina Barbosa/0000-0002-8171-435X; Honorato-Sampaio, Kinulpe/0000-0002-8154-9606; Rossoni Junior, Joamyr Victor/0000-0002-1882-4249	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeigoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeigoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This work was supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeigoamento de Pessoal de Nivel Superior (CAPES), and the Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; Baar K, 2004, P NUTR SOC, V63, P269, DOI 10.1079/PNS2004334; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barbieri E, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/917085; Becker C, 2010, METHODS, V50, P237, DOI 10.1016/j.ymeth.2010.01.010; Bhatt BA, 2006, AM J PHYSIOL-REG I, V290, pR233, DOI 10.1152/ajpregu.00097.2005; Bluher S, 2014, METABOLISM; Broskey NT, 2013, J APPL PHYSIOL, V115, P765, DOI 10.1152/japplphysiol.00063.2013; Chan CYY, 2013, EUR J NUTR, V52, P1721, DOI 10.1007/s00394-012-0475-5; Chu L, 2011, EUR J APPL PHYSIOL, V111, P3135, DOI 10.1007/s00421-011-1940-1; de Lima DC, 2008, METAB BRAIN DIS, V23, P361, DOI 10.1007/s11011-008-9101-x; de Queiroz KB, 2014, MOL NUTR FOOD RES, V58, P2331, DOI 10.1002/mnfr.201400241; de Queiroz KB, 2014, LIPIDS, V49, P85, DOI 10.1007/s11745-013-3854-7; de Queiroz KB, 2012, NUTR RES, V32, P709, DOI 10.1016/j.nutres.2012.06.020; de Souza MO, 2010, NUTRITION, V26, P804, DOI 10.1016/j.nut.2009.09.007; Evangelista FS, 2003, BRAZ J MED BIOL RES, V36, P1751, DOI 10.1590/S0100-879X2003001200018; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Freyssenet D, 1996, ARCH PHYSIOL BIOCHEM, V104, P129, DOI 10.1076/apab.104.2.129.12878; Gatineau E, 2015, J NUTR, V145, P923, DOI 10.3945/jn.114.205583; GOLLNICK PD, 1969, AM J PHYSIOL, V216, P1502, DOI 10.1152/ajplegacy.1969.216.6.1502; Gomez-Cabrera MC, 2008, FREE RADICAL BIO MED, V44, P126, DOI 10.1016/j.freeradbiomed.2007.02.001; Gomez-Cabrera MC, 2006, BRIT J NUTR, V96, pS31, DOI 10.1079/BJN20061696; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Guran T, 2011, MINERVA PEDIATR, V63, P483; Hackman CL, 2014, ADOLESC HEALTH MED T, V5, P101, DOI 10.2147/AHMT.S56207; Hancock CR, 2008, P NATL ACAD SCI USA, V105, P7815, DOI 10.1073/pnas.0802057105; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heilbronn LK, 2007, J CLIN ENDOCR METAB, V92, P1467, DOI 10.1210/jc.2006-2210; Santos SHS, 2008, DIABETES, V57, P340, DOI 10.2337/db07-0953; Hood DA, 2009, APPL PHYSIOL NUTR ME, V34, P465, DOI 10.1139/H09-045; Horowitz JF, 2000, AM J CLIN NUTR, V72, p558S, DOI 10.1093/ajcn/72.2.558S; Joslowski G, 2012, INT J OBES LOND; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Kregel KC, 2006, EXERCISE PROTOCOLS U, P35; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Little JP, 2011, APPL PHYSIOL NUTR ME, V36, P598, DOI [10.1139/H11-076, 10.1139/h11-076]; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ljubicic V, 2010, BBA-GEN SUBJECTS, V1800, P223, DOI 10.1016/j.bbagen.2009.07.031; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McDevitt RM, 2001, AM J CLIN NUTR, V74, P737; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; Mittendorfer B, 2003, NUTR RES REV, V16, P97, DOI 10.1079/NRR200357; Montgomery MK, 2015, ENDOCR CONNECT, V4, DOI 10.1530/EC-14-0092; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06-S002; Morton TL, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00080; O'Neill HM, 2011, P NATL ACAD SCI USA, V108, P16092, DOI 10.1073/pnas.1105062108; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perry CGR, 2010, J PHYSIOL-LONDON, V588, P4795, DOI 10.1113/jphysiol.2010.199448; Phielix E, 2010, DIABETOLOGIA, V53, P1714, DOI 10.1007/s00125-010-1764-2; PITTS GC, 1984, AM J PHYSIOL, V246, pR495, DOI 10.1152/ajpregu.1984.246.4.R495; Pogozelski AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007934; Radak Z, 1999, FREE RADICAL BIO MED, V27, P69, DOI 10.1016/S0891-5849(99)00038-6; Rimbert V, 2004, FASEB J, V18, P737, DOI 10.1096/fj.03-1104fje; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Rowe GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041817; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Skledar MT, 2015, CENT EUR J PUBL HEAL, V23, P26, DOI 10.21101/cejph.a3956; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Stephen A, 2012, EUR J CLIN NUTR, V66, P765, DOI 10.1038/ejcn.2012.27; Stump CS, 2006, ANN MED, V38, P389, DOI 10.1080/07853890600888413; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Turner N, 2013, DIABETOLOGIA, V56, P1638, DOI 10.1007/s00125-013-2913-1; Ustunel I, 1997, ACTA ANAT, V158, P279; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xiao T, 2015, EUR REV MED PHARMACO, V19, P1779; YAMADA T, 1975, J LAB CLIN MED, V86, P38; Yan Z, 2012, EXERC SPORT SCI REV, V40, P159, DOI 10.1097/JES.0b013e3182575599; YANG XL, 1995, ANAT RECORD, V241, P255, DOI 10.1002/ar.1092410212	80	10	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2017	12	2							e0172103	10.1371/journal.pone.0172103	http://dx.doi.org/10.1371/journal.pone.0172103			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BF	28199417	Green Published, gold, Green Submitted			2023-01-03	WOS:000394424400072
J	Oh, K; Oh, EH; Baek, S; Song, EM; Kim, GU; Seo, M; Hwang, SW; Park, SH; Yang, DH; Kim, KJ; Byeon, JS; Myung, SJ; Yang, SK; Ye, BD				Oh, Kyunghwan; Oh, Eun Hye; Baek, Seunghee; Song, Eun Mi; Kim, Gwang-Un; Seo, Myeongsook; Hwang, Sung Wook; Park, Sang Hyoung; Yang, Dong-Hoon; Kim, Kyung-Jo; Byeon, Jeong-Sik; Myung, Seung-Jae; Yang, Suk-Kyun; Ye, Byong Duk			Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; OLMSTED COUNTY; ACTIVITY INDEX; SURGERY; RISK; CLASSIFICATION; PREVALENCE; MINNESOTA; SERUM	Intestinal inflammation and mucosal damage in Crohn's disease (CD) are believed to progress even during clinical remission. We investigated the long-term prognosis of CD patients in clinical remission according to serum C-reactive protein (CRP) levels. This study included 339 CD patients in clinical remission (Crohn's disease activity index < 150) for more than 6 months between January 2008 and December 2010. Clinical outcomes were compared between patients with normal and elevated CRP levels during clinical remission. During clinical remission, 150 patients had normal CRP consistently and 189 had elevated CRP at least once. During follow-up (median, 7.9 years [interquartile range, 6.8-8.0]), the Kaplan Meier analysis with the log-rank test showed that normal CRP group had a longer CD related hospitalization-free survival (P = 0.007) and a longer CD-related intestinal resection free survival (P = 0.046) than elevated CRP group. In multivariate analysis, elevated CRP was significantly and independently associated with an increased risk of subsequent CD related hospitalization (adjusted hazard ratio [aHR] 1.787, 95% confidence interval [CI]: 1.245-2.565, P = 0.002) and of subsequent CD-related intestinal resection (aHR 1.726, 95% CI: 1.003-2.969, P = 0.049). The most common reason for CD-related hospitalization was penetrating complications (35.6%). Even when CD patients are in clinical remission, elevated CRP is significantly associated with subsequent CD-related hospitalization and CD-related intestinal resection during follow-up. CD patients in clinical remission but elevated CRP should receive more careful attention and timely interventions to improve long-term outcomes.	[Oh, Kyunghwan] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea; [Oh, Eun Hye; Song, Eun Mi; Kim, Gwang-Un; Seo, Myeongsook; Hwang, Sung Wook; Park, Sang Hyoung; Yang, Dong-Hoon; Kim, Kyung-Jo; Byeon, Jeong-Sik; Myung, Seung-Jae; Yang, Suk-Kyun; Ye, Byong Duk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea; [Baek, Seunghee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea; [Hwang, Sung Wook; Park, Sang Hyoung; Kim, Kyung-Jo; Yang, Suk-Kyun; Ye, Byong Duk] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Ye, BD (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea.; Ye, BD (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea.	bdye@amc.seoul.kr	Ye, Byong Duk/AAF-4955-2020; Park, Sang Hyoung/CAH-4735-2022; Yang, Dong-Hoon/B-3437-2015	Ye, Byong Duk/0000-0001-6647-6325; Yang, Dong-Hoon/0000-0001-7756-2704				Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; ANDRE C, 1983, SCOT MED J, V28, P25, DOI 10.1177/003693308302800106; Baert F, 2010, GASTROENTEROLOGY, V138, P463, DOI 10.1053/j.gastro.2009.09.056; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BOIRIVANT M, 1988, J CLIN GASTROENTEROL, V10, P401, DOI 10.1097/00004836-198808000-00011; Bouguen G, 2011, GUT, V60, P1178, DOI 10.1136/gut.2010.234617; Click B, 2015, INFLAMM BOWEL DIS, V21, P2254, DOI 10.1097/MIB.0000000000000516; D'Haens G, 2008, LANCET, V371, P660, DOI 10.1016/S0140-6736(08)60304-9; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; Hu PJ, 2015, INTEST RES, V13, P188, DOI 10.5217/ir.2015.13.3.188; Jones J, 2008, CLIN GASTROENTEROL H, V6, P1218, DOI 10.1016/j.cgh.2008.06.010; Lajos SK, 2012, INFLAMM BOWEL DIS, V18, P1647, DOI 10.1002/ibd.21933; Lee YJ, 2006, ENDOSCOPY, V38, P592, DOI 10.1055/s-2006-924996; Loftus EV, 1998, GASTROENTEROLOGY, V114, P1161, DOI 10.1016/S0016-5085(98)70421-4; MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Niewiadomski O, 2015, J GASTROEN HEPATOL, V30, P1346, DOI 10.1111/jgh.12967; Pandey A, 2015, INFLAMM BOWEL DIS, V21, P2625, DOI 10.1097/MIB.0000000000000525; Papi C, 2013, DIGEST LIVER DIS, V45, P978, DOI 10.1016/j.dld.2013.07.006; Pariente B, 2011, INFLAMM BOWEL DIS, V17, P1415, DOI 10.1002/ibd.21506; Park SH, 2014, INFLAMM BOWEL DIS, V20, P488, DOI 10.1097/01.MIB.0000441203.56196.46; Peyrin-Biroulet L, 2015, AM J GASTROENTEROL, V110, P1324, DOI 10.1038/ajg.2015.233; Peyrin-Biroulet L, 2014, GUT, V63, P88, DOI 10.1136/gutjnl-2013-304984; Peyrin-Biroulet L, 2012, AM J GASTROENTEROL, V107, P1693, DOI 10.1038/ajg.2012.298; Peyrin-Biroulet L, 2011, J CROHNS COLITIS, V5, P477, DOI 10.1016/j.crohns.2011.06.009; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; Schoepfer AM, 2010, AM J GASTROENTEROL, V105, P162, DOI 10.1038/ajg.2009.545; Solem CA, 2005, INFLAMM BOWEL DIS, V11, P707, DOI 10.1097/01.MIB.0000173271.18319.53; Sorrentino D, 2016, INFLAMM BOWEL DIS, V22, P476, DOI 10.1097/MIB.0000000000000612; Thia K, 2011, INFLAMM BOWEL DIS, V17, P105, DOI 10.1002/ibd.21400; Veloso FT, 2001, INFLAMM BOWEL DIS, V7, P306, DOI 10.1097/00054725-200111000-00005; Yang SK, 2008, INFLAMM BOWEL DIS, V14, P542, DOI 10.1002/ibd.20310	33	26	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2017	12	6							e0179266	10.1371/journal.pone.0179266	http://dx.doi.org/10.1371/journal.pone.0179266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX8NF	28622356	Green Published, gold, Green Submitted			2023-01-03	WOS:000403506300017
J	Miranda, I; Sousa, V; Ferreira, J; Pereira, H				Miranda, Isabel; Sousa, Vicelina; Ferreira, Joana; Pereira, Helena			Chemical characterization and extractives composition of heartwood and sapwood from Quercus faginea	PLOS ONE			English	Article							AMERICAN OAK WOODS; WEIGHT PHENOLIC-COMPOUNDS; ANTIOXIDANT CAPACITY; GEOGRAPHICAL ORIGIN; DENSITY COMPONENTS; RING WIDTH; SPANISH; ELLAGITANNINS; PORTUGUESE; EVOLUTION	Heartwood and sapwood of Quercus faginea were evaluated in relation to summative chemical composition and non-polar and polar extracts composition, including an assessment of antioxidant properties (DPPH and FRAP). Twenty trees from two sites in Portugal were analysed. Heartwood had approximately two times more solvent extractible compounds than sapwood (on average 19.0% and 9.5%). The lipophilic extractible compounds were below 1%, and most of them were polar e.g. ethanol-soluble compounds corresponded to 65% of total extractives in heartwood and 43% in sapwood. Lignin content was similar in sapwood and heartwood (28.1% and 28.6% of extractive-free wood respectively) as well as the sugar composition. Site did not influence the chemical composition. The lipophilic extractible compounds from both sapwood and heartwood included mainly saturated fatty acids (23.0% and 36.9% respectively) and aromatic compounds were also abundant in sapwood (22.9%). The ethanol-water extractibles had a high content of phenolic substances (558.0 and 319.4 mg GAE/g extract, respectively of heartwood and sapwood). The polyphenolic composition was similar in heartwood and sapwood with higher content of ellagitannins (168.9 and 153.5 mg tannic acid/g of extract in sapwood and heartwood respectively) and very low content of condensed tannins. The antioxidant activity was very high with IC50 of 2.6 mu g/ml and 3.3 mu g/ml for sapwood and heartwood respectively, as compared to standard antioxidants (IC50 of 3.8 mu g/ml for Trolox). The ferric reducing ability was 2.8 and 2.0 mMol Trolox equivalents/g extract of heartwood and sapwood respectively. The variability between trees was low and no differences between the two sites were found. Q. faginea showed a very good potential for cooperage and other applications for which a source of compounds with antioxidant properties is desirable.	[Miranda, Isabel; Sousa, Vicelina; Ferreira, Joana; Pereira, Helena] Univ Lisbon, Inst Super Agron, Ctr Estudos Florestais, Lisbon, Portugal	Universidade de Lisboa	Ferreira, J (corresponding author), Univ Lisbon, Inst Super Agron, Ctr Estudos Florestais, Lisbon, Portugal.	jpferreira@isa.ulisboa.pt	Ferreira, Joana/I-6369-2019; Pereira, Helena/V-5236-2019; Sousa, Vicelina/B-3067-2016	Ferreira, Joana/0000-0002-7637-3466; Pereira, Helena/0000-0002-5393-4443; Sousa, Vicelina/0000-0003-4221-0041; Miranda, Isabel/0000-0003-0280-5219	Portuguese Science Foundation (FCT) [PTDC/AGR-AAM/69077/2006]; FCT [UID/AGR/00239/2013, SFRH/BPD/97970/2013]	Portuguese Science Foundation (FCT)(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	The sampling for this research was supported by the Portuguese Project OAKWOODS (PTDC/AGR-AAM/69077/2006) from the Portuguese Science Foundation (FCT) and we thank Jose L. Louzada for providing the samples from Site 1 and Sofia Knapic for project management. We also thank Joaquina Silva and Lidia Silva for help with the chemical analysis. Centro de Estudos Florestais is a research unit funded by FCT under UID/AGR/00239/2013. The second author acknowledges a post-doc scholarship by FCT (SFRH/BPD/97970/2013).	Abdalla S, 2014, BIORESOURCES, V9, P3396; Alanon ME, 2011, FOOD CHEM, V129, P1584, DOI 10.1016/j.foodchem.2011.06.013; Alanon ME, 2011, FOOD CHEM, V128, P997, DOI 10.1016/j.foodchem.2011.04.005; [Anonymous], 2013, IFN6 AR US SOL ESP F; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Blanchette R.A., 1992, DEFENSE MECH WOODY P; Cadahia E, 2003, J AGR FOOD CHEM, V51, P5923, DOI 10.1021/jf0302456; Cadahia E, 2001, J AGR FOOD CHEM, V49, P1790, DOI 10.1021/jf0006168; Cadahia E, 2001, J AGR FOOD CHEM, V49, P3677, DOI 10.1021/jf010288r; Canas S, 2000, HOLZFORSCHUNG, V54, P255, DOI 10.1515/HF.2000.043; Castro-Vazquez L, 2013, EUR FOOD RES TECHNOL, V237, P367, DOI 10.1007/s00217-013-1999-5; de Simon BF, 1999, J AGR FOOD CHEM, V47, P1687, DOI 10.1021/jf9805855; de Simon BF, 1999, HOLZFORSCHUNG, V53, P147, DOI 10.1515/HF.1999.024; De Simon BF, 2006, J AGR FOOD CHEM, V54, P8314, DOI 10.1021/jf061546t; deSimon BF, 1996, J AGR FOOD CHEM, V44, P1507, DOI 10.1021/jf9502461; EGLINTON G, 1968, PHYTOCHEMISTRY, V7, P313, DOI 10.1016/S0031-9422(00)86330-X; EKMAN R, 1979, Acta Academiae Aboensis Ser B Mathematica et Physica, V39, P1; Fries A, 2000, CAN J FOREST RES, V30, P1707, DOI 10.1139/cjfr-30-11-1707; Hernandez RB, 2005, CIENCIA FORESTAL MEX, V30, P25; Jordao AM, 2007, HOLZFORSCHUNG, V61, P155, DOI 10.1515/HF.2007.028; Knapic S, 2007, ANN FOREST SCI, V64, P211, DOI 10.1051/forest:2006105; Knapic S, 2011, CAN J FOREST RES, V41, P1212, DOI [10.1139/X11-038, 10.1139/x11-038]; KOLATTUKUDY PE, 1974, LIPIDS, V9, P682, DOI 10.1007/BF02532176; Lourenco A, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01612; Lourenco A, 2008, J WOOD SCI, V54, P464, DOI 10.1007/s10086-008-0972-6; MILLER DP, 1992, AM J ENOL VITICULT, V43, P333; Miranda I, 2006, CAN J FOREST RES, V36, P2675, DOI 10.1139/X06-130; Miranda I, 2011, J WOOD SCI, V57, P171, DOI 10.1007/s10086-010-1164-8; Morais MC, 2012, WOOD SCI TECHNOL, V46, P709, DOI 10.1007/s00226-011-0438-7; Pereira H., 2003, WOOD QUALITY ITS BIO, P53; Reboredo F, 2014, J FORESTRY RES, V25, P249, DOI 10.1007/s11676-014-0456-z; Ruiz-Aquino F, 2015, IND CROP PROD, V65, P90, DOI 10.1016/j.indcrop.2014.11.024; Salem MZM, 2014, BIORESOURCES, V9, P2382; Sanz M, 2012, ANAL CHIM ACTA, V732, P33, DOI 10.1016/j.aca.2011.12.012; SCALBERT A, 1988, PHYTOCHEMISTRY, V27, P3483, DOI 10.1016/0031-9422(88)80753-2; SEIKEL MK, 1971, PHYTOCHEMISTRY, V10, P2249, DOI 10.1016/S0031-9422(00)97238-8; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Sjostrom E, 1993, WOOD CHEM, V2nd, DOI DOI 10.1016/B978-0-08-092589-9.50005-X; Sousa VB, 2013, WOOD FIBER SCI, V45, P405; Sousa VB, 2015, IFOREST, V8, DOI 10.3832/ifor1346-008; Sousa VB, 2014, IAWA J, V35, P293, DOI 10.1163/22941932-00000067; Willis RB, 1998, ANALYST, V123, P435, DOI 10.1039/a706862j; Zhang B, 2015, INT J MOL SCI, V16, P6978, DOI 10.3390/ijms16046978	44	37	37	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2017	12	6							e0179268	10.1371/journal.pone.0179268	http://dx.doi.org/10.1371/journal.pone.0179268			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX5KN	28614371	Green Published, gold, Green Submitted			2023-01-03	WOS:000403280900038
J	Christensen, A; Pike, CJ				Christensen, Amy; Pike, Christian J.			Age-dependent regulation of obesity and Alzheimer-related outcomes by hormone therapy in female 3xTg-AD mice	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-ALPHA; TRANSGENIC MOUSE MODEL; HIGH-FAT DIET; COGNITIVE IMPAIRMENT; INSULIN-RESISTANCE; ADIPOSE-TISSUE; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; AMYLOID DEPOSITION; KNOCKOUT MICE	Depletion of ovarian hormones at menopause is associated with increased Alzheimer's disease (AD) risk. Hormone loss also increases central adiposity, which promotes AD development. One strategy to improve health outcomes in postmenopausal women is estrogen based hormone therapy (HT), though its efficacy is controversial. The window of opportunity hypothesis posits that HT is beneficial only if initiated near the onset of menopause. Here, we tested this hypothesis by assessing the efficacy of HT against diet-induced obesity and AD-related pathology in female 3xTg-AD mice at early versus late middle-age. HT protected against obesity and reduced P-amyloid burden only at early middle-age. One mechanism that contributes to AD pathogenesis is microglial activation, which is increased by obesity and reduced by estrogens. In parallel to its effects on P-amyloid accumulation, we observed that HT reduced morphological evidence of microglial activation in early but not late middle age. These findings suggest that HT may be effective during human perimenopause in reducing indices of obesity and AD-related pathology, a conclusion consistent with the window of opportunity hypothesis.	[Christensen, Amy; Pike, Christian J.] Univ Southern Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90007 USA	University of Southern California	Pike, CJ (corresponding author), Univ Southern Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90007 USA.	cjpike@usc.edu	Pike, Christian J/D-4013-2018	Christensen, Amy/0000-0002-3357-0523; Pike, Christian/0000-0003-4577-7668	National Institute on Aging [AG026572, T32 AG052374]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG026572, R01AG034103, T32AG052374] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by National Institute on Aging (https://www.nia.nih.gov/) grant AG026572 awarded to R. Brinton/CJP. AC was supported in part by National Institute on Aging (https://www.nia.nih.gov/) grant T32 AG052374. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aenlle KK, 2009, NEUROBIOL AGING, V30, P932, DOI 10.1016/j.neurobiolaging.2007.09.004; Arimoto JM, 2013, ENDOCRINOLOGY, V154, P2101, DOI 10.1210/en.2012-2046; Ayoub AE, 2003, J NEUROSCI, V23, P7759; Bagger YZ, 2005, MENOPAUSE, V12, P12, DOI 10.1097/00042192-200512010-00005; Barron AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078554; Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Brossia LJ, 2009, J AM ASSOC LAB ANIM, V48, P517; Buckman LB, 2014, BRAIN BEHAV IMMUN, V35, P33, DOI 10.1016/j.bbi.2013.06.007; Cai M, 2014, NEUROSCI LETT, V558, P115, DOI 10.1016/j.neulet.2013.11.007; Cao DF, 2007, J BIOL CHEM, V282, P36275, DOI 10.1074/jbc.M703561200; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Carroll JC, 2008, ENDOCRINOLOGY, V149, P2607, DOI 10.1210/en.2007-1346; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Carroll JC, 2010, ENDOCRINOLOGY, V151, P2713, DOI 10.1210/en.2009-1487; Christensen A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00130; Collins DE, 2017, COMPARATIVE MED, V67, P11; Daniel JM, 2006, ENDOCRINOLOGY, V147, P607, DOI 10.1210/en.2005-0998; Davis KE, 2013, MOL METAB, V2, P227, DOI 10.1016/j.molmet.2013.05.006; Davis SR, 2012, CLIMACTERIC, V15, P419, DOI 10.3109/13697137.2012.707385; Ekdahl CT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00041; FELICIO LS, 1984, BIOL REPROD, V31, P446, DOI 10.1095/biolreprod31.3.446; Finch CE, 2014, J STEROID BIOCHEM, V142, P132, DOI 10.1016/j.jsbmb.2013.03.010; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Frick KM, 2002, NEUROSCIENCE, V115, P547, DOI 10.1016/S0306-4522(02)00377-9; Fugger HN, 2000, BRAIN RES, V883, P258, DOI 10.1016/S0006-8993(00)02993-0; Gandy S, 2000, EXP GERONTOL, V35, P503, DOI 10.1016/S0531-5565(00)00116-9; Gao S, 2010, BIOCHEM BIOPH RES CO, V398, P619, DOI 10.1016/j.bbrc.2010.05.114; Gardner WU, 1937, ENDOCRINOLOGY, V21, P727, DOI 10.1210/endo-21-6-727; Gimenez-Llort L, 2007, NEUROSCI BIOBEHAV R, V31, P125, DOI 10.1016/j.neubiorev.2006.07.007; Gimenez-Llort L, 2008, NEUROIMMUNOMODULAT, V15, P331, DOI 10.1159/000156475; Gold M, 2015, SEMIN IMMUNOPATHOL, V37, P607, DOI 10.1007/s00281-015-0518-0; Gonzalez C, 2000, J ENDOCRINOL, V166, P283, DOI 10.1677/joe.0.1660283; Guillemot-Legris O, 2017, TRENDS NEUROSCI, V40, P237, DOI 10.1016/j.tins.2017.02.005; Guillemot-Legris O, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0666-8; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Henderson VW, 2005, J NEUROL NEUROSUR PS, V76, P103, DOI 10.1136/jnnp.2003.024927; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Hughes TF, 2009, NEUROLOGY, V72, P1741, DOI 10.1212/WNL.0b013e3181a60a58; Hwang LL, 2010, OBESITY, V18, P463, DOI 10.1038/oby.2009.273; Jayaraman A, 2014, ENDOCRINOLOGY, V155, P1398, DOI 10.1210/en.2013-1725; Jayaraman A, 2012, ENDOCRINOLOGY, V153, P5467, DOI 10.1210/en.2012-1464; Kanaya AM, 2003, AM J EPIDEMIOL, V158, P1161, DOI 10.1093/aje/kwg271; Kanoski SE, 2011, PHYSIOL BEHAV, V103, P59, DOI 10.1016/j.physbeh.2010.12.003; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; KIRK EA, 1995, J LIPID RES, V36, P1522; Knight EM, 2014, NEUROBIOL AGING, V35, P1821, DOI 10.1016/j.neurobiolaging.2014.02.010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maesako M, 2012, J BIOL CHEM, V287, P23024, DOI 10.1074/jbc.M112.367011; Maki PM, 2013, MENOPAUSE, V20, P695, DOI [10.1097/GME.0b013e3182960cf8, 10.1097/gme.0b013e3182960cf8]; Manrique C, 2012, CARDIORENAL MED, V2, P200, DOI 10.1159/000339563; Markowska AL, 2002, J NEUROSCI, V22, P10985; Mela V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048915; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Ordonez P, 2007, EXP PHYSIOL, V92, P241, DOI 10.1113/expphysiol.2006.035006; Paganini-Hill A, 1998, Int J Pharm Compd, V2, P24; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Palm R, 2014, J NEUROCHEM, V130, P115, DOI 10.1111/jnc.12706; Pan XD, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-45; Parachikova A, 2010, J ALZHEIMERS DIS, V21, P527, DOI 10.3233/JAD-2010-100204; Petanceska SS, 2000, EXP GERONTOL, V35, P1317, DOI 10.1016/S0531-5565(00)00157-1; Pettersson US, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046057; Picard F, 2002, P NATL ACAD SCI USA, V99, P15644, DOI 10.1073/pnas.202612199; Pike CJ, 2017, J NEUROSCI RES, V95, P671, DOI 10.1002/jnr.23827; Pike CJ, 2009, FRONT NEUROENDOCRIN, V30, P239, DOI 10.1016/j.yfrne.2009.04.015; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Profenno LA, 2010, BIOL PSYCHIAT, V67, P505, DOI 10.1016/j.biopsych.2009.02.013; Puig KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030378; Rae EA, 2015, NEUROSCI BIOBEHAV R, V57, P238, DOI 10.1016/j.neubiorev.2015.09.002; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rosario ER, 2006, J NEUROSCI, V26, P13384, DOI 10.1523/JNEUROSCI.2514-06.2006; Setti SE, 2015, PHYSIOL BEHAV, V141, P1, DOI 10.1016/j.physbeh.2014.12.036; Shao HB, 2012, NEUROLOGY, V79, P1846, DOI 10.1212/WNL.0b013e318271f823; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; SIITERI PK, 1987, AM J CLIN NUTR, V45, P277, DOI 10.1093/ajcn/45.1.277; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Stubbins RE, 2012, EUR J NUTR, V51, P861, DOI 10.1007/s00394-011-0266-4; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thaler JP, 2010, FRONT NEUROENDOCRIN, V31, P79, DOI 10.1016/j.yfrne.2009.10.002; Tucsek Z, 2014, J GERONTOL A-BIOL, V69, P1212, DOI 10.1093/gerona/glt177; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Whitmer RA, 2008, NEUROLOGY; Whitmer RA, 2011, ANN NEUROL, V69, P163, DOI 10.1002/ana.22239; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Xu WL, 2011, NEUROLOGY, V76, P1568, DOI 10.1212/WNL.0b013e3182190d09; Yamanaka M, 2012, J NEUROSCI, V32, P17321, DOI 10.1523/JNEUROSCI.1569-12.2012; Yin F, 2015, NEUROBIOL AGING, V36, P2282, DOI 10.1016/j.neurobiolaging.2015.03.013; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhao LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031267; Zhao LQ, 2011, NEUROBIOL AGING, V32, P1949, DOI 10.1016/j.neurobiolaging.2009.12.010	98	20	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2017	12	6							e0178490	10.1371/journal.pone.0178490	http://dx.doi.org/10.1371/journal.pone.0178490			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6MJ	28575011	Green Published, Green Submitted, gold			2023-01-03	WOS:000402624300056
J	Leung, FW				Leung, Felix W.			Trends in Use of Sedation for Low-Risk Endoscopy Looking Beyond Monitored Anesthesia Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WATER EXCHANGE; CONTROLLED-TRIAL; GASTROENTEROLOGY; COLONOSCOPIES		[Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leung, FW (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, 16111 Plummer St,111G, North Hills, CA 91343 USA.	felix.leung@va.gov			VA Medical Center research funds	VA Medical Center research funds	This work was supported in part by VA Medical Center research funds.	Adams MA, 2017, JAMA INTERN MED, V177, P436, DOI 10.1001/jamainternmed.2016.8566; Cadoni S, 2015, CLIN GASTROENTEROL H, V13, P1972, DOI 10.1016/j.cgh.2015.04.178; Hsieh YH, 2014, AM J GASTROENTEROL, V109, P1390, DOI 10.1038/ajg.2014.126; Leung Felix W, 2011, J Interv Gastroenterol, V1, P172; Leung FW, 2010, GASTROINTEST ENDOSC, V72, P693, DOI 10.1016/j.gie.2010.05.020; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Liu HS, 2012, JAMA-J AM MED ASSOC, V307, P1178, DOI 10.1001/jama.2012.270; Luo H, 2013, GASTROINTEST ENDOSC, V77, P767, DOI 10.1016/j.gie.2012.12.007; Nakshabendi R, 2016, ANN GASTROENTEROL, V29, P50; Predmore Z, 2017, AM J GASTROENTEROL, V112, P297, DOI 10.1038/ajg.2016.266	10	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 16	2017	317	19					2006	2007		10.1001/jama.2017.4114	http://dx.doi.org/10.1001/jama.2017.4114			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU8VB	28510664				2023-01-03	WOS:000401315500019
J	Alimohammadi, M; Lahiani, MH; McGehee, D; Khodakovskaya, M				Alimohammadi, Mohammad; Lahiani, Mohamed Hassen; McGehee, Diamond; Khodakovskaya, Mariya			Polyphenolic extract of InsP 5-ptase expressing tomato plants reduce the proliferation of MCF-7 breast cancer cells	PLOS ONE			English	Article							PHARMACEUTICAL PROTEINS; DIETARY FLAVONOIDS; GENE-EXPRESSION; DOWN-REGULATION; HEALTH; METABOANALYST; ANTIOXIDANTS; ARABIDOPSIS; APOPTOSIS; FOOD	In recent years, by extensive achievements in understanding the mechanisms and the pathways affected by cancer, the focus of cancer research is shifting from developing new chemotherapy methods to using natural compounds with therapeutic properties to reduce the adverse effects of synthetic drugs on human health. We used fruit extracts from previously generated human type I InsP 5-ptase gene expressing transgenic tomato plants for assessment of the anti-cancer activity of established genetically modified tomato lines. Cellular assays (MTT, Fluorescent microscopy, Flow Cytometry analysis) were used to confirm that InsP 5-ptase fruit extract was more effective for reducing the proliferation of breast cancer cells compared to wild-type tomato fruit extract. Metabolome analysis of InsP 5-ptase expressing tomato fruits performed by LC-MS identified tomato metabolites that may play a key role in the increased anti-cancer activity observed for the transgenic fruits. Total transcriptome analysis of cancer cells (MCF-7 line) exposed to an extract of transgenic fruits revealed a number of differently regulated genes in the cells treated with transgenic extract compared to untreated cells or cells treated with wild-type tomato extract. Together, this data demonstrate the potential role of the plant derived metabolites in suppressing cell viability of cancer cells and further prove the potential application of plant genetic engineering in the cancer research and drug discovery.	[Alimohammadi, Mohammad; Lahiani, Mohamed Hassen; McGehee, Diamond; Khodakovskaya, Mariya] Univ Arkansas, Dept Biol, Little Rock, AR 72204 USA; [Khodakovskaya, Mariya] Russian Acad Sci, Inst Biol & Soil Sci, Far Eastern Branch, Vladivostok, Russia	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Russian Academy of Sciences; Federal Scientific Center of the East Asia Terrestrial Biodiversity, Far Eastern Branch of the Russian Academy of Sciences	Khodakovskaya, M (corresponding author), Univ Arkansas, Dept Biol, Little Rock, AR 72204 USA.; Khodakovskaya, M (corresponding author), Russian Acad Sci, Inst Biol & Soil Sci, Far Eastern Branch, Vladivostok, Russia.	mvkhodakovsk@ualr.edu	Alimohammadi, Mohammad/I-6462-2019	Lahiani, Mohamed H./0000-0003-0551-2606	National Space Grant College Fellowship Program (NNXISAR7H) through Research Infrastructure Award provided by Arkansas Space Grant Consortium	National Space Grant College Fellowship Program (NNXISAR7H) through Research Infrastructure Award provided by Arkansas Space Grant Consortium	Authors are grateful to Arkansas Space Grant Consortium for providing a stipend to Diamond McGehee. This project was supported by National Space Grant College Fellowship Program (NNXISAR7H) through Research Infrastructure Award provided by Arkansas Space Grant Consortium (award to MK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abaza MSI, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0194-0; Agati G, 2012, PLANT SCI, V196, P67, DOI 10.1016/j.plantsci.2012.07.014; Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102; Alimohammadi M, 2012, J EXP BOT, V63, P825, DOI 10.1093/jxb/err306; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Aruoma OI, 1998, J AM OIL CHEM SOC, V75, P199, DOI 10.1007/s11746-998-0032-9; Barr FG, 1999, CANCER RES, V59, p1711S; Batra P, 2013, 3 BIOTECH, V3, P439, DOI 10.1007/s13205-013-0117-5; Boik J., 2001, J NAT PROD; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Bruno AK, 2004, J EXP BOT, V55, P2541, DOI 10.1093/jxb/erh273; Canene-Adams K, 2005, J NUTR, V135, P1226, DOI 10.1093/jn/135.5.1226; Chahar Maheep K, 2011, Pharmacogn Rev, V5, P1, DOI 10.4103/0973-7847.79093; Chan FL, 2000, CANCER LETT, V160, P219, DOI 10.1016/S0304-3835(00)00591-7; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Diantini A, 2012, ONCOL LETT, V3, P1069, DOI 10.3892/ol.2012.596; Fankhauser C, 2002, PLANTA, V216, P1, DOI 10.1007/s00425-002-0831-4; Filkowski J, 2004, PLANT J, V38, P60, DOI 10.1111/j.1365-313X.2004.02020.x; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Gomez-Romero M, 2010, PHYTOCHEMISTRY, V71, P1848, DOI 10.1016/j.phytochem.2010.08.002; Grennan AK, 2009, PLANT PHYSIOL, V151, P1701, DOI 10.1104/pp.109.900308; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Iijima Y, 2008, PLANT J, V54, P949, DOI 10.1111/j.1365-313X.2008.03434.x; Imai Y, 2004, CANCER RES, V64, P4346, DOI 10.1158/0008-5472.CAN-04-0078; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Jiao YL, 2007, NAT REV GENET, V8, P217, DOI 10.1038/nrg2049; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanno S, 2005, BIOL PHARM BULL, V28, P527, DOI 10.1248/bpb.28.527; Keijer J, 2008, CURR OPIN LIPIDOL, V19, P4, DOI 10.1097/MOL.0b013e3282f39f95; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740; Khodakovskaya M, 2010, PLANT BIOTECHNOL J, V8, P170, DOI 10.1111/j.1467-7652.2009.00472.x; Kim BW, 2008, CANCER BIOL THER, V7, P1080, DOI 10.4161/cbt.7.7.6164; Kleine T, 2007, PLANT PHYSIOL, V144, P1391, DOI 10.1104/pp.107.098293; KUBASEK WL, 1992, PLANT CELL, V4, P1229, DOI 10.1105/tpc.4.10.1229; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Langner E, 2012, WSPOLCZESNA ONKOL, V16, P394, DOI 10.5114/wo.2012.31767; Liu YS, 2003, PLANT BIOTECHNOL J, V1, P195, DOI 10.1046/j.1467-7652.2003.00018.x; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Moco S, 2006, PLANT PHYSIOL, V141, P1205, DOI 10.1104/pp.106.078428; Parr AJ, 2000, J SCI FOOD AGR, V80, P985, DOI [10.1002/(SICI)1097-0010(20000515)80:7<985::AID-JSFA572>3.0.CO;2-7, 10.1002/(SICI)1097-0010(20000515)80:7&lt;985::AID-JSFA572&gt;3.0.CO;2-7]; Patel JM, 2008, REV POTENTIAL HLTH B; Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; Rigano MM, 2013, INT J MOL SCI, V14, P2753, DOI 10.3390/ijms14022753; Rischer H, 2013, CURR PHARM DESIGN, V19, P5640, DOI 10.2174/1381612811319310017; Rosati C, 2000, PLANT J, V24, P413, DOI 10.1046/j.1365-313x.2000.00880.x; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Santangelo Carmela, 2007, Ann Ist Super Sanita, V43, P394; Shen YC, 2007, J AGR FOOD CHEM, V55, P6475, DOI 10.1021/jf070799z; Shinbo Y, 2006, BIOTECH AGR FOREST, V57, P165; SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49; Stoclet J. -C., 2011, ANNALES PHARMACEUTIQUES FRANCAISES, V69, P78, DOI 10.1016/j.pharma.2010.11.004; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tian WX, 2006, CURR MED CHEM, V13, P967, DOI 10.2174/092986706776361012; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; Twyman RM, 2003, TRENDS BIOTECHNOL, V21, P570, DOI 10.1016/j.tibtech.2003.10.002; Ververidis Filippos, 2007, Biotechnology Journal, V2, P1214, DOI 10.1002/biot.200700084; Wallstrom P, 2000, PUBLIC HEALTH NUTR, V3, P263, DOI 10.1017/S1368980000000306; Wenzel H, 2000, CANCER RES, V60, P3823; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Xia JG, 2012, NUCLEIC ACIDS RES, V40, pW127, DOI 10.1093/nar/gks374; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Xiao ZP, 2011, MINI-REV MED CHEM, V11, P169, DOI 10.2174/138955711794519546; Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7; Zand RSR, 2000, BREAST CANCER RES TR, V62, P35, DOI 10.1023/A:1006422302173; Zhang SZ, 2004, MOL PHARMACOL, V65, P1208, DOI 10.1124/mol.65.5.1208	72	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2017	12	4							e175778	10.1371/journal.pone.0175778	http://dx.doi.org/10.1371/journal.pone.0175778			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET6EL	28448505	Green Published, Green Submitted, gold			2023-01-03	WOS:000400383600025
J	Kullberg, A; Sharp, L; Johansson, H; Brandberg, Y; Bergenmar, M				Kullberg, Anna; Sharp, Lena; Johansson, Hemming; Brandberg, Yvonne; Bergenmar, Mia			Patient satisfaction after implementation of person-centred handover in oncological inpatient care - A cross-sectional study	PLOS ONE			English	Article							INFORMATION EXCHANGE; NURSING HANDOVER; BEDSIDE; PARTICIPATION	Effective nurse shift-to-shift handover is a prerequisite for high-quality inpatient care. Combining person-centeredness with the need for improved handover rituals, we introduced and evaluated person-centered handover (PCH) in an oncological inpatient setting. PCH is the shift-to-shift nursing report performed together with the patient according to a set structure focused on patient participation, relevant clinical information, and patient safety. Non-verbal handover, standard at the department, is conducted via the electronic health record, in absence of the patient, and without a set structure. The aim of the study was to compare person-centered handover with non-verbal handover in an oncological inpatient setting with regard to patient satisfaction. A cross-sectional design featuring two points of measurement at one intervention ward and two control wards was applied. The EORTC IN-PATSAT32 questionnaire was used for measuring patient satisfaction. Baseline measurements were taken during the spring of 2014, when all three wards used a non-verbal handover model, and included responses from 116 patients. Follow-up measurements (comparing PCH and non-verbal handover) involved 209 patients and were on-going from September 2014 to May 2015. After the introduction of PCH, one change in patient satisfaction was detected regarding the subscale measuring exchange of information between caregivers. Patients from the intervention ward scored statistically higher after the implementation of PCH when compared to the control wards (p = .0058). The difference remained after a multivariate regression analysis controlling for clinical variables. In conclusion, PCH is feasible in oncological inpatient care but does not seem to affect patient satisfaction.	[Kullberg, Anna; Johansson, Hemming; Brandberg, Yvonne; Bergenmar, Mia] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Sharp, Lena] Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden; [Sharp, Lena] Reg Canc Ctr, Stockholm, Sweden; [Johansson, Hemming] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden; [Bergenmar, Mia] Karolinska Univ Hosp, Ctr Digest Dis, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Kullberg, A (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.	anna.kullberg@ki.se	Kullberg, Anna/M-1447-2019	Bergenmar, Mia/0000-0002-7256-6105				Alharbi TSJ, 2012, HEALTH POLICY, V108, P294, DOI 10.1016/j.healthpol.2012.09.003; Blegen Mary A, 2009, J Patient Saf, V5, P139, DOI 10.1097/PTS.0b013e3181b53f6e; Bredart A, 2007, EUR J CANCER, V43, P323, DOI 10.1016/j.ejca.2006.10.016; Bredart A, 2005, EUR J CANCER, V41, P2120, DOI 10.1016/j.ejca.2005.04.041; Chaboyer W, 2010, INT J NURS PRACT, V16, P27, DOI 10.1111/j.1440-172X.2009.01809.x; Chaboyer W, 2009, J NURS CARE QUAL, V24, P136, DOI 10.1097/01.NCQ.0000347450.90676.d9; Cohen MD, 2010, QUAL SAF HEALTH CARE, V19, P493, DOI 10.1136/qshc.2009.033480; Davis K, 2014, MIRROR MIRROR WALL 2; Doyle C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001570; Ekman I, 2011, EUR J CARDIOVASC NUR, V10, P248, DOI 10.1016/j.ejcnurse.2011.06.008; Farley H, 2014, ANN EMERG MED, V64, P351, DOI 10.1016/j.annemergmed.2014.02.021; Kerr D, 2014, J CLIN NURS, V23, P1685, DOI 10.1111/jocn.12308; Kullberg A, 2015, EUR J ONCOL NURS, V19, P142, DOI 10.1016/j.ejon.2014.10.005; Lee RG, 2003, SOC SCI MED, V56, P449, DOI 10.1016/S0277-9536(02)00045-X; Longtin Y, 2010, MAYO CLIN PROC, V85, P53, DOI 10.4065/mcp.2009.0248; Malfait S, 2016, J ADV NURS; McMurray A, 2011, COLLEGIAN, V18, P19, DOI 10.1016/j.colegn.2010.04.004; Meum T, 2011, INT J TELEMED APPL, V2011, DOI 10.1155/2011/505426; Novak K, 2012, J PEDIATR NURS, V27, P760, DOI 10.1016/j.pedn.2012.09.001; Papastavrou E, 2014, BMC NURS, V13, DOI 10.1186/1472-6955-13-26; Sand-Jecklin K, 2014, J CLIN NURS, V23, P2854, DOI 10.1111/jocn.12575; Sharp S, 2015, CONTEMP NURSE, V52, P1, DOI DOI 10.1080/10376178.2015.102098; Smeulers M, 2014, COCHRANE DB SYST REV, V6; Sondergaard Eva Gad, 2013, BMC Res Notes, V6, P378, DOI 10.1186/1756-0500-6-378; Spooner AJ, 2013, INT J NURS PRACT, V19, P214, DOI 10.1111/ijn.12058; Tidwell T, 2011, J NEUROSCI NURS, V43, pE1, DOI 10.1097/JNN.0b013e3182212a1d; Vaismoradi M, 2015, J CLIN NURS, V24, P627, DOI 10.1111/jocn.12664; Vardanalys, 2014, VARDANALYS VARDEN PA; Vines MM, 2014, J NURSES PROF DEV, V30, P166, DOI 10.1097/NND.0000000000000057; Wentworth L, 2012, J NURS CARE QUAL, V27, P125, DOI 10.1097/NCQ.0b013e31823cc9a0; Wolf DM, 2008, J NURS CARE QUAL, V23, P316, DOI 10.1097/01.NCQ.0000336672.02725.a5	31	6	6	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2017	12	4							e0175397	10.1371/journal.pone.0175397	http://dx.doi.org/10.1371/journal.pone.0175397			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ES2QB	28384314	Green Published, Green Submitted, gold			2023-01-03	WOS:000399371900168
J	Ahrens, LAJ; Vonwil, D; Christensen, J; Shastri, VP				Ahrens, Lucas A. J.; Vonwil, Daniel; Christensen, Jon; Shastri, V. Prasad			Gelatin device for the delivery of growth factors involved in endochondral ossification	PLOS ONE			English	Article							BONE-FORMATION; CROSS-LINKING; ELECTROSPUN GELATIN; CONTROLLED-RELEASE; POLYMER IMPLANTS; STEM-CELLS; TGF-BETA; IN-VITRO; DIFFERENTIATION; VEGF	Controlled release drug delivery systems are well established as oral and implantable dosage forms. However, the controlled release paradigm can also be used to present complex soluble signals responsible for cellular organization during development. Endochondral ossification (EO), the developmental process of bone formation from a cartilage matrix is controlled by several soluble signals with distinct functions that vary in structure, molecular weight and stability. This makes delivering them from a single vehicle rather challenging. Herein, a gelatin-based delivery system suitable for the delivery of small molecules as well as recombinant human (rh) proteins (rhWNT3A, rhFGF2, rhVEGF, rhBMP4) is reported. The release behavior and biological activity of the released molecules was validated using analytical and biological assays, including cell reporter systems. The simplicity of fabrication of the gelatin device should foster its adaptation by the diverse scientific community interested in interrogating developmental processes, in vivo.	[Ahrens, Lucas A. J.; Vonwil, Daniel; Christensen, Jon; Shastri, V. Prasad] Univ Freiburg, Inst Macromol Chem, Hermann Staudinger Haus, Freiburg, Germany; [Ahrens, Lucas A. J.; Christensen, Jon; Shastri, V. Prasad] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	University of Freiburg; University of Freiburg	Shastri, VP (corresponding author), Univ Freiburg, Inst Macromol Chem, Hermann Staudinger Haus, Freiburg, Germany.; Shastri, VP (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.	prasad.shastri@gmail.com			Swiss National Science Foundation (SNF) [CRSII3_136179]; Deutsche Forschungsgemeinschaft, Excellence Initiative of the German Federal and State Governments [EXC 294]	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Deutsche Forschungsgemeinschaft, Excellence Initiative of the German Federal and State Governments(German Research Foundation (DFG))	This study was supported by the Swiss National Science Foundation (SNF) (grant no. CRSII3_136179) to VPS and Deutsche Forschungsgemeinschaft, Excellence Initiative of the German Federal and State Governments Grant EXC 294. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bigi A, 2002, BIOMATERIALS, V23, P4827, DOI 10.1016/S0142-9612(02)00235-1; Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284; BREM H, 1991, J NEUROSURG, V74, P441, DOI 10.3171/jns.1991.74.3.0441; Brem H, 2001, J CONTROL RELEASE, V74, P63, DOI 10.1016/S0168-3659(01)00311-X; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Capan Y., 2003, AAPS PHARMSCITECH, V4, P147; Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929; Christensen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060051; COSTANTINO HR, 1995, BIO-TECHNOL, V13, P493, DOI 10.1038/nbt0595-493; Del Gaudio C, 2013, BIOMATERIALS, V34, P7754, DOI 10.1016/j.biomaterials.2013.06.040; Dhamdhere GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083650; DISILVIO L, 1994, BIOMATERIALS, V15, P931, DOI 10.1016/0142-9612(94)90120-1; DISILVIO L, 1994, J MATER SCI-MATER M, V5, P819, DOI 10.1007/BF00213141; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FOLKMAN J, 1964, J Surg Res, V4, P139, DOI 10.1016/S0022-4804(64)80040-8; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017; Gospodarowicz D., 1986, J CELL PHYSL, V128, P475, DOI DOI 10.1002/JCP.1041280317; Groppa E, 2015, EMBO MOL MED, V7, P1366, DOI 10.15252/emmm.201405003; Guglieri S, 2008, BIOCHEMISTRY-US, V47, P13862, DOI 10.1021/bi801007p; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Iwanaga K, 2003, J MICROENCAPSUL, V20, P767, DOI 10.1080/02652040310001600523; Jeon O, 2007, BIOMATERIALS, V28, P2763, DOI 10.1016/j.biomaterials.2007.02.023; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546; Kodama N, 2009, BONE, V44, P699, DOI 10.1016/j.bone.2008.12.017; Kress H, 2009, NAT METHODS, V6, P905, DOI 10.1038/nmeth.1400; Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200; Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168-3659(01)00498-9; Lee KY, 2000, NATURE, V408, P998, DOI 10.1038/35050141; Lee TJ, 2013, BIOCHEM BIOPH RES CO, V430, P793, DOI 10.1016/j.bbrc.2012.11.067; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008; Liu J, 2005, ANGEW CHEM INT EDIT, V44, P1987, DOI 10.1002/anie.200462552; LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210; Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009; Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456; Merino R, 1999, DEVELOPMENT, V126, P5515; Morrell NT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002930; Ofner CM, 1996, PHARM RES-DORDR, V13, P1821; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Paguirigan AL, 2007, NAT PROTOC, V2, P1782, DOI 10.1038/nprot.2007.256; Park K, 2014, J CONTROL RELEASE, V190, P3, DOI 10.1016/j.jconrel.2014.03.054; PARKER KL, 1989, J CLIN ENDOCR METAB, V69, P689, DOI 10.1210/jcem-69-3-689; Parsons-Wingerter P, 2000, ARTERIOSCLER THROMB, V20; Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019; Patel ZS, 2008, PHARM RES-DORDR, V25, P2370, DOI 10.1007/s11095-008-9685-1; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0; Purpura KA, 2012, BIOMATERIALS, V33, P1271, DOI 10.1016/j.biomaterials.2011.10.051; Ratanavaraporn J, 2011, BIOMATERIALS, V32, P2797, DOI 10.1016/j.biomaterials.2010.12.052; RHINE WD, 1980, J PHARM SCI, V69, P265, DOI 10.1002/jps.2600690305; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Sarem M, 2013, CARBOHYD POLYM, V93, P635, DOI 10.1016/j.carbpol.2012.11.099; Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Sisson K, 2009, BIOMACROMOLECULES, V10, P1675, DOI 10.1021/bm900036s; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Srisuwan T, 2012, TISSUE CELL, V44, P111, DOI 10.1016/j.tice.2011.12.003; SUN H W, 1990, Pediatric Dentistry, V12, P303; Tabata Y, 1998, BIOMATERIALS, V19, P1781, DOI 10.1016/S0142-9612(98)00089-1; Tabata Y, 1999, BIOMATERIALS, V20, P2169, DOI 10.1016/S0142-9612(99)00121-0; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tsumaki N, 2005, CYTOKINE GROWTH F R, V16, P279, DOI 10.1016/j.cytogfr.2005.04.001; Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777; Van Vlierberghe S, 2011, BIOMACROMOLECULES, V12, P1387, DOI 10.1021/bm200083n; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010; Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908; Wuelling M, 2011, ENDOCR DEV, V21, P1, DOI 10.1159/000328081; Yamamoto M, 2001, J BIOMAT SCI-POLYM E, V12, P77, DOI 10.1163/156856201744461; Young S, 2005, J CONTROL RELEASE, V109, P256, DOI 10.1016/j.jconrel.2005.09.023; Yu L, 2012, DEV BIOL, V372, P263, DOI 10.1016/j.ydbio.2012.09.021; Yu L, 2010, DEVELOPMENT, V137, P551, DOI 10.1242/dev.042424; Zhu GZ, 2000, NAT BIOTECHNOL, V18, P52, DOI 10.1038/71916	82	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0175095	10.1371/journal.pone.0175095	http://dx.doi.org/10.1371/journal.pone.0175095			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28380024	Green Submitted, gold, Green Published			2023-01-03	WOS:000399353500097
J	Hasegawa, Y; Tachibana, Y; Ono, T; Kishimoto, H				Hasegawa, Yoko; Tachibana, Yoshihisa; Ono, Takahiro; Kishimoto, Hiromitsu			Flavour-enhanced cortisol release during gum chewing	PLOS ONE			English	Article							SALIVARY CORTISOL; STRESS; RESPONSES; FEEDBACK; DISEASE; REWARD; MOOD; MEN	There is some evidence to suggest that chewing gum reduces chronic stress. However, it remains controversial how the taste and odour properties of chewing gum influence stress. The present study was designed to investigate this issue in human subjects. Using an enzyme-linked immunosorbent assay, we tested salivary cortisol concentration, which is thought to be a stress marker, in 96 adults who chewed gum with different combinations of taste and odour. Subjects could discriminate between the types of gum without prior information. Salivary cortisol concentrations were highest and lowest for the subjects who chewed the most flavourful gum and the least flavourful gum, respectively. These findings suggest that the salivary cortisol level during gum chewing is not a marker of negative emotions (i.e., stressful conditions) as traditionally considered but, rather, an index of positive emotions that can facilitate biological responses to overcome stressful conditions.	[Hasegawa, Yoko; Kishimoto, Hiromitsu] Hyogo Coll Med, Dept Dent & Oral Surg, Nishinomiya, Hyogo, Japan; [Tachibana, Yoshihisa] Kobe Univ, Grad Sch Med, Div Syst Neurosci, Kobe, Hyogo, Japan; [Ono, Takahiro] Niigata Univ, Grad Sch Med & Dent Sci, Div Comprehens Prosthodont, Niigata, Japan	Hyogo College of Medicine; Kobe University; Niigata University	Hasegawa, Y (corresponding author), Hyogo Coll Med, Dept Dent & Oral Surg, Nishinomiya, Hyogo, Japan.	cem17150@hyo-med.ac.jp		Hasegawa, Yoko/0000-0001-9112-5981	KAKENHI from the Ministry of Education, Science and Culture of Japan [25463043, 16K11640]; Society for Research on Umami Taste and Foundation for Total Health Promotion; Lotte Research Promotion Grant;  [24120522]	KAKENHI from the Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Society for Research on Umami Taste and Foundation for Total Health Promotion; Lotte Research Promotion Grant; 	This study was supported by KAKENHI from the Ministry of Education, Science and Culture of Japan (Grant No. 25463043, No. 16K11640), Grant-in-Aid for Scientific Research on Innovative Areas (No. 24120522), the Society for Research on Umami Taste and Foundation for Total Health Promotion, and a Lotte Research Promotion Grant.	Allen A.P., 2011, J BEHAV NEUROSCIENCE, V9, P7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Carnell S, 2012, INT REV PSYCHIATR, V24, P189, DOI 10.3109/09540261.2012.676988; Deiss V, 2009, FOOD QUAL PREFER, V20, P57, DOI 10.1016/j.foodqual.2008.07.004; Dinan TG, 2006, GASTROENTEROLOGY, V130, P304, DOI 10.1053/j.gastro.2005.11.033; Gray G, 2012, APPETITE, V58, P554, DOI 10.1016/j.appet.2011.11.013; Groschl M, 2006, STEROIDS, V71, P1097, DOI 10.1016/j.steroids.2006.09.007; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hasegawa Y, 2009, CLIN ORAL INVEST; Hellhammer DH, 2009, PSYCHONEUROENDOCRINO, V34, P163, DOI 10.1016/j.psyneuen.2008.10.026; Iso H, 2002, CIRCULATION, V106, P1229, DOI 10.1161/01.CIR.0000028145.58654.41; Kaufman J, 2000, BIOL PSYCHIAT, V48, P778, DOI 10.1016/S0006-3223(00)00998-7; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Ladd CO, 2004, BIOL PSYCHIAT, V55, P367, DOI 10.1016/j.biopsych.2003.10.007; Lovallo W. R., 2004, STRESS HLTH BIOL PSY; MANUCK SB, 1986, ARTERIOSCLEROSIS, V6, P2, DOI 10.1161/01.ATV.6.1.2; Matsui F, 2009, ENDOCR J, V56, P1083, DOI 10.1507/endocrj.K09E-186; Matsumoto M, 2009, NAT NEUROSCI, V12, P77, DOI 10.1038/nn.2233; Ministry of Environment and Rural and Marine, 2008, EUFOR CHAD MISS GREA, P1; Nishijo H, 2000, J NUTR, V130, p954S, DOI 10.1093/jn/130.4.954S; Pecoraro N, 2004, ENDOCRINOLOGY, V145, P3754, DOI 10.1210/en.2004-0305; Petrowski K, 2014, PSYCHONEUROENDOCRINO, V48, P64, DOI 10.1016/j.psyneuen.2014.06.008; Scholey A, 2009, PHYSIOL BEHAV, V97, P304, DOI 10.1016/j.physbeh.2009.02.028; Shepherd GM, 2006, NATURE, V444, P316, DOI 10.1038/nature05405; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Smith A, 2010, NUTR NEUROSCI, V13, P7, DOI 10.1179/147683010X12611460763526; Spielman AI, 1998, CRIT REV ORAL BIOL M, V9, P267, DOI 10.1177/10454411980090030201; Tahara Yasuaki, 2007, J Prosthodont, V16, P129, DOI 10.1111/j.1532-849X.2007.00178.x; Ventura R, 2005, CEREB CORTEX, V15, P1877, DOI 10.1093/cercor/bhi066; Yamamoto T, 2006, ARCH HISTOL CYTOL, V69, P243, DOI 10.1679/aohc.69.243; Yu HC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055705, 10.1371/journal.pone.0066447, 10.1371/journal.pone.0057111]	35	7	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2017	12	4							e0173475	10.1371/journal.pone.0173475	http://dx.doi.org/10.1371/journal.pone.0173475			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES2JD	28379983	gold, Green Submitted, Green Published			2023-01-03	WOS:000399353500019
J	Premji, SS; Currie, G; Reilly, S; Dosani, A; Oliver, LM; Lodha, AK; Young, M				Premji, Shahirose S.; Currie, Genevieve; Reilly, Sandra; Dosani, Aliyah; Oliver, Lynnette May; Lodha, Abhay K.; Young, Marilyn			A qualitative study: Mothers of late preterm infants relate their experiences of community-based care	PLOS ONE			English	Article							RISK-FACTORS; NEAR-TERM; CONFIDENCE; BIRTH	Purpose In Alberta, the high occurrence of late preterm infants and early hospital discharge of mother-infant dyads has implications for postpartum care in the community. Shortened hospital stay and complexities surrounding the care of biologically and developmentally immature late preterm infants heighten anxiety and fears. Our descriptive phenomenological study explores mothers' experience of caring for their late preterm infants in the community. Methods Eleven mothers were interviewed using a semi-structured interview guide. Interview transcripts were analysed using an interpretive thematic approach. Findings The mothers' hospital experience informed their perspective that being a late preterm infant was not a ''big deal,'' and they tended to treat their infant as normal. ''Feeding was really problem,'' especially the variability in feeding effectiveness, which was not anticipated. Failing to recognize late preterm infants' feeding distress exemplified lack of knowledge of feeding cues and tendencies to either rationalize or minimize feeding concerns. Public health nurses represent a source of informational support for managing neonatal morbidities associated with being late preterm; however, maternal experiences with public health nurses varied. Some nurses used a directive style that overwhelmed certain mothers. Seeing multiple public health nurses and care providers was not always effective, given inconsistent and contradictory guidance to care. These new and changing situations increased maternal anxiety and stress and influenced maternal confidence in care. Fathers, family, and friends were important sources of emotional support. Conclusion After discharge, mothers report their lack of preparation to meet the special needs of their late preterm infants. Current approaches to community-based care can threaten maternal confidence in care. New models and pathways of care for late preterm infants and their families need to be responsive to the spectrum of feeding issues encountered, limit duplication of services, and ensure consistent and effective care that parents will accept.	[Premji, Shahirose S.; Reilly, Sandra; Oliver, Lynnette May] Univ Calgary, Fac Nursing, Calgary, AB, Canada; [Premji, Shahirose S.; Lodha, Abhay K.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Premji, Shahirose S.; Reilly, Sandra; Dosani, Aliyah] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada; [Premji, Shahirose S.; Lodha, Abhay K.] Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Currie, Genevieve; Dosani, Aliyah] Mt Royal Univ, Sch Nursing & Midwifery, Calgary, AB, Canada; [Lodha, Abhay K.] Alberta Hlth Serv, Div Neonatol, Dept Paediat, Calgary, AB, Canada; [Young, Marilyn] Alberta Hlth Serv, Publ Hlth Calgary Zone, Prenatal & Postpartum Serv, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; Mount Royal University; Alberta Health Services (AHS); University of Calgary; Alberta Health Services (AHS); University of Calgary	Premji, SS (corresponding author), Univ Calgary, Fac Nursing, Calgary, AB, Canada.; Premji, SS (corresponding author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.; Premji, SS (corresponding author), Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada.; Premji, SS (corresponding author), Alberta Childrens Hosp Res Inst, Calgary, AB, Canada.	premjis@ucalgary.ca		Sadrudin Premji, Shahirose/0000-0003-0323-8009; Dosani, Aliyah/0000-0001-6817-3571	Alberta Centre for Child, Family & Community Research	Alberta Centre for Child, Family & Community Research	The study was funded by the Alberta Centre for Child, Family & Community Research (http://research4children.com/).The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abidin R. R., 1995, PSYCHOL ASSESSMENT R, V3rd; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Bakewell-Sachs S, 2007, NEWBORN INFANT NURS, V7, P67, DOI 10.1053/j.nainr.2007.05.001; Bunik M, 2011, BREASTFEED MED, V6, P151, DOI 10.1089/bfm.2011.9990; Canadian Institute for Health Information, 2014, NEWB BORN HOSP CAN I; Creswell J.W., 2017, QUAL INQ; DeMauro SB, 2011, CLIN PEDIATR, V50, P957, DOI 10.1177/0009922811409028; Demirci JR, 2015, MATERN CHILD NUTR, V11, P59, DOI 10.1111/j.1740-8709.2012.00463.x; Gagliardi AR, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0399-1; Golec L, 2009, J PERINATOL, V29, P600, DOI 10.1038/jp.2009.98; Howe TH, 2014, RES DEV DISABIL, V35, P1748, DOI 10.1016/j.ridd.2014.02.015; Hummel P., 2003, NEWBORN INFANT NURS, V3, P88; Kugelman A, 2013, PEDIATRICS, V132, P741, DOI 10.1542/peds.2013-1131; Kuzniewicz MW, 2013, CLIN PERINATOL, V40, P753, DOI [10.1016/j.c1p.2013.07.008, 10.1016/j.clp.2013.07.008]; Leigh B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-24; Mally PV, 2010, CURR PROB PEDIATR AD, V40, P218, DOI 10.1016/j.cppeds.2010.07.005; McEwen Bruce S, 2006, Dialogues Clin Neurosci, V8, P367; McGowan JE, 2011, PEDIATRICS, V127, P1111, DOI 10.1542/peds.2010-2257; Olafsen KS, 2007, SCAND J PSYCHOL, V48, P499, DOI 10.1111/j.1467-9450.2007.00619.x; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Premji SS, 2015, CARING LATE PRETERM; Shapiro-Mendoza, 2009, NEOREVIEWS, V10, P287; Shapiro-Mendoza CK, 2006, SEMIN PERINATOL, V30, P54, DOI 10.1053/j.semperi.2006.02.002; Singer LT, 2003, J DEV BEHAV PEDIATR, V24, P233, DOI 10.1097/00004703-200308000-00003; Solomon J., 2015, HDB ATTACHMENT THEOR; Starks H, 2007, QUAL HEALTH RES, V17, P1372, DOI 10.1177/1049732307307031; Tu MT, 2007, DEV PSYCHOBIOL, V49, P150, DOI 10.1002/dev.20204; Voegtline KM, 2010, INFANT BEHAV DEV, V33, P545, DOI 10.1016/j.infbeh.2010.07.006; Wang ML, 2004, PEDIATRICS, V114, P372, DOI 10.1542/peds.114.2.372; Warren PL, 2005, J ADV NURS, V50, P479; Young PC, 2013, PEDIATRICS, V131, pE1538, DOI 10.1542/peds.2012-2634; Zanardo V, 2011, EARLY HUM DEV, V87, P321, DOI 10.1016/j.earlhumdev.2011.01.035	32	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2017	12	3							e0174419	10.1371/journal.pone.0174419	http://dx.doi.org/10.1371/journal.pone.0174419			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ER8VS	28334033	Green Published, gold, Green Submitted			2023-01-03	WOS:000399102200096
J	Bitar, A; De, R; Melgar, S; Aung, KM; Rahman, A; Qadri, F; Wai, SN; Shirin, T; Hammarstrom, ML				Bitar, Aziz; De, Rituparna; Melgar, Silvia; Aung, Kyaw Min; Rahman, Arman; Qadri, Firdausi; Wai, Sun Nyunt; Shirin, Tahmina; Hammarstrom, Marie-Louise			Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera	PLOS ONE			English	Article							ENTEROTOXIGENIC ESCHERICHIA-COLI; HELICOBACTER-PYLORI; ANTIMICROBIAL PEPTIDES; INFLAMMATORY RESPONSE; GENE-EXPRESSION; T-CELLS; MICRORNAS; EPIDEMIOLOGY; ACTIVATION; IMMUNITY	The potential immunomodulatory role of microRNAs in small intestine of patients with acute watery diarrhea caused by Vibrio cholerae O1 or enterotoxigenic Escherichia coli (ETEC) infection was investigated. Duodenal biopsies were obtained from study participants at the acute (day 2) and convalescent (day 21) stages of disease and from healthy individuals. Levels of miR 146a miR 155 and miR 375 and target gene (IRAK1 TRAF6 CARD10) and 11 cytokine mRNAs were determined by qRT PCR. The cellular source of microRNAs in biopsies was analyzed by in situ hybridization. The ability of V. cholerae bacteria and their secreted products to cause changes in microRNA and mRNA levels in polarized tight monolayers of intestinal epithelial cells was investigated. miR 146a and miR 155 were expressed at significantly elevated levels at acute stage of V. cholerae infection and declined to normal at convalescent stage (P< 0.009 versus controls P = 0.03 versus convalescent stage pairwise). Both microRNAs were mainly expressed in the epithelium. Only marginal down regulation of target genes IRAK1 and CARD10 was seen and a weak cytokine profile was identified in the acute infected mucosa. No elevation of microRNA levels was seen in ETEC infection. Challenge of tight monolayers with the wild type V. cholerae O1 strain C6706 and clinical isolates from two study participants caused significant increase in miR 155 and miR 146a by the strain C6706 (P< 0.01). One clinical isolate caused reduction in IRAK1 levels (P< 0.05) and none of the strains induced inflammatory cytokines. In contrast secreted factors from these strains caused markedly increased levels of IL 8 IL 1a and CARD10 (P< 0.001) without inducing microRNA expression. Thus miR 146a and miR155 are expressed in the duodenal epithelium at the acute stage of cholera. The inducer is probably the V. cholerae bacterium. By inducing microRNAs the bacterium can limit the Innate immune response of the host,including inflamation evoked by its own secreted factors,there by decreasing the riskof being eliminated	[Bitar, Aziz; De, Rituparna; Aung, Kyaw Min; Hammarstrom, Marie-Louise] Umea Univ, Dept Clin Microbiol, Immunol, Umea, Sweden; [De, Rituparna; Aung, Kyaw Min; Wai, Sun Nyunt] Umea Univ, Lab Mol Infect Med Sweden MIMS, Dept Mol Biol, Umea, Sweden; [Melgar, Silvia] Univ Coll Cork, APC Microbiome Inst, Cork, Ireland; [Rahman, Arman] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin, Ireland; [Qadri, Firdausi] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh; [Shirin, Tahmina] Natl Influenza Ctr, Inst Epidemiol Dis Control & Res, Dept Virol, Dhaka, Bangladesh	Umea University; Umea University; University College Cork; University College Dublin; International Centre for Diarrhoeal Disease Research (ICDDR)	Hammarstrom, ML (corresponding author), Umea Univ, Dept Clin Microbiol, Immunol, Umea, Sweden.; Shirin, T (corresponding author), Natl Influenza Ctr, Inst Epidemiol Dis Control & Res, Dept Virol, Dhaka, Bangladesh.	tahmina.shirin14@gmail.com; marie-louise.hammarstrom@umu.se	Al, Mamun M./AAF-5850-2019; Rahman, Arman/K-8539-2017; Qadri, Firdausi/AAF-4583-2019	Rahman, Arman/0000-0003-4648-156X; Wai, Sun Nyunt/0000-0003-4793-4671; Shirin, Tahmina/0000-0002-5061-3783; Hammarstrom, Marie-Louise/0000-0001-6182-4423; De, Dr.Rituparna/0000-0002-8573-7276; melgar, silvia/0000-0001-7463-3343	icddr; Swedish International Development Cooperation Agency (SIDA) [INT-ICDDR, B-HN-01-AV]; Swedish Research Council-Natural and Engineering Sciences [2013-4522]; Umea University; Kempe Foundations [SMK-1454]; Science Foundation Ireland(SFI) [SFI/12/RC/2273]; Found of Donations to the Medical Faculty; County of VaEsterbotten; Government of Bangladesh; Canada; Swedenand; UK	icddr; Swedish International Development Cooperation Agency (SIDA); Swedish Research Council-Natural and Engineering Sciences(Swedish Research Council); Umea University; Kempe Foundations; Science Foundation Ireland(SFI)(Science Foundation Ireland); Found of Donations to the Medical Faculty; County of VaEsterbotten; Government of Bangladesh; Canada; Swedenand; UK	This research was supported by the icddr,b and by grants from the Swedish International Development Cooperation Agency (SIDA) grant INT-ICDDR,B-HN-01-AV to F.Q.,the Swedish Research Council-Natural and Engineering Sciences grant no. 2013-4522 to M-L.H. and grant no.2014-4401 to S.N.W.,the TORNADO-project within the 7th framework program theme,grant agreement no.222720-2 to M-L.H.,the Fund for Biotechnology-oriented Basic Science at Umea University to M-L.H.,the Kempe Foundations grant no.SMK-1454 to S.N.W.,the Science Foundation Ireland(SFI) to S.M. under grant no.SFI/12/RC/2273 to APC Microbiome Institute,the Found of Donations to the Medical Faculty ,Umea University to M-L.H., and a combined medical practice-and research fellowship from the County of VaEsterbotten to A.Z..icddr,b is thankful to the donors for their support to its research efforts. icddr,b is also grateful to the Government of Bangladesh,Canada,Swedenand the UK for providing core/unrestricted support.The funders had no role in study design,data collection and analysis,decision to publish,or preparation of the manuscript	Belair C, 2009, CLIN MICROBIOL INFEC, V15, P806, DOI 10.1111/j.1469-0691.2009.02960.x; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bhaumik D, 2009, CELL CYCLE, V8, P1822; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Bielig H, 2011, INFECT IMMUN, V79, P1418, DOI 10.1128/IAI.00754-10; Biton M, 2011, NAT IMMUNOL, V12, P239, DOI 10.1038/ni.1994; Cheng Y, 2012, INFLAMMATION, V35, P1308, DOI 10.1007/s10753-012-9443-8; Cowan C, 2014, INVEST OPHTH VIS SCI, V55, P4944, DOI 10.1167/iovs.13-13631; Fahlgren A, 2003, CLIN EXP IMMUNOL, V131, P90, DOI 10.1046/j.1365-2249.2003.02035.x; Faruque SM, 1998, MICROBIOL MOL BIOL R, V62, P1301, DOI 10.1128/MMBR.62.4.1301-1314.1998; Forsberg G, 2002, GASTROENTEROLOGY, V123, P667, DOI 10.1053/gast.2002.35355; Guo Z, 2015, J GASTROEN HEPATOL, V30, P109, DOI 10.1111/jgh.12644; IWANAGA M, 1985, J CLIN MICROBIOL, V22, P405, DOI 10.1128/JCM.22.3.405-408.1985; KAHN MU, 1988, T R SOC TROP MED HYG, V82, P485; Kuchta A, 2011, CLIN VACCINE IMMUNOL, V111, P1001; Li L, 2010, SCAND J IMMUNOL, V71, P227, DOI 10.1111/j.1365-3083.2010.02383.x; Liu Z, 2010, MICROBES INFECT, V12, P854, DOI 10.1016/j.micinf.2010.06.002; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUNDQVIST C, 1994, J IMMUNOL, V153, P2302; Nahid MA, 2011, CELL MOL IMMUNOL, V8, P388, DOI 10.1038/cmi.2011.26; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Ou G, 2009, SCAND J IMMUNOL, V69, P150, DOI 10.1111/j.1365-3083.2008.02208.x; Ou GW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007806; Pauley KM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2493; Qadri F, 2004, GUT, V53, P62, DOI 10.1136/gut.53.1.62; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Queen J, 2015, INFECT IMMUN, V83, P2496, DOI 10.1128/IAI.02461-14; Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578; Sack RB, 2003, J INFECT DIS, V187, P96, DOI 10.1086/345865; Schaefer JS, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0069-0; Sheikh A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000908; Shirin T, 2011, MICROBES INFECT, V13, P1111, DOI 10.1016/j.micinf.2011.06.014; Sjoberg V, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2014.9; Sjoberg V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053414; Sjoling A, 2006, MICROBES INFECT, V8, P2797, DOI 10.1016/j.micinf.2006.08.011; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Vaitkevicius K, 2006, P NATL ACAD SCI USA, V103, P9280, DOI 10.1073/pnas.0601754103; West CE, 2012, CLIN EXP ALLERGY, V42, P540, DOI 10.1111/j.1365-2222.2011.03941.x; Xiao B, 2009, J INFECT DIS, V200, P916, DOI 10.1086/605443	41	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2017	12	3							0173817	10.1371/journal.pone.0173817	http://dx.doi.org/10.1371/journal.pone.0173817			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER6VC	28319200	gold, Green Published, Green Submitted			2023-01-03	WOS:000398945800031
J	Simonetti, A; Ezzeldin, H; Menis, M; McKean, S; Izurieta, H; Anderson, SA; Forshee, RA				Simonetti, Arianna; Ezzeldin, Hussein; Menis, Mikhail; McKean, Stephen; Izurieta, Hector; Anderson, Steven A.; Forshee, Richard A.			Modeling the potential impact on the US blood supply of transfusing critically ill patients with fresher stored red blood cells	PLOS ONE			English	Article							STORAGE DURATION; AGE; MORTALITY; LENGTH; STAY	Background Although some studies have suggested that transfusion recipients may have better medical outcomes if transfused with red blood cell units stored for a short time, the overall body of evidence shows mixed results. It is important to understand how using fresher stored red blood cell units for certain patient groups may affect blood availability. Methods Based on the Stock-and-Flow simulation model of the US blood supply developed by Simonetti et al. 2014, we evaluated a newly implemented allocation method of preferentially transfusing fresher stored red blood cell units to a subset of high-risk group of critically ill patients and its potential impact on supply. Results Simulation results showed that, depending on the scenario, the US blood total supply might be reduced between 2-42%, when compared to the standard of care in transfusion medicine practice. Among our simulated scenarios, we observed that the number of expired red blood cell units modulated the supply levels. The age threshold of the required red blood cell units was inversely correlated with both the supply levels and the number of transfused units that failed to meet that age threshold. Conclusion To our knowledge, this study represents the first attempt to develop a comprehensive framework to evaluate the impact of preferentially transfusing fresher stored red blood cells to the higher-risk critically ill patients on supply. Model results show the difficulties to identify an optimal scenario.	[Simonetti, Arianna; Ezzeldin, Hussein; Menis, Mikhail; Izurieta, Hector; Anderson, Steven A.; Forshee, Richard A.] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA; [McKean, Stephen] Acumen LLC, Burlingame, CA USA	US Food & Drug Administration (FDA)	Simonetti, A (corresponding author), US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	Arianna.Simonetti@fda.hhs.gov		Simonetti, Arianna/0000-0003-4711-7858	OBE from MCMi [Z01BS03005-03]; internal FDA/CBER; Research Participation Program at the Center for Biologics Evaluation and Research; Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy; US Food and Drug Administration	OBE from MCMi; internal FDA/CBER; Research Participation Program at the Center for Biologics Evaluation and Research; Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy(United States Department of Energy (DOE)); US Food and Drug Administration	This research was supported in the form of grant n. Z01BS03005-03 OBE from MCMi and by internal FDA/CBER funding. This project was also supported in part by the Research Participation Program at the Center for Biologics Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the US Food and Drug Administration (HE). Furthermore, Acumen LLC provided support in the form of salary for author SM. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Anderson SA, 2007, TRANSFUSION, V47, P582, DOI 10.1111/j.1537-2995.2007.01159.x; Atkinson MP, 2012, TRANSFUSION, V52, P108, DOI 10.1111/j.1537-2995.2011.03239.x; Aubron C, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-2; Blood Centers of the Pacific Community Blood Center of Greater Kansas City Mississippi Valley Regional Blood Center New York Blood Center and South Texas Blood and Tissue Center, 2010, NEW YORK BLOOD CTR S; Centers for Medicare & Medicaid Services, 2013, FIL ORD GEN INF; Centers for Medicare & Medicaid Services, 2012, MED PROGR GEN INF; Hart AC, 2004, ICD 9 CM EXPERT HOSP; Keller ME, 2002, J TRAUMA, V53, P1023, DOI 10.1097/00005373-200211000-00037; Koch CG, 2013, ANN THORAC SURG, V96, P1894, DOI 10.1016/j.athoracsur.2013.05.116; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lacroix J, 2015, NEW ENGL J MED, V372, P1410, DOI 10.1056/NEJMoa1500704; Lelubre C, 2013, CRIT CARE, V17, DOI 10.1186/cc12600; Lelubre C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-43; Mattison M., 2013, HOSP MANAGEMENT OLDE; Murrell Z, 2005, AM SURGEON, V71, P781; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Pettila V, 2011, CRIT CARE, V15, DOI 10.1186/cc10142; Services UDoHaH, 2013, 2011 NATL BLOOD COLL; Simonetti A, 2014, TRANSFUSION, V54, P828, DOI 10.1111/trf.12392; Spinella PC, 2009, CRIT CARE, V13, DOI 10.1186/cc8050; Steiner ME, 2015, NEW ENGL J MED, V372, P1419, DOI 10.1056/NEJMoa1414219; Vyrostek S.B., 2001, MMWR SURVEILL SUMM, V53, P1; Weinberg JA, 2008, J TRAUMA, V65, P794, DOI 10.1097/TA.0b013e318184aa11; Weinberg JA, 2008, J TRAUMA, V65, P279, DOI 10.1097/TA.0b013e31817c9687; White A, SHOULD PATIENTS ONLY; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	26	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2017	12	3							e0174033	10.1371/journal.pone.0174033	http://dx.doi.org/10.1371/journal.pone.0174033			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER6VC	28319164	Green Submitted, Green Published, gold			2023-01-03	WOS:000398945800044
J	He, XF; Ye, F; Zhao, BC; Tang, HL; Wang, J; Xiao, XS; Xie, XM				He, Xiaofang; Ye, Fen; Zhao, Bingcheng; Tang, Hailin; Wang, Jin; Xiao, Xiangsheng; Xie, Xiaoming			Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients	PLOS ONE			English	Article							RECONSTRUCTION; INITIATION; THERAPY; DIAGNOSIS; IMPACT; MASTECTOMY; EXPERIENCE; SURVIVAL; RECEIPT; SURGERY	Purpose Delay performance of adjuvant chemotherapy (AC) after surgery has been presented to affect survival of breast cancer patients adversely, but the risk factors for delay in initiation remain controversial. Therefore, we conducted this systematic review of the literature and meta-analysis aiming at identifying the risk factors for delay of adjuvant chemotherapy (DAC) in non-metastatic breast cancer patients. Methods The search was performed on PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang Database from inception up to July 2016. DAC was defined as receiving AC beyond 8-week after surgery. Data were combined and analyzed using random-effects model or fixed-effects model for risk factors considered by at least 3 studies. Heterogeneity was analyzed with meta-regression analysis of year of publication and sample size. Publication bias was studied with Egger's test. Results A total of 12 observational studies including 186982 non-metastatic breast cancer patients were eligible and 12 risk factors were analyzed. Combined results demonstrated that black race (vs white; OR, 1.18; 95% CI, 1.01 +/- 1.39), rural residents (vs urban; OR, 1.60; 95% CI, 1.27 +/- 2.03) and receiving mastectomy (vs breast conserving surgery; OR, 1.35; 95% CI, 1.00 +/- 1.83) were significantly associated with DAC, while married patients (vs single; OR, 0.58; 95% CI, 0.38 +/- 0.89) was less likely to have a delay in initiation. No significant impact from year of publication or sample size on the heterogeneity across studies was found, and no potential publication bias existed among the included studies. Conclusions Risk factors associated with DAC included black race, rural residents, receiving mastectomy and single status. Identifying of these risk factors could further help decisions making in clinical practice.	[He, Xiaofang; Ye, Fen; Tang, Hailin; Wang, Jin; Xiao, Xiangsheng; Xie, Xiaoming] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhao, Bingcheng] Sun Yat Sen Univ, First Affiliated Hosp, Dept Anesthesiol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Xie, XM (corresponding author), Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	xiexm@sysucc.org.cn	Zhao, Bingcheng/AAG-8383-2021; xiao, xiang/GWU-6035-2022		National Natural Science Foundation of China [81472575, 81272514, 81372133]; Key Program of the National Natural Science Foundation of China [31030061]; Science and Technology Planning Project of Guangdong and Guangzhou [2013B060300009, 2014J4100169]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong and Guangzhou	This study was supported by funds from the National Natural Science Foundation of China (81472575, 81272514, 81372133), the Key Program of the National Natural Science Foundation of China (31030061), the Science and Technology Planning Project of Guangdong and Guangzhou (2013B060300009,2014J4100169). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Alderman AK, 2010, CANCER-AM CANCER SOC, V116, P1791, DOI 10.1002/cncr.24891; Balasubramanian BA, 2012, ETHNIC DIS, V22, P288; Barry PN, 2014, AM J CLIN ONCOL-CANC, V37, P575, DOI 10.1097/COC.0b013e318280d79f; Bickell NA, 2006, J CLIN ONCOL, V24, P1357, DOI 10.1200/JCO.2005.04.5799; Breen N, 1996, BREAST CANCER RES TR, V40, P105, DOI 10.1007/BF01806006; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Cold S, 2005, BRIT J CANCER, V93, P627, DOI 10.1038/sj.bjc.6602734; Colleoni M, 2000, J CLIN ONCOL, V18, P584, DOI 10.1200/JCO.2000.18.3.584; Ejlertsen B, 2016, DAN MED J, V63; Ejlertsen B, 2014, ACTA ONCOL, V53, P174, DOI 10.3109/0284186X.2013.850738; Fedewa SA, 2010, J CLIN ONCOL, V28, P4135, DOI 10.1200/JCO.2009.27.2427; Freedman RA, 2013, HEALTH SERV RES, V48, P1669, DOI 10.1111/1475-6773.12063; Gagliato DD, 2014, J CLIN ONCOL, V32, P735, DOI 10.1200/JCO.2013.49.7693; Guidry JJ, 1997, CANCER PRACT, V5, P361; Gwyn K, 2004, CANCER, V100, P1595, DOI 10.1002/cncr.20169; Harmeling JX, 2015, BREAST CANCER RES TR, V153, P241, DOI 10.1007/s10549-015-3539-4; Herndon JE, 2013, PSYCHO-ONCOLOGY, V22, P315, DOI 10.1002/pon.2094; Hershman DL, 2006, BREAST CANCER RES TR, V99, P313, DOI 10.1007/s10549-006-9206-z; Jeevan R, 2015, BRIT J SURG, V102, P1064, DOI 10.1002/bjs.9847; Lipscomb J, 2012, BREAST CANCER RES TR, V133, P285, DOI 10.1007/s10549-011-1916-1; Lohrisch C, 2006, J CLIN ONCOL, V24, P4888, DOI 10.1200/JCO.2005.01.6089; Neal RD, 2005, BRIT J CANCER, V92, P1971, DOI 10.1038/sj.bjc.6602623; Olsen MA, 2008, ARCH SURG-CHICAGO, V143, P53, DOI 10.1001/archsurg.2007.11; Raphael MJ, 2016, BREAST CANC RES TREA, V8, P8; SAFER MA, 1979, MED CARE, V17, P11, DOI 10.1097/00005650-197901000-00002; Sanchez CJ, 2007, BREAST CANCER RES TR, V101, P215, DOI 10.1007/s10549-006-9282-0; Seneviratne S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-839; Gorin SS, 2006, ARCH INTERN MED, V166, P2244, DOI 10.1001/archinte.166.20.2244; Sheppard VB, 2013, BREAST CANCER RES TR, V139, P207, DOI 10.1007/s10549-013-2520-3; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simon MS, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/453985; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Takahashi N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004798	35	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2017	12	3							e0173862	10.1371/journal.pone.0173862	http://dx.doi.org/10.1371/journal.pone.0173862			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN9KE	28301555	Green Published, gold, Green Submitted			2023-01-03	WOS:000396318300083
J	Sumida, I; Yamaguchi, H; Das, IJ; Anetai, Y; Kizaki, H; Aboshi, K; Tsujii, M; Yamada, Y; Tamari, K; Seo, Y; Isohashi, F; Yoshioka, Y; Ogawa, K				Sumida, Iori; Yamaguchi, Hajime; Das, Indra J.; Anetai, Yusuke; Kizaki, Hisao; Aboshi, Keiko; Tsujii, Mari; Yamada, Yuji; Tamari, Keisuke; Seo, Yuji; Isohashi, Fumiaki; Yoshioka, Yasuo; Ogawa, Kazuhiko			Robust plan optimization using edgeenhanced intensity for intrafraction organ deformation in prostate intensity-modulated radiation therapy	PLOS ONE			English	Article							GEOMETRIC UNCERTAINTIES; IMAGE GUIDANCE; DOSE DELIVERY; MOTION; IMRT; CANCER; IMPLEMENTATION; RADIOTHERAPY; DELINEATION; SIMULATION	This study evaluated a method for prostate intensity-modulated radiation therapy (IMRT) based on edge-enhanced (EE) intensity in the presence of intrafraction organ deformation using the data of 37 patients treated with step-and-shoot IMRT. On the assumption that the patient setup error was already accounted for by image guidance, only organ deformation over the treatment course was considered. Once the clinical target volume (CTV), rectum, and bladder were delineated and assigned dose constraints for dose optimization, each voxel in the CTV derived from the DICOM RT-dose grid could have a stochastic dose from the different voxel location according to the probability density function as an organ deformation. The stochastic dose for the CTV was calculated as the mean dose at the location through changing the voxel location randomly 1000 times. In the EE approach, the underdose region in the CTV was delineated and optimized with higher dose constraints that resulted in an edge-enhanced intensity beam to the CTV. This was compared to a planning target volume (PTV) margin (PM) approach in which a CTV to PTV margin equivalent to the magnitude of organ deformation was added to obtain an optimized dose distribution. The total monitor units, number of segments, and conformity index were compared between the two approaches, and the dose based on the organ deformation of the CTV, rectum, and bladder was evaluated. The total monitor units, number of segments, and conformity index were significantly lower with the EE approach than with the PM approach, while maintaining the dose coverage to the CTV with organ deformation. The dose to the rectum and bladder were significantly reduced in the EE approach compared with the PM approach. We conclude that the EE approach is superior to the PM with regard to intrafraction organ deformation.	[Sumida, Iori; Anetai, Yusuke; Tamari, Keisuke; Seo, Yuji; Isohashi, Fumiaki; Yoshioka, Yasuo; Ogawa, Kazuhiko] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita, Osaka, Japan; [Yamaguchi, Hajime; Kizaki, Hisao; Aboshi, Keiko; Tsujii, Mari; Yamada, Yuji] NTT West Osaka Hosp, Dept Radiat Oncol, Tennoji Ku, Osaka, Japan; [Das, Indra J.] NYU, Dept Radiat Oncol, Langone Med Ctr, New York, NY USA	Osaka University; New York University; NYU Langone Medical Center	Sumida, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita, Osaka, Japan.	sumida@radonc.med.osaka-u.ac.jp		Sumida, Iori/0000-0001-7669-0325				[Anonymous], 2010, J ICRU, V10, P27, DOI 10.1093/jicru/ndq008; [Anonymous], 1993, 50 ICRU; Bell LJ, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0467-8; Bortfeld T, 2004, SEMIN RADIAT ONCOL, V14, P41, DOI 10.1053/j.semradonc.2003.10.011; Bortfeld T, 2002, PHYS MED BIOL, V47, P2203, DOI 10.1088/0031-9155/47/13/302; Chan TCY, 2010, PHYS MED BIOL, V55, P515, DOI 10.1088/0031-9155/55/2/012; Cheung R, 2005, INT J RADIAT ONCOL, V61, P993, DOI 10.1016/j.ijrobp.2004.07.723; Chu M, 2005, PHYS MED BIOL, V50, P5463, DOI 10.1088/0031-9155/50/23/003; Craig T, 2003, MED PHYS, V30, P2001, DOI 10.1118/1.1589492; Fredriksson A, 2016, PHYS MED BIOL, V61, P2067, DOI 10.1088/0031-9155/61/5/2067; Ge YY, 2014, MED PHYS, V41, DOI 10.1118/1.4873682; Ghilezan MJ, 2005, INT J RADIAT ONCOL, V62, P406, DOI 10.1016/j.ijrobp.2003.10.017; Gill S, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-174; Hogg R.V., 1992, APPL STAT ENG PHYS S; KALLMAN P, 1992, INT J RADIAT BIOL, V62, P249, DOI 10.1080/09553009214552071; Kim Y, 2006, INT J RADIAT ONCOL, V66, P1528, DOI 10.1016/j.ijrobp.2006.08.032; LEBESQUE JV, 1991, RADIOTHER ONCOL, V22, P45, DOI 10.1016/0167-8140(91)90068-R; Li HS, 2008, MED PHYS, V35, P1703, DOI 10.1118/1.2897972; Maleike D, 2006, PHYS MED BIOL, V51, P2237, DOI 10.1088/0031-9155/51/9/009; Mavroidis P, 2014, RADIOTHER ONCOL, V112, P418, DOI 10.1016/j.radonc.2014.05.011; Ogino I, 2011, J RADIAT RES, V52, P199, DOI 10.1269/jrr.10126; Pollack A, 2003, WORLD J UROL, V21, P200, DOI 10.1007/s00345-003-0356-x; Rancati T, 2004, RADIOTHER ONCOL, V73, P21, DOI 10.1016/j.radonc.2004.08.013; Rassiah-Szegedi P, 2011, J APPL CLIN MED PHYS, V12, P194, DOI 10.1120/jacmp.v12i3.3516; Roy A, 2016, J APPL CLIN MED PHYS, V17, P44, DOI 10.1120/jacmp.v17i6.6411; Scaife J, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140343; Sumida I, 2016, J RADIAT RES, V57, P691, DOI 10.1093/jrr/rrw073; Trofimov A, 2005, PHYS MED BIOL, V50, P2779, DOI 10.1088/0031-9155/50/12/004; Tuomikoski L, 2013, ACTA ONCOL, V52, P1451, DOI 10.3109/0284186X.2013.813639; Unkelbach J, 2005, MED PHYS, V32, P2471, DOI 10.1118/1.1929167; van Herk M, 2002, INT J RADIAT ONCOL, V52, P1407, DOI 10.1016/S0360-3016(01)02805-X; Wu QW, 2002, INT J RADIAT ONCOL, V52, P224, DOI 10.1016/S0360-3016(01)02585-8; Xu HJ, 2015, MED PHYS, V42, P5435, DOI 10.1118/1.4928490; Yock AD, 2013, INT J RADIAT ONCOL, V87, P596, DOI 10.1016/j.ijrobp.2013.06.2036	34	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2017	12	3							e0173643	10.1371/journal.pone.0173643	http://dx.doi.org/10.1371/journal.pone.0173643			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6CJ	28282417	Green Published, gold, Green Submitted			2023-01-03	WOS:000396091800060
J	Uehara, T; Watanabe, M; Suzuki, H; Furusawa, Y; Arano, Y				Uehara, Tomoya; Watanabe, Mariko; Suzuki, Hiroyuki; Furusawa, Yoshiya; Arano, Yasushi			Amino acid transport system - A substrate predicts the therapeutic effects of particle radiotherapy	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CARBON ION RADIOTHERAPY; IN-VIVO; CLINICAL-APPLICATIONS; C-11-METHIONINE PET; PROTEIN-SYNTHESIS; METHIONINE-PET; IMAGING AGENTS; TUMOR-TISSUE; CELL-LINES	L-[methyl-C-11]Methionine (C-11-Met) is useful for estimating the therapeutic efficacy of particle radiotherapy at early stages of the treatment. Given the short half-life of C-11, the development of longer-lived F-18- and I-123-labeled probes that afford diagnostic information similar to C-11-Met, are being sought. Tumor uptake of C-11-Met is involved in many cellular functions such as amino acid transport System-L, protein synthesis, and transmethylation. Among these processes, since the energy-dependent intracellular functions involved with C-11-Met are more reflective of the radiotherapeutic effects, we evaluated the activity of the amino acid transport System-A as an another energy-dependent cellular function in order to estimate radiotherapeutic effects. In this study, using a carbon-ion beam as the radiation source, the activity of System-A was evaluated by a specific System-A substrate, alpha-[1-C-14]-methyl-aminoisobutyric acid (C-14-MeAIB). Cellular growth and the accumulation of C-14-MeAIB or C-14-Met were evaluated over time in vitro in cultured human salivary gland (HSG) tumor cells (3-Gy) or in vivo in murine xenografts of HSG tumors (6- or 25-Gy) before and after irradiation with the carbon-ion beam. Post 3-Gy irradiation, in vitro accumulation of C-14-Met and C-14-MeAIB decreased over a 5-day period. In xenografts of HSG tumors in mice, tumor re-growth was observed in vivo on day-10 after a 6-Gy irradiation dose, but no re-growth was detected after the 25-Gy irradiation dose. Consistent with the growth results, the in vivo tumor accumulation of C-14-MeAIB did not decrease after the 6-Gy irradiation dose, whereas a significant decrease was observed after the 25-Gy irradiation dose. These results indicate that the activity of energy dependent System-A transporter may reflect the therapeutic efficacy of carbon-ion radiotherapy and suggests that longer half-life radionuclide-labeled probes for System-A may also provide widely available probes to evaluate the effects of particle radiotherapy on tumors at early stage of the treatment.	[Uehara, Tomoya; Watanabe, Mariko; Suzuki, Hiroyuki; Arano, Yasushi] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Imaging & Radiotherapy, Chiba, Japan; [Furusawa, Yoshiya] Natl Inst Radiol Sci, Natl Inst Quantum & Radiol Sci & Technol, Chiba, Japan	Chiba University; National Institutes for Quantum Science & Technology	Uehara, T (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Imaging & Radiotherapy, Chiba, Japan.	tuehara@chiba-u.jp	Furusawa, Yoshiya/A-4487-2012	Furusawa, Yoshiya/0000-0003-4213-7331; Suzuki, Hiroyuki/0000-0002-9560-4274	JSPS [08838332]; Special Coordination Funds for Research Projects; Heavy Ions at the National Institute of Radiological Sciences-Heavy-Ion Medical accelerator in Chiba (NIRS-HIMAC)	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Special Coordination Funds for Research Projects; Heavy Ions at the National Institute of Radiological Sciences-Heavy-Ion Medical accelerator in Chiba (NIRS-HIMAC)	This work was supported by a JSPS Grant-in-Aid for Young Scientists (B) Grant Number 08838332 and by the Special Coordination Funds for Research Projects with Heavy Ions at the National Institute of Radiological Sciences-Heavy-Ion Medical accelerator in Chiba (NIRS-HIMAC).	BUSTANY P, 1986, J NEURO-ONCOL, V3, P397, DOI 10.1007/BF00165590; Buus S, 2004, RADIOTHER ONCOL, V73, P289, DOI 10.1016/j.radonc.2004.09.009; Cascini GL, 2006, J NUCL MED, V47, P1241; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Dosanjh M, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20120660; Dosanjh M, 2010, BRIT J RADIOL, V83, P811, DOI 10.1259/bjr/49490647; Furusawa Y, 2000, RADIAT RES, V154, P485, DOI 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2; Hambermeier A, 2015, AMINO ACIDS, V47, P335, DOI [10.1007/s00726-014-1863-3, DOI 10.1007/S00726-014-1863-3]; Harris SM, 2013, J NUCL MED, V54, P1902, DOI 10.2967/jnumed.112.118125; Heiss P, 1999, J NUCL MED, V40, P1367; Heiss WD, 2014, J NUCL MED, V55, P1219, DOI 10.2967/jnumed.114.142661; ISHIWATA K, 1993, J NUCL MED, V34, P1936; Iwata H, 2014, INT J RADIAT ONCOL, V90, pS779, DOI 10.1016/j.ijrobp.2014.05.2254; Jager PL, 2001, J NUCL MED, V42, P432; Jeraj R, 2015, J NUCL MED, V56, P1752, DOI 10.2967/jnumed.114.141424; Kagawa K, 2002, INT J RADIAT ONCOL, V54, P928, DOI 10.1016/S0360-3016(02)02949-8; Kamada T, 2015, LANCET ONCOL, V16, pE93, DOI 10.1016/S1470-2045(14)70412-7; Kanai T, 1997, RADIAT RES, V147, P78, DOI 10.2307/3579446; Kanai T, 1999, INT J RADIAT ONCOL, V44, P201, DOI 10.1016/S0360-3016(98)00544-6; Kitagawa A, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3670742; Kondo T., 2013, RAD EMERG MED, V2, P1; KUBOTA K, 1995, NUCL MED BIOL, V22, P193, DOI 10.1016/0969-8051(94)00099-6; KUBOTA R, 1995, J NUCL MED, V36, P484; Kuwahara H, 2010, FREE RADICAL BIO MED, V48, P1252, DOI 10.1016/j.freeradbiomed.2010.02.011; Langen KJ, 2006, NUCL MED BIOL, V33, P287, DOI 10.1016/j.nucmedbio.2006.01.002; Laser BS, 2013, NEURO-ONCOLOGY, V15, P506, DOI 10.1093/neuonc/nos321; Luckerath K, 2015, ONCOTARGET, V6, P8418; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; McConathy J, 2012, MED RES REV, V32, P868, DOI 10.1002/med.20250; Nagren K, 2000, J LABELLED COMPD RAD, V43, P1013, DOI 10.1002/1099-1344(200009)43:10<1013::AID-JLCR387>3.0.CO;2-H; Nishii R, 2013, ANN NUCL MED, V27, P808, DOI 10.1007/s12149-013-0750-4; Nishimura T, 2014, BBA-BIOMEMBRANES, V1838, P1306, DOI 10.1016/j.bbamem.2014.01.004; Okayasu R, 2012, INT J CANCER, V130, P991, DOI 10.1002/ijc.26445; Ono M, 2013, BRAIN RES, V1535, P24, DOI 10.1016/j.brainres.2013.08.037; Salem A, 2006, EUR J CANCER, V42, P1720, DOI 10.1016/j.ejca.2006.02.021; Samnick S, 2001, NUCL MED BIOL, V28, P13, DOI 10.1016/S0969-8051(00)00176-1; Schlaff CD, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-88; SHIRASUNA K, 1986, CANCER RES, V46, P1418; Sutinen E, 2001, EUR J NUCL MED, V28, P847, DOI 10.1007/s002590100548; Toubaru S, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-143; Tsujii H, 2014, CARBON ION RADIOTHER; Uehara T, 2009, NUCL MED BIOL, V36, P985, DOI 10.1016/j.nucmedbio.2009.07.005; Van de Wiele C, 2003, INT J RADIAT ONCOL, V55, P5, DOI 10.1016/S0360-3016(02)04122-6; Wang YC, 2013, JACC-CARDIOVASC IMAG, V6, P512, DOI 10.1016/j.jcmg.2012.06.017; Watabe T, 2017, EUR J NUCL MED MOL I, V44, P321, DOI 10.1007/s00259-016-3487-1; Yu WP, 2015, NUCL MED BIOL, V42, P8, DOI 10.1016/j.nucmedbio.2014.07.002; Zhang H, 2004, CLIN CANCER RES, V10, P1764, DOI 10.1158/1078-0432.CCR-0190-3	47	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2017	12	2							e0173096	10.1371/journal.pone.0173096	http://dx.doi.org/10.1371/journal.pone.0173096			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN4LY	28245294	gold, Green Published, Green Submitted			2023-01-03	WOS:000395980200055
J	Blute, ML; Damaschke, N; Wagner, J; Yang, B; Gleave, M; Fazli, L; Shi, FF; Abel, EJ; Downs, TM; Huang, W; Jarrard, DF				Blute, Michael L., Jr.; Damaschke, Nathan; Wagner, Jennifer; Yang, Bing; Gleave, Martin; Fazli, Ladan; Shi, Fangfang; Abel, E. Jason; Downs, Tracy M.; Huang, Wei; Jarrard, David F.			Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy	PLOS ONE			English	Article							CELLULAR SENESCENCE; IN-VIVO; PROGRESSION; CASTRATION; CARCINOMA; PROLIFERATION; EXPRESSION; APOPTOSIS; ANTIGEN; TUMORS	Purpose Androgen deprivation therapy (ADT) commonly leads to incomplete cell death and the fate of persistent cells involves, in part, a senescent phenotype. Senescence is terminal growth arrest in response to cell stress that is characterized by increased lysosomal-beta-galactosidase (GLB1) the origin of senescence associated-beta-gal activity (SA-beta-gal). In the current study senescence is examined in vivo after ADT use in a neoadjuvant trial. Methods and materials Tissue microarrays were generated from prostate cancer specimens (n = 126) from a multicenter neoadjuvant ADT trial. Arrays were subjected to multiplexed immunofluorescent staining for GLB1, Ki67, cleaved caspase 3 (CC3) and E-cadherin. Automated quantitative imaging was performed using Vectra T and expression correlated with clinicopathologic features. Results Tissue was analyzed from 59 patients treated with neoadjuvant ADT and 67 receiving no therapy preoperatively. Median follow-up was 85.3 mo and median ADT treatment was 5 mo. In PC treated with neoadjuvant ADT, GLB1 expression increased in intermediate Gleason score (GS 6-7; p = 0.001), but not high grade (GS 8-10) cancer. Significantly higher levels of GLB1 were seen in tissues undergoing neoadjuvant ADT longer than 5 months compared to untreated tissues (p = 0.002). In contrast, apoptosis significantly increased earlier (1-4 mo) after ADT treatment (p < 0.5). Conclusions Increased GLB1 after neoadjuvant ADT occurs primarily among more clinically favorable intermediate grade cancers and enrichment of the phenotype occurs in a temporally prolonged fashion. Senescence may explain the persistence of PCa cells after ADT. Given concerns for the detrimental longer term presence of senescent cells, targeting these cells for removal may improve outcomes.	[Blute, Michael L., Jr.; Damaschke, Nathan; Wagner, Jennifer; Yang, Bing; Shi, Fangfang; Abel, E. Jason; Downs, Tracy M.; Jarrard, David F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Urol, Highland Ave, Madison, WI 53706 USA; [Gleave, Martin; Fazli, Ladan] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Abel, E. Jason; Downs, Tracy M.; Huang, Wei; Jarrard, David F.] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA; [Huang, Wei] Univ Wisconsin, Dept Pathol, Sch Med & Publ Hlth, Highland Ave, Madison, WI 53706 USA; [Jarrard, David F.] Univ Wisconsin, Environm & Mol Toxicol, Univ Ave Madison, Madison, WI 53706 USA; [Jarrard, David F.] Wisconsin Inst Med Res, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of British Columbia; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarrard, DF (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Urol, Highland Ave, Madison, WI 53706 USA.; Jarrard, DF (corresponding author), Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA.; Jarrard, DF (corresponding author), Univ Wisconsin, Environm & Mol Toxicol, Univ Ave Madison, Madison, WI 53706 USA.; Jarrard, DF (corresponding author), Wisconsin Inst Med Res, Madison, WI 53705 USA.	jarrard@urology.wisc.edu		Gleave, Martin/0000-0003-4235-0167	Department of Defense Prostate Cancer Research Program; Prostate Cancer Foundation; Gen6 Foundation;  [T32CA009614];  [T32CA009135]; NATIONAL CANCER INSTITUTE [T32CA009135] Funding Source: NIH RePORTER	Department of Defense Prostate Cancer Research Program(United States Department of Defense); Prostate Cancer Foundation; Gen6 Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by: Department of Defense Prostate Cancer Research Program; Prostate Cancer Foundation; Training grants to MLB (T32CA009614) and ND (Cancer Biology T32CA009135); and the Gen6 Foundation.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Benaim EA, 2002, EUR UROL, V42, P12, DOI 10.1016/S0302-2838(02)00238-5; Benaim EA, 2002, UROLOGY, V59, P73, DOI 10.1016/S0090-4295(01)01440-6; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chi KN, 2005, J NATL CANCER I, V97, P1287, DOI 10.1093/jnci/dji252; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Ewald JA, 2013, PROSTATE, V73, P337, DOI 10.1002/pros.22571; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922; Glass TR, 2003, J UROLOGY, V169, P164, DOI 10.1016/S0022-5347(05)64059-1; Grivas PD, 2013, CRIT REV ONCOL HEMAT, V85, P82, DOI 10.1016/j.critrevonc.2012.05.003; Halvorsen Ole Johan, 2008, APMIS Suppl, P5; Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784; Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299; KELLY WK, 1993, J CLIN ONCOL, V11, P607, DOI 10.1200/JCO.1993.11.4.607; Kucway R, 2002, J UROLOGY, V167, P2443, DOI 10.1016/S0022-5347(05)65001-X; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Montironi R, 1998, J CLIN PATHOL, V51, P5, DOI 10.1136/jcp.51.1.5; NEWLING DWW, 1993, EUR UROL, V24, P87; NEWLING DWW, 1993, CANCER, V72, P3793, DOI 10.1002/1097-0142(19931215)72:12+<3793::AID-CNCR2820721706>3.0.CO;2-U; Pernicova Z, 2011, NEOPLASIA, V13, P526, DOI 10.1593/neo.11182; Sciarra A, 2012, UROL ONCOL-SEMIN ORI, V30, P614, DOI 10.1016/j.urolonc.2010.09.006; Smitherman AB, 2003, PROSTATE, V57, P24, DOI 10.1002/pros.10271; Sweeney C., 2014, CHAARTED STUDY ABSTR; Tangen Catherine M, 2003, Clin Prostate Cancer, V2, P41, DOI 10.3816/CGC.2003.n.011; Vaillancourt L, 1996, AM J SURG PATHOL, V20, P86, DOI 10.1097/00000478-199601000-00010; Wagner J., 2015, INDOLENT PROSTATE CA; Wang Q, 2013, JNCI-J NATL CANCER I, V105, P1463, DOI 10.1093/jnci/djt241; Warren M, 2009, APPL IMMUNOHISTO M M, V17, P23, DOI 10.1097/PAI.0b013e31817c3334; WESTIN P, 1995, AM J PATHOL, V146, P1368; Xie N, 2015, INT J CANCER, V136, pE27, DOI 10.1002/ijc.29147	33	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2017	12	2							e0172048	10.1371/journal.pone.0172048	http://dx.doi.org/10.1371/journal.pone.0172048			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5VB	28234906	gold, Green Published, Green Submitted			2023-01-03	WOS:000394688200043
J	Kilmer, B				Kilmer, Beau			Recreational Cannabis - Minimizing the Health Risks from Legalization	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kilmer, Beau] RAND Drug Policy Res Ctr, Santa Monica, CA 90401 USA		Kilmer, B (corresponding author), RAND Drug Policy Res Ctr, Santa Monica, CA 90401 USA.							Caulkins J., 2016, MARIJUANA LEGALIZATI, DOI DOI 10.7249/CB525-1; Caulkins J.P., 2015, CONSIDERING MARIJUAN; Silins E, 2014, LANCET PSYCHIAT, V1, P286, DOI 10.1016/S2215-0366(14)70307-4; van der Pol P, 2014, ADDICTION, V109, P1101, DOI 10.1111/add.12508; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309	5	43	45	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2017	376	8					705	707		10.1056/NEJMp1614783	http://dx.doi.org/10.1056/NEJMp1614783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EM9JO	28225673				2023-01-03	WOS:000395627900001
J	Skielboe, AK; Bandholm, TQ; Hakmann, S; Mourier, M; Kallemose, T; Dixen, U				Skielboe, Ane Katrine; Bandholm, Thomas Quaade; Hakmann, Stine; Mourier, Malene; Kallemose, Thomas; Dixen, Ulrik			Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation A randomized controlled trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; RISK; REDUCTION; PREVALENCE; DURATION; ADULTS; LIFE; ECG	Background Physical activity at moderate-high intensity is recommended to prevent lifestyle diseases. Patients with atrial fibrillation are at risk of a sedentary lifestyle due to fear of exercise-induced episodes of atrial fibrillation. The burden of arrhythmia can be reduced by physical exercise. The effect of exercise intensity on burden of atrial fibrillation needs to be studied further. Methods and results In a 12-week randomized controlled trial, 76 patients with paroxysmal/persistent atrial fibrillation were allocated to perform exercise at either low intensity or high intensity (50% and 80% of maximal perceived exertion, respectively). Primary outcome was burden of AF measured by daily electrocardiography-reporting during 12 weeks. Secondarily, change in maximal oxygen uptake (peak VO2) and 1-year hospitalization was compared between low and high intensity exercise. Sixty-three patients completed the follow-up. In the intention-to-treat analysis, we found no statistical difference in burden of atrial fibrillation between low and high intensity exercise (incidence rate ratio 0.742, 95% CI 0.29-1.91, P = 0.538). No serious adverse events were reported and there was no difference in hospitalization between the two exercise groups. Both exercise groups improved significantly in peak VO2 (low intensity: 3.62 mL O-2/kg/min, SD 3.77; high intensity: 2.87 mL O-2/kg/min, SD 4.98), with no statistical difference between-groups (mean difference: 0.76 mL O-2/kg/min, 95% CI -3.22-1.7). Conclusions High intensity physical exercise was not superior to low intensity physical exercise in reducing burden of atrial fibrillation. HI exercise was well tolerated; no evidence of an increased risk was found for HI compared to LI exercise. Larger studies are required to further prove our findings.	[Skielboe, Ane Katrine; Hakmann, Stine; Dixen, Ulrik] Copenhagen Univ Hosp Amager & Hvidovre, Dept Cardiol, Hvidovre, Denmark; [Bandholm, Thomas Quaade; Kallemose, Thomas] Copenhagen Univ Hosp Amager & Hvidovre, Clin Res Ctr, Hvidovre, Denmark; [Bandholm, Thomas Quaade; Mourier, Malene] Copenhagen Univ Hosp Amager & Hvidovre, Dept Phys Therapy, Phys Med & Rehabil Res Copenhagen PMR C, Hvidovre, Denmark; [Bandholm, Thomas Quaade] Copenhagen Univ Hosp Amager & Hvidovre, Dept Orthoped Surg, Hvidovre, Denmark		Skielboe, AK (corresponding author), Copenhagen Univ Hosp Amager & Hvidovre, Dept Cardiol, Hvidovre, Denmark.	a.k.skielboe@gmail.com	Bandholm, Thomas/AAZ-8632-2020	Bandholm, Thomas/0000-0001-6884-1971; Skielboe, Ane Katrine/0000-0001-9523-3760	Danish Heart Foundation [13-04-R95-A4645-22748, 14-R97-A5061]; Knud & Dagny Gad Foundation [42680/Ivo]; Hvidovre Hospital's Research Foundation; Eva & Henry Fraenkel's Foundation; Health Foundation; Thorkild Steenbeck's Grant; Master Joiner Sophus Jacobsen & wife Astrid Jacobsens Foundation; Den Midtjyske Bladfond; Toyota Foundation; Arvid Nilsson's Foundation; C. C. Klestrup & wife Henriette Klestrups Memorial Grant	Danish Heart Foundation; Knud & Dagny Gad Foundation; Hvidovre Hospital's Research Foundation; Eva & Henry Fraenkel's Foundation; Health Foundation; Thorkild Steenbeck's Grant; Master Joiner Sophus Jacobsen & wife Astrid Jacobsens Foundation; Den Midtjyske Bladfond; Toyota Foundation; Arvid Nilsson's Foundation; C. C. Klestrup & wife Henriette Klestrups Memorial Grant	Several private and public foundations have kindly offered grant support: The Danish Heart Foundation (AKS), Grant number 13-04-R95-A4645-22748 & 14-R97-A5061, https://www.njerteforeningen.dk/?gclid=CP2WoauGwMwCFSLicgodtVgMUA; Knud & Dagny Gad Foundation, Grant number 42680/Ivo, http://gadandresenfonden.DK; Hvidovre Hospital's Research Foundation (AKS), Grant number n.a., http://www.hospital.dk/forskning/Sider/Forskning.aspx; Eva & Henry Fraenkel's Foundation (UD), Grant number n.a., http://www.fraenkelsmindefond.org/;, The Health Foundation (UD), Grant number n.a., http://www.helsefonden.dk/; Thorkild Steenbeck's Grant (UD), Grant number n.a., no website; Master Joiner Sophus Jacobsen & wife Astrid Jacobsens Foundation (UD), Grant number n.a., no website; Den Midtjyske Bladfond (UD), Grant number n.a., no website; Toyota Foundation (UD), Grant number n. a., no website. Arvid Nilsson's Foundation (UD), Grant number n.a., http://arvidnilssonsfond.dk/; C. C. Klestrup & wife Henriette Klestrups Memorial Grant (UD), Grant number n.a., no website. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521; Andersen K, 2013, ECOSYSTEMS, P1; [Anonymous], 2009, NUTR REV, V67, P114, DOI 10.1111/j.1753-4887.2008.00136.x; ATWOOD JE, 1988, J AM COLL CARDIOL, V11, P508, DOI 10.1016/0735-1097(88)91524-0; Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Boriani G, 2011, STROKE, V42, P1768, DOI 10.1161/STROKEAHA.110.609297; Botto GL, 2009, J CARDIOVASC ELECTR, V20, P241, DOI 10.1111/j.1540-8167.2008.01320.x; Bubien RS, 1996, CIRCULATION, V94, P1585, DOI 10.1161/01.CIR.94.7.1585; Capucci A, 2005, J AM COLL CARDIOL, V46, P1913, DOI 10.1016/j.jacc.2005.07.044; COUMEL P, 1994, EUR HEART J, V15, P9, DOI 10.1093/eurheartj/15.suppl_A.9; Dieberg G, 2015, J APPL PHYSIOL, V119, P726, DOI 10.1152/japplphysiol.00904.2014; Doliwa PS, 2009, SCAND CARDIOVASC J, V43, P163, DOI 10.1080/14017430802593435; DUNBAR CC, 1992, MED SCI SPORT EXER, V24, P94; Edvardsen E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085276; Giacomantonio NB, 2013, CAN J CARDIOL, V29, P483, DOI 10.1016/j.cjca.2012.07.003; Glotzer TV, 2009, CIRC-ARRHYTHMIA ELEC, V2, P474, DOI 10.1161/CIRCEP.109.849638; Hegbom Finn, 2006, J Cardiopulm Rehabil, V26, P24, DOI 10.1097/00008483-200601000-00005; Hendrikx T, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-41; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Ingemansson MP, 1998, HEART, V80, P71, DOI 10.1136/hrt.80.1.71; Johnson JS, 1998, CHEST, V113, P816, DOI 10.1378/chest.113.3.816; Kwok CS, 2014, INT J CARDIOL, V177, P467, DOI 10.1016/j.ijcard.2014.09.104; Lowres N, 2012, EUR J PREV CARDIOL, V19, P1091, DOI 10.1177/1741826711422505; Malmo V, 2016, CIRCULATION; Members AF, 2012, EUROPACE, V14, P1385, DOI [10.1093/europace/eus305, DOI 10.1093/EUROPACE/EUS305]; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Mozaffarian D, 2008, CIRCULATION, V118, P800, DOI 10.1161/CIRCULATIONAHA.108.785626; Myrstad M, 2014, AM J CARDIOL, V114, P1229, DOI 10.1016/j.amjcard.2014.07.047; Olshansky B, 2014, PHYSICIAN SPORTSMED, V42, P45, DOI 10.3810/psm.2014.02.2047; Osbak PS, 2011, AM HEART J, V162, P1080, DOI 10.1016/j.ahj.2011.09.013; Pathak RK, 2015, J AM COLL CARDIOL, V66, P985, DOI 10.1016/j.jacc.2015.06.488; Pathak RK, 2014, J AM COLL CARDIOL, V64, P2222, DOI 10.1016/j.jacc.2014.09.028; Plisiene J, 2008, CLIN RES CARDIOL, V97, P820, DOI 10.1007/s00392-008-0692-3; Reed JL, 2013, CAN J CARDIOL, V29, P1721, DOI 10.1016/j.cjca.2013.09.020; Stefansdottir H, 2011, EUROPACE, V13, P1110, DOI 10.1093/europace/eur132; Turakhia MP, 2015, CIRC-ARRHYTHMIA ELEC, V8, P1040, DOI 10.1161/CIRCEP.114.003057; Wanahita N, 2008, AM HEART J, V155, P310, DOI 10.1016/j.ahj.2007.10.004; Wang TJ, 2004, JAMA-J AM MED ASSOC, V292, P2471, DOI 10.1001/jama.292.20.2471; Wilhelm M, 2014, EUR J PREV CARDIOL, V21, P1040, DOI 10.1177/2047487313476414; World Health Organization, 2010, CONSOLIDATED GUIDELI	41	20	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2017	12	2							e0170060	10.1371/journal.pone.0170060	http://dx.doi.org/10.1371/journal.pone.0170060			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL5SX	28231325	Green Submitted, Green Published, gold			2023-01-03	WOS:000394682400002
J	Poolman, RW; Agoritsas, T; Siemieniuk, RAC; Harris, IA; Schipper, IB; Mollon, B; Smith, M; Albin, A; Nador, S; Sasges, W; Schandelmaier, S; Lytvyn, L; Kuijpers, T; van Beers, LWAH; Verhofstad, MHJ; Vandvik, PO				Poolman, Rudolf W.; Agoritsas, Thomas; Siemieniuk, Reed A. C.; Harris, Ian A.; Schipper, Inger B.; Mollon, Brent; Smith, Maureen; Albin, Alexandra; Nador, Sally; Sasges, Will; Schandelmaier, Stefan; Lytvyn, Lyubov; Kuijpers, Ton; van Beers, Loes W. A. H.; Verhofstad, Michael H. J.; Vandvik, Per Olav			RAPID RECOMMENDATIONS Low intensity pulsed ultrasound (LIPUS) for bone healing: a clinical practice guideline	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GRADE; MATURATION; FRACTURES; QUALITY; CALLUS		[Poolman, Rudolf W.; van Beers, Loes W. A. H.] Joint Res, OLVG, Dept Orthopaed Surg, NL-1090 HM Amsterdam, Netherlands; [Agoritsas, Thomas; Siemieniuk, Reed A. C.; Schandelmaier, Stefan] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, CH-1211 Geneva, Switzerland; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, CH-1211 Geneva, Switzerland; [Siemieniuk, Reed A. C.] Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; [Harris, Ian A.] UNSW Australia, South Western Sydney Clin Sch, Sydney, NSW 2052, Australia; [Harris, Ian A.] Ingham Inst Appl Med Res, Whitlam Orthopaed Res Ctr, Liverpool, NSW 2170, Australia; [Schipper, Inger B.] Leiden Univ, Med Ctr, Dept Surg, NL-2333 Leiden, Netherlands; [Mollon, Brent] Orillia Soldiers Mem Hosp, Orillia, ON L3V 5W6, Canada; [Nador, Sally] Kindred Northlake Hosp, Northlake, TX USA; [Schandelmaier, Stefan] Univ Basel Hosp, Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland; [Lytvyn, Lyubov] Oslo Univ Hosp, Forskningsveien 2b, N-0317 Oslo, Norway; [Kuijpers, Ton] Dutch Coll Gen Practitioners, NL-3502 GE Utrecht, Netherlands; [van Beers, Loes W. A. H.] OLVG, Dept Physiotherapy, NL-1090 HM Amsterdam, Netherlands; [Verhofstad, Michael H. J.] Erasmus MC Univ Rotterdam, Dept Surg, Trauma Res Unit Erasmus, NL-3000 CA Rotterdam, Netherlands; [Vandvik, Per Olav] Univ Oslo, Inst Hlth & Soc, Fac Med, N-0318 Oslo, Norway; [Vandvik, Per Olav] Innlandet Hosp Trust Div, Dept Med, Gjovik, Norway	McMaster University; University of Geneva; University of Geneva; University of Toronto; University of New South Wales Sydney; Ingham Institute for Applied Medical Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Basel; University of Oslo; Erasmus University Rotterdam; Erasmus MC; University of Oslo; Innlandet Hospital Trust	Poolman, RW (corresponding author), Joint Res, OLVG, Dept Orthopaed Surg, NL-1090 HM Amsterdam, Netherlands.	rwp@jointresearch.org	Agoritsas, Thomas/F-4321-2014; Schandelmaier, Stefan/GLV-3722-2022; Poolman, Rudolf/AAM-7815-2020; Schipper, Inger/ABE-7796-2021	Agoritsas, Thomas/0000-0002-6182-9969; Schandelmaier, Stefan/0000-0002-8429-0337; Poolman, Rudolf/0000-0003-3178-2247; Schipper, Inger/0000-0001-9952-3079; Verhofstad, Michael/0000-0001-8448-5903				Alonso-Coello P, 2016, BMJ, V353, pi2089, DOI [DOI 10.1136/BMJ.I2089, 10.1136/bmj.i2089]; [Anonymous], 2005, KNOWLEDGE ENTERPRISE; Barrena E, 2016, EVALUATION OF EFFICA; Busse JW, 2008, ACTA ORTHOP, V79, P689, DOI 10.1080/17453670810016722; Busse JW, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5351; Donaldson LJ, 2008, J EPIDEMIOL COMMUN H, V62, P174, DOI 10.1136/jech.2006.056622; Ebrahim S, 2014, CAN J SURG, V57, pE105, DOI 10.1503/cjs.010113; El-Mowafi H, 2005, INT ORTHOP, V29, P121, DOI 10.1007/s00264-004-0625-3; Food and Drug Administration, 2000, APPR ORD; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Kisch T, 2015, BONE MICROCIRCULATIO; Mills LA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002276; National Institute for Health and Clinical Excellence, 2010, LOW INT PULS ULTR PR; OrthoInfo, 2011, OST KNEE; Poolman RW, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b11; Prasad V, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-1; Rue JPH, 2004, ORTHOPEDICS, V27, P1192, DOI 10.3928/0147-7447-20041101-18; Schandelmaier S, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j656; Scolaro JA, 2014, J BONE JOINT SURG AM, V96A, P674, DOI 10.2106/JBJS.M.00081; Siemieniuk RA, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i5191; Tsumaki N, 2004, J BONE JOINT SURG AM, V86A, P2399, DOI 10.2106/00004623-200411000-00006; Vandvik PO, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i5085; Wachovia Capital Markets, 2007, EQ RES BON GROWTH ST	24	44	46	3	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2017	356								j576	10.1136/bmj.j576	http://dx.doi.org/10.1136/bmj.j576			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM9KS	28228381	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000395631000002
J	Kua, KP; Lee, SWH				Kua, Kok Pim; Lee, Shaun Wen Huey			Complementary and alternative medicine for the treatment of bronchiolitis in infants: A systematic review	PLOS ONE			English	Review							CHILDREN; HOSPITALIZATIONS; EFFICACY; SULFATE; SAFETY	Background Bronchiolitis is a common cause of hospitalization among infants. The limited effectiveness of conventional medication has prompted the use of complementary and alternative medicine ( CAM) as alternative or adjunctive therapy for the management of bronchiolitis. Aims To determine the effectiveness and safety of CAM for the treatment of bronchiolitis in infants aged less than 2 years. Methods A systematic electronic search was performed in Medline, Embase, CINAHL, AMED, and Cochrane Central Register of Controlled Trials ( CENTRAL) from their respective inception to June 30, 2016 for studies evaluating CAM as an intervention to treat bronchiolitis in infants ( 1 month to 2 years of age). The CAM could be any form of treatment defined by the National Center for Complementary and Integrative Health ( NCCIH) and was utilized either as a single agent or adjunctive therapy. The predefined primary outcome was length of hospital stay. Secondary outcomes were time to resolution of bronchiolitis symptoms, adverse events, and all other clinical outcomes reported by the included studies. Results The review identified 11 studies ( 8 randomized controlled trials and 3 cohort studies) examining four herbal preparations and four supplements used either as adjunctive or alternative therapy for bronchiolitis in 904 infants. Most studies were of moderate quality. Among six studies reporting on length of stay, a significant benefit was found for Chinese herbal medicine compared to ribavirin in one cohort study ( n = 66) and vitamin D compared to placebo in one randomized controlled trial ( n = 89). Studies of Chinese herbal medicine ( 4 studies, n = 365), vitamin D ( 1 study, n = 89), N-acetylcysteine ( 1 study, n = 100), and magnesium ( 2 studies, n = 176) showed some benefits with respect to clinical severity scores, oxygen saturation, and other symptoms, although data were sparse for any single intervention and the outcomes assessed and reported varied across studies. Only five studies reported on adverse events; no serious adverse events were reported. Conclusions Among 11 studies examining the effect of CAM on inpatients with bronchiolitis, six reported on the review's primary outcome of length of hospital stay. In general, findings did not show a significant benefit associated with the primary outcome. Preliminary evidence indicated that Chinese herbal medicine mixtures, vitamin D, N-acetylcysteine, and magnesium might be useful in managing the symptoms of bronchiolitis. However, the evidence was not sufficient or rigorous enough to formulate recommendations for the use of any CAM. Among studies that reported adverse events, no serious harms were noted.	[Kua, Kok Pim; Lee, Shaun Wen Huey] Monash Univ, Sch Pharm, Bandar Sunway, Selangor, Malaysia; [Kua, Kok Pim] Minist Hlth, Dept Pharm, Petaling Dist Hlth Off, Kelana Jaya, Selangor, Malaysia	Monash University; Monash University Sunway; Kementerian Kesihatan Malaysia	Lee, SWH (corresponding author), Monash Univ, Sch Pharm, Bandar Sunway, Selangor, Malaysia.	shaun.lee@monash.edu	Lee, Shaun/E-9934-2014	Lee, Shaun/0000-0001-7361-6576; Kua, Kok Pim/0000-0001-7910-4301				[Anonymous], 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P162; [Anonymous], COMPL ALT INT HLTH W; Arvind J, 2013, AUSTRALAS MED J, V6, P550; Bansal A, 2011, INDIAN J PEDIATR, V78, P33, DOI 10.1007/s12098-010-0244-5; Dahiru Tukur, 2008, Ann Ib Postgrad Med, V6, P21; Dawson-Caswell M, 2011, AM FAM PHYSICIAN, V83, P141; Dubben HH, 2005, BRIT MED J, V331, P433, DOI 10.1136/bmj.38478.497164.F7; Feng X, 2006, J TRADITIONAL CHINES, V26, P266; Fernandes RM, 2015, PEDIATRICS, V135, pE1399, DOI 10.1542/peds.2014-3557; Florin TA, 2016, LANCET; Fraser WD, 2013, CALCIFIED TISSUE INT, V92, P118, DOI 10.1007/s00223-012-9693-3; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Heydarian F, 2011, IRAN J PEDIATR, V21, P231; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Jiang LH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004560.pub4; Kemper KJ, 2001, ARCH DIS CHILD, V84, P6, DOI 10.1136/adc.84.1.6; Kose M, 2014, EUR J PEDIATR, V173, P1157, DOI 10.1007/s00431-014-2309-3; Krzywinski M, 2013, NAT METHODS, V10, P1041, DOI 10.1038/nmeth.2698; Langley JM, 2003, J INFECT DIS, V188, P1764, DOI 10.1086/379740; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; MILNER AD, 1989, THORAX, V44, P1, DOI 10.1136/thx.44.1.1; Modaresi MR, 2015, INDIAN J PEDIAT; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Institute for Health and Care Excellence, BRONCH CHILDR DIAGN; Naz F, 2014, JCPSP-J COLL PHYSICI, V24, P408, DOI 06.2014/JCPSP.408411; Pocock SJ, 2016, NEW ENGL J MED, V375, P861, DOI 10.1056/NEJMra1510064; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Ricci V, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2305; Saad K, 2015, PEDIAT ALLER IMM PUL, V28, P102, DOI 10.1089/ped.2015.0492; Shang X, 2015, CLIN RESP J; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Turner LA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-67; U.S. Food and Drug Administration, PED EXCL 695 STUD AG; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Viswanathan M, 2003, AHRQ PUBLICATION; WANG EEL, 1992, AM REV RESPIR DIS, V145, P106, DOI 10.1164/ajrccm/145.1.106; Wang WS, 1997, SHANXI J TRADITIONAL, V13, P20; Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108; Welliver J R, 1993, Pediatr Rev, V14, P134, DOI 10.1542/pir.14-4-134; Wells GA, 2015, NEWCASTLE OTTAWA SCA	44	11	13	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2017	12	2							e0172289	10.1371/journal.pone.0172289	http://dx.doi.org/10.1371/journal.pone.0172289			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BI	28212381	gold, Green Submitted, Green Published			2023-01-03	WOS:000394424700029
J	Stark, J				Stark, James			The art of medicine The age of youth	LANCET			English	Editorial Material									[Stark, James] Univ Leeds, Sch Philosophy Relig & Hist Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Stark, J (corresponding author), Univ Leeds, Sch Philosophy Relig & Hist Sci, Leeds LS2 9JT, W Yorkshire, England.	J.F.Stark@leeds.ac.uk		Stark, James/0000-0002-0638-0804	Arts and Humanities Research Council [AH/N007735/1] Funding Source: researchfish; AHRC [AH/N007735/1] Funding Source: UKRI	Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); AHRC(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC))		Boia L., 2004, FOREVER YOUNG CULTUR; Haycock DB, 2009, MORTAL COIL SHORT HI; Hoberman J, 2005, TESTOSTERONE DREAMS: REJUVENATION, APHRODISIA, DOPING; McGrady P., 1968, THE YOUTH DOCTORS; Sengoopta Chandak, 2006, MOST SECRET QUINTESS; Stark JF, 2014, MED HIST, V58, P498, DOI 10.1017/mdh.2014.50; Trimmer Eric J., 1967, REJUVENATION HIST ID	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2016	388	10059					2470	2471		10.1016/S0140-6736(16)32181-X	http://dx.doi.org/10.1016/S0140-6736(16)32181-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	EC5IA	28328462	Green Accepted			2023-01-03	WOS:000388166300015
J	Hong, M; Jung, J; Park, HS; Lee, SM; Jeong, NJ; Kim, SH; Lee, KW; Lee, JA; Kim, MS				Hong, Moonju; Jung, Jeeyoun; Park, Hee-Sook; Lee, So Min; Jeong, Nam-Joo; Kim, Soon-Hee; Lee, Kyoung-Won; Lee, Ju-A; Kim, Myung-Sunny			Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways	PLOS ONE			English	Article							FATTY LIVER-DISEASE; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; ACTIVE FRACTION; BLOOD-STASIS; TNF-ALPHA; MEDICINE; RATS; IDENTIFICATION	Shaofu Zhuyu decoction (SFZYD, also known as Sobokchugeo-tang), a classical prescription drug in traditional East Asian medicine, has been used to treat blood stasis syndrome (BSS). Hepatic steatosis is the result of excess caloric intake, and its pathogenesis involves internal retention of phlegm and dampness, blood stasis, and liver Qi stagnation. To evaluate the effects of treatment with SFZYD on obesity-induced inflammation and hepatic steatosis, we fed male C57BL/6N mice a high fat diet (HFD) for 8 weeks and then treated them with SFZYD by oral gavage for an additional 4 weeks. The results of histological and biochemical examinations indicated that SFZYD treatment ameliorates systemic inflammation and hepatic steatosis. A partial least squares-discriminant analysis (PLS-DA) scores plot of serum metabolites showed that HFD mice began to produce metabolites similar to those of normal chow (NC) mice after SFZYD administration. We noted significant alterations in the levels of twenty-seven metabolites, alterations indicating that SFZYD regulates the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism. Increases in the levels of TCA cycle intermediate metabolites, such as 2-oxoglutaric acid, isocitric acid, and malic acid, in the serum of obese mice were significantly reversed after SFZYD treatment. In addition to inducing changes in the above metabolites, treatment with SFZYD also recovered the expression of genes related to hepatic mitochondrial dysfunction, including Ucp2, Cpt1 alpha, and Ppargc1 alpha, as well as the expression of genes involved in lipid metabolism and inflammation, without affecting glucose uptake or insulin signaling. Taken together, these findings suggest that treatment with SFZYD ameliorated obesity-induced systemic inflammation and hepatic steatosis by regulating inflammatory cytokine and adipokine levels in the circulation and various tissues. Moreover, treatment with SFZYD also reversed alterations in the levels of metabolites of the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism.	[Hong, Moonju; Park, Hee-Sook; Jeong, Nam-Joo; Kim, Soon-Hee; Lee, Kyoung-Won; Kim, Myung-Sunny] Korea Food Res Inst, Div Metab & Nutr, Gyeonggi Do, South Korea; [Hong, Moonju; Kim, Myung-Sunny] Korea Univ Sci & Technol, Dept Food Biotechnol, Gyeonggi Do, South Korea; [Jung, Jeeyoun; Lee, So Min; Lee, Ju-A] Korea Inst Oriental Med, KM Fundamental Res Div, Daejeon, South Korea	Korea Food Research Institute (KFRI); Korea Institute of Oriental Medicine (KIOM)	Kim, MS (corresponding author), Korea Food Res Inst, Div Metab & Nutr, Gyeonggi Do, South Korea.; Kim, MS (corresponding author), Korea Univ Sci & Technol, Dept Food Biotechnol, Gyeonggi Do, South Korea.	truka@kfri.re.kr	Jung, Jeeyoun/G-8438-2018	Hong, Moonju/0000-0001-7688-6803	Korea Institute of Oriental Medicine [K15113, K15114]; Korea Food Research Institute [E0150302-2]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE024748] Funding Source: NIH RePORTER	Korea Institute of Oriental Medicine; Korea Food Research Institute; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the Korea Institute of Oriental Medicine (K15113 and K15114) and the Korea Food Research Institute (E0150302-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Korea Institute of Oriental Medicine (K15113 and K15114) and the Korea Food Research Institute (E0150302-2). We thank Drs. K.S. Sung and C.E. Lee for providing technical support for the animal experiments.	Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Crespo J, 2001, HEPATOLOGY, V34, P1158, DOI 10.1053/jhep.2001.29628; Dietrich P, 2014, BEST PRACT RES CL GA, V28, P637, DOI 10.1016/j.bpg.2014.07.008; Dong H, 2012, CHIN J INTEGR MED, V18, P152, DOI 10.1007/s11655-012-0993-2; El-Benna J, 2005, ARCH IMMUNOL THER EX, V53, P199; Eriksson L, 2008, J CHEMOMETR, V22, P594, DOI 10.1002/cem.1187; Fan M., 2011, BEIJING J TRADIT CHI, V30, P455; Freemerman AJ, 2014, J BIOL CHEM, V289, P7884, DOI 10.1074/jbc.M113.522037; Gall WE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010883; Grattagliano I, 2012, CLIN BIOCHEM, V45, P610, DOI 10.1016/j.clinbiochem.2012.03.024; Guo N, 2014, J CHROMATOGR A, V1362, P89, DOI 10.1016/j.chroma.2014.08.028; Gupte P, 2004, J GASTROEN HEPATOL, V19, P854, DOI 10.1111/j.1440-1746.2004.03312.x; Huang XC, 2016, J ETHNOPHARMACOL, V186, P234, DOI 10.1016/j.jep.2016.03.067; Hui JM, 2004, HEPATOLOGY, V40, P46, DOI 10.1002/hep.20280; Jia W, 2006, PHYTOTHER RES, V20, P819, DOI 10.1002/ptr.1905; Kim M, 2002, J COMMUN HEALTH, V27, P109, DOI 10.1023/A:1014509200352; Kim MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082847; Kim SH, 2016, J ETHNOPHARMACOL, V192, P201, DOI 10.1016/j.jep.2016.07.023; KUNJARA S, 1993, BIOCHEM MED METAB B, V49, P217, DOI 10.1006/bmmb.1993.1024; Lan K, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/819147; Li SM, 2014, CHIN J INTEGR MED, V20, P483, DOI 10.1007/s11655-014-1803-9; Li ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/jhep.2003.50048; Liu CG, 2013, BIOL PHARM BULL, V36, P1700; Liu L, 2010, MOLECULES, V15, P5066, DOI 10.3390/molecules15085066; Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008; Park HS, 2016, MOL NUTR FOOD RES, V60, P1944, DOI 10.1002/mnfr.201500689; Rodriguez-Gallego E, 2015, INT J OBESITY, V39, P279, DOI 10.1038/ijo.2014.53; Su SL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/901943; Su SL, 2010, AM J CHINESE MED, V38, P777, DOI 10.1142/S0192415X10008238; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Tan GG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034157; van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505; Westerbacka J, 2007, DIABETES, V56, P2759, DOI 10.2337/db07-0156; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yonghe CMY, 2007, J TRADITIONAL CHINES, V27, P115; Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19288; Zhao XJ, 2008, J CHROMATOGR B, V873, P151, DOI 10.1016/j.jchromb.2008.08.010	39	26	27	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2017	12	6							e0178514	10.1371/journal.pone.0178514	http://dx.doi.org/10.1371/journal.pone.0178514			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW6HZ	28441416	Green Published, Green Submitted, gold			2023-01-03	WOS:000402611800069
